<SEC-DOCUMENT>0001213900-25-022192.txt : 20250310
<SEC-HEADER>0001213900-25-022192.hdr.sgml : 20250310
<ACCEPTANCE-DATETIME>20250310160658
ACCESSION NUMBER:		0001213900-25-022192
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		106
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250310
DATE AS OF CHANGE:		20250310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PURPLE BIOTECH LTD.
		CENTRAL INDEX KEY:			0001614744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37643
		FILM NUMBER:		25723704

	BUSINESS ADDRESS:	
		STREET 1:		4 OPPENHEIMER STREET
		STREET 2:		SCIENCE PARK
		CITY:			REHOVOT
		STATE:			L3
		ZIP:			7670104
		BUSINESS PHONE:		97239333121

	MAIL ADDRESS:	
		STREET 1:		4 OPPENHEIMER STREET
		STREET 2:		SCIENCE PARK
		CITY:			REHOVOT
		STATE:			L3
		ZIP:			7670104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Kitov Pharma Ltd.
		DATE OF NAME CHANGE:	20180125

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Kitov Pharmaceuticals Holdings Ltd.
		DATE OF NAME CHANGE:	20140724
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0232483-20f_purple.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 10 16:44:16 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ppbt="http://Purplebiotech.com/20241231" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-28475">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentRegistrationStatement" id="ixv-28476">&#9744;</ix:nonNumeric>&#160;REGISTRATION STATEMENT PURSUANT TO
SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="ixv-28477">&#9746;</ix:nonNumeric>&#8239;ANNUAL REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended <b><span style="text-decoration:underline"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-28478"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-28479">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-28480">2024</ix:nonNumeric></ix:nonNumeric></span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="ixv-28481">&#9744;</ix:nonNumeric>&#160;TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="ixv-28482">&#9744;</ix:nonNumeric>&#160;SHELL COMPANY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of event requiring this shell company report
________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-75"><b><span style="text-decoration:underline">001-37643</span></b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 100%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-28483">Purple Biotech Ltd.</ix:nonNumeric> </b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact name of Registrant as specified in its charter)</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation of Registrant&#8217;s name into English)</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-102"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Israel</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Jurisdiction of incorporation or organization)</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-113"><b>4 Oppenheimer Street</b></ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-116"><b>Science Park</b></ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-28484">Rehovot</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-28485">7670104</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-28486">Israel</ix:nonNumeric></b></p></td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-28487">Gil Efron</ix:nonNumeric>, Chief Executive Officer </b></span></td></tr> <tr style="vertical-align: top"> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-132"><b>4 Oppenheimer Street</b></ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-135"><b>Science Park</b></ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-28488">Rehovot</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-28489">7670104</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-28490">Israel</ix:nonNumeric></b></p></td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tel: <span style="-sec-ix-hidden: hidden-fact-0"><span style="-sec-ix-hidden: hidden-fact-1">+972-3-933-3121</span></span>; Fax: <ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelFaxNumber" id="ixv-28491">+972-3-5097196</ix:nonNumeric></b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(b) of the Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-170"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>American Depositary Shares, each representing 200 Ordinary Shares<sup>(1)</sup></b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-176"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PPBT</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName" id="ixv-28492">NASDAQ</ix:nonNumeric> Capital Market</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evidenced by American
    Depositary Receipts.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    registered or to be registered pursuant to Section 12(g) of the Act:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title of Class)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities for which there
    is a reporting obligation pursuant to Section 15(d) of the Act:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title of Class)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate the number of outstanding
shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-28493">517,128,717</ix:nonFraction>
Ordinary Shares, no par value (including 1 ordinary share held in treasury).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark if
the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-28494">No</ix:nonNumeric>&#160;&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this report is an annual
or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-28495">No</ix:nonNumeric>&#160;&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-28496">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-28497">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;&#160;No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of
the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9744;</span></td> <td style="width: 23%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 21%; padding-left: 9pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-288"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="width: 29%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="width: 1%"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-295"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company
that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use
the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section
13(a) of the Exchange Act.&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8224; The term &#8220;new
or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting
Standards Codification after April 5, 2012.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm
that prepared or issued its audit report.&#160;<ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="ixv-28498">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If securities are registered
pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing
reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-28499">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of
the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark which
basis of accounting the registrant has used to prepare the financial statements included in this filing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">U.S. GAAP&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-hidden: hidden-fact-2">International Financial Reporting
Standards</span> as issued by the International Accounting Standards Board&#160;&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If &#8220;Other&#8221; has
been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to
follow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Item 17&#160;&#9744;&#160;&#160;&#160;Item 18&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this is an annual report,
indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport" id="ixv-28500">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1.</b></span></td>
    <td style="vertical-align: top; width: 82%; text-align: justify"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></span></a></td>
    <td style="vertical-align: bottom; width: 9%; text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 2.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OFFER STATISTICS AND EXPECTED TIMETABLE</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 3.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>KEY INFORMATION</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INFORMATION ON THE COMPANY</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">46</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4A.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNRESOLVED STAFF COMMENTS</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">80</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 5.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING AND FINANCIAL REVIEW AND PROSPECTS</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">81</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 6.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">87</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 7.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">106</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 8.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INFORMATION</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">109</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 9.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE OFFER AND LISTING</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">110</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 10.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADDITIONAL INFORMATION</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">110</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 11.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">124</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 12.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">125</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 13.</b></span></td>
    <td style="vertical-align: top"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">126</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 14.</b></span></td>
    <td style="vertical-align: top"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">126</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 15.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTROLS AND PROCEDURES</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">126</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[RESERVED]</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">126</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM&#160;16A.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AUDIT COMMITTEE FINANCIAL EXPERT</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">126</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16B.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CODE OF ETHICS</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">127</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16C.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">127</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16D.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">128</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16E.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">128</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16F.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">128</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16G.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CORPORATE GOVERNANCE</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">128</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16H.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MINE SAFETY DISCLOSURE</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">129</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16I.</b></span></td>
    <td style="vertical-align: top"><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">129</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16J.</b></span></td>
    <td style="vertical-align: top"><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INSIDER TRADING POLICIES</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">129</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16K.</b></span></td>
    <td style="vertical-align: top"><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYBERSECURITY</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">129</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 17.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL STATEMENTS</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">131</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 18.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL STATEMENTS</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">131</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 19.</b></span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBITS</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">131</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Unless the context otherwise indicates or requires, all references
to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Registrant,&#8221;
    &#8220;Purple&#8221;, &#8220;Purple Biotech&#8221;, &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221;
    &#8220;our company&#8221; and similar designations refer to Purple Biotech Ltd., together with (i) its former wholly-owned subsidiary,
    Kitov Pharmaceuticals, (ii) its majority owned subsidiary, TyrNovo, (iii) its wholly owned subsidiary, FameWave, (iv) its wholly
    owned subsidiary, Immunorizon, and (v) its wholly owned subsidiary Purple Biotech GmbH (in the process of dissolution), except where
    otherwise stated or where it is clear that the terms mean only Purple Biotech Ltd. exclusive of any subsidiaries, </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;TyrNovo&#8221; refers
    to TyrNovo Ltd., the majority owned subsidiary of Purple Biotech,</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FameWave&#8221;
    refers to FameWave Ltd., the wholly owned subsidiary of Purple Biotech,</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Immunorizon&#8221;
    refers to Immunorizon Ltd., the wholly owned subsidiary of Purple Biotech, </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;dollar&#8221;, &#8220;US$&#8221;
    or &#8220;$&#8221; refer to U.S. dollars, the lawful currency of the United States of America,</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#8220;Euro&#8221;
    or &#8220;&#8364;&#8221; refer to the Euro, the lawful currency of the European Union member states,</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;NIS&#8221; refers
    to the New Israeli Shekel, the lawful currency of the State of Israel,</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;IFRS&#8221; refers
    to the International Financial Reporting Standards as issued by the International Accounting Standards Board,</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;ordinary shares,&#8221;
    &#8220;our shares&#8221; and similar expressions refer to the Registrant&#8217;s ordinary shares, no par value per share,</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;ADSs&#8221; refers
    to the Registrant&#8217;s American Depositary Shares,</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Companies Law&#8221;
    refers to the Israeli Companies Law, 5759-1999,</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Securities Act&#8221;
    refers to the Securities Act of 1933, as amended,</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SEC&#8221; refers
    to the United States Securities and Exchange Commission, </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;NASDAQ&#8221; refers
    to The NASDAQ Capital Market, except where otherwise stated or where it is clear that the term means any of the NASDAQ exchanges,
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;TASE&#8221; refers
    to the Tel Aviv Stock Exchange.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
all information contained in this Annual Report on Form 20-F gives retrospective effect to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective as January 4,
    2019, we effected a consolidation of our share capital at a ratio of 1:20, such that: each 20 ordinary shares were consolidated into
    one ordinary share.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective as of August
    21, 2020, we effected a change in the ratio of ordinary shares to each ADS, such that the ratio of ADSs to ordinary shares changed
    from one (1) ADS representing one (1) ordinary share to a new ratio of one (1) ADS representing ten (10) ordinary shares. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective as of September
    17, 2024, we effected a change in the ratio of ordinary shares to each ADS, such that the ratio of ADSs to ordinary shares changed
    from one (1) ADS representing ten (10) ordinary shares to a new ratio of one (1) ADS representing two hundred (200) ordinary shares.
    All ADS numbers in this Annual Report on Form 20-F are presented on a post-ratio change basis. </span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Glossary of Industry Terms </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, for convenience,
the following terms used in this Annual Report on Form 20-F are defined as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;API&#8221;</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 79%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Active Pharmaceutical
    Ingredient</b> &#8211; any substance or mixture of substances intended to be used in the manufacture of a drug product and that,
    when used in the production process, becomes an active ingredient in the drug product.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;approved product&#8221;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A product that has been
    approved for marketing by a regulatory authority.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;BLA&#8221;&#160;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Biologics License Application
    </b>&#8211; An application submitted to the FDA to request approval to market a new biological product in the United States.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>cGMP</b>&#8221;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Current Good Manufacturing
    Practice</b>&#160;&#8211; minimum requirements of the FDA and other regulatory authorities for the methods, facilities, and controls
    used in the manufacturing, processing, and packing of a drug product that is intended for human use to ensure that the product is
    safe for use and has the ingredients and strength that it claims to have.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>Clinical</b>&#8221;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pertaining to human studies.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>CMC</b>&#8221;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemistry, manufacturing,
    and controls.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#8220;Consensi&#8221;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An FDA approved fixed-dose
    combination drug treatment intended for the treatment of osteoarthritis pain and for hypertension, previously developed and commercialized
    by the Company. During 2021, the Company determined to discontinue operations related to Consensi.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;CROs&#8221;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract research organizations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;FDA&#8221;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States Food and
    Drug Administration.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;Formulation&#8221;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All the active and inactive
    materials contained in a final medical product.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;IND&#8221;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investigational New
    Drug (Application) &#8211; </b>an application to test an experimental drug in human beings and that requires clearance by the FDA
    for clinical trials to be initiated.</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;NDA&#8221;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New Drug Application
    - </b>an application submitted to the FDA to approve marketing a new pharmaceutical drug in the United States.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;PDX&#8221;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient-derived xenograft
    - an animal model in which patient-derived tumor tissue at low passage are implanted in animals, used to conserve original tumor
    characteristics and to provide relevant predictive insights into clinical outcomes when evaluating new cancer therapies.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;Pharmacokinetics&#8221;</b>, <b>&#8220;PK&#8221;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The study of the absorption,
    distribution, metabolism and excretion of a drug from the body; the pharmacokinetic indices provide, among other things, information
    on the extent and time of the patient&#8217;s exposure to the material. It is the study of how the body affects the drug.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;preclinical&#8221;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug development studies
    performed outside of a human living organism or cell, using living cells, or appropriate animal models. The studies begin before
    trials in humans and assess safety, toxicity, and efficacy. Since drug development is dynamic, preclinical studies are performed
    throughout the drug development lifecycle.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;therapeutic candidate&#8221;</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A product that is undergoing
    development, preclinical trials, clinical trials and/or has a pending NDA/BLA in review by the FDA or similar marketing application
    being reviewed by a foreign regulatory authority, but has not been approved for commercialization.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Trademarks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have proprietary rights
to trademarks used in this Annual Report on Form 20-F that are important to our business, some of which are registered under applicable
intellectual property laws. Solely for convenience, trademarks and trade names referred to in this Annual Report may appear without the
&#8220;&#174;&#8221; or &#8220;&#8482;&#8221; symbols, but such references are not intended to indicate, in any way, that we will not
assert, to the fullest extent possible under applicable law, our rights or the rights of the applicable licensor to these trademarks
and trade names. We do not intend our use or display of other companies&#8217; trademarks, trade names or service marks to imply a relationship
with, or endorsement or sponsorship of us by, any other companies. Each trademark, trade name or service mark of any other company appearing
in this Annual Report on Form 20-F is the property of its respective holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>FORWARD-LOOKING STATEMENTS</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of the statements under
the sections entitled &#8220;Item 3. Key Information &#8212; D. Risk Factors,&#8221; &#8220;Item 4. Information on the Company,&#8221;
&#8220;Item 5. Operating and Financial Review and Prospects&#8221; and elsewhere in this Annual Report on Form 20-F may include forward
looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements. In some cases, you can identify forward-looking statements by terms including &#8220;anticipates&#8221;,
&#8220;believes&#8221;, &#8220;could&#8221;, &#8220;estimates&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;may&#8221;,
&#8220;plans&#8221;, &#8220;potential&#8221;, &#8220;predicts&#8221;, &#8220;projects&#8221;, &#8220;should&#8221;, &#8220;will&#8221;,
&#8220;would&#8221;, and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our
current views with respect to future events and are based on assumptions and subject to risks and uncertainties. In addition, the section
of this Annual Report on Form 20-F entitled &#8220;Item 4. Information on the Company&#8221; contains information obtained from independent
industry and other sources. You should not put undue reliance on any forward-looking statements. Unless we are required to do so under
U.S. federal securities laws or other applicable laws, we do not intend to update or revise any forward-looking statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Factors that could cause
our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited
to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the initiation, timing,
    progress and results of our research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development
    efforts, including the safety and efficacy of our therapeutic candidates, as well as the extent and number of additional studies
    that we may be required to conduct;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to advance
    our therapeutic candidates into the next stages of clinical trials, or to successfully complete our planned and ongoing preclinical
    studies or clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our receipt of regulatory
    clarity and approvals for our therapeutic candidates and the timing of other regulatory filings and approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to acquire
    or in-license additional therapeutic candidates, integrate acquired therapeutic candidates successfully into our business and to
    realize the anticipated benefits of acquisitions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a delay or rejection of
    an IND, NDA or BLA for one or more of our therapeutic candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain
    compliance with the NASDAQ listing standards;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the regulatory environment
    and changes in the health policies and regimes in the countries in which we operate including the impact of any change in regulation
    and legislation that could affect the pharmaceutical industry, and the difficulty of predicting actions of the FDA or any other applicable
    regulator of pharmaceutical products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the research, manufacturing,
    preclinical and clinical development, commercialization, and market acceptance of our therapeutic candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully
    acquire, develop or commercialize our pharmaceutical products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish
    collaborations for our therapeutic candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the interpretation of the
    properties and characteristics of our therapeutic candidates and of the results obtained with our therapeutic candidates in preclinical
    studies or clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the implementation of our
    business model, strategic plans for our business and therapeutic candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope of protection
    we are able to establish and maintain for intellectual property rights covering our therapeutic candidates and our ability to operate
    our business without infringing the intellectual property rights of others;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">estimates of our expenses,
    revenues, capital requirements and our need for and ability to access sufficient additional financing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of competitive
    companies and technologies on our industry; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of the political,
    economic, security and public health situation in Israel, the U.S. and other countries in which we may operate or obtain approvals
    for our products or our business, including the impact of the current conditions in Israel on our business, which may exacerbate
    the magnitude of the factors discussed above.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to predict our
operating results or the effects of various events on our operating results is inherently uncertain. Therefore, we caution you to review
carefully the risks and uncertainties described under the heading &#8220;Item 3. Key Information &#8211; D. Risk Factors&#8221; in this
Annual Report on Form 20-F for a discussion of these and other risks that relate to our business and investing in Purple Biotech&#8217;s
ADSs and ordinary shares. Such factors and many other factors beyond our control could cause our actual results, performance or achievements
to be materially different from any future results, performance or achievements that may be expressed or implied by the forward-looking
statements. The forward-looking statements contained in this Annual Report on Form 20-F are expressly qualified in their entirety by
this cautionary statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>SUMMARY OF RISK FACTORS</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of some of the principal risks we face. The list below is not exhaustive, and investors should read the &#8220;Risk Factors&#8221; section
included in Item 3 in full.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a clinical stage
    biotechnology company with a history of operating losses. We expect to incur significant additional losses in the future and may
    never be profitable;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our limited operating history
    as a biotechnology research and development company makes it difficult to evaluate our business and prospects, and we depend on the
    success of a limited portfolio of therapeutic candidates for our future revenue, which could impair our ability to achieve profitability;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need to raise additional
    capital to achieve our strategic objectives of developing and commercializing our therapeutic candidates, and to develop, acquire
    and/or in-license additional therapeutic candidates, and our failure to raise sufficient capital would significantly impair our ability
    to fund our future operations, develop our current or future therapeutic candidates, seek regulatory approval that is a prerequisite
    to selling any product, attract development or commercial partners, and retain key personnel;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our long-term capital requirements
    are uncertain and subject to numerous risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our clinical trials may
    fail to demonstrate adequately the safety and efficacy of our therapeutic candidates, which would prevent or delay regulatory approval
    and commercialization;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">Regulations are constantly changing, and in the future our business
may be subject to additional regulations that could increase our compliance costs or delay our ability to market our product candidates,
if at all;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our therapeutic candidates
    may cause undesirable side effects or have other properties that could halt clinical development, prevent regulatory approval, limit
    commercial potential, or result in significant negative consequences;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we and/or our potential
    commercialization partners are unable to obtain FDA and/or other foreign regulatory authority approval for our therapeutic candidates,
    we and/or our potential commercialization partners, will be unable to commercialize our therapeutic candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical studies, CMC,
    and clinical trials may involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials
    may not be predictive of future results. We and/or our potential commercialization partners will not be able to commercialize our
    therapeutic candidates without developing CMC satisfactorily to regulatory authorities, completing preclinical and clinical studies,
    and then seeking to obtain regulatory approval, if such trials show that our therapeutic candidates are safe and effective;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we do not establish
    collaborations for our oncology therapeutic candidates or any other therapeutic candidates that we may develop or acquire in the
    future and/or commercialize such therapeutic candidates, or otherwise raise substantial additional capital, we will likely need to
    alter our development and any commercialization plans;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any collaborative arrangements
    that we establish may not be successful or we may otherwise not realize the anticipated benefits from these collaborations. We do
    not control third parties with whom we have or may have collaborative arrangements, and we rely on them to achieve results which
    may be significant to us. In addition, any future collaboration arrangements may place the development, manufacturing and commercialization
    of our oncology therapeutic candidates or any other therapeutic candidates that we may develop or acquire in the future, outside
    our control, and may require us to relinquish important rights or may otherwise be on terms unfavorable to us;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current business model
    is based largely upon the development or acquisition and commercialization of new combination products and new therapeutic candidates
    that may have not yet been administered to humans or have limited history of treatment with humans. Unexpected difficulties or delays
    in successfully developing, acquiring or commercializing such combination and new drugs could have an adverse effect on our business,
    financial condition and results of operations;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely mainly on third
    parties to conduct our CMC, research and development, preclinical studies and clinical trials, and those third parties may not perform
    satisfactorily, including, but not limited to, failing to conform with quality standards for our therapeutic candidates, which may
    endanger our clinical trial participants and/or fail to meet established deadlines for the completion of such studies and trials;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If third parties do not
    manufacture our current therapeutic candidates or any other therapeutic candidate that we may develop or acquire in the future in
    sufficient quantities in the required timeframe, at the required quality standards and at an acceptable cost, preclinical, clinical
    development and commercialization of our therapeutic candidates could be delayed;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 0.5pt; text-align: justify; text-indent: -0.5pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 0.5pt; text-align: justify; text-indent: -0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely on third-party contract vendors to manufacture and supply us with API that is compliant with the International Conference of
    Harmonization Q7 guidance and other applicable laws and regulations, in the quality and quantities we require on a timely basis;
    </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 0.5pt; text-align: justify; text-indent: -0.5pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 0.5pt; text-align: justify; text-indent: -0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    anticipate continued reliance on third-party manufacturers if we are successful in obtaining marketing approval from the FDA and/or
    other regulatory agencies for NT219, CM24, our CAPTN-3 tribody platform&#8217;s leading therapeutic candidate IM1240 or any other
    therapeutic candidates we may develop or acquire in the future;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 0.5pt; text-align: justify; text-indent: -0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    and our third-party manufacturers are, and will be, subject to regulations of the FDA and other foreign regulatory authorities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 0.5pt; text-align: justify; text-indent: -0.5pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 0.5pt; text-align: justify; text-indent: -0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    oncology therapeutic candidates and/or any other therapeutic candidate that we may develop or acquire in the future, if approved,
    will be subject to ongoing regulatory review. If we fail to comply with continuing U.S. and applicable foreign laws, regulations
    and guidelines, we could lose the FDA and/or other regulatory agencies&#8217; approval(s) we will obtain (if any), and our business
    would be seriously harmed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may depend on a partner to conduct clinical trials with CM24, NT219 and/or other therapeutic candidates, and we may enter into future
    collaboration agreements with collaboration partners to develop and conduct clinical trials with, obtain regulatory approvals for,
    and to market and sell our therapeutic candidates. If such collaboration fails to perform as expected, our clinical trials and/or
    development plans will be delayed, and we will be required to seek other partners, which we may not be able to engage in a timely
    manner, if at all, and which may delay our development plans and therefore the potential for us to generate future revenue from our
    therapeutic candidates would be significantly reduced and our business would be significantly harmed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="padding-left: 0.5pt; text-align: justify">The manufacture of our therapeutic candidates is complex, and we may
encounter difficulties in production, particularly with respect to process development or scaling-up of our manufacturing capabilities.
If we, or any of our third-party manufacturers, encounter such difficulties, our ability to supply drugs for clinical trials or our products
(if approved) for patients on a timely basis could be materially delayed or adversely affected. In addition, this may cause an increase
in costs that could result in our inability to maintain a commercially viable cost structure;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 0.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
    each of CM24, NT219 and CAPTN-3, our tribody platform with its leading therapeutic candidate, IM1240, represents a novel approach
    to the treatment of disease, there are many uncertainties regarding the development, the market acceptance, third-party reimbursement
    coverage and the commercial potential of these therapeutic candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 0.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with any obligations under our in-license agreements with Yissum Research and Development Company (&#8220;Yissum&#8221;)
    and/or Tel Hashomer &#8211; Medical Research Infrastructure and Services Ltd. (&#8220;THM&#8221;) or any future license agreement,
    or disputes arise with respect to those agreements, it could have a negative impact on our intellectual property rights and we could
    lose our rights to NT219 and/or CM24 or any further therapeutic candidates, which could have a material adverse effect on our business,
    financial condition and results of operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 0.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    shareholders may not realize a benefit from our acquisitions of therapeutic candidates commensurate with the ownership dilution they
    experienced in connection with the transactions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 0.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="padding-left: 0.5pt; text-align: justify">The markets for our oncology therapeutic candidates are rapidly changing
and competitive, and new drug delivery mechanisms, drug delivery technologies, new drugs and new treatments which may be developed by
others could impair our ability to maintain and grow our business and remain competitive.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 0.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business and operations may be materially adversely affected in the event of computer system failures or security or breaches due
    to cyber-attacks or cyber intrusions, including ransomware, phishing attacks and other malicious intrusions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 0.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
    claims of intellectual property infringement and other legal challenges may require us to spend substantial time and money and could
    prevent us from, or delay us in, developing or commercializing our therapeutic candidates. An adverse result in any infringement
    claims or other legal challenges could have a material adverse effect on our business, results of operations and on our financial
    condition;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 0.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be unable to adequately protect or enforce our rights to intellectual
property, causing us to lose valuable rights. Loss of any of our intellectual property rights may lead us to lose market share and could
have an adverse effect on our business, results of operations and financial condition;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 0.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    conduct our operations in Israel, and therefore, political, economic and military instability in Israel and its region may adversely
    affect our business, results of operations, and financial condition; and&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 0.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="padding-left: 0.5pt; text-align: justify">We may not meet the continued listing requirements of NASDAQ, which
could result in a delisting of the ADSs from NASDAQ;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT
AND ADVISERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors and Senior
    Management</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Advisors</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Auditors</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. KEY INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Reserved]</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B</b>.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capitalization and Indebtedness</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C</b>.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reasons for the Offer
    and Use of Proceeds</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk Factors</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>You should carefully consider
the risks we describe below, in addition to the other information set forth elsewhere in this Annual Report on Form 20-F, including our
consolidated financial statements and the related notes beginning on page F-1, which could materially adversely affect our business,
financial condition and future results. If any of the following risks actually occur, our business, financial condition and results of
operations could be materially and adversely affected. In that event, the trading price of Purple Biotech&#8217;s ordinary shares and
American Depositary Shares could decline.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Financial Condition and
Capital Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We are a clinical stage
biotechnology company with a history of operating losses. We expect to incur significant additional losses in the future and may never
be profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical stage biotechnology
company, and we are focused on the development and commercialization of innovative pharmaceutical drugs. We currently have two oncology
therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are
not being sold, marketed or commercialized, and a preclinical tribody platform, CAPTN-3, with its leading therapeutic candidate, IM1240.
Each of our therapeutic candidates will require additional preclinical and/or clinical trials or other testing before we can obtain regulatory
approval, if we are able to obtain regulatory approval at all. We must obtain regulatory approval for these therapeutic candidates, or
any other therapeutic candidate that we may develop or acquire in the future before we can sell such therapeutic candidates. We have
incurred losses from commencement of our pharmaceutical research and development activities through December 31, 2024, of approximately
$144.7 million as a result of revenue and cost of goods, research and development activities, clinical trial related activities, investment/acquisition
activities, listing for trading and fund-raising related activities, selling, general and administrative, finance expenses and other
expenses. We may incur significant additional losses as we continue to focus our resources on advancing CM24, NT219, CAPTN-3, with its
leading therapeutic candidate, IM1240, or other therapeutic candidates that we may develop, in-license, or acquire in the future. Our
ability to generate revenue and achieve profitability depends mainly upon our ability, alone or with others, to successfully develop,
in-license, or acquire, and obtain the required regulatory approvals for our oncology therapeutic candidates in the United States and
various other territories and then to successfully commercialize our oncology therapeutic candidates. We may be unable to achieve any
or all these goals with regard to CM24, NT219, CAPTN-3 with its leading therapeutic candidate, IM1240, or any other therapeutic candidates
that we may develop, in-license, or acquire in the future. As a result, we may never be profitable or achieve significant or sustained
revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 9; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our limited operating
history as a biotechnology research and development company makes it difficult to evaluate our business and prospects, and we depend
on the success of a limited portfolio of therapeutic candidates for our future revenue, which could impair our ability to achieve profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a limited operating
history as a biotechnology research and development company, and our operations to date have been limited primarily to developing our
therapeutic candidates, CM24 and NT219, and CAPTN-3, our tribody platform with its leading therapeutic candidate, IM1240; research and
development; raising capital; and recruiting scientific, CMC, regulatory and management personnel and third-party partners. To date,
the only revenue we have received has been the initial milestone payments in connection with commercialization agreements for Consensi,
which were terminated in 2021. We may not be able to commercialize or obtain regulatory approval for our therapeutic candidates, CM24
and NT219, CAPTN-3, our tribody platform with its leading therapeutic candidate, IM1240, or any additional therapeutic candidate we may
develop, in-license and/or acquire in the future. Our future growth and success depend upon our ability to continue funding the development
of our therapeutic candidates and on the successful commercialization of such therapeutic candidates. If we are unable to obtain regulatory
clearances or approvals for our therapeutic candidates and future products, our ability to gain any revenues and to achieve profitability
would be adversely affected. Consequently, any predictions about our future performance may not be accurate, and you may not be able
to fully assess our ability to complete development of or commercialize our therapeutic candidates, acquire or in-license other therapeutic
candidates, obtain regulatory approvals, or achieve market acceptance or favorable pricing for our therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We will need to raise
additional capital to achieve our strategic objectives of developing and commercializing our therapeutic candidates, and to develop,
acquire and/or in-license additional therapeutic candidates, and our failure to raise sufficient capital would significantly impair our
ability to fund our future operations, develop our current or future therapeutic candidates, seek regulatory approval that is a prerequisite
to selling any product, attract development or commercial partners and retain key personnel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will need to continue
to expend substantial funds in research and development, including CMC, preclinical and clinical trials of our therapeutic candidates
CM24 and NT219, and CAPTN-3, with its leading therapeutic candidate, IM1240, as well as to acquire or in-license additional therapeutic
candidates. We plan to fund our future operations through the out-licensing and/or commercialization of our therapeutic candidates and
by raising additional capital through grants or debt or equity financing. However, we cannot be certain that we will be able to raise
capital on commercially reasonable terms or at all, or that our actual cash requirements will not be greater than anticipated. We may
have difficulty raising the needed capital or securing a development or commercialization partner in the future as a result of, among
other factors, our lack of revenues from commercialization of our therapeutic candidates, as well as the inherent business risks associated
with our company and present and future market conditions. In addition, global and local economic and geopolitical conditions may make
it more difficult for us to raise needed capital or secure a development or commercialization partner in the future and may impact our
liquidity. If we are unable to obtain future financing, we may be forced to delay, reduce the scope of, or eliminate one or more of our
research, development or commercialization programs related to our therapeutic candidates or any other therapeutic candidates that we
may acquire, in-license or develop in the future, or to delay the acquisition or in-license of any additional therapeutic candidates,
any of which may have a material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">To
the extent that we raise additional capital through the sale of equity, including under our open market sale agreement (the &#8220;Sales
Agreement&#8221;) that we entered into with Jefferies LLC (&#8220;Jefferies&#8221;) in June 2021, for the offer and sale, from time to
time, of ADSs through an &#8220;at-the-market&#8221; equity offering program (&#8220;ATM program&#8221;), with Jefferies acting as our
agent, or under our Form F-3 shelf registration statement filed with the SEC in December 2022, your ownership interest will be diluted,
and the terms of any securities so sold may include liquidation or other preferences that adversely affect your rights as a shareholder.
Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting
or restricting our ability to take specific actions such as incurring debt, making capital expenditures or declaring dividends. If we
raise additional funds through grants, collaboration, strategic alliance and licensing arrangements with third parties, we may have to
relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms that are not
favorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our long-term capital
requirements are uncertain and subject to numerous risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate that so long
as no significant revenues are generated from our oncology therapeutic candidates, we will need to raise substantial additional funds
to develop and/or commercialize our therapeutic candidates and to develop, acquire or in-license any additional therapeutic candidates,
as our current cash and short-term investments are not sufficient to complete the research and development of our therapeutic candidates
in their current phase of development and any additional therapeutic candidates that we may acquire, in-license or develop in the future,
and to fund our related expenses. Our long-term capital requirements are expected to depend on many potential factors, including, among
others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully
    out-license and/or commercialize our oncology therapeutic candidates, or any other therapeutic candidates that we may acquire, in-license,
    or develop in the future, including securing commercialization agreements with third parties and favorable pricing and market share;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress, success,
    and cost of our preclinical and/or clinical trials and research and development programs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully
    complete the required CMC development for our oncology therapeutic candidates or any other therapeutic candidates that we may acquire,
    in-license, or develop in the future;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs, timing and outcome
    of regulatory review and obtaining and maintaining regulatory approval of our oncology therapeutic candidates or any other therapeutic
    candidates that we may acquire, in-license, or develop in the future, and addressing regulatory and other issues that may arise post-approval
    for such oncology therapeutic candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of obtaining
    new patents and enforcing our issued patents and defending intellectual property-related claims;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of developing
    and maintaining our third parties&#8217; cGMP manufacturing standards;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our consumption of available
    resources more rapidly than currently anticipated, resulting in the need for additional funding sooner than anticipated;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain recommendations
    and publish studies regarding the efficacy and/or safety of our oncology therapeutic candidates or any other therapeutic candidates
    that we may acquire or develop in the future that may be published by government agencies, professional organizations, academic or
    medical journals or other key opinion leaders; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sufficient coverage and
    reimbursement by third-party payers for our therapeutic candidates; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of seeking out
    and acquiring or engaging in-licensing or similar transactions for other oncological candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to obtain
approval, commercialize or out-license our oncology therapeutic candidates, or any other therapeutic candidates that we may acquire,
in-license or develop in the future, maintain approval, or obtain future financing, we may be forced to delay, reduce the scope of, or
eliminate one or more of our research and development programs related to the therapeutic candidates, which may have a material adverse
effect on our business, financial condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Business, Operations and
Regulatory Matters </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our clinical trials
may fail to demonstrate adequately the safety and efficacy of our therapeutic candidates, which would prevent or delay regulatory approval
and commercialization.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The clinical trials of our
therapeutic candidates are, and the manufacturing and marketing of our products will be, subject to extensive and rigorous review and
regulation by numerous government authorities in the United States and in other countries where we intend to test and market our therapeutic
candidates. Before obtaining regulatory approvals for the commercial sale of any of our therapeutic candidates, we must demonstrate through
lengthy, complex and expensive preclinical testing and clinical trials that our therapeutic candidates are both safe and effective for
use in each target indication. In particular, because some of our therapeutic candidates are subject to regulation as biological drug
products, we will need to demonstrate that they are safe, pure and potent for use in their target indications. Each product candidate
must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. The risk/benefit
profile required for drug product approval will vary depending on these factors and may include not only the ability to show tumor shrinkage,
but also adequate duration of response, a delay in the progression of the disease, and/or an improvement in survival. For example, response
rates from the use of our therapeutic candidates may not be sufficient to obtain regulatory approval unless we can also show an adequate
overall survival of patients. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain.
Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our
therapeutic candidates may not be predictive of the results of later-stage clinical trials. The results of studies in one set of patients
or line of treatment may not be predictive of those obtained in another. We expect that there may be greater variability in results for
products processed and administered on a patient-by-patient basis, as anticipated for our therapeutic candidates, than for &#8220;off-the-shelf&#8221;
products, like many other drugs. There is typically an extremely high rate of attrition from the failure of therapeutic candidates proceeding
through clinical trials. Therapeutic candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile
despite having progressed through preclinical studies and initial clinical trials. Many companies in the pharmaceutical industry have
suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising
results in earlier trials. Most therapeutic candidates that begin clinical trials are never approved by regulatory authorities for commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, even if such
trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we
do, and more trials could be required before we submit our therapeutic candidates for approval. To the extent that the results of the
trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to
expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our
therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Regulations are constantly
changing, and in the future our business may be subject to additional regulations that could increase our compliance costs or delay our
ability to market our product candidates, if at all. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe we understand
the current laws and regulations to which our products are and will be subject. However, federal, state and foreign laws and regulations
relating to approval and marketing of our product candidates are subject to future changes, as are administrative interpretations of
laws and regulations. If we fail to comply with such future changes in federal, state, and foreign laws and regulations, we may fail
to obtain approval to market our product candidates, or we may be subject to enforcement actions. In addition, if such federal, state,
and foreign laws and regulations change, we may incur additional costs in seeking regulatory approval. If we are slow or unable to adapt
to changes in such laws and regulations, or in the promulgation of new laws or regulations, we may be unable to obtain regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">Recently, President Trump&#8217;s
administration issued a memorandum instructing U.S. executive agencies to prepare for reductions in workforce at governmental agencies,
which likely includes the FDA. If the new administration takes action that substantially reduces FDA&#8217;s workforce, in particular,
at the Center for Drug Evaluation and Research, we may face significant delay in obtaining approval and subsequently marketing our product
candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our therapeutic candidates
may cause undesirable side effects or have other properties that could halt clinical development, prevent regulatory approval, limit
commercial potential, or result in significant negative consequences.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable side effects
or adverse events caused by our therapeutic candidates, or related to the combination therapies, could cause us or regulatory authorities
to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval
by the FDA or other comparable foreign regulatory authorities. Results of our trials could reveal a high and unacceptable severity and
prevalence of side effects or unexpected characteristics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If unacceptable toxicities
arise in the development of our therapeutic candidates, the FDA or comparable foreign regulatory authorities could order us to cease
clinical trials or deny approval of our therapeutic candidates for any or all targeted indications. Treatment-related side effects could
also affect patient recruitment, or the ability of enrolled subjects to complete the trial or result in potential product liability claims.
In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. Any of these occurrences
may harm our business, financial condition and prospects significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we and/or our potential
commercialization partners are unable to obtain FDA and/or other foreign regulatory authority approval for our therapeutic candidates,
we and/or our potential commercialization partners will be unable to commercialize our therapeutic candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not marketed,
distributed or sold any oncology drug product. Our oncology therapeutic candidates are each subject to extensive governmental laws, regulations
and guidelines relating to development, preclinical and clinical trials, manufacturing, and commercialization of drugs. We may not be
able to obtain regulatory approval for any of our therapeutic candidates in a timely manner or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any material delay in obtaining,
or the failure to obtain, required regulatory approvals will increase our costs and materially and adversely affect our ability to generate
future revenues. Any regulatory approval to market a therapeutic candidate may be subject to restrictive conditions of use, including
cautionary information, thereby limiting the size of the market for the therapeutic candidate. We also are, and will be, subject to numerous
regulatory requirements from both the FDA and foreign state agencies that govern the conduct of preclinical and clinical trials, manufacturing
and marketing authorization, pricing, and third-party reimbursement. Moreover, approval by one regulatory authority does not ensure approval
by other regulatory authorities in separate jurisdictions. Each jurisdiction may have different approval processes and may impose additional
testing requirements for our therapeutic candidates than other jurisdictions. Additionally, the FDA or other foreign regulatory bodies
may change their approval policies or adopt new laws, regulations or guidelines in a manner that delays or impairs our ability to obtain
the necessary regulatory approvals to commercialize our therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Preclinical studies,
CMC, and clinical trials may involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials
may not be predictive of future results. We and/or our potential commercialization partners will not be able to commercialize our therapeutic
candidates without developing CMC satisfactorily to regulatory authorities, completing preclinical and clinical studies, and then seeking
to obtain regulatory approval, if such trials show that our therapeutic candidates are safe and effective.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited experience
in conducting and managing CMC, preclinical studies and clinical trials that are required to obtain regulatory approval and commence
commercial sales of our therapeutic candidates. Developing and implementing CMC and planning and conducting preclinical studies and clinical
trials are expensive, complex, can take many years to complete and have uncertain outcomes. We cannot predict whether we, independently
or through third parties, will encounter problems with any of the completed, ongoing or planned CMC, preclinical studies and/or clinical
trials that will cause delays, including suspension of preclinical studies and/or clinical trials, delays in recruiting patients into
the clinical trials, or delay of data analysis or release of the final report in our preclinical studies or clinical studies. Implementation
of CMC and the preclinical studies and clinical trials of our therapeutic candidates may take significantly longer to complete than is
estimated. Failure can occur at any stage of the testing, and we may experience numerous unforeseen events during, or as a result of,
CMC, the preclinical studies and/or clinical trial process that could delay or prevent commercialization of our current or future therapeutic
candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with CMC and
the preclinical studies and clinical trials for our therapeutic candidates and other therapeutic candidates that we may seek to develop
in the future, either on our own or through licensing or partnering agreements, we face various risks, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in conducting preclinical
    studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in manufacturing
    the drug substance and drug product for preclinical studies and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in manufacturing
    the drug substance and drug product following NDA or BLA approval, if we receive such approval at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in securing clinical
    investigators or trial sites for clinical trials that must be completed for us to obtain any approval that we seek;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in receiving import
    or other government approvals to ensure appropriate drug supply, and shortages of combination drugs used in our clinical studies;
    </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining institutional
    review board (human ethics committee) and other regulatory approvals to commence a clinical trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative or inconclusive
    results from preclinical and/or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or other foreign
    regulatory authorities may disagree with the number, design, size, conduct or implementation of our clinical studies and may not
    approve initiation of certain clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the clinical trials may
    be delayed or not completed due to the failure to recruit suitable candidates or if there is a lower rate of suitable candidates
    than anticipated or if there is a delay in recruiting suitable candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an inability to monitor
    patients adequately during or after treatment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">problems with investigator
    or patient compliance with the trial protocols;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a therapeutic candidate
    may not prove safe or efficacious;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there may be unexpected
    or even serious adverse events and side effects from the use of a therapeutic candidate;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results with respect
    to any therapeutic candidate may not confirm the positive results from earlier preclinical studies or clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results may not meet
    the level of statistical significance required by the FDA or other foreign regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results will leave
    only limited and/or restrictive uses, including the inclusion of warnings and contraindications, which could significantly limit
    the marketability and profitability of the therapeutic candidate;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our therapeutic candidates
    may not be reimbursed under different healthcare programs such as Medicare, Medicaid or private health insurance programs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes to the current
    regulatory requirements related to clinical trials which can delay, hinder or lead to unexpected costs in connection with our receiving
    the applicable regulatory approvals; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of other
    drugs that provide alternative and/or superior treatments to our drugs and therapeutic candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A number of companies in
the pharmaceutical and biotechnology industries, including those with greater resources and experience than us, have suffered significant
setbacks in advanced clinical trials, even after seeing promising results in earlier preclinical studies and/or clinical trials. As such,
we do not know whether any clinical trials we may conduct will demonstrate adequate efficacy and safety sufficient to obtain regulatory
approval to market our therapeutic candidates. If any of the preclinical studies and/or clinical trials of any therapeutic candidate
do not produce favorable results sufficient to establish our therapeutic candidate as safe and effective in accordance with FDA regulations,
our ability to obtain regulatory approval for the therapeutic candidate may be adversely impacted, which will have a material adverse
effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we do not establish
collaborations for our oncology therapeutic candidates or any other therapeutic candidates that we may develop or acquire in the future,
and/or commercialize such therapeutic candidates, or otherwise raise substantial additional capital, we will likely need to alter our
development and any commercialization plans.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug development programs,
mainly the potential commercialization of our oncology therapeutic candidates, or any other therapeutic candidates that we may develop
or acquire in the future, will require additional cash to fund expenses. As such, our strategy includes selectively partnering or collaborating
with multiple pharmaceutical and biotechnology companies (including by way of out-licensing) to assist us in furthering development and
potential commercialization of our therapeutic candidates, in some or all jurisdictions. We may not be successful in such collaborations
with such third parties on acceptable terms, or at all. In addition, if we fail to negotiate and maintain suitable development or commercialization
agreements (such as out-licensing agreements), we may have to limit the size or scope of our activities or we may have to delay one or
more of our development or commercialization programs. Any failure to enter into or maintain development or commercialization agreements
with respect to the development, marketing and commercialization of our therapeutic candidates, or any other therapeutic candidates that
we may develop or acquire in the future, or failure to develop or acquire, market and commercialize such therapeutic candidates, will
have an adverse effect on our business, financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Any collaborative arrangements
that we establish may not be successful or we may otherwise not realize the anticipated benefits from these collaborations. We do not
control third parties with whom we have or may have collaborative arrangements, and we rely on them to achieve results which may be significant
to us. In addition, any future collaboration arrangements may place the development, manufacturing and commercialization of our oncology
therapeutic candidates or any other therapeutic candidates that we may develop or acquire in the future, outside our control, and may
require us to relinquish important rights or may otherwise be on terms unfavorable to us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our collaborative arrangements
require us to rely on external consultants, advisors, experts and service providers for assistance in several key functions, including
preclinical and clinical development, manufacturing, regulatory, market research, and intellectual property. We do not control these
third parties, but we rely on them to achieve results, which may be significant to us. Our collaborative arrangements may not be successful,
or we may otherwise not realize the anticipated benefits from these collaborations. Additionally, we are responsible for any quality
or regulatory issue that a collaborator may have that affects one or more of our therapeutic candidates. Relying upon collaborative arrangements
to develop and/or commercialize our oncology therapeutic candidates or any other therapeutic candidates that we may develop or acquire
in the future subjects us to a number of risks, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to control
    the amount and timing of resources that our collaborators may devote to our drug product or therapeutic candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be held liable should
    a collaborator fail to comply with applicable laws, rules, or regulations when performing services for us;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our collaborators may experience
    financial difficulties or changes in business focus;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our collaborators may experience
    quality or regulatory issues that negatively affect our therapeutic candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our collaborators may fail
    to secure adequate commercial supplies in a timely manner for our drug products upon marketing approval, if at all;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may suffer losses due
    to our collaborators&#8217; failure to perform their duties and we may not be able to be reimbursed by our collaborators for such
    losses;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our collaborators may have
    a shortage of qualified personnel;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to relinquish
    important rights, such as local trademark, marketing and distribution rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business combinations or
    significant changes in a collaborator&#8217;s business strategy may adversely affect a collaborator&#8217;s willingness or ability
    to complete its obligations under any arrangement;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under certain circumstances,
    a collaborator could move forward with a competing therapeutic candidate developed either independently or in collaboration with
    others, including our competitors; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborative arrangements
    are often terminated or allowed to expire, which could delay and increase the cost of development of our therapeutic candidates,
    or our collaborators may not deliver assignments on schedule, which could delay the development of our therapeutic candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of these or other
scenarios materialize, they could have an adverse effect on our business, financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our current business
model is based largely upon the development or acquisition and commercialization of new combination products and new therapeutic candidates
that may have not yet been administered to humans or have limited history of treatment with humans. Unexpected difficulties or delays
in successfully developing, acquiring or commercializing such combination and new drugs could have an adverse effect on our business,
financial condition and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have two oncology
therapeutic candidates that are in the clinical trial phase, CM24 and NT219. Despite the performance of numerous clinical studies with
these therapeutic candidates, patients as a monotherapy and in combination with other drugs, we cannot be certain whether any of our
therapeutic candidates will be safe and efficacious when used in either monotherapy settings or in combination with the current or other
known cancer treatments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Developing combination products
with existing drugs or therapies currently on the market brings additional risks to seeking regulatory approval. Even if an existing
drug or therapy is currently approved as safe and effective by the FDA, such drug or therapy may be removed from the market or otherwise
become unavailable for continued use, which could hinder our ability to complete our clinical trials and/or obtain regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we cannot be
certain that the FDA or any foreign regulatory body will consider our oncology therapeutic candidates, whether alone or combined with
other cancer treatments, or any other therapeutic candidate that we may develop or acquire in the future to be sufficiently safe and
effective to support acceptance of a marketing application. Any delays in perfecting the combination, the production of the combination,
or in market acceptance of the combination or new therapeutic candidates could have an adverse effect on our business, financial condition
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, as part of our strategy
for growth, we may consider the acquisition of additional therapeutic candidates at various stages of development and in a variety of
therapeutic areas, and we may consider the acquisition or marketing rights of approved drug products as well. However, we may not be
able to identify suitable acquisition candidates, complete acquisitions or integrate acquisitions successfully into our business. In
this regard, acquisitions involve numerous risks, including difficulties in the integration of the acquired therapeutic candidates and/or
drug product and the diversion of management&#8217;s attention from other business concerns. Although we will endeavor to evaluate the
risks inherent in any particular transaction, there can be no assurance that we will properly ascertain all such risks. In addition,
acquisitions could result in the incurrence of substantial additional indebtedness and other expenses or in potentially dilutive issuances
of equity securities. There can be no assurance that difficulties encountered with acquisitions will not have a material adverse effect
on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We rely mainly on third
parties to conduct our CMC, research and development, preclinical studies and clinical trials, and those third parties may not perform
satisfactorily, including, but not limited to, failing to conform quality standards for our therapeutic candidates, which may endanger
our clinical trial participants, and/or fail to meet established deadlines for the completion of such studies and trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have the ability
independently to conduct CMC, research and development, preclinical studies or clinical trials for our product candidates, and to a large
degree we rely on third parties, such as contract manufacturing organizations, CROs, medical institutions, contract laboratories, current
and potential development or commercialization partners, clinical investigators and independent study monitors, to perform these functions.
Our reliance on these third parties for development activities reduces our control over these activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, these third
parties may also have relationships with other entities, some of which may be our competitors. Although we have, in the ordinary course
of business, entered into agreements with these third parties, we continue to be responsible for confirming that each of our preclinical
studies and clinical trials is conducted in accordance with its general investigational plan and protocol. Moreover, the FDA and other
regulatory agencies require us and our applicable third-party collaborators to comply with regulations and standards, commonly referred
to as current good laboratory practices (cGLP), current good manufacturing practices (cGMP), and current good clinical practices (cGCP),
for manufacturing and conducting, recording and reporting the results of preclinical and clinical trials to assure that data and reported
results are credible and accurate and that the clinical trial participants are adequately protected. We cannot guarantee that our third-party
collaborators will remain compliant with the applicable regulations. If our third-party collaborators are unable to comply with FDA regulations
and standards, including, but not limited to, cGLPs, cGMPs and cGCPs, we may be forced to suspend or delay our clinical trials, which
could significantly delay our ability to achieve marketing approval. Regulatory authorities in other jurisdictions may have similar responsibilities
and requirements. Our reliance on third parties does not relieve us of these responsibilities and requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we believe our contract
manufacturing organizations, CROs and other third-party entities that support our manufacturing, research and development, preclinical
or clinical practices with which we are working have generally performed well. However, if these third parties do not successfully carry
out their contractual duties or meet expected deadlines, we may not meet our deadlines or we may be required to replace them. Although
we believe that there are a number of other third-party contractors we could engage to continue these activities, finding replacements
may result in a delay of clinical trials and/or commercialization of products and additional costs. Accordingly, we may be delayed in
obtaining regulatory approvals for our oncology therapeutic candidate or any therapeutic candidate that we may develop or acquire in
the future, and we may be delayed in our efforts to successfully commercialize such therapeutic candidates for targeted diseases or fail
to maintain marketing authorization to our drug products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we rely substantially
on third-party data managers for CMC and the preclinical study and clinical trial data that we present to regulatory authorities in order
to obtain marketing authorizations. Although we attempt to audit and control the quality of third-party data, we cannot guarantee the
authenticity or accuracy of such data, nor can we be certain that such data has not been fraudulently generated. There is no assurance
that these third parties will pass FDA or regulatory audits, which could delay or prevent regulatory approval or cause revocation of
already approved marketing authorization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If third parties do
not manufacture our current therapeutic candidates or any other therapeutic candidate that we may develop or acquire in the future in
sufficient quantities in the required timeframe, at the required quality standards and at an acceptable cost, preclinical, clinical development
and commercialization of our therapeutic candidates could be delayed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently own or
operate manufacturing facilities, and we rely, and expect to continue to rely, on third parties to manufacture preclinical, clinical
and commercial quantities of our oncology therapeutic candidates or any other therapeutic candidate that we may develop or acquire in
the future. Our reliance on third parties includes our reliance on them to develop manufacturing processes and manufacture such therapeutic
candidates at a required standard of quality, including quality assurance related to regulatory compliance. Our current and anticipated
future reliance upon others for the development and manufacture of our oncology therapeutic candidates or any other therapeutic candidate
that we may develop or acquire in the future may adversely affect our future profit margins, if any, and our ability to develop such
therapeutic candidates and commercialize any such therapeutic candidates at a required standard of quality and on a timely and competitive
basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to maintain
our existing or future third-party manufacturing arrangements on acceptable terms, if at all. If for some reason our existing or future
manufacturers do not perform as agreed or expected, or our existing or future manufacturers otherwise terminate their arrangements with
us, we may be required to replace them. Although we are not entirely dependent upon our existing manufacturing agreements since we could
replace them with other third-party manufacturers, we may incur added costs and delays in identifying, engaging, qualifying and training
any such replacements, and in receiving regulatory approval for such replacements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We rely on third-party
contract vendors to manufacture and supply us with API and other materials used in the manufacture of a drug product to be compliant
with the International Conference of Harmonization Q7 guidance and other applicable laws and regulations, in the quality and quantities
we require on a timely basis.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not manufacture
any API ourselves. Instead, we rely on third-party vendors for the manufacture and supply of our APIs and other materials that are used
to manufacture and formulate our oncology therapeutic candidates. While there are many potential API manufacturers and suppliers in the
market, if these manufacturers or suppliers are incapable or unwilling to meet our current or future needs on acceptable terms or at
all, or the current or future demand of the public, if any, we could experience delays in developing or conducting clinical trials for
our current therapeutic candidates, CM24, NT219 and IM1240, or any other therapeutic candidate that we may develop or acquire in the
future, and incur additional costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While there may be several
alternative manufacturers or suppliers of API in the market, we have not conducted extensive audits and investigations into the quality
or availability of their APIs. In addition, we may acquire therapeutic candidates which already have long term commitments to a specific
API supplier. As a result, we can provide no assurances that supply sources will not be interrupted from time to time. Changing API manufacturers
or suppliers or finding and qualifying new API manufacturers or suppliers can be costly and take a significant amount of time. Many APIs
require significant lead time to manufacture. There can also be challenges in maintaining similar quality or technical standards from
one manufacturing batch to the next.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are not able to find
stable, reliable manufacturers or suppliers of our APIs and other materials used in the manufacture of our oncology therapeutic candidates,
we may not be able to produce enough supplies of our oncology therapeutic candidates to meet our needs for further development and/or
to conduct clinical trials, which could affect our business, financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We anticipate continued
reliance on third-party manufacturers if we are successful in obtaining marketing approval from the FDA and/or other regulatory agencies
for CM24, NT2194, our CAPTN-3 tribody platform&#8217;s leading therapeutic candidate, IM1240, or any other therapeutic candidates we
may develop or acquire in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our CM24, NT219
and IM1240 therapeutic candidates have been manufactured in relatively small quantities by third-party manufacturers. Once our oncology
therapeutic candidates and/or any other therapeutic candidate that we may develop or acquire in the future is approved for marketing
and commercial sale, if at all, we still expect that we will continue to rely, at least initially, on third-party manufacturers to produce
commercial quantities of such approved therapeutic candidates. These manufacturers may not be able to successfully increase the manufacturing
capacity for any such therapeutic candidates that may be approved in the future in a timely or economic manner, or at all. Significant
scale-up of manufacturing may require additional validation studies, which the FDA must review and approve. If we are unable to successfully
increase the manufacturing capacity for our oncology therapeutic candidates or any therapeutic candidate that we may develop or acquire
in the future, or we are unable to establish alternative manufacturing capabilities and in a timely manner, the commercial launch of
any such therapeutic candidates that are approved in the future may be delayed or there may be a shortage in supply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We and our third-party
manufacturers are, and will be, subject to regulations of the FDA and other foreign regulatory authorities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and our third-party contract
manufacturers are, and will be, required to adhere to laws, regulations and guidelines of the FDA and other foreign regulatory authorities
setting forth cGMPs. These laws, regulations and guidelines cover all aspects of the manufacturing, testing, quality control and recordkeeping
relating to our oncology therapeutic candidates when we initiate their clinical trials. We and our third-party contract manufacturers
may not be able to comply with applicable laws, regulations and guidelines. We and our third-party contract manufacturers are and will
be subject to unannounced inspections by the FDA, state regulators and similar foreign regulatory authorities outside the U.S. Our failure,
or the failure of our third-party contract manufacturers, to comply with applicable laws, regulations and guidelines could result in
the imposition of sanctions on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing
approval of our therapeutic candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of our
therapeutic candidates, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect regulatory
approval and supplies of our therapeutic candidates and materially and adversely affect our business, financial condition and results
of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our oncology therapeutic
candidates and/or any other therapeutic candidate that we may develop or acquire in the future, if approved, will be subject to ongoing
regulatory review. If we fail to comply with continuing U.S. and applicable foreign laws, regulations and guidelines, our clinical trials
may be placed on hold, we could lose the FDA and/or other regulatory agencies&#8217; approval(s) we will obtain (if any), and our business
would be seriously harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our oncology therapeutic
candidates and/or any other therapeutic candidate that we may develop or acquire in the future receives regulatory approval to commercialize,
such therapeutic candidate will be subject to ongoing post-marketing surveillance programs and regulatory review. We and our commercialization
partners, as applicable, are subject to ongoing reporting obligations, including pharmacovigilance, or drug safety, and our manufacturing
operations, and those of contract manufacturers that we select will be subject to continuing regulatory review, including inspections
by the FDA and other foreign regulatory authorities, if a product is approved for commercialization in such foreign jurisdictions. The
results of this ongoing review may result in the withdrawal of an approved product from the market, the interruption of manufacturing
operations or the imposition of labeling or marketing limitations. In addition, since many more patients are treated with drugs following
their marketing post-approval, unanticipated adverse reactions or serious adverse reactions that were not observed in preclinical and/or
clinical trials may be observed during the commercial marketing of a drug product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we move forward with commercializing
drug products, we may also periodically discuss with the FDA and other regulatory authorities certain clinical, regulatory and manufacturing
matters and our views may, at times, differ from those of the FDA and other regulatory authorities. If we are required to conduct additional
clinical trials or other testing of an approved drug product, we may face substantial additional expenses, and/or we have our approval
to commercialize a drug product revoked by the FDA or a foreign regulatory body, should we obtain approval to commercialize in such foreign
jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the manufacturer
and the facilities that we or our commercialization partners use or may use to manufacture drug products in the future will be subject
to periodic and unannounced review and inspection by the FDA and other foreign regulatory authorities. Later discovery of previously
unknown problems with a drug product or a therapeutic candidate, the manufacturer or manufacturing process, or failure to comply with
our post-approval requirements, rules and regulatory requirements, may result in actions such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on such drug
    product, therapeutic candidate, manufacturer or manufacturing process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance of Form 483 inspection
    observations, untitled letters, warning letters from the FDA or other foreign regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of the product
    or therapeutic candidate from the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or withdrawal
    of regulatory approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to approve pending
    applications or supplements to approved applications that we or our potential commercialization partners submit;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary or mandatory
    recall;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to permit the import
    or export of our therapeutic candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detentions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition
    of civil or criminal penalties and fines; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse publicity or changes
    to the drug&#8217;s labeling.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA or foreign regulatory
authorities&#8217; policies may change, or additional government regulations may be enacted that could prevent, limit or delay regulatory
approval of our oncology therapeutic candidates. If we, or our current or potential commercialization partners, suppliers, third-party
contractors or clinical investigators are slow to adapt, or are unable to adapt, to changes in existing regulatory requirements or the
adoption of new regulatory requirements or policies, we or our potential commercialization partners may lose marketing approval for our
oncology therapeutic candidates or any other therapeutic candidate that we may develop or acquire in the future, that obtain regulatory
approval, resulting in decreased or lost revenue from milestones, product sales or royalties and could also result in other civil or
criminal sanctions, including fines and penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Regulatory approval
of our oncology therapeutic candidates (if any) will be limited by the FDA and similar foreign authorities to those specific indications
and conditions for which clinical safety and efficacy have been demonstrated, and the promotion of such product candidates for off-label
uses, or in a manner that otherwise violates applicable FDA regulations, could adversely affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approval of
therapeutic candidates is limited to those specific diseases and indications for which such therapeutic candidates have been deemed safe
and effective by the FDA or similar foreign authorities. Marketing or commercializing of therapeutic candidates to treat a new symptom
or indication, that was not approved by the FDA or similar foreign authorities would be considered promotion of off-label, or unapproved
use, and would require us to file a supplemental new drug application and obtain regulatory approval. We will rely on physicians to prescribe
and administer our therapeutic candidates (if approved for marketing by the FDA or similar foreign authorities) or as the product labeling
directs and for the indications described on the labeling. To the extent any physicians prescribe such product to patients for off-label
uses, or the use of such products depart from the approved use, this may increase the risk of injury or other adverse events to the patients
and the risk of filing product liability claims against us. Product liability claims are expensive to defend regardless of merit and
could result in substantial damage awards against us or harm our reputation. Furthermore, any off-label use may not effectively treat
the conditions associated with such use, which could harm our reputation in the marketplace among physicians and patients, adversely
affecting our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While physicians may choose
to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those approved by regulatory
authorities, our ability to promote our therapeutic candidates (if approved for marketing by the FDA or similar foreign authorities)
is limited to those indications that are specifically approved by the FDA or other regulatory authorities. Although regulatory authorities
generally do not regulate the behavior of physicians, they do restrict communications by companies on the subject of off-label use. If
the promotional activities related to our therapeutic candidates fail to comply with these regulations or guidelines, we may be subject
to warnings from, or enforcement action by, the FDA or other regulatory authorities. In addition, failure to follow FDA rules and guidelines
relating to promotion and advertising can lead to other negative consequences that could adversely affect our operations, such as the
suspension or withdrawal of our therapeutic candidates from the market, enforcement letters, and corrective actions. Other regulatory
authorities, including the Department of Justice, may impose separately penalties including, but not limited to, fines, disgorgement
of money, operating restrictions, or criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA requires that our
and our future distribution partners&#8217; sales and marketing efforts, as well as promotions, comply with various laws and regulations.
Prescription drug promotions must be consistent with and not contrary to labeling, present &#8220;fair balance&#8221; between risks and
benefits, be truthful and not false or misleading, be adequately substantiated (when required), and include adequate directions for use.
In addition to the requirements applicable to approved drug products, we may also be subject to enforcement action in connection with
any promotion of an investigational new drug. A sponsor or investigator, or any person acting on behalf of a sponsor or investigator,
may not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under
investigation or otherwise promote the drug candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
the FDA investigates the marketing and promotional materials or other communications for our current or future commercial products and
finds that any of our commercial products are being marketed or promoted in violation of the applicable regulatory restrictions, we and
our distribution partners could be subject to FDA enforcement action, or civil or criminal action taken by the U.S authorities, which
may result in substantial monetary penalties and/or harm to our reputation. Any enforcement action (or related lawsuit, which could follow
such action) brought against us in connection with alleged violations of applicable drug promotion requirements, or prohibitions, could
harm our business and our reputation, as well as the reputation of any approved drug products we may promote or commercialize.</span>&#160;
<span style="font-family: Times New Roman, Times, Serif">Such enforcement actions may also result in significant monetary damages.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may encounter substantial
delays in the clinical trials for our therapeutic candidates, or we may not be able to conduct their trials on the timelines we expect,
or we may not be able to complete them at all. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical testing is expensive,
time-consuming, and subject to uncertainty. Currently, two of our therapeutic candidates are in the clinical trial phase, CM24 and NT219,
and while we currently intend to continue clinical testing of CM24 and NT219, we cannot guarantee that either of these therapeutic candidates&#8217;
and/or any future therapeutic candidates&#8217; clinical studies will be initiated or conducted as planned, or completed on schedule,
if at all, and issues may arise, including issues outside of our control, that could delay or prevent future clinical trials. A failure
of one or more clinical studies can occur at any stage of testing, and clinical studies for any of our therapeutic candidates may not
be successful. Events that may prevent successful or timely completion of clinical development include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in reaching a consensus
    with regulatory agencies on study design;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in reaching agreement
    on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the terms of which can be
    subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining required
    Institutional Review Board (IRB) approval at each clinical study site;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the departure of a principal
    investigator from a clinical site, which could cause delays in conducting the clinical trial at a particular clinical site;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the shortage of staff in
    clinical sites; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition of a temporary
    or permanent clinical hold by regulatory agencies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in recruiting suitable
    patients to participate in clinical studies for CM24, NT219 or future therapeutic candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us or our CROs,
    or third parties, to adhere to clinical study requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to perform in accordance
    with the FDA&#8217;s cGCPs, requirements, or applicable regulatory guidelines in other countries;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients dropping out of
    a study;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence of adverse events
    associated with the product candidate that are viewed to outweigh its potential benefits;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in regulatory requirements
    and guidance that require amending or submitting new clinical protocols;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the standard
    of care on which a clinical development plan was based, which may require new or additional trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of clinical studies
    of CM24 and NT219 and/or future therapeutic candidates being greater than we anticipate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">management&#8217;s decision
    to allocate internal resources to other projects;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical studies of CM24,
    NT219 and/or future therapeutic candidates producing negative or inconclusive results, which may result in us deciding, or regulators
    requiring, conduct of additional clinical studies or abandon product development programs; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in manufacturing,
    testing, release, validating, or import/export of sufficient stable quantities of CM24, NT219, and/or future therapeutic candidates
    or approved drugs for use in clinical studies or the inability to do any of the foregoing, including any quality issues associated
    with contract manufacturers.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may conduct clinical research
in collaboration with medical centers and investigators who would sponsor these studies. In such cases, we will have limited control
over the performance of the study, its design, the recruitment of patients to the study and its schedule. Such studies may not provide
the adequate data required by the FDA or similar regulatory agencies or provide results that are not sufficient to determine the safety
or efficacy of our therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also may conduct clinical
research in collaboration with other biotechnology and biologics entities in which we combine CM24, NT219 and/or other or future therapeutic
candidates with the technologies of such collaborators. Such collaborations may be subject to additional delays because of the management
of the trials or the necessity of obtaining additional approvals for therapeutics used in the combination trials, or a shortage in the
availability of such collaborators&#8217; drug products. These combination therapies will require additional testing and clinical trials,
will require additional FDA regulatory approval, and will increase our future expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if we make manufacturing
or formulation changes to CM24, NT219 and/or other or future therapeutic candidates, we may be required, or may elect, to conduct additional
studies to bridge the modified therapeutic candidates to earlier versions. Clinical study delays could also shorten any periods during
which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair
our ability to commercialize these therapeutic candidates successfully and may harm our business and the results of our operations.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A number of factors, including
scheduling conflicts with participating clinicians and clinical institutions, and difficulties in identifying and enrolling patients
who meet trial eligibility criteria, may cause significant delays in clinical studies. We may not commence or complete clinical trials
involving any of our therapeutic candidates as projected or may not conduct them successfully.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to rely on medical
institutions, academic institutions, or CROs to conduct, supervise, or monitor some or all aspects of clinical trials involving our therapeutic
candidates. If we fail to commence or complete, or experience delays in, any of its planned clinical trials, we may experience delays
in its clinical development and/or commercialization plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we encounter difficulties
enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timely completion of
clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients
who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety
of reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size and nature of
    the patient population;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patient eligibility
    criteria defined in the protocol;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of the study population
    required for analysis of the trial&#8217;s endpoints;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proximity of patients
    to trial sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit
    clinical trial investigators with the appropriate competencies and experience;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing clinical trials
    for similar therapies or other new therapeutics;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&#8217; and patients&#8217;
    perceptions of the potential advantages and side effects of the product candidate being studied in relation to other available therapies,
    including any new drugs or treatments that may be approved for the indications we are investigating;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and
    maintain patient consents; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that patients
    enrolled in clinical trials will not complete a clinical trial, will withdraw from a clinical trial, or will withdraw from one arm
    of the study, which could cause an imbalance between study arms and result in informative censoring, causing the results of a study
    arm to be uninterpretable; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of epidemics,
    endemics or pandemics on the ability of patients to visit the testing sites and the effect of the disease on potential patients who
    contracted the disease.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our clinical trials will
compete with other clinical trials for therapeutic candidates that are in the same therapeutic areas as our therapeutic candidates, and
this competition may reduce the number and types of patients available to us, because some patients who might have opted to enroll in
our clinical trials may instead opt to enroll in a trial being conducted by one of our competitors. Accordingly, we cannot guarantee
that the trials will progress as planned or as scheduled. Delays in patient enrollment may result in increased costs or may affect the
timing or outcome of our ongoing clinical trial and planned clinical trials, which could prevent completion of these trials and adversely
affect our ability to advance the development of our therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we can enroll a sufficient
number of patients in our clinical trials, delays in patient enrollment may result in increased costs or may affect the timing or outcome
of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development
of our therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may depend on a
partner to conduct clinical trials with CM24, NT219 and/or other therapeutic candidates, and we may enter into future collaboration agreements
with collaboration partners to develop and conduct clinical trials with, obtain regulatory approvals for, and to market and sell our
therapeutic candidates. If such collaboration fails to perform as expected, our clinical trials and/or development plans will be delayed,
and we will be required to seek other partners, which we may not be able to engage in a timely manner, if at all, and which may delay
our development plans and therefore the potential for us to generate future revenue from our therapeutic candidates would be significantly
reduced and our business would be significantly harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a clinical
collaboration and supply agreement with Bristol Myers Squibb Company (NYSE:BMY) for the phase 1/2 study of CM24 in combination with a
programmed cell death protein 1 (PD-1) antibody nivolumab, and an expansion study to also evaluate CM24 and nivolumab, together with
nab-paclitaxel, in patients with pancreatic cancer. We initiated the phase 1b/2 portion of the phase 1/2 study in March 2021 and in December
2024, we reported the final data for the study. We entered into a research agreement with the University of Colorado for an investigator-initiated
Phase 2 study with NT219 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck, which is expected to be
initiated in the first half of 2025. We rely and may in the future continue to rely on our collaboration partners to develop, supply,
conduct clinical trials, and/or commercialize our therapeutic candidates and approved products we may market in the future, if any. We
may also enter into collaboration agreements with other parties in the future relating to such therapeutic candidates. Ultimately, if
such therapeutic candidates are advanced through clinical trials, certain of the collaboration partners may have certain rights in connection
with the commercialization of the therapeutic candidate, such as rights of first offer to be responsible for commercialization of these
therapeutic candidates. If these collaboration partners do not perform in the manner we expect or fail to fulfill their responsibilities
in a timely manner or at all, if the agreements with them terminate or if the quality or accuracy of the clinical data they obtain is
compromised, the clinical development, regulatory approval and commercialization efforts related to our therapeutic candidates could
be delayed or terminated, and it could become necessary for us to assume the responsibility at our own expense for the clinical development
of such therapeutic candidates and seek replacement collaboration and/or development partners. In that event, we would likely be required
to limit the size and scope of efforts for the development and commercialization of such product candidate; we would likely be required
to seek additional financing to fund further development or identify alternative strategic collaboration partners; our potential to obtain
regulatory approval for, and to generate future revenue from, such therapeutic candidates would be significantly reduced or delayed;
and it could have a material adverse effect on our business, financial position, results of operations and future growth prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Collaborations involving
our therapeutic candidates pose a number of risks, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration partners
    have significant discretion in determining the efforts and resources that they will apply to these partnerships;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration partners
    may have limited supply of products, such as a PD-1 antibody, which we require for the development of our therapeutic candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration partners
    may not perform their obligations as expected;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration partners
    may not pursue development of our therapeutic candidates or may elect not to continue or renew development programs, based on clinical
    trial results, changes in the collaboration partners&#8217; strategic focus or available funding or external factors, such as an
    acquisition, that divert resources or create competing priorities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration partners
    may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
    candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration partners
    may have or could independently develop, or develop with third parties, products that compete directly or indirectly with our out-licensed
    therapeutic candidates;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements with collaboration
    partners, including disagreements over proprietary rights, contract interpretation or the conduct of product research, development
    or commercialization programs, may cause delays or lead to termination of such programs, or require us to assume unplanned expenditures,
    responsibilities or liabilities with respect to therapeutic candidates we have out licensed, or may result in costly and time-consuming
    litigation or arbitration;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration partners
    may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration agreements
    may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization
    of the applicable therapeutic candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, collaboration
agreements may provide the collaboration partners with rights to terminate such agreements and licenses granted under such agreements
under various conditions, which, if exercised, would adversely affect our product development efforts, could make it difficult for us
to attract new collaboration partners and may adversely affect our reputation. Any such termination of any current or future agreement
with a collaboration partner could have a material adverse effect on our business, financial position and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The manufacture of
our therapeutic candidates is complex, and we may encounter difficulties in production, particularly with respect to process development
or scaling-up of our manufacturing capabilities. If we, or any of our third-party manufacturers encounter such difficulties, our ability
to supply drugs for clinical trials or our products (if approved) for patients on a timely basis could be materially delayed or adversely
affected. In addition, this may cause an increase in costs that could result in our inability to maintain a commercially viable cost
structure.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NT219 is a small molecule
chemical compound, and CM24 and IM1240, the leading therapeutic candidate of CAPTN-3, our tribody platform, are biologic compounds, and
the process of manufacturing each is complex, highly regulated and subject to multiple risks. Even minor deviations from normal manufacturing
processes for each of CM24, NT219 and IM1240 and/or any future therapeutic candidate could result in reduced production yields, product
defects, and other supply disruptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Developing commercially viable
processes is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical
trials or commercialization, including, among others, cost overruns, potential problems with process scale-up, process reproducibility,
stability issues, lot consistency, and timely availability of raw materials. As a result of these challenges, we may experience delays
in our therapeutic candidates&#8217; preclinical development, clinical development and/or commercialization plans. We may ultimately
be unable to reduce the cost of goods for each of our therapeutic candidates to levels that will allow for an attractive return on investment
if and when those therapeutic candidates are commercialized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Because each of CM24,
NT219 and CAPTN-3, our tribody platform with its leading therapeutic candidate, IM1240, represents a novel approach to the treatment
of disease, there are many uncertainties regarding the development, the market acceptance, third-party reimbursement coverage and the
commercial potential of these therapeutic candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
the approaches offered by CM24, NT219 or CAPTN-3, our tribody platform with its leading therapeutic candidate, IM1240, will gain broad
acceptance among physicians or patients, or that governmental agencies or third-party medical insurers will be willing to provide reimbursement
coverage for proposed therapeutic candidates. Since each of CM24, NT219 and CAPTN-3, our tribody platform with its leading therapeutic
candidate, IM1240, represents a new approach to treating various conditions, it may be difficult, in any event, to accurately estimate
the potential revenues from these therapeutic candidates. Accordingly, we may spend large amounts of money trying to obtain approval
for therapeutic candidates that have an uncertain commercial market. The market for any products that we may successfully develop utilizing
our therapeutics candidates will also depend on the cost of the product. We do not yet have sufficient information to reliably estimate
what it will cost to commercially manufacture these therapeutic candidates, and the actual cost to manufacture these therapeutic products
could materially and adversely affect the commercial viability of these products. Our goal is to reduce the cost of manufacturing our
therapeutic candidates. However, unless we reduce those costs to an acceptable amount, we may never be able to develop a commercially
viable product. If we do not successfully develop and commercialize our therapeutic candidates based upon this approach or find suitable
and economical sources for materials used in the production of these therapeutic candidates, these therapeutic candidates will not become
profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our therapeutic candidates
may be provided to patients in combination with other agents provided by third parties. The cost of such combination therapy may increase
the overall cost of our therapeutic candidates&#8217; based therapies and may result in issues regarding the allocation of reimbursements
between our therapeutic candidates and the other agents, all of which may adversely affect the ability to obtain reimbursement coverage
for the combination therapy from third-party medical insurers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we fail to comply
with any obligations under our in-license agreements with Yissum and/or THM or any future license agreement, or disputes arise with respect
to those agreements, it could have a negative impact on our intellectual property rights and we could lose our rights to NT219 and/or
CM24 or any future therapeutic candidate, which could have a material adverse effect on our business, financial condition and results
of operation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a party to a license
agreement with each of Yissum, the technology transfer company of the Hebrew University of Jerusalem, and THM, pursuant to which we license
rights to our therapeutic candidates NT219 and CM24, respectively. These license agreements impose, and any additional licensing arrangements
that we may enter into with third parties may impose, diligence, development and commercialization timelines, milestone payment, royalty,
insurance and other obligations on us. Our rights to use the licensed intellectual property are subject to the continuation of and our
compliance with the terms of these agreements. Disputes may arise regarding our rights to intellectual property licensed to us from a
third party, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope of rights granted
    under the license agreement and other interpretation-related issues;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which our
    technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sublicensing of patent
    and other rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our diligence obligations
    under the license agreement and what activities satisfy those diligence obligations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ownership of inventions
    and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope and duration
    of our payment obligations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to further
    license the technology to third parties;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our rights upon termination
    of such agreement; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope and duration
    of exclusivity obligations of each party to the agreement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If disputes over intellectual
property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current
licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidates.
If we fail to comply with our obligations under current or future licensing agreements or if other events occur that are not within our
control, these agreements may be terminated or the scope of our rights under them may be reduced, we could lose the rights to our therapeutic
candidates NT219 and CM24 or any other therapeutic candidate we license, and we might be unable to develop, manufacture or market any
product that is licensed under these agreements, could experience delays in developing or commercializing these therapeutic candidates
or incur additional costs, any of which could have a material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we may have
disputes over intellectual property rights related to our therapeutic candidates developed under service agreements or material transfer
agreements with third parties. Such third parties may claim rights to certain know-how or intellectual property that may require us to
enter into license agreements with such parties and pay royalties for such rights or to engage in legal proceedings with these parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our shareholders may
not realize a benefit from our acquisitions of therapeutic candidates commensurate with the ownership dilution they experienced in connection
with the transactions. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to realize
the strategic and financial benefits anticipated from an acquisition (through the acquisition of a company or a company&#8217;s assets),
or in-licensing of therapeutic candidates, our shareholders may have experienced substantial dilution of their ownership interest without
receiving any commensurate benefit. Due to the substantial number of the ADSs (including ADSs issuable upon exercise of the warrants to
purchase ADSs) which were issued to shareholders in the acquisitions and the private placements we completed and may complete in the future
in order to acquire our therapeutic candidates, the ownership stake and relative voting power of each ordinary share held by our previous
shareholders was and may in the future be significantly reduced. Significant management attention and resources will be required to integrate
and operate any acquired company or new product. Delays in this process could adversely affect our business, financial results, financial
condition and price of our ordinary shares and/or ADSs following any acquisition or in-licensing agreement. Even if we are able to integrate
the acquired business operations successfully, there can be no assurance that its integration will result in the realization of the full
benefits of synergies, innovation, and operational efficiencies that may be possible from such integration and that the benefits will
be achieved within a reasonable period of time. We may be required to recognize impairment charges on goodwill or other intangible assets
acquired through our past or future acquisitions of therapeutic candidates if expected benefits from these acquisitions fail to materialize
and such assets&#8217; carrying values exceed their fair values, which could adversely affect our business, financial condition and results
of operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
example, in February 2023 we completed the acquisition of 100% of the shares of Immunorizon, which is developing multi-specific T and
NK cell engager oncology therapies that potentially selectively activate the immune response within the tumor microenvironment (TME),
in exchange for an aggregate upfront payment of $3.5 million in cash and an aggregate $3.5 million in ADSs (or 110,759 ADSs representing
ordinary shares) and additional long-term milestones set at an aggregate amount of $94 million, with royalties out of net sales</span>&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">.
Following our October 2023 registered direct offering, we issued to certain of the former shareholders of Immunorizon an aggregate 34,975
additional ADSs, pursuant to a one-time anti-dilution protection provision under the agreement that we entered into with Immunorizon
in connection with the acquisition of Immunorizon in February 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we have completed the
process for the integration of Immunorizon&#8217;s technology platform and allocated resources to the ongoing research and development
related to the platform, given the challenges involved with the development of a biological product and the financial challenges, we
may not be able to realize the anticipated benefits of the acquisition, which may materially adversely affect our growth and future operating
results as well as our financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We depend on our ability
to identify and acquire or in-license therapeutic candidates to achieve commercial success.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We own the rights to our
therapeutic candidates, each of which was acquired by us from a third-party: NT219 (acquired in connection with the acquisition of the
majority shareholdings of TyrNovo in 2017), CM24 (acquired in connection with the acquisition of FameWave in 2020) and CAPTN-3, our tribody
platform (acquired in connection with the acquisition of Immunorizon in February 2023). We evaluate internally and with external consultants
each potential therapeutic candidate. However, there can be no assurance as to our ability to accurately or consistently select therapeutic
candidates that have the highest likelihood of achieving commercial success.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our business could
suffer if we are unable to attract and retain key employees. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The loss of the services
of members of senior management or other key personnel could delay or otherwise adversely impact the successful completion of our planned
CMC, research and development, preclinical studies and/or clinical trials or the commercialization of our therapeutic candidates or otherwise
affect our ability to manage our company effectively and to carry out our business plan and raise necessary funds to continue our development
plans. We do not maintain key-man life insurance for any of our personnel. Although we have entered into employment or consultancy agreements
with every member of our senior management team, members of our senior management team may resign at any time. High demand exists for
senior management and other key personnel in the pharmaceutical industry. There can be no assurance that we will be able to continue
to retain and attract such personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our growth and success also
depend on our ability to attract and retain additional highly qualified scientific, technical, business development, marketing, managerial
and finance personnel. If we expand our research and clinical development or purchase or in-license new products or product candidates,
we may need to expand our qualified personnel to advance the development and commercialization of our products. In addition, if we elect
to independently commercialize any therapeutic candidate, we will need to expand our marketing and sales capabilities. We experience
intense competition for qualified personnel, and the existence of non-competition agreements between prospective employees and their
former employers may prevent us from hiring those individuals or subject us to liability from their former employers. While we attempt
to provide competitive compensation packages to attract and retain key personnel, many of our competitors are likely to have greater
resources and more experience than we have, making it difficult for us to compete successfully for key personnel. Compensation packages
for our senior officers are subject to approval of our compensation committee and board of directors (the &#8220;Board&#8221;) and, in
certain instances, our shareholders. We may not be able to achieve the required corporate approvals for proposed compensation packages,
further making it difficult for us to compete successfully with other companies to attract and retain key personnel. If we cannot attract
and retain sufficiently qualified technical employees on acceptable terms, we may not be able to develop and commercialize competitive
therapeutic candidates. Further, any failure to effectively integrate new personnel could prevent our business from successfully growing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We are an international
business, and we are exposed to various global and local risks that could have an adverse effect on our business</i>. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate our business in
multiple international jurisdictions. Such operations could be affected by changes in foreign exchange rates, capital and exchange controls,
travel restrictions, public health restrictions, expropriation and other restrictive government actions, changes in intellectual property
legal protections and remedies, trade regulations and procedures and actions affecting approval, production, export and import of pharmaceutical
products, pricing, and marketing of, reimbursement for and access to, our products, as well as by political unrest, unstable governments
and legal systems and inter-governmental disputes. Any of these changes could adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our subsidiary, TyrNovo,
has received Israeli governmental grants to assist in the funding of its research and development activities. The IIA grants which TyrNovo&#8217;s
technology, including NT219, has received for research and development expenditures restrict its ability to manufacture products and
transfer (including by way of license for R&amp;D purposes) know-how outside of Israel and require it to satisfy specified conditions.
In addition, we may encounter difficulties partnering TyrNovo&#8217;s therapeutic candidates with entities outside of Israel due to certain
restrictions regarding manufacturing and transferring of know-how (including by a way of license for R&amp;D purposes) outside of Israel
imposed due to the receipt of the IIA grants. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TyrNovo&#8217;s technologies,
including NT219, were developed, in part, with grants from the Israel Innovation Authority, or IIA (formerly known as the Office of the
Chief Scientist of the Ministry of Economy and Industry) in the aggregate amount of approximately NIS 5.5 million (or approximately $1.5
million). As of December 31, 2024, TyrNovo had not paid any royalties to the IIA and had a contingent obligation to the IIA (including
interest) of $2.3 million. The requirements and restrictions for such grants are set forth in the Encouragement of Research, Development
and Technological Innovation in Industry Law, 5744-1984 (formerly known as the Law for the Encouragement of Research and Development in
Industry, 5744-1984), or the Innovation Law, the IIA&#8217;s rules and guidelines and the terms of these grants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, the recipients
of IIA grants are obligated to pay the IIA royalties from the revenues generated from the sale of products and related services developed
as a result of a research and development program funded, in whole or in part, by the IIA, at rates which are determined under the IIA&#8217;s
rules and guidelines (generally of 3% to 6% on sales of IIA-funded products or related services, which rates may be increased under certain
circumstances) up to the aggregate amount of the total grants received by the IIA (which may be increased under certain circumstances,
as described below), plus annual interest (as determined in the IIA&#8217;s rules and guidelines). Following the full payment of such
royalties and interest, there is generally no further liability for royalty payments; however, other restrictions under the Innovation
Law continue to apply, as described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the IIA&#8217;s rules
and guidelines, TyrNovo is generally prohibited from manufacturing products developed using the IIA funding outside of the State of Israel
without the prior approval of the IIA (except for the transfer of less than 10% of the manufacturing capacity in the aggregate which
requires only a notice) and subject to payment of increased royalties (up to 300% of the grant amount plus accrued interest, depending
on the manufacturing volume that is performed outside of Israel). TyrNovo received the IIA&#8217;s approval for the production of NT219&#8217;s
API and final product by certain third-party manufacturers outside of Israel in consideration for (among other things) the future payment
of increased royalties as stipulated under the IIA&#8217;s rules and guidelines. Additionally, under the IIA&#8217;s rules and guidelines,
TyrNovo is prohibited from transferring the IIA-funded know-how and related intellectual property rights outside of the State of Israel,
except under limited circumstances and only with the prior approval of the IIA. TyrNovo may not receive the required approvals for any
proposed transfer, and even if received, TyrNovo may be required to pay the IIA a redemption fee of up to 600% of the grant amounts (less
paid royalties, if any, and depreciation, but no less than the total grants received) plus accrued interest. Approval of the transfer
of know-how to an Israeli company is also required, and may be granted if the recipient assumes all of our responsibilities towards the
IIA, including the restrictions on the transfer of know-how and the manufacturing rights outside of Israel and the obligation to pay
royalties, and, although such transfer will not be subject to the payment of a redemption fee, there will be an obligation to pay royalties
to the IIA from the income of such sale transaction as part of the royalty payment obligation. No assurance can be given that approval
for any such transfer, if requested, will be granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These restrictions may impair
our ability to perform or outsource manufacturing outside of Israel or otherwise transfer or sell TyrNovo&#8217;s IIA funded know-how
outside of Israel. Furthermore, the consideration available to TyrNovo&#8217;s and/or our shareholders in a transaction involving the
transfer outside of Israel of know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts
that TyrNovo is required to pay to the IIA. If TyrNovo fails to comply with the requirements of the Innovation Law and the IIA&#8217;s
rules and guidelines, TyrNovo may be required to return certain grants previously received along with interest and penalties and may
become subject to criminal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We have in the past,
and may in the future, become subject to litigation or claims arising in or outside the ordinary course of business that could negatively
affect our business operations and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have in the past, and
may in the future, become subject to litigation or claims arising in or outside the ordinary course of business (other than intellectual
property infringement actions) that could negatively affect our business operations and financial condition, including securities class
actions and shareholder derivative actions, both of which are typically expensive to defend. Such claims and litigation proceedings may
be brought by third parties, including our competitors, advisors, service providers, partners or collaborators, employees, and governmental
or regulatory bodies. For information on past legal proceedings, please see &#8220;Item 8. Financial Information &#8211; A. Consolidated
Statements and Other Financial Information &#8211; Legal Proceedings.&#8221; Any claims and lawsuits, and the disposition of such claims
and lawsuits, could be time-consuming and expensive to resolve, divert management attention and resources, and lead to attempts on the
part of other parties to pursue similar claims. We may not be able to determine the amount of any potential losses and other costs we
may incur due to the inherent uncertainties of litigation and settlement negotiations. In the event we are required or decide to pay
amounts in connection with any claims or lawsuits, such amounts could be significant and could have a material adverse impact on our
liquidity, business, financial condition and results of operations. In addition, depending on the nature and timing of any such dispute,
a resolution of a legal matter could materially affect our future operating results, our cash flows or both. Additionally, we may be
unable to maintain our existing directors&#8217; and officers&#8217; liability insurance in the future at satisfactory rates or adequate
coverage amounts and may incur significant increases in insurance costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Risks Related to Our Industry</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Even if our oncology
therapeutic candidates or any other therapeutic candidate that we develop or in-license in the future receive regulatory approval, they
may not become or remain commercially viable products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that our oncology
therapeutic candidates and/or any other therapeutic candidate that we may develop or acquire in the future are approved for commercialization
by the FDA or a foreign authority, they may not be commercially viable products. For example, if we or our potential commercialization
partners receive regulatory approval to market a therapeutic candidate, approval may be subject to limitations on the indicated uses
or subject to labeling or marketing restrictions which could materially and adversely affect the marketability and profitability of the
therapeutic candidate. In addition, a new therapeutic candidate may appear promising at an early stage of development or after preclinical
studies and/or clinical trials but never reach the market, or it may reach the market but not result in sufficient product sales, if
any. A therapeutic candidate may not result in commercial success for various reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in large-scale manufacturing, including yield and quality;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">low market acceptance by
    physicians, healthcare payers, patients and the medical community as a result of lower demonstrated clinical safety or efficacy compared
    to other products, prevalence and severity of adverse side effects, or other potential disadvantages relative to alternative treatment
    methods;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient or unfavorable
    levels of reimbursement from government or third-party payers, such as insurance companies, health maintenance organizations and
    other health plan administrators;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">infringement on proprietary
    rights of others for which we or our potential commercialization partners have not received licenses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incompatibility with other
    therapeutic candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other potential advantages
    of alternative treatment methods and competitive forces that may make it more difficult for us to penetrate a particular market segment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ineffective marketing and
    distribution support;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of significant competitive
    advantages over existing products on the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of cost-effectiveness;
    or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing of market introduction
    of competitive products.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable, either
on our own or through third parties, to manufacture, commercialize and market our oncology therapeutic candidates or any other therapeutic
candidates that we may develop or acquire in the future when planned, or develop or acquire commercially viable therapeutic candidates,
we may not achieve any market acceptance or generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The markets for our
oncology therapeutic candidates are rapidly changing and competitive, and new drug delivery mechanisms, drug delivery technologies, new
drugs and new treatments which may be developed by others could impair our ability to maintain and grow our business and remain competitive.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pharmaceutical and biotechnology
industry is highly competitive, and we face significant competition from many pharmaceutical, biopharmaceutical and biotechnology companies
that are researching and marketing products designed to address the indications treated by our oncology therapeutic candidates. There
are various other companies that currently market or are in the process of developing products that address all of the indications or
diseases treated by our therapeutic candidates, some of them are in a more progressed stage of development than us and may reach the
market before we do.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New drug delivery mechanisms,
drug delivery technologies, new drugs and new treatments that have been developed or that are in the process of being developed by others
may render our oncology therapeutic candidates noncompetitive or obsolete, or we may be unable to keep pace with technological developments
or other market factors. Some of these technologies may have an entirely different platform or means of treating the same indications
as CM24, NT219, CAPTN-3, our tribody platform with its leading therapeutic candidate, IM1240, or other therapeutic candidates that we
may develop or in-license in the future. Technological competition from pharmaceutical and biotechnology companies, universities, governmental
entities and others, is intense and is expected to increase. Many of these entities have significantly greater research and development
capabilities, human resources and budgets than we do, as well as substantially more marketing, manufacturing, financial and managerial
resources. These entities represent significant competition for us. Acquisitions of, or investments in, competing pharmaceutical or biotechnology
companies by large corporations could increase such competitors&#8217; financial, marketing, manufacturing and other resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The potential widespread
acceptance of therapies that are alternatives to ours may limit market acceptance of our formulations or therapeutic candidates, even
if commercialized. Many of our targeted diseases and conditions can also be treated by other medications or drug delivery technologies.
These treatments may be widely accepted in medical communities and have a longer history of use. The established use of these competitive
drugs may limit the potential for our oncology therapeutic candidates to receive widespread acceptance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Third-party payers
may not adequately reimburse customers for our oncology therapeutic candidates, if approved for marketing in the United States or other
markets, and such oncology therapeutic candidates might not be purchased or used, which may result in our revenues and profits not developing
or increasing.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our revenues and profits
will depend heavily upon the availability of adequate coverage and reimbursement for the use of our oncology therapeutic candidates,
if approved, from governmental and/or other third-party payers, both in the U.S. and in foreign markets. There may be significant delays
in obtaining coverage for newly approved therapeutic candidates. Moreover, eligibility for coverage does not necessarily signify that
an approved product will be reimbursed in all cases or at a sufficient rate, including one that covers our costs, such as research, development,
manufacture, sale, and distribution costs. Accordingly, even if we succeed in bringing one or more of our therapeutic candidates to the
market, they may not be considered cost-effective, and the amount reimbursed may be insufficient to allow us to sell our approved products
on a competitive basis. Reimbursement by a third-party payer may depend upon a number of factors, including the third-party payer&#8217;s
determination that the use of an approved product is, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a covered benefit under
    its health plan;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe, effective and medically
    necessary;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate for the specific
    patient;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective, including
    compared to approved alternate therapies; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither experimental nor
    investigational.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining reimbursement approval
for an approved product from each government or other third-party payer is a time-consuming and costly process that could require us
or our current or potential development and commercialization partners to provide supporting scientific, clinical and cost-effectiveness
data for the use of an approved product to each payer. Even when a payer determines that an approved product is eligible for reimbursement,
the payer may impose coverage limitations that preclude or restrict payment for some uses that are approved by the FDA or other foreign
regulatory authorities. Reimbursement rates may vary according to the use of the approved product and the clinical setting in which it
is used, may be based on payments allowed for lower-cost products that are already reimbursed, may be incorporated into existing payments
for other products or services, and may reflect budgetary constraints or imperfections in Medicare, Medicaid or other data used to calculate
these rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Increasingly, the third-party
payers who reimburse patients or healthcare providers, such as government and private insurance plans, are seeking greater upfront discounts,
additional rebates, and other concessions to reduce the prices for approved products. If the price we are able to charge for any approved
product, or the reimbursement provided for such approved product, is inadequate or becomes inadequate in light of our development and
other costs, our return on investment could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S., there have been,
and we expect that there will continue to be, federal and state proposals to constrain expenditures for medical products and services
which may affect payments for our oncology therapeutic candidates, if approved. We believe that legislation that reduces reimbursement
for our oncology therapeutic candidates, if approved, could adversely impact how much or under what circumstances healthcare providers
will prescribe or administer our oncology therapeutic candidates, if approved. This could materially and adversely impact our business
by reducing our ability to generate revenue, raise capital, obtain additional collaborators and market our oncology therapeutic candidates,
if approved. At this stage, we are unable to estimate the extent of the direct or indirect impact of any such federal and state proposals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, coverage and reimbursement
policies are subject to change and are not always consistent across different payers or even federal healthcare programs. For example,
the Centers for Medicare and Medicaid Services (CMS) frequently change product descriptors, coverage policies, product and service codes,
payment methodologies and reimbursement values which may be revised or interpreted in ways that could significantly affect our business
and products. Government and private third-party payers often follow Medicare coverage policy and payment limitations in setting their
own reimbursement rates. Moreover, both CMS and other third-party payers may have sufficient market power to demand significant price
reductions. Such price reductions and/or other significant coverage policies or payment limitations could materially and adversely affect
our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Legislative or regulatory
reform of the healthcare system in the United States may harm our business. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 23, 2010, President
Obama signed the &#8220;Patient Protection and Affordable Care Act&#8221; (P.L. 111-148) (the &#8220;ACA&#8221;) and on March 30, 2010,
he signed the &#8220;Health Care and Education Reconciliation Act&#8221; (P.L. 111-152), collectively commonly referred to as the &#8220;Healthcare
Reform Law.&#8221; The Healthcare Reform Law included a number of new rules&#160;regarding health insurance, the provision of healthcare,
conditions to reimbursement for healthcare services provided to Medicare and Medicaid patients, and other healthcare policy reforms.
Through the law-making process, substantial changes have been and continue to be made to the current system for paying for healthcare
in the U.S., including changes made to extend medical benefits to certain Americans who lacked insurance coverage and to contain or reduce
healthcare costs (such as by reducing or conditioning reimbursement amounts for healthcare services and drugs, and imposing additional
taxes, fees, and rebate obligations on pharmaceutical and medical device companies). This legislation was one of the most comprehensive
and significant reforms ever experienced by the U.S. in the healthcare industry and has significantly changed the way healthcare is financed
by both governmental and private insurers. This legislation has impacted the scope of healthcare insurance and incentives for consumers
and insurance companies, among others.&#160;Additionally, the Healthcare Reform Law&#8217;s provisions were designed to encourage providers
to find cost savings in their clinical operations. Pharmaceuticals represent a significant portion of the cost of providing care. This
environment has caused changes in the purchasing habits of consumers and providers and resulted in specific attention to the pricing
negotiation, product selection and utilization review surrounding pharmaceuticals which could result in lower pricing and/or reduced
market acceptance for any drug products we may commercialize in the U.S. in the future. At this stage, it is difficult to estimate the
full extent of the direct or indirect impact of the Healthcare Reform Law on us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the healthcare regulatory
environment has seen significant changes in recent&#160;years and is still in flux.&#160;Legislative initiatives to modify, limit, replace,
or repeal the ACA and judicial challenges have continued for over a decade.&#160;However, as of the Supreme Court&#8217;s ruling ordering
the dismissal of, arguably, the most promising case challenging the ACA to-date on June 17, 2021, it appears that the ACA will remain
in-effect in its current form for the foreseeable future; however, we cannot predict what additional challenges may arise in the future,
the outcome thereof, or the impact any such actions may have on our business. The Biden administration also introduced various measures
in 2021 focusing on healthcare and drug pricing, in particular. For example, on January 28, 2021, President Biden issued an executive
order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which
began on February 15, 2021, and remained open through August 15, 2021. The executive order also instructed certain governmental agencies
to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid
demonstration projects and waiver programs that include work requirements and policies that create unnecessary barriers to obtaining
access to health insurance coverage through Medicaid or the ACA. On the legislative front, the American Rescue Plan Act of 2021 was signed
into law on March 11, 2021, which, in relevant part, eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s
average manufacturer price, for single source drugs and innovator multiple source drugs, beginning January 1, 2024. And, in July 2021,
the Biden administration released an executive order entitled, &#8220;Promoting Competition in the American Economy,&#8221; with multiple
provisions aimed at prescription drugs. In response, on September 9, 2021, HHS released a &#8220;Comprehensive Plan for Addressing High
Drug Prices&#8221; that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress
could pursue as well as potential administrative actions HHS can take to advance these principles. And, in August 2022, the Inflation
Reduction Act (&#8220;IRA&#8221;) was signed into law, which will, among other things, allow U.S. Department of Health and Human Services
(&#8220;HHS&#8221;) to negotiate the selling price of certain drugs and biologics that the Centers for Medicare&#160;&amp; Medicaid Services
(&#8220;CMS&#8221;) reimburses under Medicare Part&#160;B and Part&#160;D, although only high-expenditure single-source drugs that have
been approved for at least 7&#160;years (11&#160;years for biologics) can be selected by CMS for negotiation, with the negotiated price
taking effect two&#160;years after the selection&#160;year. The negotiated prices, which will first become effective in 2026, will be
capped at a statutory ceiling price. Beginning in October&#160;2023, the IRA also began penalizing drug manufacturers that increase prices
of Medicare Part&#160;B and Part&#160;D drugs at a rate greater than the rate of inflation. The IRA permits the Secretary of HHS to implement
many of these provisions through guidance, as opposed to regulation, for the initial&#160;years. Manufacturers that fail to comply with
the IRA may be subject to various penalties, including civil monetary penalties. The IRA also extends enhanced subsidies for individuals
purchasing health insurance coverage in ACA marketplaces through plan&#160;year 2025. Additionally, in December 2023, the Biden-Harris
Administration announced further related initiatives under the IRA to lower prescription costs and increase competition with help from
HHS, the DOJ, and the FTC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is uncertainty as to
what healthcare programs and regulations may be implemented or changed at the federal and/or state level in the U.S. or the effect of
any future legislation or regulation. However, in early January 2024, the FDA did approve a plan from Florida to import low-cost drugs
from Canada. Furthermore, we cannot yet assess the impact that President Trump&#8217;s second term will have on healthcare programs and
regulations or the pharmaceutical industry in general. However, it is possible that such initiatives could have an adverse effect on
our ability to obtain approval and/or successfully commercialize products in the U.S. in the future, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We are subject to additional
federal and state healthcare laws and regulations relating to our business, and our failure to comply with those laws could have a material
adverse effect on our results of operations and financial conditions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare providers, physicians,
and third-party payers play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain marketing
approval. Our current or future arrangements with healthcare providers, physicians, marketers or sales personnel, third-party payers,
patients, and others in a position to refer, recommend, purchase, or use our products may expose us to broadly applicable U.S. federal
and state fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we market, sell and distribute any product candidates for which we obtain FDA approval. The applicable healthcare laws
to which we have been and/or may be subject include, but are not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback
    Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration,
    directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation
    of, any good or service for which payment may be made under government healthcare programs such as the Medicare and Medicaid programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Inducement
    Law (also known as the Civil Monetary Penalties Law), which prohibits a person from offering or transferring remuneration to a Medicare
    or State healthcare program beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection
    of a particular provider, practitioner or supplier of any item or service for which payment may be made, in whole or in part, by
    Medicare or a State healthcare program;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Ethics in Patient Referrals
    Act of 1989, commonly referred to as the Stark Law, which prohibits physicians from referring Medicare or Medicaid patients for certain
    designated health services where that physician or family member has a financial relationship with the entity providing the designated
    health service, unless an exception applies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal false claims laws
    that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment
    from Medicare, Medicaid or other government healthcare programs that are false or fraudulent;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the so-called federal &#8220;Sunshine
    Act&#8221;, which requires certain pharmaceutical and medical device companies to monitor and report certain payments and other transfers
    of value to physicians, as defined by such law, certain other healthcare professionals, and teaching hospitals and ownership and
    investment interests held by physicians and their immediate family members to CMS for disclosure to the public;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Health Insurance
    Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations, which impose obligations on certain covered
    entities and their business associates with respect to safeguarding the privacy, security, and transmission of individually identifiable
    health information, and require notification to affected individuals, regulatory authorities, and potentially the media of certain
    breaches of security of individually identifiable health information;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA&#8217;s fraud and
    abuse provisions, which impose criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or
    knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection
    with the delivery of or payment for healthcare benefits, items or services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Food, Drug,
    and Cosmetic Act, which, among other things, strictly regulate drug product and medical device marketing, prohibits manufacturers
    from marketing such products for off-label use, and regulates the distribution of samples;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal criminal laws that
    prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;
    and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state law equivalents of
    each of the above federal laws, such as anti-kickback, false claims, transparency and reporting laws which may apply to items or
    services reimbursed by any third-party payer, including commercial insurers, many of which differ from each other in significant
    ways, thus complicating compliance efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Compliance efforts may involve
substantial costs and resources, and if our operations or business arrangements are found to be in violation of any such requirements,
we may be subject to penalties, including civil or criminal penalties, monetary damages, the curtailment or restructuring of our operations,
or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare
and Medicaid, any of which could adversely affect our financial results. Any action against us for an alleged or suspected violation
could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business,
even if our defense is successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most recently, there has
been a trend in federal and state legislation aimed at lowering costs for drug products, including by requiring pharmaceutical companies
to disclose information about their pricing and production and marketing costs, and heightened governmental scrutiny over the manner
in which pharmaceutical manufacturers set prices for their marketed products. There have been several presidential executive orders and
U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency
to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient
programs, and reform government program reimbursement methodologies for drugs. For example, on October 10, 2018, the Patient Right to
Know Drug Prices Act (for private plans) and the Know the Lowest Price Act (for Medicare Parts C and D) were signed into law, which prohibited
health plans from restricting pharmacies from informing individuals regarding prices for certain drugs. On November 20, 2020, the U.S.
Department of Health and Human Services finalized a regulation removing safe harbor protection for price reductions from pharmaceutical
manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required
by law. The implementation of the rule has been delayed in response to ongoing litigation. In addition, in November 2020, CMS issued
an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments
for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021.
Given resulting litigation and preliminary injunctions that were issued, the rule was not implemented and will not be implemented without
further rulemaking. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control
pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures. For example, in June 2016 Vermont became the first state to pass legislation
requiring certain drug companies to disclose information relating to justification of certain price increases, and many other states
have since followed suit. These efforts and any other such legislation requiring publication of drug costs could materially and adversely
impact our business, financial condition, and results of operations by promoting a reduction in drug prices or encouraging purchasers
to use other low-cost, established drugs or therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, there has been
a trend of increased federal and state regulation of payments made to physicians or others in a position to refer, purchase, or recommend
drug products. For example, some states impose a legal obligation on companies to adhere to voluntary industry codes of behavior (e.g.,
the PhRMA Code), which apply to pharmaceutical companies&#8217; interactions with healthcare providers, some mandate implementation of
corporate compliance programs, along with the tracking and reporting of gifts, compensation, and other remuneration to physicians, and
some states limit or prohibit such gifts. Further, the Healthcare Reform Law, among other things, amended the intent requirement of the
federal Anti-Kickback Statute so that a person or entity can now be found guilty of fraud or an anti-kickback violation without actual
knowledge of the statute or specific intent to violate it. In addition, the Healthcare Reform Law provides that the government may assert
that a claim including items or services resulting from a violation of the federal Anti-Kickback Statue constitutes a false or fraudulent
claim for purposes of the False Claims Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The scope and enforcement
of these laws are broad, often uncertain and subject to change in the current environment of healthcare reform, especially in light of
the lack of applicable precedent and guidance in many areas. We cannot predict the impact that new legislation or any changes in existing
legislation will have on our business, financial condition, or results of operations. Federal or state regulatory authorities may challenge
our prior and/or future activities under these laws. Any such challenge could have a material adverse effect on our reputation, business,
results of operations, and financial condition. Any state or federal regulatory review of us, regardless of the outcome, would be costly
and time-consuming and could negatively and adversely affect our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We could be exposed
to significant drug product liability claims, which could be time consuming and costly to defend, divert management attention and adversely
impact our ability to obtain and maintain insurance coverage.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The clinical trials that
we conduct, conducted or may have to conduct, and the testing, manufacturing, marketing and commercial sale of our oncology therapeutic
candidates or any other therapeutic candidates that we may develop or acquire in the future, involve and will involve an inherent risk
that significant liability claims may be asserted against us. Should we decide to seek additional insurance against such risks before
we initiate clinical trials or commence our product sales, there is a risk that such insurance will be unavailable to us, or if it can
be obtained at such time, that it will be available only at an unaffordable cost. Even if we obtain insurance, it may prove inadequate
to cover claims or litigation costs, especially in the case of wrongful death claims. Product liability claims or other claims related
to our therapeutic candidates or any other therapeutic candidate that we may develop or acquire in the future, regardless of their outcome
and merit, could require us to spend significant time and money in litigation or to pay significant settlement amounts or judgments.
Any successful product liability or other claim may prevent us from obtaining adequate liability insurance in the future on commercially
desirable or reasonable terms. An inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against
potential product liability claims could prevent or inhibit the commercialization of our therapeutic candidates or any other therapeutic
candidates that we may develop or acquire in the future. A product liability claim could also significantly harm our reputation and delay
market acceptance of our therapeutic candidates or any other therapeutic candidate that we may develop or acquire in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our business involves
risks related to handling regulated substances which could severely affect our ability to conduct research and development of our therapeutic
candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with our current
or potential development and commercialization partners&#8217; research and clinical development activities, as well as the manufacture
of materials and therapeutic candidates, we and our current or potential development and commercialization partners are subject to foreign,
federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent
discharge, handling and disposal of certain materials, biological specimens and wastes. We and our current or potential development and
commercialization partners may be required to incur significant costs to comply with environmental and health and safety regulations
in the future. Our research and clinical development, as well as the activities of our manufacturing and current or potential development
and commercialization partners, both now and in the future, may involve the controlled use of hazardous materials, including but not
limited to certain hazardous chemicals. We cannot eliminate the risk of accidental contamination or injury from these materials. In the
event of such an occurrence, we could be held liable for any damages that result, and any such liability could exceed our resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Unfavorable macroeconomic
conditions and other adverse macroeconomic factors could adversely affect our business, financial condition, cash flow or results of
operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unfavorable macroeconomic
conditions and other adverse macroeconomic factors have resulted, among other matters, in tightening in the debt and equity markets,
and high levels of inflation. For example, tightening of the equity markets makes it more difficult to raise capital at a reasonable
valuation, or at all. In addition, the U.S. Bureau of Labor Statistics has reported for the period from January 2022 to January 2023,
the Consumer Price Index for All Urban Consumers rose 6.4 percent, from January 2023 to January 2024, the Consumer Price Index for All
Urban Consumers rose 3.1 percent, and from January 2024 to January 2025, the Consumer Price Index for All Urban Consumers rose 3.0 percent.
If the inflationary pressure continues for a prolonged period, it may continue to result in increased costs of labor, cost of clinical
trials, and costs of manufacturing which could adversely affect our results of operations. Furthermore, in recent years, there has been
a significant increase in interest rates that impacted the cost of debt, liquidity and valuations of companies and other assets. Our
results of operations could be adversely affected by general conditions in the global and local macroeconomic economic conditions affecting
the financial markets. An economic downturn could result in a variety of risks to our business, including weakened demand for our therapeutic
candidates and our inability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could
also strain our partners and suppliers, possibly resulting in supply disruption, or cause future customers to delay making payments for
our products. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate
and financial market conditions could adversely impact our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b><i>Our
business and operations may be materially adversely affected in the event of computer system failures or security or breaches due to
cyber-attacks or cyber intrusions, including ransomware, phishing attacks and other malicious intrusions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
recent years, cybersecurity threats have become a greater risk and focus for companies. In particular, ransomware attacks, where a hacker
locks and threatens to delete or disclose the victim&#8217;s data unless a ransom is paid, has become a major risk. We and those of our
third-party contract manufacturers and other third parties on which we rely are at risk of cyber-attacks or cyber intrusions via the
Internet, computer viruses, break-ins, malware, ransomware, phishing attacks, hacking, denial-of-service attacks or other attacks and
similar disruptions from unauthorized use of, or access to, computer systems (including from internal and external sources). These types
of incidents continue to be prevalent and pervasive across industries, including in our industry. In addition, we expect information
security risks to continue to increase due to the proliferation of new technologies and the increased sophistication and activities of
organized crime, hackers, terrorists and other external parties, including foreign state actors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Despite
the implementation of security measures, our internal computer systems, and those of our third-party contract manufacturers and other
third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyber-attacks, cyber intrusions,
natural disasters, fire, terrorism, war, and telecommunication and electrical failures. If such an event were to occur and interrupt
our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data
from ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs
to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or
applications, loss of trade secrets or inappropriate disclosure of confidential or proprietary information, including protected health
information or personal data of employees or former employees, access to our clinical data, we could incur liability and the further
development of our therapeutic candidates could be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Scrutiny of sustainability
and environmental, social, and governance (&#8220;ESG&#8221;) initiatives could increase our costs or otherwise adversely impact our
business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
recent years, increasing attention has been given to corporate activities related to ESG practices from investors and other stakeholders
with various views on these topics. For example, certain institutional and individual investors have requested various ESG-related information
and disclosures as they increasingly incorporate ESG criteria in making investment and voting decisions. Such requests may result in
increased costs, enhanced compliance or disclosure obligations, or other adverse impacts on our business, financial condition or results
of operations. If our ESG practices and reporting do not meet investor or other stakeholder expectations, we may be subject to investor
or regulator engagement regarding such matters. In addition, our failure to comply with any applicable sustainability rules or regulations
that may be adopted could lead to penalties and adversely impact our reputation, access to capital and employee retention. Such ESG matters
may also impact our third-party contract manufacturers and other third parties on which we rely, which may augment or cause additional
impacts on our business, financial condition, or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Third-party claims
of intellectual property infringement and other legal challenges may require us to spend substantial time and money and could prevent
us from or delay us in developing or commercializing our therapeutic candidates. An adverse result in any infringement claims or other
legal challenges could have a material adverse effect on our business, results of operations and on our financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The development, manufacture,
use, offer for sale, sale or importation of our therapeutic candidates may infringe on the claims of third-party patents or other intellectual
property rights. The nature of claims contained in unpublished patent filings around the world is unknown to us, and it is impossible
to know which countries patent holders may choose for the extension of their filings under the Patent Cooperation Treaty, or other mechanisms.
We may not have identified all patents, published applications or published literature that affect our business either by blocking our
ability to commercialize our products or potential products, by preventing the patentability of one or more aspects of our products or
potential products, or by covering the same or similar technologies that may affect our ability to market our products and potential
products. For example, we may not have conducted a patent clearance search sufficient to identify potentially obstructing third party
patent rights. Because patent applications in Europe, the United States and many foreign jurisdictions are typically not published until
18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that
others have not filed patents that may cover our technologies, our product candidates or the use of our product candidates. In some cases,
however, patent applications remain confidential in the U.S. Patent and Trademark Office, or the USPTO, for the entire time prior to
issuance as a U.S. patent. We cannot be certain that we or our licensors were the first to invent, or the first to file, patent applications
covering our products and candidates. We also may not know if our competitors filed patent applications for technology covered by our
pending applications. Competitors may have filed patent applications or received patents and may obtain additional patents and proprietary
rights that block or compete with our patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, pending patent
applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies,
our product candidates or the use of our product candidates. As a result, we may become party to, or threatened with, future adversarial
proceedings or litigation regarding patents with respect to our product candidates and technology. The scope of a patent claim is determined
by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of
the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our
drug candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly
predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration
date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability
to develop and market our drug candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our
ability to develop and market our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third parties may assert
that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with
claims to materials, formulations, methods of manufacture, or methods of treatment related to the use or manufacture of our commercial
products or drug product candidates. We cannot guarantee that any of our search and review is sufficiently complete and thorough, nor
can we be sure that we have identified each and every patent and pending application in the United States and abroad that is relevant
or necessary to the commercialization of our commercial products or drug product candidates. Because patent applications can take many
years to issue, there may be currently pending patent applications that may later result in issued patents that our commercial products
or drug product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies
infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process
of any of our commercial products or drug product candidates, any molecules formed during the manufacturing process or any final product
itself, the holders of any such patents may be able to block our ability to import or otherwise continue commercialization of such commercial
product or to commercialize such drug product candidate unless we obtained a license under the applicable patents, or until such patents
expire or are finally determined to be invalid or unenforceable. Similarly, if any third-party patents were held by a court of competent
jurisdiction to cover aspects of our formulations, processes for manufacture, or methods of use, the holders of any such patents may
be able to block our ability to continue the commercialization of our commercial products or to develop and commercialize the applicable
drug product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of patent infringement
claims, or to avoid potential claims, we may choose or be required to seek a license from a third-party and would most likely be required
to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to
obtain a license, the rights may be non-exclusive, which could potentially limit our competitive advantage. Ultimately, we could be prevented
from commercializing a therapeutic candidate or be forced to cease some aspect of our business operations if, as a result of actual or
threatened patent infringement or other claims, we are unable to enter into licenses on acceptable terms.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parties making claims against
us may obtain injunctive or other equitable relief, which could effectively block our ability to further commercialize our commercial
products or develop and commercialize one or more of our drug product candidates. Defense of these claims, regardless of their merit,
would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event
of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217;
fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which
may be impossible or require substantial time and monetary expenditure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost to us of any intellectual
property litigation or other infringement proceeding, even if resolved in our favor, could be substantial. Some of our competitors may
be able to sustain the costs of such litigation or proceedings more effectively because of their substantially greater financial resources.
Uncertainties resulting from the initiation and continuation or defense of intellectual property litigation or other legal proceedings
or litigation could have a material adverse effect on our ability to compete in the marketplace. Intellectual property litigation and
other proceedings may also absorb significant cash resources and management attention and time. Consequently, we are unable to guarantee
that we will be able to manufacture, use, offer for sale, sell or import our therapeutic candidates in the event of an infringement action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may be unable to
adequately protect or enforce our rights to intellectual property, causing us to lose valuable rights. Loss of any of our intellectual
property rights may lead us to lose market share and could have an adverse effect on our business, results of operations and financial
condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends, in part,
on our ability, and the ability of our potential development and commercialization partners to obtain patent protection for our therapeutic
candidates, maintain the confidentiality of our trade secrets and know-how, operate without infringing on the proprietary rights of others
and prevent others from infringing our proprietary rights. We may become involved in proceedings, including oppositions, post grant reviews,
interferences, derivation proceedings, inter parties&#8217; reviews, patent nullification proceedings, or re-examinations challenging
our patent rights or the patent rights of others, and the outcome of any such proceedings are uncertain. An adverse determination in
any such proceeding could reduce the scope of, or invalidate, important patent rights, allow third parties to commercialize our technology,
products and/or product candidates and compete directly with us without being obligated to make any payments to us, or result in our
inability to manufacture or commercialize products and/or product candidates without infringing third-party patent rights. Litigation
or other proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if the breadth
or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating
with us to license, develop or commercialize current or future product candidates. Even if our patent applications are successfully issued
as patents, they may not be issued in a form that will provide us with any meaningful protection, prevent competitors from competing
with us, or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing
similar or alternative technologies or products in a non-infringing manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigations in general, there is a risk that some of
our confidential information could be compromised by disclosure during intellectual property litigation or proceeding. Such litigation
or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any
future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation
or proceedings adequately. Most of our competitors are larger than we are and have substantially greater resources. They are, therefore,
likely to be able to sustain the costs of complex intellectual property litigation or proceedings more effectively than we can because
of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts,
we may not be able to prevent third parties from infringing, misappropriating or otherwise violating our intellectual property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We try to protect our proprietary
position by, among other things, filing U.S. and other patent applications related to our therapeutic candidates, inventions and improvements
that may be important to the continuing development of our therapeutic candidates. Because the patent position of pharmaceutical companies
involves complex legal and factual questions, we cannot predict the validity and enforceability of any patents we may obtain with certainty.
The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates
in the United States or in other foreign countries. Publications of discoveries in the scientific literature often lag behind the actual
discoveries, and patent applications in the United States and other jurisdictions remain confidential for a period of time after filing,
and some remain so until issued. We cannot be certain that we were the first to file any patent application related to our product candidates,
or whether we were the first to make the inventions claimed in our owned patents or pending patent applications, nor can we know whether
those from whom we license patents were the first to make the inventions claimed or were the first to file. As a result, the issuance,
scope, validity, enforceability and commercial value of our patent rights are highly uncertain. There is no assurance that all potentially
relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent
from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates,
third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable
or invalidated, which could allow third parties to commercialize our technology or products and compete directly with us, without payment
to us, or result in our inability to manufacture or commercialize products without infringing third party patent rights. Furthermore,
even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity
for commercial products or drug product candidates, prevent others from designing around our claims or provide us with a competitive
advantage. Any of these outcomes could impair our ability to prevent competition from third parties, which may have a material adverse
impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, the issuance of
a patent, while presumed valid and enforceable, is not conclusive as to its validity or its enforceability and it may not provide us
with adequate proprietary protection or competitive advantages against competitors with similar products. Competitors may also be able
to design around our patents. Other parties may develop and obtain patent protection for more effective technologies, designs or methods.
We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants, vendors,
former employees and current employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors may independently
develop products similar to ours or design around or otherwise circumvent any patents that may be issued to or licensed by us. Our pending
patent applications, and those that we may file in the future or those we may license from third parties may not result in patents being
issued. If these patents are issued, they may not provide us with proprietary protection or competitive advantages. The degree of future
protection to be afforded by our proprietary rights is uncertain because legal means afford only limited protection and may not adequately
protect our rights or permit us to gain or keep our competitive advantage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, our ability
to enforce our patent rights depends on our ability to detect infringement. It is difficult to detect infringers who do not advertise
the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s
or potential competitor&#8217;s product, particularly in litigation in countries other than the U.S. that do not provide an extensive
discovery procedure. Any litigation to enforce or defend our patent rights, if any, even if we were to prevail, could be costly and time-consuming
and would divert the attention of our management and key personnel from its business operations. We may not prevail in any lawsuits that
we initiate and the damages or other remedies awarded if it were to prevail may not be commercially meaningful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent rights are territorial;
thus, the patent protection we have sought will only extend, if issued, to those countries, if any, in which we will be issued patents.
Even so, the laws of certain countries do not protect our intellectual property rights to the same extent as do the laws of the U.S.
Competitors may successfully challenge any of our patents, produce similar drugs or products that do not infringe such patents, or produce
drugs in countries where we have not applied for patent protection or that do not respect such patents. Furthermore, it is not possible
to know the scope of claims that will be allowed in published applications and it is also not possible to know which claims of granted
patents, if any, will be deemed enforceable in a court of law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting, and
defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some
countries outside the United States can be less extensive than those in the United States. Consequently, we may not be able to prevent
third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using
our inventions in and into the United States or other jurisdictions. As part of ordinary course prosecution and maintenance activities,
we determine whether to seek patent protection outside the U.S. and in which countries. This also applies to patents we have acquired
or in-licensed from third parties. In some cases this means that we, or our predecessors in interest or licensors of patents within our
portfolio, have sought patent protection in a limited number of countries for patents covering our product candidates. Competitors may
use our technologies in jurisdictions where we have not obtained or are unable to adequately enforce patent protection to develop their
own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is
not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property
rights may not be effective or sufficient to prevent them from competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain
countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual
property protection, particularly those relating to pharmaceutical products, which could make it difficult for us to stop the infringement
of our patents, the reproduction of our manufacturing or other know-how or marketing of competing products in violation of our proprietary
rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or
interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us.
We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful.
Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial
advantage from the intellectual property that we develop or license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the completion of development
and registration of any future patents, third parties may still act to manufacture or market our therapeutic candidates in infringement
of our patent protected rights. Such manufacture or marketing of our therapeutic candidates in infringement of any patent-protected rights
is likely to cause us damage and lead to a reduction in the prices of our therapeutic candidates, thereby reducing our potential profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may invest a significant
amount of time and expense in the development of our therapeutic candidates only to be subject to significant delay and patent litigation
before they may be commercialized. In addition, due to the extensive time needed to develop, test and obtain regulatory approval for
our therapeutic candidates, any patents that may be issued that protect our therapeutic candidates may expire early during commercialization.
This may reduce or eliminate any market advantages that such patents may give us. Patents have a limited lifespan. In the United States,
if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional
filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents
covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition
from competitive medications. Following patent expiration, we may face increased competition through the entry of generic products into
the market and a subsequent decline in market share and profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing some of
our therapeutic candidates in collaboration with academic and other research institutes and biopharmaceutical companies. While we attempt
to ensure that our intellectual property is protected under the terms of our collaboration agreements with such institutes, these institutes
may have claims to our intellectual property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We do not have patent
protection in certain countries, and we may not be able to effectively enforce our intellectual property rights in certain countries,
which could significantly erode the market for our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to seek regulatory
approval to market our oncology therapeutic candidates in a number of foreign countries. Our oncology therapeutic candidates are not
protected by patents in certain countries, which means that competitors may be free to sell products that incorporate the same technology
that is used in our products in those countries. In addition, the laws and practices in some foreign countries may not protect intellectual
property rights to the same extent as in the United States. We or our licensors may not be able to effectively obtain, maintain or enforce
rights with respect to the intellectual property relating to our oncology product candidates in those countries. In that regard, we believe
that although China is one of the largest potential markets for some of our products under development, some of our product candidates
are less protected by patents in China than in the U.S., and it may be difficult to enforce intellectual property rights in China. Our
lack of patent protection in one or more countries, or the inability to obtain, maintain or enforce intellectual property rights in one
or more countries, could adversely affect our ability to commercialize our products in those countries and could otherwise have a material
adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we are unable to
protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to filing patents,
we generally try to protect our trade secrets, know-how and technology by entering into confidentiality or non-disclosure agreements
with parties that have access to it, such as our current or potential development and commercialization partners, employees, contractors
and consultants. We also enter into agreements that purport to require the disclosure and assignment to us of all, or certain, rights
to the ideas, developments, discoveries and inventions of our employees, advisors, research collaborators, contractors and consultants
while we employ or engage them. However, these agreements can be difficult and costly to enforce or may not provide adequate remedies.
Any of these parties may breach the confidentiality agreements and willfully or unintentionally disclose our confidential information,
or our competitors might learn of the information in some other way. The disclosure to, or independent development by, a competitor of
any trade secret, know-how or other technology not protected by a patent could materially adversely affect any competitive advantage
we may have over any such competitor. In addition, monitoring infringement of intellectual property rights is difficult, and we cannot
be certain that the steps we have taken will prevent unauthorized use of our know-how, particularly in China and other countries in which
the laws may not protect our proprietary rights as fully as the laws of the United States. Accordingly, other parties, including competitors,
may improperly duplicate our products using our proprietary technologies. Pursuing legal remedies against persons infringing our patents
or otherwise improperly using our proprietary information is a costly and time-consuming process that would divert management&#8217;s
attention and other resources from the conduct of our normal business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we expect all of
our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, and any third parties
who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any
assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information
will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially
equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive
position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed
inadequate, we may have insufficient recourse against third parties for misappropriating such trade secrets. In addition, others may
independently discover our trade secrets and proprietary information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that any of
our employees, advisors, research collaborators, contractors or consultants independently develop, or use independently developed, intellectual
property in connection with any of our projects, disputes may arise as to the proprietary rights to this type of information. If a dispute
arises with respect to any proprietary right, enforcement of our rights can be costly and unpredictable, and a court may determine that
the right belongs to a third-party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may be subject to
other patent-related litigation or proceedings that could be costly to defend and uncertain in their outcome.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to infringement
claims against us, we may in the future become a party to other patent litigation or proceedings before regulatory agencies, including
interference or re-examination proceedings filed with the U.S. Patent and Trademark Office (USPTO) or opposition proceedings in other
foreign patent offices regarding intellectual property rights with respect to our therapeutic candidates, as well as other disputes regarding
intellectual property rights with our current and potential development and commercialization partners, or others with whom we have contractual
or other business relationships. Post-issuance oppositions are not uncommon, and we and our current and potential development and commercialization
partners will be required to defend these opposition procedures as a matter of course. Opposition procedures may be costly, and there
is a risk that we may not prevail.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In particular, we may be
subject to a third-party pre-issuance submission of prior art or become involved in opposition, derivation, reexamination, <i>inter partes
</i>review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of
defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial
and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of,
or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without
payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition,
if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from
collaborating with us to license, develop or commercialize current or future product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Obtaining and maintaining
our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed
by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodic maintenance fees
on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The
USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late
fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment
or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance
events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond
to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents.
In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may be subject to
claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third
parties, such as trade secrets of their former employers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also be subject to
claims based on the actions of employees and consultants with respect to the usage or disclosure of intellectual property learned at
other employers. We employ and utilize the services of individuals who were previously employed or provided services to universities
or other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants, and independent contractors
do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees,
consultants, or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets
or other proprietary information, of any of our employee&#8217;s, consultant&#8217;s or independent contractor&#8217;s former employer
or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition
to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could materially adversely impact our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, we may be subject
to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property
as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others
who are involved in developing our drug product candidates. Litigation may be necessary to defend against these and other claims challenging
inventorship or our ownership of our patents or other intellectual property. If we fail in defending any such claims, in addition to
paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable
intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against
such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to our Operations in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
conduct our operations in Israel and therefore, political, economic and military instability in Israel and its region may adversely affect
our business, results of operations, and financial condition. </i></b></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we are incorporated
under the laws of the state of Israel and our operations are conducted in Israel, our business and operations are directly affected by
economic, political, geopolitical and military conditions in Israel. Any hostilities involving Israel, or the interruption or curtailment
of trade within Israel or between Israel and its trading partners could adversely affect our operations and results of operations and
could make it more difficult for us to raise capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the establishment of
the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations
active in the region, including Hamas (an Islamist militia and political group in the Gaza Strip) and Hezbollah (an Islamist militia
and political group in Lebanon) ), which have involved missile strikes, hostile infiltrations, terrorism against civilian targets in
various parts of Israel, and recently abduction of soldiers and citizens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 7, 2023, Hamas
terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military
targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers. In response, Israel&#8217;s security
cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued
rocket and terror attacks. Subsequent to the commencement of the Hamas-Israel war, Hezbollah in Lebanon launched missile, rocket and
shooting attacks against Israeli military sites, troops and Israeli towns in northern Israel; and the Houthis, a military organization
based in Yemen, launched a series of attacks on global shipping routes in the Red Sea, as well as direct attacks on various parts of
Israel. In response to these attacks, the Israeli army carried out a number of targeted strikes on sites belonging to Hezbollah and conducted
ground operations in southern Lebanon. In addition, in April and October 2024, Iran launched direct attacks on Israel, involving hundreds
of drones and ballistic missiles launched directly towards highly populated civilian areas and military bases. In November 2024, a ceasefire
agreement was reached between Hezbollah in Lebanon and Israel, and in January 2025, a temporary ceasefire agreement was reached between
Hamas in Gaza and Israel; however, we cannot predict if and to what extent these ceasefire agreements will remain in effect or will be
upheld and military activity and hostilities continue to exist at varying levels of intensity, and the situation remains volatile, with
the potential for escalation into a broader regional conflict involving additional terrorist organizations and possibly other countries.
Also, the fall of the Assad regime in Syria may create geopolitical instability in the region. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the war broke out in
October 2023, our operations have not been adversely affected in a material manner, and we have not experienced material disruptions
to our business operations. We currently do not have active clinical studies in Israel and CM24 and NT219 are both manufactured by service
providers outside of Israel. Most of our research and development work is being conducted by third-party entities outside of Israel.
However, a prolonged and/or heightened conflict could have an adverse effect on our business, financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial insurance
does not cover losses that may occur as a result of events associated with the security situation in the Middle East. Although the Israeli
government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot
assure you that this government coverage will be maintained or, if maintained, will be sufficient to compensate us fully for damages
incurred. Any losses or damages incurred by us could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global perception of
Israel and Israeli companies, influenced by actions by international judicial bodies, may lead to increased sanctions and other negative
measures against Israel and Israeli companies. In addition, the political and security situation in Israel could also result in parties
with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under
those agreements pursuant to force majeure provisions in such agreements. There is also a growing movement among countries, activists,
and organizations to boycott Israeli goods and services or restrict business with Israel and Israeli companies. These restrictive laws
and policies, along with any future rulings from international tribunals against Israel, may have an adverse impact on our operating
results, financial condition or our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Israeli security cabinet&#8217;s declaration
of war against Hamas and possible hostilities with other organizations, several hundred thousand Israeli military reservists were drafted
to perform immediate military service. As of March 6, 2025, none of our current employees in Israel are currently on active military duty.
However, military service call ups that result in absences of personnel for extended periods may materially and adversely affect our business,
prospects, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, political conditions
within Israel may affect our operations. Israel held five general elections between 2019 and 2022, and prior to October 2023, the Israeli
government pursued extensive changes to Israel&#8217;s judicial system, and has recently renewed its efforts to effect such changes.
In response to the foregoing developments, certain individuals, organizations, and institutions, both within and outside of Israel, voiced
concerns that such proposed changes, if adopted, may negatively impact the business environment in Israel. Such proposed changes may
also lead to political instability or civil unrest. Actual or perceived political instability in Israel or any negative changes in the
political environment, may individually or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial
condition, results of operations and the market price of our shares, as well as on our ability to raise additional capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>It may be difficult
to enforce a U.S. judgment against us and our officers and directors in Israel or the United States, to assert U.S. securities laws claims
in Israel or to serve process on our officers and directors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated in Israel.
All of our executive officers and most of our directors reside outside of the United States, and all of our assets and most of the assets
of our executive officers and directors are located outside of the United States. Therefore, a judgment obtained in the United States
against us or such executive officers and our directors, including one based on the civil liability provisions of the U.S. federal securities
laws, may not be collectible in the United States, and it may be difficult for you to affect service of process on these persons in the
United States. In addition, it may be difficult to assert U.S. securities law claims in original actions instituted in Israel or obtain
a judgment in Israel based on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse to hear a claim
based on an alleged violation of U.S. securities laws against us or our non-U.S. officers and directors on the grounds that Israel is
not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear such a claim, it may determine
that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law
must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also
be governed by Israeli law. There is little binding case law in Israel that addresses the matters described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, Israeli courts
might not enforce judgments obtained in the United States against us or our non-U.S. directors and executive officers, which may make
it difficult to collect on judgments rendered against us or our non-U.S. officers and directors by either a U.S. or foreign court. Moreover,
an Israeli court will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of
judgments of Israeli courts (subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of
the State of Israel, if it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that
was given in the same matter between the same parties, or if a suit in the same matter between the same parties was pending before a
court or tribunal in Israel at the time the foreign action was brought.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Claims for indemnification
by our directors and officers may reduce our available funds to satisfy successful shareholder claims against us and may reduce the amount
of money available to us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law and our
amended and restated articles of association permit us to indemnify our directors and officers for acts performed by them in their capacity
as directors and officers. The Companies Law and our amended and restated articles of association provide that a company may not exempt
or indemnify a director or an office holder nor enter into an insurance contract, which would provide coverage for any monetary liability
incurred as a result of (a) a breach by the director or officer of his duty of loyalty, except for insurance and indemnification where
the director or officer acted in good faith and had a reasonable basis to believe that the act would not prejudice the company; (b) a
breach by the director or officer of his duty of care if the breach was done intentionally or recklessly, except if the breach was solely
as a result of negligence; (c) any act or omission done with the intent to derive an illegal personal benefit; or (d) any fine, civil
fine, monetary sanctions, or forfeit imposed on the officer or director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have issued letters of
indemnification to our directors and officers, pursuant to which we have agreed to indemnify them in advance for any liability or expense
imposed on or incurred by them in connection with acts they perform in their capacity as a director or officer, to the fullest extent
permitted by applicable law, to the extent that these liabilities are not covered by insurance. The total amount of the indemnity will
not exceed 25% of our then consolidated shareholders&#8217; equity, per our most recent audited or reviewed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our indemnification obligations
limit the personal liability of our directors and officers for monetary damages for breach of their duties as directors by shifting the
burden of such losses and expenses to us. Although we have obtained directors&#8217; and officers&#8217; liability insurance, certain
liabilities or expenses covered by our indemnification obligations may not be covered by such insurance or the coverage limitation amounts
may be exceeded.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Atzmon
Claim described in &#8220;Item 8. Financial Information &#8211; A. Consolidated Statements and Other Financial Information &#8211; Legal
Proceedings&#8221;, or other claims which may be filed against our directors and officers, we may need to use a significant amount of
our funds to satisfy our indemnification obligations, which could severely harm our business and financial condition and limit the funds
available to shareholders who may choose to bring a claim against our company. See the risk factor titled &#8220;<i>Third-party claims
of intellectual property infringement and other legal challenges may require us to spend substantial time and money and could prevent
us from or delay us in developing or commercializing our therapeutic candidates. An adverse result in any infringement claims or other
legal challenges could have a material adverse effect on our business, results of operations and on our financial condition,&#8221;</i>
under the risk factor section titled &#8220;Risks Related to Intellectual Property&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These provisions and resultant
costs may also discourage us from bringing a lawsuit against directors and officers for breaches of their duties and may similarly discourage
the filing of derivative litigation by our shareholders against the directors and officers even though such actions, if successful, might
otherwise benefit our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Provisions of Israeli
law and our amended and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of the
Company, or an acquisition of a significant portion of our shares, which could prevent a change of control, and negatively affect the
market price of our ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli corporate law regulates
mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for certain transactions
involving directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions.
These provisions of Israeli law may delay, prevent or make difficult an acquisition of us, which could prevent a change of control and
therefore depress the price of our shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Israeli tax
considerations may make potential transactions unappealing to us or to our shareholders, especially for those shareholders whose country
of residence does not have a tax treaty with Israel which exempts such shareholders from Israeli tax. For example, Israeli tax law does
not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral
in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a
holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies
are subject to certain restrictions. Moreover, with respect to certain share exchange transactions, the tax deferral is limited in time,
and when such time expires, the tax becomes payable even if no disposition of the shares has occurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our amended
and restated articles of association also contain provisions that could delay or prevent changes in control. These provisions include
matters in connection with the election and removal of directors, such as our staggered Board, the right of our Board to appoint additional
directors to fill vacancies on the Board, the size of our Board, the terms of office of our directors and the special majority required
to amend such provision in our amended and restated articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, under our amended
and restated articles of association, we have 50,000,000 shares of authorized non-voting senior preferred shares, which can be issued
by our Board, which contain superior liquidation and dividend rights, and may contain other rights, including conversion, redemption,
optional and other special rights, qualifications, limitations or restrictions, equivalent or superior to our ordinary shares, without
further action by our shareholders, unless shareholder approval is otherwise required by applicable law, the rules of any exchange or
other market on which our securities may then be listed or traded, our articles of association then in effect, or any other applicable
rules and regulations. Furthermore, in a merger between Israeli companies, if the non-surviving entity has more than one class of shares,
the merger may need to be approved by each class of shareholders, including any classes of otherwise non-voting shares, such as our authorized
non-voting senior preferred shares. See <i>&#8220;We can issue non-voting senior preferred shares without shareholder approval, which
could adversely affect the rights of holders of ordinary shares.&#8221;</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These and other similar provisions
could delay, prevent or impede an acquisition of us by a third-party or our merger with another company, or an acquisition of a significant
portion of our shares, and may make it more difficult for our shareholders to elect different individuals to our Board, even if doing
so would be considered to be beneficial by some of our shareholders, and may limit the price that investors may be willing to pay in
the future for our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Because a certain portion
of our expenses is incurred in currencies other than the U.S. dollar, our results of operations may be harmed by currency fluctuations
and inflation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our reporting and functional
currency is the U.S. dollar. Most of the royalty payments from potential development and commercialization partners are expected to be
payable in U.S. dollars, and we expect our revenues from future sales or licensing agreements to be denominated mainly in U.S. dollars.
We pay a portion of our expenses in U.S. dollars; however, a portion of our expenses, related to salaries of our employees in Israel,
our office lease and payment to part of the service providers in Israel, are paid in NIS and in other currencies, such as euro to our
suppliers in Europe. In addition, a portion of our financial assets is held from time to time in NIS. As a result, we are exposed to
currency fluctuation risks and inflation. For example, if the NIS appreciates against the U.S. dollar, our NIS expenses as reported in
U.S. dollars may be higher than anticipated. In addition, if the NIS depreciates against the U.S. dollar, the U.S. dollar value of our
financial assets held in NIS will decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Your rights and responsibilities
as a shareholder are governed by Israeli law, which may differ in some respects from the rights and responsibilities of shareholders
of U.S. companies. Israeli law may impose obligations and responsibilities on a shareholder of an Israeli company that are not imposed
upon shareholders of corporations in the U.S.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
Israeli law. The rights and responsibilities of the holders of our ordinary shares are governed by our amended and restated articles
of association and Israeli law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders
in typical U.S.-based corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary
manner in exercising its rights and fulfilling its obligations toward the company and other shareholders and to refrain from abusing
its power in the company, including, among other things, in voting at the general meeting of shareholders on matters such as amendments
to a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers and acquisitions and related
party transactions requiring shareholder approval under the Companies Law. In addition, a controlling shareholder of an Israeli company
or a shareholder who knows that it possesses the power to determine the outcome of a shareholder vote or who has the power to appoint
or prevent the appointment of a director or executive officer in the company or has other powers toward the company has a duty of fairness
toward the company. There is limited case law available to assist us in understanding the implications of these provisions that govern
shareholders&#8217; actions. These provisions may be interpreted to impose additional obligations and responsibilities on holders of
our ordinary shares and/or ADSs that are not typically imposed on shareholders of U.S. corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our amended and restated
articles of association designate courts located either within the State of Israel, or the Federal District Courts of the United States,
as the exclusive forum for certain litigation that may be initiated by our shareholders, which could limit our shareholders&#8217; ability
to bring a favorable or convenient judicial forum for disputes with us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated
articles of association provide that, unless we consent in writing to the selection of an alternative forum, the Tel Aviv District Court
(Economic Division in the State of Israel (or, if the Tel Aviv District Court does not have jurisdiction, and no other Israeli court
has jurisdiction, the federal district court for the District of New York) shall be the sole and exclusive forum for (1) any derivative
action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors,
officers or other employees to us or our shareholders, and (3) any action asserting a claim arising pursuant to any provision of the
Companies Law or the Israeli Securities Law 5728-1968, in all cases subject to the court&#8217;s having personal jurisdiction over the
indispensable parties named as defendants. In addition, other than with respect to plaintiffs or a class of plaintiffs which may be entitled
to assert a cause of action arising under the Securities Act in the courts of the State of Israel, the federal district courts of the
United States for the District of New York shall otherwise be the exclusive forum for any complaint asserting a cause of action arising
under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in our shares or ADSs shall be deemed to
have notice of and consented to these provisions. This forum selection provision limits shareholders&#8217; choice in selecting a judicial
forum for disputes with us that it finds favorable or convenient and may have the effect of discouraging lawsuits against us or our directors
and officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Primarily Related to the ADSs and Our Ordinary Shares</b></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The market price of
our ordinary shares and ADSs is subject to fluctuation, which could result in substantial losses by investors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market in general,
and the market price of our ordinary shares on the TASE and ADSs on NASDAQ, are subject to fluctuation, and changes in the price of our
listed securities may be unrelated to our operating performance. The market prices of our ordinary shares on the TASE and ADSs on NASDAQ
have fluctuated in the past, and we expect it will continue to do so. The market price of our ordinary shares and ADSs is and will be
subject to a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of technological
    innovations or new therapeutic candidates by us or by others;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us of
    significant acquisitions, strategic partnerships, in-licensing, out-licensing, joint ventures or capital commitments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcement by us of preclinical
    and clinical results;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our need to raise additional
    capital;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expiration or terminations
    of licenses, research contracts or other development or commercialization agreements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">public concern as to the
    safety of drugs that we, our current or potential development and commercialization partners or others develop;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the volatility of market
    prices for shares of biotechnology companies generally;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success or failure of research
    and development projects;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">departure of key personnel;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments concerning
    intellectual property rights or regulatory approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations in our and our
    competitors&#8217; results of operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in earnings estimates
    or recommendations by securities analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the outcome of any litigation
    and other legal proceedings;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in government regulations
    or patent decisions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments by our current
    or potential development and commercialization partners; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic and market
    conditions and other factors, including factors unrelated to our operating performance and including the impact of Israel&#8217;s
    war with Hamas and other militant groups.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These factors and any corresponding
price fluctuations may materially and adversely affect the market price of our ordinary shares and ADSs and result in substantial losses
by investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, market prices
for listed securities of biotechnology and pharmaceutical companies have been very volatile and have experienced significant price and
volume fluctuations for reasons often unrelated to the operating performance of any one company. These fluctuations may be attributed,
among other reasons, to the general global economic environment and the instability in markets. In the past, following periods of market
volatility, shareholders have often instituted securities class action litigation. If we were involved in securities litigation, it could
have a substantial cost and divert resources and attention of management from our business, even if we are successful. See &#8220;<i>Third-party
claims of intellectual property infringement and other legal challenges may require us to spend substantial time and money and could
prevent us from or delay us in developing or commercializing our therapeutic candidates. An adverse result in any infringement claims
or other legal challenges could have a material adverse effect on our business, results of operations and on our financial condition&#8221;.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A continuation or worsening
of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital,
on our business, results of operations and financial condition, and on the market price of the ADSs or our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Future sales of our
ordinary shares or ADSs, or securities convertible into our ordinary shares or ADSs, or the perception that future sales may occur, could
reduce the market price of our ordinary shares and ADSs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 6, 2025, we had
an aggregate of 529,639,917 issued and outstanding ordinary shares (including 1 dormant ordinary share held in treasury), no issued and
outstanding non-voting senior preferred shares, outstanding non-listed warrants to purchase 731,289 ADSs (representing 146,257,800 ordinary
shares) issued to investors, underwriters and placement agents as part of a number of public and registered direct offerings by us and
126,416 outstanding options and restricted share units (&#8220;RSUs&#8221;). In the future, we may issue additional ordinary shares, ADSs
or other equity or debt securities exercisable or convertible into ordinary shares or ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 9, 2021, we entered
into the Sales Agreement with Jefferies for the sale of ADSs, pursuant to which we may offer and sell ADSs from time to time under our
ATM program, with Jefferies acting as our agent. We originally filed a prospectus for a $50.0 million ATM program, but the aggregate offering
price was subsequently reduced to $21.0 million on March 23, 2022, to $3.0 million on October 17, 2023, and to $1.33 million on January
6, 2025. As of March 6, 2025, we have sold approximately 606,037 ADSs for total gross proceeds of approximately $6.81 million under the
Sales Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 8, 2022, we filed
a registration statement on Form F-3 with the SEC utilizing a &#8220;shelf&#8221; registration process, under which we may offer and
sell, from time to time in one or more offerings, up to an aggregate of $200,000,000 of ADSs (representing our ordinary shares), ordinary
shares, preferred shares, warrants, overallotment purchase rights, subscription rights, units and/or capital notes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 2, 2024, we received
$2.0 million of gross proceeds from the exercise of certain existing warrants to purchase an aggregate of 281,675 ADSs, having original
exercise prices ranging from $25 to $400 per ADS, originally issued in October 2023, June 2020, January 2019 and June 2018, at a reduced
exercise price of $7.20 per ADS. In consideration for the exercise of the existing warrants for cash, we issued new unregistered Series
A-1 warrants to purchase up to an aggregate of 248,969 ADSs and new unregistered Series A-2 warrants to purchase up to an aggregate of
314,382 ADSs. The new warrants are exercisable at an exercise price of $8.00 per ADS. The Series A-1 warrants have a term of five years
from the issuance date and the Series A-2 warrants have a term of twenty-four months from the issuance date. In July 2024, we filed a
registration statement on Form F-1 with the SEC, under which the investors and placement agent in the offering may resell from time to
time the ADSs issuable upon exercise of the unregistered warrants issued to them in the offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">If
the registered ADSs issuable upon exercise of the unregistered warrants are sold to the public, the market price of the ADSs may decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any future sales by us or
our shareholders of a substantial number of our ordinary shares or ADSs, or securities convertible into our ordinary shares or ADSs,
or the perception that such sales may occur in the future, including sales of ordinary shares or ADSs issuable upon the exercise of warrants
or options, the vesting or RSUs or the conversion of convertible securities, may cause the market price of our ordinary shares or ADSs
or other listed securities to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may not meet the
continued listing requirements of NASDAQ, which could result in a delisting of the ADSs from NASDAQ.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ADSs are listed on NASDAQ.
We have in the past, and may in the future, be unable to comply with certain of the listing standards that we are required to meet to
maintain the listing of the ADSs on NASDAQ.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 25, 2024, we received
a letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC (the &#8220;Staff&#8221;) indicating that, based
on the closing bid price of the ADSs for the 30 consecutive business days from December 11, 2023 to January 24, 2024, we did not meet
the minimum bid price of $1.00 per share required for continued listing on NASDAQ pursuant to NASDAQ Listing Rule 5550(a)(2). In accordance
with NASDAQ Listing Rule 5810(c)(3)(A), we had an initial period of 180 calendar days from the date of the notification letter from The
Nasdaq Stock Market LLC, or until July 23, 2024, to regain compliance with the minimum bid price requirement. On July 24, 2024, we received
a letter from the Staff notifying us that NASDAQ granted us a 180-day extension, until January 21, 2025, to regain compliance with the
minimum bid price requirement. On September 17, 2024, we effected a change in the ratio of the ADSs to our ordinary shares, from one
(1) ADS representing ten (10) ordinary shares, to a new ADS ratio of one (1) ADS representing two hundred (200) ordinary shares. On October
1, 2024, we were notified by NASDAQ that we regained compliance with the minimum $1.00 bid price requirement on September 30, 2024, following
the increase of the ADS price on NASDAQ to above $1.00 per ADS for at least 10 consecutive business days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If in the future we fail
to meet the continued NASDAQ listing requirements, as a result of which NASDAQ delists the ADSs from trading on its exchange, an investor
would likely find it significantly more difficult to dispose of or obtain ADSs, and our ability to raise future capital through the sale
of ADSs could be severely limited. We additionally may not be able to list ADSs on another national securities exchange, which could
result in our securities being quoted on an over-the-counter market. If this were to occur, our shareholders could face significant material
adverse consequences, including limited availability of market quotations for ADSs and reduced liquidity for the trading of our securities.
In addition, we could experience a decreased ability to issue additional securities and obtain additional financing in the future. There
can be no assurance that an active trading market for ADSs will develop or be sustained. As a result of these factors, if the ADSs are
delisted from NASDAQ, the price of the ADSs is likely to decline. The delisting of the ADSs from NASDAQ could also have other negative
results, including the potential loss of confidence by employees, the loss of institutional investor interest and fewer business development
opportunities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the ADSs are delisted
from NASDAQ, we would remain a publicly traded company on the TASE and revert to being subject to full Israeli securities laws and disclosure
requirements. Accordingly, we will need to comply with U.S. and Israeli disclosure requirements, and we expect that these additional
reporting requirements would increase our legal and financial compliance costs and require significant management time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>In the event that the
ADSs are delisted from NASDAQ, U.S. broker-dealers may be discouraged from effecting transactions in the ADSs because they may be considered
penny stocks and thus be subject to the penny stock rules.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC has adopted a number
of rules to regulate &#8220;penny stock&#8221; that restrict transactions involving stock which is deemed to be penny stock. Such rules
include Rules 3a51-1, 15g-1, 15g-2, 15g-3, 15g-4, 15g-5, 15g-6, 15g-7, and 15g-9 under the Securities and Exchange Act of 1934, as amended
(the &#8220;Exchange Act&#8221;). These rules may have the effect of reducing the liquidity of penny stocks. &#8220;Penny stocks&#8221;
generally are equity securities with a price of less than $5.00 per share (other than securities registered on certain national securities
exchanges or quoted on NASDAQ if current price and volume information with respect to transactions in such securities is provided by
the exchange or system). Following a delisting from NASDAQ, the ADSs may constitute &#8220;penny stock&#8221; within the meaning of these
rules. The additional sales practice and disclosure requirements imposed upon U.S. broker-dealers may discourage such broker-dealers
from effecting transactions involving the ADSs, which could severely limit the market liquidity of the ADSs and impede their sale in
the secondary market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. broker-dealer selling
penny stock to anyone other than an established customer or &#8220;accredited investor&#8221; (generally, an individual with net worth
in excess of $1,000,000 or an annual income exceeding $200,000, or $300,000 together with his or her spouse) must make a special suitability
determination for the purchaser and must receive the purchaser&#8217;s written consent to the transaction prior to sale, unless the broker-dealer
or the transaction is otherwise exempt. In addition, the &#8220;penny stock&#8221; regulations require the U.S. broker-dealer to deliver,
prior to any transaction involving a &#8220;penny stock&#8221;, a disclosure schedule prepared in accordance with SEC standards relating
to the &#8220;penny stock&#8221; market, unless the broker-dealer or the transaction is otherwise exempt. A U.S. broker-dealer is also
required to disclose commissions payable to the U.S. broker-dealer and the registered representative and current quotations for the securities.
Finally, a U.S. broker-dealer is required to submit monthly statements disclosing recent price information with respect to the &#8220;penny
stock&#8221; held in a customer&#8217;s account and information with respect to the limited market in &#8220;penny stocks&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities holders should
be aware that, according to the SEC, the market for &#8220;penny stocks&#8221; has suffered in recent years from patterns of fraud and
abuse. Such patterns include (i) control of the market for the security by one or a few broker-dealers that are often related to the
promoter or issuer; (ii) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases;
(iii) &#8220;boiler room&#8221; practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales
persons; (iv) excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and (v) the wholesale dumping of
the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, resulting in investor losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We incur increased
costs and risks as a result of operating as a public company in the U.S. and Israel, and our management is and will continue to be required
to devote substantial time to compliance initiatives.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ADSs have been traded
on NASDAQ since November 20, 2015, and prior to that our ordinary shares traded on the TASE, where they continue to trade. As a public
company whose securities are listed in the United States and Israel, we incur accounting, legal and other expenses, including costs associated
with our reporting requirements under the Exchange Act and the Israeli Securities Law. We also incur costs associated with corporate
governance requirements, including requirements under Section 404 and other provisions of the Sarbanes-Oxley Act, as well as rules implemented
by the SEC and NASDAQ, and provisions of Israeli corporate and securities laws applicable to public companies. Certain aspects of Israeli
securities laws are different than U.S. securities law, and our dual listing on TASE exposes us and our management to differing regulatory
regimes which may involve increased regulatory risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Section 404 of
the Sarbanes-Oxley Act and the related rules adopted by the SEC and the Public Company Accounting Oversight Board, our management is
required to report on the effectiveness of our internal control over financial reporting. In addition, if we become an &#8220;accelerated
filer&#8221; or a &#8220;large accelerated filer&#8221; as those terms are defined under Rule 12b-2 of the Exchange Act, our independent
registered public accounting firm will be required to attest to our evaluation of internal controls over financial reporting. Unless
we successfully design and implement changes to our internal controls and management systems, or if we fail to maintain the adequacy
of these controls as such standards are modified or amended from time to time, we may not be able to comply with Section 404. As a result,
our auditors may be unable to attest to the effectiveness of our internal controls over financial reporting. This could subject us to
regulatory scrutiny and result in a loss of public confidence in our management, which could, among other things, adversely affect the
price of our ordinary shares and our ability to raise additional capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of determining
whether our existing internal controls over financial reporting systems are compliant with Section 404 and whether there are any material
weaknesses or significant deficiencies in our existing internal controls, requires the investment of substantial time and resources,
including by our chief executive officer, chief financial officer and other members of our senior management. As a result, this process
may divert internal resources and take a significant amount of time and effort to complete.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict the outcome
of evaluations we will conduct in the future, and whether we will need to implement additional remedial actions in order to implement
effective controls over financial reporting. The determination and any remedial actions required could result in us incurring additional
costs that we did not anticipate, including the hiring of outside consultants. Irrespective of compliance with Section 404, any failure
of our internal controls could have a material adverse effect on our stated results of operations and harm our reputation. As a result,
we may experience higher than anticipated operating expenses, as well as higher independent auditor fees during and after the implementation
of these changes. If we are unable to implement any of the required changes to our internal control over financial reporting effectively
or efficiently, it could adversely affect our operations, financial reporting and/or results of operations and could result in an adverse
opinion on internal controls from our independent auditors and cause the market price of our ordinary shares and ADSs to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in the laws and regulations
affecting public companies may result in increased costs to us as we respond to their requirements. These laws and regulations could
make it more difficult or costlier for us to obtain certain types of insurance, including director and officer liability insurance, and
we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage.
The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our Board,
our board committees or as executive officers. We cannot predict or estimate the amount or timing of additional costs we may incur in
order to comply with such requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We are a non-accelerated
filer, and we cannot be certain if the reduced disclosure requirements applicable to us will make the ADSs less attractive to investors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently a &#8220;non-accelerated
filer&#8221;, as that term is defined in the Securities Act. Accordingly, we take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not a &#8220;non-accelerated filers,&#8221; in particular, reduced
disclosure obligations regarding exemptions from the provisions of Section 404(b) of the Sarbanes-Oxley Act of 2002 requiring that independent
registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting. Decreased
disclosures in our SEC filings due to our status as a &#8220;non-accelerated filer&#8221; may make it harder for investors to analyze
our results of operations and financial prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict if investors
will find the ADSs less attractive if we rely on exemptions applicable to smaller reporting companies and non-accelerated filers. If
some investors find the ADSs less attractive as a result, there may be a less active trading market for the ADSs and our ordinary share
price may be more volatile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may be classified
as a Passive Foreign Investment Company, or PFIC, for U.S. federal income tax purposes in 2024 and may continue to be, or become, a PFIC
in future years, which may have negative tax consequences for U.S. investors. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be treated as a PFIC
for U.S. federal income tax purposes in any taxable year in which either (i) at least 75% of our gross income is &#8220;passive income&#8221;
or (ii) on average at least 50% of our assets by value produce passive income or are held for the production of passive income. Based
on our estimated gross income, the average value of our gross assets, and the nature of our business, we may be treated as a PFIC for
the 2024 tax year and we may also be classified as a PFIC in future years. If we are treated as a PFIC for any taxable year during which
a U.S. investor held the ADSs, certain adverse U.S. federal income tax consequences could apply to the U.S. investor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>As a foreign private
issuer, we are permitted to follow certain home country corporate governance practices instead of applicable NASDAQ requirements, which
may result in less protection than is accorded to investors under rules applicable to U.S. domestic issuers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are permitted to follow certain home country corporate governance practices instead of those otherwise required under the NASDAQ Listing
Rules for U.S. domestic issuers. We follow home country practice in Israel with regard to (among other things) director nomination procedures,
quorum requirement at shareholder meetings and approval of related party transactions and executive compensation. In addition, we follow
our home country law, instead of the NASDAQ Listing Rules, which require that we obtain shareholder approval for certain dilutive events,
such as for the establishment or amendment of certain equity-based compensation plans, an issuance that will result in a change of control
of the company, certain transactions other than a public offering involving issuances of a 20% or more interest in the Company and certain
acquisitions of the stock or assets of another company. In the future we may elect to follow additional home country corporate governance
practices instead of those otherwise required under the NASDAQ Listing Rules for U.S. domestic issuers. Following our home country governance
practices as opposed to the requirements that would otherwise apply to a U.S. company listed on NASDAQ may provide less protection than
is accorded to investors under the NASDAQ Listing Rules applicable to domestic issuers. See &#8220;Item 16G. Corporate Governance.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We are a &#8220;foreign
private issuer&#8221; and have disclosure obligations that are different from those of U.S. domestic reporting companies. As a result,
we may not provide you the same information as U.S. domestic reporting companies or we may provide information at different times, which
may make it more difficult for you to evaluate our performance and prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a foreign private
issuer and, as a result, are not subject to the same requirements as U.S. domestic issuers. Under the Exchange Act, we are subject to
reporting obligations that, in certain respects, are less detailed and/or less frequent than those of U.S. domestic reporting companies.
For example, as a foreign private issuer, we are exempt from the rules and regulations under the Exchange Act, related to the furnishing
and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing
profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file
annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as domestic companies whose
securities are registered under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to file with the
SEC, within 120 days after the end of each fiscal year ending December 31, an annual report on Form 20-F containing financial statements
which will be examined and reported on, with an opinion expressed, by an independent registered public accounting firm. In accordance
with NASDAQ Listing Rules, as a foreign private issuer, we are required to submit on Form 6-K an interim balance sheet and income statement
as of the end of the second quarter of each fiscal year. We have also agreed contractually under the Sales Agreement to provide an interim
balance sheet and income statement as of the end of the first and third quarters of each fiscal year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foreign private issuers are
also exempt from Regulation FD, which is intended to prevent issuers from making selective disclosures of material information. As a
result of all of the above, you may not have the same protections afforded to shareholders of a company that is not a foreign private
issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may lose our foreign
private issuer status in the future, which could result in significant additional costs and expenses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As discussed above, we are
a foreign private issuer, and therefore, we are not required to comply with all of the periodic disclosure and current reporting requirements
of the Exchange Act. The determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s
most recently completed second fiscal quarter, and, accordingly, the next determination will be made with respect to us on June 30, 2025.
In the future, we would lose our foreign private issuer status if (1) more than 50% of our outstanding voting securities continue to
be owned by U.S. residents and (2) a majority of our directors or executive officers are U.S. citizens or residents, or we fail to meet
additional requirements necessary to avoid loss of foreign private issuer status. If we lose our foreign private issuer status, we will
be required to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed
and extensive than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements,
and our officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions
of Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance requirements
under the NASDAQ Listing Rules. As a U.S. listed public company that is not a foreign private issuer, we will incur significant additional
legal, accounting and other expenses that we do not incur as a foreign private issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The ADS holders may
not be able to fully exercise their voting rights to the same extent as our ordinary shareholders. The depositary for the ADSs will give
us a discretionary proxy to vote our ordinary shares underlying ADSs if a holder of the ADSs does not provide voting instructions, except
in limited circumstances, which could adversely affect their interests.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ADS holders may instruct
the depositary how to vote the number of deposited ordinary shares their ADSs represent. Except by instructing the depositary, you will
not be able to exercise voting rights unless you surrender your ADSs and withdraw the shares. However, you may not know about the meeting
enough in advance to withdraw the shares. We cannot assure you that you will receive the voting materials in time to ensure that you
can instruct the depositary to vote your shares. In addition, the depositary and its agents are not responsible for failing to carry
out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise voting
rights and there may be nothing you can do if your shares are not voted as you requested, and you cannot vote in person at meetings as
a holder of ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the deposit agreement
for the ADSs, the depositary will give us a discretionary proxy to vote our ordinary shares underlying ADSs at shareholders&#8217; meetings
if a holder of the ADSs does not provide voting instructions, unless we notify the depositary that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we do not wish to receive
    a discretionary proxy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there is substantial shareholder
    opposition to the particular question; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the particular question
    would have an adverse impact on our shareholders&#8217; rights.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The effect of this discretionary
proxy is that a holder of the ADSs cannot prevent our ordinary shares underlying such ADSs from being voted, absent the situations described
above, and it may make it more difficult for shareholders to influence the management of our company. Holders of our ordinary shares
listed for trading on the TASE are not subject to this discretionary proxy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We currently do not
anticipate paying cash dividends, and accordingly, shareholders must rely on the appreciation in our ordinary shares and ADSs for any
return on their investment. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently anticipate that
we will retain future earnings, if any, for the development, operation and expansion of our business and do not anticipate declaring
or paying any cash dividends for the foreseeable future. The ability of an Israeli company to pay dividends is governed by Israeli law,
which provides that unless otherwise approved by a court, distributions, including cash dividends, may be made only out of retained earnings
as determined for statutory purposes, and only if there is no reasonable concern that the dividend distribution will prevent us from
meeting our existing and foreseeable obligations, as they become due. Subject to the foregoing, payment of future dividends, if any,
will be at the discretion of our Board and will depend on various factors, such as our financial condition, operating results, current
and anticipated cash needs and other business and economic factors that our Board may deem relevant. Since we do not have earnings, we
currently do not have any ability to pay dividends or repurchase our shares, absent court approval. Therefore, the success of an investment
in our ordinary shares and ADSs will depend upon any future appreciation in their value. There is no guarantee that our ordinary shares
and ADSs will appreciate in value or even maintain the price at which our holders have purchased their shares and ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Investors in the ADSs
may not receive the same distributions or dividends as those we make to the holders of our ordinary shares, and, in some limited circumstances,
investors in the ADSs may not receive any value for them, if it is illegal or impractical to make them available to investors in the
ADSs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The depositary for the ADSs
has agreed to pay investors in the ADSs the cash dividends or other distributions it or the custodian receives on ordinary shares or
other deposited securities underlying the ADSs, after deducting its fees and expenses. Investors in the ADSs will receive these distributions
in proportion to the number of ordinary shares their ADSs represent. However, the depositary is not responsible if it decides that it
is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution
to a holder of ADSs if it consists of securities that require registration under the Securities Act, but that are not properly registered
or distributed under an applicable exemption from registration. In addition, conversion into U.S. dollars from foreign currency that
was part of a dividend which was distributed in foreign currency made in respect of deposited ordinary shares may require the approval
or license of, or a filing with, any government or agency thereof, which may be unobtainable. In these cases, the depositary may determine
not to distribute such property and hold it as &#8220;deposited securities&#8221; or may seek to affect a substitute dividend or distribution,
including net cash proceeds from the sale of the dividends that the depositary deems an equitable and practicable substitute. We have
no obligation to register under U.S. securities laws any ADSs, ordinary shares, rights or other securities received through such distributions.
We also have no obligation to take any other action to permit the distribution of ADSs, ordinary shares, rights or anything else to holders
of ADSs. In addition, the depositary may withhold from such dividends or distributions its fees and an amount on account of taxes or
other governmental charges to the extent the depositary believes it is required to make such withholding. This means that investors in
the ADSs may not receive the same distributions or dividends as those we make to the holders of our ordinary shares, and, in some limited
circumstances, investors in the ADSs may not receive any value for such distributions or dividends if it is illegal or impractical for
us to make them available to investors in the ADSs. These restrictions may cause a material decline in the value of the ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Holders of ADSs must
act through the depositary to exercise rights of shareholders of our company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of the ADSs do not
have the same rights as our shareholders and may only exercise the voting rights with respect to the underlying ordinary shares in accordance
with the provisions of the deposit agreement for the ADSs. Under Israeli law, the minimum notice period required to convene a shareholders&#8217;
meeting is no less than 35 or 21 calendar days, depending on the proposals on the agenda for the shareholders&#8217; meeting. When a
shareholder meeting is convened, holders of the ADSs may not receive sufficient notice of the meeting to permit them to withdraw their
ordinary shares to allow them to cast their vote with respect to any specific matter. In addition, the depositary and its agents may
not be able to send notice to holders of the ADSs or carry out their voting instructions in a timely manner. We will make all reasonable
efforts to cause the depositary to extend voting rights to holders of the ADSs in a timely manner, but we cannot assure holders that
they will receive the voting materials in time to ensure that they can instruct the depositary to vote the ordinary shares underlying
their ADSs. Furthermore, the depositary and its agents will not be responsible for any failure to carry out any instructions to vote,
for the manner in which any vote is cast or for the effect of any such vote. As a result, holders of the ADSs may not be able to exercise
their right to vote and they may lack recourse if the ordinary shares underlying their ADSs are not voted as they requested. In addition,
ADS holders will not be able to call a shareholders&#8217; meeting unless they first withdraw their ordinary shares from the ADS program
and receive delivery of the underlying ordinary shares held in the Israeli market in order to allow them to submit to us a request to
call a meeting with respect to any specific matter, in accordance with the applicable provisions of the Companies Law and our amended
and restated articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our ordinary shares
and the ADSs are traded on different markets and this may result in price variations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares trade
on the TASE, and the ADSs trade on NASDAQ. Trading on these markets take place in different currencies (U.S. dollars on NASDAQ and NIS
on the TASE), and at different times (resulting from different time zones, different trading days and different public holidays in the
U.S. and Israel). The trading prices of our securities on these two markets may differ due to these and other factors. Any decrease in
the price of our securities on one of these markets could cause a decrease in the trading price of our securities on the other market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The ADSs have relatively
limited trading volume, which may limit the ability of our investors to sell their ADSs in the U.S. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ADSs have been traded
at low volumes in the past and may be traded at low volumes in the future for reasons related or unrelated to our performance. This low
trading volume may result in lesser liquidity and lower than expected market prices for ADSs, and our investors may not be able to resell
their ADSs for more than they paid for them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We can issue non-voting
senior preferred shares without shareholder approval, which could adversely affect the rights of holders of ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated
articles of association permit us to establish the rights, privileges, preferences and restrictions of future series of our non-voting
senior preferred shares, which contain superior liquidation and dividend rights, and may contain other rights, including conversion,
redemption, optional and other special rights, qualifications, limitations or restrictions, equivalent or superior to our ordinary shares
and to issue such non-voting senior preferred shares without further approval from our shareholders. The rights of holders of our ordinary
shares and ADSs may suffer as a result of the rights granted to holders of non-voting senior preferred shares that we may issue in the
future. In addition, we could issue non-voting senior preferred shares containing rights that prevent a change in control or merger,
thereby depriving holders of our ordinary shares and ADSs of an opportunity to sell their shares at a price in excess of the prevailing
market price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If equity research
analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our ordinary shares
or ADSs, the price of our ordinary shares and ADSs could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
ordinary shares and ADSs will rely in part on the research and reports that equity research analysts publish about us and our business.
The price of our ordinary shares and ADSs could decline if such research or reports are not published or if one or more securities analysts
downgrade the ADSs or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We have broad discretion
as to the use of the net proceeds from our previous offerings and may not use them effectively.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently intend to use
the net proceeds from our previous offerings, including under our ATM program, to expand our clinical development program, expand our
clinical development pipeline for additional drug products, including by way of possible acquisitions, expand our pre-clinical development
activity and for general corporate purposes, including working capital requirements. However, our management will have broad discretion
in the application of the net proceeds from our previous offerings. Our shareholders may not agree with the manner in which our management
chooses to allocate the net proceeds from our previous offerings. The failure by our management to apply these funds effectively could
have a material adverse effect on our business, financial condition and results of operations. Pending their use, we may invest the net
proceeds from our previous offerings in a manner that does not produce income. The decisions made by our management may not result in
positive returns on any investment by shareholders and shareholders will not have an opportunity to evaluate the economic, financial
or other information upon which our management bases its decisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4. INFORMATION ON THE COMPANY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>History and Development
    of the Company </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated under
the laws of the State of Israel (under a previous name) on August 12, 1968. Our ordinary shares were originally listed for trading on
the TASE in 1978 and the ADSs have been traded on NASDAQ since November 2015. Our ordinary shares are currently traded on the TASE under
the symbol &#8220;PPBT&#8221;, and the ADSs are currently traded on NASDAQ under the symbol &#8220;PPBT&#8221;. The Company is headquartered
in Rehovot, Israel and our telephone number is +972-3-933-3121. Our website address is www.purple-biotech.com. Information contained
on, or that can be accessed through, our website does not constitute a part of this Annual Report and is not incorporated by reference
herein. We have included our website address in this Annual Report solely for informational purposes. The SEC maintains an Internet site
that contains reports, proxy and information statements, and other information regarding issuers, such as us, that file electronically
with the SEC at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">In October 2012, the District
Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the
sale by our company (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to
a private company held by its then controlling shareholders, and all rights of our creditors against us were extinguished. From the completion
of these transactions until the completion of the acquisition of Kitov Pharmaceuticals described below, Purple Biotech (then known as
Kitov Pharma) did not conduct any business activities and was a public shell company listed on the TASE with no assets, debt and/or liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">On July 11, 2013, we acquired
Kitov Pharmaceuticals, which, prior to the completion of its merger with and into our company in December 2017, together with our company,
was engaged in the research and development of Consensi. As part of the acquisition, Mainrom Line Logistics Ltd. changed its name to
Kitov Pharmaceuticals Holdings Ltd., which was subsequently changed in January 2018 to Kitov Pharma Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">On January 13, 2017, we
announced that we had acquired a majority equity stake in TyrNovo, a privately held developer of novel small molecules in the oncology
therapeutic field, whose main asset is NT219.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">On April 25, 2017, the
boards of directors of each of Kitov Pharma and Kitov Pharmaceuticals approved a merger between the two entities, with Kitov Pharma remaining
as the surviving entity. The merger was completed in December 2017. Kitov Pharmaceuticals was dissolved upon the merger, and Kitov Pharma
remained as the surviving entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">In January 2020, we completed
the acquisition of FameWave, a privately held biopharmaceutical company, whose main asset is CM24, a clinical stage humanized monoclonal
antibody in the oncology therapeutic field.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">On December 7, 2020, we
changed our name to Purple Biotech Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">In December 2021, we decided
to discontinue the manufacturing and distribution of Consensi.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">In February 2023, we completed
the acquisition of Immunorizon, a privately held biotechnology company developing multi-specific antibodies as oncology therapies that
selectively activate the immune response within the tumor microenvironment (TME). For information regarding the Immunorizon acquisition,
see &#8220;Item 10 &#8211; Additional Information &#8211; C. Material Contracts &#8211; Immunorizon Acquisition.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">For a description of our
principal capital expenditures for the three years ended December 31, 2024, see &#8220;Item 5. <i>Operating and Financial Review and
Prospects</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Overview</b></span><span style="font-size: 10pt">&#160;<span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage company
developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our oncology pipeline includes
CM24, NT219 and IM1240. In developing these therapeutic candidates, we aim to address both the tumor and the TME to potentially improve
patient outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>CM24:
                                            </b>Our lead oncology drug, CM24, is a humanized monoclonal antibody designed to block the
                                            interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein
                                            that plays a key role in immune regulation, cell adhesion, and tumor progression. CEACAM1
                                            promotes tumor immune evasion and progression through multiple pathways. We have concluded
                                            a randomized, controlled, open-label, multicenter, proof of concept Phase 2 study for CM24
                                            as a combination therapy with an anti-PD-1 checkpoint inhibitor and chemotherapy for the
                                            treatment of second-line pancreatic ductal adenocarcinoma (PDAC). In December 2024, we reported
                                            the final data for the study, which demonstrated consistent improvement across all efficacy
                                            endpoints and also identified potentially predictive serum biomarkers, including pretreatment
                                            levels of CEACAM1 and a neutrophil extracellular traps (NETs) levels. Based on the emerging
                                            role of NETs in cancer and the positive findings of our study in this selected population
                                            overlapping with CEACAM1 expression, we are planning a 3-arm Phase 2b study comparing either
                                            CM24 plus a PD-1 inhibitor or CM24 monotherapy to standard of care chemotherapy in multiple
                                            tumor types selected based on their NET and CEACAM1 expressions. This design will also investigate
                                            the contribution of parts in regard to the need for PD1 blockade on top of CM24. We plan
                                            to target patients with defined serum levels of CEACAM1 and myeloperoxidase (MPO), as they
                                            are potentially more likely to benefit from CM24 treatment.
                                            We plan to initiate this study in the second half of 2025.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NT219:
                                            </b>A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate
                                            1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two major
                                            survival signal transduction pathways driving the development of cancer drug resistance.
                                            We concluded a Phase 1 dose escalation study evaluating NT219 as a monotherapy and in combination
                                            with cetuximab. NT219 demonstrated anti-tumor activity as a second-line treatment of patients
                                            with recurrent and/or metastatic squamous cell carcinoma of the head and neck. We entered
                                            into a research agreement with the University of Colorado for an investigator-initiated Phase
                                            2 study with NT219 in patients with recurrent and/or metastatic squamous cell carcinoma of
                                            the head and neck, which is expected to be initiated in the first half of 2025.&#160;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>CAPTN-3</b>:
                                            A platform technology of conditionally activated tri-specific antibodies that engages both
                                            T cells and NK cells and a specific tumor-associated antigen (TAA) to induce a strong, localized
                                            immune response within the TME. A cleavable capping technology confines the compound&#8217;s
                                            therapeutic activity to the local TME, thereby potentially increasing the anticipated therapeutic
                                            window in patients. This technology presents a novel mechanism of action by unleashing both
                                            innate and adaptive immune responses at the TME to induce an optimal anti-tumor immune response.
                                            IM1240 is the platform&#8217;s lead tribody in preclinical development that targets the 5T4
                                            antigen, which is expressed in a variety of solid tumors and is associated with advanced
                                            disease, increased invasiveness and poor clinical outcomes. Preclinical studies have shown
                                            sustained tumor regression in a triple-negative breast cancer in-vivo model and pronounced
                                            anti-tumor effects in non-small cell lung cancer patient-derived explants (PDEs). In-vivo
                                            and in-vitro data demonstrated the platform's plug-and-play capability and a potentially
                                            beneficial safety profile. During 2024, we held a pre-IND meeting with the FDA that provided
                                            a clear path forward for our development plan through Phase 1 and we expect to submit an
                                            IND application to the FDA for IM1240 during 2026.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our strategy
is to pursue the acquisition of additional oncology therapeutic candidates at various stages of development to expand and diversify our
portfolio and leverage our development capabilities. We currently do not have any binding material agreement or commitment to complete
any transaction for the acquisition of new therapeutic candidates or approved drug products.</p><div>





























</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Therapeutic Candidates </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>CM24
</i></b>is a clinical stage humanized monoclonal antibody directed against CEACAM1, a multi-faceted membrane protein belonging to the
Human Carcino-Embryonic Antigen (CEA) protein family that acts as an immune checkpoint inhibitor, a pro-angiogenic, anti-apoptotic agent
and a promoter of tumor invasiveness and metastases. Evidence has shown that CEACAM1 is expressed on different white blood cells including
lymphocytes neutrophils and monocytes and its expression is up-regulated in several cancer types. Additionally, previous publications
in the scientific literature* indicate that CEACAM1 is expressed on NETs which, among other activities, are believed to promote metastatic
processes of tumors. Preclinical studies have shown evidence that CM24 enhances the cytotoxic activity of tumor-infiltrating lymphocytes
(TILs) against various CEACAM1-positive tumor cell lines in vitro and in vivo. Our preclinical studies have shown that CM24 attenuates
NET-induced tumor cell migration. CM24 is being developed for multiple oncological indications according to the expression pattern of
its target protein. Preclinical studies provide strong justification for CM24&#8217;s mechanism of action in activating the immune system
through multiple pathways. Additional preclinical studies showed that a combination of CM24 with PD-1 and PDL-1 antibodies resulted in
a synergistic anti-cancer effect. In a Phase 1 dose escalation study of CM24 as a single agent, a stable disease rate of approximately
33% among the evaluable patients was noted. In a second Phase 1 dose escalation study of CM24 in combination with the PD-1 inhibitor
nivolumab in patients with advanced metastatic cancers, a disease control rate of 36% among the evaluable patients was noted, including
one partial response and three stable diseases. A randomized Phase 2 study of CM24 as a combination therapy with the anti-PD-1 checkpoint
inhibitor nivolumab and standard of care chemotherapy in patients with advanced metastatic pancreatic cancer as a second line treatment
has been completed recently. In December 2024, we reported positive final results from the randomized Phase 2 study, which demonstrate
clear and consistent improvement across all efficacy endpoints for CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy.
A biomarker enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated significant improvement in
the treatment arm over the control of 79% reduction in risk of death (HR 0.21, P = 0.04) with median OS improvement of 5.1 months and
over 90% reduction in risk of progression or death (HR &lt; 0.1, P = 0.003) with median Progression-Free Survival (PFS) improvement of
2.9 months and improvement in the treatment arm over the control in objective response rate (ORR) of 50% vs. 0%. An additional subgroup
analysis of patients, which comprised 80% of the patients in the study cohort, with a range of pretreatment serum CEACAM1 between 6,000
pg/mL and 15,000 pg/mL, together with patients with pretreatment serum MPO levels of 200 ng/mL and 600 ng/mL, demonstrated significant
improvement in the treatment arm over the control of 61% reduction in risk of death (HR 0.39 (<i>P </i>0.039)) with median overall survival
(OS) improvement of 2.4 months and 72% reduction in risk of progression or death (HR 0.28 (<i>P </i>0.006) with median PFS improvement
of 2.2 months. Based on the emerging role of NETs in cancer and the positive findings of our study in this selected population overlapping
with CEACAM1 expression, we are planning a 3-arm Phase 2b study comparing either CM24 plus a PD-1 inhibitor or CM24 monotherapy to standard
of care chemotherapy in multiple tumor types selected based on their NET and CEACAM1 expressions. This design will also investigate the
contribution of parts in regard to the need for PD1 blockade on top of CM24. We plan to target patients with higher serum levels of CEACAM1
and MPO, as they are potentially more likely to benefit from CM24 treatment. We plan to initiate this study in the second half of 2025.
For more information regarding CM24, see, &#8220;Item 4. Information on the Company &#8211; B. Business Overview &#8211;Our Development
Programs &#8211; CM24&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rayes RF, et al. Neutrophil
    Extracellular Trap-Associated CEACAM1 as a Putative Therapeutic Target to Prevent Metastatic Progression of Colon Carcinoma. J Immunol.
    2020 Apr 15;204(8):2285-2294. PMID: 32169849; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Masucci MT, Et. al. The
    Emerging Role of Neutrophil Extracellular Traps (NETs) in Tumor Progression and Metastasis. Front Immunol. 2020 Sep 16;11:1749. PMID:
    33042107.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>NT219
</i></b>is a novel small molecule that targets IRS1/2 to degradation and demonstrates the ability of inhibiting both IRS1/2 and STAT3,
two key oncology-related proteins, which play major roles in cancer cell survival, drug resistance, angiogenesis, metastasis and immune
evasion. NT219 demonstrated efficacy in multiple xenograft and patient-derived xenograft (PDX) preclinical models as a monotherapy but
mainly in combination with various classes of cancer drugs such as targeted therapies against Epidermal Growth Factor Receptor (EGFR),
Mitogen-Activated Protein Kinase (MEK), mutated BRAF, mTOR) and chemotherapies, overcoming drug resistance and suppressing refractory
tumors to these approved therapies. Suppression of refractory tumors to immune checkpoint inhibitors by the combination of NT219 with
anti-PD1 therapy was presented as well, accompanied by reprogramming of the immune profile and conversion of immunosuppressive TME to
immunoreactive. We conducted a phase 1 dose escalation study of NT219 as a single agent in highly pretreated patients with recurrent
advanced metastatic solid tumors, for whom no approved therapy is available, and a dose escalation phase of NT219 in combination with
cetuximab, for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck and colorectal adenocarcinoma.
The Phase 1 dose escalation study demonstrated anti-tumor activity at the NT219 target exposure level, with a manageable safety profile,
in combination with cetuximab as a second line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the
head and neck. In February 2024, we determined the recommended phase 2 dose (RP2D) for NT219. In February 2025, we entered into a research
agreement with the University of Colorado for an investigator-initiated Phase 2 study with NT219 in patients with recurrent and/or metastatic
squamous cell carcinoma of the head and neck, which is expected to be initiated in the first half of 2025. For more information regarding
NT219, see &#8220;Item 4. Information on the Company &#8211; B. Business Overview &#8211; Our Development Programs &#8211;
NT219.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>CAPTN-3
</b>is a platform of conditionally activated tri-specific antibodies that engages both T cells and NK cells to induce a strong, localized
anti-tumor immune response within the TME is in pre-clinical development. A cleavable capping technology confines the compound&#8217;s
therapeutic activity to the local TME, thereby potentially increasing the anticipated therapeutic window in patients. This technology
presents a novel mechanism of action by unleashing both innate and adaptive immune systems at the TME to induce an optimal anti-tumor
immune response. IM1240 is the platform&#8217;s lead tribody in preclinical development that targets 5T4-expressing tumors. 5T4 is expressed
in a variety of solid tumors and is associated with advanced disease, increased invasiveness and poor clinical outcomes. Our portfolio
includes additional early-stage assets, targeting other receptors and TAA. CAPTN-3 demonstrated sustained tumor regression in a triple
negative breast cancer in-vivo model as well as dose dependent activity pronounced anti-tumor effect of the engager arms in non-small
cell lung cancer PDEs. IM1240 demonstrated that cytokine release is 5T4-dependent and suppressed by the conditionally activated capping
technology, suggesting a potentially beneficial safety profile of this tribody. The data further demonstrated additional tribodies, suggesting
CAPTN-3&#8217;s plug-and-play platform capability. During 2024, we held a pre-IND meeting with the FDA that provided a clear path forward
for our development plan through Phase 1 and we expect to submit an IND application to the FDA for IM1240 during 2026. For more information
regarding the CAPTN-3 tribody platform, see &#8220;Item 4. Information on the Company &#8211; B. Business Overview &#8211; Our Development
Programs &#8211; CAPTN-3.&#8221; </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Competitive Strengths </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pharmaceutical market
is characterized by large international pharmaceutical companies that develop a wide range of products, both generic and innovative,
which operate alongside smaller companies, such as ours, that develop a specific drug or a combination of drugs. Therefore, many small
companies enter into agreements with such global companies during the drug development stage in order to continue the development or
marketing of the drug, taking advantage of the financial, marketing and/or other resources available to such global companies. At the
same time, global companies tend to enter into agreements with smaller companies in order to save development time and resources. The
global drug sector is a highly developed market with a turnover of hundreds of billions of U.S. dollars and intense competition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe there are several
advantages to the therapeutic candidates we are developing, as set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">CM24</span>:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CEACAM1 is unique among the
CEACAM family members in that it is widely distributed among various species and it has the largest number of splice variants compared
to other members of the family. Moreover, CEACAM1 also has the widest tissue distribution of all characterized family members (source:
Current Opinion in Cell Biology Volume 18, Issue 5, October 2006, Pages 565-571). Accordingly, CM24 may have a competitive advantage
over other CEACAM-targeting agents in that its inhibitory effect may be more general and target several splice variants and more tissues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional potential advantages
of CM24 over other CEACAM-targeting technologies may include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As CM24
    blocks the homo- as well as the hetero-dimerization, i.e. blocks both CEACAM1-CEACAM1 as well as CEACAM1-CEACAM5 interaction - it
    has the potential to be more effective in controlling the contact inhibition of cancerous cells with cells of the immune system.
    CM24 acts as an immune adhesion inhibitor molecule &#8211; a mechanism that is central to the immune evasion mechanism of neoplastic
    cells.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition
    to its contribution to tumor suppression, CEACAM1 also has a modulatory role in multiple cell types such as T-cells, NK cells, monocytes
    and neutrophils.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEACAM1 has been proposed
    to be a ligand for T-cell Immunoglobulin and Mucin domain-3 (TIM-3) &#8211; another immune checkpoint inhibitor. By activating TIM-3
    with CM24, a synergistic effect may be expected. The relationship between CEACAM1 and TIM-3 has been described as a mechanism that
    may overcome immune fatigue and T-cell exhaustion (Nature. 2015 Jan 15; 517(7534): 386&#8211;390; Acharya N, et al. J Immunotherapy
    8:e911-22, 2020).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEACAM1 has been associated
    with trophism for cancer cells and the metastatic phenotype manifested through its expression on NETs (Rayes RF, et al.&#160;J Immunology.
    2020) and our data.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEACAM1 is expressed on
    NETs which, among other activities, are believed to promote metastatic processes of tumors.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEACAM1 has been associated
    with trophism for cancer cells and the metastatic phenotype manifested through its expression on NETs (Rayes RF, et al.&#160;J Immunology.
    2020) and our data.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CM24 has been evaluated as
monotherapy at escalating doses up to 10mg/kg in a phase 1 clinical trial, where 27 patients with different cancers in advanced stages
were treated with the monoclonal antibody. There were no dose limiting toxicities which were associated with CM24, nor any drug related
mortalities. In a second, Phase 1b study, CM24 at 3 dose levels, 10, 15 and 20mg/kg, was administered in combination with standard dose
of nivolumab to a total of 14 patients with PDAC, Colorectal cancer (CRC) and papillary thyroid cancer. The combination of CM24 and nivolumab
was well tolerated and demonstrated initial signals of efficacy. We completed a randomized, controlled, open label, multicenter Phase
2 study evaluating CM24 in combination with nivolumab and standard of care chemotherapy in patients with pancreatic ductal adenocarcinoma
as a second line treatment as compared to standard of care chemotherapy was initiated and enrollment was completed during December 2023.
&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2024, we reported
positive final results from the randomized Phase 2 study, which demonstrate clear and consistent improvement across all efficacy endpoints
for CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy. A biomarker enriched patient population analysis based on pretreatment
ranges of serum CEACAM1 demonstrated significant improvement in the treatment arm over the control of 79% reduction in risk of death
(HR 0.21, P = 0.04) with median OS improvement of 5.1 months and over 90% reduction in risk of progression or death (HR &lt; 0.1, P =
0.003) with median PFS improvement of 2.9 months and improvement in the treatment arm over the control in ORR of 50% vs. 0%. An additional
subgroup analysis of patients, which comprised 80% of the patients in the study cohort, with a range of pretreatment serum CEACAM1 between
6,000 pg/mL and 15,000 pg/mL, together with patients with pretreatment serum MPO levels of 200 ng/mL and 600 ng/mL, demonstrated significant
improvement in the treatment arm over the control of 61% reduction in risk of death (HR 0.39 (<i>P </i>0.039)) with median OS improvement
of 2.4 months and 72% reduction in risk of progression or death (HR 0.28 (<i>P </i>0.006) with median PFS improvement of 2.2 months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">NT219</span>:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NT219 is a first-in-class
drug candidate and, to the best of our knowledge, currently the only one that inhibits both IRS1/2 and STAT3. Theinhibition of both has
been demonstrated to be essential to facilitate a significant anti-tumor effect and overcome drug resistance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NT219 binds covalently to
IRS1 and IRS2 and targets them to degradation, gaining a sustained inhibition of IRS1/2-mediated signaling. Prolonged inhibition of STAT3
was also demonstrated, long after the drug was washed out.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">NT219
inhibits major cancer survival pathways downstream IRS1/2, such as the AKT and the </span><span style="font-family: Symbol">b</span><span style="font-family: Times New Roman, Times, Serif">-catenin,
known to be involved in drug resistance, cancer stem cell renewal, immune evasion, and metastasis. &#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NT219 is a small molecule,
and small molecules are typically less expensive to develop and have less complex CMC as compared to proteins or antibodies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical development,
NT219 demonstrated several advantageous effects in animal models, such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">single agent activity in
    PDX and xenograft models;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overcoming drug resistance
    acquired by various cancer types;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">synergistic anti-tumor
    effects in combination with approved cancer therapies belonging to various classes such as chemotherapy and targeted therapies; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suppression of refractory tumors to immune checkpoint
    inhibitors by the combination of NT219 with anti- Programmed Cell Death Protein 1 (PD1) therapy. The effect on tumor growth was accompanied
    by the conversion of immunosuppressive TME to immunoreactive (upregulation of cytotoxic T cells and NK cells paralleled with a decrease
    in T regulatory cells, tumor-associated macrophages and monocytic and granulocytic myeloid-derived suppressor cells (MDSCs).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the monotherapy portion
of the phase 1/2 dose escalation study of NT219, no dose limiting toxicities (DLTs) have been observed and NT219 has been found to be
well tolerated with no treatment-related Grade 4/5 AEs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the phase 1/2 dose escalation
study of NT219 in combination with cetuximab, anti-tumor activity was observed in previously treated HPV negative 2L/3L R/M squamous cell
carcinoma of head and neck cancer (SCCHN) patients. Overall, 25 patients were enrolled in the combination arm; 23 patients were evaluable
for efficacy, 8 of which were at the highest dose levels of 50+100 mg/kg that reached or surpassed NT219 target exposure level. Out of
these 8 patients, 2 patients demonstrated confirmed partial response (PR), and 3 patients demonstrated stable disease, representing ORR
of 25% and disease control rate (DCR) of 62.5%. Median follow-up across all dose levels was 9.4 months (95% CI: 3.4-10.0, 8&#160;out of
15 patients remaining in follow up). Safety profile was well tolerated and manageable up to and including at 100mg/kg. Most common treatment
emergent adverse events (AEs) were infusion related reactions and nausea, and no treatment-related Grade 4/5 AEs were observed. Pharmacokinetic
analysis demonstrated dose dependent increase. Biomarker analysis of biopsies collected from SCCHN patients before treatment with NT219
(50mg/kg) and cetuximab demonstrated enhanced activation of IGF1R and STAT3 in responders (PR) as compared to non-responding patients
(progressed disease), suggesting these NT219&#8217;s targets as potential biomarkers for NT219+cetuximab therapy. Based on the phase 1/2
dose escalation study, we determined the RP2D for NT219 at 100mg/kg. In February 2025, we entered into a research agreement with the University
of Colorado for an investigator-initiated Phase 2 study with NT219 in patients with recurrent and/or metastatic squamous cell carcinoma
of the head and neck, which is expected to be initiated in the first half of 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">CAPTN-3 and IM1240:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CAPTN-3, our tribody platform
of conditionally activated tri-specific antibodies, is a multi-valent antibody designed to activate anti-tumoral immune response against
TAA positive tumors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The two features described
below represent advantages of our tribody platform as they provide specific anti-tumor effects at the tumor site with reduced side effects,
as well as efficient activation of the anti-tumoral immune response.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual activation of T cells
    and NK cells to induce a stronger specific immune response against cancer cells (Kyrysyuk et al., Annu. Rev. Immunol. 2023. 41:17&#8211;38);
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A cleavable capping system
    aimed to prevent systemic T cell activation, improve safety profile and pharmacokinetic properties, and widen the therapeutic index.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">The tribody platform is
a wide platform that allows incorporation of antibodies against various TAAs, and thereby produces a pipeline of products that target
multiple cancer types expressing these TAAs. It is also versatile in terms of the NK cell targets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">The IM1240 therapeutic
candidate has distinctive features that we believe could allow it to outperform competitors. 5T4 is a well-studied TAA, minimally expressed
in healthy tissues and associated with poor prognosis in multiple cancer types.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">CAPTN-3 demonstrated sustained
tumor regression in a triple negative breast cancer in-vivo model as well as dose dependent activity and pronounced anti-tumor effects
of the engager arms in non-small cell lung cancer PDEs. IM1240 demonstrated that cytokine release is 5T4-dependent and suppressed by
the conditionally activated capping technology, suggesting a potentially beneficial safety profile of this tribody. The data further
demonstrated additional tribodies, suggesting CAPTN-3&#8217;s plug and play platform capability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our goal is to become a leading
player in the development and commercialization of innovative drugs that treat unmet medical needs and can capitalize on significant
market opportunities, focusing on oncology therapeutics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Key elements of our strategy
are to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">focus on oncology therapeutic
    assets for treatment of unmet medical needs, representing a significant market opportunity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">leverage our expertise
    in the clinical and regulatory processes in the United States, together with our research and development capabilities and network
    of professional advisors, to efficiently develop therapeutic candidates in pre-clinical and clinical stages of development and achieve
    marketing authorization;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand our line of therapeutic
    candidates through the acquisition or in-licensing of technologies, products and drugs in the oncology space intended to meet clinical
    needs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop new disruptive
    and innovative technologies in collaboration with third parties, as well as using our in-house capabilities; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cooperate with third parties,
    to both develop and commercialize therapeutic candidates in order to share costs and leverage the expertise of others.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our oncology therapeutic
candidates, CM24, NT219 and CAPTN-3, our tribody platform with its leading therapeutic candidate, IM1240, are further described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Development Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CM24 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Background</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CM24 is a humanized monoclonal
antibody directed against CEACAM1, a multi-faceted membrane protein belonging to the Human CEA protein family that acts as an immune
checkpoint inhibitor, a pro-angiogenic, anti apoptotic agent, and a protein that promotes tumor invasiveness and metastases. Evidence
has shown that CEACAM1 is expressed on tumor infiltrating lymphocytes and its expression is up-regulated in several cancer types. Moreover,
CEACAM1 is associated with mechanisms of trophism and metastases in cancer, manifest through mechanisms such as neutrophil extracellular
traps.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The technology originated
from the laboratory of Dr. Gal Markel from Sheba Medical Center and initially developed by cCAM Biotherapeutics Ltd. (cCAM), which was
acquired by Merck Sharp and Dohme Corp. (MSD), in 2015.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MSD conducted a phase 1 clinical
trial, including patients with metastatic&#160;melanoma, non-small cell lung cancer, bladder, gastric, colorectal and ovarian cancer
patients. In this initial Phase 1 dose ranging study of CM24 as single agent, a stable disease rate of approximately 33% among the evaluable
patients was noted as best overall response. Despite no known safety risks, MSD discontinued the clinical study and returned the rights
of CM24 to former cCAM shareholders and founders of FameWave. Review of the Phase 1 study results by external scientific advisors retained
by us suggested that while CM24 was generally safe, higher doses of the antibody along with a modified dosing regimen in a defined patient
population would be warranted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Mechanism of Action</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">CM24
is a humanized monoclonal antibody directed against CEACAM1, a multi-faceted membrane protein belonging to the Human CEA protein family
that acts as an immune checkpoint inhibitor, a pro-angiogenic, anti apoptotic agent, and a protein that promotes tumor invasiveness and
metastases.</span>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CEACAM1 belongs to the CEA
superfamily. CEACAM1 interacts with itself (i.e., hemophilic interaction) and with CEACAM5 (heterophilic interaction), as well as with
various bacterial proteins. Different functions have been attributed to the CEACAM1 protein: anti-proliferative properties in carcinomas
of the colon and prostate, or facilitation of proliferation in melanoma; central involvement in angiogenesis, insulin clearance and immune-modulation.
CEACAM1 is expressed by many types of tumors and is associated with poor prognosis in cutaneous melanoma, uveal melanoma, hepatocellular
carcinoma, cholangiocarcinoma, gastroesophageal adenocarcinoma colorectal adenocarcinoma and lung cancer. In addition, increased CEACAM1
expression on cancer tissues and peripheral blood lymphocytes and elevated serum CEACAM1 were observed in patients with melanoma, osteosarcoma
and pancreatic carcinoma. These collective observations provide a strong justification for the development of a therapeutic approach
that targets the tumor promoting functions of CEACAM1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Earlier preclinical studies
revealed CM24 reversed CEACAM1-mediated immune evasion by abrogating CEACAM1-CEACAM1 interactions, restoring Zeta-chain-associated protein
kinase 70 (ZAP70) phosphorylation and TCR-driven effector functions, while maintaining antigen-restricted recognition. This abrogates
the immunosuppressive function of CEACAM1, promoting cell killing by T cells and NK cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CM24 is a blocking monoclonal
antibody that prevents CEACAM1-CEACAM1 and CEACAM1-CEACAM5 interactions, thus enhancing the cytotoxic activity of lymphocytes, attenuating
metastatic processes, preventing angiogenesis, and promoting tumor apoptosis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CEACAM1 is also part of the
NETs complex. NETs are regarded as an important member of the TME, which contribute to metastatic dissemination and immune evasion. We
have demonstrated direct binding of CM24 to NETs, and inhibition of NET-induced cancer cell migration by CM24. The effects on NETs demonstrate
a novel mechanism of action for CM24, which may support the role of CM24 in controlling immune evasion, metastasis, NET-related complications
and patient&#8217;s survival.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CM24 Suppresses Neutrophil
Extracellular Trap (NET)-Induced Migration and Metastasis of Cancer Cells&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i><img alt="" src="image_002.jpg"/>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preclinical and Mechanism of Action and
Target Validation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Preclinical
studies have shown evidence that CM24 enhances the cytotoxic activity of tumor-infiltrating lymphocytes (TILs) against various CEACAM1-positive
tumor cell lines. Our preclinical studies have shown that CM24 attenuates NET-induced tumor cell migration. CM24 is being developed for
multiple oncological indications according to the expression pattern of its target protein. Additional preclinical studies showed that
a combination of CM24 with PD-1 and PDL-1 antibodies resulted in a synergistic anti-cancer effect. Additional preclinical studies provide
strong justification for CM24&#8217;s mechanism of action in activating the immune system through multiple pathways as validated by world
renowned researchers at Harvard Medical School and MIT, in an article published in Nature<sup>*</sup> as well as by Dr. Gal Markel from
the Tel HaShomer Medical Center<sup>**</sup>. </span>&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Huang Y-H, et al., (2015)
    Nature, 517(7534): 386&#8211;390. Doi:10.1038/nature13848</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Markel G., et al., (2006)
    J Immunol., 177:6062-6071; doi: 10.4049/jimmunol.177.9.6062</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Phase 1 Clinical Trial</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MSD conducted an interventional,
Phase 1, first in human, non-randomized,&#160;single group assignment, open-label,&#160;multi-centered and&#160;multiple escalating&#160;doses
study to assess the safety, efficacy, pharmacokinetics&#160;and tolerability&#160;of&#160;the CM24 antibody&#160;in&#160;the treatment
of&#160;subjects&#160;with selected advanced or recurrent malignancies including melanoma, non-small cell lung adenocarcinoma (NSCLC)
and bladder, gastric, colorectal or ovarian cancer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The main objectives of the
MSD clinical study were to assess the safety and tolerability of CM24 and to determine the recommended dose for Phase 2 trials, characterization
of the pharmacokinetic profile and immunogenicity of CM24, and to evaluate the preliminary efficacy of the drug. The trial was conducted
at four sites in the U.S. and Israel and was designed as a dose escalation stage that was to be followed by an expansion stage. The trial
was concluded following administration of CM24 to 27 patients and prior to determining the recommended phase 2 level and reaching the
expansion stage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Main conclusions by us from
the Phase 1 clinical trials results:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CM24 was found to be generally
    safe and well tolerated. There were no DLTs up to 10mg/kg and no drug related morbidity.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Target saturation was not
    reached up to 10mg/kg. PK was variable across all patients showing slower clearance and higher half-life with increasing dose. PK
    modeling suggested that full receptor occupancy may likely require doses &gt;10mg/kg to be administered every 2 weeks.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment related adverse
    events noted in 17 subjects: 82% Grade 1, 16% Grade 2 and 2.7% Grade 3. Most frequent were increased liver function tests (LFTs)
    and anorexia. The two Grade 3 events were headache and abdominal pain; there were 2 deaths that occurred within 30 days from the
    last administration of CM24 due to disease progression.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A stable disease rate of
    approximately 33% among the 24 evaluable patients was achieved, mostly in the two highest dose groups, where approximately half of
    the evaluable patients achieved stable disease.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Phase 1 study showed
that CM24 was generally well tolerated and resulted in a stable disease rate of approximately 33% in the evaluable patients. The Phase
1 study was not designed to pre-screen CEACAM-1 levels on tumor tissue. Furthermore, in this Phase 1 study, no PD-1 inhibitor was tested
in combination with CM24. As noted, the doses used in the study were below those required to reach target saturation as determined by
pharmacokinetic evaluations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Phase 1/2 Clinical Trials </span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Phase 1/2 study that included
three parts has been completed. The trial was conducted in clinical collaboration with Bristol Myers Squibb.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first part of the study
included a dose escalation of CM24 at 10, 15 and 20mg/kg, in combination with standard dose of the PD-1 inhibitor nivolumab, in patients
with selected solid tumors who have received up to 2 prior regimens for their advanced and/or metastatic disease. The primary objective
of this part of the study was to evaluate safety, tolerability, PK and determine the RP2D.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2021, we reported
on the first dose cohort of the dose escalation phase (10mg/kg), where one patient with refractory advanced MSI-S pancreatic cancer having
been previously treated with two previous regimens, had a confirmed partial response to CM24 and nivolumab, both with respect to imaging
and biochemical markers. The responsive patient showed a 40% reduction in tumor size following two cycles of treatment with CM24 in combination
with nivolumab 480mg/kg q1 month. In addition, levels of CA19-9 tumor marker dropped by 56%, compared to baseline levels. Additionally,
there were no dose-limiting toxicities or serious adverse events observed in any of the three patients enrolled in the first dose cohort
of the study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
July 2023, we reported clinical data from the first part of the Phase 1/2 study. Fourteen patients were evaluable for efficacy, out of
which 11 were PDAC patients. The best overall response included 1 PR (PDAC) and 2 Stable Disease (SD) (1 PDAC and 1 papillary thyroid
cancer (PTC)). No DLTs were observed across all dose levels; no Grade 4 or higher adverse events (AEs) or treatment related deaths have
been reported. Pharmacokinetic analysis of CM24 shows exposure is dose-proportional across the 3 doses in this study. Median OS of 4.6
months (95% CI 2.0-11.3) for 11 PDAC patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The second part of the study
was designed as a safety (primary endpoint) run-in stage, enrolled patients with advanced/metastatic PDAC who have received up to one
prior regimen for their disease. In this part of the study, PDAC patients received CM24 at 20mg/kg plus nivolumab at 240mg (both q2 weeks)
and one of the following two standard of care chemotherapy regimens of either gemcitabine and nab-paclitaxel or liposomal-irinotecan
(Nal-IRI), 5-fluorouracil and leucovorin. A total of 16 PDAC patients were enrolled in this part of the trial, eight patients per chemotherapy
regimen. No DLT were noted by any of the patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The third part of the study
was a randomized Phase 2 study. In December 2024, we reported positive final results from the randomized Phase 2 study, which demonstrate
clear and consistent improvement across all efficacy endpoints for CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy.
The primary endpoint of the study is OS and the secondary endpoints include PFS, ORR and DCR. A Bayesian methodology was used to estimate
the magnitude of effect of the experimental arm versus the standard-of-care arm in each chemotherapy cohort; the study was not powered
for hypothesis testing. A total of 63 patients were enrolled, across 18 centers in the United States, Spain, and Israel in two parallel
and independent randomized study cohorts (total of 2 arms per cohort). The experimental arms administered patients with CM24 plus nivolumab
and one of two standard-of-care chemotherapies for second-line PDAC, dependent on prior first line therapy regimen; either gemcitabine/nab-paclitaxel
or liposomal irinotecan (Nal-IRI)/5-fluorouracil (5-FU) and leucovorin (LV) (Nal-IRI/5FU/LV), while the control arms administered either
respective chemotherapy alone. CA19-9 as well as additional exploratory biomarkers were also evaluated. Of the 63 patients enrolled,
32 were in the gemcitabine/nab-paclitaxel study (experimental and control) and 31 were in the Nal-IRI/5FU/LV study (experimental and
control). The gemcitabine/nab-paclitaxel-based part of the study was impacted by informative censoring of the control arm that led to
an imbalance between the control and experimental arms, rendering this part of the study unsuitable for analysis; this part of the study
has no impact on the CM24+nivolumab+Nal-IRI/5FU/LV portion of the study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The study&#8217;s final efficacy
results in the Nal-IRI/5FU/LV intent to treat (ITT) cohort population are summarized in the following table:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 34%; border: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Metric</b></span></td>
    <td style="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CM24 + Nivolumab + <br/>
Nal/IRI/5FU/LV Arm<br/>
(n = 16)</b></span></td>
    <td style="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nal/IRI/5FU/LV Arm<br/>
(n = 15)</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hazard ratio for OS</span></td>
    <td colspan="2" style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.81 (95% CI: 0.38-1.71)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median OS</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.92 months</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.55 months</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 months OS rate</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53%</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47%</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hazard Ratio for PFS</span></td>
    <td colspan="2" style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.75 (95% CI: 0.35-1.61)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median PFS</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9 months</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0 months</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 months PFS rate</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67%</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47%</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 months PFS rate</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17%</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13%</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORR</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7%</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DCR</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63%</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47%</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A consistent and continuous
decrease of CA19-9, a clinically validated PDAC biomarker, was observed in the experimental arm reaching a median percentage reduction
from baseline of approximately 80% vs. an increase of 40% in the control arm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subgroup analysis of patients
with a range of pretreatment serum CEACAM1 between 6,000 pg/mL and 15,000 pg/mL, resulted in statistically significant results as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 34%; border: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Metric</b></span></td>
    <td style="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CM24 + Nivolumab + <br/>
Nal/IRI/5FU/LV Arm<br/>
(n = 4)</b></span></td>
    <td style="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nal/IRI/5FU/LV Arm<br/>
(n = 7)</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hazard ratio for OS</span></td>
    <td colspan="2" style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.21 (95% CI: 0.04-1.06)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median OS</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9 months</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9 months</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hazard ratio for PFS</span></td>
    <td colspan="2" style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lt; 0.1 (95% CI: 0-inf)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median PFS</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7 months</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8 months</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORR</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50%</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DCR</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43%</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An additional subgroup analysis
of patients, which comprised 80% of the patients in the study cohort, with a range of pretreatment serum CEACAM1 between 6,000 pg/mL
and 15,000 pg/mL together with patients with pretreatment serum MPO levels of 200 ng/mL to 600 ng/mL, resulted in statistically significant
results as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 34%; border: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Metric</b></span></td>
    <td style="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CM24 + Nivolumab + <br/>
Nal/IRI/5FU/LV Arm<br/>
(n = 13)</b></span></td>
    <td style="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nal/IRI/5FU/LV Arm<br/>
(n = 11)</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hazard ratio for OS</span></td>
    <td colspan="2" style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.39 (95% CI: 0.16-0.98)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median OS</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.90 months</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.50 months</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hazard ratio for PFS</span></td>
    <td colspan="2" style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.28 (95% CI: 0.11-0.73)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median PFS</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 months</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9 months</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORR</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31%</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DCR</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69%</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36%</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional biomarkers analysis
based on the patient pretreatment biopsies, demonstrated significant OS and PFS benefit (HR 0.1, P=0.013 and HR 0.19, P=0.033, respectively)
in patients with both high tumor CEACAM1 ( &gt;100) and low Combined Positive Score (CPS&#8804;1) (a measure of PD-L1 positive tumor cells)
supporting the CM24/nivolumab combined treatment and its mechanistic rationale, and may open a new opportunity for patients who are not
eligible for anti-PD1 therapy in various indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CM24+nivolumab+Nal/IRI/5FU/LV
regimen was well tolerated, with the most frequent treatment emergent Grade 3 or higher adverse events being diarrhea (4 patients in
the experimental arm vs. 1 patient in the control arm), fatigue (2 patients in the experimental arm vs. no patients in the control) and
neutropenia (2 patients in the experimental arm vs. no patients in the control). Accordingly, no meaningful difference in safety and
tolerability were observed between the experimental arm and standard-of-care arm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Based
on the emerging role of NETs in cancer and the positive findings of our study in this selected population overlapping with CEACAM1 expression,
we are planning a 3-arm Phase 2b study </span>&#160;<span style="font-family: Times New Roman, Times, Serif">comparing either CM24 plus
a PD-1 inhibitor or CM24 monotherapy to standard of care chemotherapy in multiple tumor types selected based on their NET and CEACAM1
expressions. This design will also investigate the contribution of parts in regard to the need for PD1 blockade on top of CM24. We plan
to target patients with higher serum levels of CEACAM1 and MPO, as they are potentially more likely to benefit from CM24 treatment. We
plan to initiate this study in the second half of 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Competitive Oncology Drugs in Development that Target CEACAM1
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The competitive landscape
for CEACAM1-targeting monoclonal antibodies (mAbs) in oncology is still in early development, with most competing programs remaining
in the preclinical phase. Companies such as Ymmunobio (Switzerland), Agenus/Diatheria (Italy), and Neologics Bioscience (China) are developing
anti-CEACAM1 mAbs, but, to the best of our knowledge, none have progressed beyond preclinical studies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NT219 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NT219 is a small molecule
that presents what we believe is a new concept in cancer therapy by inhibiting two oncology-related pathways, namely the IRS 1 and IRS
2 and STAT3. NT219 technology has been tested in a number of PDX models where biopsies from patients are implanted into mice and used
to test various cancer drugs. In such models, NT219, alone and in combination with several approved oncology drugs, displayed potent
anti-tumor effects and increased survival in experimental animals harboring various cancers by preventing the tumors from developing
resistance to approved cytotoxic, immune-oncologic, and targeted drug treatments, and by re-sensitizing tumors to the approved drugs
even after resistance has been acquired<i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Background on Cancer Drug Resistance </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are high-level
summaries of the therapeutic areas we are currently investigating for NT219:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Solid malignancies (e.g.,
head and neck, pancreatic, colon and non-small cell lung cancer).</i> According to the Journal of Oncology Practice, in 2020 roughly
one in every 19 people worldwide would either be diagnosed with a solid tumor or be a cancer survivor. According to the American Cancer
Society, lung, pancreatic, and colon malignancies have high mortality rates and poor five-year survival prognosis. Novel, emerging therapeutic
approaches for targeting solid tumors are being developed and tested.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Tumor Resistance to Cancer
Therapies</i>. Resistance to chemotherapy and to targeted therapies is a major problem facing oncology. The mechanisms of resistance
to &#8216;classical&#8217; cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific target proteins
share many features, such as alterations in the drug target, activation of pro-survival pathways and ineffective induction of cell death.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Evidence suggests that among
other mechanisms of resistance, inhibition of central oncological target kinases such as EGFR, MEK and mutated-BRAF could trigger feedback
activation of STAT3 and IRS-to-PI3K/AKT, major survival pathways that bypass (prevent) the anti-cancer effects of various drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Tumor Resistance to Immunotherapy</i>.
While the advent of immune checkpoint blockade (ICB) has dramatically improved the prognosis of many immune-infiltrated cancers, for
others, unfortunately, these benefits have yet to be realized. The main challenge in this field is to identify combination therapies
that can convert immunosuppressive TME to immunoreactive and combat evolved resistance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>IRS</i>. Insulin Receptor
Substrate (IRS) is a junction protein that mediates various mitogenic and anti-apoptotic signals mainly from Insulin-like Growth Factor-1
Receptor (IGF1R) and Insulin Receptor (IR), but also from other oncogenes such as v-Src and ALK-fusion proteins. IRS expression is often
up-regulated in human tumors, such as prostate, pancreatic, liver, renal and ovarian cancer. Resistance to several anti-cancer therapies
(e.g., inhibitors of EGFR, MEK, mutated-BRAF, mTOR, as well as cytotoxic chemotherapy) may be mediated by IRS up-regulation, as demonstrated
in peer reviewed research articles published in scientific journals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>STAT3. </i>STAT3 plays
crucial roles in several cellular processes such as cell proliferation and survival and has been found to be aberrantly activated in
many cancer types (such as NSCLC, head and neck cancer, pancreatic cancer and many others). Much research has explored the leading mechanisms
for regulating the STAT3 pathway and its role in promoting tumorigenesis. Evidence suggests that feedback activation of STAT3 plays a
prominent role in mediating drug resistance to a broad spectrum of targeted cancer therapies and chemotherapies (such as inhibitors of
EGFR, MEK, ALK, as well as 5FU, oxaliplatin and irinotecan).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mechanism of Action</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NT219 is a first in class
small molecule and the only therapeutic candidate to the best of our knowledge that acts as a dual inhibitor of IRS1/2 and STAT3, both
of which play major roles in oncogenesis and cancer drug resistance. While most targeted anti-cancer drugs inhibit the &#8220;ON&#8221;
signal, NT219 activates the &#8220;OFF&#8221; switch, leading to serine phosphorylation and degradation of IRS-1/2, reducing STAT3 phosphorylation,
and extensively blocking major oncogenic pathways.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IRS down-regulation can be
mediated by several oncogenic pathways (EGFR, MAPK, mTOR, etc.). Blockade of these pathways by various drugs, could inhibit serine phosphorylation
of IRS, leading to the activation of IRS to AKT survival bypass. Therefore, degradation of IRS1/2 by NT219 could potentially prevent
resistance and prolong the tumor&#8217;s response to various targeted drugs, as depicted below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_003.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been reports in
peer reviewed academic literature describing the involvement of Insulin-like Growth Factor-1 Receptor (IGF1R) up-regulation in drug-resistance.
In these cases, blockage of IGF1R direct substrates, IRS1/2, by NT219 could potentially overcome drug resistance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The same principle is true
for STAT3. Feedback activation of STAT3 is a common resistance mechanism to many targeted cancer therapies (such as the inhibitors of
EGFR, MEK, BRAF) and cytotoxic chemotherapies. Combining these cancer therapies with NT219, which disrupt this feedback mechanism, could
potentially enhance cell death and delay resistance, suggesting a co-treatment strategy that may be broadly effective in oncogene-addicted
tumors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Degradation of IRS proteins
and blockage of STAT3 by NT219 could potentially prevent resistance to multiple anti-cancer drugs, extend the duration of effective drug
treatment, and restore drug sensitivity in resistant tumors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NT219 has high affinity and
selective binding to its target proteins. NT219 binds covalently to IRS 1/2 and with low nano-molar affinity to the STAT3. Data from
preclinical work showed that a short exposure of cancerous cells to NT219 was sufficient to trigger irreversible shutdown of these pathways,
resulting in a long-term anti-cancer effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2021, we reported
additional preclinical data supporting the mechanism of action of NT219, that was presented in a poster entitled &#8220;Adaptation of
colorectal cancer cells to the brain microenvironment: The role of IRS2,&#8221; at the American Association of Cancer Research (AACR)
2021 Annual Meeting. CRC represents the fourth most frequent cause of brain metastasis, which is the most common brain tumor. The preclinical
data updates and expands on the results previously reported by the Company in collaboration with Dr. Ido Wolf, Head of the Oncology Division
at Tel Aviv Sourasky Medical Center. The study included an analysis of more than 16,000 human CRC local and metastasis samples and revealed
an increased amplification of IRS2 in brain metastases. In an in vitro system mimicking the brain microenvironment, IRS2-overexpressed
CRC cells showed prolonged survival. Importantly, transcriptomic analysis demonstrated significant enrichment of the oxidative phosphorylation
(OXPHOS) pathway by IRS2. CRC cells expressing IRS2 showed increased mitochondrial activity and glycolysis-independent viability. Inhibition
of IRS2 using NT219 dose- dependently inhibited IRS2-expressing cells viability and OXPHOS genes expression. The Wnt/&#946;-catenin pathway
was among the most significantly enriched pathways in the brain metastasis, as IRS2-expressing cells showed increased transcriptional
activity of the &#946;-catenin. In addition, NT219 decreased the transcriptional activity of &#946;-catenin in IRS2- expressing CRC cells
to a greater extent than AKT and PI3K inhibitors, and most significantly suggested relevance of IRS2 in activating &#946;- catenin. It
was further shown that 5-FU, a chemotherapy approved for treating CRC, elevated &#946;-catenin expression, and that NT219 diminished
both 5FU-induced and the basal level of the &#946;-catenin expression. Utilizing an intracranial animal model, it was also demonstrated
that while 5-FU alone had no significant effect, the combination of 5-FU and NT219 significantly inhibited the formation of brain metastasis
and extended survival rates of the study mice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, an article
was published in Nature Cancer demonstrating mechanisms behind cancer cell persistence frequency and potential of NT219 to reduce therapeutic
resistance. The article titled, &#8220;IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during
EGFR inhibition therapy&#8221;. The lead author of the publication is Ravid Straussman, M.D., Ph.D., Department of Molecular Cell Biology,
Weizmann Institute of Science, Rehovot, Israel. The article demonstrated mechanistic evidence of cancer cells&#8217; inherited therapeutic
resistance, termed chance to persist (CTP). It was shown in preclinical models, that the CTP EGFR inhibition is modulated by serine/threonine
phosphorylation of the IRS1. Specifically, it has been shown that higher phosphorylation of IRS1 multiple serine/threonine sites, which
blocks IRS1 activity, results in increased susceptibility to EGFR inhibitors. A combination of NT219, which triggers serine phosphorylation
and subsequent degradation of IRS1 and EGFR inhibitors, resulted in a synergistic effect, leading to tumor regression and delayed recurrence
upon treatment withdrawal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preclinical results</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical studies, NT219,
in combination with several approved cancer drugs, displayed potent anti-tumor effects and increased survival in various cancers by preventing
the tumors from developing drug resistance and restoring sensitivity to the drugs after resistance is acquired. NT219 has shown efficacy
in various PDX models originated from head and neck, cancer, non-small cell lung cancer (NSCLC), sarcoma, melanoma, pancreatic, and colon
cancers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efficacy of NT219 was demonstrated
in combination with three major classes of oncology drugs:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Antibodies such as the
    EGFR antibody (Erbitux) and the immuno-oncology anti-PD1 antibody (Opdivo&#8482;, Keytruda);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kinase Inhibitors such
    as blockers of EGFR (Tagrisso, Tarceva), MEK (Mekinist), Mutated BRAF (Zelboraf), and mTOR (Afinitor); and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemotherapy agents such
    as gemcitabine (Gemzar), 5FU, and Oxaliplatin.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2021, we expanded an existing
research agreement, led by Menashe Bar-Eli, Ph.D., Professor, Department of Cancer Biology, at The University of Texas MD Anderson Cancer
Center, to evaluate the potential efficacy of the combination of NT219 and immuno-oncology drugs, such as anti-CTLA4 or anti-PD1/PDL1
antibodies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2023, we reported
preclinical results of this research and supportive mechanism of action data, that was presented in a poster entitled &#8220;NT219 induces
tumor PD-L1 expression and potentiates anti-PD-1 efficacy&#8221; at the American Association of Cancer Research (AACR) 2023 Annual Meeting.
The findings showed that NT219 sensitizes resistant melanoma tumors to &#945;PD-1 and prolongs mouse survival, providing a rationale
for combining anti-PD-1 therapy with NT219 as a potential strategy to overcome resistance to immune checkpoint blockade (ICB) therapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immune profiling of the ICB-resistant
tumors following treatment of the mice with the combination of NT219 with &#945;-PD-1 or &#945;-CTLA4 demonstrates reprograming of
the TME and reveals enhanced infiltration and activation of cytotoxic T cells and NK cells, paralleled with a decrease in T regulatory
cells, M2 macrophages and monocytic and MDSCs, suggesting the potential of this combinations to restore the efficacy of anti-PD-1 and
anti-CTLA4 therapies by converting immunosuppressive TME to immunoreactive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2024, we reported
preclinical data, showing the potential of NT219 to effectively suppress cancer stem cells, a critical cell population for tumor propagation,
characterized by self-renewal and multipotency, and known to promote resistance and tumor recurrence, in a poster presentation entitled
&#8220;NT219, a dual inhibitor of IRS1/2 and STAT3, suppresses cancer stem cell mediated resistance to KRAS<sup>G12C</sup>&#160;and KRAS<sup>G12D</sup>&#160;inhibitors
in solid tumor&#8221; at the American Association of Cancer Research (AACR) 2024 Annual Meeting. In addition, the data demonstrated the
synergistic effect of NT219 and mKRAS inhibitors, suggesting a novel mechanism to combat resistance to both KRAS<sup>G12C </sup>and KRAS<sup>G12D</sup>&#160;inhibitors
in lung cancer and pancreatic cancers, respectively, both aggressive diseases with unmet medical need.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Clinical
Development</i></b></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NT219 clinical development
strategy will align with preclinical findings, focusing on STAT3 and IRS/AKT pathway inhibition as key resistance mechanisms. Initial
tumor targets will reflect MEK/ERK pathway involvement, particularly those with <i>erb-b</i> pathway dependence or driver mutations.
Additionally, evidence of NT219's single-agent activity in preclinical studies will be considered in the clinical plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The primary endpoint of the
NT219 first-in-human study was to evaluate the drug&#8217;s safety both as a monotherapy and in combination with the antibody cetuximab.
Initial evidence supporting NT219&#8217;s efficacy was assessed as a secondary endpoint.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first in human Phase
1 study of NT219 evaluated single agent NT219 at a dose escalation, in patients with advanced cancer diseases. Patients for this component
of the trial (deemed Part A) were evaluated for safety as the primary endpoint, and efficacy as a secondary endpoint. The escalation
took the form of a 3+3 standard design, together with a &#8220;backfill&#8221; groups enrolling of up to 3 additional patients at doses
which had already been deemed safe. Patients were administered NT219 weekly until disease progression or study withdrawal for any other
cause<b>. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Part B of the Phase 1 clinical
trial of NT219 was a dose escalation study of NT219, beginning with 6mg/kg, in combination with the standard dose of cetuximab (ERBITUX&#174;),
in patients with recurrent and/or metastatic SCCHN and colorectal adenocarcinoma (CRC). In this arm, patients with advanced cancer, who
were eligible for cetuximab therapy (e.g., SCCHN and CRC), received a combination of the drugs, with NT219 being administered first,
followed by cetuximab, in a similar course of weekly administrations. The combination was evaluated in a similar 3+3 design and backfill
groups as described for single agent part of the study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These two parts of the study
provided information regarding the safety of NT219 as a single agent and in combination with cetuximab, including the determination of
the RP2D, as well as preliminary efficacy signal of NT219 as a single agent and in combination with cetuximab.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the dose escalation part
of the study of NT219 as a single agent, 20 patients were evaluable of which 2 patients demonstrated partial response (1 confirmed, 1
nonconfirmed) and 5 patients demonstrated stable disease. In the dose escalation study of NT219 in combination with cetuximab, anti-tumor
activity was observed in previously treated HPV negative 2L/3L R/M SCCHN patients. 18 SCCHN patients were enrolled in the combination
arm; 16 patients were evaluable for efficacy, 8 of which were at the highest dose levels of 50+100 mg/kg. Out of these 8 patients, 2 patients
demonstrated confirmed partial response and 3 patients demonstrated stable disease, representing a 25% objective response rate (ORR) and
62.5% disease control rate (DCR). Median follow-up across all dose levels is 9.4 months (95% CI: 3.4-10.0, 8&#160;out of 15 patients remaining
in follow up). Safety profile was well tolerated and manageable including at the recommended dose level of 100mg/kg. Most common treatment
emergent AEs were infusion related reactions and nausea and no treatment-related Grade 4/5 AEs were observed. Pharmacokinetic analysis
demonstrated dose dependent increase.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Biomarker analysis of biopsies
collected from SCCHN patients before treatment with NT219 (50mg/kg) and cetuximab, demonstrated enhanced activation of IGF1R and STAT3
in responders (PR) as compared to non-responding patients (progressed disease), suggesting these NT219&#8217;s targets as potential biomarkers
for NT219+cetuximab therapy. We believe these initial results should be further explored in a higher number of patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The recommended Phase 2 dose
for NT219 in combination with cetuximab for the treatment of R/M SCCHN patients based on the Phase 1/2 dose escalation study was determined
to be 100mg/kg.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2025, we entered
into a research agreement with the University of Colorado for an investigator-initiated Phase 2 study with NT219 in patients with recurrent
and/or metastatic squamous cell carcinoma of the head and neck, which is expected to be initiated in the first half of 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Competitive Oncology Drugs in Development
that Target IRS1/2 or STAT3 </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not familiar with
other therapeutic candidates acting as dual inhibitor of both IRS1/2 and STAT3. Similarly, we are not aware of any other inhibitor of
IRS1/2 in active development. However, there are some clinical-stage STAT3 inhibitors, such as danvatirsen, an antisense nucleotide developed
by AstraZeneca for pancreatic, NSCLC and mismatch repair deficient colorectal cancers. Although they are not direct competitors of NT219,
inhibitors of Insulin Like Growth Factor 1 Receptor (IGF1R) acting upstream of IRS1/2, such as dalotuzumab, developed by Merck &amp;
Co for pancreatic cancer, or ganitumab, developed by Amgen in Ewing Sarcoma, are also closely monitored.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CAPTN-3 Tribody Platform </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Background</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For decades, cancer research
has been heavily focused on therapeutic modalities directly targeting cancer cells such as radio- or chemotherapy. Despite providing
significant improvement of patient outcome, these treatments have significant limitations related to poor tolerability and acquired resistance
mechanisms. More recently, further to a better understanding of tumor escape mechanisms, the rise of immuno-oncology approaches opened
new horizons. Immune checkpoint inhibitors designed to release effector immune cells from inhibitory signals delivered by cancer cells
and the TME have become the backbone therapy in numerous oncology indications and new strategies have been explored to redirect immune
cells towards malignant cancer cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">T cell engagers is an emerging
therapeutic modality that consists in linking tumor infiltrating T cells to target tumor cells via antibody-derived products. By binding
to a TAA with one arm and to the CD3 molecule associated with the T cell receptor (TCR) with the other arm, T cell engagers promote the
formation of a cytolytic synapse between T cells and cancer cells leading to destruction of the tumor. Conceptually, any cytotoxic immune
effector cell can be engaged by this modality including CD8+ T cells, gamma-delta T cells, NK and NKT cells. In this context, T-cell
engagement is independent of the specific recognition of a peptide-MHC complex and in principle, every tumor infiltrating T cell with
cytotoxic potential is expected to be activated by T cell engagers. The first success with this new approach came from blinatumomab,
a CD19/CD3 bispecific that achieved 40% complete response in patients with acute lymphocytic leukemia (ALL) leading to accelerated approval
by the FDA in 2018. Based on our knowledge, multiple T cell engagers are currently being explored in advanced clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The increase in T cell engagers
or more generally immuno-engagers that are in development is directly related to the progress in protein engineering technologies allowing
to derive new antibody-based compounds with distinctive features. Compared to monospecific monoclonal antibodies, multi-specific constructs
potentiate antibody-mediated effects, for example they can be used to &#8220;crosslink&#8221; immune cells and cancer cells expressing
specific TAAs, they can bind two epitopes on the same target to avoid resistance or they can interact with several TAAs or several immune
cells. Numerous formats of bispecific antibody-based therapeutic candidates are being investigated in clinical studies and the possibilities
are further increasing with the emergence of tri- and multi-specific compounds some of which have already shown potential promising data
and are entering clinical testing. The main field for all of these compounds is oncology, and in general, at least one of the specificities
is intended to redirect T- or NK cells. Based on new research and clinical insights, the rationale for dual engagement of T and NK cells
is attaining stronger recognition and this is one of the main features of our tribody platform.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>CAPTN-3 Tribody Platform Description</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our CAPTN-3 tribody platform
is comprised of conditionally activated tri-specific antibodies that engage both T cells and NK cells and a specific TAA to induce a
strong, localized immune response within the TME. A cleavable capping technology confines the compound&#8217;s therapeutic activity to
the local TME, which increases the anticipated therapeutic window in patients. This technology presents a novel mechanism of action by
unleashing both innate and adaptive immune responses at the TME to induce an optimal anti-tumor immune response.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">T cell engagement is achieved
through binding CD3 using a commercially validated antibody fragment. CD3 is a protein complex associated with the T cell receptor on
the surface of both CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Agonistic binding to CD3&#949; triggers T cell activation that is
mediated by Lck/Zap70 and leads to downstream activation of multiple signaling pathways such as NK-kB or NF-AT. Anti-CD3 is the backbone
of the vast majority of bispecific T cell engagers. Three were already approved by the US FDA (Blinatumomab, CD3&#215;CD19 in 2014 for
acute lymphoblastic leukemia, Tebentafusp, CD3&#215;IMCgp100 in 2022 for Uveal Melanoma, teclistamab, CD3xBCMA in 2022 for Multiple
Myeloma) and a large number other BiTE are currently in clinical development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NK cell mediated activity
is manifested by the NK cell engager arms of NKG2A or NKG2D. The NKG2A arm of the tribody blocks the interaction between NKG2A, an inhibitory
receptor expressed on NK cells or CD8+ T-cells, and the HLA-E ligand expressed on cancer cells. Blockage of the inhibitory effect of
NKG2A-HLA-E interaction allows NK and T-cell activation and thereby, promotes tumor suppression, and consequently induces cell killing.
The NKG2D of the tribody arm inhibits the interaction between NKG2D, an activating receptor expressed on NK cells and CD8+ T-cells,
and its ligands expressed on cancer cells, eliciting cytotoxicity of NK and T cells against the tumor. This activation of NKG2D triggers
cellular proliferation, cytokine production, and cancer cell killing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to its unique
combination of the TAA, CD3 and NK cells binding arms, our CAPTN-3 tribody platform is also differentiated from competing products with
a cleavable cap, which limits the compound&#8217;s therapeutic activity to the local TME. This cap is attached to the anti-CD3 moiety
and blocks its interaction with circulating CD3 positive T cells thereby impeding potential off-tumor adverse reactions. The cap is designed
to be cleaved-off by multiple TME-specific proteases, which increase the likelihood for&#160;cleavage by many tumor types. Upon removal
of this cap, the anti-CD3 moiety of the molecule is freed to bind and activate T lymphocytes via CD3.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead tribody in preclinical
development is IM1240 that targets 5T4 expressing tumors. 5T4 is expressed in a variety of solid tumors and is associated with advanced
disease, increased invasiveness and poor clinical outcome. IM1240 is directed towards 5T4 (also known as trophoblast glycoprotein (TPBG)),
using a proprietary set of complementarity-determining regions (CDRs). 5T4 is an oncofetal surface protein that is not found on adult
healthy tissues but is abnormally expressed in several cancer types. This specific expression pattern as well as the correlation with
poor prognosis in different cancer diseases such as lung, gastric, head and neck and other cancers makes it an ideal TAA for various
therapeutic approaches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preclinical data</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IM1240 is the outcome of
significant lead optimization work to maximize the compounds properties in terms of affinity, efficacy and safety. The different tribodies
demonstrated high affinity for 5T4, CD3 and NK cell inhibitory receptor and efficient anti-tumor responses in in vitro killing assays.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The benefit of the dual T
cell/ NK cell activation was demonstrated in cytotoxicity assays against various 5T4<sup>+</sup> cancer cells lines, and in an autologous
patient-derived NSCLC explant study, where the 5T4xCD3xNK tribody was more potent than either the 5T4xCD3 or the 5T4xNK variants. In
terms of specificity no cytotoxicity was observed in 5T4 negative cancer cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The relevance and robustness
of the cleavable capping system was investigated in xenograft models using immune-competent mice. Sustained tumor regression was achieved
with the tribody harboring a cleavable cap. The effect was superior to a variant with no cap, illustrating the detrimental effect of
peripheral engagement of tumor-irrelevant T cells. The efficacy was completely lost using a variant with non-cleavable cap in which the
CD3 arm of the tribody remained blocked.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional preclinical data
for CAPTN-3 demonstrated that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lead compound, IM1240, demonstrated high affinity binding towards CD3 &amp; NKG2A proteins and CD3 &amp; NKG2A expressing cells, while
no binding was detected using the mutated versions of the tribody, indicating specificity. The synergistic effects of the&#160;</span><span style="font-family: Symbol; font-size: 10pt">a</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CD3
and&#160;</span><span style="font-family: Symbol; font-size: 10pt">a</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NKG2A
arms in suppressing 5T4<sup>+</sup>&#160;non-small cell lung cancer (NSCLC) PDEs at 10nM were demonstrated, emphasizing CAPTN-3&#8217;s
potential advantage in a clinically relevant biological assay. A dose-dependent effect of IM1240 was shown.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sustained
tumor regression in triple negative breast cancer humanized mice was demonstrated for the capped tribody, which was superior to the uncapped
tribody. No effect was shown with the non-cleavable capped tribody whose CD3 binding function is irreversibly blocked.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cytotoxic
effect and binding to CD3 was fully recovered following capping cleavage.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PBMC-mediated
cytotoxicity against 5T4<sup>+</sup>&#160;cancer cells was demonstrated at picomolar EC50 while no effect was observed in 5T4<sup>-</sup>&#160;cancer
cells.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IM1240
and non-capped tribody inhibited NKG2A-HLA-E interaction in a dose-dependent manner, while NKG2A mutated tribody had no effect.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NK
cell mediated cytotoxicity against HLA-E expressing cancer cells was demonstrated, while NKG2A mutated tribody had no effect.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
cytokine release assay from hPBMC showed a 5T4<sup>+</sup>&#160;cancer cell dependency and was inhibited by the cap, showing superior
safety profile.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plug
and Play abilities of the platform were demonstrated through different tribodies targeting 5T4 (aCD3xa5T4xaNKG2A), EGFR (aCD3xaEGFRxaNKG2A)
and NKG2D (aCD3xa5T4xaNKG2D) which demonstrated low nM and selective binding to cells overexpressing the target, and efficient PBMC and
NK mediated cytotoxicity.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional preclinical investigations
are ongoing to complete the functional characterization of the compound and, in parallel, the development of GMP manufacturing processes
required to conduct IND-enabling studies is underway. During 2024, we held a pre-IND meeting with the FDA that provided a clear path
forward for our development plan through Phase 1 and we expect to submit an IND application to the FDA for IM1240 during 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Competitive Oncology Multi- specific Drugs
in Development that Target 5T4</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
face potential competition from companies developing therapies targeting 5T4, as well as those utilizing proteolytically cleaved, conditionally
activated platforms. Several companies are advancing 5T4-targeted therapies, including antibody-drug conjugates (ADCs), bispecific antibodies,
and T-cell engagers, which may directly compete with IM1240. Additionally, several companies are developing conditionally activated biologics
designed to enhance tumor selectivity while minimizing off-tumor toxicity. The potential of our approach differentiates IM1240, we believe,
through its unique mechanism of action and potential clinical benefits.</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patents, trademarks and licenses and market
exclusivity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our policy is to seek to
protect our proprietary position by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology,
inventions and improvements that are important to the development of our business. We also rely on our trade secrets, know-how and continuing
technological innovation to develop and maintain our proprietary position. We vigorously defend our intellectual property to preserve
our rights and gain the benefit of our technological investments. Our business is not dependent, however, upon any single patent, trademark
or contract. See &#8220;Item 3. Key Information &#8211; D. Risk Factors &#8211; Risks Related to Intellectual Property&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><span style="text-decoration:underline">CM24</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FameWave&#8217;s patent and
patent application portfolio, covering the entire CEACAM1 antibody termed CM24 and other antibodies and uses thereof, includes six patent
families, covering anti CEACAM1 antibodies and their uses in the treatment of cancer and other diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent Family 1</i>
    relates to anti-human CEACAM1 antibodies, hybridoma cells producing these antibodies and methods of using the antibodies. United
    States patents as well as European counterparts were granted, as well as patents in Brazil, Canada, China, Israel, Japan, Korea and
    Russia, all of which have a maximum term of April 28, 2030. The European patents were validated in France; Germany; Ireland; Italy;
    The Netherlands; Poland; Spain; Switzerland; and United Kingdom.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent Family 2</i>
    relates to method of diagnosing melanoma or monitoring progression of melanoma, the method comprising determining a level of human
    CEACAM1 on isolated lymphocytes of a human subject in need thereof, wherein an upregulation of said level of CEACAM1 above a predetermined
    threshold is indicative of melanoma or stage thereof in said subject. Patents were granted in Israel and Europe. The European patent
    was validated in United Kingdom, Ireland, The Netherlands, Germany, Spain, Italy, France and Switzerland. All granted patents have
    a maximum term of July 20, 2030.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent Family 3</i>
relates to antibodies (in particular chimeric antibodies) as well as molecules having at least the antigen-binding portion of an antibody
against the human protein CEACAM1. Two United States patents as well as two European counterparts were granted. The European patents
are validated in Germany, France, Spain, Italy, United Kingdom, Ireland, The Netherlands, Poland and Switzerland. Patents were also granted
in Brazil, Canada, China, India, Israel, Japan, Korea and Russia. The patents of this family have a maximum term of October 9, 2032,
except for the U.S. patents that has a maximum term of May 22, 2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent Family 4</i>
    relates to compositions comprising anti-human CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking
    the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer. Patents have been granted in
    the United States, Europe (2 patents), Brazil, Canada, China, India, Japan, Korea, Mexico and Russia. The European patents were validated
    in United Kingdom, Ireland, The Netherlands, Germany, Spain, Italy, France, Switzerland and Poland. These patents have a maximum
    term of November 24, 2034. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent Family 5</i>
    relates to humanized antibodies, including CM24, capable of specific binding to human CEACAM1 molecules containing human-to-murine
    back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences. Patents have been granted in the United
    States (2 patents), Europe, Brazil, Canada, China, Eurasia (validated in Russia), India, Israel, Japan Korea and Mexico (2 patents)
    with a maximum term of April 26, 2035. The European patent was validated in United Kingdom, Ireland, The Netherlands, Germany, Spain,
    Italy, France, Switzerland and Poland. A continuation-in-part application is pending in the United States. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent Family 6</i>
    relates to use of CM24 in inhibition of NET-mediated activities and in prevention and treatment of pathologies associated with these
    activities. An international (PCT) application was filed on November 9, 2023, claiming priority from U.S. provisional applications
    filed on November 10, 2022, and September 21, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>License Agreement with Tel HaShomer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 16, 2012, cCAM entered
into a license agreement with THM and Ramot at Tel Aviv University Ltd. (&#8220;Ramot&#8221;), which was effective as of May 25, 2010,
pursuant to which THM and Ramot granted cCAM a worldwide, royalty-bearing, exclusive license to develop, manufacture, produce, market
and sell any biopharmaceutical product and/or diagnostic product using patents and inventions owned by THM and Ramot in connection with
uses of the glycoprotein CEACAM1 (the &#8220;THM License Agreement&#8221;). The THM License Agreement was subsequently amended in 2013
and in 2015.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In conjunction with the closing
of the reversion agreement amongst MSD, cCAM and FameWave, the parties executed an Assignment and Assumption Agreement by and between
FameWave and cCAM (an MSD subsidiary), according to which cCAM assigned to FameWave all its rights, title and interest in, to and under
the License Agreement, which Assignment and Assumption Agreement was countersigned by each of Ramot and THM, as a condition for closing
of such reversion agreement (defined as the transfer of those certain assets from cCAM and MSD to FameWave).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the THM
License Agreement, THM and Ramot retain ownership of the licensed information (defined as the patents and inventions licensed under the
License Agreement). However, FameWave will own all rights to any data and information created and/or generated by cCAM and subsequently
by FameWave, whether or not its development is based on the licensed information, including any proprietary intellectual or industrial
property rights. FameWave and THM and/or Ramot will jointly own all rights to any data and information mutually created and/or generated
by FameWave together with THS/Ramot/Sheba employees or agents, or TAU&#8217;s students, employees or agents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FameWave has the right to
grant sub-licenses to third parties in accordance with the terms set forth in the THM License Agreement. THM and Ramot retain the right
to use the licensed information solely for academic and/or scholarly purposes, provided that such use does not harm and/or expose FameWave&#8217;s
confidential information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration for the
license grant, FameWave agreed to pay to THM an annual license fee, royalties based on a percentage of &#8220;Net Sales&#8221;, a percentage
of the sales-based sublicense fees, and a percentage of the sublicense fees. Additionally, FameWave has undertaken to pay certain milestone
payments and a percentage of all consideration received by FameWave or its shareholders as a result of or in connection with an exit
event (as defined). Finally, THM also received an assignable warrant to purchase, upon the closing of an IPO of FameWave, ordinary shares
of FameWave, at a price equal to a certain percentage of the forecast initial market value of FameWave for each share as was determined,
prior to the IPO, for the purpose of the IPO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FameWave agreed to bear sole
responsibility and payment obligations for any damage caused by or on behalf of FameWave or any sublicensee as a result of or in connection
with the THM License Agreement and/or the exercise of the license. FameWave is also required to indemnify THM, Sheba, TAU and Ramot,
and their respective employees, agents and representatives, from and against any and all loss, liability, claims, damages and expenses
(including legal costs and attorneys&#8217; fees) of whatever kind or nature by a third-party that arise out of and/or result from the
THM License Agreement and/or the exercise of the license, or to the extent that they are based on a claim that the licensed information,
the products or other material produced by FameWave infringes any third-party&#8217;s intellectual property rights including copyright,
trade secret, patent, or trademark.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the THM License
Agreement, FameWave undertook to develop, manufacture, sell and market products pursuant to the milestones and time schedule attached
to the THM License Agreement. FameWave is required to bear all costs and fees incurred prior to and during the term of the THM License
Agreement, in connection with the preparation, filing, maintenance, prosecution and the like of any patents deemed necessary to protect
the licensed information, and in case of third-party infringement, FameWave is obligated, at its expense, to institute, prosecute and
control any action or proceeding with respect to such infringement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">THM
is entitled to appoint an observer to FameWave&#8217;s board of directors who has all the rights of any other director of FameWave save
for the right to vote. To date, THM has not acted on this right.</span>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FameWave has agreed to purchase
and maintain, at its own expense, insurance which covers its liability pursuant to the THM License Agreement, in its name and naming
the indemnified parties as additional insured parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of the THM License
Agreement continues on a product-by-product and country-by-country basis, until the later of (i) the date of expiry of the last of the
licensed patents in such country; or (ii) the expiry of a period of 15 years from the first commercial sale in such country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THM and Ramot may terminate
the THM License Agreement and/or the license if (i) the first commercial sale of the product has not been made within two years from
FDA or CE marketing approval; (ii) FameWave breaches any of its obligations under the THM License Agreement and such breach is not cured
within 60-90 days, depending on the materiality of the breach; (iii) FameWave breaches any of FameWave&#8217;s obligations under the
THM License Agreement, and such breach remains uncured for 90 days after written notice; (iv) FameWave becomes insolvent, or petitions
are filed against it under insolvency laws; (v) FameWave has ceased to carry on business as an ongoing concern; or (vi) FameWave has
challenged, challenges, or causes any third-party to challenge, the intellectual property rights or other rights or THM or Ramot to the
licensed information anywhere in the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon termination of the THM
License Agreement, other than due to expiration of the THM License Agreement, all rights granted to FameWace revert to THM and Ramot
and FameWave will not be entitled to make any further use in the licensed information. The THM License Agreement is governed by the laws
of the State of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><span style="text-decoration:underline">NT219</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TyrNovo&#8217;s patent and
patent application portfolio, covering NT219 and other compounds, includes six patent families, covering compounds that modulate protein
kinase signaling and their use in treatment of protein kinase related disorders, including cancer and neurodegenerative disorders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent Family 1 relates
    to compounds modulating the insulin-like growth factor receptor signaling and methods of using these compounds as chemotherapeutic
    agents for the treatment of protein kinase related disorders, in particular cancer. This family includes a U.S. patent which is due
    to expire on April 2, 2028. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent Family 2 also relates
    to compounds modulating the insulin-like growth factor receptor signaling and methods of using these compounds as chemotherapeutic
    agents for the treatment of protein kinase related disorders, in particular cancer, and specifically discloses and claims NT219.
    Patents were granted in Europe and Israel, and have a maximum term of June 7, 2029, and in the United States, with a maximum term
    of April 2, 2028. A reissue application of the U.S. patent has been filed. The European patent was validated in France, Germany,
    Italy, The Netherlands, Spain, Switzerland, and the United Kingdom.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent Family 3 relates
    to compounds having a benzo[e][1,3]thiazin-7-one core and methods of using these compounds as chemotherapeutic agents for the treatment
    of protein kinase related disorders, in particular cancer. Patents were granted in Europe and the United States, with a maximum term
    of December 27, 2031, and April 9, 2032, respectively. The European patent was validated in France, Germany, Italy, Spain, and the
    United Kingdom.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent Family 4 relates
    to combinations of the compounds disclosed in Patent Families 1-3, acting as dual modulators of IRS and STAT3, with various targeted
    drug classes (inhibitors of EGFR, mTOR; MEK or mutated B-Raf), as well as chemotherapeutic agents (Gemcitabine, 5-FU, Irinotecan
    and Oxaliplatin), and use of such combinations for the treatment of cancer. Patents were granted in Australia, Brazil, China, Europe
    and Israel, and have a maximum term of February 4, 2036, and in the United States, with a maximum term of August 12, 2036. Patent
    applications are pending in Canada (allowed), Europe, Japan (allowed), and the United States. The European patent was validated in
    Switzerland, Germany, Spain, France, Great Britain, Ireland, Italy and The Netherlands. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent Family 5 relates
    to specific combinations of the compounds disclosed in Patent Families 1-3, with various antibodies against PD-1 protein and/or anti-programmed
    cell death protein 1 ligand (PD-L1). Patents were granted in Japan and Russia and have a maximum term of November 16, 2037. Patent
    applications are pending in Brazil, Canada, China, Europe, Israel (allowed), Mexico, and the United States. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">Patent Family 6 relates to NT219 trans isomer, a method to prevent its conversion from the trans active form to a less active form (cis)
and a method of maintaining the active form during manufacturing, storage and handling until administered to the patient. A Chinese patent
was granted and has a maximum term of February 17, 2042. Patent applications are pending in Brazil, Canada, China, Europe, India, Israel,
Japan, Korea, Mexico, and the United States.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Exclusive License Agreement with Yissum</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2013, TyrNovo entered
into a license agreement with Yissum, which was subsequently amended in April 2014 and March 2017, pursuant to which Yissum has granted
TyrNovo an exclusive license (with the right to sublicense) for the development, use, manufacturing and commercialization of products
using certain patents and know-how owned by Yissum and patent applications filed by Yissum in connection with unique inhibitors of the
IGF-1R Pathway (the &#8220;Yissum License Agreement&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the Yissum
License Agreement, Yissum shall retain the ownership of the Licensed Technology (as such term is defined therein). All rights in the
results of the activities carried out by TyrNovo or third parties in the development of these products (and certain results obtained
under material transfer agreements signed by TyrNovo and Yissum (the &#8220;TyrNovo MTAs&#8221;)) shall be solely owned by TyrNovo (unless
an employee of the Hebrew University of Jerusalem or each of its branches is an inventor of any of the patents claiming such results,
in which case they shall be owned jointly by Yissum and TyrNovo). TyrNovo has the right to grant sub-licenses to third parties in accordance
with the terms set forth in the Yissum License Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TyrNovo has agreed to pay
Yissum a percentage of &#8220;net sales&#8221; as royalties and to pay Yissum a percentage of the income that it receives from granting
sub-licenses to third parties. Additionally, in the event of an M&amp;A prior to an IPO, TyrNovo will be required to pay Yissum a percentage
of the proceeds received under such M&amp;A. In the event of an IPO, then prior to the closing of such IPO, TyrNovo shall issue to Yissum
such number of ordinary shares equal to a certain percentage of all TyrNovo shares. According to the settlement agreement with BIRAD
and an amendment to the Yissum license agreement, BIRAD is entitled to receive a portion of Yissum&#8217;s royalties on net sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TyrNovo is required to indemnify
Yissum, the Hebrew University of Jerusalem, their directors, employees, executive officers, consultants or representatives and any other
persons acting on their behalf under the license against any liability, including product liability, damages, losses, expenses, fees
and reasonable legal expenses arising out of TyrNovo&#8217;s actions or omissions or which derive from its use, development, manufacture,
marketing, sale or sublicensing of any licensed product, licensed technology, and certain information obtained under the TyrNovo MTAs,
or exercise of the Yissum License Agreement, and the TyrNovo MTAs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TyrNovo has agreed to maintain,
and to add Yissum as an additional insured party with respect to, clinical trials, comprehensive general liability and product liability
insurance as well as an insurance policy with respect to the foregoing indemnification prior to the time when it commences clinical trials
and concludes its first commercial sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of the Yissum License
Agreement shall expire upon the later of (i) the date of expiration in such country of the last to expire licensed patent included in
the licensed technology; or (ii) the end of a period of 15 years from the first commercial sale in such country, while the license granted
under the Yissum License Agreement will terminate upon the later of (unless the license has been earlier terminated or expired) (i) the
date of expiration in such country of the last to expire licensed patent included in the licensed technology; (ii) the date of expiration
of any exclusivity on the product granted by a regulatory or government body in such country; or (iii) the end of a period of 15 years
from the first commercial sale in such country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TyrNovo has the right to
terminate the Yissum License Agreement upon a prior written notice. Either party has the right to terminate the Yissum License Agreement
if the other party is in material breach and has not cured such material breach within a certain number of days as of the receipt of
a written notice notifying it of such breach. Additionally, Yissum has the right to terminate the Yissum License Agreement immediately
in the event that TyrNovo does not comply with its obligation (following a certain amount of months cure period) to use commercially
reasonable efforts to develop and commercialize the products; if an attachment is made over the majority of TyrNovo&#8217;s assets or
if execution proceedings are taken against TyrNovo and are not set aside within a certain amount of days; or if TyrNovo challenges in
any forum the validity of one or more of the licensed patents. Upon termination of the Yissum License Agreement, TyrNovo shall assign
to Yissum all the results obtained during the development of the product. If Yissum licenses to third parties such results, then TyrNovo
shall be entitled to a percentage of the net proceeds actually received by Yissum from such third parties, up to an amount covering TyrNovo&#8217;s
expenses incurred during the development of such assigned results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><span style="text-decoration:underline">CAPTN-3 Tribody Platform</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent Family 1 relates
    to conditionally activated tri-specific antibodies that engage T cells, NK cells, and tumor cells, including the antibody clone identified
    as IM1240, compositions thereof, and methods of use thereof for treating cancer in a subject in need. The tri-specific antibodies
    further include a cleavable capping technology for regulating the binding/activation of T cells to within a TME and for extending
    the half-life of the antibodies. National Phase applications have been entered and are pending in Australia, Brazil, Canada, China,
    Europe, Israel, India, Japan, the Republic of Korea, Mexico, and the United States. The expected term of any granted national phase
    application is May 4, 2041, not including patent term extension.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">In addition, we own four additional patent families related to conditionally activated tri-specific antibodies that engage T cells, NK
cells and tumor cells including different TAAs with their respective CDRs and compositions thereof, and methods of use thereof for treating
cancer as well as GvHD, viral or bacterial infections in a subject in need. National phase applications, for a patent family related to
anti 5T4 antibodies have been entered in Australia, Brazil, Canada, China, Eurasia, Europe, Israel, India, Japan, the Republic of Korea,
Mexico, and the United States. National phase applications, for a patent family related to anti NKG3D antibodies have been entered in
Australia, Brazil, Canada, China, Eurasia, Europe, Israel, India, Japan, the Republic of Korea, Mexico, and the United States. National
phase applications, for a patent family related to anti ROR1 antibodies have been entered in Europe, Israel, and the United States.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We own three patent families
covering uses of a monoclonal antibody, which we are currently evaluating for their potential for further development, for the purpose
of treating cancer and infectious diseases, based on these patents.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Market exclusivity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the branded pharmaceutical
industry, the majority of a branded drug&#8217;s commercial value is usually realized during the period in which the product has market
exclusivity. In the U.S. and some other countries, when market exclusivity expires and generic versions of a product are approved and
marketed, there can often be very substantial and rapid declines in the branded product&#8217;s sales. The rate of this decline varies
by country and by therapeutic category, and the number of generic competitor entrants to the market, among other factors; however, following
patent expiration, branded products often continue to have market viability based upon the goodwill of the product name, which typically
benefits from trademark protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A pharmaceutical brand product&#8217;s
market exclusivity is generally determined by two forms of intellectual property: patent rights held by the brand company and any regulatory
forms of exclusivity to which the NDA-holder is entitled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents are a key determinant
of market exclusivity for most branded pharmaceuticals. Patents provide the brand company with the right to exclude others from practicing
an invention related to the medicine. Patents may cover, among other things, the active ingredient(s), various uses of a drug product,
pharmaceutical formulations, drug delivery mechanisms and processes for (or intermediates useful in) the manufacture of products, and
polymorphs. Protection for individual products extends for varying periods in accordance with the expiration dates of patents in the
various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent, its scope of
coverage and the availability of meaningful legal remedies in the country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market exclusivity is also
sometimes influenced by regulatory exclusivity rights. Many developed countries provide certain non-patent incentives for the development
of medicines. For example, the U.S., the European Union and Japan each provide for a minimum period of time after the approval of a new
drug during which the regulatory agency may not rely upon the data of the original party who developed the drug to approve a competitor&#8217;s
generic copy. Regulatory exclusivity rights are also available in certain markets as incentives for research on new indications, on orphan
drugs and on medicines useful in treating pediatric patients. Regulatory exclusivity rights are independent of any patent rights and
can be particularly important when a drug lacks broad patent protection. Most regulatory forms of exclusivity, however, do not prevent
a competitor from gaining regulatory approval prior to the expiration of regulatory data exclusivity on the basis of the competitor&#8217;s
own safety and efficacy data on its drug, even when that drug is identical to that marketed by the innovator.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is not possible to predict
the length of market exclusivity for any of our branded products with certainty because of the complex interaction between patent and
regulatory forms of exclusivity, and inherent uncertainties concerning patent litigation. There can be no assurance that a particular
product will enjoy market exclusivity for the full period of time that we currently estimate or that the exclusivity will be limited
to the estimate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulations and Funding </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmaceutical companies
are subject to extensive regulation by foreign, federal, state and local agencies, such as the FDA in the U.S., the Ministry of Health
in Israel, or the various European regulatory authorities. The manufacture, distribution, marketing and sale of pharmaceutical products
are subject to government regulation in the U.S. and various foreign countries. Additionally, in the U.S., we must follow the rules and
regulations established by the FDA requiring the presentation of data indicating that our products are safe and efficacious and are manufactured
in accordance with cGMP regulations. If we do not comply with applicable requirements, we may be fined, the government may refuse to
approve our marketing applications or allow us to manufacture or market our products, our products may be subject to detention and/or
seizure, shipments of our products could be refused entry into the United States, and we may be criminally prosecuted. We and our manufacturers
and CROs may also be subject to regulations under other foreign, federal, state and local laws, including, but not limited to, the U.S.
Occupational Safety and Health Act, the Resource Conservation and Recovery Act, the Clean Air Act and import, export and customs regulations
as well as the laws and regulations of other countries. As a result, pharmaceutical companies must ensure their compliance with the Foreign
Corrupt Practices Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These regulatory requirements
impact our operations and differ from one country to another, so that securing the applicable regulatory approvals of one country does
not necessarily imply the approval of another country. The approval procedures involve high costs and are manpower intensive, usually
extend over many years and require highly skilled and professional resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>U.S. Food and Drug Administration Approval
Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The steps usually required
to be taken before a new drug may be marketed in the U.S. generally include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of preclinical
    laboratory and animal testing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of required
    chemistry, manufacturing and controls testing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the submission to the FDA
    of an IND application, which must be evaluated and found acceptable by the FDA before human clinical trials may commence;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of (or reference
    to) adequate and well-controlled human clinical trials and studies to establish the safety, pharmacokinetics and efficacy of the
    proposed drug for its intended use;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission and approval
    of an NDA; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">agreement with FDA of the
    language on the package insert.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical studies are conducted
under protocols detailing, among other things, the objectives of the study, what types of patients may enter the study, schedules of
tests and procedures, drugs, dosages, and length of study, as well as the parameters to be used in monitoring safety, and the efficacy
criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must be submitted to the FDA as part
of the IND process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In all the countries that
are signatories of the Helsinki Declaration (including Israel), the prerequisite for conducting clinical trials (on human subjects) is
securing the preliminary approval of the competent authorities of that country to conduct medical experiments on human subjects in compliance
with the other principles established by the Helsinki Declaration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The clinical testing of a
drug product candidate generally is conducted in three sequential phases prior to approval, but the phases may overlap or be combined.
A fourth, or post approval, phase may include additional clinical studies. The phases are generally as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase I.</i> The Phase
    I clinical trial is generally conducted on 8-20 healthy volunteers. Phase I clinical trials typically involve administering escalating
    doses of the therapeutic candidate in the healthy volunteers to assess safety, dosage tolerance, absorption, metabolism, distribution
    and excretion. In the case of some products for severe or life-threatening diseases, such as cancer, and especially when the product
    may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase II. </i>The Phase
    II clinical trial involves administering the therapeutic candidate to a small population of sick patients to identify possible adverse
    events, or safety risks, and preliminary indicia of efficacy for the targeted disease or medical condition;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase III.</i> The Phase
    III clinical trial usually comprises multi-center, double-blind controlled trials in hundreds or even thousands of subjects at various
    sites to assess as fully as possible both the safety and the effectiveness of a drug. Specifically, the Phase III clinical trial
    is intended to make a comparison between the therapeutic candidate and the standard therapy and/or placebo. These trials are intended
    to establish the overall benefit/risk profile of the product and to provide an adequate basis for product labeling; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase IV</i>. In some
    cases, the FDA may condition approval of an NDA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical
    trials after approval. In other cases, a sponsor may voluntarily conduct additional clinical trials after approval to gain more information
    about the drug. Such post-approval studies are typically referred to as Phase IV clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All clinical trials used
as support for an IND or application for marketing approval must be conducted in accordance with the FDA&#8217;s good clinical practices,
or GCP, requirements, including clinical trials conducted outside of the United States. If a clinical trial conducted outside of the
United States is not conducted in accordance with the FDA&#8217;s GCP requirements, the FDA may not accept the study as support for an
IND or application for marketing approval. The FDA may order the temporary or permanent discontinuation of a clinical study at any time
or impose other sanctions if it believes that the clinical study is not being conducted in accordance with FDA requirements or that the
participants are being exposed to an unacceptable health risk. An institutional review board, or IRB, generally must approve the clinical
trial design and patient informed consent at study sites that the IRB oversees and also may halt a study, either temporarily or permanently,
for failure to comply with the IRB&#8217;s requirements, or may impose other conditions. Additionally, some clinical studies, mostly
in certain types of Phase III clinical trial studies where it is required under the applicable clinical trial protocol, are overseen
by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or committee.
This group recommends whether or not a trial may move forward at designated check points based on access to certain data from the study.
The clinical study sponsor may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a therapeutic candidate
matures through the clinical testing phases, manufacturing processes are further defined, refined, controlled, and eventually validated
around the time that the Phase III clinical trial is completed. The level of control and validation required by the FDA increases as
clinical studies progress. We and the third-party manufacturers on which we rely for the manufacture of our therapeutic candidates and
their respective components (including the APIs) are subject to requirements that drugs be manufactured, packaged and labeled in conformity
with cGMP and other FDA requirements specific to investigational drug candidates. To comply with cGMP requirements and other requirements,
manufacturers must continue to spend time, money and effort to meet requirements relating to personnel, facilities, equipment, production
and process, labeling and packaging, quality control, recordkeeping and other requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming completion of all
required testing in accordance with all applicable regulatory requirements, detailed information on the product candidate is submitted
to the FDA in the form of an NDA, requesting approval to market the product for one or more indications, together with payment of a user
fee, unless waived. An NDA includes all relevant data available from pertinent nonclinical and clinical studies, including negative or
ambiguous results as well as positive findings, together with detailed information on the chemistry, manufacture, controls and proposed
labeling, among other things. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish
the safety and efficacy of the product candidate for its intended use to the satisfaction of the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an NDA submission is accepted
for filing, the FDA begins an in-depth review of the NDA. Under the Prescription Drug User Fee Act, or PDUFA, the FDA&#8217;s goal is
to complete its initial review and respond to the applicant within ten months of submission, unless the application relates to an unmet
medical need, or is for a serious or life-threatening indication, in which case the goal may be within six months of NDA submission.
However, PDUFA goal dates are not legal mandates, and the FDA response often occurs several months beyond the original PDUFA goal date.
Further, the review process and the target response date under PDUFA may be extended if the FDA requests or the NDA sponsor otherwise
provides additional information or clarification regarding information already provided in the NDA. The NDA review process can, accordingly,
be very lengthy. During its review of an NDA, the FDA may refer the application to an advisory committee for review, evaluation and recommendation
as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it typically
follows such recommendations. Data from clinical studies are not always conclusive and the FDA and/or any advisory committee it appoints
may interpret data differently than the applicant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the FDA evaluates the
NDA and performs a pre-approval inspection, or &#8220;PAI&#8221;, on manufacturing facilities where the drug product and/or its API will
be produced, the FDA will either approve commercial marketing of the therapeutic candidate with prescribing information for specific
indications or issue a complete response letter indicating that the application is not ready for approval and stating the conditions
that must be met in order to secure approval of the NDA. If the complete response letter requires additional data and the applicant subsequently
submits that data, the FDA nevertheless may ultimately decide that the NDA does not satisfy its criteria for approval. The FDA could
also approve the NDA with a Risk Evaluation and Mitigation Strategies, or REMS, plan to mitigate risks, which could include medication
guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and
other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development
of adequate controls and specifications, or a commitment to conduct post-marketing testing. Such post-marketing testing may include Phase
IV clinical trials and surveillance to further assess and monitor the product&#8217;s safety and efficacy after approval. Regulatory
approval of drug product candidates for serious or life-threatening indications may require that participants in clinical studies be
followed for long periods to determine the OS benefit of the drug product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA approves one of
our therapeutic candidates, we will be required to comply with a number of post-approval regulatory requirements. We would be required
to report, among other things, certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information
and comply with requirements concerning advertising and promotional labeling for any of our therapeutic candidates. Also, quality control
and manufacturing procedures must conform to cGMP for approved drug products after our NDA is approved, if at all, and the FDA periodically
inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural, substantive and recordkeeping requirements.
If we seek to make certain changes to an approved product, such as certain manufacturing changes, we will need FDA review and approval
before the change can be implemented. For example, if we change the manufacturer of a product or our API, the FDA may require stability
or other data from the new manufacturer, and such data will take time and are costly to generate, and the delay associated with generating
these data may cause interruptions in our ability to meet commercial demand, if any. While physicians may use products for indications
that have not been approved by the FDA, we may not label or promote the product for an indication that has not been approved. Securing
FDA approval for new indications is similar to the process for approval of the original indication and requires, among other things,
submitting data from adequate and well-controlled studies that demonstrate the product&#8217;s safety and efficacy in the new indication.
Even if such studies are conducted, the FDA may not approve any change in a timely fashion, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Section 505(b)(1) New Drug Applications</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Section 505(b)(1) NDA or
BLA, known as the &#8220;full NDA or BLA,&#8221; is an application that contains full reports of investigations of safety and efficacy
performed by the drug sponsor. CM24 and NT219 are not a combination therapeutic candidate or a therapeutic candidate that is comprised
of an API that has already undergone some or all necessary human clinical trials in another therapeutic candidate. Therefore, if CM24
or NT219 are approved for human clinical trials by the FDA or any foreign regulatory agency and show adequate safety and efficacy data
in human clinical trials, we anticipate that CM24 and NT219 will require a 505(b)(1) BLA or NDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Special Protocol Assessment</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The special protocol assessment,
or SPA, process is designed to facilitate the FDA&#8217;s review and approval of drugs by allowing the FDA to evaluate the proposed design
and size of Phase III clinical trials that are intended to form the primary basis for determining a drug product&#8217;s efficacy. Upon
specific request by a clinical trial sponsor, the FDA will evaluate the protocol and respond to a sponsor&#8217;s questions regarding,
among other things, primary efficacy endpoints, trial design and data analysis plans, within 45 days of receipt of the request.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA ultimately assesses
whether the protocol design and planned analysis of the trial are acceptable to support regulatory approval of the therapeutic candidate
with respect to effectiveness of the indication studied. All agreements and disagreements between the FDA and the sponsor regarding an
SPA must be clearly documented in an SPA letter or the minutes of a meeting between the sponsor and the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if the FDA agrees to
the design, execution and analyses proposed in protocols reviewed under the SPA process, the FDA may revoke or alter its agreement, such
as under the following circumstances:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">public health concerns
    emerge that were unrecognized at the time of the protocol assessment, or the director of the review division determines that a substantial
    scientific issue essential to determining safety or efficacy has been identified after testing has begun;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a sponsor fails to follow
    a protocol that was agreed upon with the FDA; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relevant data, assumptions
    or information provided by the sponsor in a request for SPA change, are found to be false statements or misstatements, or are found
    to omit relevant facts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a documented
SPA may be modified, and such modification will be deemed binding on the FDA review division, except under the circumstances described
above, if the FDA and the sponsor agree in writing to modify the protocol and such modification is intended to improve the study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>European Regulatory Authorities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to perform trials
in Europe or market or sell our therapeutic candidates in Europe, we must comply with EU Clinical Trial Regulation (CTR) 536/2014, which
stipulates that sponsors seeking approval to conduct a clinical trial in one or more European countries must submit a single online application
via the Clinical Trials Information System (CTIS). This streamlined process enhances efficiency by enabling simultaneous evaluation by
multiple European regulatory authorities and ethics committees, facilitating faster approval and coordination of multinational trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regarding marketing approval
for new drugs, the centralized procedure, managed by the European Medicines Agency (EMA), allows for a single application for marketing
authorization valid across all EU Member States. The European Commission is the authorizing body for all centrally authorized products
and makes a legally binding decision based on EMA's recommendation. Once granted by the European Commission, the centralized marketing
authorization is valid in all EU Member States as well as in the European Economic Area (EEA) countries: Iceland, Liechtenstein, and
Norway. Our therapeutic candidates, such as CM24, NT219 or IM1240, may be approved through the centralized process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Israeli Ministry of Health </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are subject
to permits from the Israeli Ministry of Health as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">First, pertaining to the
import of drugs and/or raw materials, we are required to apply to the Israeli Ministry of Health (&#8220;IMOH&#8221;) for approval from
its medical devices and accessories unit (AMAR).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Second, pertaining to research
and development, when we conduct trials in humans in Israel, the trials will be subject to the approval of the Helsinki Committee, which
acts by force of the Public Health Regulations (Trials in Human Beings), 1980 (Trials in Human Subjects Regulations), as amended, and
according to the guidelines of the Helsinki declaration, or any other approval required by the Ministry of Health. According to the Trials
in Human Beings Regulations, the Helsinki Committee must plan and approve every experimental process that involves human beings. The
Helsinki Committee is an institutional committee that acts in the medical institution in Israel where the trial is performed and is the
party that approves and supervises the entire trial process. In practice, the physician, who is the principal investigator in the trial,
submits an application that includes, among other documents, the investigator brochure, clinical trial protocol and the informed consent
form, on behalf of the requesting party. This committee may request changes and/or additional documents. Applications which are approved
by the Helsinki Committee are forwarded to the &#8220;high committee&#8221; at the IMOH, which reviews all documents. The IMOH may request
additional changes or documents (Investigational Medicinal Product Document, or, for short IMPD, which includes details regarding the
manufacturing testing and quality of the drug to be tested) as part of its approval process. The IMOH sends its decision, along with
that of the IMOH, to the manager of the medical institute for approval. According to the procedure for medical trials in human beings
of the IMOH, the Helsinki Committee will not approve performance of a medical trial, unless it is absolutely convinced that the following
conditions, among others, are fulfilled: (a) the expected benefits for the participant in the medical trial and to the requesting party
justify the risk and the inconvenience involved in the medical trial to its participant; (b) the available medical and scientific information
justifies the performance to the requested medical trial; (c) the medical trial is planned in a scientific manner that enables a solution
to the tested question and is described in a clear, detailed and precise manner in the protocol of the medical trial, conforming with
the Helsinki principles declaration; (d) the risk to the participant in the medical trial is as minimal as possible; (e) optimal monitoring
and follow-up of the participant in the medical trial; (f) the initiator, the Principal Investigator and the medical institute are capable
and undertake to allocate the resources required for adequate execution of the medical trial, including qualified personnel and required
equipment; (g) the Principal Investigator, the sub-investigator(s) have the appropriate training in the conduct of clinical trials and
have necessary professional experience in conducting such said clinical trials; the investigators will follow GCP guidelines, the IMOH
and local SOPs; and (h) the nature of the commercial agreement with the Principal Investigator and the medical institute does not impair
the adequate performance of the medical trial. The IMOH also licenses and regulates the marketing of pharmaceuticals in Israel, requiring
the relevant pharmaceutical to meet internationally recognized cGMP standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pervasive and continuing regulation in
the U.S.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After a drug is approved
for marketing and enters the marketplace, numerous regulatory requirements continue to apply. These include, but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cGMP regulations require
    manufacturers, including third-party manufacturers, to follow stringent requirements for the methods, facilities and controls used
    in manufacturing, processing and packing of a drug product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">labeling, promotion, and
    advertising regulations and the FDA prohibitions against the promotion of drugs for unapproved uses (known as off-label uses), as
    well as requirements to provide adequate information on both risks and benefits during promotion of the drug;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval of product modifications
    or use of a drug for an indication other than approved in an NDA and/or BLA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse drug experience
    regulations, which require us to report information on adverse events within the FDA&#8217;s specified timeframe;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-market testing and
    surveillance requirements, including Phase IV trials, when necessary for&#160;public health protection, or to provide additional
    safety and effectiveness data for the drug;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional FDA reviews
    and approvals after the initial approval, particularly for any modification in conditions of use, active ingredient(s), route of
    administration, dosage form, strength or bioavailability, which may require submission accompanied by additional clinical data (which
    may require additional clinical studies) necessary to demonstrate the safety and effectiveness of the product with the proposed changes;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s recall
    authority, whereby it can ask, or under certain conditions order, drug manufacturers to recall from the market a product that is
    in violation of governing laws and regulation. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other U.S. Healthcare Laws and Compliance
Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For products distributed
in the United States, we are also subject to additional healthcare regulation and enforcement by the federal government and the states
in which we conduct our business. Potentially applicable federal and state healthcare laws and regulations that may affect our business
include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Anti-Kickback
    Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration,
    directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order,
    or recommendation of, any good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Anti-Inducement
    Law (also known as the Civil Monetary Penalties Law), which prohibits a person from offering or transferring remuneration to a Medicare
    or State healthcare program beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection
    of a particular provider, practitioner or supplier of any item or service for which payment may be made, in whole or in part, by
    Medicare or a State healthcare program;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Ethics in Patient Referrals
    Act, commonly referred to as the Stark Law, and its corresponding regulations, prohibit physicians from referring patients for designated
    health services (including outpatient prescription drugs) reimbursed under the Medicare program to entities with which the physicians
    or their immediate family members have a financial relationship, subject to narrow regulatory exceptions, and prohibits those entities
    from submitting claims to Medicare for payment of items or services provided to a referred beneficiary;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal False Claims
    Act imposes criminal and civil penalties, as well as permitting civil whistleblower or qui tam actions, against individuals or entities
    for knowingly presenting, or causing to be presented, to the federal government claims for payment that are false or fraudulent or
    making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The so-called federal &#8220;Sunshine
    Act&#8221; requires certain pharmaceutical and medical device companies to monitor and report certain payments and other transfers
    of value to physicians (as defined by such law), certain other healthcare providers, and teaching hospitals as well as ownership
    and investment interests held by physicians and their immediate family members to CMS for disclosure to the public;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Health Insurance Portability
    and Accountability Act of 1996, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program
    and also prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement
    in connection with the delivery of or payment for healthcare benefits, items, or services. This statute also imposes obligations,
    including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable
    health information on certain covered entities (including healthcare providers, health plans, and healthcare clearinghouses), and
    their business associates that provide services to or on behalf of the covered entity that involve the use or disclosure of individually
    identifiable health information; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous state laws and
    regulations, such as state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving
    healthcare items or services reimbursed by non-governmental third-party payers, including private insurers, and some state laws that
    require pharmaceutical companies to report or disclose pricing or other financial information and to comply with the pharmaceutical
    industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reimbursement in the United States</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of our oncology therapeutic
candidates, if approved, in the United States may depend, in significant part, on the extent to which the approved products will be covered
and reimbursed by third-party payers, such as government health programs, commercial insurance and managed healthcare organizations.
Patients who are prescribed treatments for their conditions and providers prescribing treatments generally rely on third-party payers
to reimburse all or part of the associated healthcare costs. Patients and providers are unlikely to use our products unless coverage
is provided and reimbursement is adequate to cover a significant portion of the cost of therapies in which our products are used. There
is significant uncertainty related to third-party payer coverage and reimbursement of newly approved products. In the United States,
no uniform policy of coverage and reimbursement for products exists among third-party payers. Therefore, coverage and reimbursement for
products can differ significantly from payer to payer. Decisions regarding the extent of coverage and amount of reimbursement to be provided
for each of our product candidates will be made on a plan-by-plan basis. One payer&#8217;s determination to provide coverage for a product
does not assure that other payers will also provide coverage, and adequate reimbursement, for the product. Additionally, the coverage
determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for
the use of our approved product and therapeutic candidates to each payer separately, with no assurance that coverage and adequate reimbursement
will be obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The third-party payers are
increasingly challenging the prices charged for medical products and services. Additionally, the containment of healthcare costs has
become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The United States government
and state legislatures have shown significant interest in implementing cost-containment programs, including price controls, restrictions
on reimbursement, discount and rebate requirements, and requirements for substitution of generic products. Adoption of price controls
and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could
further limit our net revenue and results. If these third-party payers do not consider our drug products to be cost-effective compared
to other available therapies, they may not cover our therapeutic candidates, if approved, as a benefit under their plans or, if they
do, the level of payment may not be sufficient to allow us to sell our drug products on a profitable basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Medicare Prescription
Drug Improvement and Modernization Act of 2003 (the MMA) imposed new requirements for the distribution and pricing of prescription drugs
for Medicare beneficiaries and included a major expansion of the prescription drug benefit under Medicare Part D. Under Part D, Medicare
beneficiaries may enroll in prescription drug plans offered by private entities which will provide coverage of outpatient prescription
drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare
Advantage plans. Unlike Medicare Parts A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required
to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover
and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class
of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription
drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government reimbursement for some of the costs of prescription
drugs may increase demand for our therapeutic candidates, if approved, if they are covered by a Part D prescription drug plan. However,
any negotiated prices for our therapeutic candidates, if approved, covered by a Part D prescription drug plan will likely be lower than
the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payers
often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results
from the MMA may result in a similar reduction in payments from non-governmental payers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Patient Protection and Affordable Care
Act</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March&#160;23, 2010, President
Obama signed the &#8220;Patient Protection and Affordable Care Act&#8221; (P.L. 111-148) (the &#8220;ACA&#8221;) and on March&#160;30,
2010, he signed the &#8220;Health Care and Education Reconciliation Act&#8221; (P.L. 111-152), collectively commonly referred to as the
&#8220;Healthcare Reform Law.&#8221; The Healthcare Reform Law included a number of new rules&#160;regarding health insurance, the provision
of healthcare, conditions to reimbursement for healthcare services provided to Medicare and Medicaid patients, and other healthcare policy
reforms. Through the law-making process, substantial changes have been and continue to be made to the current system for paying for healthcare
in the U.S., including changes made to extend medical benefits to certain Americans who lacked insurance coverage and to contain or reduce
healthcare costs (such as by reducing or conditioning reimbursement amounts for healthcare services and drugs, and imposing additional
taxes, fees, and rebate obligations on pharmaceutical and medical device companies). This legislation was one of the most comprehensive
and significant reforms ever experienced by the U.S. in the healthcare industry and has significantly changed the way healthcare is financed
by both governmental and private insurers. This legislation has impacted the scope of healthcare insurance and incentives for consumers
and insurance companies, among others.&#160;Additionally, the Healthcare Reform Law&#8217;s provisions were designed to encourage providers
to find cost savings in their clinical operations. Pharmaceuticals represent a significant portion of the cost of providing care. This
environment has caused changes in the purchasing habits of consumers and providers and resulted in specific attention to the pricing
negotiation, product selection and utilization review surrounding pharmaceuticals. This attention may result in products we may commercialize
or promote in the future and our therapeutic candidates, being chosen less frequently or the pricing being substantially lowered.&#160;At
this stage, it is difficult to estimate the full extent of the direct or indirect impact of the Healthcare Reform Law on us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These structural changes
could entail further modifications to the existing system of private payers and government programs (such as Medicare, Medicaid, and
the Children&#8217;s Health Insurance Program), creation of government-sponsored healthcare insurance sources, or some combination of
both, as well as other changes. Restructuring the coverage of medical care in the U.S. could impact the reimbursement for prescribed
drugs and pharmaceuticals, including products we and our development or commercialization partners are currently developing or those
that we may commercialize or promote in the future. If reimbursement for any product we may commercialize or promote or approved therapeutic
candidates is substantially reduced or otherwise adversely affected in the future, or rebate obligations associated with them are substantially
increased, it could have a material adverse effect on our reputation, business, financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Extending medical benefits
to those who currently lack coverage will likely result in substantial costs to the U.S. federal government, which may force significant
additional changes to the healthcare system in the U.S. Much of the funding for expanded healthcare coverage may be sought through cost
savings. While some of these savings may come from realizing greater efficiencies in delivering care, improving the effectiveness of
preventive care and enhancing the overall quality of care, much of the cost savings may come from reducing the cost of care and increased
enforcement activities. Cost of care could be reduced further by decreasing the level of reimbursement for medical services or products
(including any product we may commercialize or promote or those therapeutic candidates currently being developed by us), or by restricting
coverage (and, thereby, utilization) of medical services or products. In either case, a reduction in the utilization of, or reimbursement
for any product we may commercialize or promote or any therapeutic candidate for which we receive marketing approval in the future, could
have a material adverse effect on our reputation, business, financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Several states and private
entities initially mounted legal challenges to the Healthcare Reform Law, in particular, the ACA, and they continue to litigate various
aspects of the legislation. On June 28, 2012, the U.S. Supreme Court generally upheld the provisions of the ACA at issue as constitutional.
However, the U.S. Supreme Court held that the legislation improperly required the states to expand their Medicaid programs to cover more
individuals. As a result, states have a choice as to whether they will expand the number of individuals covered by their respective state
Medicaid programs. Some states have not expanded their Medicaid programs and have chosen to develop other cost-saving and coverage measures
to provide care to currently uninsured individuals. Many of these efforts to date have included the institution of Medicaid-managed care
programs. The manner in which these cost-saving and coverage measures are implemented could have a material adverse effect on our reputation,
business, financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the healthcare regulatory
environment has seen significant changes in recent&#160;years and is still in flux.&#160;Legislative initiatives to modify, limit, replace,
or repeal the ACA and judicial challenges have continued.&#160;We cannot predict the impact on our business of future legislative and
legal challenges to the ACA or other aspects of the Healthcare Reform Law or other changes to the current laws and regulations. The financial
impact of U.S. healthcare reform legislation over the next few&#160;years will depend on a number of factors, including the policies
reflected in implementing regulations and guidance and changes in sales volumes for therapeutics affected by the legislation. From time
to time, legislation is drafted, introduced and passed in the U.S. Congress that could significantly change the statutory provisions
governing coverage, reimbursement, and marketing of pharmaceutical products. In addition, third-party payer coverage and reimbursement
policies are often revised or interpreted in ways that may significantly affect our business and our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During his first term in
office, President Trump supported the repeal of all or portions of the ACA. President Trump also issued an executive order in which he
stated that it is his administration&#8217;s policy to seek the prompt repeal of the ACA and in which he directed executive departments
and federal agencies to waive, defer, grant exemptions from, or delay the implementation of the provisions of the ACA to the maximum
extent permitted by law. Congress has enacted legislation that repeals certain portions of the ACA, including but not limited to the
Tax Cuts and Jobs Act, passed in December&#160;2017, which included a provision that eliminates the penalty under the ACA&#8217;s individual
mandate, effective January&#160;1, 2019, as well as the Bipartisan Budget Act of 2018, passed in February&#160;2018, which, among other
things, repealed the Independent Payment Advisory Board (which was established by the ACA and was intended to reduce the rate of growth
in Medicare spending). We cannot yet assess the impact that President Trump&#8217;s second term will have on the pharmaceutical industry,
but it may be significant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, in December&#160;2018,
a district court in Texas held that the individual mandate is unconstitutional and that the rest of the ACA is, therefore, invalid. On
appeal, the Fifth Circuit Court of Appeals affirmed the holding on the individual mandate but remanded the case back to the lower court
to reassess whether and how such holding affects the validity of the rest of the ACA. The Fifth Circuit&#8217;s decision on the individual
mandate was appealed to the U.S. Supreme Court. On June 17, 2021, the Supreme Court held that the plaintiffs (comprised of the state
of Texas, as well as numerous other states and certain individuals) did not have standing to challenge the constitutionality of the ACA&#8217;s
individual mandate and, accordingly, vacated the Fifth Circuit&#8217;s decision and instructed the district court to dismiss the case.
As a result, the ACA will remain in-effect in its current form for the foreseeable future; however, we cannot predict what additional
challenges may arise in the future, the outcome thereof, or the impact any such actions may have on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Biden administration
also introduced various measures in 2021 focusing on healthcare and drug pricing, in particular. For example, on January 28, 2021, President
Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through
the ACA marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive order also instructed
certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among
others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the ACA. On the legislative front, the American Rescue
Plan Act of 2021 was signed into law on March 11, 2021, which, in relevant part, eliminates the statutory Medicaid drug rebate cap, currently
set at 100% of a drug&#8217;s average manufacturer price, for single source drugs and innovator multiple source drugs, beginning January
1, 2024. And, in July 2021, the Biden administration released an executive order entitled, &#8220;Promoting Competition in the American
Economy,&#8221; with multiple provisions aimed at prescription drugs. In response, on September 9, 2021, HHS released a &#8220;Comprehensive
Plan for Addressing High Drug Prices&#8221; that outlines principles for drug pricing reform and sets out a variety of potential legislative
policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. And, on August
16, 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was signed into law. Among other things, the IRA requires manufacturers
of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare
Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program
with a new discounting program (beginning in 2025). The IRA also authorizes HHS to implement many of these provisions through guidance,
as opposed to regulation, for the initial years. We cannot yet assess the impact that the IRA will have on the pharmaceutical industry,
but it is expected to be significant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is uncertainty as to
what healthcare programs and regulations may be implemented or changed at the federal and/or state level in the U.S. or the effect of
any future legislation or regulation. Furthermore, we cannot predict what actions the Trump administration will implement in connection
with the Health Reform Law or the IRA. However, it is possible that such initiatives could have an adverse effect on our ability to obtain
approval and/or successfully commercialize products in the U.S. in the future, if applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Grants from the Israel Innovation Authority,
or the IIA (formerly known as the Office of the Chief Scientist or the OCS)</i>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Innovation Law and
the IIA&#8217;s rules and guidelines, a qualifying research and development program may be eligible for grants of up to 50% of the program&#8217;s
approved research and development expenses. In general, the recipient of the grants is required to return the grants by the payment of
royalties on the revenues generated from the sale of IIA-funded products (and related services), generally at a rate of 3% or 5% of revenues
(which rates may be increased under certain circumstances, as described below) up to the aggregate amount of the total grants received
by the IIA (which may be increased under certain circumstances, as described below), plus annual interest (as determined in the IIA&#8217;s
rules and guidelines). Following the full payment of such royalties and interest, there is generally no further liability for royalty
payment. Nonetheless, the restrictions under the Innovation Law (as generally specified below) will continue to apply even after repayment
of the full amount of royalties payable pursuant to the grants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The pertinent obligations under
the Innovation Law and IIA&#8217;s rules and guidelines are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Local
    manufacturing obligation</i>. The terms of the grants under the Innovation Law and the IIA&#8217;s rules and guidelines provide that
    a company that received IIA grants, or the Recipient Company, is prohibited from manufacturing products developed using these IIA
    grants outside of Israel (unless the IIA approved grant program includes a pre-determined portion of manufacturing that may be performed
    outside Israel) without receiving prior approval from the IIA (except for the transfer of less than 10% of the manufacturing capacity
    in the aggregate in excess of such pre-approved portion (if any), which requires only a notice). If the Recipient Company receives
    approval to manufacture products developed with IIA&#8217;s grants outside of Israel in excess of such pre-approved portion (if any),
    it will be required to pay increased royalties to the IIA, up to 300% of the grant amount plus accrued interest, depending on the
    manufacturing volume that is performed outside of Israel in excess of any pre-approved portion. The Recipient Company may also be
    subject to accelerated royalty repayment rates; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Certain reporting obligations</i>.
    A recipient of IIA grant is required to notify the IIA of certain events enumerated in the IIA&#8217;s rules and guidelines; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Know-how transfer limitation</i>.
    Under the IIA&#8217;s rules and guidelines, the transfer of IIA funded know-how outside of Israel requires prior IIA approval and
    is generally subject to payment of a redemption fee to the IIA calculated according to formulas provided under the IIA&#8217;s rules
    and guidelines, up to 600% of the grants amount (less paid royalties, if any, and depreciation, but no less than the total grants
    received) plus accrued interest. Upon payment of such a fee, the know-how and the manufacturing rights of the products supported
    by such IIA funding cease to be subject to the Innovation Law and to the IIA&#8217;s rules and guidelines.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Approval of the transfer of
IIA funded know-how to another Israeli company is also required and may be granted only if the recipient assumes all of our responsibilities
towards the IIA, including the restrictions on the transfer of know-how and manufacturing rights outside of Israel (although such transfer
will not be subject to the payment of a redemption fee, such transfer will include an obligation to pay royalties to the IIA from the
income of such sale transaction as part of the royalty payment obligation).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">TyrNovo received the IIA&#8217;s
approval for the production of NT219&#8217;s API and final product by certain third-party manufacturers outside of Israel in consideration
for (among other things) the future payment of increased royalties as stipulated under the IIA&#8217;s rules and guidelines and described
above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The IIA&#8217;s approval is
not required for the export of any products resulting from the IIA research or development grants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, TyrNovo
had received grants from the IIA in a total amount of approximately NIS 5.5 million (approximately $1.51 million), no royalties had been
paid in respect to the grants received by TyrNovo from the IIA and it had a contingent obligation to the IIA (including interest) of $2.3
million. There is no guarantee that TyrNovo will receive any further grants from the IIA or that the grants will be in the scope received
in the past.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The restrictions under the
Innovation Law may impair our ability to enter into agreements to perform or outsource manufacturing outside of Israel, or otherwise
transfer or sell TyrNovo&#8217;s IIA funded know-how outside of Israel, without the approval of the IIA. Furthermore, in the event that
we undertake a transaction involving the transfer to a non-Israeli entity of TyrNovo know-how developed with IIA funding pursuant to
a merger or similar transaction, the consideration available to TyrNovo&#8217;s and/or our shareholders may be reduced by the amounts
it is required to pay to the IIA. Further, failure to comply with the requirements under the Innovation Law and the IIA&#8217;s rules
and guidelines may subject TyrNovo to financial sanctions, to mandatory repayment of grants received by it (together with interest and
penalties). In addition, the Government of Israel may, from time to time, audit sales of products which it claims incorporate technology
funded via IIA programs and this may lead to additional royalties being payable on additional products and may subject such products
to the restrictions and obligations specified hereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organizational
Structure</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our corporate structure consists
of Purple Biotech Ltd., incorporated under the laws of the State of Israel, our wholly-owned subsidiaries, FameWave, incorporated under
the laws of the State of Israel, Kitov USA Inc. (currently inactive), incorporated under the laws of the state of Delaware, Purple Biotech
GmbH, incorporated under the laws of Switzerland (currently inactive and in the process of dissolution), and Immunorizon Ltd., incorporated
under the laws of the State of Israel, and our majority owned subsidiary TyrNovo, incorporated under the laws of the State of Israel,
of which we own approximately 98.47% of its shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property,
Plant and Equipment</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">All of our facilities are leased,
and we do not own any real property. The principal executive offices for Purple Biotech, TyrNovo, FameWave and Immunorizon are in a commercial
office building located in the Science Park in Rehovot, Israel. Our current office space of approximately 625 square meters is subject
to a 63.5-month lease, which commenced on September 15, 2020, and expires on December 31, 2025, and we have an option to extend such
lease for an additional 60 months beyond the current term. Of our office space, 400 square meters were subleased to a third party until
December 31, 2025, and the third party has an option to extend the lease period for an additional 60 months, subject to our decision
to extend the main lease agreement for an additional 60 months. We have no material tangible fixed assets apart from the property described
above. We believe our facilities are adequate and suitable for our current needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4A. UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 5. OPERATING AND FINANCIAL
REVIEW AND PROSPECTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>You should read the following
discussion of our financial condition and results of operations in conjunction with the financial statements and the notes thereto included
elsewhere in this Annual Report on Form 20-F. The following discussion contains forward-looking statements that reflect our plans, estimates
and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause
or contribute to these differences include those discussed below and elsewhere in this Annual Report on Form 20-F, particularly those
in &#8220;Item 3. Key Information &#8211; D. Risk Factors.&#8221; See also &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. Our
oncology pipeline includes CM24, NT219 and IM1240. In developing these therapeutic candidates, we aim to address both the tumor and the
TME to potentially improve patient outcomes. For details regarding our oncology therapeutic candidates, see, &#8220;Item 4. Information
on the Company &#8211; B. Business Overview.&#8221;</span>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition, our strategy is
to pursue the acquisition of additional oncology therapeutic candidates at various stages of development to expand and diversify our
portfolio and leverage our development capabilities. We currently do not have any binding material agreement or commitment to complete
any transaction for the acquisition of new therapeutic candidates or approved drug products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since commencement of our
pharmaceutical research and development operations, we have generated significant losses mainly in connection with the research and development
of our therapeutic candidates. Such research and development activities are expected to expand over time and will require further resources
if we are to be successful. As a result, we expect to continue incurring operating losses, which may be substantial over the next several
years, and will need to obtain additional funds to further develop our research and development programs. As of December 31, 2024, we
had an accumulated deficit of $144.7 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We plan to fund our future
operations through commercialization and/or out-licensing of our therapeutic candidates and to raise additional capital in the future
through either debt or equity financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Components of Statement of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our research and development
costs are comprised of basic scientific research, preclinical studies, CMC development, clinical studies and medical research. Our research
and development team combine clinical and regulatory development expertise mainly in the United States and Israel, and research and development
capabilities of our scientific team in Israel. Our research and development activities are focused on our two oncology therapeutic candidates
that are in the clinical trial phase, CM24 and NT219, including CMC, regulatory and clinical development, and CAPTN-3, our tribody platform
with its leading therapeutic candidate, IM1240, which is in the preclinical development stage. A significant portion of our research
and development activities, including our preclinical and clinical studies, are performed through subcontractors such as CROs and third-party
manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our research and development
expenses may fluctuate depending on the scope and timing of certain high-expense activities such as CMC activities and clinical trials.
For example, in 2022, we conducted two clinical studies and expanded the clinical development upon completion of the dose escalation
phases in CM24, in addition to CMC activity to support the studies, resulting in an increase in our research and development expenses.
In 2023, we initiated a phase 2 study of CM24 and completed patient enrollment in the study in December 2023, in addition to CMC activity
to support the studies, resulting in an increase in our research and development expenses in 2023. In 2024, we concluded the phase 2
study of CM24, which reduced clinical trials expenses, resulting in a decrease in our research and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Research and development expenses
also include compensation for our employees and consultants for medical, regulatory and development work. As of December 31, 2024, our
research and development staff consisted of 4 full-time employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We charge all research and
development expenses to operations as they are incurred. We expect our research and development expense to remain our primary expense
in the near future, as we continue to develop our therapeutic candidates and technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Set forth below is a summary
of the research and development expenses for the years ended December 31, 2024, 2023 and 2022. All the costs in 2024 and 2023 were incurred
in connection with the development of CM24, NT219 and CAPTN-3. In 2022 all the costs were incurred in connection with the development
of NT219 and CM24.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="10" style="text-align: center"><b>(U.S. dollars in thousands)</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Total research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,620</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,034</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,320</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition to the major cost
of preclinical studies, clinical trials, and CMC development, research and development expenses include consulting expenses for regulatory
and project management work required for the development of our therapeutic candidate portfolio. Set forth below is a summary of our
research and development expenses based on the type of expenditure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="10" style="text-align: center"><b>(U.S. dollars in thousands)</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Salary and salary related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,536</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,323</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,382</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">768</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">768</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Service providers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,967</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,943</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,170</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,620</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,034</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,320</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Due to the inherently unpredictable
nature of clinical development processes, we are unable to estimate with any certainty the costs we will incur in the continued development
of our therapeutic candidates for potential commercialization. Our future research and development expenses will depend on the success
of the preclinical and clinical trials for our therapeutic candidates, as well as the availability of resources, and will be based on
ongoing assessments of the commercial potential of our therapeutic candidates and other therapeutic candidates we may acquire. In addition,
we cannot forecast with any degree of certainty which therapeutic candidates may be subject to future commercialization arrangements,
when such commercialization arrangements will be secured, if at all, and to what degree such arrangements would affect our development
plans and capital requirements. See &#8220;Item 3. Key Information &#8211; D. Risk Factors &#8211; <i>If we and/or our potential commercialization
partners are unable to obtain FDA and/or other foreign regulatory authority approval for our therapeutic candidates, we and/or our potential
commercialization partners will be unable to commercialize our therapeutic candidates</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As we obtain results from preclinical
studies and/or clinical trials, we may elect to discontinue or delay development and preclinical studies and/or clinical trials for certain
therapeutic candidates in order to focus our resources on more promising therapeutic candidates or projects. Alternatively, we may elect
to allocate more resources towards our current therapeutic candidates than currently anticipated. Completion of preclinical studies and/or
clinical trials by us or by our future licensees may last several years or more, although the exact duration generally varies based on
the nature, complexity, novelty and intended use of a therapeutic candidate. See &#8220;Item 3. Key Information &#8211; D. Risk Factors
&#8211; Risks Related to Our Business, Operations and Regulatory Matters.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The lengthy process of completing
CMC and/or preclinical studies and/or clinical trials and seeking regulatory approvals for our therapeutic candidates requires substantial
expenditures. Any failure or delay in completing preclinical and/or clinical trials, or in obtaining regulatory approvals, could cause
a delay in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse
effect on our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Selling, General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Selling, general and administrative
expenses consist primarily of compensation for directors, employees and consultants in executive and operational functions. Other significant
selling, general and administrative expenses include insurance premiums, professional fees of external auditors and legal services, travel
costs and legal expenses, less reimbursement of legal expenses associated with class action claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Expenses (income) on account of warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Expenses
(income) on account of warrants comprises mainly the fair value adjustments of warrants. As more fully described in Note 9, Note 15 and
Note 18B to our audited consolidated financial statements included elsewhere in this Annual Report, the warrants issued in our October
2023 and </span>&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">July 2024 financings were considered a derivative
instrument (due to a cashless exercise feature and customary terms in the event of a fundamental transaction) and were recorded as a
liability at fair value upon issuance and the fair value is adjusted at any reporting date. The changes in the warrants&#8217; fair value
are recorded as financial expenses/income. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Finance Income and Finance Expense</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finance expense comprises
primarily issuance expenses and bank fees. Finance income comprises primarily changes in the fair value of financial instruments and assets
and interest income from funds held in bank deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Adjusted Operating Loss </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We define adjusted operating
loss as operating loss, adjusted for certain non-cash items such as share-based compensation expenses. Our management believes that excluding
non-cash charges related to share-based compensation provides useful information to investors in addition to our financial results prepared
in accordance with IFRS because of their non-cash nature, varying available valuation methodologies among companies and the subjectivity
of the assumptions and the variety of award types that a company can use under the relevant accounting guidance, which may obscure trends
in our core operating performance. We present adjusted operating loss because we use this non-IFRS financial measure to assess our operational
performance, for financial and operational decision-making, and as a means to evaluate period-to-period comparisons on a consistent basis.
Non-IFRS financial measures have limitations as an analytical tool and should not be considered in isolation from, or as a substitute
for, financial information presented under IFRS. You should read these non-IFRS measures in conjunction with the discussion of our IFRS
results of operations and together with our audited consolidated financial statements and related notes included elsewhere in this Annual
Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We expect to continue reporting
non-IFRS financial measures, adjusting for the item described above or similar non-cash items, and we expect to continue to incur expenses
similar to the non-cash, non-IFRS adjustment described above. Accordingly, unless otherwise stated, the exclusion of this and other similar
items in the presentation of non-IFRS financial measures should not be construed as an inference that these items are unusual, infrequent
or non-recurring. Adjusted operating loss is not a recognized term under IFRS and does not purport to be an alternative to IFRS net operating
loss as an indicator of operating performance or any other IFRS measure. Moreover, because not all companies use identical measures and
calculations, the presentation of adjusted operating loss may not be comparable to other similarly titled measures of other companies.
See &#8220;Reconciliation of Adjusted Operating Loss&#8221; below for a reconciliation of non-IFRS adjusted operating loss to IFRS operating
loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies and Estimates
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial
statements in conformity with IFRS, as issued by the International Accounting Standards Board, requires management to make estimates and
assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates
and judgments are subject to an inherent degree of uncertainty and actual results may differ. Our material accounting policies are more
fully described in Note 3 to our audited consolidated financial statements included elsewhere in this Annual Report. Critical accounting
estimates and judgments are evaluated and are based on historical experience and other factors, including expectations of future events
that are believed to be reasonable under the circumstances, and are particularly important to the portrayal of our financial position
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Assessment of Probability of Contingent Liabilities
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in">We make assessments of whether
it is more likely than not that an outflow of economic resources will be required in respect of pending legal claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recoverability of Intangible Assets </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We annually perform an impairment
test relating to our intangible assets with indefinite useful life, by comparing the recoverable amount of the intangible assets with
their carrying amount. During 2024, the Company impaired the in-process research and development related to Purple GmbH following the
decision to dissolve Purple GmbH. As of December 31, 2024, the recoverable amount of our intangible assets exceeded their carrying amount,
therefore, no impairment loss was recorded. For additional information, see Note 4 of our audited consolidated financial statements included
elsewhere in this Annual Report</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Results</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a discussion of our results
of operations for the year ended December 31, 2022, including a year-to-year comparison between 2023 and 2022, and a discussion of our
liquidity and capital resources for the year ended December 31, 2022, see &#8220;Item 5. Operating and Financial Review and Prospects<i>&#8221;
</i>in our Annual Report on Form 20-F for the year ended December 31, 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Comparison of the Year Ended December 31,
2024 to the Year Ended December 31, 2023 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Research and Development Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Research and development expenses
for the year ended December 31, 2024, were $7.6 million, a decrease of $9.4 million, or 55.3%, compared to $17.0 million for the year
ended December 31, 2023. The decrease was primarily due to reduced clinical trial expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Selling, General and Administrative Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Selling, general and administrative
expenses for the year ended December 31, 2024, were $3.2 million, a decrease of $2.0 million, or 38.5%, compared to $5.2
million for the year ended December 31, 2023. The decrease was primarily due to a decrease in salary and
salary related costs and share-based payment expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Operating Loss</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our operating loss for the
year ended December 31, 2024 was $11.0 million, a decrease of $11.3 million, or 50.7%, compared to $22.3 million for the year ended December
31, 2023. The decrease was primarily due to the decrease in research and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Adjusted Operating Loss</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On a non-IFRS basis, adjusted
operating loss for the year ended December 31, 2024 was $10.4 million, a decrease of $10.0 million, compared to $20.4 million for the
year ended December 31, 2023, primarily due to the decrease in research and development expenses. See &#8220;Reconciliation of Adjusted
Operating Loss&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Finance Income, net</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finance income, net for the
year ended December 31, 2024, was $3.7 million, compared to $2.3 million for the year ended December 31, 2023. The increase was primarily
due to a $1.6 million decrease in issuance expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Net Loss</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss for the year
ended December 31, 2024, was $7.3 million, or $4.44 basic loss per ADS and $4.99 diluted loss per ADS, compared to a net loss of
$20.0 million, or $17.96 basic and diluted loss per ADS, for the year ended December 31, 2023. The decrease in net loss was
primarily due to a $11.3 million decrease in operating expenses and a $1.4 million increase in financial income net.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Reconciliation of Adjusted Operating Loss</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table provides
a reconciliation of non-IFRS operating loss to IFRS operating loss for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/>
 December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating loss for the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,005</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">22,271</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Less share-based compensation expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(582</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,875</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Non-IFRS adjusted operating loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,423</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">20,396</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our oncology therapeutic candidates
are in the research and development stage and therefore, we do not generate revenues from those candidates. Since the commencement of
our operations as a pharmaceutical research and development company, our activities have primarily been financed by equity offerings,
as well as private loans which were subsequently fully repaid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In December 2024, we raised
$2.8 million of gross proceeds in a registered direct offering of 472,668 ADSs at a purchase price of $6.00 per ADS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2024, we raised $2.0
million of gross proceeds from the exercise of certain existing warrants to purchase an aggregate of 281,675 ADSs, having original exercise
prices ranging from $25 to $400 per ADS, originally issued in October 2023, June 2020, January 2019 and June 2018, at a reduced exercise
price of $7.20 per ADS. In consideration for the exercise of the existing warrants for cash, we issued new unregistered Series A-1 warrants
to purchase up to an aggregate of 248,969 ADSs and new unregistered Series A-2 warrants to purchase up to an aggregate of 314,382 ADSs.
The new warrants are exercisable at an exercise price of $8.00 per ADS. The Series A-1 warrants have a term of five years from the issuance
date and the Series A-2 warrants have a term of twenty-four months from the issuance date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2023, we raised
$5.0 million of gross proceeds in a registered direct offering of 121,500 ADSs and pre-funded warrants to purchase up to 5,891 ADS. In
addition, in a concurrent private placement, we issued unregistered warrants to purchase up to 217,391 ADSs. The warrants have an exercise
price of $25.00 per ADS and are exercisable for a period of five and one-half years. In connection with the offering and effective upon
the closing of the offering, we amended certain existing warrants to purchase up to an aggregate of 31,578 ADSs that were previously issued
in June 2020 and June 2018 at exercise prices of $180.00 to $560.00 per ADS, respectively, such that the amended warrants have a reduced
exercise price of $25.00 per ADS and an extended term of five and a half years from the closing of the offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 9, 2021, we entered
into the Sales Agreement with Jefferies for the sale of ADSs, pursuant to which we may offer and sell, from time to time, ADSs through
our ATM program, with Jefferies acting as our agent. We originally filed a prospectus for a $50.0 million ATM program, but the aggregate
offering price was subsequently reduced to $21.0 million on March 23, 2022, to $3.0 million on October 17, 2023, and to $1.33 million
on January 6, 2025. As of March 6, 2025, we have sold approximately 606,037 of ADSs, for total gross proceeds of approximately $6.81 million,
under the Sales Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, we
had on hand approximately $8.2 million in cash and cash equivalents and in short-term deposits. We believe that our current cash and
cash equivalents are sufficient to satisfy liquidity requirements for at least the next 12 months. Since we do not know whether, if at
all, we will generate significant revenues from our therapeutic candidates should we decide to continue the development of our CM24,
NT219 and IM1240, and to develop any additional therapeutic candidates, we will need substantial additional funds to acquire, develop,
and/or commercialize such therapeutic candidates. However, additional financing may not be available on acceptable terms, if at all.
Our long-term capital requirements will depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress, success and
    cost of our preclinical studies and/or clinical trials, and research and development programs; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully
    commercialize our CM24, NT219 and CAPTN-3, our tribody platform, with its leading therapeutic candidate, IM1240, therapeutic candidates,
    including securing commercialization agreements with third parties, favorable pricing and market share;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs, timing and outcome
    of regulatory review, obtaining regulatory approval of our therapeutic candidates and addressing regulatory and other issues that
    may arise post-approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of obtaining
    and enforcing our issued patents and defending intellectual property-related claims; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our consumption of available
    resources more rapidly than currently anticipated, resulting in the need for additional funding sooner than anticipated.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash Flow</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Operating activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2024, net cash used in operating activities was approximately $14.4 million compared to approximately $19.9 million for the year
ended December 31, 2023. The $5.5 million decrease in net cash used in operating activities in 2024 compared to 2023 was due to a decrease
in operating losses, net of adjustments, partially offset by the net change in assets and liabilities. The cash used in operating activities
consisted of expenses related to the development of CM24, NT219 and CAPTN-3, our tribody platform with its leading therapeutic candidate
IM1240, as well as general and administrative expenses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investment activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Net cash provided by investing
activities was $0.5 million for the year ended December 31, 2024, compared to $13.9 million for the year ended December 31, 2023. The
decrease in net cash provided by investing activities in 2024 compared to 2023 was mainly due to a decrease in short term and long-term
deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Financing activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities was $6.8 million for the year ended December 31, 2024, compared to net cash provided by financing activities of $5.4 million
for the year ended December 31, 2023. Net cash provided by financing activities for the year ended December 31, 2024, consisted of $1.8
million net of placement agent fees from the July 2024
warrant inducement transaction, $2.5 million net proceeds from the December 2024 registered direct offering and $2.85 million net proceeds
from our ATM program. Net cash provided by financing activities for the year ended December 31, 2023, consisted of $4.3 million net proceeds
from the October 2023 registered direct offering and $1.5 million net proceeds from our ATM program. The net proceeds from the financing
activities in 2024 and 2023 were used to finance our operating activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, we
had no borrowings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, and
as of the date of this Annual Report on Form 20-F, we had no commitments for capital expenditures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Contractual obligations </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a party to contractual
obligations involving commitments to make payments to third parties. These obligations impact our short-term and long-term liquidity and
capital resource needs. Our long-term contractual obligations primarily consist of the lease agreement for our offices, which is in effect
until December 31, 2025, with a current lease liability of $183,000 as of December 31, 2024 (see &#8220;Item 4. Information on the Company
&#8211; D. Property, Plant and Equipment).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span>&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development, Patents and Licenses</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">See above under Item 5 - Operating
and Financial Review and Prospects &#8211; A. Operating results &#8211; Components of Statement of Operations - Research and Development
Expenses.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trend
Information</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are a pharmaceutical company
which focuses its activities on the development of our therapeutic candidate. It is not possible for us to predict with any degree of
accuracy the outcome of our research and development with regard to our therapeutic candidate. Our research and development expenditure
is our primary expenditure, although we may incur substantial expenditures should we acquire any new therapeutic candidates. Increases
or decreases in research and development expenditure are primarily attributable to the level and results of our CMC, preclinical studies
and clinical trial activities and the amount of expenditure on those studies and trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Estimates</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Senior Management</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table sets forth
the name, age and position of each of our executive officers and directors, as of the date of this Annual Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Rowinsky,
    M.D.<sup>(1)</sup></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director and Chairman of the Board</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Isaac Israel <sup>(1)(4)</sup></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simcha Rock, CPA, MBA<sup>(2)(3)</sup></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ido Agmon, MBA<sup>(2)
    (3)</sup></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Gagnon <sup>(3)(4)</sup></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suzana Nahum-Zilberberg<sup>(1)(2)</sup></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yael Margolin, M.Sc., Ph.D
    </span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gil Efron, CPA, MA</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    and Acting Chief Financial Officer</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hadas Reuveni, Ph.D.</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President of Research
    and Development</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Schickler, Ph.D.</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head of Clinical and Regulatory
    Affairs </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of Nominations Committee</span><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of Compensation
    Committee </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of Audit Committee</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of Pricing Committee
    for the ATM program </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Directors
</b></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Eric Rowinsky, M.D.,</i>
has served as the Chairman of Purple Biotech&#8217;s Board since October 2019. Dr. Eric Rowinsky&#8217;s principal expertise is in the
development and registration of novel therapeutics to treat cancer and related disorders. &#160;Dr. Rowinsky currently serves as consulting
Chief Medical Officer and/or advisor for drug development and registrational strategies to several biopharma companies worldwide. Since
July 2021, Dr. Rowinsky has served as the Chief Medical Officer of Hummingbird Biotherapeutics, a life-science company. From 2015 to
2021, Dr. Rowinsky served as Executive Chairman of the Board of Directors and President of Inspira, Inc. (formerly Rgenix, Inc) and is
currently serving as its President, Chairman of the Scientific Advisory Board, and Director. Dr. Rowinsky also served as the Chief Scientific
Officer of Clearpath Development Inc., from 2015-2021, and has served as a consulting Chief Medical Officer of Oncotartis, Inc. since
2018 and as an advisor to Everest Medicines, Inc. since 2017. Additionally, Dr. Rowinsky has been an independent consultant since 2016
and works with many other life science companies in providing expertise in developing and registering a wide range of novel cancer therapeutics.
Dr. Rowinsky served as Executive Vice President, Chief Medical Officer and Head of Research and Development of Stemline Therapeutics,
Inc., a clinical-stage biopharmaceutical company, from November 2011 until October 2015. Prior to joining Stemline, Dr. Rowinsky was
co-founder and Chief Executive Officer of Primrose Therapeutics, Inc., a start-up biotechnology company, from June 2010 until its acquisition
in September 2011. Dr. Rowinsky also served as a drug development and regulatory strategy consultant to the ImClone-Lilly Oncology Business
Unit and several other biopharmaceutical and life sciences companies from 2010 to 2011. From 2005 to 2009, Dr. Rowinsky was Executive
Vice President and Chief Medical Officer of ImClone Systems Inc., where he led the FDA approval of Erbitux for head and neck and colorectal
cancers and advanced eight other monoclonal antibodies through clinical development. From 1996 to 2004, Dr. Rowinsky held several positions
at the Cancer Therapy and Research Center, including Director of the Institute of Drug Development, or IDD, and the SBC Endowed Chair
for Early Drug Development at the IDD. From 1996 to 2006, Dr. Rowinsky was a Clinical Professor of Medicine at the University of Texas
Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at The Johns Hopkins University
School of Medicine. Dr. Rowinsky was a longstanding National Cancer Institute principal and co-principal investigator from 1990 to 2004
and was integrally involved in pivotal clinical and preclinical investigations that led to the development of numerous cancer therapeutics,
including paclitaxel, docetaxel, topotecan, irinotecan, erlotinib, gefitinib, ramucirumab, tagraxofusp and temsirolimus among others.
Dr. Rowinsky was also an Adjunct Professor of Medicine at New York University School of Medicine (2008-2018). Dr. Rowinsky presently
serves on the boards of directors of the public companies Biogen Idec, Inc., Fortress Biosciences, Inc., and Verastem Inc. Dr. Rowinsky
formerly served on the boards of directors of the public companies Navidea Biopharmaceuticals Inc. (2010-2018), BIND Therapeutics (2014-2016),
and Biophytis S.A. (2018-2019), as well as at a number of privately held companies. Dr. Rowinsky received a B.A. degree from New York
University (1977) and an M.D. degree from Vanderbilt University School of Medicine (1981). Dr. Rowinsky completed his residency in internal
medicine at the University of California, San Diego (1984) and completed his fellowship in medical oncology at The Johns Hopkins Oncology
Center (1987).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Isaac Israel</i>&#160;has
served as a member of Purple Biotech&#8217;s Board since October 2012. Mr. Israel served as our chief executive officer from October
2012 until July 2022 and has served as an advisor to Purple Biotech since October 2022. Mr. Israel served as our Acting Chief Executive
Officer from March 2023 to August 2023, during which period Mr. Israel&#8217;s engagement as an advisor to the Company was suspended.
Mr. Israel was the founding chief executive officer of BeeContact Ltd. (formerly TASE:BCNT), from 2001 until 2007. Since 2008, Mr. Israel
has served as founding chief executive officer of Uneri Capital Ltd., a consulting firm in the capital markets field, owned by Mr. Israel,
which specializes in the healthcare sector. Mr. Israel served as a member of the board of directors of various private and public healthcare
corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Simcha Rock, CPA, MBA, </i>has
served as a member of Purple Biotech&#8217;s Board since July 2013. Mr. Rock served as our Chief Financial Officer from July 2013 until
he retired from such position as of December 31, 2018, and subsequently served as a strategic consultant to us until December 31, 2019.
Prior to joining us, Mr. Rock was a private equity manager at Edmond de Rothschild Private Equity Management, a firm specializing in
the management of venture capital and other private equity investments funds, from February 2000 until January 2011, with responsibility
for all financial, legal and administrative matters for several investment funds. Prior to 2000, Mr. Rock held financial management positions
at Intel Electronics Ltd., The Jerusalem College of Technology, and JC Technologies Ltd. Mr. Rock holds a B.A. degree from Yeshiva University
and an MBA degree from Cleveland State University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Ido Agmon, MBA,</i> has
served as a member of Purple Biotech&#8217;s Board since June 2016. Since 2012, Mr. Agmon has been acting as an independent consultant
and investment manager, providing start-ups, investment funds and technology-based ventures with advice in strategic and financial planning,
fund-raising and related business development activities. From 2014 until the end of 2016, Mr. Agmon was a manager of Aviv New-Tech (formerly
Aviv Bio-Invest), a private investment fund which manages a portfolio of public Israeli and global biomed and technology companies, of
which he was a co-founder, and where he was responsible for analysis and evaluation of investments in Israeli and global biomed companies.
From 2009 until 2011, Mr. Agmon served as the chief executive officer of Meytav Technology Incubator, an Israeli-based accelerator for
biotech, pharma &amp; medtech ventures with over 20 portfolio companies. Mr. Agmon has served as a board member at several biomed ventures.
From 2007 until 2009, Mr. Agmon served as the Director of Business Development at ATI incubator, a technology incubator specializing
in biomed and cleantech projects, responsible for deal-flow and project evaluation. Mr. Agmon holds a B.A. degree in Business Administration
and Life Sciences from Tel Aviv University, Tel Aviv, Israel, and an MBA degree from the Hebrew University of Jerusalem, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Robert Gagnon, MBA,</i>
has served as a member of Purple Biotech&#8217;s Board since March 2021. Mr. Gagnon currently serves as Chief Financial Officer of Remix
Therapeutics. Prior to that, Mr. Gagnon was Operating Partner of Gurnet Point Capital, a healthcare venture capital and private equity
fund. Prior to joining Gurnet Point Capital in 2022, Mr. Gagnon was Chief Financial Officer of Verastem Oncology. Before joining Verastem
in 2018, Mr. Gagnon served as the Chief Financial Officer at Harvard Bioscience, Inc. Prior to that, Mr. Gagnon served as Executive Vice
President, Chief Financial Officer and Treasurer at Clean Harbors, Inc., as well as Chief Accounting Officer and Controller at Biogen
Idec, Inc. Earlier in his career, Mr. Gagnon worked in a variety of senior positions at Deloitte &amp; Touche, LLP and PricewaterhouseCoopers,
LLP. Mr. Gagnon holds an M.B.A. degree from the MIT Sloan School of Management and a B.A. degree in accounting from Bentley College.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Suzana Nahum-Zilberberg,
MBA,</i> has served as a member of Purple Biotech&#8217;s Board since May 2021. Ms. Nahum-Zilberberg currently serves as Vice Chairman
of the Board of BioLight Life Science, which is traded on the TASE, and from 2011 to 2020 served as the chief executive officer of BioLight.
Ms. Nahum-Zilberberg also serves as a director at Human Xtention Ltd., Matricelf Ltd. and Nextferm Technologies Ltd., all of which are
traded on the TASE, and a number of private companies. Prior to joining BioLight, Ms. Nahum-Zilberberg held a number of leadership positions
at Teva Pharmaceuticals Industries, including Vice President of Asia and Pacific and Director in the office of the President and chief
executive officer. Ms. Nahum-Zilberberg holds a B.A. degree in accounting and economics and an M.B.A. degree, both from Tel Aviv University,
a Certified Director degree from Tel Aviv University, an M.A. degree in Holocaust Studies from Haifa University, and studied at the INSEAD
Asian International Executive Program. Ms. Nahum-Zilberberg is a certified public accountant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Dr. Yael Margolin, Ph.D.
</i>has served as a member of Purple Biotech&#8217;s Board since December 2023. Since 2019, Dr. Margolin has served as a board member
to several public and private companies in the healthtech industry, including: Point Biopharma Global (NASDAQ: PNT), Scinai Immunotherapeutics
(NASDAQ: SCNI), Quris AI, MakeSense, Neovac, Welltech Ventures, Ramot at Tel Aviv University and TAU Ventures by Tel Aviv University.
From 2005 to 2019, she served as President, Chief Executive Officer and director of Gamida Cell Ltd. (NASDAQ: GMDA), a clinical stage
biopharmaceutical company, leading the company from preclinical development through phase 3 international registration studies. Prior
to that, Dr. Margolin was Vice President of Denali Ventures LLC, a venture capital firm focused on healthcare, and a program manager
at Teva Pharmaceuticals. Dr. Margolin is a founder of mentoring@8400, a boutique voluntary mentoring program for young chief executive
officers in Israel. Dr. Margolin holds a B.Sc. degree in biology and a M.Sc. degree (<i>cum laude</i>) both from Tel Aviv University
in Israel, a Ph.D. from the Weitzman Institute of Science in Israel and was a post-doctoral associate at the Yale University School of
Medicine<i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Gil Efron </i>has served
as our Chief Executive Offer since July 2022 and as our Acting Chief Financial Officer since November 2024. Prior to that, Mr. Efron
served as our President and Chief Financial Officer since June 2021. Prior to that, Mr. Efron served as our Deputy Chief Executive Officer
and Chief Financial Officer, from October 2018. Prior to joining us, Mr. Efron served as Deputy CEO and CFO of Kamada Ltd., a NASDAQ
and TASE dual-listed plasma-derived protein therapeutics company, from September 2011 to November 2017. Prior to that, Mr. Efron served
as the CFO of NASDAQ listed RRsat Global Communications Ltd. (Nasdaq: RRST), from September 2005 to March 2011. Prior to that, Mr. Efron
served in various finance executive positions. Mr. Efron holds a B.A. degree in Economics and Accounting and an M.A. degree in Business
Administration from the Hebrew University of Jerusalem and was granted a certified public accountant&#8217;s license (non-active) in
Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Dr. Hadas Reuveni, Ph.D.,
</i>has served as the Company&#8217;s Vice President of Research and Development since 2017. Dr. Reuveni, a co-inventor of the TyrNovo
technology, received her Ph.D., <i>summa cum laude</i>, for anti-cancer drug discovery from the Hebrew University of Jerusalem. Dr. Reuveni
managed the discovery and the preclinical development of TyrNovo&#8217;s portfolio since 2005 and has more than two decades of research
and development experience in biotechnology. From 2005 to 2012, Dr. Reuveni served as the Chief Executive Officer of NovoTyr Ltd., a
biotechnology start-up company, a predecessor company to TyrNovo, developing small molecules for the treatment of cancer and neurodegenerative
diseases, which was established by Dr. Reuveni and Prof. Levitzki in 2005. Dr. Reuveni also founded and served as a director and Chief
Scientific Officer of AngioB Ltd., a start-up company that developed GPCR-based agents for multiple indications, between 2006-2010. Prior
to these roles, Dr. Reuveni was the Director of Research &amp; Development at Keryx Biopharmaceuticals (NASDAQ:KRX) between 2001-2004.
Dr. Reuveni has served as a scientific consultant for Integra Holdings Ltd., Campus Bio Management Ltd. and BioLineRX (NASDAQ/TASE BLRX).
Dr. Reuveni holds a B.Sc. degree in chemistry, an M.Sc. degree in biological chemistry and a Ph.D. in biological chemistry and drug discovery,
all from the Hebrew University of Jerusalem, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Michael Schickler, Ph.D.,
</i>has served as the Company&#8217;s Head of Clinical and Regulatory Affairs since January 2020. Prior to assuming this role, Dr. Schickler
served as the Chief Executive Officer of FameWave until the closing of the FameWave Acquisition. Dr. Schickler has also provided consulting
services for medical device and healthcare companies since July 2018, advising on various matters pertaining to biopharmaceutical drug
development, including as a consultant to the Company since March 2019. From May 2001 to July 2018, Dr. Schickler served as Chief Executive
Officer of CureTech Ltd. (&#8220;CureTech&#8221;), a biotechnology company developing novel immunotherapies for the treatment and control
of cancer. During his time at CureTech, Dr. Schickler led the company from the establishment of its operations through its development
into a clinical-stage company with activities spanning basic research through GMP manufacturing and worldwide clinical operations. Dr.
Schickler has served on the board of directors of CureTech since October 2018 and previously served on the board of directors of Accellta
Ltd. Dr. Schickler received his Diploma in Business Administration from the University of Lincoln, Lincoln, United Kingdom, his Ph.D.
in Biology from The Weizmann Institute of Science, Rehovot, Israel and his B.Sc. degree in Biology from The Faculty of Life Sciences,
Tel Aviv University, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The aggregate compensation
paid, and in-kind benefits granted, to or accrued on behalf of all our directors and officers for their services, in all capacities,
to us during the year ended December 31, 2024, was approximately $2.2 million (including $0.6 million share-based compensation related
costs). As of December 31, 2024, the total amount set aside as an actuarial estimate by us to provide pension, retirement or similar
benefits to our officers (we do not provide any such benefits to our directors in such capacities) was in the aggregate amount of approximately
$140,000. These amounts include compensation of our former Chief Financial Officer and former Vice President of Operations, both of whom
ceased to serve in such capacities on October 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our directors and executive
officers hold exemption and indemnification letters and are covered under our director&#8217;s and officer&#8217;s liability insurance
policy. For information on exemption and indemnification letters granted to our officers and directors, see &#8220;Item 6 Directors,
Senior Management and Employees&#8212;C. Board Practices&#8212;Exculpation, Insurance and Indemnification of Directors and Officers&#8221;.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December&#160;31, 2024,
(i) options to purchase 15,644,481 of our ordinary shares granted to our officers and directors were outstanding, of which options to
purchase 11,250,981 of our ordinary shares had vested; and (ii) 3,493,500 restricted stock units (&#8220;RSUs&#8221;) awarded to our
officers and directors were outstanding. For information regarding our 2016 Equity-Based Incentive Plan, see &#8220;Item 6. Directors,
Senior Management and Employees&#8212;E. Share Ownership&#8212;2016 Equity-Based Incentive Plan.&#8221; For information regarding the
corporate approvals for officer and director compensation, see &#8220;Item 6. Directors, Senior Management and Employees&#8212;C. Board
Practices&#8212;Compensation of Directors and Executive Officers.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Compensation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
approved by our shareholders at our extraordinary general meeting in July 2017, our independent and non-executive directors (other than
our chairman) are entitled to an annual fee of $40,000 for services as a member of our Board, an additional $3,500 annual fee for service
on each permanent Board committee, and an additional $7,000 annual fee for service on the board of directors of a subsidiary (if applicable);
provided, however, that the maximum annual fee for services on our Board, on Board committees and/or on the board of directors of any
subsidiaries shall not exceed $47,000. The above dollar denominated fees, and all other dollar denominated payments that we pay our directors
based in Israel are paid in NIS based on the NIS/$ exchange rate at the beginning of the month in which such amounts are paid, but not
lower than the exchange rate in effect on January 1, 2017. Dr. Rowinsky, the chairman of our Board, is entitled to an annual fee of $60,000
for services as a member of our Board, as Chairman of the Board, for service on any committee of the Board, and for service on the board
of directors of a subsidiary. Since August 2024, the members of the Board agreed to voluntarily and irrevocably waive, until further
notice, an amount equal to 20% of their respective director service fees for participation as members of the Board, each permanent Board
committee, and on the board of directors of a Subsidiary (if applicable).</span> &#160;&#160;<span style="font-family: Times New Roman, Times, Serif">All
such director annual fees shall be paid pro-rata for any service during part of a year. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition, we pay Dr. Rowinsky
a monthly fee for his service as the chairman of our medical and clinical committee, which was in the amount of $10,000 for the period
commencing on April 1, 2022 and until March 31, 2023 (as approved by our shareholders at our annual general meeting held in August 2022),
and in the amount of $5,000 for the period commencing on April 1, 2023 and for such additional period at the discretion of the Board
(as approved by our shareholders at our annual general meeting held in June 2023). Since August 2024, this fee has been reduced by 20%
pursuant to the voluntary and irrevocable waiver provided by Dr. Rowinsky.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Each of our Compensation Committee,
Board and shareholders have also approved ancillary benefits such that we may subsidize ongoing corporate governance or other professional
training for directors in amounts up to $5,000 per director per annum. We also reimburse the directors for any direct expenses incurred
during the performance of their duties (e.g., travel, parking, telephone, meals, etc.).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">There are no arrangements or
understandings between us and any of our subsidiaries, on the one hand, and any of our directors, on the other hand, providing for benefits
upon termination of their employment or service as directors of our company or any of our subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">To our knowledge, there are
no agreements and arrangements between any director and any third-party relating to compensation or other payment in connection with
their candidacy or service on our Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Executive Compensation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The table below sets forth
the annual compensation paid to each of our five most highly compensated office holders (as defined in the Companies Law) for the year
ended December 31, 2024, broken out by component and on an individual basis, as recorded in our financial statements for such year. For
so long as we qualify as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies
to disclose the compensation of our chief executive officer and other two most highly compensated executive officers on an individual,
rather than an aggregate, basis, rather we are required under Israeli law to disclose in the proxy statement for our annual general meeting
of our shareholders (or to include a reference therein to other previously furnished public disclosure) the annual compensation of our
five most highly compensated office holders on an individual basis, rather than on an aggregate basis, as recorded in the Company&#8217;s
financial statements for such year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; white-space: nowrap; font-weight: bold">Name</td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; font-weight: bold">Position</td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; font-weight: bold">Salary
    or<br/>
    other<br/>
    expenses<sup>1</sup></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus<br/>
    expenses <br/>
    and <br/>
    accruals</b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-<br/>
    based<br/>
    expenses<sup>2</sup></b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<sup>3</sup></b></span></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 21%; text-align: left">Gil Efron</td><td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: left">Chief&#160;Executive&#160;Officer and Acting Chief Financial Officer</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">368,153</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">203,347</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">571,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Dr. Hadas Reuveni</td><td>&#160;</td>
    <td style="text-align: left">Vice President of Research and Development</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">205,628</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,409</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,037</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Dr. Michael Schickler</td><td>&#160;</td>
    <td style="text-align: left">Head of Clinical and Regulatory Affairs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">197,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,409</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296,498</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Fhima<sup>4</sup>&#160;</span></td><td>&#160;</td>
    <td style="text-align: left">Former Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">175,832</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,377</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,455</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ido Morpurgo<sup>5</sup>&#160;</span></td><td>&#160;</td>
    <td style="text-align: left">Former Vice President Operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">146,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,317</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,309</td><td style="text-align: left"/></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes social benefits,
    such as payments to the National Insurance Institute, advanced education funds, managers&#8217; insurance and pension funds; vacation
    pay; and recuperation pay as mandated by Israeli law, and car lease or vehicle use reimbursement related benefits.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of share-based
    payments was estimated using the Black and Scholes model. &#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total compensation
    amounts do not include any amounts recorded for an increase in actuarial estimate calculations for post-employment benefit liabilities
    for the office holder, nor any accruals for unused vacation time. Compensation amounts which were paid or otherwise measured in NIS
    have been translated into US$ for purposes of this report at average representative exchange rates for the year.</span></td></tr>
  </table><div>
</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">4</td><td style="text-align: justify">Lior Fhima ceased to serve as our Chief Financial Officer on
October 30, 2024.</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">5</td><td style="text-align: justify">Ido Morpurgo ceased to serve as our Vice President Operations
on October 30, 2024.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Agreements with Executive Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have entered into engagement
agreements with each of our executive officers. All of these agreements contain customary provisions regarding noncompetition, confidentiality
of information and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable
laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Employment Agreement with Gil Efron, our Chief
Executive Officer </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In July 2022, we entered into
an employment agreement with Mr. Gil Efron in his capacity as our chief executive officer, which may be terminated by either party upon
90 days&#8217; advance notice to the other party. Mr. Efron&#8217;s terms of engagement as our chief executive officer were approved
by our shareholders at our annual general meeting held on August 25, 2022, and include (among other things) the following compensation
and benefits:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Monthly Salary</i>: A base
monthly gross salary of approximately $24,600 (&#8220;Monthly Salary&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Annual Bonus</i>: An annual
bonus that shall not exceed six times the Monthly Salary, subject to the achievement of measurable criteria determined by the Compensation
Committee and Board on an annual basis, in accordance with our compensation policy, as in effect from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Special bonus(es) for an
M&amp;A Transaction or Commercial Transaction</i>: A special bonus for each M&amp;A Transaction and Commercial Transaction consummated
during each calendar year in an amount equal to, in the aggregate in any calendar year, the lesser of (1) an amount equal to six times
the Monthly Salary and (2) 1.5% of (y) in the case of an M&amp;A Transaction signed during the term of employment, the Company valuation
determined in such M&amp;A Transaction, and (z) in the case of a Commercial Transaction consummated during the term of employment, the
estimated revenues to the Company in such Commercial Transaction, and subject to the restrictions set forth in our compensation policy.
&#8220;<i>M&amp;A Transaction</i>&#8221; means one or more related transactions of either: (A) a sale (including an exchange), lease,
license or any other transfer or disposition of all or substantially all of the Company&#8217;s shares or assets; or (B) any merger (including,
a reverse merger and a reverse triangular merger), reorganization, amalgamation, consolidation or like transaction of the Company with
or into another entity in which the holders of the Company&#8217;s voting power immediately prior to the consummation of such transaction
hold less than 50% of the Company&#8217;s voting power or the voting power of the resulting or surviving entity or acquiring company
immediately following the consummation of such transaction. &#8220;<i>Commercial Transaction</i>&#8221; means any commercial agreement
entered into by the Company or any of its subsidiaries with estimated revenues to the Company and/or the applicable subsidiary of at
least $5,000,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Retirement Grant</i>. A
retirement grant of six times the Monthly Salary upon termination of Mr. Efron&#8217;s engagement with us, provided that the termination
is not due to circumstances that do not entitle an employee to severance payments under any applicable law and/or under any judicial
decision of a competent tribunal.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Leased
Car</i>. A leased car with a monthly operational lease cost to the Company that shall not exceed NIS 6,000 (approximately $1,654), grossed
up for tax purposes, not including reimbursement of petrol expenses and other car expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Change of Control Provision</i>.
Any equity-based awards approved for grant to Mr. Efron (including the options granted to him on May 23, 2022 in his former role as President
and Chief Financial Officer), shall include a provision according to which the vesting of any such outstanding equity awards shall accelerate
in full upon a change of control, as defined by our Compensation Committee and Board, subject to shareholder approval of any such awards
to the extent required in accordance with applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Equity Award</i>. A
one-time grant to Mr. Efron of an equity-based award comprised of options to purchase up to 3,750,000 ordinary shares (equivalent to
18,750 ADSs) and 150,000 RSUs for ordinary shares (equivalent to 750 ADSs). The options have an exercise price of US$4.9. The
options and RSUs vest over a period of three years, with one-third of each of the awards vesting on the first anniversary of the
date of the approval of the awards by our Board on July 11, 2022, and an additional 8.33% of each of the awards vesting at the end
of each subsequent three-month period thereafter, subject to Mr. Efron&#8217;s continued engagement by the Company on each
applicable vesting date. Any outstanding unexercised options shall expire five years following the date of the approval of the
equity awards by our Board. The vesting of any such equity awards that are outstanding shall accelerate in full upon a change of
control, as defined by our Compensation Committee and Board. The equity award is subject to our 2016 Plan and the applicable award
agreement entered into with Mr. Efron. The equity award was granted pursuant to the capital gains track of Section 102 of the Israel
Income Tax Ordinance [New Version] 5721-1961 (the &#8220;Israeli Income Tax Ordinance&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">For the approval of compensation
arrangements with directors and executive officers, see &#8220;Item 6. Directors, Senior Management and Employees&#8212;C. Board Practices&#8212;Compensation
of Directors and Executive Officers.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Practices</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our Board presently consists
of seven directors. All of our directors also serve as directors of our subsidiaries TyrNovo, FameWave and Immunorizon. Each of Dr. Rowinsky,
Mr. Rock, Ms. Margolin, Mr. Gagnon, Mr. Agmon, and Ms. Nahum-Zilberberg qualifies as an independent director under the corporate governance
standards of the NASDAQ Listing Rules and the independence requirements of Rule 10A-3 of the Exchange Act. Accordingly, a majority of
our Board members are independent as required by the NASDAQ Listing Rules. Furthermore, our Audit Committee consists of at least three
independent directors (within the meaning of NASDAQ and SEC rules), and our Compensation Committee consists of at least two independent
directors (within the meaning of NASDAQ rules).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our directors are divided into
three classes with staggered three-year terms. Each class of directors consists, as nearly as possible, of one-third of the members of
our Board (who are not external directors, if any were appointed), referred to as the &#8220;first class&#8221;; the &#8220;second class&#8221;;
and the &#8220;third class&#8221;. If the number of directors is not equally divisible by three, each of the first class and the second
class will be comprised of a different number, the closest and lowest to one-third, while the third class will be comprised of the remaining
directors (who are not external directors, if any were appointed). If the number of directors changes, the number of directors in each
class will change in accordance with the foregoing rule. The term of one class of directors expires at each annual general meeting, at
which the election (or re-election) of directors of the class whose term expired at such annual general meeting shall be for a term that
expires on the date of the third annual general meeting following such election (or re-election) and until his or her respective successor
has been elected and qualified. At our 2025 annual general meeting of shareholders, the appointment of the directors included in the
first class (Dr. Rowinsky, Mr. Agmon and Mr. Gagnon) shall end. At our 2026 annual general meeting of shareholders, the appointment of
the directors included in the second class (Mr. Rock and Ms. Margolin) shall end. At our 2027 annual general meeting of shareholders,
the appointment of the directors included in the third class (Mr. Israel and Ms. Nahum-Zilberberg) shall end.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our Board may appoint a director
at any time to fill any vacancies until the annual meeting of our shareholders set to take place at the end of the three-year-term for
the class of directors to which such director is so appointed by the Board, provided that the total number of the members of the Board
serving at such time will not exceed the maximum number of directors that may serve on the Board. The shareholders may at all times replace
or dismiss a director (in the case of replacement, only if the appointed director is not a corporation) by a majority of (a) 75% of the
voting rights participating and voting on the matter in the applicable general meeting of our shareholders and (b) more than 47.9% of
all of our voting rights as of the record date established for the applicable general meeting of our shareholders (the &#8220;Special
Majority&#8221;). A director to be replaced shall be given a reasonable opportunity to address the shareholders at their meeting. The
tenure of a director expires pursuant to the provisions of our amended and restated articles of association and the Companies Law, upon
death or if he/she becomes incompetent, unless removed from office earlier as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under our amended and restated
articles of association, the number of directors on our Board will be no less than four and no more than nine (including any external
directors, to the extent that we may be required to appoint external directors in accordance with the Companies Law and any Regulations
enacted thereunder). The majority of the members of the Board shall be residents of Israel and our center of management shall be in Israel,
unless, in each case, our center of management shall have been transferred to another country in accordance with a resolution of our
Board by a majority of three quarters (75%) of the participating director votes. The provisions in our amended and restated articles
of association regarding the maximum number of directors that may serve on our Board and the composition of our Board and the appointment
and removal of directors, may be amended only by our shareholders by the Special Majority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
Board must determine the minimum number of directors who are required to have financial and accounting expertise (as defined in regulations
promulgated under the Companies Law). Our Board has determined that we require at least one director with the requisite financial and
accounting expertise and that Mr. Rock, Ms. Nahum-Zilberberg and Mr. Gagnon are each deemed to have such expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>External Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, companies
incorporated under the laws of the State of Israel that are &#8220;public companies,&#8221; including companies with shares listed on
NASDAQ, are required to appoint at least two external directors who meet the qualification requirements in the Companies Law. However,
pursuant to regulations promulgated under the Companies Law, companies with shares traded on a U.S. stock exchange, including NASDAQ,
may, subject to certain conditions, &#8220;opt out&#8221; from the Companies Law requirements to appoint external directors and related
Companies Law rules concerning the composition of the audit committee and compensation committee of the board of directors. In accordance
with these regulations, in July 2016, we elected to &#8220;opt out&#8221; from the Companies Law requirements to appoint external directors
and related Companies Law rules concerning the composition of the audit committee and compensation committee of the board of directors.
Under these regulations, the exemptions from such Companies Law requirements will continue to be available to us so long as: (i) we do
not have a &#8220;controlling shareholder&#8221; (within the meaning of the Companies Law), (ii) our shares are traded on a U.S. stock
exchange, including NASDAQ, and (iii) we comply with the director independence requirements, the audit committee and the compensation
committee composition requirements, under U.S. laws (including applicable NASDAQ Rules) applicable to U.S. domestic issuers.&#160;If
a company has elected to avail itself from the requirement to appoint external directors and at the time a director is appointed all
members of the board of directors are of the same gender, a director of the other gender must be appointed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Should any person or entity
in the future be deemed to be a controlling shareholder (within the meaning of the Companies Law), we will be required to convene a special
general meeting of the shareholders at the earliest possible date, the agenda of which shall include the appointment of at least two
external directors. Following such an appointment, all of the external directors shall be appointed to each of our audit committee and
compensation committee, and at least one external director shall be appointed to each committee of the board of directors authorized
to exercise any of the powers of the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b>Audit Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of any public company must appoint an audit committee. Companies listed on foreign stock exchanges, including NASDAQ,
which have elected to &#8220;opt out&#8221; of the Companies Law requirements relating to external directors and related rules concerning
the composition of the audit committee and compensation committee, such as our company (as described above), are exempt from the audit
committee composition requirements under the Companies Law, but must comply with the audit committee composition requirements of the
applicable foreign exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the NASDAQ Listing Rules,
we are required to maintain an audit committee consisting of at least three independent directors, within the meaning of the Exchange
Act and NASDAQ Listing Rules, all of whom are financially literate and one of whom has accounting or related financial management expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><i>Audit Committee Role</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
roles of the audit committee are, among others, as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommend to the board
    of directors to recommend to our shareholders to appoint and approve the compensation of the independent registered public accounting
    firm engaged to audit our financial statements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitor deficiencies in
    the management of the Company, among other things, in consultation with the independent registered public accounting firm and internal
    auditor, and advises the board of directors on how to correct such deficiencies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decide whether to approve
    engagements or transactions that require the audit committee&#8217;s approval under the Companies Law relating generally to certain
    related party transactions and whether such transaction is &#8220;extraordinary&#8221; or &#8220;material&#8221; under the Companies
    Law. The audit committee must pre-determine procedures for a competitive process, or other procedures, before approving related party
    transactions with controlling shareholders, even if such transactions are deemed by the audit committee not to be extraordinary transactions.
    This process is to be supervised by the audit committee, or by any person authorized for such supervision, or via any other method
    approved by the audit committee;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine the approval
    process for transactions that are not negligible, as well as determine which types of non-negligible transactions would require the
    approval of the audit committee. Non-negligible transactions are defined as related party transactions with a controlling shareholder,
    or in which the controlling shareholder has a personal interest, even if they are deemed by the audit committee not to be extraordinary
    transactions but which have been classified by the audit committee as non-negligible transactions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meet and receive reports
    from both the internal auditors and the independent registered public accounting firm dealing with matters that arise in connection
    with their audits; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulate the Company&#8217;s
    rules on employee complaints, and implement a whistleblower protection plan with respect to employee complaints of business irregularities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In accordance with the Sarbanes-Oxley
Act of 2002 and the NASDAQ Listing Rules, the audit committee is also directly responsible for the appointment, compensation and performance
of our independent auditors, and pre-approves audit and non-audit services to be provided by the independent auditors. In addition, the
audit committee is responsible for assisting the board of directors in reviewing our annual financial statements, the adequacy of our
internal controls and our compliance with legal and regulatory requirements. The audit committee also oversees our major financial risk
exposures and policies for managing such potential risks, discusses with management and our independent auditor significant risks or
exposure and assesses the steps management has taken to minimize such risk. Our audit committee also oversees the management and investment
of our cash and cash equivalents and makes investment decisions with respect to our financial assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our Board has adopted an audit
committee charter setting forth the responsibilities of the audit committee, which are consistent with the provisions of the Companies
Law, the rules and regulations of the SEC and the NASDAQ Listing Rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our audit committee currently
consists of Mr. Ido Agmon, Mr. Rob Gagnon and Mr. Simcha Rock. Mr. Rock serves as the Chairman of the audit committee. Our Board has
determined that each member of our audit committee is independent under NASDAQ Listing Rules and the Exchange Act, and that all members
of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the NASDAQ
Listing Rules. Our Board has also determined that each of Robert Gagnon and Simcha Rock are audit committee financial experts as defined
by the SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of an Israeli public company is required to appoint a compensation committee in accordance with the requirements set
forth in the Companies Law. Companies listed on foreign stock exchanges, including NASDAQ, which have elected to &#8220;opt out&#8221;
of the Companies Law requirements relating to external directors and related rules concerning the composition of the audit committee
and compensation committee, such as our company (as described above), are exempt from the compensation committee composition requirements
under the Companies Law, but must comply with the compensation committee composition requirements of the applicable foreign exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the NASDAQ Listing Rules,
we are required to maintain a compensation committee consisting of at least two independent directors, within the meaning of the NASDAQ
Listing Rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In accordance with the Companies
Law, the roles of the compensation committee are, among others, as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to recommend to the board
    of directors (i) the compensation policy for directors and officers, (ii) once every three years, whether the compensation policy
    that had been approved should be extended for a period of more than three years; and (iii) updates to the compensation policy, from
    time to time. In addition, the compensation committee is required to periodically examine the implementation of the compensation
    policy; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to decide whether to approve
    the terms of office and employment of directors and officers that require approval of the compensation committee and determining
    whether to exempt, under certain circumstances, a transaction with our chief executive officer from the approval of the general meeting
    of our shareholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition to the roles mentioned
above, our compensation committee also makes recommendations to our Board regarding the award of equity-based grants to our employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our Board has adopted a compensation
committee charter setting forth the responsibilities of the compensation committee, which are consistent with the provisions of the Companies
Law, the rules and regulations of the SEC and the NASDAQ Listing Rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our compensation committee
currently consists of Mr. Ido Agmon, Ms. Suzana Nahum-Zilberberg and Mr. Simcha Rock. Mr. Ido Agmon serves as the Chairman of the compensation
committee. Our Board has determined that each member of our compensation committee is independent under the NASDAQ Listing Rules, including
the additional independence requirements applicable to the members of a compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Policy</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, Israeli
public companies must adopt a compensation policy with respect to the terms of service and employment of their directors and officers.
The compensation policy must be approved by the board of directors (after considering the recommendations of the compensation committee)
and subject to limited exceptions, by the shareholders by a simple majority of shareholder votes provided that either: (i) such majority
includes at least a majority of the shares voted by those shareholders who are non-controlling shareholders and do not have a personal
interest in the approval of the compensation policy, who are present at the meeting and vote on the matter (excluding abstentions) or
(ii) the total number of votes voted against the proposal among the shareholders mentioned in paragraph (i) does exceed two percent (2%)
of the voting rights in the company, referred to as the &#8220;Special Majority for Compensation.&#8221; Under special circumstances,
the board of directors may approve the compensation policy despite the objection of the shareholders on the condition that the compensation
committee and then the board of directors decide, on the basis of detailed arguments and after discussing again the compensation policy,
that approval of the compensation policy, despite the objection of the meeting of shareholders, is for the benefit of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the Israeli Companies
Law, the compensation policy must generally be re-approved once every three years by the board of directors, after considering the recommendations
of the compensation committee, and by the shareholders by the Special Majority for Compensation. Any amendment to the compensation policy
is subject to the same approval requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On June 15, 2023, our shareholders
approved our current compensation policy for executive officers and directors (the &#8220;Compensation Policy&#8221;). The Compensation
Policy does not, on its own, grant any rights to our directors or officers. The Compensation Policy includes both long-term and short-term
compensation elements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Compensation Policy includes
a provision relating to the recovery of compensation (clawback) in the event of a restatement of our financial statements, which in addition
to the Israeli law clawback requirements, is intended to comply with the clawback requirements of the NASDAQ Listing Rules. Under the
recovery provision, in the event we are required to prepare an accounting restatement, we may be required to recover from each executive
officer and director any amount of incentive-based compensation received by such executive officer or director that exceeds the amount
of incentive-based compensation that otherwise would have been received by the officer or director had such compensation been determined
based on the restated amounts in the accounting restatement (computed without regard to any taxes paid). The compensation recovery is
subject to certain exceptions in cases where our Compensation Committee determined that recovery would be impracticable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In general, compensation for
officers will be examined while taking into consideration the following parameters, including, among others (i) education, qualifications,
expertise, tenure (with us in particular, and in the officer&#8217;s profession in general), professional experience and achievements
of the officer; (ii) the fulfilment by the officer of the targets set for him/her, if relevant; (iii) the officer&#8217;s position, the
scope of his/her responsibility and previous wage agreements that were signed with the officer; and (iv) the ratio between the total
cost of the proposed engagement terms of an officer and the total cost of the wages for all of our other employees, officers and contractors,
and in particular compared to the average or median wage of such employees, officers and contractors and the effect of this ratio and
difference, if any, on labor relations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our Compensation Policy aims
to strike a balance between short and long-term performance incentives for executives, linking their pay to performance and aligning
our executive officers&#8217; interests with those of the Company and our shareholders. We believe that it allows us to provide meaningful
incentives that reflect both our short- and long-term goals and performance, as well as our executive officers&#8217; individual performance
and impact on shareholder value, while providing compensation that is competitive in the global marketplace in which we recruit talent
and designed to reduce incentives to take excessive risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The brief overview above is
qualified in its entirety by reference to the full text of our Compensation Policy, which is attached as&#160;Exhibit 4.9 to this Annual
Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nominations Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2020, our Board
established a nominations committee, whose role is (among other things) to identify, review and evaluate candidates to serve as members
of the Board, consistent with criteria approved by the Board, recommend to the Board nominees for election as directors of the Company,
and review and evaluate incumbent members of the Board. Our Board elected to rely on the &#8220;foreign private issuer exemption&#8221;
with respect to the composition of our nominations committee and nominations of our directors, and determined that our nominations committee
need not be composed solely of independent directors (within the meaning of NASDAQ Listing Rules). Our nominations committee currently
consists of Dr. Eric Rowinsky, Ms. Suzana Nahum Zilberberg and Mr. Isaac Israel. Dr. Rowinsky serves as the Chairman of the nominations
committee.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pricing Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In April 2021, our Board established
a non-independent pricing committee in connection with the establishment of our ATM program, whose role is to approve sales to be conducted
pursuant to the Sales Agreement entered into in connection with the ATM program. Our pricing committee currently consists of Mr. Robert
Gagnon and Mr. Isaac Israel. Mr. Isaac Israel serves as the Chairman of the pricing committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Internal Auditor</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Companies Law, the board of directors of a public company must appoint an internal auditor based on the recommendation of the audit
committee. The role of the internal auditor is, among other things, to examine whether a company&#8217;s actions comply with applicable
law and orderly business procedure. Under the Companies Law, the internal auditor may not be a related party or an office holder or a
relative of a related party or of an office holder, nor may the internal auditor be the company&#8217;s independent auditor or the representative
of the same. A &#8220;related party&#8221; is defined in the Companies Law as (i) a holder of 5% or more of the issued share capital
or voting power in a company, (ii) any person or entity who has the right to designate one or more directors or to designate the chief
executive officer of the company, or (iii) any person who serves as a director or as a chief executive officer of the company. Mr. Yisrael
Gewirtz, a partner at Fahn Kanne Control Management Ltd., a member firm of Grant Thornton International, serves as our internal auditor.
</span>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fiduciary Duties and Approval of Certain Related
Party Transactions and Compensation under Israeli Law </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fiduciary Duties of Office Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Companies Law imposes a
duty of care and a fiduciary duty on all office holders of a company. The duty of care of an office holder is based on the definition
of negligence under the Israeli Torts Ordinance (New Version) 5728-1968. This duty of care requires an office holder to act with the
degree of proficiency with which a reasonable office holder in the same position would have acted under the same circumstances. The duty
of care includes, among other things, a duty to use reasonable means, in light of the circumstances, to obtain:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information on the business
    advisability of a given action brought for his or her approval or performed by virtue of his or her position; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all other important information
    pertaining to such action.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fiduciary duty incumbent
on an office holder requires him or her to act in good faith and for the benefit of the company, and includes, among other things, the
duty to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any act involving
    a conflict of interest between the performance of his or her duties in the company and his or her other duties or personal affairs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any activity
    that is competitive with the business of the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from exploiting
    any business opportunity of the company for the purpose of gaining a personal advantage for himself or herself or others; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose to the company
    any information or documents relating to the company&#8217;s affairs which the office holder received as a result of his or her position
    as an office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We may approve an act specified
above which would otherwise constitute a breach of the office holder&#8217;s fiduciary duty, provided that the office holder acted in
good faith, the act or its approval does not harm the company, and the office holder discloses his or her personal interest a sufficient
time before the approval of such act. Any such approval is subject to the terms of the Companies Law, setting forth, among other things,
the appropriate corporate bodies of the company entitled to provide such approval, and the methods of obtaining such approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disclosure of Personal Interests of an
Office Holder and Approval of Transactions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Companies Law requires
that an office holder promptly disclose to the company any personal interest (within the meaning of the Companies Law, as described below)
that he or she may have and all related material information or documents relating to any existing or proposed transaction by the company.
An interested office holder&#8217;s disclosure must be made promptly and, in any event, no later than the first meeting of the board
of directors at which the transaction is considered. An office holder is not obliged to disclose such information if the personal interest
of the office holder derives solely from a personal interest of a relative (as defined in the Companies Law) in a transaction that is
not considered an extraordinary transaction (as defined in the Companies Law, as described below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, once
an office holder has complied with the above disclosure requirement, a company may approve a transaction between the company and the
office holder or a third-party in which the office holder has a personal interest, subject to the approval requirements set forth in
the Companies Law, provided the transaction is to the company&#8217;s benefit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
transaction with an office holder or with a third party in which the office holder has a personal interest, which is not an extraordinary
transaction, requires approval by the board of directors, unless provided otherwise in the company&#8217;s articles of association. Our
amended and restated articles of association provide that transactions in which officers have a personal interest that are not extraordinary
transactions can be approved by the joint approval of our chief executive officer and chief financial officer, or, in the event either
of them has a personal interest in such transaction, by one of our directors who does not have a personal interest in such transaction
appointed by our Board for such purpose instead of such interested officer. In the event that both our chief executive officer and chief
financial officer have a personal interest in such a transaction, the approval of two directors appointed by the board of directors for
such purpose and who do not have personal interests in the approval of such transaction, will be required. If the transaction considered
is an extraordinary transaction with either an office holder or with a third-party in which the office holder has a personal interest,
then, pursuant to the Companies Law, audit committee approval is required prior to approval by the board of directors. For the approval
of compensation arrangements with directors and executive officers, see below &#8220;Compensation of Directors and Executive Officers.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Any persons who have a personal
interest in the approval of a transaction (except for a transaction with an office holder or with a third-party in which the office holder
has a personal interest that is not an extraordinary transaction) that is brought before a meeting of the board of directors, or the
audit committee, may not be present at the meeting or vote on the matter. However, if the chairman of the board of directors or the chairman
of the audit committee has determined that the presence of an office holder with a personal interest is required for the purpose of presenting
the matter, such office holder may be present at the meeting. Notwithstanding the foregoing, a director who has a personal interest may
be present at the meeting and vote on the matter if a majority of the directors or members of the audit committee have a personal interest
in the approval of such transaction. If a majority of the directors at a board of directors meeting have a personal interest in the transaction,
such transaction also requires approval of the shareholders of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A &#8220;personal interest&#8221;
is defined under the Companies Law as the personal interest of a person in an action or in a transaction of the company, including the
personal interest of such person&#8217;s relative or the interest of any other corporate body in which the person or such person&#8217;s
relative is a director or general manager, a 5% shareholder or holds 5% or more of the voting rights, or has the right to appoint at
least one director or the general manager, but excluding a personal interest stemming solely from the fact of holding shares in the company.
A personal interest also includes (1) a personal interest of a person who votes according to a proxy of another person, including in
the event that the other person has no personal interest, and (2) a personal interest of a person who gave a proxy to another person
to vote on his or her behalf regardless of whether the discretion of how to vote lies with the person voting or not.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">An &#8220;extraordinary transaction&#8221;
is defined under the Companies Law as any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transaction other than
    in the ordinary course of business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transaction that is not
    on market terms; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transaction that may
    have a material impact on the company&#8217;s profitability, assets or liabilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disclosure of Personal Interests of a Controlling
Shareholder and Approval of Transactions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Companies Law also requires
that a controlling shareholder promptly disclose to the company any personal interest that he or she may have and all related material
information or documents relating to any existing or proposed transaction by the company. A controlling shareholder&#8217;s disclosure
must be made promptly and, in any event, no later than the first meeting of the board of directors at which the transaction is considered.
Extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a
private placement in which a controlling shareholder has a personal interest, and the terms of engagement of the company, directly or
indirectly, with a controlling shareholder or a controlling shareholder&#8217;s relative (including through a corporation controlled
by a controlling shareholder), regarding the company&#8217;s receipt of services from the controlling shareholder, and if such controlling
shareholder is also an office holder of the company, regarding his or her terms of employment, require the approval of each of (i) the
audit committee or the compensation committee with respect to the terms of the engagement of the company, (ii) the board of directors
and (iii), unless exempted under the regulations promulgated under the Companies Law, the shareholders, in that order. In addition, the
shareholder approval must fulfill one of the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a majority of the shares
    held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving
    the transaction, excluding abstentions; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the shares voted by shareholders
    who have no personal interest in the transaction who vote against the transaction represent no more than 2% of the voting rights
    in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition, any extraordinary
transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a term of more than three
years requires the abovementioned approval every three years, however, such transactions not involving the receipt of services or compensation
can be approved for a longer term, provided that the audit committee determines that such longer term is reasonable under the circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation of Directors and Executive Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Directors</i>. Under the
Companies Law, the compensation of our directors with respect to their service as a director, as well as their engagement in other roles
(if the director is so engaged) requires the approval of our compensation committee, the subsequent approval of the board of directors
and, unless exempted under the regulations promulgated under the Companies Law, the approval of the shareholders at a general meeting.
The approval of the compensation committee and board of directors must be in accordance with the compensation policy. In special circumstances,
the compensation committee and board of directors may approve compensation of a director that is inconsistent with the compensation policy
(or approve compensation prior to the approval of a new compensation policy upon expiration of the term of the previous compensation
policy), provided that those provisions that must be included in and considered when determining the compensation policy according to
the Companies Law have been considered by the compensation committee and board of directors and shareholder approval is required by the
Special Majority for Compensation, as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Executive Officers other
than the Chief Executive Officer</i>. The Companies Law requires the compensation of a public company&#8217;s executive officers (other
than the chief executive officer) who are not directors to be approved by, first, the compensation committee, second, by the company&#8217;s
board of directors and third, if such compensation arrangement is inconsistent with the company&#8217;s duly approved compensation policy(or
if compensation is approved prior to the approval of a new compensation policy upon expiration of the term of the previous compensation
policy), also by the company&#8217;s shareholders by the Special Majority for Compensation provided that the provisions that must be
included in, and must be considered while determining the compensation policy according to the Companies Law, have been considered by
the compensation committee and the board of directors. If the shareholders of the company do not approve a compensation arrangement with
an executive officer that is inconsistent with the company&#8217;s compensation policy, the compensation committee and board of directors
may, in special circumstances, override the shareholders&#8217; decision provided each of the compensation committee and board of directors
discuss the arrangement again and consider (among other things) the shareholders&#8217; objections and provide detailed reasons for their
decision. An amendment to an existing compensation arrangement with an office holder who is not a director (other than the chief executive
officer) requires only the approval of the compensation committee if the compensation committee determines that the amendment is not
material relative to the existing arrangement. However, pursuant to relief regulations promulgated under the Companies Law, non-material
amendments to the compensation of executive officers (who are subordinate to the chief executive officer) shall not require the approval
of the compensation committee and may be approved by the chief executive officer of the company provided that: (i) the company&#8217;s
compensation policy provides that such amendments within the parameters established in the compensation policy may be approved by the
chief executive officer, and (ii) the compensation is consistent with the company&#8217;s compensation policy. Our Compensation Policy
provides that non-material amendments to the compensation of executive officers who are subordinate to the chief executive officer may
be approved solely by the chief executive officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Chief Executive Officer</i>.
The compensation paid to a public company&#8217;s chief executive officer is required to be approved by, first, the company&#8217;s compensation
committee; second, the company&#8217;s board of directors, and, unless exempted under the regulations promulgated under the Companies
Law, by the company&#8217;s shareholders by the Special Majority for Compensation, as described above. However, if the shareholders of
the company do not approve the compensation arrangement with a chief executive officer who is not a director, the compensation committee
and board of directors may, in special circumstances, override the shareholders&#8217; decision if each of the compensation committee
and the board of directors discuss the arrangement again and consider (among other things) the shareholders&#8217; objection and provide
detailed reasons for their decision. The renewal or extension of the engagement with a public company&#8217;s chief executive officer
need not be approved by the shareholders of the company if the terms and conditions of such renewal or extension are no more beneficial
than the previous engagement or there is no substantial difference in the terms and conditions and other relevant circumstances, and
the terms and conditions of such renewal or extension are in accordance with the company&#8217;s compensation policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Approval of the chief executive
officers&#8217; compensation by the compensation committee and board of directors should be in accordance with the company&#8217;s compensation
policy; however, in special circumstances, compensation terms of a chief executive officer that are inconsistent with such policy may
be approved by the compensation committee and board of directors provided that they each have considered the provisions that must be
considered and included in the compensation policy according to the Companies Law, and that shareholder approval was obtained by the
Special Majority for Compensation. The compensation committee may waive the shareholder approval requirement for the initial engagement
terms of a candidate for the chief executive officer position, provided that: (i) the compensation arrangement is consistent with the
company&#8217;s compensation policy, (ii) the chief executive officer candidate did not have a business or employment relationship in
the previous two years with the company or a controlling shareholder of the company (and in a company without a controlling officer,
a business or employment relationship with the chairman of the board of directors, a substantial shareholder, or the most senior office
holder in the company), and (iii) the compensation committee determines that subjecting the approval of the engagement to a shareholder
vote would impede the engagement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The engagement with a public
company&#8217;s chief executive officer or a director need not be approved by the shareholders of the company with respect to the period
from the commencement of the engagement until the next shareholder meeting convened by the company, if the terms and conditions of such
engagement were approved by the compensation committee and the board of directors of the company, the terms and conditions of such engagement
are in accordance with the company&#8217;s compensation policy approved in accordance with the Companies Law, and if the terms and conditions
of such engagement are no more beneficial than the terms and conditions of the person previously serving in such role or there is no
substantial difference in the terms and conditions of the previous engagement versus the new one under the circumstances, including the
scope of engagement.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Duties of Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in an acceptable manner in exercising
its rights and performing its obligations to the company and other shareholders, including, among other things, when voting at meetings
of shareholders on the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an amendment to the articles
    of association;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an increase in the company&#8217;s
    authorized share capital;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of related
    party transactions and actions that require shareholder approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A shareholder also has a general
duty to refrain from discriminating against other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The remedies generally available
upon a breach of contract will also apply to a breach of the shareholder duties mentioned above, and in the event of discrimination against
other shareholders, additional remedies are available to the injured shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition, any controlling
shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under
a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder, or any other power
with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does not describe the substance
of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach
of the duty to act with fairness, considering the shareholder&#8217;s position in the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exculpation, Insurance and Indemnification
of Directors and Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
company may not exculpate an office holder from liability for a breach of a fiduciary duty. An Israeli company may exculpate an office
holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty
of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles
of association include such a provision. The company may not exculpate in advance a director from liability arising out of breach of
duty of care with respect to a prohibited dividend or distribution to shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law and
the Israeli Securities Law, 5738&#8211;1968 (&#8220;Securities Law&#8221;), a company may indemnify an office holder in respect of the
following liabilities, payments and expenses incurred for acts performed by the office holder in such capacity, either in advance of
an event or following an event, provided its articles of association include a provision authorizing such indemnification:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a monetary liability incurred
    by or imposed on an office holder in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s
    award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in
    advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based
    on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined
    by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events
    and amount or criteria;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses,
    including reasonable attorneys&#8217; fees, incurred by the office holder as a result of an investigation or proceeding instituted
    against an office holder by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment
    was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed
    upon such office holder as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial
    liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent or in connection
    with a monetary sanction;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a monetary liability imposed
    on an office holder in favor of a payment for a breach offended at an Administrative Procedure (as defined below) as set forth in
    Section 52(54)(a)(1)(a) to the Securities Law;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses associated with
    an Administrative Procedure conducted regarding an office holder, including reasonable litigation expenses and reasonable attorneys&#8217;
    fees; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses,
    including attorneys&#8217; fees, incurred by the office holder or imposed by a court in proceedings instituted against an office
    holder by the company, on its behalf, or by a third-party, or in connection with criminal proceedings in which the office holder
    was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">An &#8220;Administrative Procedure&#8221;
is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement
Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject
to conditions) to the Securities Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law and
the Securities Law, a company may insure an office holder against the following liabilities incurred for acts performed in its capacity
as an office holder if and to the extent provided in the company&#8217;s articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of a fiduciary
    duty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would
    not harm the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of care
    to the company or to a third-party, to the extent such a breach arises out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a monetary liability imposed
    on the office holder in favor of a third-party;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a monetary liability imposed
    on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)(a)(1)(a) of the Securities
    Law; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by an
    office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneys&#8217;
    fees.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
company may not indemnify, exculpate or insure an office holder against any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of fiduciary duty,
    except for indemnification and insurance for a breach of the fiduciary duty to the company to the extent that the office holder acted
    in good faith and had a reasonable basis to believe that the act would not prejudice the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of care
    committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an act or omission committed
    with intent to derive illegal personal benefit; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fine, monetary sanction
    or forfeit levied against the office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, exculpation,
indemnification and insurance of office holders must generally be approved by the compensation committee and the board of directors and,
with respect to directors or controlling shareholders, their relatives and third parties in which such controlling shareholders have
a personal interest, also by the shareholders. The compensation committee may approve the procurement of directors&#8217; and officers&#8217;
liability insurance policy without the need for shareholder approval, if it determines that, pursuant to the relief regulations promulgated
under the Companies Law, the provision of such insurance coverage to the office holders under our directors and officers liabilities
insurance policy is on market terms, is not likely to have a material adverse effect on our profits, assets or obligations, and is consistent
with our Compensation Policy which was approved by our shareholders in accordance with the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by
law. Our office holders are currently covered by a directors&#8217; and officers&#8217; liability insurance policy within the parameters
set forth in our Compensation Policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have issued letters of indemnity
(the &#8220;Indemnity Letters&#8221;) to each of our current office holders pursuant to which we undertook to indemnify such office holders
to the fullest extent permitted by applicable law, to the extent that these liabilities are not covered by insurance. This indemnification
is limited to events determined as foreseeable by our Board based on our activities, as set forth in the Indemnity Letters. According
to the Indemnity Letters, the total accumulative sum of indemnification that may be paid by us to all office holders will not exceed
a sum equal to 25% of our shareholders&#8217; equity according to our latest audited or reviewed consolidated financial statements, as
of the date of indemnification. The payment of indemnity amounts will not prejudice the right of office holders to receive insurance
coverage benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition, we have issued
letters of exemption to each of our current office holders exculpating them from a breach of their duty of care to us to the fullest
extent permitted by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We expect to indemnify Isaac
Israel for obligations, including the deductibles for our directors&#8217; and officers&#8217; liability insurance policy, and we may
be required to pay costs and expenses he may incur related to the &#8220;Atzmon Claim&#8221; described in &#8220;Item 8. Financial Information
&#8211; A. Consolidated Statements and Other Financial Information &#8211; Legal Proceedings&#8221;, pursuant to the Indemnity Letter
issued to him. To our knowledge, other than with respect to the foregoing proceeding, there is no previous or pending litigation or proceedings
against any of our office holders as to which indemnification is being, or may be sought, nor are we aware of any other pending or threatened
litigation or proceeding that may result in claims for indemnification by any office holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Insofar as indemnifications
for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing
provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities
Act and is therefore unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, the
Company had employees as follows: (i) five in business development, general and administrative roles; and (ii) four in research and development
roles. All of such employees were located in Israel. During 2024, we prioritized our activities and conducted cost saving measures, including
a reduction in workforce.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2023, the
Company had employees as follows: (i) seven in business development, general and administrative roles; and (ii) thirteen in research
and development roles. All of such employees were located in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2022, the
Company had employees as follows: (i) eight in business development, general and administrative roles; and (ii) twelve in research and
development roles. All of such employees were located in Israel other than one employee in business development located in Switzerland.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">While none of our employees
is party to a collective bargaining agreement, in Israel we are subject to certain labor statutes and national labor court precedent
rulings, as well as to certain provisions of the collective bargaining agreements between the Histadrut (General Federation of Labor
in Israel) and the Coordination Bureau of Economic Organizations, including the Industrialists&#8217; Associations. These provisions
of collective bargaining agreements are applicable to our Israeli employees by virtue of extension orders issued in accordance with relevant
labor laws and regulations of the Israeli Ministry of Labor and Welfare, and which apply such agreement provisions to our employees even
though they are not directly part of a union that has signed a collective bargaining agreement. The laws and labor court rulings that
apply to our employees principally concern the minimum wage laws, procedures for dismissing employees, determination of severance pay,
leaves of absence (such as annual vacation or maternity leave), sick pay and other conditions for employment. The extension orders which
apply to our employees principally concern the requirement for length of the workday and workweek, mandatory contributions to a pension
fund, annual recreation allowance, travel expenses payment and other conditions of employment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Israeli law generally requires
severance pay, which may be funded by managers&#8217; insurance and/or a pension fund, upon the retirement or death of an employee or
termination of employment without cause (as defined in the Severance Pay Law, 5723-1963). Furthermore, Israeli employees and employers
are required to pay predetermined sums to the National Insurance Institute, which is similar to the United States Social Security Administration.
Such amounts also include payments for the national health insurance. We also contribute funds on behalf of most of our employees either
to a fund known as managers&#8217; insurance, to a pension fund or to a combination of both, as required by Israeli law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have never experienced labor-related
work stoppages or strikes and believe that our relations with our employees are satisfactory.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
Ownership</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 6, 2025, (i) no
officer or director beneficially owned 1% or more of our outstanding ordinary shares, other than Mr. Gil Efron, our Chief Executive Officer,
who beneficially owned 7,316,323 of our ordinary shares, representing 1.37% of our ordinary shares as of such date. The number of shares
beneficially owned by Mr. Efron, includes 5,703,623 ordinary shares issuable upon exercise of options held by Mr. Efron currently exercisable
or which will be exercisable within 60 days of March 6, 2025; and (ii) all officers and directors as a group (9 persons) beneficially
owned 19,715,875 of our ordinary shares, representing 3.63% of our ordinary shares as of such date. Such number of ordinary shares includes
13,188,315 ordinary shares issuable upon exercise of options and/or RSUs which will be exercisable or shall vest (as applicable) within
60 days of March 6, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The beneficial ownership of
our ordinary shares is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner
of a security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or
investment power, which includes the power to dispose of or to direct the disposition of the security. We deem ordinary shares issuable
pursuant to options or RSUs that are currently exercisable or exercisable or that vest (as applicable) within 60 days of March 6, 2025,
if any, to be outstanding and to be beneficially owned by the person holding the options or RSUs for the purposes of computing the percentage
ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person.
The percentage of ordinary shares beneficially owned is based on 529,639,917 ordinary shares (not including 1 ordinary share held in treasury)
outstanding as of March 6, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2016 Equity-Based Incentive Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 18, 2016, we adopted
the Purple Biotech Ltd. 2016 Equity-Based Incentive Plan, or the 2016 Equity Incentive Plan. The 2016 Equity Incentive Plan provides
for the grant to our directors, officers, employees and consultants and to the directors, officers, employees and consultants of our
subsidiaries and affiliates, of equity-based incentive awards, including, amongst others, options, RSUs, restricted shares, with either
our ordinary shares or ADSs underlying the applicable award. The 2016 Equity Incentive Plan provides for awards to be granted at the
determination of our Board (who is entitled to delegate its powers under the 2016 Equity Incentive Plan to the compensation committee
or audit committee of our Board) in accordance with applicable laws. The exercise price and vesting period of awards are determined by
our Board. As of December 31, 2024, 24,101,171 ordinary shares were reserved for the grant of awards under the 2016 Equity Incentive Plan.
Our Board may, subject to any other approvals required under any applicable law, increase or decrease the number of ordinary shares reserved
under the 2016 Equity Incentive Plan. As of December 31, 2024, options to purchase 20,364,323 ordinary shares and 4,918,917 RSUs were
outstanding under the 2016 Equity Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The 2016 Equity Incentive Plan
will be effective until the earliest of (a) its cancellation by our Board and (b) April 18, 2026. Nevertheless, awards granted prior
to the 2016 Equity Incentive Plan&#8217;s expiration date, whether vested or not vested up to that date, will remain effective and will
not expire prior to their expiration date as set forth in the notice of grant of award (but in any event not in excess of 10 years from
the grant date).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Upon termination of engagement
with the Company for any reason, other than in the event of death or for cause, all unvested options will expire and all vested options
at time of termination will generally be exercisable within up 12 months after the date of such termination, unless otherwise determined
by the Board (or the committee, as applicable), subject to the terms of the 2016 Equity Incentive Plan and the governing award agreement.
If we terminate a grantee for cause (as defined in the 2016 Equity Incentive Plan) the grantee&#8217;s right to exercise all vested and
unvested options granted to him will expire immediately, unless otherwise determined by the Board (or the committee, as applicable).
Upon termination of engagement with the Company due to death, all the vested options at the time of termination will be exercisable by
the grantee&#8217;s heirs or estate, for one year from the date of death, unless otherwise determined by the Board (or the committee,
as applicable), subject to the terms of the 2016 Equity Incentive Plan and the governing award agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The 2016 Equity Incentive Plan
enables us to grant awards through one of the following Israeli tax programs, at our discretion and subject to the applicable legal limitations:
(a) according to section 102 of the Israeli Income Tax Ordinance,
through a program with a trustee that is appointed by us, (b) according to section 102 of the Israeli Income Tax Ordinance, without a
trustee, or (c) according to the provisions of section 3(9) in the Israeli Income Tax Ordinance. The 2016 Equity Incentive Plan also
enables us to grant options as Incentive Stock Options for U.S. tax purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Board may, at any time
and from time to time, suspend, terminate, modify or amend the 2016 Equity Incentive Plan, whether retroactively or prospectively; provided,
however, that, unless otherwise determined by the Board, an amendment which requires shareholder approval in order for the plan to continue
to comply with any applicable law shall not be effective unless approved by the requisite vote of shareholders, and provided further,
that except as provided by the 2016 Equity Incentive Plan, no suspension, termination, modification or amendment may adversely affect
any award previously granted, without the written consent of grantees holding a majority in interest of the awards so affected, and in
the event that such consent is obtained, all awards so affected shall be deemed amended, and the holders thereof shall be bound, as set
forth in such consent. Our Board will determine, at its sole discretion, if a certain change may materially impair the rights of the
grantee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The 2016 Equity Incentive Plan
is administered by our Board, regarding the granting of awards and the terms of award grants, including option exercise price, method
of payment, vesting schedule, acceleration of vesting and the other matters necessary in the administration of such plan. Awards granted
under the 2016 Equity Incentive Plan to eligible Israeli employees, officers and directors are granted under Section 102 of the Israel
Income Tax Ordinance, pursuant to which the awards or the ordinary shares (or ADSs in accordance with a ruling from the Israel Tax Authority
dated June 19, 2016, or Tax Ruling) issued upon their exercise must be allocated or issued to a trustee and be held in trust for two
years from the date upon which such awards were granted in order to benefit from the provisions of Section 102. Under Section 102, any
tax payable by a grantee from the grant or exercise of the awards is deferred until the transfer of the awards or ordinary shares (or
ADSs, in accordance with the Tax Ruling) by the trustee to the grantee or upon the sale of the awards or ordinary shares (or ADSs, in
accordance with the Tax Ruling), and gains may qualify to be taxed as capital gains at a rate equal to 25%, subject to compliance with
specified conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">There was no erroneously awarded
compensation that was required to be recovered pursuant to the clawback provisions under our Compensation Policy during the fiscal year
ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>ITEM
</b></span><b>7. MAJOR <span style="text-transform: uppercase">SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Major
Shareholders</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information with respect to the beneficial ownership of our ordinary shares as of March 6, 2025 by each person or entity known to us to
beneficially own 5% or more of our outstanding ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The beneficial ownership of
our ordinary shares is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner
of a security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or
investment power, which includes the power to dispose of or to direct the disposition of the security. For purposes of the table below,
we deem ordinary shares issuable pursuant to options or warrants that are currently exercisable or exercisable within 60 days of March
6, 2025 and ordinary shares underlying RSUs that vest within 60 days of March 6, 2025, if any, to be outstanding and to be beneficially
owned by the person holding the options warrants or RSUs for the purposes of computing the percentage ownership of that person, but we
do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. The calculation of beneficial
ownership is based on 529,639,917 ordinary shares (not including 1 ordinary share held in treasury) outstanding as of March 6, 2025. Each
one (1) ADS held represents two hundred (200) ordinary shares. The data presented is based on information disclosed in public regulatory
filings in the U.S., in accordance with applicable laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share<br/> Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Percentage</b>&#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Armistice Capital, LLC (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">44,600,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.42</td><td style="width: 1%; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based solely on, and qualified
    in its entirety with reference to, Amendment No. 1 to Schedule 13G filed by Armistice Capital, LLC (&#8220;Armistice Capital&#8221;)
    with the SEC on November 14, 2024.&#160;&#160;According to the Schedule 13G/A, Armistice Capital is the investment manager of Armistice
    Capital Master Fund Ltd. (the &#8220;Master Fund&#8221;), the direct holder of the 223,000 ADS (equivalent to 44,600,000 ordinary
    shares), and pursuant to an investment management agreement, Armistice Capital exercises voting and investment power over the ordinary
    shares held by the Master Fund and thus may be deemed to beneficially own the ordinary shares held by the Master Fund. Mr. Boyd,
    as the managing member of Armistice Capital, may be deemed to beneficially own the ordinary shares held by the Master Fund. The Master
    Fund disclaims beneficial ownership of the ordinary shares directly held by it by virtue of its inability to vote or dispose of such
    securities as a result of its investment management agreement with Armistice Capital. In addition, Armistice Capital holds warrants
    to purchase 497,938 additional ADSs (equivalent to 99,587,600 ordinary shares) that include a 4.99% beneficial ownership limitation.
    </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">None of our shareholders has
different voting rights from other shareholders. To the best of our knowledge, we are not owned or controlled, directly or indirectly,
by another corporation or by any foreign government. We are not aware of any arrangement that may, at a subsequent date, result in a
change of control of our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Changes
in Percentage Ownership by Major Shareholders</i></b></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">To our knowledge, the only
significant change in the percentage ownership held by our major shareholders (i.e., shareholders that are the beneficial owners of 5%
or more of our ordinary shares) as reported in our Annual Reports on Form 20-F during the past three years, is that the beneficial ownership
percentage of Armistice Capital, LLC increased from less than 5% to 9.99% in October 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Record Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York Mellon,
or BNY, is the holder of record for our ADR program, pursuant to which each ADS represents two hundred (200) ordinary shares. As of March
5, 2025, BNY held 444,246,800 ordinary shares in custody representing 84.9% of the outstanding ordinary shares at that date. Certain of
these ordinary shares were held by brokers or other nominees. As a result, the number of holders of record or registered holders in the
United States is not representative of the number of beneficial holders or of the residence of beneficial holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Transactions</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following is a description
of our related party transactions, as defined under Item 7.B of Form 20-F, since January 1, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Service Agreements with Subsidiaries</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Purple
Biotech provides services to its wholly owned subsidiaries, FameWave, Purple Biotech GmbH </span>&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">and
Immunorizon, and its majority owned subsidiary, TyrNovo (including research and development services, corporate management, business
development services, accounting services, legal services and others), and the subsidiaries reimburse Purple Biotech for these services
at the rate of cost plus 3% (in the case of FameWave, TyrNovo and Immunorizon) and cost plus 10% (in the case of Purple Biotech GmbH).
Purple Biotech ceased to provide services to Purple Biotech GmbH, which is inactive and currently in the process of dissolution, at the
end of 2024. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Agreements with Directors and Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Employment agreements</i>.
We have entered into employment agreements with each of our executive officers. See &#8220;Item 6. Directors, Senior Management and Employees
&#8211; B. Compensation&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Options and restricted share
units</i>. We have granted options to purchase our ordinary shares and RSUs to our executive officers and directors. We describe our
equity-based incentive plan under Item 6.&#160;&#8220;Directors, Senior Management and Employees - E. Share Ownership 2016 Equity-Based
Incentive Plan.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Directors&#8217; and officers&#8217;
exculpation, indemnification and insurance</i>. We have granted exemption and indemnification letters to our officers and directors,
and our officers and directors are currently covered by a directors&#8217; and officers&#8217; liability insurance. See &#8220;Item 6.
Directors, Senior Management and Employees - C. Board Practices - Exculpation, Insurance and Indemnification of Directors and Officers.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Agreements with Mr. Isaac Israel </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Advisor Agreement </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Mr. Isaac Israel has been engaged
to serve as an advisor to the Company in a 50% capacity, since October 10, 2022 (except from March 2023 to August 2023, during which
time Mr. Israel&#8217;s served as the Company&#8217;s Acting Chief Executive Officer, as described below). Mr. Israel has served as a
director since October 2012 and served as our chief executive officer from October 2012 until July 10, 2022, and his former services
agreement with the Company formally terminated on October 10, 2022. As an advisor to the Company, Mr. Israel will actively seek to identify
and shall take an active role in the execution of new strategic business initiatives and shall support the Company in its fund-raising
activities. The advisory services were provided for an initial period of 12 months, effective as of October 10, 2022, the engagement
was automatically extended for a 12-month period and will automatically be extended for successive 12-month periods thereunder, under
the same conditions, as detailed below, unless terminated by either party upon 90 days&#8217; advance notice to the other party (&#8220;Engagement
Period&#8221;). At our annual general meeting held on August 25, 2022, our shareholders approved the payment of the following compensation
to Mr. Israel, in consideration for his service as an advisor:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Monthly Fee</i>. A monthly
advisory fee in the amount of $6,700 (plus VAT) (excluding out-of-pocket expenses as approved by the Company) (&#8220;Monthly Fee&#8221;),
payable commencing as of January 10, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Transaction Bonus(es)</i>.
Commencing as of October 10, 2022, Mr. Israel will be entitled to the following transaction bonuses: (1) for contribution to the achievement
of a Strategic Transaction signed during the Engagement Period: (i) in the event of a transaction under clause (A) or (B) below - 1%
of the Company value determined for the transaction; or (ii) in the event of a commercial agreement under clause (C) below - 1% of the
cash actually received by the Company or the applicable subsidiary, and subject to the restrictions set forth in our Compensation Policy.
&#8220;Strategic Transaction&#8221; means one or more related transactions of either: (A) sale (including an exchange), lease, license
or any transfer or disposition of all or substantially all of the Company&#8217;s shares or assets; (B) any merger (including, a reverse
merger and a reverse triangular merger), reorganization, amalgamation, consolidation or like transaction of the Company with or into
another entity in which the holders of the Company&#8217;s voting power immediately prior to the consummation of such transaction hold
less than 50% of the Company&#8217;s voting power or the voting power of the resulting or surviving entity or acquiring company immediately
following the consummation of such transaction; or (C) any commercial agreement entered into by the Company or any of its subsidiaries
with estimated revenues to the Company or the applicable subsidiary of at least $5 million; (2) for contribution to the achievement of
a financing transaction (excluding a financing under the Company&#8217;s existing ATM program) closed during the Engagement Period &#8211;
1% of the cash actually received by the Company in the applicable financing transaction. In the event of the signing of a Strategic Transaction
during the Engagement Period or the closing of a financing transaction (excluding a financing under the Company&#8217;s existing ATM
program) during the Engagement Period, which does not qualify for the above monetary bonus &#8211; Mr. Israel shall be entitled to a
transaction bonus equal to four times the Monthly Fee. The total transaction bonus(es) will not exceed an annual amount (during any consecutive
12-month period) of $2,000,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Other</i>. The above dollar
denominated fees, and all other dollar denominated payments will be paid in NIS based on the NIS/$ exchange rate at the beginning of
the month in which such amounts are paid, but not lower than the exchange rate in effect on January 1, 2017. The Monthly Fee is subject
to adjustment in the event that a general salary increase (&#8220;<i>tosefet yoker</i>&#8221;) is implemented in Israel due to the increase
in the Israel consumer price index, under certain circumstances. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Acting Chief Executive Officer Services</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Mr. Israel served as Acting
Chief Executive Officer from March 2023 to August 2023, while Mr. Gil Efron, our Chief Executive Officer, was on medical leave. During
his service as our Acting Chief Executive Officer, the terms of Mr. Israel&#8217;s engagement as an advisor to the Company, as described
above, were suspended and he was not entitled to additional compensation for service as a non-executive director. At our annual general
meeting held on June 15, 2023, our shareholders approved the payment of the following compensation to Mr. Israel in consideration for
his service as Acting Chief Executive Officer:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Monthly Fee</span></i>:
A monthly fee in the amount of US$30,000 plus VAT (the &#8220;Monthly Fee&#8221;), plus out-of-pocket expenses as approved by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Signing and Retention
Bonuses</span></i>: A cash bonus equal to one Monthly Fee as a signing bonus. In addition, to the extent Mr. Israel would be required to
serve as our Acting Chief Executive Officer for a period in excess of six months, he would have been entitled to a cash bonus equal to
1.5 times his Monthly Fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Transaction Bonus(es)</span></i>:
Mr. Israel was entitled to the same transaction bonuses to which he is entitled in his capacity as an advisor to the Company, as described
above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify; text-indent: -18pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i><span style="text-decoration:underline">Car
expenses</span></i>. A monthly payment for car expenses of NIS 5,000 (approximately $1,378).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Other</span></i>: Dollar
denominated payments were to be paid in NIS based on the NIS/$ exchange rate at the beginning of the month in which such amounts are
paid, but not lower than the exchange rate in effect on January 1, 2017. The Monthly Fee was subject to adjustment in the event that
a general salary increase (&#8220;<i>tosefet yoker</i>&#8221;) is implemented in Israel due to the increase in the Israel consumer price
index, under certain circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Insurance, Indemnification
and Exemption</span></i>. During his service as Acting Chief Executive Officer, Mr. Israel continued to benefit from our directors&#8217;
and officers&#8217; liability insurance policy, as in effect from time to time, and the indemnification and exemption letter agreements
that we previously entered into with him.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Medical and Clinical Committee Chairman
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Dr. Rowinsky, the chairman
of our Board, serves as the chairman of our medical and clinical committee established in March 2022. We pay Dr. Rowinsky a monthly fee
for his service as the chairman of our medical and clinical committee, which was in the amount of $10,000 for the period commencing on
April 1, 2022 and until March 31, 2023 (as approved by our shareholders at our annual general meeting held in August 2022) and in the
amount of $5,000 for the period commencing on April 1, 2023 and for such additional period at the discretion of the Board (as approved
by our shareholders at our annual general meeting held in June 2023). Since August 2024, this fee has been reduced by 20% pursuant to
a voluntary and irrevocable waiver provided by Dr. Rowinsky. The medical and clinical committee&#8217;s primary responsibilities are
to: (i) assist our clinical team in the design, planning and supervision of clinical trials; (ii) support our Head of Clinical and Regulatory
Affairs in the medical aspects of clinical trials; (iii) support the Company&#8217;s Chief Medical Officer; and (iv) assist in the medical
and clinical review of potential new business opportunities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interests
of Experts and Counsel</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 8. FINANCIAL INFORMATION</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>Consolidated Statements and Other Financial Information</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Consolidated Financial
Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">See Item 18 &#8220;Financial Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">From time to time, we may become
party to legal proceedings and claims in the ordinary course of business or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>2017 Motions to Approve a Class Action in Israel</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On February 16, 2017, we announced
that four lawsuits and motions to approve the lawsuits as a class action lawsuit were filed against us and certain of our office holders
in the Tel Aviv District Court (Economic Division), and served on us, relating to the then ongoing formal investigation by the Israel
Securities Authority (the &#8220;ISA Investigation&#8221;) into our public disclosures around certain aspects of the studies related
to our then lead drug candidate, Consensi (the &#8220;2017 Motions&#8221;). One of these motions was subsequently withdrawn.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The petitioners in one of the
motions petitioned the court to dismiss the other 2017 Motions (the &#8220;Petition for Dismissal&#8221;). On December 19, 2017, the
court granted the Petition for Dismissal and dismissed the other outstanding 2017 Motions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remaining motion from
the 2017 Motions (the &#8220;Surviving Motion&#8221;) was filed against us, our executive directors and certain of our present and former
directors, by certain shareholders who requested to act as representatives of all shareholders of record from December 10, 2015, until
February 6, 2017. The plaintiffs alleged, among other things, that we included misleading information in our public filings which caused
the class for which the plaintiffs sought recognition, an aggregate loss of approximately NIS 29 million (approximately $8 million). The
court ordered a stay of proceedings due to the then-ongoing ISA Investigation. Following approval of an enforcement arrangement in connection
with the ISA Investigation, the stay was lifted. On May 29, 2020, the petitioners in the Surviving Motion filed an amended lawsuit and
motion to approve the lawsuit as a class action. On November 15, 2020, the respondents filed their responses to the amended motion to
approve the lawsuit as a class action. Following the submission of these responses, and as suggested by the court, the parties attended
mediation, but without success. The plaintiffs then filed a motion to submit a new expert opinion as a response to the respondents&#8217;
claims. The court approved the motion on January 3, 2022. On April 7, 2022, the plaintiffs provided their answers to the respondents&#8217;
responses, which included a new opinion. Evidentiary hearings took place on November 13, 2022, November 20, 2022, and November 22, 2022.
The plaintiffs furnished their summaries on June 8, 2023, the respondents furnished their summaries on March 17, 2024, and the plaintiffs
furnished their response summaries on April 18, 2024. On June 19, 2024, the court dismissed the Surviving Motion and the motion to approve
the lawsuit as a class action. Each party will bear its own court expenses.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Atzmon Claim</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 17, 2022, Fidelity
Venture Capital Ltd., a private Israeli company (&#8220;Fidelity VC&#8221;) and Mr. Dror Atzmon, an Israeli resident and citizen believed
to be the sole shareholder of Fidelity VC (Mr. Atzmon, together with Fidelity VC, the &#8220;Atzmon Plaintiffs&#8221;), filed a statement
of claim in the Economic Division of the Tel Aviv District Court (the &#8220;Atzmon Claim&#8221;) against the Company and a number of
other defendants, including our former chief executive officer. The Atzmon Plaintiffs are seeking damages for approximately NIS 9 million
(approximately $2.5 million) in connection with various claims relating to alleged contractual breaches and torts arising from an alleged
contractual undertaking for the Company to engage the Atzmon Plaintiffs to provide advisory services to the Company following our initial
public offering in the United States and listing on NASDAQ in November 2015. We were served with the statement of claim on January 22,
2023. On August 3, 2023, the court ordered the parties to inform it of their willingness to a mediation process; the parties subsequently
agreed to a mediation process, a mediator was appointed and a mediation process is ongoing. We reject all the claims presented in the
Atzmon Claim. At this preliminary stage we are unable, with any degree of certainty, to make any evaluations or any assessments with respect
to the probability of success or the scope of potential exposure, if any, of the Atzmon Claim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Other than as described above,
we are not currently a party to any significant legal or arbitration proceedings involving any third-party, including governmental proceedings,
pending or known to be contemplated, which may have, or have had in the recent past, significant effects on the Company&#8217;s financial
position or profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have never declared or paid
cash dividends to our shareholders and do not anticipate paying any cash dividends for the foreseeable future. We anticipate that, for
the foreseeable future, we will retain any future earnings to finance operations and the development of our business. The distribution
of dividends may also be limited by the Companies Law, which permits the distribution of dividends, including share repurchases, only
out of retained earnings or earnings derived over the two most recent fiscal years prior to the distribution, whichever is higher, according
to the then last reviewed or audited financial statements (less the amount of previously distributed dividends, if not already reduced
from the earnings), provided that the end of the period to which the financial statements relate is not more than six months prior to
the date of the distribution (referred to as the &#8220;profit test&#8221;). If we do not meet the profit test, then we may distribute
dividends only with court approval. In each case, we are only permitted to distribute a dividend if the Board and, if applicable, the
court, determines that that there is no reasonable concern that payment of a dividend will prevent a company from satisfying its existing
and foreseeable obligations as they become due (referred to as the &#8220;solvency test&#8221;). Pursuant to regulations promulgated
under the Companies Law, as an Israeli company dual listed on the TASE and the Nasdaq, the Board may resolve to distribute a dividend
by way of a share repurchase program if it does not meet the profit test without seeking the approval of the court, subject to the following:
(i) the company meets the solvency test; and (ii) the company provided a notice to certain creditors regarding its intention to distribute
a dividend by way of a share repurchase program without meeting the profit test and no such creditor submits an objection within 30 days
of the notice (otherwise, court approval would be required for such distribution in accordance with the requirements of the Companies
Law).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under our amended and restated
articles of association, our Board has sole discretion whether to pay dividends, subject to the provision of the Companies Law. Payment
of dividends may be subject to Israeli withholding taxes. See &#8220;Item 10 &#8211; Additional Information &#8211; E. Taxation &#8211;
Israeli Tax Considerations and Government Programs&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant
Changes</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Except as otherwise disclosed
in this Annual Report on Form 20-F, no significant change has occurred since December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9. THE OFFER AND LISTING</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offer
and Listing Details</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our ordinary shares are currently
traded on the TASE under the symbol &#8220;PPBT&#8221;. The ADSs are currently traded on NASDAQ under the symbol &#8220;PPBT&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plan
of Distribution</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Markets</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">See &#8220;&#8212;Offer and
Listing Details&#8221; above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selling
Shareholders</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dilution</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expenses
of the Issue</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 10. ADDITIONAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
Capital</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Memorandum
and Articles of Association</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A copy of our memorandum of
association and amended and restated articles of association are attached as Exhibit 1.1 and Exhibit 1.2 to this Annual Report, respectively.
Other than as set forth below, the information called for by this Item is set forth in Exhibit 2.1 to this Annual Report and is incorporated
by reference into this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Securities Registers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our registration company for
our shares is the Registration Company of United Mizrahi Bank Ltd., and its address is 7 Jabotinsky St., Ramat Gan, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our transfer agent and registrar
for the ADSs is the depositary for the ADRs, The Bank of New York Mellon, and its address is 101 Barclay Street, New York, NY.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Objects and Purposes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">According to our memorandum
of association and our amended and restated articles of association, we are permitted to engage in any legal business. Our registration
number with the Israeli Registrar of Companies is public company number 520031238.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shareholder Meetings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under regulations promulgated
under the Companies Law, we are required to publish notices at least 21 days prior to a shareholders&#8217; meeting and if the agenda
of the meeting includes, among other things, the appointment or removal of directors, the approval of transactions with office holders
or interested or related parties or the approval of a merger, notice must be provided at least 35 days prior to the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">According to the Companies
Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders
of record on a date to be decided by the board of directors, which, as a company listed both on the TASE and the Nasdaq, may be between
four and 60 days prior to the date of the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Holders of ordinary shares
are entitled to one vote for each ordinary share held on all matters submitted to a vote of shareholders. Pursuant to our articles of
association, the quorum required for a meeting of shareholders consists of at least two shareholders present, in person or by proxy,
who hold or represent, in the aggregate, at least 25% of our voting rights. If within half an hour from the time appointed for the meeting
no quorum is present, it will be adjourned to the same day in the following week at the same time and place or to such other day and/or
time and/or place as prescribed by the board of directors in a notice to the shareholders. If within half an hour from the time appointed
for the adjourned meeting no quorum is present, the quorum for such reconvened meeting shall be any number of participants present and
holding any portion of our voting rights, except where such meeting was called at the request of our shareholders, in which case the
quorum required is one or more shareholders, present in person or by proxy and holding at least 5% of our issued share capital and at
least 1% of our voting rights or holding at least 5% of our voting rights. With the agreement of a meeting at which a quorum is present,
the chairman may, and on the demand of the meeting he must, adjourn the meeting from time to time and from place to place, as the meeting
resolves.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
Israeli law, annual general meetings of our shareholders are to be held once every year within a period of not more than 15 months after
the last preceding annual general shareholders&#8217; meeting. Our Board may call special general meetings of shareholders. The Companies
Law and our amended and restated articles of association provide that a special general meeting of shareholders may be called by the
board of directors or by a request of (i) two or more directors or 25% of the directors in office, or (ii) one or more shareholders holding,
in the aggregate, either (a) at least 5% of our issued share capital and at least 1% of our voting rights, or (b) at least 5% of our
voting rights, subject to the provisions set forth in our amended and restated articles of association</span>&#160;<span style="font-family: Times New Roman, Times, Serif">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The ADS holders may instruct
the depositary how to vote the number of deposited ordinary shares their ADSs represent. If we request the depositary to solicit your
voting instructions (and we are not required to do so), the depositary will notify you of a shareholders&#8217; meeting and send or make
voting materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct
the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary
will try, as far as practical, subject to the laws of Israel and the provisions of our amended and restated articles of association or
similar documents, to vote or to have its agents vote the shares or other deposited securities as instructed by ADS holders. If we do
not request the depositary to solicit your voting instructions, you can still send voting instructions, and, in that case, the depositary
may try to vote as you instruct, but it is not required to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Except by instructing the
depositary as described above, you will not be able to exercise voting rights unless you surrender your ADSs and withdraw the shares.
However, you may not know about the meeting enough in advance to withdraw the shares.</i> In any event, the depositary will not exercise
any discretion in voting deposited securities and it will only vote or attempt to vote as instructed by the holder of the ADSs or as
described in the following sentence. If we asked the depositary to solicit your instructions at least 30 days before the meeting date
but the depositary does not receive voting instructions from you by the specified date, it will consider you to have authorized and directed
it to give a discretionary proxy to a person designated by us to vote the number of deposited securities represented by your ADSs. The
depositary will give a discretionary proxy in those circumstances to vote on all matters to be voted upon, unless we notify the depositary
that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we do not wish to receive
    a discretionary proxy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there is substantial shareholder
    opposition to the particular matter; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the particular matter materially
    and adversely affects the rights of our shareholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are required to notify the
depositary if one of the conditions specified above exists.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We cannot assure you that you
will receive the voting materials in time to ensure that you can instruct the depositary to vote your shares. In addition, the depositary
and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions.
<i>This means that you may not be able to exercise voting rights and there may be nothing you can do if your shares are not voted as
you requested.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In order to give you a reasonable
opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities, if we request the depositary
to act, we undertook to give the depositary notice of any such meeting and details concerning the matters to be voted upon at least 30
days in advance of the meeting date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Borrowing powers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the Companies Law
and our amended and restated articles of association, our Board may exercise all powers and take all actions that are not required under
law or under our amended and restated articles of association to be exercised or taken by our shareholders, including the power to borrow
money for company purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">For information regarding the
approval of director compensation and interested party transactions and the rights of directors to vote on transactions in which they
have a personal interest under Israeli law, see &#8220;Item 6. Directors, Senior Management and Employees &#8211; C. Board Practices
&#8211; Fiduciary Duties and Approval of Certain Related Party Transactions and Compensation under Israeli Law.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exclusive Forum for Shareholder Litigation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association provide that, unless we consent in writing to the selection of an alternative forum, the Tel Aviv District Court (Economic
Division in the State of Israel (or, if the Tel Aviv District Court does not have jurisdiction, and no other Israeli court has jurisdiction,
the federal district court for the District of New York) shall be the sole and exclusive forum for (1) any derivative action or proceeding
brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other
employees to us or our shareholders, and (3) any action asserting a claim arising pursuant to any provision of the Companies Law or the
Securities Law, in all cases subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants.
In addition, unless we consent in writing to the selection of an alternative forum, and other than with respect to plaintiffs or a class
of plaintiffs which may be entitled to assert claims in the courts of the State of Israel with respect to any causes of action arising
under the Securities Act, the federal district courts of the United States for the District of New York shall be the exclusive forum
for any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring
any interest in shares of our capital stock shall be deemed to have notice of and consented to these provisions. This forum selection
provision will limit shareholders&#8217; choice in selecting a judicial forum for disputes with us that it finds favorable or convenient
and may have the effect of discouraging lawsuits against us or our directors and officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
Contracts</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Immunorizon Acquisition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>The following is a summary
of the material terms of the Immunorizon Share Purchase Agreement dated February 1, 2023 (the &#8220;Share Purchase Agreement&#8221;).
The summary of the material terms of the Share Purchase Agreement (including any of its ancillary agreements) below and elsewhere in
this Annual Report on Form 20-F is qualified in its entirety by reference to the Share Purchase Agreement and/or the applicable ancillary
agreement, which are filed as exhibits to this Annual Report. This summary may not contain all of the information about the Share Purchase
Agreement and/or any applicable ancillary that is important to you. We urge you to read carefully the Share Purchase Agreement (including
any of its ancillary agreements) in its entirety as these are the legal documents governing the transactions.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Share Purchase Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On February 1, 2023, we entered
into the Share Purchase Agreement, pursuant to which we acquired 100% of the issued and outstanding shareholdings from the shareholders
of Immunorizon Ltd. and Immunorizon became a wholly-owned subsidiary of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
consideration for the transfer of 100% of Immunorizon&#8217;s shares to us and the other obligations set forth in the Share Purchase
Agreement, we paid an aggregate purchase price consisting of an aggregate upfront payment of $3.5 million in cash and an aggregate $3.5
million in ADSs, at a price per ADS equal to the NASDAQ volume-weighted average price of the ADSs for the 60-day period preceding the
execution date of the agreement the (&#8220;PPS&#8221;). Additional long-term milestones are set at an aggregate amount of $94 million,
with royalties out of net sales. Those long-term milestones include (i) development milestones consisting of pre-clinical and clinical
milestones, (ii) regulatory milestones and (iii) sales milestones. The accumulated transaction payments, excluding the upfront payment,
will not exceed $100 million. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The ADSs were issued to certain
major shareholders of Immunorizon (the &#8220;Major Selling Shareholders&#8221;) and were subject to a three-month lock-up period, and
we undertook to file a resale registration statement with the SEC to register the ADSs for resale following the lock-up period, as further
described below (see &#8220;Lock-Up and Registration Rights Agreement&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the Share
Purchase Agreement, in the event that during one year following the closing of the agreement, the Company enters into an agreement or
makes a filing pursuant to which it issues ADSs or other equity securities in a financing transaction (other than under its ATM program
used for an accumulated amount of up to $2,000,000 worth of ADSs sold during any 90 days period following the closing of the Share Purchase
Agreement, a non-cash transaction or a strategic transaction such as strategic joint venture, pre-clinical or clinical collaboration),
at a price per ADS lower than the PPS (such new price, the &#8220;New PPS&#8221;) (a &#8220;Dilutive Event&#8221;), and at such time
a Major Selling Shareholder still holds any ADSs issued to it under the Share Purchase Agreement, the Company shall issue such Major
Selling Shareholder additional ADSs (&#8220;Additional ADSs&#8221;) equal to: (i) (A) the number of such ADSs held by such Major Selling
Shareholder at such time, multiplied by (B) the PPS divided by (C) the New PPS, minus (ii) the number of such ADSs held by such Major
Selling Shareholder at such time. Such protection shall only be provided once. Following the October 2023 registered direct offering,
which constituted a Dilutive Event, we issued to the Major Shareholders an aggregate 34,974 Additional ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Lock-Up and Registration Rights Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At the closing of the transactions
contemplated by the Share Purchase Agreement, we entered into a Lock-Up and Registration Rights Agreement (the &#8220;Lock-Up and Registration
Rights Agreement&#8221;) with the Major Selling Shareholders under which the Major Selling Shareholders agreed not to, directly or indirectly,
in any single transaction or series of related transactions, transfer any of the ADSs issued at the closing of the Share Purchase Agreement
during the three-month period following the closing of the Share Purchase Agreement without the prior written consent of the Company
(subject to limited exceptions).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition, we undertook to
file, by no later than 45 days following the closing of the Share Purchase Agreement, a registration statement on Form F-3 with the SEC
(the &#8220;Registration Statement&#8221;) registering the resale, following the lock-up period, of the ADSs issued to the Major Selling
Shareholders upon the closing of the Share Purchase Agreement and any Additional ADSs issued thereafter (if any). We undertook to use
commercially reasonable efforts to keep the resale Registration Statement effective for at least 24 months from the date of the Lock-Up
and Registration Rights Agreement (or such shorter period as will terminate when the Major Selling Shareholders cease to hold the ADSs
or all of our securities covered by the Registration Statement have been sold or withdrawn). On March 23, 2023, we filed the Registration
Statement with the SEC, and it was declared effective on April 5, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Distribution
Agreement with Coeptis</b></span>&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In January 2019, we entered
into an exclusive marketing and distribution agreement with Coeptis for the commercialization of Consensi in the U.S. market. The agreement
provided for total milestone payments from Coeptis of $3.5 million, of which we received the initial $1 million milestone concurrent
with finalization of the agreement, and a $1.5 million reimbursement payment upon completion of an agreed CMC plan. In addition, the
agreement entitled us to 60% of Coeptis&#8217; net profit on Consensi sales until such time as we have received $13 million in such profit
distributions, following which we would then be entitled to 40% of Coeptis&#8217; net profit on all subsequent Consensi sales. In October
2019, we amended the agreement with Coeptis. Under the terms of the amended agreement, we were entitled to receive 20% in royalties on
net sales of Consensi with minimum royalties of $4.5 million over three years. In addition, we were entitled to receive up to $99.5 million
in milestone and reimbursement payments, of which $3.5 million was already received and $96 million was subject to certain pre-defined
commercial milestones. The agreement was for a term of 15 years and could be extended for additional two-year terms, and included customary
provisions, as well as certain residual rights and obligations of the parties, following termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In October 2021, we and Coeptis
agreed to terminate the distribution agreement and entered into a settlement agreement (the &#8220;Settlement Agreement&#8221;). In accordance
with the Settlement Agreement, Coeptis transferred its remaining inventory of Consensi to the Company and in settlement of Coeptis&#8217;
outstanding obligations under the distribution agreement, issued to the Company a convertible note (the &#8220;Note&#8221;) in the amount
of $1.5 million payable on or before March 2023 (the &#8220;Maturity Date&#8221;) , bearing interest of 5% per annum, which may be converted
in whole or in part at any time by the Company into Coeptis shares. The conversion price was set at $5 per share, subject to certain
adjustments, under such terms and conditions as agreed between the parties and set forth in the Note, and the conversion price was subsequently
reduced to $3 per share under the Addendum referred to below. Coeptis may prepay the principal amount of the Note plus accrued and unpaid
interest at any time prior to the Maturity Date. Coeptis also granted to the Company a warrant, exercisable for a period of three years,
to purchase a number of Coeptis shares as set forth therein, with an exercise price that is the same as the conversion price as determined
under the Note.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In October 2022, Coeptis announced
the completion of its business combination with Bull Horn Holdings Corp., a special purpose acquisition company (&#8220;Bull Horn&#8221;
and the &#8220;Merger&#8221;). The combined company has been renamed &#8220;Coeptis Therapeutics Holdings, Inc.&#8221; and its public
shares began trading on the Nasdaq Global Market. In October 2022, in connection with the consummation of the Merger, we and Coeptis
signed an addendum to the Note (the &#8220;Addendum&#8221;) according to which, the Note will remain outstanding following the Merger
and shall become an obligation of Bull Horn in accordance with its terms, so that (i) it will automatically become convertible into shares
of common stock of Bull Horn instead of shares of common stock of Coeptis, (ii) the number of shares of common stock issuable upon conversion
of the Note and the related exercise price will reflect adjustments based on the same exchange ratio of the Coeptis shareholders in connection
with the exchange of their shares of Coeptis common stock for shares of common stock in Bull Horn in connection with the Merger, and
(iii) section 13(b) of the Note (&#8216;Registration Rights&#8217;) will be read to apply to any future public offering of Bull Horn&#8217;s
common stock. Under the Addendum, Coeptis acknowledged that it consummated a Qualified Offering and that the price per share in such
Qualified Offering is $3 per share of common stock, which led to reduction of the conversion price under the Note to $3 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2023, the Note was
amended to extend the Maturity Date to March 31, 2024 and to provide for the repayment of the Note in four installments, with the last
installment (including interest) to be paid by March 31, 2024. On June 19, 2024, we entered into a Note Payoff agreement with Coeptis
and agreed to convert 50% of the then outstanding principal, approximately $219 thousand, into 50,000 shares of Coeptis&#8217; common
stock, and to update the Maturity Date for the payment of the remaining unpaid principal and accrued interest to August 31, 2024. In January
2025, the remaining principal amount was paid.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Other
Agreements</b></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">For a description of other
agreements, please see &#8220;Item 3. Key Information &#8211; D. Risk Factors &#8211; Risks Related to Our Business, Operations and Regulatory
Matters&#8221;, &#8220;Item 4. Information on the Company &#8211; B. Business Overview &#8211; Intellectual Property&#8221;, &#8220;Item
4. Information on the Company - B. Business Overview - Intellectual Property &#8211;License Agreement with Tel HaShomer&#8221;, &#8220;Item
4. Information on the Company- B. Business Overview - Intellectual Property &#8211; Exclusive License Agreement with Yissum.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange
Controls</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">There are currently no material
Israeli currency control restrictions on payments of dividends or other distributions with respect to our securities or the proceeds
from the sale of our securities, except under certain circumstances, for shareholders who are subjects of countries that are, or have
been, in a state of war with Israel. However, legislation remains in effect pursuant to which currency controls can be imposed by administrative
action at any time. Israeli residents have an obligation to file reports with the Bank of Israel regarding certain transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Taxation</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following description is
not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our
ordinary shares and ADSs. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well
as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Israeli Tax Considerations and Government
Programs </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following is a summary
of the material Israeli tax laws applicable to us, and some Israeli Government programs benefiting us. This section also contains a discussion
of some Israeli tax consequences to persons owning our ordinary shares and ADSs. This summary does not discuss all the aspects of Israeli
tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors
subject to special treatment under Israeli law. Examples of this kind of investor include traders in securities or persons that own,
directly or indirectly, 10% or more of our outstanding voting capital, all of whom are subject to special tax regimes not covered in
this discussion. Some parts of this discussion are based on a new tax legislation which has not been subject to judicial or administrative
interpretation. The discussion below is subject to change, including due to amendments under Israeli law or changes to the applicable
judicial or administrative interpretations of Israeli law, which change could affect the tax consequences described below. The discussion
should not be construed as legal or professional tax advice and does not cover all possible tax considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Shareholders are urged to consult
their own tax advisors as to the Israeli or other tax consequences of the purchase, ownership and disposition of our Ordinary Shares
and ADSs, including, in particular, the effect of any foreign, state or local taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General Corporate Tax Structure in Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Israeli companies are generally
subject to company tax on their taxable income. The Israeli corporate tax rate is 23% since 2018.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Capital Gains</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Israeli law generally imposes
a capital gains tax on the sale of any capital assets by residents of Israel, as defined for Israeli tax purposes, and on the sale of
capital assets by a non-resident of Israel if those assets (i) are located in Israel, (ii) are shares or a right to shares in an Israeli
resident corporation, or (iii) represent, directly or indirectly, rights to assets located in Israel, or (iv) a right in a foreign resident
corporation, which in its essence is the owner of a direct or indirect right to property located in Israel (with respect to the portion
of the gain attributed to the property located in Israel), unless a specific exemption is available or unless a tax treaty between Israel
and the shareholder&#8217;s country of residence provides otherwise. The law distinguishes between real gain and inflationary surplus.
The inflationary surplus is a portion of the total capital gain, which is equivalent to the increase of the relevant asset&#8217;s purchase
price, which is attributable to the increase in the Israeli consumer price index between the date of purchase and the date of sale. The
real gain is the excess of the total capital gain over the inflationary surplus.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The tax rate applicable to
capital gains derived from the sale of the ordinary shares or ADSs, whether listed on a stock market or not, is subject to a marginal
tax rate according to Section 121 of the Israeli Income Tax Ordinance but shall not exceed 25% for Israeli individuals, unless such shareholder
claims a deduction for financing expenses in connection with such shares, in which case the gain will generally be taxed at a rate of
30%. Additionally, if such shareholder is considered a &#8220;significant shareholder&#8221; at any time during the 12-month period preceding
such sale (i.e., such shareholder holds directly or indirectly, including jointly with others, at least 10% of any means of control in
the company) the tax rate will be 30%. However, different tax rates may apply to dealers in securities and shareholders who acquired
their shares prior to an initial public offering. Israeli companies are subject to the corporate tax rate as specified in Section 126
of the Ordinance on capital gains derived from the sale of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Corporate and individual shareholders
dealing in securities in Israel are taxed at the tax rates applicable to business income which is 23% for corporations, and a marginal
tax rate of up to 47% for individuals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
real capital gains generated from the sale of our Ordinary Shares or ADSs by a non-Israeli shareholder may be exempt from Israeli tax
under the Israeli Income Tax Ordinance provided that the following cumulative conditions are met: (i) the Ordinary Shares or ADSs were
purchased upon or after the registration of the Ordinary Shares or ADSs on a non-Israeli stock exchange (NASDAQ); and (ii) the seller
does not have a permanent establishment in Israel to which the generated capital gain is attributed. However, non-Israeli resident corporations
will not be entitled to the foregoing exemption if Israeli residents: (i)&#160;hold more than 25% or more means of control in such non-Israeli
corporation or (ii)&#160;are the beneficiaries of, or are entitled to, 25% or more of the income or profits of such non-Israeli corporation,
whether directly or indirectly. In addition, such exemption would not be available to a person whose gains from selling or otherwise
disposing of the Ordinary Shares or ADSs are deemed to be business income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition, the sale of the
Ordinary Shares or ADSs may be exempt from Israeli capital gain tax under the provisions of an applicable double tax treaty (subject
to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for such an exemption). For example, the Convention
between the Government of the U.S. and the Government of the State of Israel with respect to Taxes on Income (the &#8220;U.S.- Israel
Double Tax Treaty&#8221;) exempts a U.S. resident (for purposes of the treaty) from Israeli capital gains tax in connection with the
sale of the Ordinary Shares or ADSs, provided that: (i) the U.S. resident owned, directly or indirectly, less than 10% of the voting
power of the company at any time within the 12 month period preceding such sale; (ii) the U.S. resident, being an individual, is present
in Israel for a period or periods of less than 183 days in the aggregate during the taxable year; (iii) the capital gain from the sale,
exchange or disposition was not derived through a permanent establishment of the U.S. resident; and (iv) the capital gains arising from
such sale, exchange or disposition is not attributed to real estate located in Israel or a resident in Israel; however, under the U.S-Israel
Double Tax Treaty, the taxpayer would be permitted to claim a credit for such taxes against the U.S. federal income tax imposed with
respect to such sale, exchange or disposition, subject to the limitations under U.S. law applicable to foreign tax credits. The U.S-Israel
Double Tax Treaty does not relate to U.S. state or local taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Payers of consideration for
the Ordinary Shares or ADSs, including the purchaser, the Israeli stockbroker or the financial institution through which the Ordinary
Shares or ADSs are held, are obligated, subject to certain exemptions, to withhold tax upon sale of Ordinary Shares or ADSs from the
amount of consideration paid upon the sale of the securities (or on the real capital gain realized on the sale, if known), at a rate
of 25% for an individual or at a rate of corporate tax for a corporation (23% in 2018 and thereafter).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Upon the sale of traded securities,
a detailed return, including a computation of the tax due, must be filed and an advanced payment must be paid to the Israel Tax Authority
on January 31 and July 31 of every tax year in respect of sales of traded securities made within the previous six months. However, if
all tax due was withheld at source according to applicable provisions of the Israeli Income Tax Ordinance and regulations promulgated
thereunder, such return need not be filed and no advance payment must be paid. Capital gains are also reportable on annual income tax
returns.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividends</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Dividends distributed by a
company from income, which is not attributed to an Approved Enterprise, a Benefited Enterprise, a Preferred Enterprise or a Preferred
Technology Enterprise, as defined in the Israel&#8217;s Encouragement of Capital Investment Law, 1959, to a shareholder who is an Israeli
resident individual will be generally subject to income tax at a rate of 25%. However, a 30% tax rate will generally apply if the dividend
recipient is a Controlling Shareholder, as defined above, at the time of distribution or at any time during the preceding 12-month period.
If the recipient of the dividend is an Israeli resident corporation, such dividend will generally not be subject to tax provided that
the income from which such dividend is distributed, derived or accrued within Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Non-Israeli residents (either
an individual or a corporation) are generally subject to Israeli tax on the receipt of dividends at the rate of 25% (30% if the dividend
recipient is a Controlling Shareholder at the time of distribution or at any time during the preceding 12-month period). Dividends distributed
by an Israeli resident company from income, which is attributed to a Preferred Enterprise or Preferred Technology Enterprise, to a non-Israeli
resident (either an individual or a corporation) are generally subject to withholding tax at a rate of 20%. These rates may be reduced
under the provisions of an applicable double tax treaty. For example, under the U.S.-Israel Double Tax Treaty, the following tax rates
will apply in respect of dividends distributed by an Israeli resident company to a U.S. resident: (i) if the U.S. resident is a corporation
which holds during that portion of the taxable year which precedes the date of payment of the dividend and during the whole of its prior
taxable year (if any), at least 10% of the outstanding shares of the voting stock of the Israeli resident paying corporation and not
more than 25% of the gross income of the Israeli resident paying corporation for such prior taxable year (if any) consists of certain
types of interest or dividends the tax rate is 12.5%; (ii) if both the conditions mentioned in clause (i) above are met and the dividend
is paid from an Israeli resident company&#8217;s income which was entitled to a reduced tax rate under The Law for the Encouragement
of Capital Investments, 1959, the tax rate is 15%; and (iii) in all other cases, the tax rate is 25%. The aforementioned rates under
the U.S.-Israel Double Tax Treaty will not apply if the dividend income is attributed to a permanent establishment of the U.S. resident
in Israel and is subject to certain exemptions under such treaty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Payers of dividends on our
shares, including the Israeli stockbroker effectuating the transaction, or the financial institution through which the securities are
held, are required, subject to any of the foregoing exemptions, reduced tax rates and the demonstration of a shareholder of his, her
or its foreign residency, to withhold taxes upon the distribution of dividends at a rate of 25%, provided that the shares are registered
with a nominee company (for corporations and individuals).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Excess Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Individual holders who are
subject to tax in Israel (whether any such individual is an Israeli resident or non-Israeli resident) and who have taxable income that
exceeds a certain threshold in a tax year (NIS 698,280 for 2023 and NIS 721,560 for 2024 and 2025), will be subject to an additional
tax on any income in excess of such amount, at the rate of 3% on any such taxable income prior to January 1, 2025 and commencing January
1, 2025, at the rate of 3% of any such active taxable income and 5% of any such passive taxable income. For this purpose, passive taxable
income includes taxable capital gains from the sale of securities and taxable income from interest and dividends, subject to the provisions
of an applicable double tax treaty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Estate and Gift Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Israeli law presently does
not impose estate or gift taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. Federal Income Tax Considerations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description
of certain U.S. federal income tax consequences relating to the ownership and disposition of the ADSs by a holder. This description addresses
only the U.S. federal income tax consequences to holders that are initial purchasers of the ADSs and that hold such ADSs as capital assets.
This description does not address tax considerations applicable to holders that may be subject to special tax rules, including, without
limitation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks, financial institutions or insurance companies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">real estate investment trusts, regulated investment companies or grantor trusts;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dealers or traders in securities, commodities or currencies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax exempt entities or organizations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain former citizens or residents of the United States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that received the ADSs as compensation for the performance of services;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that will hold the ADSs as part of a &#8220;hedging,&#8221; &#8220;integrated&#8221; or &#8220;conversion&#8221; transaction or as a position in a &#8220;straddle&#8221; for U.S. federal income tax purposes;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">partnerships (including entities classified as partnerships for U.S. federal income tax purposes) or other pass- through entities, or holders that will hold the ADSs through such an entity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Holders (as defined below) whose &#8220;functional currency&#8221; is not the U.S. dollar; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">holders that own directly, indirectly or through attribution 10% or more of the voting power or value of our shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, this description
does not address the U.S. federal estate, gift, or alternative minimum tax consequences, or any U.S. state, local or non-U.S. tax consequences
of the acquisition, ownership and disposition of the ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This description is based
on the U.S. Internal Revenue Code of 1986, as amended, or the Code, existing, proposed and temporary U.S. Treasury Regulations promulgated
thereunder and administrative and judicial interpretations thereof, in each case as in effect and available on the date hereof. All the
foregoing is subject to change, which change could apply retroactively and could affect the tax consequences described below. There can
be no assurances that the U.S. Internal Revenue Service, or IRS, will not take a different position concerning the tax consequences of
the acquisition, ownership and disposition of the ADSs or that such a position would not be sustained. Holders should consult their own
tax advisers concerning the U.S. federal, state, local and foreign tax consequences of acquiring, owning and disposing of the ADSs in
their particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this description,
the term &#8220;U.S. Holder&#8221; means a beneficial owner of the ADSs that, for U.S. federal income tax purposes, is (i) a citizen or
resident of the United States, (ii) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or
organized in or under the laws of the United States, any state thereof, or the District of Columbia, (iii) an estate the income of which
is subject to U.S. federal income tax regardless of its source or (iv) a trust (x) with respect to which a court within the United States
is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of its
substantial decisions or (y) that has elected to be treated as a domestic trust for U.S. federal income tax purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A &#8220;Non-U.S. Holder&#8221;
is a beneficial owner of the ADSs that is neither a U.S. Holder nor a partnership (or other entity treated as a partnership for U.S. federal
income tax purposes).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a partnership (or any other
entity treated as a partnership for U.S. federal income tax purposes) holds the ADSs, the U.S. federal income tax consequences relating
to an investment in the ADSs will depend in part upon the status of the partner and the activities of the partnership. Such a partner
or partnership should consult its tax advisor regarding the U.S. federal income tax consequences of acquiring, owning and disposing of
the ADSs in its particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Persons considering an investment
in the ADSs should consult their own tax advisors as to the particular tax consequences applicable to them relating to the acquisition,
ownership and disposition of the ADSs, including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Exchange of ADSs for
Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, if you hold ADSs,
you will be treated as the holder of the underlying ordinary shares represented by those ADSs for U.S. federal income tax purposes. Accordingly,
gain or loss generally will not be recognized if you exchange ADSs for the underlying ordinary shares represented by those ADSs. In addition,
you will receive a basis in your ordinary shares equal to the basis of your ADSs exchanged for such shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Taxation of Dividends
and Other Distributions on the ADSs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussion
below under &#8220;Passive Foreign Investment Company Consequences,&#8221; if you are a U.S. Holder, the gross amount of any distribution
made to you with respect to the ADSs before reduction for any Israeli taxes withheld therefrom, generally will be includible in your income
as dividend income to the extent such distribution is paid out of our current or accumulated earnings and profits as determined under
U.S. federal income tax principles. Non-corporate U.S. Holders may qualify for the lower rates of taxation with respect to dividends on
ADSs applicable to &#8220;qualified dividends,&#8221; provided that certain conditions are met, including certain holding period requirements
and the absence of certain risk reduction transactions. Such lower rate of taxation shall not apply if we are a PFIC for the taxable year
in which we pay a dividend. Moreover, such dividends will not be eligible for the dividends received deduction generally allowed to corporate
U.S. Holders irrespective of PFIC status. To the extent that the amount of any distribution by us exceeds our current and accumulated
earnings and profits as determined under U.S. federal income tax principles, it will be treated first as a tax-free return of your adjusted
tax basis in the ADSs and thereafter as either long-term or short-term capital gain depending upon whether the U.S. Holder has held the
ADSs for more than one year as of the time such distribution is received.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a U.S. Holder,
dividends paid to you with respect to the ADSs will be foreign source income for foreign tax credit purposes. Subject to certain conditions
and limitations, Israeli tax withheld on dividends may be deducted from your taxable income or credited against your U.S. federal income
tax liability. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income.
For this purpose, dividends generally constitute &#8220;passive category income.&#8221; A foreign tax credit for foreign taxes imposed
on distributions may be denied if you do not satisfy certain minimum holding period requirements. The rules relating to the determination
of the foreign tax credit are complex, and you should consult your tax advisor to determine whether and to what extent you will be entitled
to this credit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of a distribution
paid to a U.S. Holder in a foreign currency will be the dollar value of the foreign currency calculated by reference to the spot exchange
rate on the day the U.S. Holder receives the distribution, regardless of whether the foreign currency is converted into U.S. dollars at
that time. Any foreign currency gain or loss a U.S. Holder realizes on a subsequent conversion of foreign currency into U.S. dollars will
be U.S. source ordinary income or loss. If dividends received in foreign currency are converted into U.S. dollars on the day they are
received, a U.S. Holder generally should not be required to recognize foreign currency gain or loss in respect of the dividend.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussion
below under &#8220;Backup Withholding Tax and Information Reporting Requirements,&#8221; if you are a Non-U.S. Holder, you generally will
not be subject to U.S. federal income (or withholding) tax on dividends received by you on your ADSs, unless:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">you conduct a trade or business in the U.S. and such income is effectively connected with that trade or business (and, if required by an applicable income tax treaty, the dividends are attributable to a permanent establishment or fixed base that such holder maintains in the U.S.); or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">you are an individual and have been present in the U.S. for 183 days or more in the taxable year of such sale or exchange and certain other conditions are met.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Sale, Exchange or Other
Disposition of the ADSs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussion
below under &#8220;Passive Foreign Investment Company Consequences,&#8221; if you are a U.S. Holder, you generally will recognize gain
or loss on the sale, exchange or other disposition of the ADSs equal to the difference between the amount realized on such sale, exchange
or other disposition and your adjusted tax basis in the ADSs and such gain or loss will be capital gain or loss. The adjusted tax basis
in an ADS generally will be initially determined as described above in &#8220;Tax Basis of each ADS.&#8221; If you are a non-corporate
U.S. Holder, capital gain from the sale, exchange or other disposition of an ADS is generally eligible for a preferential rate of taxation
applicable to capital gains, if your holding period determined at the time of such sale, exchange or other disposition for such ADS exceeds
one year (i.e., such gain is long-term capital gain). The deductibility of capital losses is subject to limitations. Any such gain or
loss generally will be treated as U.S. source income or loss for foreign tax credit limitation purposes. A foreign tax credit for foreign
taxes imposed on capital gains may be denied if you do not satisfy certain minimum holding period requirements. The rules relating to
the determination of the foreign tax credit are complex, and it is possible that the ability of a U.S. Holder to claim a foreign tax credit
for any such Israeli tax will be limited. You should consult your tax advisor to determine whether, and to what extent, you will be entitled
to this credit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussion
below under &#8220;Backup Withholding Tax and Information Reporting Requirements,&#8221; if you are a Non-U.S. Holder, you generally will
not be subject to U.S. federal income or withholding tax on any gain realized on the sale or exchange of such ADSs unless:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such gain is effectively connected with your conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, the gain is attributable to a permanent establishment or fixed base that you maintain in the United States); or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">you are an individual and have been present in the United States for 183 days or more in the taxable year of such sale or exchange and certain other conditions are met.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Passive Foreign Investment
Company Consequences </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be classified as a
PFIC for the 2024 tax year. If we are indeed so classified for 2024 or in any other taxable year, a U.S. Holder would be subject to special
rules generally intended to reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. Holder could derive
from investing in a non-U.S. company that does not distribute all of its earnings on a current basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-U.S. corporation will
be classified as a PFIC for federal income tax purposes in any taxable year in which, after applying certain look-through rules with respect
to the income and assets of subsidiaries, either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 75% of its gross income is &#8220;passive income&#8221;; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 50% of the average quarterly value of its total gross assets (which may be determined in part by the market value of the ADSs, which is subject to change) is attributable to assets that produce &#8220;passive income&#8221; or are held for the production of passive income.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Passive income for this purpose
generally includes dividends, interest, royalties, rents, gains from commodities and securities transactions, the excess of gains over
losses from the disposition of assets which produce passive income, and includes amounts derived by reason of the temporary investment
of funds raised in offerings of the ADSs. If a non-U.S. corporation owns at least 25% by value of the stock of another corporation, the
non-U.S. corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation
and as receiving directly its proportionate share of the other corporation&#8217;s income. If we are classified as a PFIC in any year
with respect to which a U.S. Holder owns the ADSs, we will generally continue to be treated as a PFIC with respect to such U.S. Holder
in all succeeding years during which the U.S. Holder owns the ADSs, regardless of whether we continue to meet the tests described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are indeed properly
classified as a PFIC, and you are a U.S. Holder, then unless you make one of the elections described below, a special tax regime will
apply to both (a) any &#8220;excess distribution&#8221; by us to you (generally, your ratable portion of distributions in any year which
are greater than 125% of the average annual distribution received by you in the shorter of the three preceding years or your holding period
for the ADSs) and (b) any gain realized on the sale or other disposition of the ADSs. Under this regime, any excess distribution and realized
gain will be treated as ordinary income and will be subject to tax as if (i) the excess distribution or gain had been realized ratably
over your holding period, (ii) the amount deemed realized in each year had been subject to tax in each year of that holding period at
the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC,
which would be subject to tax, at the U.S. Holder&#8217;s regular ordinary income rate for the current year and would not be subject to
the interest charge discussed below), and (iii) the interest charge generally applicable to underpayments of tax had been imposed on the
taxes deemed to have been payable in those years. In addition, dividend distributions made to you will not qualify for the lower rates
of taxation applicable to long-term capital gains discussed above under &#8220;Distributions.&#8221; Certain elections may be available
that would result in an alternative treatment (such as mark-to-market treatment) of the ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a U.S. Holder makes the
mark-to-market election, then, in lieu of being subject to the tax and interest charge rules discussed above, the U.S. Holder generally
will recognize as ordinary income any excess of the fair market value of the ADSs at the end of each taxable year over their adjusted
tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over their fair market value
at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market
election). If a U.S. Holder makes the election, the U.S. Holder&#8217;s tax basis in its ADSs will be adjusted to reflect these income
or loss amounts. Any gain recognized on the sale or other disposition of ADSs in a year when we are a PFIC will be treated as ordinary
income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result
of the mark-to-market election).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The mark-to-market election
is available only if we are a PFIC and the ADSs are &#8220;regularly traded&#8221; on a &#8220;qualified exchange.&#8221; The ADSs will
be treated as &#8220;regularly traded&#8221; in any calendar year in which more than a de minimis quantity of the ADSs are traded on a
qualified exchange on at least 15 days during each calendar quarter. NASDAQ is a qualified exchange for this purpose. Because a mark-to-market
election cannot be made for any lower-tier PFICs that we may own, a U.S. Holder may continue to be subject to the tax and interest charge
rules discussed above with respect to such holder&#8217;s indirect interest in any investments held by us that are treated as an equity
interest in a PFIC for U.S. federal income tax purposes, including stock in any of our subsidiaries that are treated as PFICs. If a U.S.
Holder makes a mark-to-market election, it will be effective for the taxable year for which the election is made and all subsequent taxable
years unless the ADSs are no longer regularly traded on a qualified exchange or the IRS consents to the revocation of the election.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are determined to be
a PFIC, the general tax treatment for U.S. Holders described in this section would apply to indirect distributions and gains deemed to
be realized by U.S. Holders in respect of any of our subsidiaries that also may be determined to be PFICs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;If we are a PFIC and
a U.S. Holder makes a Qualified Electing Fund Election under Section 1295 of the Code (&#8220;QEF Election&#8221;) for the first tax year
in which its holding period of its ADSs begins, such U.S. Holder generally will not be subject to the PFIC rules discussed above with
respect to its ADSs. However, a U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such U.S. Holder&#8217;s
pro rata share of (a) the net capital gain of the Company, which will be taxed as long-term capital gain to such U.S. Holder, and (b)
the ordinary earnings of the Company, which will be taxed as ordinary income to such U.S. Holder. Generally, &#8220;net capital gain&#8221;
is the excess of (a) net long-term capital gain over (b) net short-term capital gain, and &#8220;ordinary earnings&#8221; are the excess
of (a) &#8220;earnings and profits&#8221; over (b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal
income tax on such amounts for each tax year in which the Company is a PFIC, regardless of whether such amounts are actually distributed
to such U.S. Holder by the Company. However, a U.S. Holder that makes a QEF Election may, subject to certain limitations, elect to defer
payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any
such interest paid will be treated as &#8220;personal interest,&#8221; which is not deductible.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder that makes a
QEF Election generally (a) may receive a tax-free distribution from the Company to the extent that such distribution represents &#8220;earnings
and profits&#8221; of the Company that were previously included in income by the U.S. Holder because of such QEF Election and (b) will
adjust such U.S. Holder&#8217;s tax basis in the ADSs to reflect the amount included in income or allowed as a tax-free distribution because
of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or
other taxable disposition of ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The procedure for making a
QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely.
A QEF Election will be treated as timely if it is made for the first year in the U.S. Holder&#8217;s holding period for the ADSs in which
the Company was a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such
U.S. Holder files a U.S. federal income tax return for such year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A QEF Election will apply
to the tax year for which such QEF Election is made and to all subsequent tax years, unless such QEF Election is invalidated or terminated
or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Company
ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which the Company
is not a PFIC. Accordingly, if the Company becomes a PFIC in a subsequent tax year, the QEF Election will be effective, and the U.S. Holder
will be subject to the QEF rules described above during a subsequent tax year in which the Company qualifies as a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders should be aware
that, for each tax year that the Company is a PFIC, the Company can provide no assurances that it will satisfy the record-keeping requirements
or make available to U.S. Holders a PFIC Annual Information Statement or any other information such U.S. Holders require to make a QEF
Election with respect to the Company or any subsidiary that also is classified as a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not intend to provide
the information necessary for U.S. Holders to make qualified electing fund elections if we are classified as a PFIC. U.S. Holders should
consult their tax advisors to determine whether any of these elections would be available and if so, what the consequences of the alternative
treatments would be in their particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder who owns ADSs
during any year in which we are a PFIC, will be required to file an IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign
Investment Company or Qualified Electing Fund) with respect to us, generally with the U.S. Holder&#8217;s federal income tax return for
that year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders should consult
their tax advisors regarding application of the PFIC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Medicare Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain U.S. Holders that
are individuals, estates or trusts are subject to a 3.8% tax on all or a portion of their &#8220;net investment income,&#8221; which may
apply to all or a portion of the following items with respect to ADSs: dividend or other distributions, gains from dispositions and &#8220;excess
distributions&#8221; and income from &#8220;mark-to-market&#8221; elections under the PFIC rules, if applicable. Each U.S. Holder that
is an individual, estate or trust is urged to consult its tax advisors regarding the applicability of the Medicare tax to its income and
gains in respect of its investment in the ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Backup Withholding Tax
and Information Reporting Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. backup withholding tax
and information reporting requirements may apply to certain payments to certain holders of the ADSs. Information reporting generally will
apply to payments of dividends on the ADSs, and to proceeds from the sale or redemption of the ADSs made within the United States, or
by a U.S. payer or U.S. middleman, to a holder of the ADSs, other than an exempt recipient (including a payee that is not a U.S. person
that provides an appropriate certification and certain other persons). A payer may be required to withhold backup withholding tax from
any payments of dividends on the ADSs, or the proceeds from the sale or redemption of the ADSs within the United States, or by a U.S.
payer or U.S. middleman, to a holder, other than an exempt recipient, if such holder fails to furnish its correct taxpayer identification
number or otherwise fails to comply with, or establish an exemption from, such backup withholding tax requirements. Any amounts withheld
under the backup withholding rules will be allowed as a credit against the beneficial owner&#8217;s U.S. federal income tax liability,
if any, and any excess amounts withheld under the backup withholding rules may be refunded, provided that the required information is
timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Foreign Asset Reporting</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain U.S. Holders who are
individuals are required to report information relating to an interest in the ADSs, subject to certain exceptions (including an exception
for shares held in accounts maintained by financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets)
with their federal income tax return. U.S. Holders are urged to consult their tax advisors regarding their information reporting obligations,
if any, with respect to their ownership and disposition of the ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>THE DISCUSSION ABOVE IS
A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE OF IMPORTANCE TO A HOLDER OF OUR SECURITIES. EACH HOLDER OF OUR SECURITIES
IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE PARTICULAR TAX CONSEQUENCES TO SUCH HOLDER OF THE ACQUISITION, OWNERSHIP AND DISPOSITION
OF OUR SECURITIES IN LIGHT OF THE HOLDER&#8217;S OWN CIRCUMSTANCES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends and Paying Agents</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statement by Experts</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Documents on Display</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are required to file reports
and other information with the SEC under the Exchange Act, and the regulations thereunder applicable to foreign private issuers. The SEC
maintains an Internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically
with the SEC. Our filings with the SEC are available to the public through its web site at http://www.sec.gov. These SEC filings are also
generally available to the public on (i) the Israel Securities Authority&#8217;s Magna website at www.magna.isa.gov.il, (ii) the TASE&#8217;s
website at http://www.maya.tase.co.il, and (iii) from commercial document retrieval services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act relating to the furnishing and content of proxy statements, and our officers, directors
and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions contained in Section
16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with
the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we are required
to file with the SEC, within 120 days after the end of each fiscal year ending December 31, an annual report on Form 20-F containing financial
statements which are examined and reported on, with an opinion expressed, by an independent registered public accounting firm. We also
furnish to the SEC under cover of Form 6-K material information required to be made public in Israel, filed with and made public by any
stock exchange or distributed by us to our shareholders. In addition, in accordance with the NASDAQ Listing Rules, as a foreign private
issuer we are required to submit on Form 6-K an interim balance sheet and income statement as of the end of the second quarter of each
fiscal year. We have also undertaken under the Sales Agreement for our ATM program to submit to the SEC, on Form 6-K, an interim balance
sheet and income statement as of the end of the first and/or third quarters of each fiscal year if we shall desire to sell ADSs pursuant
to the Sales Agreement during certain time periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
at www.purple-biotech.com. Information contained on, or that can be accessed through, our website does not constitute a part of this annual
report. We have included our website address in this annual report solely as an inactive textual reference. We will post on our website
any materials required to be posted on such website under applicable laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statements in this Annual
Report on Form 20-F about any of our agreements, contracts or other documents is not necessarily complete. If the agreement, contract
or document is filed as an exhibit to this Annual Report on Form 20-F, the agreement, contract or document is deemed to modify the description
contained in this annual report. We urge you to review the exhibits themselves for a complete description of the contract or document.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiary Information</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market risk is the risk of
loss related to changes in market prices, including interest rates and foreign exchange rates, of financial instruments that may adversely
impact our financial position, results of operations or cash flows. Our overall risk management program focuses on the unpredictability
of financial markets and seeks to minimize potential adverse effects on our financial performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risk of Interest Rate Fluctuation and Credit
Exposure Risk </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At present, our credit and
interest risk arise from cash and cash equivalents, deposits with banks as well as accounts receivable. A substantial portion of our liquid
instruments is invested in short-term deposits with Bank Leumi le-Israel Ltd. and Bank Mizrachi-Tefachot, major Israeli banking institutions,
as well as with Valley Bank, NY, USA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate that because our
liquid instruments are invested mainly in short-term bank deposits, the credit and interest risk associated with these balances is immaterial.
The primary objective of our investment activities is to preserve principal while maximizing the income we receive from our investments,
without significantly increasing risk and loss. Our investments are exposed to market risk due to fluctuations in interest rates, which
may affect our interest income and the fair market value of our investments. We manage this exposure by performing ongoing evaluations
of our investments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Price Risk </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have short-term tradeable
securities, in the amount of approximately $275 thousand as of December 31, 2024, which may be impacted by fluctuations in the capital
markets.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign Currency Exchange Risk </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our foreign currency exposures
give rise to market risk associated with exchange rate movements of the U.S. dollar, our functional and reporting currency, mainly against
the NIS and other currencies. Although the U.S. dollar is our functional currency and reporting currency, a portion of our expenses are
denominated in NIS. Our NIS expenses consist principally of payments to employees or service providers, rent and short-term investments
in NIS. We anticipate that a sizable portion of our expenses will continue to be denominated in currencies other than the U.S. dollar.
If the U.S. dollar fluctuates significantly against the NIS, it may have a negative impact on our results of operations. We mitigate our
foreign exchange risk by aligning the currencies of our short-term investments with the currencies of anticipated expenses, based on our
expected cash flows. Furthermore, we manage this risk by hedging our monthly salary expenses that are denominated in NIS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Portfolio diversification
is performed based on risk level limits that we set. We have in the past, and may in the future, enter into currency hedging transactions
to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures,
however, may not adequately protect us from the material adverse effects of such fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below is a sensitivity
test to possible changes in U.S. dollars/NIS exchange rate as of December 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Sensitive instrument</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income&#160;(loss)&#160;from<br/> change&#160;in&#160;exchange rate <br/> (U.S.&#160;dollars&#160;in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value<br/> (U.S.&#160;dollars<br/> in&#160;thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income&#160;(loss)&#160;from<br/> change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Down&#160;2%</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Down&#160;5%</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Up&#160;5%</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Up&#160;2%</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents and deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">423</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(8</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other&#160;payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(723</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Post employment benefit liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">(140</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total&#160;income (loss)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(10</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(4</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below is a sensitivity
test to possible changes in U.S. dollars/Euro exchange rate as of December 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Sensitive instrument</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income&#160;(loss)&#160;from<br/> change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value<br/> (U.S.&#160;dollars<br/> in&#160;thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income&#160;(loss)&#160;from<br/> change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Down&#160;2%</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Down&#160;5%</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Up&#160;5%</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Up&#160;2%</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Cash and cash equivalents and deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">39</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(92</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other&#160;payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">(50</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total&#160;income (loss)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(2</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(5</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN
EQUITY SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Debt Securities</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants and Rights</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Securities</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>American Depositary Shares</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the American Depositary
Shares, or ADSs, represents two hundred (200) ordinary shares (or a right to receive two hundred (200) ordinary shares). The ADSs trade
on NASDAQ.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The form of the deposit agreement
for the ADSs and the form of American Depositary Receipt (ADR) that represents an ADS have been incorporated by reference as exhibits
to this Annual Report on Form 20-F. Copies of the deposit agreement are available for inspection at the principal office of The Bank of
New York Mellon, located at 101 Barclay Street, New York, New York 10286.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fees and Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding: 0pt; width: 49%; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Persons depositing or withdrawing shares or ADS holders must pay:</i></b></span></td>
    <td style="padding: 0pt; width: 2%; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; padding: 0pt; width: 49%; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For:</i></b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Issuance of ADSs, including issuances resulting
    from a distribution of shares or rights or other property</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cancellation of ADSs for the purpose of withdrawal,
    including if the deposit agreement terminates</p></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$.05 (or less) per ADS</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any cash distribution to ADS holders</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$.05 (or less) per ADS per calendar year</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depositary services</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration or transfer fees</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the depositary</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement) converting foreign currency to U.S. dollars</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As necessary</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any charges incurred by the depositary or its agents for servicing the deposited securities</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As necessary</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The depositary collects its
fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or
from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the
amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary
services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants
acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of
securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to
provide fee-attracting services until its fees for those services are paid.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the depositary
may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program,
waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing
its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency or other service providers that are
owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND
DELINQUENCIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS
OF SECURITY HOLDERS AND USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. CONTROLS AND PROCEDURES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>(a) Disclosure Controls
and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have performed an evaluation
of the effectiveness of our disclosure controls and procedures that are designed to ensure that the material financial and non-financial
information required to be disclosed to the SEC is recorded, processed, summarized and reported timely. Based on our evaluation, our
management, including the chief executive officer who also serves as acting chief financial officer, has concluded that our disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) as of the end
of the period covered by this report, were effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>(b) Management&#8217;s
Annual Report on Internal Control over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) promulgated
under the Exchange Act. Our internal control system was designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation and fair presentation of published financial statements for external purposes in accordance with generally
accepted accounting principles. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even
those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation
and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the
risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures
may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, including
the chief executive officer who also serves as acting chief financial officer, conducted an evaluation, pursuant to Rule 13a-15(c) promulgated
under the Exchange Act, of the effectiveness, as of the end of the period covered by this Annual Report, of its internal control over
financial reporting based on the framework in&#160;Internal Control&#8212;Integrated Framework&#160;issued by the Committee of Sponsoring
Organizations of the Treadway Commission (2013). Based on the results of this evaluation, management concluded that as of December 31,
2024, our internal control over financial reporting was effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
there can be no assurance that our controls and procedures will detect or uncover all failures in our controls over measurement and disclosure
in our financial statements or detect instances of fraud, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>(c) Attestation Report
of the Registered Public Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>(d) Changes in Internal
Control over Financial Reporting</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes in our
internal control over financial reporting that occurred during the year ended December 31, 2024, that have materially affected, or are
reasonably likely to materially affect, our internal control over financial reporting. During 2024, we adjusted our internal control over
financial reporting to address the departure of our former Chief Financial Officer.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16. [RESERVED]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board has determined that
each of Mr. Gagnon and Mr. Rock is an &#8220;audit committee financial expert&#8221; as defined in Item 16A of Form 20-F under the Exchange
Act. Our Board has also determined that each of the members of our audit committee, Mr. Agmon, Mr. Gagnon and Mr. Rock, qualifies as an
independent director under the NASDAQ Listing Rules and satisfies the independence requirements of Rule 10A-3 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16B. CODE OF ETHICS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board adopted a Code of
Business Conduct and Ethics (the &#8220;Code&#8221;) that applies to all our employees, including without limitation our chief executive
officer, chief financial officer and controller. Our Code is intended to meet the definition of &#8220;code of ethics&#8221; under Item
16B of 20-F under the Exchange Act. A copy of the Code may be viewed on our website at&#160;www.purple-biotech.com. Information contained
on, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 20-F and is not incorporated
by reference herein. We will disclose on our website any amendment to, or waiver from, a provision of our Code to the extent required
under the rules of the SEC or Nasdaq. There have been no material changes to our Code since our most recent Annual Report Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements of at December 31, 2024 and 2023, and for each of the three years in the period ended December 31, 2024, appearing in this
Annual Report have been audited by Somekh Chaikin, a member firm of KPMG International (the &#8220;Auditor&#8221;), independent registered
public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report
given on the authority of such firm as experts in accounting and auditing. Our Auditor&#8217;s location is Tel Aviv, Israel, and the Auditor&#8217;s
Firm ID is <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-28501">1057</ix:nonNumeric>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the approximate total compensation that was expensed by the Company and its subsidiaries to the Auditor, for each of the years ended December
31, 2024 and 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands of U.S. dollars)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">128</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">162</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">135</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">164</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Audit fees&#8221; include fees for services performed in connection with the Company&#8217;s annual audit, certain procedures regarding the Company&#8217;s interim financial results, fees related to our public offerings and registration statements, and consultation concerning financial accounting and reporting standards.</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees relate to services provided regarding tax compliance.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of the audit services
and tax services described in the table above were approved in advance by the audit committee in accordance with paragraph (c)(7)(i)(B)
of Rule 2-01 of Regulation S-X.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit committee&#8217;s pre-approval policies
and procedures</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the rules
of the SEC, Israeli law and our amended and restated articles of association, the appointment of our independent auditors requires the
approval of the shareholders of the Company following the approvals of our Audit Committee and Board. Under the Companies Law and our
amended and restated articles of association, our shareholders are authorized at the annual general meeting to appoint the Company&#8217;s
independent auditor to hold office until the end of the next annual general meeting or for a longer period that shall not extend beyond
the end of the third annual meeting following the annual meeting at which the auditor was appointed. At our 2023 annual general meeting
of shareholders, our shareholders appointed Somekh Chaikin, a member of KPMG International, as our independent registered public accounting
firm, for a period of three years, until the annual general meeting of shareholders to be held in 2026, at which time the appointment
of an auditor will be presented to the shareholders once again.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law and
our amended and restated articles of association, the board of directors is authorized to determine the independent auditor&#8217;s remuneration.
In addition, SEC rules require that a listed company&#8217;s audit committee pre-approve the appointment and remuneration of the independent
auditor. Our amended and restated articles of association include a provision which states that for so long as our securities are listed
for trading on an exchange in the United States, such authority of the board of directors to set the remuneration of the auditor for audit
services and/or for additional services, will be deemed to have been delegated by the board of directors to the audit committee of the
board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The advance approval of the
Audit Committee is required for all audit and non-audit services provided by our auditors. All services provided by our auditors are approved
in advance by the Audit Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS
FOR AUDIT COMMITTEES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16E. PURCHASES OF EQUITY SECURITIES BY
THE ISSUER AND AFFILIATED PURCHASERS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING
ACCOUNTANT.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16G. CORPORATE GOVERNANCE </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are permitted to follow Israeli corporate governance practices instead of certain NASDAQ Listing Rules, provided that we disclose which
requirements we are not following and the equivalent Israeli requirement. We currently rely on this &#8220;foreign private issuer exemption&#8221;
with respect to the following items:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distribution of annual and quarterly reports to shareholders</i>. Under Israeli law, as a public company whose shares are traded on the TASE, we are not required to distribute annual and quarterly reports directly to shareholders and the generally accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports publicly available through the website of the Israel Securities Authority and the TASE. In addition, we make our audited financial statements available to our shareholders at our offices.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation of Officers. </i>We comply with the requirements set forth under the Companies Law with respect to the approval of officer compensation. For a discussion regarding the approvals required under the Companies Law and the regulations promulgated thereunder for the approval of compensation of the chief executive officer, all other executive officers and directors, see &#8220;Item 6.C &#8211; Board Practices &#8211; Fiduciary Duties and Approval of Certain Related Party Transactions and Compensation under Israeli Law&#8221;.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shareholder Approval. </i>We seek shareholder approval for all corporate actions requiring such approval in accordance with the requirements of the Companies Law, which are different from the shareholder approval requirements under the NASDAQ Listing Rules, including NASDAQ Listing Rule 5635. The NASDAQ Listing Rules require that we obtain shareholder approval for certain dilutive events, such as (i) for the establishment or amendment of certain equity-based compensation plans and arrangements, (ii) issuances that will result in a change of control of a company, (iii) certain transactions other than a public offering involving issuances of 20% or more of the shares or voting power in a company, and (iv) certain acquisitions of the stock or assets of another company involving issuances of 20% or more of the shares or voting power in a company or if any director, officer or holder of 5% or more of the shares or voting power of the company has a 5% or greater interest in the company or assets to be acquired or consideration to be paid and the transaction could result in an increase in the outstanding common shares or voting power by 5% or more.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Companies Law, shareholder approval is required for any transaction, including any grant of equity-based compensation, to a director or a controlling shareholder, but it is not generally required to establish or amend an equity-based compensation plan. Similarly, shareholder approval is required under Israeli law for a private placement that is deemed an &#8220;extraordinary private placement&#8221; or that involves a director or controlling shareholder. An &#8220;extraordinary private placement&#8221; is a private placement in which a company issues securities representing 20% or more of its voting rights prior to the issuance and the consideration received pursuant to such issuance is not comprised, in whole or in part, solely of cash or securities registered for trade on an exchange or which is not made pursuant to market conditions, and as a result of which the shareholdings of a 5% holder of the shares or voting rights of the company increases or as a result of which a person will become a holder of 5% of the shares or voting rights of the company or a controlling shareholder after the issuance.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Approval of Related Party Transactions</i>. All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transactions set forth in sections 268 to 275 of the Companies Law and the regulations promulgated thereunder, which require the approval of the audit committee, the compensation committee, the board of directors and shareholders, as may be applicable, for specified transactions, rather than approval by the audit committee or other independent body of our Board as required under the NASDAQ Listing Rules.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Quorum of Shareholder Meetings.</i> Under the NASDAQ Listing rules, the minimum quorum required for an ordinary meeting of shareholders consists of 33&#160;1/3% of the issued share capital. As permitted under the Companies Law, pursuant to our amended and restated articles of association, the quorum required for a meeting of our shareholders consists of at least two shareholders present in person or by proxy who hold or represent at least 25% of the voting rights of our shares (and in an adjourned meeting, with some exceptions, any number of shareholders), instead of 33&#160;1/3% of the issued share capital required under the NASDAQ Listing Rules.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nominations Committee</i>&#160;<i>and Nominations of our Directors.</i> Under Israeli law and our amended articles of association, our directors are not required to be selected, or recommended for board of director selection, by independent directors constituting a majority of the board&#8217;s independent directors or by a nominations committee comprised solely of independent directors, as required by the NASDAQ Listing Rules. With the exception of directors elected by our Board due to vacancy, our directors are elected by an annual general meeting of our shareholders to hold office until the next annual meeting following three years from his or her election. The nominations for directors, which are presented to our shareholders, are generally made by our directors, but nominations may be made by one or more of our shareholders as provided in our amended and restated articles of association and under the Companies Law. However, in September 2020, we established a non-independent nominations committee, whose role is (among other things) to identify and recommend to our Board for selection, director nominees, consistent with criteria approved by the Board. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as stated above, we
currently comply with the rules generally applicable to U.S. domestic companies listed on NASDAQ. We may in the future decide to use the
foreign private issuer exemption with respect to some or all of the other NASDAQ Listing Rules related to corporate governance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16H. MINE SAFETY DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16J. INSIDER TRADING POLICIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have <ix:nonNumeric contextRef="c78" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-28502">adopted</ix:nonNumeric> a policy that
governs the trading in our securities by our directors, officers, employees and certain other covered persons, and which is reasonably
designed to promote compliance with applicable insider trading laws, rules and regulations and applicable NASDAQ listing standards. A
copy of our Insider Trading Policy is included as Exhibit 4.23 <span style="font-family: Times New Roman, Times, Serif">&#160;</span>to
this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16K. CYBERSECURITY </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-12315"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate in the biotechnology
sector, which is subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of
operations, including intellectual property theft; fraud; extortion; harm to employees; violation of privacy laws and other litigation
and legal risk; and reputational risk. We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity
measures to safeguard our information systems and protect the confidentiality, <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="ixv-28503">integrity</ix:nonNumeric>, and availability of our data. We currently have
security measures in place to protect patients&#8217;, employees&#8217; and vendors&#8217; information and prevent data loss and other
security breaches, including a cybersecurity risk assessment program. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-28504">Both management and the Company&#8217;s <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="ixv-28505">Audit Committee</ix:nonNumeric> are actively
involved in the continuous assessment of risks from cybersecurity threats, including prevention, mitigation and detection.</ix:nonNumeric></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="ixv-12333"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risk Management and Strategy</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2"><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_2" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cybersecurity assessment
program outlines policies and procedures and technology we use to oversee and identify risks from cybersecurity threats, and focuses on
the following areas:</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_4" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3"><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_3" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Vigilance</i>: The Company maintains cybersecurity threat operations with the goal of identifying, preventing and mitigating cybersecurity threats and responding to cybersecurity incidents in accordance with our established disaster recovery policy.</span></td></tr>
  </table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_5" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_4"><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_4" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Systems Safeguards</i>: The Company deploys systems safeguards that are designed to protect the Company&#8217;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through ongoing vulnerability assessments and cybersecurity threat intelligence.</span></td></tr>
  </table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_6" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_5"><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_5" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="ixv-12381"><i>Third Party Service Provider</i>: The Company utilizes a third-party service provider to assist the Company to identify, assess, prevent and respond to cybersecurity risks.</ix:nonNumeric> </span></td></tr> </table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_7" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_6"><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_6" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Training</i>: The Company provides periodic training for personnel regarding cybersecurity threats, which reinforces the Company&#8217;s information security policies, standards and practices.</span></td></tr>
  </table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_8" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_7"><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_7" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Incident Response and Recovery Planning</i>: The Company has established and maintains a plan that addresses the Company&#8217;s response to a cybersecurity incident and the recovery from a cybersecurity incident, which plan is evaluated periodically.</span></td></tr>
  </table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_9" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_8"><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_8" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_7"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Communication and Disclosure</i>: The Company&#8217;s established plan includes procedures for the communication of cybersecurity incidents so that decisions regarding the disclosure and reporting of such incidents can be made in a timely manner.</span></td></tr>
  </table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_9"><ix:continuation id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_8"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Governance</i>: The management&#8217;s oversight of cybersecurity risk management is supported by the Company&#8217;s Audit Committee.</span></td></tr>
  </table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="ixv-12438"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Governance </i></b></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_2" id="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management is responsible
for day-to-day assessment and management of risks from cybersecurity threats, including the prevention, mitigation, detection, and remediation
of cybersecurity incidents (if any). The Company&#8217;s Chief Executive Officer is the member of the Company&#8217;s management who is
principally responsible for overseeing the Company&#8217;s cybersecurity risk management program.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_3" id="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Audit
Committee, in conjunction with management, oversees the assessment of the Company&#8217;s risks from cybersecurity threats, including
prevention and mitigation. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="ixv-28506">The Company&#8217;s Audit Committee receives periodic updates from the Company&#8217;s Chief Executive Officer
with respect to the management of risks from cybersecurity threats. Additionally, the Audit Committee, in conjunction with management,
considers risks from cybersecurity threats as part of its oversight of the Company&#8217;s business strategy, risk management, and financial
oversight.</ix:nonNumeric></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_4" id="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We engage a third-party consultant
to help us assess and identify risks from cybersecurity threats, including the threat of a cybersecurity incident, and assisted us to
establish our cybersecurity program and manage our risk assessment program. Our third-party consultant monitors cybersecurity threats
to our software.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, no risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially
affect our business strategy, results of operations or financial condition. However, an actual or perceived breach of our cybersecurity
could damage our reputation, interfere with the progress of our clinical trials and/or our efforts to pursue regulatory approvals for
our therapeutic candidates, or subject us to third-party lawsuits, regulatory fines or other actions or liabilities, any of which could
adversely affect our business, operating results or financial condition. For further information, see &#8220;Item 3. Key Information &#8211;
D. Risk Factors &#8211; Risks Related to Our Industry &#8211; <i>Our business and operations may be materially adversely affected in the
event of computer system failures or security or breaches due to cyber-attacks or cyber intrusions, including ransomware, phishing attacks
and other malicious intrusions</i>.&#8221;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 17. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registrant has responded
to Item 18 in lieu of responding to this Item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 18. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See our consolidated financial
statements as of December 31, 2024 and 2023 and for the three-year period ended December 31, 2024, beginning on page F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>ITEM
19. EXHIBITS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exhibits filed with or
incorporated into this Annual Report on Form 20-F are listed in the index of exhibits below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; width: 9%"><span style="text-decoration: none; font-family: Times New Roman, Times, Serif"><b>Exhibit
    Number</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; width: 90%"><span style="text-decoration: none; font-family: Times New Roman, Times, Serif"><b>Exhibit&#160;Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">1.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020041930/ea131388ex99-3_purplebiotech.htm">Memorandum of Association of the Registrant (originally filed as Exhibit 99.3 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on December 10, 2020 and incorporated herein by reference thereto)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">1.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020041930/ea131388ex99-2_purplebiotech.htm">Amended and Restated Articles of Association of the Registrant (originally filed as Exhibit 99.2 to the Registrant&#8217;s Form 6-K furnished to with the Securities and Exchange Commission on December 10, 2020 and incorporated herein by reference thereto)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023248301ex2-1_purple.htm">Description
of Share Capital</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000114420415056393/v420652_ex4-1.htm">Form of Deposit Agreement among the Registrant, the Bank of New York Mellon, as Depositary, and all Owners and Holders from time to time of American Depositary Shares issued hereunder (incorporated by reference to Exhibit 4.1 to our Registration Statement on Form F-1 as filed with the Securities and Exchange Commission on September 24, 2015)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000114420415056393/v420652_ex4-1.htm">Form of American Depositary Receipt (included in Exhibit 2.2)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020005814/ff12019a1ex4-18_kitovpharma.htm">Form of Warrant, dated January 7, 2020, between Purple Biotech Ltd. issued to former FameWave shareholders (incorporated by reference to Exhibit 4.18 to the Registrant&#8217;s Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on March 10, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020005814/ff12019a1ex4-21_kitovpharma.htm">Form of Placement Agent Warrant issued to Placement Agent in the March 2020 public offering (incorporated by reference to Exhibit 4.21 to the Registrant&#8217;s Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on March 10, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020009562/ea120836ex99-2_kitovpharma.htm">Form of Placement Agent Warrant issued to Placement Agent in the April 2020 private placement (incorporated by reference to Exhibit 99.2 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on April 20, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020011385/ea121534ex4-1_kitov.htm">Form of Warrant issued to investors in the May 2020 private placement (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on May 8, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020011385/ea121534ex4-2_kitov.htm">Form of Placement Agent Warrant issued to Placement Agent in the May 2020 public offering (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on May 8, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020015790/ea123437aex4-1_kitov.htm">Form of Warrant issued to purchasers in the June 2020 offering (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on June 25, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020016163/ea123580ex4-2_kitovpharma.htm">Form of Placement Agent Warrant issued to Placement Agent in the June 2020 public offering (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Form 6-K/A furnished to the Securities and Exchange Commission on June 29, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.11</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000101376223004983/ea186957ex4-4_purplebio.htm">Form of Amendment to Existing Warrants issued to the purchaser in the October 2023 offering (incorporated by reference to Exhibit 4.4 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on October 19, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.12</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390024058591/ea020886901ex1-3_purplebio.htm">Form
of Series A-1 Warrant issued to the purchaser in the July 2024 warrant exercise and reload transaction (incorporated by reference to
Exhibit 1.3 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on July 2, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.13</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390024058591/ea020886901ex1-4_purplebio.htm">Form
of Series A-2 Warrant issued to the purchaser in the July 2024 warrant exercise and reload transaction (incorporated by reference to
Exhibit 1.4 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on July 2, 2024)</a> </span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-family: Times New Roman, Times, Serif">2.14</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline;text-decoration: none"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390024058591/ea020886901ex1-5_purplebio.htm">Form of Placement Agent Warrant issued to the Placement Agent in the July 2024 warrant exercise and reload transaction (incorporated by reference to Exhibit 1.5 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on July 2, 2024)</a> </span></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2.15</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline;text-decoration: none"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390024105347/ea022352601ex4-2_purplebio.htm">Form of Placement Agent Warrant issued to the Placement Agent in the December 2024 offering (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on December 4, 2024)</a> </span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000114420415056393/v420652_ex10-5.htm">Form of Letter of Exemption adopted on July 2013 (unofficial English translation from Hebrew) (incorporated by reference to Exhibit 10.5 to our Registration Statement on Form F-1&#160;filed with the Securities and Exchange Commission on September 24, 2015)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000114420415056393/v420652_ex10-6.htm">Form of Letter of Indemnity adopted on July 2013 (unofficial English translation from Hebrew) (incorporated by reference to Exhibit 10.6 to our Registration Statement on Form F-1 as filed with the Securities and Exchange Commission on September 24, 2015)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390022011191/f20f2021ex4-3_purplebiotech.htm">Purple Biotech Ltd. 2016 Equity-Based Incentive Plan, as amended (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Annual Report on Form 20-F as filed with the Securities and Exchange Commission on March 9, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.4*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390017004462/f20f2016ex4xiv_kitovpharma.htm">License Agreement, dated as of August 15, 2013, by and between Yissum Research Development Company of The Hebrew University of Jerusalem, Ltd. and TyrNovo Ltd. (incorporated by reference to Exhibit 4.14 to the Registrant&#8217;s Annual Report on Form 20-F as filed with the Securities and Exchange Commission on May 1, 2017)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.5*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390017004462/f20f2016ex4xv_kitovpharma.htm">First Amendment to License Agreement, dated as of April 8, 2014, by and between Yissum Research Development Company of The Hebrew University of Jerusalem, Ltd. and TyrNovo Ltd. (incorporated by reference to Exhibit 4.15 to the Registrant&#8217;s Annual Report on Form 20-F as filed with the Securities and Exchange Commission on May 1, 2017)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.6*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390017004462/f20f2016ex4xvi_kitovpharma.htm">Second Amendment to License Agreement, dated as of March 16, 2017, by and between Yissum Research Development Company of The Hebrew University of Jerusalem, Ltd. and TyrNovo Ltd. (incorporated by reference to Exhibit 4.16 to the Registrant&#8217;s Annual Report on Form 20-F as filed with the Securities and Exchange Commission on May 1, 2017)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390023034584/ea177738ex99-1_purplebio.htm">Purple Biotech Ltd. Office Holder Compensation Policy approved the shareholders on June 15, 2023 (incorporated by reference to Exhibit A to the Proxy Statement included as Exhibit 99.1 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on May 1, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390020005814/ff12019a1ex10-21_kitovpharma.htm">Form of Securities Purchase Agreement dated as of March 12, 2020 by and between the Registrant and the purchasers in the March 2020 public offering (incorporated by reference to Exhibit 10.21 to the Registrant&#8217;s Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on March 10, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.9**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390020008240/f20f2019a1ex4-23_kitov.htm">Amended and Restated License effective as of the 25th day of May, 2010 by and between: Tel Hashomer - Medical Research, Infrastructure and Services Ltd and Ramot at Tel Aviv University Ltd. and cCAM Biotherapeutics Ltd. (incorporated by reference to Exhibit 4.23 to the Registrant&#8217;s Annual Report on Form 20-F/A as filed with the Securities and Exchange Commission on March 31, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.10**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390020008240/f20f2019a1ex4-24_kitov.htm">First Amendment to Amended and Restated License Agreement, by and between Tel Hashomer &#8211; Medical Research, Infrastructure and Services Ltd., Ramot at Tel Aviv University Ltd. and cCAM Biotherapeutics Ltd. (incorporated by reference to Exhibit 4.24 to the Registrant&#8217;s Annual Report on Form 20-F/A as filed with the Securities and Exchange Commission on March 31, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.11</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020008240/f20f2019a1ex4-25_kitov.htm">Second Amendment to Amended and Restated License Agreement, by and between Tel Hashomer &#8211; Medical Research, Infrastructure and Services Ltd., Ramot at Tel Aviv University Ltd. and cCAM Biotherapeutics Ltd. (incorporated by reference to Exhibit 4.25 to the Registrant&#8217;s Annual Report on Form 20-F/A as filed with the Securities and Exchange Commission on March 31, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.12</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020008240/f20f2019a1ex4-26_kitov.htm">Assignment and Assumption Agreement effective as of March 21, 2019, between Tel Hashomer &#8211; Medical Research, Infrastructure and Services Ltd., Ramot at Tel Aviv University Ltd., FameWave Ltd. and cCAM Biotherapeutics Ltd. (incorporated by reference to Exhibit 4.26 to the Registrant&#8217;s Annual Report on Form 20-F/A as filed with the Securities and Exchange Commission on March 31, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.13 </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020009562/ea120836ex99-4_kitovpharma.htm">Form of Warrant Exercise Agreement, dated as of April 19, 2020, entered into between the Registrant and the warrant holders in the April 2020 private placement (incorporated by reference to Exhibit 99.4 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on April 20, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.14</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020011385/ea121534ex1-1_kitov.htm">Form of Securities Purchase Agreement dated as of May 6, 2020 by and between the Registrant and the purchasers in the May 2020 offering (incorporated by reference to Exhibit 1.1 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on May 8, 2020)</a></span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-family: Times New Roman, Times, Serif">4.15</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390020015790/ea123437aex1-1_kitov.htm">Form of Securities Purchase Agreement dated as of June 23, 2020 by and between the Registrant and the purchasers in the June 2020 offering (incorporated by reference to Exhibit 1.1 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on June 25, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.16</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000121390021031718/ea142416ex1-1_purplebiotech.htm">Open Market Sale Agreement<sup>SM</sup>, dated as of June 9, 2021, by and between the Company and Jefferies LLC (incorporated by reference to Exhibit 1.1 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on June 9, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.17**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390023017024/f20f2022ex4-25_purple.htm">Share Purchase Agreement by and among Purple Biotech Ltd., the Shareholders of Immunorizon Ltd. and M. Arkin (1999) Ltd. dated as of February 1, 2023 (incorporated by reference to Exhibit 4.25 to the Registrant&#8217;s Annual Report on Form 20-F furnished to the Securities and Exchange Commission on March 3, 2023</a><span style="text-decoration:underline">)</span></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.18</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000101376223004983/ea186957ex4-1_purplebio.htm">Form of Securities Purchase Agreement dated as of October 17, 2023 by and between the Registrant and the purchaser in the October 2023 offering (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on October 19, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.19</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1614744/000101376223004983/ea186957ex4-4_purplebio.htm">Form of Amendment to Existing Warrants issued to the purchaser in the October 2023 offering (incorporated by reference to Exhibit 4.4 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on October 19, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.20</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline;text-decoration: none"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390024058591/ea020886901ex1-1_purplebio.htm">Form of Warrant Reprice and Reload Letter dated as of July 1, 2024 by and between the Registrant and the purchaser issued in the July 2024 warrant exercise and reload transaction (incorporated by reference to Exhibit 1.1 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on July 2, 2024)</a> </span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline;text-decoration: none">4.21</span></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390024058591/ea020886901ex1-2_purplebio.htm">Form
of Warrant Reprice and Reload Letter dated as of July 1, 2024 by and between the Registrant and the purchaser issued in the July 2024
warrant exercise and reload transaction (incorporated by reference to Exhibit 1.2 to the Registrant&#8217;s Form 6-K furnished to the
Securities and Exchange Commission on July 2, 2024)</a> </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.22</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1614744/000121390024105347/ea022352601ex4-1_purplebio.htm">Form
of Securities Purchase Agreement dated as of December 3, 2024 by and between the Registrant and the purchasers in the December 2024 offering
(incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Form 6-K furnished to the Securities and Exchange Commission on December
4, 2024)</a> </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">4.23</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><a href="ea023248301ex4-23_purple.htm">Insider
Trading Policy</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">8.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023248301ex8-1_purple.htm">List of subsidiaries of the Registrant</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">12.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea023248301ex12-1_purple.htm"><span style="font-family: Times New Roman, Times, Serif">Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">13.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea023248301ex13-1_purple.htm"><span style="font-family: Times New Roman, Times, Serif">Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">15.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea023248301ex15-1_purple.htm"><span style="font-family: Times New Roman, Times, Serif">Consent of Somekh Chaikin, independent registered public accounting firm, a Member Firm of KPMG International</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">101.INS</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">101.SCH</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">101.CAL</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">101.DEF</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">101.LAB</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">101.PRE</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential treatment granted with respect to portions of this Exhibit.</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portions of this exhibit has been redacted because it is both not material and is the type that the registrant treats as private or confidential. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registrant hereby certifies that it meets
all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report
on Form 20-F on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURPLE BIOTECH LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; width: 60%; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 4%; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 5%; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 31%; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gil Efron</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;&#160;</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gil Efron</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    and <br/>
Acting Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 10,
    2025</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>









</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Purple
Biotech Ltd.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>As
of December 31, 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>In
U.S. Dollars</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Index</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 89%"><span style="font-family: Times New Roman, Times, Serif"><a href="#p_001"><span style="font-size: 10pt"><b>Report
    of Independent Registered Public Accounting Firm</b></span></a></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-2</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#p_002"><span style="font-size: 10pt"><b>Consolidated Statements
    of Financial Position</b></span></a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-4</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#p_003"><span style="font-size: 10pt"><b>Consolidated Statements
    of Operations and Other Comprehensive Loss</b></span></a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-5</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#p_004"><span style="font-size: 10pt"><b>Consolidated Statements
    of Changes in Equity</b></span></a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-6</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#p_005"><span style="font-size: 10pt"><b>Consolidated Statements
    of Cash Flows</b></span></a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-9</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p_006"><span style="font-size: 10pt"><b>Notes
    to the Consolidated Financial Statements</b></span></a></span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-11
    &#8211; F-41</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Page; Sequence: 143; Options: NewSection --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="p_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Report
of Independent Registered Public Accounting Firm</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Shareholders and Board of Directors<br/>
Purple Biotech Ltd.:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AuditorOpinionTextBlock-c0_cont_1" escape="true" name="dei:AuditorOpinionTextBlock" id="ixv-13184"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Opinion on the Consolidated Financial Statements</i></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_AuditorOpinionTextBlock-c0_cont_1"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated statements of financial
position of Purple Biotech Ltd. and its subsidiaries (hereinafter &#8211;&#8220;the Company&#8221;) as of December&#160;31, 2024 and 2023,
the related consolidated statements of operations and other comprehensive loss, changes in equity, and cash flows for each of the years
in the three year period ended December&#160;31, 2024, and the related notes (collectively, the consolidated financial statements). In
our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as
of December&#160;31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three year period
ended December&#160;31, 2024, in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board ("IFRS
Accounting Standards").</p></ix:continuation><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Basis for Opinion</i></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These consolidated financial statements are the responsibility of the
Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audits included performing procedures to
assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide
a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 145 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Critical Audit Matter</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The critical audit matter communicated below is a matter arising from
the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee
and that: (1) relate<i>s</i> to accounts or disclosures that are material to the consolidated financial statements and (2) involved our
especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion
on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing
a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><i>Fair value of intangible assets</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">As discussed in Notes 3D and 4 to the consolidated financial statements,
intangible assets, consisting of in-process research and development (IPR&amp;D), were USD 27,842 thousand as of December 31, 2024. IPR&amp;D
is related to the TyrNovo, FameWave and Immunorizon acquisitions completed in prior years. The Company tests its intangible assets for
impairment on an annual basis, or more frequently if there are indications of impairment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">We identified the evaluation of the estimated fair value of the intangible
assets determined by the Company as part of the annual impairment test as a critical audit matter. Specifically, the evaluation of certain
key assumptions into the fair value determination, including future expenses for completing development of the intangible assets, success
rates, future revenues, and discount rate, involved a high degree of subjective auditor judgment. Changes in these assumptions could have
had a significant effect on the Company&#8217;s fair value determination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The following are the primary procedures we performed to address this
critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company&#8217;s
determination of fair value of the intangible assets, including controls related to the key assumptions described above. We assessed the
Company&#8217;s estimate of future expenses by comparing it to budgeted expenses approved by the board of directors and to industry data
reports, and inquiring of operations and finance personnel regarding the status of IPR&amp;D efforts. We compared actual expenses for
developing the TyrNovo, FameWave and Immunorizon IPR&amp;D incurred in the current year to the amounts originally forecasted in order
to assess the Company&#8217;s ability to accurately forecast. We compared the successes rate and future revenues estimated by the Company
to industry data reports. We involved valuation professionals with specialized skills and knowledge, who assisted in evaluating the Company&#8217;s
discount rate assumption by assessing the methodology and parameters used in the determination. We performed a sensitivity analysis over
the estimated successes rate, future revenues, and discount rate assumptions by considering the effect of a range of potential outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-28507">Somekh Chaikin</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member Firm of KPMG International</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2011.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-28508">Tel-Aviv, Israel</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 10, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 146 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>Purple
Biotech Ltd.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="p_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
Statements of Financial Position as of December 31,</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">5, 18A</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28509">7,401</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28510">14,489</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Short term deposits</td><td>&#160;</td>
    <td style="text-align: center">18A</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-28511">848</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-28512">850</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other investments</td><td>&#160;</td>
    <td style="text-align: center">18B</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInvestments" scale="3" unitRef="usd" id="ixv-28513">275</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInvestments" scale="3" unitRef="usd" id="ixv-28514">73</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">7</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="3" unitRef="usd" id="ixv-28515">384</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="3" unitRef="usd" id="ixv-28516">376</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-28517">8,908</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-28518">15,788</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify">Non-current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Right to use assets</td><td>&#160;</td>
    <td style="text-align: center">6</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="3" unitRef="usd" id="ixv-28519">164</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="3" unitRef="usd" id="ixv-28520">316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Fixed assets, net</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28521">124</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-28522">154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">4</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28523">27,842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28524">28,044</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non - current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-28525">28,130</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-28526">28,514</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-28527">37,038</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-28528">44,302</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Current maturity of lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">6</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-28529">183</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-28530">188</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Trade payable</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-28531">1,455</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-28532">3,532</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Warrants</td><td>&#160;</td>
    <td style="text-align: center">18B</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentWarrantLiability" scale="3" unitRef="usd" id="ixv-28533">1,149</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="ifrs-full:NoncurrentWarrantLiability" scale="3" unitRef="usd">2,518</ix:nonFraction></td><td style="text-align: left">(*)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">8</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentPayables" scale="3" unitRef="usd" id="ixv-28535">1,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentPayables" scale="3" unitRef="usd" id="ixv-28536">3,463</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-28537">3,987</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-28538">9,701</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Non-current liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: center">6</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-28539">163</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Post-employment benefit liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">17</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" scale="3" unitRef="usd" id="ixv-28540">140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" scale="3" unitRef="usd" id="ixv-28541">141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non - current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="3" unitRef="usd" id="ixv-28542">140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="3" unitRef="usd" id="ixv-28543">304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Equity</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Share capital, no par value</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share premium</td><td>&#160;</td>
    <td style="text-align: center">9</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-28544">147,631</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-28545">133,184</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Receipts on account of warrants</td><td>&#160;</td>
    <td style="text-align: center">9</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:ReceiptsOnAccountsOfWarrant" scale="3" unitRef="usd" id="ixv-28546">21,145</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:ReceiptsOnAccountsOfWarrant" scale="3" unitRef="usd" id="ixv-28547">28,467</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Capital reserve for share-based payments</td><td>&#160;</td>
    <td style="text-align: center">10</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-28548">8,875</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-28549">10,088</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Capital reserve from transactions with related parties</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CapitalReserve" scale="3" unitRef="usd" id="ixv-28550">761</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CapitalReserve" scale="3" unitRef="usd" id="ixv-28551">761</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Capital reserve from hedging</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="3" unitRef="usd" id="ixv-28552">19</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Capital reserve from transactions with non- controlling interest</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:CapitalReserveFromTransactionsWithNon-ControllingInterest" scale="3" sign="-" unitRef="usd" id="ixv-28553">859</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:CapitalReserveFromTransactionsWithNon-ControllingInterest" scale="3" sign="-" unitRef="usd" id="ixv-28554">859</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-28555">144,693</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-28556">137,453</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Equity attributable to owners of the Company</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-28557">32,860</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-28558">34,207</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncontrollingInterests" scale="3" unitRef="usd" id="ixv-28559">51</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncontrollingInterests" scale="3" unitRef="usd" id="ixv-28560">90</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28561">32,911</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28562">34,297</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total liabilities and equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-28563">37,038</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-28564">44,302</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">*</span></td> <td style="font-size: 10pt; text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-size: 10pt">Restated following amendments to IAS 1 - see Note 2F</span></ix:footnote></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 147 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="p_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
Statements of Operations and Other Comprehensive Loss</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended December 31</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USD&#160;thousands</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USD&#160;thousands</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USD&#160;thousands</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development expenses</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-28565">7,620</ix:nonFraction></b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-28566">17,034</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-28567">16,320</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales,
    general and administrative expenses</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;14</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28568">3,183</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28569">5,237</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28570">6,283</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
    loss</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLoss" scale="3" unitRef="usd" id="ixv-28571">202</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-7; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-8; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
    Loss</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OperatingExpense" scale="3" unitRef="usd" id="ixv-28572">11,005</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OperatingExpense" scale="3" unitRef="usd" id="ixv-28573">22,271</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OperatingExpense" scale="3" unitRef="usd" id="ixv-28574">22,603</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of warrants</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15A</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="3" unitRef="usd" id="ixv-28575">3,341</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="3" unitRef="usd" id="ixv-28576">3,497</ix:nonFraction>)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-9; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    expenses</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15B</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28577">483</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28578">2,195</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28579">67</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    income</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15B</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-28580">868</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-28581">992</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-28582">910</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Finance
    income, net</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" unitRef="usd" id="ixv-28583">3,726</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" unitRef="usd" id="ixv-28584">2,294</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" unitRef="usd" id="ixv-28585">843</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss
    for the year</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28586">7,279</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28587">19,977</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28588">21,760</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
    comprehensive loss:</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Items
    that will be transferred to profit or loss:</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss (profit)
    from cash flow hedges</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeBeforeTaxCashFlowHedges" scale="3" sign="-" unitRef="usd" id="ixv-28589">19</ix:nonFraction></b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeBeforeTaxCashFlowHedges" scale="3" unitRef="usd" id="ixv-28590">25</ix:nonFraction>)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeBeforeTaxCashFlowHedges" scale="3" sign="-" unitRef="usd" id="ixv-28591">6</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
    comprehensive loss for the year</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-28592">7,298</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-28593">19,952</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-28594">21,766</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss
    attributable to:</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owners
    of the Company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-28595">7,240</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-28596">19,880</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-28597">21,668</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-controlling
    interests</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-28598">39</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-28599">97</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-28600">92</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28601">7,279</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28602">19,977</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28603">21,760</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
    comprehensive loss attributable to:</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owners
    of the Company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-28604">7,259</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-28605">19,855</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-28606">21,674</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-controlling
    interests</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-28607">39</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-28608">97</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-28609">92</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-28610">7,298</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-28611">19,952</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-28612">21,766</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss
    per share data</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    loss per ADS - USD</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-28613">4.44</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(*)<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" id="ix_1_fact" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares">17.96</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" id="ix_2_fact" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares">23.97</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
    loss per ADS - USD</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-28616">4.99</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" id="ix_3_fact" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares">17.96</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" id="ix_4_fact" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares">23.97</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of ADSs used in calculating basic loss per ADS </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-28619">1,639,566</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right">(*)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_5_fact" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares">1,106,665</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_6_fact" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares">904,054</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of ADSs used in calculating diluted loss per ADS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-28622">1,639,787</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_7_fact" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares">1,106,665</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right">(*)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_8_fact" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares">904,054</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">*</span></td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Restated to reflect a 1:20 reverse ratio of the ADS&#8217;s, that took place September 2024 (see Note 9A)</span></ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 148 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="p_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
Statements of Changes in Equity</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Share<br/>
    Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Share<br/>
    premium</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Receipts&#160;on<br/>
    account of<br/> warrants</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital<br/>
    reserve<br/> for<br/> share-<br/> based<br/> payments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital
    reserve from hedging</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital<br/>
    reserve<br/> from<br/> transactions<br/> with<br/> related<br/> parties</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital<br/>
    reserve<br/> from<br/> transactions<br/> with<br/> Non-<br/> controlling<br/> interest</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
    loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Non-<br/>
    controlling<br/> interests</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total<br/>
    equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 12%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of January&#160;1, 2024</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-10; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28625">133,184</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28626">28,467</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28627">10,088</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28628">19</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28629">761</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28630">859</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28631">137,453</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28632">34,207</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28633">90</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28634">34,297</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Transactions
    with owners of the Company:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-11; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-28635">5,065</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-12; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-28636">109</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-13; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-14; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-15; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-16; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-28637">5,174</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-17; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-28638">5,174</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant
    inducement transaction</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-28639">7,378</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" sign="-" unitRef="usd" id="ixv-28640">7,322</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-28641">100</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-28642">156</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-28643">156</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payments</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-18; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-28644">2,004</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-19; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" sign="-" unitRef="usd" id="ixv-28645">1,422</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-20; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-28646">582</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-28647">582</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    transactions with owners of the Company</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-28648">14,447</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" sign="-" unitRef="usd" id="ixv-28649">7,322</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" sign="-" unitRef="usd" id="ixv-28650">1,213</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-28651">5,912</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-28652">5,912</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    for the year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28653">7,240</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28654">7,240</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28655">39</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28656">7,279</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    comprehensive <br/> loss for the year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-28657">19</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-28658">19</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-28659">19</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of December&#160;31, 2024</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28660">147,631</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28661">21,145</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28662">8,875</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28663">761</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28664">859</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28665">144,693</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28666">32,860</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28667">51</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28668">32,911</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 149 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
Statements of Changes in Equity</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Share<br/>
    Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Share<br/>
    premium</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Receipts&#160;on<br/>
    account of<br/> warrants</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital<br/>
    reserve<br/> for<br/> share-<br/> based<br/> payments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital
    reserve from hedging</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital<br/>
    reserve<br/> from<br/> transactions<br/> with<br/> related<br/> parties</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital<br/>
    reserve<br/> from<br/> transactions<br/> with<br/> Non-<br/> controlling<br/> interest</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
    loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Non-<br/>
    controlling<br/> interests</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total<br/>
    equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 12%; font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of January&#160;1, 2023</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28669">126,407</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28670">28,017</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28671">10,164</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28672">6</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28673">761</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28674">859</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28675">117,573</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28676">46,911</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28677">187</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28678">47,098</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Transactions
    with owners of the Company:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-28679">1,045</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-28680">450</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-28681">1,495</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-28682">1,495</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">ADS issued
    in connection with the purchase of a subsidiary (see Note 4C)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" scale="3" unitRef="usd" id="ixv-28683">3,781</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" scale="3" unitRef="usd" id="ixv-28684">3,781</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" scale="3" unitRef="usd" id="ixv-28685">3,781</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payments</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-28686">1,951</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" sign="-" unitRef="usd" id="ixv-28687">76</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-28688">1,875</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-28689">1,875</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    transactions with owners of the Company</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-28690">6,777</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-28691">450</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" sign="-" unitRef="usd" id="ixv-28692">76</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-28693">7,151</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-28694">7,151</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    for the year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28695">19,880</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28696">19,880</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28697">97</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28698">19,977</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Other
    comprehensive <br/> profit for the period</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-28699">25</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-28700">25</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-28701">25</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of December&#160;31, 2023</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28702">133,184</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28703">28,467</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28704">10,088</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28705">19</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28706">761</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28707">859</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28708">137,453</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28709">34,207</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28710">90</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28711">34,297</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><!-- Field: Page; Sequence: 150 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
Statements of Changes in Equity</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Share<br/>
    Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Share<br/>
    premium</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Receipts&#160;on<br/>
    account of<br/> warrants</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital<br/>
    reserve<br/> for<br/> share-<br/> based<br/> payments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital
    reserve from hedging</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital<br/>
    reserve<br/> from<br/> transactions<br/> with<br/> related<br/> parties</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital<br/>
    reserve<br/> from<br/> transactions<br/> with<br/> Non-<br/> controlling<br/> interest</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
    loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Non-<br/>
    controlling<br/> interests</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total<br/>
    equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 12%; font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of January&#160;1, 2022</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28712">123,951</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28713">28,017</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28714">8,862</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28715">761</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28716">859</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28717">95,905</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28718">64,827</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28719">279</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28720">65,106</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Transactions
    with owners of the Company:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-28721">1,346</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-28722">1,346</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-28723">1,346</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-103; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-28724">1,110</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-104; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-28725">1,302</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-28726">2,412</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-28727">2,412</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    transactions with owners of the Company</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-110; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-28728">2,456</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-111; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-28729">1,302</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-112; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-28730">3,758</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-28731">3,758</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    for the year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28732">21,668</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28733">21,668</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28734">92</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28735">21,760</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Other
    comprehensive loss for the period</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-28736">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-28737">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-28738">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of December&#160;31, 2022</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28739">126,407</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28740">28,017</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28741">10,164</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28742">6</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28743">761</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28744">859</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-28745">117,573</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28746">46,911</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28747">187</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-28748">47,098</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 151 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="p_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
Statements of Cash Flows for the year ended December 31,</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Cash flows from operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    for the year</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperations" scale="3" unitRef="usd" id="ixv-28749">7,279</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperations" scale="3" unitRef="usd" id="ixv-28750">19,977</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperations" scale="3" unitRef="usd" id="ixv-28751">21,760</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Adjustments:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" unitRef="usd" id="ixv-28752">186</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" unitRef="usd" id="ixv-28753">197</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" unitRef="usd" id="ixv-28754">201</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Impairment
    loss</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-28755">202</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-133; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-134; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Finance
    income, net</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" unitRef="usd" id="ixv-28756">3,726</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" unitRef="usd" id="ixv-28757">2,294</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" unitRef="usd" id="ixv-28758">843</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payments</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28759">582</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28760">1,875</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-28761">2,412</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28762">10,035</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28763">20,199</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28764">19,990</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Changes
    in assets and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Changes
    in other current assets</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-28765">96</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-28766">178</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-28767">313</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Changes
    in trade payables</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" sign="-" unitRef="usd" id="ixv-28768">2,076</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" unitRef="usd" id="ixv-28769">1,334</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" unitRef="usd" id="ixv-28770">799</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Changes
    in other payables</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="3" sign="-" unitRef="usd" id="ixv-28771">2,352</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="3" sign="-" unitRef="usd" id="ixv-28772">1,076</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="3" unitRef="usd" id="ixv-28773">2,132</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Changes
    in post-employment benefit liabilities</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-135; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-28774">162</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" scale="3" unitRef="usd" id="ixv-28775">11</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:AdjustmentsForChangesInAssetsAndLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-28776">4,332</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:AdjustmentsForChangesInAssetsAndLiabilities" scale="3" unitRef="usd" id="ixv-28777">274</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:AdjustmentsForChangesInAssetsAndLiabilities" scale="3" unitRef="usd" id="ixv-28778">3,255</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28779">14,367</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28780">19,925</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-28781">16,735</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    flows from investing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Acquisition
    of subsidiary, net of cash acquired (see Note 4C)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-136; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:CashAssumedAsPartOfAcquisitionOfFamewave" scale="3" unitRef="usd" id="ixv-28782">3,549</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Proceed
    from other investments</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-28783">187</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-28784">875</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Acquisition
    of intangible asset</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-140; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-28785">202</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Decrease
    in short term deposits</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:Decreaseincreaseinshorttermdeposits" scale="3" unitRef="usd" id="ixv-28786">2</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:Decreaseincreaseinshorttermdeposits" scale="3" unitRef="usd" id="ixv-28787">15,803</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:Decreaseincreaseinshorttermdeposits" scale="3" unitRef="usd" id="ixv-28788">19,658</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Decrease
    in long term deposits</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-141; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-142; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncreaseDecreaseInLongTermDeposits" scale="3" unitRef="usd" id="ixv-28789">160</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    received</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-28790">320</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-28791">755</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-28792">324</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Acquisition
    of fixed assets</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-143; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-28793">3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-28794">26</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by investing activities</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-28795">509</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-28796">13,881</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-28797">19,914</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    flows from financing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from issuance of ADSs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-28798">5,809</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-28799">1,563</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-28800">1,498</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">ADS issuance
    expenses paid</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsForShareIssueCosts" scale="3" unitRef="usd" id="ixv-28801">556</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsForShareIssueCosts" scale="3" unitRef="usd" id="ixv-28802">229</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsForShareIssueCosts" scale="3" unitRef="usd" id="ixv-28803">152</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from issuance of warrants and prefunded warrants</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-144; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:ProceedsFromIssuingWarrants" scale="3" unitRef="usd" id="ixv-28804">5,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-145; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from warrant inducement transaction</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-28805">2,028</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-146; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-147; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Warrants
    issuance expenses paid</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:WarrantsIssuanceExpensesPaid" scale="3" unitRef="usd" id="ixv-28806">280</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:WarrantsIssuanceExpensesPaid" scale="3" unitRef="usd" id="ixv-28807">661</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-148; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Repayment
    of lease liability</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-28808">183</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-28809">168</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-28810">165</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    paid</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-28811">44</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-28812">56</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-28813">67</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-28814">6,774</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-28815">5,449</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-28816">1,114</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 152 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USD&#160;thousands</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
    increase (decrease) in cash and cash equivalents</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-28817">7,084</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-28818">595</ix:nonFraction>)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28819">4,293</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
    and cash equivalents at the beginning of the year</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28820">14,489</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28821">15,030</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28822">10,890</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect
    of translation adjustments on cash and cash equivalents</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-28823">4</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28824">54</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-28825">153</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
    and cash equivalents at end of the year</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28826">7,401</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28827">14,489</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28828">15,030</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 153 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="p_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="ixv-19893"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
1 - General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Reporting
entity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purple Biotech Ltd. (hereinafter: the &#8220;<b>Company</b>&#8221; or &#8220;<b>Purple</b>&#8221;) is a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance. The Company&#8217;s oncology pipeline includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophils extracellular traps is a novel target for the treatment of multiple cancer indications. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. CAPTN-3 is a preclinical platform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The cleavable capping technology confines the compound&#8217;s therapeutic activity to the local tumor microenvironment. The third arm specifically targets the Tumor Associated Antigen (TAA). IM1240 is the first tri-specific antibody in development that targets 5T4 expressed in a variety of solid tumors and is correlated with advanced disease, increased invasiveness, and poor clinical outcomes.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company was incorporated in Israel as a private company in August 1968, and has been listed for trading on the Tel Aviv Stock Exchange
since September 1978. In October 2012, the Company disposed of all of its previous operations, and in July 2013, the Company acquired
shares of Kitov Pharma Ltd. from its shareholders, in exchange for the Company&#8217;s shares. In December 2020 the Company changed its
name from Kitov Pharma Ltd. to Purple Biotech Ltd.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s securities (American Depository Shares (&#8220;ADS&#8221;)) were listed for trading on the NASDAQ in November 2015. Each ADS represents <ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="ppbt:AmericanDepositorySharesOrdinaryShares" scale="0" unitRef="shares" id="ixv-28829"><ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="ppbt:AmericanDepositorySharesOrdinaryShares" scale="0" unitRef="shares" id="ixv-28830">200</ix:nonFraction></ix:nonFraction> ordinary shares with <span style="-sec-ix-hidden: hidden-fact-149"><span style="-sec-ix-hidden: hidden-fact-150">no</span></span> par value following a reverse split on August 23, 2020 and &#160;September 17, 2024 (see Note 9A). Each <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-28831">200</ix:nonFraction> warrants enable the purchase of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ppbt:AmericanDepositorySharesPurchase" scale="0" unitRef="shares" id="ixv-28832">1</ix:nonFraction> ADS.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s address is 4 Oppenheimer St., Science Park Rehovot 7670104 Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2017, the Company
    acquired the majority of shares of TyrNovo Ltd. (hereinafter: &#8220;TyrNovo&#8221;). During 2018, the Company acquired additional
    shares of TyrNovo from various minority shareholders, see also Note 4A.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
January 2020, the Company acquired <ix:nonFraction contextRef="c83" decimals="2" format="ixt:num-dot-decimal" name="ppbt:PercentageOfContractToAcquire" scale="-2" unitRef="pure" id="ixv-28833">100</ix:nonFraction>% of FameWave Ltd. (hereinafter &#8220;FameWave&#8221;), see also Note 4B.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
October 28, 2021, the Company established a fully owned subsidiary Purple Biotech GmbH (hereinafter &#8220;<b>Purple GmbH</b>&#8221;)
which is currently in dissolving process following the termination of its activities in Switzerland.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
February 2023, the Company acquired <ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="ppbt:PercentageOfContractToAcquire" scale="-2" unitRef="pure" id="ixv-28834">100</ix:nonFraction>% of Immunorizon Ltd. (hereinafter &#8220;Immunorizon&#8221;), see also Note 4C.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company together with TyrNovo, FameWave, Immunorizon and Purple GmbH are referred to, in these consolidated financial statements, as
&#8220;<b>the Group</b>&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Since incorporation through December 31, 2024, the Group has incurred losses and negative cash flows from operations mainly attributed to its development efforts and has an accumulated loss of USD <ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ppbt:RetainedEarning" scale="6" unitRef="usd" id="ixv-28835">144.7</ix:nonFraction> million. The Group has financed its operations mainly through private and public financing rounds. Through December 31, 2024, the Company raised (excluding exercise of warrants) a total of USD <ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ppbt:PrivateAndPublicFinancingTotal" scale="6" unitRef="usd" id="ixv-28836">108.5</ix:nonFraction> million net of issuance expenses, see also Note 9.</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Based on the projected cash flows and
current cash balances, management currently is of the opinion that its existing cash will be sufficient to fund operations for at least
the next 12 months. Subsequently, management&#8217;s plans include pursuing out licensing, alternative financing arrangements, or reducing
expenditures as necessary to meet the Company&#8217;s future cash requirements. </p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">However, there is no assurance that, if required, the Company will be able to raise additional capital when needed, on favorable terms, or at all or reduce discretionary spending to provide the required liquidity.</p></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 154 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
1 - General (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Following
    the brutal attacks on Israel, the mobilization of army reserves and the Government declaring a state of war (&#8220;Iron Swords&#8221;
    war) in October 2023, there was a decrease in Israel&#8217;s economic and business activity. The security situation has led, inter
    alia, to a disruption in the chain of supply and production, a decrease in the volume of national transportation, a shortage in manpower
    as well as a decrease in the value of financial assets and a rise in the exchange rate of foreign currencies in relation to the shekel.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Any
    hostilities involving Israel, or the interruption or curtailment of trade within Israel or between Israel and its trading partners
    could adversely affect the Company&#8217;s operations and results of operations and could make it more difficult for the Company
    to raise capital. Both CM24 and NT219 are manufactured by service providers outside of Israel. Most of the research and development
    work is being conducted by third-party entities outside of Israel. However, a prolonged war can cause disruptions or delays to activities
    performed in Israel, as the result of shortage of staff, resulting in an adverse effect on the Company&#8217;s business, financial
    condition and results of operation.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Additionally,
    all of Company&#8217;s employees are located and reside in Israel. Shelter-in-place and work-from-home measures, government-imposed
    restrictions on movement and travel and other precautions that may be taken to address the ongoing conflict may temporarily disrupt
    the employees&#8217; ability to effectively perform the daily tasks.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <span style="font-family: Times New Roman, Times, Serif">It
    is currently not possible to predict the duration or severity of the ongoing conflict or its effects on Company&#8217;s business,
    operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt Company&#8217;s business
    and operations, interrupt the sources and availability of supply and hamper the ability to raise additional funds or sell Company&#8217;s
    securities, among others.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="ixv-20023"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
2 - Basis of Preparation of the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statement of compliance
    with International Financial Reporting Standards</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group has prepared the consolidated financial statements in accordance with IFRS Accounting Standards (hereinafter: &#8220;IFRS&#8221;),
as issued by the International Accounting Standard Board (&#8220;IASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements were approved by the board of directors on March 6, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Functional and presentation
    currency</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements are presented in US dollars (USD), which is the Group&#8217;s functional currency, rounded to the nearest
<ix:nonFraction contextRef="c0" decimals="-3" format="ixt-sec:numwordsen" name="ppbt:FunctionalCurrency" scale="3" unitRef="usd" id="ixv-28837">one</ix:nonFraction> thousand, unless otherwise noted. The USD is the currency that represents the principal economic environment in which the Group operates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of measurement</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements have been prepared on the historical cost basis except for the following assets and liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments and
    derivatives measured at fair value through profit or loss;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities for employee
    benefits</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
further information regarding the measurement of these assets and liabilities see Note 3 regarding material accounting policies.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 155 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
2 - Basis of Preparation of the Consolidated Financial Statements (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_2" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates and
    judgment</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
preparation of consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions
that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results
may differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Management
prepares the estimates on the basis of past experience, various facts, external circumstances, and reasonable assumptions according to
the pertinent circumstances of each estimate. The preparation of accounting estimates used in the preparation of the Group&#8217;s consolidated
financial statements requires management of the Group to make assumptions regarding circumstances and events that involve considerable
uncertainty. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized
in the period in which the estimates are revised and in any future periods affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Information
about assumptions made by the Group with respect to the future and other reasons for uncertainty with respect to estimates that have
a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in the next financial year are
included in the following notes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimate</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    assumptions</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 23%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Possible
    effects</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reference</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><p style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">Assessment
    of probability of contingent liabilities</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether it is more likely than not that an outflow
    of economic resources will be required in respect of legal claims pending against the Company and its investees</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reversal or creation of a provision for a claim</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For information on the Company&#8217;s exposure to
    claims see Note 12B regarding contingent liabilities</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recoverability of intangible assets</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The discounted cash flows method includes assumptions
    such as future expenses, future revenues, success rates (in respect of transition between phases of the R&amp;D of the clinical trials
    until reaching regulatory approval and marketing) and discount rate. </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of the in-process research and development
    in profit or loss</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 4 regarding Intangible assets</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Determination
of fair value </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Preparation
of the financial statements requires the Group to determine the fair value of certain assets and liabilities. The Group&#8217;s management
regularly reviews significant unobservable inputs and valuation adjustments, including obtaining valuations prepared by third parties
and assessing the evidence to support the conclusion that these valuations meet the requirements of IFRS, including the level in the
fair value hierarchy in which the valuations should be classified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">When
determining the fair value of an asset or liability, the Group uses market data as much as possible. There are three levels of fair value
measurements in the fair value hierarchy that are based on the data used in the measurement, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: quoted prices
    (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: inputs other than
    quoted prices included in Level 1 that are observable, either directly or indirectly.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: inputs that are
    not based on observable market data (unobservable inputs).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Further
information about the assumptions made in measuring fair value of share-based payments, intangible assets and financial instruments are
included in Note 10, Note 4 and Note 18, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 156 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
2 - Basis of Preparation of the Consolidated Financial Statements (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange rates and linkage
    bases</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balances
in foreign currency (mainly the New Israeli Shekel, or NIS) or linked thereto are included in the consolidated financial statements at
the representative exchange rates, as published by the Bank of Israel, which were prevailing as of the statement of financial position
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" id="ixv-20324"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Data
on exchange rates are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Representative</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">exchange rate<br/>
    of USD</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(NIS/USD
    1)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Date of consolidated financial statements:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">December 31, 2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:AverageForeignExchangeRate" scale="0" unitRef="pure" id="ixv-28838">3.647</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:AverageForeignExchangeRate" scale="0" unitRef="pure" id="ixv-28839">3.627</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:AverageForeignExchangeRate" scale="0" unitRef="pure" id="ixv-28840">3.519</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Changes in exchange rates
    for the year ended:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">December 31, 2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ppbt:PercentageOfExchangeRate" scale="-2" unitRef="pure" id="ixv-28841">0.5</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ppbt:PercentageOfExchangeRate" scale="-2" unitRef="pure" id="ixv-28842">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ppbt:PercentageOfExchangeRate" scale="-2" unitRef="pure" id="ixv-28843">13</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change in accounting
    policy</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Amendment
to IAS 1, Presentation of Financial Statements: Classification of liabilities as current or non-current &#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
amendment replaces the specific classification requirement of certain liabilities as current or non-current. According to the amendment,
a liability will be classified as non-current when the entity has a right to defer payment for a period of at least 12 months after the
reporting period, which is &#8220;substantive&#8221; (Substance) and which exists at the end of the reporting period. The amendment clarifies
that the conversion right of a liability will affect the classification of the instrument as a whole as current or non-current unless
the conversion component is equity. The amendment is affective retrospectively for reporting periods beginning on or after January 1,
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
a result of implementing the amendment, the Company changed its policy regarding the classification of warrants classified as a liability.
Prior to the implementation of the amendment, when classifying the warrants as current or non-current, the conversion options of the
counterparty were not considered. Following the implementation of the amendment, since the warrants include a conversion component, the
Company takes into account the possible date at which the warrants can be converted, when classifying the warrants as current or non-current.
Since the conversion option can be exercised within <ix:nonNumeric contextRef="c85" format="ixt-sec:durmonth" name="ppbt:StockOptionExercisedPeriod" id="ixv-28844">12</ix:nonNumeric> months after the reporting period, the Company retrospectively classified the
warrants as a current liability.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 157 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="ixv-20502"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 3
- Material Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accounting policies set out below have been consistently applied for all periods presented in these consolidated financial statements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="ppbt:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" id="ixv-20512"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of consolidation</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_2" id="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition of Subsidiaries</b></span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_3" id="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Upon
acquisition of subsidiaries, the Company evaluates whether the acquisition is considered a business acquisition or an acquisition of
an asset (or group of assets). If the Company reaches the conclusion that the subsidiary acquired is a considered a business, it accounts
for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the
acquisition is generally measured at fair value, as are the identifiable net assets acquired. Transaction costs are expensed as incurred,
except if related to the issue of debt or equity securities. If the acquired subsidiary is not considered a business, the Company accounts
for the acquisition as a purchase of assets. The Company uses the optional concentration test to determine the accounting treatment of
such acquisitions. In applying the concentration test, an entity determines whether substantially all the fair value of the gross assets
acquired is concentrated in a single asset or group of similar assets. If so, the asset is not considered a business. As of December
31, 2024, the acquisitions made by the Company were determined to be an acquisition of assets, see Note 4.&#160;</span></p></ix:continuation>

<ix:continuation continuedAt="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_4" id="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Contingent
considerations transferred for acquisition of subsidiaries are recorded when the terms and conditions for payment of the consideration
are met.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_5" id="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiaries</b></span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_6" id="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Subsidiaries
are entities controlled by the Group. The financial statements of subsidiaries are included in the consolidated financial statements
from the date on which control commences until the date on which control ceases.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_7" id="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-controlling interests</b></span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_8" id="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-controlling
interests that are instruments that give rise to a present ownership interest and entitle the holder to a share of net assets in the
event of liquidation (for example: ordinary shares), are measured at the date of the business combination at fair value.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Changes
in the Group&#8217;s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="ixv-20586"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign currency transactions</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Transactions
in foreign currencies are translated to USD which is the functional currency of Group entities at exchange rates at the dates of the
transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional
currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between its cost in
the functional currency on date of translation, and the monetary cost in foreign currency translated at the exchange rate at the end
of the year.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-monetary
items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.</span></p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 158 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
3 - Material Accounting Policies (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_2" id="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="ixv-20637"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial instruments</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-derivative financial
    assets</b></span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Initial
recognition and measurement of financial assets</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group initially recognizes debt instruments issued on the date that they are created. All other financial assets are recognized initially
on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially
measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. &#160;</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Subsequent
measurement and gains and losses</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Financial
assets at fair value through profit or loss</i></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
assets are subsequently measured at fair value. Net gains and losses, including any interest income, are recognized in profit or loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-derivative financial
    liabilities</b></span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-derivative
financial liabilities include: finance lease liabilities, accounts payables and other payables.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Initial
recognition of financial liabilities</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial
liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument.
Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value
less any directly attributable transaction costs.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Subsequent
measurement of financial liabilities</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_13" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Subsequent
to initial recognition these financial liabilities are measured at amortized cost using the effective interest method.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_14" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Derecognition
of financial liabilities</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_15" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial
liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled
or transferred to equity.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 159 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
3 - Material Accounting Policies (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_3" id="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_2"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_16" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_15"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative financial
    instruments </b></span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_17" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
part of the October 2023 and July 2024 capital raising agreements, the Company issued new warrants and amended previous warrants that
were classified as derivative financial instruments.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_18" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Measurement
of derivative financial instruments</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_19" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Derivatives
are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial
recognition, derivatives are measured at fair value, and changes therein are accounted for as described below.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_20" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these
derivatives is based on an evaluation and classified as level 3.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_21" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_20"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share capital</b></span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_22" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Ordinary
shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized
as a deduction from equity.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_23" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Incremental
costs directly attributable to an expected issuance of an instrument that will be classified as an equity instrument are recognized as
an asset in deferred expenses in the statement of financial position. The costs are deducted from equity upon the initial recognition
of the equity instruments, or are amortized as financing expenses in the statement of income when the issuance is no longer expected
to take place.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_24" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_23"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuance of parcel of
    securities</b></span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_25" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consideration received from the issuance of parcel of securities is attributed initially to financial liabilities that are measured each
period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair
value. The remaining amount is allocated to equity.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_26" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Direct
issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed
to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described
above.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_27" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
part of the October 2023 capital raising, the Company issued pre-funded warrants and amended terms for previous warrants. The Company
classified the pre-funded warrants as an equity instrument due to their negligible exercise price.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
amended terms for previously issued warrants increased the fair value of those warrants. The amended terms were part of the capital raising
and therefore the Company accounted for the increase in value as issuance cost.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 160 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Note
3 - Material Accounting Policies (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_4" id="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" id="ixv-20905"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intangible assets</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research and development</b></span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expenditure
on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized
in profit or loss when incurred.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Development
activities involves research for new or substantially improved drug candidates and processes, the manufacturing of such candidates and
the pre-clinical and clinical studies for these candidates. Development expenditure are capitalized only if development costs can be
measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group
has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are
recognized in profit and loss as expense.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other intangible assets</b></span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Other intangible assets, including
in-process research and development in respect of the Company&#8217;s acquisition of TyrNovo, Famewave, Immunorizion, and asset purchased
by Purple GmbH (see also Note 4), which have infinite useful lives, are measured at cost less accumulated impairment losses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether
events and circumstances continue to support the decision that the intangible asset has an indefinite useful life and if any impairment
may be needed.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" id="ixv-20977"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impairment</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Timing
of impairment testing</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
carrying amounts of the Group&#8217;s non-financial assets, are reviewed at each reporting date to determine whether there is any indication
of impairment. If any such indication exists, then the asset&#8217;s recoverable amount is estimated.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Once
a year and on the same date, or more frequently if there are indications of impairment, the Group estimates the recoverable amount of
each cash generating unit that contains intangible assets that have indefinite useful lives.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Measurement
of recoverable amount</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs of disposal.
In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects
the assessments of market participants regarding the time value of money and the risks specific to the asset or cash-generating unit,
for which the estimated future cash flows from the asset or cash-generating unit were not adjusted.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recognition
of impairment loss</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">An
impairment loss is recognized if the carrying amount of an asset or cash-generating unit exceeds its estimated recoverable amount. Impairment
losses are recognized in profit or loss.&#160;</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 161 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
3 - Material Accounting Policies (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_5" id="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="ixv-21064"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss per share</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group presents basic and diluted loss per share data for its ordinary share capital (including pre-funded warrants). Basic loss per share
is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding
during the year. The loss per share data is presented in the profit and loss statement as loss per ADS giving effect to the number of
<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ppbt:NumberOfShare" scale="0" unitRef="shares" id="ixv-28845">200</ix:nonFraction> shares per <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ppbt:NumberOfPerShare" scale="0" unitRef="usdPershares" id="ixv-28846">1</ix:nonFraction> ADS.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" id="ixv-21081"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee benefits</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance and pension companies,
and they are classified as defined contribution plans and as defined benefit plans.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and
has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are
recognized as an expense in profit or loss in the periods during which related services are rendered by employees.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Short-term
employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
liability is recognized for the amount expected to be paid under short-term cash bonus if the Group has a present legal or constructive
obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="ixv-21115"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-based payment transactions</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
grant date fair value of share-based payment awards granted to employees is recognized as a salary expense, with a corresponding increase
in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect
of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect
the number of awards that are expected to vest.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="ixv-21131"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Provisions</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated
reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
provision for legal claims is recognized if, as a result of a past event, the Company has a present legal or constructive obligation
and it is more likely than not that an outflow of economic benefits will be required to settle the obligation and the amount of obligation
can be estimated reliably.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 162 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Note
3 - Material Accounting Policies (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_6" id="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" id="ixv-21185"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing income and expense</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Finance
income comprises changes in the fair value of the financial liability through profit and loss, gains on changes in the fair value of
financial assets at fair value through profit or loss and income from short- term and long-term deposits, foreign currency gains, and
the reclassification of net gains and losses previously recognized in other comprehensive income on cash flow hedges of foreign currency.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Finance
expenses include loss from exchange rate differences and interest fee.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Interest
income or expense is recognized, using the effective interest method.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the statements of cash flows, interest received is presented as part of cash flows from investing activities and interest paid is presented
as part of cash flows from financing activities.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="ixv-21216"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>K.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income tax expense</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Income
tax comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that they
relate to a business combination, or are recognized directly in equity or in other comprehensive income.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Deferred
tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that
future taxable profits will be available against which they can be utilized.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company has not recognized deferred tax assets as no future taxable profits are expected in the foreseeable future.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="ixv-21243"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>L.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Leased
assets and lease liabilities</b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Contracts
that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as
leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments (these
payments do not include certain variable lease payments), and concurrently recognizes a right-to-use asset at the same amount of the
lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 163 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 3
- Material Accounting Policies (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_6"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Since
the interest rate implicit in the Group&#8217;s leases is not readily determinable, the incremental borrowing rate of the lessee is used.
Subsequent to initial recognition, the right-to-use asset is accounted for using the cost model, and depreciated over the shorter of
the lease term or useful life of the asset.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>The
lease term</b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably
certain that the lessee will or will not exercise the option, respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Depreciation
of right-to-use asset</b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">After
lease commencement, a right-to-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses
and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over contractual lease
period as follows: office lease from September 15 2020 for <ix:nonNumeric contextRef="c86" format="ixt-sec:duryear" name="ppbt:DepreciationRightofuseAssetsUsefulLife" id="ixv-28847">5</ix:nonNumeric> years and 3.5 months.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory" id="ixv-21321"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>M.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Accounting standards issued but not yet effective</b></span></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
number of new accounting standards are effective for annual reporting periods beginning after 1 January 2025 and earlier application
is permitted. However, the Group has not early adopted the following new or amended accounting standards in preparing these consolidated
financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IFRS 18 Presentation and Disclosure in Financial Statements</b></span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IFRS
18 will replace IAS 1 Presentation of Financial Statements and applies for annual reporting periods beginning on or after 1 January 2027.
The new standard introduces the following key new requirements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 1in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Entities
                                            are required to classify all income and expenses into five categories in the statement of
                                            profit or loss, namely the operating, investing, financing, discontinued operations and income
                                            tax categories. Entities are also required to present a newly-defined operating profit subtotal.
                                            Entities&#8217; net profit will not change.</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 1in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Management-defined
                                            performance measures (MPMs) are disclosed in a single note in the financial statements.</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 1in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Enhanced
                                            guidance is provided on how to group information in the financial statements.</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_8" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, all entities are required to use the operating profit subtotal as the starting point for the statement of cash flows when presenting
operating cash flows under the indirect method.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group is still in the process of assessing the impact of the new standard, particularly with respect to the structure of the Group&#8217;s
statement of profit or loss, the statement of cash flows and the additional disclosures required for MPMs. The Group is also assessing
the impact on how information is grouped in the financial statements, including for items currently labelled as &#8216;other&#8217;.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 164 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" id="ixv-21413"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 4
- Intangible Assets </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" id="ixv-21420"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>As of
December 31, 2024, and 2023:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D related to TyrNovo
    (see 4A below)</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28848">6,172</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28849">6,172</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D related to Famewave (see 4B below)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28850">14,310</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28851">14,310</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D related to Immunorizon (see 4C below)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28852">7,360</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28853">7,360</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D related to
    Purple GmbH</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-151; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28854">202</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total intangible assets</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28855">27,842</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28856">28,044</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition of Tyrnovo</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the years 2017 to 2019 the Company acquired shares in Tyrnovo, a company developing NT219.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Since
2019 the Company owns <ix:nonFraction contextRef="c87" decimals="4" format="ixt:num-dot-decimal" name="ppbt:EquityMethodInvestmentsOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-28857">98.47</ix:nonFraction>% of Tyrnovo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition of Famewave</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
January 7, 2020 the Company completed the purchase of <ix:nonFraction contextRef="c88" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" scale="-2" unitRef="pure" id="ixv-28858">100</ix:nonFraction>% of FameWave Ltd, a privately held biopharmaceutical Company developing CM24,
(&#8220;FameWave&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consideration was recorded based on the fair value of the assets purchased.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition of Immunorizon</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In February 2023 the Company completed
the acquisition of <ix:nonFraction contextRef="c89" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" scale="-2" unitRef="pure" id="ixv-28859">100</ix:nonFraction>% of Immunorizon Ltd, a privately held biotech Company developing CAPTN-3, a platform for multispecific T and NK
cell engager oncology therapies that selectively activate the immune response within the tumor microenvironment, (&#8220;Immunorizon&#8221;)
from its shareholders in consideration of an aggregate upfront payment of $<ix:nonFraction contextRef="c90" decimals="-5" format="ixt:num-dot-decimal" name="ppbt:AggregateUpfrontPayment" scale="6" unitRef="usd" id="ixv-28860">3.5</ix:nonFraction> million in cash, an aggregate of $<ix:nonFraction contextRef="c84" decimals="-5" format="ixt:num-dot-decimal" name="ppbt:AggregateUpfrontPayment" scale="6" unitRef="usd" id="ixv-28861">3.5</ix:nonFraction> million in ADSs (or
<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="ppbt:AmericanDepositorySharesOrdinaryShares" scale="0" unitRef="shares" id="ixv-28862">110,759</ix:nonFraction> ADSs representing ordinary shares at a price per ADS equal to the NASDAQ volume-weighted average price of the Company&#8217;s
ADSs for the 60-day period preceding the execution date of the agreement) with three months lock up period including a price protection
mechanism for 12 months (see Note 9D3). Additional future considerations include future payments when achieving certain long-term milestones
set at an aggregate amount of $<ix:nonFraction contextRef="c84" decimals="-6" format="ixt:num-dot-decimal" name="ppbt:LongTermMilestonesAggregateAmount" scale="6" unitRef="usd" id="ixv-28863">94</ix:nonFraction> million, including royalties on net sales. The acquisition closed on February 15, 2023. The total acquisition
amounted to $ <ix:nonFraction contextRef="c84" decimals="-5" format="ixt:num-dot-decimal" name="ppbt:TotalAcquisitionAmount" scale="6" unitRef="usd" id="ixv-28864">3.6</ix:nonFraction> million.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
acquisition was recorded based on the fair value of the consideration transferred and was accounted for as an asset purchase as it did
not meet the definition of a business combination in accordance with IFRS 3.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 165 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 4
- Intangible Assets (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Identifiable
assets acquired and liabilities assumed</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ppbt:ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="ixv-21657"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-28865">44</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Intangible asset (1)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" id="ix_9_fact" name="ifrs-full:OtherIntangibleAssets" scale="3" unitRef="usd">7,360</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other receivables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-28867">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Trade payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-28868">28</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="3" unitRef="usd" id="ixv-28869">2</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total net identifiable
    assets</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" scale="3" unitRef="usd" id="ixv-28870">7,375</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Intangible asset - In process research and development</span></ix:footnote></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top"><td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The fair value of the intangible asset recognized at the acquisition date was determined according to the fair value of the issued equity (<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ppbt:FairValueOfIssuedEquity" scale="0" unitRef="shares" id="ixv-28871">110,759</ix:nonFraction> ADSs) which amounted to USD <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueOfIssuedIntangibleAssets" scale="3" unitRef="usd" id="ixv-28872">3,781</ix:nonFraction> thousand and the cash paid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">According to the agreement, the equity issued included a price protection mechanism for a dilutive event as defined in the agreement, as well as a lock up period of three months. Following the October 2023 registered direct offering, which constituted a dilutive event, the Company issued to the former shareholders of Immunorizon an aggregate <ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="ppbt:AggregateShareholdersOfImmunorizon" scale="0" unitRef="shares" id="ixv-28873">34,974</ix:nonFraction> Additional ADSs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The fair value of equity issued was based on the assumptions below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share price - <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ppbt:SharesPrice" scale="0" unitRef="usdPershares" id="ixv-28874">1.59</ix:nonFraction></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility - <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="ppbt:DescriptionOfExpectedVolatilityPercentage" scale="-2" unitRef="pure" id="ixv-28875">70.89</ix:nonFraction>%</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual risk-free rate &#8211; <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ppbt:DescriptionOfExpectedAnnualRiskFreeRate" scale="-2" unitRef="pure" id="ixv-28876">4.5</ix:nonFraction>%</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield- <span style="-sec-ix-hidden: hidden-fact-152">0%</span></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DLOM &#8211; <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ppbt:PercentageOfDiscountsForLacksOfMarketability" scale="-2" unitRef="pure" id="ixv-28877">10.8</ix:nonFraction>%</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D</b>.</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2024 the Company impaired the IPR&amp;D related to Purple GmbH following the decision to dissolve Purple GmbH (see note 1).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E</b>.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, the recoverable amount of the in-process research and development assets (hereinafter &#8211; &#8220;intangible assets&#8221;) was based on their value in use and was determined by discounting the future cash flows to be generated from them by using the discounted cash flows method, on the annual year test. The recoverable amount of the intangible assets exceeds their carrying amount, thus no impairment loss was recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discounted cash flows model considered the risks associated with the clinical/preclinical phase of the intangible assets and the probability of success for each development phase. Certain estimations were determined using industry data reports.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discount rate used for calculating intangible assets recoverable amount was <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ppbt:IntangibleAssetsRecoverableAmountPercentage" scale="-2" unitRef="pure" id="ixv-28878">19.5</ix:nonFraction>%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company performed sensitivity analysis for estimations such as discount rate and royalty rate and concluded that the recoverable amount of the intangible assets exceeds their carrying amount.</p></td></tr> </table></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 166 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="ixv-21865"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Note
5 - Cash and Cash Equivalents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ppbt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock" id="ixv-21871"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance in USD</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28879">7,050</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28880">14,007</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance in other currencies</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c102" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28881">351</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28882">482</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total cash and cash equivalents</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28883">7,401</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28884">14,489</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfLeasesExplanatory" id="ixv-21967"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 6
&#8211; Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group has lease agreements with respect to offices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information regarding
    material lease agreements</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company entered into an agreement for the lease of offices in Rehovot as from September 15, 2020 for a period of <ix:nonNumeric contextRef="c104" format="ixt-sec:duryear" name="ppbt:AgreementLeaseTerm" id="ixv-28885">5</ix:nonNumeric> years and <ix:nonNumeric contextRef="c105" format="ixt-sec:durmonth" name="ppbt:AgreementLeaseTerm" id="ixv-28886">3.5</ix:nonNumeric> months.
Accordingly, the Company initially recognized in the statement of financial position a right-to-use asset in the amount of USD <ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" unitRef="usd" id="ixv-28887">817</ix:nonFraction> thousand
concurrently with the recognition of a lease liability in the same amount. The agreement has an option to extend the lease, for additional
<ix:nonNumeric contextRef="c86" format="ixt-sec:duryear" name="ppbt:AgreementLeaseAdditionalTerm" id="ixv-28888">5</ix:nonNumeric> years. This additional period is not included in the lease payments used-in the calculation of the liability as the Company does not
expect it is reasonably certain it will exercise the option. The Company has an option to extend the lease agreements for an additional
<ix:nonNumeric contextRef="c86" format="ixt-sec:duryear" name="ppbt:AgreementLeaseTerm" id="ixv-28889">5</ix:nonNumeric> years at the terms as those of the existing agreement with addition of <ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="ppbt:CurrentTerms" scale="-2" unitRef="pure" id="ixv-28890">5</ix:nonFraction>% to the current terms and CPI linked.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Right-to-use assets</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="ixv-22001"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">Carrying
amounts of right-to-use assets and change during the period:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Office
    lease</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2024</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="3" unitRef="usd" id="ixv-28891">316</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Depreciation on right-to-use assets</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c107" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" unitRef="usd" id="ixv-28892">152</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="3" unitRef="usd" id="ixv-28893">164</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="3" unitRef="usd" id="ixv-28894">467</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Depreciation on right-to-use assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" unitRef="usd" id="ixv-28895">151</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="3" unitRef="usd" id="ixv-28896">316</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 167 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 6
- Leases (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfLeasesExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease liability</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" id="ixv-22146"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Maturity
analysis of the Company&#8217;s lease liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Less than one year</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c111" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-28897">183</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c112" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-28898">188</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">One to two years</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-153; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c114" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-28899">188</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-28900">183</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-28901">376</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Current maturities of
    lease liability</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-28902">183</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-28903">188</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Long-term lease liability</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-154; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-28904">163</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional information
    on leases</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory" id="ixv-22362"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Amounts
recognized in profit or loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Interest expenses
    on lease liability</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" unitRef="usd" id="ixv-28905">23</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" unitRef="usd" id="ixv-28906">37</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory" id="ixv-22423"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 7
- Other Current Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ppbt:DisclosureOfOtherCurrentAssettextBlock" id="ixv-22429"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-28907">109</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-28908">171</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other receivables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-28909">275</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-28910">205</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total other current assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="3" unitRef="usd" id="ixv-28911">384</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="3" unitRef="usd" id="ixv-28912">376</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Page; Sequence: 168 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="ixv-22504"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 8
- Other Payables</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" id="ixv-22510"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Due to related parties - salary
    related</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" scale="3" unitRef="usd" id="ixv-28913">317</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" scale="3" unitRef="usd" id="ixv-28914">620</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses and other</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AccrualsClassifiedAsCurrent" scale="3" unitRef="usd" id="ixv-28915">692</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AccrualsClassifiedAsCurrent" scale="3" unitRef="usd" id="ixv-28916">2,521</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Government authorities</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentGovernmentGrants" scale="3" unitRef="usd" id="ixv-28917">65</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentGovernmentGrants" scale="3" unitRef="usd" id="ixv-28918">53</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Salary related</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:SalaryRelatedOtherPayablesCurrent" scale="3" unitRef="usd" id="ixv-28919">126</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:SalaryRelatedOtherPayablesCurrent" scale="3" unitRef="usd" id="ixv-28920">269</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentPayables" scale="3" unitRef="usd" id="ixv-28921">1,200</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentPayables" scale="3" unitRef="usd" id="ixv-28922">3,463</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="ixv-22644"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Note
9 - Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company&#8217;s authorized share capital is <ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-28923">1,000,000,000</ix:nonFraction> ordinary shares, with no par value, and <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ppbt:NonVotingSeniorPreferredShares" scale="0" unitRef="shares" id="ixv-28924">50,000,000</ix:nonFraction> non-voting senior preferred shares, with no par value, divided into 5 classes of <ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-28925">10,000,000</ix:nonFraction> preferred shares in each class.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">On September 17, 2024 the ratio between ADSs and shares was changed from <ix:nonNumeric contextRef="c0" name="ppbt:StockholdersEquityReversesStockSplit" id="ixv-28926">1:10 to 1:200</ix:nonNumeric> (each 1 ADS equal 200 shares). In these consolidated financial statements, all numbers of ADSs reflect the reverse share split and ADS ratio change retrospectively</span></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="ixv-22671"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The Company&#8217;s share capital</b></span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2024</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> paid-in</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> paid-in</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Shares, no par value</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="3" unitRef="shares" id="ixv-28927">1,000,000</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="3" unitRef="shares" id="ixv-28928">517,129</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c156" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="3" unitRef="shares" id="ixv-28929">1,000,000</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c156" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="3" unitRef="shares" id="ixv-28930">252,379</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class A preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="3" unitRef="shares" id="ixv-28931">10,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-155; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c158" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="3" unitRef="shares" id="ixv-28932">10,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-156; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class B preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c159" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="3" unitRef="shares" id="ixv-28933">10,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-157; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c160" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="3" unitRef="shares" id="ixv-28934">10,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-158; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class C preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c161" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="3" unitRef="shares" id="ixv-28935">10,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-159; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c162" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="3" unitRef="shares" id="ixv-28936">10,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-160; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class D preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c163" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="3" unitRef="shares" id="ixv-28937">10,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-161; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c164" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="3" unitRef="shares" id="ixv-28938">10,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-162; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class E preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c165" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="3" unitRef="shares" id="ixv-28939">10,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-163; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="3" unitRef="shares" id="ixv-28940">10,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-164; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 169 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Note
9 - Equity (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock-c0_cont_1" escape="true" name="ppbt:DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock" id="ixv-22982"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes in share capital during the year</b></span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(*)2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(*)2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of ADSs in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Issued as at
    January 1</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="3" unitRef="shares" id="ixv-28941">1,261</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" id="ix_10_fact" name="ifrs-full:NumberOfSharesIssued" scale="3" unitRef="shares">924</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" id="ix_11_fact" name="ifrs-full:NumberOfSharesIssued" scale="3" unitRef="shares">890</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of ADSs (See D below)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:NumberOfIssuanceShares" scale="3" unitRef="shares" id="ixv-28944">930</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_12_fact" name="ppbt:NumberOfIssuanceShares" scale="3" unitRef="shares">319</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" id="ix_13_fact" name="ppbt:NumberOfIssuanceShares" scale="3" unitRef="shares">27</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Vesting of RSUs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:NumberOfVestingOfRsus" scale="3" unitRef="shares" id="ixv-28947">16</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_14_fact" name="ppbt:NumberOfVestingOfRsus" scale="3" unitRef="shares">18</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" id="ix_15_fact" name="ppbt:NumberOfVestingOfRsus" scale="3" unitRef="shares">7</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercise
    of warrants and prefunded warrants</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:NumberOfExerciseOfWarrants" scale="3" unitRef="shares" id="ixv-28950">379</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-165; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-166; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Issued
    as at December 31</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="3" unitRef="shares" id="ixv-28951">2,586</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_16_fact" name="ifrs-full:NumberOfSharesIssued" scale="3" unitRef="shares">1,261</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" id="ix_17_fact" name="ifrs-full:NumberOfSharesIssued" scale="3" unitRef="shares">924</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>*</b></span></td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Restated to reflect a <ix:nonNumeric contextRef="c117" name="ppbt:ReverseRatio" id="ixv-28954">1:20</ix:nonNumeric> reverse ratio that took place in September 2024. (see also note 9A)</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing rounds</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On December 5, 2024, in a registered direct offering on the NASDAQ, the Company raised USD <ix:nonFraction contextRef="c118" decimals="-4" format="ixt:num-dot-decimal" name="ppbt:FundsRaisedAmount" scale="6" unitRef="usd" id="ixv-28955">2.83</ix:nonFraction> million gross (approximately USD <ix:nonFraction contextRef="c119" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="6" unitRef="usd" id="ixv-28956">2.5</ix:nonFraction> million net of placement agent fees). In this registered direct offering, the Company issued an aggregate of <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="ppbt:NumberOfNonTradableWarrants" scale="0" unitRef="shares" id="ixv-28957">472,668</ix:nonFraction> ADSs at a purchase price of USD <ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="usdPershares" id="ixv-28958">6</ix:nonFraction> per ADS that were recorded in equity in the amount of USD <ix:nonFraction contextRef="c119" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="6" unitRef="usd" id="ixv-28959">2.5</ix:nonFraction> million net of issuance expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In addition, the Company issued to the placement agent (or its designees) registered compensation warrants to purchase up to <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="ppbt:FundsRaisedshares" scale="0" unitRef="shares" id="ixv-28960">33,087</ix:nonFraction> ADSs at a value of USD <ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" unitRef="usd" id="ixv-28961">109</ix:nonFraction> thousand which is included in the net amount raised above, at an exercise price of USD <span style="-sec-ix-hidden: hidden-fact-167">7. 5</span> per ADS. The registered placement agent warrants are immediately exercisable and have a term of <ix:nonNumeric contextRef="c119" format="ixt-sec:duryear" name="ppbt:WarrantsTerm" id="ixv-28962">5</ix:nonNumeric> years from the date of the effective date of the offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On July 2, 2024 the Company raised USD&#160;<ix:nonFraction contextRef="c121" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:WarrantReserve" scale="6" unitRef="usd" id="ixv-28963">2</ix:nonFraction>&#160;million gross (approximately USD&#160;<ix:nonFraction contextRef="c122" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="6" unitRef="usd" id="ixv-28964">1.8</ix:nonFraction>&#160;million net of placement agent fees) in a warrant inducement transaction. In this transaction, the Company induced the exercise of certain existing warrants to purchase an aggregate of <ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="ppbt:NumberOfNonTradableWarrants" scale="0" unitRef="shares" id="ixv-28965">281,675</ix:nonFraction> American Depositary Shares (ADSs) of which <ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="ppbt:DepositaryShares" scale="0" unitRef="shares" id="ixv-28966">166,469</ix:nonFraction> ADSs held in abeyance. The existing warrants had original exercise prices ranging from $<ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="usdPershares" id="ixv-28967">25</ix:nonFraction> to $<ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="usdPershares" id="ixv-28968">400</ix:nonFraction> per ADS and were originally issued by the Company in October 2023, June 2020, January 2019 and June 2018. The exercise price for these existing warrants was reduced to $<ix:nonFraction contextRef="c124" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28969">7.2</ix:nonFraction> per ADS.&#160;As of December 31, 2024, no ADSs are held in abeyance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration for the exercise of the existing
warrants, the Company issued new unregistered Series A-1 warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="ppbt:PurchaseOfCommonStockAndWarrants" scale="0" unitRef="shares" id="ixv-28970">248,969</ix:nonFraction> ADSs and new unregistered
Series A-2 warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="ppbt:PurchaseOfCommonStockAndWarrants" scale="0" unitRef="shares" id="ixv-28971">314,382</ix:nonFraction> ADSs. The new warrants are immediately exercisable at an exercise price
of $<ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28972">8</ix:nonFraction> per ADS. The Series A-1 warrants have a term of five years from the issuance date and the Series A-2 warrants have a term of twenty-four
months from the issuance date. The cash received in the transaction was allocated to the new warrants, which were recorded as a liability
at their fair value adjusted, for deferred difference between the transaction price and the fair value, of USD <ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-28973">2,028</ix:nonFraction> thousand, and the
exercise of the existing warrants was treated as a reclassification from the receipt on account of warrants to share premium.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company issued to the placement agent (or its designees) unregistered compensation warrants to purchase up to <ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="ppbt:WarrantsIssued" scale="0" unitRef="shares" id="ixv-28974">19,717</ix:nonFraction> ADSs at an exercise price of USD&#160;<ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28975">9</ix:nonFraction>&#160;per ADS at value of $<ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-28976">100</ix:nonFraction> thousand. The unregistered placement agent warrants are immediately exercisable and have a term of&#160;<ix:nonNumeric contextRef="c124" format="ixt-sec:durwordsen" name="ppbt:WarrantsTerm" id="ixv-28977">five years</ix:nonNumeric>&#160;from the date of July 2, 2024.</p></td></tr>
</table></ix:continuation><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 170 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes to the Consolidated Financial Statements</b></span></p><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 9 - Equity (Cont&#8217;d)</b></span></p><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_3" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On October 19, 2023, in a registered direct offering on the NASDAQ, the Company raised USD <ix:nonFraction contextRef="c133" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:WarrantReserve" scale="6" unitRef="usd" id="ixv-28978">5</ix:nonFraction> million gross (approximately USD <ix:nonFraction contextRef="c134" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="6" unitRef="usd" id="ixv-28979">4.3</ix:nonFraction> million net of placement agent fees). In this registered direct offering, the Company issued an aggregate of <ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="ppbt:PurchaseOfCommonStockAndWarrants" scale="0" unitRef="shares" id="ixv-28980">121,500</ix:nonFraction> ADSs at a purchase price of USD <ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="usdPershares" id="ixv-28981">23</ix:nonFraction> per ADS and pre-funded warrants to purchase up to <ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="ppbt:IssuesOfEquity" scale="0" unitRef="shares" id="ixv-28982">95,891</ix:nonFraction> ADS. The Company also issued unregistered warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="ppbt:PurchaseOfCommonStockAndWarrants" scale="0" unitRef="shares" id="ixv-28983">217,391</ix:nonFraction> ADSs (hereinafter the &#8220;October 2023 warrants&#8221;) which are immediately exercisable, that were recorded as a liability at their fair value at a value of USD <ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:ExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-28984">5,348</ix:nonFraction> thousand. <ix:nonNumeric contextRef="c0" name="ppbt:WarrantTermDescription" id="ixv-28985">The October 2023 warrants have a term of five and a half years and have an exercise price of USD <ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28986">25</ix:nonFraction> per ADS</ix:nonNumeric>. During 2024, the pre-funded warrants and the October warrants were exercised as part of the warrant inducement transaction in July.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In connection with the offering and effective upon October 19, 2023, the Company amended certain existing warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="ppbt:PurchaseOfCommonStockAndWarrants" scale="0" unitRef="shares" id="ixv-28987">31,578</ix:nonFraction> ADSs that were previously issued in June 2020 and June 2018 at exercise prices of $<ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28988">180</ix:nonFraction> and $<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28989">560</ix:nonFraction> per ADS, respectively, such that the amended warrants have a reduced exercise price of $<ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28990">25</ix:nonFraction> per ADS and <ix:nonNumeric contextRef="c143" name="ppbt:WarrantTermDescription" id="ixv-28991">an extended term of five and a half years from the closing of the offering</ix:nonNumeric>. The Company recorded USD <ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="3" unitRef="usd" id="ixv-28992">761</ix:nonFraction> thousand in issuance expenses in relation to the amendment. During 2024, these warrants were exercised as part of the warrant inducement transaction in July.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In addition, the Company issued to the placement agent (or its designees) unregistered compensation warrants to purchase up to <ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="ppbt:FundsRaisedshares" scale="0" unitRef="shares" id="ixv-28993">15,217</ix:nonFraction> ADSs at a value of USD <ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" unitRef="usd" id="ixv-28994">357</ix:nonFraction> thousand at an exercise price of USD <ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28995">28.75</ix:nonFraction> per ADS. The unregistered placement agent warrants are immediately exercisable and have a term of <ix:nonNumeric contextRef="c142" format="ixt-sec:durwordsen" name="ppbt:WarrantsTerm" id="ixv-28996">five years</ix:nonNumeric> from the date of October 19, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In connection with the October 2023 Offering, the Company issued <ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="ppbt:PurchaseOfCommonStockAndWarrants" scale="0" unitRef="shares" id="ixv-28997">34,975</ix:nonFraction> ADSs pursuant to an anti-dilution mechanism of that certain Lock-Up and Registration Rights Agreements entered into with former Immunorizon shareholders in connection with the acquisition of Immunorizon in February 2023 (refer to Note 4C).</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 9, 2021, the Company entered into sales agreement with Jefferies LLC, for the sale of ADSs. In accordance with the terms of the sales agreement, the Company may offer and sell ADSs from time to time through Jefferies, acting as the Company&#8217;s agent. The Company originally filed a prospectus for a $<ix:nonFraction contextRef="c148" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceContractsIssuedThatAreAssets" scale="6" unitRef="usd" id="ixv-28998">50.0</ix:nonFraction> million &#8220;at the market&#8221; equity offering program (&#8220;ATM Program&#8221;), but the aggregate offering price was subsequently reduced to $<ix:nonFraction contextRef="c149" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="6" unitRef="usd" id="ixv-28999">21.0</ix:nonFraction> million on March 23, 2022, to $<ix:nonFraction contextRef="c150" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="6" unitRef="usd" id="ixv-29000">3.0</ix:nonFraction> million on October 17, 2023 and to $<ix:nonFraction contextRef="c151" decimals="-4" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="6" unitRef="usd" id="ixv-29001">1.33</ix:nonFraction> million on January 6 ,2025. During 2024, 2023 and 2022 the Company sold, under the ATM Program, <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ppbt:SalesAgreementShares" scale="0" unitRef="shares" id="ixv-29002">457,801</ix:nonFraction>, <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ppbt:SalesAgreementShares" scale="0" unitRef="shares" id="ixv-29003">52,202</ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ppbt:SalesAgreementShares" scale="0" unitRef="shares" id="ixv-29004">27,170</ix:nonFraction> ADSs at an average price of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" unitRef="usdPershares" id="ixv-29005">9</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" unitRef="usdPershares" id="ixv-29006">32.6</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" unitRef="usdPershares" id="ixv-29007">53</ix:nonFraction> per ADS and raised USD <ix:nonFraction contextRef="c67" decimals="-4" format="ixt:num-dot-decimal" name="ifrs-full:WarrantReserve" scale="6" unitRef="usd" id="ixv-29008">2.97</ix:nonFraction> million, USD <ix:nonFraction contextRef="c3" decimals="-4" format="ixt:num-dot-decimal" name="ifrs-full:WarrantReserve" scale="6" unitRef="usd" id="ixv-29009">1.56</ix:nonFraction> million and USD <ix:nonFraction contextRef="c46" decimals="-4" format="ixt:num-dot-decimal" name="ifrs-full:WarrantReserve" scale="6" unitRef="usd" id="ixv-29010">1.49</ix:nonFraction> million gross (approximately USD <ix:nonFraction contextRef="c0" decimals="-4" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="6" unitRef="usd" id="ixv-29011">2.85</ix:nonFraction> million, USD <ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="6" unitRef="usd" id="ixv-29012">1.5</ix:nonFraction> million and USD <ix:nonFraction contextRef="c5" decimals="-4" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="6" unitRef="usd" id="ixv-29013">1.44</ix:nonFraction> million net of placement agent fees), respectively.</span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 171 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Note
9 - Equity (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other equity transactions</b></span></td></tr> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2024, the Company issued <ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="3" unitRef="shares" id="ixv-29014">3,142</ix:nonFraction> thousand ordinary shares on account of vested RSUs granted in 2021, 2022, 2023 to officers, board members and employees.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2023, the Company issued <ix:nonFraction contextRef="c153" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="3" unitRef="shares" id="ixv-29015">3,680</ix:nonFraction> thousand ordinary shares on account of vested RSUs granted in 2021, 2022 to officers, board members and employees.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2022, the Company issued <ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="3" unitRef="shares" id="ixv-29016">1,380</ix:nonFraction> thousand ordinary shares on account of vested RSUs granted in 2020 and 2021 to officers, board members and employees.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2023 the Company
    acquired Immunoraizon &#8211; see note 4C.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-controlling interests</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ppbt:DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock" id="ixv-23419"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the information relating to Tyrnovo that has non-controlling interests of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="ppbt:noncontrollingInterests" scale="-2" unitRef="pure" id="ixv-29017">1.53</ix:nonFraction>%, before any intra-group eliminations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">TyrNovo
    Ltd.</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">in
    USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-current assets</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" unitRef="usd" id="ixv-29018">6</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" unitRef="usd" id="ixv-29019">6</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:CurrentAsset" scale="3" unitRef="usd" id="ixv-29020">184</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:CurrentAsset" scale="3" unitRef="usd" id="ixv-29021">247</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current liabilities</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:CurrentLiabiliti" scale="3" sign="-" unitRef="usd" id="ixv-29022">25,901</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:CurrentLiabiliti" scale="3" sign="-" unitRef="usd" id="ixv-29023">23,419</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net assets</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NetAssetsLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-29024">25,711</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NetAssetsLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-29025">23,166</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net assets attributable to non-controlling
    interests</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:NetAssetsAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-29026">394</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:NetAssetsAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-29027">355</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Loss for the year</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-29028">2,545</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-29029">6,365</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Loss allocated to non-controlling interests</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:NetAssetsAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-29030">39</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:NetAssetsAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-29031">97</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 172 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="ixv-23608"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 10
- Share-based Payment Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On August 15, 2024, the board of directors of the Company granted <ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29032">3,150</ix:nonFraction> thousand options (to purchase the equivalent of <ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29033">15,750</ix:nonFraction> ADSs) and <ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29034">3,150</ix:nonFraction> thousand RSUs (equivalent to <ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29035">15,750</ix:nonFraction> ADSs) to employees. The options have an exercise price of USD <ix:nonFraction contextRef="c170" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29036">0.037</ix:nonFraction> per <ix:nonFraction contextRef="c171" decimals="0" format="ixt-sec:numwordsen" name="ppbt:OptionExerciseOrdinaryShare" scale="0" unitRef="shares" id="ixv-29037">one</ix:nonFraction> ordinary share. The options and RSUs will vest over <ix:nonNumeric contextRef="c169" format="ixt-sec:duryear" name="ppbt:VestingPeriod" id="ixv-29038">3</ix:nonNumeric> years from the date of grant. The options are exercisable for <ix:nonNumeric contextRef="c167" format="ixt-sec:duryear" name="ppbt:ExercisePeriod" id="ixv-29039">5</ix:nonNumeric> years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD <ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-29040">190</ix:nonFraction> thousand. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On March 2, 2023, the board of directors of the Company granted <ix:nonFraction contextRef="c173" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29041">45</ix:nonFraction> thousand options (to purchase the equivalent of <ix:nonFraction contextRef="c174" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29042">225</ix:nonFraction> ADSs) and <ix:nonFraction contextRef="c175" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29043">45</ix:nonFraction> thousand RSUs (equivalent to <ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29044">225</ix:nonFraction> ADSs) to an employee. The options have an exercise price of USD <ix:nonFraction contextRef="c173" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29045">0.198</ix:nonFraction> per <ix:nonFraction contextRef="c177" decimals="0" format="ixt-sec:numwordsen" name="ppbt:OptionExerciseOrdinaryShare" scale="0" unitRef="shares" id="ixv-29046">one</ix:nonFraction> ordinary share. The options and RSUs will vest over <ix:nonNumeric contextRef="c175" format="ixt-sec:duryear" name="ppbt:VestingPeriod" id="ixv-29047">3</ix:nonNumeric> years from the date of grant. The options are exercisable for <ix:nonNumeric contextRef="c173" format="ixt-sec:duryear" name="ppbt:ExercisePeriod" id="ixv-29048">5</ix:nonNumeric> years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD <ix:nonFraction contextRef="c178" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-29049">16</ix:nonFraction> thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On April 24, 2023, the board of directors of the Company granted <ix:nonFraction contextRef="c179" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29050">2,732</ix:nonFraction> thousand options (to purchase the equivalent of <ix:nonFraction contextRef="c180" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29051">14</ix:nonFraction> thousand ADSs) and <ix:nonFraction contextRef="c181" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29052">2,732</ix:nonFraction> thousand RSUs (equivalent to <ix:nonFraction contextRef="c182" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29053">14</ix:nonFraction> thousand ADSs) to the Board members, subject to the approval of the shareholders, and to employees. The options have an exercise price of USD <ix:nonFraction contextRef="c179" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29054">0.190</ix:nonFraction> per <ix:nonFraction contextRef="c183" decimals="0" format="ixt-sec:numwordsen" name="ppbt:OptionExerciseOrdinaryShare" scale="0" unitRef="shares" id="ixv-29055">one</ix:nonFraction> ordinary share. The options and RSUs will vest over <ix:nonNumeric contextRef="c184" format="ixt-sec:duryear" name="ppbt:VestingPeriod" id="ixv-29056">3</ix:nonNumeric> years from the date of grant. The options are exercisable for <ix:nonNumeric contextRef="c179" format="ixt-sec:duryear" name="ppbt:ExercisePeriod" id="ixv-29057">5</ix:nonNumeric> years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD <ix:nonFraction contextRef="c185" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-29058">729</ix:nonFraction> thousand. The board members grant was approved by the shareholders on June 15, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On October 31, 2022, the board of directors of the Company granted <ix:nonFraction contextRef="c186" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29059">750</ix:nonFraction> thousand options and <ix:nonFraction contextRef="c187" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29060">750</ix:nonFraction> thousand RSUs to an employee. The options have an exercise price of USD <ix:nonFraction contextRef="c187" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29061">0.208</ix:nonFraction> per <ix:nonFraction contextRef="c188" decimals="0" format="ixt-sec:numwordsen" name="ppbt:OptionExerciseOrdinaryShare" scale="0" unitRef="shares" id="ixv-29062">one</ix:nonFraction> ordinary share. The options and RSUs will vest over <ix:nonNumeric contextRef="c187" format="ixt-sec:duryear" name="ppbt:VestingPeriod" id="ixv-29063">3</ix:nonNumeric> years from the date of grant. The options are exercisable for <ix:nonNumeric contextRef="c186" format="ixt-sec:duryear" name="ppbt:ExercisePeriod" id="ixv-29064">5</ix:nonNumeric> years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD <ix:nonFraction contextRef="c189" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-29065">267</ix:nonFraction> thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On July 11, 2022, the board of directors of the Company granted <ix:nonFraction contextRef="c190" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29066">3,750</ix:nonFraction> thousand options and <ix:nonFraction contextRef="c191" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29067">150</ix:nonFraction> thousand RSUs to the new CEO, subject to approval in the annual general meeting. The options have an exercise price of USD <ix:nonFraction contextRef="c190" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29068">0.245</ix:nonFraction> per <ix:nonFraction contextRef="c192" decimals="0" format="ixt-sec:numwordsen" name="ppbt:OptionExerciseOrdinaryShare" scale="0" unitRef="shares" id="ixv-29069">one</ix:nonFraction> ordinary share. The options and RSUs will vest over <ix:nonNumeric contextRef="c191" format="ixt-sec:duryear" name="ppbt:VestingPeriod" id="ixv-29070">3</ix:nonNumeric> years from the date of grant. The options are exercisable for <ix:nonNumeric contextRef="c190" format="ixt-sec:duryear" name="ppbt:ExercisePeriod" id="ixv-29071">5</ix:nonNumeric> years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD <ix:nonFraction contextRef="c193" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-29072">591</ix:nonFraction> thousand. This grant was approved by the shareholders on August 25, 2022.</span></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
May 23, 2022, the board of directors of the Company granted <ix:nonFraction contextRef="c194" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29073">6,635</ix:nonFraction> thousand options and <ix:nonFraction contextRef="c195" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29074">5,885</ix:nonFraction> thousand RSUs to officers and employees.
The options have an exercise price of USD <ix:nonFraction contextRef="c194" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29075">0.304</ix:nonFraction> per <ix:nonFraction contextRef="c196" decimals="0" format="ixt-sec:numwordsen" name="ppbt:OptionExerciseOrdinaryShare" scale="0" unitRef="shares" id="ixv-29076">one</ix:nonFraction> ordinary share, and for certain employee and consultant USD <ix:nonFraction contextRef="c197" decimals="3" format="ixt:num-dot-decimal" name="ppbt:ConsultantPerShares" scale="0" unitRef="usdPershares" id="ixv-29077">0.276</ix:nonFraction> per <ix:nonFraction contextRef="c198" decimals="0" format="ixt-sec:numwordsen" name="ppbt:OptionExerciseOrdinaryShare" scale="0" unitRef="shares" id="ixv-29078">one</ix:nonFraction> ordinary
share eligible as from June 23, 2022. The options and RSUs will vest over <ix:nonNumeric contextRef="c199" format="ixt-sec:duryear" name="ppbt:VestingPeriod" id="ixv-29079">3</ix:nonNumeric> years from the date of grant. The options are exercisable
for <ix:nonNumeric contextRef="c194" format="ixt-sec:duryear" name="ppbt:ExercisePeriod" id="ixv-29080">5</ix:nonNumeric> years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD <ix:nonFraction contextRef="c200" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-29081">3,237</ix:nonFraction> thousand.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 173 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 10
- Share-based Payment Arrangements (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top"><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="ixv-23682"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The number and weighted average exercise prices (in USD) of share options are as follows:</b></span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    on January 1</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29082">0.46</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29083">0.52</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29084">0.97</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-29085">19,218,783</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-29086">18,468,235</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-29087">7,751,303</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Expired
    and forfeited during the year</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29088">0.84</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29089">0.54</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29090">0.82</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29091">2,004,460</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29092">2,026,452</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29093">418,068</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted
    during the year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29094">0.037</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29095">0.19</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29096">0.28</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29097">3,150,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29098">2,777,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29099">11,135,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    on December 31</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29100">0.36</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29101">0.46</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29102">0.52</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-29103">20,364,323</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-29104">19,218,783</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-29105">18,468,235</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    on December 31</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29106">0.45</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29107">0.62</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29108">0.97</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29109">14,420,406</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29110">10,923,032</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29111">6,144,318</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The exercise price is denominated in
NIS and is re-measured using historic exchange rates. Options are exercisable to shares, each ADS represent <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ppbt:AmericanDepostioryShares" scale="0" unitRef="shares" id="ixv-29112">200</ix:nonFraction> shares.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
options outstanding at December 31, 2024 had an exercise price of USD <ix:nonFraction contextRef="c201" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29113">0.037</ix:nonFraction>- USD <ix:nonFraction contextRef="c202" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-29114">6</ix:nonFraction> (2023 - USD <ix:nonFraction contextRef="c203" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29115">0.190</ix:nonFraction>- USD <ix:nonFraction contextRef="c204" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-29116">6</ix:nonFraction>, 2022 -USD <ix:nonFraction contextRef="c205" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29117">0.208</ix:nonFraction>- USD <ix:nonFraction contextRef="c206" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-29118">6</ix:nonFraction>),
and weighted average contractual life of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-29119">2.51</ix:nonNumeric> years (2023 &#8211; <ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-29120">3.10</ix:nonNumeric> years, 2022 &#8211; <ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-29121">3.87</ix:nonNumeric> years).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock-c0_cont_1" escape="true" name="ppbt:DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock" id="ixv-24013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The number of RSUs are as follows:</b></span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29122">5,770,750</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29123">7,857,917</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Granted during the year</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" unitRef="pure" id="ixv-29124">3,150,000</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" unitRef="pure" id="ixv-29125">2,777,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Forfeited during the year</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29126">859,584</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29127">1,187,292</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Vested during the year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29128">3,142,249</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29129">3,676,875</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29130">4,918,917</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-29131">5,770,750</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">Each
RSU is convertible to <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="ppbt:ConvertibleShares" scale="0" unitRef="shares" id="ixv-29132">one</ix:nonFraction> share, each ADS represent <ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="ppbt:AmericanDepostioryShares" scale="0" unitRef="shares" id="ixv-29133">200</ix:nonFraction> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company&#8217;s
    share options granted to employees, directors and consultants, where fair value of service was not measurable, was measured using
    the binominal model, using the fair value of the traded warrants with similar terms, making certain adjustments to reflect the specific
    terms of the options based on the expected duration.&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E</b>.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="ixv-24160"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following assumptions were used<b>:</b></span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation id="_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Share Price - USD</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-29134">0.036</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-29135">0.160</ix:nonFraction>-<ix:nonFraction contextRef="c209" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-29136">0.226</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise price - USD</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-29137">0.037</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-29138">0.19</ix:nonFraction> -<ix:nonFraction contextRef="c209" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-29139">0.2</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29140">95.93</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29141">93.54</ix:nonFraction>-<ix:nonFraction contextRef="c209" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29142">96.04</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected duration (years)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" unitRef="pure" id="ixv-29143">2</ix:nonFraction>-<ix:nonFraction contextRef="c211" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" unitRef="pure" id="ixv-29144">2.8</ix:nonFraction></b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" unitRef="pure" id="ixv-29145">2</ix:nonFraction>-<ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" unitRef="pure" id="ixv-29146">5</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk free rate interest rate (%)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29147">3.88</ix:nonFraction></td><td style="font-weight: bold; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29148">3.56</ix:nonFraction>%-<ix:nonFraction contextRef="c209" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29149">4.31</ix:nonFraction>%</span></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfExpensesByNatureExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="ixv-24252"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expenses recognized in the consolidated financial statements:</b></span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfExpensesByNatureExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research and development expenses</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c212" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-29150">117</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c213" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-29151">768</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c214" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-29152">768</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative
    expenses</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-29153">465</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-29154">1,107</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-29155">1,644</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total share-based expense
    recognized</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-29156">582</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-29157">1,875</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-29158">2,412</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 174 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="ixv-24430"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 11
- Transactions and Balances with Related Parties </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition to their salaries or fees, the Group also provides share option programs to directors and officers and contributes to a post-employment
defined contribution plan on behalf of employees, see Note 8 for the balances and Note 10 regarding share-based payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
CEO is entitled to termination benefits of up to 6 monthly salaries or fees, See Note 17.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company pays the members of the board an annual fee for their service and an additional fee for serving on boards committees. In addition,
the Company pays the chairman of the board a monthly fee for his service as the chairman of our medical and clinical committee. A monthly
fee is being paid to one of the directors who has been engaged as an advisor in a <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ppbt:PercentageOfCapacityOfAnAdvisor" scale="-2" unitRef="pure" id="ixv-29159">50</ix:nonFraction>% capacity</span>, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
bonuses for certain strategic or financing transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">Expenses
of key management personnel:</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" id="ixv-24456"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Company recorded expenses to executive officers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Short - term employee benefits</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c218" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-29160">1,257</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c219" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-29161">2,066</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-29162">2,623</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Post-employment benefits</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c218" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" sign="-" unitRef="usd" id="ixv-29163">1</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c219" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" unitRef="usd" id="ixv-29164">12</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" unitRef="usd" id="ixv-29165">11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Share based payments</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c218" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-29166">378</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c219" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-29167">1,346</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-29168">1,930</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c218" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" unitRef="usd" id="ixv-29169">1,634</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c219" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" unitRef="usd" id="ixv-29170">3,424</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" unitRef="usd" id="ixv-29171">4,564</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company recorded expenses to directors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Short - term benefits</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-29172">394</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c222" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-29173">427</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-29174">448</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Share based payments</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-29175">193</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c222" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-29176">284</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-29177">311</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" unitRef="usd" id="ixv-29178">587</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c222" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" unitRef="usd" id="ixv-29179">711</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="3" unitRef="usd" id="ixv-29180">759</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="ixv-24794"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 12
- Commitments and contingent liabilities </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commitments</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TyrNovo, has obligations
    to the Israel Innovation Authority (hereinafter: &#8220;IIA&#8221;) with respect to grants it received from the IIA in connection
    with TyrNovo&#8217;s technology. The requirements and restrictions for such grants are found in the Encouragement of Research, Development
    and Technological Innovation in Industry Law 5744-1984 and in the IIA&#8217;s rules and guidelines and the terms of these grants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In general, a recipient company is
obligated to pay the IIA royalties from the revenues generated from the sale of products and related services developed as a result of,
a research and development program funded , in whole or in part, by the IIA (currently a yearly rate of <ix:nonFraction contextRef="c224" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" unitRef="pure" id="ixv-29181">3</ix:nonFraction>% to <ix:nonFraction contextRef="c225" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" unitRef="pure" id="ixv-29182">6</ix:nonFraction>%), up to the aggregate
amount of the total grants received by the IIA, plus annual interest. The recipient company is also obligated to manufacture its drug
in Israel unless it receives the approval of the IIA in which case it will be required to pay the higher rate mentioned above. A recipient
company is not required to repay the grants if it does not generate revenue.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">TyrNovo&#8217;s
technologies were developed, in part, with funds from IIA grants, and accordingly is obligated to pay royalties on sales of any of its
IIA funded products and related services.&#160; &#160;As of December 31, 2024, the maximum royalty amount that would be payable by TyrNovo,
excluding interest, is approximately NIS <ix:nonFraction contextRef="c226" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromRoyalties" scale="6" unitRef="ils" id="ixv-29183">5.5</ix:nonFraction> million (USD <ix:nonFraction contextRef="c226" decimals="-4" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromRoyalties" scale="6" unitRef="usd" id="ixv-29184">1.51</ix:nonFraction> million), and as of such date, TyrNovo had not paid any royalties to the
IIA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group does not recognize a liability for royalties because there is no reasonable assurance, as of the reporting period, that the underlying
sales will occur in the future. Therefore, the financial statements do not include a liability for these royalties.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 175 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Note
12 - Commitments and contingent liabilities (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_2" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TyrNovo has entered into a
    license agreement (the &#8220;License Agreement&#8221;) with Yissum Research Development Company of the Hebrew University of
    Jerusalem Ltd. (hereafter &#8220;Yissum&#8221;) dated August 15, 2013, as amended. In accordance with the License Agreement, Yissum
    granted the Company an exclusive license to commercialize, exploit, develop, manufacture, market, import, export, distribute, offer
    to sell, or sell products, that are derived from Yissum&#8217;s licensed technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties at a rate of up to three percent (<ix:nonFraction contextRef="c227" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" unitRef="pure" id="ixv-29185">3</ix:nonFraction>%) of net sales. </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sublicense fees at a rate of twelve percent (<ix:nonFraction contextRef="c227" decimals="2" format="ixt:num-dot-decimal" name="ppbt:PercentageOfSublicenseConsideration" scale="-2" unitRef="pure" id="ixv-29186">12</ix:nonFraction>%) of sublicense consideration.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, Yissum is entitled to receive an exit fee of <ix:nonFraction contextRef="c227" decimals="2" format="ixt:num-dot-decimal" name="ppbt:PercentageOfReceiveExitFee" scale="-2" unitRef="pure" id="ixv-29187">12</ix:nonFraction>% of the transaction proceeds in the event of certain pre - defined transactions
set forth in the License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">BIRAD
Research &amp; Development Company Ltd. (BIRAD) is entitled to receive a portion of Yissum&#8217;s royalties on net sales according to
an amendment to the License Agreement signed between TyrNovo and Yissum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements do not include a liability for royalties or sublicense fees for this license agreement as there is
no minimum payments and thus obligation will be recognized when the related sales will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">cCAM
    Biotherapeutics Ltd. (cCam), a subsidiary of Merck Sharp and Dohme Corp. (MSD), has entered into a license agreement with Tel Hashomer
    &#8211; Medical Research Infrastructure and Services Ltd. (&#8220;THM&#8221;) and Ramot at Tel Aviv University Ltd. (&#8220;Ramot&#8221;)
    dated April 16, 2012, which was effective as of May 25, 2010, as subsequently amended (the &#8220;THM License Agreement&#8221;).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
    conjunction with the closing of the reversion agreement amongst (MSD), cCAM and FameWave, the parties executed an Assignment and
    Assumption Agreement by and between FameWave and cCAM, according to which cCAM assigned to FameWave all its rights, title and interest
    in, to and under the THM License Agreement.&#160;Pursuant to the THM License Agreement, THM and Ramot granted FameWave a worldwide,
    royalty-bearing, exclusive license to develop, manufacture, produce, market and sell any biopharmaceutical product and/or diagnostic
    product using patents and inventions owned by THM and Ramot in connection with uses of the glycoprotein CEACAM1.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
consideration for the license grant, FameWave shall pay to THM the following during the term of the license:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An annual license fee of $<ix:nonFraction contextRef="c228" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:LicenceFeeIncome" scale="0" unitRef="usd" id="ixv-29188">10,000</ix:nonFraction> which is credited towards any royalties to be paid during such year.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties of three and &#160;a half percent (<ix:nonFraction contextRef="c229" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" unitRef="pure" id="ixv-29189">3.5</ix:nonFraction>%) of net sales with respect to Biopharmaceutical Products, and royalties of six and &#160;a half percent (<ix:nonFraction contextRef="c230" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" unitRef="pure" id="ixv-29190">6.5</ix:nonFraction>%) of net sales with respect to Diagnostic Products.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sublicense fees at a rate of twenty percent (<ix:nonFraction contextRef="c228" decimals="2" format="ixt:num-dot-decimal" name="ppbt:PercentageOfSublicenseConsideration" scale="-2" unitRef="pure" id="ixv-29191">20</ix:nonFraction>%) of sublicense consideration with respect to Biopharmaceutical Products, and sublicense fees at a rate of twelve percent (<ix:nonFraction contextRef="c230" decimals="2" format="ixt:num-dot-decimal" name="ppbt:PercentageOfSublicenseConsideration" scale="-2" unitRef="pure" id="ixv-29192">12</ix:nonFraction>%) of sublicense consideration with respect to Diagnostic Products.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">FameWave
has undertaken to pay certain milestone payments upon the completion of certain pre-defined clinical and sales milestones.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 176 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Note
12 - Commitments and contingent liabilities (Cont&#8217;d)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, THM (on behalf of the licensors) are entitled to receive an exit fee of up to three and a half percent (<ix:nonFraction contextRef="c228" decimals="3" format="ixt:num-dot-decimal" name="ppbt:PercentageOfReceiveExitFee" scale="-2" unitRef="pure" id="ixv-29193">3.5</ix:nonFraction>%) of all consideration
received because of or in connection with an exit event (as defined in the THM License Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Finally,
THM also received an assignable warrant to purchase, upon the closing of any IPO of FameWave, ordinary shares of FameWave, at a price
equal to a certain percentage of the forecast initial market value of FameWave for each share as determined, prior to the IPO, for the
purpose of the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
accordance with the THM License Agreement, THM is entitled to appoint an observer to FameWave&#8217;s board of directors who has all
the rights of any other director of FameWave expect for the right to vote. To date, THM has not acted on this right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements do not include a liability for royalties or sublicense fees for this license agreement as there is
no minimum payments and thus obligation will be recognized when the related sales will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Claims</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In February 2017, four lawsuits and motions to approve the lawsuits as a class action lawsuit (each, a &#8220;Motion&#8221;), were filed against the Company and certain of its office holders at the Tel Aviv District Court (Economic Division), with each Motion relating to the Company announcement that the Israeli Securities Authority (the &#8220;ISA&#8221;) has begun a formal investigation into, amongst other matters, the Company&#8217;s public disclosures around certain aspects of the studies related to its therapeutic candidate, Consensi (the &#8220;2017 Motions&#8221;). One of these motions was subsequently withdrawn. The petitioners in one of the motions petitioned the court to dismiss the other two of the 2017 Motions (&#8220;Petition for Dismissal&#8221;). On December 19, 2017 the court granted the Petition for Dismissal and dismissed the other remaining 2017 Motions. The remaining motion (the &#8220;Surviving Motion&#8221;) was filed against the Company, the Company&#8217;s executive directors and certain of its present and former directors, by certain shareholders who are requesting to act as representatives of all shareholders of record from December 10, 2015 until February 6, 2017. The plaintiffs allege, among other things, that the Company included misleading information in its public filings which caused the class for which the plaintiffs are seeking recognition an aggregate loss of approximately NIS <ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:GainsOnLitigationSettlements" scale="6" unitRef="ils" id="ixv-29194">29</ix:nonFraction> million (approximately USD <ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:GainsOnLitigationSettlements" scale="6" unitRef="usd" id="ixv-29195">8.0</ix:nonFraction> million). The court ordered a stay of proceedings due to the then-ongoing ISA Investigation. Following approval of an enforcement arrangement in connection with the ISA investigation, the stay was lifted.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
June 19, 2024, the Court issued its final decision in the 2017 Motion, whereby it fully dismissed the lawsuit against the defendants
as well as the motion to approve the lawsuit as a class action lawsuit. Each party will bear its own court expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On November 17, 2022, Fidelity Venture Capital Ltd., a private Israeli company (&#8220;Fidelity VC&#8221;) and Mr. Dror Atzmon, an Israeli resident and citizen believed to be the sole shareholder of Fidelity VC (Mr. Atzmon, together with Fidelity VC, the &#8220;Atzmon Plaintiffs&#8221;), filed a statement of claim in the Economic Division of the Tel Aviv District Court (the &#8220;Atzmon Claim&#8221;) against the Company and a number of other defendants, including our former chief executive officer. The Atzmon Plaintiffs are seeking damages for approximately NIS <ix:nonFraction contextRef="c231" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:GainsOnLitigationSettlements" scale="6" unitRef="ils" id="ixv-29196">9</ix:nonFraction> million (approximately USD <ix:nonFraction contextRef="c231" decimals="-2" format="ixt:num-dot-decimal" name="ifrs-full:GainsOnLitigationSettlements" scale="3" unitRef="usd" id="ixv-29197">2.5</ix:nonFraction> million) in connection with various claims relating to alleged contractual breaches and torts arising from an alleged contractual undertaking for the Company to engage the Atzmon Plaintiffs to provide advisory services to the Company following the initial public offering in the United States and listing on NASDAQ in November 2015.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company rejects all the claims presented in the Atzmon Claim. On August 3, 2023, the court ordered the parties to inform of their willingness to a mediation process. The parties agreed to a mediation process, a mediator has been appointed and mediation is ongoing. At this stage the Company is unable, with any degree of certainty, to make any evaluations or any assessments with respect to the probability of success or the scope of potential exposure, if any, of the Atzmon Claim.</span></p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 177 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory" id="ixv-25086"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
13 - Research and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ppbt:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock" id="ixv-25092"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Salaries, wages and related
    expenses</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29198">1,536</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c233" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29199">2,323</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c234" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29200">2,382</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Share-based payments (see also Note 10)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29201">117</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c236" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29202">768</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29203">768</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Service providers</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c238" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29204">5,967</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c239" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29205">13,943</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c240" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29206">13,170</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29207">7,620</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29208">17,034</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-29209">16,320</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.05pt; text-indent: -18.05pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory" id="ixv-25272"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 14
- Sales, General and Administrative Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.05pt; text-indent: -18.05pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" id="ixv-25278"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Salaries,
    wages and related expenses</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WagesAndSalaries" scale="3" unitRef="usd" id="ixv-29210">925</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WagesAndSalaries" scale="3" unitRef="usd" id="ixv-29211">1,769</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WagesAndSalaries" scale="3" unitRef="usd" id="ixv-29212">1,845</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payments (see also Note 10)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" unitRef="usd" id="ixv-29213">272</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" unitRef="usd" id="ixv-29214">823</ix:nonFraction></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" unitRef="usd" id="ixv-29215">1,333</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Reimbursement
    of legal fees</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:ReimbursementOfLegalFeesExpense" scale="3" unitRef="usd" id="ixv-29216">86</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:ReimbursementOfLegalFeesExpense" scale="3" unitRef="usd" id="ixv-29217">116</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:ReimbursementOfLegalFeesExpense" scale="3" unitRef="usd" id="ixv-29218">63</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Other
    professional fees</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" unitRef="usd" id="ixv-29219">772</ix:nonFraction></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" unitRef="usd" id="ixv-29220">1,005</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" unitRef="usd" id="ixv-29221">885</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Board
    member remuneration and insurance</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DirectorsRemunerationExpense" scale="3" unitRef="usd" id="ixv-29222">627</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DirectorsRemunerationExpense" scale="3" unitRef="usd" id="ixv-29223">818</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DirectorsRemunerationExpense" scale="3" unitRef="usd" id="ixv-29224">1,152</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Board
    member share-based payments (see also Note 10)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" unitRef="usd" id="ixv-29225">193</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" unitRef="usd" id="ixv-29226">284</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" unitRef="usd" id="ixv-29227">311</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Maintenance
    expenses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="3" unitRef="usd" id="ixv-29228">62</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="3" unitRef="usd" id="ixv-29229">196</ix:nonFraction></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="3" unitRef="usd" id="ixv-29230">120</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Travel
    and car expenses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TravelExpense" scale="3" unitRef="usd" id="ixv-29231">108</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TravelExpense" scale="3" unitRef="usd" id="ixv-29232">130</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TravelExpense" scale="3" unitRef="usd" id="ixv-29233">144</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-29234">186</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-29235">197</ix:nonFraction></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-29236">201</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:GeneralAndAdministrativeExpensesOther" scale="3" unitRef="usd" id="ixv-29237">124</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:GeneralAndAdministrativeExpensesOther" scale="3" unitRef="usd" id="ixv-29238">131</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:GeneralAndAdministrativeExpensesOther" scale="3" unitRef="usd" id="ixv-29239">355</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29240">3,183</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29241">5,237</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-29242">6,283</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 178 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="ixv-25661"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 15
- Finance Expense (Income), net</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.05pt; text-indent: -18.05pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Revaluation of warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The gain is related to the fair value adjustments of warrants. The 2023 and 2024 warrants included a cashless exercise feature and customary conditions in case of occurrence of a fundamental transaction. The 2023 warrants were exercised in July 2024, and 2024 warrants will expire within <ix:nonNumeric contextRef="c211" format="ixt-sec:duryear" name="ppbt:WarrantsExpireTerm" id="ixv-29243">5</ix:nonNumeric> or <ix:nonNumeric contextRef="c210" format="ixt-sec:duryear" name="ppbt:WarrantsExpireTerm" id="ixv-29244">2</ix:nonNumeric> years from issuance of those warrants (see also note 9D2).</span></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinanceCostExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinanceCostExplanatory" id="ixv-25689"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Finance expenses and income</b></span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfFinanceCostExplanatory-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Finance expenses</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Fees and interest expense</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-29245">41</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-29246">56</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-29247">67</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Loss from exchange rate differences, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ForeignExchangeLoss" scale="3" unitRef="usd" id="ixv-29248">11</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ForeignExchangeLoss" scale="3" unitRef="usd" id="ixv-29249">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Issuance expenses (see note 9D)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IssuanceExpenses" scale="3" unitRef="usd" id="ixv-29250">406</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IssuanceExpenses" scale="3" unitRef="usd" id="ixv-29251">2,126</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:OtherfinancialCost" scale="3" unitRef="usd" id="ixv-29252">25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="3" unitRef="usd" id="ixv-29253">483</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="3" unitRef="usd" id="ixv-29254">2,195</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="3" unitRef="usd" id="ixv-29255">67</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFinanceIncomeExplanatory" id="ixv-25804"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Interest income
    from deposits</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnDeposits" scale="3" unitRef="usd" id="ixv-29256">260</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnDeposits" scale="3" unitRef="usd" id="ixv-29257">474</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnDeposits" scale="3" unitRef="usd" id="ixv-29258">532</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Income from exchange rate
    differences, net</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-174; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-175; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ForeignExchangeGain" scale="3" unitRef="usd" id="ixv-29259">62</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Changes in fair value of
    finance instruments (see Note 18B2)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" scale="3" unitRef="usd" id="ixv-29260">608</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" scale="3" unitRef="usd" id="ixv-29261">517</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" scale="3" unitRef="usd" id="ixv-29262">245</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-176; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:OtherExpense" scale="3" sign="-" unitRef="usd" id="ixv-29263">1</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:OtherExpense" scale="3" sign="-" unitRef="usd" id="ixv-29264">71</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncome" scale="3" unitRef="usd" id="ixv-29265">868</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncome" scale="3" unitRef="usd" id="ixv-29266">992</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncome" scale="3" unitRef="usd" id="ixv-29267">910</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="ixv-26005"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 16
- Taxes on Income</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate tax rate</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
tax rate applicable to the Group is <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ApplicableTaxRate" scale="-2" unitRef="pure" id="ixv-29268">23</ix:nonFraction>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Carry-forward
    losses</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
    Company and its subsidiaries incurred losses through 2024, which are not expected to be utilized in the foreseeable future. Therefore,
    the Group did not record current taxes or deferred tax assets.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
2024, the main reconciling item from the statutory tax rate of the Company (<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ppbt:StatutoryTaxRate" scale="-2" unitRef="pure" id="ixv-29269">23</ix:nonFraction>%, representing a theoretical tax benefit of approximately
USD <ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" scale="6" unitRef="usd" id="ixv-29270">1.7</ix:nonFraction> million) to the effective tax rate (<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ppbt:EffectiveTaxRate" scale="-2" unitRef="pure" id="ixv-29271">0</ix:nonFraction>%) is mainly due to the fact that deferred taxes were not created in respect of current
year tax losses and benefits.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
carry-forward loss for tax purposes of the Company and its subsidiaries, and the unrecognized research and development expenses, amount
to USD <ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="ppbt:UnrecognizedResearchAndDevelopmentExpenses" scale="6" unitRef="usd" id="ixv-29272">100</ix:nonFraction> million as of December 31, 2024 (2023 &#8211; USD <ix:nonFraction contextRef="c4" decimals="-6" format="ixt:num-dot-decimal" name="ppbt:UnrecognizedResearchAndDevelopmentExpenses" scale="6" unitRef="usd" id="ixv-29273">96</ix:nonFraction> million, 2022 &#8211; USD <ix:nonFraction contextRef="c5" decimals="-6" format="ixt:num-dot-decimal" name="ppbt:UnrecognizedResearchAndDevelopmentExpenses" scale="6" unitRef="usd" id="ixv-29274">82</ix:nonFraction> million).</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 179 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" id="ixv-26075"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 17
- Employee benefits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock-c0_cont_1" escape="true" name="ppbt:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" id="ixv-26087"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefits include post-employment benefits and short-term benefits.</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">Balances
include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year ended<br/> December&#160;31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Short-term
    benefits</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-29275">331</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-29276">549</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Post-employment benefit
    liabilities</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss" scale="3" unitRef="usd" id="ixv-29277">140</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss" scale="3" unitRef="usd" id="ixv-29278">141</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Post-employment benefit
    plans &#8211; defined contribution plan</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ppbt:DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock" id="ixv-26206"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company has a defined contribution plan in respect of the Company&#8217;s liability in respect of its employees who are subject to Section
14 of the Severance Pay Law&#160;&#8211; 1963.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Amount recognized
    as expense in respect of defined contribution plan</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" scale="3" unitRef="usd" id="ixv-29279">322</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" scale="3" unitRef="usd" id="ixv-29280">401</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" scale="3" unitRef="usd" id="ixv-29281">390</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain of the Company&#8217;s executives are entitled to annual and special bonuses under the terms of their employment and consulting agreements. These bonuses will become due upon the achievement of certain goals or agreements. These consolidated financial statements include bonuses expenses in the amount of USD <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:EmployeeBenefitBonus" scale="3" unitRef="usd" id="ixv-29282">68</ix:nonFraction> thousand for the year ended December 31, 2024, USD <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:EmployeeBenefitBonus" scale="3" unitRef="usd" id="ixv-29283">446</ix:nonFraction> thousand for the year ended December 31, 2023, and USD <ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:EmployeeBenefitBonus" scale="3" unitRef="usd" id="ixv-29284">406</ix:nonFraction> thousand for the year ended December 31, 2022.&#160;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The CEO is entitled to benefits upon termination of employment, see Note 11 on related parties. These benefits are measured based on the time of service and monthly pay and the expected term of his employment. These consolidated financial statements include a liability due to these grants of USD <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:EmployeeBenefitsLiabilityDueGrants" scale="3" unitRef="usd" id="ixv-29285">140</ix:nonFraction> thousand and USD <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:EmployeeBenefitsLiabilityDueGrants" scale="3" unitRef="usd" id="ixv-29286">141</ix:nonFraction> thousand, as of December 31, 2024 and 2023, respectively.</span></td></tr> </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 180 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="ixv-26333"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
18 - Financial Instruments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Framework
for risk management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Board of Directors has overall responsibility for the establishment and oversight of the Group&#8217;s risk management framework.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group&#8217;s risk management practice was formulated to identify and analyze the risks that the Group faces, to set appropriate limits
for the risks and controls, and to monitor the risks and their compliance with the limits. The risk policy and risk management methods
are reviewed regularly to reflect changes in market conditions and in the Group&#8217;s operations. The Group acts to develop an effective
control environment in which all employees understand their roles and commitment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group Audit Committee oversees how management monitors compliance with the Group&#8217;s risk management policies and procedures, and
reviews the adequacy of the risk management framework in relation to the risks faced by the Group. The Group Audit Committee is assisted
in its oversight role by Internal Audit. Internal Audit undertakes both regular and ad hoc reviews of risk management controls and procedures,
the results of which are reported to the Audit Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk management</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1</b>.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit risk</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Credit
risk is the risk of financial loss to the Group if a debtor or counterparty to a financial instrument fails to meet its contractual obligations,
and arises mainly from the Company&#8217;s receivables. The Group restricts exposure to credit risk by investing only in bank deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group held cash and cash equivalents
and short-term deposits of USD <ix:nonFraction contextRef="c241" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-29287">8,249</ix:nonFraction> thousand at December 31, 2024 (2023 &#8211; USD <ix:nonFraction contextRef="c242" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-29288">15,339</ix:nonFraction> thousand). These are held with banks, which
are rated BBB+ or BBB-, based on S&amp;P Rating Agency ratings. The short-term deposits, mainly in USD, bear fixed interest ranging between
<ix:nonFraction contextRef="c243" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-29289">0.2</ix:nonFraction>% - <ix:nonFraction contextRef="c244" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-29290">4.46</ix:nonFraction>%.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024 the Group has an amount of USD <ix:nonFraction contextRef="c241" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:ShortTermDepositsGuaranteedForLeasesAndCredit" scale="3" unitRef="usd" id="ixv-29291">148</ix:nonFraction> thousand in short term deposits guaranteed for the Group&#8217;s leases and credit
and an amount of USD <ix:nonFraction contextRef="c241" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:ShortTermDepositsGuaranteedForHedgingTransactions" scale="3" unitRef="usd" id="ixv-29292">700</ix:nonFraction> thousand in short term deposits guaranteed for hedging transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market risk</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Market
risk is the risk that changes in market prices, such as foreign currency exchange rates, the CPI, interest rates and the prices of equity
instruments, will influence the Group&#8217;s results or the value of its holdings in financial instruments. The objective of market
risk management is to manage and control market risk exposures within acceptable parameters, while optimizing returns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group hedges the foreign currency risk exposure that derives from salary expenses by means of foreign currency derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Therefore,
as at December 31, 2024 the Group is of the opinion that these hedging relationships continue to qualify for hedge accounting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Currency risk</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group is exposed to currency risk mainly for cash and purchases for research and development expenses that are denominated in NIS and
EURO. Therefore, the Group is exposed to exchange rate fluctuations in these currencies against the dollar and takes steps to reduce
the currency risk by maintaining its liquid resources in accordance with its future needs.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 181 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 18
- Financial Instruments (Cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c258" escape="true" name="ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" id="ixv-26461"><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_2" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Sensitive
    instrument</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> &#160;(U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value<br/>
    (U.S.&#160;dollars<br/> in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents and deposits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29293">8</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c260" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29294">21</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c261" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" unitRef="usd" id="ixv-29295">423</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c262" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29296">21</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c263" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29297">8</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c264" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29298">14</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c265" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29299">35</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c266" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" unitRef="usd" id="ixv-29300">704</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c267" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29301">35</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c268" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29302">14</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c269" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29303">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c270" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29304">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c271" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" sign="-" unitRef="usd" id="ixv-29305">60</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c272" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29306">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c273" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29307">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other&#160;payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c274" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29308">14</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c275" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29309">36</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c276" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" sign="-" unitRef="usd" id="ixv-29310">723</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c277" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29311">36</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c278" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29312">14</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Post-employment benefit
    liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c279" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29313">3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c280" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29314">7</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c281" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" sign="-" unitRef="usd" id="ixv-29315">140</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c282" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29316">7</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c283" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29317">3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total&#160;income (loss)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c284" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29318">4</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c285" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29319">10</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c287" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29320">10</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c288" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29321">4</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is a sensitivity test to possible changes in USD/ EURO exchange rate as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Sensitive
    instrument</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value<br/>
    (U.S.&#160;dollars<br/> in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents and deposits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c289" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29322">1</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c290" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29323">2</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c291" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" unitRef="usd" id="ixv-29324">39</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c292" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29325">2</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c293" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29326">1</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c294" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29327">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c295" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29328">5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" sign="-" unitRef="usd" id="ixv-29329">92</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29330">5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c298" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29331">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other&#160;payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c299" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29332">1</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c300" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29333">2</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c301" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" sign="-" unitRef="usd" id="ixv-29334">50</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c302" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29335">2</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c303" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29336">1</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total&#160;income (loss)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c304" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29337">2</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c305" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29338">5</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c307" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29339">5</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c308" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29340">2</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Sensitive
    instrument</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> &#160;(U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value<br/>
    (U.S.&#160;dollars<br/> in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents and deposits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c309" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29341">11</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c310" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29342">28</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c311" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" unitRef="usd" id="ixv-29343">550</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c312" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29344">28</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c313" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29345">11</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c314" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29346">13</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c315" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29347">33</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c316" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" unitRef="usd" id="ixv-29348">660</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c317" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29349">33</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c318" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29350">13</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c319" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29351">5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c320" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29352">11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c321" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" sign="-" unitRef="usd" id="ixv-29353">225</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c322" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29354">11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c323" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29355">5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other&#160;payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c324" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29356">27</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c325" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29357">67</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c326" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" sign="-" unitRef="usd" id="ixv-29358">1,340</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c327" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29359">67</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c328" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29360">27</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Post-employment benefit
    liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c329" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29361">3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c330" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29362">7</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c331" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" sign="-" unitRef="usd" id="ixv-29363">141</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c332" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29364">7</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c333" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29365">3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total&#160;income (loss)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c334" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29366">11</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c335" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29367">24</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c337" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29368">24</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c338" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29369">11</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is a sensitivity test to possible changes in USD/ EURO exchange rate as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Sensitive
    instrument</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value<br/>
    (U.S.&#160;dollars<br/> in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents and deposits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c339" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29370">1</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c340" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" unitRef="usd" id="ixv-29371">2</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c341" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" unitRef="usd" id="ixv-29372">48</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c342" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29373">2</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c343" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" sign="-" unitRef="usd" id="ixv-29374">1</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c344" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29375">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c345" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29376">8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c346" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" sign="-" unitRef="usd" id="ixv-29377">153</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c347" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29378">8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c348" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29379">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other&#160;payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c349" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29380">5</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c350" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29381">12</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c351" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossValue" scale="3" sign="-" unitRef="usd" id="ixv-29382">232</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c352" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29383">12</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c353" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29384">5</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total&#160;income (loss)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c208" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29385">7</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c354" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateDown" scale="3" sign="-" unitRef="usd" id="ixv-29386">18</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c209" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29387">18</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c355" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:IncomelossFromChangeInExchangeRateUp" scale="3" unitRef="usd" id="ixv-29388">7</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 182 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 18
- Financial Instruments (Cont&#8217;d)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_3" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments measured
    at fair value:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The carrying amounts of certain financial assets and liabilities, including cash and cash equivalents, short term deposits, trade payables, and other payables are the same or proximate to their fair value.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify">In October 2021, the Company received a convertible note in the amount of $<ix:nonFraction contextRef="c245" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfConvertibleInstruments" scale="6" unitRef="usd" id="ixv-29389">1.5</ix:nonFraction> million and a warrant for <ix:nonFraction contextRef="c245" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:ConvertibleWarrants" scale="3" unitRef="shares" id="ixv-29390">300</ix:nonFraction> thousand Coeptis shares as part of Coeptis termination at an exercise price of $<ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="ppbt:TerminationExercisePrice" scale="0" unitRef="usdPershares" id="ixv-29391">5</ix:nonFraction> per warrant. As of December 31, 2023, the outstanding balance of the convertible note was $<ix:nonFraction contextRef="c247" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfConvertibleInstruments" scale="3" unitRef="usd" id="ixv-29392">625</ix:nonFraction> thousands.</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">On
June 19, 2024 the Company entered into a payoff agreement with Coeptis in which the Company will receive payment in the amount of $<ix:nonFraction contextRef="c248" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfConvertibleInstruments" scale="3" unitRef="usd" id="ixv-29393">219</ix:nonFraction>
thousand (received in January 2025) and <ix:nonFraction contextRef="c248" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:ConvertiblesWarrants" scale="3" unitRef="usd" id="ixv-29394">50</ix:nonFraction> thousand Coeptis shares, in lieu of the outstanding convertible note and warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">As
a result of this agreement, the financial instruments (convertible note and warrant) were derecognized as of December 31, 2024. The fair
value of these financial instruments prior to derecognition were $<ix:nonFraction contextRef="c249" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInvestments" scale="3" unitRef="usd" id="ixv-29395">73</ix:nonFraction> thousand as of December 31, 2023, and $<ix:nonFraction contextRef="c250" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInvestments" scale="3" unitRef="usd" id="ixv-29396">431</ix:nonFraction> thousand as of December
31, 2022. Additionally, the shares received were recognized as a financial asset at a fair value of USD <ix:nonFraction contextRef="c251" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FinancialAssetAtAFairValue" scale="3" unitRef="usd" id="ixv-29397">275</ix:nonFraction> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In October 2023, as part of a registered direct offering, the Company issued <ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="ppbt:WarrantsIssued" scale="0" unitRef="shares" id="ixv-29398">217,391</ix:nonFraction> warrants, and amended certain existing warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="ppbt:WarrantsIssued" scale="0" unitRef="shares" id="ixv-29399">27,777</ix:nonFraction> of the Company&#8217;s ADSs that were previously issued in June 2020 at exercise prices of $<ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="usdPershares" id="ixv-29400">180</ix:nonFraction> per ADS such that effective upon the closing of the offering the amended warrants will have a reduced exercise price of $<ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="ppbt:WarrantExercisePricePerShare" scale="0" unitRef="usdPershares" id="ixv-29401">25</ix:nonFraction> per ADS and will expire five and a one-half years from the closing date of the offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On July 2, 2024 the Company induced the exercise of certain existing warrants (Including the above October warrants) to purchase an aggregate of <ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="ppbt:DepositarysShares" scale="0" unitRef="shares" id="ixv-29402">281,675</ix:nonFraction> American Depositary Shares (ADSs). In consideration for the exercise of the existing warrants, the Company issued new unregistered Series A-1 warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="ppbt:AggregateWarrantsShares" scale="0" unitRef="shares" id="ixv-29403">248,969</ix:nonFraction> ADSs and new unregistered Series A-2 warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" name="ppbt:AggregateWarrantsShares" scale="0" unitRef="shares" id="ixv-29404">314,381</ix:nonFraction> ADSs (see Note 9D2).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The warrants were classified as a non-current financial liability as they can be settled in cash on the occurrence of Fundamental Transaction as determined in the agreement. This liability was initially recognized at its fair value on the closing date of the offering and is subsequently accounted for fair value at each balance sheet date and recorded through profit and loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of these financial instruments as of December 31, 2024
was measured at USD <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FinancialInstrumentAmount" scale="3" unitRef="usd" id="ixv-29405">1,149</ix:nonFraction> thousand (net of deferred difference of USD <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:NetOfDeferredDifferenceAmount" scale="3" unitRef="usd" id="ixv-29406">302</ix:nonFraction> thousand), (December 31, 2023 USD <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FinancialInstrumentAmount" scale="3" unitRef="usd" id="ixv-29407">2,518</ix:nonFraction> thousand).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFairValueOfFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory" id="ixv-27692"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value hierarchy of financial instruments measured at fair value:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfFairValueOfFinancialInstrumentsExplanatory-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Financial asset and liabilities</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Securities (see Note 18B (2))</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c356" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:Securities" scale="3" unitRef="usd" id="ixv-29408">275</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:Securities" scale="3" unitRef="usd" id="ixv-29409">275</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Financial liability of warrants</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c361" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" unitRef="usd" id="ixv-29410">1,149</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" unitRef="usd" id="ixv-29411">1,149</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Financial asset and liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible debt instrument and
    warrant (see Note 18B (2))</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-185; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-186; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c364" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DerivativeFinancialAssets" scale="3" unitRef="usd" id="ixv-29412">73</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DerivativeFinancialAssets" scale="3" unitRef="usd" id="ixv-29413">73</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Financial liability of
    warrants</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-187; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-188; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c364" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" unitRef="usd" id="ixv-29414">2,518</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" unitRef="usd" id="ixv-29415">2,518</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock-c0_cont_1" escape="true" name="ppbt:ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock" id="ixv-27923"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Details
regarding fair value measurement at Level 3:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Financial asset-<br/> convertible note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Financial liability-<br/> warrant</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Balance as of January 1, 2024</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c365" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementBalance" scale="3" unitRef="usd" id="ixv-29416">73</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c366" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementBalance" scale="3" unitRef="usd" id="ixv-29417">2,518</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c368" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementExercise" scale="3" sign="-" unitRef="usd" id="ixv-29418">56</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c368" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementIssuance" scale="3" unitRef="usd" id="ixv-29419">2,028</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Proceed</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c367" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementIssuanceProceed" scale="3" sign="-" unitRef="usd" id="ixv-29420">187</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revaluation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c367" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementRevaluation" scale="3" unitRef="usd" id="ixv-29421">114</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c368" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementRevaluation" scale="3" sign="-" unitRef="usd" id="ixv-29422">3,341</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Balance as of December 31, 2024</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c370" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementBalance" scale="3" unitRef="usd" id="ixv-29423">1,149</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 183 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to the Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 18
- Financial Instruments (Cont&#8217;d)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_3"><ix:continuation id="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Financial
    asset-<br/> convertible note</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Financial
    liability-<br/> warrant</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c371" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementBalance" scale="3" unitRef="usd" id="ixv-29424">431</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Issuance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c374" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementIssuance" scale="3" unitRef="usd" id="ixv-29425">6,015</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Proceed</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c373" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementIssuanceProceed" scale="3" sign="-" unitRef="usd" id="ixv-29426">875</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revaluation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c373" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementRevaluation" scale="3" unitRef="usd" id="ixv-29427">517</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c374" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementRevaluation" scale="3" sign="-" unitRef="usd" id="ixv-29428">3,497</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c365" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementBalance" scale="3" unitRef="usd" id="ixv-29429">73</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c366" decimals="-3" format="ixt:num-dot-decimal" name="ppbt:FairValueMeasurementBalance" scale="3" unitRef="usd" id="ixv-29430">2,518</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" id="ixv-28160"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    instrument</b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation<br/>
    method for<br/>
    determining <br/>
    fair value</b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant<br/>
    unobservable<br/>
    inputs</b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended December 31, 2024</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    (see note 9D1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Black
    - Scholes</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expected
    term</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c375" format="ixt-sec:duryear" name="ppbt:DescriptionOfOptionLifeShareOptionGranted" id="ixv-29431">4.5</ix:nonNumeric>, <ix:nonNumeric contextRef="c376" format="ixt-sec:duryear" name="ppbt:DescriptionOfOptionLifeShareOptionGranted" id="ixv-29432">1.5</ix:nonNumeric> years</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; width: 30%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; width: 15%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expected
    volatility</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c375" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29433">97.31</ix:nonFraction>%, <ix:nonFraction contextRef="c376" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29434">129.83</ix:nonFraction></b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"><b>%</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annual
    risk free interest</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c375" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29435">4.30</ix:nonFraction>%, <ix:nonFraction contextRef="c376" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29436">4.54</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividend
    yield</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c377" decimals="2" format="ixt:num-dot-decimal" name="ppbt:ExpectedDividendAsPercentageShareOptionsdividendYield" scale="-2" unitRef="pure" id="ixv-29437">0</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended December 31, 2023</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Black
    - Scholes</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expected
    term</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c374" format="ixt-sec:duryear" name="ppbt:DescriptionOfOptionLifeShareOptionGranted" id="ixv-29438">5.3</ix:nonNumeric> years</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expected
    volatility</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c374" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29439">89.94</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annual
    risk free interest</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c374" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29440">3.88</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividend
    yield</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c374" decimals="2" format="ixt:num-dot-decimal" name="ppbt:ExpectedDividendAsPercentageShareOptionsdividendYield" scale="-2" unitRef="pure" id="ixv-29441">0</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    debt instrument</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DLOM</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c378" decimals="3" format="ixt:num-dot-decimal" name="ppbt:Discountforlackofmarketability" scale="-2" unitRef="pure" id="ixv-29442">26.1</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="ixv-28447"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
19 - Subsequent Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;  border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">1.</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">On February 11, 2025, the board of directors of the Company agreed to grant <ix:nonFraction contextRef="c379" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29443">10,500</ix:nonFraction> thousand options (to purchase the equivalent of <ix:nonFraction contextRef="c380" decimals="-2" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29444">52.5</ix:nonFraction> thousand ADSs) and <ix:nonFraction contextRef="c381" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29445">10,500</ix:nonFraction> thousand RSUs (equivalent to <ix:nonFraction contextRef="c382" decimals="-2" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="3" unitRef="pure" id="ixv-29446">52.5</ix:nonFraction> thousand ADSs) to the Board members and CEO, subject to the approval of the shareholders. The options have an exercise price of USD <ix:nonFraction contextRef="c383" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-29447">3.40</ix:nonFraction> per one ADS. The options and RSUs will vest over <ix:nonNumeric contextRef="c384" format="ixt-sec:duryear" name="ppbt:VestingPeriod" id="ixv-29448">3</ix:nonNumeric> years from the date of grant. The options are exercisable for <ix:nonNumeric contextRef="c385" format="ixt-sec:duryear" name="ppbt:StockOptionExercisedPeriod" id="ixv-29449">5</ix:nonNumeric> years from grant date. The estimated fair value of these options and RSUs as of the board approval date was measured at USD <ix:nonFraction contextRef="c386" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-29450">282</ix:nonFraction> thousand.</span></td></tr> </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 184; Options: Last --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>






































































</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>






















































































</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c1" id="hidden-fact-0" name="dei:CityAreaCode">+972</ix:nonNumeric>
<ix:nonNumeric contextRef="c1" id="hidden-fact-1" name="dei:LocalPhoneNumber">3-933-3121</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" id="hidden-fact-2" name="dei:DocumentAccountingStandard">International Financial Reporting Standards</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="ifrs-full:NoncurrentLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-4" name="ifrs-full:IssuedCapital" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="ifrs-full:IssuedCapital" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-6" name="ifrs-full:OtherReserves" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="ifrs-full:ImpairmentLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-8" name="ifrs-full:ImpairmentLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-9" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-10" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-11" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-12" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-13" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-14" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-15" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-16" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-17" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-18" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-19" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-20" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-21" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-22" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-23" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-24" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-25" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-26" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-27" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-28" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-29" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-30" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-31" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-32" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-33" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-34" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-35" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-36" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-37" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-38" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-39" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-40" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-41" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-42" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-43" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-44" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-45" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-46" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-47" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-48" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-49" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-50" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-51" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-52" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-53" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-54" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-55" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-56" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-57" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-58" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-59" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-60" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-61" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-62" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-63" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-64" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-65" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-66" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-67" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-68" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-69" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-70" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-71" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-72" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-73" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-74" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-75" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-76" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-77" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-78" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-79" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-80" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-81" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-82" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-83" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-84" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-85" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-86" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-87" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-88" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-89" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-90" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-91" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-92" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-93" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-94" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-95" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-96" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-97" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-98" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-99" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-100" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-101" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-102" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-103" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-104" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-105" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-106" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-107" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-108" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-109" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-110" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-111" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-112" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-113" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-114" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-115" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-116" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-117" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c69" id="hidden-fact-118" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-119" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-120" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-121" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-122" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-123" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-124" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c69" id="hidden-fact-125" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-126" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-127" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-128" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-129" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-130" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-131" name="ifrs-full:OtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-132" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-133" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-134" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-135" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-136" name="ppbt:CashAssumedAsPartOfAcquisitionOfFamewave" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-137" name="ppbt:CashAssumedAsPartOfAcquisitionOfFamewave" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-138" name="ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-139" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-140" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-141" name="ppbt:IncreaseDecreaseInLongTermDeposits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-142" name="ppbt:IncreaseDecreaseInLongTermDeposits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-143" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-144" name="ppbt:ProceedsFromIssuingWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-145" name="ppbt:ProceedsFromIssuingWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-146" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-147" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-148" name="ppbt:WarrantsIssuanceExpensesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-149" name="ppbt:CommonStockNoParValues" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-150" name="ppbt:CommonStockNoParValues" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-151" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-152" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c113" id="hidden-fact-153" name="ifrs-full:LeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-154" name="ifrs-full:NoncurrentLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c157" id="hidden-fact-155" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c158" id="hidden-fact-156" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c159" id="hidden-fact-157" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c160" id="hidden-fact-158" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c161" id="hidden-fact-159" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c162" id="hidden-fact-160" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c163" id="hidden-fact-161" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c164" id="hidden-fact-162" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c165" id="hidden-fact-163" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c166" id="hidden-fact-164" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-165" name="ppbt:NumberOfExerciseOfWarrants" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-166" name="ppbt:NumberOfExerciseOfWarrants" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c120" decimals="1" id="hidden-fact-167" name="ifrs-full:ExercisePriceShareOptionsGranted2019" unitRef="usdPershares">7.5</ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-168" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-169" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-170" name="ifrs-full:ForeignExchangeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-171" name="ppbt:IssuanceExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-172" name="ppbt:OtherfinancialCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-173" name="ppbt:OtherfinancialCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-174" name="ifrs-full:ForeignExchangeGain" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-175" name="ifrs-full:ForeignExchangeGain" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-176" name="ppbt:OtherExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c286" id="hidden-fact-177" name="ppbt:IncomelossValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c306" id="hidden-fact-178" name="ppbt:IncomelossValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c336" id="hidden-fact-179" name="ppbt:IncomelossValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-180" name="ppbt:IncomelossValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c357" id="hidden-fact-181" name="ppbt:Securities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c358" id="hidden-fact-182" name="ppbt:Securities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c359" id="hidden-fact-183" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c360" id="hidden-fact-184" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c362" id="hidden-fact-185" name="ifrs-full:DerivativeFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c363" id="hidden-fact-186" name="ifrs-full:DerivativeFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c362" id="hidden-fact-187" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c363" id="hidden-fact-188" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c367" id="hidden-fact-189" name="ppbt:FairValueMeasurementExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c367" id="hidden-fact-190" name="ppbt:FairValueMeasurementIssuance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c368" id="hidden-fact-191" name="ppbt:FairValueMeasurementIssuanceProceed" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c369" id="hidden-fact-192" name="ppbt:FairValueMeasurementBalance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c372" id="hidden-fact-193" name="ppbt:FairValueMeasurementBalance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c373" id="hidden-fact-194" name="ppbt:FairValueMeasurementIssuance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c374" id="hidden-fact-195" name="ppbt:FairValueMeasurementIssuanceProceed" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-29649">0001614744</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-29650">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-29651">FY</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="ppbt-20241231.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_1_fact ix_2_fact ix_3_fact ix_4_fact ix_5_fact ix_6_fact ix_7_fact ix_8_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_9_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_10_fact ix_11_fact ix_12_fact ix_13_fact ix_14_fact ix_15_fact hidden-fact-165 hidden-fact-166 ix_16_fact ix_17_fact" toRefs="ix_3_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-23</xbrli:startDate>
    <xbrli:endDate>2020-08-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-17</xbrli:startDate>
    <xbrli:endDate>2024-09-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-08-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-01</xbrli:startDate>
    <xbrli:endDate>2023-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-15</xbrli:startDate>
    <xbrli:endDate>2020-09-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-12-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ppbt:AdsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-01</xbrli:startDate>
    <xbrli:endDate>2023-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-31</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToTryNovosee5ABelowMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToTryNovosee5ABelowMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToFamewaveSee5BBelowMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToFamewaveSee5BBelowMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToImmunorizonSee5CBelowMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToImmunorizonSee5CBelowMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToPurpleGmbHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToPurpleGmbHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">srt:OtherCurrencyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">srt:OtherCurrencyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:RehovotMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ppbt:LeaseAgreementOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-15</xbrli:startDate>
    <xbrli:endDate>2020-09-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:RehovotMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ppbt:LeaseAgreementsTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-15</xbrli:startDate>
    <xbrli:endDate>2020-09-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-05</xbrli:startDate>
    <xbrli:endDate>2024-12-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-05</xbrli:startDate>
    <xbrli:endDate>2024-12-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">ppbt:PrivatePlacementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">ppbt:PrivatePlacementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-02</xbrli:startDate>
    <xbrli:endDate>2024-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">ppbt:PublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-02</xbrli:startDate>
    <xbrli:endDate>2024-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-02</xbrli:startDate>
    <xbrli:endDate>2024-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-02</xbrli:startDate>
    <xbrli:endDate>2024-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:PublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-02</xbrli:startDate>
    <xbrli:endDate>2024-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:PublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-02</xbrli:startDate>
    <xbrli:endDate>2024-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-02</xbrli:startDate>
    <xbrli:endDate>2024-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">ppbt:PrivatePlacementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">ppbt:PrivatePlacementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-10-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:PublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-10-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:PublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-10-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-12</xbrli:startDate>
    <xbrli:endDate>2023-10-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-12</xbrli:startDate>
    <xbrli:endDate>2023-10-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-12</xbrli:startDate>
    <xbrli:endDate>2023-10-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-12</xbrli:startDate>
    <xbrli:endDate>2023-10-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-12</xbrli:startDate>
    <xbrli:endDate>2023-10-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-19</xbrli:startDate>
    <xbrli:endDate>2023-10-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-12</xbrli:startDate>
    <xbrli:endDate>2023-10-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:PublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-31</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ppbt:ATMProgramMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-23</xbrli:startDate>
    <xbrli:endDate>2022-03-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ppbt:ATMProgramMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-17</xbrli:startDate>
    <xbrli:endDate>2023-10-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ppbt:ATMProgramMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-06</xbrli:startDate>
    <xbrli:endDate>2025-01-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:OrdinaryShareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:OrdinaryShareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredShareClassMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredShareClassMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredShareClassBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredShareClassBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredClassCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredClassCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredClassDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredClassDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:ClassEPreferredSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:ClassEPreferredSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-15</xbrli:startDate>
    <xbrli:endDate>2024-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-15</xbrli:startDate>
    <xbrli:endDate>2024-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-15</xbrli:startDate>
    <xbrli:endDate>2024-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-15</xbrli:startDate>
    <xbrli:endDate>2024-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-15</xbrli:startDate>
    <xbrli:endDate>2024-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-02</xbrli:startDate>
    <xbrli:endDate>2023-03-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-02</xbrli:startDate>
    <xbrli:endDate>2023-03-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-02</xbrli:startDate>
    <xbrli:endDate>2023-03-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-02</xbrli:startDate>
    <xbrli:endDate>2023-03-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-02</xbrli:startDate>
    <xbrli:endDate>2023-03-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-24</xbrli:startDate>
    <xbrli:endDate>2023-04-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-24</xbrli:startDate>
    <xbrli:endDate>2023-04-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-24</xbrli:startDate>
    <xbrli:endDate>2023-04-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-24</xbrli:startDate>
    <xbrli:endDate>2023-04-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-24</xbrli:startDate>
    <xbrli:endDate>2023-04-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-24</xbrli:startDate>
    <xbrli:endDate>2023-04-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-31</xbrli:startDate>
    <xbrli:endDate>2022-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-31</xbrli:startDate>
    <xbrli:endDate>2022-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-31</xbrli:startDate>
    <xbrli:endDate>2022-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-11</xbrli:startDate>
    <xbrli:endDate>2022-07-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-11</xbrli:startDate>
    <xbrli:endDate>2022-07-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-11</xbrli:startDate>
    <xbrli:endDate>2022-07-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-07-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-23</xbrli:startDate>
    <xbrli:endDate>2022-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-23</xbrli:startDate>
    <xbrli:endDate>2022-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZ7uO1Q1bYM5N9HuAVhCBKc3Dilxy5HOYIdYl1h0YHGyqqhp5yL2C/pvkGqpTQ7NfV8dDJWElNwr7uGWGMl/FOCtmi0tB2eTtzKmmQ0hcQ60BPTfIvmWs+j5xoLJ2ifHK3Qzc5tu1CRRSrKp5kfOFheAU8ndp9+zFyGXNaa6jOMefzDkABcY69jtuMijqkJ3ohuLKcwkZmZewn4yToUYFOOphhxC2BFvS+tYW/ahnLboX1rpZx72Aoi] CSR-->
  <xbrli:period>
    <xbrli:startDate>2022-05-23</xbrli:startDate>
    <xbrli:endDate>2022-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">srt:OfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-23</xbrli:startDate>
    <xbrli:endDate>2022-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-23</xbrli:startDate>
    <xbrli:endDate>2022-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-23</xbrli:startDate>
    <xbrli:endDate>2022-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:RangesAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ppbt:RangesAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:TryNovosTechnologiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:YissumsLicensedTechnologyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:THMMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ppbt:BiopharmaceuticalProductMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:THMMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ppbt:DiagnosticProductsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:THMMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-07</xbrli:startDate>
    <xbrli:endDate>2022-11-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:SalariesWagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:SalariesWagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:SalariesWagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ShareBasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ShareBasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ShareBasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ServiceProvidersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ServiceProvidersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ServiceProvidersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2021-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ppbt:January2025Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-19</xbrli:startDate>
    <xbrli:endDate>2024-06-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ppbt:January2025Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ppbt:January2025Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ppbt:January2025Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-02</xbrli:startDate>
    <xbrli:endDate>2024-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:SeriesA1WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-02</xbrli:startDate>
    <xbrli:endDate>2024-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:SeriesA2WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-02</xbrli:startDate>
    <xbrli:endDate>2024-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c336">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c337">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c338">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c339">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c340">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c341">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c342">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c343">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c344">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c345">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c346">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c347">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c348">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c349">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c350">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c351">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c352">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c353">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c354">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c355">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c356">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c357">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c358">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c359">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c360">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c361">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c362">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c363">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c364">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c365">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c366">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c367">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c368">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c369">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c370">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c371">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c372">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c373">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c374">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c375">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c376">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c377">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c378">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:ConvertibleDebtInstrumentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c379">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-11</xbrli:startDate>
    <xbrli:endDate>2025-02-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c380">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ppbt:AmericanDepositorySharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-11</xbrli:startDate>
    <xbrli:endDate>2025-02-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c381">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-11</xbrli:startDate>
    <xbrli:endDate>2025-02-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c382">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ppbt:AmericanDepositorySharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-11</xbrli:startDate>
    <xbrli:endDate>2025-02-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c383">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c384">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ppbt:OptionsAndRSUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-11</xbrli:startDate>
    <xbrli:endDate>2025-02-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c385">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-11</xbrli:startDate>
    <xbrli:endDate>2025-02-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c386">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001614744</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ppbt:OptionsAndRSUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="ils">
  <xbrli:measure>iso4217:ILS</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ea023248301ex2-1_purple.htm
<DESCRIPTION>DESCRIPTION OF SHARE CAPITAL
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>DESCRIPTION OF SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following description
of our share capital and certain provisions of our articles of association are summaries and do not purport to be complete. The description
is qualified by reference to our corporate documents, copies of which are filed with the SEC as exhibits to the Annual Report on Form
20-F of which this Exhibit forms a part.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Authorized Share Capital.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized share capital
is 1,000,000,000 ordinary shares, with no par value, and 50,000,000 non-voting senior preferred shares, with no par value, divided into
5 classes of 10,000,000 preferred shares in each class. Pursuant to the approval and recommendation of our Board of Directors, we are
seeking the approval of our shareholders at the annual general meeting of shareholders scheduled to be held on April 15, 2025, to increase
our authorized ordinary share capital from 1,000,000,000 ordinary shares, with no par value, to 100,000,000,000 ordinary shares, with
no par value, and to amend our articles of association accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description
of certain rights attached to our ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Voting Rights.</I> Holders
of ordinary shares have one vote for each ordinary share held on all matters submitted to a vote of shareholders. The ordinary shares
do not have preemptive rights, preferred rights or any other right to purchase our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Foreign Ownership</I>.
Neither our amended and restated articles of association nor the laws of the State of Israel restrict the ownership or voting of ordinary
shares by non-residents of Israel, except under certain circumstances for ownership by nationals of certain countries that are, or have
been, in a state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Transfer of Shares</I>.
Our fully paid ordinary shares may generally be freely transferred under our amended and restated articles of association, unless the
transfer is restricted or prohibited by applicable law or the rules of the stock exchange on which the shares are traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Election of
Directors</I>. Under our amended and restated articles of association, the number of directors on our Board of Directors will be no
less than four and no more than nine (including any external directors, to the extent that we may be required to appoint external
directors in accordance with the Companies Law and any Regulations enacted thereunder) (&#8220;Maximum Number&#8221;). The majority
of the members of the Board shall be residents of Israel, unless our center of management shall have been transferred to another
country in accordance with a resolution of our Board by a majority of three quarters (75%) of the participating director votes. The
number of directors may be changed, at any time and from time to time, by our shareholders with a majority of (a) 75% of the voting
rights participating and voting on the matter in the applicable general meeting of our shareholders and (b) more than 47.9% of all
of the voting rights in the Company as of the record date established for the applicable general meeting of our shareholders
(&#8220;Special Majority&#8221;). In accordance with our amended and restated articles of association, the directors elected to
serve are divided into three classes, with each class comprising one-third of the members of our Board of Directors (who are not
external directors, if any were appointed), (hereinafter the &#8220;first class&#8221;; the &#8220;second class&#8221;; and the
&#8220;third class&#8221;). If the number of directors is not equally divisible by three, each of the first class and the second
class will be comprised of a different number, the closest and lowest to one-third, while the third class will be comprised of the
remaining directors (who are not external directors, if any were appointed). If the number of directors changes, the number of
directors in each class will change in accordance with the aforesaid rule. In the annual general meeting of our shareholders that
will take place each year, the shareholders shall be entitled to elect directors who shall be elected for a three-year term to
replace the class of directors whose term in office has expired as of such annual general meeting of our shareholders. Our Board of
Directors may appoint a director at any time to fill any vacancies until the annual meeting of our shareholders set to take place at
the end of the three-year term for the class of directors to which such director is so appointed by the Board, provided that the
total number of the members of the Board serving at such time will not exceed the Maximum Number. The shareholders may at all times,
by a Special Majority vote of the shareholders, dismiss a director. A director to be replaced shall be given a reasonable
opportunity to address the shareholders at their meeting. The tenure of a director expires pursuant to the provisions of our amended
and restated articles of association and the Companies Law, upon death or if s/he becomes incompetent, unless removed from office as
described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><I></I></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><I>Dividend and Liquidation
Rights</I>. Subject to preferences that may be applicable to any then outstanding preferred shares, our profits, in respect of which a
resolution was passed to distribute them as dividend or bonus shares, shall be paid pro rata to the amount of shares held by the shareholders.
See &#8220;Item 8. &#8220;Financial Information &#8211; A. Consolidated Statements and Other Financial Information &#8211; Dividend Policy&#8221;
for more details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of our liquidation,
subject to any preferences that may be applicable to any then outstanding preferred shares, after satisfaction of liabilities to creditors,
our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our amended and
restated articles of association, our Board of Directors is authorized to fix, by resolution of the Board of Directors, (i) the number
of issued preferred shares (subject to the maximum number of preferred shares authorized in such class), (ii) the designation of such
class of preferred shares, and (iii) the preferences, qualifications, and special or relative rights or privileges, which may include,
among others, dividend rights, liquidation preferences, conversion rights and redemption rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description
of certain rights attached to our preferred shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Voting Rights</I>. All
preferred shares shall be non-voting shares and shall not vest the holder thereof with any right to participate in the Company&#8217;s
general meetings, to receive notice thereof and/or to vote thereat, except as otherwise specifically required by Israeli law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">So long as any preferred shares
are outstanding, the adoption of a resolution, by a regular majority in voting power of the preferred shares who are present, entitled
to vote thereon (if any) and voting thereon, voting together as a single class, given in person or by proxy or by an authorized proxy
holder, at a meeting of holders of preferred shares shall be necessary for effecting or validating: (i) any amendment or alteration of
the memorandum of association or articles of association so as to authorize or create, or increase the authorized amount of, any class
or series of shares that will rank senior to the outstanding class or classes of preferred shares as to dividend rights and distribution
rights upon the liquidation, winding up or dissolution of our company; (ii) any amendment of any provision of our articles of association
so as to adversely affect the special rights, preferences, privileges or voting powers of the preferred shares; and (iii) any consummation
of a binding share exchange or reclassification involving the preferred shares, or of a merger or consolidation of our company with or
into another entity, unless in each case (x) the Preferred Shares remain outstanding or, in the case of any such merger or consolidation
with respect to which the Company is not the surviving or resulting entity (or the Preferred Shares are otherwise exchanged or reclassified),
are converted or reclassified into or exchanged for preferred shares of the surviving or resulting entity or its ultimate parent, and
(y) such Preferred Shares that remain outstanding or such preferred shares, as the case may be, have rights, preferences, privileges and
voting powers of the surviving or resulting entity or its ultimate parent that, taken as a whole, are not materially less favorable to
the holders thereof than the rights, preferences, privileges and voting powers, taken as a whole, of the Preferred Shares immediately
prior to the consummation of such transaction</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rules and procedures for
calling and conducting any meeting of the holders of preferred shares (including, without limitation, the fixing of a record date in connection
therewith), the solicitation and use of proxies at such a meeting, the obtaining of written consents and any other procedural aspect or
matter with regard to such a meeting or such consents shall be governed by any rules the Board of Directors, in its discretion, may adopt
from time to time, which rules and procedures shall conform to the requirements of our amended and restated articles of association, applicable
law and, if applicable, the rules of any national securities exchange or other trading facility on which the preferred shares are listed
or traded at the time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Foreign Ownership</I>.
Neither our amended and restated articles of association nor the laws of the State of Israel restrict the ownership or voting of preferred
shares by non-residents of Israel, except under certain circumstances for ownership by nationals of certain countries that are, or have
been, in a state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our fully paid preferred shares
may generally be freely transferred under our amended and restated articles of association, unless the transfer is restricted or prohibited
by applicable law or the rules of the stock exchange on which the shares are traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Conversion</I>. Subject
to the actual terms of issuance determined by our Board of Directors for any preferred shares when issued, our Preferred Shares may be
convertible into our ordinary shares or another series of preferred shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Dividend and Liquidation
Rights</I>. Issuance of preferred shares by our Board of Directors may result in such shares having dividend or liquidation preferences
senior to the rights of the holders of our ordinary shares. Each preferred share shall be entitled to receive upon distribution, and in
preference to our ordinary shares, (i) dividends in excess of the general dividends issued to all shareholders including holders of ordinary
shares, and/or (ii) amounts paid in a distribution of our surplus assets on winding up, in an amount equal to the original issue price
for such preferred shares (adjusted for share combinations or subdivisions or other recapitalizations of our shares), and less the amount
of any dividend previously paid in preference, all pro rata to the number of the preferred shares issued and outstanding at such time.
Furthermore, and after payment of the preferred shares&#8217; dividend preferences or liquidation preferences, each preferred share shall
be entitled to receive upon distribution (i) a general dividend issued to all shareholders, (ii) bonus shares, and (iii) amounts paid
in a distribution of our surplus assets on winding up, all pro rata to the total number of ordinary shares and preferred shares issued
and outstanding at such time. See above &#8220;Rights of Our Ordinary Shares&#8211;&#8211;Dividend and Liquidation Rights&#8221; for additional
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our Board of Directors
has no intention at the present time of doing so, it could authorize the issuance of a series of preferred shares that could, depending
on the terms of such series, impede the completion of a merger, tender offer, change of control or other takeover attempt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exchange Controls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no material
Israeli currency control restrictions on payments of dividends or other distributions with respect to our securities or the proceeds from
the sale of our securities, except under certain circumstances, for shareholders who are subjects of countries that are, or have been,
in a state of war with Israel or otherwise as set forth in this section. However, legislation remains in effect pursuant to which currency
controls can be imposed by administrative action at any time. Israeli residents have an obligation to file reports with the Bank of Israel
regarding certain transactions. In addition, Bank of Israel regulations require us to submit regular quarterly update reports concerning
foreign investments in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Access to Corporate Records</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, shareholders
are provided access to minutes of our general meetings, our shareholders register and principal shareholders register, our amended and
restated articles of association, our financial statements and any document that we are required by law to file publicly with the Israeli
Companies Registrar or the Israel Securities Authority. In addition, shareholders may request to be provided with any document related
to an action or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law. We may
deny this request if we believe it has not been made in good faith or if such denial is necessary to protect our interest or protect a
trade secret or patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Modification of Class Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law and
our amended and restated articles of association, the rights attached to any class of share, such as voting, liquidation and dividend
rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a separate class
meeting, or otherwise in accordance with the rights attached to such class of shares, as set forth in our amended and restated articles
of association. According to our amended and restated articles of association, the enlargement of an existing class of shares or the issuance
of additional shares thereof, shall not be deemed to modify the rights attached to the previously issued shares of such class or of any
other class, unless otherwise provided by the terms of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Acquisitions under Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Special Tender Offer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Companies
Law, an acquisition pursuant to which a purchaser will hold a &#8220;controlling stake&#8221;, that is defined as 25% or more of the voting
rights if no other shareholder holds a controlling stake, or an acquisition pursuant to which such purchaser will hold more than 45% of
the voting rights of the company if no other shareholder owns more than 45% of the voting rights, may not be performed by way of market
accumulation, but rather by way of a special tender offer (as defined in the Companies Law) made to all of the company&#8217;s shareholders
on a pro rata basis, or pursuant to a private placement approved by the company&#8217;s shareholders with the purpose of approving the
acquisition of controlling stake, or 45% or more of the company&#8217;s voting rights. In accordance with the Companies Law, such procedures
are not required if the controlling stake or 45% of the company&#8217;s voting rights are purchased from an existing holder or a controlling
stake or 45% of the company&#8217;s voting rights. A special tender offer may not be consummated unless a majority of the shareholders
who announced their stand on such offer have accepted it (in counting the total votes of such shareholders, shares held by the controlling
shareholders, shareholders who have personal interest in the offer, shareholders who own 25% or more of the voting rights in the company,
relatives or representatives of any of the above or the bidder and corporations under their control, shall not be taken into account).
A shareholder may be free to object to such an offer without such objection being deemed as a waiver of his right to sell its respective
shares if the transaction is approved by a majority of the company&#8217;s shareholders despite his objection. In such case, a shareholder
who objected to the offer may agree to sell its shares within four days from the last date provided to agree to such an offer. Shares
purchased not in accordance with those provisions will become &#8220;dormant shares&#8221; and will not grant the purchaser any rights
so long as they are held by the purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a special
tender offer is made, a company&#8217;s board of directors is required to express its opinion on the advisability of the offer, or shall
abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. In addition, the
board of directors must disclose any personal interest each member of the board of directors has in the offer or stems therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a special
tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such
controlling person or entity shall refrain from making a subsequent tender offer for the purchase of shares of the target company and
cannot execute a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person
or entity undertook to effect such an offer or merger in the initial special tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Full Tender Offer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person wishing to acquire
shares or a class of shares of an Israeli public company and who would, as a result, own more than 90% of the target company&#8217;s issued
and outstanding share capital or of certain class of its shares, is required by the Companies Law to make a full tender offer (as defined
in the Companies Law) to all of the company&#8217;s shareholders for the purchase of all of the issued and outstanding shares of the company
or class of shares. If either (i) the shareholders who do not accept the offer hold, in the aggregate, less than 5% of the issued and
outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal
interest in the offer accept the offer, or (ii) the shareholders who do not accept the offer hold less than 2% of the issued and outstanding
share capital of the company or of the applicable class, then all of the shares that the acquirer offered to purchase will be transferred
to the acquirer by operation of law. However, a shareholder that had its shares so transferred, whether or not it accepted the tender
offer (unless otherwise provided in the offering memorandum), may, within six (6) months from the date of acceptance of the tender offer,
petition the court to determine that the tender offer was for less than fair value and that the fair value should be paid as determined
by the court. If the shareholders who did not accept the tender offer hold at least 5% of the issued and outstanding share capital of
the company or of the applicable class of shares, the acquirer may not acquire shares of the company that will increase its holdings to
more than 90% of the company&#8217;s issued and outstanding share capital or of the applicable class from shareholders who accepted the
tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Mergers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law provides
that corporate mergers require the approval of both companies&#8217; boards of directors and shareholders. The board of directors of a
merging company is required pursuant to the Companies Law to discuss and determine whether in its opinion there exists a reasonable concern
that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors, taking
into account the financial status of the merging companies. If the board of directors has determined that such a concern exists, it may
not approve a proposed merger. In the event, however, that shares of the target company are held by the acquiring company or by a person
holding 25% or more of any type of controlling means of the acquiring company, the merger will not be approved if a majority of the shareholders
of the target company attending and voting at the meeting at which the merger is considered (without taking into account, for that purpose,
the shares held by the acquiring company or by a person holding 25% or more of any type of controlling means of the acquiring company)
object to and do not vote in favor of the merger. If a person holds 25% or more of any type of controlling means of more than one merging
company, the same provisions shall apply with regard to the shareholders&#8217; vote with respect to each such company. Upon the request
of a creditor of either party to the proposed merger, the court may delay or prevent the merger if the court concludes that there exists
a reasonable concern that as a result of the merger the surviving company will be unable to satisfy the target company&#8217;s obligations.
Furthermore, a merger may not close unless at least 30 days have passed from the time that the general meeting of each of the merging
companies was held and at least 50 days have passed from the date on which the merger proposal was sent to the Israeli Registrar of Companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Significant Private Placements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, if
(i) as a result of a private placement a person would become a controlling shareholder or (ii) a private placement will entitle investors
to receive 20% or more of the voting rights of a company as calculated before the private placement, and all or part of the private placement
consideration is not in cash or in public traded securities or is not in market terms and if as a result of the private placement the
holdings of a substantial shareholder shall increase or as a result of it a person shall become a substantial shareholder, then in either
case, the allotment must be approved by the board of directors and by the shareholders of the company. A &#8220;substantial shareholder&#8221;
in connection with a private placement as set forth above, is defined as a shareholder who holds five percent or more of the company&#8217;s
outstanding share capital or voting rights, and which assumes the exercise of all of the securities convertible into shares either held
by that person prior to such private placement or offered to such person under the private placement. In order for the private placement
to be on &#8220;market terms&#8221; the board of directors has to determine and explain in detail that the private placement is on market
terms, unless proven otherwise. Otherwise, under the Companies Law, a private placement of securities does not require approval at a general
meeting of the shareholders of a company; provided however, that in other special circumstances, such as a private placement completed
in lieu of a special tender offer, or a private placement under circumstances which qualifies as a related party transaction requiring
shareholder approval, approval at a general meeting of the shareholders of a company is then also required. A Registered Direct Offering
in the United States is generally considered a private placement under the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF AMERICAN DEPOSITARY SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York Mellon,
as depositary, registers and delivers the American Depositary Shares, also referred to as ADSs. Each ADS represents two hundred ordinary
shares (or a right to receive two hundred ordinary shares) deposited with Bank Hapoalim or Bank Leumi, as custodian for the depositary
in Israel. Each ADS will also represent any other securities, cash or other property which may be held by the depositary. The depositary&#8217;s
office at which the ADSs will be administered is located at 101 Barclay Street, New York, New York 10286. The Bank of New York Mellon&#8217;s
principal executive office is located at One Wall Street, New York, New York 10286.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may hold ADSs either (A)
directly (i) by having an American Depositary Receipt, also referred to as an ADR, which is a certificate evidencing a specific number
of ADSs, registered in your name, or (ii) by having uncertificated ADSs registered in your name, or (B) indirectly by holding a security
entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in The Depository Trust
Company, also called DTC. If you hold ADSs directly, you are a registered ADS holder, also referred to as an ADS holder. This description
assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution
to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out
what those procedures are.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Registered holders of uncertificated
ADSs will receive statements from the depositary confirming their holdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an ADS holder, we will
not treat you as one of our shareholders and you will not have shareholder rights. Israeli law governs shareholder rights. The depositary
will be the holder of the shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement
among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well
as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the
form of ADR. Directions on how to obtain copies of those documents are provided under the heading &#8220;Where You Can Find Additional
Information&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividends and Other Distributions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>How will you receive
dividends and other distributions on the shares?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The depositary has agreed
to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on shares or other deposited
securities, upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of shares
your ADSs represent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Cash.</B> The depositary
will convert any cash dividend or other cash distribution we pay on the shares into U.S. dollars, if it can do so on a reasonable basis
and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be
obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible
to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest
the foreign currency and it will not be liable for any interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before making a distribution,
any withholding taxes, or other governmental charges that must be paid will be deducted. See &#8220;Item 10. &#8220;Additional Information
&#8211; D. Taxation &#8211; Israeli Tax Considerations and Government Programs - Taxation of Shareholders&#8221; for more details. It
will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate
during a time when the depositary cannot convert the foreign currency, you may lose some of the value of the distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Shares.</B> The depositary
may distribute additional ADSs representing any shares we distribute as a dividend or free distribution. The depositary will only distribute
whole ADSs. It will sell shares which would require it to deliver a fraction of an ADS (or ADSs representing those shares) and distribute
the net proceeds in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will
also represent the new shares. The depositary may sell a portion of the distributed shares (or ADSs representing those shares) sufficient
to pay its fees and expenses in connection with that distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Rights to purchase additional
shares.</B> If we offer holders of our securities any rights to subscribe for additional shares or any other rights, the depositary may
(i) exercise those rights on behalf of ADS holders, (ii) distribute those rights to ADS holders or (iii) sell those rights and distribute
the net proceeds to ADS holders, in each case after deduction or upon payment of its fees and expenses. To the extent the depositary does
not do any of those things, it will allow the rights to lapse. In that case, you will receive no value for them. The depositary will exercise
or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that doing so does not require registration
of any securities under the Securities Act of 1933, as amended, or the &#8220;Securities Act.&#8221; If the depositary will exercise rights,
it will purchase the securities to which the rights relate and distribute those securities or, in the case of shares, new ADSs representing
the new shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities laws
may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain
ADS holders, and the securities distributed may be subject to restrictions on transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Other Distributions. </B>The
depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal and
practical. If it cannot make the distribution in that way, the depositary has a choice. It may decide to sell what we distributed
and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case
ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other
than ADSs) to ADS holders unless it receives satisfactory assurances from us that such distribution does not require registration of
such securities under the Securities Act. The depositary may sell a portion of the distributed securities or property sufficient to
pay its fees and expenses in connection with that distribution. U.S. securities laws may restrict the ability of the depositary to
distribute securities to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The depositary is not responsible
if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register
ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution
of ADSs, shares, rights or anything else to ADS holders. <I>This means that you may not receive the distributions we make on our shares
or any value for them if it is illegal or impractical for us to make them available to you.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Deposit, Withdrawal and Cancellation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>How are ADSs issued?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The depositary will deliver
ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian. Upon payment of its fees and expenses
and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number
of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>How can ADS holders withdraw the deposited
securities?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may surrender your ADSs
for the purpose of withdrawal at the depositary&#8217;s office. Upon payment of its fees and expenses and of any taxes or governmental
charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the shares and any other deposited securities
underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk
and expense, the depositary will deliver the deposited securities at its office, if feasible. The depositary may charge you a fee and
its expenses for instructing the custodian regarding delivery of deposited securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>How do ADS holders interchange between certificated
ADSs and uncertificated ADSs?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may surrender your ADR
to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send to
the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Alternatively, upon receipt
by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs
for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Voting Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>How do you vote?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADS holders may instruct the
depositary how to vote the number of deposited shares their ADSs represent. If we request the depositary to solicit your voting instructions
(and we are not required to do so), the depositary will notify you of a shareholders&#8217; meeting and send or make voting materials
available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary how
to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far
as practical, subject to the laws of Israel and the provisions of our articles of association or similar documents, to vote or to have
its agents vote the shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit
your voting instructions, you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but
it is not required to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Except by instructing the
depositary as described above, you won&#8217;t be able to exercise voting rights unless you surrender your ADSs and withdraw the shares.
However, you may not know about the meeting enough in advance to withdraw the shares.</I> In any event, the depositary will not exercise
any discretion in voting deposited securities and it will only vote or attempt to vote as instructed by the holder of the ADSs or as described
in the following sentence. If we asked the depositary to solicit your instructions at least 30 days before the meeting date but the depositary
does not receive voting instructions from you by the specified date, it will consider you to have authorized and directed it to give a
discretionary proxy to a person designated by us to vote the number of deposited securities represented by your ADSs. The depositary will
give a discretionary proxy in those circumstances to vote on all questions at to be voted upon unless we notify the depositary that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">we do not wish to receive a discretionary proxy;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">there is substantial shareholder opposition to the particular question; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">the particular question would have an adverse impact on our shareholders.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are required to notify
the depositary if one of the conditions specified above exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
you will receive the voting materials in time to ensure that you can instruct the depositary to vote your shares. In addition, the depositary
and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions.
<I>This means that you may not be able to exercise voting rights and there may be nothing you can do if your shares are not voted as you
requested.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to give you a reasonable
opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities, if we request the depositary
to act, we agree to give the depositary notice of any such meeting and details concerning the matters to be voted upon at least 30 days
in advance of the meeting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Fees and Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-indent: -0.125in; padding: 0.25pt 0.25pt 0.75pt 0.125in"><B><I>Persons depositing or withdrawing shares
or ADS holders must pay</I>:</B></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>For</I>:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 2%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$.05 (or less) per ADS</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any cash distribution to ADS holders</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to ADS holders</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$.05 (or less) per ADS per calendar year</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depositary services</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration or transfer fees</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the depositary</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">converting foreign currency to U.S. dollars</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As necessary </FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any charges incurred by the depositary or its agents for servicing the deposited securities</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As necessary</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The depositary collects
its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of
withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting
those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may
collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging
the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any
cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated
to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are
paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the depositary
may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program,
waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing
its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency or other service providers that are
owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The depositary may convert
foreign currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as an agent,
fiduciary or broker on behalf of any other person and earns revenue, including, without limitation, fees and spreads that it will retain
for its own account. The spread is the difference between the exchange rate assigned to the currency conversion made under the deposit
agreement and the rate that the depositary or its affiliate receives in an offsetting foreign currency trade. The depositary makes no
representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most favorable
rate that could be obtained at the time or as to the method by which that rate will be determined, subject to its obligations under the
deposit agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Payment of Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You will be responsible for
any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary
may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until those
taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes
owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the
number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid
the taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Tender and Exchange Offers; Redemption, Replacement
or Cancellation of Deposited Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The depositary will not tender
deposited securities in any voluntary tender or exchange offer unless instructed to do by an ADS holder surrendering ADSs and subject
to any conditions or procedures the depositary may establish.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If deposited securities are
redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call
for surrender of a corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of
those ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If there is any change in
the deposited securities such as a sub-division, combination or other reclassification, or any merger, consolidation, recapitalization
or reorganization affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu
of the old deposited securities, the depositary will hold those replacement securities as deposited securities under the deposit agreement.
However, if the depositary decides it would not be lawful to hold the replacement securities because those securities could not be distributed
to ADS holders or for any other reason, the depositary may instead sell the replacement securities and distribute the net proceeds upon
surrender of the ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If there is a replacement
of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs
representing the new deposited securities or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If there are no deposited
securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become
apparently worthless, the depositary may call for surrender of those ADSs or cancel those ADSs upon notice to the ADS holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Amendment and Termination</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>How may the deposit agreement be amended?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may agree with the depositary
to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except
for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar
items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary
notifies ADS holders of the amendment. <I>At the time an amendment becomes effective, you are considered, by continuing to hold your ADSs,
to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>How may the deposit agreement be terminated?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The depositary will initiate
termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">60 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">we delist our shares from an exchange on which they were listed and do not list the shares on another exchange;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">we appear to be insolvent or enter insolvency proceedings;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">there are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">there has been a replacement of deposited securities.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the deposit agreement will
terminate, the depositary will notify ADS holders at least 90 days before the termination date. At any time after the termination date,
the depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any
other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro rata benefit of the
ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the termination date
and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that
the depositary may refuse to accept a surrender for the purpose of withdrawing deposited securities if it would interfere with the selling
process. The depositary may refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities
have been sold. The depositary will continue to collect distributions on deposited securities, <U>but</U>, after the termination date,
the depositary is not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities
to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement except
as described in this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations on Obligations and Liability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The deposit agreement expressly
limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and
the depositary:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify">are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">are not liable if we are or it is prevented or delayed by law or circumstances beyond our or its control from performing our or its obligations under the deposit agreement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">are not liable if we or it exercises discretion permitted under the deposit agreement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the deposit agreement,
we and the depositary agree to indemnify each other under certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Requirements for Depositary Actions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before the depositary will
deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary may require:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify">payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any shares or other deposited securities;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The depositary may refuse
to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time
if the depositary or we think it advisable to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Right to Receive the Shares Underlying your
ADSs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADS holders have the right
to cancel their ADSs and withdraw the underlying shares at any time except:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify">when temporary delays arise because: (i) the depositary has closed its transfer books or we have closed our transfer books; (ii) the transfer of shares is blocked to permit voting at a shareholders&#8217; meeting; or (iii) we are paying a dividend on our shares;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">when you owe money to pay fees, taxes and similar charges; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of shares or other deposited securities.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This right of withdrawal may
not be limited by any other provision of the deposit agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pre-release of ADSs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The deposit agreement permits
the depositary to deliver ADSs before deposit of the underlying shares. This is called a pre-release of the ADSs. The depositary may also
deliver shares upon cancellation of pre-released ADSs (even if the ADSs are canceled before the pre-release transaction has been closed
out). A pre-release is closed out as soon as the underlying shares are delivered to the depositary. The depositary may receive ADSs instead
of shares to close out a pre-release. The depositary may pre-release ADSs only under the following conditions: (1) before or at the time
of the pre-release, the person to whom the pre-release is being made represents to the depositary in writing that it or its customer owns
the shares or ADSs to be deposited; (2) the pre-release is fully collateralized with cash or other collateral that the depositary considers
appropriate; and (3) the depositary must be able to close out the pre-release on not more than five business days&#8217; notice. In addition,
the number of ADSs that may be outstanding at any time as a result of pre-release will not normally exceed 30% of the total number of
ordinary shares deposited under the deposit agreement, although the depositary may disregard the limit from time to time if it thinks
it is appropriate to do so. The depositary has full discretion as to how and to what extent it may disregard the limit for the amount
of ADSs that may be outstanding at any time as a result of the pre-release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Direct Registration System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the deposit agreement,
all parties to the deposit agreement acknowledge that the Direct Registration System, also referred to as DRS, and Profile Modification
System, also referred to as Profile, will apply to the ADSs. DRS is a system administered by DTC that facilitates interchange between
registered holding of uncertificated ADSs and holding of security entitlements in ADSs through DTC and a DTC participant. Profile is a
feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of uncertificated ADSs, to direct the depositary
to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the
depositary of prior authorization from the ADS holder to register that transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with and in
accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary
will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of
transfer and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding
any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary&#8217;s reliance
on and compliance with instructions received by the depositary through the DRS/Profile system and in accordance with the deposit agreement
will not constitute negligence or bad faith on the part of the depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shareholder Communications; Inspection of Register
of Holders of ADSs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The depositary will make available
for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally
available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications
available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those
holders about a matter unrelated to our business or the ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our transfer agent and registrar
will be the depositary for the ADSs, Bank of New York Mellon, and its address is 101 Barclay Street, New York, NY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares are currently
traded on the TASE under the symbol &#8220;PPBT.&#8221; The ADSs are listed on The Nasdaq Capital Market under the symbol &#8220;PPBT.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.23
<SEQUENCE>3
<FILENAME>ea023248301ex4-23_purple.htm
<DESCRIPTION>INSIDER TRADING POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.23</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURPLE BIOTECH LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(the &ldquo;Company&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INSIDER TRADING POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dated: March [&#9679;], 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 30%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a dual-listed company whose securities are
publicly traded on the Tel Aviv Stock Exchange (&quot;<B>TASE</B>&quot;) and on the NASDAQ Stock Market (&quot;<B>NASDAQ</B>&quot;), the
Company is subject to various rules and regulations, including, the Israeli Companies Law, 5759-1999 (the &quot;<B>Companies Law</B>&quot;),
the Israeli Securities Law, 5728-1969, and the regulations promulgated thereunder, as well as guidelines and directives issued by the
Israel Securities Authority (the &quot;<B>ISA</B>&quot;) and the rules of the TASE (collectively, the &quot;<B>Israeli Securities Law</B>&quot;),
the U.S. Securities Act of 1933, as amended and the U.S. Securities Exchange Act of 1934, as amended and the regulations promulgated thereunder,
as well as the guidelines and directives issued by the U.S. Securities and Exchange Commission (the &quot;<B>SEC</B>&quot;) and the NASDAQ
Listing Rules (collectively, the &quot;<B>US Securities Law</B>&quot;; the Israeli Securities Law and the US Securities Law shall be referred
to together as the &quot;<B>Securities Laws</B>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This policy (the &quot;<B>Policy</B>&quot;) provides
guidelines to employees, consultants, affiliates, officers and directors of Purple Biotech Ltd. (the &quot;<B>Company</B>&quot;) with
respect to transactions in the Company's securities. The object of the restrictions on engaging in transactions in the Company's securities
in this Policy is to assist in compliance with the requirements of the relevant laws by Insiders (as defined below). This Policy does
not detail all of the laws connected with transactions in the Company&rsquo;s securities; accordingly, it is recommended to the Insiders
that in cases of any doubt in respect of the legality of a transaction in the Company's securities, they should approach the Company&rsquo;s
Compliance Officer (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPLICABILITY OF POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Policy applies to all transactions in the
Company's securities, including ordinary shares, options for ordinary shares and any other securities the Company may issue from time
to time, such as preferred shares, warrants and convertible debentures, as well as to derivative securities relating to the Company's
shares, whether or not issued by the Company, such as exchange-traded options. For avoidance of doubt the Policy also covers purchases
of Company securities, not just sales, as well as any decisions in connection with Company equity-based incentive compensation (exercises;
dispositions; etc.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Policy applies to all officers of the Company,
all members of the Company's board of directors, a shareholder who holds the right to appoint a director, and all employees and consultants
of the Company and its subsidiaries who receive or have access to Material Non-public Information (as defined below) regarding the Company.
This group of people, members of their immediate families, and members of their households are sometimes referred to in this Policy as
&quot;<B>Insiders</B>.&quot; The Securities Laws governing insider trading would also apply to any person who receives Material Non-public
Information from an Insider as well as certain principal shareholders of the Company, who under certain circumstances could also be considered
Insiders under the Securities Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any person who possesses Material Non-public Information
regarding the Company is an Insider for so long as the Material Non-public Information is not publicly known. Any employee or consultant
can be an Insider from time to time, and would at those times be subject to this Policy (or the applicable provisions of an agreement,
such as a non-disclosure agreement, in the case of a consultant) and/or the provisions of the Securities Law which are applicable to Insiders
(including certain provisions with respect to legal presumptions under the Securities Laws which apply to Insiders).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEFINITION OF MATERIAL NON-PUBLIC INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trading in securities while in the possession
of inside information is generally not a basis for liability unless the information is &quot;material&quot;. &quot;Material information&quot;
is defined as information, both positive and negative, for which there is a substantial likelihood that a reasonable investor would consider
such information important in making his or her investment decisions, or information that likely would affect the price of a company's
securities. Information can be material even if it relates to future, speculative or contingent events and even if it is significant only
when considered in combination with publicly available information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While it may be difficult under this standard
to determine whether particular information is material, there are various categories of information that are particularly sensitive and,
as a general rule, should always be considered material. Examples of such information include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The results or developments, favorable or not, of a clinical trial</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Significant clinical or regulatory developments </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A significant financing transaction (including public or private offerings
or sales of debt or equity securities) or significant borrowing </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A significant corporate transaction, such as an acquisition, merger, sale
of material Company&rsquo;s assets, joint venture, tender offer or other significant transaction</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 17.85pt">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Potential new collaborations and material developments
(positive or negative) of existing collaborations </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Earnings from commercialization</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Major or unexpected change to cash position</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Impending bankruptcy or financial liquidity problems</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Gain or loss of a substantial customer or supplier</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Obtaining or losing material contracts, license or collaboration</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Significant disputes with major suppliers or customers</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes in dividend policy</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">New product announcements of a significant nature </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Significant product defects or modifications </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Significant pricing changes </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock splits</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Criminal charge or government investigations</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Significant litigation exposure due to actual or threatened litigation or
investigation or major development in or the resolution of such investigation or litigation</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Major changes in senior management</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Major changes in accounting methods</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information is &quot;non-public&quot; as to a
security until it has been effectively communicated to the public through a press release or other appropriate news media, or appropriate
public filing with the SEC and/or the ISA, and enough time has elapsed to permit the public to absorb and evaluate the information. In
many cases, this process may require the passage of several trading days after any initial disclosure. If there can be any doubt whatsoever
as to whether information has been effectively communicated to the marketplace, such information should be considered non-public until
such time as there is no longer any doubt that the information has been communicated to the marketplace and is no longer non-public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMPLIANCE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Policy does not constitute a substitute for
consultation with the Company's legal counsel or the Compliance Officer (the &quot;Compliance Officer&quot;). In the event of doubt regarding
any directive and/or action to be taken in accordance with this Policy, including identifying information which should be considered non-public
information and/or material information, one should take a conservative approach and immediately consult with the Compliance Officer,
who will determine if s/he should seek the advice of the Company&rsquo;s legal counsel, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee will appoint the Compliance
Officer from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATEMENT OF POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>General Policy</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is the policy of the Company to prohibit the
unauthorized disclosure of any non-public information acquired in the workplace and the misuse of Material Non-public Information in securities
trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Specific Policies</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. <I>Trading on Material Non-public Information.</I></B>
No Insider shall engage in any transaction involving a purchase or sale of the Company's securities, including any offer to purchase or
offer to sell, during any period commencing with the date that he or she possesses Material Non-public Information concerning the Company
and ending at the close of business on the second Trading Day following the public disclosure of that information, or at such time as
such non-public information is no longer material. As used herein, the term &quot;<B>Trading Day</B>&quot; means a day on the stock exchanges
in which a Transaction is taking place is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assuming the NASDAQ is open each day, below is an example of when a
transaction can take place:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR>
    <TD STYLE="padding: 4pt; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; width: 55%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Announcement on Monday</B></FONT></TD>
    <TD STYLE="padding: 4pt; border: Black 1.5pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>First Day for Transaction</B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 4pt; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before Market Opens</FONT></TD>
    <TD STYLE="padding: 4pt; border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wednesday</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 4pt; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While Market is Open</FONT></TD>
    <TD STYLE="padding: 4pt; border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thursday</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 4pt; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After Market Closes</FONT></TD>
    <TD STYLE="padding: 4pt; border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thursday</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This example is applicable for any other case
in this document where two Trading Days following the date of public disclosure are required prior to a transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. <I>Tipping</I></B><I>. </I>No Insider shall
disclose (&quot;<B>Tip</B>&quot;) Material Non-public Information to any other person (including family members) where such information
may be used by such person to his or her profit by trading in the securities of companies to which such information relates, nor shall
such Insider or related person make recommendations or express opinions on the basis of Material Non-public Information as to trading
in the Company's securities, including comments on share price or rumors of other corporate developments that are of possible significance
to the investing public, unless it is in the framework part of such person's position with the Company (e.g., public relations) or has
been specifically authorized by the Company in each instance. Even if a person is not in possession of Material Non-public Information,
such person shall not recommend to any other person that they buy or sell securities of the Company (&quot;Tipping&quot; Material Non-public
Information is always prohibited, and any such recommendation could be imputed to the Company and may be misleading if such person does
not have all relevant information).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Care should be taken so that Material Non-public
Information is <U>never</U> discussed in places where it may be overheard, such as in restaurants, elevators, restrooms, and other public
places. In the event a person, contrary to the provision of this Policy, expresses opinions on the basis of Material Non-public Information
as to trading in the Company's securities or comments on the Company's share price or rumors of other corporate developments that are
of possible significance to the investing public, such person should promptly contact the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. <I>Confidentiality of Non-public Information.</I></B>
Non-public information, whether or not material, relating to the Company is the property of the Company and the unauthorized disclosure
of such information is forbidden. All memoranda, correspondence and other documents that reflect non-public information must be kept in
a secure place, such as a locked office or a locked file cabinet, so that they cannot be seen by third persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4. <I>SEC Rule l0b5-1</I></B><I>. </I>Notwithstanding
the prohibition against insider trading, Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and Company policy permit
directors, officers, employees and consultants of the Company to establish a Rule 10b5-1 compliant trading plan to enable trades in the
Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Rule 10b5-1 plan is a written plan for trading
securities that is designed in accordance with Rule 10b5-1(c).&nbsp;Any person executing pre-planned transactions pursuant to a Rule 10b5-1
plan that was established in good faith at a time when that person was unaware of Material Non-public Information has an affirmative defense
against accusations of insider trading, even if actual trades made pursuant to the plan are executed at a time when the individual may
be aware of Material Non-public Information that would otherwise subject that person to insider trading liability.&nbsp;&nbsp;Accordingly,
Rule 10b5-1 plans are especially useful for people presumed to often have inside information, such as officers and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rule 10b5-1 provides that a person's purchase
or sale is not &quot;on the basis of&quot; Material Non-public Information if the person making the purchase or sale demonstrates that
before becoming aware of the information, the person had (1) entered into a binding contract to purchase or sell the security, (2) instructed
another person to purchase or sell the security for the instructing person's account, or (3) adopted a written plan for trading securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The contract, instruction, or plan described above
must (1) specify the amount of securities to be purchased or sold and the price at which and the date on which the securities were to
be purchased or sold; (2) include a written formula or algorithm, or computer program, for determining the amount of securities to be
purchased or sold and the price at which and the date on which the securities were to be purchased or sold; or (3) not permit the person
to exercise any subsequent influence over how, when, or whether to effect purchases or sales; provided, in addition, that any other person
who, pursuant to the contract, instruction, or plan, did exercise such influence must not have been aware of the Material Non-public Information
when doing so; and finally, the purchase or sale that occurred must have been pursuant to the contract, instruction, or plan, without
deviation. Further, no purchases or sales may occur under the plan following its adoption until the expiration of any cooling-off period
required under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that a person has established such
a plan, s/he may amend or replace his or her trading plan, instructions and contracts only during periods when trading is permitted in
accordance with this Policy. In addition, persons adopting such plans should notify the Compliance Officer of the existence of such plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POTENTIAL CRIMINAL AND CIVIL LIABILITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND/OR DISCIPLINARY ACTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. <I>Liability for Insider Trading</I></B><I>.
</I>Under U.S. securities law, insiders may be subject to fines of up to $5,000,000, civil penalties of up to three times the amount of
the profit gained or loss avoided and/or up to twenty years in jail for each transaction in the Company's securities at a time when they
have knowledge of Material Non-public Information regarding the Company. Under Israeli law, an insider may be subject to penalties of
approximately NIS 1,000,000 or to imprisonment for a term of up to five years. The Israel Securities Authority may also declare the insider
unfit to serve as an officer or director of a public company for a certain period of time. There is culpability under Israeli administrative
enforcement rules for transactions by Insiders while the Company is in possession of inside information &ndash; even if the Insider was
not himself in possession of such inside information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. <I>Liability for Tipping.</I></B> Insiders
may also be liable for improper transactions by any person (commonly referred to as a &quot;<B>Tippee</B>&quot;) to whom they have disclosed
non-public information regarding the Company or to whom they have made recommendations or expressed opinions on the basis of such information
as to trading in the Company's securities. The SEC has imposed large penalties even when the disclosing person did not profit from the
trading. The ISA, SEC, the stock exchanges and the National Association of Securities Dealers, Inc. use sophisticated electronic surveillance
techniques to uncover insider trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. <I>Possible Disciplinary Actions</I></B><I>.
</I>Employees, officers, consultants and directors of the Company who violate this Policy shall also be subject to disciplinary action
by the Company, which may among other things include ineligibility for future participation in the Company's equity incentive plans or
termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADDITIONAL GUIDELINES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. <I>Blackout Periods</I></B><I>. </I>To ensure
compliance with this Policy, and applicable Securities Laws, the Company requires that all directors, officers, consultants and employees
having access to Material Non-public Information refrain from conducting transactions involving the purchase or sale of the Company's
securities periods in which the Company expects to make a material public relations announcement in the near future (e.g. with respect
to items listed in the section above defining Material Non-public Information), so designated by the Compliance Officer as a period during
which no Insider shall engage in any transaction involving Company securities (each a &quot;<B>Blackout Period</B>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purpose behind the Blackout Period is to help
establish a diligent effort to avoid any improper transaction (or the appearance of an improper transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A person may request that the Compliance Officer
consider a specific exemption as a result of extenuating personal circumstances to allow trading during the Blackout Period. The Compliance
Officer will consult with legal counsel in order to evaluate the request. Should the request be granted, the Insider should nonetheless
be particularly careful with respect to trading during the Blackout Period, because the Insider may, at such time, have access to (or
later be deemed to have had access to) Material Non-public Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It should be noted that at any time, even if not
during a Blackout Period, any person possessing Material Non-public Information concerning the Company should not engage in any transaction
in the Company's securities until such information has been known publicly for at least two Trading Days. Although the Company may from
time to time recommend during a certain period of time, even if not during the Blackout Period, that directors, officers, selected employees
and others suspend trading because of developments known to the Company and not yet disclosed to the public, each person is individually
responsible at all times for compliance with the Securities Laws and the prohibitions against insider trading. Trading in the Company's
securities at a time other than during the Blackout Period should <B><I><U>not</U></I></B> be considered a &quot;safe harbor,&quot; and
all employees, directors, officers and other persons should use good judgment at all times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the avoidance of doubts and misunderstanding,
<U>all Insiders must receive prior approval</U> for any transaction in Company shares from the Compliance Officer. Such preapproval shall
be documented in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The individual will notify the Compliance Officer
in writing, prior to the proposed trade(s), of the proposed trade(s), and that he or she is not aware of Material Non-public Information
regarding the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the written approval of the Compliance Officer,
the Insider may execute the trade set forth in such notice. Once the approval has expired for reasons and circumstances detailed in this
policy, a new notice and certification pursuant to this section must be given in order for the Insider to trade in Company securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The existence of the foregoing approval procedures
does not in any way obligate the Compliance Officer (or, in the case of any trade by the Compliance Officer, the Chief Executive Officer
or the Chief Financial Officer of the Company) to approve any trades requested by Insiders, hardship or extenuating circumstances applicants
or the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. <I>Individual Responsibility.</I></B> Every
officer, director and employee has the individual responsibility to comply with this Policy against insider trading, regardless of whether
the Company has recommended a trading window to that Insider or any other Insiders of the Company. The guidelines set forth in this Policy
are guidelines only, and appropriate judgment should be exercised in connection with any trade in the Company's securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An Insider may, from time to time, have to forego
a proposed transaction in the Company's securities even if he or she planned to make the transaction before learning of the Material Non-public
Information and even though the Insider believes he or she may suffer an economic loss or forego anticipated profit by waiting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPLICABILITY OF POLICY TO INSIDE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGARDING OTHER COMPANIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Policy and the guidelines described herein
also apply to Material Non-public Information relating to other companies, including the Company's customers, vendors or suppliers (each
a &quot;Business Partner&quot;), when that information is obtained in the course of employment with, or other services performed on behalf
of, the Company. Civil and criminal penalties, and termination of employment, may result from trading on inside information regarding
such Business Partners. All employees should treat Material Non-public Information about Business Partners with the same care required
with respect to information related directly to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Attachment A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Receipt and Acknowledgment</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon first receiving a copy of the Purple Biotech
Ltd. Insider Trading Policy or any revised version thereof, each member of the Board of Directors, each officer designated under the Policy
as an &ldquo;Insider&rdquo; must sign and return to the Office of the Chief Financial Officer the following receipt and acknowledgement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, _______________________________________, hereby
acknowledge that I have received and read a copy of Purple Biotech Ltd. Insider Trading Policy and agree to comply with its terms. I understand
that violation of insider trading or tipping laws or regulations may subject me to severe civil and/or criminal penalties, and that violation
of the terms of the above-titled policy may subject me to discipline by the Company up to and including termination for cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(Print Name) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>4
<FILENAME>ea023248301ex8-1_purple.htm
<DESCRIPTION>LIST OF SUBSIDIARIES OF THE REGISTRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 8.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Purple Biotech Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the list of our
subsidiaries, including the name, jurisdiction of incorporation and the proportion of our ownership interest, as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of Subsidiary</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction of Incorporation</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ownership</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyrnovo Ltd.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.47%</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kitov USA Inc.<SUP>*</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FameWave Ltd.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immunorizon Ltd.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kitov USA Inc., established in 2019, is currently inactive.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>5
<FILENAME>ea023248301ex12-1_purple.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER<BR>
AND ACTING CHIEF FINANCIAL OFFICER<BR>
UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Gil Efron, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on
                                            Form 20-F of Purple Biotech Ltd.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does
                                            not contain any untrue statement of a material fact or omit to state a material fact necessary
                                            to make the statements made, in light of the circumstances under which such statements were
                                            made, not misleading with respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial
                                            statements, and other financial information included in this report, fairly present in all
                                            material respects the financial condition, results of operations and cash flows of the company
                                            as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">I am responsible for establishing and
                                            maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
                                            and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
                                            Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the company&rsquo;s auditors
                                            and the audit committee of the company&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 10, 2025</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gil Efron</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gil Efron</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    and Acting Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>ea023248301ex13-1_purple.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND
ACTING CHIEF FINACIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the
Sarbanes-Oxley Act of 2002, the undersigned officer of Purple Biotech Ltd. (the &ldquo;Company&rdquo;) hereby certifies, to such officer&rsquo;s
knowledge that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Company&rsquo;s Annual Report on Form 20-F for the year ended
                                            December 31, 2024, to which this statement is furnished as an exhibit (the &ldquo;Report&rdquo;),
                                            fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of
                                            the Securities Exchange Act of 1934, as amended; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>The information contained in the Report fairly presents, in all material
                                            respects, the financial condition and results of operations of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 10,
    2025</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Gil Efron</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gil Efron</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer and Acting Chief Financial Officer</P></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">The foregoing certification is being furnished
solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether made before or after
the date hereof, regardless of any general incorporation language in such filing.</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>ea023248301ex15-1_purple.htm
<DESCRIPTION>CONSENT OF SOMEKH CHAIKIN, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, A MEMBER FIRM OF KPMG INTERNATIONAL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the incorporation by reference
in registration statements No. 333-226195, No. 333-233793, No. 333-233795, No. 333-238229, No. 333-239807, No. 333-268710 and No.
333-270769 on Form F-3, registration statements No. 333-235729, No. 333-275216 and No.&nbsp;333-280947 on Form F-1, and registration
statements No. 333-211478, No. 333-218538, No. 333-230584, No. 333-238481 and No. 333-264107 on Form S-8 of our report dated March
10, 2025, with respect to the consolidated financial statements of Purple Biotech Ltd. and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Somekh Chaikin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member Firm of KPMG International</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 10, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'P <P# 2(  A$! Q$!_\0
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M+..'\3]5S;*9Y1HG&ZO&6BLXM1<'?R;WUW1>HH P /08HKK/*"BBB@ HHHH
M**** "BBB@ HHHH ***,@=3B@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@!BA>QR1]1U]O\]*\N\2_%3P#X7\6:#X'UOQ#:Z=XFU\,-'L
M3P7^7&#G@!O0YR#DXYQVVIZC%I%A<7GD7-R;=0WV6U&^^O&&  OW22<YY(SC
M.1P#^??Q4\!6/Q3EU[Q%XBL)[3XC>)\>"OAQ9VEW_P @%0"!K.M@$!<''8@
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MOCU\+-=UN?5/"'@R[\->(_#5M=@%[#4O$&/[=5".SLJ<# )"DC@5]=EV&?\
MJ/FL[WOQ'!IM.ZCR2ZV=D^==4M#\)SO.<)A_'+A3!V;F^%N((.22NN9QDHWW
MLU':]G?2Y_5'12#D ^H%+7R)^[+5)]TG]Z04C#((]01^8I:0]#]#0']:;_+S
M['Q#X[\$_!CPY\:_ 5YK0\1VGBGQUXC.L:+I.D'/AJ^\3Z$H(UG7.1API&#D
MC.3@ UXS\7?C5\;?A]\0M6M[C5;G1M._M?4?^$1TJ]\-?VAX<U_PTJKAFUH8
M*2  <##(0!Q@8]4_:3^.E[\.?$6A>'?#VDZ)/K]OI#^)KO7M2TN345T-&?\
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M>G4@[L8; QD<@%I-Z)-OR3?Y";26K2]6E^;1W*J!DY!]QV^O/T^E>2ZS\6/
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M[$8KY_U[X#W^KZSI&J^!_$5QX2^)_C*\U/Q/XC^QWHTWPWX3\"<\8T  #_F
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MI_07#6=_6L%E6-<7'^VXIRB_BA[J=GHK-;-V5VF^I\7^"?#?_"8>+='\.?\
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MLKO=I>IPO#M/_9'9]KNW73\SR.'Q7_9MKXGOM*OM-U'P/X8_LO1?M5YC4O\
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MS*^&E/S')&UL>F!CZC^'_P"U7\(/B =/L1XC@\.:[<66I7=WH_B$BQ-E_8K
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MZ$"/^$8W1R+K+H^T%'56&&4&N^L_VO/BW\/+_5-#^+/PO:Y'A'2=(L_$NOZ
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M FK:39\:%JG'_P!?'U[YKN+S3=#L[_4+[Q'?6W]H>*+S2[+6/#VD_P#(,O\
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MM[>[O/MM]X?M;TQZ7>ZD1DNRL PZ?=Z]<D8./I>&&WM(8;:$""&V M;88XY
M  YY)VG\1SC''S.)^J6C]4YEHK\UO+?SO;;3U5C],RYYFWF3QC7*YOV=K/W>
M9VM\K?<:U%!('4@?6BN(]=;+T7Y(****!A1110 4444 %%%% !1110 4444
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MUS6BR,FNN1'N8GC>P7[IR!DU_0#X8U?7(O$HT_7[BTG.E^$1K.JWF!8*#K+
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MQ;!>W/A?Q)\8/&&I>-=8TRR-E=>'G#7_ (;OM*5BFC:0VK2"-_+C!0[@?GW
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MO-7T0-XO^,OP)\$XU[1R%\1H@8D?\(N1XJ51D\*HP!B;V1]QZW_P69T/1O\
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MQ1\:/B-X]MO&GQ5\=6>I6=]::%9?V7X:T0:_K+:[K(CS(KZV_F[,/(@QM8*
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ML_VLZJ!_Q)?,& VQD!8$+Z#]&-&TBRT*PL-#T."TT_1M+LM.L=*L;8#%GIZ
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M7Q6\1_$_X9ZU:Z9X;^)_VZ\U?3O'8\+G5@&TA-;)\72>'/#X29HV_P"$41&
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M]_EW/C+QE^V9^S'X3U'QOI.N_%KPY::[\-[K5+#Q;H._4GU.QU715S)I;QF
MJ)5(P A>-B=X R16Q^SA^T[\+_VF?"5WXJ^'5[<[;2Z-IJ^@ZH#8:IH+DD;6
MB +<Y# KD9W A<#/F'[0/Q8_9_/PN^/?AZW\?_" >-M*\(^.=%\2Z/<:SX-7
MQ%8^)_[#)_LC6U>7S$UW#;3"ZE@VW*$)N7\;?V5/V5O"'B/X"Z3\;;#]HZ[_
M &?/&]SXA\2:/>:M=:N^FZ9J.F:*[)M)_P"$@\(^(R%V@MMD9U!+21HA5V_4
M.%>"^'LXX.SG.L7F=?),UH<1</Y!&4:=?/H.-:C5J2G*EAZ+J)4U!>]R2G%R
MCR.<FHR_FWQ(\4.+>$?$_A3AKAW*>%\YR?.^&.).(^(O;<04>&ZM/^P'%1C2
MX@SZ4,DC*4Y1_=N2O-/F32YE^R7[>_Q-\%?#K]F#XEV'BN\T];KQQX<U/P=X
M=\/W1)O=;U/6T>,1*) KL2K;BVS!/&[Y0!\W_L:_LN?$JZ_9M^'%W?\ Q]^.
MOPXNM4NX_&=GX4\)7NAZ=IMCI;:Z=<.BA=>\.%Q_PDVX-(2H14?<"</CY=^&
M7P#^&NL?M&?VM\4OB^/VG_ 7P[\#)XR^(OQ5U;Q@NG^!_AKJ9*GP/HQ5O$_B
M@>(#XJC\QRH8L F0KL/+/[?_  A^(?A'XM> O#WC_P  SSW?A/7+(:AX>N+O
M2-8\.E].8".,C2-;C@D14VOEMBY)SQ@D8\0ULJX?X0AP;D^82SEU.(UQ-G_$
M-6C4PU-/DE3HX:A0Q%.-:E%<JYX^S4DG%26G*M^ <%G_ !OQS_Q%?B'+J62P
M7#+X6X8X8PW$E+B72.=2GG>?9]GO#TYY)4;2A"A2YFU&W*M;KW?^#_@/]*=2
M+T'T'\J6OS7?5:IZI]T]4_GN?T7_ %IM\O+L%%%% !111D#J<4"NNZTWU7^8
M44F0>A!_&E) ZD#ZT#NGLT_1I_DV%%%% !1110 4444 %%%% !1110]@*1X9
M1G WD^W"@_SKX:^(G[4?B/PGX?\ B+JD7[._QLG_ .$%B\31VFK7.D:-8^&]
M=&AKDZU%*_B,,?#Y(R)2A8A2VU7P5^XY2<Q\'_6$=.VTC/TZG/I7SY^T\N?V
M=/C)_L_"SQTQ^ATB?^O%>ADWU9YOE.$Q,54YZU"$DY."E"=>E3J>^M4U&3ZJ
M_=*Y\UQ3B,7A.&\]QF"O[6EPOQ'*DDES*K'#5I4G%-/WE**Y;Q:O;1V1\.?L
MS?\ !3_X.?%G05T_XLZGIGPI\9VEQY5_'J$CMX9U]4!,;:#K391W7[N7*Y7E
MFXYX/]L[]L+P!\4_ =]^SM^SW+<_%?XC?%<6'ABZ7PK:_P!J:=H&ER/N9Y'W
M,N6PS<9P&)+9XKX9_9L^+GPU\0?!CPS\)K?]D+5?V@_B/H7B#Q/=W=S<Z+%_
M9>FZ;K>MNS2?V]H<;DL0RJ1PH"9P<G'W=^SM^U+^SQ\(_&?_  @/CC]G&3]D
MKQSKI%K97&L:/"FEZD!T0:ZD:@#.""6Y(PS;"U?T/GG!N49+GN9YME'"G$LY
M9+3C4I<-/B/(*D?K"C"<.((T8/\ U@GDJDXUE"G2G)**IJ5TD?Q-P[XD\6\9
M<&<-<-\1<><,Y+1SW(I</\4\2OAGB%9^H.NU+A]<02IQX>AG<HJ.45)MJ/O.
M:FFV?H+^R]\'I?@M\"? /P]U"Y%QJ^A^'XXM8NR"=VJ:Q(VM:YD'H?M$I P.
M0%(SFOI56Y<#HJ@#\.X&?K^IYZ5\^?"CXV6/Q@OO&EQX=\'>)+/PCX7O5T?P
M_P#$'5[?^S/#GQ&+;FU?6O!(C=O.\.B4"(>(U<QR,S%<[=I^A(=IWX!X[]NP
MX/IS^./3&?YOS+$8O%8S,\5BH<N9RG4E*,KWC[2?.DU*UG=N+ND[JS4=4?W%
MD66X/*LFR?*,HE?*<HHTZ<)MW<U&G!1?-KSW^-M.2O)V+PZ#O1117.ME?>RO
MZV5SW HHHI@%%%(W0_0_RH R9OOGWC4GZ@<'_/O7YS?\%1OCQX]_9L_8O^*'
MQO\ A7KMKX<\;^!%\-7^CW5[9#5--=AK"*=)UC1@2&C96 /R\Y R!D5^C(RS
M GC>A!]N?P]/YX]OR@_X+;V4-W_P3/\ VD?/^T[;;1O#UYFUY;*Z]H8';&/F
M/!]OQ]#)XPQ.;95&=DISA";DE:TVXRO=6LDGN?.\58G&8/A_.,;@K^UI\/5)
M1:OS*<;M--+F;6CMOII9ZKPS_@G#_P %M_V>OVRK#1O /Q,O=&^"_P ?@$L/
M^$<UF_-AX8\=:FK1Y/@?6G90YPI=_#<C-,#G:9 0@_==6Q!\JH2S=$;<",<'
M@GC)]N_7-?Y%7@GP)XV\1^)O ^E>'-/N=.U'QEXDTSPQX/UB\)TW3+_Q/_;.
M,?VWC^'KGGL /7_1V_X);?!/]O?X'?"@>%_VT/BKX+\>V-KH^FV?@32K/S/$
M'C;PFJB,/I.O^-_EC\2!455#L'QD!2 &Q]=QIPME.0\N,P>:QFI_8O>[LFU!
MQ<D[.5G%IRVM;1/\S\,>.^(N)V\#G&42_=QN^(K.+M9J*J0E&,E=*T96BF^L
MC];L*0"0,#U&<?IGK_C00@YX!/0CK^E5]WR@CN3C(]23T_3_ .O7CGQP^(-_
M\,OA_JWBG2M+_M.^M$6UM+-B19[FS@R!=H P"O3J", *0?@,.OK+Y5I>5K;)
MW>G_  ;KY'[+BL0L)AI8IJZ2O*RNY)7WLM;VNK]SVPD8&3D?C@_B.^,^QY_!
M01C/;US_ %/Y<XKXL_9W^/GBCXFZ]J'ACQ7I6FBXM;(:O::II;'RF5FP 4/R
MYY(4@ G.TDKP/M+ VA<\'D?3.?ZBM<5AL1@L2\-B5':]U9Z63Z-K;[SGR_,,
M-F6%6+PJ=G=6E%Q::Z:I7ZZV\AU%%%9GHA1110 4444 %%%% !1110 449&,
MY&/7M1D'H0:!77=?>O\ ,*0]#GT-&1QR.>G(Y^GK02,=CUP/7VHU71_C_70?
MSM?9Z>B:N]K]=O,HVP3#;!MY;)8G^1/?M@'N.HI[D%<XW8Z=1R/ISUQQWXKA
M/'GCWPA\,_"6L>-_'VN:?X9\,:%:&]U?5M5N]FG:>BD!F?(R1D@84!CD$=#C
MYG_9P_;#\ _'JZN=$&EW7@+Q?JG]I>)O"'@GQ)>*/%'BOX6[A_8/Q.&BA"VA
M>'?%"EC&KAB6R'<ELCLHX;%U\+/%JE-1C;FDH[/56N[-M*U[;75]&>96S+ 8
M?%+!8C,H_P!J2C[L%;5-NWPW5MK72OHT>+?&#]GGX_\ C*;XRV/A[P_^R&ND
M>.G\4'PU>:K\+];7XDZAI^N:.T/EZ]KR,(I/$F\LI\1,6&]5+('"$?('[)__
M  2D$FA7&M_M03:U=3B\SX=\ Z3K(TU; @\:MK.MZ ZEY&/& < ]3G:I_6OX
M@?M!_#3PAX;\?ZM!XX\!:KKWP\T;Q#?ZMX>;Q5HZ:FFIZ%HS:ZVC%)'617V$
M!E95:,D'RV(D"_)_[)/_  44^%O[1>F75CXYU;PW\,?'UNK'^P-8U<Z?IFNZ
M9@,FKZ)JVM&,2Q@\$!@S#Y#G<6'Z+PKG'B'EG"'%$.&::>33GD+XCJ4:<:G$
M$&G-TIQCR2J\C7+SU*4>:%N5RA&:DOP/Q'R#P:SSQ/X#PWB/5C'BW_5GB%<,
M\-<1U/9<-\1TY->V<GS0IMQ3<HQG.,9J[E=Q2E\@_M8_\$_O#WP1\(WGQR_9
MXO=:T[4?A_>:?XI\0> M>NCXBTG7M-T!F;^U"K.S[DA /_"-\1RE&8"(LD9_
M3']G_P#:L^&OQ+^"W@'XB>(_&'@OP7?ZK;V&CZKH&J^)=&T_^SO$SG^QSHKA
MY$&[S2R1!,E1Y? 4,1\W_M\_M<_"SPC\(?%WPN\'>(=.\:_$_P"(VDGP;I&@
M>%KD^(FT\ZXOE_VSK*:&6>)",GMD,V,;R:[;]E;]CCX=>&?V>_ 'AWXM_##P
M3XB\3,T?C#51XC\-:+J5_8:R-;;7M#5I-C$-X9\V-$7D[XU"@DR*W1Q!7Q.9
M^'668GC",J><PXFE'AUSA[+B"MPW[)2G*I3<*;G1CG+LI5XN]I\KE%2/,X#P
M.09%XRYEE?AS4_XPQ\*R7%/#?#=1U.%>&>)(2YLDC3J.=2G_ &WG<;NK&%6<
M5&#E-1;BC],AT'T'^>>?SI:1>@YSP.?7CK2U^3']0W773NFUIY/7IM\@HHR/
M44>H!Y_E0UNMNGH%]+[E!F4$"8@-SD$GKVS]03Q^?>C'FY#C"@CG.!Q_GW(S
MQW%?@C^UMJO[3GPO^.'B;XO2V_Q:^$WAY1_8_AKX@?"J\UKXM_".^\+Z+DZ$
M_P 5_A6_[SP_(Y+%V\+_ #NQ8N2S-G-O/V\/VL_B/\,;CP_\./"%AXD\;JVG
M/9?&#]GNWTGXC^%K_39 =^C:]X%UYE\2^!/$+$E@LHD"-@Q["*^DH<&XS%X7
M+,7A,SIR@[J?OQ3A=7E[1-V:C:SM9I;QZKX+$\9X7"8S,L'B\LJ)P=XI)_O+
M727POXM+6[NS/WX@-QD9C!&>,,#QZ\'Z[N!^%6V'"Y4G'8'@8Q]?\:_%3]@O
M0/V\+OXO?\)M^T%!\64\#WGA_5-(O;3XD^(O!NFZ;8/O#:*^B^!_#BG!<G#R
M,, -ECS7[6,P &6QTR0,_CT/7V]?2O'S?+_[-Q:PJS*%7JY46IQE*[;CS<TV
MFM+^]U:TV/I<DS=YKA/K<LLGDZ=THU$KM:6>RW6NVV^[+0Z#Z#KU_&EHHKC/
M9"BBB@ HHHH **** "D;H?H?Y4M(>ASZ&A[ 9#YW-R>$R!D^P/?KS^-<7XYL
M/"^J^#/$ECXM^S-X7N]'U&Q\1"[N&L]/.E.I&LM(0RE4"AS)(2.XWY)SVN!O
MY[Q=_48_PS7YV?M0?LP_"G3?@U^T'XWBL_%5SJWB#PQX[\9WRWGCCQC_ &>=
M7_L.5BZZ.MP55#L $?E.P()+X8;/0RS#+%8_*<*Y.G[2O1@JB5Y0<YTZ<9*S
M6J<K[WNEHVCYSB;%K Y'G..E!5(4>&<14E3E\$U"G5J3A)).\9Q@XRMJXR<?
MM*WT)^S]X"^"7@+P':6?P"M_#[^#KJZO[L:GX?O8]32^U$,YDDU35P':20D@
M2"7' 14&,[_F_P#X*<>&O FJ?LK>.M3\56NF'5]%;3+[P+=3K$NIIXG75U":
M7I38#/)*4"@J"!C&,)\OYK?L??!W]H_PC\$=!^+OP9_:/\/^"[#Q)JOBBSUC
MP!X]ADL_#8U/1M;;06U>,:RLDY/[I2ZJG.8P-S' ]0^(OP(^+'C36/ 'BG]H
M'XD:/^T;JNO^.M.MOAQ\"OA[J@TKPS?N6)U_6=>UAB/#^@Z%X6\/$R$F(A^2
M7+, ?V*7#5'A?C"6=8GCMYQ3R?/[U'&&>OB*I[.$?:4:G/1=)THQC[&4YU?9
MQ@W%*R4E_*F'X^QW'GAW2X0RCPNIY)5XRR-+G57AN/#G#F0YY6<5Q.E"K'.W
M6YHNK')E!YTJD^?FLDSZU_8N\'_$7XD_!W]GSQ]XJ_:&\7?8/#]II>KKX,\*
M#P?IOAG4=,=%T71O!OC5_#RG^W4 " ,2JM,A3Y652WZF[")2W)P %7DX&0.1
MZ]S[\_7XR^$WA?\ 98\5?$/5O&WPHTSPVWC_ .#][JOPS\1ZOX,36-,T[0=3
M.E)_;.AE%$?AO774. 3Y3&(@-(^Y<O\ 9H;=N0-\R]<'WZ$X[_G],5^0YUBX
MYCFV9XR,?9PJU*DE'EC'E4YU*EVH)1YO>M*2NY.3DVY2:/ZKX9RN64<-Y1DS
MS3^V99)1I4I5;23ERPA'5S]YJ\;QYVVDE'IK<'09ZX&:6BBO+/HPHHHH ***
M* *]>3_%KX+_  X^.O@35_AG\6?"VF^-?!&O?8!J_AW5U9M-OFTN4."Z*0VW
M<#D9'&1N&"1ZRLG."3@>N,G\^:2JU@TT]MFKK\=&N^C.=VQ5XNS3TE%V:Y>J
M:U35KZ-6=MC\</\ @J/^P!X"^//[#?B7X=?"3P#X=\*>)?@]:-\0/@_:>$]&
M72SIVI:(-^LZ1I":%Y3(/%'A]'@"*LDA+(TG1RG2_P#!'O\ :X/[7'['7@O4
MO$5Z;CXH_"@+\,_BC;W9WZF=6T+<FA:TR,,*OB;PZ$E#!]S,6P %;=^L5QL_
M=J<\DA<?3:0?8Y_QK^6KX&W _P"";W_!:KQ_\$5(T;X ?MR6K>)/ UJ RZ98
M^/M98ZSH^%)+#'B1==\,+R<'7@<]2?H\ WF^4YGD[?-/)T^(X<]^=I-0J1BV
MW*6EGRIRLTKPLDX_GV=1?#W%>3\18.$89/G7_&-\3**2C&5K9#444HQC:;E"
M<U%:/WI=#^J0 8' QV_R:QM3TNPUBQGTS5+*VU&PN01=VEU@J0>>1C'! Q@@
M^AQUV01M!XQ@?2EKYK\']S_X<_2-&NC5M-FFK:;W3T]3B_"_@+P=X*%P/"OA
MW3M#^U$-=?8K;87XS@D<X]<'''/%=I29'J/SI<@]#FFVV]6V_-MO\;L$HI>Z
MHI?W4DOP204444AA1110 4444 %%%% !1UHH/0XZ]J *;8\GY@<<X )R>.>F
M/8CIUQ556;'RQX&>K-U&>@SS].2 >*MDD#YAN/8XX'U/^?3TKYO^//[3OP?_
M &=]-AU/XE^)K?3KF[YTG0;1OMWB/7& &%T;14/FRD<DA04Q@$@D5TQV:Z:M
MMNR2MV;7KJ_1&V79=C<UQ<<#E.65,YS6I\,*<)2G*-[2<8QC*ZBKWE90CIS5
M(GOC0K.5N 2SVP80GI_K,J=PSR4Y(S^@'/\ /7\>/VM/VR?B7\=OC/\ !;X&
M:OXL&C^%]833_"&E_"KP)HFH>);/3M%94US6]=\;^(<+H!=]H0 ?>8*@Y /U
M]H'_  5P_9[NM2@L-6T3QMX>L+I3CQ#>6NE:EI9ZXR=!>4CKR<$G/0\5X+_P
M3J\5:#XR_;6_:;\1^&=5M-9T'7M*U.^T75;7!%]8-XQ<+V^;!8\XZ@' [++L
MQ668F.)<(YPDVE"48N,-[>ZOLJ\FTE;63LV[/].AX-9J^$/$#'\795Q%D<\E
MX:IU.'*D9*-.566>T:<G.<95$K1>D7+FY4NCNO OBUJ?[4GC.X^#7P\^/NA?
MVWX_N+'/P@^".O:MI$FG>+?$^@+NUW]H']HK6D#>&F\.^$@<KX20$L3E5+,=
MW[(?LH_LPZ!\ -'U'5M2U=O'GQ@\<LM]\1_BIJZ(=5U_4D<YT?1=TG_$A\->
M'%C86_AI-JH,N^77:GY+?\%!/A+\4?BG^VGHQT_P/X^N/!NIV?P=^$EIX@TG
M1]5&EII>N>-CKOB#5SKD9V#RB"A"G *D$D@D_P!$EI']DCB@ R+2T2U'7G!4
MDC/T.>_ )QW^PXIS#ER?)\-A7"FLXA*I5I44HQBW=N[3YE&";7*U%.7O._*H
MK^5>%,F?^L?$V+QRG)Y1.,*<ZG,^;W;Z<R:;:6K3;OII=L^1OV@_@3\&(/A+
M\=/%4'PM\ CQ+KW@?QUXEU;Q ?#>D_VKJ/B4Z$ZKK,NM21F3>6V[B7!)PS,,
M.K_S?? B[_99U[1=)\._&>R&BZ!X.LO$UYXNU/PKH^L#XD^//%.N:V3X&T;0
MR%/AO_A'O"OAL@'DJ-JA0N7)_K+^)?@\>/OA_P"-O!1NVT\>,/"7B3PRMT!D
MV+:[I#QEL''$>?,/7Y>0,C%?G]^RO_P3C^&GP3L;F\^(FE>'/BCXWU2=I!JV
MJZ0VH^&]$*\A-#T;7U;RE) W-C?UV@8P?%RSBCBO(L)/"\.9L\F<VI5).3FF
MX1Y597=[)NRM)-M2MS),_9*'AW]'SC/*,SSKQ3X6EGW&F23HT.$.63A)9!77
M_"[3]J]*3G)QY7>,DF[1GHG\@_\ !/&S_8E\'_V_XCN_$>GW/Q&TOQ+XXUKP
MW>>/_+TXZ%X$T4LNA_V0KX\,KKD?AO8[F)_.8%@F N)/UT_9\^*GB+XQ^#]2
M\;ZQ\/-2^'6E:EXDU1? MMK-YG4_%7@,;6T'QE+HXQ_8)\3QR&1(9"792')R
MRO7Q!^W9^QO\(/$GPD\7_$7P5X>T?P7XU^'6BIXF T'3TT[3->TW0^1H^LZ5
M'MC=#N"[=H(^]N&2*^J?V-_B5JOQH_9U\ ^,/$A<:^UGJ'AG6;P#B^U3P^YT
M5M83D$&0*-_J"6ZUAF&<9MGN*^N<1YL\XS=QO=WM"*5_<A=0II6;Y81BKMMI
MR;:]>7AEX=\+\#Y=Q5X4Y4LFX3GQ+_JWQ-PU+EC5R#B-Q<Z4G63G5SV-2#YX
M5)RE*DN:*Y6DG]B*[M_#]>H_F>/Q_6G^2"#SVY&X?S _6F'! VOM  '3J/IQ
MV]N*\*^+/[0WPA^"MM;S_$3QOHOAV6[&+2UO;T#4;T\AO+TA<2/_ +Q0X(R"
MO;@LWJGRZZWV7JY/3RMK<^?PN7XW-,5]3P.63KS;]V,(2G*7:T::DU%NUV[1
M2>LEL>B>*_&7A[X?>%]9\7^,-4M=#\-:#9O?:KJMVWR6<8(!8A0> & QC.3D
M<9Q8\'^*O#OCSPYH_B_PMJEKK?AG7;%;[2=6LCFPO].<[%<9 ^7Y6 + 9VGC
M'!_+[]JG]J;X%?&3]DWXU:3X!^(6B:CJ]KI&EG^S+MDT_5&SK>B/QHFO*C<,
MPX8< _4U]/?L%'/[)7P+CR>?!Z/[*'U:1!C\8B>/6N%U[XN44U:VZUTNE?1O
M:]_7KV^RS'@+&93P-'B;-U4R7-O]:'PU'ANI"4)2IK)%G2K+GC%N+;C&\;QU
M^)[/[&GA$\)$NW/.,X(YZ=/7\L^HZ_S>?M2^)/'_ .R5^VY_PN&ST+1]"L+K
M^SO$?AVU\&:*OAG3_BY\+XW:/QW\-M; ^7Q!\0_"Y7_A+8F"J&0JP5<[:_I'
M*+]GP6."<;L'(.#_ %[^W'&2//?$/P]\$^-[[PQJWBCPWHOB34/!VKC7/"-W
MJ]DNH2:%JVU0-7T?G(<*5^8Y.T<G&VO;RC-UEE>:Q454IU(3A*&T9QE&4;:W
MC=\UFFEHW;5)/\@XAX<6?4(O"YB\FS13IS]I&"DW&,HN46K7?NII:M-M*R;U
MXWX<_'SX3?%F\GT'P'XITS6M>M/#FE>)-9T&,D:GINF:X-L+ZK&58*S,=A4E
MB"1@NI)KW( [E4@A2=K;NL@5.#QC!4^G4GGD5^'?P)^(/@CX8?M^?MC>(?&W
MBK1?"6@VEGJ86\UB\.G@8UC022QP#T! /]XCIDU^@?A#]M[]E[QKK$'AW1/B
MSH<&O7+$V2:RFK>'EO%Y.(UUU$8$@  ,7ZX[5YKQ,6V[K64N6[N[7=GJV^UM
M=+:)63/V3B'PVSG*<33_ +'ROB7.LJ?"W#7$DJJX?J<K>>9'3JU4G3BXRC&:
MJ>]'F:23E&+NC[2Z455@=)X%8,"K $,""""."#D@CK@^O//-6LC&<C'KVJ/Z
M^9\'MHTXM:.+T::T::Z.+T:Z-6"BBB@ HHHH ***,@=3B@ HHR/4<=?:LDWM
MD;K[#Y]NU_!:?:OLGVE3J '3)7.2I^Z6+$$D' 7!HLVG9-V3O;6VG6U[";2M
M=I7=E=I7?97:N_)7?D3L@.'SQ$6?'.<8# ?I^//O7P'\7_ '[5_Q#\'?&;PA
M!X_^#W]@^,;7Q;I'@W26\.:VNJ6'A?6=(>#2-)UO5R5']OAI26D5/+99$D#$
M>61]^.X&$QQ(3'GG(& H_GT-?'OQJ_:0^&7@CX=?$^^\._%'P!_PGO@SPYXK
M%II%UXET=M2L/%&B:4THTAM%=]Y.57<I!&YSRRY(]#)%BWC<J^II2J>VI.FI
M1<ESJI#V<I*SE:,[.3WBDY+5(^<XG> 62YW_ &TVLG_U8XB5?E:4O9>PJ*I;
M5-R5._(EU:[GY[?LZ?\ !)S1H?!MM/\ M*ZYK&M:O]K=M*\$Z%XAE?PYX2"C
M.V+55*22L?56(&.C$BN9_:I_8?C_ &6?!&H?'W]FKQAXK\)0^&+1K/QSX535
MW4:CX4UQO^)X=%UJ0!XY " R,2 1\K$9"[_[-O\ P56B'@ZQC_:3\-^(=-NV
MO=1.D>/] \.&+2O$.FH<!GTB-'D9MA"_\4N)D_=H J_,S8W[0G[9A_;"AT7]
ME/\ 9J\.ZC<7/Q7O"NK^*O%=N_A]!X6T$#6M9ET;29@)IM$,*B-II"6.2!DD
ML?Z#MXJ?ZZM\1>Q_LBT7Q/SO#?ZO?ZM^RCS;>\I>SY7&[_M=5M>Y_%?_ !SU
M_P 0T;X#]NN,?]7[<,?\E+_K'_K-[5_V!?11='VO=_V-R;(^Y_@O^T]^S7HG
MP1^$%]8:WX1^'%CXGTO1;.R\%:5_Q,;ZP\2:S<+HIT0)H!EQ-_;I,9D"C>ZY
M5H01L^_+985SM;.Y@XSG.&!X/TSD]NGKBOGOX'_ CPM\#?ACX(^'FF:9IUQ<
M>&M%TZQN=6.E:4E]KFJD(-8UB0J!MDD+;BV,J3M7<P!;Z$M75MP48VGRQG(P
M!W(XZX/U.,U^!9R\L>;9J\HYO[)]M6Y%-Q;:]M5Y&N6WNN%N1-<ZI^S]H_:.
M1_:G#']J?ZMY'_:Z2SI<+<//B3:[XA]C2]JW:RTLE-=)J3;LT:]%%%>2?2!1
M110 44F0.I _&D)&#R.A[_Y]11Y]._0+].O;K]V_X'YW?&OPW^T3=?%07O@Z
MX\17'A_.FMX<_LF\"Z78D$ESK@/OR>3ZD\\_>VE_;AI^GC4MGVW[(AN@N !?
MX7.,8&,;B,<>G%: 4-L/IUX].1G///\ /'TI02=_7T _P_K[UM7K_6(I67NQ
M2:22V5EI9;VUMYGG8; ?5L7F&+NVZCNDV[+2^BO;JEHM"3 _G^O6OYZO^#@O
MX):GJ_[.?PZ_:E\#0'_A9'[,/Q(\+^*;+5;3_D(1^%]8UB.)HTX&U1XB&AD#
MNQ<KCH/Z%:\/^/\ \+=*^.'P2^*GPHUN(3Z;\0_ _B?PK(,?>37-&EB4#C@&
M5E;/]U<=ZZ<ES!Y9FV68GHWR2OLXS7(U.^G+:3^*ZTVW.#B++O[3X?S/"6U2
M]I'3[5.U1-63=URZ-:WV:.<_95^,VD?M&_LZ?![XSZ)<)<:=\1? GAKQ-C 7
M_B:%!_;> , ;-=21<^B9QSBO5_B#:>*[WP=K\/@B]@M?%%U9'^R;IL8#?+CG
MZ;L'IUYSBOP&_P"#>'XI:F/@?\</V4O&,UP/&7[-'Q@\4Z.FF7O_ "$4\,:W
MJTH#-@C*CQ#H^N@\Y^8G(QD?T;MV.>H[=A_^O(Q[4\YPW]FYOF6%>S;JQLM.
M5WE%+I:TM;7CIOM8X<Q_]J9!EF)ZV=.3TWA^ZE?6]URZIV:>C5[GS1^SMI'Q
M@TCP[JT/Q9O;F[N3>?\ $H;5+T:EJ03!Y=AQ@$Y522Q/W1@,1](X.SOZX_'^
M7?\ 6K2E>W'/XG^N*4  <=/Z_P">*XZU;ZSS.R5[?"DEHDEHDM7:[>[?WGL8
M>A]6PWU:]UK9MZZN_7]!:***S.@**** "BBB@ HHHH *"< GT&:*",@CU&*
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MQ!QP:^!_VG_^"HOPF^'OA4P_!+6K/Q]XUU%VM-/U1;4R>&M$)"XE<O&IUMP
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MKQIX*\C2?#&L6V@^$]'T?3M4L],4+K0T77-;UJ.=VVZ$R0OO5?+^=OF" /\
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M]'=;MZ7V:/[FH::::.VFVCMI_=T]WRL244451L%(WW6SSP>/PI:0\ D=<'%
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MUX;T6QU_4?A9K&F^'+/^Q="3Y];UM]D::(K+M1FW* 22P+L!^@JCY<'OG/\
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MQ&TTB,OXQT'P<T<8_P"$=RZ[ ZQ22H-XC 5@GZ;?LG?'/4/A-^SA\ O!&L_
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M/\(++4X)]:^(/C_Q+X7TN=)+#P]]LTC3G)<JK!M6""0"/.7&?,X("]2/$_\
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M;<^24X*WVDW]5@Y /7(!_.EI!T'T'3I^%+7P7J_Z_ _HOT_X/S\^_G<****
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M_9K_ &9;[QQIOC#6?&GC^Z\<>&+*3Q3XJ\2.X%AKAUS 32= $>Y I88:%2Q
M(*[64_J&491X9\2\4X#'8K->(T\ZXAG.7"T:7*XSJ0K5'*?$*FH>R]I>4HN"
MM>[;N?S-GV??2#X#X$Q^0X/A3A:=#@SARE2I^)DN(X24\+D4Z-*,(\.<CF\\
ME0<8IZTY2NU=V/V5\$_MD?"#QYK7P_\ ">FP_$<ZW\1N?#IU/X6^-],TP_\
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MA\.-=T/0=>FEB"##'>BJH(#M&JDIR7PW_P""@/[$7QE^(EM\'?A-^UK^S_\
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M?\+:^.?_  G7CB'>/#X\4C/A?QP(]Y/@L'!<GGZ=_P""GGA?0_\ @K-\7?\
M@FCXI^%M]86WB_XL_L#_ +1/[1?P(U6UNB?[!^,G@?1/#WCO0L$+EE'B31!X
M99FR%.[<V$.,+:V^7XV-_J^VBU]-.O8_K<^+7[0?P(^ (\'0?&?XP?#;X32_
M$7Q&/"G@4>/O&&C>&3XJ\3D(5T;07U^53KFO;5!**&<Y4XQG.KXC^-7PA\'?
M$'P5\+_%'Q.\%:%\1OB,-2'@3X?:OXFTG3_&GBM=!4'6'\/:#))_;^N!%(=F
MCC*N5/)92*_@O_;0^.UY_P %4O@G<_MU^,=!.F>"?V.KS]B3]G3PEI.K63Z=
MJ1_:T\<_&3P[K?[1^M9/"_\ "*1C0?"X4;0XUYF .7-?LK_P4&\4?L4_";_@
MLI_P3)^*6K?$OX&^"_C5'XZ^,2_M!>)?%WQ'T/3_ !/X6\+?\*64>!=+\<C7
MO$B)\/\ PX78+X*#+"HD#!5\LH[K$?[,E;7:]M=_Z7</J_DMG_PVQ_5+165;
M7D%[:PWUC/!=6UU:B[M;FV*XO1MR&7KE6!7N3S@XP0-0]#]#3W,#!OKN#3;.
M>]OI;>VL+8&YO+FX8A47N201C "X/.#@ <\\]X6\:>$_&NGO?^$-;TWQ#IHN
M1:F\TJ]6_C!7DY<?=Z#.XX R03BN4^,OPRLOB]\,?$_PYO=<U+0[7Q/I;Z>V
MJZ82NHV0;#"2/@@E2 ,$@'+\@\GP/]D?]DR']F'2O%]N/&%QXLN/%%UI;73&
MS73].L#HBL 8P"V."=S$CC@ AF([L/A<J659EBGF<EFRJ14::@^223BDW967
M*F[6M915[MJWSV)Q><?ZP9;@L-E*ED_(Y3XA<T^5V;]FXMWO)JUY*S3TM8^V
MI)8H(VEF.(0!R1G@YQ]<]>OK7PSXWCU3]I3QW;^"-+GGM?A3X8O!>>(]5M&
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M._L\2Z%\"K7X9ZK^T%\:/%/A/3+VT^%'AW15U&QL=,UG2V_L8:ZSJW[J;8
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M.]33Q>ZD>[;F4<XS\H)YX4X)KJ;*?SHH9H9;>XM[C_EYMRI7N P(W<=!CMW
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M&)Q4N7":RLF]-EKJV[)+1K7KT9#KK#K2^J]>_J?5VI:MI.A6K7NJZE;:?:C
M-Q=W 5,^V\X/3JN<9]S7Y\_$']LV\U@P67P0\-W&NV%TW]CZOXMUBQU;3=-\
M/ZOKRLFA,"$!W>4P\1;CD^6 I)RQ;R:^\"_%?X\7D\'Q6UZXL+[2M)/B_P !
MZ#]GT:33=>T[6"=8<:/)H+%FD7P^AB<LS2>8I5SD,1]&>#_#7ARTCOSX(\*V
MVF^$/B+I!LO%_A2T _XD/BC0\C^V<>F,9]2 <<#'H+#X7"V>*?-+31-63NKM
M/5M[VZ-JVAQ*MBL3=)63?;5[]=/NTL?.\'P(\5Z_JFL7WQA\5:AXN^(_PYO-
M,UG2/#]U>_VEX9U[PR#_ &[C 'KD')!!&,')(^F=&\*:5+:>)])\'Z);:=X
M\966EZS]EM;/GPGXH]\ #G'. !GL.E=!#9Z5H]M;SZY?_P#"2:QX7T<@6FD_
M\N&E]?\ B>?X8Z\?2M?:I?:X\/AXSV^BZ=XP\-&_\"78NC8:=?ZH!G^Q=;1
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M !*@@$X]2<;NS;6P-'3K5--LA"<!LM=761CDC+8X_P!CVZ'Z5S?COQ1;^ _
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MV?;?]$Q[X/\ ,]/IUK\I_$GQS^*GBJ_^W7WBK4M-M_\ ESTG2?\ B6Z9I_\
M@>G-5]-^+7B.:P_X17QQJNM^)/ UU>:7>:QI/VS^S=3L,9_Y >N?6OHOJUU>
MU^NJOY]4?3_ZJ8OZI=WVN][[<W?UZ'[[?LX_M$>,/@WXLL/$5D=2_LBZN_\
MBKO"EUC.NZ9V920?^*C!.02#[Y%?T>>&_$FB>,="TCQ1X;O[?4-&UZRT_5])
MO;3!^W::^QD89QD#<0,=#\N>*_DET?4K&]TO1]<TJ^_XI^ZT?2[VSN_YY/\
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MZ?L>#HX;&X*CCOM5*5.?NMV;G3ISNN\6Y-*UTU;?K^2$WQ]\2:9=^*(/BUX
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M"OP'KG@/2_!_A6"?3;GP]:Z.;WQ)_P!!/_A*.?\ D"?T/Y=>/Z?OV1OA=?\
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M#CW6M.BG=[7=O5_YBLNR^Y?Y!1112&%(W0_0_P J6CK0!\[?M, K^SM\??\
M:^$7CLX^GAS7!T_X"17\''_!&X?\;&_V>3V_X2751_Y1->_QK_0-\9^%=*\9
M^%/%_@;6HI?[(\8:!JOAO55@SN.G:[HSZ+.$QSN$+N%QG;WRN17\FW_!*+]A
MOP1X/_X*7?'&!?$>MZU;_LPWOB:[\"6N1IOVW4WUP>'V?7,AE+*K$@8() !.
M,D??<*XN.'X=XL@WK[--]N6;E33OZZ?\!G\X>+^28K%^(7A1B\(](\31@_\
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MBSC6Z]M6ZW7QKS:/N. O^2'X37_5,9 OFH1NO5=5NNJ1;HHHKQS[$**** #
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M4 %%%% !1110 F!Z#C..!WZ_GWI< =!110'_  _S[^OF%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;:/]I?XBZ?XZ^%G@8^']$UOXFZ+K&A^(_P#A1WAS0/%:_P!MA_"Q\'>+F)#
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MT(^-OBEX'3PT?#/AWP!+XATB6-Y$\6%P-C$3 -&:][_P75_:QTZ\U'XLZO\
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M[8MY_P $L_CM\9OAKI6F?M.>+K_X9_$K2_!!\.ZSH"^-_ WA_P -_P#"+_\
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MO#GA9?$$+H520")S$2&!8[2GYK>(/^"YO[87AS0O%?Q\OOV!?#NI?L4_!_\
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M?L.?LQ_M=GX#>"[?7?CK^W%HW[)EUX*;QCK!TS0_#.N?&CQ#\)/^$RT37?\
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M\?M@6?[=O['WP6_:FL?!\_@*Y^)VD:M)J_@B\O5U!_#WB;0M<USP_KVB+K*
M!U37]%<*_4 1H1(Q+M]T4&04444 %%%% !1110 4444 %%%% !1110 56GAA
MFB,,RYA('?KCISV&"1_6K-% 'XM_"#_@BW^R_P#L^?M*Z-^T5\$?B+^UC\.;
M;1/'FJ^/K7]GKPG^T'K6G?LTC5-?:0:W _PHP\(\/'^V'\0GPT]PL1G4!5/F
M+&?1=2_X)*?LKZQ^SWXN_9?O;WXJ/\./&/[4I_;"UED\9?\ %1'XHMXVB\>_
M\AC^P,GP]_PD>BAQX:,;!$##S%W%7_5W<H[_ *'_  HWKZ_H?\*=GV?W"^L>
M?XKI\S\X_%/_  39_9_\9#]N7^UK[XC _P#!0SPYI/AGX]FT\7#%GI>A>"CX
M#T5? JKH)_X1PKX=.T[VE ;D!L9'RM\?/^"#'[%'[1&L^ -<\4ZS^T-X3'@[
M]GWP-^S'XCL_AE\:=:\#Z?\ %SX/^ =%.A^!=!^*2Z(H'B,>%P9&5]RH_P K
M%67YA^XN]?7]#_A1O7U_0_X4<K[/[F'UG^\_O_X)^?7PY_X)Y_ +X9_%;X+_
M !?\,2^/AXI^ _[*Z_L?^ [35?$\NHZ2/@ZDGA\HNNZ0(POB#Q&7T*(_\)+G
M+AG&QD4[_A?7/^#>[]@W5_"GPG\*:5J?[0GP_P!8^% \<V-A\0?AK\:]<\#_
M !,\7> ?'OC6;QYK_P ,O&^OZ''CQ%X!77=9$GD")'A<?-*0RNO[V[U]?T/^
M%&Y?7^=%I=G^(?6?/\5_F?C'^TM_P1._92_:'^*&G_&>R\<_M,_L]?$F3P?X
M9^'WB/Q#^RY\==:^$FI_$CPMX%T8:#X$C\=2)&Z:\WA/0,1(1M=DW+F1E<R=
M%^TI_P $8?V1?VH?B=X:^,'C_6?C[X<\<:;\-M'^$7C[5_AE\:_%WPZ/QW\"
M:%HRZ+HNB?&UM!"MX[V#&7/E,ZG800VQ_P!?**0SX8\ _L*?LZ> OV*;#]@9
M?"^I^(OV<++X;:E\)3X3\:ZPVJZG?>!M9>19-$UC6U59'<-K#*I"Y)56"\%3
M\L?"#_@E=\%_V//V:OVG?AA\%(OC5\?-0^-OPN\4^%?^$2_:%^-.L?$5K_2H
M?!_B+0O!GPRT+6_$93PUX$\-DZX(A(JY0.'#.@4)^QU%37_VA7;ZW>K\GZ[K
MR _G8_8C_P"")OPTT+_@CY\/_P#@G_\ M/:1KFB^)_%&KCXS?%+5_AGXQ;2O
M&NB?&9]>_M[1M:T7QLD3[?$/@](]!\,QRE?+8:)M#(I9J])^*W_! #]B'XM7
MWA'7-2\8?M4>&O$&E_#CPO\ "_XJ>(_!G[0GC'PYJG[2_A7P-H8T+0)/VB=8
M3=)\0O$8T/;"_B5C;R<2@/M $O[O450'Y7_&G_@DY^R9\9K;]E'3[73_ (C_
M  >M?V+B+/X$-\"OB!JGPW_L#PL)- $W@K6!'YG]O^'_ !&="2-UVQY.5:5B
MSLW@L7_! _\ 8'M/C8WQBAL/C9_PBZ_$L_%FP_9G/Q>UP_LKZ'\4,)J__"9Z
M-\$A$?#BZ[_PD:_\),GS21+XNS,H5"Q'[E44 ?D!\./^"./['WPK\:_#_P"(
MG@R7XM6OQ.\&+\>1XD^)U[X[34O'/QKT[]I%MOCK1_C?KAT!'^(*0E<^#,QJ
M/!XT:(PRG# \1X[_ ."%'[%_Q#^!'[,_P1_M;X^^"+?]DS1/$_A?X/?%7X:?
M&#6?!'QOL? _CK7&UWQQX*UOQUX?4/KWA_Q6?ED1XS@E-H5E</\ MM10!^?O
MQW_8*_9R_:)_9#M_V*/'FE^*W^$6DZ/X#TCP[<^'_%NLZ7XX\/:AX$:&3P-X
MQTCQF4EF_P"$H37-(5T\1N@\UI,.D:R+M^4?AK_P0X_8B^'/PS_:8^$NK#XZ
M_&'P_P#M;:5X#TCXV:M\;/BYK/Q&\;:]J7@8D>!O&.B>-RD7B/PYXE\+,R"+
MQ-&RL&T1,1F*-O,_;"B@#\O_ (!_\$N_V=/@%^S5\:?V68=;^,'Q;\ ?'^SU
M?1OBIX@^.OQ2USXE>.=>TC6M%D\-C1DUS7(2-$T+PIX<C0>#XD4O$[L79V*-
M+QG[+?\ P1__ &:/V2O'WP9^)7@#QG^T/XR\9_ CX=>//A-\/[_XQ?%.;QFL
M7@;XH:\FOZQHTP&@6\D\7A:>,CP5&CQ)X5@)APT+22-^N=% 'XK^!?\ @AK^
MPI\,O"O[8O@;PKIWQ1@T?]N'1M7\-?%:XG\='4=3\(^%O$&M3:_J_@_X72'P
M]$O@+PV?$.LOXD>,)<,LSPME8X@Y]H\??\$J_P!FWQW\8OV0?C?#J_QA\'>/
M_P!B_P )>%_ 'PXU;P!\1M6\,#Q9X$\%'09=%\&_%1$4OX_T)I=$#RB3R7D:
M5\R ,<_J!10'ET[=/NV/P7^&?_!.C7)O^"WO[07_  46\8_#+1O"?PWTS]GK
MP3\//@_J\7B'2=0U3QQ\3]:$G_"=?$W^PHW\S0'7PXH\)X\2MYLC_-$JC.S[
M)_;A_P"";7[.O[?J> -8^+,WQ(\$_$;X2WFIZA\+/C9\$?B+K7PG^,'@7^W2
M$US1M"\;:"=__"/^*$51-&Z,'PFS:_F!OT?HH _'?]EO_@C7^QC^QI\7O"'Q
MW^""?&[1?BMX=L/%&G^./%NL?&/Q?XFU#X[-K\IW:M\;TUMY#X^UZ&9Y&\)-
MB-(LDH)<NR]O^VS_ ,$F/V7_ -O7QYX&^*OQ3U#XQ?#GXK^!M'U+P9:?$S]G
MWXIZQ\(_&^M^ ->U5=;UOX9>,=7\/!VU[PRSIQ%(V\,[D2#8B-^J-% '\_/_
M  4 _P""9B_M6?MA_P#!*>73?A-HMQ\ ?V0_$OBKQ3\7OB!K'B1?[7/A3P)H
M_AT_"KX,+H*'_A)_$,?B7Q)I,?B)Y!E4(!=SN+'[BU7_ ()K?LZZE^V]JO[=
M1O/BGIWQ8\5_#D_##QWX)TGQU]A^"'Q'\,#09/!*_P#"<?"[RGM_$$D6@ZML
M5II%C5A&7D:5HTE_22B@#\)?A9_P0._X)_\ P9^+FG_$O0[#XZ^(_#_@K6?$
MOBGX6_ ?QK\:=;\3?L]?!CQ-K[NK:U\*_A<ZK%X=\0Q_VUK#^#F628Q*70JC
MM%+)[9\+O^"0/[)7P@'[*-U\.YOBQX>\7?L@Z9\2_#G@+Q]:>.@_C?Q9X$^*
M.N:]XB\;?#/XK:V?#H'Q \ _\))K3O#X;(18F* 892TGZW44#N^[^]GY7?#3
M_@D]^R]\'='_ &0=%\'3?$_[#^P]\1_C#\3/@A_:OB\7TC>)OCE_PD!\<P^-
MW.@QMX@T*3^WI3 <QB,EBW*DOSGC[_@C]^Q]\2OAY^TSX"\867Q)OK#]IW]I
M-OVL?$>OVWCB73?$?PX^.RZ2FB:-XT^%.LZ"L+^!)O"MO&_D-")(T;S27G4;
M3^N6Q?3]3_C1L7T_4_XT[ON_O?\ F:?6)?S?^3?UUU^X^$OV)_V'/!'[#'@+
MQCX!\(?&#]H?XR:?XO\ $G_"47NJ_M+_ !>UKXN>)-/\K1DT2/1]#UG6T230
M]!VH&\J,$R.2&+DJY_&+]CO_ ((&?#O7/$_COXO_ +9^E?%>V\80?ML?&'XY
M^&_@[H'QVU?4OV?/B3X9_P"$U_M_X4>-?&WPLT(?\(Q_PD2INED5'1V5,$,'
M7']1E%(R/A"+_@GU^S?-XN_;.\4^(_#6M^-K?]O"T\*V/[0?A/QIK1U7P1KN
ME^!_!0\!:%I&BZ$WEC08T\/'#;=Y8$-\A4@?+'[)'_!$S]C7]D#XM:;\:/"E
M_P#&KXL>,?!F@:IX5^%:_M"?%[6OBYX;^#/A?7$;1=;T/X5:+KIQX;SX= \-
M%W$G[H%"JNX\O]EJ* /P9\._\&^W[ WAGXD^'?'FA7G[0MO:>"/C1I7QR^&_
MPTN?CKXMO_@_\*?%>B^()->=? _PP5U\,Z%H7B1EE\\2+)*(V@CCDVQ")9D_
MX-]?V![/XEK\1+"[_:-TVUTGX[:1^T;X&^&-G\=_%R?"#X;_ !1T;QP/'<FM
M>!?ACN7PUH)\1^(!))*KQNS+L2-U*E#^\%%.[[O[W_F.[[O[W_F?DA9?\$>_
MV3M&_;/F_;=\/W_QM\)_$'5O'@^+GB3X:>%?BYK.G?L^>+?C$BG=\3/$'PMC
M(BUSQ*5."^](G<\1;0H'FWC'_@AQ^QKXW^(/QM\?WOB/]H;3[?\ :!^+W@3X
MZ^,_AYI'Q?U?3/AE8?$_P-XT3QXGBW1/!0\/^7X>N/%WB+2HSXS+,PD"LJ%%
M*E/VXHI;;:>F@C\5_P!I;_@A;^Q'^T_\</%_QN\7W'QU\$ZA\4;G2[OXY_#[
MX4_&C7_AU\(?VA!H8'E+\6/!&@L6\2$$'SG:>)F VDC<6KZYT;]@WX!>%/C[
MI_[0GA[2M9\/>)=+_9CB_8^T3PMHNM&P\$Z'\'-(UM]=T31M%\/B,!-<0;2D
MIDD+J'+[2FZ3[OHH'=]W][_S/D_]D#]E'X9_L5_ /P)^S?\ !NX\37/P^\"-
MXG;1O^$UUL^(_$N-?UW6O$&N!]9(!);7]:8D$80%UYR&KZPHHH$%%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $" ?@# 2(  A$! Q$!_\0
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M*,ETNKZIIV9+10. !Z45U'$%%%% !1110 4444 %%%% !1110 4444 %%%%
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MJW_LS6+7^U+W_C\S_/KQ_AWJAX/T'PYX/L-1U72KZY_XFF/MEW=_\2WZ<?T
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M&'A?Q9XD_;(^#/\ P2B\7Z9KTW@+_@DM\:?CO^TS<:M=KJZ>']>^&7B%,?\
M!/C1$UJ<*-=G\*^&OC=XU'ES;1O^#L:R*"K _P!8WDQJIV*HVD'.!NQV![CC
M(^A(.>*^6/@_^S%X+^$'QA_:)^..D>)?'WB[X@_M+^*/ ^O^,;KQIK&D:E:^
M%=)^'?@T>"/!G@;P-%I6@>'#H?P_T*V75_$(\/7UQXGE'BWQ3XHU!+K==HB=
M#G5>;8.;4?[+]CF\G3YO=CG+S7,LSRJ2LHOEA_:E=-*T7++*-VN917+/ .6
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MS?V:Y[;<U-4TDVF][2B?Q,?M,>._AY^T9XI_;U\0>!_$-SXD^%?Q'_X++?\
M!(SPO:>)M U+5O#O_"6>&E\&_!CP[K6N>"M95WN#H/B4&1O WBSPE,8O&61X
MY\$B830L?J'QU^PM^R<GQV_X+%?#"T^#?A+3?AK\&_V-O@U\8_@O\*M,%]8?
M#;X/_&CQK\,/C['XF^-/PL^%ML4\*> ?C/(/A_X+G3XG^#_",7C6W(9SXN3_
M (2N>U;^L(JP(&<Y4!?F.,A?FZ< XZY ]?3+CMW(<'C!503S@#(QTX///4<\
MFL,13?U-8##0<&\M=YR>DE++,JRBFU)M7_LV>6_VG%<U_:57%\U1O$O7V*^N
M2QM>3E*5+V,6G\-\TCF?,G:R?)_PFI6M9*2]Q_5G_+'J_C7X)^,?B-_P3X\2
M_P#!4K7/!.N_L<>)?^"8G@+Q-X4U7]J9M!;]EG7?VQM:'AZY\=ZG\47\>-_P
MK/7/C.WPUF,_@!/&Q;RS<^)W\"1CQFZBOG_1/@S:_%7PU_P3 ^%GQ8T+Q;XJ
M_9S\=_\ !5?]MFQ^ /@_XC7'BV&\U_\ 8\A^"_[1/B+X0>"=;T_Q2DNO>(?@
MSXFT#1F>W\)>,H7A\5?!R7P[X+E23P!<;*_L>VKD<X*[B ,[3O'.>PR,$#U
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M=ITVW"M3BFU=.R7-%7LVW"6L9=7YE9^";'1]9_X0"^T/[3;VMY]MO+NZL_\
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M#T'/7@<XZ4M%*R[+[E_D F!Z#\A1@>@_(4M%,/Z^\,#TI,#T'Y4M%']?C?\
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M^OXXS7G_ (\^,'PY^&.C?\)'XQ\1VVFZ?_SZ8_YBO\^?7U[Y%>?_ !"\80>
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MY,_G9/5??;KWVW_ ^2/B=-8^5J$$_P#GG^?^<YK\[_BI#X.FBN/MWVFV_/\
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M'.K6:<E%W=KW3E'JWND>7_\ "-SV>C6\_P#97V;1\_\ +I9\^^>..!^%>?\
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MX>ZY_H\\\%MIMO\ ]/??@]NGZX^E>P1?#']HS7;7R=+\ :T+?_ITT?I^?/\
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M2LGHDN;2W:Y](:QX;\'?%2U\^?[-X<\0?\OEW:=?[5]O\Y'!' KW+X+?M?\
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M>UV?TF@C[P;!//*^OZ<T_)]5/U./TZ?KZ5^+?A7_ (*JZMI<I@^+WP;U30>
M+%?"=V/$M]? =<1J4 R<9(.3Z=17TIX3_P""E_[.'B.7R-0U+7?"C=SXKT63
M2OT+/Z9Z9[?3U\-F."Q:O&<8VZ2>_HVEHO7[C\ZS/PRXYREM8G):LE9M2H\E
M5-+K[D[JZU2<=FM6[I?H9@^H_P"^A_C3LMW!(XZ@Y_/KWKY>TC]L7]F76IH+
M?3/C#X*N)KA_L\=NFIIN+C/RE67 '..2PQQ7T19:SI>IQ"?3;ZWO8^Q@N$<'
MVR&(_E_AW>UI]'!NSV<7T_N3?Y:'R.*RS-L'&^,RNO16UZM"M3CO;XJE*,?_
M "97Z-W-<J1L&>@.<_5N?H.OTY[4TL,,P.3D#&?4GI]>GH?K7A'[0_QKL?@#
M\+?$/Q0U3P[XD\1:9H"@WMGX=L&U'4+2.7>#J;J9/ET>$HK3/MRJN@VC?M7\
MJ?V3_P#@IOK$WB#0?"/[3FJ^'=0T+XD:U]C^%WQX\/P:3X;\":_J+R,TW@K6
M=!<RQ^&?$/AGS-&:80^+/%K3MKT?F2J8T=?<P&09IFF"JXS!TO:1IIWA#EE.
M7+><U&%W)M1^SN_LJ1\5F7%.4Y3FN7Y3C).$ZWPR>D8WTC=NRM>W5^=C]U B
MX&1SWY-&U?3]3_C7EFL_%_X8>'=5TK0-<\>>%]%UC7]*_MS2=+OM6@L+[4-*
M(7.IQJS(QBQ@;F4'(^\>@[W3=8T[6(!=:9?6U_">//MF5U)]-P'7']:\AT:D
M4W*$DEHVX323O;5N"2U3ZZ'NK&4I248U*<I/:*G3<FNEHJHY/2VT38HHHK,[
M",'Y,_W3^?/^!_ _2ODW]I_]G>S^-GAJ"]TLIIWCKPSNOO"FL!0K1R ,S:9(
M0=HBFV^GRN0<E6)'UF-H7KD'/;KV_"D!0]B,\$<\Y&,>G?OBN?$8>.(@XO9J
MW=6>VO1K=.VO71G;EN8XO*<;3QN#FX5*4E)-/?5<T96LW&23C);M.Z::1_)%
M\;/A7>Z^-8GM]*_L3QQX8O/L7B32;OOJF.O!QCT[?I7PQK$VN37^G^%8(#IM
MO]L_TS5KO_TR_P">_P"%?UC?M=_LP0>/K#_A97@.R-OX_P!!M6%S:VPPWBK2
MD'.B2M]T9.2APH(X]!7\^/Q@^&/VP7'CGPY!<G4,?8?$FDW?_+@,_P"'<GZB
MO@<RPCRF6BW>C2\]-D_G_P ,?WOX6^(&$XVR=9?-\E6,5&=-S7,I\B6SDFT]
MXNVJ\[I>3PZ;!!8?88(/]'^QG[9=_A^?I7P?\3O 8\'^*-1T3PYH=M;>#_B-
M>:7>^)-6N[,_\A3_ *CF?^9=/^<=OM#0=8%Y]H@GG_TBUYO+0\]?IGO7+ZE]
MA\>:]<:'?07/_"/_ &/[%>?9.>O]<'UP?2O6X;S-X7%+%XMO797LM=+ZNW5/
M8^TXVRS!2X>RSA[!QOG#;<I*-WRMMZM)OX6]Y>1R_P *_AOX5\+>"/L/V'3;
M;1M4L_\ 3/M?_0+_ "_/@U[1H/P]_9>\5>'+?PK?:5X;T2XNM'U3[':6EX0+
M_P!=:_7T_6OB?1_!,%G%XHT/Q'\1O$FAW'_$T_L>[N_^)EIEAI>?Z=,C^77N
M/"OPQ^!_B31K?Q'H?B/4M3_LO1_[%_X2&T\2:SIO_$T_]U_K@?D#S3SG+EB\
MX6<+-+ZQ:7S3LEJGT6QYV3Y8\JX=>!QZOE,E*+3T;;3BUKKJVU\_0T/"'P'L
M?@#X\T?2O#FJW/BWP!='Q1>_Z79_\@_5/[%_YCF?;_/6OL#X2^ K[4I;>#2K
M'_B875YJGV/[)9_V;IEAU_\ K]17QO\ #'XD:KK'Q5N?AE?0:EJ7]@WFEV5G
M=VG/V_\ L(==<_/!/7WK]@/@SXD\*Z#JFH>!X(+FV\;Z7_INL_VMD_;]*/\
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M$=KO?S3^[?YGL/AQ32QF59LI)VOSOF7FU?F7?1'J'CS0? \T6G_88-$Q;?\
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M2O[-\0:7_:EEK'_4>TO_ *#73I_^KBO4/VKO$GQB\-^//!_C'5?"ESX)N/\
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M/H]_I^JV_P#Q\:!>?Z&?^H7_ )'/J:_1^&'PK\6O!MN)_P#B9?VI9_Z9:?\
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MZ/\ \NG7I_G/I[BO6-'F@^RW$\'V:YM[7T/7\?;IGU_&O!_@!^SKX.^ ,O\
MQ(Y]2U*XNM'TO[9=W=F?\GCMC]*ZCXJ?$[2O!.@ZAI5C??:=8U3^U/\ 1/;I
MG'3MW[_E7K\1YEA&OKB>ZZ/2[5MKV^5CY_),+B\5C'A.6SONXV_&R_-GR/KW
MB6?_ (2/6/L,'^C_ -L?R[<^_)_.NXAFG\W1X/\ EXNM8\+\>H_MK0!_GGZG
MBO)]!LY[S5/^GC_C]_P_/^G6OI[X'>$5^(WQV^&'@F*RN-1MM3U?^V]9:U.!
MI^EZ#W)]/4<8[<]?PK$?[7G*M_,FK?XD]EZGZ'Q XY1P%G/UV27[NINTG_#G
M>]VO7]=#^I:RC$5I!&1_ ./KEO?CIW-7*H2306]N)IY1!#;J";BX( '&#RQ'
M'09ZGH!P:_.?]H3_ (*(> _A[J<'PE^ .@W?[4/[2.O7!L_#7PG^&(DO],L-
M3(9%/CCXGR)'\+_":QZUA&C\6>,O";,6*LT?DL9_TU;+T7Y(_P S9.\I/O*3
M^^4G^I[1^UC^U)X4_9>^&O\ PE6M6P\1^/\ Q#>IX6^#_P ,;"X:3Q1\2_B#
MK5Q%I.AZ)H&D.R32PVZZO'K_ (PN@0/"GA2*:YFCD"Q[_(_V(/V9?%?P\M_%
M_P"T-\>';7OVFOVBGA\3_$N\N[(%? ?ALR.V@?!CP^$625="\$Z"GASP\9S]
MEC\4MH4=PG@[PH\4D$?._L\?L8^,W^*EO^UC^V!XET[XF_M/MH[:%X1TW2"R
M_#/X+>&,:^!H7@/1%4&1BVO:Z&\3>)I_%-R/[;<PRJXW5^GM,D**** "BBB@
M H/ )]**.M &%K&C:;XATV]TK5[.WO\ 3]0MFMKNUN8 Z2HX(8.I!."2"!C*
MG!#=Z_&OX_\ [&GBOX0W>K>-?@9I-UXA\"7=T;S6/AZ=NIZEH;+D,N@MKK.@
MT!=I9X@[,HR067YZ_:X +[YXX'/Z<^_X4FT'J<^Q&<CTR<8R"/Q/%<N)PN%Q
M4>7%1C)6]V^ZZ:.S[[-?<?2<-<69OPIC8XS*JDDGI.FY-PE&ZNN6^DK7M)*Z
MV::T/Y4]8\$^ /BU:B>"#^S=0ZWEIQIOV#_('Z]J^;_$GPE\<>"?]18W6I:/
M_P!!:T[XSQZ_YZGO_2K^T#^Q-X(^*[S^*?!5S_PKKXCK=B[_ .$CTJT5M/U"
M0#YO^$@T50(=<XQMWL"6R.#@'\H/%NE>/?@CJ]MX0^,VBW.BS7=Y]BT?Q9]C
M_P"*'UW@?*=;/*D C*D @G! )Q7P699)B\+>44W&[LTNEVUHD^G3^E_9'AUX
MNX'B!+!4LUCD4U'FE"HX7DTESVYFE).7,KQOO=I)J_YHPWD%YF#_ )>/^GOK
M^/\ 7_'-:'DP>5_S[<?X>W^&.>>M?<&O?#'P!XJBN+B>QMO[0S_Q]Z2?P../
MU[UX_K'P!URSA\_PYKEJ+?\ Y]+L]3T_'I^?.37@8C,I82RUWM:[W_X='ZWA
M^*\FQ5[N/G*T5>VG->UE??YG@_\ S[_9_P#1O7['V_\ U8&,=:/)$T5O;SP?
M7[7_ )Z^]=1J7@GQ7HW_ !_:'<\?_6_']!V_&O9^&[Z\_P"6%S;=?KU^O'N.
MGXUMKC$\7C&W'31[6MU3_P CZ'#9EE'U2ZS3:^RV\E97\E9GG\W@_P .3W7_
M "+GAJYN/^P-HW_Z_;]*]@\$^%K'1[7[=]AM=-M[K_GTL^,_6M#1_"EO9_OY
M_P#CX'!_^M_+V[UH:]KUCH-K<3SSY_T+[%]D_'K]/\^M)83!8IWP<4N_NQ_2
M/X7^\XL5G>.^J>]*2R6[3J2<M$VU*3;:^%>]OT#6/MVI7^G^%-#@N;KQ!XHO
M-+T6SM+3IG'\J_IZ_9J^#UI\"?@UX)^'UO#$VH:3HVF_\)!=+C=J/B%XD.M:
MHY)()EGRP8 #8J*<G)/YD_\ !//]D#7?[6M_VAOB]IGV9^6^&'A[5<MJVFQJ
MJDZQK'&TW#.^JB-&((6428/RA_VS8[LJ.&&!WYQC]>1W[$8S7Z#D>6K"898E
MZ2FKVM]E-:M65KM[KUT1_$'CIQQ'.<X7#F59L\YR7)))<]_=E5:=XIIOG]G=
MIMMI322NT[61T&?2B@=!GTHKZ _ PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **,CUZ=?:DR/4?F*/Z_3\]/4!:*3(]1^=+0 44F1ZC\_7I1D>H_/UZ
M4?U^GYZ>NF^@?U^OY:^FNVHM%)D>H_.ER/4<YQ^'7\N]&V^FV^F^V_?IWZ7#
M_@_AO]W7MUL&!Z5XW\3]$^(OBFRBT'P/XK?P)9:C9,-5\8Z39:9J7B;3LC$8
MT:/7(I/#_P PVEWDBE9?F>- I*M[)D>HHHTZV#:S735/MV/BCQ3^Q/\ !O7M
M*MM,/AO1[FVMO]-N[O5(V.K7VJX!&KOK"[I X')&W QR1P*^2_CO_P $O])\
M86T$WPSOM-\'ZQ_97]A+>6S:M_H>F8^ZH5CSVPV&SVZU^PP))^\?R^AZ#/Y?
MT)IXP>I!STXQT_SG\?0UYV*RS"8KXHI/Y?DTN_\ 6A]1EG&O$N5**PF9S45]
MEZKTNV[=E:VUMD?S*W?_  32^*/P9C^&'@S3]0T-O!5TA\-ZQXIU8ZQJ+V.I
M9VZ"VM+H)4[2?E#$A,\;NM?IK^R#^PM;_ >\\1:[XH.B:WXBUV[&-5TM63.F
M]D.X#ELGL21T&:_2::WM[N*6WGBBN()QMN;>X!*D$  $8=>P'( XX(ZBW'$D
M$8CCP !A2?P';^70'K6&'R3!X5[7::M?UTT:>_3J^E]#U<S\2.)<VP?U/%U;
M)IQ;2:;3TNGSW3L_[RZ[[PP106D(@AB%O!;@8 &%Z<XY/KR<GTXJY@=<<^M%
M%>NK6TV\CX)N[;;NV[MO=O7?KW"D..I'3\^*6CK3 YSQ#X<T;Q9I5_H6O:=;
M:KI.I6IM;RSNT$B2H<Y#=".3G*E6!''!P/R.^-/[$GB/P%'>:[\&M/N/%7A%
M[E&_X5[=R12:EH.ER']R-%?6F:/^P?"Z;7 CW^+\DI%-+C<?V14  D9/;@8/
MO[]^:;Q_>(X[C/4?7T/Y@^U>?B<NPF+3YE9ZV>K=[;OY[K9GTG#?%N<\)XV.
M-RBK*$E9.#DW!I--KE<K1;_FC9VZ/4_DTU[X,^%?$E_J']AS_P#"-^*;7_C\
MTG5[/^S?^)I^/7N.N?2N'A\-_%OX>ZA<_8;ZY^S_ //W:?X?SZ=17]+?QQ_9
M0^&GQIAGU">S7PKXU#&XM/&N@64<6JF0!=HU< A=<0D,?+G??R,,, /^7/CS
M]G+]HKX8:A]@N?!]Q\3](%X++2/$'A8A3?:7Z:YHAXT #IE21D8!/6OEZ^6Y
MMEB;P-Y)W:Y;[7?:^WH?U3PGXW8'/L&L'G<E#.-$G4<8Q>WPRFU%^ETUV/S*
MUCXG?&*\M;B"^\5ZE;=_^0/G^O3OGZ=Z\GFL_BI>3>?!I6F^),_\O>K:Q_9O
MY?\ %-\>WU]^/K#QYXV\*WG[@6-S;:A:WGV+[)]C]1UQ_P#7Z_2IO W@;XH_
M%R2WB^%WP\\5^(;479LSK%M:A?"]AJ8Y)UTL0 !U)./?O7 \1G.+_P!C:EYZ
M2WZ]'U[:GZ?_ *T9%@L']>QE2E&R3;YZ4;>;?/&R^9\LS>)/BIX/M;>>#P!X
M2U//^A?:_P#A,-9_T_M_T+?'?%?J%^Q)\%_V_-"T_5?BSIGP@^ _A34/'&C_
M -B:!/XK^*OC)]6T#2_[7,PU=O#R?!)G+-&-XC_X2YF=>54CK];_ +,G_!.^
M'PWJ$/CSX\S:;XB\3?:7O;7P/;,FH^%-,E!"C4G+9;6YFW @RQ[%R!\SD+7Z
MQ6=M!;110P+Y<4/W01@ <XX.<YY_#'/K]!DN1O"7QF,=Y[J-KM>;WY=?GZ+?
M^9_&'Q3PW$3>39)F,Y44FJDTVH/3X8K[?9MKDU:7,T[?E$?V$_VG/C)?Z6_[
M7/[<GQ(\1^#8'U"YN/A+\!M+U;]GW2%.U5"ZO\4_A'XH\'^)_$")&@(C\21L
M"<E4+%S7W1\$OV9_@9^SCHQT'X/_  R\(^"?M%EI5GK'B+3/#>F#QEXO?2+=
MXX]6\<>,UC'B/Q9KQ;<S^(?$]U/*)"JA\F,#Z*^M%?3G\]^NX4444 %%%% !
M1110 4444 %%%!X!/I0 U5QGWX_#G^=<AXO\$>%_'>C7?A[Q;H>G:YH]V,7-
MG>6ZO&_'!&3N!Z]&Z=<C&.L5CD G@_C4A.,<=3CZ4-<VZ3OW2[>?D*$WA[2A
M*46FFG&3C).Z::<6FM;=[>9^,'QC_P""?'C;P?J-]XK_ &?M>74M(VZC?'X:
M>(+ID4[U!&D:)K+,SPJQ# +*01C;N8X)^'[OQAJOA"ZGT3XF>!_$GA*>UO!9
M7=W=6?!!Z'/3&/3OGCFOZ>^64Y ...1[<C'Y=?YXKA?$WP]\#^-X;>W\9^$/
M#GBB*!MUJ-=T;3-4%FY!!V+/&VS.!D1_B<UX&*X<P6+3=DI7;6UK[Z:77X_(
M_7>&?%O&Y.EA<XRR.=T;)*4I.%2*2MK]F6T=;Q=UK>Y_,]XV\8>'-2T:W^PZ
MK]IY_P"?S^7T_P#UUXO-XWT.SB_Y"F<?] GC_.![U_0-XK_X)L?LI^+]:GUR
M?P1?:;<7(.ZSTG59M.TGJ?\ F%@>4".X*@YSG'(K?\#_ /!/G]F#P%<?;K#X
M?IK,^>3XKNI/$[8'7C7!*,$=SCGUZUY'^KF*VO"W:[V].7M_PY^SY?\ 2(X3
MP>#M_8=5S2TCR1MS6^&[G9:V5WVV[_SY>$/#?QA^+^IV^A_#/X=>)-:U"Z_T
MVTNS9_V;X9X'7^W?$'';U]?6OV$_9E_X)J>'_ .J67CSXU:K;^.O%=I>G6+#
M08HW'AG1-87:?[;CC8*SZZ!P\P(0#E2V"5_4#P[X5\-^#[!=*\,Z'I?A^PC.
MX6NF626-HI]52- BG_:49[9KI2"% 4XR<Y]<'\#@>F!SGM7L9;DF#PGO63D^
M^U[ZW5K;][^G5?F'''CWQ;Q7A)9/@?\ A#R75>SI->TG%IJSG&SA=;\COM[Z
MN+#"D,:11@"-1P._X?YX[=JFP,YP,^O>@=!GTHKWNENG8_"VVVY-W;U;>[;U
MNWN]V]6]PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *K<L_)&3&
M>/?!_KBOSN_X*>?M)?%_]D']B?XQ_M!? 31_ GB3XN^"%\ 67@7P]\5+76K_
M ,"ZGJ_C?XE>"/ $<7B!/#WB/PAKS0@>)FE4V_B>T<30Q%FD3,=?HEC+-WX7
MI[<#]17YQ?\ !4'X(?%+]HG]BWXF?"3X-^%SXU^('B'Q/\#=1TCP^-7T;PZ-
M0L/!/QK^'?COQ"#K'B+7_#&@P ^&_#VL!?-O5621HX$AEE""/AS#F5)<JNXU
M\JTUL_\ A6P%T[:J+5U)](N5]+D2JJE.%9JZ?.FDF[+^S,>D[6:;3<6EUDE;
M6QX9:_\ !3&>;_@EP_[:<G@O18/C];6'_"J;OX&V\VLWVFV7[:O_  G1^!)^
M#/FQ#_A(%T?_ (7?_P 4]Y@D-]%X1?[2)6 ,C)^P_P#\%-)/'W[!7P+_ &I/
MVTY?!?P]^+GQ1\:_$[X9ZGX ^!?@CXG^-1XK^('@'XG_ !"\$6_A+X+?"K0/
M^%M_&?Q_X@D\/^!)/$$GAKP=!XTO]QUZ8)]GM]]OX9IG_!.W]H*P_P""HVKZ
MZ;30[?\ X)O+\29?V_=)T>VUC2/[0'[=6J>"$^$<WA5_#!F_X2G_ (1U"^M_
M'F20@>#1XUU\CS/M:R6Z?)WA+_@FU^U5X2_9U_X)]ZQXF^#_ ,4/%7BS]E;X
M[?MN:I\7?@#\#OVJ?^&=?C5KOPU_:9^*7CG4_#OC+X5_&OX2_&OX0^&+GQ'X
M2T*Z\/\ B63POXF^+_A!/%7A#7O%'@.XFM9MF2%?$3C+%58*4\V61^RI1BE+
M(9QSC$95G4)\R7/.<HQK)\[MELLNFY*]1/CIK%0E##U7[..4//9U)1;FL^A+
M*(RR2,6VU%1YL!"22C+^TXY@KV5,_3;]IC_@KE\!?@9\!?A7\=_AYX7^)/QX
MT'XC_M-^"/V<M6T70/AK\>])\6_#/Q-K?C33/#WCA/'7@T_!;Q7\1_!'Q#\&
M0:^CV?P(\:^$?"?CWQU<&/P=X*MQ?%*^A/B/_P %%/V3_A3HMAK?Q$\4?$WP
M[IVH>"=+^(WB"$_LU_M07WB#X3^ ]7-S!HWC#]H'P_H_P;NO$G[-OAV4Z1K3
MG6_C[;?"Q((]"NI9F*VMW);?F7\8/V$?'VH?L:ZE%^SQ^R9\2OA]\2U_;Z_9
MS_;,UCX._%?]KAOCW\>_C):_"7QM\(-=\1ZGXQ^+?QC^,_Q3^&^B_%_Q-X9\
M#'PU%X;/[07BSP,(?#FA22>/RWB6>&TS?V]/@A^WO^TSJOQUTV']GW]JSQC\
M*/C!^QKIOA7]G3X3_#_]LWX9_LO>'/@+^T3K.E>/]*^)UC^V##\)OVB_"#?&
M*'7(M?\  XMD\*^*?VDO@[);Z'XC\'3>"&2Z_P"$TE*DYT:.84T[9@L3R4I)
M)Q]B\GRK,8S24N5K^TWF:M>[246XM.*NA*5>I@98B'+@53FY).SY_P"UJF6<
MK23?-_9O+.[NFVY*Z]Y_K)XT_;T_93\&?$+PU\,]9^*UWJ7BGQAI7P_\36MS
MX$^'OQ*^(_@3PKX<^)^L'0_A7K?Q.^)_P[\">+OAG\'?#_Q2NT-IX'USXN>,
M_!MMXTVS/X0>\'R+X#^S7_P4[^&'QW_:8_:\_9WU/X:?%SX=W'[)GCQO"G_"
MR/&7PL^/.F^"O%&B:7\-M&\>>(?&7CCQIK_P7\'?#'X&I"UWJT7A3PYXP\:-
M+X_\'6]I\0_!;W7A3Q/:!_B;QE^RW^U[X4E_9W\1?LY_ +XG_##]JSPY\'/V
M4_A)XA_:9\ _M%_"-?V=_$7@#X8R>"Y_B3X,_:\^"7Q \5S>)/$4G@V&3XE^
M&O D_P )OA3\8O&,YUN.6V^,?@FWG,-M]!?#WX'?M;_"#]J3_@J??^!/A;J5
MJ?VQ5\,?%;]F[]I6;Q!\(]3^$O@CXD>"?V8_#WPJT?PK\5?!^L?$1?C7'K)^
M(OAJ.0CPW\(?%?@N3PA-:Q_\)@DR2Q0F*;H4\7=1S-Y?+.W;F44ZF5RC+*&D
ME%2G/FE+3FYVFVFGA).,)6KXC#X:5=?V8X_V+RK^99K*:S=2LI.T4HK9RC=;
M/ZU$^IM+_P""E/[*?B.X\<Z1X4\0_$K4_%OA'X7>(?C#H_@S6?V>/VD?"WB/
MXJ?#GP;MAUCQM\#=*\1_!RVUW]H+PM]HGT*-/$7P%M?BJ#_;.@S"-A<Q";XX
M\!?\%9;W]HW]AO\ 9_\ VL?A7H'A_P#9Y\1_%/XT?LS> /&&A?M2_#+]J1OA
MMHVF?&[XFZ'X)U;PE\+/B=X=^#/A&#XL>(?$$4Z67@OXF^%[67X/>&_%MY:?
M\+)\7^%K".1A\Y?LN?L=_M<:G^V1^SO\9OB[\"OVGO!]KX7_ &/OVA?A5\??
MBQ^TA^VGH_[1$GBSX]?%-_A'+<:K\+OAEX>_:0^*_AOX6?!WQ)<>'?$<OA&+
MX3^$?A 1$C0>._ 7A&/PIX*^T5? '[''[8$?_!+W]E#]CG6?V;_$_A/XI?LH
M_M/?L9CQ)-J?Q%^ U]X,^)7PS^"?[2_A3QSXR^)OPPU70_C!XKE?P^/A]X>D
M\11>'/BIX7\'>,))Y?L2> IYDB*=,8U%6HNI"<_:K(W-Q<>6C_QE%3*LY<XR
M=[?V=&&9JUV\MG%V2YK17JXE4N7#.Z57.87;2:A_JI+-\HD[*TKYLHY6FF[.
M>JNK+]F;K]O#]EM/C7=? B'XC:]J'CVR\7:1\.=5O]%^%WQ?U7X3:'\3=5).
MD_"_7OV@M#^'MQ\"=$^)DYDW/\,M?^*5OXW1F6%_"RR3QAO)O^"EOQ?_ &L/
MV<?V:OC+^TS^SG\0/V=M)T?X"_!CQ_\ $[Q)\/OC-^S]\1_BIJ?CF[\$://X
MACTG1?&_@3]JSX"0^!H[BWM)+<M<^#_&+F:47"[ $MG\3_8Y^'G[5/[(_B/X
MO?L\3_LQ:O\ $'P/\1OVR?C3\=M&_:@TCXG?!SPU\-(/A?\ 'GXEGQ]KLGCC
MP_<_$)_C=-\9O!9UK6O#EOX<\+_!J3P/XOCT/0C_ ,)OX1AFG,?U/_P4@^$/
MQ$^.W[ W[7WP9^$/A]_%GQ*^*'[.OQ8\ ^!?#"ZMHWAUM?\ %/BSP;K.BZ)I
M8UOQ#KGA[P_I -U>)Y]SX@O+>QMT)>>0I$\8X\0\0LNP-904L<IQ]Y3B[IUL
M%[2+IK5)4?KLO>OS_5%*-K-2]+"<[S.6'Q#2P+HIIVNE4=)MVE97_>.*Z)6M
M9:LY+X6_M)^-_A7H/P2'[:OQU^#&L>,OVJO&/@CP'\ ]*^"/[,OQE^%>FOXV
M\0^#/$7C6?P=K4NM_&W]J0-*NB>&=?O8O%OB*;X7^&8;?19H)D2]N8J[/XG?
M\%#OV0?@OIGQQU;XH_&:/PIH_P"S/XU^%_P\^.>M:EX,^(G]C_#[QG\<AX6/
MPMT75;V'PQ+#K,/B5?&VA3R^(/#;7_A3PK#<-+XQU'PNEE<"'Y6_;%_9I^-?
MB#X;_P#!/'X@?#?X=7/Q)\;_ +%'QY^$WQH\9?!C2/%G@OPWXJ\=>&M.^%7C
M#X5>,]#\#:OXZ\2^%OAB_B;PRWQ#7Q/91^*?&OA'PG=MH)4^+K::2*.;\^_B
M_P#L7_MR?';P-_P45U;5?V8+CP;XH_:4_;G_ ."?_P 8?A?X#U'XM?!S7-1O
M/A%\"-=^ EOXUU?7=8T/XEMH&A>(O#WAWP%KLGBWP\?$_E2O')%\/IO&)DM9
M+OLJ/ZSCGAHN,8+/9N4XJ,4LGCGO#4<LDV[+F_LC,\WJ5'+[>5OFN^9/Q:-?
M&4,JP6(Q2C/,'D>3[:6SJ65YQ_:T'!=%F&694UNK9ENT]/U?O_\ @KI^P)8-
MXNL[KXO>.+?Q-X#MFUCQ;\.[G]FO]JA/BYH?@A='7Q ?BG/\$W^#!^*!^"@T
M!Q=-\>8?![?!X(PW>-VD;RF]K^)'[<?[,_POT?X4ZWJ?Q%U?Q1)\<?#S>,O@
M_P"'?@Q\-?B_^T9\1/B1X&ET_2=</C;P;\*_@)\/?B7\1=>\)Q:-KND7=YXI
MMO"Q\,>'(-:M&NKPQO#'+\MZ]^S-\9+O]OW]LOXW1>!8I_AK\6?V ?@W\#?
MGBP:UX.)\0_$OPUXR^/VL^(_!HT4ZPWB71F:T\=^"IE\1>(X8O",K>;#%*3#
M(4^,/V6OV7?VQ?V,IOV#_C9/^RYKWQYU?P-_P3*^'_[$GQT^"_P]^)'P%TKX
MN_"?QUX/USP_XVBUWP_K?Q8^)G@GX*^.O#<DCZ[X5\8MX9^+UK*)?#_AF:V_
MX3$0K)'G2D_8SLM4V^5N2;<_]:V[-I+]W+*LI3TDW_::2:D\&CT:GUGZQ'2Z
M]Q.RT=X9.V]]-<SS1-::Y;=O?F_4/Q=_P4I_8I\#?!CX8?M$:]\>M*'P?^+_
M (S_ .%7_#7QCH'A#XB^,SXK^*(BUZ0?#<Z!X2\->*/%>C?$#S?!'B+PO<>$
M/%'ANR\7+XUMO^$%6TC\<O%X7G^N/ ?C;3OB-X4\.^-?#UAXLT_2/$EA#JNF
M6_Q \">/OA5XSM;=S,2NO> /B/H'A'XA>&KE'1/,\/>*O"WAZ\"8,T"QSQD_
M@CX3_P""?7[2FD>&OV1M:U/P#H5QXMN/^"OWQ4_;]^.'@K0/&7A6^T?X'^ ?
MB;HOQE\G2[?7=;B\-MX\U_PS/XE\&+XOF\)6CSW_ (QUCQ3=6<%[:0PR/_1?
M"C@L';/S<'OAFE<_GE>>>F,=Z=!S=%+$1:]^*4DU9P_LG*I2YE:]WFF89G%.
M\5_L*5G9R%+F6)BDW9PFY.RM&7]LYI"*LK7OE&6Y9/J_^%%[*R+@.0#ZC-&!
MZ#_/_P"H?E1THKH.H*:RA@<J"<'J >WO3J* VU6_EN<;<^"/"E[?6^JW'A_2
M;B_ML_9;M[.$R1D^A"[2.P)#>W3%=#!I]E9J!;6D$';$%LB]NYC1?YU>Q@EB
M<#)X_$X_GGI33(>PQ^9_R/\ .:;2OHDWO=12?WI)_.YH\7BZ\;3JU916BC.K
M4DFEY.HU;39HDP.F!CTQ1@#H!^5*#D ^HS12,[*][*_>RO\ ?:_XA1110 44
M44 %%&0>A!H) ZD#ZT %%%% !1110 4444 & .@Q11D'H0:,@=3B@ I, ]0#
M^%+10 4444 )@'J!^5+110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4F!Z#\A2T4?U]SNON>J[/7?4/Z_3\M/0,#THP/0<=/:BBBR[+
M^M?S ,#T%%%&1ZT:>5WZ7VM^6GIIMH 8'7'/K28'H/RI:*++71:[Z+6^]]-;
M^=Q:>7X= P/0<=/:BBB@=EV7W+_(,#THP/0?_JZ?E110 8'I28'H/R%!('4@
M?4@?SJE_:%C_ ,_EK_X%)_\ %4KI/=)OS2;_ !3?XC4'+:#EZ1<ORC(O44@9
M3T(/T(-+3$%%%% !1110 44F1UR,>N12;T_O+_WT/\: W'4F!Z#\A2T9'K0
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MJMJS#[UGK$:30L1TRR.6;L"._-;C@\8'3^N!]37G?POGGF^'_@F6\ELIY_\
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M!XS+'_@L1^RWJV@6GBC2-#^+^I:+JG@C6/&NDW5KX0TG%]'H/]B'5M$C4>)
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M\,);^\OM=\9:1X;UCP[;V7]I"^TW6671=:<Y^ZT>@:SK3JW574,#D"OZF_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* "BBB@ P/3_ #_DFBBBBP!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "8 Z #\*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #[ ;,# 2(  A$! Q$!_\0
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MQ.4IXNM)\MHQC!*/2SZKH[K7I]Q:HHHKH2LDNQ84444P"BBB@ HHHH ****
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M>>]^MS]6G^ZE[.I*//92LOY7L[;Z]]NP[>OK^A_PIU%%4":>S"BBB@84444
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MS!XFL;*616;3]8T;Q9+-/J,$]NWS%XWE*Q-.B/N 9>>1\[KJ>GL-PNX2OKO
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MG4?AC-XI\3OI7B[X@:#X>B!'BO6M<TVRNA>Z;ISSW1O+26X%I';7$#S??OQ
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M;*XC*AY$+!B"V2"#7 P_MN?M?AL2?&+Q,B!0RC[6J+Y>/EVK]F< ;<8 =L
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MV3Y:!44':JA0!61J6E?M=?#&W?4-!UCP?\<?"]B6ENM(UY+C2OB)<V<>1/\
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MP6\?BJV2WG;PC%<6%K IEU1=,\Q)3'IK7$:C/2^#_P#@X4\)ZEX/_:$E\5_
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M!"^/OAYXL\)3M\FO>'M2TZ0A-Q"BT='E"'!.;IMJC&6SO0%1NK^+7Q+X:O\
MP1XK\0^"=2AGAOO#>I:AIC6\T;+=/;:;=S6,=V+?#2M!,L D695:(JP(8CFO
MWSPEQ^"A@*N%J2IJJXP?-)KG2<DMV]+2OHMEY'^<'TTLHS=YUA,YA[>EED*'
ML'BU!RPF&4::<J^(O&22Y=.9.'O+?H8@9K:<WBL'MY1Y$T1!R\GW7D"D;E#'
M+ E1P1SCD_4O['.D>#-7^-^K7/CC1/[4\)>'_ASKFH:A:31F6&TM[.RC>YU@
MIC,[1)/%*L-L)[IV?,4,K*ZCY6N7, MY9%80S.L2Y1BFTX EW*"H!&&R3C#
M]=V-W2->U'PX=2_L/5KVPN-8T[5=!U.ZA?B72-0D$3P)L.2AMHHL8SE< C((
M'ZQBZ->LI4\-&5:,DW^[E:<4^MUJNRML?Q#P_F&1X+&T5B?89U0M&K4S%Q<J
M,YN7O48.]ER;M-L_3CP9^S7X3^'&B_&:[\8:?;^(-7\?>'/$'B'X-30VSS2:
M'X$>TBN[*\PBN(9HKF=+!%EV7<HB:>*W-I(MR?%OB-I.BZ3\0?@CX$T=?#HL
M/$GA3X<:O?>#D\//)K4]MJ^BZ7=7EW=7IM?(,A$[-.9+A7:0L64'I\PR?%SX
MGS2:?J#>-=>EN='\,OX-T>VGO(VMK7PXY1(+0(9,8@MUCCY W;/6DO?BY\1;
MR'3XDUV&YU/P^+9-/DFL;%)Q91(L<9M]<9AJ<3VT:J$M7"VJE0D)9%!KYJIE
MF=TZG-#"U9>TDU-N_*EJU97=GLGJTVFVE>R_1LUX[X$A]5HT,JPUXNTVJ>M^
M1+5IK3F[]#ZE_;5\%>'/A5=7_A[P%X8L]&\'WFN/JEQX]@LVEOCJP5I]1\)+
M(T:V=E9V+R?8XE#K=;$$<(F9<GR3Q/;K\,OV4M,T?['867C+XV:F/$4<-Q&S
MZA9>$])$-U9FV,BF8Q/<RO;A6*W)4>=)"J-O/CVM_$#QSX@T;5_"VM>*[WQ!
MX<\1Z[)XCGT[66-S%'JEM%%+=36K+YDD4U[>+,"6VQ!GR6"$-6A\3?B%J_Q9
MUG3=:N$M-.T_PSX>L?#'AFVN"K2Z7IL%O%'>&*.+<&>Z\H*"JD[FR>!FO3PV
M7YK&G9X>M*4H*,G)J^F[5DM;[NW4^8Q_$&1..(QN7X#"PJ/V2HTW!N$W*HN=
M-7N^6#;5G=/5Z:'U%\;;#P]X8^"G[/$6BVGACP]#X[T*RU3Q#:R>%YK[5-:-
MOJ5E;M)'JWV.1HI=1,AD$4$I<>:6";,-7M/QB^''@BPTW49(?!VD:Q!:?$3X
M;^&[#1O"]NT?B?P#:ZS# EYJ7B%Y%C\_3KJ<2!VA:8\&1]H8$_GG-\5_'VH>
M'M%\(W^K0WG@_P -VKW'AO2;JUM;F\TVYB<-:6::A<$2VZ,%CE(MV\F-EV[@
M0!1;?%7X@6U]JNN#QAK%EK/B*+0Y?$DMLGVA=5G\/W+KIEM*T@(:.VMA&6G^
M](.C&0E:S_L/,N:4_88F\F[VDE%:MI)6\[?*_4^BPO&G#&%QF$P];+\/44L)
M2J5'4IJ2CB793C%V245K9/5=6?6_[;/@+P[\+OL&B>!O"-L^B>)-?M-3U+XJ
M*(9K2RU>31(H[CP?&L3M<VHL[)4U**6:".T+3"W6;[8LENOP.6+$MNW;CNW9
M!W9YW94D'.<@@D'.02.:ZR_^(WC?6-,U31=>\1W<UAXEOK;Q!J%G,[7NEQ:S
M+<2Q7EU;VS[VM+B>SV3E5"Q1;S"&#H47D=HBC5F?"!1AY6B1F7  8A6*$L.3
MY99,YVDK@UOALNS' _OY4L3*=/DLY224VY6?,DDMGLGT/D.(,TEG>>N>4Y=E
MKP^$C.MRU)_5TH3BX1M*52$9NZVU=]7H-FE=&0JI:24+!:Q@'#' $LFX[43!
M!)WLN>JY-?T#?\$:[G4G\!?$2R4S2:'8>+52W28JR'47CD:]:,Y)5/,5N" O
M*@ D8K^?I&+M)=&4&TMHHXHY%4N/MMZH^RP*%#,\DK,JKL4X)^8KUK^I?_@E
MU\)-0^%G[-'AV77+:>TU[Q]/>^+[ZWN45)XGU8M>VD+D,RC;;RY4EP$&$;:Y
MVCXCQ3S#V."A2KT7&6(I74I6;YN1.7+;:R?6_P")_0_T0N'\]QWB&\SQM&>$
MRVA+GE+"XBG.BY*L^6/NJ5E>U[R::T6NI^E]N8U3D0 ,H=2(VP5()!' (4C)
M&?F'< TYH1(-ZG<BA7@B5Y+="[C<[.T>&*DG.'4MP<@YYK(\(4%7!CCC1,X8
M85HP4P" 6#*01A3U/&0<2_:K2,;7;;L^0LQ(0%>#DD +R#P3QWK^:Z&(H1I\
MLJG)+FDUS[.[=ETVTZ;'^M;56I*HZ<.=QJ-*-[?NDERS>]Y.VZT?9'A_QJ^!
M?@;XNV=I)J\<N@>,],D2[\,^/= DFL/$GA[4K3:]DL&J6\*37&F/(H%YIUP_
MDRQ;DQ@\>?\ P?\ BGK=SXDU[X"?&B94^*_A?3DNK#7+ OI^G?$KPM(Y>#Q'
MX81,6LFL)&D<OB"RAE^WV]Q+*)+=45]OU5< 74 :)O.B5M_E(A?>O)!1EX8,
MO(()!!/)%?,'[1?PAN?'&AZ=XO\ "!FT;XG_  Y\[Q%X.\4Q@1WVF6B2_;M5
M\/V[!U:8:O;(UO+%-N5 Y&X-A1O:I;FC4I5(O903YH^MW9W7;[R)5)+W?J];
MF7Q:JWR/IQK&VF=9@\J[0&"HX94!Y 4@GY0.%/< 'VJC>L5>.R,+SVH#SB0'
M$D<C,[HV2PW#+DGR]Q7@MQ7G/P:^*NC_ !;^'V@^/+*2VL9;E'TO7M-1RYTK
MQ%9VT;:OHMPI4/#=Z;>"6VEMI1YL4D9CDRW%>BRK>L^GS6Y*_8?-2>U8KNN!
M*H1@68A1Y0S@$]>G84.;A;VE2E24G9.2TD][+7?J8U7*7+&4*M'723:2;[?<
M[^2,K[=/IL<22Q22VTH,\MW+,]M )-^V2 3S;(&82DI'&DC&08,08$&K5O>6
M*RQQ7<;VKR75PZI KQHDDLA81W8=59YER5D=04+@D-CYC^=W[<NH?M>?"2;P
MS^T#^S;#:?$[P!\.(73XV?LWZS;@GQGX5N+A9=1\8> M1F:WC/BKP[:F6ZET
MY9G>2XA,<,4S94_2WP _:-^&/[1_PB\-?%KX6>*9O$'AW54A2:SN=/GC\3>&
MM8BCA^W^%/%NF7%O'J.E^+='N':QU/3;VWBNGN[>YEMUGMP)CT)X=1NZ\9M[
M*&CCOO>^C_7<VC1CAXJI.I*HJGNQ7,FXM:W?:ZT/I^*V1!A6R)(PDL)&5!(P
MS(QR!@Y( /IR>ABNFFL+9&L8&G"8B8G"NL:848$A5G "\%0V<;AD59M9M\<4
MI*DR(K%@RLA.T[BK(2C#.<%&9".59EP35U1I7M96MYL3&)BH16=DC#;3*L2A
MI)<'&W8K%\_(&45BFW.]ERK5=6WMKY6]"U.,OAOIO?\ X9$$VIF%[4R(55K=
MYIAM8M&AZS3(H+PPEP5$\@6%F  <GBOECQ?\<OAKXS\1_%+]GCPIXOT?6/BY
MX/\  JZ_XL\'6TLL]YX=T_6)2MB^IW"Q#3+2ZN%.\:7+?+JD4)2:>RCC(<_.
MG[;?[7OC#X>ZAX1_91_9MMM-\=_MH_&6W>P\&V32?;/#?P>\/M_H>M?&'XJ!
M"L=AX7LM/>X>RTS49;>XO-<-N]G!<P(C-Z9^QC^QEX8_94\ ZEH\6I3>/?BS
MXYU.Z\0_'?XR>);**Y\5?%CQKJ"I/JNMW>I7$C:C9:9$7ET_3M$6..VLG3,,
M2V@$DGS/%G#^'XCR;,\IJXB6%GFV Q>7QJ>QE6A&&+P\Z%1R44^5QA4;BY.U
M][[&^&Q5?!XK"8JA1]M]6Q5#$S6ON_5ZD:L+VLVI3CRR5U=72:/BIOA?\0KU
M'MH?!>OI;P@Q&:**-4N98_D,D2>:)(XY&!9 RH0&P0&!Q#!\&OB,)K:[?P'?
M/JUJ&BTK5[NRAFU31+8D+<6]K<%W*QWB91EC?&"?,'!-?M?I]O);VHAG@D:1
M" ;J<0M+<[0 ;B58BZ)).<R.BX"L^!D#)L^5+YFX1 H>54N@XXXQM&..<'&.
MF"17^:L/V9_"V$S'&8ZAXBYGEV-KU,7.GB,OP]18JC''2KO$0C/#*C*,*L,1
M*$E-RC))*UTV_P!XJ_21SB>'J8-\-8"LIJDJLXT*_/>E"%.+O*HTM(*]DTGM
MH?B#-\#_ !?(ES;CX:-#::D;B#5-/FT+3WT^[2^18[Z[O8(RR7-U(8ED\PJ\
MF]MP)(JAJ/P!UW6)M^M?"6RU=)+<:?)%JWA32]7#Z8[":*REN;X_:;:WTI@D
M&G0V&Y(HXXU0%%!K]SVMB22;=<DD]83W/3Y?K_\ 7I?L.>?(7GG[T7_Q%=U+
M]G+EE+$+$T?&'BY5E.52<G3QZ]K.>%6"E*HUB$Y2EAHJA)]8*VJ21A_Q,#CG
MRR_U9P\9*$8-1I5$FH]_._F?A>O[/&I&2.6?X.:!J-Q;JL6G7VM^#;"\O].@
MMU"1VXN4260P1HH33%B8F!!&)_*(.-"Q^"'B+3);VZT?X5)HUWK'GG4[_3-"
MLM'U>_-W$MM,FO7.G%EU*&*&-#$ZRO-,1NE42%@/W ^P?],%_P"^HO\ XBC[
M!_TP7_OJ+_XBHI_LW\MC"G2GXO<45L/3P\\(L-B*&,JT/JU2E4I2H^SG7:]G
M^]E422_B:M-7NX?2!Q5.<:L>%,)[2#O&7L:MT^][GXGM\+?B4S OX1UIV\I5
M9Q;#!<+AB S@C)R1GUP37W?^QSX7\3>'-"\6P^(-'N]*>ZU.QDM5NU1&ECMX
M3'*P =L;& 7#8+=4W#FOL'[ ?^>"_P#?4?\ \16I#:D1KE64A0% V;<8'78<
MMT )(' XQG%?H_@1]!7AOP-X\R[CC*.*L?F^,P&#Q>!I8:I@X8/#J&.O]8JX
MB4HN=>7+)QIJ$X<LO>?,G8\CC'QIS;CG)*^08S+Z6"PE6I0JRDHU5*+HS4X*
MES2Y4^9>_P R?NZ*VY$T3NQ=%W*Y+*<J,@\YP2",^A ^E%7U5U4 J.!VR!^
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M6=DM(KJ?V@)_P5Y_8+>-7_X6\5S$DC*WA?6RT0=0P6;&GMY<JYQ)&Y#HX96
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M"02=/DBBU$ID']XL#QOQY;N&4GZ'MC*XP-J KO2,'+",\H/FPRX!QAPK9^\
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MBWA_Q:&8'P9\0B03ROA75 IYZKMLRN#U&TE<=#C&?[E+WPUHMY();S2[2[D
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M9.#GMV[TP>&_&+$[O GC0+DXQX=U<J!GC;BSY&#D'_#-?W$'P;X9P-GA_2
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M*K*D\*HH(D:#? DCC!;#["Q_=L5(-=&T*S1*)%VC8N8UP-G R@(./EZ#'''
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)"GJ15@7,(0,SA0(_,9F#!0H;;DL0%!+?=4G<W501S7\3OQ#_P""R7[6UM\
M_@]8>+_C/I'PF\0>%OVQ_BY^R]\>_CK\-OAO9?$*?Q3X7\'>#;K7?"^M^'O
M<PG;3C<7L$4>KKI"WYLC++;F4&*9V_H)_P""2O[1_P 9?VI_V*OA[\8_C]JE
MGK_BGQ%K7C""R\9:?IVGZ+IOC;X?Z;J4L/A?Q'-HVF7%S:Z3KFJ6 M=1N=+B
M?_1Y[B6*V$L,:O1IT27H'R2^_P#5GZP Y //([@@_D>1]#S2U7MG1H(BKO(%
MC13))G>Y50"SG^)SC+$9!8D@G-3@@@$=" 1]#S0(6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5;&UT_Q)<:180R0Z[;:5JMVY>SDWPHUQ"L@!]Z^'/^"6?[&7AWQ=\#O%]O\
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M^-=.U+2-4L=-U"2.34IXH=*U>>STBR;?;6,,,,?RH 3^S^T!I8QD(#@*"0
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M(2SX).YF+,22Q)R3R<$5:485 .  !CV"G _04 .HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>ppbt-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 10 16:44:15 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://Purplebiotech.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ppbt="http://Purplebiotech.com/20241231">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ppbt-20241231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ppbt-20241231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ppbt-20241231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ppbt-20241231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://Purplebiotech.com/role/ConsolidatedBalanceSheet" id="ppbt_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" id="ppbt_r_ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable">
        <link:definition>995302 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0" id="ppbt_r_ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0">
        <link:definition>995302 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ShareholdersEquityType2or3" id="ppbt_r_ShareholdersEquityType2or3">
        <link:definition>995303 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ConsolidatedCashFlow" id="ppbt_r_ConsolidatedCashFlow">
        <link:definition>995304 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/General" id="ppbt_r_General">
        <link:definition>995305 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatements" id="ppbt_r_BasisofPreparationoftheConsolidatedFinancialStatements">
        <link:definition>995306 - Disclosure - Basis of Preparation of the Consolidated Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/MaterialAccountingPolicies" id="ppbt_r_MaterialAccountingPolicies">
        <link:definition>995307 - Disclosure - Material Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/IntangibleAssets" id="ppbt_r_IntangibleAssets">
        <link:definition>995308 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/CashandCashEquivalents" id="ppbt_r_CashandCashEquivalents">
        <link:definition>995309 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/Leases" id="ppbt_r_Leases">
        <link:definition>995310 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/OtherCurrentAssets" id="ppbt_r_OtherCurrentAssets">
        <link:definition>995311 - Disclosure - Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/OtherPayables" id="ppbt_r_OtherPayables">
        <link:definition>995312 - Disclosure - Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/Equity" id="ppbt_r_Equity">
        <link:definition>995313 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ShareBasedPaymentArrangements" id="ppbt_r_ShareBasedPaymentArrangements">
        <link:definition>995314 - Disclosure - Share-Based Payment Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedParties" id="ppbt_r_TransactionsandBalanceswithRelatedParties">
        <link:definition>995315 - Disclosure - Transactions and Balances with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/CommitmentsandContingentLiabilities" id="ppbt_r_CommitmentsandContingentLiabilities">
        <link:definition>995316 - Disclosure - Commitments and Contingent Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ResearchandDevelopmentExpenses" id="ppbt_r_ResearchandDevelopmentExpenses">
        <link:definition>995317 - Disclosure - Research and Development Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpenses" id="ppbt_r_SalesGeneralandAdministrativeExpenses">
        <link:definition>995318 - Disclosure - Sales, General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/FinanceExpenseIncomeNet" id="ppbt_r_FinanceExpenseIncomeNet">
        <link:definition>995319 - Disclosure - Finance Expense (Income), Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/TaxesonIncome" id="ppbt_r_TaxesonIncome">
        <link:definition>995320 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/EmployeeBenefits" id="ppbt_r_EmployeeBenefits">
        <link:definition>995321 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/FinancialInstruments" id="ppbt_r_FinancialInstruments">
        <link:definition>995322 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/SubsequentEvents" id="ppbt_r_SubsequentEvents">
        <link:definition>995323 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/AccountingPoliciesByPolicy" id="ppbt_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables" id="ppbt_r_BasisofPreparationoftheConsolidatedFinancialStatementsTables">
        <link:definition>996001 - Disclosure - Basis of Preparation of the Consolidated Financial Statements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/IntangibleAssetsTables" id="ppbt_r_IntangibleAssetsTables">
        <link:definition>996002 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/CashandCashEquivalentsTables" id="ppbt_r_CashandCashEquivalentsTables">
        <link:definition>996003 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/LeasesTables" id="ppbt_r_LeasesTables">
        <link:definition>996004 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/OtherCurrentAssetsTables" id="ppbt_r_OtherCurrentAssetsTables">
        <link:definition>996005 - Disclosure - Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/OtherPayablesTables" id="ppbt_r_OtherPayablesTables">
        <link:definition>996006 - Disclosure - Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/EquityTables" id="ppbt_r_EquityTables">
        <link:definition>996007 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables" id="ppbt_r_ShareBasedPaymentArrangementsTables">
        <link:definition>996008 - Disclosure - Share-Based Payment Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables" id="ppbt_r_TransactionsandBalanceswithRelatedPartiesTables">
        <link:definition>996009 - Disclosure - Transactions and Balances with Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ResearchandDevelopmentExpensesTables" id="ppbt_r_ResearchandDevelopmentExpensesTables">
        <link:definition>996010 - Disclosure - Research and Development Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesTables" id="ppbt_r_SalesGeneralandAdministrativeExpensesTables">
        <link:definition>996011 - Disclosure - Sales, General and Administrative Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables" id="ppbt_r_FinanceExpenseIncomeNetTables">
        <link:definition>996012 - Disclosure - Finance Expense (Income), Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/EmployeeBenefitsTables" id="ppbt_r_EmployeeBenefitsTables">
        <link:definition>996013 - Disclosure - Employee Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/FinancialInstrumentsTables" id="ppbt_r_FinancialInstrumentsTables">
        <link:definition>996014 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/GeneralDetails" id="ppbt_r_GeneralDetails">
        <link:definition>996015 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails" id="ppbt_r_BasisofPreparationoftheConsolidatedFinancialStatementsDetails">
        <link:definition>996016 - Disclosure - Basis of Preparation of the Consolidated Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofDataonExchangeRatesTable" id="ppbt_r_ScheduleofDataonExchangeRatesTable">
        <link:definition>996017 - Disclosure - Basis of Preparation of the Consolidated Financial Statements - Schedule of Data on Exchange Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/MaterialAccountingPoliciesDetails" id="ppbt_r_MaterialAccountingPoliciesDetails">
        <link:definition>996018 - Disclosure - Material Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/IntangibleAssetsDetails" id="ppbt_r_IntangibleAssetsDetails">
        <link:definition>996019 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable" id="ppbt_r_ScheduleofIntangibleAssetsTable">
        <link:definition>996020 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable" id="ppbt_r_ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable">
        <link:definition>996021 - Disclosure - Intangible Assets - Schedule of Recognized Amounts of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable" id="ppbt_r_ScheduleofCashandCashEquivalentsTable">
        <link:definition>996022 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/LeasesDetails" id="ppbt_r_LeasesDetails">
        <link:definition>996023 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable" id="ppbt_r_ScheduleofCarryingAmountsofRighttoUseAssetsTable">
        <link:definition>996024 - Disclosure - Leases - Schedule of Carrying Amounts of Right-to-Use Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable" id="ppbt_r_ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable">
        <link:definition>996025 - Disclosure - Leases - Schedule of Maturity Analysis of the Company's Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofAmountsRecognizedinProfitorLossTable" id="ppbt_r_ScheduleofAmountsRecognizedinProfitorLossTable">
        <link:definition>996026 - Disclosure - Leases - Schedule of Amounts Recognized in Profit or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable" id="ppbt_r_ScheduleofOtherCurrentAssetsTable">
        <link:definition>996027 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofOtherPayablesTable" id="ppbt_r_ScheduleofOtherPayablesTable">
        <link:definition>996028 - Disclosure - Other Payables - Schedule of Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/EquityDetails" id="ppbt_r_EquityDetails">
        <link:definition>996029 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofShareCapitalTable" id="ppbt_r_ScheduleofShareCapitalTable">
        <link:definition>996030 - Disclosure - Equity - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable" id="ppbt_r_ScheduleofChangesinShareCapitalTable">
        <link:definition>996031 - Disclosure - Equity - Schedule of Changes in Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable" id="ppbt_r_ScheduleoftheInformationRelatingtoNonControllingInterestsTable">
        <link:definition>996032 - Disclosure - Equity - Schedule of the Information Relating to Non-Controlling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" id="ppbt_r_ShareBasedPaymentArrangementsDetails">
        <link:definition>996033 - Disclosure - Share-Based Payment Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable" id="ppbt_r_ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable">
        <link:definition>996034 - Disclosure - Share-Based Payment Arrangements - Schedule of Number and Weighted Average Exercise Prices of Share Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable" id="ppbt_r_ScheduleofNumberofRSUsTable">
        <link:definition>996035 - Disclosure - Share-Based Payment Arrangements - Schedule of Number of RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable" id="ppbt_r_ScheduleofAssumptionswereUsedTable">
        <link:definition>996036 - Disclosure - Share-Based Payment Arrangements - Schedule of Assumptions were Used (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable" id="ppbt_r_ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable">
        <link:definition>996037 - Disclosure - Share-Based Payment Arrangements - Schedule of Expenses Recognized in the Consolidated Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZ7uO1Q1bYM5N9HuAVhCBKc3Dilxy5HOYIdYl1h0YHGyqqhp5yL2C/pvkGqpTQ7NfV8dDJWElNwr7uGWGMl/FOCtmi0tB2eTtzKmmQ0hcQ60BPTfIvmWs+j5xoLJ2ifHK3Qzc5tu1CRRSrKp5kfOFheAU8ndp9+zFyGXNaa6jOMefzDkABcY69jtuMijqkJ3ohuLKcwkZmZewn4yToUYFOOphhxC2BFvS9vWe0aD1XZcRqD47OUobbP] CSR-->
      <link:roleType roleURI="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesDetails" id="ppbt_r_TransactionsandBalanceswithRelatedPartiesDetails">
        <link:definition>996038 - Disclosure - Transactions and Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable" id="ppbt_r_ScheduleofRecordedExpensesTable">
        <link:definition>996039 - Disclosure - Transactions and Balances with Related Parties - Schedule of Recorded Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" id="ppbt_r_CommitmentsandContingentLiabilitiesDetails">
        <link:definition>996040 - Disclosure - Commitments and Contingent Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable" id="ppbt_r_ScheduleofResearchandDevelopmentExpensesTable">
        <link:definition>996041 - Disclosure - Research and Development Expenses - Schedule of Research and Development Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" id="ppbt_r_ScheduleofSalesGeneralandAdministrativeExpensesTable">
        <link:definition>996042 - Disclosure - Sales, General and Administrative Expenses - Schedule of Sales, General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails" id="ppbt_r_FinanceExpenseIncomeNetDetails">
        <link:definition>996043 - Disclosure - Finance Expense (Income), Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable" id="ppbt_r_ScheduleofFinanceExpensesTable">
        <link:definition>996044 - Disclosure - Finance Expense (Income), Net - Schedule of Finance Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable" id="ppbt_r_ScheduleofFinanceIncomeTable">
        <link:definition>996045 - Disclosure - Finance Expense (Income), Net - Schedule of Finance Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/TaxesonIncomeDetails" id="ppbt_r_TaxesonIncomeDetails">
        <link:definition>996046 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/EmployeeBenefitsDetails" id="ppbt_r_EmployeeBenefitsDetails">
        <link:definition>996047 - Disclosure - Employee Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofPostEmployeeBenefitsTable" id="ppbt_r_ScheduleofPostEmployeeBenefitsTable">
        <link:definition>996048 - Disclosure - Employee Benefits - Schedule of Post-Employee Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofDefinedContributionPlaninRespectofitsEmployeesTable" id="ppbt_r_ScheduleofDefinedContributionPlaninRespectofitsEmployeesTable">
        <link:definition>996049 - Disclosure - Employee Benefits - Schedule of Defined Contribution Plan in Respect of its Employees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/FinancialInstrumentsDetails" id="ppbt_r_FinancialInstrumentsDetails">
        <link:definition>996050 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" id="ppbt_r_ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable">
        <link:definition>996051 - Disclosure - Financial Instruments - Schedule of Sensitivity Test to Possible Changes in Exchange Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable" id="ppbt_r_ScheduleofFinancialInstrumentsMeasuredatFairValueTable">
        <link:definition>996052 - Disclosure - Financial Instruments - Schedule of Financial Instruments Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable" id="ppbt_r_ScheduleofDetailsRegardingFairValueMeasurementTable">
        <link:definition>996053 - Disclosure - Financial Instruments - Schedule of Details Regarding Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable" id="ppbt_r_ScheduleofFairValueMeasurementTable">
        <link:definition>996054 - Disclosure - Financial Instruments - Schedule of Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/SubsequentEventsDetails" id="ppbt_r_SubsequentEventsDetails">
        <link:definition>996055 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Purplebiotech.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:element name="ConsolidatedStatementsOfChangesInEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ConsolidatedStatementsOfChangesInEquityAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfRecognizedAmountsOfAssetsAcquiredAndLiabilitiesAssumedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfRecognizedAmountsOfAssetsAcquiredAndLiabilitiesAssumedAbstract"/>
  <xs:element name="ScheduleOfCashAndCashEquivalentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfCashAndCashEquivalentsAbstract"/>
  <xs:element name="ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract"/>
  <xs:element name="ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfShareCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfShareCapitalAbstract"/>
  <xs:element name="ScheduleOfAssumptionsWereUsedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfAssumptionsWereUsedAbstract"/>
  <xs:element name="ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract"/>
  <xs:element name="ScheduleOfRecordedExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfRecordedExpensesAbstract"/>
  <xs:element name="ScheduleOfResearchAndDevelopmentExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfResearchAndDevelopmentExpensesAbstract"/>
  <xs:element name="ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="ScheduleOfFinanceExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfFinanceExpensesAbstract"/>
  <xs:element name="ScheduleOfFinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfFinanceIncomeAbstract"/>
  <xs:element name="ScheduleOfPostEmployeeBenefitsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfPostEmployeeBenefitsAbstract"/>
  <xs:element name="ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract"/>
  <xs:element name="ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract"/>
  <xs:element name="ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract"/>
  <xs:element name="ScheduleOfDetailsRegardingFairValueMeasurementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementAbstract"/>
  <xs:element name="ScheduleOfFairValueMeasurementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfFairValueMeasurementAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_UnlabeledAbstract"/>
  <xs:element name="ItemsThatWillBeTransferredToProfitOrLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_UnlabeledAbstract1"/>
  <xs:element name="TransactionsWithOwnersOfTheCompanyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_TransactionsWithOwnersOfTheCompanyAbstract"/>
  <xs:element name="TransactionsWithOwnersOfTheCompanyAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_TransactionsWithOwnersOfTheCompanyAbstract0"/>
  <xs:element name="TransactionsWithOwnersOfTheCompanyAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_TransactionsWithOwnersOfTheCompanyAbstract1"/>
  <xs:element name="ChangesInAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ChangesInAssetsAndLiabilitiesAbstract"/>
  <xs:element name="CashFlowsFromInvestingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CashFlowsFromInvestingActivitiesAbstract"/>
  <xs:element name="CashFlowsFromFinancingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CashFlowsFromFinancingActivitiesAbstract"/>
  <xs:element name="ChangesInExchangeRatesForTheYearEndedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ChangesInExchangeRatesForTheYearEndedAbstract"/>
  <xs:element name="FinanceExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FinanceExpensesAbstract"/>
  <xs:element name="FinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FinanceIncomeAbstract"/>
  <xs:element name="FinancialAssetAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FinancialAssetAndLiabilitiesAbstract"/>
  <xs:element name="FinancialAssetAndLiabilitiesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FinancialAssetAndLiabilitiesAbstract0"/>
  <xs:element name="ForTheYearEndedDecember312023Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ForTheYearEndedDecember312023Abstract"/>
  <xs:element name="ReceiptsOnAccountsOfWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ReceiptsOnAccountsOfWarrant"/>
  <xs:element name="CapitalReserveFromTransactionsWithNon-ControllingInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest"/>
  <xs:element name="AdjustmentsForChangesInAssetsAndLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_AdjustmentsForChangesInAssetsAndLiabilities"/>
  <xs:element name="CashAssumedAsPartOfAcquisitionOfFamewave" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave"/>
  <xs:element name="Decreaseincreaseinshorttermdeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_Decreaseincreaseinshorttermdeposits"/>
  <xs:element name="IncreaseDecreaseInLongTermDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IncreaseDecreaseInLongTermDeposits"/>
  <xs:element name="ProceedsFromIssuingWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ProceedsFromIssuingWarrants"/>
  <xs:element name="WarrantsIssuanceExpensesPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_WarrantsIssuanceExpensesPaid"/>
  <xs:element name="DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock"/>
  <xs:element name="ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
  <xs:element name="IntangibleAssetsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_IntangibleAssetsTablesTable"/>
  <xs:element name="IntangibleAssetsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IntangibleAssetsTablesLineItems"/>
  <xs:element name="DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock"/>
  <xs:element name="DisclosureOfOtherCurrentAssettextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DisclosureOfOtherCurrentAssettextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_TransactionsandBalanceswithRelatedPartiesTablesTable"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems"/>
  <xs:element name="DisclosureOfResearchAndDevelopmentExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock"/>
  <xs:element name="DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock"/>
  <xs:element name="FinanceExpenseIncomeNetTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_FinanceExpenseIncomeNetTablesTable"/>
  <xs:element name="FinanceExpenseIncomeNetTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FinanceExpenseIncomeNetTablesLineItems"/>
  <xs:element name="DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock"/>
  <xs:element name="ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock"/>
  <xs:element name="FinancialInstrumentsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_FinancialInstrumentsTablesTable"/>
  <xs:element name="FinancialInstrumentsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FinancialInstrumentsTablesLineItems"/>
  <xs:element name="PercentageOfExchangeRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PercentageOfExchangeRate"/>
  <xs:element name="IntangibleAssetsScheduleofIntangibleAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_IntangibleAssetsScheduleofIntangibleAssetsDetailsTable"/>
  <xs:element name="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable"/>
  <xs:element name="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems"/>
  <xs:element name="CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable"/>
  <xs:element name="LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable"/>
  <xs:element name="LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable"/>
  <xs:element name="GovernmentAuthorities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_GovernmentAuthorities"/>
  <xs:element name="SalaryRelatedOtherPayablesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_SalaryRelatedOtherPayablesCurrent"/>
  <xs:element name="ClassesOfPreferredSharesDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ClassesOfPreferredSharesDomainDomain"/>
  <xs:element name="EquityScheduleofShareCapitalDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_EquityScheduleofShareCapitalDetailsTable"/>
  <xs:element name="NumberOfIssuanceShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_NumberOfIssuanceShares"/>
  <xs:element name="NumberOfVestingOfRsus" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_NumberOfVestingOfRsus"/>
  <xs:element name="NumberOfExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_NumberOfExerciseOfWarrants"/>
  <xs:element name="CurrentAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CurrentAsset"/>
  <xs:element name="CurrentLiabiliti" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CurrentLiabiliti"/>
  <xs:element name="NetAssetsAttributableToNoncontrollingInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_NetAssetsAttributableToNoncontrollingInterest"/>
  <xs:element name="NetAssetsAttributableToNoncontrollingInterests" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_NetAssetsAttributableToNoncontrollingInterests"/>
  <xs:element name="ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable"/>
  <xs:element name="ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable"/>
  <xs:element name="ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable"/>
  <xs:element name="ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems"/>
  <xs:element name="SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable"/>
  <xs:element name="ReimbursementOfLegalFeesExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ReimbursementOfLegalFeesExpense"/>
  <xs:element name="GeneralAndAdministrativeExpensesOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_GeneralAndAdministrativeExpensesOther"/>
  <xs:element name="IssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IssuanceExpenses"/>
  <xs:element name="OtherfinancialCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_OtherfinancialCost"/>
  <xs:element name="OtherExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_OtherExpense"/>
  <xs:element name="FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable"/>
  <xs:element name="IncomelossFromChangeInExchangeRateDown" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IncomelossFromChangeInExchangeRateDown"/>
  <xs:element name="IncomelossValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IncomelossValue"/>
  <xs:element name="IncomelossFromChangeInExchangeRateUp" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IncomelossFromChangeInExchangeRateUp"/>
  <xs:element name="FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable"/>
  <xs:element name="Securities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_Securities"/>
  <xs:element name="FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable"/>
  <xs:element name="FairValueMeasurementBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FairValueMeasurementBalance"/>
  <xs:element name="FairValueMeasurementExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FairValueMeasurementExercise"/>
  <xs:element name="FairValueMeasurementIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FairValueMeasurementIssuance"/>
  <xs:element name="FairValueMeasurementIssuanceProceed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FairValueMeasurementIssuanceProceed"/>
  <xs:element name="FairValueMeasurementRevaluation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FairValueMeasurementRevaluation"/>
  <xs:element name="FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable"/>
  <xs:element name="DescriptionOfOptionLifeShareOptionGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DescriptionOfOptionLifeShareOptionGranted"/>
  <xs:element name="ExpectedDividendAsPercentageShareOptionsdividendYield" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield"/>
  <xs:element name="Discountforlackofmarketability" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_Discountforlackofmarketability"/>
  <xs:element name="GeneralDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_GeneralDetailsTable"/>
  <xs:element name="AmericanDepositorySharesOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_AmericanDepositorySharesOrdinaryShares"/>
  <xs:element name="CommonStockNoParValues" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CommonStockNoParValues"/>
  <xs:element name="AmericanDepositorySharesPurchase" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_AmericanDepositorySharesPurchase"/>
  <xs:element name="PercentageOfContractToAcquire" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PercentageOfContractToAcquire"/>
  <xs:element name="RetainedEarning" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_RetainedEarning"/>
  <xs:element name="PrivateAndPublicFinancingTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PrivateAndPublicFinancingTotal"/>
  <xs:element name="BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable"/>
  <xs:element name="BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems"/>
  <xs:element name="FunctionalCurrency" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FunctionalCurrency"/>
  <xs:element name="StockOptionExercisedPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_StockOptionExercisedPeriod"/>
  <xs:element name="NumberOfShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_NumberOfShare"/>
  <xs:element name="NumberOfPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_NumberOfPerShare"/>
  <xs:element name="DepreciationRightofuseAssetsUsefulLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DepreciationRightofuseAssetsUsefulLife"/>
  <xs:element name="IntangibleAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_IntangibleAssetsDetailsTable"/>
  <xs:element name="IntangibleAssetsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IntangibleAssetsDetailsLineItems"/>
  <xs:element name="EquityMethodInvestmentsOwnershipPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_EquityMethodInvestmentsOwnershipPercentage"/>
  <xs:element name="AggregateUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_AggregateUpfrontPayment"/>
  <xs:element name="LongTermMilestonesAggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_LongTermMilestonesAggregateAmount"/>
  <xs:element name="TotalAcquisitionAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_TotalAcquisitionAmount"/>
  <xs:element name="FairValueOfIssuedEquity" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FairValueOfIssuedEquity"/>
  <xs:element name="FairValueOfIssuedIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FairValueOfIssuedIntangibleAssets"/>
  <xs:element name="AggregateShareholdersOfImmunorizon" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_AggregateShareholdersOfImmunorizon"/>
  <xs:element name="SharesPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ppbt_SharesPrice"/>
  <xs:element name="DescriptionOfExpectedVolatilityPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DescriptionOfExpectedVolatilityPercentage"/>
  <xs:element name="DescriptionOfExpectedAnnualRiskFreeRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DescriptionOfExpectedAnnualRiskFreeRate"/>
  <xs:element name="PercentageOfDiscountsForLacksOfMarketability" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PercentageOfDiscountsForLacksOfMarketability"/>
  <xs:element name="IntangibleAssetsRecoverableAmountPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IntangibleAssetsRecoverableAmountPercentage"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_LeasesDetailsTable"/>
  <xs:element name="AgreementLeaseTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_AgreementLeaseTerm"/>
  <xs:element name="AgreementLeaseAdditionalTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_AgreementLeaseAdditionalTerm"/>
  <xs:element name="CurrentTerms" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CurrentTerms"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_EquityDetailsTable"/>
  <xs:element name="NonVotingSeniorPreferredShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_NonVotingSeniorPreferredShares"/>
  <xs:element name="StockholdersEquityReversesStockSplit" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_StockholdersEquityReversesStockSplit"/>
  <xs:element name="ReverseRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ReverseRatio"/>
  <xs:element name="FundsRaisedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FundsRaisedAmount"/>
  <xs:element name="NumberOfNonTradableWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_NumberOfNonTradableWarrants"/>
  <xs:element name="FundsRaisedshares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FundsRaisedshares"/>
  <xs:element name="WarrantsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_WarrantsTerm"/>
  <xs:element name="DepositaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DepositaryShares"/>
  <xs:element name="PurchaseOfCommonStockAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PurchaseOfCommonStockAndWarrants"/>
  <xs:element name="WarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_WarrantsIssued"/>
  <xs:element name="IssuesOfEquity" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IssuesOfEquity"/>
  <xs:element name="ExerciseOfWarrantsEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ExerciseOfWarrantsEquity"/>
  <xs:element name="WarrantTermDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_WarrantTermDescription"/>
  <xs:element name="SalesAgreementShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_SalesAgreementShares"/>
  <xs:element name="noncontrollingInterests" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_noncontrollingInterests"/>
  <xs:element name="ShareBasedPaymentArrangementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_ShareBasedPaymentArrangementsDetailsTable"/>
  <xs:element name="OptionExerciseOrdinaryShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_OptionExerciseOrdinaryShare"/>
  <xs:element name="VestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_VestingPeriod"/>
  <xs:element name="ExercisePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ExercisePeriod"/>
  <xs:element name="ConsultantPerShares" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ConsultantPerShares"/>
  <xs:element name="AmericanDepostioryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_AmericanDepostioryShares"/>
  <xs:element name="ConvertibleShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ConvertibleShares"/>
  <xs:element name="PercentageOfCapacityOfAnAdvisor" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PercentageOfCapacityOfAnAdvisor"/>
  <xs:element name="RangesDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_RangesDomainDomain"/>
  <xs:element name="CommitmentsandContingentLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_CommitmentsandContingentLiabilitiesDetailsTable"/>
  <xs:element name="PercentageOfSublicenseConsideration" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PercentageOfSublicenseConsideration"/>
  <xs:element name="PercentageOfReceiveExitFee" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PercentageOfReceiveExitFee"/>
  <xs:element name="FinanceExpenseIncomeNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_FinanceExpenseIncomeNetDetailsTable"/>
  <xs:element name="WarrantsExpireTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_WarrantsExpireTerm"/>
  <xs:element name="StatutoryTaxRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_StatutoryTaxRate"/>
  <xs:element name="EffectiveTaxRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_EffectiveTaxRate"/>
  <xs:element name="UnrecognizedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_UnrecognizedResearchAndDevelopmentExpenses"/>
  <xs:element name="EmployeeBenefitBonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_EmployeeBenefitBonus"/>
  <xs:element name="EmployeeBenefitsLiabilityDueGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_EmployeeBenefitsLiabilityDueGrants"/>
  <xs:element name="FinancialInstrumentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_FinancialInstrumentsDetailsTable"/>
  <xs:element name="ShortTermDepositsGuaranteedForLeasesAndCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit"/>
  <xs:element name="ShortTermDepositsGuaranteedForHedgingTransactions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ShortTermDepositsGuaranteedForHedgingTransactions"/>
  <xs:element name="ConvertibleWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ConvertibleWarrants"/>
  <xs:element name="TerminationExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ppbt_TerminationExercisePrice"/>
  <xs:element name="ConvertiblesWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ConvertiblesWarrants"/>
  <xs:element name="FinancialAssetAtAFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FinancialAssetAtAFairValue"/>
  <xs:element name="WarrantExercisePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ppbt_WarrantExercisePricePerShare"/>
  <xs:element name="DepositarysShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DepositarysShares"/>
  <xs:element name="AggregateWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_AggregateWarrantsShares"/>
  <xs:element name="FinancialInstrumentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FinancialInstrumentAmount"/>
  <xs:element name="NetOfDeferredDifferenceAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ppbt_NetOfDeferredDifferenceAmount"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ppbt_SubsequentEventsDetailsTable"/>
  <xs:element name="ClassesOfPreferredSharesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="ppbt_ClassesOfPreferredSharesAxis"/>
  <xs:element name="RangesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="ppbt_RangesAxis"/>
  <xs:element name="ADSMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ADSMember"/>
  <xs:element name="ATMProgramMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ATMProgramMember"/>
  <xs:element name="AccountPayablesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_AccountPayablesMember"/>
  <xs:element name="AdsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_AdsMember"/>
  <xs:element name="AmericanDepositorySharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_AmericanDepositorySharesMember"/>
  <xs:element name="BiopharmaceuticalProductMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_BiopharmaceuticalProductMember"/>
  <xs:element name="BoardOfDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_BoardOfDirectorsMember"/>
  <xs:element name="CapitalReserveFromTransactionsWithNonControllingInterestMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember"/>
  <xs:element name="CapitalReserveFromTransactionsWithRelatedPartiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember"/>
  <xs:element name="CashAndCashEquivalentsAndDepositsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CashAndCashEquivalentsAndDepositsMember"/>
  <xs:element name="ClassEPreferredSharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ClassEPreferredSharesMember"/>
  <xs:element name="ConvertibleDebtInstrumentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ConvertibleDebtInstrumentMember"/>
  <xs:element name="ConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ConvertibleNoteMember"/>
  <xs:element name="DiagnosticProductsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DiagnosticProductsMember"/>
  <xs:element name="DownRangeOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DownRangeOneMember"/>
  <xs:element name="EUROMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_EUROMember"/>
  <xs:element name="IPRDRelatedToFamewaveSee5BBelowMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IPRDRelatedToFamewaveSee5BBelowMember"/>
  <xs:element name="IPRDRelatedToImmunorizonSee5CBelowMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IPRDRelatedToImmunorizonSee5CBelowMember"/>
  <xs:element name="IPRDRelatedToPurpleGmbHMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IPRDRelatedToPurpleGmbHMember"/>
  <xs:element name="IPRDRelatedToTryNovosee5ABelowMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_IPRDRelatedToTryNovosee5ABelowMember"/>
  <xs:element name="January2025Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_January2025Member"/>
  <xs:element name="LeaseAgreementOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_LeaseAgreementOneMember"/>
  <xs:element name="LeaseAgreementsTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_LeaseAgreementsTwoMember"/>
  <xs:element name="NISMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_NISMember"/>
  <xs:element name="OptionsAndRSUsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_OptionsAndRSUsMember"/>
  <xs:element name="OrdinaryShareMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_OrdinaryShareMember"/>
  <xs:element name="OtherCurrentAssetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_OtherCurrentAssetMember"/>
  <xs:element name="OtherPayablesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_OtherPayablesMember"/>
  <xs:element name="PostemploymentBenefitLiabilitiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PostemploymentBenefitLiabilitiesMember"/>
  <xs:element name="PreferredClassCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PreferredClassCMember"/>
  <xs:element name="PreferredClassDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PreferredClassDMember"/>
  <xs:element name="PreferredShareClassBMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PreferredShareClassBMember"/>
  <xs:element name="PreferredShareClassMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PreferredShareClassMember"/>
  <xs:element name="PrivatePlacementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PrivatePlacementsMember"/>
  <xs:element name="PublicOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_PublicOfferingMember"/>
  <xs:element name="ReceiptsOnAccountOfWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ReceiptsOnAccountOfWarrantsMember"/>
  <xs:element name="RehovotMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_RehovotMember"/>
  <xs:element name="ResearchAndDevelopmentExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ResearchAndDevelopmentExpensesMember"/>
  <xs:element name="SalariesWagesAndRelatedExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_SalariesWagesAndRelatedExpensesMember"/>
  <xs:element name="SeriesA1WarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_SeriesA1WarrantsMember"/>
  <xs:element name="SeriesA2WarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_SeriesA2WarrantsMember"/>
  <xs:element name="ServiceProvidersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ServiceProvidersMember"/>
  <xs:element name="ShareBasedPaymentArrangementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ShareBasedPaymentArrangementsMember"/>
  <xs:element name="ShareBasedPaymentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ShareBasedPaymentsMember"/>
  <xs:element name="SubsequentEventsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_SubsequentEventsMember"/>
  <xs:element name="THMMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_THMMember"/>
  <xs:element name="TryNovosTechnologiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_TryNovosTechnologiesMember"/>
  <xs:element name="UpRangeOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_UpRangeOneMember"/>
  <xs:element name="WarrantsoneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_WarrantsoneMember"/>
  <xs:element name="YissumsLicensedTechnologyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_YissumsLicensedTechnologyMember"/>
  <xs:element name="CashAndCashEquivalentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CashAndCashEquivalentLineItems"/>
  <xs:element name="CommitmentsAndContingentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CommitmentsAndContingentLiabilitiesAbstract"/>
  <xs:element name="CommitmentsAndContingentLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_CommitmentsAndContingentLiabilitiesLineItems"/>
  <xs:element name="EquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_EquityLineItems"/>
  <xs:element name="FinanceExpenseIncomeNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FinanceExpenseIncomeNetAbstract"/>
  <xs:element name="FinanceExpenseIncomeNetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_FinanceExpenseIncomeNetLineItems"/>
  <xs:element name="GeneralAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_GeneralAbstract"/>
  <xs:element name="GeneralLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_GeneralLineItems"/>
  <xs:element name="LeasesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_LeasesLineItems"/>
  <xs:element name="ResearchAndDevelopmentExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ResearchAndDevelopmentExpensesAbstract"/>
  <xs:element name="ScheduleOfAssumptionsWereUsedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfAssumptionsWereUsedLineItems"/>
  <xs:element name="ScheduleOfNumberOfRSUsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfNumberOfRSUsAbstract"/>
  <xs:element name="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems"/>
  <xs:element name="TaxesOnIncomeabstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_TaxesOnIncomeabstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ppbt_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>ppbt-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 10 16:44:15 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ConsolidatedBalanceSheet" roleURI="http://Purplebiotech.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" roleURI="http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0" roleURI="http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ConsolidatedCashFlow" roleURI="http://Purplebiotech.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable" roleURI="http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofOtherPayablesTable" roleURI="http://Purplebiotech.com/role/ScheduleofOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofRecordedExpensesTable" roleURI="http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofSalesGeneralandAdministrativeExpensesTable" roleURI="http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofFinanceExpensesTable" roleURI="http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofFinanceIncomeTable" roleURI="http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable"/>
  <calculationLink xlink:role="http://Purplebiotech.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentInvestments" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_RightofuseAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentWarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_NoncurrentWarrantLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentPayables" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_IssuedCapital" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_SharePremium" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ppbt_ReceiptsOnAccountsOfWarrant" xlink:href="ppbt-20241231.xsd#ppbt_ReceiptsOnAccountsOfWarrant"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ppbt_ReceiptsOnAccountsOfWarrant" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalReserve"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_CapitalReserve" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_OtherReserves" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest" xlink:href="ppbt-20241231.xsd#ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_RetainedEarnings" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_NoncontrollingInterests" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_ImpairmentLoss" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceCosts" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_FinanceIncomeCost" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_OperatingExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://Purplebiotech.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_ProfitLossFromContinuingOperations" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForFinanceIncome" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ppbt_AdjustmentsForChangesInAssetsAndLiabilities" xlink:href="ppbt-20241231.xsd#ppbt_AdjustmentsForChangesInAssetsAndLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ppbt_AdjustmentsForChangesInAssetsAndLiabilities" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ppbt_AdjustmentsForChangesInAssetsAndLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="2" weight="1"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZ7uO1Q1bYM5N9HuAVhCBKc3Dilxy5HOYIdYl1h0YHGyqqhp5yL2C/pvkGqpTQ7NfV8dDJWElNwr7uGWGMl/FOCtmi0tB2eTtzKmmQ0hcQ60BPTfIvmWs+j5xoLJ2ifHK3Qzc5tu1CRRSrKp5kfOFheAU8ndp9+zFyGXNaa6jOMefzDkABcY69jtuMijqkJ3ohuLKcwkZmZewn4yToUYFOOphhxC2BFvS/n1Qod56s4jPELOHQsJFJ8] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ppbt_AdjustmentsForChangesInAssetsAndLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ppbt_AdjustmentsForChangesInAssetsAndLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ppbt_AdjustmentsForChangesInAssetsAndLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ppbt_Decreaseincreaseinshorttermdeposits" xlink:href="ppbt-20241231.xsd#ppbt_Decreaseincreaseinshorttermdeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ppbt_Decreaseincreaseinshorttermdeposits" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ppbt_IncreaseDecreaseInLongTermDeposits" xlink:href="ppbt-20241231.xsd#ppbt_IncreaseDecreaseInLongTermDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ppbt_IncreaseDecreaseInLongTermDeposits" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave" xlink:href="ppbt-20241231.xsd#ppbt_CashAssumedAsPartOfAcquisitionOfFamewave"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ppbt_ProceedsFromIssuingWarrants" xlink:href="ppbt-20241231.xsd#ppbt_ProceedsFromIssuingWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ppbt_ProceedsFromIssuingWarrants" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsForShareIssueCosts" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantsIssuanceExpensesPaid" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsIssuanceExpensesPaid"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ppbt_WarrantsIssuanceExpensesPaid" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="ifrs-full_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="ifrs-full_OtherIntangibleAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="ifrs-full_OtherReceivables" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="ifrs-full_OtherPayables" order="5" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ppbt_GovernmentAuthorities" xlink:href="ppbt-20241231.xsd#ppbt_GovernmentAuthorities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ppbt_GovernmentAuthorities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://Purplebiotech.com/role/ScheduleofOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentPayables"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentGovernmentGrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_CurrentGovernmentGrants" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ppbt_SalaryRelatedOtherPayablesCurrent" xlink:href="ppbt-20241231.xsd#ppbt_SalaryRelatedOtherPayablesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ppbt_SalaryRelatedOtherPayablesCurrent" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WagesAndSalaries"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_WagesAndSalaries" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfessionalFeesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_ProfessionalFeesExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DirectorsRemunerationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_DirectorsRemunerationExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RentalExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RentalExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_RentalExpense" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TravelExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_TravelExpense" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_DepreciationExpense" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="ppbt_GeneralAndAdministrativeExpensesOther" xlink:href="ppbt-20241231.xsd#ppbt_GeneralAndAdministrativeExpensesOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ppbt_GeneralAndAdministrativeExpensesOther" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="ppbt_ReimbursementOfLegalFeesExpense" xlink:href="ppbt-20241231.xsd#ppbt_ReimbursementOfLegalFeesExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ppbt_ReimbursementOfLegalFeesExpense" order="10" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherExpenseByNature"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_FeeAndCommissionExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ForeignExchangeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_ForeignExchangeLoss" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ppbt_IssuanceExpenses" xlink:href="ppbt-20241231.xsd#ppbt_IssuanceExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ppbt_IssuanceExpenses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ppbt_OtherfinancialCost" xlink:href="ppbt-20241231.xsd#ppbt_OtherfinancialCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ppbt_OtherfinancialCost" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncome"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrs-full_InterestIncomeOnDeposits" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeGain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ForeignExchangeGain"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrs-full_ForeignExchangeGain" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrs-full_GainsOnChangeInFairValueOfDerivatives" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ppbt_OtherExpense" xlink:href="ppbt-20241231.xsd#ppbt_OtherExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ppbt_OtherExpense" order="4" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>ppbt-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 10 16:44:15 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ConsolidatedBalanceSheet" roleURI="http://Purplebiotech.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" roleURI="http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ShareholdersEquityType2or3" roleURI="http://Purplebiotech.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ConsolidatedCashFlow" roleURI="http://Purplebiotech.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_General" roleURI="http://Purplebiotech.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_BasisofPreparationoftheConsolidatedFinancialStatements" roleURI="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_MaterialAccountingPolicies" roleURI="http://Purplebiotech.com/role/MaterialAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_IntangibleAssets" roleURI="http://Purplebiotech.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_CashandCashEquivalents" roleURI="http://Purplebiotech.com/role/CashandCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_Leases" roleURI="http://Purplebiotech.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_OtherCurrentAssets" roleURI="http://Purplebiotech.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_OtherPayables" roleURI="http://Purplebiotech.com/role/OtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_Equity" roleURI="http://Purplebiotech.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ShareBasedPaymentArrangements" roleURI="http://Purplebiotech.com/role/ShareBasedPaymentArrangements"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_TransactionsandBalanceswithRelatedParties" roleURI="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_CommitmentsandContingentLiabilities" roleURI="http://Purplebiotech.com/role/CommitmentsandContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ResearchandDevelopmentExpenses" roleURI="http://Purplebiotech.com/role/ResearchandDevelopmentExpenses"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_SalesGeneralandAdministrativeExpenses" roleURI="http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_FinanceExpenseIncomeNet" roleURI="http://Purplebiotech.com/role/FinanceExpenseIncomeNet"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_TaxesonIncome" roleURI="http://Purplebiotech.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_EmployeeBenefits" roleURI="http://Purplebiotech.com/role/EmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_FinancialInstruments" roleURI="http://Purplebiotech.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_SubsequentEvents" roleURI="http://Purplebiotech.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_AccountingPoliciesByPolicy" roleURI="http://Purplebiotech.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_BasisofPreparationoftheConsolidatedFinancialStatementsTables" roleURI="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_IntangibleAssetsTables" roleURI="http://Purplebiotech.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_CashandCashEquivalentsTables" roleURI="http://Purplebiotech.com/role/CashandCashEquivalentsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_LeasesTables" roleURI="http://Purplebiotech.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_OtherCurrentAssetsTables" roleURI="http://Purplebiotech.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_OtherPayablesTables" roleURI="http://Purplebiotech.com/role/OtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_EquityTables" roleURI="http://Purplebiotech.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ShareBasedPaymentArrangementsTables" roleURI="http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ResearchandDevelopmentExpensesTables" roleURI="http://Purplebiotech.com/role/ResearchandDevelopmentExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_SalesGeneralandAdministrativeExpensesTables" roleURI="http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_FinanceExpenseIncomeNetTables" roleURI="http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_EmployeeBenefitsTables" roleURI="http://Purplebiotech.com/role/EmployeeBenefitsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_FinancialInstrumentsTables" roleURI="http://Purplebiotech.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofDataonExchangeRatesTable" roleURI="http://Purplebiotech.com/role/ScheduleofDataonExchangeRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofIntangibleAssetsTable" roleURI="http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable" roleURI="http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofCashandCashEquivalentsTable" roleURI="http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofCarryingAmountsofRighttoUseAssetsTable" roleURI="http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable" roleURI="http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofAmountsRecognizedinProfitorLossTable" roleURI="http://Purplebiotech.com/role/ScheduleofAmountsRecognizedinProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofOtherPayablesTable" roleURI="http://Purplebiotech.com/role/ScheduleofOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofShareCapitalTable" roleURI="http://Purplebiotech.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofChangesinShareCapitalTable" roleURI="http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleoftheInformationRelatingtoNonControllingInterestsTable" roleURI="http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable" roleURI="http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofNumberofRSUsTable" roleURI="http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofAssumptionswereUsedTable" roleURI="http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable" roleURI="http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofRecordedExpensesTable" roleURI="http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofSalesGeneralandAdministrativeExpensesTable" roleURI="http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofFinanceExpensesTable" roleURI="http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofFinanceIncomeTable" roleURI="http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofPostEmployeeBenefitsTable" roleURI="http://Purplebiotech.com/role/ScheduleofPostEmployeeBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofDefinedContributionPlaninRespectofitsEmployeesTable" roleURI="http://Purplebiotech.com/role/ScheduleofDefinedContributionPlaninRespectofitsEmployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" roleURI="http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofFinancialInstrumentsMeasuredatFairValueTable" roleURI="http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofDetailsRegardingFairValueMeasurementTable" roleURI="http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofFairValueMeasurementTable" roleURI="http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_GeneralDetails" roleURI="http://Purplebiotech.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_BasisofPreparationoftheConsolidatedFinancialStatementsDetails" roleURI="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_MaterialAccountingPoliciesDetails" roleURI="http://Purplebiotech.com/role/MaterialAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_IntangibleAssetsDetails" roleURI="http://Purplebiotech.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_LeasesDetails" roleURI="http://Purplebiotech.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_EquityDetails" roleURI="http://Purplebiotech.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ShareBasedPaymentArrangementsDetails" roleURI="http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_CommitmentsandContingentLiabilitiesDetails" roleURI="http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_FinanceExpenseIncomeNetDetails" roleURI="http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_TaxesonIncomeDetails" roleURI="http://Purplebiotech.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_EmployeeBenefitsDetails" roleURI="http://Purplebiotech.com/role/EmployeeBenefitsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_FinancialInstrumentsDetails" roleURI="http://Purplebiotech.com/role/FinancialInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_SubsequentEventsDetails" roleURI="http://Purplebiotech.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#DocumentAndEntityInformation" roleURI="http://Purplebiotech.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_RightofuseAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentWarrantLiability" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherCurrentPayables" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_IssuedCapital" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_SharePremium" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ReceiptsOnAccountsOfWarrant" xlink:href="ppbt-20241231.xsd#ppbt_ReceiptsOnAccountsOfWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ppbt_ReceiptsOnAccountsOfWarrant" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CapitalReserve" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherReserves" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest" xlink:href="ppbt-20241231.xsd#ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_RetainedEarnings" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncontrollingInterests" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Equity" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="29" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ImpairmentLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OperatingExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncomeCost" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_IssuedCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_SharePremiumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ReceiptsOnAccountOfWarrantsMember" xlink:href="ppbt-20241231.xsd#ppbt_ReceiptsOnAccountOfWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ppbt_ReceiptsOnAccountOfWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfCashFlowHedgesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfCashFlowHedgesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfCashFlowHedgesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember" xlink:href="ppbt-20241231.xsd#ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember" xlink:href="ppbt-20241231.xsd#ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_RetainedEarningsMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncome" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AdjustmentsForChangesInAssetsAndLiabilities" xlink:href="ppbt-20241231.xsd#ppbt_AdjustmentsForChangesInAssetsAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ppbt_AdjustmentsForChangesInAssetsAndLiabilities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave" xlink:href="ppbt-20241231.xsd#ppbt_CashAssumedAsPartOfAcquisitionOfFamewave"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_Decreaseincreaseinshorttermdeposits" xlink:href="ppbt-20241231.xsd#ppbt_Decreaseincreaseinshorttermdeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ppbt_Decreaseincreaseinshorttermdeposits" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_IncreaseDecreaseInLongTermDeposits" xlink:href="ppbt-20241231.xsd#ppbt_IncreaseDecreaseInLongTermDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ppbt_IncreaseDecreaseInLongTermDeposits" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PaymentsForShareIssueCosts" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ProceedsFromIssuingWarrants" xlink:href="ppbt-20241231.xsd#ppbt_ProceedsFromIssuingWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ppbt_ProceedsFromIssuingWarrants" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantsIssuanceExpensesPaid" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsIssuanceExpensesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ppbt_WarrantsIssuanceExpensesPaid" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="30" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/General" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_GeneralAbstract" xlink:href="ppbt-20241231.xsd#ppbt_GeneralAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_GeneralAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/MaterialAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/IntangibleAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/CashandCashEquivalents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/OtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/OtherPayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ShareBasedPaymentArrangements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/CommitmentsandContingentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_CommitmentsAndContingentLiabilitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_CommitmentsAndContingentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_CommitmentsAndContingentLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ResearchandDevelopmentExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_ResearchAndDevelopmentExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ResearchAndDevelopmentExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ResearchAndDevelopmentExpensesAbstract" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/FinanceExpenseIncomeNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_FinanceExpenseIncomeNetAbstract" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_FinanceExpenseIncomeNetAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/TaxesonIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_TaxesOnIncomeabstract" xlink:href="ppbt-20241231.xsd#ppbt_TaxesOnIncomeabstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_TaxesOnIncomeabstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/EmployeeBenefits" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/FinancialInstruments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/IntangibleAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsTablesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsTablesTable" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_IntangibleAssetsTablesLineItems" xlink:to="ppbt_IntangibleAssetsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsTablesLineItems" xlink:to="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsTablesLineItems" xlink:to="ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/CashandCashEquivalentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/OtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfOtherCurrentAssettextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfOtherCurrentAssettextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:to="ppbt_DisclosureOfOtherCurrentAssettextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/OtherPayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:href="ppbt-20241231.xsd#ppbt_TransactionsandBalanceswithRelatedPartiesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="ppbt_TransactionsandBalanceswithRelatedPartiesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ResearchandDevelopmentExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_ResearchAndDevelopmentExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ResearchAndDevelopmentExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ResearchAndDevelopmentExpensesAbstract" xlink:to="ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_FinanceExpenseIncomeNetTablesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinanceExpenseIncomeNetTablesTable" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_FinanceExpenseIncomeNetTablesLineItems" xlink:to="ppbt_FinanceExpenseIncomeNetTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_FinanceExpenseIncomeNetTablesLineItems" xlink:to="ifrs-full_DisclosureOfFinanceCostExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_FinanceExpenseIncomeNetTablesLineItems" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/EmployeeBenefitsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsTablesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsTablesTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_FinancialInstrumentsTablesLineItems" xlink:to="ppbt_FinancialInstrumentsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_FinancialInstrumentsTablesTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrencyRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrencyRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_CurrencyRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_FinancialInstrumentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_FinancialInstrumentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_FinancialInstrumentsTablesLineItems" xlink:to="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_FinancialInstrumentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofDataonExchangeRatesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeRatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ForeignExchangeRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AverageForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ForeignExchangeRatesAbstract" xlink:to="ifrs-full_AverageForeignExchangeRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PercentageOfExchangeRate" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfExchangeRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ForeignExchangeRatesAbstract" xlink:to="ppbt_PercentageOfExchangeRate" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsScheduleofIntangibleAssetsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsScheduleofIntangibleAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ppbt_IntangibleAssetsScheduleofIntangibleAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_IntangibleAssetsScheduleofIntangibleAssetsDetailsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_IPRDRelatedToTryNovosee5ABelowMember" xlink:href="ppbt-20241231.xsd#ppbt_IPRDRelatedToTryNovosee5ABelowMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="ppbt_IPRDRelatedToTryNovosee5ABelowMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_IPRDRelatedToFamewaveSee5BBelowMember" xlink:href="ppbt-20241231.xsd#ppbt_IPRDRelatedToFamewaveSee5BBelowMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="ppbt_IPRDRelatedToFamewaveSee5BBelowMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_IPRDRelatedToImmunorizonSee5CBelowMember" xlink:href="ppbt-20241231.xsd#ppbt_IPRDRelatedToImmunorizonSee5CBelowMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="ppbt_IPRDRelatedToImmunorizonSee5CBelowMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_IPRDRelatedToPurpleGmbHMember" xlink:href="ppbt-20241231.xsd#ppbt_IPRDRelatedToPurpleGmbHMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="ppbt_IPRDRelatedToPurpleGmbHMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ifrs-full_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ifrs-full_OtherIntangibleAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ifrs-full_OtherReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ifrs-full_OtherPayables" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_CashAndCashEquivalentLineItems" xlink:href="ppbt-20241231.xsd#ppbt_CashAndCashEquivalentLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_CashAndCashEquivalentLineItems" xlink:to="ppbt_CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable" xlink:to="srt_CurrencyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OtherCurrencyMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OtherCurrencyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="srt_OtherCurrencyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_CashAndCashEquivalentLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ppbt_LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseReceivablesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseReceivablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="ifrs-full_LeaseReceivablesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_RightofuseAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="ppbt_LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable" xlink:to="ifrs-full_MaturityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofAmountsRecognizedinProfitorLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ppbt_GovernmentAuthorities" xlink:href="ppbt-20241231.xsd#ppbt_GovernmentAuthorities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ppbt_GovernmentAuthorities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_CurrentGovernmentGrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_SalaryRelatedOtherPayablesCurrent" xlink:href="ppbt-20241231.xsd#ppbt_SalaryRelatedOtherPayablesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ppbt_SalaryRelatedOtherPayablesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_OtherCurrentPayables" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_EquityScheduleofShareCapitalDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_EquityScheduleofShareCapitalDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ppbt_EquityScheduleofShareCapitalDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ClassesOfPreferredSharesAxis" xlink:href="ppbt-20241231.xsd#ppbt_ClassesOfPreferredSharesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_EquityScheduleofShareCapitalDetailsTable" xlink:to="ppbt_ClassesOfPreferredSharesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ClassesOfPreferredSharesDomainDomain" xlink:href="ppbt-20241231.xsd#ppbt_ClassesOfPreferredSharesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ppbt_ClassesOfPreferredSharesAxis" xlink:to="ppbt_ClassesOfPreferredSharesDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ClassesOfPreferredSharesDomainDomain_0" xlink:href="ppbt-20241231.xsd#ppbt_ClassesOfPreferredSharesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ppbt_ClassesOfPreferredSharesAxis" xlink:to="ppbt_ClassesOfPreferredSharesDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_OrdinaryShareMember" xlink:href="ppbt-20241231.xsd#ppbt_OrdinaryShareMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ClassesOfPreferredSharesDomainDomain" xlink:to="ppbt_OrdinaryShareMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PreferredShareClassMember" xlink:href="ppbt-20241231.xsd#ppbt_PreferredShareClassMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ClassesOfPreferredSharesDomainDomain" xlink:to="ppbt_PreferredShareClassMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PreferredShareClassBMember" xlink:href="ppbt-20241231.xsd#ppbt_PreferredShareClassBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ClassesOfPreferredSharesDomainDomain" xlink:to="ppbt_PreferredShareClassBMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PreferredClassCMember" xlink:href="ppbt-20241231.xsd#ppbt_PreferredClassCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ClassesOfPreferredSharesDomainDomain" xlink:to="ppbt_PreferredClassCMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PreferredClassDMember" xlink:href="ppbt-20241231.xsd#ppbt_PreferredClassDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ClassesOfPreferredSharesDomainDomain" xlink:to="ppbt_PreferredClassDMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ClassEPreferredSharesMember" xlink:href="ppbt-20241231.xsd#ppbt_ClassEPreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ClassesOfPreferredSharesDomainDomain" xlink:to="ppbt_ClassEPreferredSharesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_NumberOfIssuanceShares" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfIssuanceShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ppbt_NumberOfIssuanceShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_NumberOfVestingOfRsus" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfVestingOfRsus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ppbt_NumberOfVestingOfRsus" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_NumberOfExerciseOfWarrants" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ppbt_NumberOfExerciseOfWarrants" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_CurrentAsset" xlink:href="ppbt-20241231.xsd#ppbt_CurrentAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract" xlink:to="ppbt_CurrentAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_CurrentLiabiliti" xlink:href="ppbt-20241231.xsd#ppbt_CurrentLiabiliti"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract" xlink:to="ppbt_CurrentLiabiliti" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract" xlink:to="ifrs-full_NetAssetsLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_NetAssetsAttributableToNoncontrollingInterest" xlink:href="ppbt-20241231.xsd#ppbt_NetAssetsAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract" xlink:to="ppbt_NetAssetsAttributableToNoncontrollingInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_NetAssetsAttributableToNoncontrollingInterests" xlink:href="ppbt-20241231.xsd#ppbt_NetAssetsAttributableToNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract" xlink:to="ppbt_NetAssetsAttributableToNoncontrollingInterests" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfNumberOfRSUsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfNumberOfRSUsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfNumberOfRSUsAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfNumberOfRSUsAbstract" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfNumberOfRSUsAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfNumberOfRSUsAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfAssumptionsWereUsedLineItems" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfAssumptionsWereUsedLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ppbt_ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable" xlink:to="ifrs-full_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ppbt_ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ResearchAndDevelopmentExpensesMember" xlink:href="ppbt-20241231.xsd#ppbt_ResearchAndDevelopmentExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ppbt_ResearchAndDevelopmentExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ppbt_TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensation" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems" xlink:href="ppbt-20241231.xsd#ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems" xlink:to="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_SalariesWagesAndRelatedExpensesMember" xlink:href="ppbt-20241231.xsd#ppbt_SalariesWagesAndRelatedExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ppbt_SalariesWagesAndRelatedExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShareBasedPaymentsMember" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ppbt_ShareBasedPaymentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ServiceProvidersMember" xlink:href="ppbt-20241231.xsd#ppbt_ServiceProvidersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ppbt_ServiceProvidersMember" order="2" xbrldt:closed="true"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZ7uO1Q1bYM5N9HuAVhCBKc3Dilxy5HOYIdYl1h0YHGyqqhp5yL2C/pvkGqpTQ7NfV8dDJWElNwr7uGWGMl/FOCtmi0tB2eTtzKmmQ0hcQ60BPTfIvmWs+j5xoLJ2ifHK3Qzc5tu1CRRSrKp5kfOFheAU8ndp9+zFyGXNaa6jOMefzDkABcY69jtuMijqkJ3ohuLKcwkZmZewn4yToUYFOOphhxC2BFvS+ODcInO3ULMPUyuBQ+JuBH] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ppbt_SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WagesAndSalaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_WagesAndSalaries" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ReimbursementOfLegalFeesExpense" xlink:href="ppbt-20241231.xsd#ppbt_ReimbursementOfLegalFeesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ppbt_ReimbursementOfLegalFeesExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfessionalFeesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_ProfessionalFeesExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DirectorsRemunerationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_DirectorsRemunerationExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RentalExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RentalExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_RentalExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TravelExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_TravelExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_DepreciationExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_GeneralAndAdministrativeExpensesOther" xlink:href="ppbt-20241231.xsd#ppbt_GeneralAndAdministrativeExpensesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ppbt_GeneralAndAdministrativeExpensesOther" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfFinanceExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfFinanceExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfFinanceExpensesAbstract" xlink:to="ifrs-full_FeeAndCommissionExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ForeignExchangeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfFinanceExpensesAbstract" xlink:to="ifrs-full_ForeignExchangeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_IssuanceExpenses" xlink:href="ppbt-20241231.xsd#ppbt_IssuanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfFinanceExpensesAbstract" xlink:to="ppbt_IssuanceExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_OtherfinancialCost" xlink:href="ppbt-20241231.xsd#ppbt_OtherfinancialCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfFinanceExpensesAbstract" xlink:to="ppbt_OtherfinancialCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherExpenseByNature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfFinanceExpensesAbstract" xlink:to="ifrs-full_OtherExpenseByNature" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfFinanceIncomeAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfFinanceIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfFinanceIncomeAbstract" xlink:to="ifrs-full_InterestIncomeOnDeposits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeGain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ForeignExchangeGain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfFinanceIncomeAbstract" xlink:to="ifrs-full_ForeignExchangeGain" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfFinanceIncomeAbstract" xlink:to="ifrs-full_GainsOnChangeInFairValueOfDerivatives" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_OtherExpense" xlink:href="ppbt-20241231.xsd#ppbt_OtherExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfFinanceIncomeAbstract" xlink:to="ppbt_OtherExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfFinanceIncomeAbstract" xlink:to="ifrs-full_OtherFinanceIncome" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofPostEmployeeBenefitsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfPostEmployeeBenefitsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfPostEmployeeBenefitsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfPostEmployeeBenefitsAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfPostEmployeeBenefitsAbstract" xlink:to="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofDefinedContributionPlaninRespectofitsEmployeesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" xlink:to="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" xlink:to="ifrs-full_RangeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_DownRangeOneMember" xlink:href="ppbt-20241231.xsd#ppbt_DownRangeOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ppbt_DownRangeOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_UpRangeOneMember" xlink:href="ppbt-20241231.xsd#ppbt_UpRangeOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ppbt_UpRangeOneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_EUROMember" xlink:href="ppbt-20241231.xsd#ppbt_EUROMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="ppbt_EUROMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_NISMember" xlink:href="ppbt-20241231.xsd#ppbt_NISMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="ppbt_NISMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_CashAndCashEquivalentsAndDepositsMember" xlink:href="ppbt-20241231.xsd#ppbt_CashAndCashEquivalentsAndDepositsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain" xlink:to="ppbt_CashAndCashEquivalentsAndDepositsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_OtherCurrentAssetMember" xlink:href="ppbt-20241231.xsd#ppbt_OtherCurrentAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain" xlink:to="ppbt_OtherCurrentAssetMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AccountPayablesMember" xlink:href="ppbt-20241231.xsd#ppbt_AccountPayablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain" xlink:to="ppbt_AccountPayablesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_OtherPayablesMember" xlink:href="ppbt-20241231.xsd#ppbt_OtherPayablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain" xlink:to="ppbt_OtherPayablesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PostemploymentBenefitLiabilitiesMember" xlink:href="ppbt-20241231.xsd#ppbt_PostemploymentBenefitLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain" xlink:to="ppbt_PostemploymentBenefitLiabilitiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_IncomelossFromChangeInExchangeRateDown" xlink:href="ppbt-20241231.xsd#ppbt_IncomelossFromChangeInExchangeRateDown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_IncomelossFromChangeInExchangeRateDown" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_IncomelossValue" xlink:href="ppbt-20241231.xsd#ppbt_IncomelossValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_IncomelossValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_IncomelossFromChangeInExchangeRateUp" xlink:href="ppbt-20241231.xsd#ppbt_IncomelossFromChangeInExchangeRateUp"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_IncomelossFromChangeInExchangeRateUp" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_Securities" xlink:href="ppbt-20241231.xsd#ppbt_Securities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_Securities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DerivativeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DerivativeFinancialAssets" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ConvertibleNoteMember" xlink:href="ppbt-20241231.xsd#ppbt_ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsDomain" xlink:to="ppbt_ConvertibleNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantsoneMember" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsoneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsDomain" xlink:to="ppbt_WarrantsoneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueMeasurementBalance" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_FairValueMeasurementBalance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueMeasurementExercise" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_FairValueMeasurementExercise" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueMeasurementIssuance" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_FairValueMeasurementIssuance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueMeasurementIssuanceProceed" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementIssuanceProceed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_FairValueMeasurementIssuanceProceed" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueMeasurementRevaluation" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementRevaluation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_FairValueMeasurementRevaluation" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" xlink:to="ifrs-full_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantsoneMember" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsoneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsDomain" xlink:to="ppbt_WarrantsoneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ConvertibleDebtInstrumentMember" xlink:href="ppbt-20241231.xsd#ppbt_ConvertibleDebtInstrumentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsDomain" xlink:to="ppbt_ConvertibleDebtInstrumentMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ppbt_WarrantsoneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_DescriptionOfOptionLifeShareOptionGranted" xlink:href="ppbt-20241231.xsd#ppbt_DescriptionOfOptionLifeShareOptionGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_DescriptionOfOptionLifeShareOptionGranted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield" xlink:href="ppbt-20241231.xsd#ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_Discountforlackofmarketability" xlink:href="ppbt-20241231.xsd#ppbt_Discountforlackofmarketability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_Discountforlackofmarketability" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/GeneralDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_GeneralLineItems" xlink:href="ppbt-20241231.xsd#ppbt_GeneralLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_GeneralDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_GeneralDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_GeneralLineItems" xlink:to="ppbt_GeneralDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AmericanDepositorySharesOrdinaryShares" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepositorySharesOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_GeneralLineItems" xlink:to="ppbt_AmericanDepositorySharesOrdinaryShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_CommonStockNoParValues" xlink:href="ppbt-20241231.xsd#ppbt_CommonStockNoParValues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_GeneralLineItems" xlink:to="ppbt_CommonStockNoParValues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_GeneralLineItems" xlink:to="ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AmericanDepositorySharesPurchase" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepositorySharesPurchase"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_GeneralLineItems" xlink:to="ppbt_AmericanDepositorySharesPurchase" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PercentageOfContractToAcquire" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfContractToAcquire"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_GeneralLineItems" xlink:to="ppbt_PercentageOfContractToAcquire" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_RetainedEarning" xlink:href="ppbt-20241231.xsd#ppbt_RetainedEarning"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_GeneralLineItems" xlink:to="ppbt_RetainedEarning" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PrivateAndPublicFinancingTotal" xlink:href="ppbt-20241231.xsd#ppbt_PrivateAndPublicFinancingTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_GeneralLineItems" xlink:to="ppbt_PrivateAndPublicFinancingTotal" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems" xlink:href="ppbt-20241231.xsd#ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems" xlink:to="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="ifrs-full_ShareOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_FunctionalCurrency" xlink:href="ppbt-20241231.xsd#ppbt_FunctionalCurrency"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems" xlink:to="ppbt_FunctionalCurrency" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_StockOptionExercisedPeriod" xlink:href="ppbt-20241231.xsd#ppbt_StockOptionExercisedPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems" xlink:to="ppbt_StockOptionExercisedPeriod" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/MaterialAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract"/>
    <loc xlink:type="locator" xlink:label="ppbt_NumberOfShare" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="ppbt_NumberOfShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_NumberOfPerShare" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="ppbt_NumberOfPerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_DepreciationRightofuseAssetsUsefulLife" xlink:href="ppbt-20241231.xsd#ppbt_DepreciationRightofuseAssetsUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="ppbt_DepreciationRightofuseAssetsUsefulLife" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/IntangibleAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsDetailsLineItems" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_IntangibleAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_IntangibleAssetsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AdsMember" xlink:href="ppbt-20241231.xsd#ppbt_AdsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ppbt_AdsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_EquityMethodInvestmentsOwnershipPercentage" xlink:href="ppbt-20241231.xsd#ppbt_EquityMethodInvestmentsOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_EquityMethodInvestmentsOwnershipPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AggregateUpfrontPayment" xlink:href="ppbt-20241231.xsd#ppbt_AggregateUpfrontPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_AggregateUpfrontPayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AmericanDepositorySharesOrdinaryShares" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepositorySharesOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_AmericanDepositorySharesOrdinaryShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_LongTermMilestonesAggregateAmount" xlink:href="ppbt-20241231.xsd#ppbt_LongTermMilestonesAggregateAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_LongTermMilestonesAggregateAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_TotalAcquisitionAmount" xlink:href="ppbt-20241231.xsd#ppbt_TotalAcquisitionAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_TotalAcquisitionAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueOfIssuedEquity" xlink:href="ppbt-20241231.xsd#ppbt_FairValueOfIssuedEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_FairValueOfIssuedEquity" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueOfIssuedIntangibleAssets" xlink:href="ppbt-20241231.xsd#ppbt_FairValueOfIssuedIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_FairValueOfIssuedIntangibleAssets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AggregateShareholdersOfImmunorizon" xlink:href="ppbt-20241231.xsd#ppbt_AggregateShareholdersOfImmunorizon"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_AggregateShareholdersOfImmunorizon" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_SharesPrice" xlink:href="ppbt-20241231.xsd#ppbt_SharesPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_SharesPrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_DescriptionOfExpectedVolatilityPercentage" xlink:href="ppbt-20241231.xsd#ppbt_DescriptionOfExpectedVolatilityPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_DescriptionOfExpectedVolatilityPercentage" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_DescriptionOfExpectedAnnualRiskFreeRate" xlink:href="ppbt-20241231.xsd#ppbt_DescriptionOfExpectedAnnualRiskFreeRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_DescriptionOfExpectedAnnualRiskFreeRate" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PercentageOfDiscountsForLacksOfMarketability" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfDiscountsForLacksOfMarketability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_PercentageOfDiscountsForLacksOfMarketability" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsRecoverableAmountPercentage" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsRecoverableAmountPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_IntangibleAssetsRecoverableAmountPercentage" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_LeasesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_LeasesLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_LeasesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_LeasesLineItems" xlink:to="ppbt_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_LeasesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_LeasesDetailsTable" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_RehovotMember" xlink:href="ppbt-20241231.xsd#ppbt_RehovotMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ppbt_RehovotMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_LeaseAgreementOneMember" xlink:href="ppbt-20241231.xsd#ppbt_LeaseAgreementOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="ppbt_LeaseAgreementOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_LeaseAgreementsTwoMember" xlink:href="ppbt-20241231.xsd#ppbt_LeaseAgreementsTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="ppbt_LeaseAgreementsTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AgreementLeaseTerm" xlink:href="ppbt-20241231.xsd#ppbt_AgreementLeaseTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_LeasesLineItems" xlink:to="ppbt_AgreementLeaseTerm" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_LeasesLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AgreementLeaseAdditionalTerm" xlink:href="ppbt-20241231.xsd#ppbt_AgreementLeaseAdditionalTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_LeasesLineItems" xlink:to="ppbt_AgreementLeaseAdditionalTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_CurrentTerms" xlink:href="ppbt-20241231.xsd#ppbt_CurrentTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_LeasesLineItems" xlink:to="ppbt_CurrentTerms" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_EquityLineItems" xlink:href="ppbt-20241231.xsd#ppbt_EquityLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_EquityDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_EquityDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_EquityDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_EquityDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_EquityDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_EquityDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_EquityDetailsTable" xlink:to="ifrs-full_RangeAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_EquityDetailsTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_EquityDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AdsMember" xlink:href="ppbt-20241231.xsd#ppbt_AdsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="ppbt_AdsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PrivatePlacementsMember" xlink:href="ppbt-20241231.xsd#ppbt_PrivatePlacementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:to="ppbt_PrivatePlacementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PublicOfferingMember" xlink:href="ppbt-20241231.xsd#ppbt_PublicOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:to="ppbt_PublicOfferingMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreferenceSharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreferenceSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_PreferenceSharesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ATMProgramMember" xlink:href="ppbt-20241231.xsd#ppbt_ATMProgramMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ppbt_ATMProgramMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_SubsequentEventsMember" xlink:href="ppbt-20241231.xsd#ppbt_SubsequentEventsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="ppbt_SubsequentEventsMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ppbt_AdsMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ppbt_PublicOfferingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_RestrictedShareUnitsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_NonVotingSeniorPreferredShares" xlink:href="ppbt-20241231.xsd#ppbt_NonVotingSeniorPreferredShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_NonVotingSeniorPreferredShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_StockholdersEquityReversesStockSplit" xlink:href="ppbt-20241231.xsd#ppbt_StockholdersEquityReversesStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_StockholdersEquityReversesStockSplit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ReverseRatio" xlink:href="ppbt-20241231.xsd#ppbt_ReverseRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_ReverseRatio" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_FundsRaisedAmount" xlink:href="ppbt-20241231.xsd#ppbt_FundsRaisedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_FundsRaisedAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfessionalFeesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ifrs-full_ProfessionalFeesExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_NumberOfNonTradableWarrants" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfNonTradableWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_NumberOfNonTradableWarrants" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ifrs-full_ParValuePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_FundsRaisedshares" xlink:href="ppbt-20241231.xsd#ppbt_FundsRaisedshares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_FundsRaisedshares" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantsTerm" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_WarrantsTerm" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ifrs-full_WarrantReserve" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_DepositaryShares" xlink:href="ppbt-20241231.xsd#ppbt_DepositaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_DepositaryShares" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PurchaseOfCommonStockAndWarrants" xlink:href="ppbt-20241231.xsd#ppbt_PurchaseOfCommonStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_PurchaseOfCommonStockAndWarrants" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ifrs-full_WarrantLiability" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantsIssued" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_WarrantsIssued" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_IssuesOfEquity" xlink:href="ppbt-20241231.xsd#ppbt_IssuesOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_IssuesOfEquity" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ExerciseOfWarrantsEquity" xlink:href="ppbt-20241231.xsd#ppbt_ExerciseOfWarrantsEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_ExerciseOfWarrantsEquity" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantTermDescription" xlink:href="ppbt-20241231.xsd#ppbt_WarrantTermDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_WarrantTermDescription" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherExpenseByNature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ifrs-full_OtherExpenseByNature" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceContractsIssuedThatAreAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InsuranceContractsIssuedThatAreAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ifrs-full_InsuranceContractsIssuedThatAreAssets" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_SalesAgreementShares" xlink:href="ppbt-20241231.xsd#ppbt_SalesAgreementShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_SalesAgreementShares" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePrice2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_noncontrollingInterests" xlink:href="ppbt-20241231.xsd#ppbt_noncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_noncontrollingInterests" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShareBasedPaymentArrangementsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentArrangementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ppbt_ShareBasedPaymentArrangementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_ShareBasedPaymentArrangementsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_ShareBasedPaymentArrangementsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_ShareBasedPaymentArrangementsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_ShareBasedPaymentArrangementsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_ShareBasedPaymentArrangementsDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_ShareBasedPaymentArrangementsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AdsMember" xlink:href="ppbt-20241231.xsd#ppbt_AdsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="ppbt_AdsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="ifrs-full_RestrictedShareUnitsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShareBasedPaymentArrangementsMember" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="ppbt_ShareBasedPaymentArrangementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="srt_OfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_BoardOfDirectorsMember" xlink:href="ppbt-20241231.xsd#ppbt_BoardOfDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ppbt_BoardOfDirectorsMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_RestrictedShareUnitsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_OptionExerciseOrdinaryShare" xlink:href="ppbt-20241231.xsd#ppbt_OptionExerciseOrdinaryShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ppbt_OptionExerciseOrdinaryShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_VestingPeriod" xlink:href="ppbt-20241231.xsd#ppbt_VestingPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ppbt_VestingPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ExercisePeriod" xlink:href="ppbt-20241231.xsd#ppbt_ExercisePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ppbt_ExercisePeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ConsultantPerShares" xlink:href="ppbt-20241231.xsd#ppbt_ConsultantPerShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ppbt_ConsultantPerShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AmericanDepostioryShares" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepostioryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ppbt_AmericanDepostioryShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ConvertibleShares" xlink:href="ppbt-20241231.xsd#ppbt_ConvertibleShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ppbt_ConvertibleShares" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ppbt_PercentageOfCapacityOfAnAdvisor" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfCapacityOfAnAdvisor"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ppbt_PercentageOfCapacityOfAnAdvisor" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_CommitmentsAndContingentLiabilitiesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_CommitmentsAndContingentLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_CommitmentsandContingentLiabilitiesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_CommitmentsandContingentLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="ppbt_CommitmentsandContingentLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_RangesAxis" xlink:href="ppbt-20241231.xsd#ppbt_RangesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="ppbt_RangesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_RangesDomainDomain" xlink:href="ppbt-20241231.xsd#ppbt_RangesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ppbt_RangesAxis" xlink:to="ppbt_RangesDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_RangesDomainDomain_0" xlink:href="ppbt-20241231.xsd#ppbt_RangesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ppbt_RangesAxis" xlink:to="ppbt_RangesDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_RangesDomainDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_RangesDomainDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_TryNovosTechnologiesMember" xlink:href="ppbt-20241231.xsd#ppbt_TryNovosTechnologiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ppbt_TryNovosTechnologiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_YissumsLicensedTechnologyMember" xlink:href="ppbt-20241231.xsd#ppbt_YissumsLicensedTechnologyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ppbt_YissumsLicensedTechnologyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_THMMember" xlink:href="ppbt-20241231.xsd#ppbt_THMMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ppbt_THMMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_BiopharmaceuticalProductMember" xlink:href="ppbt-20241231.xsd#ppbt_BiopharmaceuticalProductMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ppbt_BiopharmaceuticalProductMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_DiagnosticProductsMember" xlink:href="ppbt-20241231.xsd#ppbt_DiagnosticProductsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ppbt_DiagnosticProductsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PercentageOfEntitysRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="ifrs-full_PercentageOfEntitysRevenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromRoyalties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="ifrs-full_RevenueFromRoyalties" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PercentageOfSublicenseConsideration" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfSublicenseConsideration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="ppbt_PercentageOfSublicenseConsideration" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_PercentageOfReceiveExitFee" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfReceiveExitFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="ppbt_PercentageOfReceiveExitFee" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LicenceFeeIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicenceFeeIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="ifrs-full_LicenceFeeIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsOnLitigationSettlements" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsOnLitigationSettlements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="ifrs-full_GainsOnLitigationSettlements" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_FinanceExpenseIncomeNetLineItems" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinanceExpenseIncomeNetDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ppbt_FinanceExpenseIncomeNetLineItems" xlink:to="ppbt_FinanceExpenseIncomeNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_FinanceExpenseIncomeNetDetailsTable" xlink:to="ifrs-full_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantsExpireTerm" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsExpireTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_FinanceExpenseIncomeNetLineItems" xlink:to="ppbt_WarrantsExpireTerm" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/TaxesonIncomeDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ppbt_TaxesOnIncomeabstract" xlink:href="ppbt-20241231.xsd#ppbt_TaxesOnIncomeabstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_TaxesOnIncomeabstract" xlink:to="ifrs-full_ApplicableTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_StatutoryTaxRate" xlink:href="ppbt-20241231.xsd#ppbt_StatutoryTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_TaxesOnIncomeabstract" xlink:to="ppbt_StatutoryTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_TaxesOnIncomeabstract" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_EffectiveTaxRate" xlink:href="ppbt-20241231.xsd#ppbt_EffectiveTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_TaxesOnIncomeabstract" xlink:to="ppbt_EffectiveTaxRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_UnrecognizedResearchAndDevelopmentExpenses" xlink:href="ppbt-20241231.xsd#ppbt_UnrecognizedResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ppbt_TaxesOnIncomeabstract" xlink:to="ppbt_UnrecognizedResearchAndDevelopmentExpenses" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/EmployeeBenefitsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ppbt_EmployeeBenefitBonus" xlink:href="ppbt-20241231.xsd#ppbt_EmployeeBenefitBonus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="ppbt_EmployeeBenefitBonus" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_EmployeeBenefitsLiabilityDueGrants" xlink:href="ppbt-20241231.xsd#ppbt_EmployeeBenefitsLiabilityDueGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="ppbt_EmployeeBenefitsLiabilityDueGrants" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_FinancialInstrumentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ADSMember" xlink:href="ppbt-20241231.xsd#ppbt_ADSMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ppbt_ADSMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_SeriesA1WarrantsMember" xlink:href="ppbt-20241231.xsd#ppbt_SeriesA1WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ppbt_SeriesA1WarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_SeriesA2WarrantsMember" xlink:href="ppbt-20241231.xsd#ppbt_SeriesA2WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ppbt_SeriesA2WarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreditRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_CreditRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_January2025Member" xlink:href="ppbt-20241231.xsd#ppbt_January2025Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ppbt_January2025Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit" xlink:href="ppbt-20241231.xsd#ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShortTermDepositsGuaranteedForHedgingTransactions" xlink:href="ppbt-20241231.xsd#ppbt_ShortTermDepositsGuaranteedForHedgingTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_ShortTermDepositsGuaranteedForHedgingTransactions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfConvertibleInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_IssueOfConvertibleInstruments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ConvertibleWarrants" xlink:href="ppbt-20241231.xsd#ppbt_ConvertibleWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_ConvertibleWarrants" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_TerminationExercisePrice" xlink:href="ppbt-20241231.xsd#ppbt_TerminationExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_TerminationExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_ConvertiblesWarrants" xlink:href="ppbt-20241231.xsd#ppbt_ConvertiblesWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_ConvertiblesWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CurrentInvestments" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialAssetAtAFairValue" xlink:href="ppbt-20241231.xsd#ppbt_FinancialAssetAtAFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_FinancialAssetAtAFairValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantsIssued" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_WarrantsIssued" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantExercisePricePerShare" xlink:href="ppbt-20241231.xsd#ppbt_WarrantExercisePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_WarrantExercisePricePerShare" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_DepositarysShares" xlink:href="ppbt-20241231.xsd#ppbt_DepositarysShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_DepositarysShares" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AggregateWarrantsShares" xlink:href="ppbt-20241231.xsd#ppbt_AggregateWarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_AggregateWarrantsShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentAmount" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_FinancialInstrumentAmount" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_NetOfDeferredDifferenceAmount" xlink:href="ppbt-20241231.xsd#ppbt_NetOfDeferredDifferenceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ppbt_NetOfDeferredDifferenceAmount" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <loc xlink:type="locator" xlink:label="ppbt_SubsequentEventsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ppbt_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_SubsequentEventsDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_SubsequentEventsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_SubsequentEventsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ppbt_SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_AmericanDepositorySharesMember" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepositorySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ppbt_AmericanDepositorySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_SubsequentEventsMember" xlink:href="ppbt-20241231.xsd#ppbt_SubsequentEventsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="ppbt_SubsequentEventsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_RestrictedShareUnitsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_ShareOptionsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_OptionsAndRSUsMember" xlink:href="ppbt-20241231.xsd#ppbt_OptionsAndRSUsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ppbt_OptionsAndRSUsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_VestingPeriod" xlink:href="ppbt-20241231.xsd#ppbt_VestingPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ppbt_VestingPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ppbt_StockOptionExercisedPeriod" xlink:href="ppbt-20241231.xsd#ppbt_StockOptionExercisedPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ppbt_StockOptionExercisedPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://Purplebiotech.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelFaxNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelFaxNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelFaxNumber" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorOpinionTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>ppbt-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 10 16:44:15 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total non - current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US">Total non - current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US">Equity attributable to owners of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US">Operating Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl0" xml:lang="en-US">Loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US">Total comprehensive loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US">Total cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2"/>
    <loc xlink:type="locator" xlink:label="ppbt_GeneralAbstract" xlink:href="ppbt-20241231.xsd#ppbt_GeneralAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_GeneralAbstract_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_GeneralAbstract" xlink:to="ppbt_GeneralAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_lbl" xml:lang="en-US">Basis of Preparation of the Consolidated Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeRatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ForeignExchangeRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ForeignExchangeRatesAbstract_lbl" xml:lang="en-US">Schedule of Data on Exchange Rates [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeRatesAbstract" xlink:to="ifrs-full_ForeignExchangeRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract_lbl" xml:lang="en-US">Material Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" xml:lang="en-US">Total net identifiable assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US">Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_RightofuseAssets_lbl0" xml:lang="en-US">Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl1" xml:lang="en-US">Right to use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US">Classes of financial instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US">Maturity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Amounts Recognized in Profit or Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule of Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xml:lang="en-US">Total other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentAssets_lbl0" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract_lbl" xml:lang="en-US">Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xml:lang="en-US">Schedule of Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US">Total other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentPayables_lbl0" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl0" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ClassesOfPreferredSharesAxis" xlink:href="ppbt-20241231.xsd#ppbt_ClassesOfPreferredSharesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ClassesOfPreferredSharesAxis_lbl" xml:lang="en-US">Classes Of Preferred Shares [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ClassesOfPreferredSharesAxis" xlink:to="ppbt_ClassesOfPreferredSharesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xml:lang="en-US">Schedule of Changes in Share Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Issued as at January 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl0" xml:lang="en-US">Issued as at December 31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl1" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">Schedule of the Information Relating to Non-Controlling Interests [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract_lbl" xml:lang="en-US">Schedule of Number and Weighted Average Exercise Prices of Share Options [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US">Number of options, Outstanding beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl0" xml:lang="en-US">Number of options, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfNumberOfRSUsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfNumberOfRSUsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfNumberOfRSUsAbstract_lbl" xml:lang="en-US">Schedule of Number of RSUs [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfNumberOfRSUsAbstract" xlink:to="ppbt_ScheduleOfNumberOfRSUsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Outstanding at January 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Outstanding at December 31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US">Transactions and Balances with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CommitmentsAndContingentLiabilitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_CommitmentsAndContingentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CommitmentsAndContingentLiabilitiesAbstract_lbl" xml:lang="en-US">Commitments and Contingent Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CommitmentsAndContingentLiabilitiesAbstract" xlink:to="ppbt_CommitmentsAndContingentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ResearchAndDevelopmentExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ResearchAndDevelopmentExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ResearchAndDevelopmentExpensesAbstract_lbl" xml:lang="en-US">Research and Development Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ResearchAndDevelopmentExpensesAbstract" xlink:to="ppbt_ResearchAndDevelopmentExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">Sales, General and Administrative Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">Schedule of Sales, General and Administrative Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract" xlink:to="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, General and Administrative Expenses total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Sales, general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinanceExpenseIncomeNetAbstract" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinanceExpenseIncomeNetAbstract_lbl" xml:lang="en-US">Finance Expense (Income), Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinanceExpenseIncomeNetAbstract" xlink:to="ppbt_FinanceExpenseIncomeNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherExpenseByNature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherExpenseByNature_lbl" xml:lang="en-US">Total finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherExpenseByNature_lbl0" xml:lang="en-US">Issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_TaxesOnIncomeabstract" xlink:href="ppbt-20241231.xsd#ppbt_TaxesOnIncomeabstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_TaxesOnIncomeabstract_lbl" xml:lang="en-US">Taxes on Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TaxesOnIncomeabstract" xlink:to="ppbt_TaxesOnIncomeabstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_lbl" xml:lang="en-US">Employee Benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfPostEmployeeBenefitsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfPostEmployeeBenefitsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfPostEmployeeBenefitsAbstract_lbl" xml:lang="en-US">Schedule of Post-Employee Benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfPostEmployeeBenefitsAbstract" xlink:to="ppbt_ScheduleOfPostEmployeeBenefitsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract_lbl" xml:lang="en-US">Schedule of Defined Contribution Plan in Respect of its Employees [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract" xlink:to="ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US">Financial Instruments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US">Types of risks [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_lbl" xml:lang="en-US">Continuing involvement in derecognised financial assets by type of instrument [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US">Geographical areas [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US">Levels of fair value hierarchy [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueMeasurementBalance" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ppbt_FairValueMeasurementBalance_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementBalance" xlink:to="ppbt_FairValueMeasurementBalance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ppbt_FairValueMeasurementBalance_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementBalance" xlink:to="ppbt_FairValueMeasurementBalance_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US">Classes of assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl" xml:lang="en-US">Short term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents and short-term and long-terms deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentInvestments_lbl" xml:lang="en-US">Other investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentInvestments_lbl0" xml:lang="en-US">Fair value financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Total intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Current maturity of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl0" xml:lang="en-US">Current maturities of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentWarrantLiability_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentWarrantLiability" xlink:to="ifrs-full_NoncurrentWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_UnlabeledAbstract" xlink:href="ppbt-20241231.xsd#ppbt_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_UnlabeledAbstract" xlink:to="ppbt_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl0" xml:lang="en-US">Long-term lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl" xml:lang="en-US">Post-employment benefit liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:to="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US">Share capital, no par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ReceiptsOnAccountsOfWarrant" xlink:href="ppbt-20241231.xsd#ppbt_ReceiptsOnAccountsOfWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ReceiptsOnAccountsOfWarrant_lbl" xml:lang="en-US">Receipts on account of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ReceiptsOnAccountsOfWarrant" xlink:to="ppbt_ReceiptsOnAccountsOfWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl" xml:lang="en-US">Capital reserve for share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalReserve_lbl" xml:lang="en-US">Capital reserve from transactions with related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserve" xlink:to="ifrs-full_CapitalReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US">Capital reserve from hedging</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest" xlink:href="ppbt-20241231.xsd#ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest_lbl" xml:lang="en-US">Capital reserve from transactions with non- controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest" xlink:to="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLoss_lbl" xml:lang="en-US">Impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLoss" xlink:to="ifrs-full_ImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Other comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract_lbl" xml:lang="en-US">Items that will be transferred to profit or loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract" xlink:to="ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xml:lang="en-US">Loss attributable to:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Total comprehensive loss attributable to:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share data</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsPerShareAbstract" xlink:to="ifrs-full_BasicEarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_UnlabeledAbstract0" xlink:href="ppbt-20241231.xsd#ppbt_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_UnlabeledAbstract0" xlink:to="ppbt_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Basic loss per ADS - USD (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Diluted loss per ADS - USD (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_UnlabeledAbstract1" xlink:href="ppbt-20241231.xsd#ppbt_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_UnlabeledAbstract1" xlink:to="ppbt_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Number of ADSs used in calculating basic loss per ADS (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US">Number of ADSs used in calculating diluted loss per ADS (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_TransactionsWithOwnersOfTheCompanyAbstract" xlink:href="ppbt-20241231.xsd#ppbt_TransactionsWithOwnersOfTheCompanyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_TransactionsWithOwnersOfTheCompanyAbstract_lbl" xml:lang="en-US">Transactions with owners of the Company:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TransactionsWithOwnersOfTheCompanyAbstract" xlink:to="ppbt_TransactionsWithOwnersOfTheCompanyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US">Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US">Warrant inducement transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US">Share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl" xml:lang="en-US">Total transactions with owners of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US">Other comprehensive profit (loss) for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_TransactionsWithOwnersOfTheCompanyAbstract0" xlink:href="ppbt-20241231.xsd#ppbt_TransactionsWithOwnersOfTheCompanyAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_TransactionsWithOwnersOfTheCompanyAbstract0_lbl" xml:lang="en-US">Transactions with owners of the Company:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TransactionsWithOwnersOfTheCompanyAbstract0" xlink:to="ppbt_TransactionsWithOwnersOfTheCompanyAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_lbl" xml:lang="en-US">ADS issued in connection with the purchase of a subsidiary (see Note 4C)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:to="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_TransactionsWithOwnersOfTheCompanyAbstract1" xlink:href="ppbt-20241231.xsd#ppbt_TransactionsWithOwnersOfTheCompanyAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_TransactionsWithOwnersOfTheCompanyAbstract1_lbl" xml:lang="en-US">Transactions with owners of the Company:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TransactionsWithOwnersOfTheCompanyAbstract1" xlink:to="ppbt_TransactionsWithOwnersOfTheCompanyAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl0" xml:lang="en-US">Total share-based expense recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl" xml:lang="en-US">Total adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ChangesInAssetsAndLiabilitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ChangesInAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ChangesInAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ChangesInAssetsAndLiabilitiesAbstract" xlink:to="ppbt_ChangesInAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Changes in other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Changes in trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_lbl" xml:lang="en-US">Changes in other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl" xml:lang="en-US">Changes in post-employment benefit liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_AdjustmentsForChangesInAssetsAndLiabilities" xlink:href="ppbt-20241231.xsd#ppbt_AdjustmentsForChangesInAssetsAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ppbt_AdjustmentsForChangesInAssetsAndLiabilities_lbl" xml:lang="en-US">Changes in assets and liabilities, total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AdjustmentsForChangesInAssetsAndLiabilities" xlink:to="ppbt_AdjustmentsForChangesInAssetsAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CashFlowsFromInvestingActivitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_CashFlowsFromInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_CashFlowsFromInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CashFlowsFromInvestingActivitiesAbstract" xlink:to="ppbt_CashFlowsFromInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Proceed from other investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_Decreaseincreaseinshorttermdeposits" xlink:href="ppbt-20241231.xsd#ppbt_Decreaseincreaseinshorttermdeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_Decreaseincreaseinshorttermdeposits_lbl" xml:lang="en-US">Decrease in short term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_Decreaseincreaseinshorttermdeposits" xlink:to="ppbt_Decreaseincreaseinshorttermdeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IncreaseDecreaseInLongTermDeposits" xlink:href="ppbt-20241231.xsd#ppbt_IncreaseDecreaseInLongTermDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_IncreaseDecreaseInLongTermDeposits_lbl" xml:lang="en-US">Decrease in long term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IncreaseDecreaseInLongTermDeposits" xlink:to="ppbt_IncreaseDecreaseInLongTermDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Interest received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CashFlowsFromFinancingActivitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_CashFlowsFromFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_CashFlowsFromFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CashFlowsFromFinancingActivitiesAbstract" xlink:to="ppbt_CashFlowsFromFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US">Proceeds from issuance of ADSs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ProceedsFromIssuingWarrants" xlink:href="ppbt-20241231.xsd#ppbt_ProceedsFromIssuingWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ProceedsFromIssuingWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrants and prefunded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ProceedsFromIssuingWarrants" xlink:to="ppbt_ProceedsFromIssuingWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US">Proceeds from warrant inducement transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of translation adjustments on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US">Change in fair value of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US">Finance income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges_lbl" xml:lang="en-US">Loss (profit) from cash flow hedges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US">Owners of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xml:lang="en-US">Owners of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLossFromContinuingOperations_lbl" xml:lang="en-US">Loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperations" xlink:to="ifrs-full_ProfitLossFromContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl" xml:lang="en-US">Finance income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncome" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave" xlink:href="ppbt-20241231.xsd#ppbt_CashAssumedAsPartOfAcquisitionOfFamewave"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave_lbl" xml:lang="en-US">Acquisition of subsidiary, net of cash acquired (see Note 4C)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave" xlink:to="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Acquisition of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Acquisition of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US">ADS issuance expenses paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantsIssuanceExpensesPaid" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsIssuanceExpensesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ppbt_WarrantsIssuanceExpensesPaid_lbl" xml:lang="en-US">Warrants issuance expenses paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsIssuanceExpensesPaid" xlink:to="ppbt_WarrantsIssuanceExpensesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Repayment of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ReceiptsOnAccountOfWarrantsMember" xlink:href="ppbt-20241231.xsd#ppbt_ReceiptsOnAccountOfWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ReceiptsOnAccountOfWarrantsMember_lbl" xml:lang="en-US">Receipts on account of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ReceiptsOnAccountOfWarrantsMember" xlink:to="ppbt_ReceiptsOnAccountOfWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xml:lang="en-US">Capital reserve for share- based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfCashFlowHedgesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfCashFlowHedgesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfCashFlowHedgesMember_lbl" xml:lang="en-US">Capital reserve from hedging</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfCashFlowHedgesMember" xlink:to="ifrs-full_ReserveOfCashFlowHedgesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember" xlink:href="ppbt-20241231.xsd#ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember_lbl" xml:lang="en-US">Capital reserve from transactions with related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember" xlink:to="ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember" xlink:href="ppbt-20241231.xsd#ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember_lbl" xml:lang="en-US">Capital reserve from transactions with Non- controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember" xlink:to="ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US">General</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US">Basis of Preparation of the Consolidated Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl" xml:lang="en-US">Schedule of Data on Exchange Rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl0" xml:lang="en-US">Schedule of Sensitivity Test to Possible Changes in Exchange Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AverageForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AverageForeignExchangeRate_lbl" xml:lang="en-US">Representative exchange rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageForeignExchangeRate" xlink:to="ifrs-full_AverageForeignExchangeRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ChangesInExchangeRatesForTheYearEndedAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ChangesInExchangeRatesForTheYearEndedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ChangesInExchangeRatesForTheYearEndedAbstract_lbl" xml:lang="en-US">Changes in exchange rates for the year ended:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ChangesInExchangeRatesForTheYearEndedAbstract" xlink:to="ppbt_ChangesInExchangeRatesForTheYearEndedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PercentageOfExchangeRate" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfExchangeRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PercentageOfExchangeRate_lbl" xml:lang="en-US">Representative exchange rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfExchangeRate" xlink:to="ppbt_PercentageOfExchangeRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xml:lang="en-US">Material Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xml:lang="en-US">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_lbl" xml:lang="en-US">Schedule of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of Recognized Amounts of Assets Acquired and Liabilities Assumed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIntangibleAssets_lbl" xml:lang="en-US">Intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIntangibleAssets" xlink:to="ifrs-full_OtherIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xml:lang="en-US">Schedule of Carrying Amounts of Right-to-Use Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_lbl" xml:lang="en-US">Schedule of Maturity Analysis of the Company&apos;s Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory_lbl" xml:lang="en-US">Schedule of Amounts Recognized in Profit or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US">Interest expenses on lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US">Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfOtherCurrentAssettextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfOtherCurrentAssettextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DisclosureOfOtherCurrentAssettextBlock_lbl" xml:lang="en-US">Schedule of Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfOtherCurrentAssettextBlock" xlink:to="ppbt_DisclosureOfOtherCurrentAssettextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_GovernmentAuthorities" xlink:href="ppbt-20241231.xsd#ppbt_GovernmentAuthorities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_GovernmentAuthorities_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_GovernmentAuthorities" xlink:to="ppbt_GovernmentAuthorities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_lbl" xml:lang="en-US">Due to related parties - salary related</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent_lbl" xml:lang="en-US">Accrued expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentGovernmentGrants_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentGovernmentGrants" xlink:to="ifrs-full_CurrentGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_SalaryRelatedOtherPayablesCurrent" xlink:href="ppbt-20241231.xsd#ppbt_SalaryRelatedOtherPayablesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_SalaryRelatedOtherPayablesCurrent_lbl" xml:lang="en-US">Salary related</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SalaryRelatedOtherPayablesCurrent" xlink:to="ppbt_SalaryRelatedOtherPayablesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US">Schedule of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US">Number of shares, Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xml:lang="en-US">Number of shares, Issued and paid-in</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_NumberOfIssuanceShares" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfIssuanceShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_NumberOfIssuanceShares_lbl" xml:lang="en-US">Issuance of ADSs (See D below and 4C)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfIssuanceShares" xlink:to="ppbt_NumberOfIssuanceShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_NumberOfVestingOfRsus" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfVestingOfRsus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_NumberOfVestingOfRsus_lbl" xml:lang="en-US">Vesting of RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfVestingOfRsus" xlink:to="ppbt_NumberOfVestingOfRsus_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_NumberOfExerciseOfWarrants" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_NumberOfExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfExerciseOfWarrants" xlink:to="ppbt_NumberOfExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock_lbl" xml:lang="en-US">Schedule of the Information Relating to Non-Controlling Interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CurrentAsset" xlink:href="ppbt-20241231.xsd#ppbt_CurrentAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_CurrentAsset_lbl" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CurrentAsset" xlink:to="ppbt_CurrentAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CurrentLiabiliti" xlink:href="ppbt-20241231.xsd#ppbt_CurrentLiabiliti"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_CurrentLiabiliti_lbl" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CurrentLiabiliti" xlink:to="ppbt_CurrentLiabiliti_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NetAssetsLiabilities_lbl" xml:lang="en-US">Net assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_NetAssetsLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_NetAssetsAttributableToNoncontrollingInterest" xlink:href="ppbt-20241231.xsd#ppbt_NetAssetsAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_NetAssetsAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net assets attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NetAssetsAttributableToNoncontrollingInterest" xlink:to="ppbt_NetAssetsAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_NetAssetsAttributableToNoncontrollingInterests" xlink:href="ppbt-20241231.xsd#ppbt_NetAssetsAttributableToNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_NetAssetsAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Loss allocated to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NetAssetsAttributableToNoncontrollingInterests" xlink:to="ppbt_NetAssetsAttributableToNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">Share-based Payment Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US">Schedule of Number and Weighted Average Exercise Prices of Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Expired and forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of options, Granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Granted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number of options grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock_lbl" xml:lang="en-US">Schedule of Number of RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US">Granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US">Schedule of Assumptions were Used</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Share Price - USD (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Exercise price - USD (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xml:lang="en-US">Expected duration (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk free rate interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0" xml:lang="en-US">annual risk free interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US">Schedule of Expenses Recognized in the Consolidated Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xml:lang="en-US">Transactions and Balances with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US">Schedule of Recorded Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US">Short - term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl" xml:lang="en-US">Post-employment benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US">Share based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">Commitments and contingent liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock" xlink:to="ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xml:lang="en-US">Sales, General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Sales, General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:to="ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WagesAndSalaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US">Salaries, wages and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US">Share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfessionalFeesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US">Other professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl0" xml:lang="en-US">Placement agent fees and other offering related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DirectorsRemunerationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DirectorsRemunerationExpense_lbl" xml:lang="en-US">Board member remuneration and insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DirectorsRemunerationExpense" xlink:to="ifrs-full_DirectorsRemunerationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_lbl" xml:lang="en-US">Board member share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RentalExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RentalExpense_lbl" xml:lang="en-US">Maintenance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalExpense" xlink:to="ifrs-full_RentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TravelExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TravelExpense_lbl" xml:lang="en-US">Travel and car expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TravelExpense" xlink:to="ifrs-full_TravelExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_GeneralAndAdministrativeExpensesOther" xlink:href="ppbt-20241231.xsd#ppbt_GeneralAndAdministrativeExpensesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_GeneralAndAdministrativeExpensesOther_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_GeneralAndAdministrativeExpensesOther" xlink:to="ppbt_GeneralAndAdministrativeExpensesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US">Finance Expense (Income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl" xml:lang="en-US">Schedule of Finance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinanceExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FinanceExpensesAbstract_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinanceExpensesAbstract" xlink:to="ppbt_FinanceExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl" xml:lang="en-US">Fees and interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ForeignExchangeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ForeignExchangeLoss_lbl" xml:lang="en-US">Loss from exchange rate differences, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeLoss" xlink:to="ifrs-full_ForeignExchangeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IssuanceExpenses" xlink:href="ppbt-20241231.xsd#ppbt_IssuanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_IssuanceExpenses_lbl" xml:lang="en-US">Issuance expenses (see note 9D)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IssuanceExpenses" xlink:to="ppbt_IssuanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_OtherfinancialCost" xlink:href="ppbt-20241231.xsd#ppbt_OtherfinancialCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_OtherfinancialCost_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OtherfinancialCost" xlink:to="ppbt_OtherfinancialCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExplanatory_lbl" xml:lang="en-US">Schedule of Finance Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinanceIncomeAbstract" xlink:href="ppbt-20241231.xsd#ppbt_FinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FinanceIncomeAbstract_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinanceIncomeAbstract" xlink:to="ppbt_FinanceIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_OtherExpense" xlink:href="ppbt-20241231.xsd#ppbt_OtherExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_OtherExpense_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OtherExpense" xlink:to="ppbt_OtherExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">Taxes on Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">Employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Post-Employee Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US">Short-term benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss_lbl" xml:lang="en-US">Post-employment benefit liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xlink:to="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Defined Contribution Plan in Respect of its Employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl" xml:lang="en-US">Amount recognized as expense in respect of defined contribution plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IncomelossFromChangeInExchangeRateDown" xlink:href="ppbt-20241231.xsd#ppbt_IncomelossFromChangeInExchangeRateDown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_IncomelossFromChangeInExchangeRateDown_lbl" xml:lang="en-US">Income (loss) from change in exchange rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IncomelossFromChangeInExchangeRateDown" xlink:to="ppbt_IncomelossFromChangeInExchangeRateDown_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IncomelossValue" xlink:href="ppbt-20241231.xsd#ppbt_IncomelossValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_IncomelossValue_lbl" xml:lang="en-US">Income (loss) value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IncomelossValue" xlink:to="ppbt_IncomelossValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IncomelossFromChangeInExchangeRateUp" xlink:href="ppbt-20241231.xsd#ppbt_IncomelossFromChangeInExchangeRateUp"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_IncomelossFromChangeInExchangeRateUp_lbl" xml:lang="en-US">Income (loss) from change in exchange rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IncomelossFromChangeInExchangeRateUp" xlink:to="ppbt_IncomelossFromChangeInExchangeRateUp_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Schedule of Financial Instruments Measured at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialAssetAndLiabilitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_FinancialAssetAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FinancialAssetAndLiabilitiesAbstract_lbl" xml:lang="en-US">Financial asset and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialAssetAndLiabilitiesAbstract" xlink:to="ppbt_FinancialAssetAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_Securities" xlink:href="ppbt-20241231.xsd#ppbt_Securities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_Securities_lbl" xml:lang="en-US">Securities (see Note 18B (2))</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_Securities" xlink:to="ppbt_Securities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xml:lang="en-US">Financial liability of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativeFinancialLiabilities" xlink:to="ifrs-full_DerivativeFinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialAssetAndLiabilitiesAbstract0" xlink:href="ppbt-20241231.xsd#ppbt_FinancialAssetAndLiabilitiesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FinancialAssetAndLiabilitiesAbstract0_lbl" xml:lang="en-US">Financial asset and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialAssetAndLiabilitiesAbstract0" xlink:to="ppbt_FinancialAssetAndLiabilitiesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DerivativeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DerivativeFinancialAssets_lbl" xml:lang="en-US">Convertible debt instrument and warrant (see Note 18B (2))</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativeFinancialAssets" xlink:to="ifrs-full_DerivativeFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock_lbl" xml:lang="en-US">Schedule of Details Regarding Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock" xlink:to="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueMeasurementExercise" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FairValueMeasurementExercise_lbl" xml:lang="en-US">Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementExercise" xlink:to="ppbt_FairValueMeasurementExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueMeasurementIssuance" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FairValueMeasurementIssuance_lbl" xml:lang="en-US">Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementIssuance" xlink:to="ppbt_FairValueMeasurementIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueMeasurementIssuanceProceed" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementIssuanceProceed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FairValueMeasurementIssuanceProceed_lbl" xml:lang="en-US">Proceed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementIssuanceProceed" xlink:to="ppbt_FairValueMeasurementIssuanceProceed_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueMeasurementRevaluation" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementRevaluation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FairValueMeasurementRevaluation_lbl" xml:lang="en-US">Revaluation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementRevaluation" xlink:to="ppbt_FairValueMeasurementRevaluation_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DescriptionOfOptionLifeShareOptionGranted" xlink:href="ppbt-20241231.xsd#ppbt_DescriptionOfOptionLifeShareOptionGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DescriptionOfOptionLifeShareOptionGranted_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DescriptionOfOptionLifeShareOptionGranted" xlink:to="ppbt_DescriptionOfOptionLifeShareOptionGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield" xlink:href="ppbt-20241231.xsd#ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield_lbl" xml:lang="en-US">dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield" xlink:to="ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ForTheYearEndedDecember312023Abstract" xlink:href="ppbt-20241231.xsd#ppbt_ForTheYearEndedDecember312023Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ForTheYearEndedDecember312023Abstract_lbl" xml:lang="en-US">For the year ended December 31, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ForTheYearEndedDecember312023Abstract" xlink:to="ppbt_ForTheYearEndedDecember312023Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_Discountforlackofmarketability" xlink:href="ppbt-20241231.xsd#ppbt_Discountforlackofmarketability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_Discountforlackofmarketability_lbl" xml:lang="en-US">DLOM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_Discountforlackofmarketability" xlink:to="ppbt_Discountforlackofmarketability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US">Depreciation on right-to-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of options, Expired and forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Vested during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ReimbursementOfLegalFeesExpense" xlink:href="ppbt-20241231.xsd#ppbt_ReimbursementOfLegalFeesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ppbt_ReimbursementOfLegalFeesExpense_lbl" xml:lang="en-US">Reimbursement of legal fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ReimbursementOfLegalFeesExpense" xlink:to="ppbt_ReimbursementOfLegalFeesExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestIncomeOnDeposits_lbl" xml:lang="en-US">Interest income from deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnDeposits" xlink:to="ifrs-full_InterestIncomeOnDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeGain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ForeignExchangeGain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ForeignExchangeGain_lbl" xml:lang="en-US">Income from exchange rate differences, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeGain" xlink:to="ifrs-full_ForeignExchangeGain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GainsOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US">Changes in fair value of finance instruments (see Note 18B2)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_GainsOnChangeInFairValueOfDerivatives_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_OtherFinanceIncome_lbl" xml:lang="en-US">Total finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrs-full_OtherFinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IPRDRelatedToTryNovosee5ABelowMember" xlink:href="ppbt-20241231.xsd#ppbt_IPRDRelatedToTryNovosee5ABelowMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_IPRDRelatedToTryNovosee5ABelowMember_lbl" xml:lang="en-US">IPR&amp;D related to TyrNovo (see 4A below) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IPRDRelatedToTryNovosee5ABelowMember" xlink:to="ppbt_IPRDRelatedToTryNovosee5ABelowMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IPRDRelatedToFamewaveSee5BBelowMember" xlink:href="ppbt-20241231.xsd#ppbt_IPRDRelatedToFamewaveSee5BBelowMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_IPRDRelatedToFamewaveSee5BBelowMember_lbl" xml:lang="en-US">IPR&amp;D related to Famewave (see 4B below) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IPRDRelatedToFamewaveSee5BBelowMember" xlink:to="ppbt_IPRDRelatedToFamewaveSee5BBelowMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IPRDRelatedToImmunorizonSee5CBelowMember" xlink:href="ppbt-20241231.xsd#ppbt_IPRDRelatedToImmunorizonSee5CBelowMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_IPRDRelatedToImmunorizonSee5CBelowMember_lbl" xml:lang="en-US">IPR&amp;D related to Immunorizon (see 4C below) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IPRDRelatedToImmunorizonSee5CBelowMember" xlink:to="ppbt_IPRDRelatedToImmunorizonSee5CBelowMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IPRDRelatedToPurpleGmbHMember" xlink:href="ppbt-20241231.xsd#ppbt_IPRDRelatedToPurpleGmbHMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_IPRDRelatedToPurpleGmbHMember_lbl" xml:lang="en-US">IPR&amp;D related to Purple GmbH [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IPRDRelatedToPurpleGmbHMember" xlink:to="ppbt_IPRDRelatedToPurpleGmbHMember_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_USD_lbl" xml:lang="en-US">Balance in USD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OtherCurrencyMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OtherCurrencyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OtherCurrencyMember_lbl" xml:lang="en-US">Balance in other currencies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OtherCurrencyMember" xlink:to="srt_OtherCurrencyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseReceivablesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseReceivablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseReceivablesMember_lbl" xml:lang="en-US">Office lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseReceivablesMember" xlink:to="ifrs-full_LeaseReceivablesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US">Less than one year	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xml:lang="en-US">One to two years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_OrdinaryShareMember" xlink:href="ppbt-20241231.xsd#ppbt_OrdinaryShareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_OrdinaryShareMember_lbl" xml:lang="en-US">Ordinary Share [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OrdinaryShareMember" xlink:to="ppbt_OrdinaryShareMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PreferredShareClassMember" xlink:href="ppbt-20241231.xsd#ppbt_PreferredShareClassMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PreferredShareClassMember_lbl" xml:lang="en-US">Class A Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PreferredShareClassMember" xlink:to="ppbt_PreferredShareClassMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PreferredShareClassBMember" xlink:href="ppbt-20241231.xsd#ppbt_PreferredShareClassBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PreferredShareClassBMember_lbl" xml:lang="en-US">Class B Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PreferredShareClassBMember" xlink:to="ppbt_PreferredShareClassBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PreferredClassCMember" xlink:href="ppbt-20241231.xsd#ppbt_PreferredClassCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PreferredClassCMember_lbl" xml:lang="en-US">Class C Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PreferredClassCMember" xlink:to="ppbt_PreferredClassCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PreferredClassDMember" xlink:href="ppbt-20241231.xsd#ppbt_PreferredClassDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PreferredClassDMember_lbl" xml:lang="en-US">Class D Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PreferredClassDMember" xlink:to="ppbt_PreferredClassDMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ClassEPreferredSharesMember" xlink:href="ppbt-20241231.xsd#ppbt_ClassEPreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ClassEPreferredSharesMember_lbl" xml:lang="en-US">Class E Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ClassEPreferredSharesMember" xlink:to="ppbt_ClassEPreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl0" xml:lang="en-US">Down 2% [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl1" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl0" xml:lang="en-US">Up 5% [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl1" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ppbt_ResearchAndDevelopmentExpensesMember" xlink:href="ppbt-20241231.xsd#ppbt_ResearchAndDevelopmentExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ResearchAndDevelopmentExpensesMember_lbl" xml:lang="en-US">Research and development expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ResearchAndDevelopmentExpensesMember" xlink:to="ppbt_ResearchAndDevelopmentExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">Selling, general and administrative expense [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Executive Officers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_SalariesWagesAndRelatedExpensesMember" xlink:href="ppbt-20241231.xsd#ppbt_SalariesWagesAndRelatedExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_SalariesWagesAndRelatedExpensesMember_lbl" xml:lang="en-US">Salaries, wages and related expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SalariesWagesAndRelatedExpensesMember" xlink:to="ppbt_SalariesWagesAndRelatedExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShareBasedPaymentsMember" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ShareBasedPaymentsMember_lbl" xml:lang="en-US">Share-based payments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ShareBasedPaymentsMember" xlink:to="ppbt_ShareBasedPaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ServiceProvidersMember" xlink:href="ppbt-20241231.xsd#ppbt_ServiceProvidersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ServiceProvidersMember_lbl" xml:lang="en-US">Service providers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ServiceProvidersMember" xlink:to="ppbt_ServiceProvidersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrencyRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrencyRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US">Currency risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CashAndCashEquivalentsAndDepositsMember" xlink:href="ppbt-20241231.xsd#ppbt_CashAndCashEquivalentsAndDepositsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_CashAndCashEquivalentsAndDepositsMember_lbl" xml:lang="en-US">Cash And Cash Equivalents And Deposits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CashAndCashEquivalentsAndDepositsMember" xlink:to="ppbt_CashAndCashEquivalentsAndDepositsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ppbt_CashAndCashEquivalentsAndDepositsMember_lbl0" xml:lang="en-US">Cash and cash equivalents and deposits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CashAndCashEquivalentsAndDepositsMember" xlink:to="ppbt_CashAndCashEquivalentsAndDepositsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_EUROMember" xlink:href="ppbt-20241231.xsd#ppbt_EUROMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_EUROMember_lbl" xml:lang="en-US">EURO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EUROMember" xlink:to="ppbt_EUROMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_OtherCurrentAssetMember" xlink:href="ppbt-20241231.xsd#ppbt_OtherCurrentAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_OtherCurrentAssetMember_lbl" xml:lang="en-US">Other Current Asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OtherCurrentAssetMember" xlink:to="ppbt_OtherCurrentAssetMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ppbt_OtherCurrentAssetMember_lbl0" xml:lang="en-US">Other current assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OtherCurrentAssetMember" xlink:to="ppbt_OtherCurrentAssetMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_AccountPayablesMember" xlink:href="ppbt-20241231.xsd#ppbt_AccountPayablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_AccountPayablesMember_lbl" xml:lang="en-US">Account Payables [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AccountPayablesMember" xlink:to="ppbt_AccountPayablesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ppbt_AccountPayablesMember_lbl0" xml:lang="en-US">Accounts payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AccountPayablesMember" xlink:to="ppbt_AccountPayablesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_OtherPayablesMember" xlink:href="ppbt-20241231.xsd#ppbt_OtherPayablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_OtherPayablesMember_lbl" xml:lang="en-US">Other Payables [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OtherPayablesMember" xlink:to="ppbt_OtherPayablesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ppbt_OtherPayablesMember_lbl0" xml:lang="en-US">Other payables [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OtherPayablesMember" xlink:to="ppbt_OtherPayablesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_PostemploymentBenefitLiabilitiesMember" xlink:href="ppbt-20241231.xsd#ppbt_PostemploymentBenefitLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PostemploymentBenefitLiabilitiesMember_lbl" xml:lang="en-US">Post-employment benefit liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PostemploymentBenefitLiabilitiesMember" xlink:to="ppbt_PostemploymentBenefitLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_NISMember" xlink:href="ppbt-20241231.xsd#ppbt_NISMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_NISMember_lbl" xml:lang="en-US">NIS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NISMember" xlink:to="ppbt_NISMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DownRangeOneMember" xlink:href="ppbt-20241231.xsd#ppbt_DownRangeOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DownRangeOneMember_lbl" xml:lang="en-US">Down 5% [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DownRangeOneMember" xlink:to="ppbt_DownRangeOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_UpRangeOneMember" xlink:href="ppbt-20241231.xsd#ppbt_UpRangeOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_UpRangeOneMember_lbl" xml:lang="en-US">Up 2% [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_UpRangeOneMember" xlink:to="ppbt_UpRangeOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ConvertibleNoteMember" xlink:href="ppbt-20241231.xsd#ppbt_ConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ConvertibleNoteMember_lbl" xml:lang="en-US">Convertible note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConvertibleNoteMember" xlink:to="ppbt_ConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantsoneMember" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsoneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_WarrantsoneMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsoneMember" xlink:to="ppbt_WarrantsoneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ConvertibleDebtInstrumentMember" xlink:href="ppbt-20241231.xsd#ppbt_ConvertibleDebtInstrumentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ConvertibleDebtInstrumentMember_lbl" xml:lang="en-US">Convertible debt instrument [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConvertibleDebtInstrumentMember" xlink:to="ppbt_ConvertibleDebtInstrumentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US">Classes of share capital [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl" xml:lang="en-US">Liabilities arising from financing activities [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl" xml:lang="en-US">Types of antidilutive instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis_lbl" xml:lang="en-US">Classes of ordinary shares [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US">Non-adjusting events after reporting period [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_RangesAxis" xlink:href="ppbt-20241231.xsd#ppbt_RangesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_RangesAxis_lbl" xml:lang="en-US">Ranges [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_RangesAxis" xlink:to="ppbt_RangesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_AmericanDepositorySharesOrdinaryShares" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepositorySharesOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_AmericanDepositorySharesOrdinaryShares_lbl" xml:lang="en-US">American depository ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AmericanDepositorySharesOrdinaryShares" xlink:to="ppbt_AmericanDepositorySharesOrdinaryShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ppbt_AmericanDepositorySharesOrdinaryShares_lbl0" xml:lang="en-US">Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AmericanDepositorySharesOrdinaryShares" xlink:to="ppbt_AmericanDepositorySharesOrdinaryShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_CommonStockNoParValues" xlink:href="ppbt-20241231.xsd#ppbt_CommonStockNoParValues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_CommonStockNoParValues_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CommonStockNoParValues" xlink:to="ppbt_CommonStockNoParValues_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares_lbl" xml:lang="en-US">Warrants shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_AmericanDepositorySharesPurchase" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepositorySharesPurchase"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_AmericanDepositorySharesPurchase_lbl" xml:lang="en-US">American depository shares purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AmericanDepositorySharesPurchase" xlink:to="ppbt_AmericanDepositorySharesPurchase_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PercentageOfContractToAcquire" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfContractToAcquire"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PercentageOfContractToAcquire_lbl" xml:lang="en-US">Contract to acquire, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfContractToAcquire" xlink:to="ppbt_PercentageOfContractToAcquire_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_RetainedEarning" xlink:href="ppbt-20241231.xsd#ppbt_RetainedEarning"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_RetainedEarning_lbl" xml:lang="en-US">Retained earnings (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_RetainedEarning" xlink:to="ppbt_RetainedEarning_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PrivateAndPublicFinancingTotal" xlink:href="ppbt-20241231.xsd#ppbt_PrivateAndPublicFinancingTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PrivateAndPublicFinancingTotal_lbl" xml:lang="en-US">Net of issuance expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PrivateAndPublicFinancingTotal" xlink:to="ppbt_PrivateAndPublicFinancingTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FunctionalCurrency" xlink:href="ppbt-20241231.xsd#ppbt_FunctionalCurrency"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FunctionalCurrency_lbl" xml:lang="en-US">Functional currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FunctionalCurrency" xlink:to="ppbt_FunctionalCurrency_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_StockOptionExercisedPeriod" xlink:href="ppbt-20241231.xsd#ppbt_StockOptionExercisedPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_StockOptionExercisedPeriod_lbl" xml:lang="en-US">Stock option exercised period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_StockOptionExercisedPeriod" xlink:to="ppbt_StockOptionExercisedPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ppbt_StockOptionExercisedPeriod_lbl0" xml:lang="en-US">Options exercised period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_StockOptionExercisedPeriod" xlink:to="ppbt_StockOptionExercisedPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_NumberOfShare" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_NumberOfShare_lbl" xml:lang="en-US">Number of Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfShare" xlink:to="ppbt_NumberOfShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_NumberOfPerShare" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_NumberOfPerShare_lbl" xml:lang="en-US">Number of per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfPerShare" xlink:to="ppbt_NumberOfPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DepreciationRightofuseAssetsUsefulLife" xlink:href="ppbt-20241231.xsd#ppbt_DepreciationRightofuseAssetsUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DepreciationRightofuseAssetsUsefulLife_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DepreciationRightofuseAssetsUsefulLife" xlink:to="ppbt_DepreciationRightofuseAssetsUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_EquityMethodInvestmentsOwnershipPercentage" xlink:href="ppbt-20241231.xsd#ppbt_EquityMethodInvestmentsOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_EquityMethodInvestmentsOwnershipPercentage_lbl" xml:lang="en-US">Direct ownership of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EquityMethodInvestmentsOwnershipPercentage" xlink:to="ppbt_EquityMethodInvestmentsOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xml:lang="en-US">Percentage of voting equity interests acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_AggregateUpfrontPayment" xlink:href="ppbt-20241231.xsd#ppbt_AggregateUpfrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_AggregateUpfrontPayment_lbl" xml:lang="en-US">Aggregate upfront payment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AggregateUpfrontPayment" xlink:to="ppbt_AggregateUpfrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_LongTermMilestonesAggregateAmount" xlink:href="ppbt-20241231.xsd#ppbt_LongTermMilestonesAggregateAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_LongTermMilestonesAggregateAmount_lbl" xml:lang="en-US">Long term milestones aggregate amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_LongTermMilestonesAggregateAmount" xlink:to="ppbt_LongTermMilestonesAggregateAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_TotalAcquisitionAmount" xlink:href="ppbt-20241231.xsd#ppbt_TotalAcquisitionAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_TotalAcquisitionAmount_lbl" xml:lang="en-US">Total acquisition (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TotalAcquisitionAmount" xlink:to="ppbt_TotalAcquisitionAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueOfIssuedEquity" xlink:href="ppbt-20241231.xsd#ppbt_FairValueOfIssuedEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FairValueOfIssuedEquity_lbl" xml:lang="en-US">Fair value of issued equity (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueOfIssuedEquity" xlink:to="ppbt_FairValueOfIssuedEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FairValueOfIssuedIntangibleAssets" xlink:href="ppbt-20241231.xsd#ppbt_FairValueOfIssuedIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FairValueOfIssuedIntangibleAssets_lbl" xml:lang="en-US">Fair value of issued intangible assets (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueOfIssuedIntangibleAssets" xlink:to="ppbt_FairValueOfIssuedIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_AggregateShareholdersOfImmunorizon" xlink:href="ppbt-20241231.xsd#ppbt_AggregateShareholdersOfImmunorizon"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_AggregateShareholdersOfImmunorizon_lbl" xml:lang="en-US">Aggregate shareholders of immunorizon (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AggregateShareholdersOfImmunorizon" xlink:to="ppbt_AggregateShareholdersOfImmunorizon_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_SharesPrice" xlink:href="ppbt-20241231.xsd#ppbt_SharesPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_SharesPrice_lbl" xml:lang="en-US">Share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SharesPrice" xlink:to="ppbt_SharesPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DescriptionOfExpectedVolatilityPercentage" xlink:href="ppbt-20241231.xsd#ppbt_DescriptionOfExpectedVolatilityPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DescriptionOfExpectedVolatilityPercentage_lbl" xml:lang="en-US">Description of expected volatility percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DescriptionOfExpectedVolatilityPercentage" xlink:to="ppbt_DescriptionOfExpectedVolatilityPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DescriptionOfExpectedAnnualRiskFreeRate" xlink:href="ppbt-20241231.xsd#ppbt_DescriptionOfExpectedAnnualRiskFreeRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DescriptionOfExpectedAnnualRiskFreeRate_lbl" xml:lang="en-US">Description of expected annual risk free rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DescriptionOfExpectedAnnualRiskFreeRate" xlink:to="ppbt_DescriptionOfExpectedAnnualRiskFreeRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PercentageOfDiscountsForLacksOfMarketability" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfDiscountsForLacksOfMarketability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PercentageOfDiscountsForLacksOfMarketability_lbl" xml:lang="en-US">Percentage of discount for lack of marketability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfDiscountsForLacksOfMarketability" xlink:to="ppbt_PercentageOfDiscountsForLacksOfMarketability_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsRecoverableAmountPercentage" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsRecoverableAmountPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_IntangibleAssetsRecoverableAmountPercentage_lbl" xml:lang="en-US">Intangible assets recoverable amount percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IntangibleAssetsRecoverableAmountPercentage" xlink:to="ppbt_IntangibleAssetsRecoverableAmountPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_AgreementLeaseTerm" xlink:href="ppbt-20241231.xsd#ppbt_AgreementLeaseTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_AgreementLeaseTerm_lbl" xml:lang="en-US">Agreement lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AgreementLeaseTerm" xlink:to="ppbt_AgreementLeaseTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US">Lease liability and right-of-use asset (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_AgreementLeaseAdditionalTerm" xlink:href="ppbt-20241231.xsd#ppbt_AgreementLeaseAdditionalTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_AgreementLeaseAdditionalTerm_lbl" xml:lang="en-US">Agreement lease additional term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AgreementLeaseAdditionalTerm" xlink:to="ppbt_AgreementLeaseAdditionalTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CurrentTerms" xlink:href="ppbt-20241231.xsd#ppbt_CurrentTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_CurrentTerms_lbl" xml:lang="en-US">Percentage of current terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CurrentTerms" xlink:to="ppbt_CurrentTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Authorized share capital (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_NonVotingSeniorPreferredShares" xlink:href="ppbt-20241231.xsd#ppbt_NonVotingSeniorPreferredShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_NonVotingSeniorPreferredShares_lbl" xml:lang="en-US">Non-voting senior preferred shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NonVotingSeniorPreferredShares" xlink:to="ppbt_NonVotingSeniorPreferredShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_StockholdersEquityReversesStockSplit" xlink:href="ppbt-20241231.xsd#ppbt_StockholdersEquityReversesStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_StockholdersEquityReversesStockSplit_lbl" xml:lang="en-US">Stockholders equity reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_StockholdersEquityReversesStockSplit" xlink:to="ppbt_StockholdersEquityReversesStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ReverseRatio" xlink:href="ppbt-20241231.xsd#ppbt_ReverseRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ReverseRatio_lbl" xml:lang="en-US">Reverse ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ReverseRatio" xlink:to="ppbt_ReverseRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FundsRaisedAmount" xlink:href="ppbt-20241231.xsd#ppbt_FundsRaisedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FundsRaisedAmount_lbl" xml:lang="en-US">Company funds raised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FundsRaisedAmount" xlink:to="ppbt_FundsRaisedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_NumberOfNonTradableWarrants" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfNonTradableWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_NumberOfNonTradableWarrants_lbl" xml:lang="en-US">Aggregate shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfNonTradableWarrants" xlink:to="ppbt_NumberOfNonTradableWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">Public offering issued price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl0" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US">Net of issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FundsRaisedshares" xlink:href="ppbt-20241231.xsd#ppbt_FundsRaisedshares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FundsRaisedshares_lbl" xml:lang="en-US">Funds raised amount (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FundsRaisedshares" xlink:to="ppbt_FundsRaisedshares_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantsTerm" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_WarrantsTerm_lbl" xml:lang="en-US">Warrants term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsTerm" xlink:to="ppbt_WarrantsTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantReserve_lbl" xml:lang="en-US">Warrant inducement transaction gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantReserve" xlink:to="ifrs-full_WarrantReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DepositaryShares" xlink:href="ppbt-20241231.xsd#ppbt_DepositaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DepositaryShares_lbl" xml:lang="en-US">Depositary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DepositaryShares" xlink:to="ppbt_DepositaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PurchaseOfCommonStockAndWarrants" xlink:href="ppbt-20241231.xsd#ppbt_PurchaseOfCommonStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PurchaseOfCommonStockAndWarrants_lbl" xml:lang="en-US">Warrants to purchase shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PurchaseOfCommonStockAndWarrants" xlink:to="ppbt_PurchaseOfCommonStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantLiability_lbl" xml:lang="en-US">Warrant liability fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantsIssued" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_WarrantsIssued_lbl" xml:lang="en-US">Warrant purchased (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsIssued" xlink:to="ppbt_WarrantsIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ppbt_WarrantsIssued_lbl0" xml:lang="en-US">Warrants issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsIssued" xlink:to="ppbt_WarrantsIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_IssuesOfEquity" xlink:href="ppbt-20241231.xsd#ppbt_IssuesOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_IssuesOfEquity_lbl" xml:lang="en-US">Issue of equity (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IssuesOfEquity" xlink:to="ppbt_IssuesOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ExerciseOfWarrantsEquity" xlink:href="ppbt-20241231.xsd#ppbt_ExerciseOfWarrantsEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ExerciseOfWarrantsEquity_lbl" xml:lang="en-US">Warrants fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ExerciseOfWarrantsEquity" xlink:to="ppbt_ExerciseOfWarrantsEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantTermDescription" xlink:href="ppbt-20241231.xsd#ppbt_WarrantTermDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_WarrantTermDescription_lbl" xml:lang="en-US">Warrant term, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantTermDescription" xlink:to="ppbt_WarrantTermDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceContractsIssuedThatAreAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InsuranceContractsIssuedThatAreAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InsuranceContractsIssuedThatAreAssets_lbl" xml:lang="en-US">Prospectus amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceContractsIssuedThatAreAssets" xlink:to="ifrs-full_InsuranceContractsIssuedThatAreAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_SalesAgreementShares" xlink:href="ppbt-20241231.xsd#ppbt_SalesAgreementShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_SalesAgreementShares_lbl" xml:lang="en-US">Sales agreement (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SalesAgreementShares" xlink:to="ppbt_SalesAgreementShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePrice2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US">Average price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePrice2019" xlink:to="ifrs-full_WeightedAverageSharePrice2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_noncontrollingInterests" xlink:href="ppbt-20241231.xsd#ppbt_noncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_noncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_noncontrollingInterests" xlink:to="ppbt_noncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Exercise price of option (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_OptionExerciseOrdinaryShare" xlink:href="ppbt-20241231.xsd#ppbt_OptionExerciseOrdinaryShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_OptionExerciseOrdinaryShare_lbl" xml:lang="en-US">Option exercise ordinary share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OptionExerciseOrdinaryShare" xlink:to="ppbt_OptionExerciseOrdinaryShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_VestingPeriod" xlink:href="ppbt-20241231.xsd#ppbt_VestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_VestingPeriod_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_VestingPeriod" xlink:to="ppbt_VestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ExercisePeriod" xlink:href="ppbt-20241231.xsd#ppbt_ExercisePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ExercisePeriod_lbl" xml:lang="en-US">Exercisable period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ExercisePeriod" xlink:to="ppbt_ExercisePeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl" xml:lang="en-US">Fair value options value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl0" xml:lang="en-US">Estimated fair value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ConsultantPerShares" xlink:href="ppbt-20241231.xsd#ppbt_ConsultantPerShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ConsultantPerShares_lbl" xml:lang="en-US">Consultant per shares (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConsultantPerShares" xlink:to="ppbt_ConsultantPerShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_AmericanDepostioryShares" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepostioryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_AmericanDepostioryShares_lbl" xml:lang="en-US">American shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AmericanDepostioryShares" xlink:to="ppbt_AmericanDepostioryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Weighted average contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ConvertibleShares" xlink:href="ppbt-20241231.xsd#ppbt_ConvertibleShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ConvertibleShares_lbl" xml:lang="en-US">Convertible shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConvertibleShares" xlink:to="ppbt_ConvertibleShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PercentageOfCapacityOfAnAdvisor" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfCapacityOfAnAdvisor"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PercentageOfCapacityOfAnAdvisor_lbl" xml:lang="en-US">Percentage of capacity of an advisor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfCapacityOfAnAdvisor" xlink:to="ppbt_PercentageOfCapacityOfAnAdvisor_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PercentageOfEntitysRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl" xml:lang="en-US">Annual interest rate of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfEntitysRevenue" xlink:to="ifrs-full_PercentageOfEntitysRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromRoyalties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromRoyalties_lbl" xml:lang="en-US">Royalty payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromRoyalties" xlink:to="ifrs-full_RevenueFromRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PercentageOfSublicenseConsideration" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfSublicenseConsideration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PercentageOfSublicenseConsideration_lbl" xml:lang="en-US">Percentage of sublicense consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfSublicenseConsideration" xlink:to="ppbt_PercentageOfSublicenseConsideration_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PercentageOfReceiveExitFee" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfReceiveExitFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PercentageOfReceiveExitFee_lbl" xml:lang="en-US">Percentage of exit fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfReceiveExitFee" xlink:to="ppbt_PercentageOfReceiveExitFee_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LicenceFeeIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicenceFeeIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LicenceFeeIncome_lbl" xml:lang="en-US">Annual license fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LicenceFeeIncome" xlink:to="ifrs-full_LicenceFeeIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsOnLitigationSettlements" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsOnLitigationSettlements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsOnLitigationSettlements_lbl" xml:lang="en-US">Gains on litigation settlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsOnLitigationSettlements" xlink:to="ifrs-full_GainsOnLitigationSettlements_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantsExpireTerm" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsExpireTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_WarrantsExpireTerm_lbl" xml:lang="en-US">Warrants expire term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsExpireTerm" xlink:to="ppbt_WarrantsExpireTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US">Tax rate applicable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_StatutoryTaxRate" xlink:href="ppbt-20241231.xsd#ppbt_StatutoryTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_StatutoryTaxRate_lbl" xml:lang="en-US">Statutory tax rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_StatutoryTaxRate" xlink:to="ppbt_StatutoryTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl" xml:lang="en-US">Tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_EffectiveTaxRate" xlink:href="ppbt-20241231.xsd#ppbt_EffectiveTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_EffectiveTaxRate_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EffectiveTaxRate" xlink:to="ppbt_EffectiveTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_UnrecognizedResearchAndDevelopmentExpenses" xlink:href="ppbt-20241231.xsd#ppbt_UnrecognizedResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_UnrecognizedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Unrecognized research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_UnrecognizedResearchAndDevelopmentExpenses" xlink:to="ppbt_UnrecognizedResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_EmployeeBenefitBonus" xlink:href="ppbt-20241231.xsd#ppbt_EmployeeBenefitBonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_EmployeeBenefitBonus_lbl" xml:lang="en-US">Bonuses expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EmployeeBenefitBonus" xlink:to="ppbt_EmployeeBenefitBonus_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_EmployeeBenefitsLiabilityDueGrants" xlink:href="ppbt-20241231.xsd#ppbt_EmployeeBenefitsLiabilityDueGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_EmployeeBenefitsLiabilityDueGrants_lbl" xml:lang="en-US">Employee benefits liability due grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EmployeeBenefitsLiabilityDueGrants" xlink:to="ppbt_EmployeeBenefitsLiabilityDueGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US">Bear fixed interest, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit" xlink:href="ppbt-20241231.xsd#ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit_lbl" xml:lang="en-US">Short term deposits guaranteed for leases and credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit" xlink:to="ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShortTermDepositsGuaranteedForHedgingTransactions" xlink:href="ppbt-20241231.xsd#ppbt_ShortTermDepositsGuaranteedForHedgingTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ShortTermDepositsGuaranteedForHedgingTransactions_lbl" xml:lang="en-US">Short term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ShortTermDepositsGuaranteedForHedgingTransactions" xlink:to="ppbt_ShortTermDepositsGuaranteedForHedgingTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfConvertibleInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfConvertibleInstruments_lbl" xml:lang="en-US">Convertible note amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ifrs-full_IssueOfConvertibleInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ConvertibleWarrants" xlink:href="ppbt-20241231.xsd#ppbt_ConvertibleWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ConvertibleWarrants_lbl" xml:lang="en-US">Convertible warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConvertibleWarrants" xlink:to="ppbt_ConvertibleWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_TerminationExercisePrice" xlink:href="ppbt-20241231.xsd#ppbt_TerminationExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_TerminationExercisePrice_lbl" xml:lang="en-US">Termination exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TerminationExercisePrice" xlink:to="ppbt_TerminationExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ConvertiblesWarrants" xlink:href="ppbt-20241231.xsd#ppbt_ConvertiblesWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ConvertiblesWarrants_lbl" xml:lang="en-US">Convertible warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConvertiblesWarrants" xlink:to="ppbt_ConvertiblesWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialAssetAtAFairValue" xlink:href="ppbt-20241231.xsd#ppbt_FinancialAssetAtAFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FinancialAssetAtAFairValue_lbl" xml:lang="en-US">Financial asset at a fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialAssetAtAFairValue" xlink:to="ppbt_FinancialAssetAtAFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_WarrantExercisePricePerShare" xlink:href="ppbt-20241231.xsd#ppbt_WarrantExercisePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_WarrantExercisePricePerShare_lbl" xml:lang="en-US">Warrants exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantExercisePricePerShare" xlink:to="ppbt_WarrantExercisePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DepositarysShares" xlink:href="ppbt-20241231.xsd#ppbt_DepositarysShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DepositarysShares_lbl" xml:lang="en-US">Depositary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DepositarysShares" xlink:to="ppbt_DepositarysShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_AggregateWarrantsShares" xlink:href="ppbt-20241231.xsd#ppbt_AggregateWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_AggregateWarrantsShares_lbl" xml:lang="en-US">Aggregate warrants shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AggregateWarrantsShares" xlink:to="ppbt_AggregateWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentAmount" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FinancialInstrumentAmount_lbl" xml:lang="en-US">Financial instrument amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialInstrumentAmount" xlink:to="ppbt_FinancialInstrumentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_NetOfDeferredDifferenceAmount" xlink:href="ppbt-20241231.xsd#ppbt_NetOfDeferredDifferenceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_NetOfDeferredDifferenceAmount_lbl" xml:lang="en-US">Net of deferred difference amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NetOfDeferredDifferenceAmount" xlink:to="ppbt_NetOfDeferredDifferenceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Basis of consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:to="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US">Foreign currency transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl" xml:lang="en-US">Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US">Loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">Employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US">Share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US">Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory_lbl" xml:lang="en-US">Financing income and expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl" xml:lang="en-US">Accounting standards issued but not yet effective</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareOptionsMember_lbl" xml:lang="en-US">Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOptionsMember" xlink:to="ifrs-full_ShareOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_AdsMember" xlink:href="ppbt-20241231.xsd#ppbt_AdsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_AdsMember_lbl" xml:lang="en-US">ADS [Member]</label>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZ7uO1Q1bYM5N9HuAVhCBKc3Dilxy5HOYIdYl1h0YHGyqqhp5yL2C/pvkGqpTQ7NfV8dDJWElNwr7uGWGMl/FOCtmi0tB2eTtzKmmQ0hcQ60BPTfIvmWs+j5xoLJ2ifHK3Qzc5tu1CRRSrKp5kfOFheAU8ndp9+zFyGXNaa6jOMefzDkABcY69jtuMijqkJ3ohuLKcwkZmZewn4yToUYFOOphhxC2BFvS+NOINC7erWqRoNST5xNM0O] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AdsMember" xlink:to="ppbt_AdsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ppbt_AdsMember_lbl0" xml:lang="en-US">Ads [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AdsMember" xlink:to="ppbt_AdsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_RehovotMember" xlink:href="ppbt-20241231.xsd#ppbt_RehovotMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_RehovotMember_lbl" xml:lang="en-US">Rehovot [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_RehovotMember" xlink:to="ppbt_RehovotMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_LeaseAgreementOneMember" xlink:href="ppbt-20241231.xsd#ppbt_LeaseAgreementOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_LeaseAgreementOneMember_lbl" xml:lang="en-US">Lease Agreement One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_LeaseAgreementOneMember" xlink:to="ppbt_LeaseAgreementOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_LeaseAgreementsTwoMember" xlink:href="ppbt-20241231.xsd#ppbt_LeaseAgreementsTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_LeaseAgreementsTwoMember_lbl" xml:lang="en-US">Lease Agreements Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_LeaseAgreementsTwoMember" xlink:to="ppbt_LeaseAgreementsTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl0" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreferenceSharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreferenceSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PreferenceSharesMember_lbl" xml:lang="en-US">Preferred Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreferenceSharesMember" xlink:to="ifrs-full_PreferenceSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PrivatePlacementsMember" xlink:href="ppbt-20241231.xsd#ppbt_PrivatePlacementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PrivatePlacementsMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PrivatePlacementsMember" xlink:to="ppbt_PrivatePlacementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_PublicOfferingMember" xlink:href="ppbt-20241231.xsd#ppbt_PublicOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_PublicOfferingMember_lbl" xml:lang="en-US">Public offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PublicOfferingMember" xlink:to="ppbt_PublicOfferingMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ppbt_PublicOfferingMember_lbl0" xml:lang="en-US">PublicOfferingMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PublicOfferingMember" xlink:to="ppbt_PublicOfferingMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ATMProgramMember" xlink:href="ppbt-20241231.xsd#ppbt_ATMProgramMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ATMProgramMember_lbl" xml:lang="en-US">ATM Program [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ATMProgramMember" xlink:to="ppbt_ATMProgramMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_SubsequentEventsMember" xlink:href="ppbt-20241231.xsd#ppbt_SubsequentEventsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_SubsequentEventsMember_lbl" xml:lang="en-US">Subsequent Events [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SubsequentEventsMember" xlink:to="ppbt_SubsequentEventsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RestrictedShareUnitsMember_lbl" xml:lang="en-US">RSUs Granted [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedShareUnitsMember" xlink:to="ifrs-full_RestrictedShareUnitsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RestrictedShareUnitsMember_lbl0" xml:lang="en-US">Restricted share units [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedShareUnitsMember" xlink:to="ifrs-full_RestrictedShareUnitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_RestrictedShareUnitsMember_lbl1" xml:lang="en-US">Restricted Share Units (RSU) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedShareUnitsMember" xlink:to="ifrs-full_RestrictedShareUnitsMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ppbt_BoardOfDirectorsMember" xlink:href="ppbt-20241231.xsd#ppbt_BoardOfDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_BoardOfDirectorsMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_BoardOfDirectorsMember" xlink:to="ppbt_BoardOfDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShareBasedPaymentArrangementsMember" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentArrangementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ShareBasedPaymentArrangementsMember_lbl" xml:lang="en-US">Share Based Payment Arrangements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ShareBasedPaymentArrangementsMember" xlink:to="ppbt_ShareBasedPaymentArrangementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_TryNovosTechnologiesMember" xlink:href="ppbt-20241231.xsd#ppbt_TryNovosTechnologiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_TryNovosTechnologiesMember_lbl" xml:lang="en-US">TryNovo&apos;s Technologies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TryNovosTechnologiesMember" xlink:to="ppbt_TryNovosTechnologiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_YissumsLicensedTechnologyMember" xlink:href="ppbt-20241231.xsd#ppbt_YissumsLicensedTechnologyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_YissumsLicensedTechnologyMember_lbl" xml:lang="en-US">Yissum&#8217;s licensed technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_YissumsLicensedTechnologyMember" xlink:to="ppbt_YissumsLicensedTechnologyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ppbt_YissumsLicensedTechnologyMember_lbl0" xml:lang="en-US">Yissum&#8217;s Licensed Technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_YissumsLicensedTechnologyMember" xlink:to="ppbt_YissumsLicensedTechnologyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_THMMember" xlink:href="ppbt-20241231.xsd#ppbt_THMMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_THMMember_lbl" xml:lang="en-US">THM [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_THMMember" xlink:to="ppbt_THMMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_BiopharmaceuticalProductMember" xlink:href="ppbt-20241231.xsd#ppbt_BiopharmaceuticalProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_BiopharmaceuticalProductMember_lbl" xml:lang="en-US">Biopharmaceutical Product [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_BiopharmaceuticalProductMember" xlink:to="ppbt_BiopharmaceuticalProductMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_DiagnosticProductsMember" xlink:href="ppbt-20241231.xsd#ppbt_DiagnosticProductsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_DiagnosticProductsMember_lbl" xml:lang="en-US">Diagnostic Products [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DiagnosticProductsMember" xlink:to="ppbt_DiagnosticProductsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreditRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CreditRiskMember_lbl" xml:lang="en-US">Credit risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CreditRiskMember_lbl0" xml:lang="en-US">Credit risk [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_January2025Member" xlink:href="ppbt-20241231.xsd#ppbt_January2025Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_January2025Member_lbl" xml:lang="en-US">January 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_January2025Member" xlink:to="ppbt_January2025Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ADSMember" xlink:href="ppbt-20241231.xsd#ppbt_ADSMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_ADSMember_lbl" xml:lang="en-US">ADS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ADSMember" xlink:to="ppbt_ADSMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_SeriesA1WarrantsMember" xlink:href="ppbt-20241231.xsd#ppbt_SeriesA1WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_SeriesA1WarrantsMember_lbl" xml:lang="en-US">Series A-1 warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SeriesA1WarrantsMember" xlink:to="ppbt_SeriesA1WarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_SeriesA2WarrantsMember" xlink:href="ppbt-20241231.xsd#ppbt_SeriesA2WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_SeriesA2WarrantsMember_lbl" xml:lang="en-US">Series A-2 warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SeriesA2WarrantsMember" xlink:to="ppbt_SeriesA2WarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_AmericanDepositorySharesMember" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepositorySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_AmericanDepositorySharesMember_lbl" xml:lang="en-US">ADS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AmericanDepositorySharesMember" xlink:to="ppbt_AmericanDepositorySharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_OptionsAndRSUsMember" xlink:href="ppbt-20241231.xsd#ppbt_OptionsAndRSUsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_OptionsAndRSUsMember_lbl" xml:lang="en-US">Options and RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OptionsAndRSUsMember" xlink:to="ppbt_OptionsAndRSUsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityDomain_lbl" xml:lang="en-US">Components of equity [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ComponentsOfEquityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsTablesTable" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IntangibleAssetsTablesTable_lbl" xml:lang="en-US">Intangible Assets (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IntangibleAssetsTablesTable" xlink:to="ppbt_IntangibleAssetsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsTablesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_IntangibleAssetsTablesLineItems_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IntangibleAssetsTablesLineItems" xlink:to="ppbt_IntangibleAssetsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:href="ppbt-20241231.xsd#ppbt_TransactionsandBalanceswithRelatedPartiesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_TransactionsandBalanceswithRelatedPartiesTablesTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:to="ppbt_TransactionsandBalanceswithRelatedPartiesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems_lbl" xml:lang="en-US">Transactions and Balances with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinanceExpenseIncomeNetTablesTable" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinanceExpenseIncomeNetTablesTable_lbl" xml:lang="en-US">Finance Expense (Income), Net (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinanceExpenseIncomeNetTablesTable" xlink:to="ppbt_FinanceExpenseIncomeNetTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinanceExpenseIncomeNetTablesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ppbt_FinanceExpenseIncomeNetTablesLineItems_lbl" xml:lang="en-US">Finance Expense (Income), Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinanceExpenseIncomeNetTablesLineItems" xlink:to="ppbt_FinanceExpenseIncomeNetTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksDomain_lbl" xml:lang="en-US">Types of risks [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_TypesOfRisksDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsTablesTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinancialInstrumentsTablesTable_lbl" xml:lang="en-US">Financial Instruments (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialInstrumentsTablesTable" xlink:to="ppbt_FinancialInstrumentsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsTablesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinancialInstrumentsTablesLineItems_lbl" xml:lang="en-US">Financial Instruments (Tables) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialInstrumentsTablesLineItems" xlink:to="ppbt_FinancialInstrumentsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_lbl" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsScheduleofIntangibleAssetsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsScheduleofIntangibleAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IntangibleAssetsScheduleofIntangibleAssetsDetailsTable_lbl" xml:lang="en-US">Intangible Assets - Schedule of Intangible Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IntangibleAssetsScheduleofIntangibleAssetsDetailsTable" xlink:to="ppbt_IntangibleAssetsScheduleofIntangibleAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US">Schedule of Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable_lbl" xml:lang="en-US">Intangible Assets - Schedule of Recognized Amounts of Assets Acquired and Liabilities Assumed (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable" xlink:to="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems_lbl" xml:lang="en-US">Schedule of Recognized Amounts Assets Acquired and Liabilities Assumed [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable_lbl" xml:lang="en-US">Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable" xlink:to="ppbt_CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CashAndCashEquivalentLineItems" xlink:href="ppbt-20241231.xsd#ppbt_CashAndCashEquivalentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CashAndCashEquivalentLineItems_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CashAndCashEquivalentLineItems" xlink:to="ppbt_CashAndCashEquivalentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Classes of financial instruments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable_lbl" xml:lang="en-US">Leases - Schedule of Carrying Amounts of Right-to-Use Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable" xlink:to="ppbt_LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xml:lang="en-US">Schedule of Carrying Amounts of Right-to-Use Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityDomain_lbl" xml:lang="en-US">Maturity [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_MaturityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable_lbl" xml:lang="en-US">Leases - Schedule of Maturity Analysis of the Company&apos;s Lease Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable" xlink:to="ppbt_LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_lbl" xml:lang="en-US">Schedule of Maturity Analysis of the Company&apos;s Lease Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ClassesOfPreferredSharesDomainDomain" xlink:href="ppbt-20241231.xsd#ppbt_ClassesOfPreferredSharesDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ClassesOfPreferredSharesDomainDomain_lbl" xml:lang="en-US">ClassesOfPreferredSharesDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ClassesOfPreferredSharesDomainDomain" xlink:to="ppbt_ClassesOfPreferredSharesDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_EquityScheduleofShareCapitalDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_EquityScheduleofShareCapitalDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_EquityScheduleofShareCapitalDetailsTable_lbl" xml:lang="en-US">Equity - Schedule of Share Capital (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EquityScheduleofShareCapitalDetailsTable" xlink:to="ppbt_EquityScheduleofShareCapitalDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US">Schedule of Share Capital [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeDomain_lbl" xml:lang="en-US">Range [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_RangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangements - Schedule of Assumptions were Used (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable" xlink:to="ppbt_ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfAssumptionsWereUsedLineItems" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfAssumptionsWereUsedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfAssumptionsWereUsedLineItems_lbl" xml:lang="en-US">Schedule of Assumptions were Used [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ppbt_ScheduleOfAssumptionsWereUsedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_lbl" xml:lang="en-US">Attribution of expenses by nature to their function [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangements - Schedule of Expenses Recognized in the Consolidated Financial Statements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable" xlink:to="ppbt_ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US">Schedule of Expenses Recognized in the Consolidated Financial Statements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties - Schedule of Recorded Expenses (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable" xlink:to="ppbt_TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US">Schedule of Recorded Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable_lbl" xml:lang="en-US">Research and Development Expenses - Schedule of Research and Development Expenses (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable" xlink:to="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems" xlink:href="ppbt-20241231.xsd#ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems_lbl" xml:lang="en-US">Schedule of Research and Development Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems" xlink:to="ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable_lbl" xml:lang="en-US">Sales, General and Administrative Expenses - Schedule of Sales, General and Administrative Expenses (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable" xlink:to="ppbt_SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems_lbl" xml:lang="en-US">Schedule of Sales, General and Administrative Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasDomain_lbl" xml:lang="en-US">Geographical areas [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="ifrs-full_GeographicalAreasDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain_lbl" xml:lang="en-US">Continuing involvement in derecognised financial assets by type of instrument [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain" xlink:to="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable_lbl" xml:lang="en-US">Financial Instruments - Schedule of Sensitivity Test to Possible Changes in Exchange Rate (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" xlink:to="ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US">Financial Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain_lbl" xml:lang="en-US">Levels of fair value hierarchy [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable_lbl" xml:lang="en-US">Financial Instruments - Schedule of Financial Instruments Measured at Fair Value (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable" xlink:to="ppbt_FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl0" xml:lang="en-US">Financial Instruments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsDomain_lbl" xml:lang="en-US">Classes of assets [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsDomain" xlink:to="ifrs-full_ClassesOfAssetsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable_lbl" xml:lang="en-US">Financial Instruments - Schedule of Details Regarding Fair Value Measurement (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable" xlink:to="ppbt_FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable_lbl" xml:lang="en-US">Financial Instruments - Schedule of Fair Value Measurement (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" xlink:to="ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_GeneralDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_GeneralDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_GeneralDetailsTable_lbl" xml:lang="en-US">General (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_GeneralDetailsTable" xlink:to="ppbt_GeneralDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_GeneralLineItems" xlink:href="ppbt-20241231.xsd#ppbt_GeneralLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_GeneralLineItems_lbl" xml:lang="en-US">General [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_GeneralLineItems" xlink:to="ppbt_GeneralLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl" xml:lang="en-US">Types of share-based payment arrangements [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable_lbl" xml:lang="en-US">Basis of Preparation of the Consolidated Financial Statements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable" xlink:to="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems" xlink:href="ppbt-20241231.xsd#ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems_lbl" xml:lang="en-US">Basis of Preparation of the Consolidated Financial Statements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems" xlink:to="ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_lbl" xml:lang="en-US">Classes of share capital [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IntangibleAssetsDetailsTable_lbl" xml:lang="en-US">Intangible Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IntangibleAssetsDetailsTable" xlink:to="ppbt_IntangibleAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_IntangibleAssetsDetailsLineItems" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IntangibleAssetsDetailsLineItems_lbl" xml:lang="en-US">Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IntangibleAssetsDetailsLineItems" xlink:to="ppbt_IntangibleAssetsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl" xml:lang="en-US">Categories of related parties [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_lbl" xml:lang="en-US">Liabilities arising from financing activities [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_LeasesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_LeasesDetailsTable" xlink:to="ppbt_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_LeasesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_LeasesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_LeasesLineItems_lbl" xml:lang="en-US">Leases [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_LeasesLineItems" xlink:to="ppbt_LeasesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_lbl" xml:lang="en-US">Types of antidilutive instruments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain_lbl" xml:lang="en-US">Classes of ordinary shares [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:to="ifrs-full_ClassesOfOrdinarySharesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl" xml:lang="en-US">Non-adjusting events after reporting period [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_EquityDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EquityDetailsTable" xlink:to="ppbt_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_EquityLineItems" xlink:href="ppbt-20241231.xsd#ppbt_EquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_EquityLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EquityLineItems" xlink:to="ppbt_EquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_ShareBasedPaymentArrangementsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentArrangementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ShareBasedPaymentArrangementsDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ShareBasedPaymentArrangementsDetailsTable" xlink:to="ppbt_ShareBasedPaymentArrangementsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl0" xml:lang="en-US">Share-Based Payment Arrangements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_RangesDomainDomain" xlink:href="ppbt-20241231.xsd#ppbt_RangesDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_RangesDomainDomain_lbl" xml:lang="en-US">RangesDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_RangesDomainDomain" xlink:to="ppbt_RangesDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CommitmentsandContingentLiabilitiesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_CommitmentsandContingentLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CommitmentsandContingentLiabilitiesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingent Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="ppbt_CommitmentsandContingentLiabilitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_CommitmentsAndContingentLiabilitiesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_CommitmentsAndContingentLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CommitmentsAndContingentLiabilitiesLineItems_lbl" xml:lang="en-US">Commitments and Contingent Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="ppbt_CommitmentsAndContingentLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinanceExpenseIncomeNetDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinanceExpenseIncomeNetDetailsTable_lbl" xml:lang="en-US">Finance Expense (Income), Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinanceExpenseIncomeNetDetailsTable" xlink:to="ppbt_FinanceExpenseIncomeNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinanceExpenseIncomeNetLineItems" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinanceExpenseIncomeNetLineItems_lbl" xml:lang="en-US">Finance Expense (Income), Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinanceExpenseIncomeNetLineItems" xlink:to="ppbt_FinanceExpenseIncomeNetLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_FinancialInstrumentsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinancialInstrumentsDetailsTable_lbl" xml:lang="en-US">Financial Instruments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialInstrumentsDetailsTable" xlink:to="ppbt_FinancialInstrumentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ppbt_SubsequentEventsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SubsequentEventsDetailsTable" xlink:to="ppbt_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_AdjustmentsForChangesInAssetsAndLiabilities_lbl0" xml:lang="en-US">Adjustments for changes in assets and liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AdjustmentsForChangesInAssetsAndLiabilities" xlink:to="ppbt_AdjustmentsForChangesInAssetsAndLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_AggregateShareholdersOfImmunorizon_lbl0" xml:lang="en-US">The aggregate shareholders of immunorizon.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AggregateShareholdersOfImmunorizon" xlink:to="ppbt_AggregateShareholdersOfImmunorizon_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_AggregateUpfrontPayment_lbl0" xml:lang="en-US">The amount of Aggregate upfront payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AggregateUpfrontPayment" xlink:to="ppbt_AggregateUpfrontPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_AggregateWarrantsShares_lbl0" xml:lang="en-US">Aggregate warrants shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AggregateWarrantsShares" xlink:to="ppbt_AggregateWarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_AgreementLeaseAdditionalTerm_lbl0" xml:lang="en-US">Agreement Lease Additional Term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AgreementLeaseAdditionalTerm" xlink:to="ppbt_AgreementLeaseAdditionalTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_AgreementLeaseTerm_lbl0" xml:lang="en-US">Agreement Lease Term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AgreementLeaseTerm" xlink:to="ppbt_AgreementLeaseTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_AmericanDepositorySharesOrdinaryShares_lbl1" xml:lang="en-US">American depository shares ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AmericanDepositorySharesOrdinaryShares" xlink:to="ppbt_AmericanDepositorySharesOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_AmericanDepositorySharesPurchase_lbl0" xml:lang="en-US">Number of ADS purchase.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AmericanDepositorySharesPurchase" xlink:to="ppbt_AmericanDepositorySharesPurchase_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_AmericanDepostioryShares_lbl0" xml:lang="en-US">American depostiory shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AmericanDepostioryShares" xlink:to="ppbt_AmericanDepostioryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest_lbl0" xml:lang="en-US">Capital reserve from transactions with non- controlling interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest" xlink:to="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave_lbl0" xml:lang="en-US">The cash outflow for the purchase of interests in associates. [Refer: Associates [member]]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave" xlink:to="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_CommonStockNoParValues_lbl0" xml:lang="en-US">Common stock no par value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CommonStockNoParValues" xlink:to="ppbt_CommonStockNoParValues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_ConvertibleShares_lbl0" xml:lang="en-US">Convertible shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConvertibleShares" xlink:to="ppbt_ConvertibleShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_ConvertibleWarrants_lbl0" xml:lang="en-US">Convertible warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConvertibleWarrants" xlink:to="ppbt_ConvertibleWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_ConvertiblesWarrants_lbl0" xml:lang="en-US">Amount of convertible warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConvertiblesWarrants" xlink:to="ppbt_ConvertiblesWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_CurrentAsset_lbl0" xml:lang="en-US">The value of Corrent assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CurrentAsset" xlink:to="ppbt_CurrentAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_Decreaseincreaseinshorttermdeposits_lbl0" xml:lang="en-US">Decrease increase in short term deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_Decreaseincreaseinshorttermdeposits" xlink:to="ppbt_Decreaseincreaseinshorttermdeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DepositaryShares_lbl0" xml:lang="en-US">Depositary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DepositaryShares" xlink:to="ppbt_DepositaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DepositarysShares_lbl0" xml:lang="en-US">Depositary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DepositarysShares" xlink:to="ppbt_DepositarysShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for basis of consolidation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:to="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DescriptionOfExpectedAnnualRiskFreeRate_lbl0" xml:lang="en-US">Description of expected annual risk free rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DescriptionOfExpectedAnnualRiskFreeRate" xlink:to="ppbt_DescriptionOfExpectedAnnualRiskFreeRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DescriptionOfExpectedVolatilityPercentage_lbl0" xml:lang="en-US">Description of expected volatility percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DescriptionOfExpectedVolatilityPercentage" xlink:to="ppbt_DescriptionOfExpectedVolatilityPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DescriptionOfOptionLifeShareOptionGranted_lbl0" xml:lang="en-US">Expected term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DescriptionOfOptionLifeShareOptionGranted" xlink:to="ppbt_DescriptionOfOptionLifeShareOptionGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about cash and cash equivalents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock_lbl0" xml:lang="en-US">Disclosure Of Detailed Information About Changes In Share Capital Explanatory Table Text Block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about defined contribution plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about employee benefits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock_lbl0" xml:lang="en-US">DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about restricted stock unit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about of trade and other payables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DisclosureOfOtherCurrentAssettextBlock_lbl0" xml:lang="en-US">The disclosure of other current assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfOtherCurrentAssettextBlock" xlink:to="ppbt_DisclosureOfOtherCurrentAssettextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock_lbl0" xml:lang="en-US">No definition available.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock" xlink:to="ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_lbl0" xml:lang="en-US">Disclosures Of DetailedInformationAboutGeneralAndAdministrativeExpenses Explanatory [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:to="ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_Discountforlackofmarketability_lbl0" xml:lang="en-US">Discount for lack of marketability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_Discountforlackofmarketability" xlink:to="ppbt_Discountforlackofmarketability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_EffectiveTaxRate_lbl0" xml:lang="en-US">Effective tax rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EffectiveTaxRate" xlink:to="ppbt_EffectiveTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_EmployeeBenefitBonus_lbl0" xml:lang="en-US">Employee benefit bonus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EmployeeBenefitBonus" xlink:to="ppbt_EmployeeBenefitBonus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_EmployeeBenefitsLiabilityDueGrants_lbl0" xml:lang="en-US">Employee benefits liability due grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EmployeeBenefitsLiabilityDueGrants" xlink:to="ppbt_EmployeeBenefitsLiabilityDueGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_EquityMethodInvestmentsOwnershipPercentage_lbl0" xml:lang="en-US">Direct ownership of equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EquityMethodInvestmentsOwnershipPercentage" xlink:to="ppbt_EquityMethodInvestmentsOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_ExercisePeriod_lbl0" xml:lang="en-US">It represents exercise period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ExercisePeriod" xlink:to="ppbt_ExercisePeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield_lbl0" xml:lang="en-US">Percentage of dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield" xlink:to="ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_FairValueMeasurementBalance_lbl1" xml:lang="en-US">Fair Value Measurement Balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementBalance" xlink:to="ppbt_FairValueMeasurementBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_FairValueMeasurementExercise_lbl0" xml:lang="en-US">Represent the fair value of exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementExercise" xlink:to="ppbt_FairValueMeasurementExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_FairValueMeasurementIssuance_lbl0" xml:lang="en-US">Fair Value Measurement Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementIssuance" xlink:to="ppbt_FairValueMeasurementIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_FairValueMeasurementIssuanceProceed_lbl0" xml:lang="en-US">Fair Value Measurement Proceed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementIssuanceProceed" xlink:to="ppbt_FairValueMeasurementIssuanceProceed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_FairValueMeasurementRevaluation_lbl0" xml:lang="en-US">Fair Value Measurement Revaluation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementRevaluation" xlink:to="ppbt_FairValueMeasurementRevaluation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_FairValueOfIssuedEquity_lbl0" xml:lang="en-US">Fair value of issued equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueOfIssuedEquity" xlink:to="ppbt_FairValueOfIssuedEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_FairValueOfIssuedIntangibleAssets_lbl0" xml:lang="en-US">The fair value of issued intangible assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueOfIssuedIntangibleAssets" xlink:to="ppbt_FairValueOfIssuedIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_FinancialAssetAtAFairValue_lbl0" xml:lang="en-US">Amount of financial asset at a fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialAssetAtAFairValue" xlink:to="ppbt_FinancialAssetAtAFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_FinancialInstrumentAmount_lbl0" xml:lang="en-US">Financial instrument amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialInstrumentAmount" xlink:to="ppbt_FinancialInstrumentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_FunctionalCurrency_lbl0" xml:lang="en-US">The amount of functional currency.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FunctionalCurrency" xlink:to="ppbt_FunctionalCurrency_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_FundsRaisedAmount_lbl0" xml:lang="en-US">Funds raised amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FundsRaisedAmount" xlink:to="ppbt_FundsRaisedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_FundsRaisedshares_lbl0" xml:lang="en-US">Funds raised amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FundsRaisedshares" xlink:to="ppbt_FundsRaisedshares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_GeneralAndAdministrativeExpensesOther_lbl0" xml:lang="en-US">The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the &apos;function of expense&apos; form for its analysis of expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_GeneralAndAdministrativeExpensesOther" xlink:to="ppbt_GeneralAndAdministrativeExpensesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_GovernmentAuthorities_lbl0" xml:lang="en-US">Government authorities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_GovernmentAuthorities" xlink:to="ppbt_GovernmentAuthorities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_IncomelossFromChangeInExchangeRateDown_lbl0" xml:lang="en-US">Amount of income (loss) from change in exchange rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IncomelossFromChangeInExchangeRateDown" xlink:to="ppbt_IncomelossFromChangeInExchangeRateDown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_IncomelossFromChangeInExchangeRateUp_lbl0" xml:lang="en-US">Amount of income (loss) from change in exchange rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IncomelossFromChangeInExchangeRateUp" xlink:to="ppbt_IncomelossFromChangeInExchangeRateUp_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_IncomelossValue_lbl0" xml:lang="en-US">Income loss value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IncomelossValue" xlink:to="ppbt_IncomelossValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_IncreaseDecreaseInLongTermDeposits_lbl0" xml:lang="en-US">Decrease in long term deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IncreaseDecreaseInLongTermDeposits" xlink:to="ppbt_IncreaseDecreaseInLongTermDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_IntangibleAssetsRecoverableAmountPercentage_lbl0" xml:lang="en-US">Intangible assets recoverable amount percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IntangibleAssetsRecoverableAmountPercentage" xlink:to="ppbt_IntangibleAssetsRecoverableAmountPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_IssuanceExpenses_lbl0" xml:lang="en-US">The amount of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IssuanceExpenses" xlink:to="ppbt_IssuanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_IssuesOfEquity_lbl0" xml:lang="en-US">Issue of equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IssuesOfEquity" xlink:to="ppbt_IssuesOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_LongTermMilestonesAggregateAmount_lbl0" xml:lang="en-US">The amount of long term Milestones aggregate amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_LongTermMilestonesAggregateAmount" xlink:to="ppbt_LongTermMilestonesAggregateAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_NetAssetsAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">The value of Mount of net assets attributable to non-controling interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NetAssetsAttributableToNoncontrollingInterest" xlink:to="ppbt_NetAssetsAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_NetAssetsAttributableToNoncontrollingInterests_lbl0" xml:lang="en-US">The amount of net assets attributable to non-controlling interests.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NetAssetsAttributableToNoncontrollingInterests" xlink:to="ppbt_NetAssetsAttributableToNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_NetOfDeferredDifferenceAmount_lbl0" xml:lang="en-US">Amount of net of deffered difference amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NetOfDeferredDifferenceAmount" xlink:to="ppbt_NetOfDeferredDifferenceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_NonVotingSeniorPreferredShares_lbl0" xml:lang="en-US">Non-voting senior preferred shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NonVotingSeniorPreferredShares" xlink:to="ppbt_NonVotingSeniorPreferredShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_NumberOfExerciseOfWarrants_lbl0" xml:lang="en-US">Exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfExerciseOfWarrants" xlink:to="ppbt_NumberOfExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_NumberOfIssuanceShares_lbl0" xml:lang="en-US">The number of issuance shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfIssuanceShares" xlink:to="ppbt_NumberOfIssuanceShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_NumberOfNonTradableWarrants_lbl0" xml:lang="en-US">Number Of Non Tradable Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfNonTradableWarrants" xlink:to="ppbt_NumberOfNonTradableWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_NumberOfPerShare_lbl0" xml:lang="en-US">Number of per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfPerShare" xlink:to="ppbt_NumberOfPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_NumberOfShare_lbl0" xml:lang="en-US">Number of share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfShare" xlink:to="ppbt_NumberOfShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_NumberOfVestingOfRsus_lbl0" xml:lang="en-US">Number Of Vesting Of Rsus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfVestingOfRsus" xlink:to="ppbt_NumberOfVestingOfRsus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_OptionExerciseOrdinaryShare_lbl0" xml:lang="en-US">Option exercise ordinary share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OptionExerciseOrdinaryShare" xlink:to="ppbt_OptionExerciseOrdinaryShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_OtherExpense_lbl0" xml:lang="en-US">Other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OtherExpense" xlink:to="ppbt_OtherExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_OtherfinancialCost_lbl0" xml:lang="en-US">Other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OtherfinancialCost" xlink:to="ppbt_OtherfinancialCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_PercentageOfCapacityOfAnAdvisor_lbl0" xml:lang="en-US">Percentage of capacity of an advisor.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfCapacityOfAnAdvisor" xlink:to="ppbt_PercentageOfCapacityOfAnAdvisor_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_PercentageOfContractToAcquire_lbl0" xml:lang="en-US">Contract to acquire, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfContractToAcquire" xlink:to="ppbt_PercentageOfContractToAcquire_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_PercentageOfDiscountsForLacksOfMarketability_lbl0" xml:lang="en-US">Percentage of discounts for lacks of marketability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfDiscountsForLacksOfMarketability" xlink:to="ppbt_PercentageOfDiscountsForLacksOfMarketability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_PercentageOfExchangeRate_lbl0" xml:lang="en-US">Percentage of exchange rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfExchangeRate" xlink:to="ppbt_PercentageOfExchangeRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_PercentageOfReceiveExitFee_lbl0" xml:lang="en-US">Percentage of receive exit fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfReceiveExitFee" xlink:to="ppbt_PercentageOfReceiveExitFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_PercentageOfSublicenseConsideration_lbl0" xml:lang="en-US">Percentage of sublicense consideration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfSublicenseConsideration" xlink:to="ppbt_PercentageOfSublicenseConsideration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_ProceedsFromIssuingWarrants_lbl0" xml:lang="en-US">The cash inflow from issuing warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ProceedsFromIssuingWarrants" xlink:to="ppbt_ProceedsFromIssuingWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_PurchaseOfCommonStockAndWarrants_lbl0" xml:lang="en-US">The company granted representative of the non traded warrants to purchase of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PurchaseOfCommonStockAndWarrants" xlink:to="ppbt_PurchaseOfCommonStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_ReceiptsOnAccountsOfWarrant_lbl0" xml:lang="en-US">The amount of receipts on account of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ReceiptsOnAccountsOfWarrant" xlink:to="ppbt_ReceiptsOnAccountsOfWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_ReimbursementOfLegalFeesExpense_lbl0" xml:lang="en-US">Reimbursement of legal fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ReimbursementOfLegalFeesExpense" xlink:to="ppbt_ReimbursementOfLegalFeesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_ReverseRatio_lbl0" xml:lang="en-US">Reverse Ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ReverseRatio" xlink:to="ppbt_ReverseRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_SalaryRelatedOtherPayablesCurrent_lbl0" xml:lang="en-US">The amount of current salary related payables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SalaryRelatedOtherPayablesCurrent" xlink:to="ppbt_SalaryRelatedOtherPayablesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_SalesAgreementShares_lbl0" xml:lang="en-US">Sales agreement shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SalesAgreementShares" xlink:to="ppbt_SalesAgreementShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about recognized amounts assets acquired and liabilities assumed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_Securities_lbl0" xml:lang="en-US">The amount of Securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_Securities" xlink:to="ppbt_Securities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_SharesPrice_lbl0" xml:lang="en-US">Share price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SharesPrice" xlink:to="ppbt_SharesPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_ShortTermDepositsGuaranteedForHedgingTransactions_lbl0" xml:lang="en-US">Amount of short term deposits guaranteed for hedging transactions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ShortTermDepositsGuaranteedForHedgingTransactions" xlink:to="ppbt_ShortTermDepositsGuaranteedForHedgingTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit_lbl0" xml:lang="en-US">Amount of short term deposits guaranteed for leases and credit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit" xlink:to="ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_StatutoryTaxRate_lbl0" xml:lang="en-US">Statutory tax rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_StatutoryTaxRate" xlink:to="ppbt_StatutoryTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_StockOptionExercisedPeriod_lbl1" xml:lang="en-US">Stock option exercised period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_StockOptionExercisedPeriod" xlink:to="ppbt_StockOptionExercisedPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_StockholdersEquityReversesStockSplit_lbl0" xml:lang="en-US">Stockholders equity reverse stock split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_StockholdersEquityReversesStockSplit" xlink:to="ppbt_StockholdersEquityReversesStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_TerminationExercisePrice_lbl0" xml:lang="en-US">The exercise price of share options terminated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TerminationExercisePrice" xlink:to="ppbt_TerminationExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_TotalAcquisitionAmount_lbl0" xml:lang="en-US">Amount of total acquisition .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TotalAcquisitionAmount" xlink:to="ppbt_TotalAcquisitionAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_UnrecognizedResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">The amount of unrecognized research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_UnrecognizedResearchAndDevelopmentExpenses" xlink:to="ppbt_UnrecognizedResearchAndDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_VestingPeriod_lbl0" xml:lang="en-US">It represents vesting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_VestingPeriod" xlink:to="ppbt_VestingPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_WarrantExercisePricePerShare_lbl0" xml:lang="en-US">Exercise price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantExercisePricePerShare" xlink:to="ppbt_WarrantExercisePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_WarrantTermDescription_lbl0" xml:lang="en-US">Description of warrant term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantTermDescription" xlink:to="ppbt_WarrantTermDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_WarrantsExpireTerm_lbl0" xml:lang="en-US">Warrants Expire Term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsExpireTerm" xlink:to="ppbt_WarrantsExpireTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_WarrantsIssuanceExpensesPaid_lbl0" xml:lang="en-US">The cash outflow for warrants issuance expenses paid, classified as financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsIssuanceExpensesPaid" xlink:to="ppbt_WarrantsIssuanceExpensesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_WarrantsIssued_lbl1" xml:lang="en-US">Number of warrants issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsIssued" xlink:to="ppbt_WarrantsIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_WarrantsTerm_lbl0" xml:lang="en-US">Period of time between issuance and maturity of warrants, in PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsTerm" xlink:to="ppbt_WarrantsTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_noncontrollingInterests_lbl0" xml:lang="en-US">Non-controlling interests.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_noncontrollingInterests" xlink:to="ppbt_noncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember_lbl0" xml:lang="en-US">Capital reserve from transactions with Non-controlling interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember" xlink:to="ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_WarrantsTerm_lbl1" xml:lang="en-US">Warrants Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsTerm" xlink:to="ppbt_WarrantsTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl0" xml:lang="en-US">Issued capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_OtherfinancialCost_lbl1" xml:lang="en-US">Otherfinancial Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OtherfinancialCost" xlink:to="ppbt_OtherfinancialCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IntangibleAssetsTablesLineItems_lbl0" xml:lang="en-US">Intangible Assets Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IntangibleAssetsTablesLineItems" xlink:to="ppbt_IntangibleAssetsTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosures Of Detailed Information About General And Administrative Expenses Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:to="ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CommonStockNoParValues_lbl1" xml:lang="en-US">Common Stock No Par Values</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CommonStockNoParValues" xlink:to="ppbt_CommonStockNoParValues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PercentageOfCapacityOfAnAdvisor_lbl1" xml:lang="en-US">Percentage Of Capacity Of An Advisor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfCapacityOfAnAdvisor" xlink:to="ppbt_PercentageOfCapacityOfAnAdvisor_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_AccountPayablesMember_lbl1" xml:lang="en-US">Account Payables Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AccountPayablesMember" xlink:to="ppbt_AccountPayablesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_lbl0" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InsuranceContractsIssuedThatAreAssets_lbl0" xml:lang="en-US">Insurance contracts issued that are assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceContractsIssuedThatAreAssets" xlink:to="ifrs-full_InsuranceContractsIssuedThatAreAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ProceedsFromIssuingWarrants_lbl1" xml:lang="en-US">Proceeds From Issuing Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ProceedsFromIssuingWarrants" xlink:to="ppbt_ProceedsFromIssuingWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl0" xml:lang="en-US">Current prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_OptionExerciseOrdinaryShare_lbl1" xml:lang="en-US">Option Exercise Ordinary Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OptionExerciseOrdinaryShare" xlink:to="ppbt_OptionExerciseOrdinaryShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl0" xml:lang="en-US">Percentage of voting equity interests acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Defined Contribution Plan Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentWarrantLiability_lbl0" xml:lang="en-US">Non-current warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentWarrantLiability" xlink:to="ifrs-full_NoncurrentWarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PreferredClassCMember_lbl0" xml:lang="en-US">Preferred Class CMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PreferredClassCMember" xlink:to="ppbt_PreferredClassCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_OtherExpense_lbl1" xml:lang="en-US">Other Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OtherExpense" xlink:to="ppbt_OtherExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IPRDRelatedToImmunorizonSee5CBelowMember_lbl0" xml:lang="en-US">IPRDRelated To Immunorizon See5 CBelow Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IPRDRelatedToImmunorizonSee5CBelowMember" xlink:to="ppbt_IPRDRelatedToImmunorizonSee5CBelowMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_AmericanDepositorySharesPurchase_lbl1" xml:lang="en-US">American Depository Shares Purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AmericanDepositorySharesPurchase" xlink:to="ppbt_AmericanDepositorySharesPurchase_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IssuesOfEquity_lbl1" xml:lang="en-US">Issues Of Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IssuesOfEquity" xlink:to="ppbt_IssuesOfEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromRoyalties_lbl0" xml:lang="en-US">Royalty income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromRoyalties" xlink:to="ifrs-full_RevenueFromRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl0" xml:lang="en-US">Derivative financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativeFinancialLiabilities" xlink:to="ifrs-full_DerivativeFinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FairValueOfIssuedEquity_lbl1" xml:lang="en-US">Fair Value Of Issued Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueOfIssuedEquity" xlink:to="ppbt_FairValueOfIssuedEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreditRiskMember_lbl1" xml:lang="en-US">Credit risk [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl0" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_RangesAxis_lbl0" xml:lang="en-US">Ranges Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_RangesAxis" xlink:to="ppbt_RangesAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl1" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_AggregateUpfrontPayment_lbl1" xml:lang="en-US">Aggregate Upfront Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AggregateUpfrontPayment" xlink:to="ppbt_AggregateUpfrontPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_LongTermMilestonesAggregateAmount_lbl1" xml:lang="en-US">Long Term Milestones Aggregate Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_LongTermMilestonesAggregateAmount" xlink:to="ppbt_LongTermMilestonesAggregateAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ATMProgramMember_lbl0" xml:lang="en-US">ATMProgram Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ATMProgramMember" xlink:to="ppbt_ATMProgramMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrencyRiskMember_lbl0" xml:lang="en-US">Currency risk [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl0" xml:lang="en-US">Disclosure of material accounting policy information [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentAssets_lbl1" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_NumberOfShare_lbl1" xml:lang="en-US">Number Of Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfShare" xlink:to="ppbt_NumberOfShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl0" xml:lang="en-US">Post-employment benefit expense, defined contribution plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfFinanceIncomeAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfFinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfFinanceIncomeAbstract_lbl" xml:lang="en-US">Schedule Of Finance Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfFinanceIncomeAbstract" xlink:to="ppbt_ScheduleOfFinanceIncomeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalReserve_lbl0" xml:lang="en-US">Capital reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserve" xlink:to="ifrs-full_CapitalReserve_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfFairValueMeasurementAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfFairValueMeasurementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfFairValueMeasurementAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Measurement Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfFairValueMeasurementAbstract" xlink:to="ppbt_ScheduleOfFairValueMeasurementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Cash And Cash Equivalent Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ConsultantPerShares_lbl0" xml:lang="en-US">Consultant Per Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConsultantPerShares" xlink:to="ppbt_ConsultantPerShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl0" xml:lang="en-US">Key management personnel compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DirectorsRemunerationExpense_lbl0" xml:lang="en-US">Directors&apos; remuneration expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DirectorsRemunerationExpense" xlink:to="ifrs-full_DirectorsRemunerationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 1 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_TotalAcquisitionAmount_lbl1" xml:lang="en-US">Total Acquisition Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TotalAcquisitionAmount" xlink:to="ppbt_TotalAcquisitionAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave_lbl1" xml:lang="en-US">Cash Assumed As Part Of Acquisition Of Famewave</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave" xlink:to="ppbt_CashAssumedAsPartOfAcquisitionOfFamewave_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfCashFlowHedgesMember_lbl0" xml:lang="en-US">Reserve of cash flow hedges [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfCashFlowHedgesMember" xlink:to="ifrs-full_ReserveOfCashFlowHedgesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PurchaseOfCommonStockAndWarrants_lbl1" xml:lang="en-US">Purchase Of Common Stock And Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PurchaseOfCommonStockAndWarrants" xlink:to="ppbt_PurchaseOfCommonStockAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IPRDRelatedToFamewaveSee5BBelowMember_lbl0" xml:lang="en-US">IPRDRelated To Famewave See5 BBelow Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IPRDRelatedToFamewaveSee5BBelowMember" xlink:to="ppbt_IPRDRelatedToFamewaveSee5BBelowMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl0" xml:lang="en-US">Number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_AmericanDepositorySharesMember_lbl0" xml:lang="en-US">American Depository Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AmericanDepositorySharesMember" xlink:to="ppbt_AmericanDepositorySharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ChangesInExchangeRatesForTheYearEndedAbstract_lbl0" xml:lang="en-US">Changes In Exchange Rates For The Year Ended Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ChangesInExchangeRatesForTheYearEndedAbstract" xlink:to="ppbt_ChangesInExchangeRatesForTheYearEndedAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Interest received, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl0" xml:lang="en-US">Later than one year and not later than two years [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfCashAndCashEquivalentsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfCashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Schedule Of Cash And Cash Equivalents Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfCashAndCashEquivalentsAbstract" xlink:to="ppbt_ScheduleOfCashAndCashEquivalentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl0" xml:lang="en-US">Disclosure of expenses by nature [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LicenceFeeIncome_lbl0" xml:lang="en-US">Licence fee income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LicenceFeeIncome" xlink:to="ifrs-full_LicenceFeeIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_StockOptionExercisedPeriod_lbl2" xml:lang="en-US">Stock Option Exercised Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_StockOptionExercisedPeriod" xlink:to="ppbt_StockOptionExercisedPeriod_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinanceExpensesAbstract_lbl0" xml:lang="en-US">Finance Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinanceExpensesAbstract" xlink:to="ppbt_FinanceExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IPRDRelatedToPurpleGmbHMember_lbl0" xml:lang="en-US">IPRDRelated To Purple Gmb HMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IPRDRelatedToPurpleGmbHMember" xlink:to="ppbt_IPRDRelatedToPurpleGmbHMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_Securities_lbl1" xml:lang="en-US">Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_Securities" xlink:to="ppbt_Securities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_THMMember_lbl0" xml:lang="en-US">THMMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_THMMember" xlink:to="ppbt_THMMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PercentageOfContractToAcquire_lbl1" xml:lang="en-US">Percentage Of Contract To Acquire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfContractToAcquire" xlink:to="ppbt_PercentageOfContractToAcquire_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Trade And Other Payables Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AverageForeignExchangeRate_lbl0" xml:lang="en-US">Average foreign exchange rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageForeignExchangeRate" xlink:to="ifrs-full_AverageForeignExchangeRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl1" xml:lang="en-US">Expected dividend as percentage, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl0" xml:lang="en-US">Other comprehensive income [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl0" xml:lang="en-US">Depreciation, right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Recognized Amounts Assets Acquired And Liabilities Assumed Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl0" xml:lang="en-US">Share issue related cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl1" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl0" xml:lang="en-US">Statement of comprehensive income [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems_lbl0" xml:lang="en-US">Transactionsand Balanceswith Related Parties Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_NetAssetsAttributableToNoncontrollingInterests_lbl1" xml:lang="en-US">Net Assets Attributable To Noncontrolling Interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NetAssetsAttributableToNoncontrollingInterests" xlink:to="ppbt_NetAssetsAttributableToNoncontrollingInterests_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl0" xml:lang="en-US">Non-controlling interests [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Current trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for impairment of assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for interest income and expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_StockholdersEquityReversesStockSplit_lbl1" xml:lang="en-US">Stockholders Equity Reverses Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_StockholdersEquityReversesStockSplit" xlink:to="ppbt_StockholdersEquityReversesStockSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ShareBasedPaymentsMember_lbl0" xml:lang="en-US">Share Based Payments Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ShareBasedPaymentsMember" xlink:to="ppbt_ShareBasedPaymentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl0" xml:lang="en-US">Non-current provisions for employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:to="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, post-employment benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Exercise price of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_TryNovosTechnologiesMember_lbl0" xml:lang="en-US">Try Novos Technologies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TryNovosTechnologiesMember" xlink:to="ppbt_TryNovosTechnologiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinancialAssetAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Financial Asset And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialAssetAndLiabilitiesAbstract" xlink:to="ppbt_FinancialAssetAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_EquityMethodInvestmentsOwnershipPercentage_lbl1" xml:lang="en-US">Equity Method Investments Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EquityMethodInvestmentsOwnershipPercentage" xlink:to="ppbt_EquityMethodInvestmentsOwnershipPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_RetainedEarning_lbl0" xml:lang="en-US">Retained Earning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_RetainedEarning" xlink:to="ppbt_RetainedEarning_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FairValueMeasurementIssuance_lbl1" xml:lang="en-US">Fair Value Measurement Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementIssuance" xlink:to="ppbt_FairValueMeasurementIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_EUROMember_lbl0" xml:lang="en-US">EUROMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EUROMember" xlink:to="ppbt_EUROMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PublicOfferingMember_lbl1" xml:lang="en-US">Public Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PublicOfferingMember" xlink:to="ppbt_PublicOfferingMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_TransactionsWithOwnersOfTheCompanyAbstract1_lbl0" xml:lang="en-US">Transactions With Owners Of The Company Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TransactionsWithOwnersOfTheCompanyAbstract1" xlink:to="ppbt_TransactionsWithOwnersOfTheCompanyAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_TransactionsWithOwnersOfTheCompanyAbstract0_lbl0" xml:lang="en-US">Transactions With Owners Of The Company Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TransactionsWithOwnersOfTheCompanyAbstract0" xlink:to="ppbt_TransactionsWithOwnersOfTheCompanyAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_UnlabeledAbstract1" xlink:to="ppbt_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_UnlabeledAbstract0" xlink:to="ppbt_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Non-current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TravelExpense_lbl0" xml:lang="en-US">Travel expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TravelExpense" xlink:to="ifrs-full_TravelExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl0" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DescriptionOfExpectedVolatilityPercentage_lbl1" xml:lang="en-US">Description Of Expected Volatility Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DescriptionOfExpectedVolatilityPercentage" xlink:to="ppbt_DescriptionOfExpectedVolatilityPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IncomelossFromChangeInExchangeRateUp_lbl1" xml:lang="en-US">Incomeloss From Change In Exchange Rate Up</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IncomelossFromChangeInExchangeRateUp" xlink:to="ppbt_IncomelossFromChangeInExchangeRateUp_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0" xml:lang="en-US">Disclosure of transactions between related parties [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_NISMember_lbl0" xml:lang="en-US">NISMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NISMember" xlink:to="ppbt_NISMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExplanatory_lbl0" xml:lang="en-US">Disclosure of finance income [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ForeignExchangeGain_lbl0" xml:lang="en-US">Foreign exchange gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeGain" xlink:to="ifrs-full_ForeignExchangeGain_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_AmericanDepostioryShares_lbl1" xml:lang="en-US">American Depostiory Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AmericanDepostioryShares" xlink:to="ppbt_AmericanDepostioryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Interest paid, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy For Basis Of Consolidation Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:to="ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Profit (loss), attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Details Regarding Fair Value Measurement Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock" xlink:to="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract_lbl" xml:lang="en-US">Schedule Of Financial Instruments Measured At Fair Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract" xlink:to="ppbt_ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl0" xml:lang="en-US">Other reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IncomelossFromChangeInExchangeRateDown_lbl1" xml:lang="en-US">Incomeloss From Change In Exchange Rate Down</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IncomelossFromChangeInExchangeRateDown" xlink:to="ppbt_IncomelossFromChangeInExchangeRateDown_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl1" xml:lang="en-US">Par value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_Discountforlackofmarketability_lbl1" xml:lang="en-US">Discountforlackofmarketability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_Discountforlackofmarketability" xlink:to="ppbt_Discountforlackofmarketability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DepositarysShares_lbl1" xml:lang="en-US">Depositarys Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DepositarysShares" xlink:to="ppbt_DepositarysShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl0" xml:lang="en-US">Non-current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl1" xml:lang="en-US">Expected volatility, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FairValueMeasurementBalance_lbl2" xml:lang="en-US">Fair Value Measurement Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementBalance" xlink:to="ppbt_FairValueMeasurementBalance_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentPayables_lbl1" xml:lang="en-US">Other current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember_lbl1" xml:lang="en-US">Capital Reserve From Transactions With Non Controlling Interest Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember" xlink:to="ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_RehovotMember_lbl0" xml:lang="en-US">Rehovot Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_RehovotMember" xlink:to="ppbt_RehovotMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl0" xml:lang="en-US">Increase (decrease) through transactions with owners, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DepreciationRightofuseAssetsUsefulLife_lbl0" xml:lang="en-US">Depreciation Rightofuse Assets Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DepreciationRightofuseAssetsUsefulLife" xlink:to="ppbt_DepreciationRightofuseAssetsUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl0" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US">Schedule Of Expenses Recognized In The Consolidated Financial Statements Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract" xlink:to="ppbt_ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_WarrantsIssued_lbl2" xml:lang="en-US">Warrants Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsIssued" xlink:to="ppbt_WarrantsIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IncomelossValue_lbl1" xml:lang="en-US">Incomeloss Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IncomelossValue" xlink:to="ppbt_IncomelossValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Weighted average share price, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CashAndCashEquivalentsAndDepositsMember_lbl1" xml:lang="en-US">Cash And Cash Equivalents And Deposits Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CashAndCashEquivalentsAndDepositsMember" xlink:to="ppbt_CashAndCashEquivalentsAndDepositsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_lbl0" xml:lang="en-US">Expense from share-based payment transactions with parties other than employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfRecordedExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfRecordedExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfRecordedExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Recorded Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfRecordedExpensesAbstract" xlink:to="ppbt_ScheduleOfRecordedExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0" xml:lang="en-US">Disclosure of classes of share capital [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in employee benefit liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl0" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of finance income (cost) [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl0" xml:lang="en-US">Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce deferred tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_lbl0" xml:lang="en-US">Increase (decrease) through acquisition of subsidiary, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:to="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_NumberOfExerciseOfWarrants_lbl1" xml:lang="en-US">Number Of Exercise Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfExerciseOfWarrants" xlink:to="ppbt_NumberOfExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinanceExpenseIncomeNetTablesLineItems_lbl0" xml:lang="en-US">Finance Expense Income Net Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinanceExpenseIncomeNetTablesLineItems" xlink:to="ppbt_FinanceExpenseIncomeNetTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl2" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_NumberOfNonTradableWarrants_lbl1" xml:lang="en-US">Number Of Non Tradable Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfNonTradableWarrants" xlink:to="ppbt_NumberOfNonTradableWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_UnlabeledAbstract" xlink:to="ppbt_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl2" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_SubsequentEventsMember_lbl0" xml:lang="en-US">Subsequent Events Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SubsequentEventsMember" xlink:to="ppbt_SubsequentEventsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_NetOfDeferredDifferenceAmount_lbl1" xml:lang="en-US">Net Of Deferred Difference Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NetOfDeferredDifferenceAmount" xlink:to="ppbt_NetOfDeferredDifferenceAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl0" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfRecognizedAmountsOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfRecognizedAmountsOfAssetsAcquiredAndLiabilitiesAssumedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfRecognizedAmountsOfAssetsAcquiredAndLiabilitiesAssumedAbstract_lbl" xml:lang="en-US">Schedule Of Recognized Amounts Of Assets Acquired And Liabilities Assumed Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfRecognizedAmountsOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ppbt_ScheduleOfRecognizedAmountsOfAssetsAcquiredAndLiabilitiesAssumedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Proceeds from sales of other long-term assets, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIntangibleAssets_lbl0" xml:lang="en-US">Other intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIntangibleAssets" xlink:to="ifrs-full_OtherIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl2" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl0" xml:lang="en-US">Adjustments for depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl0" xml:lang="en-US">Expense from share-based payment transactions with employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_Decreaseincreaseinshorttermdeposits_lbl1" xml:lang="en-US">Decreaseincreaseinshorttermdeposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_Decreaseincreaseinshorttermdeposits" xlink:to="ppbt_Decreaseincreaseinshorttermdeposits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests_lbl0" xml:lang="en-US">Profit (loss) from continuing operations attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of other equity instruments forfeited in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfIntangibleAssetsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfIntangibleAssetsAbstract" xlink:to="ppbt_ScheduleOfIntangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CashFlowsFromFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Flows From Financing Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CashFlowsFromFinancingActivitiesAbstract" xlink:to="ppbt_CashFlowsFromFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl1" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_WarrantsIssuanceExpensesPaid_lbl1" xml:lang="en-US">Warrants Issuance Expenses Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsIssuanceExpensesPaid" xlink:to="ppbt_WarrantsIssuanceExpensesPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Restricted Stock Unit Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterests_lbl0" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_noncontrollingInterests_lbl1" xml:lang="en-US">noncontrolling Interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_noncontrollingInterests" xlink:to="ppbt_noncontrollingInterests_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PreferredShareClassMember_lbl0" xml:lang="en-US">Preferred Share Class Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PreferredShareClassMember" xlink:to="ppbt_PreferredShareClassMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PercentageOfReceiveExitFee_lbl1" xml:lang="en-US">Percentage Of Receive Exit Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfReceiveExitFee" xlink:to="ppbt_PercentageOfReceiveExitFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl0" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CurrentLiabiliti_lbl0" xml:lang="en-US">Current Liabiliti</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CurrentLiabiliti" xlink:to="ppbt_CurrentLiabiliti_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_NetAssetsAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Net Assets Attributable To Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NetAssetsAttributableToNoncontrollingInterest" xlink:to="ppbt_NetAssetsAttributableToNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit_lbl1" xml:lang="en-US">Short Term Deposits Guaranteed For Leases And Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit" xlink:to="ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ClassesOfPreferredSharesAxis_lbl0" xml:lang="en-US">Classes Of Preferred Shares Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ClassesOfPreferredSharesAxis" xlink:to="ppbt_ClassesOfPreferredSharesAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DescriptionOfExpectedAnnualRiskFreeRate_lbl1" xml:lang="en-US">Description Of Expected Annual Risk Free Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DescriptionOfExpectedAnnualRiskFreeRate" xlink:to="ppbt_DescriptionOfExpectedAnnualRiskFreeRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ExerciseOfWarrantsEquity_lbl0" xml:lang="en-US">Exercise Of Warrants Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ExerciseOfWarrantsEquity" xlink:to="ppbt_ExerciseOfWarrantsEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl0" xml:lang="en-US">Option life, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl0" xml:lang="en-US">Identifiable assets acquired (liabilities assumed)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl0" xml:lang="en-US">Basic earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_LeaseAgreementOneMember_lbl0" xml:lang="en-US">Lease Agreement One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_LeaseAgreementOneMember" xlink:to="ppbt_LeaseAgreementOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FundsRaisedshares_lbl1" xml:lang="en-US">Funds Raisedshares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FundsRaisedshares" xlink:to="ppbt_FundsRaisedshares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestIncomeOnDeposits_lbl0" xml:lang="en-US">Interest income on deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnDeposits" xlink:to="ifrs-full_InterestIncomeOnDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PercentageOfSublicenseConsideration_lbl1" xml:lang="en-US">Percentage Of Sublicense Consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfSublicenseConsideration" xlink:to="ppbt_PercentageOfSublicenseConsideration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl0" xml:lang="en-US">Comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent_lbl0" xml:lang="en-US">Accruals classified as current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl0" xml:lang="en-US">Assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl0" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IssuanceExpenses_lbl1" xml:lang="en-US">Issuance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IssuanceExpenses" xlink:to="ppbt_IssuanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_January2025Member_lbl0" xml:lang="en-US">January2025 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_January2025Member" xlink:to="ppbt_January2025Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained earnings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl0" xml:lang="en-US">Interest expense on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinanceIncome_lbl0" xml:lang="en-US">Other finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrs-full_OtherFinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl0" xml:lang="en-US">Reserve of share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_AggregateShareholdersOfImmunorizon_lbl1" xml:lang="en-US">Aggregate Shareholders Of Immunorizon</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AggregateShareholdersOfImmunorizon" xlink:to="ppbt_AggregateShareholdersOfImmunorizon_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges_lbl0" xml:lang="en-US">Other comprehensive income, before tax, cash flow hedges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl0" xml:lang="en-US">Fee and commission expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0" xml:lang="en-US">Disclosure of income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_WarrantsoneMember_lbl0" xml:lang="en-US">Warrantsone Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsoneMember" xlink:to="ppbt_WarrantsoneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of fair value of financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_SalariesWagesAndRelatedExpensesMember_lbl0" xml:lang="en-US">Salaries Wages And Related Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SalariesWagesAndRelatedExpensesMember" xlink:to="ppbt_SalariesWagesAndRelatedExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ReimbursementOfLegalFeesExpense_lbl1" xml:lang="en-US">Reimbursement Of Legal Fees Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ReimbursementOfLegalFeesExpense" xlink:to="ppbt_ReimbursementOfLegalFeesExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ServiceProvidersMember_lbl0" xml:lang="en-US">Service Providers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ServiceProvidersMember" xlink:to="ppbt_ServiceProvidersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl1" xml:lang="en-US">Adjustments for share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of other current assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CashFlowsFromInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Flows From Investing Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CashFlowsFromInvestingActivitiesAbstract" xlink:to="ppbt_CashFlowsFromInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinancialInstrumentAmount_lbl1" xml:lang="en-US">Financial Instrument Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialInstrumentAmount" xlink:to="ppbt_FinancialInstrumentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_OtherCurrentAssetMember_lbl1" xml:lang="en-US">Other Current Asset Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OtherCurrentAssetMember" xlink:to="ppbt_OtherCurrentAssetMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_AmericanDepositorySharesOrdinaryShares_lbl2" xml:lang="en-US">American Depository Shares Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AmericanDepositorySharesOrdinaryShares" xlink:to="ppbt_AmericanDepositorySharesOrdinaryShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0" xml:lang="en-US">Disclosure of changes in accounting policies [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ReverseRatio_lbl1" xml:lang="en-US">Reverse Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ReverseRatio" xlink:to="ppbt_ReverseRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WagesAndSalaries_lbl0" xml:lang="en-US">Wages and salaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of general information about financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_WarrantsExpireTerm_lbl1" xml:lang="en-US">Warrants Expire Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantsExpireTerm" xlink:to="ppbt_WarrantsExpireTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ConvertibleShares_lbl1" xml:lang="en-US">Convertible Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConvertibleShares" xlink:to="ppbt_ConvertibleShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_SalaryRelatedOtherPayablesCurrent_lbl1" xml:lang="en-US">Salary Related Other Payables Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SalaryRelatedOtherPayablesCurrent" xlink:to="ppbt_SalaryRelatedOtherPayablesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLoss_lbl0" xml:lang="en-US">Impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLoss" xlink:to="ifrs-full_ImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_GeneralAndAdministrativeExpensesOther_lbl1" xml:lang="en-US">General And Administrative Expenses Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_GeneralAndAdministrativeExpensesOther" xlink:to="ppbt_GeneralAndAdministrativeExpensesOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_LeaseAgreementsTwoMember_lbl0" xml:lang="en-US">Lease Agreements Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_LeaseAgreementsTwoMember" xlink:to="ppbt_LeaseAgreementsTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperations_lbl0" xml:lang="en-US">Profit (loss) from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperations" xlink:to="ifrs-full_ProfitLossFromContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl0" xml:lang="en-US">Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl0" xml:lang="en-US">Not later than one year [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_lbl0" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PrivateAndPublicFinancingTotal_lbl0" xml:lang="en-US">Private And Public Financing Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PrivateAndPublicFinancingTotal" xlink:to="ppbt_PrivateAndPublicFinancingTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl0" xml:lang="en-US">Finance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl0" xml:lang="en-US">Weighted average share price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePrice2019" xlink:to="ifrs-full_WeightedAverageSharePrice2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ChangesInAssetsAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Changes In Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ChangesInAssetsAndLiabilitiesAbstract" xlink:to="ppbt_ChangesInAssetsAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">Selling, general and administrative expense [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Carrying Amounts Of Right To Use Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract" xlink:to="ppbt_ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_SeriesA2WarrantsMember_lbl0" xml:lang="en-US">Series A2 Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SeriesA2WarrantsMember" xlink:to="ppbt_SeriesA2WarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PreferredClassDMember_lbl0" xml:lang="en-US">Preferred Class DMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PreferredClassDMember" xlink:to="ppbt_PreferredClassDMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl0" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ApplicableTaxRate_lbl0" xml:lang="en-US">Applicable tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract_lbl" xml:lang="en-US">Schedule Of Sensitivity Test To Possible Changes In Exchange Rate Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract" xlink:to="ppbt_ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_AdsMember_lbl1" xml:lang="en-US">Ads Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AdsMember" xlink:to="ppbt_AdsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FairValueOfIssuedIntangibleAssets_lbl1" xml:lang="en-US">Fair Value Of Issued Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueOfIssuedIntangibleAssets" xlink:to="ppbt_FairValueOfIssuedIntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_StatutoryTaxRate_lbl1" xml:lang="en-US">Statutory Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_StatutoryTaxRate" xlink:to="ppbt_StatutoryTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FairValueMeasurementRevaluation_lbl1" xml:lang="en-US">Fair Value Measurement Revaluation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementRevaluation" xlink:to="ppbt_FairValueMeasurementRevaluation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_SeriesA1WarrantsMember_lbl0" xml:lang="en-US">Series A1 Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SeriesA1WarrantsMember" xlink:to="ppbt_SeriesA1WarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl0" xml:lang="en-US">Adjustments for finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncome" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl1" xml:lang="en-US">Non-current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_NumberOfVestingOfRsus_lbl1" xml:lang="en-US">Number Of Vesting Of Rsus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfVestingOfRsus" xlink:to="ppbt_NumberOfVestingOfRsus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Changes In Share Capital Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield_lbl1" xml:lang="en-US">Expected Dividend As Percentage Share Optionsdividend Yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield" xlink:to="ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IncreaseDecreaseInLongTermDeposits_lbl1" xml:lang="en-US">Increase Decrease In Long Term Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IncreaseDecreaseInLongTermDeposits" xlink:to="ppbt_IncreaseDecreaseInLongTermDeposits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PreferredShareClassBMember_lbl0" xml:lang="en-US">Preferred Share Class BMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PreferredShareClassBMember" xlink:to="ppbt_PreferredShareClassBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PrivatePlacementsMember_lbl0" xml:lang="en-US">Private Placements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PrivatePlacementsMember" xlink:to="ppbt_PrivatePlacementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IPRDRelatedToTryNovosee5ABelowMember_lbl0" xml:lang="en-US">IPRDRelated To Try Novosee5 ABelow Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IPRDRelatedToTryNovosee5ABelowMember" xlink:to="ppbt_IPRDRelatedToTryNovosee5ABelowMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl0" xml:lang="en-US">Disclosure of leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss_lbl0" xml:lang="en-US">Post-employment benefit expense in profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xlink:to="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ForTheYearEndedDecember312023Abstract_lbl0" xml:lang="en-US">For The Year Ended December312023 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ForTheYearEndedDecember312023Abstract" xlink:to="ppbt_ForTheYearEndedDecember312023Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PostemploymentBenefitLiabilitiesMember_lbl0" xml:lang="en-US">Postemployment Benefit Liabilities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PostemploymentBenefitLiabilitiesMember" xlink:to="ppbt_PostemploymentBenefitLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_SharesPrice_lbl1" xml:lang="en-US">Shares Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SharesPrice" xlink:to="ppbt_SharesPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_IntangibleAssetsRecoverableAmountPercentage_lbl1" xml:lang="en-US">Intangible Assets Recoverable Amount Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_IntangibleAssetsRecoverableAmountPercentage" xlink:to="ppbt_IntangibleAssetsRecoverableAmountPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in other operating payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of research and development expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ReceiptsOnAccountOfWarrantsMember_lbl0" xml:lang="en-US">Receipts On Account Of Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ReceiptsOnAccountOfWarrantsMember" xlink:to="ppbt_ReceiptsOnAccountOfWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DerivativeFinancialAssets_lbl0" xml:lang="en-US">Derivative financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativeFinancialAssets" xlink:to="ifrs-full_DerivativeFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_NonVotingSeniorPreferredShares_lbl1" xml:lang="en-US">Non Voting Senior Preferred Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NonVotingSeniorPreferredShares" xlink:to="ppbt_NonVotingSeniorPreferredShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="ppbt_ConsolidatedStatementsOfChangesInEquityAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ConsolidatedStatementsOfChangesInEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ConsolidatedStatementsOfChangesInEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements Of Changes In Equity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConsolidatedStatementsOfChangesInEquityAbstract" xlink:to="ppbt_ConsolidatedStatementsOfChangesInEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsPerShareAbstract_lbl0" xml:lang="en-US">Basic earnings per share [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsPerShareAbstract" xlink:to="ifrs-full_BasicEarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_EmployeeBenefitBonus_lbl1" xml:lang="en-US">Employee Benefit Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EmployeeBenefitBonus" xlink:to="ppbt_EmployeeBenefitBonus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreferenceSharesMember_lbl0" xml:lang="en-US">Preference shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreferenceSharesMember" xlink:to="ifrs-full_PreferenceSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ClassEPreferredSharesMember_lbl0" xml:lang="en-US">Class EPreferred Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ClassEPreferredSharesMember" xlink:to="ppbt_ClassEPreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_EmployeeBenefitsLiabilityDueGrants_lbl1" xml:lang="en-US">Employee Benefits Liability Due Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EmployeeBenefitsLiabilityDueGrants" xlink:to="ppbt_EmployeeBenefitsLiabilityDueGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Comprehensive income, attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_NumberOfIssuanceShares_lbl1" xml:lang="en-US">Number Of Issuance Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfIssuanceShares" xlink:to="ppbt_NumberOfIssuanceShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantsMember_lbl0" xml:lang="en-US">Warrants [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl0" xml:lang="en-US">Equity and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_GovernmentAuthorities_lbl1" xml:lang="en-US">Government Authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_GovernmentAuthorities" xlink:to="ppbt_GovernmentAuthorities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_WarrantTermDescription_lbl1" xml:lang="en-US">Warrant Term Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantTermDescription" xlink:to="ppbt_WarrantTermDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_AgreementLeaseAdditionalTerm_lbl1" xml:lang="en-US">Agreement Lease Additional Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AgreementLeaseAdditionalTerm" xlink:to="ppbt_AgreementLeaseAdditionalTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl0" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FundsRaisedAmount_lbl1" xml:lang="en-US">Funds Raised Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FundsRaisedAmount" xlink:to="ppbt_FundsRaisedAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ExercisePeriod_lbl1" xml:lang="en-US">Exercise Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ExercisePeriod" xlink:to="ppbt_ExercisePeriod_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl0" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl1" xml:lang="en-US">Professional fees expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_AdjustmentsForChangesInAssetsAndLiabilities_lbl1" xml:lang="en-US">Adjustments For Changes In Assets And Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AdjustmentsForChangesInAssetsAndLiabilities" xlink:to="ppbt_AdjustmentsForChangesInAssetsAndLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">Selling, general and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OtherCurrencyMember_lbl0" xml:lang="en-US">Other Currency [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OtherCurrencyMember" xlink:to="srt_OtherCurrencyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PercentageOfDiscountsForLacksOfMarketability_lbl1" xml:lang="en-US">Percentage Of Discounts For Lacks Of Marketability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfDiscountsForLacksOfMarketability" xlink:to="ppbt_PercentageOfDiscountsForLacksOfMarketability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_UnrecognizedResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US">Unrecognized Research And Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_UnrecognizedResearchAndDevelopmentExpenses" xlink:to="ppbt_UnrecognizedResearchAndDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentGovernmentGrants_lbl0" xml:lang="en-US">Current government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentGovernmentGrants" xlink:to="ifrs-full_CurrentGovernmentGrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_OptionsAndRSUsMember_lbl0" xml:lang="en-US">Options And RSUs Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OptionsAndRSUsMember" xlink:to="ppbt_OptionsAndRSUsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfConvertibleInstruments_lbl0" xml:lang="en-US">Issue of convertible instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ifrs-full_IssueOfConvertibleInstruments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest_lbl1" xml:lang="en-US">Capital Reserve From Transactions With Non- Controlling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest" xlink:to="ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember_lbl0" xml:lang="en-US">Capital Reserve From Transactions With Related Parties Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember" xlink:to="ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DisclosureOfOtherCurrentAssettextBlock_lbl1" xml:lang="en-US">Disclosure Of Other Current Assettext Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfOtherCurrentAssettextBlock" xlink:to="ppbt_DisclosureOfOtherCurrentAssettextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl2" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DownRangeOneMember_lbl0" xml:lang="en-US">Down Range One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DownRangeOneMember" xlink:to="ppbt_DownRangeOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInvestments_lbl1" xml:lang="en-US">Current investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl1" xml:lang="en-US">Risk free interest rate, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_AggregateWarrantsShares_lbl1" xml:lang="en-US">Aggregate Warrants Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AggregateWarrantsShares" xlink:to="ppbt_AggregateWarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DepositaryShares_lbl1" xml:lang="en-US">Depositary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DepositaryShares" xlink:to="ppbt_DepositaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl0" xml:lang="en-US">Share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CurrentAsset_lbl1" xml:lang="en-US">Current Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CurrentAsset" xlink:to="ppbt_CurrentAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl0" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantLiability_lbl0" xml:lang="en-US">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0" xml:lang="en-US">Reserve of share-based payments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_NumberOfPerShare_lbl1" xml:lang="en-US">Number Of Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_NumberOfPerShare" xlink:to="ppbt_NumberOfPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl0" xml:lang="en-US">United States of America, Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_UpRangeOneMember_lbl0" xml:lang="en-US">Up Range One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_UpRangeOneMember" xlink:to="ppbt_UpRangeOneMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfDetailsRegardingFairValueMeasurementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementAbstract_lbl" xml:lang="en-US">Schedule Of Details Regarding Fair Value Measurement Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementAbstract" xlink:to="ppbt_ScheduleOfDetailsRegardingFairValueMeasurementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl0" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl1" xml:lang="en-US">Disclosure of effect of changes in foreign exchange rates [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Employee Benefits Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl0" xml:lang="en-US">Borrowings, interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FunctionalCurrency_lbl1" xml:lang="en-US">Functional Currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FunctionalCurrency" xlink:to="ppbt_FunctionalCurrency_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_YissumsLicensedTechnologyMember_lbl1" xml:lang="en-US">Yissums Licensed Technology Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_YissumsLicensedTechnologyMember" xlink:to="ppbt_YissumsLicensedTechnologyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract_lbl0" xml:lang="en-US">Items That Will Be Transferred To Profit Or Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract" xlink:to="ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl0" xml:lang="en-US">Profit (loss), attributable to [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DescriptionOfOptionLifeShareOptionGranted_lbl1" xml:lang="en-US">Description Of Option Life Share Option Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DescriptionOfOptionLifeShareOptionGranted" xlink:to="ppbt_DescriptionOfOptionLifeShareOptionGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ShortTermDepositsGuaranteedForHedgingTransactions_lbl1" xml:lang="en-US">Short Term Deposits Guaranteed For Hedging Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ShortTermDepositsGuaranteedForHedgingTransactions" xlink:to="ppbt_ShortTermDepositsGuaranteedForHedgingTransactions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_OtherPayablesMember_lbl1" xml:lang="en-US">Other Payables Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OtherPayablesMember" xlink:to="ppbt_OtherPayablesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl0" xml:lang="en-US">Payments for share issue costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FairValueMeasurementIssuanceProceed_lbl1" xml:lang="en-US">Fair Value Measurement Issuance Proceed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementIssuanceProceed" xlink:to="ppbt_FairValueMeasurementIssuanceProceed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl0" xml:lang="en-US">Issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl0" xml:lang="en-US">Disclosure of finance cost [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfAssumptionsWereUsedAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfAssumptionsWereUsedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfAssumptionsWereUsedAbstract_lbl" xml:lang="en-US">Schedule Of Assumptions Were Used Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfAssumptionsWereUsedAbstract" xlink:to="ppbt_ScheduleOfAssumptionsWereUsedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseReceivablesMember_lbl0" xml:lang="en-US">Lease receivables [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseReceivablesMember" xlink:to="ifrs-full_LeaseReceivablesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DiagnosticProductsMember_lbl0" xml:lang="en-US">Diagnostic Products Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DiagnosticProductsMember" xlink:to="ppbt_DiagnosticProductsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl1" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl0" xml:lang="en-US">Equity attributable to owners of parent [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ForeignExchangeLoss_lbl0" xml:lang="en-US">Foreign exchange loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeLoss" xlink:to="ifrs-full_ForeignExchangeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl0" xml:lang="en-US">Other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl1" xml:lang="en-US">Short-term deposits, classified as cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl0" xml:lang="en-US">Number of shares authorised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantReserve_lbl0" xml:lang="en-US">Warrant reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantReserve" xlink:to="ifrs-full_WarrantReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_SalesAgreementShares_lbl1" xml:lang="en-US">Sales Agreement Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_SalesAgreementShares" xlink:to="ppbt_SalesAgreementShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_TransactionsWithOwnersOfTheCompanyAbstract_lbl0" xml:lang="en-US">Transactions With Owners Of The Company Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TransactionsWithOwnersOfTheCompanyAbstract" xlink:to="ppbt_TransactionsWithOwnersOfTheCompanyAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl3" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_BoardOfDirectorsMember_lbl0" xml:lang="en-US">Board Of Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_BoardOfDirectorsMember" xlink:to="ppbt_BoardOfDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_WarrantExercisePricePerShare_lbl1" xml:lang="en-US">Warrant Exercise Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_WarrantExercisePricePerShare" xlink:to="ppbt_WarrantExercisePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl0" xml:lang="en-US">Additions to right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ConvertibleWarrants_lbl1" xml:lang="en-US">Convertible Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConvertibleWarrants" xlink:to="ppbt_ConvertibleWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl0" xml:lang="en-US">Diluted earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_lbl0" xml:lang="en-US">Current payables to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_CurrentTerms_lbl0" xml:lang="en-US">Current Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_CurrentTerms" xlink:to="ppbt_CurrentTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ReceiptsOnAccountsOfWarrant_lbl1" xml:lang="en-US">Receipts On Accounts Of Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ReceiptsOnAccountsOfWarrant" xlink:to="ppbt_ReceiptsOnAccountsOfWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl1" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl1"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfShareCapitalAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfShareCapitalAbstract_lbl" xml:lang="en-US">Schedule Of Share Capital Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfShareCapitalAbstract" xlink:to="ppbt_ScheduleOfShareCapitalAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl1" xml:lang="en-US">Intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl0" xml:lang="en-US">Percentage of entity&apos;s revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfEntitysRevenue" xlink:to="ifrs-full_PercentageOfEntitysRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FairValueMeasurementExercise_lbl1" xml:lang="en-US">Fair Value Measurement Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FairValueMeasurementExercise" xlink:to="ppbt_FairValueMeasurementExercise_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl0" xml:lang="en-US">Proceeds from issuing shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Research And Development Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock" xlink:to="ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ADSMember_lbl0" xml:lang="en-US">ADSMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ADSMember" xlink:to="ppbt_ADSMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_AgreementLeaseTerm_lbl1" xml:lang="en-US">Agreement Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_AgreementLeaseTerm" xlink:to="ppbt_AgreementLeaseTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Maturity Analysis Of The Companys Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract" xlink:to="ppbt_ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_PercentageOfExchangeRate_lbl1" xml:lang="en-US">Percentage Of Exchange Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_PercentageOfExchangeRate" xlink:to="ppbt_PercentageOfExchangeRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsOnChangeInFairValueOfDerivatives_lbl0" xml:lang="en-US">Gains on change in fair value of derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_GainsOnChangeInFairValueOfDerivatives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ShareBasedPaymentArrangementsMember_lbl0" xml:lang="en-US">Share Based Payment Arrangements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ShareBasedPaymentArrangementsMember" xlink:to="ppbt_ShareBasedPaymentArrangementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OperatingExpense_lbl0" xml:lang="en-US">Operating expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsOnLitigationSettlements_lbl0" xml:lang="en-US">Gains on litigation settlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsOnLitigationSettlements" xlink:to="ifrs-full_GainsOnLitigationSettlements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_EffectiveTaxRate_lbl1" xml:lang="en-US">Effective Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_EffectiveTaxRate" xlink:to="ppbt_EffectiveTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_TerminationExercisePrice_lbl1" xml:lang="en-US">Termination Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_TerminationExercisePrice" xlink:to="ppbt_TerminationExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 3 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl1" xml:lang="en-US">Profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfFinanceExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfFinanceExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfFinanceExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Finance Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfFinanceExpensesAbstract" xlink:to="ppbt_ScheduleOfFinanceExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ConvertiblesWarrants_lbl1" xml:lang="en-US">Convertibles Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConvertiblesWarrants" xlink:to="ppbt_ConvertiblesWarrants_lbl1"/>
    <loc xlink:type="locator" xlink:label="ppbt_ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfResearchAndDevelopmentExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ScheduleOfResearchAndDevelopmentExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Research And Development Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:to="ppbt_ScheduleOfResearchAndDevelopmentExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares_lbl0" xml:lang="en-US">Dilutive effect of warrants on weighted average number of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_OrdinaryShareMember_lbl0" xml:lang="en-US">Ordinary Share Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_OrdinaryShareMember" xlink:to="ppbt_OrdinaryShareMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ResearchAndDevelopmentExpensesMember_lbl0" xml:lang="en-US">Research And Development Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ResearchAndDevelopmentExpensesMember" xlink:to="ppbt_ResearchAndDevelopmentExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Noncontrolling Interests Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock" xlink:to="ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RentalExpense_lbl0" xml:lang="en-US">Rental expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalExpense" xlink:to="ifrs-full_RentalExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestrictedShareUnitsMember_lbl2" xml:lang="en-US">Restricted share units [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedShareUnitsMember" xlink:to="ifrs-full_RestrictedShareUnitsMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory_lbl0" xml:lang="en-US">Disclosure of additional information about leasing activities for lessor [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for intangible assets and goodwill [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl0" xml:lang="en-US">Issue of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl2" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of general and administrative expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ConvertibleNoteMember_lbl0" xml:lang="en-US">Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConvertibleNoteMember" xlink:to="ppbt_ConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinancialAssetAndLiabilitiesAbstract0_lbl0" xml:lang="en-US">Financial Asset And Liabilities Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialAssetAndLiabilitiesAbstract0" xlink:to="ppbt_FinancialAssetAndLiabilitiesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Disclosure of employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1" xml:lang="en-US">Exercise price, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl0" xml:lang="en-US">Short-term employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncomeCost_lbl0" xml:lang="en-US">Finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_BiopharmaceuticalProductMember_lbl0" xml:lang="en-US">Biopharmaceutical Product Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_BiopharmaceuticalProductMember" xlink:to="ppbt_BiopharmaceuticalProductMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_VestingPeriod_lbl1" xml:lang="en-US">Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_VestingPeriod" xlink:to="ppbt_VestingPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl0" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReceivables_lbl0" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0" xml:lang="en-US">Disclosure of information about key management personnel [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl0" xml:lang="en-US">Gains (losses) on change in fair value of derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_lbl0" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherExpenseByNature_lbl1" xml:lang="en-US">Other expenses, by nature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOptionsMember_lbl0" xml:lang="en-US">Share options [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOptionsMember" xlink:to="ifrs-full_ShareOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_ConvertibleDebtInstrumentMember_lbl0" xml:lang="en-US">Convertible Debt Instrument Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_ConvertibleDebtInstrumentMember" xlink:to="ppbt_ConvertibleDebtInstrumentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinancialAssetAtAFairValue_lbl1" xml:lang="en-US">Financial Asset At AFair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinancialAssetAtAFairValue" xlink:to="ppbt_FinancialAssetAtAFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 2 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl2" xml:lang="en-US">Number of share options granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Equity attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ppbt_FinanceIncomeAbstract_lbl0" xml:lang="en-US">Finance Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ppbt_FinanceIncomeAbstract" xlink:to="ppbt_FinanceIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for provisions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0" xml:lang="en-US">Number of shares issued and fully paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetAssetsLiabilities_lbl0" xml:lang="en-US">Assets (liabilities)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_NetAssetsLiabilities_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>ppbt-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 10 16:44:15 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ConsolidatedBalanceSheet" roleURI="http://Purplebiotech.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" roleURI="http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ShareholdersEquityType2or3" roleURI="http://Purplebiotech.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ConsolidatedCashFlow" roleURI="http://Purplebiotech.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_General" roleURI="http://Purplebiotech.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_BasisofPreparationoftheConsolidatedFinancialStatements" roleURI="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_MaterialAccountingPolicies" roleURI="http://Purplebiotech.com/role/MaterialAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_IntangibleAssets" roleURI="http://Purplebiotech.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_CashandCashEquivalents" roleURI="http://Purplebiotech.com/role/CashandCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_Leases" roleURI="http://Purplebiotech.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_OtherCurrentAssets" roleURI="http://Purplebiotech.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_OtherPayables" roleURI="http://Purplebiotech.com/role/OtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_Equity" roleURI="http://Purplebiotech.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ShareBasedPaymentArrangements" roleURI="http://Purplebiotech.com/role/ShareBasedPaymentArrangements"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_TransactionsandBalanceswithRelatedParties" roleURI="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_CommitmentsandContingentLiabilities" roleURI="http://Purplebiotech.com/role/CommitmentsandContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ResearchandDevelopmentExpenses" roleURI="http://Purplebiotech.com/role/ResearchandDevelopmentExpenses"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_SalesGeneralandAdministrativeExpenses" roleURI="http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_FinanceExpenseIncomeNet" roleURI="http://Purplebiotech.com/role/FinanceExpenseIncomeNet"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_TaxesonIncome" roleURI="http://Purplebiotech.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_EmployeeBenefits" roleURI="http://Purplebiotech.com/role/EmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_FinancialInstruments" roleURI="http://Purplebiotech.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_SubsequentEvents" roleURI="http://Purplebiotech.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_AccountingPoliciesByPolicy" roleURI="http://Purplebiotech.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_BasisofPreparationoftheConsolidatedFinancialStatementsTables" roleURI="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_IntangibleAssetsTables" roleURI="http://Purplebiotech.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_CashandCashEquivalentsTables" roleURI="http://Purplebiotech.com/role/CashandCashEquivalentsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_LeasesTables" roleURI="http://Purplebiotech.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_OtherCurrentAssetsTables" roleURI="http://Purplebiotech.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_OtherPayablesTables" roleURI="http://Purplebiotech.com/role/OtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_EquityTables" roleURI="http://Purplebiotech.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ShareBasedPaymentArrangementsTables" roleURI="http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ResearchandDevelopmentExpensesTables" roleURI="http://Purplebiotech.com/role/ResearchandDevelopmentExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_SalesGeneralandAdministrativeExpensesTables" roleURI="http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_FinanceExpenseIncomeNetTables" roleURI="http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_EmployeeBenefitsTables" roleURI="http://Purplebiotech.com/role/EmployeeBenefitsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_FinancialInstrumentsTables" roleURI="http://Purplebiotech.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofDataonExchangeRatesTable" roleURI="http://Purplebiotech.com/role/ScheduleofDataonExchangeRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofIntangibleAssetsTable" roleURI="http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable" roleURI="http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofCashandCashEquivalentsTable" roleURI="http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofCarryingAmountsofRighttoUseAssetsTable" roleURI="http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable" roleURI="http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofAmountsRecognizedinProfitorLossTable" roleURI="http://Purplebiotech.com/role/ScheduleofAmountsRecognizedinProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofOtherPayablesTable" roleURI="http://Purplebiotech.com/role/ScheduleofOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofShareCapitalTable" roleURI="http://Purplebiotech.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofChangesinShareCapitalTable" roleURI="http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleoftheInformationRelatingtoNonControllingInterestsTable" roleURI="http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable" roleURI="http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofNumberofRSUsTable" roleURI="http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofAssumptionswereUsedTable" roleURI="http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable" roleURI="http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofRecordedExpensesTable" roleURI="http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofSalesGeneralandAdministrativeExpensesTable" roleURI="http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofFinanceExpensesTable" roleURI="http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofFinanceIncomeTable" roleURI="http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofPostEmployeeBenefitsTable" roleURI="http://Purplebiotech.com/role/ScheduleofPostEmployeeBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofDefinedContributionPlaninRespectofitsEmployeesTable" roleURI="http://Purplebiotech.com/role/ScheduleofDefinedContributionPlaninRespectofitsEmployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" roleURI="http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofFinancialInstrumentsMeasuredatFairValueTable" roleURI="http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofDetailsRegardingFairValueMeasurementTable" roleURI="http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ScheduleofFairValueMeasurementTable" roleURI="http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_GeneralDetails" roleURI="http://Purplebiotech.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_BasisofPreparationoftheConsolidatedFinancialStatementsDetails" roleURI="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_MaterialAccountingPoliciesDetails" roleURI="http://Purplebiotech.com/role/MaterialAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_IntangibleAssetsDetails" roleURI="http://Purplebiotech.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_LeasesDetails" roleURI="http://Purplebiotech.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_EquityDetails" roleURI="http://Purplebiotech.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_ShareBasedPaymentArrangementsDetails" roleURI="http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_CommitmentsandContingentLiabilitiesDetails" roleURI="http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_FinanceExpenseIncomeNetDetails" roleURI="http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_TaxesonIncomeDetails" roleURI="http://Purplebiotech.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_EmployeeBenefitsDetails" roleURI="http://Purplebiotech.com/role/EmployeeBenefitsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_FinancialInstrumentsDetails" roleURI="http://Purplebiotech.com/role/FinancialInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ppbt-20241231.xsd#ppbt_r_SubsequentEventsDetails" roleURI="http://Purplebiotech.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_CurrentInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_RightofuseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_LiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentWarrantLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentPayables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_SharePremium" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceiptsOnAccountsOfWarrant" xlink:href="ppbt-20241231.xsd#ppbt_ReceiptsOnAccountsOfWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ReceiptsOnAccountsOfWarrant" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_CapitalReserve" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherReserves" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalReserveFromTransactionsWithNon-ControllingInterest" xlink:href="ppbt-20241231.xsd#ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="CapitalReserveFromTransactionsWithNon-ControllingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_NoncontrollingInterests" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_Equity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ImpairmentLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OperatingExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncomeCost" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ItemsThatWillBeTransferredToProfitOrLossAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ItemsThatWillBeTransferredToProfitOrLossAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ItemsThatWillBeTransferredToProfitOrLossAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ItemsThatWillBeTransferredToProfitOrLossAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLoss_0" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncome_0" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsPerShareAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BasicEarningsPerShareAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BasicEarningsPerShareAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BasicEarningsPerShareAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BasicEarningsPerShareAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsOfChangesInEquityAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ConsolidatedStatementsOfChangesInEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_IssuedCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_SharePremiumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceiptsOnAccountOfWarrantsMember" xlink:href="ppbt-20241231.xsd#ppbt_ReceiptsOnAccountOfWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ReceiptsOnAccountOfWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfCashFlowHedgesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfCashFlowHedgesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfCashFlowHedgesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalReserveFromTransactionsWithRelatedPartiesMember" xlink:href="ppbt-20241231.xsd#ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="CapitalReserveFromTransactionsWithRelatedPartiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalReserveFromTransactionsWithNonControllingInterestMember" xlink:href="ppbt-20241231.xsd#ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="CapitalReserveFromTransactionsWithNonControllingInterestMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_RetainedEarningsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="10.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncome" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesInAssetsAndLiabilitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ChangesInAssetsAndLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ChangesInAssetsAndLiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForChangesInAssetsAndLiabilities" xlink:href="ppbt-20241231.xsd#ppbt_AdjustmentsForChangesInAssetsAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="AdjustmentsForChangesInAssetsAndLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromInvestingActivitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_CashFlowsFromInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="CashFlowsFromInvestingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashAssumedAsPartOfAcquisitionOfFamewave" xlink:href="ppbt-20241231.xsd#ppbt_CashAssumedAsPartOfAcquisitionOfFamewave"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="CashAssumedAsPartOfAcquisitionOfFamewave" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="Decreaseincreaseinshorttermdeposits" xlink:href="ppbt-20241231.xsd#ppbt_Decreaseincreaseinshorttermdeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="Decreaseincreaseinshorttermdeposits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInLongTermDeposits" xlink:href="ppbt-20241231.xsd#ppbt_IncreaseDecreaseInLongTermDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="IncreaseDecreaseInLongTermDeposits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromFinancingActivitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_CashFlowsFromFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="CashFlowsFromFinancingActivitiesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsForShareIssueCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuingWarrants" xlink:href="ppbt-20241231.xsd#ppbt_ProceedsFromIssuingWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuingWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssuanceExpensesPaid" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsIssuanceExpensesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="WarrantsIssuanceExpensesPaid" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/General" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="GeneralAbstract" xlink:href="ppbt-20241231.xsd#ppbt_GeneralAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/MaterialAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/IntangibleAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/CashandCashEquivalents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/OtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/OtherPayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ShareBasedPaymentArrangements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/CommitmentsandContingentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CommitmentsAndContingentLiabilitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_CommitmentsAndContingentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingentLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ResearchandDevelopmentExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ResearchAndDevelopmentExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/FinanceExpenseIncomeNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="FinanceExpenseIncomeNetAbstract" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpenseIncomeNetAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/TaxesonIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="TaxesOnIncomeabstract" xlink:href="ppbt-20241231.xsd#ppbt_TaxesOnIncomeabstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesOnIncomeabstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/EmployeeBenefits" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/FinancialInstruments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/IntangibleAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsTablesTable" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsTablesTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsTablesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="IntangibleAssetsTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsTablesTable" xlink:to="IntangibleAssetsTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsTablesLineItems" xlink:to="ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsTablesLineItems" xlink:to="ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/CashandCashEquivalentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/OtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherCurrentAssettextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfOtherCurrentAssettextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:to="DisclosureOfOtherCurrentAssettextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/OtherPayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:href="ppbt-20241231.xsd#ppbt_TransactionsandBalanceswithRelatedPartiesTablesTable"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:to="TransactionsandBalanceswithRelatedPartiesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ResearchandDevelopmentExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ResearchAndDevelopmentExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfResearchAndDevelopmentExpensesTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="DisclosureOfResearchAndDevelopmentExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="FinanceExpenseIncomeNetAbstract" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetAbstract"/>
    <loc xlink:type="locator" xlink:label="FinanceExpenseIncomeNetTablesTable" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetTablesTable"/>
    <loc xlink:type="locator" xlink:label="FinanceExpenseIncomeNetTablesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpenseIncomeNetAbstract" xlink:to="FinanceExpenseIncomeNetTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpenseIncomeNetTablesTable" xlink:to="FinanceExpenseIncomeNetTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpenseIncomeNetTablesLineItems" xlink:to="ifrs-full_DisclosureOfFinanceCostExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpenseIncomeNetTablesLineItems" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/EmployeeBenefitsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsTablesTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsTablesTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsTablesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="FinancialInstrumentsTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsTablesTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrencyRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrencyRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_CurrencyRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsTablesTable" xlink:to="FinancialInstrumentsTablesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsTablesLineItems" xlink:to="ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofDataonExchangeRatesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeRatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ForeignExchangeRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AverageForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ForeignExchangeRatesAbstract" xlink:to="ifrs-full_AverageForeignExchangeRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfExchangeRate" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfExchangeRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ForeignExchangeRatesAbstract" xlink:to="PercentageOfExchangeRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsScheduleofIntangibleAssetsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsScheduleofIntangibleAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="IntangibleAssetsScheduleofIntangibleAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsScheduleofIntangibleAssetsDetailsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="IPRDRelatedToTryNovosee5ABelowMember" xlink:href="ppbt-20241231.xsd#ppbt_IPRDRelatedToTryNovosee5ABelowMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="IPRDRelatedToTryNovosee5ABelowMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IPRDRelatedToFamewaveSee5BBelowMember" xlink:href="ppbt-20241231.xsd#ppbt_IPRDRelatedToFamewaveSee5BBelowMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="IPRDRelatedToFamewaveSee5BBelowMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IPRDRelatedToImmunorizonSee5CBelowMember" xlink:href="ppbt-20241231.xsd#ppbt_IPRDRelatedToImmunorizonSee5CBelowMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="IPRDRelatedToImmunorizonSee5CBelowMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IPRDRelatedToPurpleGmbHMember" xlink:href="ppbt-20241231.xsd#ppbt_IPRDRelatedToPurpleGmbHMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="IPRDRelatedToPurpleGmbHMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsScheduleofIntangibleAssetsDetailsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRecognizedAmountsOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfRecognizedAmountsOfAssetsAcquiredAndLiabilitiesAssumedAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRecognizedAmountsOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable" xlink:to="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ifrs-full_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ifrs-full_OtherIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ifrs-full_OtherReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ifrs-full_OtherPayables" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashAndCashEquivalentsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfCashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CashAndCashEquivalentLineItems" xlink:href="ppbt-20241231.xsd#ppbt_CashAndCashEquivalentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAndCashEquivalentsAbstract" xlink:to="CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable" xlink:to="srt_CurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_USD" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OtherCurrencyMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OtherCurrencyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="srt_OtherCurrencyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable" xlink:to="CashAndCashEquivalentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract" xlink:to="LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseReceivablesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseReceivablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_LeaseReceivablesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_RightofuseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_RightofuseAssets_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract" xlink:to="LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable" xlink:to="ifrs-full_MaturityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofAmountsRecognizedinProfitorLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="GovernmentAuthorities" xlink:href="ppbt-20241231.xsd#ppbt_GovernmentAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="GovernmentAuthorities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_CurrentGovernmentGrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalaryRelatedOtherPayablesCurrent" xlink:href="ppbt-20241231.xsd#ppbt_SalaryRelatedOtherPayablesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="SalaryRelatedOtherPayablesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_OtherCurrentPayables" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareCapitalAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityScheduleofShareCapitalDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_EquityScheduleofShareCapitalDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalAbstract" xlink:to="EquityScheduleofShareCapitalDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ClassesOfPreferredSharesAxis" xlink:href="ppbt-20241231.xsd#ppbt_ClassesOfPreferredSharesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofShareCapitalDetailsTable" xlink:to="ClassesOfPreferredSharesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShareMember" xlink:href="ppbt-20241231.xsd#ppbt_OrdinaryShareMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfPreferredSharesAxis" xlink:to="OrdinaryShareMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredShareClassMember" xlink:href="ppbt-20241231.xsd#ppbt_PreferredShareClassMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfPreferredSharesAxis" xlink:to="PreferredShareClassMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredShareClassBMember" xlink:href="ppbt-20241231.xsd#ppbt_PreferredShareClassBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfPreferredSharesAxis" xlink:to="PreferredShareClassBMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredClassCMember" xlink:href="ppbt-20241231.xsd#ppbt_PreferredClassCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfPreferredSharesAxis" xlink:to="PreferredClassCMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredClassDMember" xlink:href="ppbt-20241231.xsd#ppbt_PreferredClassDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfPreferredSharesAxis" xlink:to="PreferredClassDMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassEPreferredSharesMember" xlink:href="ppbt-20241231.xsd#ppbt_ClassEPreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfPreferredSharesAxis" xlink:to="ClassEPreferredSharesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofShareCapitalDetailsTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfIssuanceShares" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfIssuanceShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="NumberOfIssuanceShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfVestingOfRsus" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfVestingOfRsus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="NumberOfVestingOfRsus" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfExerciseOfWarrants" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="NumberOfExerciseOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentAsset" xlink:href="ppbt-20241231.xsd#ppbt_CurrentAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="CurrentAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentLiabiliti" xlink:href="ppbt-20241231.xsd#ppbt_CurrentLiabiliti"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="CurrentLiabiliti" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract" xlink:to="ifrs-full_NetAssetsLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetAssetsAttributableToNoncontrollingInterest" xlink:href="ppbt-20241231.xsd#ppbt_NetAssetsAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="NetAssetsAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetAssetsAttributableToNoncontrollingInterests" xlink:href="ppbt-20241231.xsd#ppbt_NetAssetsAttributableToNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="NetAssetsAttributableToNoncontrollingInterests" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNumberOfRSUsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfNumberOfRSUsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNumberOfRSUsAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNumberOfRSUsAbstract" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNumberOfRSUsAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNumberOfRSUsAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNumberOfRSUsAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssumptionsWereUsedAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfAssumptionsWereUsedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAssumptionsWereUsedLineItems" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfAssumptionsWereUsedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssumptionsWereUsedAbstract" xlink:to="ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable" xlink:to="ifrs-full_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZ7uO1Q1bYM5N9HuAVhCBKc3Dilxy5HOYIdYl1h0YHGyqqhp5yL2C/pvkGqpTQ7NfV8dDJWElNwr7uGWGMl/FOCtmi0tB2eTtzKmmQ0hcQ60BPTfIvmWs+j5xoLJ2ifHK3Qzc5tu1CRRSrKp5kfOFheAU8ndp9+zFyGXNaa6jOMefzDkABcY69jtuMijqkJ3ohuLKcwkZmZewn4yToUYFOOphhxC2BFvS9v+Az2mWKre6bpwvKpYewS] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable" xlink:to="ScheduleOfAssumptionsWereUsedLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssumptionsWereUsedLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract" xlink:to="ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpensesMember" xlink:href="ppbt-20241231.xsd#ppbt_ResearchAndDevelopmentExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ResearchAndDevelopmentExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRecordedExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfRecordedExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRecordedExpensesAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfResearchAndDevelopmentExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems" xlink:href="ppbt-20241231.xsd#ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:to="ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SalariesWagesAndRelatedExpensesMember" xlink:href="ppbt-20241231.xsd#ppbt_SalariesWagesAndRelatedExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="SalariesWagesAndRelatedExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsMember" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ShareBasedPaymentsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServiceProvidersMember" xlink:href="ppbt-20241231.xsd#ppbt_ServiceProvidersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ServiceProvidersMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable" xlink:to="ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract" xlink:to="SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable" xlink:to="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WagesAndSalaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_WagesAndSalaries" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReimbursementOfLegalFeesExpense" xlink:href="ppbt-20241231.xsd#ppbt_ReimbursementOfLegalFeesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ReimbursementOfLegalFeesExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfessionalFeesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_ProfessionalFeesExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DirectorsRemunerationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_DirectorsRemunerationExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RentalExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RentalExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_RentalExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TravelExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_TravelExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_DepreciationExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpensesOther" xlink:href="ppbt-20241231.xsd#ppbt_GeneralAndAdministrativeExpensesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="GeneralAndAdministrativeExpensesOther" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinanceExpensesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfFinanceExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceExpensesAbstract" xlink:to="ifrs-full_FeeAndCommissionExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ForeignExchangeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceExpensesAbstract" xlink:to="ifrs-full_ForeignExchangeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceExpenses" xlink:href="ppbt-20241231.xsd#ppbt_IssuanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceExpensesAbstract" xlink:to="IssuanceExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherfinancialCost" xlink:href="ppbt-20241231.xsd#ppbt_OtherfinancialCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceExpensesAbstract" xlink:to="OtherfinancialCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherExpenseByNature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceExpensesAbstract" xlink:to="ifrs-full_OtherExpenseByNature" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinanceIncomeAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfFinanceIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeAbstract" xlink:href="ppbt-20241231.xsd#ppbt_FinanceIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceIncomeAbstract" xlink:to="FinanceIncomeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="ifrs-full_InterestIncomeOnDeposits" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeGain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ForeignExchangeGain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="ifrs-full_ForeignExchangeGain" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="ifrs-full_GainsOnChangeInFairValueOfDerivatives" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="OtherExpense" xlink:href="ppbt-20241231.xsd#ppbt_OtherExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="OtherExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="ifrs-full_OtherFinanceIncome" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofPostEmployeeBenefitsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPostEmployeeBenefitsAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfPostEmployeeBenefitsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPostEmployeeBenefitsAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPostEmployeeBenefitsAbstract" xlink:to="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofDefinedContributionPlaninRespectofitsEmployeesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract" xlink:to="FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EUROMember" xlink:href="ppbt-20241231.xsd#ppbt_EUROMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="EUROMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NISMember" xlink:href="ppbt-20241231.xsd#ppbt_NISMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="NISMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" xlink:to="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CashAndCashEquivalentsAndDepositsMember" xlink:href="ppbt-20241231.xsd#ppbt_CashAndCashEquivalentsAndDepositsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="CashAndCashEquivalentsAndDepositsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherCurrentAssetMember" xlink:href="ppbt-20241231.xsd#ppbt_OtherCurrentAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="OtherCurrentAssetMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountPayablesMember" xlink:href="ppbt-20241231.xsd#ppbt_AccountPayablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="AccountPayablesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherPayablesMember" xlink:href="ppbt-20241231.xsd#ppbt_OtherPayablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="OtherPayablesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PostemploymentBenefitLiabilitiesMember" xlink:href="ppbt-20241231.xsd#ppbt_PostemploymentBenefitLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="PostemploymentBenefitLiabilitiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" xlink:to="ifrs-full_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DownRangeOneMember" xlink:href="ppbt-20241231.xsd#ppbt_DownRangeOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="DownRangeOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="UpRangeOneMember" xlink:href="ppbt-20241231.xsd#ppbt_UpRangeOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="UpRangeOneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncomelossFromChangeInExchangeRateDown" xlink:href="ppbt-20241231.xsd#ppbt_IncomelossFromChangeInExchangeRateDown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="IncomelossFromChangeInExchangeRateDown" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomelossValue" xlink:href="ppbt-20241231.xsd#ppbt_IncomelossValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="IncomelossValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomelossFromChangeInExchangeRateUp" xlink:href="ppbt-20241231.xsd#ppbt_IncomelossFromChangeInExchangeRateUp"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="IncomelossFromChangeInExchangeRateUp" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract" xlink:to="FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialAssetAndLiabilitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_FinancialAssetAndLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="FinancialAssetAndLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Securities" xlink:href="ppbt-20241231.xsd#ppbt_Securities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetAndLiabilitiesAbstract" xlink:to="Securities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DerivativeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetAndLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetAndLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDetailsRegardingFairValueMeasurementAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfDetailsRegardingFairValueMeasurementAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDetailsRegardingFairValueMeasurementAbstract" xlink:to="FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNoteMember" xlink:href="ppbt-20241231.xsd#ppbt_ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ConvertibleNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsoneMember" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsoneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="WarrantsoneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementBalance" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="FairValueMeasurementBalance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementExercise" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="FairValueMeasurementExercise" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementIssuance" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="FairValueMeasurementIssuance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementIssuanceProceed" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementIssuanceProceed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="FairValueMeasurementIssuanceProceed" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementRevaluation" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementRevaluation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="FairValueMeasurementRevaluation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementBalance_0" xlink:href="ppbt-20241231.xsd#ppbt_FairValueMeasurementBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="FairValueMeasurementBalance_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueMeasurementAbstract" xlink:href="ppbt-20241231.xsd#ppbt_ScheduleOfFairValueMeasurementAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueMeasurementAbstract" xlink:to="FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WarrantsoneMember" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsoneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="WarrantsoneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WarrantsoneMember_0" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsoneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="WarrantsoneMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleDebtInstrumentMember" xlink:href="ppbt-20241231.xsd#ppbt_ConvertibleDebtInstrumentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ConvertibleDebtInstrumentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfOptionLifeShareOptionGranted" xlink:href="ppbt-20241231.xsd#ppbt_DescriptionOfOptionLifeShareOptionGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="DescriptionOfOptionLifeShareOptionGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedDividendAsPercentageShareOptionsdividendYield" xlink:href="ppbt-20241231.xsd#ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ExpectedDividendAsPercentageShareOptionsdividendYield" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Discountforlackofmarketability" xlink:href="ppbt-20241231.xsd#ppbt_Discountforlackofmarketability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="Discountforlackofmarketability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForTheYearEndedDecember312023Abstract" xlink:href="ppbt-20241231.xsd#ppbt_ForTheYearEndedDecember312023Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ForTheYearEndedDecember312023Abstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/GeneralDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="GeneralAbstract" xlink:href="ppbt-20241231.xsd#ppbt_GeneralAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_GeneralDetailsTable"/>
    <loc xlink:type="locator" xlink:label="GeneralLineItems" xlink:href="ppbt-20241231.xsd#ppbt_GeneralLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAbstract" xlink:to="GeneralDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="GeneralLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AmericanDepositorySharesOrdinaryShares" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepositorySharesOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralLineItems" xlink:to="AmericanDepositorySharesOrdinaryShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockNoParValues" xlink:href="ppbt-20241231.xsd#ppbt_CommonStockNoParValues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralLineItems" xlink:to="CommonStockNoParValues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralLineItems" xlink:to="ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmericanDepositorySharesPurchase" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepositorySharesPurchase"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralLineItems" xlink:to="AmericanDepositorySharesPurchase" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfContractToAcquire" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfContractToAcquire"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralLineItems" xlink:to="PercentageOfContractToAcquire" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RetainedEarning" xlink:href="ppbt-20241231.xsd#ppbt_RetainedEarning"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralLineItems" xlink:to="RetainedEarning" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivateAndPublicFinancingTotal" xlink:href="ppbt-20241231.xsd#ppbt_PrivateAndPublicFinancingTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralLineItems" xlink:to="PrivateAndPublicFinancingTotal" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <loc xlink:type="locator" xlink:label="BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems" xlink:href="ppbt-20241231.xsd#ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_ShareOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable" xlink:to="BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FunctionalCurrency" xlink:href="ppbt-20241231.xsd#ppbt_FunctionalCurrency"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems" xlink:to="FunctionalCurrency" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionExercisedPeriod" xlink:href="ppbt-20241231.xsd#ppbt_StockOptionExercisedPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems" xlink:to="StockOptionExercisedPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/MaterialAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfShare" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="NumberOfShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfPerShare" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="NumberOfPerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepreciationRightofuseAssetsUsefulLife" xlink:href="ppbt-20241231.xsd#ppbt_DepreciationRightofuseAssetsUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DepreciationRightofuseAssetsUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/IntangibleAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsLineItems" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="IntangibleAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AdsMember" xlink:href="ppbt-20241231.xsd#ppbt_AdsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="AdsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="IntangibleAssetsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentsOwnershipPercentage" xlink:href="ppbt-20241231.xsd#ppbt_EquityMethodInvestmentsOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="EquityMethodInvestmentsOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateUpfrontPayment" xlink:href="ppbt-20241231.xsd#ppbt_AggregateUpfrontPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="AggregateUpfrontPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmericanDepositorySharesOrdinaryShares" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepositorySharesOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="AmericanDepositorySharesOrdinaryShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermMilestonesAggregateAmount" xlink:href="ppbt-20241231.xsd#ppbt_LongTermMilestonesAggregateAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="LongTermMilestonesAggregateAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalAcquisitionAmount" xlink:href="ppbt-20241231.xsd#ppbt_TotalAcquisitionAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="TotalAcquisitionAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfIssuedEquity" xlink:href="ppbt-20241231.xsd#ppbt_FairValueOfIssuedEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="FairValueOfIssuedEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfIssuedIntangibleAssets" xlink:href="ppbt-20241231.xsd#ppbt_FairValueOfIssuedIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="FairValueOfIssuedIntangibleAssets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateShareholdersOfImmunorizon" xlink:href="ppbt-20241231.xsd#ppbt_AggregateShareholdersOfImmunorizon"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="AggregateShareholdersOfImmunorizon" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesPrice" xlink:href="ppbt-20241231.xsd#ppbt_SharesPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="SharesPrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfExpectedVolatilityPercentage" xlink:href="ppbt-20241231.xsd#ppbt_DescriptionOfExpectedVolatilityPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="DescriptionOfExpectedVolatilityPercentage" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfExpectedAnnualRiskFreeRate" xlink:href="ppbt-20241231.xsd#ppbt_DescriptionOfExpectedAnnualRiskFreeRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="DescriptionOfExpectedAnnualRiskFreeRate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfDiscountsForLacksOfMarketability" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfDiscountsForLacksOfMarketability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="PercentageOfDiscountsForLacksOfMarketability" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsRecoverableAmountPercentage" xlink:href="ppbt-20241231.xsd#ppbt_IntangibleAssetsRecoverableAmountPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="IntangibleAssetsRecoverableAmountPercentage" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_LeasesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RehovotMember" xlink:href="ppbt-20241231.xsd#ppbt_RehovotMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="RehovotMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LeaseAgreementOneMember" xlink:href="ppbt-20241231.xsd#ppbt_LeaseAgreementOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="LeaseAgreementOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseAgreementsTwoMember" xlink:href="ppbt-20241231.xsd#ppbt_LeaseAgreementsTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="LeaseAgreementsTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="LeasesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AgreementLeaseTerm" xlink:href="ppbt-20241231.xsd#ppbt_AgreementLeaseTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesLineItems" xlink:to="AgreementLeaseTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementLeaseAdditionalTerm" xlink:href="ppbt-20241231.xsd#ppbt_AgreementLeaseAdditionalTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesLineItems" xlink:to="AgreementLeaseAdditionalTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentTerms" xlink:href="ppbt-20241231.xsd#ppbt_CurrentTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesLineItems" xlink:to="CurrentTerms" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityLineItems" xlink:href="ppbt-20241231.xsd#ppbt_EquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PublicOfferingMember" xlink:href="ppbt-20241231.xsd#ppbt_PublicOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="PublicOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreferenceSharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreferenceSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_PreferenceSharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATMProgramMember" xlink:href="ppbt-20241231.xsd#ppbt_ATMProgramMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ATMProgramMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AdsMember" xlink:href="ppbt-20241231.xsd#ppbt_AdsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="AdsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_WarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_RestrictedShareUnitsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AdsMember_0" xlink:href="ppbt-20241231.xsd#ppbt_AdsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="AdsMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementsMember" xlink:href="ppbt-20241231.xsd#ppbt_PrivatePlacementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="PrivatePlacementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicOfferingMember_0" xlink:href="ppbt-20241231.xsd#ppbt_PublicOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="PublicOfferingMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsMember" xlink:href="ppbt-20241231.xsd#ppbt_SubsequentEventsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="SubsequentEventsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="EquityLineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonVotingSeniorPreferredShares" xlink:href="ppbt-20241231.xsd#ppbt_NonVotingSeniorPreferredShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="NonVotingSeniorPreferredShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityReversesStockSplit" xlink:href="ppbt-20241231.xsd#ppbt_StockholdersEquityReversesStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="StockholdersEquityReversesStockSplit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseRatio" xlink:href="ppbt-20241231.xsd#ppbt_ReverseRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="ReverseRatio" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FundsRaisedAmount" xlink:href="ppbt-20241231.xsd#ppbt_FundsRaisedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="FundsRaisedAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfessionalFeesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="ifrs-full_ProfessionalFeesExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfNonTradableWarrants" xlink:href="ppbt-20241231.xsd#ppbt_NumberOfNonTradableWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="NumberOfNonTradableWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="ifrs-full_ParValuePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FundsRaisedshares" xlink:href="ppbt-20241231.xsd#ppbt_FundsRaisedshares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="FundsRaisedshares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsTerm" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="WarrantsTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="ifrs-full_WarrantReserve" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepositaryShares" xlink:href="ppbt-20241231.xsd#ppbt_DepositaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="DepositaryShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfCommonStockAndWarrants" xlink:href="ppbt-20241231.xsd#ppbt_PurchaseOfCommonStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="PurchaseOfCommonStockAndWarrants" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="ifrs-full_WarrantLiability" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssued" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="WarrantsIssued" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuesOfEquity" xlink:href="ppbt-20241231.xsd#ppbt_IssuesOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="IssuesOfEquity" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfWarrantsEquity" xlink:href="ppbt-20241231.xsd#ppbt_ExerciseOfWarrantsEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="ExerciseOfWarrantsEquity" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantTermDescription" xlink:href="ppbt-20241231.xsd#ppbt_WarrantTermDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="WarrantTermDescription" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherExpenseByNature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="ifrs-full_OtherExpenseByNature" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceContractsIssuedThatAreAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InsuranceContractsIssuedThatAreAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="ifrs-full_InsuranceContractsIssuedThatAreAssets" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalesAgreementShares" xlink:href="ppbt-20241231.xsd#ppbt_SalesAgreementShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="SalesAgreementShares" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePrice2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="noncontrollingInterests" xlink:href="ppbt-20241231.xsd#ppbt_noncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityLineItems" xlink:to="noncontrollingInterests" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentArrangementsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentArrangementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ShareBasedPaymentArrangementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AdsMember" xlink:href="ppbt-20241231.xsd#ppbt_AdsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="AdsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_RestrictedShareUnitsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_RestrictedShareUnitsMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BoardOfDirectorsMember" xlink:href="ppbt-20241231.xsd#ppbt_BoardOfDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="BoardOfDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementsDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentArrangementsMember" xlink:href="ppbt-20241231.xsd#ppbt_ShareBasedPaymentArrangementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ShareBasedPaymentArrangementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="srt_OfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementsDetailsTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionExerciseOrdinaryShare" xlink:href="ppbt-20241231.xsd#ppbt_OptionExerciseOrdinaryShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="OptionExerciseOrdinaryShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingPeriod" xlink:href="ppbt-20241231.xsd#ppbt_VestingPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="VestingPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePeriod" xlink:href="ppbt-20241231.xsd#ppbt_ExercisePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ExercisePeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultantPerShares" xlink:href="ppbt-20241231.xsd#ppbt_ConsultantPerShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ConsultantPerShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmericanDepostioryShares" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepostioryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="AmericanDepostioryShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleShares" xlink:href="ppbt-20241231.xsd#ppbt_ConvertibleShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ConvertibleShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCapacityOfAnAdvisor" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfCapacityOfAnAdvisor"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="PercentageOfCapacityOfAnAdvisor" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CommitmentsAndContingentLiabilitiesAbstract" xlink:href="ppbt-20241231.xsd#ppbt_CommitmentsAndContingentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingentLiabilitiesDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_CommitmentsandContingentLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsAndContingentLiabilitiesLineItems" xlink:href="ppbt-20241231.xsd#ppbt_CommitmentsAndContingentLiabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingentLiabilitiesAbstract" xlink:to="CommitmentsandContingentLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RangesAxis" xlink:href="ppbt-20241231.xsd#ppbt_RangesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="RangesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RangesDomainDomain" xlink:href="ppbt-20241231.xsd#ppbt_RangesDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesAxis" xlink:to="RangesDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TryNovosTechnologiesMember" xlink:href="ppbt-20241231.xsd#ppbt_TryNovosTechnologiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="TryNovosTechnologiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YissumsLicensedTechnologyMember" xlink:href="ppbt-20241231.xsd#ppbt_YissumsLicensedTechnologyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="YissumsLicensedTechnologyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="THMMember" xlink:href="ppbt-20241231.xsd#ppbt_THMMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="THMMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BiopharmaceuticalProductMember" xlink:href="ppbt-20241231.xsd#ppbt_BiopharmaceuticalProductMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="BiopharmaceuticalProductMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DiagnosticProductsMember" xlink:href="ppbt-20241231.xsd#ppbt_DiagnosticProductsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="DiagnosticProductsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="CommitmentsAndContingentLiabilitiesLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PercentageOfEntitysRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingentLiabilitiesLineItems" xlink:to="ifrs-full_PercentageOfEntitysRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromRoyalties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingentLiabilitiesLineItems" xlink:to="ifrs-full_RevenueFromRoyalties" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfSublicenseConsideration" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfSublicenseConsideration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingentLiabilitiesLineItems" xlink:to="PercentageOfSublicenseConsideration" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfReceiveExitFee" xlink:href="ppbt-20241231.xsd#ppbt_PercentageOfReceiveExitFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingentLiabilitiesLineItems" xlink:to="PercentageOfReceiveExitFee" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LicenceFeeIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicenceFeeIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingentLiabilitiesLineItems" xlink:to="ifrs-full_LicenceFeeIncome" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsOnLitigationSettlements" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsOnLitigationSettlements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingentLiabilitiesLineItems" xlink:to="ifrs-full_GainsOnLitigationSettlements" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="FinanceExpenseIncomeNetAbstract" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetAbstract"/>
    <loc xlink:type="locator" xlink:label="FinanceExpenseIncomeNetDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FinanceExpenseIncomeNetLineItems" xlink:href="ppbt-20241231.xsd#ppbt_FinanceExpenseIncomeNetLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpenseIncomeNetAbstract" xlink:to="FinanceExpenseIncomeNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpenseIncomeNetDetailsTable" xlink:to="ifrs-full_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpenseIncomeNetDetailsTable" xlink:to="FinanceExpenseIncomeNetLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WarrantsExpireTerm" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsExpireTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpenseIncomeNetLineItems" xlink:to="WarrantsExpireTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/TaxesonIncomeDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="TaxesOnIncomeabstract" xlink:href="ppbt-20241231.xsd#ppbt_TaxesOnIncomeabstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesOnIncomeabstract" xlink:to="ifrs-full_ApplicableTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryTaxRate" xlink:href="ppbt-20241231.xsd#ppbt_StatutoryTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesOnIncomeabstract" xlink:to="StatutoryTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesOnIncomeabstract" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveTaxRate" xlink:href="ppbt-20241231.xsd#ppbt_EffectiveTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesOnIncomeabstract" xlink:to="EffectiveTaxRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrecognizedResearchAndDevelopmentExpenses" xlink:href="ppbt-20241231.xsd#ppbt_UnrecognizedResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesOnIncomeabstract" xlink:to="UnrecognizedResearchAndDevelopmentExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/EmployeeBenefitsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitBonus" xlink:href="ppbt-20241231.xsd#ppbt_EmployeeBenefitBonus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="EmployeeBenefitBonus" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitsLiabilityDueGrants" xlink:href="ppbt-20241231.xsd#ppbt_EmployeeBenefitsLiabilityDueGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="EmployeeBenefitsLiabilityDueGrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="FinancialInstrumentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreditRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_CreditRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January2025Member" xlink:href="ppbt-20241231.xsd#ppbt_January2025Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="January2025Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ADSMember" xlink:href="ppbt-20241231.xsd#ppbt_ADSMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ADSMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesA1WarrantsMember" xlink:href="ppbt-20241231.xsd#ppbt_SeriesA1WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="SeriesA1WarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesA2WarrantsMember" xlink:href="ppbt-20241231.xsd#ppbt_SeriesA2WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="SeriesA2WarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShortTermDepositsGuaranteedForLeasesAndCredit" xlink:href="ppbt-20241231.xsd#ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ShortTermDepositsGuaranteedForLeasesAndCredit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShortTermDepositsGuaranteedForHedgingTransactions" xlink:href="ppbt-20241231.xsd#ppbt_ShortTermDepositsGuaranteedForHedgingTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ShortTermDepositsGuaranteedForHedgingTransactions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfConvertibleInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_IssueOfConvertibleInstruments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleWarrants" xlink:href="ppbt-20241231.xsd#ppbt_ConvertibleWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ConvertibleWarrants" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TerminationExercisePrice" xlink:href="ppbt-20241231.xsd#ppbt_TerminationExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="TerminationExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertiblesWarrants" xlink:href="ppbt-20241231.xsd#ppbt_ConvertiblesWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ConvertiblesWarrants" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CurrentInvestments" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialAssetAtAFairValue" xlink:href="ppbt-20241231.xsd#ppbt_FinancialAssetAtAFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="FinancialAssetAtAFairValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssued" xlink:href="ppbt-20241231.xsd#ppbt_WarrantsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="WarrantsIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantExercisePricePerShare" xlink:href="ppbt-20241231.xsd#ppbt_WarrantExercisePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="WarrantExercisePricePerShare" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepositarysShares" xlink:href="ppbt-20241231.xsd#ppbt_DepositarysShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="DepositarysShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateWarrantsShares" xlink:href="ppbt-20241231.xsd#ppbt_AggregateWarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="AggregateWarrantsShares" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentAmount" xlink:href="ppbt-20241231.xsd#ppbt_FinancialInstrumentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="FinancialInstrumentAmount" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetOfDeferredDifferenceAmount" xlink:href="ppbt-20241231.xsd#ppbt_NetOfDeferredDifferenceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="NetOfDeferredDifferenceAmount" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://Purplebiotech.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="ppbt-20241231.xsd#ppbt_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsMember" xlink:href="ppbt-20241231.xsd#ppbt_SubsequentEventsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="SubsequentEventsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AmericanDepositorySharesMember" xlink:href="ppbt-20241231.xsd#ppbt_AmericanDepositorySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="AmericanDepositorySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_RestrictedShareUnitsMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_ShareOptionsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsAndRSUsMember" xlink:href="ppbt-20241231.xsd#ppbt_OptionsAndRSUsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="OptionsAndRSUsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingPeriod" xlink:href="ppbt-20241231.xsd#ppbt_VestingPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="VestingPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionExercisedPeriod" xlink:href="ppbt-20241231.xsd#ppbt_StockOptionExercisedPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="StockOptionExercisedPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556772080336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Purple Biotech Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001614744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4 Oppenheimer Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Science Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rehovot<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">7670104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 200 Ordinary Shares(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PPBT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">517,128,717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Gil Efron<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">+972-3-5097196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4 Oppenheimer Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Science Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rehovot<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">7670104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3-933-3121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556768896224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Somekh Chaikin<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Opinion on the Consolidated Financial Statements</i></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated statements of financial
position of Purple Biotech Ltd. and its subsidiaries (hereinafter &#8211;&#8220;the Company&#8221;) as of December&#160;31, 2024 and 2023,
the related consolidated statements of operations and other comprehensive loss, changes in equity, and cash flows for each of the years
in the three year period ended December&#160;31, 2024, and the related notes (collectively, the consolidated financial statements). In
our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as
of December&#160;31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three year period
ended December&#160;31, 2024, in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board ("IFRS
Accounting Standards").</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556768091728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,401<span></span>
</td>
<td class="nump">$ 14,489<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short term deposits</a></td>
<td class="nump">848<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Other investments</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">8,908<span></span>
</td>
<td class="nump">15,788<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right to use assets</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Fixed assets, net</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">27,842<span></span>
</td>
<td class="nump">28,044<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non - current assets</a></td>
<td class="nump">28,130<span></span>
</td>
<td class="nump">28,514<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">37,038<span></span>
</td>
<td class="nump">44,302<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current maturity of lease liabilities</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payable</a></td>
<td class="nump">1,455<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentWarrantLiability', window );">Warrants</a></td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Other payables</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">3,463<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">3,987<span></span>
</td>
<td class="nump">9,701<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits', window );">Post-employment benefit liabilities</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non - current liabilities</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital, no par value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="nump">147,631<span></span>
</td>
<td class="nump">133,184<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ReceiptsOnAccountsOfWarrant', window );">Receipts on account of warrants</a></td>
<td class="nump">21,145<span></span>
</td>
<td class="nump">28,467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Capital reserve for share-based payments</a></td>
<td class="nump">8,875<span></span>
</td>
<td class="nump">10,088<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalReserve', window );">Capital reserve from transactions with related parties</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Capital reserve from hedging</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest', window );">Capital reserve from transactions with non- controlling interest</a></td>
<td class="num">(859)<span></span>
</td>
<td class="num">(859)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated loss</a></td>
<td class="num">(144,693)<span></span>
</td>
<td class="num">(137,453)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Equity attributable to owners of the Company</a></td>
<td class="nump">32,860<span></span>
</td>
<td class="nump">34,207<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">32,911<span></span>
</td>
<td class="nump">34,297<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 37,038<span></span>
</td>
<td class="nump">$ 44,302<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Restated following amendments to IAS 1 - see Note 2F</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the capital reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current warrant liabilities. [Refer: Warrant liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital reserve from transactions with non- controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ReceiptsOnAccountsOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receipts on account of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ReceiptsOnAccountsOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770863488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Other Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 7,620<span></span>
</td>
<td class="nump">$ 17,034<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 16,320<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Sales, general and administrative expenses</a></td>
<td class="nump">3,183<span></span>
</td>
<td class="nump">5,237<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,283<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLoss', window );">Impairment loss</a></td>
<td class="nump">202<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating Loss</a></td>
<td class="nump">11,005<span></span>
</td>
<td class="nump">22,271<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,603<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrants</a></td>
<td class="num">(3,341)<span></span>
</td>
<td class="num">(3,497)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">483<span></span>
</td>
<td class="nump">2,195<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(868)<span></span>
</td>
<td class="num">(992)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(910)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income, net</a></td>
<td class="num">(3,726)<span></span>
</td>
<td class="num">(2,294)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(843)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="nump">7,279<span></span>
</td>
<td class="nump">19,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract', window );"><strong>Items that will be transferred to profit or loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges', window );">Loss (profit) from cash flow hedges</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the year</a></td>
<td class="nump">7,298<span></span>
</td>
<td class="nump">19,952<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,766<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Loss attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Owners of the Company</a></td>
<td class="nump">7,240<span></span>
</td>
<td class="nump">19,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,668<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="nump">7,279<span></span>
</td>
<td class="nump">19,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Total comprehensive loss attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Owners of the Company</a></td>
<td class="nump">7,259<span></span>
</td>
<td class="nump">19,855<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,674<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the year</a></td>
<td class="nump">$ 7,298<span></span>
</td>
<td class="nump">$ 19,952<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 21,766<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsPerShareAbstract', window );"><strong>Loss per share data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per ADS - USD (in Dollars per share)</a></td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="nump">$ 17.96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 23.97<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per ADS - USD (in Dollars per share)</a></td>
<td class="nump">$ 4.99<span></span>
</td>
<td class="nump">$ 17.96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 23.97<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Number of ADSs used in calculating basic loss per ADS (in Shares)</a></td>
<td class="nump">1,639,566<span></span>
</td>
<td class="nump">1,106,665<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">904,054<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Number of ADSs used in calculating diluted loss per ADS (in Shares)</a></td>
<td class="nump">1,639,787<span></span>
</td>
<td class="nump">1,106,665<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">904,054<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Restated to reflect a 1:20 reverse ratio of the ADS&#8217;s, that took place September 2024 (see Note 9A)</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 130<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_130_d_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 130<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_130_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, before tax, after reclassification adjustments, related to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income, before tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556771864832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Share Capital</div></th>
<th class="th"><div>Share premium</div></th>
<th class="th"><div>Receipts on account of warrants</div></th>
<th class="th"><div>Capital reserve for share- based payments</div></th>
<th class="th"><div>Capital reserve from hedging</div></th>
<th class="th"><div>Capital reserve from transactions with related parties</div></th>
<th class="th"><div>Capital reserve from transactions with Non- controlling interest</div></th>
<th class="th"><div>Accumulated loss</div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Non-controlling interests</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 123,951<span></span>
</td>
<td class="nump">$ 28,017<span></span>
</td>
<td class="nump">$ 8,862<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 761<span></span>
</td>
<td class="num">$ (859)<span></span>
</td>
<td class="num">$ (95,905)<span></span>
</td>
<td class="nump">$ 64,827<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 65,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,110<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,412<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total transactions with owners of the Company</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,456<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,758<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(21,668)<span></span>
</td>
<td class="num">(21,668)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="num">(21,760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive profit (loss) for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">126,407<span></span>
</td>
<td class="nump">28,017<span></span>
</td>
<td class="nump">10,164<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="num">(859)<span></span>
</td>
<td class="num">(117,573)<span></span>
</td>
<td class="nump">46,911<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">47,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary', window );">ADS issued in connection with the purchase of a subsidiary (see Note 4C)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,781<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,781<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,951<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,875<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total transactions with owners of the Company</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,777<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,151<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,880)<span></span>
</td>
<td class="num">(19,880)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(19,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive profit (loss) for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">133,184<span></span>
</td>
<td class="nump">28,467<span></span>
</td>
<td class="nump">10,088<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="num">(859)<span></span>
</td>
<td class="num">(137,453)<span></span>
</td>
<td class="nump">34,207<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">34,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,065<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,174<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Warrant inducement transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,378<span></span>
</td>
<td class="num">(7,322)<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,004<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,422)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total transactions with owners of the Company</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14,447<span></span>
</td>
<td class="num">(7,322)<span></span>
</td>
<td class="num">(1,213)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,912<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,240)<span></span>
</td>
<td class="num">(7,240)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(7,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive profit (loss) for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 147,631<span></span>
</td>
<td class="nump">$ 21,145<span></span>
</td>
<td class="nump">$ 8,875<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 761<span></span>
</td>
<td class="num">$ (859)<span></span>
</td>
<td class="num">$ (144,693)<span></span>
</td>
<td class="nump">$ 32,860<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 32,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the acquisition of subsidiaries. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from transactions with owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556772081456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Loss for the year</a></td>
<td class="num">$ (7,279)<span></span>
</td>
<td class="num">$ (19,977)<span></span>
</td>
<td class="num">$ (21,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss</a></td>
<td class="nump">202<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncome', window );">Finance income, net</a></td>
<td class="num">(3,726)<span></span>
</td>
<td class="num">(2,294)<span></span>
</td>
<td class="num">(843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payments</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Total adjustments</a></td>
<td class="num">(10,035)<span></span>
</td>
<td class="num">(20,199)<span></span>
</td>
<td class="num">(19,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ChangesInAssetsAndLiabilitiesAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets', window );">Changes in other current assets</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Changes in trade payables</a></td>
<td class="num">(2,076)<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables', window );">Changes in other payables</a></td>
<td class="num">(2,352)<span></span>
</td>
<td class="num">(1,076)<span></span>
</td>
<td class="nump">2,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities', window );">Changes in post-employment benefit liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AdjustmentsForChangesInAssetsAndLiabilities', window );">Changes in assets and liabilities, total</a></td>
<td class="num">(4,332)<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">3,255<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,367)<span></span>
</td>
<td class="num">(19,925)<span></span>
</td>
<td class="num">(16,735)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CashFlowsFromInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CashAssumedAsPartOfAcquisitionOfFamewave', window );">Acquisition of subsidiary, net of cash acquired (see Note 4C)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,549)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities', window );">Proceed from other investments</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisition of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_Decreaseincreaseinshorttermdeposits', window );">Decrease in short term deposits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">15,803<span></span>
</td>
<td class="nump">19,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncreaseDecreaseInLongTermDeposits', window );">Decrease in long term deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities', window );">Interest received</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">13,881<span></span>
</td>
<td class="nump">19,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CashFlowsFromFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuance of ADSs</a></td>
<td class="nump">5,809<span></span>
</td>
<td class="nump">1,563<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">ADS issuance expenses paid</a></td>
<td class="num">(556)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ProceedsFromIssuingWarrants', window );">Proceeds from issuance of warrants and prefunded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from warrant inducement transaction</a></td>
<td class="nump">2,028<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_WarrantsIssuanceExpensesPaid', window );">Warrants issuance expenses paid</a></td>
<td class="num">(280)<span></span>
</td>
<td class="num">(661)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liability</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,774<span></span>
</td>
<td class="nump">5,449<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(7,084)<span></span>
</td>
<td class="num">(595)<span></span>
</td>
<td class="nump">4,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the year</a></td>
<td class="nump">14,489<span></span>
</td>
<td class="nump">15,030<span></span>
</td>
<td class="nump">10,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of translation adjustments on cash and cash equivalents</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of the year</a></td>
<td class="nump">$ 7,401<span></span>
</td>
<td class="nump">$ 14,489<span></span>
</td>
<td class="nump">$ 15,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_AdjustmentsForChangesInAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for changes in assets and liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_AdjustmentsForChangesInAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_CashAssumedAsPartOfAcquisitionOfFamewave">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of interests in associates. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_CashAssumedAsPartOfAcquisitionOfFamewave</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_CashFlowsFromFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_CashFlowsFromFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_CashFlowsFromInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_CashFlowsFromInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ChangesInAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ChangesInAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_Decreaseincreaseinshorttermdeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease increase in short term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_Decreaseincreaseinshorttermdeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_IncreaseDecreaseInLongTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_IncreaseDecreaseInLongTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ProceedsFromIssuingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ProceedsFromIssuingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_WarrantsIssuanceExpensesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for warrants issuance expenses paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_WarrantsIssuanceExpensesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770301040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_GeneralAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">General</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
1 - General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Reporting
entity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purple Biotech Ltd. (hereinafter: the &#8220;<b>Company</b>&#8221; or &#8220;<b>Purple</b>&#8221;) is a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance. The Company&#8217;s oncology pipeline includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophils extracellular traps is a novel target for the treatment of multiple cancer indications. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. CAPTN-3 is a preclinical platform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The cleavable capping technology confines the compound&#8217;s therapeutic activity to the local tumor microenvironment. The third arm specifically targets the Tumor Associated Antigen (TAA). IM1240 is the first tri-specific antibody in development that targets 5T4 expressed in a variety of solid tumors and is correlated with advanced disease, increased invasiveness, and poor clinical outcomes.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company was incorporated in Israel as a private company in August 1968, and has been listed for trading on the Tel Aviv Stock Exchange
since September 1978. In October 2012, the Company disposed of all of its previous operations, and in July 2013, the Company acquired
shares of Kitov Pharma Ltd. from its shareholders, in exchange for the Company&#8217;s shares. In December 2020 the Company changed its
name from Kitov Pharma Ltd. to Purple Biotech Ltd.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s securities (American Depository Shares (&#8220;ADS&#8221;)) were listed for trading on the NASDAQ in November 2015. Each ADS represents 200 ordinary shares with <span style="-sec-ix-hidden: hidden-fact-149"><span style="-sec-ix-hidden: hidden-fact-150">no</span></span> par value following a reverse split on August 23, 2020 and &#160;September 17, 2024 (see Note 9A). Each 200 warrants enable the purchase of 1 ADS.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s address is 4 Oppenheimer St., Science Park Rehovot 7670104 Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2017, the Company
    acquired the majority of shares of TyrNovo Ltd. (hereinafter: &#8220;TyrNovo&#8221;). During 2018, the Company acquired additional
    shares of TyrNovo from various minority shareholders, see also Note 4A.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
January 2020, the Company acquired 100% of FameWave Ltd. (hereinafter &#8220;FameWave&#8221;), see also Note 4B.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
October 28, 2021, the Company established a fully owned subsidiary Purple Biotech GmbH (hereinafter &#8220;<b>Purple GmbH</b>&#8221;)
which is currently in dissolving process following the termination of its activities in Switzerland.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
February 2023, the Company acquired 100% of Immunorizon Ltd. (hereinafter &#8220;Immunorizon&#8221;), see also Note 4C.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company together with TyrNovo, FameWave, Immunorizon and Purple GmbH are referred to, in these consolidated financial statements, as
&#8220;<b>the Group</b>&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Since incorporation through December 31, 2024, the Group has incurred losses and negative cash flows from operations mainly attributed to its development efforts and has an accumulated loss of USD 144.7 million. The Group has financed its operations mainly through private and public financing rounds. Through December 31, 2024, the Company raised (excluding exercise of warrants) a total of USD 108.5 million net of issuance expenses, see also Note 9.</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Based on the projected cash flows and
current cash balances, management currently is of the opinion that its existing cash will be sufficient to fund operations for at least
the next 12 months. Subsequently, management&#8217;s plans include pursuing out licensing, alternative financing arrangements, or reducing
expenditures as necessary to meet the Company&#8217;s future cash requirements. </p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">However, there is no assurance that, if required, the Company will be able to raise additional capital when needed, on favorable terms, or at all or reduce discretionary spending to provide the required liquidity.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Following
    the brutal attacks on Israel, the mobilization of army reserves and the Government declaring a state of war (&#8220;Iron Swords&#8221;
    war) in October 2023, there was a decrease in Israel&#8217;s economic and business activity. The security situation has led, inter
    alia, to a disruption in the chain of supply and production, a decrease in the volume of national transportation, a shortage in manpower
    as well as a decrease in the value of financial assets and a rise in the exchange rate of foreign currencies in relation to the shekel.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Any
    hostilities involving Israel, or the interruption or curtailment of trade within Israel or between Israel and its trading partners
    could adversely affect the Company&#8217;s operations and results of operations and could make it more difficult for the Company
    to raise capital. Both CM24 and NT219 are manufactured by service providers outside of Israel. Most of the research and development
    work is being conducted by third-party entities outside of Israel. However, a prolonged war can cause disruptions or delays to activities
    performed in Israel, as the result of shortage of staff, resulting in an adverse effect on the Company&#8217;s business, financial
    condition and results of operation.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Additionally,
    all of Company&#8217;s employees are located and reside in Israel. Shelter-in-place and work-from-home measures, government-imposed
    restrictions on movement and travel and other precautions that may be taken to address the ongoing conflict may temporarily disrupt
    the employees&#8217; ability to effectively perform the daily tasks.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <span style="font-family: Times New Roman, Times, Serif">It
    is currently not possible to predict the duration or severity of the ongoing conflict or its effects on Company&#8217;s business,
    operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt Company&#8217;s business
    and operations, interrupt the sources and availability of supply and hamper the ability to raise additional funds or sell Company&#8217;s
    securities, among others.</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_GeneralAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_GeneralAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556774066672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation of the Consolidated Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Basis of Preparation of the Consolidated Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Preparation of the Consolidated Financial Statements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
2 - Basis of Preparation of the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statement of compliance
    with International Financial Reporting Standards</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group has prepared the consolidated financial statements in accordance with IFRS Accounting Standards (hereinafter: &#8220;IFRS&#8221;),
as issued by the International Accounting Standard Board (&#8220;IASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements were approved by the board of directors on March 6, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Functional and presentation
    currency</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements are presented in US dollars (USD), which is the Group&#8217;s functional currency, rounded to the nearest
one thousand, unless otherwise noted. The USD is the currency that represents the principal economic environment in which the Group operates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of measurement</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements have been prepared on the historical cost basis except for the following assets and liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments and
    derivatives measured at fair value through profit or loss;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities for employee
    benefits</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
further information regarding the measurement of these assets and liabilities see Note 3 regarding material accounting policies.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates and
    judgment</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
preparation of consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions
that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results
may differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Management
prepares the estimates on the basis of past experience, various facts, external circumstances, and reasonable assumptions according to
the pertinent circumstances of each estimate. The preparation of accounting estimates used in the preparation of the Group&#8217;s consolidated
financial statements requires management of the Group to make assumptions regarding circumstances and events that involve considerable
uncertainty. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized
in the period in which the estimates are revised and in any future periods affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Information
about assumptions made by the Group with respect to the future and other reasons for uncertainty with respect to estimates that have
a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in the next financial year are
included in the following notes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimate</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    assumptions</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 23%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Possible
    effects</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reference</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><p style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">Assessment
    of probability of contingent liabilities</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether it is more likely than not that an outflow
    of economic resources will be required in respect of legal claims pending against the Company and its investees</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reversal or creation of a provision for a claim</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For information on the Company&#8217;s exposure to
    claims see Note 12B regarding contingent liabilities</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recoverability of intangible assets</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The discounted cash flows method includes assumptions
    such as future expenses, future revenues, success rates (in respect of transition between phases of the R&amp;D of the clinical trials
    until reaching regulatory approval and marketing) and discount rate. </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of the in-process research and development
    in profit or loss</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 4 regarding Intangible assets</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Determination
of fair value </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Preparation
of the financial statements requires the Group to determine the fair value of certain assets and liabilities. The Group&#8217;s management
regularly reviews significant unobservable inputs and valuation adjustments, including obtaining valuations prepared by third parties
and assessing the evidence to support the conclusion that these valuations meet the requirements of IFRS, including the level in the
fair value hierarchy in which the valuations should be classified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">When
determining the fair value of an asset or liability, the Group uses market data as much as possible. There are three levels of fair value
measurements in the fair value hierarchy that are based on the data used in the measurement, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: quoted prices
    (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: inputs other than
    quoted prices included in Level 1 that are observable, either directly or indirectly.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: inputs that are
    not based on observable market data (unobservable inputs).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Further
information about the assumptions made in measuring fair value of share-based payments, intangible assets and financial instruments are
included in Note 10, Note 4 and Note 18, respectively.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange rates and linkage
    bases</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balances
in foreign currency (mainly the New Israeli Shekel, or NIS) or linked thereto are included in the consolidated financial statements at
the representative exchange rates, as published by the Bank of Israel, which were prevailing as of the statement of financial position
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Data
on exchange rates are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Representative</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">exchange rate<br/>
    of USD</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(NIS/USD
    1)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Date of consolidated financial statements:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">December 31, 2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.647</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.627</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.519</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Changes in exchange rates
    for the year ended:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">December 31, 2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.5</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change in accounting
    policy</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Amendment
to IAS 1, Presentation of Financial Statements: Classification of liabilities as current or non-current &#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
amendment replaces the specific classification requirement of certain liabilities as current or non-current. According to the amendment,
a liability will be classified as non-current when the entity has a right to defer payment for a period of at least 12 months after the
reporting period, which is &#8220;substantive&#8221; (Substance) and which exists at the end of the reporting period. The amendment clarifies
that the conversion right of a liability will affect the classification of the instrument as a whole as current or non-current unless
the conversion component is equity. The amendment is affective retrospectively for reporting periods beginning on or after January 1,
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
a result of implementing the amendment, the Company changed its policy regarding the classification of warrants classified as a liability.
Prior to the implementation of the amendment, when classifying the warrants as current or non-current, the conversion options of the
counterparty were not considered. Following the implementation of the amendment, since the warrants include a conversion component, the
Company takes into account the possible date at which the warrants can be converted, when classifying the warrants as current or non-current.
Since the conversion option can be exercised within 12 months after the reporting period, the Company retrospectively classified the
warrants as a current liability.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556774077488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract', window );"><strong>Material Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">Material Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 3
- Material Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accounting policies set out below have been consistently applied for all periods presented in these consolidated financial statements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of consolidation</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition of Subsidiaries</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Upon
acquisition of subsidiaries, the Company evaluates whether the acquisition is considered a business acquisition or an acquisition of
an asset (or group of assets). If the Company reaches the conclusion that the subsidiary acquired is a considered a business, it accounts
for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the
acquisition is generally measured at fair value, as are the identifiable net assets acquired. Transaction costs are expensed as incurred,
except if related to the issue of debt or equity securities. If the acquired subsidiary is not considered a business, the Company accounts
for the acquisition as a purchase of assets. The Company uses the optional concentration test to determine the accounting treatment of
such acquisitions. In applying the concentration test, an entity determines whether substantially all the fair value of the gross assets
acquired is concentrated in a single asset or group of similar assets. If so, the asset is not considered a business. As of December
31, 2024, the acquisitions made by the Company were determined to be an acquisition of assets, see Note 4.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Contingent
considerations transferred for acquisition of subsidiaries are recorded when the terms and conditions for payment of the consideration
are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiaries</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Subsidiaries
are entities controlled by the Group. The financial statements of subsidiaries are included in the consolidated financial statements
from the date on which control commences until the date on which control ceases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-controlling interests</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-controlling
interests that are instruments that give rise to a present ownership interest and entitle the holder to a share of net assets in the
event of liquidation (for example: ordinary shares), are measured at the date of the business combination at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Changes
in the Group&#8217;s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign currency transactions</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Transactions
in foreign currencies are translated to USD which is the functional currency of Group entities at exchange rates at the dates of the
transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional
currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between its cost in
the functional currency on date of translation, and the monetary cost in foreign currency translated at the exchange rate at the end
of the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-monetary
items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial instruments</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-derivative financial
    assets</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Initial
recognition and measurement of financial assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group initially recognizes debt instruments issued on the date that they are created. All other financial assets are recognized initially
on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially
measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Subsequent
measurement and gains and losses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Financial
assets at fair value through profit or loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
assets are subsequently measured at fair value. Net gains and losses, including any interest income, are recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-derivative financial
    liabilities</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-derivative
financial liabilities include: finance lease liabilities, accounts payables and other payables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Initial
recognition of financial liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial
liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument.
Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value
less any directly attributable transaction costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Subsequent
measurement of financial liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Subsequent
to initial recognition these financial liabilities are measured at amortized cost using the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Derecognition
of financial liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial
liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled
or transferred to equity.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative financial
    instruments </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
part of the October 2023 and July 2024 capital raising agreements, the Company issued new warrants and amended previous warrants that
were classified as derivative financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Measurement
of derivative financial instruments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Derivatives
are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial
recognition, derivatives are measured at fair value, and changes therein are accounted for as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these
derivatives is based on an evaluation and classified as level 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share capital</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Ordinary
shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized
as a deduction from equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Incremental
costs directly attributable to an expected issuance of an instrument that will be classified as an equity instrument are recognized as
an asset in deferred expenses in the statement of financial position. The costs are deducted from equity upon the initial recognition
of the equity instruments, or are amortized as financing expenses in the statement of income when the issuance is no longer expected
to take place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuance of parcel of
    securities</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consideration received from the issuance of parcel of securities is attributed initially to financial liabilities that are measured each
period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair
value. The remaining amount is allocated to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Direct
issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed
to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
part of the October 2023 capital raising, the Company issued pre-funded warrants and amended terms for previous warrants. The Company
classified the pre-funded warrants as an equity instrument due to their negligible exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
amended terms for previously issued warrants increased the fair value of those warrants. The amended terms were part of the capital raising
and therefore the Company accounted for the increase in value as issuance cost.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intangible assets</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research and development</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expenditure
on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized
in profit or loss when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Development
activities involves research for new or substantially improved drug candidates and processes, the manufacturing of such candidates and
the pre-clinical and clinical studies for these candidates. Development expenditure are capitalized only if development costs can be
measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group
has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are
recognized in profit and loss as expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other intangible assets</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Other intangible assets, including
in-process research and development in respect of the Company&#8217;s acquisition of TyrNovo, Famewave, Immunorizion, and asset purchased
by Purple GmbH (see also Note 4), which have infinite useful lives, are measured at cost less accumulated impairment losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether
events and circumstances continue to support the decision that the intangible asset has an indefinite useful life and if any impairment
may be needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impairment</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Timing
of impairment testing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
carrying amounts of the Group&#8217;s non-financial assets, are reviewed at each reporting date to determine whether there is any indication
of impairment. If any such indication exists, then the asset&#8217;s recoverable amount is estimated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Once
a year and on the same date, or more frequently if there are indications of impairment, the Group estimates the recoverable amount of
each cash generating unit that contains intangible assets that have indefinite useful lives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Measurement
of recoverable amount</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs of disposal.
In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects
the assessments of market participants regarding the time value of money and the risks specific to the asset or cash-generating unit,
for which the estimated future cash flows from the asset or cash-generating unit were not adjusted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recognition
of impairment loss</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">An
impairment loss is recognized if the carrying amount of an asset or cash-generating unit exceeds its estimated recoverable amount. Impairment
losses are recognized in profit or loss.&#160;</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss per share</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group presents basic and diluted loss per share data for its ordinary share capital (including pre-funded warrants). Basic loss per share
is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding
during the year. The loss per share data is presented in the profit and loss statement as loss per ADS giving effect to the number of
200 shares per 1 ADS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee benefits</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance and pension companies,
and they are classified as defined contribution plans and as defined benefit plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and
has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are
recognized as an expense in profit or loss in the periods during which related services are rendered by employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Short-term
employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
liability is recognized for the amount expected to be paid under short-term cash bonus if the Group has a present legal or constructive
obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-based payment transactions</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
grant date fair value of share-based payment awards granted to employees is recognized as a salary expense, with a corresponding increase
in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect
of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect
the number of awards that are expected to vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Provisions</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated
reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
provision for legal claims is recognized if, as a result of a past event, the Company has a present legal or constructive obligation
and it is more likely than not that an outflow of economic benefits will be required to settle the obligation and the amount of obligation
can be estimated reliably.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing income and expense</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Finance
income comprises changes in the fair value of the financial liability through profit and loss, gains on changes in the fair value of
financial assets at fair value through profit or loss and income from short- term and long-term deposits, foreign currency gains, and
the reclassification of net gains and losses previously recognized in other comprehensive income on cash flow hedges of foreign currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Finance
expenses include loss from exchange rate differences and interest fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Interest
income or expense is recognized, using the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the statements of cash flows, interest received is presented as part of cash flows from investing activities and interest paid is presented
as part of cash flows from financing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>K.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income tax expense</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Income
tax comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that they
relate to a business combination, or are recognized directly in equity or in other comprehensive income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Deferred
tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that
future taxable profits will be available against which they can be utilized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company has not recognized deferred tax assets as no future taxable profits are expected in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>L.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Leased
assets and lease liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Contracts
that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as
leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments (these
payments do not include certain variable lease payments), and concurrently recognizes a right-to-use asset at the same amount of the
lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Since
the interest rate implicit in the Group&#8217;s leases is not readily determinable, the incremental borrowing rate of the lessee is used.
Subsequent to initial recognition, the right-to-use asset is accounted for using the cost model, and depreciated over the shorter of
the lease term or useful life of the asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>The
lease term</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably
certain that the lessee will or will not exercise the option, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Depreciation
of right-to-use asset</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">After
lease commencement, a right-to-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses
and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over contractual lease
period as follows: office lease from September 15 2020 for 5 years and 3.5 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>M.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Accounting standards issued but not yet effective</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
number of new accounting standards are effective for annual reporting periods beginning after 1 January 2025 and earlier application
is permitted. However, the Group has not early adopted the following new or amended accounting standards in preparing these consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IFRS 18 Presentation and Disclosure in Financial Statements</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IFRS
18 will replace IAS 1 Presentation of Financial Statements and applies for annual reporting periods beginning on or after 1 January 2027.
The new standard introduces the following key new requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Entities
                                            are required to classify all income and expenses into five categories in the statement of
                                            profit or loss, namely the operating, investing, financing, discontinued operations and income
                                            tax categories. Entities are also required to present a newly-defined operating profit subtotal.
                                            Entities&#8217; net profit will not change.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Management-defined
                                            performance measures (MPMs) are disclosed in a single note in the financial statements.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Enhanced
                                            guidance is provided on how to group information in the financial statements.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, all entities are required to use the operating profit subtotal as the starting point for the statement of cash flows when presenting
operating cash flows under the indirect method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group is still in the process of assessing the impact of the new standard, particularly with respect to the structure of the Group&#8217;s
statement of profit or loss, the statement of cash flows and the additional disclosures required for MPMs. The Group is also assessing
the impact on how information is grouped in the financial statements, including for items currently labelled as &#8216;other&#8217;.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556771655584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 4
- Intangible Assets </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>As of
December 31, 2024, and 2023:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D related to TyrNovo
    (see 4A below)</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,172</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,172</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D related to Famewave (see 4B below)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,310</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,310</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D related to Immunorizon (see 4C below)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,360</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D related to
    Purple GmbH</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-151; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total intangible assets</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,842</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,044</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition of Tyrnovo</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the years 2017 to 2019 the Company acquired shares in Tyrnovo, a company developing NT219.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Since
2019 the Company owns 98.47% of Tyrnovo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition of Famewave</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
January 7, 2020 the Company completed the purchase of 100% of FameWave Ltd, a privately held biopharmaceutical Company developing CM24,
(&#8220;FameWave&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consideration was recorded based on the fair value of the assets purchased.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition of Immunorizon</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In February 2023 the Company completed
the acquisition of 100% of Immunorizon Ltd, a privately held biotech Company developing CAPTN-3, a platform for multispecific T and NK
cell engager oncology therapies that selectively activate the immune response within the tumor microenvironment, (&#8220;Immunorizon&#8221;)
from its shareholders in consideration of an aggregate upfront payment of $3.5 million in cash, an aggregate of $3.5 million in ADSs (or
110,759 ADSs representing ordinary shares at a price per ADS equal to the NASDAQ volume-weighted average price of the Company&#8217;s
ADSs for the 60-day period preceding the execution date of the agreement) with three months lock up period including a price protection
mechanism for 12 months (see Note 9D3). Additional future considerations include future payments when achieving certain long-term milestones
set at an aggregate amount of $94 million, including royalties on net sales. The acquisition closed on February 15, 2023. The total acquisition
amounted to $ 3.6 million.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
acquisition was recorded based on the fair value of the consideration transferred and was accounted for as an asset purchase as it did
not meet the definition of a business combination in accordance with IFRS 3.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Identifiable
assets acquired and liabilities assumed</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Intangible asset (1)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other receivables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Trade payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total net identifiable
    assets</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,375</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Intangible asset - In process research and development</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top"><td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The fair value of the intangible asset recognized at the acquisition date was determined according to the fair value of the issued equity (110,759 ADSs) which amounted to USD 3,781 thousand and the cash paid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">According to the agreement, the equity issued included a price protection mechanism for a dilutive event as defined in the agreement, as well as a lock up period of three months. Following the October 2023 registered direct offering, which constituted a dilutive event, the Company issued to the former shareholders of Immunorizon an aggregate 34,974 Additional ADSs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The fair value of equity issued was based on the assumptions below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share price - 1.59</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility - 70.89%</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual risk-free rate &#8211; 4.5%</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield- <span style="-sec-ix-hidden: hidden-fact-152">0%</span></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DLOM &#8211; 10.8%</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D</b>.</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2024 the Company impaired the IPR&amp;D related to Purple GmbH following the decision to dissolve Purple GmbH (see note 1).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E</b>.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, the recoverable amount of the in-process research and development assets (hereinafter &#8211; &#8220;intangible assets&#8221;) was based on their value in use and was determined by discounting the future cash flows to be generated from them by using the discounted cash flows method, on the annual year test. The recoverable amount of the intangible assets exceeds their carrying amount, thus no impairment loss was recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discounted cash flows model considered the risks associated with the clinical/preclinical phase of the intangible assets and the probability of success for each development phase. Certain estimations were determined using industry data reports.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discount rate used for calculating intangible assets recoverable amount was 19.5%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company performed sensitivity analysis for estimations such as discount rate and royalty rate and concluded that the recoverable amount of the intangible assets exceeds their carrying amount.</p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769800080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Note
5 - Cash and Cash Equivalents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance in USD</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,050</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,007</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance in other currencies</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">351</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">482</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total cash and cash equivalents</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,401</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,489</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770294592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 6
&#8211; Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group has lease agreements with respect to offices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information regarding
    material lease agreements</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company entered into an agreement for the lease of offices in Rehovot as from September 15, 2020 for a period of 5 years and 3.5 months.
Accordingly, the Company initially recognized in the statement of financial position a right-to-use asset in the amount of USD 817 thousand
concurrently with the recognition of a lease liability in the same amount. The agreement has an option to extend the lease, for additional
5 years. This additional period is not included in the lease payments used-in the calculation of the liability as the Company does not
expect it is reasonably certain it will exercise the option. The Company has an option to extend the lease agreements for an additional
5 years at the terms as those of the existing agreement with addition of 5% to the current terms and CPI linked.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Right-to-use assets</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">Carrying
amounts of right-to-use assets and change during the period:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Office
    lease</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2024</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">316</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Depreciation on right-to-use assets</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(152</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">164</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">467</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Depreciation on right-to-use assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(151</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">316</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease liability</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Maturity
analysis of the Company&#8217;s lease liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Less than one year</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">183</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">188</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">One to two years</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-153; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">188</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">183</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">376</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Current maturities of
    lease liability</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">183</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">188</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Long-term lease liability</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-154; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">163</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional information
    on leases</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Amounts
recognized in profit or loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Interest expenses
    on lease liability</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770503744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory', window );">Other Current Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 7
- Other Current Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">109</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">171</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other receivables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">275</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">205</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total other current assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">384</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">376</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current assets. [Refer: Other current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556768186464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Other Payables</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 8
- Other Payables</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Due to related parties - salary
    related</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">317</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">620</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses and other</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">692</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,521</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Government authorities</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">65</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">53</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Salary related</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">126</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">269</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,200</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,463</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770498080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Note
9 - Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company&#8217;s authorized share capital is 1,000,000,000 ordinary shares, with no par value, and 50,000,000 non-voting senior preferred shares, with no par value, divided into 5 classes of 10,000,000 preferred shares in each class.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">On September 17, 2024 the ratio between ADSs and shares was changed from 1:10 to 1:200 (each 1 ADS equal 200 shares). In these consolidated financial statements, all numbers of ADSs reflect the reverse share split and ADS ratio change retrospectively</span></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The Company&#8217;s share capital</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2024</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> paid-in</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> paid-in</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Shares, no par value</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,000,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">517,129</span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,000,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">252,379</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class A preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-155; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-156; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class B preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-157; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-158; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class C preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-159; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-160; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class D preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-161; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-162; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class E preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-163; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-164; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes in share capital during the year</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(*)2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(*)2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of ADSs in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Issued as at
    January 1</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,261</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">924</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">890</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of ADSs (See D below)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">930</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">319</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Vesting of RSUs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercise
    of warrants and prefunded warrants</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">379</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-165; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-166; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Issued
    as at December 31</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,586</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,261</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">924</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>*</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Restated to reflect a 1:20 reverse ratio that took place in September 2024. (see also note 9A)</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing rounds</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On December 5, 2024, in a registered direct offering on the NASDAQ, the Company raised USD 2.83 million gross (approximately USD 2.5 million net of placement agent fees). In this registered direct offering, the Company issued an aggregate of 472,668 ADSs at a purchase price of USD 6 per ADS that were recorded in equity in the amount of USD 2.5 million net of issuance expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In addition, the Company issued to the placement agent (or its designees) registered compensation warrants to purchase up to 33,087 ADSs at a value of USD 109 thousand which is included in the net amount raised above, at an exercise price of USD <span style="-sec-ix-hidden: hidden-fact-167">7. 5</span> per ADS. The registered placement agent warrants are immediately exercisable and have a term of 5 years from the date of the effective date of the offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On July 2, 2024 the Company raised USD&#160;2&#160;million gross (approximately USD&#160;1.8&#160;million net of placement agent fees) in a warrant inducement transaction. In this transaction, the Company induced the exercise of certain existing warrants to purchase an aggregate of 281,675 American Depositary Shares (ADSs) of which 166,469 ADSs held in abeyance. The existing warrants had original exercise prices ranging from $25 to $400 per ADS and were originally issued by the Company in October 2023, June 2020, January 2019 and June 2018. The exercise price for these existing warrants was reduced to $7.2 per ADS.&#160;As of December 31, 2024, no ADSs are held in abeyance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration for the exercise of the existing
warrants, the Company issued new unregistered Series A-1 warrants to purchase up to an aggregate of 248,969 ADSs and new unregistered
Series A-2 warrants to purchase up to an aggregate of 314,382 ADSs. The new warrants are immediately exercisable at an exercise price
of $8 per ADS. The Series A-1 warrants have a term of five years from the issuance date and the Series A-2 warrants have a term of twenty-four
months from the issuance date. The cash received in the transaction was allocated to the new warrants, which were recorded as a liability
at their fair value adjusted, for deferred difference between the transaction price and the fair value, of USD 2,028 thousand, and the
exercise of the existing warrants was treated as a reclassification from the receipt on account of warrants to share premium.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company issued to the placement agent (or its designees) unregistered compensation warrants to purchase up to 19,717 ADSs at an exercise price of USD&#160;9&#160;per ADS at value of $100 thousand. The unregistered placement agent warrants are immediately exercisable and have a term of&#160;five years&#160;from the date of July 2, 2024.</p></td></tr>
</table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On October 19, 2023, in a registered direct offering on the NASDAQ, the Company raised USD 5 million gross (approximately USD 4.3 million net of placement agent fees). In this registered direct offering, the Company issued an aggregate of 121,500 ADSs at a purchase price of USD 23 per ADS and pre-funded warrants to purchase up to 95,891 ADS. The Company also issued unregistered warrants to purchase up to an aggregate of 217,391 ADSs (hereinafter the &#8220;October 2023 warrants&#8221;) which are immediately exercisable, that were recorded as a liability at their fair value at a value of USD 5,348 thousand. The October 2023 warrants have a term of five and a half years and have an exercise price of USD 25 per ADS. During 2024, the pre-funded warrants and the October warrants were exercised as part of the warrant inducement transaction in July.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In connection with the offering and effective upon October 19, 2023, the Company amended certain existing warrants to purchase up to an aggregate of 31,578 ADSs that were previously issued in June 2020 and June 2018 at exercise prices of $180 and $560 per ADS, respectively, such that the amended warrants have a reduced exercise price of $25 per ADS and an extended term of five and a half years from the closing of the offering. The Company recorded USD 761 thousand in issuance expenses in relation to the amendment. During 2024, these warrants were exercised as part of the warrant inducement transaction in July.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In addition, the Company issued to the placement agent (or its designees) unregistered compensation warrants to purchase up to 15,217 ADSs at a value of USD 357 thousand at an exercise price of USD 28.75 per ADS. The unregistered placement agent warrants are immediately exercisable and have a term of five years from the date of October 19, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In connection with the October 2023 Offering, the Company issued 34,975 ADSs pursuant to an anti-dilution mechanism of that certain Lock-Up and Registration Rights Agreements entered into with former Immunorizon shareholders in connection with the acquisition of Immunorizon in February 2023 (refer to Note 4C).</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 9, 2021, the Company entered into sales agreement with Jefferies LLC, for the sale of ADSs. In accordance with the terms of the sales agreement, the Company may offer and sell ADSs from time to time through Jefferies, acting as the Company&#8217;s agent. The Company originally filed a prospectus for a $50.0 million &#8220;at the market&#8221; equity offering program (&#8220;ATM Program&#8221;), but the aggregate offering price was subsequently reduced to $21.0 million on March 23, 2022, to $3.0 million on October 17, 2023 and to $1.33 million on January 6 ,2025. During 2024, 2023 and 2022 the Company sold, under the ATM Program, 457,801, 52,202 and 27,170 ADSs at an average price of $9, $32.6 and $53 per ADS and raised USD 2.97 million, USD 1.56 million and USD 1.49 million gross (approximately USD 2.85 million, USD 1.5 million and USD 1.44 million net of placement agent fees), respectively.</span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other equity transactions</b></span></td></tr> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2024, the Company issued 3,142 thousand ordinary shares on account of vested RSUs granted in 2021, 2022, 2023 to officers, board members and employees.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2023, the Company issued 3,680 thousand ordinary shares on account of vested RSUs granted in 2021, 2022 to officers, board members and employees.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2022, the Company issued 1,380 thousand ordinary shares on account of vested RSUs granted in 2020 and 2021 to officers, board members and employees.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2023 the Company
    acquired Immunoraizon &#8211; see note 4C.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-controlling interests</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the information relating to Tyrnovo that has non-controlling interests of 1.53%, before any intra-group eliminations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">TyrNovo
    Ltd.</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">in
    USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-current assets</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">184</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">247</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current liabilities</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(25,901</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23,419</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net assets</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(25,711</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23,166</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net assets attributable to non-controlling
    interests</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(394</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(355</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Loss for the year</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,545</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,365</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Loss allocated to non-controlling interests</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">97</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556771052000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based Payment Arrangements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 10
- Share-based Payment Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On August 15, 2024, the board of directors of the Company granted 3,150 thousand options (to purchase the equivalent of 15,750 ADSs) and 3,150 thousand RSUs (equivalent to 15,750 ADSs) to employees. The options have an exercise price of USD 0.037 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 190 thousand. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On March 2, 2023, the board of directors of the Company granted 45 thousand options (to purchase the equivalent of 225 ADSs) and 45 thousand RSUs (equivalent to 225 ADSs) to an employee. The options have an exercise price of USD 0.198 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 16 thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On April 24, 2023, the board of directors of the Company granted 2,732 thousand options (to purchase the equivalent of 14 thousand ADSs) and 2,732 thousand RSUs (equivalent to 14 thousand ADSs) to the Board members, subject to the approval of the shareholders, and to employees. The options have an exercise price of USD 0.190 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 729 thousand. The board members grant was approved by the shareholders on June 15, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On October 31, 2022, the board of directors of the Company granted 750 thousand options and 750 thousand RSUs to an employee. The options have an exercise price of USD 0.208 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 267 thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On July 11, 2022, the board of directors of the Company granted 3,750 thousand options and 150 thousand RSUs to the new CEO, subject to approval in the annual general meeting. The options have an exercise price of USD 0.245 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 591 thousand. This grant was approved by the shareholders on August 25, 2022.</span></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
May 23, 2022, the board of directors of the Company granted 6,635 thousand options and 5,885 thousand RSUs to officers and employees.
The options have an exercise price of USD 0.304 per one ordinary share, and for certain employee and consultant USD 0.276 per one ordinary
share eligible as from June 23, 2022. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable
for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 3,237 thousand.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top"><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The number and weighted average exercise prices (in USD) of share options are as follows:</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    on January 1</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.46</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.52</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.97</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,218,783</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,468,235</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,751,303</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Expired
    and forfeited during the year</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.84</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.54</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.82</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,004,460</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,026,452</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(418,068</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted
    during the year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.037</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.19</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.28</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,150,000</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,777,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,135,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    on December 31</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.36</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.46</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.52</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,364,323</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,218,783</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,468,235</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    on December 31</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.45</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.62</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.97</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,420,406</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,923,032</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,144,318</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The exercise price is denominated in
NIS and is re-measured using historic exchange rates. Options are exercisable to shares, each ADS represent 200 shares.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
options outstanding at December 31, 2024 had an exercise price of USD 0.037- USD 6 (2023 - USD 0.190- USD 6, 2022 -USD 0.208- USD 6),
and weighted average contractual life of 2.51 years (2023 &#8211; 3.10 years, 2022 &#8211; 3.87 years).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The number of RSUs are as follows:</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,770,750</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,857,917</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Granted during the year</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,150,000</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,777,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Forfeited during the year</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(859,584</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,187,292</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Vested during the year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,142,249</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,676,875</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,918,917</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,770,750</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">Each
RSU is convertible to one share, each ADS represent 200 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company&#8217;s
    share options granted to employees, directors and consultants, where fair value of service was not measurable, was measured using
    the binominal model, using the fair value of the traded warrants with similar terms, making certain adjustments to reflect the specific
    terms of the options based on the expected duration.&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E</b>.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following assumptions were used<b>:</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Share Price - USD</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">0.036</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.160-0.226</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise price - USD</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0.037</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.19 -0.2</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">95.93</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">93.54-96.04</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected duration (years)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>2-2.8</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2-5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk free rate interest rate (%)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3.88</td><td style="font-weight: bold; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.56%-4.31%</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expenses recognized in the consolidated financial statements:</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research and development expenses</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">117</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">768</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">768</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative
    expenses</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">465</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,107</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,644</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total share-based expense
    recognized</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">582</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,875</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,412</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556768841472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Transactions and Balances with Related Parties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 11
- Transactions and Balances with Related Parties </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition to their salaries or fees, the Group also provides share option programs to directors and officers and contributes to a post-employment
defined contribution plan on behalf of employees, see Note 8 for the balances and Note 10 regarding share-based payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
CEO is entitled to termination benefits of up to 6 monthly salaries or fees, See Note 17.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company pays the members of the board an annual fee for their service and an additional fee for serving on boards committees. In addition,
the Company pays the chairman of the board a monthly fee for his service as the chairman of our medical and clinical committee. A monthly
fee is being paid to one of the directors who has been engaged as an advisor in a 50% capacity</span>, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
bonuses for certain strategic or financing transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">Expenses
of key management personnel:</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Company recorded expenses to executive officers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Short - term employee benefits</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,257</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,066</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,623</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Post-employment benefits</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Share based payments</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">378</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,346</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,930</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,634</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,424</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,564</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company recorded expenses to directors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Short - term benefits</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">394</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">427</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">448</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Share based payments</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">193</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">284</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">311</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">587</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">711</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">759</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556772006480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CommitmentsAndContingentLiabilitiesAbstract', window );"><strong>Commitments and Contingent Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Commitments and contingent liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 12
- Commitments and contingent liabilities </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commitments</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TyrNovo, has obligations
    to the Israel Innovation Authority (hereinafter: &#8220;IIA&#8221;) with respect to grants it received from the IIA in connection
    with TyrNovo&#8217;s technology. The requirements and restrictions for such grants are found in the Encouragement of Research, Development
    and Technological Innovation in Industry Law 5744-1984 and in the IIA&#8217;s rules and guidelines and the terms of these grants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In general, a recipient company is
obligated to pay the IIA royalties from the revenues generated from the sale of products and related services developed as a result of,
a research and development program funded , in whole or in part, by the IIA (currently a yearly rate of 3% to 6%), up to the aggregate
amount of the total grants received by the IIA, plus annual interest. The recipient company is also obligated to manufacture its drug
in Israel unless it receives the approval of the IIA in which case it will be required to pay the higher rate mentioned above. A recipient
company is not required to repay the grants if it does not generate revenue.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">TyrNovo&#8217;s
technologies were developed, in part, with funds from IIA grants, and accordingly is obligated to pay royalties on sales of any of its
IIA funded products and related services.&#160; &#160;As of December 31, 2024, the maximum royalty amount that would be payable by TyrNovo,
excluding interest, is approximately NIS 5.5 million (USD 1.51 million), and as of such date, TyrNovo had not paid any royalties to the
IIA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group does not recognize a liability for royalties because there is no reasonable assurance, as of the reporting period, that the underlying
sales will occur in the future. Therefore, the financial statements do not include a liability for these royalties.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TyrNovo has entered into a
    license agreement (the &#8220;License Agreement&#8221;) with Yissum Research Development Company of the Hebrew University of
    Jerusalem Ltd. (hereafter &#8220;Yissum&#8221;) dated August 15, 2013, as amended. In accordance with the License Agreement, Yissum
    granted the Company an exclusive license to commercialize, exploit, develop, manufacture, market, import, export, distribute, offer
    to sell, or sell products, that are derived from Yissum&#8217;s licensed technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties at a rate of up to three percent (3%) of net sales. </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sublicense fees at a rate of twelve percent (12%) of sublicense consideration.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, Yissum is entitled to receive an exit fee of 12% of the transaction proceeds in the event of certain pre - defined transactions
set forth in the License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">BIRAD
Research &amp; Development Company Ltd. (BIRAD) is entitled to receive a portion of Yissum&#8217;s royalties on net sales according to
an amendment to the License Agreement signed between TyrNovo and Yissum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements do not include a liability for royalties or sublicense fees for this license agreement as there is
no minimum payments and thus obligation will be recognized when the related sales will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">cCAM
    Biotherapeutics Ltd. (cCam), a subsidiary of Merck Sharp and Dohme Corp. (MSD), has entered into a license agreement with Tel Hashomer
    &#8211; Medical Research Infrastructure and Services Ltd. (&#8220;THM&#8221;) and Ramot at Tel Aviv University Ltd. (&#8220;Ramot&#8221;)
    dated April 16, 2012, which was effective as of May 25, 2010, as subsequently amended (the &#8220;THM License Agreement&#8221;).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
    conjunction with the closing of the reversion agreement amongst (MSD), cCAM and FameWave, the parties executed an Assignment and
    Assumption Agreement by and between FameWave and cCAM, according to which cCAM assigned to FameWave all its rights, title and interest
    in, to and under the THM License Agreement.&#160;Pursuant to the THM License Agreement, THM and Ramot granted FameWave a worldwide,
    royalty-bearing, exclusive license to develop, manufacture, produce, market and sell any biopharmaceutical product and/or diagnostic
    product using patents and inventions owned by THM and Ramot in connection with uses of the glycoprotein CEACAM1.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
consideration for the license grant, FameWave shall pay to THM the following during the term of the license:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An annual license fee of $10,000 which is credited towards any royalties to be paid during such year.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties of three and &#160;a half percent (3.5%) of net sales with respect to Biopharmaceutical Products, and royalties of six and &#160;a half percent (6.5%) of net sales with respect to Diagnostic Products.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sublicense fees at a rate of twenty percent (20%) of sublicense consideration with respect to Biopharmaceutical Products, and sublicense fees at a rate of twelve percent (12%) of sublicense consideration with respect to Diagnostic Products.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">FameWave
has undertaken to pay certain milestone payments upon the completion of certain pre-defined clinical and sales milestones.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, THM (on behalf of the licensors) are entitled to receive an exit fee of up to three and a half percent (3.5%) of all consideration
received because of or in connection with an exit event (as defined in the THM License Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Finally,
THM also received an assignable warrant to purchase, upon the closing of any IPO of FameWave, ordinary shares of FameWave, at a price
equal to a certain percentage of the forecast initial market value of FameWave for each share as determined, prior to the IPO, for the
purpose of the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
accordance with the THM License Agreement, THM is entitled to appoint an observer to FameWave&#8217;s board of directors who has all
the rights of any other director of FameWave expect for the right to vote. To date, THM has not acted on this right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements do not include a liability for royalties or sublicense fees for this license agreement as there is
no minimum payments and thus obligation will be recognized when the related sales will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Claims</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In February 2017, four lawsuits and motions to approve the lawsuits as a class action lawsuit (each, a &#8220;Motion&#8221;), were filed against the Company and certain of its office holders at the Tel Aviv District Court (Economic Division), with each Motion relating to the Company announcement that the Israeli Securities Authority (the &#8220;ISA&#8221;) has begun a formal investigation into, amongst other matters, the Company&#8217;s public disclosures around certain aspects of the studies related to its therapeutic candidate, Consensi (the &#8220;2017 Motions&#8221;). One of these motions was subsequently withdrawn. The petitioners in one of the motions petitioned the court to dismiss the other two of the 2017 Motions (&#8220;Petition for Dismissal&#8221;). On December 19, 2017 the court granted the Petition for Dismissal and dismissed the other remaining 2017 Motions. The remaining motion (the &#8220;Surviving Motion&#8221;) was filed against the Company, the Company&#8217;s executive directors and certain of its present and former directors, by certain shareholders who are requesting to act as representatives of all shareholders of record from December 10, 2015 until February 6, 2017. The plaintiffs allege, among other things, that the Company included misleading information in its public filings which caused the class for which the plaintiffs are seeking recognition an aggregate loss of approximately NIS 29 million (approximately USD 8.0 million). The court ordered a stay of proceedings due to the then-ongoing ISA Investigation. Following approval of an enforcement arrangement in connection with the ISA investigation, the stay was lifted.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
June 19, 2024, the Court issued its final decision in the 2017 Motion, whereby it fully dismissed the lawsuit against the defendants
as well as the motion to approve the lawsuit as a class action lawsuit. Each party will bear its own court expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On November 17, 2022, Fidelity Venture Capital Ltd., a private Israeli company (&#8220;Fidelity VC&#8221;) and Mr. Dror Atzmon, an Israeli resident and citizen believed to be the sole shareholder of Fidelity VC (Mr. Atzmon, together with Fidelity VC, the &#8220;Atzmon Plaintiffs&#8221;), filed a statement of claim in the Economic Division of the Tel Aviv District Court (the &#8220;Atzmon Claim&#8221;) against the Company and a number of other defendants, including our former chief executive officer. The Atzmon Plaintiffs are seeking damages for approximately NIS 9 million (approximately USD 2.5 million) in connection with various claims relating to alleged contractual breaches and torts arising from an alleged contractual undertaking for the Company to engage the Atzmon Plaintiffs to provide advisory services to the Company following the initial public offering in the United States and listing on NASDAQ in November 2015.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company rejects all the claims presented in the Atzmon Claim. On August 3, 2023, the court ordered the parties to inform of their willingness to a mediation process. The parties agreed to a mediation process, a mediator has been appointed and mediation is ongoing. At this stage the Company is unable, with any degree of certainty, to make any evaluations or any assessments with respect to the probability of success or the scope of potential exposure, if any, of the Atzmon Claim.</span></p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_CommitmentsAndContingentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_CommitmentsAndContingentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556774046496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ResearchAndDevelopmentExpensesAbstract', window );"><strong>Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
13 - Research and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Salaries, wages and related
    expenses</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,536</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,323</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,382</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Share-based payments (see also Note 10)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">117</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">768</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">768</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Service providers</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,967</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,943</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,170</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,620</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,034</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,320</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556800198672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sales, General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Sales, General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory', window );">Sales, General and Administrative Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 14
- Sales, General and Administrative Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.05pt; text-indent: -18.05pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Salaries,
    wages and related expenses</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">925</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,769</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,845</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payments (see also Note 10)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">272</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right">823</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,333</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Reimbursement
    of legal fees</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(86</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(116</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Other
    professional fees</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right">772</td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,005</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">885</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Board
    member remuneration and insurance</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">627</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">818</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,152</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Board
    member share-based payments (see also Note 10)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">193</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">284</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">311</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Maintenance
    expenses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">62</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right">196</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">120</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Travel
    and car expenses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">108</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">130</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">144</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">186</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right">197</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">201</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">124</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">131</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">355</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,183</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,237</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,283</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of general and administrative expenses. [Refer: Administrative expenses]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556768197440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Expense (Income), Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FinanceExpenseIncomeNetAbstract', window );"><strong>Finance Expense (Income), Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Finance Expense (Income), net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 15
- Finance Expense (Income), net</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.05pt; text-indent: -18.05pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Revaluation of warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The gain is related to the fair value adjustments of warrants. The 2023 and 2024 warrants included a cashless exercise feature and customary conditions in case of occurrence of a fundamental transaction. The 2023 warrants were exercised in July 2024, and 2024 warrants will expire within 5 or 2 years from issuance of those warrants (see also note 9D2).</span></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Finance expenses and income</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Finance expenses</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Fees and interest expense</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">41</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">56</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">67</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Loss from exchange rate differences, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">11</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Issuance expenses (see note 9D)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">406</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,126</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">25</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">483</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,195</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">67</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Interest income
    from deposits</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(260</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(474</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(532</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Income from exchange rate
    differences, net</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-174; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-175; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(62</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Changes in fair value of
    finance instruments (see Note 18B2)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(608</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(517</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(245</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-176; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(71</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(868</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(992</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(910</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FinanceExpenseIncomeNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FinanceExpenseIncomeNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556774108640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_TaxesOnIncomeabstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Taxes on Income</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 16
- Taxes on Income</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate tax rate</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
tax rate applicable to the Group is 23%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Carry-forward
    losses</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
    Company and its subsidiaries incurred losses through 2024, which are not expected to be utilized in the foreseeable future. Therefore,
    the Group did not record current taxes or deferred tax assets.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
2024, the main reconciling item from the statutory tax rate of the Company (23%, representing a theoretical tax benefit of approximately
USD 1.7 million) to the effective tax rate (0%) is mainly due to the fact that deferred taxes were not created in respect of current
year tax losses and benefits.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
carry-forward loss for tax purposes of the Company and its subsidiaries, and the unrecognized research and development expenses, amount
to USD 100 million as of December 31, 2024 (2023 &#8211; USD 96 million, 2022 &#8211; USD 82 million).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_TaxesOnIncomeabstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_TaxesOnIncomeabstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556778222704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract', window );"><strong>Employee Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Employee benefits</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 17
- Employee benefits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefits include post-employment benefits and short-term benefits.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">Balances
include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year ended<br/> December&#160;31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Short-term
    benefits</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">331</span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">549</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Post-employment benefit
    liabilities</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">140</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">141</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Post-employment benefit
    plans &#8211; defined contribution plan</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company has a defined contribution plan in respect of the Company&#8217;s liability in respect of its employees who are subject to Section
14 of the Severance Pay Law&#160;&#8211; 1963.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Amount recognized
    as expense in respect of defined contribution plan</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">322</span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">401</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">390</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain of the Company&#8217;s executives are entitled to annual and special bonuses under the terms of their employment and consulting agreements. These bonuses will become due upon the achievement of certain goals or agreements. These consolidated financial statements include bonuses expenses in the amount of USD 68 thousand for the year ended December 31, 2024, USD 446 thousand for the year ended December 31, 2023, and USD 406 thousand for the year ended December 31, 2022.&#160;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The CEO is entitled to benefits upon termination of employment, see Note 11 on related parties. These benefits are measured based on the time of service and monthly pay and the expected term of his employment. These consolidated financial statements include a liability due to these grants of USD 140 thousand and USD 141 thousand, as of December 31, 2024 and 2023, respectively.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556774133600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
18 - Financial Instruments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Framework
for risk management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Board of Directors has overall responsibility for the establishment and oversight of the Group&#8217;s risk management framework.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group&#8217;s risk management practice was formulated to identify and analyze the risks that the Group faces, to set appropriate limits
for the risks and controls, and to monitor the risks and their compliance with the limits. The risk policy and risk management methods
are reviewed regularly to reflect changes in market conditions and in the Group&#8217;s operations. The Group acts to develop an effective
control environment in which all employees understand their roles and commitment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group Audit Committee oversees how management monitors compliance with the Group&#8217;s risk management policies and procedures, and
reviews the adequacy of the risk management framework in relation to the risks faced by the Group. The Group Audit Committee is assisted
in its oversight role by Internal Audit. Internal Audit undertakes both regular and ad hoc reviews of risk management controls and procedures,
the results of which are reported to the Audit Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk management</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1</b>.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit risk</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Credit
risk is the risk of financial loss to the Group if a debtor or counterparty to a financial instrument fails to meet its contractual obligations,
and arises mainly from the Company&#8217;s receivables. The Group restricts exposure to credit risk by investing only in bank deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group held cash and cash equivalents
and short-term deposits of USD 8,249 thousand at December 31, 2024 (2023 &#8211; USD 15,339 thousand). These are held with banks, which
are rated BBB+ or BBB-, based on S&amp;P Rating Agency ratings. The short-term deposits, mainly in USD, bear fixed interest ranging between
0.2% - 4.46%.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024 the Group has an amount of USD 148 thousand in short term deposits guaranteed for the Group&#8217;s leases and credit
and an amount of USD 700 thousand in short term deposits guaranteed for hedging transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market risk</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Market
risk is the risk that changes in market prices, such as foreign currency exchange rates, the CPI, interest rates and the prices of equity
instruments, will influence the Group&#8217;s results or the value of its holdings in financial instruments. The objective of market
risk management is to manage and control market risk exposures within acceptable parameters, while optimizing returns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group hedges the foreign currency risk exposure that derives from salary expenses by means of foreign currency derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Therefore,
as at December 31, 2024 the Group is of the opinion that these hedging relationships continue to qualify for hedge accounting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Currency risk</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group is exposed to currency risk mainly for cash and purchases for research and development expenses that are denominated in NIS and
EURO. Therefore, the Group is exposed to exchange rate fluctuations in these currencies against the dollar and takes steps to reduce
the currency risk by maintaining its liquid resources in accordance with its future needs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Sensitive
    instrument</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> &#160;(U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value<br/>
    (U.S.&#160;dollars<br/> in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents and deposits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">423</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">35</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">704</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(35</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other&#160;payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(723</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Post-employment benefit
    liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(140</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total&#160;income (loss)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is a sensitivity test to possible changes in USD/ EURO exchange rate as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Sensitive
    instrument</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value<br/>
    (U.S.&#160;dollars<br/> in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents and deposits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(92</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other&#160;payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total&#160;income (loss)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Sensitive
    instrument</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> &#160;(U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value<br/>
    (U.S.&#160;dollars<br/> in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents and deposits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">550</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(28</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">660</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(225</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other&#160;payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(67</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,340</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">67</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Post-employment benefit
    liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(141</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total&#160;income (loss)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(24</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is a sensitivity test to possible changes in USD/ EURO exchange rate as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Sensitive
    instrument</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value<br/>
    (U.S.&#160;dollars<br/> in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents and deposits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(153</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other&#160;payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(12</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(232</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total&#160;income (loss)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments measured
    at fair value:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The carrying amounts of certain financial assets and liabilities, including cash and cash equivalents, short term deposits, trade payables, and other payables are the same or proximate to their fair value.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify">In October 2021, the Company received a convertible note in the amount of $1.5 million and a warrant for 300 thousand Coeptis shares as part of Coeptis termination at an exercise price of $5 per warrant. As of December 31, 2023, the outstanding balance of the convertible note was $625 thousands.</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">On
June 19, 2024 the Company entered into a payoff agreement with Coeptis in which the Company will receive payment in the amount of $219
thousand (received in January 2025) and 50 thousand Coeptis shares, in lieu of the outstanding convertible note and warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">As
a result of this agreement, the financial instruments (convertible note and warrant) were derecognized as of December 31, 2024. The fair
value of these financial instruments prior to derecognition were $73 thousand as of December 31, 2023, and $431 thousand as of December
31, 2022. Additionally, the shares received were recognized as a financial asset at a fair value of USD 275 thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In October 2023, as part of a registered direct offering, the Company issued 217,391 warrants, and amended certain existing warrants to purchase up to an aggregate of 27,777 of the Company&#8217;s ADSs that were previously issued in June 2020 at exercise prices of $180 per ADS such that effective upon the closing of the offering the amended warrants will have a reduced exercise price of $25 per ADS and will expire five and a one-half years from the closing date of the offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On July 2, 2024 the Company induced the exercise of certain existing warrants (Including the above October warrants) to purchase an aggregate of 281,675 American Depositary Shares (ADSs). In consideration for the exercise of the existing warrants, the Company issued new unregistered Series A-1 warrants to purchase up to an aggregate of 248,969 ADSs and new unregistered Series A-2 warrants to purchase up to an aggregate of 314,381 ADSs (see Note 9D2).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The warrants were classified as a non-current financial liability as they can be settled in cash on the occurrence of Fundamental Transaction as determined in the agreement. This liability was initially recognized at its fair value on the closing date of the offering and is subsequently accounted for fair value at each balance sheet date and recorded through profit and loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of these financial instruments as of December 31, 2024
was measured at USD 1,149 thousand (net of deferred difference of USD 302 thousand), (December 31, 2023 USD 2,518 thousand).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value hierarchy of financial instruments measured at fair value:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Financial asset and liabilities</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Securities (see Note 18B (2))</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">275</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">275</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Financial liability of warrants</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,149</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,149</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Financial asset and liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible debt instrument and
    warrant (see Note 18B (2))</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-185; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-186; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">73</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">73</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Financial liability of
    warrants</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-187; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-188; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,518</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,518</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Details
regarding fair value measurement at Level 3:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Financial asset-<br/> convertible note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Financial liability-<br/> warrant</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Balance as of January 1, 2024</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">73</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">2,518</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(56</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,028</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Proceed</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(187</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revaluation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">114</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(3,341</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Balance as of December 31, 2024</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,149</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Financial
    asset-<br/> convertible note</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Financial
    liability-<br/> warrant</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">431</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Issuance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,015</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Proceed</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(875</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revaluation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">517</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,497</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,518</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    instrument</b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation<br/>
    method for<br/>
    determining <br/>
    fair value</b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant<br/>
    unobservable<br/>
    inputs</b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended December 31, 2024</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    (see note 9D1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Black
    - Scholes</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expected
    term</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.5, 1.5 years</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; width: 30%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; width: 15%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expected
    volatility</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>97.31%, 129.83</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"><b>%</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annual
    risk free interest</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.30%, 4.54</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividend
    yield</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended December 31, 2023</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Black
    - Scholes</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expected
    term</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3 years</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expected
    volatility</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89.94</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annual
    risk free interest</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.88</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividend
    yield</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    debt instrument</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DLOM</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556773861744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note
19 - Subsequent Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;  border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">1.</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">On February 11, 2025, the board of directors of the Company agreed to grant 10,500 thousand options (to purchase the equivalent of 52.5 thousand ADSs) and 10,500 thousand RSUs (equivalent to 52.5 thousand ADSs) to the Board members and CEO, subject to the approval of the shareholders. The options have an exercise price of USD 3.40 per one ADS. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The estimated fair value of these options and RSUs as of the board approval date was measured at USD 282 thousand.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769068992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556768278912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate in the biotechnology
sector, which is subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of
operations, including intellectual property theft; fraud; extortion; harm to employees; violation of privacy laws and other litigation
and legal risk; and reputational risk. We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity
measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data. We currently have
security measures in place to protect patients&#8217;, employees&#8217; and vendors&#8217; information and prevent data loss and other
security breaches, including a cybersecurity risk assessment program. Both management and the Company&#8217;s Audit Committee are actively
involved in the continuous assessment of risks from cybersecurity threats, including prevention, mitigation and detection.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risk Management and Strategy</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cybersecurity assessment
program outlines policies and procedures and technology we use to oversee and identify risks from cybersecurity threats, and focuses on
the following areas:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Vigilance</i>: The Company maintains cybersecurity threat operations with the goal of identifying, preventing and mitigating cybersecurity threats and responding to cybersecurity incidents in accordance with our established disaster recovery policy.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Systems Safeguards</i>: The Company deploys systems safeguards that are designed to protect the Company&#8217;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through ongoing vulnerability assessments and cybersecurity threat intelligence.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Third Party Service Provider</i>: The Company utilizes a third-party service provider to assist the Company to identify, assess, prevent and respond to cybersecurity risks. </span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Training</i>: The Company provides periodic training for personnel regarding cybersecurity threats, which reinforces the Company&#8217;s information security policies, standards and practices.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Incident Response and Recovery Planning</i>: The Company has established and maintains a plan that addresses the Company&#8217;s response to a cybersecurity incident and the recovery from a cybersecurity incident, which plan is evaluated periodically.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Communication and Disclosure</i>: The Company&#8217;s established plan includes procedures for the communication of cybersecurity incidents so that decisions regarding the disclosure and reporting of such incidents can be made in a timely manner.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Governance</i>: The management&#8217;s oversight of cybersecurity risk management is supported by the Company&#8217;s Audit Committee.</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Both management and the Company&#8217;s Audit Committee are actively
involved in the continuous assessment of risks from cybersecurity threats, including prevention, mitigation and detection.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risk Management and Strategy</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cybersecurity assessment
program outlines policies and procedures and technology we use to oversee and identify risks from cybersecurity threats, and focuses on
the following areas:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Vigilance</i>: The Company maintains cybersecurity threat operations with the goal of identifying, preventing and mitigating cybersecurity threats and responding to cybersecurity incidents in accordance with our established disaster recovery policy.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Systems Safeguards</i>: The Company deploys systems safeguards that are designed to protect the Company&#8217;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through ongoing vulnerability assessments and cybersecurity threat intelligence.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Third Party Service Provider</i>: The Company utilizes a third-party service provider to assist the Company to identify, assess, prevent and respond to cybersecurity risks. </span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Training</i>: The Company provides periodic training for personnel regarding cybersecurity threats, which reinforces the Company&#8217;s information security policies, standards and practices.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Incident Response and Recovery Planning</i>: The Company has established and maintains a plan that addresses the Company&#8217;s response to a cybersecurity incident and the recovery from a cybersecurity incident, which plan is evaluated periodically.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Communication and Disclosure</i>: The Company&#8217;s established plan includes procedures for the communication of cybersecurity incidents so that decisions regarding the disclosure and reporting of such incidents can be made in a timely manner.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Governance</i>: The management&#8217;s oversight of cybersecurity risk management is supported by the Company&#8217;s Audit Committee.</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Governance </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management is responsible
for day-to-day assessment and management of risks from cybersecurity threats, including the prevention, mitigation, detection, and remediation
of cybersecurity incidents (if any). The Company&#8217;s Chief Executive Officer is the member of the Company&#8217;s management who is
principally responsible for overseeing the Company&#8217;s cybersecurity risk management program.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Audit
Committee, in conjunction with management, oversees the assessment of the Company&#8217;s risks from cybersecurity threats, including
prevention and mitigation. The Company&#8217;s Audit Committee receives periodic updates from the Company&#8217;s Chief Executive Officer
with respect to the management of risks from cybersecurity threats. Additionally, the Audit Committee, in conjunction with management,
considers risks from cybersecurity threats as part of its oversight of the Company&#8217;s business strategy, risk management, and financial
oversight.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We engage a third-party consultant
to help us assess and identify risks from cybersecurity threats, including the threat of a cybersecurity incident, and assisted us to
establish our cybersecurity program and manage our risk assessment program. Our third-party consultant monitors cybersecurity threats
to our software.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, no risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially
affect our business strategy, results of operations or financial condition. However, an actual or perceived breach of our cybersecurity
could damage our reputation, interfere with the progress of our clinical trials and/or our efforts to pursue regulatory approvals for
our therapeutic candidates, or subject us to third-party lawsuits, regulatory fines or other actions or liabilities, any of which could
adversely affect our business, operating results or financial condition. For further information, see &#8220;Item 3. Key Information &#8211;
D. Risk Factors &#8211; Risks Related to Our Industry &#8211; <i>Our business and operations may be materially adversely affected in the
event of computer system failures or security or breaches due to cyber-attacks or cyber intrusions, including ransomware, phishing attacks
and other malicious intrusions</i>.&#8221;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">The Company&#8217;s Audit Committee receives periodic updates from the Company&#8217;s Chief Executive Officer
with respect to the management of risks from cybersecurity threats. Additionally, the Audit Committee, in conjunction with management,
considers risks from cybersecurity threats as part of its oversight of the Company&#8217;s business strategy, risk management, and financial
oversight.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556772089184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of consolidation</b></span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition of Subsidiaries</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Upon
acquisition of subsidiaries, the Company evaluates whether the acquisition is considered a business acquisition or an acquisition of
an asset (or group of assets). If the Company reaches the conclusion that the subsidiary acquired is a considered a business, it accounts
for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the
acquisition is generally measured at fair value, as are the identifiable net assets acquired. Transaction costs are expensed as incurred,
except if related to the issue of debt or equity securities. If the acquired subsidiary is not considered a business, the Company accounts
for the acquisition as a purchase of assets. The Company uses the optional concentration test to determine the accounting treatment of
such acquisitions. In applying the concentration test, an entity determines whether substantially all the fair value of the gross assets
acquired is concentrated in a single asset or group of similar assets. If so, the asset is not considered a business. As of December
31, 2024, the acquisitions made by the Company were determined to be an acquisition of assets, see Note 4.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Contingent
considerations transferred for acquisition of subsidiaries are recorded when the terms and conditions for payment of the consideration
are met.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiaries</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Subsidiaries
are entities controlled by the Group. The financial statements of subsidiaries are included in the consolidated financial statements
from the date on which control commences until the date on which control ceases.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-controlling interests</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-controlling
interests that are instruments that give rise to a present ownership interest and entitle the holder to a share of net assets in the
event of liquidation (for example: ordinary shares), are measured at the date of the business combination at fair value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Changes
in the Group&#8217;s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency transactions</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign currency transactions</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Transactions
in foreign currencies are translated to USD which is the functional currency of Group entities at exchange rates at the dates of the
transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional
currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between its cost in
the functional currency on date of translation, and the monetary cost in foreign currency translated at the exchange rate at the end
of the year.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-monetary
items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial instruments</b></span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-derivative financial
    assets</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Initial
recognition and measurement of financial assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group initially recognizes debt instruments issued on the date that they are created. All other financial assets are recognized initially
on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially
measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. &#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Subsequent
measurement and gains and losses</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Financial
assets at fair value through profit or loss</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
assets are subsequently measured at fair value. Net gains and losses, including any interest income, are recognized in profit or loss.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-derivative financial
    liabilities</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-derivative
financial liabilities include: finance lease liabilities, accounts payables and other payables.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Initial
recognition of financial liabilities</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial
liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument.
Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value
less any directly attributable transaction costs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Subsequent
measurement of financial liabilities</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Subsequent
to initial recognition these financial liabilities are measured at amortized cost using the effective interest method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Derecognition
of financial liabilities</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial
liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled
or transferred to equity.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative financial
    instruments </b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
part of the October 2023 and July 2024 capital raising agreements, the Company issued new warrants and amended previous warrants that
were classified as derivative financial instruments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Measurement
of derivative financial instruments</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Derivatives
are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial
recognition, derivatives are measured at fair value, and changes therein are accounted for as described below.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these
derivatives is based on an evaluation and classified as level 3.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share capital</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Ordinary
shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized
as a deduction from equity.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Incremental
costs directly attributable to an expected issuance of an instrument that will be classified as an equity instrument are recognized as
an asset in deferred expenses in the statement of financial position. The costs are deducted from equity upon the initial recognition
of the equity instruments, or are amortized as financing expenses in the statement of income when the issuance is no longer expected
to take place.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuance of parcel of
    securities</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consideration received from the issuance of parcel of securities is attributed initially to financial liabilities that are measured each
period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair
value. The remaining amount is allocated to equity.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Direct
issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed
to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described
above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
part of the October 2023 capital raising, the Company issued pre-funded warrants and amended terms for previous warrants. The Company
classified the pre-funded warrants as an equity instrument due to their negligible exercise price.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
amended terms for previously issued warrants increased the fair value of those warrants. The amended terms were part of the capital raising
and therefore the Company accounted for the increase in value as issuance cost.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intangible assets</b></span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research and development</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expenditure
on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized
in profit or loss when incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Development
activities involves research for new or substantially improved drug candidates and processes, the manufacturing of such candidates and
the pre-clinical and clinical studies for these candidates. Development expenditure are capitalized only if development costs can be
measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group
has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are
recognized in profit and loss as expense.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other intangible assets</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Other intangible assets, including
in-process research and development in respect of the Company&#8217;s acquisition of TyrNovo, Famewave, Immunorizion, and asset purchased
by Purple GmbH (see also Note 4), which have infinite useful lives, are measured at cost less accumulated impairment losses.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether
events and circumstances continue to support the decision that the intangible asset has an indefinite useful life and if any impairment
may be needed.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory', window );">Impairment</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impairment</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Timing
of impairment testing</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
carrying amounts of the Group&#8217;s non-financial assets, are reviewed at each reporting date to determine whether there is any indication
of impairment. If any such indication exists, then the asset&#8217;s recoverable amount is estimated.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Once
a year and on the same date, or more frequently if there are indications of impairment, the Group estimates the recoverable amount of
each cash generating unit that contains intangible assets that have indefinite useful lives.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Measurement
of recoverable amount</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs of disposal.
In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects
the assessments of market participants regarding the time value of money and the risks specific to the asset or cash-generating unit,
for which the estimated future cash flows from the asset or cash-generating unit were not adjusted.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recognition
of impairment loss</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">An
impairment loss is recognized if the carrying amount of an asset or cash-generating unit exceeds its estimated recoverable amount. Impairment
losses are recognized in profit or loss.&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss per share</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group presents basic and diluted loss per share data for its ordinary share capital (including pre-funded warrants). Basic loss per share
is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding
during the year. The loss per share data is presented in the profit and loss statement as loss per ADS giving effect to the number of
200 shares per 1 ADS.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefits</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee benefits</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance and pension companies,
and they are classified as defined contribution plans and as defined benefit plans.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and
has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are
recognized as an expense in profit or loss in the periods during which related services are rendered by employees.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Short-term
employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
liability is recognized for the amount expected to be paid under short-term cash bonus if the Group has a present legal or constructive
obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based payment transactions</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-based payment transactions</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
grant date fair value of share-based payment awards granted to employees is recognized as a salary expense, with a corresponding increase
in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect
of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect
the number of awards that are expected to vest.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Provisions</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated
reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
provision for legal claims is recognized if, as a result of a past event, the Company has a present legal or constructive obligation
and it is more likely than not that an outflow of economic benefits will be required to settle the obligation and the amount of obligation
can be estimated reliably.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory', window );">Financing income and expense</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing income and expense</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Finance
income comprises changes in the fair value of the financial liability through profit and loss, gains on changes in the fair value of
financial assets at fair value through profit or loss and income from short- term and long-term deposits, foreign currency gains, and
the reclassification of net gains and losses previously recognized in other comprehensive income on cash flow hedges of foreign currency.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Finance
expenses include loss from exchange rate differences and interest fee.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Interest
income or expense is recognized, using the effective interest method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the statements of cash flows, interest received is presented as part of cash flows from investing activities and interest paid is presented
as part of cash flows from financing activities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income tax expense</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>K.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income tax expense</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Income
tax comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that they
relate to a business combination, or are recognized directly in equity or in other comprehensive income.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Deferred
tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that
future taxable profits will be available against which they can be utilized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company has not recognized deferred tax assets as no future taxable profits are expected in the foreseeable future.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>L.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Leased
assets and lease liabilities</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Contracts
that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as
leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments (these
payments do not include certain variable lease payments), and concurrently recognizes a right-to-use asset at the same amount of the
lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Since
the interest rate implicit in the Group&#8217;s leases is not readily determinable, the incremental borrowing rate of the lessee is used.
Subsequent to initial recognition, the right-to-use asset is accounted for using the cost model, and depreciated over the shorter of
the lease term or useful life of the asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>The
lease term</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably
certain that the lessee will or will not exercise the option, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Depreciation
of right-to-use asset</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">After
lease commencement, a right-to-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses
and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over contractual lease
period as follows: office lease from September 15 2020 for 5 years and 3.5 months.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory', window );">Accounting standards issued but not yet effective</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>M.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Accounting standards issued but not yet effective</b></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
number of new accounting standards are effective for annual reporting periods beginning after 1 January 2025 and earlier application
is permitted. However, the Group has not early adopted the following new or amended accounting standards in preparing these consolidated
financial statements.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IFRS 18 Presentation and Disclosure in Financial Statements</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IFRS
18 will replace IAS 1 Presentation of Financial Statements and applies for annual reporting periods beginning on or after 1 January 2027.
The new standard introduces the following key new requirements.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Entities
                                            are required to classify all income and expenses into five categories in the statement of
                                            profit or loss, namely the operating, investing, financing, discontinued operations and income
                                            tax categories. Entities are also required to present a newly-defined operating profit subtotal.
                                            Entities&#8217; net profit will not change.</span></td></tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Management-defined
                                            performance measures (MPMs) are disclosed in a single note in the financial statements.</span></td></tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Enhanced
                                            guidance is provided on how to group information in the financial statements.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, all entities are required to use the operating profit subtotal as the starting point for the statement of cash flows when presenting
operating cash flows under the indirect method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group is still in the process of assessing the impact of the new standard, particularly with respect to the structure of the Group&#8217;s
statement of profit or loss, the statement of cash flows and the additional disclosures required for MPMs. The Group is also assessing
the impact on how information is grouped in the financial statements, including for items currently labelled as &#8216;other&#8217;.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income and expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes made to accounting policies by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for basis of consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556802293072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation of the Consolidated Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Basis of Preparation of the Consolidated Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory', window );">Schedule of Data on Exchange Rates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Data
on exchange rates are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Representative</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">exchange rate<br/>
    of USD</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(NIS/USD
    1)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Date of consolidated financial statements:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">December 31, 2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.647</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.627</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.519</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Changes in exchange rates
    for the year ended:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">December 31, 2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.5</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the effect of changes in foreign exchange rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS21_g51-57_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556802277904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IntangibleAssetsTablesLineItems', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory', window );">Schedule of Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>As of
December 31, 2024, and 2023:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D related to TyrNovo
    (see 4A below)</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,172</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,172</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D related to Famewave (see 4B below)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,310</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,310</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D related to Immunorizon (see 4C below)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,360</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D related to
    Purple GmbH</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-151; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total intangible assets</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,842</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,044</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Amounts of Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Intangible asset (1)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other receivables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Trade payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total net identifiable
    assets</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,375</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Intangible asset - In process research and development</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_IntangibleAssetsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_IntangibleAssetsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about recognized amounts assets acquired and liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556774098768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance in USD</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,050</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,007</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance in other currencies</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">351</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">482</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total cash and cash equivalents</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,401</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,489</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770689392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Schedule of Carrying Amounts of Right-to-Use Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">Carrying
amounts of right-to-use assets and change during the period:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Office
    lease</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2024</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">316</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Depreciation on right-to-use assets</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(152</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">164</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">467</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Depreciation on right-to-use assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(151</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">316</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory', window );">Schedule of Maturity Analysis of the Company's Lease Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Maturity
analysis of the Company&#8217;s lease liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Less than one year</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">183</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">188</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">One to two years</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-153; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">188</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">183</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">376</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Current maturities of
    lease liability</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">183</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">188</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Long-term lease liability</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-154; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">163</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory', window );">Schedule of Amounts Recognized in Profit or Loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Amounts
recognized in profit or loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Interest expenses
    on lease liability</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of additional information about leasing activities of a lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 92<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_92&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 97<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_97&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769795792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DisclosureOfOtherCurrentAssettextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">109</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">171</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other receivables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">275</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">205</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total other current assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">384</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">376</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DisclosureOfOtherCurrentAssettextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DisclosureOfOtherCurrentAssettextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556774080304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock', window );">Schedule of Other Payables</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Due to related parties - salary
    related</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">317</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">620</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses and other</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">692</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,521</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Government authorities</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">65</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">53</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Salary related</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">126</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">269</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,200</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,463</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about of trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769232896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of Share Capital</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The Company&#8217;s share capital</b></span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2024</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> paid-in</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> paid-in</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Shares, no par value</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,000,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">517,129</span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,000,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">252,379</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class A preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-155; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-156; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class B preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-157; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-158; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class C preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-159; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-160; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class D preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-161; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-162; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Class E preferred shares, no par value</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-163; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-164; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock', window );">Schedule of Changes in Share Capital</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes in share capital during the year</b></span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(*)2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(*)2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of ADSs in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Issued as at
    January 1</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,261</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">924</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">890</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of ADSs (See D below)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">930</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">319</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Vesting of RSUs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercise
    of warrants and prefunded warrants</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">379</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-165; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-166; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Issued
    as at December 31</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,586</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,261</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">924</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>*</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Restated to reflect a 1:20 reverse ratio that took place in September 2024. (see also note 9A)</span></td>
</tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock', window );">Schedule of the Information Relating to Non-Controlling Interests</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the information relating to Tyrnovo that has non-controlling interests of 1.53%, before any intra-group eliminations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">TyrNovo
    Ltd.</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">in
    USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-current assets</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">184</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">247</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current liabilities</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(25,901</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23,419</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net assets</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(25,711</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23,166</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net assets attributable to non-controlling
    interests</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(394</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(355</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Loss for the year</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,545</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,365</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Loss allocated to non-controlling interests</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">97</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Changes In Share Capital Explanatory Table Text Block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770304080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of Number and Weighted Average Exercise Prices of Share Options</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The number and weighted average exercise prices (in USD) of share options are as follows:</b></span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    on January 1</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.46</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.52</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.97</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,218,783</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,468,235</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,751,303</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Expired
    and forfeited during the year</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.84</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.54</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.82</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,004,460</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,026,452</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(418,068</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted
    during the year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.037</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.19</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.28</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,150,000</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,777,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,135,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    on December 31</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.36</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.46</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.52</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,364,323</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,218,783</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,468,235</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    on December 31</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.45</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.62</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.97</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,420,406</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,923,032</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,144,318</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock', window );">Schedule of Number of RSUs</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The number of RSUs are as follows:</b></span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,770,750</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,857,917</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Granted during the year</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,150,000</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,777,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Forfeited during the year</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(859,584</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,187,292</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Vested during the year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,142,249</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,676,875</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,918,917</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,770,750</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Schedule of Assumptions were Used</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following assumptions were used<b>:</b></span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Share Price - USD</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">0.036</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.160-0.226</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise price - USD</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0.037</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.19 -0.2</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">95.93</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">93.54-96.04</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected duration (years)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>2-2.8</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2-5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk free rate interest rate (%)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3.88</td><td style="font-weight: bold; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.56%-4.31%</span></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Schedule of Expenses Recognized in the Consolidated Financial Statements</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expenses recognized in the consolidated financial statements:</b></span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research and development expenses</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">117</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">768</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">768</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative
    expenses</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">465</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,107</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,644</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total share-based expense
    recognized</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">582</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,875</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,412</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about restricted stock unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769781440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Schedule of Recorded Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Company recorded expenses to executive officers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Short - term employee benefits</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,257</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,066</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,623</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Post-employment benefits</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Share based payments</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">378</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,346</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,930</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,634</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,424</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,564</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company recorded expenses to directors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Short - term benefits</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">394</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">427</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">448</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Share based payments</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">193</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">284</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">311</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">587</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">711</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">759</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556768195408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ResearchAndDevelopmentExpensesAbstract', window );"><strong>Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock', window );">Schedule of Research and Development Expenses</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Salaries, wages and related
    expenses</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,536</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,323</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,382</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Share-based payments (see also Note 10)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">117</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">768</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">768</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Service providers</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,967</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,943</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,170</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,620</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,034</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,320</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556768185136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sales, General and Administrative Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Sales, General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock', window );">Schedule of Sales, General and Administrative Expenses</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Salaries,
    wages and related expenses</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">925</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,769</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,845</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payments (see also Note 10)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">272</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right">823</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,333</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Reimbursement
    of legal fees</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(86</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(116</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Other
    professional fees</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right">772</td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,005</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">885</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Board
    member remuneration and insurance</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">627</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">818</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,152</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Board
    member share-based payments (see also Note 10)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">193</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">284</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">311</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Maintenance
    expenses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">62</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right">196</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">120</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Travel
    and car expenses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">108</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">130</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">144</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">186</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right">197</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">201</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">124</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">131</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">355</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,183</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,237</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,283</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosures Of DetailedInformationAboutGeneralAndAdministrativeExpenses Explanatory [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769795792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Expense (Income), Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FinanceExpenseIncomeNetTablesLineItems', window );"><strong>Finance Expense (Income), Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceCostExplanatory', window );">Schedule of Finance Expenses</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Finance expenses and income</b></span><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Finance expenses</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Fees and interest expense</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">41</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">56</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">67</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Loss from exchange rate differences, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">11</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Issuance expenses (see note 9D)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">406</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,126</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">25</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">483</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,195</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">67</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExplanatory', window );">Schedule of Finance Income</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Interest income
    from deposits</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(260</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(474</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(532</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Income from exchange rate
    differences, net</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-174; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-175; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(62</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Changes in fair value of
    finance instruments (see Note 18B2)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(608</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(517</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(245</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-176; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(71</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(868</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(992</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(910</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceCostExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance cost. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceCostExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FinanceExpenseIncomeNetTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FinanceExpenseIncomeNetTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556771041424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract', window );"><strong>Employee Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock', window );">Schedule of Post-Employee Benefits</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefits include post-employment benefits and short-term benefits.</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year ended<br/> December&#160;31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Short-term
    benefits</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">331</span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">549</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Post-employment benefit
    liabilities</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">140</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">141</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock', window );">Schedule of Defined Contribution Plan in Respect of its Employees</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company has a defined contribution plan in respect of the Company&#8217;s liability in respect of its employees who are subject to Section
14 of the Severance Pay Law&#160;&#8211; 1963.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Amount recognized
    as expense in respect of defined contribution plan</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">322</span></td><td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">401</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">390</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769290592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FinancialInstrumentsTablesLineItems', window );"><strong>Financial Instruments (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory', window );">Schedule of Sensitivity Test to Possible Changes in Exchange Rate</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Data
on exchange rates are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Representative</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">exchange rate<br/>
    of USD</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(NIS/USD
    1)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Date of consolidated financial statements:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">December 31, 2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.647</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.627</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.519</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Changes in exchange rates
    for the year ended:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">December 31, 2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.5</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory', window );">Schedule of Financial Instruments Measured at Fair Value</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value hierarchy of financial instruments measured at fair value:</span><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Financial asset and liabilities</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Securities (see Note 18B (2))</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">275</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">275</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Financial liability of warrants</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,149</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,149</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">USD&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Financial asset and liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible debt instrument and
    warrant (see Note 18B (2))</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-185; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-186; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">73</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">73</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Financial liability of
    warrants</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-187; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-188; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,518</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,518</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock', window );">Schedule of Details Regarding Fair Value Measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Details
regarding fair value measurement at Level 3:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Financial asset-<br/> convertible note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Financial liability-<br/> warrant</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Balance as of January 1, 2024</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">73</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">2,518</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(56</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,028</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Proceed</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(187</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revaluation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">114</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(3,341</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Balance as of December 31, 2024</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,149</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Financial
    asset-<br/> convertible note</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Financial
    liability-<br/> warrant</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">431</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Issuance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,015</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Proceed</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(875</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revaluation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">517</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,497</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,518</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Schedule of Fair Value Measurement</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    instrument</b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation<br/>
    method for<br/>
    determining <br/>
    fair value</b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant<br/>
    unobservable<br/>
    inputs</b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended December 31, 2024</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    (see note 9D1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Black
    - Scholes</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expected
    term</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.5, 1.5 years</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; width: 30%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; width: 15%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expected
    volatility</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>97.31%, 129.83</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"><b>%</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annual
    risk free interest</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.30%, 4.54</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividend
    yield</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended December 31, 2023</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Black
    - Scholes</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expected
    term</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3 years</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expected
    volatility</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89.94</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annual
    risk free interest</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.88</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividend
    yield</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    debt instrument</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DLOM</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FinancialInstrumentsTablesLineItems', window );"><strong>Financial Instruments (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory', window );">Schedule of Sensitivity Test to Possible Changes in Exchange Rate</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Sensitive
    instrument</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> &#160;(U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value<br/>
    (U.S.&#160;dollars<br/> in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents and deposits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">423</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">35</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">704</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(35</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other&#160;payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(723</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Post-employment benefit
    liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(140</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total&#160;income (loss)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is a sensitivity test to possible changes in USD/ EURO exchange rate as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Sensitive
    instrument</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value<br/>
    (U.S.&#160;dollars<br/> in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents and deposits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(92</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other&#160;payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total&#160;income (loss)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Sensitive
    instrument</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> &#160;(U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value<br/>
    (U.S.&#160;dollars<br/> in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents and deposits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">550</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(28</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">660</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(225</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other&#160;payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(67</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,340</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">67</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Post-employment benefit
    liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(141</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total&#160;income (loss)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(24</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is a sensitivity test to possible changes in USD/ EURO exchange rate as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Sensitive
    instrument</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value<br/>
    (U.S.&#160;dollars<br/> in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Income&#160;(loss)&#160;from<br/>
    change&#160;in&#160;exchange rate<br/> (U.S.&#160;dollars&#160;in&#160;thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Down&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;5%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Up&#160;2%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents and deposits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(153</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other&#160;payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(12</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(232</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total&#160;income (loss)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the effect of changes in foreign exchange rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS21_g51-57_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FinancialInstrumentsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FinancialInstrumentsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556773136592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 17, 2024</div></th>
<th class="th"><div>Aug. 23, 2020</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_GeneralLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AmericanDepositorySharesOrdinaryShares', window );">American depository ordinary shares</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">110,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CommonStockNoParValues', window );">Common stock par value (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares', window );">Warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AmericanDepositorySharesPurchase', window );">American depository shares purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PercentageOfContractToAcquire', window );">Contract to acquire, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_RetainedEarning', window );">Retained earnings (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PrivateAndPublicFinancingTotal', window );">Net of issuance expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relates to the assumed conversion of the entity&#8217;s warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_AmericanDepositorySharesOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>American depository shares ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_AmericanDepositorySharesOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_AmericanDepositorySharesPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ADS purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_AmericanDepositorySharesPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_CommonStockNoParValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock no par value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_CommonStockNoParValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_GeneralLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_GeneralLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_PercentageOfContractToAcquire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract to acquire, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_PercentageOfContractToAcquire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_PrivateAndPublicFinancingTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_PrivateAndPublicFinancingTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_RetainedEarning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_RetainedEarning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556774083408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation of the Consolidated Financial Statements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems', window );"><strong>Basis of Preparation of the Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FunctionalCurrency', window );">Functional currency</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems', window );"><strong>Basis of Preparation of the Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_StockOptionExercisedPeriod', window );">Stock option exercised period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FunctionalCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of functional currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FunctionalCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_StockOptionExercisedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option exercised period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_StockOptionExercisedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556812140800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation of the Consolidated Financial Statements - Schedule of Data on Exchange Rates (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeRatesAbstract', window );"><strong>Schedule of Data on Exchange Rates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Representative exchange rate</a></td>
<td class="nump">3.647<span></span>
</td>
<td class="nump">3.627<span></span>
</td>
<td class="nump">3.519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PercentageOfExchangeRate', window );">Representative exchange rate, percentage</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_PercentageOfExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_PercentageOfExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556774082912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material Accounting Policies (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 15, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract', window );"><strong>Material Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_NumberOfShare', window );">Number of Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_NumberOfPerShare', window );">Number of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DepreciationRightofuseAssetsUsefulLife', window );">Lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DepreciationRightofuseAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DepreciationRightofuseAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_NumberOfPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_NumberOfPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_NumberOfShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_NumberOfShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769208784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 17, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Aug. 23, 2020</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IntangibleAssetsDetailsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityMethodInvestmentsOwnershipPercentage', window );">Direct ownership of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.47%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AggregateUpfrontPayment', window );">Aggregate upfront payment (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AmericanDepositorySharesOrdinaryShares', window );">Ordinary shares (in Shares)</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">110,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_LongTermMilestonesAggregateAmount', window );">Long term milestones aggregate amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_TotalAcquisitionAmount', window );">Total acquisition (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueOfIssuedEquity', window );">Fair value of issued equity (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueOfIssuedIntangibleAssets', window );">Fair value of issued intangible assets (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AggregateShareholdersOfImmunorizon', window );">Aggregate shareholders of immunorizon (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_SharesPrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DescriptionOfExpectedVolatilityPercentage', window );">Description of expected volatility percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DescriptionOfExpectedAnnualRiskFreeRate', window );">Description of expected annual risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PercentageOfDiscountsForLacksOfMarketability', window );">Percentage of discount for lack of marketability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IntangibleAssetsRecoverableAmountPercentage', window );">Intangible assets recoverable amount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ppbt_AdsMember', window );">ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IntangibleAssetsDetailsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AggregateUpfrontPayment', window );">Aggregate upfront payment (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_AggregateShareholdersOfImmunorizon">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate shareholders of immunorizon.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_AggregateShareholdersOfImmunorizon</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_AggregateUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Aggregate upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_AggregateUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_AmericanDepositorySharesOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>American depository shares ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_AmericanDepositorySharesOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DescriptionOfExpectedAnnualRiskFreeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of expected annual risk free rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DescriptionOfExpectedAnnualRiskFreeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DescriptionOfExpectedVolatilityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of expected volatility percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DescriptionOfExpectedVolatilityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_EquityMethodInvestmentsOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct ownership of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_EquityMethodInvestmentsOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FairValueOfIssuedEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of issued equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FairValueOfIssuedEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FairValueOfIssuedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of issued intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FairValueOfIssuedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_IntangibleAssetsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_IntangibleAssetsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_IntangibleAssetsRecoverableAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets recoverable amount percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_IntangibleAssetsRecoverableAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_LongTermMilestonesAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of long term Milestones aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_LongTermMilestonesAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_PercentageOfDiscountsForLacksOfMarketability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of discounts for lacks of marketability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_PercentageOfDiscountsForLacksOfMarketability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_SharesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_SharesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_TotalAcquisitionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of total acquisition .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_TotalAcquisitionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ppbt_AdsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ppbt_AdsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556773082384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Total intangible assets</a></td>
<td class="nump">$ 27,842<span></span>
</td>
<td class="nump">$ 28,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ppbt_IPRDRelatedToTryNovosee5ABelowMember', window );">IPR&amp;D related to TyrNovo (see 4A below) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Total intangible assets</a></td>
<td class="nump">6,172<span></span>
</td>
<td class="nump">6,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ppbt_IPRDRelatedToFamewaveSee5BBelowMember', window );">IPR&amp;D related to Famewave (see 4B below) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Total intangible assets</a></td>
<td class="nump">14,310<span></span>
</td>
<td class="nump">14,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ppbt_IPRDRelatedToImmunorizonSee5CBelowMember', window );">IPR&amp;D related to Immunorizon (see 4C below) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Total intangible assets</a></td>
<td class="nump">7,360<span></span>
</td>
<td class="nump">7,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ppbt_IPRDRelatedToPurpleGmbHMember', window );">IPR&amp;D related to Purple GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Total intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ppbt_IPRDRelatedToTryNovosee5ABelowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ppbt_IPRDRelatedToTryNovosee5ABelowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ppbt_IPRDRelatedToFamewaveSee5BBelowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ppbt_IPRDRelatedToFamewaveSee5BBelowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ppbt_IPRDRelatedToImmunorizonSee5CBelowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ppbt_IPRDRelatedToImmunorizonSee5CBelowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ppbt_IPRDRelatedToPurpleGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ppbt_IPRDRelatedToPurpleGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556768084272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Recognized Amounts of Assets Acquired and Liabilities Assumed (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems', window );"><strong>Schedule of Recognized Amounts Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Intangible asset</a></td>
<td class="nump">7,360<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="num">(28)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables</a></td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Total net identifiable assets</a></td>
<td class="nump">$ 7,375<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Intangible asset - In process research and development</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 119<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_119&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556771821776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CashAndCashEquivalentLineItems', window );"><strong>Schedule of Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 7,401<span></span>
</td>
<td class="nump">$ 14,489<span></span>
</td>
<td class="nump">$ 15,030<span></span>
</td>
<td class="nump">$ 10,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">Balance in USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CashAndCashEquivalentLineItems', window );"><strong>Schedule of Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Total cash and cash equivalents</a></td>
<td class="nump">7,050<span></span>
</td>
<td class="nump">14,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=srt_OtherCurrencyMember', window );">Balance in other currencies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CashAndCashEquivalentLineItems', window );"><strong>Schedule of Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 351<span></span>
</td>
<td class="nump">$ 482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_CashAndCashEquivalentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_CashAndCashEquivalentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=srt_OtherCurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=srt_OtherCurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770749424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 15, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AgreementLeaseTerm', window );">Agreement lease term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Lease liability and right-of-use asset (in Dollars)</a></td>
<td class="nump">$ 817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AgreementLeaseAdditionalTerm', window );">Agreement lease additional term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CurrentTerms', window );">Percentage of current terms</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_RehovotMember', window );">Rehovot [Member] | Lease Agreement One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AgreementLeaseTerm', window );">Agreement lease term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_RehovotMember', window );">Rehovot [Member] | Lease Agreements Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AgreementLeaseTerm', window );">Agreement lease term</a></td>
<td class="text">3 months 15 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_AgreementLeaseAdditionalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Lease Additional Term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_AgreementLeaseAdditionalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_AgreementLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Lease Term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_AgreementLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_CurrentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_CurrentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_RehovotMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_RehovotMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ppbt_LeaseAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ppbt_LeaseAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ppbt_LeaseAgreementsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ppbt_LeaseAgreementsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770854960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Carrying Amounts of Right-to-Use Assets (Details) - Office lease [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Schedule of Carrying Amounts of Right-to-Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning</a></td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation on right-to-use assets</a></td>
<td class="num">(152)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at ending</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770298960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturity Analysis of the Company's Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Schedule of Maturity Analysis of the Company's Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Total</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current maturities of lease liability</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Long-term lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than one year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Schedule of Maturity Analysis of the Company's Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Total</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">One to two years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Schedule of Maturity Analysis of the Company's Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556774086544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Amounts Recognized in Profit or Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Schedule of Amounts Recognized in Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expenses on lease liability</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769750480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current Assets - Schedule of Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Schedule of Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Total other current assets</a></td>
<td class="nump">$ 384<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769297232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Payables - Schedule of Other Payables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Schedule of Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Due to related parties - salary related</a></td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">2,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentGovernmentGrants', window );">Government authorities</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_SalaryRelatedOtherPayablesCurrent', window );">Salary related</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Total other payables</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 3,463<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables due to related parties. [Refer: Total for all related parties [member]; Payables to related parties]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_SalaryRelatedOtherPayablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current salary related payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_SalaryRelatedOtherPayablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556763108256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Jan. 06, 2025</div></th>
<th class="th"><div>Dec. 05, 2024</div></th>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 19, 2023</div></th>
<th class="th"><div>Oct. 19, 2023</div></th>
<th class="th"><div>Oct. 17, 2023</div></th>
<th class="th"><div>Mar. 23, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 19, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_NonVotingSeniorPreferredShares', window );">Non-voting senior preferred shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_StockholdersEquityReversesStockSplit', window );">Stockholders equity reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1:10 to 1:200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ReverseRatio', window );">Reverse ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1:20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FundsRaisedAmount', window );">Company funds raised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Placement agent fees and other offering related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,850<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,440<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_NumberOfNonTradableWarrants', window );">Aggregate shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Public offering issued price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Net of issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_WarrantsTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantReserve', window );">Warrant inducement transaction gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,560<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,490<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,970<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DepositaryShares', window );">Depositary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_WarrantsIssued', window );">Warrant purchased (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_WarrantTermDescription', window );">Warrant term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">an extended term of five and a half years from the closing of the offering<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The October 2023 warrants have a term of five and a half years and have an exercise price of USD 25 per ADS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
<td class="nump">$ 2,195<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceContractsIssuedThatAreAssets', window );">Prospectus amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_SalesAgreementShares', window );">Sales agreement (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457,801<span></span>
</td>
<td class="nump">52,202<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">27,170<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Average price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 32.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,586,000<span></span>
</td>
<td class="nump">1,261,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">924,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">890,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_noncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=ppbt_PrivatePlacementsMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Placement agent fees and other offering related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantReserve', window );">Warrant inducement transaction gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Public offering issued price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_WarrantsIssued', window );">Warrant purchased (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Public offering issued price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_WarrantsIssued', window );">Warrant purchased (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_AdsMember', window );">ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_WarrantsTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PurchaseOfCommonStockAndWarrants', window );">Warrants to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_AdsMember', window );">ADS [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Placement agent fees and other offering related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_AdsMember', window );">ADS [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_AdsMember', window );">ADS [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Placement agent fees and other offering related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FundsRaisedshares', window );">Funds raised amount (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [Member] | ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PurchaseOfCommonStockAndWarrants', window );">Warrants to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember', window );">RSUs Granted [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,142,000<span></span>
</td>
<td class="nump">3,680,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,380,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ppbt_AdsMember', window );">ADS [Member] | PublicOfferingMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_NumberOfNonTradableWarrants', window );">Aggregate shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ppbt_AdsMember', window );">ADS [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PurchaseOfCommonStockAndWarrants', window );">Warrants to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Authorized share capital (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember', window );">Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Authorized share capital (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ppbt_ATMProgramMember', window );">ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ppbt_ATMProgramMember', window );">ATM Program [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Issuance expenses</a></td>
<td class="nump">$ 1,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ppbt_PublicOfferingMember', window );">PublicOfferingMember | ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Public offering issued price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PurchaseOfCommonStockAndWarrants', window );">Warrants to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IssuesOfEquity', window );">Issue of equity (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ExerciseOfWarrantsEquity', window );">Warrants fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ppbt_PublicOfferingMember', window );">PublicOfferingMember | ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PurchaseOfCommonStockAndWarrants', window );">Warrants to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="19"></td></tr>
<tr><td colspan="19"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Restated to reflect a 1:20 reverse ratio that took place in September 2024. (see also note 9A)</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InsuranceContractsIssuedThatAreAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of insurance contracts issued that are assets. [Refer: Assets; Insurance contracts issued [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph da<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_da&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InsuranceContractsIssuedThatAreAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DepositaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depositary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DepositaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FundsRaisedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds raised amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FundsRaisedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FundsRaisedshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds raised amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FundsRaisedshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_IssuesOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_IssuesOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_NonVotingSeniorPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-voting senior preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_NonVotingSeniorPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_NumberOfNonTradableWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Non Tradable Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_NumberOfNonTradableWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_PurchaseOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The company granted representative of the non traded warrants to purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_PurchaseOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ReverseRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ReverseRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_SalesAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales agreement shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_SalesAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_StockholdersEquityReversesStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_StockholdersEquityReversesStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_WarrantTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of warrant term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_WarrantTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_WarrantsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of warrants, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_WarrantsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_noncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_noncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=ppbt_PrivatePlacementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=ppbt_PrivatePlacementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_AdsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_AdsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ppbt_AdsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ppbt_AdsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=ppbt_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=ppbt_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ppbt_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ppbt_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ppbt_SubsequentEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ppbt_SubsequentEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ppbt_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ppbt_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769805424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Schedule of Share Capital (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ClassesOfPreferredSharesAxis=ppbt_OrdinaryShareMember', window );">Ordinary Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Schedule of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares, Authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares, Issued and paid-in</a></td>
<td class="nump">517,129<span></span>
</td>
<td class="nump">252,379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ClassesOfPreferredSharesAxis=ppbt_PreferredShareClassMember', window );">Class A Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Schedule of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares, Authorized</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares, Issued and paid-in</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ClassesOfPreferredSharesAxis=ppbt_PreferredShareClassBMember', window );">Class B Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Schedule of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares, Authorized</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares, Issued and paid-in</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ClassesOfPreferredSharesAxis=ppbt_PreferredClassCMember', window );">Class C Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Schedule of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares, Authorized</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares, Issued and paid-in</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ClassesOfPreferredSharesAxis=ppbt_PreferredClassDMember', window );">Class D Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Schedule of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares, Authorized</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares, Issued and paid-in</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ClassesOfPreferredSharesAxis=ppbt_ClassEPreferredSharesMember', window );">Class E Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Schedule of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares, Authorized</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares, Issued and paid-in</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ClassesOfPreferredSharesAxis=ppbt_OrdinaryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ClassesOfPreferredSharesAxis=ppbt_OrdinaryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ClassesOfPreferredSharesAxis=ppbt_PreferredShareClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ClassesOfPreferredSharesAxis=ppbt_PreferredShareClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ClassesOfPreferredSharesAxis=ppbt_PreferredShareClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ClassesOfPreferredSharesAxis=ppbt_PreferredShareClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ClassesOfPreferredSharesAxis=ppbt_PreferredClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ClassesOfPreferredSharesAxis=ppbt_PreferredClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ClassesOfPreferredSharesAxis=ppbt_PreferredClassDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ClassesOfPreferredSharesAxis=ppbt_PreferredClassDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ClassesOfPreferredSharesAxis=ppbt_ClassEPreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ClassesOfPreferredSharesAxis=ppbt_ClassEPreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556771610768">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Changes in Share Capital (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Schedule of Changes in Share Capital [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Issued as at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">924<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">890<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_NumberOfIssuanceShares', window );">Issuance of ADSs (See D below and 4C)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">930<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_NumberOfVestingOfRsus', window );">Vesting of RSUs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_NumberOfExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">379<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Issued as at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,586<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">924<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Restated to reflect a 1:20 reverse ratio that took place in September 2024. (see also note 9A)</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_NumberOfExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_NumberOfExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_NumberOfIssuanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of issuance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_NumberOfIssuanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_NumberOfVestingOfRsus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Vesting Of Rsus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_NumberOfVestingOfRsus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770537888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of the Information Relating to Non-Controlling Interests (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract', window );"><strong>Schedule of the Information Relating to Non-Controlling Interests [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CurrentAsset', window );">Current assets</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CurrentLiabiliti', window );">Current liabilities</a></td>
<td class="num">(25,901)<span></span>
</td>
<td class="num">(23,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets</a></td>
<td class="num">(25,711)<span></span>
</td>
<td class="num">(23,166)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_NetAssetsAttributableToNoncontrollingInterest', window );">Net assets attributable to non-controlling interests</a></td>
<td class="num">(394)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests', window );">Loss for the year</a></td>
<td class="nump">2,545<span></span>
</td>
<td class="nump">6,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_NetAssetsAttributableToNoncontrollingInterests', window );">Loss allocated to non-controlling interests</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG63<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations attributable to non-controlling interests. [Refer: Profit (loss) from continuing operations; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Section Example 11<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;doctype=Implementation%20Guidance&amp;dita_xref=IFRS05_ex11_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_CurrentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of Corrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_CurrentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_CurrentLiabiliti">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_CurrentLiabiliti</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_NetAssetsAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of Mount of net assets attributable to non-controling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_NetAssetsAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_NetAssetsAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net assets attributable to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_NetAssetsAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770021136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Arrangements (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 15, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 24, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 02, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 11, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 23, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,150,000<span></span>
</td>
<td class="nump">2,777,000<span></span>
</td>
<td class="nump">11,135,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_OptionExerciseOrdinaryShare', window );">Option exercise ordinary share (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AmericanDepostioryShares', window );">American shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 3 days<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">3 years 10 months 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ConvertibleShares', window );">Convertible shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=srt_OfficerMember', window );">Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ConsultantPerShares', window );">Consultant per shares (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ppbt_ShareBasedPaymentArrangementsMember', window );">Share Based Payment Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Exercise price of option (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.037<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value options value (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ppbt_BoardOfDirectorsMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted shares</a></td>
<td class="nump">3,150,000<span></span>
</td>
<td class="nump">2,732,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
<td class="nump">6,635,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Exercise price of option (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.245<span></span>
</td>
<td class="nump">$ 0.304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ExercisePeriod', window );">Exercisable period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ppbt_BoardOfDirectorsMember', window );">Board of Directors [Member] | Share Based Payment Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_VestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember', window );">Restricted share units [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AmericanDepostioryShares', window );">American shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember', window );">Restricted share units [member] | Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted shares</a></td>
<td class="nump">3,150,000<span></span>
</td>
<td class="nump">2,732,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">5,885,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Exercise price of option (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_VestingPeriod', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value options value (in Dollars) | $</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 729<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
<td class="nump">$ 3,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_OptionExerciseOrdinaryShare', window );">Option exercise ordinary share (in Shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member] | Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Exercise price of option (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ppbt_AdsMember', window );">Ads [Member] | Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted shares</a></td>
<td class="nump">15,750<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ppbt_AdsMember', window );">Ads [Member] | Restricted share units [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember', window );">Restricted share units [member] | Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_VestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_AmericanDepostioryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>American depostiory shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_AmericanDepostioryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ConsultantPerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ConsultantPerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ConvertibleShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ConvertibleShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents exercise period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_OptionExerciseOrdinaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option exercise ordinary share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_OptionExerciseOrdinaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_VestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_VestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ppbt_ShareBasedPaymentArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ppbt_ShareBasedPaymentArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ppbt_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ppbt_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ppbt_AdsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ppbt_AdsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769453776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Arrangements - Schedule of Number and Weighted Average Exercise Prices of Share Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract', window );"><strong>Schedule of Number and Weighted Average Exercise Prices of Share Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Outstanding beginning balance</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options, Outstanding beginning balance</a></td>
<td class="nump">19,218,783<span></span>
</td>
<td class="nump">18,468,235<span></span>
</td>
<td class="nump">7,751,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options, Exercisable</a></td>
<td class="nump">14,420,406<span></span>
</td>
<td class="nump">10,923,032<span></span>
</td>
<td class="nump">6,144,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Expired and forfeited during the year</a></td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of options, Expired and forfeited during the year</a></td>
<td class="num">(2,004,460)<span></span>
</td>
<td class="num">(2,026,452)<span></span>
</td>
<td class="num">(418,068)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Granted during the year</a></td>
<td class="nump">$ 0.037<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options, Granted during the year</a></td>
<td class="nump">3,150,000<span></span>
</td>
<td class="nump">2,777,000<span></span>
</td>
<td class="nump">11,135,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Outstanding ending balance</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options, Outstanding ending balance</a></td>
<td class="nump">20,364,323<span></span>
</td>
<td class="nump">19,218,783<span></span>
</td>
<td class="nump">18,468,235<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556908307584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Arrangements - Schedule of Number of RSUs (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ScheduleOfNumberOfRSUsAbstract', window );"><strong>Schedule of Number of RSUs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding at January 1</a></td>
<td class="nump">5,770,750<span></span>
</td>
<td class="nump">7,857,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year</a></td>
<td class="nump">3,150,000<span></span>
</td>
<td class="nump">2,777,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year</a></td>
<td class="num">(859,584)<span></span>
</td>
<td class="num">(1,187,292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the year</a></td>
<td class="num">(3,142,249)<span></span>
</td>
<td class="num">(3,676,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding at December 31</a></td>
<td class="nump">4,918,917<span></span>
</td>
<td class="nump">5,770,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ScheduleOfNumberOfRSUsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ScheduleOfNumberOfRSUsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556771410080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Arrangements - Schedule of Assumptions were Used (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ScheduleOfAssumptionsWereUsedLineItems', window );"><strong>Schedule of Assumptions were Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share Price - USD (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price - USD (in Dollars per share)</a></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="nump">$ 0.037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ScheduleOfAssumptionsWereUsedLineItems', window );"><strong>Schedule of Assumptions were Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share Price - USD (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price - USD (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.54%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected duration (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.56%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ScheduleOfAssumptionsWereUsedLineItems', window );"><strong>Schedule of Assumptions were Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share Price - USD (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price - USD (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.04%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected duration (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.31%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ScheduleOfAssumptionsWereUsedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ScheduleOfAssumptionsWereUsedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770856736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Arrangements - Schedule of Expenses Recognized in the Consolidated Financial Statements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Schedule of Expenses Recognized in the Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Total share-based expense recognized</a></td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">$ 1,875<span></span>
</td>
<td class="nump">$ 2,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ppbt_ResearchAndDevelopmentExpensesMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Schedule of Expenses Recognized in the Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Total share-based expense recognized</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">768<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expense [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Schedule of Expenses Recognized in the Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Total share-based expense recognized</a></td>
<td class="nump">$ 465<span></span>
</td>
<td class="nump">$ 1,107<span></span>
</td>
<td class="nump">$ 1,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ppbt_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ppbt_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769192144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PercentageOfCapacityOfAnAdvisor', window );">Percentage of capacity of an advisor</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_PercentageOfCapacityOfAnAdvisor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of capacity of an advisor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_PercentageOfCapacityOfAnAdvisor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769451536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Recorded Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Schedule of Recorded Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short - term</a></td>
<td class="nump">$ 1,257<span></span>
</td>
<td class="nump">$ 2,066<span></span>
</td>
<td class="nump">$ 2,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share based payments</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="nump">1,930<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">1,634<span></span>
</td>
<td class="nump">3,424<span></span>
</td>
<td class="nump">4,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Schedule of Recorded Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short - term</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share based payments</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">$ 587<span></span>
</td>
<td class="nump">$ 711<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770425648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Details)<br> &#8362; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 07, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 07, 2022 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CommitmentsAndContingentLiabilitiesLineItems', window );"><strong>Commitments and Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnLitigationSettlements', window );">Gains on litigation settlements</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">&#8362; 9.0<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="nump">&#8362; 29.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_TryNovosTechnologiesMember', window );">TryNovo's Technologies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CommitmentsAndContingentLiabilitiesLineItems', window );"><strong>Commitments and Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,510,000<span></span>
</td>
<td class="nump">&#8362; 5.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_YissumsLicensedTechnologyMember', window );">Yissum&#8217;s Licensed Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CommitmentsAndContingentLiabilitiesLineItems', window );"><strong>Commitments and Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Annual interest rate of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PercentageOfSublicenseConsideration', window );">Percentage of sublicense consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PercentageOfReceiveExitFee', window );">Percentage of exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_THMMember', window );">THM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CommitmentsAndContingentLiabilitiesLineItems', window );"><strong>Commitments and Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PercentageOfSublicenseConsideration', window );">Percentage of sublicense consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PercentageOfReceiveExitFee', window );">Percentage of exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LicenceFeeIncome', window );">Annual license fee (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_THMMember', window );">THM [Member] | Biopharmaceutical Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CommitmentsAndContingentLiabilitiesLineItems', window );"><strong>Commitments and Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Annual interest rate of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_THMMember', window );">THM [Member] | Diagnostic Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CommitmentsAndContingentLiabilitiesLineItems', window );"><strong>Commitments and Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Annual interest rate of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_PercentageOfSublicenseConsideration', window );">Percentage of sublicense consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_RangesAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CommitmentsAndContingentLiabilitiesLineItems', window );"><strong>Commitments and Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Annual interest rate of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_RangesAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_CommitmentsAndContingentLiabilitiesLineItems', window );"><strong>Commitments and Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Annual interest rate of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsOnLitigationSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain on settlements of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsOnLitigationSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LicenceFeeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from licence fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LicenceFeeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_CommitmentsAndContingentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_CommitmentsAndContingentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_PercentageOfReceiveExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of receive exit fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_PercentageOfReceiveExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_PercentageOfSublicenseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sublicense consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_PercentageOfSublicenseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_TryNovosTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_TryNovosTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_YissumsLicensedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_YissumsLicensedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_THMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_THMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ppbt_BiopharmaceuticalProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ppbt_BiopharmaceuticalProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ppbt_DiagnosticProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ppbt_DiagnosticProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_RangesAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_RangesAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_RangesAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_RangesAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556774070864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses - Schedule of Research and Development Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems', window );"><strong>Schedule of Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 7,620<span></span>
</td>
<td class="nump">$ 17,034<span></span>
</td>
<td class="nump">$ 16,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ppbt_SalariesWagesAndRelatedExpensesMember', window );">Salaries, wages and related expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems', window );"><strong>Schedule of Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,536<span></span>
</td>
<td class="nump">2,323<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ppbt_ShareBasedPaymentsMember', window );">Share-based payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems', window );"><strong>Schedule of Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">768<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ppbt_ServiceProvidersMember', window );">Service providers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems', window );"><strong>Schedule of Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 5,967<span></span>
</td>
<td class="nump">$ 13,943<span></span>
</td>
<td class="nump">$ 13,170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ppbt_SalariesWagesAndRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ppbt_SalariesWagesAndRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ppbt_ShareBasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ppbt_ShareBasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ppbt_ServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ppbt_ServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769298960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sales, General and Administrative Expenses - Schedule of Sales, General and Administrative Expenses (Details) - Selling, general and administrative expense [member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems', window );"><strong>Schedule of Sales, General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Salaries, wages and related expenses</a></td>
<td class="nump">$ 925<span></span>
</td>
<td class="nump">$ 1,769<span></span>
</td>
<td class="nump">$ 1,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payments</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">823<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ReimbursementOfLegalFeesExpense', window );">Reimbursement of legal fees</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Other professional fees</a></td>
<td class="nump">772<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Board member remuneration and insurance</a></td>
<td class="nump">627<span></span>
</td>
<td class="nump">818<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees', window );">Board member share-based payments</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RentalExpense', window );">Maintenance expenses</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TravelExpense', window );">Travel and car expenses</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_GeneralAndAdministrativeExpensesOther', window );">Other</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Sales, General and Administrative Expenses total</a></td>
<td class="nump">$ 3,183<span></span>
</td>
<td class="nump">$ 5,237<span></span>
</td>
<td class="nump">$ 6,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DirectorsRemunerationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of remuneration paid or payable to the entity's directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DirectorsRemunerationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with parties other than employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised on rental activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TravelExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from travel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TravelExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_GeneralAndAdministrativeExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_GeneralAndAdministrativeExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ReimbursementOfLegalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of legal fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ReimbursementOfLegalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556768196608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Expense (Income), Net (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FinanceExpenseIncomeNetLineItems', window );"><strong>Finance Expense (Income), Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_WarrantsExpireTerm', window );">Warrants expire term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FinanceExpenseIncomeNetLineItems', window );"><strong>Finance Expense (Income), Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_WarrantsExpireTerm', window );">Warrants expire term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FinanceExpenseIncomeNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FinanceExpenseIncomeNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_WarrantsExpireTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Expire Term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_WarrantsExpireTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556778287472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Expense (Income), Net - Schedule of Finance Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ScheduleOfFinanceExpensesAbstract', window );"><strong>Schedule Of Finance Expenses Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Fees and interest expense</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeLoss', window );">Loss from exchange rate differences, net</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IssuanceExpenses', window );">Issuance expenses (see note 9D)</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_OtherfinancialCost', window );">Other</a></td>
<td class="nump">25<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Total finance expenses</a></td>
<td class="nump">$ 483<span></span>
</td>
<td class="nump">$ 2,195<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_IssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_IssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_OtherfinancialCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_OtherfinancialCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ScheduleOfFinanceExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ScheduleOfFinanceExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556774007120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Expense (Income), Net - Schedule of Finance Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FinanceIncomeAbstract', window );"><strong>Finance income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnDeposits', window );">Interest income from deposits</a></td>
<td class="num">$ (260)<span></span>
</td>
<td class="num">$ (474)<span></span>
</td>
<td class="num">$ (532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeGain', window );">Income from exchange rate differences, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">Changes in fair value of finance instruments (see Note 18B2)</a></td>
<td class="num">(608)<span></span>
</td>
<td class="num">(517)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_OtherExpense', window );">Other</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncome', window );">Total finance income</a></td>
<td class="num">$ (868)<span></span>
</td>
<td class="num">$ (992)<span></span>
</td>
<td class="num">$ (910)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on deposits. [Refer: Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556769298416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_TaxesOnIncomeabstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Tax rate applicable</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_StatutoryTaxRate', window );">Statutory tax rate.</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense', window );">Tax benefit</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_UnrecognizedResearchAndDevelopmentExpenses', window );">Unrecognized research and development expenses</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="nump">$ 96.0<span></span>
</td>
<td class="nump">$ 82.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce deferred tax expense. [Refer: Deferred tax expense (income); Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 80<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_80_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_EffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_EffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_StatutoryTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statutory tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_StatutoryTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_TaxesOnIncomeabstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_TaxesOnIncomeabstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_UnrecognizedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unrecognized research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_UnrecognizedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556771398336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract', window );"><strong>Employee Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EmployeeBenefitBonus', window );">Bonuses expenses</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 446<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_EmployeeBenefitsLiabilityDueGrants', window );">Employee benefits liability due grants</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_EmployeeBenefitBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee benefit bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_EmployeeBenefitBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_EmployeeBenefitsLiabilityDueGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee benefits liability due grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_EmployeeBenefitsLiabilityDueGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556771046336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Schedule of Post-Employee Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ScheduleOfPostEmployeeBenefitsAbstract', window );"><strong>Schedule of Post-Employee Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Short-term benefits</a></td>
<td class="nump">$ 331<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss', window );">Post-employment benefit liabilities</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense included in profit or loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ScheduleOfPostEmployeeBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ScheduleOfPostEmployeeBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556770740528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Schedule of Defined Contribution Plan in Respect of its Employees (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract', window );"><strong>Schedule of Defined Contribution Plan in Respect of its Employees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans', window );">Amount recognized as expense in respect of defined contribution plan</a></td>
<td class="nump">$ 322<span></span>
</td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556761634416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Jun. 19, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 05, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Cash and cash equivalents and short-term and long-terms deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 848<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Fair value financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_WarrantsIssued', window );">Warrants issued (in Shares)</a></td>
<td class="nump">19,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FinancialInstrumentAmount', window );">Financial instrument amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_NetOfDeferredDifferenceAmount', window );">Net of deferred difference amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Bear fixed interest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_WarrantsIssued', window );">Warrants issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Bear fixed interest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_WarrantsIssued', window );">Warrants issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_ADSMember', window );">ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_WarrantExercisePricePerShare', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DepositarysShares', window );">Depositary shares (in Shares)</a></td>
<td class="nump">281,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_SeriesA1WarrantsMember', window );">Series A-1 warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AggregateWarrantsShares', window );">Aggregate warrants shares (in Shares)</a></td>
<td class="nump">248,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_SeriesA2WarrantsMember', window );">Series A-2 warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_AggregateWarrantsShares', window );">Aggregate warrants shares (in Shares)</a></td>
<td class="nump">314,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Cash and cash equivalents and short-term and long-terms deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,249<span></span>
</td>
<td class="nump">15,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit', window );">Short term deposits guaranteed for leases and credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ShortTermDepositsGuaranteedForHedgingTransactions', window );">Short term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Convertible note amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ConvertibleWarrants', window );">Convertible warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_TerminationExercisePrice', window );">Termination exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ppbt_January2025Member', window );">January 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Convertible note amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ConvertiblesWarrants', window );">Convertible warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Fair value financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FinancialAssetAtAFairValue', window );">Financial asset at a fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity resulting from the issuing of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_AggregateWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_AggregateWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ConvertibleWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ConvertibleWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ConvertiblesWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ConvertiblesWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DepositarysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depositary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DepositarysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FinancialAssetAtAFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of financial asset at a fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FinancialAssetAtAFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FinancialInstrumentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial instrument amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FinancialInstrumentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_NetOfDeferredDifferenceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net of deffered difference amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_NetOfDeferredDifferenceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ShortTermDepositsGuaranteedForHedgingTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short term deposits guaranteed for hedging transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ShortTermDepositsGuaranteedForHedgingTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short term deposits guaranteed for leases and credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_TerminationExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_TerminationExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_WarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_WarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_ADSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_ADSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_SeriesA1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_SeriesA1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_SeriesA2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ppbt_SeriesA2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ppbt_January2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ppbt_January2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556775322192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Sensitivity Test to Possible Changes in Exchange Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ppbt_DownRangeOneMember', window );">Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ppbt_UpRangeOneMember', window );">Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_CashAndCashEquivalentsAndDepositsMember', window );">Cash and cash equivalents and deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_CashAndCashEquivalentsAndDepositsMember', window );">Cash and cash equivalents and deposits [Member] | Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_CashAndCashEquivalentsAndDepositsMember', window );">Cash and cash equivalents and deposits [Member] | Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_CashAndCashEquivalentsAndDepositsMember', window );">Cash and cash equivalents and deposits [Member] | Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_CashAndCashEquivalentsAndDepositsMember', window );">Cash and cash equivalents and deposits [Member] | Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_AccountPayablesMember', window );">Accounts payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_AccountPayablesMember', window );">Accounts payable [Member] | Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_AccountPayablesMember', window );">Accounts payable [Member] | Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_AccountPayablesMember', window );">Accounts payable [Member] | Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_AccountPayablesMember', window );">Accounts payable [Member] | Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_OtherPayablesMember', window );">Other payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_OtherPayablesMember', window );">Other payables [Member] | Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_OtherPayablesMember', window );">Other payables [Member] | Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_OtherPayablesMember', window );">Other payables [Member] | Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_OtherPayablesMember', window );">Other payables [Member] | Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Cash and cash equivalents and deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Cash and cash equivalents and deposits [Member] | Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Cash and cash equivalents and deposits [Member] | Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Cash and cash equivalents and deposits [Member] | Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Cash and cash equivalents and deposits [Member] | Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Other current assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Other current assets [Member] | Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Other current assets [Member] | Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Other current assets [Member] | Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Other current assets [Member] | Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Accounts payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Accounts payable [Member] | Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Accounts payable [Member] | Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Accounts payable [Member] | Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Accounts payable [Member] | Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Other payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="num">(723)<span></span>
</td>
<td class="num">(1,340)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Other payables [Member] | Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Other payables [Member] | Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Other payables [Member] | Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Other payables [Member] | Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Post-employment benefit liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="num">(140)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Post-employment benefit liabilities [Member] | Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Post-employment benefit liabilities [Member] | Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Post-employment benefit liabilities [Member] | Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember', window );">EURO [Member] | Post-employment benefit liabilities [Member] | Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Cash and cash equivalents and deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Cash and cash equivalents and deposits [Member] | Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Cash and cash equivalents and deposits [Member] | Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Cash and cash equivalents and deposits [Member] | Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Cash and cash equivalents and deposits [Member] | Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Accounts payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="num">(92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Accounts payable [Member] | Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Accounts payable [Member] | Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Accounts payable [Member] | Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Accounts payable [Member] | Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Other payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossValue', window );">Income (loss) value</a></td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Other payables [Member] | Down 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Other payables [Member] | Down 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateDown', window );">Income (loss) from change in exchange rate</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Other payables [Member] | Up 5% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember', window );">NIS [Member] | Other payables [Member] | Up 2% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_IncomelossFromChangeInExchangeRateUp', window );">Income (loss) from change in exchange rate</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_IncomelossFromChangeInExchangeRateDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from change in exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_IncomelossFromChangeInExchangeRateDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_IncomelossFromChangeInExchangeRateUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from change in exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_IncomelossFromChangeInExchangeRateUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_IncomelossValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income loss value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_IncomelossValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ppbt_DownRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ppbt_DownRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ppbt_UpRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ppbt_UpRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_CashAndCashEquivalentsAndDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_CashAndCashEquivalentsAndDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_AccountPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_AccountPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_OtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_OtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ppbt_EUROMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ppbt_EUROMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_OtherCurrentAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_OtherCurrentAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_PostemploymentBenefitLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=ppbt_PostemploymentBenefitLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ppbt_NISMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ppbt_NISMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556760692768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Financial Instruments Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FinancialAssetAndLiabilitiesAbstract', window );"><strong>Financial asset and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_Securities', window );">Securities (see Note 18B (2))</a></td>
<td class="nump">$ 275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Convertible debt instrument and warrant (see Note 18B (2))</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Financial liability of warrants</a></td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FinancialAssetAndLiabilitiesAbstract', window );"><strong>Financial asset and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_Securities', window );">Securities (see Note 18B (2))</a></td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Convertible debt instrument and warrant (see Note 18B (2))</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Financial liability of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FinancialAssetAndLiabilitiesAbstract', window );"><strong>Financial asset and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_Securities', window );">Securities (see Note 18B (2))</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Convertible debt instrument and warrant (see Note 18B (2))</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Financial liability of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FinancialAssetAndLiabilitiesAbstract', window );"><strong>Financial asset and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_Securities', window );">Securities (see Note 18B (2))</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Convertible debt instrument and warrant (see Note 18B (2))</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Financial liability of warrants</a></td>
<td class="nump">$ 1,149<span></span>
</td>
<td class="nump">$ 2,518<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FinancialAssetAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FinancialAssetAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_Securities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_Securities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556773133312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Details Regarding Fair Value Measurement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ppbt_ConvertibleNoteMember', window );">Convertible note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueMeasurementBalance', window );">Balance</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueMeasurementExercise', window );">Exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueMeasurementIssuance', window );">Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueMeasurementIssuanceProceed', window );">Proceed</a></td>
<td class="num">(187)<span></span>
</td>
<td class="num">(875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueMeasurementRevaluation', window );">Revaluation</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueMeasurementBalance', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ppbt_WarrantsoneMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueMeasurementBalance', window );">Balance</a></td>
<td class="nump">2,518<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueMeasurementExercise', window );">Exercise</a></td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueMeasurementIssuance', window );">Issuance</a></td>
<td class="nump">2,028<span></span>
</td>
<td class="nump">6,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueMeasurementIssuanceProceed', window );">Proceed</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueMeasurementRevaluation', window );">Revaluation</a></td>
<td class="num">(3,341)<span></span>
</td>
<td class="num">(3,497)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_FairValueMeasurementBalance', window );">Balance</a></td>
<td class="nump">$ 1,149<span></span>
</td>
<td class="nump">$ 2,518<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FairValueMeasurementBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement Balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FairValueMeasurementBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FairValueMeasurementExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the fair value of exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FairValueMeasurementExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FairValueMeasurementIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FairValueMeasurementIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FairValueMeasurementIssuanceProceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement Proceed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FairValueMeasurementIssuanceProceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_FairValueMeasurementRevaluation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement Revaluation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_FairValueMeasurementRevaluation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ppbt_ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ppbt_ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ppbt_WarrantsoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ppbt_WarrantsoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556768953456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Fair Value Measurement (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">95.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">annual risk free interest</a></td>
<td class="nump">3.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ppbt_WarrantsoneMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DescriptionOfOptionLifeShareOptionGranted', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.94%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">annual risk free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.88%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield', window );">dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ppbt_ConvertibleDebtInstrumentMember', window );">Convertible debt instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_Discountforlackofmarketability', window );">DLOM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">annual risk free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.31%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.54%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">annual risk free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.56%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ppbt_WarrantsoneMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield', window );">dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ppbt_WarrantsoneMember', window );">Warrants [Member] | Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DescriptionOfOptionLifeShareOptionGranted', window );">Expected term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">97.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">annual risk free interest</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ppbt_WarrantsoneMember', window );">Warrants [Member] | Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_DescriptionOfOptionLifeShareOptionGranted', window );">Expected term</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">129.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">annual risk free interest</a></td>
<td class="nump">4.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_DescriptionOfOptionLifeShareOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_DescriptionOfOptionLifeShareOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_Discountforlackofmarketability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount for lack of marketability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_Discountforlackofmarketability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of dividend yield</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ppbt_WarrantsoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ppbt_WarrantsoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ppbt_ConvertibleDebtInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ppbt_ConvertibleDebtInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ppbt_WarrantsoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ppbt_WarrantsoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46556773979520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Events [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Feb. 11, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ppbt_SubsequentEventsMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options grants</a></td>
<td class="nump">10,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ppbt_SubsequentEventsMember', window );">Restricted Share Units (RSU) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options grants</a></td>
<td class="nump">10,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ppbt_SubsequentEventsMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_StockOptionExercisedPeriod', window );">Options exercised period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ppbt_SubsequentEventsMember', window );">Options and RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ppbt_VestingPeriod', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated fair value (in Dollars) | $</a></td>
<td class="nump">$ 282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ppbt_SubsequentEventsMember', window );">ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options grants</a></td>
<td class="nump">52,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ppbt_SubsequentEventsMember', window );">ADS [Member] | Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options grants</a></td>
<td class="nump">52,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_StockOptionExercisedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option exercised period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_StockOptionExercisedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ppbt_VestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ppbt_VestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ppbt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ppbt_SubsequentEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ppbt_SubsequentEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ppbt_OptionsAndRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ppbt_OptionsAndRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ppbt_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ppbt_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MF^,C^Z/WG7Q9,8/W2GSCB<TFP4T "::L%/99[3[CP9\KQQ<K8?P_["K;Z-<
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MP!FJ35?HFV/HZ,089JL^%*LS6NX*_F1. N"!5G3-3H^B34\8CY>%T\@WUWK
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M#'WBBJ'X[L*&H7UP+)DQ,2\.D"7HB%6NM@< ^[O[0^J[XFBV=O\>]QZQY?Z
M]!YL]D/2>[3=OR,Q_!#;?O&]E_/Q=CG4[>GZ1RKF22Y1RF8P;.\Z@BD7VP/K
M[87BR^* =<R5XEGQ=<'HE EM +_/.)"TN] /V/_;0/]_4$L#!!0    ( -F
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MP/Q_+81^^M'>X/ FX/7_ 5!+ P04    " #9@&I:[5H.J],)  "W%@  &
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MG98KD1*Q2X[IS"R"#L 9AEVFTD)R#921LYHLZ7J,+PZ2YICC,M\P;8+7+XD
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M<X6:X&@#WB\M&M_F@2[HOE5?_A]02P,$%     @ V8!J6K1$(2GC"P  IQ\
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M-;PF9+YNATI@SY@CG_?H[;[K*;23+H^9*OE0D0]YOJ"<+Z*RX(,X\E3,&Z@
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MFI)(JT*$*'C\@O0><9ET!&._&4T!"AZO_]$YHN;,=BILEW9!)E&05-UWV C
M&(8\517%B4TL()C)# B45C)K'/AY!&%RA(UA7)E5=V>79U/W)%G/9FA(Q)=0
MWU-C<BY1<Q5-7<EIRBX:WBJ+,[C-[+HGXD\]A@@+!MK:#< EAP'/?K9]A<VY
M/53O;#SJ-%U-Y"ENZ#"R4CZ9:VUWL'+)2[DX64DNW(D\E7A+;[&9,#<_D/3+
M\8U)0:-D&HPO30WL'7/! "F9N)>.^_52_PYI$D+$EA138]KK]B2XGS#.U6X
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MPHY>)BU'5 % )XE5QF_E: /)#9$5VPA:$C5%C^,(?2]^=VPL=_:X!S%# 1K
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M*$T!? 7ZC$UD!:0M,SI51EJ)?"6URM%V;9?586HY64<J6&B5,0FP73XG*D7
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M$94+L/L;:>^V=]P!PTN;_P502P,$%     @ V8!J6B[3LN&Q!   -@L  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULC5;;;N,V$'W75Q!>=-$"B6WY
MCL0V8#N]I$BZ0;+;/A1]H*6Q180B59**XWY]9TA)<1*O=Q\22R/.F3/#,T-.
M=]H\V@S L>=<*CMK9<X5%YV.33+(N6WK A1^V6B3<X>O9MNQA0&>>J=<=GK=
M[JB3<Z%:\ZFWW9GY5)=."@5WAMDRS[G9+T'JW:P5MVK#O=AFC@R=^;3@6W@
M]Z6X,_C6:5!2D8.R0BMF8#-K+>*+Y8#6^P5_"MC9@V=&F:RU?J27ZW36ZA(A
MD) X0N#X\P0KD)* D,:_%6:K"4F.A\\U^B\^=\QES2VLM/Q+I"Z;M28MEL*&
ME]+=Z]UO4.4S)+Q$2^O_LUU8&^/BI+1.YY4S,LB%"K_\N:K#@<.D^Q6'7N70
M\[Q#(,_RBCL^GQJ]8X96(QH]^%2]-Y(3BC;EP1G\*M#/S6\ 4[+3CD,LLG22
MRF\9_'I?\8M[[%8KEUGVLTHA?0W001(-DU[-9-D[B7@%29OUXS/6Z_8&)_#Z
M369]C]<_F1G[>[&VSN#F_W,LR0 Q. Y!#7%A"Y[ K(6*MV">H#7_^"$>=2]/
M$!PT! >GT$^4_J3?<59_: =L%'W\,.G%\26KDO^<0?2KT67!,FZ9)"/C6P.
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MVEP*%^$N]+(\W"AON=D*11N\0==N>SQL!9W5+TX7_F:TU@[O6?XQPXLM&%J
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M3H+@\>IY$V+*/FMW5/2([9&.'<]S(GIB,N 9? =06&8?>:]&P/+%&=0,HTK
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M0OQ8OR.1'EH.],"SO6!$!+X=Q9&=Q"$(;E\T, O ;T(\=^2X@>M8$)^<$H:
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MM #S4REU.Z --G_GG/\-4$L#!!0    ( -F :EK\HK&65@0  "T*   9
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M-;B8QA[HH0L/"ZO:OO-ME*4^VD\+>KA0.P,ZWRI*VV'A HQ/X?(G4$L#!!0
M   ( -F :EI\<<R P0,  (@(   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;*5636_C-A"]ZU<,5*!P@,3ZL"P[J6T@3C9HBNYND'3;0]$#+8TL=B72
M):G(^?<[I&2MVWI]:"_BU\R;]S@<4HM6JL^Z1#2PKRNAEWYIS.XF"'168LWT
M6.Y0T$HA5<T,#=4VT#N%+'=.=17$89@&->/"7RW<W)-:+61C*B[P28%NZIJI
MMS56LEWZD7^8>.;;TMB)8+78L2V^H/FT>U(T"@:4G-<H-)<"%!9+_S:Z62?6
MWAG\RK'51WVP2C92?K:#QWSIAY805I@9B\"H><4[K"H+1#3^ZC'](:1U/.X?
MT!^<=M*R81KO9/4;STVY].<^Y%BPIC+/LOT1>SU3BY?)2KLOM)UM0A&S1AM9
M]\XTKKGH6K;O]^'(81Y^PR'N'6+'NPOD6-XSPU8+)5M0UIK0;,=)==Y$C@N;
ME!>C:)63GUD]<,%$AO!N3VG6"*-'D<D:+R[A YI%8"B$-0RR'F[=P<7?@(MB
M>"^%*36\$SGF?P<(B-M ,#X07,=G$>\Q&\,DNH0XC),S>)-!\,3A3?Z+8/C]
M=J.-HJ/RQRGM'7)R&MF6SXW>L0R7/M6'1O6*_NK[[Z(T_.$,[V3@G9Q#/\-;
MG$[4>;@/TB!$4^\*S@+#[1B>\955#7-%) MHF5),& V_E A;*GO@FLJS8@9S
M,!(,31>,*[!>""S_DTXQE3%Y''F/G3OE= ),Y"ZY7Y&YR*J&C@\PR)@N*]0:
M<(\JX\2O0&8:A<ZM*Q"Z3""3(N>6HO6V7FBCR2QKE$(KCT8,BD;DS')A%5":
MA6;N;C@B,W!HD6(<@N86]*>F>G-$+T]0;GE5D?F.DU?+34GV4Y *8GA#IC04
M2M:T4;IA/1E32N(X^(\TDJ1*2Q V,]?W\<48UN,A.]AE1[O0W&7(HVO)[;:-
M &CK#:A:L-Z@HHKQ'$$GBCZQ]^GEW@9M-"%H[Y^XW@,.X(:D:W-8@B2":0KI
MS/M9ZEX([K.2B2V"HJQ#SHL"W2[K[M!$$403N/(>#WH']DYFK_ "DC"%^#**
M4[+]2$IHNZ9P18-D/K$+UU,;EF1Z_U=FOV./!VW]V(G)<2<UMSF(TQ N8)3,
M$MM,)S%<>%TUG)#M_4LV,8=1:IWNG)D[BD>E( NO&/C0-=-T5>'VI*O'^3JF
MP&DX=_&CF6WB9$J(W?80?F3G9O3U1O/4V5U?QZZ)B/RIBR8X>AUJ5%OW!FJJ
MF$:8[J$89H=G]K9[7;Z:=V_T>Z:V1!TJ+,@U',^F/JCNW>L&1N[<6[.1A@K3
M=4OZ54!E#6B]D*2S']@ P\_'Z@M02P,$%     @ V8!J6@_93CVD P  YP<
M !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULC551;]LX#'[WKR \;-B
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M2XR6'<A>&AH _883#&_[\G]02P,$%     @ V8!J6FA'Y$A/!   D@H  !D
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MM2M2#>U=W00LDG+(?#ROLC5C<FULY7DT:$>F07 Q$!^W5PE"<645#>/E_77
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MY:L_#^#<_T3\J[E6N?CX'?L(YL67/$>D.U*71"E4 :JDQ*YRL:'F<FZQ!SA
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M"B+$LL>@LN\[NQIZ2@L$N%%>AE0L4*L%NA$\'.. 9\$(+.4@<A0MAU@ZL!U
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M8>)Q5CA5UIC=XD19XPVZJ='>6-+X &^ ]=J2S%3HD=L]\?1G-,&5[<%$*#*
M_CV,O26!0_'HT+@VX*WZK<A-&S1V(V8"HTA76F[4E6BM>E-N&RHX?6[:.PB
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MV/$OH/&'OMW3KXZMVKYO=_3G%L)QT^$+\/VZ!>V3#WA ^!VZ5_\+4$L#!!0
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M79=^N*/O$]3N .UOE+*GB2-HOGAF_P%02P,$%     @ V8!J6MHAZ#ML @
M7 4  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULE53=;],P$'_O7W$*
M$@()+5_M.D8;J=U@\#!1K1L\(![<Y-I8<^Q@.VWY[SD[:2A25XF7V/?UN]]=
M?#?9*?UL2D0+^TI(,PU*:^OK,#1YB14S%ZI&29:UTA6S).I-:&J-K/!!E0B3
M*+H,*\9ED$V\;J&SB6JLX!(7&DQ354S_GJ-0NVD0!P?% ]^4UBG";%*S#2[1
M/M4+35+8HQ2\0FFXDJ!Q/0UF\?5\Z/R]PS>..W-T!U?)2JEG)WPIID'D"*'
MW#H$1L<6;U (!T0T?G6809_2!1[?#^B??.U4RXH9O%'B.R]L.0VN BAPS1IA
M']3N,W;UC!Q>KH3Q7]BUOFD:0-X8JZHNF!A47+8GVW=]. JXBEX(2+J Q/-N
M$WF6M\RR;*+5#K3S)C1W\:7Z:"+'I?LI2ZO)RBG.9E]MB1IN&JU16I@9@];
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M4I:FT5]+6G^HG0/9UTK9@^ 2] LU^P-02P,$%     @ V8!J6H9FTYF! @
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MUS]SM1"40B7.:6LPR*C4JKH'KA=&KEW?.96&NE@W7=*_#:BL ;V?2VEV"WM
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MI3&@\Y6@?/<+$V!HWNEO4$L#!!0    ( -F :EIVV0R$/ ,  /8&   9
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M<KC.*4YIK)8N8?#VD2Z 00.OOL@-&5_,?4N!G;N?'8*LAB#B-T&X@%O5V,+
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M>,<][_@0^N*.SF765 @RAU]JT/NX'D3;SW4'BQTL<)%!Z=KCT5D 4R \(E>
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M:B= ]QNE;+]Q!H91O?@/4$L#!!0    ( -F :EIBH>OMHP8  #<6   9
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MGP8&[%62R(T%7?-[&V@T;.=">QE[= W!K_ J"5VN))FQO4X"*TMM/V+D9'.
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M^JK\%K@3+S^I7G*U).M"A@M:Z@TG]-JORJ^49<?(M?LR.)?&R-PU5\A35%:
MYA>2JMFJ8S>HOQ6?_ E02P,$%     @ V8!J6@7.GXC5 P  ,1,  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&ULK9A=;]LV%(;_"J$610)TUH<EVTEM
M TED;1V6(4C0]6+H!2,=VT0D4B4I._WW(R5%M5.9C@?>Q"+%]R%Y7NHPY'3+
M^)-8 TCT7.14S)RUE.6EZXIT#046 U8"56^6C!=8JB)?N:+D@+-:5.1NX'DC
MM\"$.O-I77?'YU-6R9Q0N.-(5$6!^8]KR-EVYOC.2\4]6:VEKG#GTQ*OX 'D
ME_*.JY+;43)2 !6$4<1A.7.N_,O$][2@;O$/@:W8>49Z*H^,/>G"YVSF>'I$
MD$,J-0*KGPW<0)YKDAK']Q;J='UJX>[S"SVI)Z\F\X@%W+#\*\GD>N9,')3!
M$E>YO&?;/Z"=4*1Y*<M%_1=MF[;AR$%I)20K6K$:04%H\XN?VT#L"/SP@"!H
M!<%;!<-6,'PMB X(PE80OK6'J!5$KP6')CUJ!:,Z]DVPZDC'6.+YE+,MXKJU
MHNF'VJY:K0),J%Y9#Y*KMT3IY/QWH,!QCLYBD)CDXAS]AKX\Q.CL_3EZCPA%
MMR3/U1(04U>J[K3(35MTW*"# V@?W3(JUP(M: 99CSXYH@\, %?-LYML\#+9
MZ\!(?(!R@/SQ1Q1X0=@SH!NS_*I:#5 PK.5>7SS,\@0>E7Q2RX<]\H59_B>F
M S3T#_:>F.4QI)T\-,1RV"V<8<T;'EDX__ZE7J#/$@KQK6=4UPTE[*?HO'DI
M2IS"S%&)40#?@#/_\,X?>9_Z_+$)BVW"%C9AB278GJ]AYVMHHL^O"N DQ52E
MYY()(AG_@1C/"%7[#A)KK'KLL[F!1C54[V:;N=K;INYFU[TWM(E_;>/[WCBZ
MV&^V,,[AU'!;@NV%.^K"'1G#?<.*0FVP*L^G3ZC$'&UP7@$Z4YDW9GF.N4 E
M\";PYWV!-^+[!X_Z/BU+G/A_< Y_539AB278GLVCSN:1T>:OF'-,I3!\04;
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M/O8O%\WMS4],<YETB_F*4(%R6"JD-QBK!,V;^YFF(%E9WR<\,BE943^N 6?
M=0/U?LF8?"GH#KI;LOE_4$L#!!0    ( -F :EJR0AU'BP(   \'   9
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M.%X5MS14B!6)MK<T)R[9>O*E9@6EV: T!Y3F@M*\BG9JD.*#5@V@:$W7[L4
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M;Z ^GS,FMRMY@7IRZ.Q_4$L#!!0    ( -F :EJ8AN<V5P,  %40   9
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M9(MEQ4&TF BZS$]:4RKDN2T?QO+L#DP%R/MS2L5VH@YOU;\!_G]02P,$%
M  @ V8!J6C[P(WO: @  QPD  !D   !X;"]W;W)K<VAE971S+W-H965T-3$N
M>&ULM99M;]HP$,>_RBFKIE9:R0,-T XBM4/3*K4:*NWVHNH+0PYBU8DSVT"1
M]N%W3B!E4IIN'7L#?KK__7SVY=Q?2?6H$T0#3ZG(],!)C,G/7%=/$TR9;LD<
M,YJ9294R0UTU=W6ND,6%42K<P/,Z;LIXYD3]8FRDHKY<&,$S'"G0BS1E:GV!
M0JX&CN]L!V[X/#%VP(WZ.9OC&,U=/E+4<RN5F*>8:2XS4#@;..?^V84?6(-B
MQ3>.*[W3!KN5B92/MG,9#QS/$J' J;$2C/Z6^ F%L$K$\6,CZE0^K>%N>ZO^
MN=@\;6;"-'Z2XCN/33)P>@[$.&,+86[DZ@MN-A1:O:D4NOB%5;DV#!R8+K21
MZ<:8"%*>E?_L:1.('8/@)8-@8U $PBT=%91#9EC45W(%RJXF-=LHMEI8$QS/
M[*F,C:)93G8FND+:DH;#(1K&A3Z" ^ 9W"9RH5D6Z[YKR(E=ZDXW@A>E8/""
MX!CS%OCA!PB\P(.[\1 .#XY^EW&)L0(-*M"@T&TW@]Y?T3A<&DSU0QU<*7)2
M+V*O^)G.V10'#MUAC6J)3O3^G=_Q/C8@MBO$=I-Z=#Y7B'1C#0@+"P956L?8
MK!+"&IG2#3PG%<])HU(1,A"<3;C@9@UTH*#L+3V6L^,%33&M*>\/Z<"'4@AR
M>E2'6SKI%$YLDB^CGM_MN\L:LK B"_\J4BR.N4U2)EX,6K/@ZT'K5&B=1J41
MJBF!T1<)Y(PR4"F+::EJDZ$4Z^T$QVMY87UTNA5"MQ'A!A.YE ;NKS&=H'J
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M&]O1L*TYBM>JI E,+#QK"N0&K/CM&S=T/@[E_)_,GE7 [RK@GW*/9Q40+?"
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MU7Q4"U M1+4(U6)*$P.LG;6OR6?MGR?KND+[.D\?IF"\<IY-K@V.,E+34<U
M-1/5+%2S4<U!-1?5/%3S42UH-*&^>#I?C-3.H5//=E.M&H%VCIUZ-M/FZKP[
ML8)Z#V+Z:&WZR"?;?[A/\^1Z^%Q[.3LXAM"Y]JAFH)J):A:JV:CFH)J+:AZJ
M^:@6--KS(]%E-X'VBTG&VO&L&T#[T'3<39^_8_:\ULZ>U^2SSL^;=30>ZK!?
M._)!9]*CFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J0:,)ARK3Q6S__LT]&ZK:3-W;
M\/,K?_>_J7U+440]_%*;[.D_OTF/>_3%<G^,?SY4%[.OG7U?/90Y]5WL+[)-
MF5?'6[N;46S*M-I79>_9<KDU./M(34<U ]5,5+-0S48U!]5<5/-0S4>UH-%4
M]5DLC(Y':O=0*42[C5 MIC0QRMI9_)I\%G^4K^[K>X*U]Q[\+4AOOZ1Y[X)#
M<FQPEJ%3^%'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BRE-#+QVHK_V,/OV
M.Y=6T]#Y_:BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@64YJ8=&T=@":O
M R!O)RWO:G <HB4"VOY-]]5%]]2 @?9IHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$
M:C&EB3'75@AHAU4(#+T5AIP='&EHL8#6<U_RO;.=!MJGV=/G=*]/ZZ"M;/25
M.:CFHIJ':OY!GVZ ]AFB6H1J,:6)T=+.AM?DL^$_9F69[0H1JD"Y3I7?;B6G
MQM!)\:BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@64YH0=^-V/OYX1)P:
M&Z,S\E%-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU MIC0QZ=J)^V/YQ'UH
M-1%Y+X.3$)W0/^Z[KW]G (GV:**:A6HVJCFHYJ*:AVH^J@6H%J):A&HQI8GY
MIK7Y]C?=AU_N#DXTM#8 U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"QMM_NS_[J-C
MM5-L$*%]QI0F9EI;<# ^Z';]A]_63.X-SC*TZ #5#%0S4<U"-1O5'%1S4<T;
M]TSLGU?_B'_B/MII@&HAJD6H%E.:&&9M!4'U4!9FOV1WAUU6D#N#0XS4=%0S
M4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58DH3LZXM,1A/D<L*:&T!JNFH9J":
MB6H6JMFHYJ":BVH>JOFH%J!:B&H1JL64)B9=6ULPEB\B0%U60&L/4$UO-.%.
M*WL3T] N352S4,U&-0?57%3S4,U'M0#50E2+4"VF-#'@VI*"L;RDX.W7%=#Z
M 5334<U -1/5+%2S4<U!-1?5/%3S42U M;#1GM^>:-1=ZSI"NXPI38RTMGQ@
M?%CYP.&7%="Z 5334<U -1/5+%2S4<U!-1?5O$83+BNH\_%2[5Y70-<#0+40
MU2)4BRE-3+.V8F$LKUCXH)]+;^ A;SXXO- J!50S4,U$-0O5;%1S4,U%-0_5
M?%0+4"U$M0C58DH3(F[25BE,D"J%"5JE@&HZJAFH9J*:A6HVJCFHYJ*:AVH^
MJ@6H%J):A&HQI8E)UU8I3.15"F\^VR9W!V<?6I<PV:]+Z"ZRCG9H]G38+82P
MT!YM5'-0S44U#]5\5 M0+42U"-5B2A-C2FMC2EYL\*_'Q?OJ5?MZXP@M*D U
M'=4,5#-?^=RG#\LA]AYVH04$J.:@FHMJ'JKYJ!:@6HAJ$:K%E";F65MH,#FH
MT*#*L^SIJL##P5;QVK4!N3PXZ="2 U0S4,U$-0O5;%1S4,U%-0_5_$E/ 4//
ME88 [35$M0C58DH3<ZVM.:@>RG+MH+5]Y<;@!",U'=4,5#-1S4(U&]4<5'-1
MS4,U']6"1GM^'F(^ZRY0AW89H5I,:6)\M64$$_E*!<\O;2I_*<,6+I#;@V,-
M+2Y -0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"VF-#'_VN*"";)PP00M'D U
M'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*UF-+$I&NK#";_?PL7R+L:'(=H
MX0&J&:AFHIJ%:C:J.:CFHIJ':OYD?Z&,R7CO[N)HGR&J1:@64YH8<VWEP41>
M>= 9T ZYV;A<'IQJ: T"JAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQI8GI
MUU8J3);(<!8M6$ U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*UF-*$I)NV
M!0M3Z33AMT_CE;M#LP_5=%0S4,UL-&$5I5EW(2NT2QO5'%1S4<U#-1_5 E0+
M42U"M9C2Q$AK*Q.F\LJ$SM#UX+M9RMG!B886)J":@6HFJEFH9J.:@VHNJGFH
MYJ-:@&HAJD6H%E.:&'U:&WT:,6Z=HC4/J*:CFH%J)JI9J&:CFH-J+JIYJ.:C
M6H!J(:I%J!93FIAT;1W$5%X'\?9Q*UH%@6HZJAFH9C9:9R'[[K@5+6Y -0?5
M7%3S4,U'M0#50E2+4"VF-#'2VA*(ZJ$LTIY*NV1SA>7&X/@B-1W5#%0S4<U"
M-1O5'%1S4<U#-1_5 E0+42U"M9C2Q)QK:R6FR)(+4[0J M5T5#-0S40U"]5L
M5'-0S44U#]5\5 M0+42U"-5B2A.3KJV*F+ZRY (X5UC>U> XG.V/YD:=6QWI
M:)<&JID];V \G7>'HVBA ZHYJ.:BFH=J/JH%J!:B6H1J,:6)X=46.DSEA0[F
M=G-9*'FRJF\[GMQFVRK 7KG#B%P<G%$/VO-[-(S'H\6\FU)HH0*JF:AF]7P@
MZE13.Q^(C7;JH)J+:AZJ^:@6H%J(:A&JQ90FYE1;J3"55RJ\_4H 6J?0:,\7
MIY@?3[M9A98?H)K9:,]7[=86Q_/NW2C13FU4<U#-134/U7Q4"U M1+4(U6)*
M$[.JK2N8RE= >%S/9;U*OJS6]5FPJV25*_?)>IOV1A1:8(!J>J.)0\CN8GMH
MER:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@64YJ09+.V;F FKQO8NUBI_*6\MKZ+
MG!R:9JBFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@64YH8>VUMP4PEKEW.
MT%("5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(LI34PZK4TZ^0W\WWQ:
M3>X.SCZTN #5#%0S4<U"-1O5'%1S4<UK--F"/#[:8X!J(:I%J!93FIAH;<G
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M%J!:B&H1JL64)L9=6Z]0/20&K!,TZ4A-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
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M+5E>.>-A?6\FQD.^445>P4P@N2E+)IZF4/#=R,'._L;G?+E2YH8['J[9$AY
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M ]#/%YRK_869H.O%Q_\#4$L#!!0    ( -F :EHZ@Q=_]@(  '4(   9
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;*V66V_:,!3'OXJ52=,FK<W]0@>1
MH-U5ZH:*VCU,>S#D0*(F-K,=:+_]CAW(N 342>.!^'+.W[]S8ONDO^;B4>8
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M%P,\2&39\)03+=:V!5@(C0V%'6;8)((T!OA\*83>3\P+ZK9S\@M02P,$%
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M:20=>+.F'P\8ET#GE=9X<ER#\5>6_P%02P,$%     @ V8!J6@WZ4!NW P
M(0\  !D   !X;"]W;W)K<VAE971S+W-H965T-C<N>&ULM5?1CILX%/T5BU:K
M5MH9,!"2S":1FF%66VE'&TVFNP]5'QRX!%3 U':2Z=^O;1@F(0Z=U=*7!.QS
MCL^]X(OO[$#95YX""/14Y"6?6ZD0U8UM\RB%@O!K6D$I9Q+*"B+D+=O:O&)
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MZ5R/92I9W8_5-X)6ND/94"'['7V9RAX6F +(^812\7RC%FB[XL6_4$L#!!0
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M J]2?DTVWZ%*:"#Y0I(R]8LV5:QEH'#%.,DJL.A!EN3E$S]40C0 MO\"P*D
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M^I_Z<:UZ6N!:H'Y?,B8/+WJ MDN>_@-02P,$%     @ V8!J6K1?NT9? @
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M,*4>$*4!T/-$T(FH)^8%35<9_ 902P,$%     @ V8!J6K2Z9PXT P  4@H
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M_N["(ZJ1Y&9C9.5$:BD-2IY;%GB+@;(.>+Z2TNPV-D!W+R9_ 5!+ P04
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MCIMCFTPJ4B=CADE RO.HT,894#Q/XOMG"R<!*>$[H<%)("<F@6)Q$F=Q_I/
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MUFF?#$[+ J!WN)7]TH)/3,72X#6G,:EUC';A@)$Y//+_]>XC7J^T-OAD<%K
M@,<E'-(EK5<^&9R6!<#,<#/ZV4O-EWC:6TU87X0T(V1 PQS^^+#2YZY":5WQ
MR>"T'  ^EW HG;3>^61P6A8 1\/-Z1<_K&T:IO&T9J%@P"!?.!SR;>7N(N.T
MOOAD<%H. )M+.&1/6OM\,KAQ%H"!OL#]Z9>6>VH1-(WWTE@L\@7PR!<.DWRM
MW&>L/&F-\<G@M P )I=R:* I+;VC@M.R .@=;EZ_N-A->=.L=1;R!OSSA<-
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M./HI^,T#%S?"3^9? 2S<$;1R$ 6'^$S;K8$,3LL"8(AX.X3%\V"&^,S2D$&
MC@S"T9)!FP<^CD\XLO_M9F&)H,N#*#A$9MI&#F1P6A8 %\0[)<Q>!1>65V\3
MXP5=EK8,$K1ED(ZV#//J>^8:V'$RWYM-!J=E1X#L,*C)DK:Y QF<E@4)LL"I
M)C^AHQN>CDMX<9 1"-)+3E[F'N4XF7\)<-!!"9I#R)!!-I:T_1_(X+0L)" +
MG++Q$SJZ&>2XA!<'F8(@O73C)293CE/Y%P '&Y2@>X0,&?1A2=LU@@Q.RT(.
MLL"I#S^A8[S?<04OCK$ ,7K)PTO,J!RG\K__+)P1-**0@D$&EK3=)LC@M"P
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M?+$X=I]0?^PS#4/?#P(LH].I5<$4RUL0P)^=#=,&'E@<B/2T7..KC5?(X3K
MUO10A6 SQ2L1FRF>:T#L>0./,+2O-A8'/+!5P&H'XMOC0$W9?7P?5A73ANU@
M' E##(%:M-=H$"#9">!K7Q]LE_A^&-H1P.P*?!]#8#?B"*8 -&"([Q?/P;WG
MD;=]3GGU/[\G?P%02P,$%     @ V8!J6I>*NQS     $P(   L   !?<F5L
M<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5Q
MD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC
M0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W
M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ
M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #9@&I:N:-FP>P%  !:-@
M#P   'AL+W=O<FMB;V]K+GAM;,6;WT_C.!" _Q6K3ZS$7FE^=A$@06'W*K%+
M1=&^GMS$I19)W+730O>OOXE#;VT(HWN9Y@F2AN2K[?$WXYBS9Z6?%DH]L9>R
MJ,SY8%77Z]/AT&0K47+SEUJ+"CY9*EWR&@[UX]"LM>"Y60E1E\4P.#E)AB67
MU>#B;'^OF1ZZ!ZH662U5!2>;$S^E>#9_/F\.V58:N9"%K'?G _M[(0:LE)4L
MY6^1GP].!LRLU//?2LO?JJIY,<^T*HKSP:C]X*?0M<S>G9XWD ]\8>R9FB_N
M.8"<#Y(3N.%2:E/;*^S].3!N!5S<'FUJ]546M=#7O!;?M-JL9?78W :^Q=#Y
M&K8=]C_;1CS5_Z<9U7(I,W&MLDTIJKIM1RV*!K R*[DV U;Q4IP/)FHK=/-]
MX '3O/UN-4 Y+:5/)7R@I[G%HT.YW.2R9M.J_6/XU,$*$*R %FL"QZJ0.3P]
M9_,&HOD#P]22?945=R!#!#+L#?)N[75PA$!&O4%.5MSM[AB!C/N#Y&;E0"8(
M9$(+^4U40O/"@4D1F)06YHH;:=MGIL6::WM!<UBO!)MX43Q&(,>TD-_AL5KR
M@EUFF=I4-<RW; ;]G$EA',(O".$76L(IF*=Z;)[)+HV!:=^=E4^P:?F$.")@
MV#->Y7;\LYM?&[GE11,3+B#J#6)QW INO%X<8;H8$?OB#L:]9I.-UG!=1U=B
MEA@1:Z)EF_$=A^=Z5)@61L1>:(94O7-IL/E_1"R ^8IK\1DF-9C_H:5*VXM:
M0VQ:$[B8F %&Q IX "+#;>IK;'1>\8)7F3#L6=8KYF)B;A@1RV&BRE+6K4+M
M'*+LW-LTZJWD"Q<3L\.(6 _WP@BNLW:>NQ9;4:BU[?F;%[BK%RF8(D;$CIC#
MQ&N.V:O^+>QEWE0RIFZ\ZR;,F#$"8F,T>3$,Q=?&$^QH6F6J%)^.V0_A!E"
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M:N8/>H2@Q_F#TA)E7!(D3; FT#HAUXG ZX1@)P*Q$Y*=",Q.B'8B4#LAVXG
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MEW/+[?+7Y=?.R:URQ;F^KQB>_P)02P,$%     @ V8!J6B!P#MDD @  J2\
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M+GAM;%!+ 0(4 Q0    ( -F :EK>5?"E[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -F :EJ97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ V8!J6CBN.F;:!@  P2$  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -F :EK"N=3:T@,
M .4)   8              " @1T/  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " #9@&I:,;>428H&  #9'0  &               @($E
M$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ V8!J6@D+
MZT/E!@  0B   !@              ("!Y1D  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( -F :EKM5TR+G@@  %1$   8
M  " @0 A  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #9
M@&I:^F#OR/('   5*   &               @('4*0  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ V8!J6NU:#JO3"0  MQ8  !@
M         ("!_#$  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( -F :EJT1"$IXPL  *<?   8              " @04\  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #9@&I:BB\0SVX7  "\1P
M&               @($>2   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ V8!J6O9:J KI"   A!4  !D              ("!PE\  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #9@&I:&.*E2U\"
M  !U!0  &0              @('B:   >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( -F :EHNT[+AL00  #8+   9              "
M@7AK  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ V8!J
M6LQXT4!F @  904  !D              ("!8'   'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " #9@&I:5&A!(GH"  !Q!0  &0
M        @(']<@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( -F :EH]&C]W'0P   ,D   9              " @:YU  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ V8!J6H X00,M"   VAD
M !D              ("! H(  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " #9@&I:_**QEE8$   M"@  &0              @(%FB@
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( -F :EK+T[VQ
MR@\  -$I   9              " @?..  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ V8!J6M3!PJ.B @  WP4  !D
M ("!])X  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #9
M@&I:?Y9;;3(#   6!P  &0              @('-H0  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( -F :EI\<<R P0,  (@(   9
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M970R-2YX;6Q02P$"% ,4    " #9@&I:Q\:$EA "  #<!   &0
M    @($<PP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M -F :EK\C[?4B0@  ,<<   9              " @6/%  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ V8!J6IV[]G9 &   DTX  !D
M             ("!(\X  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " #9@&I:W!;\<J@"  !&!@  &0              @(&:Y@  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( -F :EIX)/73: ,
M /4'   9              " @7GI  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ V8!J6GLR_]5G @  9P4  !D              ("!
M&.T  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #9@&I:
M<T7J;G(#  #]"   &0              @(&V[P  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( -F :EK:(>@[; (  %P%   9
M      " @5_S  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ V8!J6H9FTYF! @  ;@4  !D              ("! O8  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #9@&I:O:'&6X8$  !E"P
M&0              @(&Z^   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( -F :EI%+!V3%P4  )0,   9              " @7?]  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ V8!J6HJD5;?L
M @  I08  !D              ("!Q0(! 'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " #9@&I:65SI0ZH"  #(!0  &0
M@('H!0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -F
M:EIVV0R$/ ,  /8&   9              " @<D( 0!X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ V8!J6H0'LE\F P  C <  !D
M         ("!/ P! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M    " #9@&I:Y\6]XRL#  "V!P  &0              @(&9#P$ >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( -F :EIBH>OMHP8  #<6
M   9              " @?L2 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
M4$L! A0#%     @ V8!J6@7.GXC5 P  ,1,  !D              ("!U1D!
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #9@&I:LD(=
M1XL"   /!P  &0              @('A'0$ >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;%!+ 0(4 Q0    ( -F :EJ 2(0$L@(  +4'   9
M  " @:,@ 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
MV8!J6D6CV;!Z @  3 <  !D              ("!C",! 'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    " #9@&I:8&26N+@&   H.@  &0
M            @($])@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( -F :EJ8AN<V5P,  %40   9              " @2PM 0!X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ V8!J6EXY.<L" P
M1@@  !D              ("!NC ! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    " #9@&I:O(;8@!X#   9$   &0              @('S
M,P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( -F :EH^
M\"-[V@(  ,<)   9              " @4@W 0!X;"]W;W)K<VAE971S+W-H
M965T-3$N>&UL4$L! A0#%     @ V8!J6MTJ[AS$ @  40<  !D
M     ("!63H! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -F :EH0:)LZPAD  #+( 0 9              "
M@>!( 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ V8!J
M6B2^8VKL P  01D  !D              ("!V6(! 'AL+W=O<FMS:&5E=',O
M<VAE970U."YX;6Q02P$"% ,4    " #9@&I:PK+"A,\#  "A#0  &0
M        @('\9@$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0
M   ( -F :EI%6>.S,0,  /$)   9              " @0)K 0!X;"]W;W)K
M<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ V8!J6I[/D[#4"@  HXT
M !D              ("!:FX! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q0
M2P$"% ,4    " #9@&I:"&^LW0($  "7#P  &0              @(%U>0$
M>&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( -F :EHZ@Q=_
M]@(  '4(   9              " @:Y] 0!X;"]W;W)K<VAE971S+W-H965T
M-C,N>&UL4$L! A0#%     @ V8!J6JDE-LV?!   &QP  !D
M ("!VX ! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #9
M@&I:PYVS%'<#  ""#@  &0              @(&QA0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( -F :EI(&#V8, (  -8$   9
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M970W,"YX;6Q02P$"% ,4    " #9@&I:M%^[1E\"  !2!P  &0
M    @('AG0$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    (
M -F :EK+1+^$*@,  &$*   9              " @7>@ 0!X;"]W;W)K<VAE
M971S+W-H965T-S(N>&UL4$L! A0#%     @ V8!J6K2Z9PXT P  4@H  !D
M             ("!V*,! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"
M% ,4    " #9@&I:8?'1$P(#  #9"@  &0              @(%#IP$ >&PO
M=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( -F :EI;5O7,D0(
M '@'   9              " @7RJ 0!X;"]W;W)K<VAE971S+W-H965T-S4N
M>&UL4$L! A0#%     @ V8!J6L:MD4.% @  @08  !D              ("!
M1*T! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " #9@&I:
M<7\?7J,"   C!P  &0              @($ L $ >&PO=V]R:W-H965T<R]S
M:&5E=#<W+GAM;%!+ 0(4 Q0    ( -F :EI/54=OA0H  !*&   9
M      " @=JR 0!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%
M  @ V8!J6A5/'I/8$   \<X  !D              ("!EKT! 'AL+W=O<FMS
M:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    " #9@&I:_(Y]E=8#  #;%0
M&0              @(&ES@$ >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+
M 0(4 Q0    ( -F :EK%DU%CR ,  (,0   9              " @;+2 0!X
M;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ V8!J6DK(P8;Z
M!   T"$  !D              ("!L=8! 'AL+W=O<FMS:&5E=',O<VAE970X
M,BYX;6Q02P$"% ,4    " #9@&I:!\WV=HH#  "Q#P  &0
M@('BVP$ >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( -F
M:EJ:?_&A=@,   D7   -              "  :/? 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ V8!J6I>*NQS     $P(   L              ( !1.,!
M %]R96QS+RYR96QS4$L! A0#%     @ V8!J6KFC9L'L!0  6C8   \
M         ( !+>0! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( -F :EHT
M3CM]>@(    Q   :              "  4;J 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( -F :EH@< [9) (  *DO   3
M      "  ?CL 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !; %L ]!@
' $WO 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>387</ContextCount>
  <ElementCount>371</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable</Role>
      <ShortName>Consolidated Statements of Operations and Other Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Basis of Preparation of the Consolidated Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatements</Role>
      <ShortName>Basis of Preparation of the Consolidated Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Material Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/MaterialAccountingPolicies</Role>
      <ShortName>Material Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/CashandCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/OtherCurrentAssets</Role>
      <ShortName>Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/OtherPayables</Role>
      <ShortName>Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Share-Based Payment Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ShareBasedPaymentArrangements</Role>
      <ShortName>Share-Based Payment Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Transactions and Balances with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedParties</Role>
      <ShortName>Transactions and Balances with Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Commitments and Contingent Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/CommitmentsandContingentLiabilities</Role>
      <ShortName>Commitments and Contingent Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Research and Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ResearchandDevelopmentExpenses</Role>
      <ShortName>Research and Development Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Sales, General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpenses</Role>
      <ShortName>Sales, General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Finance Expense (Income), Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/FinanceExpenseIncomeNet</Role>
      <ShortName>Finance Expense (Income), Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995323 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/MaterialAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Basis of Preparation of the Consolidated Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables</Role>
      <ShortName>Basis of Preparation of the Consolidated Financial Statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/IntangibleAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/CashandCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/CashandCashEquivalents</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/OtherCurrentAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/OtherPayablesTables</Role>
      <ShortName>Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/OtherPayables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/Equity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Share-Based Payment Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables</Role>
      <ShortName>Share-Based Payment Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/ShareBasedPaymentArrangements</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Transactions and Balances with Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables</Role>
      <ShortName>Transactions and Balances with Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedParties</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Research and Development Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ResearchandDevelopmentExpensesTables</Role>
      <ShortName>Research and Development Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/ResearchandDevelopmentExpenses</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Sales, General and Administrative Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesTables</Role>
      <ShortName>Sales, General and Administrative Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpenses</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Finance Expense (Income), Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables</Role>
      <ShortName>Finance Expense (Income), Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/FinanceExpenseIncomeNet</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Employee Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/EmployeeBenefitsTables</Role>
      <ShortName>Employee Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/EmployeeBenefits</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/FinancialInstruments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996015 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/General</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Basis of Preparation of the Consolidated Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails</Role>
      <ShortName>Basis of Preparation of the Consolidated Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Basis of Preparation of the Consolidated Financial Statements - Schedule of Data on Exchange Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofDataonExchangeRatesTable</Role>
      <ShortName>Basis of Preparation of the Consolidated Financial Statements - Schedule of Data on Exchange Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Material Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/MaterialAccountingPoliciesDetails</Role>
      <ShortName>Material Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/IntangibleAssetsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Intangible Assets - Schedule of Recognized Amounts of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable</Role>
      <ShortName>Intangible Assets - Schedule of Recognized Amounts of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable</Role>
      <ShortName>Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/LeasesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Leases - Schedule of Carrying Amounts of Right-to-Use Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable</Role>
      <ShortName>Leases - Schedule of Carrying Amounts of Right-to-Use Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Leases - Schedule of Maturity Analysis of the Company's Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable</Role>
      <ShortName>Leases - Schedule of Maturity Analysis of the Company's Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Leases - Schedule of Amounts Recognized in Profit or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofAmountsRecognizedinProfitorLossTable</Role>
      <ShortName>Leases - Schedule of Amounts Recognized in Profit or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable</Role>
      <ShortName>Other Current Assets - Schedule of Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Other Payables - Schedule of Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofOtherPayablesTable</Role>
      <ShortName>Other Payables - Schedule of Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/EquityTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Equity - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofShareCapitalTable</Role>
      <ShortName>Equity - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Equity - Schedule of Changes in Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable</Role>
      <ShortName>Equity - Schedule of Changes in Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Equity - Schedule of the Information Relating to Non-Controlling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable</Role>
      <ShortName>Equity - Schedule of the Information Relating to Non-Controlling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Share-Based Payment Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails</Role>
      <ShortName>Share-Based Payment Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Share-Based Payment Arrangements - Schedule of Number and Weighted Average Exercise Prices of Share Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable</Role>
      <ShortName>Share-Based Payment Arrangements - Schedule of Number and Weighted Average Exercise Prices of Share Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Share-Based Payment Arrangements - Schedule of Number of RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable</Role>
      <ShortName>Share-Based Payment Arrangements - Schedule of Number of RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Share-Based Payment Arrangements - Schedule of Assumptions were Used (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable</Role>
      <ShortName>Share-Based Payment Arrangements - Schedule of Assumptions were Used (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Share-Based Payment Arrangements - Schedule of Expenses Recognized in the Consolidated Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable</Role>
      <ShortName>Share-Based Payment Arrangements - Schedule of Expenses Recognized in the Consolidated Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Transactions and Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesDetails</Role>
      <ShortName>Transactions and Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Transactions and Balances with Related Parties - Schedule of Recorded Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Recorded Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Commitments and Contingent Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingent Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/CommitmentsandContingentLiabilities</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Research and Development Expenses - Schedule of Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable</Role>
      <ShortName>Research and Development Expenses - Schedule of Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Sales, General and Administrative Expenses - Schedule of Sales, General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable</Role>
      <ShortName>Sales, General and Administrative Expenses - Schedule of Sales, General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Finance Expense (Income), Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails</Role>
      <ShortName>Finance Expense (Income), Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Finance Expense (Income), Net - Schedule of Finance Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable</Role>
      <ShortName>Finance Expense (Income), Net - Schedule of Finance Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Finance Expense (Income), Net - Schedule of Finance Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable</Role>
      <ShortName>Finance Expense (Income), Net - Schedule of Finance Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/TaxesonIncome</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Employee Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/EmployeeBenefitsDetails</Role>
      <ShortName>Employee Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/EmployeeBenefitsTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Employee Benefits - Schedule of Post-Employee Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofPostEmployeeBenefitsTable</Role>
      <ShortName>Employee Benefits - Schedule of Post-Employee Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Employee Benefits - Schedule of Defined Contribution Plan in Respect of its Employees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofDefinedContributionPlaninRespectofitsEmployeesTable</Role>
      <ShortName>Employee Benefits - Schedule of Defined Contribution Plan in Respect of its Employees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Financial Instruments - Schedule of Sensitivity Test to Possible Changes in Exchange Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable</Role>
      <ShortName>Financial Instruments - Schedule of Sensitivity Test to Possible Changes in Exchange Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Financial Instruments - Schedule of Financial Instruments Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable</Role>
      <ShortName>Financial Instruments - Schedule of Financial Instruments Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Financial Instruments - Schedule of Details Regarding Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable</Role>
      <ShortName>Financial Instruments - Schedule of Details Regarding Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Financial Instruments - Schedule of Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable</Role>
      <ShortName>Financial Instruments - Schedule of Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ea0232483-20f_purple.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Purplebiotech.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Purplebiotech.com/role/SubsequentEvents</ParentRole>
      <Position>83</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="ea0232483-20f_purple.htm">ea0232483-20f_purple.htm</File>
    <File>ppbt-20241231.xsd</File>
    <File>ppbt-20241231_cal.xml</File>
    <File>ppbt-20241231_def.xml</File>
    <File>ppbt-20241231_lab.xml</File>
    <File>ppbt-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
    <BaseTaxonomy items="870">https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>107
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0232483-20f_purple.htm": {
   "nsprefix": "ppbt",
   "nsuri": "http://Purplebiotech.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "ea0232483-20f_purple.htm"
     ]
    },
    "schema": {
     "local": [
      "ppbt-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
      "https://xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ppbt-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ppbt-20241231_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ppbt-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ppbt-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 256,
   "keyCustom": 115,
   "axisStandard": 22,
   "axisCustom": 2,
   "memberStandard": 29,
   "memberCustom": 50,
   "hidden": {
    "total": 199,
    "http://Purplebiotech.com/20241231": 28,
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 165,
    "http://xbrl.sec.gov/dei/2024": 6
   },
   "contextCount": 387,
   "entityCount": 1,
   "segmentCount": 87,
   "elementCount": 845,
   "unitCount": 5,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 870,
    "http://xbrl.sec.gov/dei/2024": 46,
    "http://xbrl.sec.gov/cyd/2024": 8,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://Purplebiotech.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable",
     "longName": "995302 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Other Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://Purplebiotech.com/role/ShareholdersEquityType2or3",
     "longName": "995303 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c58",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c58",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://Purplebiotech.com/role/ConsolidatedCashFlow",
     "longName": "995304 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLossFromContinuingOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLossFromContinuingOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://Purplebiotech.com/role/General",
     "longName": "995305 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatements",
     "longName": "995306 - Disclosure - Basis of Preparation of the Consolidated Financial Statements",
     "shortName": "Basis of Preparation of the Consolidated Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://Purplebiotech.com/role/MaterialAccountingPolicies",
     "longName": "995307 - Disclosure - Material Accounting Policies",
     "shortName": "Material Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://Purplebiotech.com/role/IntangibleAssets",
     "longName": "995308 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://Purplebiotech.com/role/CashandCashEquivalents",
     "longName": "995309 - Disclosure - Cash and Cash Equivalents",
     "shortName": "Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://Purplebiotech.com/role/Leases",
     "longName": "995310 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://Purplebiotech.com/role/OtherCurrentAssets",
     "longName": "995311 - Disclosure - Other Current Assets",
     "shortName": "Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://Purplebiotech.com/role/OtherPayables",
     "longName": "995312 - Disclosure - Other Payables",
     "shortName": "Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://Purplebiotech.com/role/Equity",
     "longName": "995313 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://Purplebiotech.com/role/ShareBasedPaymentArrangements",
     "longName": "995314 - Disclosure - Share-Based Payment Arrangements",
     "shortName": "Share-Based Payment Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedParties",
     "longName": "995315 - Disclosure - Transactions and Balances with Related Parties",
     "shortName": "Transactions and Balances with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://Purplebiotech.com/role/CommitmentsandContingentLiabilities",
     "longName": "995316 - Disclosure - Commitments and Contingent Liabilities",
     "shortName": "Commitments and Contingent Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://Purplebiotech.com/role/ResearchandDevelopmentExpenses",
     "longName": "995317 - Disclosure - Research and Development Expenses",
     "shortName": "Research and Development Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpenses",
     "longName": "995318 - Disclosure - Sales, General and Administrative Expenses",
     "shortName": "Sales, General and Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://Purplebiotech.com/role/FinanceExpenseIncomeNet",
     "longName": "995319 - Disclosure - Finance Expense (Income), Net",
     "shortName": "Finance Expense (Income), Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://Purplebiotech.com/role/TaxesonIncome",
     "longName": "995320 - Disclosure - Taxes on Income",
     "shortName": "Taxes on Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://Purplebiotech.com/role/EmployeeBenefits",
     "longName": "995321 - Disclosure - Employee Benefits",
     "shortName": "Employee Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://Purplebiotech.com/role/FinancialInstruments",
     "longName": "995322 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://Purplebiotech.com/role/SubsequentEvents",
     "longName": "995323 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c78",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c78",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://Purplebiotech.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables",
     "longName": "996001 - Disclosure - Basis of Preparation of the Consolidated Financial Statements (Tables)",
     "shortName": "Basis of Preparation of the Consolidated Financial Statements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://Purplebiotech.com/role/IntangibleAssetsTables",
     "longName": "996002 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://Purplebiotech.com/role/CashandCashEquivalentsTables",
     "longName": "996003 - Disclosure - Cash and Cash Equivalents (Tables)",
     "shortName": "Cash and Cash Equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://Purplebiotech.com/role/LeasesTables",
     "longName": "996004 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://Purplebiotech.com/role/OtherCurrentAssetsTables",
     "longName": "996005 - Disclosure - Other Current Assets (Tables)",
     "shortName": "Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DisclosureOfOtherCurrentAssettextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DisclosureOfOtherCurrentAssettextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://Purplebiotech.com/role/OtherPayablesTables",
     "longName": "996006 - Disclosure - Other Payables (Tables)",
     "shortName": "Other Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://Purplebiotech.com/role/EquityTables",
     "longName": "996007 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables",
     "longName": "996008 - Disclosure - Share-Based Payment Arrangements (Tables)",
     "shortName": "Share-Based Payment Arrangements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables",
     "longName": "996009 - Disclosure - Transactions and Balances with Related Parties (Tables)",
     "shortName": "Transactions and Balances with Related Parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://Purplebiotech.com/role/ResearchandDevelopmentExpensesTables",
     "longName": "996010 - Disclosure - Research and Development Expenses (Tables)",
     "shortName": "Research and Development Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesTables",
     "longName": "996011 - Disclosure - Sales, General and Administrative Expenses (Tables)",
     "shortName": "Sales, General and Administrative Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables",
     "longName": "996012 - Disclosure - Finance Expense (Income), Net (Tables)",
     "shortName": "Finance Expense (Income), Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceCostExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceCostExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://Purplebiotech.com/role/EmployeeBenefitsTables",
     "longName": "996013 - Disclosure - Employee Benefits (Tables)",
     "shortName": "Employee Benefits (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://Purplebiotech.com/role/FinancialInstrumentsTables",
     "longName": "996014 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://Purplebiotech.com/role/GeneralDetails",
     "longName": "996015 - Disclosure - General (Details)",
     "shortName": "General (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c80",
      "name": "ppbt:AmericanDepositorySharesOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "ppbt:AmericanDepositorySharesOrdinaryShares",
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails",
     "longName": "996016 - Disclosure - Basis of Preparation of the Consolidated Financial Statements (Details)",
     "shortName": "Basis of Preparation of the Consolidated Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ppbt:FunctionalCurrency",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:FunctionalCurrency",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://Purplebiotech.com/role/ScheduleofDataonExchangeRatesTable",
     "longName": "996017 - Disclosure - Basis of Preparation of the Consolidated Financial Statements - Schedule of Data on Exchange Rates (Details)",
     "shortName": "Basis of Preparation of the Consolidated Financial Statements - Schedule of Data on Exchange Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AverageForeignExchangeRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AverageForeignExchangeRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://Purplebiotech.com/role/MaterialAccountingPoliciesDetails",
     "longName": "996018 - Disclosure - Material Accounting Policies (Details)",
     "shortName": "Material Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ppbt:NumberOfShare",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:NumberOfShare",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://Purplebiotech.com/role/IntangibleAssetsDetails",
     "longName": "996019 - Disclosure - Intangible Assets (Details)",
     "shortName": "Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c87",
      "name": "ppbt:EquityMethodInvestmentsOwnershipPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c87",
      "name": "ppbt:EquityMethodInvestmentsOwnershipPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable",
     "longName": "996020 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c92",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable",
     "longName": "996021 - Disclosure - Intangible Assets - Schedule of Recognized Amounts of Assets Acquired and Liabilities Assumed (Details)",
     "shortName": "Intangible Assets - Schedule of Recognized Amounts of Assets Acquired and Liabilities Assumed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ppbt:ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ppbt:ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable",
     "longName": "996022 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)",
     "shortName": "Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c100",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ppbt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://Purplebiotech.com/role/LeasesDetails",
     "longName": "996023 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c86",
      "name": "ppbt:AgreementLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c86",
      "name": "ppbt:AgreementLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable",
     "longName": "996024 - Disclosure - Leases - Schedule of Carrying Amounts of Right-to-Use Assets (Details)",
     "shortName": "Leases - Schedule of Carrying Amounts of Right-to-Use Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c106",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c109",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable",
     "longName": "996025 - Disclosure - Leases - Schedule of Maturity Analysis of the Company's Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturity Analysis of the Company's Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://Purplebiotech.com/role/ScheduleofAmountsRecognizedinProfitorLossTable",
     "longName": "996026 - Disclosure - Leases - Schedule of Amounts Recognized in Profit or Loss (Details)",
     "shortName": "Leases - Schedule of Amounts Recognized in Profit or Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:InterestExpenseOnLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:InterestExpenseOnLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable",
     "longName": "996027 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details)",
     "shortName": "Other Current Assets - Schedule of Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ppbt:GovernmentAuthorities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ppbt:DisclosureOfOtherCurrentAssettextBlock",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ppbt:GovernmentAuthorities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ppbt:DisclosureOfOtherCurrentAssettextBlock",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable",
     "longName": "996028 - Disclosure - Other Payables - Schedule of Other Payables (Details)",
     "shortName": "Other Payables - Schedule of Other Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://Purplebiotech.com/role/EquityDetails",
     "longName": "996029 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ppbt:NonVotingSeniorPreferredShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:NonVotingSeniorPreferredShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://Purplebiotech.com/role/ScheduleofShareCapitalTable",
     "longName": "996030 - Disclosure - Equity - Schedule of Share Capital (Details)",
     "shortName": "Equity - Schedule of Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c155",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c155",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable",
     "longName": "996031 - Disclosure - Equity - Schedule of Changes in Share Capital (Details)",
     "shortName": "Equity - Schedule of Changes in Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:NumberOfIssuanceShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable",
     "longName": "996032 - Disclosure - Equity - Schedule of the Information Relating to Non-Controlling Interests (Details)",
     "shortName": "Equity - Schedule of the Information Relating to Non-Controlling Interests (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:OtherNoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ppbt:DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:OtherNoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ppbt:DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails",
     "longName": "996033 - Disclosure - Share-Based Payment Arrangements (Details)",
     "shortName": "Share-Based Payment Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c198",
      "name": "ppbt:OptionExerciseOrdinaryShare",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable",
     "longName": "996034 - Disclosure - Share-Based Payment Arrangements - Schedule of Number and Weighted Average Exercise Prices of Share Options (Details)",
     "shortName": "Share-Based Payment Arrangements - Schedule of Number and Weighted Average Exercise Prices of Share Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c67",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable",
     "longName": "996035 - Disclosure - Share-Based Payment Arrangements - Schedule of Number of RSUs (Details)",
     "shortName": "Share-Based Payment Arrangements - Schedule of Number of RSUs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c46",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable",
     "longName": "996036 - Disclosure - Share-Based Payment Arrangements - Schedule of Assumptions were Used (Details)",
     "shortName": "Share-Based Payment Arrangements - Schedule of Assumptions were Used (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable",
     "longName": "996037 - Disclosure - Share-Based Payment Arrangements - Schedule of Expenses Recognized in the Consolidated Financial Statements (Details)",
     "shortName": "Share-Based Payment Arrangements - Schedule of Expenses Recognized in the Consolidated Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AdjustmentsForSharebasedPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c212",
      "name": "ifrs-full:AdjustmentsForSharebasedPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesDetails",
     "longName": "996038 - Disclosure - Transactions and Balances with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ppbt:PercentageOfCapacityOfAnAdvisor",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:PercentageOfCapacityOfAnAdvisor",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable",
     "longName": "996039 - Disclosure - Transactions and Balances with Related Parties - Schedule of Recorded Expenses (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Recorded Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c218",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c218",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails",
     "longName": "996040 - Disclosure - Commitments and Contingent Liabilities (Details)",
     "shortName": "Commitments and Contingent Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c231",
      "name": "ifrs-full:GainsOnLitigationSettlements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c231",
      "name": "ifrs-full:GainsOnLitigationSettlements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable",
     "longName": "996041 - Disclosure - Research and Development Expenses - Schedule of Research and Development Expenses (Details)",
     "shortName": "Research and Development Expenses - Schedule of Research and Development Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c232",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ppbt:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock",
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable",
     "longName": "996042 - Disclosure - Sales, General and Administrative Expenses - Schedule of Sales, General and Administrative Expenses (Details)",
     "shortName": "Sales, General and Administrative Expenses - Schedule of Sales, General and Administrative Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c215",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c215",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails",
     "longName": "996043 - Disclosure - Finance Expense (Income), Net (Details)",
     "shortName": "Finance Expense (Income), Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c211",
      "name": "ppbt:WarrantsExpireTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c211",
      "name": "ppbt:WarrantsExpireTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable",
     "longName": "996044 - Disclosure - Finance Expense (Income), Net - Schedule of Finance Expenses (Details)",
     "shortName": "Finance Expense (Income), Net - Schedule of Finance Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:FeeAndCommissionExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:FeeAndCommissionExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable",
     "longName": "996045 - Disclosure - Finance Expense (Income), Net - Schedule of Finance Income (Details)",
     "shortName": "Finance Expense (Income), Net - Schedule of Finance Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:InterestIncomeOnDeposits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:InterestIncomeOnDeposits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://Purplebiotech.com/role/TaxesonIncomeDetails",
     "longName": "996046 - Disclosure - Taxes on Income (Details)",
     "shortName": "Taxes on Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://Purplebiotech.com/role/EmployeeBenefitsDetails",
     "longName": "996047 - Disclosure - Employee Benefits (Details)",
     "shortName": "Employee Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ppbt:EmployeeBenefitBonus",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:EmployeeBenefitBonus",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://Purplebiotech.com/role/ScheduleofPostEmployeeBenefitsTable",
     "longName": "996048 - Disclosure - Employee Benefits - Schedule of Post-Employee Benefits (Details)",
     "shortName": "Employee Benefits - Schedule of Post-Employee Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ShorttermEmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ShorttermEmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://Purplebiotech.com/role/ScheduleofDefinedContributionPlaninRespectofitsEmployeesTable",
     "longName": "996049 - Disclosure - Employee Benefits - Schedule of Defined Contribution Plan in Respect of its Employees (Details)",
     "shortName": "Employee Benefits - Schedule of Defined Contribution Plan in Respect of its Employees (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ppbt:DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ppbt:DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://Purplebiotech.com/role/FinancialInstrumentsDetails",
     "longName": "996050 - Disclosure - Financial Instruments (Details)",
     "shortName": "Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:FinancialInstrumentAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable",
     "longName": "996051 - Disclosure - Financial Instruments - Schedule of Sensitivity Test to Possible Changes in Exchange Rate (Details)",
     "shortName": "Financial Instruments - Schedule of Sensitivity Test to Possible Changes in Exchange Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c208",
      "name": "ppbt:IncomelossFromChangeInExchangeRateDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c208",
      "name": "ppbt:IncomelossFromChangeInExchangeRateDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable",
     "longName": "996052 - Disclosure - Financial Instruments - Schedule of Financial Instruments Measured at Fair Value (Details)",
     "shortName": "Financial Instruments - Schedule of Financial Instruments Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ppbt:Securities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ppbt:Securities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable",
     "longName": "996053 - Disclosure - Financial Instruments - Schedule of Details Regarding Fair Value Measurement (Details)",
     "shortName": "Financial Instruments - Schedule of Details Regarding Fair Value Measurement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c365",
      "name": "ppbt:FairValueMeasurementBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ppbt:ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c371",
      "name": "ppbt:FairValueMeasurementBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable",
     "longName": "996054 - Disclosure - Financial Instruments - Schedule of Fair Value Measurement (Details)",
     "shortName": "Financial Instruments - Schedule of Fair Value Measurement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c374",
      "name": "ppbt:DescriptionOfOptionLifeShareOptionGranted",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://Purplebiotech.com/role/SubsequentEventsDetails",
     "longName": "996055 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c379",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c379",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232483-20f_purple.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ppbt_ADSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ADSMember",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADS [Member]",
        "label": "ADSMember"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ATMProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ATMProgramMember",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Program [Member]",
        "label": "ATMProgram Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_AccountPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "AccountPayablesMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Account Payables [Member]",
        "verboseLabel": "Accounts payable [Member]",
        "label": "Account Payables Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccrualsClassifiedAsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable": {
       "parentTag": "ifrs-full_OtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other",
        "label": "Accruals classified as current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability and right-of-use asset (in Dollars)",
        "label": "Additions to right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ADSs used in calculating diluted loss per ADS (in Shares)",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ppbt_AdjustmentsForChangesInAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "AdjustmentsForChangesInAssetsAndLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Changes in assets and liabilities, total",
        "documentation": "Adjustments for changes in assets and liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Changes In Assets And Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ppbt_AdjustmentsForChangesInAssetsAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in other current assets",
        "label": "Adjustments for decrease (increase) in other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Adjustments for depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForFinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance income, net",
        "label": "Adjustments for finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss",
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ppbt_AdjustmentsForChangesInAssetsAndLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in post-employment benefit liabilities",
        "label": "Adjustments for increase (decrease) in employee benefit liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ppbt_AdjustmentsForChangesInAssetsAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in other payables",
        "label": "Adjustments for increase (decrease) in other operating payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ppbt_AdjustmentsForChangesInAssetsAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in trade payables",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLoss",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total adjustments",
        "label": "Adjustments to reconcile profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow",
      "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "verboseLabel": "Total share-based expense recognized",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ppbt_AdsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "AdsMember",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/IntangibleAssetsDetails",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADS [Member]",
        "verboseLabel": "Ads [Member]",
        "label": "Ads Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_AggregateShareholdersOfImmunorizon": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "AggregateShareholdersOfImmunorizon",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate shareholders of immunorizon (in Shares)",
        "documentation": "The aggregate shareholders of immunorizon.",
        "label": "Aggregate Shareholders Of Immunorizon"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_AggregateUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "AggregateUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate upfront payment (in Dollars)",
        "documentation": "The amount of Aggregate upfront payment.",
        "label": "Aggregate Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_AggregateWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "AggregateWarrantsShares",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate warrants shares (in Shares)",
        "documentation": "Aggregate warrants shares.",
        "label": "Aggregate Warrants Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r227",
      "r243",
      "r278"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r230",
      "r246",
      "r281"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "ppbt_AgreementLeaseAdditionalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "AgreementLeaseAdditionalTerm",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement lease additional term",
        "documentation": "Agreement Lease Additional Term.",
        "label": "Agreement Lease Additional Term"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_AgreementLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "AgreementLeaseTerm",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement lease term",
        "documentation": "Agreement Lease Term.",
        "label": "Agreement Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r231",
      "r247",
      "r273",
      "r282",
      "r286",
      "r294"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_AmericanDepositorySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "AmericanDepositorySharesMember",
     "presentation": [
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADS [Member]",
        "label": "American Depository Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_AmericanDepositorySharesOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "AmericanDepositorySharesOrdinaryShares",
     "presentation": [
      "http://Purplebiotech.com/role/GeneralDetails",
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American depository ordinary shares",
        "verboseLabel": "Ordinary shares (in Shares)",
        "documentation": "American depository shares ordinary shares.",
        "label": "American Depository Shares Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_AmericanDepositorySharesPurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "AmericanDepositorySharesPurchase",
     "presentation": [
      "http://Purplebiotech.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American depository shares purchase",
        "documentation": "Number of ADS purchase.",
        "label": "American Depository Shares Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_AmericanDepostioryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "AmericanDepostioryShares",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American shares (in Shares)",
        "documentation": "American depostiory shares.",
        "label": "American Depostiory Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://Purplebiotech.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax rate applicable",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92",
      "r93",
      "r94",
      "r149",
      "r151"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable",
      "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable",
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r327"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable",
      "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r327"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r204",
      "r223"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r204",
      "r223"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r204",
      "r223"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AverageForeignExchangeRate",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofDataonExchangeRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Representative exchange rate",
        "label": "Average foreign exchange rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per ADS - USD (in Dollars per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "ifrs-full_BasicEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsPerShareAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share data",
        "label": "Basic earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "BasisofPreparationoftheConsolidatedFinancialStatementsDetailsLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Preparation of the Consolidated Financial Statements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "BasisofPreparationoftheConsolidatedFinancialStatementsDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Preparation of the Consolidated Financial Statements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_BiopharmaceuticalProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "BiopharmaceuticalProductMember",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biopharmaceutical Product [Member]",
        "label": "Biopharmaceutical Product Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors [Member]",
        "label": "Board Of Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bear fixed interest, percentage",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails",
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails",
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails",
      "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable",
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable",
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of Range [Member]",
        "verboseLabel": "Down 2% [Member]",
        "netLabel": "Bottom of range [member]",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r96",
      "r113",
      "r130",
      "r173",
      "r174",
      "r346"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r223"
     ]
    },
    "ifrs-full_CapitalReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CapitalReserve",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital reserve from transactions with related parties",
        "label": "Capital reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the capital reserves."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CapitalReserveFromTransactionsWithNon-ControllingInterest",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital reserve from transactions with non- controlling interest",
        "documentation": "Capital reserve from transactions with non- controlling interest.",
        "label": "Capital Reserve From Transactions With Non- Controlling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CapitalReserveFromTransactionsWithNonControllingInterestMember",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital reserve from transactions with Non- controlling interest",
        "documentation": "Capital reserve from transactions with Non-controlling interest.",
        "label": "Capital Reserve From Transactions With Non Controlling Interest Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CapitalReserveFromTransactionsWithRelatedPartiesMember",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital reserve from transactions with related parties",
        "label": "Capital Reserve From Transactions With Related Parties Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ppbt_CashAndCashEquivalentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CashAndCashEquivalentLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet",
      "http://Purplebiotech.com/role/ConsolidatedCashFlow",
      "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at the beginning of the year",
        "periodEndLabel": "Cash and cash equivalents at end of the year",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Total cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r75",
      "r91"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_CashAndCashEquivalentsAndDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CashAndCashEquivalentsAndDepositsMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash And Cash Equivalents And Deposits [Member]",
        "verboseLabel": "Cash and cash equivalents and deposits [Member]",
        "label": "Cash And Cash Equivalents And Deposits Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_CashAssumedAsPartOfAcquisitionOfFamewave": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CashAssumedAsPartOfAcquisitionOfFamewave",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of subsidiary, net of cash acquired (see Note 4C)",
        "documentation": "The cash outflow for the purchase of interests in associates. [Refer: Associates [member]]",
        "label": "Cash Assumed As Part Of Acquisition Of Famewave"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_CashFlowsFromFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CashFlowsFromFinancingActivitiesAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Flows From Financing Activities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_CashFlowsFromInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CashFlowsFromInvestingActivitiesAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Flows From Investing Activities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r76"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r76"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r68",
      "r76"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails",
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails",
      "http://Purplebiotech.com/role/LeasesDetails",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails",
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails",
      "http://Purplebiotech.com/role/LeasesDetails",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "ppbt_ChangesInAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ChangesInAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Changes In Assets And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Officers [Member]",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ClassEPreferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ClassEPreferredSharesMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class E Preferred Shares [Member]",
        "label": "Class EPreferred Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable",
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r95",
      "r105"
     ]
    },
    "ifrs-full_ClassesOfAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfAssetsDomain",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r95",
      "r105"
     ]
    },
    "ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfEmployeeBenefitsExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r144",
      "r145"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r144",
      "r145"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_ClassesOfOrdinarySharesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfOrdinarySharesAxis",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of ordinary shares [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_ClassesOfOrdinarySharesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfOrdinarySharesDomain",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of ordinary shares [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ppbt_ClassesOfPreferredSharesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ClassesOfPreferredSharesAxis",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes Of Preferred Shares [Axis]",
        "label": "Classes Of Preferred Shares Axis"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/IntangibleAssetsDetails",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/IntangibleAssetsDetails",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "ppbt_CommitmentsAndContingentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CommitmentsAndContingentLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingent Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_CommitmentsAndContingentLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CommitmentsAndContingentLiabilitiesLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingent Liabilities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_CommitmentsandContingentLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CommitmentsandContingentLiabilitiesDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingent Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_CommonStockNoParValues": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CommonStockNoParValues",
     "presentation": [
      "http://Purplebiotech.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock par value (in Dollars per share)",
        "documentation": "Common stock no par value.",
        "label": "Common Stock No Par Values"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable",
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable",
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total comprehensive loss for the year",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r30",
      "r78",
      "r80",
      "r88",
      "r172"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-controlling interests",
        "label": "Comprehensive income, attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r0",
      "r33"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Information Relating to Non-Controlling Interests [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Owners of the Company",
        "label": "Comprehensive income, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r0",
      "r34"
     ]
    },
    "ppbt_ConsolidatedStatementsOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ConsolidatedStatementsOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements Of Changes In Equity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ConsultantPerShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ConsultantPerShares",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consultant per shares (in Dollars per share)",
        "label": "Consultant Per Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Continuing involvement in derecognised financial assets by type of instrument [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Continuing involvement in derecognised financial assets by type of instrument [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of financial instruments. It also represents the standard value for the 'Continuing involvement in derecognised financial assets by type of instrument' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ppbt_ConvertibleDebtInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ConvertibleDebtInstrumentMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt instrument [Member]",
        "label": "Convertible Debt Instrument Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ConvertibleNoteMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible note [Member]",
        "label": "Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ConvertibleShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ConvertibleShares",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible shares (in Shares)",
        "documentation": "Convertible shares.",
        "label": "Convertible Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ConvertibleWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ConvertibleWarrants",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible warrants (in Shares)",
        "documentation": "Convertible warrants.",
        "label": "Convertible Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ConvertiblesWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ConvertiblesWarrants",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible warrants",
        "documentation": "Amount of convertible warrants.",
        "label": "Convertibles Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Preparation of the Consolidated Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CreditRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CreditRiskMember",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit risk [Member]",
        "verboseLabel": "Credit risk [member]",
        "label": "Credit risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r183"
     ]
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrencyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrencyRiskMember",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency risk [Member]",
        "label": "Currency risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r147"
     ]
    },
    "ppbt_CurrentAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CurrentAsset",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "documentation": "The value of Corrent assets.",
        "label": "Current Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r84",
      "r172"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable": {
       "parentTag": "ifrs-full_OtherCurrentPayables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government authorities",
        "label": "Current government grants"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]"
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ifrs-full_CurrentInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentInvestments",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet",
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other investments",
        "verboseLabel": "Fair value financial instruments",
        "label": "Current investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current investments."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet",
      "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current maturity of lease liabilities",
        "verboseLabel": "Current maturities of lease liability",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ppbt_CurrentLiabiliti": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CurrentLiabiliti",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Current Liabiliti"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r86",
      "r172"
     ]
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other receivables",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ppbt_CurrentTerms": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "CurrentTerms",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of current terms",
        "label": "Current Terms"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r303"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]",
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r303"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r305"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r305"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r300"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Flag]",
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r301"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r299"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r299"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r299"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Third Party Engaged [Flag]",
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r302"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Role of Management [Text Block]",
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r304"
     ]
    },
    "ppbt_Decreaseincreaseinshorttermdeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "Decreaseincreaseinshorttermdeposits",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in short term deposits",
        "documentation": "Decrease increase in short term deposits.",
        "label": "Decreaseincreaseinshorttermdeposits"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r250"
     ]
    },
    "ppbt_DepositaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DepositaryShares",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depositary shares (in Shares)",
        "documentation": "Depositary shares.",
        "label": "Depositary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_DepositarysShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DepositarysShares",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depositary shares (in Shares)",
        "documentation": "Depositary shares.",
        "label": "Depositarys Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation on right-to-use assets",
        "label": "Depreciation, right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ppbt_DepreciationRightofuseAssetsUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DepreciationRightofuseAssetsUsefulLife",
     "presentation": [
      "http://Purplebiotech.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Depreciation Rightofuse Assets Useful Life"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DerivativeFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt instrument and warrant (see Note 18B (2))",
        "label": "Derivative financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liability of warrants",
        "label": "Derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock",
     "presentation": [
      "http://Purplebiotech.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of consolidation",
        "documentation": "The description of the entity's accounting policy for basis of consolidation.",
        "label": "Description Of Accounting Policy For Basis Of Consolidation Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share",
        "label": "Description of accounting policy for earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits",
        "label": "Description of accounting policy for employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency transactions",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Description of accounting policy for impairment of assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of assets."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense",
        "label": "Description of accounting policy for income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Description of accounting policy for intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing income and expense",
        "label": "Description of accounting policy for interest income and expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income and expense arising from interest."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Description of accounting policy for provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment transactions",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ppbt_DescriptionOfExpectedAnnualRiskFreeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DescriptionOfExpectedAnnualRiskFreeRate",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of expected annual risk free rate",
        "documentation": "Description of expected annual risk free rate.",
        "label": "Description Of Expected Annual Risk Free Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_DescriptionOfExpectedVolatilityPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DescriptionOfExpectedVolatilityPercentage",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of expected volatility percentage",
        "documentation": "Description of expected volatility percentage.",
        "label": "Description Of Expected Volatility Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable",
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (%)",
        "verboseLabel": "Expected volatility",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ppbt_DescriptionOfOptionLifeShareOptionGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DescriptionOfOptionLifeShareOptionGranted",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "documentation": "Expected term.",
        "label": "Description Of Option Life Share Option Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected duration (years)",
        "label": "Option life, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable",
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free rate interest rate (%)",
        "verboseLabel": "annual risk free interest",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ppbt_DiagnosticProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DiagnosticProductsMember",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diagnostic Products [Member]",
        "label": "Diagnostic Products Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per ADS - USD (in Dollars per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "ifrs-full_DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares",
     "presentation": [
      "http://Purplebiotech.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants shares",
        "label": "Dilutive effect of warrants on weighted average number of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relates to the assumed conversion of the entity\u2019s warrants."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors [Member]",
        "verboseLabel": "Board of Directors [Member]",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DirectorsRemunerationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DirectorsRemunerationExpense",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board member remuneration and insurance",
        "label": "Directors' remuneration expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of remuneration paid or payable to the entity's directors."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amounts Recognized in Profit or Loss",
        "label": "Disclosure of additional information about leasing activities for lessor [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of additional information about leasing activities of a lessor."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Preparation of the Consolidated Financial Statements",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/CashandCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting standards issued but not yet effective",
        "label": "Disclosure of changes in accounting policies [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of changes made to accounting policies by the entity."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Share Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Capital [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingent liabilities",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock",
     "presentation": [
      "http://Purplebiotech.com/role/CashandCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "documentation": "The disclosure of detailed information about cash and cash equivalents.",
        "label": "Disclosure Of Detailed Information About Cash And Cash Equivalent Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock",
     "presentation": [
      "http://Purplebiotech.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Share Capital",
        "documentation": "Disclosure Of Detailed Information About Changes In Share Capital Explanatory Table Text Block.",
        "label": "Disclosure Of Detailed Information About Changes In Share Capital Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock",
     "presentation": [
      "http://Purplebiotech.com/role/EmployeeBenefitsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Contribution Plan in Respect of its Employees",
        "documentation": "The disclosure of detailed information about defined contribution plan.",
        "label": "Disclosure Of Detailed Information About Defined Contribution Plan Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock",
     "presentation": [
      "http://Purplebiotech.com/role/EmployeeBenefitsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Post-Employee Benefits",
        "documentation": "The disclosure of detailed information about employee benefits.",
        "label": "Disclosure Of Detailed Information About Employee Benefits Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Disclosure of detailed information about intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock",
     "presentation": [
      "http://Purplebiotech.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Information Relating to Non-Controlling Interests",
        "documentation": "DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock.",
        "label": "Disclosure Of Detailed Information About Noncontrolling Interests Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Number of RSUs",
        "documentation": "The disclosure of detailed information about restricted stock unit.",
        "label": "Disclosure Of Detailed Information About Restricted Stock Unit Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
     "presentation": [
      "http://Purplebiotech.com/role/OtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Payables",
        "documentation": "The disclosure of detailed information about of trade and other payables.",
        "label": "Disclosure Of Detailed Information About Trade And Other Payables Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables",
      "http://Purplebiotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Data on Exchange Rates",
        "verboseLabel": "Schedule of Sensitivity Test to Possible Changes in Exchange Rate",
        "label": "Disclosure of effect of changes in foreign exchange rates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for the effect of changes in foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/EmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits",
        "label": "Disclosure of employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expenses Recognized in the Consolidated Financial Statements",
        "label": "Disclosure of expenses by nature [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Measurement",
        "label": "Disclosure of fair value measurement of liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Instruments Measured at Fair Value",
        "label": "Disclosure of fair value of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_DisclosureOfFinanceCostExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceCostExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finance Expenses",
        "label": "Disclosure of finance cost [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance cost. [Refer: Finance costs]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/FinanceExpenseIncomeNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Expense (Income), net",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finance Income",
        "label": "Disclosure of finance income [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income. [Refer: Finance income]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Disclosure of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails",
      "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable",
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable",
      "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable",
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Line Items]",
        "terseLabel": "Financial Instruments [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales, General and Administrative Expenses",
        "label": "Disclosure of general and administrative expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of general and administrative expenses. [Refer: Administrative expenses]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/TaxesonIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on Income",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions were Used",
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Recorded Expenses",
        "label": "Disclosure of information about key management personnel [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110"
     ]
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/MaterialAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Accounting Policies",
        "label": "Disclosure of material accounting policy information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity Analysis of the Company's Lease Liabilities",
        "label": "Disclosure of maturity analysis of operating lease payments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturity Analysis of the Company's Lease Liabilities [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Number and Weighted Average Exercise Prices of Share Options",
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOtherCurrentAssetsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/OtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets",
        "label": "Disclosure of other current assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other current assets. [Refer: Other current assets]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ppbt_DisclosureOfOtherCurrentAssettextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DisclosureOfOtherCurrentAssettextBlock",
     "presentation": [
      "http://Purplebiotech.com/role/OtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Assets",
        "documentation": "The disclosure of other current assets.",
        "label": "Disclosure Of Other Current Assettext Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Amounts of Right-to-Use Assets",
        "label": "Disclosure of quantitative information about right-of-use assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Carrying Amounts of Right-to-Use Assets [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Number and Weighted Average Exercise Prices of Share Options [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/ResearchandDevelopmentExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Disclosure of research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DisclosureOfResearchAndDevelopmentExpensesTableTextBlock",
     "presentation": [
      "http://Purplebiotech.com/role/ResearchandDevelopmentExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Research and Development Expenses",
        "documentation": "No definition available.",
        "label": "Disclosure Of Research And Development Expenses Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangements",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Expenses Recognized in the Consolidated Financial Statements [Line Items]",
        "terseLabel": "Share-Based Payment Arrangements [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/OtherPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Payables",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions and Balances with Related Parties",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Recorded Expenses [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock",
     "presentation": [
      "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Sales, General and Administrative Expenses",
        "documentation": "Disclosures Of DetailedInformationAboutGeneralAndAdministrativeExpenses Explanatory [Table Text Block]",
        "label": "Disclosures Of Detailed Information About General And Administrative Expenses Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_Discountforlackofmarketability": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "Discountforlackofmarketability",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DLOM",
        "documentation": "Discount for lack of marketability.",
        "label": "Discountforlackofmarketability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r250"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r204",
      "r223"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r204",
      "r223",
      "r274"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r204",
      "r223",
      "r274"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ppbt_DownRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "DownRangeOneMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Down 5% [Member]",
        "label": "Down Range One Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "ppbt_EUROMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "EUROMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EURO [Member]",
        "label": "EUROMember"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of translation adjustments on cash and cash equivalents",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "ppbt_EffectiveTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "EffectiveTaxRate",
     "presentation": [
      "http://Purplebiotech.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate",
        "documentation": "Effective tax rate.",
        "label": "Effective Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ppbt_EmployeeBenefitBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "EmployeeBenefitBonus",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonuses expenses",
        "documentation": "Employee benefit bonus.",
        "label": "Employee Benefit Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_EmployeeBenefitsLiabilityDueGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "EmployeeBenefitsLiabilityDueGrants",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits liability due grants",
        "documentation": "Employee benefits liability due grants.",
        "label": "Employee Benefits Liability Due Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet",
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r21",
      "r77",
      "r79",
      "r92",
      "r93",
      "r94"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Equity attributable to owners of the Company",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParentMember",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Equity attributable to owners of parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ppbt_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_EquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "EquityLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_EquityMethodInvestmentsOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "EquityMethodInvestmentsOwnershipPercentage",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct ownership of equity",
        "documentation": "Direct ownership of equity.",
        "label": "Equity Method Investments Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_EquityScheduleofShareCapitalDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "EquityScheduleofShareCapitalDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity - Schedule of Share Capital (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r227",
      "r243",
      "r278"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r224",
      "r240",
      "r275"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "ppbt_ExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ExerciseOfWarrantsEquity",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value",
        "label": "Exercise Of Warrants Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ExercisePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ExercisePeriod",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable period",
        "documentation": "It represents exercise period.",
        "label": "Exercise Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price - USD (in Dollars per share)",
        "verboseLabel": "Exercise price (in Dollars per share)",
        "label": "Exercise price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails",
      "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (%)",
        "verboseLabel": "Dividend yield",
        "label": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ExpectedDividendAsPercentageShareOptionsdividendYield",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "dividend yield",
        "documentation": "Percentage of dividend yield",
        "label": "Expected Dividend As Percentage Share Optionsdividend Yield"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "Expense from share-based payment transactions with employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board member share-based payments",
        "label": "Expense from share-based payment transactions with parties other than employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with parties other than employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FairValueMeasurementBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FairValueMeasurementBalance",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Fair Value Measurement Balance.",
        "label": "Fair Value Measurement Balance"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FairValueMeasurementExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FairValueMeasurementExercise",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise",
        "documentation": "Represent the fair value of exercise.",
        "label": "Fair Value Measurement Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FairValueMeasurementIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FairValueMeasurementIssuance",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance",
        "documentation": "Fair Value Measurement Issuance",
        "label": "Fair Value Measurement Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FairValueMeasurementIssuanceProceed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FairValueMeasurementIssuanceProceed",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceed",
        "documentation": "Fair Value Measurement Proceed.",
        "label": "Fair Value Measurement Issuance Proceed"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FairValueMeasurementRevaluation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FairValueMeasurementRevaluation",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation",
        "documentation": "Fair Value Measurement Revaluation.",
        "label": "Fair Value Measurement Revaluation"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FairValueOfIssuedEquity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FairValueOfIssuedEquity",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of issued equity (in Shares)",
        "documentation": "Fair value of issued equity.",
        "label": "Fair Value Of Issued Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FairValueOfIssuedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FairValueOfIssuedIntangibleAssets",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of issued intangible assets (in Dollars)",
        "documentation": "The fair value of issued intangible assets.",
        "label": "Fair Value Of Issued Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FeeAndCommissionExpense",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable": {
       "parentTag": "ifrs-full_OtherExpenseByNature",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fees and interest expense",
        "label": "Fee and commission expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to fees and commissions."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ppbt_FinanceExpenseIncomeNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinanceExpenseIncomeNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Expense (Income), Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FinanceExpenseIncomeNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinanceExpenseIncomeNetDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Expense (Income), Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FinanceExpenseIncomeNetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinanceExpenseIncomeNetLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Expense (Income), Net [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FinanceExpenseIncomeNetTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinanceExpenseIncomeNetTablesLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Expense (Income), Net [Abstract]",
        "label": "Finance Expense Income Net Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FinanceExpenseIncomeNetTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinanceExpenseIncomeNetTablesTable",
     "presentation": [
      "http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Expense (Income), Net (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ppbt_FinanceIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinanceIncomeAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income",
        "label": "Finance Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Finance income, net",
        "label": "Finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ppbt_FinancialAssetAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinancialAssetAndLiabilitiesAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial asset and liabilities",
        "label": "Financial Asset And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FinancialAssetAtAFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinancialAssetAtAFairValue",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial asset at a fair value",
        "documentation": "Amount of financial asset at a fair value.",
        "label": "Financial Asset At AFair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FinancialInstrumentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinancialInstrumentAmount",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instrument amount",
        "documentation": "Financial instrument amount.",
        "label": "Financial Instrument Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FinancialInstrumentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinancialInstrumentsDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - Schedule of Details Regarding Fair Value Measurement (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - Schedule of Fair Value Measurement (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - Schedule of Financial Instruments Measured at Fair Value (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - Schedule of Sensitivity Test to Possible Changes in Exchange Rate (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FinancialInstrumentsTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinancialInstrumentsTablesLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Tables) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FinancialInstrumentsTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FinancialInstrumentsTablesTable",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ForTheYearEndedDecember312023Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ForTheYearEndedDecember312023Abstract",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "For the year ended December 31, 2023",
        "label": "For The Year Ended December312023 Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ForeignExchangeGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ForeignExchangeGain",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable": {
       "parentTag": "ifrs-full_OtherFinanceIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income from exchange rate differences, net",
        "label": "Foreign exchange gain"
       }
      },
      "en": {
       "role": {
        "documentation": "The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48"
     ]
    },
    "ifrs-full_ForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ForeignExchangeLoss",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable": {
       "parentTag": "ifrs-full_OtherExpenseByNature",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from exchange rate differences, net",
        "label": "Foreign exchange loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48"
     ]
    },
    "ifrs-full_ForeignExchangeRatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ForeignExchangeRatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Data on Exchange Rates [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r231",
      "r247",
      "r282"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r231",
      "r247",
      "r282"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r231",
      "r247",
      "r282"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r231",
      "r247",
      "r282"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r231",
      "r247",
      "r282"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r234"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "ppbt_FunctionalCurrency": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FunctionalCurrency",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Functional currency",
        "documentation": "The amount of functional currency.",
        "label": "Functional Currency"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FundsRaisedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FundsRaisedAmount",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company funds raised",
        "documentation": "Funds raised amount.",
        "label": "Funds Raised Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_FundsRaisedshares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "FundsRaisedshares",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funds raised amount (in Shares)",
        "documentation": "Funds raised amount.",
        "label": "Funds Raisedshares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrants",
        "label": "Gains (losses) on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ifrs-full_GainsOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable": {
       "parentTag": "ifrs-full_OtherFinanceIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes in fair value of finance instruments (see Note 18B2)",
        "label": "Gains on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ifrs-full_GainsOnLitigationSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsOnLitigationSettlements",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains on litigation settlements",
        "label": "Gains on litigation settlements"
       }
      },
      "en": {
       "role": {
        "documentation": "The gain on settlements of litigation."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ppbt_GeneralAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "GeneralAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_GeneralAndAdministrativeExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "GeneralAndAdministrativeExpensesOther",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.",
        "label": "General And Administrative Expenses Other"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_GeneralDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "GeneralDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_GeneralLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "GeneralLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r163",
      "r175",
      "r177"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r163",
      "r175",
      "r177"
     ]
    },
    "ppbt_GovernmentAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "GovernmentAuthorities",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government authorities",
        "documentation": "Government authorities.",
        "label": "Government Authorities"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_IPRDRelatedToFamewaveSee5BBelowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IPRDRelatedToFamewaveSee5BBelowMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D related to Famewave (see 4B below) [Member]",
        "label": "IPRDRelated To Famewave See5 BBelow Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_IPRDRelatedToImmunorizonSee5CBelowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IPRDRelatedToImmunorizonSee5CBelowMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D related to Immunorizon (see 4C below) [Member]",
        "label": "IPRDRelated To Immunorizon See5 CBelow Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_IPRDRelatedToPurpleGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IPRDRelatedToPurpleGmbHMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D related to Purple GmbH [Member]",
        "label": "IPRDRelated To Purple Gmb HMember"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_IPRDRelatedToTryNovosee5ABelowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IPRDRelatedToTryNovosee5ABelowMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D related to TyrNovo (see 4A below) [Member]",
        "label": "IPRDRelated To Try Novosee5 ABelow Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r204",
      "r223"
     ]
    },
    "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net identifiable assets",
        "label": "Identifiable assets acquired (liabilities assumed)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180"
     ]
    },
    "ifrs-full_ImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss",
        "label": "Impairment loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_IncomelossFromChangeInExchangeRateDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IncomelossFromChangeInExchangeRateDown",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (loss) from change in exchange rate",
        "documentation": "Amount of income (loss) from change in exchange rate.",
        "label": "Incomeloss From Change In Exchange Rate Down"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_IncomelossFromChangeInExchangeRateUp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IncomelossFromChangeInExchangeRateUp",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (loss) from change in exchange rate",
        "documentation": "Amount of income (loss) from change in exchange rate.",
        "label": "Incomeloss From Change In Exchange Rate Up"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_IncomelossValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IncomelossValue",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (loss) value",
        "documentation": "Income loss value.",
        "label": "Incomeloss Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ppbt_IncreaseDecreaseInLongTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IncreaseDecreaseInLongTermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in long term deposits",
        "documentation": "Decrease in long term deposits.",
        "label": "Increase Decrease In Long Term Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughAcquisitionOfSubsidiary",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADS issued in connection with the purchase of a subsidiary (see Note 4C)",
        "label": "Increase (decrease) through acquisition of subsidiary, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the acquisition of subsidiaries. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant inducement transaction",
        "label": "Increase (decrease) through exercise of warrants, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransactionsWithOwners",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total transactions with owners of the Company",
        "label": "Increase (decrease) through transactions with owners, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from transactions with owners."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r231",
      "r247",
      "r273",
      "r282",
      "r286",
      "r294"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r298"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r298"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r298"
     ]
    },
    "ifrs-full_InsuranceContractsIssuedThatAreAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InsuranceContractsIssuedThatAreAssets",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prospectus amount",
        "label": "Insurance contracts issued that are assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of insurance contracts issued that are assets. [Refer: Assets; Insurance contracts issued [member]]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r120"
     ]
    },
    "ppbt_IntangibleAssetsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IntangibleAssetsDetailsLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_IntangibleAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IntangibleAssetsDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet",
      "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "verboseLabel": "Total intangible assets",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65"
     ]
    },
    "ppbt_IntangibleAssetsRecoverableAmountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IntangibleAssetsRecoverableAmountPercentage",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets recoverable amount percentage",
        "documentation": "Intangible assets recoverable amount percentage.",
        "label": "Intangible Assets Recoverable Amount Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_IntangibleAssetsScheduleofIntangibleAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IntangibleAssetsScheduleofIntangibleAssetsDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets - Schedule of Intangible Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Recognized Amounts Assets Acquired and Liabilities Assumed [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IntangibleAssetsScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets - Schedule of Recognized Amounts of Assets Acquired and Liabilities Assumed (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_IntangibleAssetsTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IntangibleAssetsTablesLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets [Abstract]",
        "label": "Intangible Assets Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_IntangibleAssetsTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IntangibleAssetsTablesTable",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofAmountsRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expenses on lease liability",
        "label": "Interest expense on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_InterestIncomeOnDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestIncomeOnDeposits",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable": {
       "parentTag": "ifrs-full_OtherFinanceIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest income from deposits",
        "label": "Interest income on deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest income on deposits. [Refer: Interest income]"
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ifrs-full_InterestPaidClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestPaidClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest paid, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as financing activities."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestReceivedClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest received",
        "label": "Interest received, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "ppbt_IssuanceExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IssuanceExpenses",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable": {
       "parentTag": "ifrs-full_OtherExpenseByNature",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance expenses (see note 9D)",
        "documentation": "The amount of issuance expenses.",
        "label": "Issuance Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfConvertibleInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssueOfConvertibleInstruments",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible note amount",
        "label": "Issue of convertible instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The change in equity resulting from the issuing of convertible instruments."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs",
        "label": "Issue of equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital, no par value",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ppbt_IssuesOfEquity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "IssuesOfEquity",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of equity (in Shares)",
        "documentation": "Issue of equity.",
        "label": "Issues Of Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ItemsThatWillBeTransferredToProfitOrLossAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items that will be transferred to profit or loss:",
        "label": "Items That Will Be Transferred To Profit Or Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_January2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "January2025Member",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 2025 [Member]",
        "label": "January2025 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Key management personnel compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post-employment benefits",
        "label": "Key management personnel compensation, post-employment benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payments",
        "label": "Key management personnel compensation, share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short - term",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One to two years [Member]",
        "label": "Later than one year and not later than two years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r119",
      "r185",
      "r188",
      "r327"
     ]
    },
    "ppbt_LeaseAgreementOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "LeaseAgreementOneMember",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Agreement One [Member]",
        "label": "Lease Agreement One Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_LeaseAgreementsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "LeaseAgreementsTwoMember",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Agreements Two [Member]",
        "label": "Lease Agreements Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ifrs-full_LeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Amounts Recognized in Profit or Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseReceivablesMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office lease [Member]",
        "label": "Lease receivables [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for receivables related to leases."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r143",
      "r184"
     ]
    },
    "ppbt_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_LeasesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "LeasesLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases - Schedule of Carrying Amounts of Right-to-Use Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases - Schedule of Maturity Analysis of the Company's Lease Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Level 1 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r63",
      "r64",
      "r93"
     ]
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level2OfFairValueHierarchyMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Level 2 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r93"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r93"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r93"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyDomain",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r93"
     ]
    },
    "ifrs-full_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesDomain",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_LicenceFeeIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LicenceFeeIncome",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license fee (in Dollars)",
        "label": "Licence fee income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from licence fees."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_LongTermMilestonesAggregateAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "LongTermMilestonesAggregateAmount",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long term milestones aggregate amount (in Dollars)",
        "documentation": "The amount of long term Milestones aggregate amount.",
        "label": "Long Term Milestones Aggregate Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r98",
      "r107",
      "r108",
      "r111",
      "r112",
      "r113",
      "r119",
      "r137",
      "r146",
      "r165",
      "r185"
     ]
    },
    "ifrs-full_MaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityDomain",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r98",
      "r107",
      "r108",
      "r111",
      "r112",
      "r113",
      "r119",
      "r137",
      "r165",
      "r185",
      "r187"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ppbt_NISMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "NISMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NIS [Member]",
        "label": "NISMember"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "ppbt_NetAssetsAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "NetAssetsAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net assets attributable to non-controlling interests",
        "documentation": "The value of Mount of net assets attributable to non-controling interest.",
        "label": "Net Assets Attributable To Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_NetAssetsAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "NetAssetsAttributableToNoncontrollingInterests",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss allocated to non-controlling interests",
        "documentation": "The amount of net assets attributable to non-controlling interests.",
        "label": "Net Assets Attributable To Noncontrolling Interests"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetAssetsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetAssetsLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net assets",
        "label": "Assets (liabilities)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets less the amount of liabilities."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r327"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_NetOfDeferredDifferenceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "NetOfDeferredDifferenceAmount",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of deferred difference amount",
        "documentation": "Amount of net of deffered difference amount.",
        "label": "Net Of Deferred Difference Amount"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r231",
      "r247",
      "r273",
      "r282"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ppbt_NonVotingSeniorPreferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "NonVotingSeniorPreferredShares",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-voting senior preferred shares (in Shares)",
        "documentation": "Non-voting senior preferred shares.",
        "label": "Non Voting Senior Preferred Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r81",
      "r83"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non - current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r85",
      "r172"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet",
      "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "verboseLabel": "Long-term lease liability",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non - current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r87",
      "r172"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentProvisionsForEmployeeBenefits",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post-employment benefit liabilities",
        "label": "Non-current provisions for employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_NoncurrentWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Non-current warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current warrant liabilities. [Refer: Warrant liability]"
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than one year\t[Member]",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r107",
      "r108",
      "r119",
      "r185",
      "r188"
     ]
    },
    "ppbt_NumberOfExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "NumberOfExerciseOfWarrants",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "documentation": "Exercise of warrants.",
        "label": "Number Of Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted during the year",
        "label": "Number of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r345"
     ]
    },
    "ppbt_NumberOfIssuanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "NumberOfIssuanceShares",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ADSs (See D below and 4C)",
        "documentation": "The number of issuance shares.",
        "label": "Number Of Issuance Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_NumberOfNonTradableWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "NumberOfNonTradableWarrants",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate shares (in Shares)",
        "documentation": "Number Of Non Tradable Warrants.",
        "label": "Number Of Non Tradable Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested during the year",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited during the year",
        "label": "Number of other equity instruments forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at January 1",
        "periodEndLabel": "Outstanding at December 31",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, Outstanding beginning balance",
        "periodEndLabel": "Number of options, Outstanding ending balance",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r126",
      "r130"
     ]
    },
    "ppbt_NumberOfPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "NumberOfPerShare",
     "presentation": [
      "http://Purplebiotech.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of per share",
        "documentation": "Number of per share.",
        "label": "Number Of Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_NumberOfShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "NumberOfShare",
     "presentation": [
      "http://Purplebiotech.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share",
        "documentation": "Number of share.",
        "label": "Number Of Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Exercisable",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, Expired and forfeited during the year",
        "label": "Number of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Granted during the year",
        "verboseLabel": "Granted shares",
        "netLabel": "Number of options grants",
        "label": "Number of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, Authorized",
        "label": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Issued as at January 1",
        "periodEndLabel": "Issued as at December 31",
        "terseLabel": "Shares issued (in Shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, Issued and paid-in",
        "label": "Number of shares issued and fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized share capital (in Shares)",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ppbt_NumberOfVestingOfRsus": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "NumberOfVestingOfRsus",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of RSUs",
        "documentation": "Number Of Vesting Of Rsus.",
        "label": "Number Of Vesting Of Rsus"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OfficerMember",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officer [Member]",
        "label": "Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss",
        "label": "Operating expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ppbt_OptionExerciseOrdinaryShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "OptionExerciseOrdinaryShare",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option exercise ordinary share (in Shares)",
        "documentation": "Option exercise ordinary share.",
        "label": "Option Exercise Ordinary Share"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_OptionsAndRSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "OptionsAndRSUsMember",
     "presentation": [
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options and RSUs [Member]",
        "label": "Options And RSUs Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_OrdinaryShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "OrdinaryShareMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Share [Member]",
        "label": "Ordinary Share Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares [Member]",
        "verboseLabel": "Ordinary shares [member]",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive profit (loss) for the period",
        "label": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r29",
      "r36",
      "r90"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeBeforeTaxCashFlowHedges",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss (profit) from cash flow hedges",
        "label": "Other comprehensive income, before tax, cash flow hedges"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, before tax, after reclassification adjustments, related to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income, before tax]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r37"
     ]
    },
    "srt_OtherCurrencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OtherCurrencyMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance in other currencies [Member]",
        "label": "Other Currency [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_OtherCurrentAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "OtherCurrentAssetMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Asset [Member]",
        "verboseLabel": "Other current assets [Member]",
        "label": "Other Current Asset Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet",
      "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other current assets",
        "terseLabel": "Other current assets",
        "label": "Other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ifrs-full_OtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet",
      "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other payables",
        "terseLabel": "Other payables",
        "label": "Other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ppbt_OtherExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "OtherExpense",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable": {
       "parentTag": "ifrs-full_OtherFinanceIncome",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "documentation": "Other.",
        "label": "Other Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherExpenseByNature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherExpenseByNature",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance expenses",
        "terseLabel": "Issuance expenses",
        "label": "Other expenses, by nature"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]"
       }
      }
     },
     "auth_ref": [
      "r39",
      "r156"
     ]
    },
    "ifrs-full_OtherFinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherFinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total finance income",
        "label": "Other finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]"
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ifrs-full_OtherIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset",
        "label": "Other intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherNoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ifrs-full_OtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherPayables",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other payables",
        "label": "Other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ppbt_OtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "OtherPayablesMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Payables [Member]",
        "verboseLabel": "Other payables [Member]",
        "label": "Other Payables Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital reserve from hedging",
        "label": "Other reserves"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ppbt_OtherfinancialCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "OtherfinancialCost",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable": {
       "parentTag": "ifrs-full_OtherExpenseByNature",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "documentation": "Other.",
        "label": "Otherfinancial Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r229",
      "r245",
      "r280"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r232",
      "r248",
      "r283"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r232",
      "r248",
      "r283"
     ]
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering issued price (in Dollars per share)",
        "verboseLabel": "Exercise price per share (in Dollars per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "ADS issuance expenses paid",
        "label": "Payments for share issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of lease liability",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "ppbt_PercentageOfCapacityOfAnAdvisor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PercentageOfCapacityOfAnAdvisor",
     "presentation": [
      "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of capacity of an advisor",
        "documentation": "Percentage of capacity of an advisor.",
        "label": "Percentage Of Capacity Of An Advisor"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_PercentageOfContractToAcquire": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PercentageOfContractToAcquire",
     "presentation": [
      "http://Purplebiotech.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract to acquire, percentage",
        "documentation": "Contract to acquire, percentage.",
        "label": "Percentage Of Contract To Acquire"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_PercentageOfDiscountsForLacksOfMarketability": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PercentageOfDiscountsForLacksOfMarketability",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of discount for lack of marketability",
        "documentation": "Percentage of discounts for lacks of marketability.",
        "label": "Percentage Of Discounts For Lacks Of Marketability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfEntitysRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PercentageOfEntitysRevenue",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual interest rate of revenues",
        "label": "Percentage of entity's revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of the entity's revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "ppbt_PercentageOfExchangeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PercentageOfExchangeRate",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofDataonExchangeRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Representative exchange rate, percentage",
        "documentation": "Percentage of exchange rate.",
        "label": "Percentage Of Exchange Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_PercentageOfReceiveExitFee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PercentageOfReceiveExitFee",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of exit fee",
        "documentation": "Percentage of receive exit fee.",
        "label": "Percentage Of Receive Exit Fee"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_PercentageOfSublicenseConsideration": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PercentageOfSublicenseConsideration",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of sublicense consideration",
        "documentation": "Percentage of sublicense consideration.",
        "label": "Percentage Of Sublicense Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of voting equity interests acquired",
        "label": "Percentage of voting equity interests acquired"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PostemploymentBenefitExpenseDefinedContributionPlans",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofDefinedContributionPlaninRespectofitsEmployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount recognized as expense in respect of defined contribution plan",
        "label": "Post-employment benefit expense, defined contribution plans"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PostemploymentBenefitExpenseInProfitOrLoss",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofPostEmployeeBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post-employment benefit liabilities",
        "label": "Post-employment benefit expense in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense included in profit or loss"
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "ppbt_PostemploymentBenefitLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PostemploymentBenefitLiabilitiesMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post-employment benefit liabilities [Member]",
        "label": "Postemployment Benefit Liabilities Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_PreferenceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PreferenceSharesMember",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Shares [Member]",
        "label": "Preference shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ppbt_PreferredClassCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PreferredClassCMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class C Preferred Shares [Member]",
        "label": "Preferred Class CMember"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_PreferredClassDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PreferredClassDMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class D Preferred Shares [Member]",
        "label": "Preferred Class DMember"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_PreferredShareClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PreferredShareClassBMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class B Preferred Shares [Member]",
        "label": "Preferred Share Class BMember"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_PreferredShareClassMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PreferredShareClassMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A Preferred Shares [Member]",
        "label": "Preferred Share Class Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_PrivateAndPublicFinancingTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PrivateAndPublicFinancingTotal",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of issuance expenses (in Dollars)",
        "label": "Private And Public Financing Total"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_PrivatePlacementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PrivatePlacementsMember",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placements Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from warrant inducement transaction",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of ADSs",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ppbt_ProceedsFromIssuingWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ProceedsFromIssuingWarrants",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of warrants and prefunded warrants",
        "documentation": "The cash inflow from issuing warrants.",
        "label": "Proceeds From Issuing Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceed from other investments",
        "label": "Proceeds from sales of other long-term assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfessionalFeesExpense",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other professional fees",
        "verboseLabel": "Placement agent fees and other offering related expenses",
        "label": "Professional fees expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable",
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss for the year",
        "terseLabel": "Loss for the year",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r28",
      "r69",
      "r78",
      "r80",
      "r149",
      "r150",
      "r172",
      "r176"
     ]
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss attributable to:",
        "label": "Profit (loss), attributable to [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-controlling interests",
        "label": "Profit (loss), attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r31",
      "r82"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Owners of the Company",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss for the year",
        "label": "Profit (loss) from continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r28",
      "r89",
      "r149",
      "r150"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss for the year",
        "label": "Profit (loss) from continuing operations attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations attributable to non-controlling interests. [Refer: Profit (loss) from continuing operations; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets, net",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r44"
     ]
    },
    "ppbt_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering [Member]",
        "verboseLabel": "PublicOfferingMember",
        "label": "Public Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_PurchaseOfCommonStockAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "PurchaseOfCommonStockAndWarrants",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase shares (in Shares)",
        "documentation": "The company granted representative of the non traded warrants to purchase of common stock.",
        "label": "Purchase Of Common Stock And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of intangible asset",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of fixed assets",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails",
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails",
      "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable",
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable",
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r96",
      "r113",
      "r130",
      "r173",
      "r174",
      "r346"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails",
      "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable",
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable",
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r96",
      "r113",
      "r130",
      "r173",
      "r174",
      "r346"
     ]
    },
    "ppbt_RangesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "RangesAxis",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges [Axis]",
        "label": "Ranges Axis"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_RangesDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "RangesDomainDomain",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RangesDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ReceiptsOnAccountOfWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ReceiptsOnAccountOfWarrantsMember",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receipts on account of warrants",
        "label": "Receipts On Account Of Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ReceiptsOnAccountsOfWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ReceiptsOnAccountsOfWarrant",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receipts on account of warrants",
        "documentation": "The amount of receipts on account of warrants.",
        "label": "Receipts On Accounts Of Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r224",
      "r240",
      "r275"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ppbt_RehovotMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "RehovotMember",
     "presentation": [
      "http://Purplebiotech.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rehovot [Member]",
        "label": "Rehovot Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ReimbursementOfLegalFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ReimbursementOfLegalFeesExpense",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reimbursement of legal fees",
        "documentation": "Reimbursement of legal fees.",
        "label": "Reimbursement Of Legal Fees Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RentalExpense",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maintenance expenses",
        "label": "Rental expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised on rental activities."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable",
      "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ppbt_ResearchAndDevelopmentExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ResearchAndDevelopmentExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ResearchAndDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ResearchAndDevelopmentExpensesMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses [Member]",
        "label": "Research And Development Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Expenses [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses - Schedule of Research and Development Expenses (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfCashFlowHedgesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfCashFlowHedgesMember",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital reserve from hedging",
        "label": "Reserve of cash flow hedges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing the accumulated portion of gain (loss) on a hedging instrument that is determined to be an effective hedge for cash flow hedges. [Refer: Cash flow hedges [member]]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r157"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPayments",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital reserve for share-based payments",
        "label": "Reserve of share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital reserve for share- based payments",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r225",
      "r241",
      "r276"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r226",
      "r242",
      "r277"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r233",
      "r249",
      "r284"
     ]
    },
    "ifrs-full_RestrictedShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RestrictedShareUnitsMember",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Granted [Member]",
        "verboseLabel": "Restricted share units [member]",
        "netLabel": "Restricted Share Units (RSU) [Member]",
        "label": "Restricted share units [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for restricted share units."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "ppbt_RetainedEarning": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "RetainedEarning",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings (in Dollars)",
        "label": "Retained Earning"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated loss",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated loss",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r157"
     ]
    },
    "ifrs-full_RevenueFromRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payable",
        "label": "Royalty income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from royalties."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ppbt_ReverseRatio": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ReverseRatio",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse ratio",
        "documentation": "Reverse Ratio.",
        "label": "Reverse Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet",
      "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "terseLabel": "Right to use assets",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r104"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ppbt_SalariesWagesAndRelatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "SalariesWagesAndRelatedExpensesMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries, wages and related expenses [Member]",
        "label": "Salaries Wages And Related Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_SalaryRelatedOtherPayablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "SalaryRelatedOtherPayablesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable": {
       "parentTag": "ifrs-full_OtherCurrentPayables",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salary related",
        "documentation": "The amount of current salary related payables.",
        "label": "Salary Related Other Payables Current"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_SalesAgreementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "SalesAgreementShares",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales agreement (in Shares)",
        "documentation": "Sales agreement shares.",
        "label": "Sales Agreement Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales, General and Administrative Expenses - Schedule of Sales, General and Administrative Expenses (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfAssumptionsWereUsedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfAssumptionsWereUsedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assumptions Were Used Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfAssumptionsWereUsedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfAssumptionsWereUsedLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assumptions were Used [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Carrying Amounts Of Right To Use Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfCashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfCashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash And Cash Equivalents Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Contribution Plan in Respect of its Employees [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfDetailsRegardingFairValueMeasurementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfDetailsRegardingFairValueMeasurementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Details Regarding Fair Value Measurement Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Details Regarding Fair Value Measurement",
        "label": "Schedule Of Details Regarding Fair Value Measurement Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Expenses Recognized In The Consolidated Financial Statements Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfFairValueMeasurementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfFairValueMeasurementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Measurement Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfFinanceExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfFinanceExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Finance Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfFinanceIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfFinanceIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Finance Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Instruments Measured At Fair Value Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturity Analysis Of The Companys Lease Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfNumberOfRSUsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfNumberOfRSUsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Number of RSUs [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfPostEmployeeBenefitsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfPostEmployeeBenefitsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Post-Employee Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Recognized Amounts of Assets Acquired and Liabilities Assumed",
        "documentation": "The disclosure of detailed information about recognized amounts assets acquired and liabilities assumed.",
        "label": "Schedule Of Recognized Amounts Assets Acquired And Liabilities Assumed Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfRecognizedAmountsOfAssetsAcquiredAndLiabilitiesAssumedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfRecognizedAmountsOfAssetsAcquiredAndLiabilitiesAssumedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Recognized Amounts Of Assets Acquired And Liabilities Assumed Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfRecordedExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfRecordedExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Recorded Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfResearchAndDevelopmentExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfResearchAndDevelopmentExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Research And Development Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Sales, General and Administrative Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Sales, General and Administrative Expenses [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Sensitivity Test To Possible Changes In Exchange Rate Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ScheduleOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ScheduleOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Capital Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_Securities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "Securities",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities (see Note 18B (2))",
        "documentation": "The amount of Securities.",
        "label": "Securities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r97",
      "r149",
      "r164",
      "r178"
     ]
    },
    "ifrs-full_SegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentsDomain",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r97",
      "r152",
      "r164",
      "r178"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable",
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Sales, General and Administrative Expenses total",
        "terseLabel": "Sales, general and administrative expenses",
        "label": "Selling, general and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales, General and Administrative Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable",
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expense [member]",
        "label": "Selling, general and administrative expense [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount of expense relating to selling, general and administrative activities of the entity. This member is used to attribute an expense by nature to a functional line item in the statement of profit or loss."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r327"
     ]
    },
    "ppbt_SeriesA1WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "SeriesA1WarrantsMember",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-1 warrants [Member]",
        "label": "Series A1 Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_SeriesA2WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "SeriesA2WarrantsMember",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-2 warrants [Member]",
        "label": "Series A2 Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ServiceProvidersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ServiceProvidersMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service providers [Member]",
        "label": "Service Providers Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ShareBasedPaymentArrangementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ShareBasedPaymentArrangementsDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ShareBasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ShareBasedPaymentArrangementsMember",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Payment Arrangements [Member]",
        "label": "Share Based Payment Arrangements Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangements - Schedule of Assumptions were Used (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangements - Schedule of Expenses Recognized in the Consolidated Financial Statements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ShareBasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ShareBasedPaymentsMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments [Member]",
        "label": "Share Based Payments Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of issuance expenses",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_ShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareOptionsMember",
     "presentation": [
      "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options [Member]",
        "label": "Share options [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share options."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share premium",
        "label": "Share premium"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share premium",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ppbt_SharesPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "SharesPrice",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in Dollars per share)",
        "documentation": "Share price.",
        "label": "Shares Price"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ShortTermDepositsGuaranteedForHedgingTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ShortTermDepositsGuaranteedForHedgingTransactions",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term deposits",
        "documentation": "Amount of short term deposits guaranteed for hedging transactions.",
        "label": "Short Term Deposits Guaranteed For Hedging Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "ShortTermDepositsGuaranteedForLeasesAndCredit",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term deposits guaranteed for leases and credit",
        "documentation": "Amount of short term deposits guaranteed for leases and credit.",
        "label": "Short Term Deposits Guaranteed For Leases And Credit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet",
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term deposits",
        "verboseLabel": "Cash and cash equivalents and short-term and long-terms deposits",
        "label": "Short-term deposits, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofPostEmployeeBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term benefits",
        "label": "Short-term employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://Purplebiotech.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total comprehensive loss attributable to:",
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_StatutoryTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "StatutoryTaxRate",
     "presentation": [
      "http://Purplebiotech.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory tax rate.",
        "documentation": "Statutory tax rate.",
        "label": "Statutory Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r217",
      "r228",
      "r244",
      "r279"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_StockOptionExercisedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "StockOptionExercisedPeriod",
     "presentation": [
      "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option exercised period",
        "verboseLabel": "Options exercised period",
        "documentation": "Stock option exercised period.",
        "label": "Stock Option Exercised Period"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_StockholdersEquityReversesStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "StockholdersEquityReversesStockSplit",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders equity reverse stock split",
        "documentation": "Stockholders equity reverse stock split.",
        "label": "Stockholders Equity Reverses Stock Split"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_SubsequentEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "SubsequentEventsMember",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Member]",
        "label": "Subsequent Events Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_THMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "THMMember",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "THM [Member]",
        "label": "THMMember"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit",
        "label": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce deferred tax expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce deferred tax expense. [Refer: Deferred tax expense (income); Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ppbt_TaxesOnIncomeabstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "TaxesOnIncomeabstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_TerminationExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "TerminationExercisePrice",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination exercise price (in Dollars per share)",
        "documentation": "The exercise price of share options terminated.",
        "label": "Termination Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails",
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails",
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails",
      "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable",
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable",
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of Range [Member]",
        "verboseLabel": "Up 5% [Member]",
        "netLabel": "Top of range [member]",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r96",
      "r113",
      "r130",
      "r173",
      "r174",
      "r346"
     ]
    },
    "ppbt_TotalAcquisitionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "TotalAcquisitionAmount",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total acquisition (in Dollars)",
        "documentation": "Amount of total acquisition .",
        "label": "Total Acquisition Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable": {
       "parentTag": "ifrs-full_OtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties - salary related",
        "label": "Current payables to related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current payables due to related parties. [Refer: Total for all related parties [member]; Payables to related parties]"
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payable",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r331"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecognizedAmountsofAssetsAcquiredandLiabilitiesAssumedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade payables",
        "label": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties - Schedule of Recorded Expenses (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "TransactionsandBalanceswithRelatedPartiesTablesLineItems",
     "presentation": [
      "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions and Balances with Related Parties [Abstract]",
        "label": "Transactionsand Balanceswith Related Parties Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_TransactionsandBalanceswithRelatedPartiesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "TransactionsandBalanceswithRelatedPartiesTablesTable",
     "presentation": [
      "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TravelExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TravelExpense",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Travel and car expenses",
        "label": "Travel expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from travel."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "ppbt_TryNovosTechnologiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "TryNovosTechnologiesMember",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TryNovo's Technologies [Member]",
        "label": "Try Novos Technologies Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsAxis",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsDomain",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails",
      "http://Purplebiotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r118",
      "r136",
      "r138",
      "r139",
      "r155"
     ]
    },
    "ifrs-full_TypesOfRisksDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksDomain",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails",
      "http://Purplebiotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r118",
      "r136",
      "r138",
      "r139",
      "r155"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails",
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "USD",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance in USD [Member]",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "ppbt_UnrecognizedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "UnrecognizedResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://Purplebiotech.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized research and development expenses",
        "documentation": "The amount of unrecognized research and development expenses.",
        "label": "Unrecognized Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_UpRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "UpRangeOneMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Up 2% [Member]",
        "label": "Up Range One Member"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_VestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "VestingPeriod",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "documentation": "It represents vesting period.",
        "label": "Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "ifrs-full_WagesAndSalaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WagesAndSalaries",
     "crdr": "debit",
     "calculation": {
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries, wages and related expenses",
        "label": "Wages and salaries"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "ppbt_WarrantExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "WarrantExercisePricePerShare",
     "presentation": [
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercise price per share (in Dollars per share)",
        "documentation": "Exercise price per share.",
        "label": "Warrant Exercise Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability fair value",
        "label": "Warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of warrant liabilities."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ifrs-full_WarrantReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantReserve",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant inducement transaction gross",
        "label": "Warrant reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]"
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "ppbt_WarrantTermDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "WarrantTermDescription",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant term, description",
        "documentation": "Description of warrant term.",
        "label": "Warrant Term Description"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_WarrantsExpireTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "WarrantsExpireTerm",
     "presentation": [
      "http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants expire term",
        "documentation": "Warrants Expire Term.",
        "label": "Warrants Expire Term"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_WarrantsIssuanceExpensesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "WarrantsIssuanceExpensesPaid",
     "crdr": "credit",
     "calculation": {
      "http://Purplebiotech.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants issuance expenses paid",
        "documentation": "The cash outflow for warrants issuance expenses paid, classified as financing activities.",
        "label": "Warrants Issuance Expenses Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_WarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "WarrantsIssued",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails",
      "http://Purplebiotech.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant purchased (in Shares)",
        "verboseLabel": "Warrants issued (in Shares)",
        "documentation": "Number of warrants issued.",
        "label": "Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for warrants."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "ppbt_WarrantsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "WarrantsTerm",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants term",
        "documentation": "Period of time between issuance and maturity of warrants, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Warrants Term"
       }
      }
     },
     "auth_ref": []
    },
    "ppbt_WarrantsoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "WarrantsoneMember",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable",
      "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "label": "Warrantsone Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercisable",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of option (in Dollars per share)",
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Expired and forfeited during the year",
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Granted during the year",
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Outstanding beginning balance",
        "periodEndLabel": "Weighted average exercise price, Outstanding ending balance",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r126"
     ]
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "crdr": "credit",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails",
      "http://Purplebiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value options value (in Dollars)",
        "verboseLabel": "Estimated fair value (in Dollars)",
        "label": "Weighted average fair value at measurement date, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average contractual life",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_WeightedAverageSharePrice2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageSharePrice2019",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average price (in Dollars per share)",
        "label": "Weighted average share price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "presentation": [
      "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Price - USD (in Dollars per share)",
        "label": "Weighted average share price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ADSs used in calculating basic loss per ADS (in Shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "ppbt_YissumsLicensedTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "YissumsLicensedTechnologyMember",
     "presentation": [
      "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Yissum\u2019s licensed technology [Member]",
        "verboseLabel": "Yissum\u2019s Licensed Technology [Member]",
        "label": "Yissums Licensed Technology Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "ppbt_noncontrollingInterests": {
     "xbrltype": "percentItemType",
     "nsuri": "http://Purplebiotech.com/20241231",
     "localname": "noncontrollingInterests",
     "presentation": [
      "http://Purplebiotech.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "documentation": "Non-controlling interests.",
        "label": "noncontrolling Interests"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "da",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_da&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "98",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_98_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2024-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2024-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI",
   "URIDate": "2024-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI",
   "URIDate": "2024-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_f_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "iiA",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_e_iiA&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2024-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "92",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_92&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2024-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2024-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_78_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2024-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2024-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2024-01-01",
   "Paragraph": "6.5.11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_6.5.11&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2025-01-01",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "A19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_A19_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "80",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_80_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Section": "Example 11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&doctype=Implementation%20Guidance&dita_xref=IFRS05_ex11_TI",
   "URIDate": "2024-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B33&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>108
<FILENAME>0001213900-25-022192-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-022192-xbrl.zip
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MN4^P;EXG;1^5M-T \X'A#8F>!WD2-U,Z_&/_Y?-W-7HGA$BX:RFMXP5S]."
MZ$%:SQ1-AB?W+^WHO:/W!Q#TQ\/S9O\,Z16?-DP33X6!>SY57U2XE+Q)AN-_
M\#T=17<4_1 &\]'9$I*^$4K=PD/_9@SUCO([RG\ RH<C 'H&)R^=XI"WMC0
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M&Z5Q0NC^'!P:HW$=C B0N(>A:V\4AT$Z(ZI37_U$Z8IH"3U3.1@^:12/L>@
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M-(GSRREL0U$X83\Q#( ;%F ;WU_G05>4=%N&9!5-EBAJ[3'UD:RU3.E^ZSR
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M3Y*)I;Q3E_)<^8>BVQ;FDK&(4]4LF(.(?<@ETE6T&CN<VL$,03AD:MR-F^T
MTAX00X*;-:A0A04Y4*6N_ :5>(GT3L)3\XB &^GRR6K)>%-BH19_[5GBN#$Z
M;4=T:2EJ NR54=Y/VR>D<B@14LI^Z 4V/C<E&-AKH&E7&E6LA"$#0U (P71Y
ME_)".N"#EN*H+.Q!+6& ^EV7!NGX]E[XEK37"/O#%E2&-+Y"BX53X:W4S_4=
M2/81K XUU*4BCJ[Q)P<70:]A)QD&,A<430M5QNX1VMR1E-W'$65B;,[GYC!)
M*]8+Y#HVZ=CD_M@$R%(%<VHR*9)P7"H%SED@^D/W^G(CYA(>XMI0)9JR")U;
M";X)\*4N(S7/O3^B7\WXV^NLOXX]*EK$)XN&M0AX.-%6*$WUED749EBABWJ9
M4)F+KPVC9@XJJ152278.4@H6:1&)HEXN3H"90-08K*](30*V1NEM*:VN4RS?
MSSG/7\,#OI5Q]IZWWOPSL8T'_@FE35'J_XO#7D"*M IXQ?#XL(?5)/@[%I20
M0HD8("=FH)MV_=*1<"?\'T3XSS"R"_]?M_'.)0A*H60+S3_$NG*.;_%\PHYB
M.XJ]OV"596:KZ"I(XL@$B:@'G"=-Z%Z;*1@00+[S& P9G?O#@J99<0D-W$P"
M_@.7/5WKKF]5B3<%L[G',X4PZEX@J<JB=!T@OB7$LJE0>L^*V+,G2/9%W;MN
M$=*IBI[Q,# 6'?AYR%4HNE\#D["2'[;@93"': I?K HMMJ)DR^@QY;=*967'
MQ!T3WRL3-T>/)>Q<1)")I?5_E,I\:[6QS#<:ILO'63:<Q.NLK8[L'Y[L*]:6
M[0.SSF"GN:>IW*W4?TO<]:&E=Q=;Z@C^FPA>I7CL03H5_P).!PZ&ZX1O"+EV
M0KJCV?O,AF<J 1LD\W3K*M;=23X<:\*U'U%MM%YJ:'"FC.UUDTK794OD8B]-
MVVUD<JW3!1U?W8*O,'U,H"O6D"QNF].1?VJ,[;F$UP3NLT]IYD([E#,$G:KH
M2/J!23KU02%P;";.I/H55R'5H$0'MNDC'BK'68FLFQOHI//+C^'<*,=\@UHI
M6UH2NC*U((9M=,=<$$WPL2:HM6P-.KW=<5;'6??$6:930%M4V"$084N#1#.O
M5)135:&,5BQ!;FN&B)0T45,1AIWC]@E"(<?8*DV%L'+;$^YLB2X[:N^H_5Y-
M(TDK8-Y-98'!-C1=L&SS*'\:T>0!9(Z(Z%RG#=YU<[4[JGT@JJ5L5HRS"F"7
M64HK/XYB0IJ1=A>NLIOG8 CY.BV7!EG.W@"80\,T\=#Z)X@\[)<I:L2;4W18
MAJW3=.@AD#==U-O1,K3KH .E;L65J!:4E[])]U1A=3<7&!4+U?Q7/(D7AJM2
M7SU?)2-MA#'"U&4$7SLVG9^Z]Q"AIG/J*?%&<=LDA&[<^$G9QI5D*+F0L6E.
M-8$5!E!0@M4%.W[E)0@9KAO@Y.SJ=](PC"GU;H:+HN.-FDX3Z@2GKBS?(\0S
M:K&D>3'8=>?X8/1S41O#-S0VSKECE?I),#)P&I*FMGLNE_;Y[M;Z?'5OG/38
M.DL:[\@@TC17A+=D>H<4LM+"!?X4 <^K*"$"P4NHK!'!6I[F"3CW[H< W:"I
MAEES:#XH/;@Z(_><.J:$!=@K,MEK_>>16L1BS,G\ ;M_JZE+=UE7K;/N+EW3
M-#QJ:0P3]*!*7YA3:65>UC=6PC->97Z@K ,^[K_ALF 2F"$Q04)-EPFVRXP6
M#CU,J)C.1;]TP_H%5X"U>/FX8"VN.E2+YG$9OP9F*?>#*5'&N'C(=Y]__O2I
M?_:G>W+DG@W/_^8>]0\N3LX>);C&16D":X#X;FD^@Z<ML"\]M: WY@F8?L$<
MU0<IO&NRR10+92QR!,&.J+P!H[.IKU,/7WRE>I;^0STE/>3 5URV)4J\24/K
M%GEI"";AS,H>_PUMAPV3OYU3]XB<NC\D;.U:#;P@KSE'PZ8=11\6!EF+$I>>
M"\8$%61BO,Z8U#@?6O#'&.*#D=3 IP*_#YPA;-<M1]_X#EV7*;88&X=<(Q.!
M\96@O07NW"0@HFP.U-V23&Y+&.N^_D'7_3-1,'J)@JM@4:*0)Y=9H48H$[.9
M!(2D9J/;:BJ?>5^0++.B()>R.HR'KNJNT5Q#(;&F0!0/ B012!/.WW/]%R,+
MZR6C40_**XA%1S4E?'1$P[@J% W7T0=VD#"*$235O)!X+X9YZ(>.?U98QQT:
M3,(QZQH<=[-A]C!ZA3$R%8,E)%Y0:BGD2+<D<RQ"1?HM:@%B@B0"^XN81OA4
M0Y+9E9++,Z8]/1!!GM K=3T*,/#M.A]URFGB!:& RO,G6DDF_7D$$F4K0&R!
MK+$KAPT1MDD_FKF]F$5GU8EB?$0"E;&YLFVMJ5)?2EC$9L2Q0"M[&%NCC%H:
MZ/AE#+>%(>_U0L=2X;LS'J5FR\Q2U2JXETD6J43V"&NJ0+E_40L,K*1Q%*FP
MDS^=_J[H[SBZW$(PNL;\+G-IHHJ@:A6P+,J!^C#62VY=1U\=?97IJXH%KYT+
ME-ZL%V8@7S/N9!\#Z<&_2$C_&^"&)%M%4G].QAK)2.X?;I##12-;M;^EH^3O
M7X?0WZHWG)FV/L8%Q[%+&>MLZOTS(];++JOM$#B2(; $E&51)-8+K"9!\)(3
MY4F.PVK%]>.4LUO2?EYMX*76)RO=:5.B$TQPSI07AAMQ$C\F!?ULLK!9:M%"
M"CA<3%.F04(A0)J&8_*J"0\HX+2=51UOD?+4 V^YN8-/B\,&*=ACEUB7P!AS
M4H.Z]AAZ ;-TA+]HQ9,BA8,BKYA9)3O260$=Y5LK&$ZH0I==/1*7FJXJ!">:
MU[@Q8GCJNEZI.*%QZ/(P3F O&?E2.%S+>YYZII"X89E+EMAC5WMDK[/>1GB;
MXOF.2QXGEYPV 7D>?#KH%29JW9(V6.R>&ZKH,IN*M4P5O $''WU=BXY8.84;
M)],F=:C H(TJ+PD#Q&W64\IHP$F@*[SPI3P]R9YH"?>5:SDH#W%+7C*37?#A
MK<RD2[R:@K6ZXMZ*5L$.@A^1!2F7N03A@BN(:J*"@5,9=+$"KUC>?7TXYEPR
M'->)@1ZJ:C-RJE'/@E5(Z,5RA"D/._2RI3T'";M"VA'BL%Q7,MWE*>]3?PLR
M^DI]Q7'D<ZZGA:)+Z"DMU]CHOU:/OD2/Q07D2(+)7#ZK-?$SL[4$"[0%<8W!
M8QU"'I'+B9+*<APE--8S\Z?"X M&*23$SJ(@S!1_OAV@I7:(:-$D]K#9KK,!
M.AO FKQ(A&)8"O5ZDB#H41&+U6Q1-+E9&KE N4#:UC7;AL3QJALA'O7$X%15
MN%M&FW%E0)R9(M%L&B1C4N*!J&#W>@K/N)9Y>@C#!\N@?V__.).[39"O.',[
ML[-3VD2A")\Q1?"C+6\4!S949V58A::E#RJ]GAX&'.GSSI0<YQ)F3G.PD-8C
MH<E[$W[R53T]-I<7493O:H2>A8[HX]0W,G[ E,&$T]2:3%C,PBO3S(C&<O"P
MFCR:>%=QHDVSO$EZE2V0F@EB#(M--RK6(,O,&BK57JO)%>MN;NG_F03=B95$
M+;>CTT*"5&;EA$ N* _RN8RGJ>0^+3#:9L9$IHQ@6?##*(A$\>KF%)I"H*Z7
MA>5,U3F)+Q1["Z5'QXYGX!'(J$Y@!YD;K:-TNLC$*M;*0/AFM'22DGP#SK3A
M@BVXV%2\"-8$!9YY)3SWI #R+7P<G5+G.=FUW#R90/;WZ\_&\=*IB1NB/,:/
M FI/=<RQUG3#]I:91V8:=6HC*TSBO$E$_)#F36?<?']9"NEV;,C7*AXL!UJ%
MMAZ*T1Y$=QC^:*T7:QFJ7@^4:(1''"E4-E:TZ21])UPI5@H66 UK/$[(&B4$
MJ^U1&E/\?E@Y/H69FQI",NKT8-C6FP*013\;+4/!76"<\"WE#^+EH^$F#=CH
M]NATZDPIRTE#D:*\<8C<2PM@!$X.<K!T)/%0#_;<B6I?TE;RZE&UE?S4724_
MC(WWS8&C#K1]I:A16=AR $D\-^U1J5(]W3=[3+=RF%P!W;;*!4%:XXC$H"B'
M+Z9-P6=.$H\BY5GYI[J,IVA/1H84(Z(2F<=I65D5 [IH'=5P4:,1NR0^S!;<
M2+&UJ,8_1$Q)^'XK5!/NAT&)=7/CS!9=^4BC3]^Y9^LTY6AI1:@&^'P+^7S!
ML0>L4KWB ?1<*5.P.U</SG%R?2[1HO[IT)3#ZNJ;K,#!'Z(^9M<%;)\#,+*P
MBYB0AFD5OWO)+(XTJ_S]E7N9 V/@!46/=674I\8EU\5 /<WUFJ/Q=TLF7!NF
MIQFE)!/@ \!'#=)WHB4[ENM8[NY9K@C9$J<%4:[&I0&Z-B]:? >,&$PT4)H5
M)@[T-%_T8;BBC8*<IFI"HL%6U06'&:LSN, DC CR'[V,XXN]W3>8O=Y[WF-'
MKG]Z<;RUC[[%*!Y3I#5#7TE#%[BA(#(T:_?AI]V]YSLE.V!I&G@U.Z#+H'89
MU(UE\[%8?&W<["52NB'U1[W2$'&KSM4:6E'HPR4E4\$/4IC4:;,?F,Q/I([G
MIER9!+?6Z?U1#0[K-S66LC\IX;,X2 ]9M1B$48>V72Z'T/$V,EBE,ULT,MYG
M$+4LRU,S'0^;MWC4L#Q:KHJ"=0Q[1(Y=R'%+52]\;%"_HE"- G^:_F)J%J0N
MZ6E XW1^*1KI3/$\;8;V)E-%&$XAYCZ269M;V:G+3EVVRI$[T(S,XKJ]V]/%
M@W;FH%HG2;S)MB@9IF4F6M9E*B*%(L(\.9-E2+WV"1@P45)*(++ _M64.!:-
ML!+J:5]R;TDA(9G95@6BZ48A]QKGK;?'BTB"25+07B-*-%J@9$.P=U\G)GL-
M:8C4]@?L&!:CB&NA*D$ILZ'Z[_8X=^J2E;:&HK#:!AZL5(6JZ-+C46#:&==Q
M1;B7)3SUWLA;#5)@T<A37[!&.:>@NF LZJ)5=&JX> +D+$,@E@$!V%&ZJ3S5
MB-92/S)L0N[KX=XE .GFZSMQ_+WB^,[;VU87D!<$5FF%PY>&>G6$3'VU!90#
MNA\A.X%]2@4$@:EUH$(H3AN"*$FTP9*H5"/%Z$+Q2H%%"EN)'Y+/]<K*U5"^
M-^>6.'C?MD.F4<_XZ9/E/DS/+=9-\LA>?*_:;B=!0RY:F-3G<&BH45W=X3RU
M[+Q?Z(XY"#J-1UD.XA4Q=!NPD"47?0Z71< ?>:"@&E>*S C@K^CA\B+35.C
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M._1JIQFX6JPEC;L\%,;N65 LA0J)K3BT*79>Z<M*!7JW\@P=V5\3_-+>:E'
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MB]1)C"NLL0$0&%7S#V-2T"I1K!JM*?N,6+T6'"_UXJ%4T"O?&BVVM-08>6G
M#?A6#NA&="Q*&N%%TB\73R;494>-;M(Q9\G9,-#4QWI5(,<O>*0%4.-BCL=
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M#$1II;0,-8$%\7"%,GVMBL/(GC=Z3%Q.E&(Q8ZI!'QT"]1:82TMBLW"676^
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M \1&0CZKB2&G?!")R0Z*MM/&%_9NU658Z6;I/$"F$-<^\[Y@&M-&:9(9"G@
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M/TSS<Z%:%L_*7"T[5RU[-E?+YFK91,+ZXPKV(/\(ZLHFZU+USGG3F,M;NT2
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M<UNS4Q\?%?JA.] <SET=,@0!WZ/LV^^@M[!KH[=[V%9A=8/N;_@&\=S$W28
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M#-(VAT"2GC#E("R/))!2;DF>I$MMO>HR]!+Z*G ]_LT_1,?W?GJLEX" 7\]
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MA8!5$=+NWF*T,] PZ^YP#2V/6B0=\(VZ!_]R_B\9)1:^&?#OO3W'\BC](N-
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M<=9.)MFP)70HDJ4D9T'.Q>D.6U:$Z3^UJX%7DHA"[N,L-&WC0QE<+\OHDE?
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M>MY"RH*D*<%J'0+^2(2W8WJ[6?!%:1]1)%.9'P/$,0%^W! ,1+)2@DH!>97
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M%:_P_$RZC<)85A2'J,N!L:3(GB,ZY'^<($?U^+XK-@^YFLUPSM284JJ9"S0
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M?E?W/>[:#6I-UX<84<F5OY-JIPCNH'G$AJ>]!AC_T#XAY9IH<O_C$/VRIW]
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M<1R\1QH#8Q2L&0[&=HWY%)N6R Y3J"X$6=ZA*!;3K'Z%8,P%U;KE=ELR) [
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M>H_2";PHKTM0%P .JI(;VVUUS?U'_8%R1F"7T 63EF-BN!(,:1SI(:<GC0\
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M:2=8N'!<%" [+6@2QB #7!1BT,Y9H X%X[1:,<1XL)2*GYI+N>72X<$\OVE
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M4P*U\(H4^9YUI,U2>YW*MVD&W%FH;,#,":[;#B 5$>#N4UV..FI=_EV*SI1
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MVAYT>BBMNFP:SKMP"D-2#\F*B)EYZ.6'[4ZT IF!22U;EDM:0=EN[Q&_,[4
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M3.%\&L8\U81$+>)_,RTFC"O>B=%.C+;X&U*>)0F$($ ?D41 Z[6=H.T$+<Q
MZ1X*K>3B&H(0K8WDX>8.W,24ZH_NB+T5'@W]LI3NYURJP+4L6NB#65SGPHSX
M8S[/[4SF%&$FH-5%VZP6!.#^DF[U0\9S=T78([!FH%ZG978"V@3'H&-+OR?$
MD=Q[K&)>DD&"T7O!EF/?JV%$ONLA\A\@5OESME<,H!AJL9R@U:E>*-L$P6]D
M4\ U1TR+^0006D8.2H(%V/4Q\?3Z?5UKUJ:0AM17#%QO2TIF3M,N3=AL:C;C
MO[.:]R1G!E^/.EG3A/Q%E2H&&-R#BD',;_#^&FZ0;D RB>]WN6S+\<J/.G*6
MW48>'=KKJI:[J)JQ579%?56V31UN3BBBV@MD:$4J2\[U@1'5/VNHDT/LEM"9
M)%?,?(U2<@[NBHK5H(>4RU5OZ[B44.KDH@?BGSVC&H)K4*2@V1%7&9BOQD^/
MJ,@ A2].FFK8,T9]YI2SFRH1_4GTIW4B!Y2(?6JM!_8;DDN[0FZ1F+0:5-Y7
M8?B+G=N8['BP]:/3MH=?LO6C4QJ<+]KZT04HTA=L_1A[,Y9??<G3N=;D!'39
MM;]_"D3YI=JV(LDP)YV**MO5(O"AF91W5Q2A%E[Z9)/B2/:VWK*GJGQ 0(8T
MI_)>N7OL^E"G3Q6'H3L[U"?N&)-O*%%\D;#3<AW:1K48%QN#S\,J=_0Z6);,
MBCO<>B#Y[I*;?T^*1:3N2-AQ20NBB<Q(-%M;3%>3XMXFV:[L,?:R]DOU"J#1
MQZ/LY.CD3#IN4'N.++^X:*FO)!;T[.39Z/'IL]&SXR?2.T-R*,O 2-9?[[WH
M\1QG4U@\R]Z' O\K-<'J5NUZ?T2\%_$!SC[@+DT^^I\7@]%[5&TN5,I26E]D
M3TZ/1R=/G[$>V&O1.K! IZGL^-'CT<G9D]'3HZ,P9690Z_9U>L2'IH:[=#@A
MOA$EZEM4N90-Y!?<Q;L+Q,>V8E$@EM)I@J;;AB;RW%T2N06N/: E.3YY/'IT
M_#A=^T5"P09N@\ CN*JI^'U/^QB__9OV!=\/9AX?M-#@FULU6)JW?L\06K-X
MJ9-MPMS^TV*\M&I 2"*3ZOU$*PQKA*]>_[ZNL_]:>:_@&<[E,78&J,YBZK!P
M8)* 7CQ7[#;'#/ZK@,P8L@M2GR1IK&HMEPF7C<NF0]8@0=[AK?A4;/)>ATX^
M[OS=*S)E+]I\/NH_.A>V!^D>0@?@,/L[B4#IEX.[YW'7>1H"9",K::*:_?GL
MZ/"(0AT5W0/)4Z@_'.@<C6KB R+^_'6.&OD.@-1E168SW1$XK'\^.3;C^O^Q
MYCLYQ1*?P'OZ\VGZD=>394/G]/@)/G0Z4EK2/Q\?GI[:3_Y7[FTIKR1$D8(8
M?(MVO0+;SI3A$1^0,?0S?7ST>'1T^D36'>UZJ.KMPB]/IPD8YD!*OO;GQX=/
MC\-$ LN(Z\G&PSQ0-\&OG^S@UUOAU\_^R/#K?V&ZCR],XN<OC>^]]P7+XJEJ
MM>N"5:W+Q;Z0@B*PJ\VEI^8++^G9BX/3V.?O[0_/LQ6Y=[\R;8]8#YVWV&9B
M/J3C045U:@EMN5H<72VCX78*% 2C[M!-&]4Z#;=@UJW4'OWSR5%L"2=W6\^&
M&_ !]D=]:VXTU"A.C,41B+6HB2D3!P?#49NRT4TS:<N%-'7@'[*U):2V6KM<
M-\N=4\E&C;^S3B";CR";%"XHK[QX_OG$7KVS_L47:-/%HN0FX$+Y6'SP<HB&
MK$-V?E]V3IX>CQX_.1-[2)C5U#)Q87Q![OOQP"*%"?SYY RW_R,O==Y9I2%&
MUJ@1UZ",E@-;#;#E_%^/1FHH^'\=/X,U(;\[]B>6R(_59.E-!$+_Y/ D/!>V
M>]+F.!A\=HGXW_WE 5]FWEUB"V321#U!8>O@@[R%+>?.#XZ'UW7X9)X\>CIZ
M]OA9S'YL&3<[/SBYQ[CN]/C1Z/3I";L'H(^A@<, W'<E.ALY&LL/K.'3PR.S
MAN] R";S,>^I#9J+%NR$,Z)_0V]@%P21E@U!?#0)UGCZT,OU!EM>^T.Q/IBA
M#YH_=)=&NI-!L<5\8O2XB-7L;E7EQXDJ3[4RQ_VUL=B LZJQ/%7#$H&&7V!U
MM^,_-9:&R=/BH_E&7PH3&0AK$YUI_YEY_\%?4F5^FST I4F3>#ES'%@-J_?1
MJXW<!?D>XD%R\&%T<X@4+6*^?%^>![$??_H/HFM,XI+*R^,V.@MRZP*3I(E1
MG]NBH1\;275;(JG<1#Z-H^IAT^!/C-?%@._P8WJRU[]S5-P0(%J8#N2D<B33
M1&$H#?O&OKC<I">^;UR&$7?8!;OFG>G8VEZ<:C-]C+837URT'X1@<\C_[VRQ
M$S$Q]41!+$'IVZ980-I R48&7BLEN!OF(<PIXRC?M(H%5PE_=1>4-UR$;#JU
ML;6Q<N^AP1^LB0W2/81MT_,,;D!M)0*VVC4;!6HV:Z)/M@;1Y+R=ADI^S"$T
M<O:#L$0TCMH/8@3[]22K5L=]_;KW\W4=+?ZS(;\GSZJ"&@Q%&_ G7M N^]])
MTV_OVU/^0'O8D*#\G'?3_)_96W!7OF*-^--/S[,]&D8\]K?+?*8>^SXZVTX8
MA\*\Z>@DY42)3ZH&E,/C<CI@!ZA[<7K$G,'2-$?3L]YD7<N9#E&(XV..FY+P
MA&5X9)9A6DZ#KN%.UV5=SE?S= I_/E:CG3,:029GG%/H::<@?4FP6WXDJYO]
MLO('X^SL[&@OW]\[X51(/IGX.X3L;X>#,OB5I\='>Y/]O=/]O?-]S9>1K\$-
M!BJ!R-"TCY_ZE:(^[/Y4F=6AUYR*M[2\9#IFW>5$&/P6NRU;#"-AY5^\$@?A
M5!<5/;.(Z)B/? EO(O@"F\MK5/EA%CST1W<350@7O\ :?-ZB.V3A+L@,H,9N
MU!C)K\:!7P1O*2R)[(T2]/("*AC'&B:_\1W<[>_PUIL^(H!/S(LP\ !9!^DW
MKY@%6OM$UH?-+(E<-77AB!+??S)+0DZ$==H[/MK?_![3E'KE@N_HXRCD-3S0
M=9-=>I>-9'SOY&AS1+RFQ!C<L7E'H*98HI@U7[9"53JO*YK';9<./F^#ZTN'
M*R[OZ9$^.D#$''N7W.K,K*F>YG V:4G&C5<@\733QY $6J)Q[-)KYNVJYJN_
M6E[.TAL?\8&\K%RXJ=FV%NTHRSYDPHW0UTXM-K+@8<?)-]AXZWIVV[+-IZ)L
M*>!9?. C-6)5R,$%=RW]5-X7R/@1#'II<97^I[T6[620EQWW!YT!G3.&I<&>
MD=1M6M 0LZG)"FB\=7F)3A0A_>DT1#S1=NT==3VF64D'-J0G<P,_#68P 2_%
MB*)U" :.MJUG1B[_T"3MK:MA+&(7+6*XBO'CXX)6\I^K1JR]G'LZ'/CQ#_Q7
M*9TD#@_ D4NBY,=!)S7%D)@-YY/?=);[,V>!K(JP<XK&POGB!%("<=?.=-*0
MKL=M@LD:]*O!.G/"M2J]>$WI.VHV!(&9]5[_T"7-*-#"A>8>L;CP(%BC3.W>
M;^ 4DNK*J<J.^8#@Q*@SI3TZTI'/^26B_:[1NF+50CMR3[H:.>VK^!JR#N'E
MI7TQT)1@Z264:+>$LDW:1,=.?;&PP-P\?@L=G[AB:CVD44H);H)N>KZ,+POK
M\%:G2]8YK[I&T+HLT!1SI1XO K>S4H$YA%(<@K"+RSXKI]@I?^.$_BL\9?V0
M@H!Y(U1%Q!X6@/$5U,<QJOE8ZN.:!;6SINQ*^5!3*3>ELY_NTMG;TMF/CG;I
M[%TZ>]"^L5HQ4ZWH$JU(-J_$F^90]A+4KM ,=RJ6+E=9I'T-"!C?PN+@^]=V
M9EAY9:[]FVS=07[=23U!1\ZROSJ<-:2\HH<+Z8>C A::&UT+ROQJ@S!H7&K[
M2L<A^[99TE,!UQ'?'X9"UGL/3;L9FN.5B=;X2@'X?<QT\ 6H8D)O<JXX2*V'
M4"1!J9^'J88_>\Q40)3:;ICWQVW(;7J;8__';?/>*_%IX6W4-M3YA.Y%^AUV
M7''_VO[.8L+@0>,BQ,;7.HYFAZD[=%'[$X F)]):^W+5L8V2=!TSG\O:557L
MT-(V,$N@&'1YGC8+CB-P1H?<"ZR61"ZH^CT$X,R2*G &,J(XW?Z>4L$3AV-I
M$]A_*+O8PXMVS8QYF+VEW X>[]A0*Q"IZK+3_.SXX'B4'9]=Z!\G_,<I__&(
M_SCC/Q[S'T]8X]!?GPTW:*-?_R >#KJU4:SKV>FC46B/[B7.QB#MAR/VF O=
M>-VV]/&"-Z%V9W0I"#9M!/I0G_/&_%">XP*G(D,$&*EL5#J4<1X-:[211"N\
M/Y^E4<<]TR;/#&#RK/Z&T=CZ@%?HU"M$9BIZ>V*,>R= 27-#M6$FU89EC9)!
M1 C['?KZ*H%3?7%^9:>M,BD>Y#A9)_M!F<:UG_S<;\>+4.1G\S4;'DA("9-V
MX:J^&R3=-("=%WD=G9'.7YS0+W!5K N'W.."&*QU$;;<C*$M.)*0V_1I5*:\
M,NE'W,WZ5<^BOGB:X4IC"#8MF8AJ-&(H_C%?%&A:6I0M([/+&GO249GFE")\
MXNE_[0KW?&!+ 4T'W-O<4]R4$_#!>$ )_$.5K5Z.+\D&]$]JYI1[;U5:\XFW
MBJ8EM[!B9U2E=B\H#0EG^7<OIU2[B<-7^QV^]N;6I0/VC+DY*4L1$8DM(@9U
MO8*K"ZH=^B"W20W@1?K<GT_E.\OFHEAJT^2,0CS^M_3O;M'XFWT_F_MW\*OY
M'D6N_O23Y4:-#;4A\;0P#/$A[**P*H;V8PP)Z*>_#JU&J8B% MG:1U<L W,R
M2#\!H X!#KUWZ5/);KD8^0E?I==::C?+XD,Q7RQ[S4C-O3&@4 RW3+!0Z1L#
MLH)X2$6%OR,79DR.0#*?<,;S[4\=D4J,2JB;>)&B7-"BI90< _YB[H@WD&R%
MF%%%-3BBX\TM+\BG?_NB9G==U,'S0UW4JJYQ-JLK;U9PAYT._#S>BUYKU'/+
M\BKBS=Q_(8>!^!$7(<N5UHL7BL8+$< 7I=3\YUMF;2?L;5;2M\#.5>L(?^OT
M5=@/FL2K],;[L[<=+MD.K5#+@PH)!X5V?"65V[<]0*.IL<'@I@1TL4#YZ];\
MQM34:'9WB0@ZQ>*O\U:;?N?J;.LR ^IH[N%95/<#"PU;OEL1UI#/L,@,@)YL
M^2R((Z %K8/_0;[BJL1\[!6R&-[A$VI[[Y7[W(.CJ?3V-[,Q@K\&U1&CWG,*
M??;-%XX\M\JBD#)*>)76S)LE*P0$PEM_<97^X7XGRH4H2>Y6!""SYD3\$04^
MZP+BN)Q<BE&F-P';*6R&(4S@%890"Y1=57#TF\XYM!K%%;IOG7^P?[(L];@I
MZ=2V33/7E59[SAI5E^7%Y0$&BF"Z)3[&#R8(8PX[="+'6%BME4NQK!.Z#AK
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M;-WLN82(<EB(=F"W,91@(W!#L6,+K9-^+FH>^*@&!H=<AY>+AJ[U53>DH>
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M4'W[=G+'+-[//L37]'\*,%]L('=;-_LF<QRY'M(WT C#> !BMF,)-:C@B#B
M;))A01_M=6>[Z7@-X(%E/;#?80D%%<P6)\+'5-*V B)D=LL"VP# !E08@P:L
M<'J>G$73V^4.C2E)J <U7U +DAC$8YA%(54+&_,.W@\]W*N_BS:?.ZGA@XA.
MO89&+9^LYPW7 QB!Q8Y2W2ZL[;9Y6JJ&A.]"&@;IVE"!J[RNOMH=]-,HO:%B
M^:>)!FQ>5L\#3\Q/?IE"MTIN&RIK(0W)@!VJA'!/VJ-3&.%+&VAJMGQAZXE-
MQ==;<F'A-#(#=3YE.KQ((\:RHIC\LM]CBA-CE#WEM.[.8I0I#"PXKZ\S"*/(
M1,[QVY:3_5+]ZOVE!)34%6$W$ =8>"4('RGNE@2OZ-SL)8&R2'%(3_SYY5L[
MC7V!X&S0QV5[O-.@V"&EE/X^^[6I"Q0OAY_*A)EZ", !_964ZEY2LH]^*TD
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MWLA10K0MKE5VVWF:<631-&C0EMZ;)"+#A\C,R/4AO$ "K.!]&=+KT#*=Q[L
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M@E&#36TN,?N#))RLW[V?><$Y+=+."&C)6=+=YG0"!38$O4?M?X=8-KBY@]B
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M;X\49;U04=8/%?&C(Z/8PXT5_8N8<5*@X((%%\H./D6MP7#]P,T5 =L1X#W
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MPOBXS-.37>9I:^;IV2[S]% S3XSJI^-;+!D%\=8[E/4%@3B^-E _W3.])@4
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M'3*"\4C/MS0'QW L<TO'NU"J63I'^V(DI9FQ20F86F889XR\&";U-1SHUA?
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M>@;><FSI,\J-R"VE>Y^+X93*8K)"/]KPW]*.XLEP1E+?&!WBQ6PF[8UNM#R
MG1U]82=>E[XM2@96=_KPN2X6,O#";&T$\J0 AJH;(ZGAF\8J%>,N9.7T1+]Z
M_\&!NZ+9#7TX='1VC(IW:9[47K]X>Z7P$[A^;(-3O_?F^%E*5RO?<<G!$1 8
M.4$P3JC2+V/?.Z9#4DN=YA.U<EL'LDB4F\G9M]9KL37D#K<>LWK9$E8@/#BT
M#0$&"K=.L04EXHQ+D2D!_%X_P@*F9HA;GM"G[M7M;F&X2CHI"9,[AA]@ZXQ#
M,U-"^\S?^/N22\R:PT9,4JZ=:BK$0&"J*?,,#1/;V&UIIMD5U7XII_9HK?=]
M7ZP7';.DHMJ\N=U+N?F U81%T@91+!^5+6EK$S4^V%USN$M;@CB6(JM)K]?:
MR?O^WL@O>I$,RP;.-!2M!6B8<Z07L"II'"Y##%WXW,8&'B'2C<>%)C@\W;:B
M[!EI;;<X7%[$+8\U 7:P'&!7_]/$,T/-%+J@6EW53C.0I;"!2BF;35D);E3J
M7TD*KZ/R?:NM<M]$^?J39<$#7Q9<D0V&@?!>JA[^6U0+\Z(.N9R=QI*Y5%VG
ME<3H%9^N\.RJ%7@1SO=W02/D0$I"!-7+:W?/^#H6SC*;6&Q=+-#K&%Z3Q"\/
M]\-?B^N$M4=J)A_%I2J@!TTNKD>;[M)(*+0Q&8+)'<<YG(22?'7IKJ>C&7A)
M&EPSRI*BAMB?E;$+AHOP$)[&?R>T/6.V%WZ_';?EB1^<5K.X9O6'>9RB'=]P
MKBU1;J%Y.*NG4![$8RSLU"@'J9%P5RD4VW+IZZ,8Q9C72P2IX0J"5'UYS;S"
MD35S&!]_7K*B;OYHU,$R,GX,SRY'[\*_Q;/YT^"HZ$R!S??1;R]CLE$K+G X
M(U<>+_0Y8Z_.30LC'IL96D89G8@4B))7AP>\JRB3&XK0CW8V1>BU1>C=31'Z
M3AX/7Z,(S<?ST>'IQ9O>7GA12E'WE!Q=KJ'=XE%[!SS99?WE6W8W[L <K!["
M"P">$K""5Z;]W7KO@24 (<_X*H6H&D!>-I"RSLFL&$/M%M@F.3BSA2=0V^*-
M,8<<^?QIT<-9Y;.>]<E=K.9IG;A&A\"G E/101/HJ><?%DV-Q@4C'VB#0140
M]*^ .H#BNFS^"J!>B/-*.LVCWS,T [X^JP]2.T'"!/4QX3HT&0"194IJ '^9
M8(<KAJ8C0&@6*.:<^X@W@;V6J=2^EMJ(G?@O'>4(2G-:"-.B3/_@FMC+I1X-
MST?Q!6#!6H=(2M"S-!#3W<$OA]-"]IL+*ZDW3EAF3BMWWNL,3-\S /%*/\\M
M),(G-WHW!*>;*3"2WY$W,R''M8\& .$H]M*']& */;2:RKP&G7P7LR")@R;#
M#PPG$3FTX\J*,M>ML=Y-3^8V$RX2]B;Y9<Q\."QS9,6F@Q4;6JG+&:=8"3$/
M>;KOK.*9URQ"O[IPU%#*T"P?LL26%EO4HSW!)65:U5#]I17\;&%8GH6L\>+P
M4.)Y+*"8*8Z-P'%X=+SG24DIZMPTG/!JE"<MK?-] >2Y_;.$.EPZ[\Z) ?<#
M?M5B#(RY\R7CII1JD:,!&%O\&BO3[X1I&3N/ (@V85TZ@6-+DP(^^QS#; 1<
MRHIXML=&E[?=K9JW@-2*CEEY;X7Y2=Z92_X?'3_^NQE=1$'!;!;3U&=U['[Y
MYI4V\.AO'+0 11!:131'/?PED/NQZ4VQ%%S^W53ZC)8TLGJ7>>JF;@X"IW'2
M._GUB$.J+'EOBJM6E"!2Q?>U"TLB8S<W+IF[G*)Q*H,T.YUW+ @"R=G0:02-
M0[,TZ$(P/\;:TDS/$C&*PPP)2!H:8JH@IID=/'F =3A,G82VB))-D2T>A_L[
M/^JSUE[9:1F4-0([6;:8S:?:\I0ES;MD1KMEZ_#UZVU_#<4T6%OP86J?. N4
M]OC%\2$NOKLS>$R;R60[6ZIID6/GZBY[Q'^:-H/R%R,X6GELBRDQ &4&VMR:
M3;T;]I.5*_QFMM8D!L@UPB$ 6V^I&LE\C-MIMIKL$$9QN10L8.LW>4Y)/76X
M,-6;9'%<NEZ:)PG3)M7D0>2LYIUP+9*;J@(V.#"QLIZ-V94L.&/[&K!J\PH<
M<UNX2L*KU'M?:+3UM 5TU*YR[LW+A([7-D[KTNK93XVX*@33'KB67#<0VZBD
M=%.1U)W?,_6U9&+4RK&[R0VRC.3CFBO.( /E:_DO2P;8D0$'=FATLHBWI?<
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M8],J;PI'%O>\5'@(3;??"O"1QX<EZ$?@16+ /F(^$K:C\/DO+\[,'_!O\Y=
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MH@PI<[62JRI<P55EOR'9O!FY O 73=]N\([L FT/+KAD@EOQ2*QL2YR%;"L
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M?&5!B4''.D=XJW)$7LN8B/]S)->6 7=+9/( 2A.X"ST:!8,$]+B>.;1JYK#
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MR0052\O%D0Z)V#3&:366KUUK\^]9GH[,L(2'41N74$$-(;]9>5/;6164%*-
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MT\P0JH=4F'4TA9_,.;[I0B*.NR[.[;FC/:'ZO%KS(-8P5UYEZI@=DS%H+I5
M>AZ&_/EALH)#@QU<M8Z^!%:ZA@>5[Q%7VV>S5*F>^(%4,U@KEV_<% '4C@-@
M\,H'\2$:W<VS>3/7ZJG+S%ZQ86EM;CCQ)Q]>)4'4$R=;JU/#:45\?L:&,F;L
M['/,0%0O2&**&MFIN:R!."NZ0O95L,]K(_1\*/&D[;NP0R;;@#.SAELUZ4Z2
M=1#NI751(G#%IEF.LL6R5:$K;_(M5%M'4BR/UMXZHVFAS!GASF[6(P&%%G=
M4N85E[M>YC<Y:^,*_ K9O-6[U'=P"TK[.@_0G'""8R#K6!!9( BV/+'*>54V
M,QH+-<-%3P=. .)DG:<%*!HE@=<YM&*<)?&G@BA'J%,BUU^+(QGDPG&"8B0\
MI\A'FT'TD<@,^?6581CG&#/&,MOO0@C(?&@;IG3*[%Y>T;.(KL1P/I8.TX6A
MN!0UC*\]BR^=\QK^KZX\AN<:K6$:-)!E4_.EQ753SU"+&/2U6Y27[LV&XFV8
M>%-G[#][-(,XK<K<0JP#]CG?B([BCY4-11ER;PP@LNN#6M+YA3TRYQ?M ZD1
M>LXN=O'RGI*-+H-GC9;:^TK_PT=>).E T4N.W*!!%AVU**T 5X;VR)249%40
MA/.T0/EK'Y.<>)_HTLD;A4X!KV#>.[GJ 1+::OC*<.ZTCKI2AJ9H';"Z=O7R
M'$S)JO$6TTVU:N?IB#K:;3!6::RU0T='=<B]V\%T#?-N#P.T+BB@ES;:+60.
M3T_JS;C#,]%29(Z"J.;R,L_"D"@&B_'B"*ZP=K3K1^J$6K=Z;@;0!6"+%Y2E
M:^J _L^7=&J8RH:4%>7;_03M3K55A? ^!$_S+VJIC:B]UE"2(=TI2Q(Z/*0<
M"N-HFLBRH0B9,?/VB\"#*#W'N4=T090A]AW$?@<M0U\7!G3QV<FY#0@)$Q>4
M$GU,*PH %B3__%H/8P)Q7(T_&3/3;R_.<BVJJ,L;FVMA!8^5%I'O,JZ)PT4[
MCL*._97Y;1.$@7(X[4'+ZG9[TB#M6WO$5Q0@OB0=3$_P(1[V(62(8:!$Z$+"
M5Y!\"!L#MBCAYN4Y*VW,;)9>:U>ZE)RG*IH8*NKGEK%7*?7)@ZWYCJ4:-SBF
M];#'W%P2;1O4M">M8XY0BA?".B^H*[+(/Y1"+9A<7O04ANXW<:=443H=9N<-
M4;UHD\$ U<<=5RY!R#(6$&)K6JLVHK=2RSB%XC"',,,CO8=]T$=('?5R%OV8
MQ+,*>F2?Q_I1YDRL;'>KZ=7VOXD(][H5 8\Z,?].%4'/Z>JK(E!<86T7I)X(
M!YD\P9Z\)R\F3EQ -4#!$]TF?#![&N"<"!365SW9=TGC\2UKJZ/7.%PQ65G[
MO(%UX-4/.+4'>E1E0&QP$?QO-:D_8YA2QK[B]/5O;P[=&X(P PR42-TB0T($
M6\P "'DM4VZ05>R I"*\!$1- L84VHF54U(R6W?U@U\%[+ZU<TNG9AYI7I?Z
M#V'<DEBQY]TPVU0?=L1+H\23QP.%PKQ*XD ,7<_4.OL<C+6].X/H%R5YQ*+Q
M[\7HD2:L3# [I6R48S+R!%7P'HQ@1<K1J+%6 ) O]!M^Z]!<E_(;QPO:>=L@
M>L.6*N^:[(1H<V_C(3GN7XJ+RAXB/T\FSEPJ)+XFP4@A_FOE'L,ZB.<#H725
MU2:2C%<=!MM;,M"Z,KEUO"=^7\^MA\;[XK^6YG:_QM>:0'.\ 3C*'^7MG4F.
MZ!ZRYK2/(U=>J?49H'T]B%^SB9_!2M(KHOHM#"DA5+]P!J43Z_@RJTGW.O=4
M>%#I@8EK12/U*\Y;Y01"RKT!Q6_MOJ"^4$XL;1[@8U$:]8%#(:9^^^$RF<7Q
M,80SFP>4]X*@U"ZWX6.L6GGM/-\%WT$/=9I?41MI8GP$?Z)I'6OQ6D',OKA<
M&>) \+\CQH-:-WE6&='EK@$:6(32HBU!GKR2.'0$Q+326A  B1F]X[6/I>RP
M1E+.^,24510SYK"%O"3)OKO]X^GA"?YKYT<P]K;]8>\W2(!),U]ALOLOHNRM
MXP863;IZ_+'RU=%8F<R30W :" RZ?G@+9B5:D>U&5F+#KN  ;E#\MBBP.UD[
MU(VB":"[G!RT_YJ;:H$*L'L]Y0JR:)J40<*0RS%3UQW4Q_TBIL05J\MJ+1)E
M$E,NF7O++,#Q(>9.0MK6GM&*Z=\2M6P+*^>Y4[J^_L->?;8%U86V/_ ;5)#>
ML?^ !J:;2<"3*9JR4R<19NV7A:&CYMJQLT%WC3/@*E;"%?)R#+1_$3--!\'@
M=S@?Y.O$'PA8<=P6HV\=CVQ\1F0]UN8Q''/]</SV+"%0!^3SE+]G%#HFVAUB
M56'G;#9 ')\WI*P(FWY=$Z0,]0K3IM =I\?R:^R:3!7&!N):(8:T5JT'H=K=
M(.)J@9\Y]*NV8DQ<8-MJ/7PNH1'QF&G>8!W/_J,*I\QKOW0NJ-V7BR_ZBZ.H
MW< YVTVNRM?[%!T2=0=2:?DB>I_4@X.%Q=*\F\-'&MS?8W%IPQSYPH>MB@ &
M1BWFQ'D<375IK AARN#2Q>84KT0]+SF*'+HD08N<1>^E"RKP/.-1>"?[JRL4
MI7P;4[,6LX*)Z'")6OF7K%A4M4,C:MIP\^"\#%HT".DFFJE@NN_/%)FD4J1_
MU(]3?ZX '+S87@,.E@(.=M> @Z?-;;<TD.!,<5:R-4?D)M'R*#V8AI4#W8<E
MVX'M-.@)U@8]+8E*(LEPY;E^/6U<99BEME=M20Y.\.%D<XT\O:D/6M-_#JUJ
M=DW(WI KI[C+9H8T3*_H#V%=VH1()]F*IP>D]AB-M71<7-RZ2*687BY@WF'I
M[U_K07QHE?E".!TCZ<E',3.J)@<0F:5]H22#M[*4O\.S5T.[T2#>L0.IWTO(
ML2=,0IZWPQ&L7<1'%&>A7NX0>+!PE]J7AJ;6%V?$ZX W7><$/F7M>R<N9#N?
MT#I)$7-GU\9\<N!@/2B!G9,6?D&T1Y.O$W(-3<(YR:_]#:"0DH0]7$S+45$(
MSQ '<^F'VM2 F&\Q5G+<6VUH,HQ<OMW)G57MWH$E;YEUI;HQ"38>*"2+/D:1
M1EXZF6HB7PP?GXCU9!< 7\0$B;!1&MH(N>X(T -@'X'9F!M_-L8FI^1V79>C
M##<*FRS?HTJS.;#4>#P,5#2>@%]/K,[:-1S-UJ4)D^:N @>0VNX5<CB+:RLX
M+@A:[6QS<4GJ3IE88&2QLX4.@8R0,<%1\.E11ZF.Z!S=VYCAV/8RFX5,!F,@
M7 R(WU OOL!:N5)N'7FY*\V'.XUQD'JQ9GZ>NL8N&L5JN97=9D#!. )>X[I7
MA(J?!Q/;GX^55$..4 B>H;'/!#&JN;4Y+5&Z]FP'T3'5(&03/H*]E \]@"[M
M:V0EJ5P;M)VG(TLIZ+2^T"@&"[+':==^4S[;,VFI=K!]L#'<W-C9Q$.9US;@
M^W^*O6D/XY[%(>J6*GKUZV& 0J)S)V$P=)'A+\7T)8F)07$6[4 PLR(4I$FX
M2D:,&>ED&6 %.+^Q>%<B"=%YP03=+1'U07ST=G<?/WCW<7?GI0^[2K&]CJ,O
M0 ;_O/\C#%P@)E1;-(XX9DQQ.R?9-/B.Q, YF8W<)A==(QS3^_429C*ZI85*
MHIXQ2!\@TJ"0]#11TF1^GDYBDRSL?TD =1%K2_N*+#9;@_*[**^\[%O6[RK*
MBO[W06&0C4+NNBYC9X>@555'I\&QLT>)!OGN2>4WG8CB2FPTI 3MS"'L1;*1
MGJ)8^HAB&%X2S\3CE@2 [;-3]F!@#J"%,R$7V1,3VUMU<IB<[3%4-72%^Y)*
MVV5W<2B]+\D#5?!" H@7PA6A@J%5V%.Q%<+B.0P3#@J>F4U)5/BB-PU:P85J
M^2MN)GHG!_%O5AI&#H8E&4A,9@$#J_#2=JZA,S]9[W9^.ETH3V*<"\ENEYU,
MHCXO5:?GI(A= <YK)?$"J%EB\VE^36LAD65),>\?V(^O:V;U'9ELYH)X,NDG
M)#J6WQS:UR CP??&U%&83G6[',+)[5H7P /*XFM^"5L$E>-![G,/J>GKQK@J
M-15)\ !N,^Y7MRIV?A&BH<06)H 3X8JT*$Y;N-3!7\*R5TFP,I)&,O ^C9X6
MD94@OHXD-VAS.2Y'#7NFK*%)S&@F2>&<6=%(5]\4OADPR<&+]65!Q.#)GTOU
M;=S&T)Y1&")BO[E&]RCSF3I4.4Y+G$,&XK+(S8J [HXE>0N[3YOEH)GMH,!E
M^4EL,Z0PYT%U)4<]"'/@G\09!<0\LLH>"8J]V,>NJ936E<@/QI'<#*UGI=5%
M$FYE3@)[C*MSU\NS(K 2Q0?/N=)$,M&(8GD<XH)1I?)M;"WS$64'G6J%Q61/
M6@:@G<NGJ57C8Y-2BEP#, ECA,$$I'^8/BW(QWD^1R2.U38@UPH!(V%!H>H9
M:28MF5#^QGFSYB=9W[W[8K=U2IUJWFHVWDE#<*F[OT]\!5/1+F/N6AX6:_YH
M#WOOL;WC_MUUQ[[V]Q]TW-_3T6(1&X#T$P!GIIP.8#[OJ@7><FA/">_HT43@
M5[V_";O($A3FDD5N"L$,N1/KE2)),O<UKP36=7_@F+'^2KE>RFDV]\.EU,D]
M$C%\8P#%SAI L11 L;<&4#S*^-E# R@*!ZLD:AGO/;-S+5WMRC',N"#!RG\2
M]UZQ%&-RQZQ4XV(AK0,*LLMJ@I*C"!X#[Z^UO#3R)PGU2I6EP_*2 ^C+0@)0
MU*AP(#IGK@?$\*X7PV&+8^\0<653#]7D2NA'Z3!^TUBVZ[+N48+QH:?+?HKQ
M[), RRP)+0D,4RZ%%RSL*4YP27LG5E0*NY_YYN\A,N?XM]@U#_B(\-T'WW-^
MX^CCA\WX8._97W:W=_8%?A+9X8.44MTZN1\U<"3=:D;'%;7(BMDJ:71GP1._
M8ZR<="?7D6I0B  K)X!FD#R,+C-DYSKSJ..3P!(ZNZZMM4(3.CG;I(P9 0;F
M5M5,Z7&N3#<VQ04+!B/5?-;/'%(8FJKVR W-B#LP+0PA5(/*E.%U!%+!61Y,
M)0QW!BSP2),1)6[M2SCJQ*<B&!-4MPBT&%"%2AQ7FH(7\C]#KJNG(D7ZA_#!
MQ6T7ZS<C18Y(TPFH _OCRC[X/R;H2X%"4E2\B^'LMO0M0=T1T3CD9.C&\=O#
MS8230:Y8CH_J4F*<2$Z#@-)!/1"GHZJLN1+7WLFW!IA I0?Z&([AB Z-*V5$
M88(\C\D^M):"V)1X=KD[@/_Q$*Y:L'&?Z$AR39W]GNI4JD[ *QRKAIWH_ZD[
MI4V#^#T9=^=5BD!X=[7\2!<7>]EJV"GQ@F1%[V*$9<,"CW'O.[;2QOH=(VN=
MFM1NS?'AII<G?XU/1B8''NK7S(PN"#LW-UD!8R-Z1\PFUW8^*]"<"GFC1'4B
M66JBY7F[L[N_G:@1X[+M+:Z,[C%[4MT^5.'3,>:6'%G\EMM$ ];Y"T<JGZ+"
MI_-F#V\EV): HB-B$P"E10Z*N&+U'GL;AWL<PINLJHF*@Z&I8JI3.1\A9ZNY
M3^-+I5V5$L 315:*3:G:B&V2Y=<*+5RQ"1L"?3IY^_X7@3MMMB&(M)41[:D6
M6X^MRS)2EBUP)G&+FZ:P=L_&X=O##YM/2%3T#^',D!W9W='*U":M*"%'Z5U?
M>95PEX(KAX=L43E/4\;.\BXF/G%=._\R(,F1NK]6KMJUTCGR!<%L&E.4B[2@
MW?&12Z&<<CI&3H@WK^MXXZ,;UR^ 2;TBQKC:VA,[+U]L+WY\IDS3P4,VT1X+
MS:?$<8Y<S;9. %5Y.<R6[A3&OAM0HM"O,B@H3?.XRX>T>.P'\6'WE1^=TQ+.
M+!QXLF0MV>Y'_:''WE"C+JH\]^V1&/##%&, X2G+/@/.P+W'EE/4\XY,^!U"
MOCU?3\W9*FFXA$R^W-7@!_X(!66\CG+*@Q%I#FRF1<P%Q0_7(A(.%MBO7X*9
MG!Y"R:S*>"HY& M$SZL\E-+.2F'<=/A*-06E"12W'1#4)$=\W?@25[':A\)4
M3I@V!EKC-:Y#1_#LH1WB!3.N]-/@N4A*EWZ0#/(I2J2'YB+-)QV,#JHU:,W$
M8?,;I/!]BE]KH8*6R ?%NSKH00N^*U44(3(RZC;)\B>% ]N@O?-]W$3*7V3G
M%WY4"F]5"D6K K1B@\-2;-T'H_HH7POG$X6LRC*U,MB >..D0YTE/@F# B'N
M7LN7Z48G7%1Y07KOY.WI:U=$HMP_3*T30+-P5MOE')I0%3H;U!N$19&<*:!O
MF?&F=K@#='=>>T'BSK*;=PW60?J2^AOD2M&QH^ $5Q]HGSPLIZP_NV<N\=R]
MGJ93*KT@G9RGQXZ9_+RC)42&1.T!])\2KG$)8/:=/L5I^R6.E87)):GC3]X
M@V5OQJ7=&K@/<I <PB3R5?"MVUE+TJ;))QG5'?PUWD@W691\)N04B6ZN9*T=
MU5Q0+-L5<H+B\F0SW>L8B:[F#ZG(VE]P&K\I,L3\122/^U] 0=!Y'0[DQWAC
MR./V[%/Z&\C) "T0%)OQ:#*1GN'"M\=/3F<X ONZT6;/P 1,6 BR*WSME/XL
ME*^("<%WQN;12.1]? \<ZE%5@(LU\V,!) LHQJ0IB[T&1M^3.:8QEJ.=XRY'
M26GX_*T)CFC0%#!0]7;JXTV_?7HK;CH3&;QO5-2G>=C&PC[/;%H_9HX///5H
MQ!WFZ?QN,='I;=YCGS;9E/-$1$ASQ:&>.N5V$BH@/7V+8@ U,>F,-@I#01J
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M,P1="-R $5=IW4D%\4:SF+A*6Z ].V+&.G"G+?@I+74I?F +A-$S57HI=>M
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M!30LC_JR84ZU-2!@\(HV\CT-?&%0!_'/-81+F\>W'3N-921WJDV+'$(?U8E
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M #7  XJ1COIE.DK5<+AAV04*A?2\_*)S'R@,D('PRYV>0=0*M^CQEF+R*2^
M%%+"X)^[U ?*"%Q!$-T#:T%P2R,X4S_22>/XTM6"-X;ZB@!D%[A8H!FB_>LF
M#)"]:N9(1>'N26HC$,H4_6"@A52HTL-4]K;:,3U*B;HJ'?!LG0Y8F@YXL4X'
MK-,!_861K\@\ZS@_$3M3/CX@P7D?J[22A_0.DP^(4@["+8H:5NQ?)RDPB-\
M1Y"2VP*&(S&P);)/"LW7"? (E[MVPDV82;%1RNA+>P^Y<G$J[DU6<A74K*F$
M3'(B%4!]@'@?31 ,0Z2BGV,5'(43'V1HSE.H=;7LXYT#G0<'(Z;@Z*!P:^%
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M2@/XGIM%$"M),_(XTKZ&-8A!<A.=F@77F9G-X6C%+W4_?_GE+!B_#O*H5:N
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MG$7-5$#D@:O5,^X&O)B:<?YV %N(TGAJJG-9#.D,$XS$M3WU"COL&%DNK)U
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M^C)K)]G__@17'EF$CC\D5M<:*]M=L82Z0>!S%<BB'8N=CV#=EY'W(0.NP8O
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MTBZ]%+VKEPGU>\[ZO7%@A.-PF]WO8.T+M#GDZ 3^KVV-E!HQIA!0Z:_S*<)
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MD,I)3.FWR#\--EA99-J)].:PA]?+._PE8%)*LH)]YLR1YP-M\%*K\5)!($-
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MD?<,:;6"H[0/=]1VO&%3*5+?)]078@[&=E>%LC09:CNH-$3(\<:]?;.JXF>
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M*(K_U(8[P#7+N9)/S=VO4I]JQ&'ETK(!HVR3$UJ5$^KF@KJY'>K+U[/#_>8
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M5=@$1YL<U93/D+C/15!K5E<C<T1B0?*LA"+3)@VVOX12_%H%?9IGY<+#3XU
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M)=WCIYJB)>84SKJF%&I<5KJ=YIH[*DO=&60!2'#-76)0/\+7DA?B#9;N# A
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M$DD>9ZLYT$0CC(=/^<.'#].]AX_2)WUOBYIJPD?7DXN0B?,)N%T_6#=V&&#
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M?I3-T;B:)RN+G12.H0HMDC>HZPR=M41+C=N/NS'0A1L3%$3[\Q1C))= F7+
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M-ZO9>KFNV>JLV=IZNJ[9>F@WX3)CQ,//.TI/,4N^O!7DSGO?A!OF892T&5+
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MN_=(>(JP!4]&TRQ'^XI]1?(/XUZ)N1A:P'X*5!R\Q:'?-L/?:7;>3UR\F(Q
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M>45AK&D]>,2Z%E7FPK6I;+47RU),/@%;P2M#(MR.29:CD8'S\QC:AA=[X9@
M&AS]D[?H:S\MDYE95HH?E0=LT<D!(%>8U/?;\=.G3_'_H@N2W@AUCQ.K$!-*
M=@L7_4HAQUB<7;IOW:(?T9'R)R2>_?50D(BH'V[!*/B)4M00I=W^^B\$1XKP
M2)=E&H=2!=WY^M^4SCXL^$IMQJ9%T$\YTP:W$><-DA;N)WXP!]*E1_GDY;XB
M07O2.-I(]!?N!W:>1H-S[[K&BK9!8V)BJTFB3J8GM>'XCXJV7)!RE<=F"S_^
MTZG>^Y3*(1L:@N= 'S=M'T^<8D'?5>VC'_[=KEUUI!])_F_T-VN5=?0Y&HF
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M6'_N[ZQ7VE_,23HZRXMI<;H*7W9I-D%(WZ8'#&#"2^R9:=$KY5H<N.SW-YB
MO/5J]U7,+@_?78A!!8)]:R;&>-)+ QLN7N2)<D_[#$0<"$*/#248%:F%2MQP
M' O)F,-H@2E,993-,YH+VI=2[5O'F0]V*1G"P<36%8[V&)6L>@B=(HI;0D_.
M/*L%H7KF0),T=$9%.-=P$UO]>\+U[!NU+1 .Z"OAF$SE6[/&\YT1N3*9AL-F
M 8W'UOS"90O<C<@.J6I]S-K$#;,^GJVS/KJS/IZOLSZ^XIOPKB4Z 791FBT(
M *9AS/B<;3/,_/9YF)\8:@TL]JH&4 +"L#W9$6V@P/@\D?"E^?]F+VK5( QJ
M$*U<_S*=HJ9/=.H'[N\=V@&][4=LG/.5SZW%"+WFN:DA3EO3D.R8WW!REE:I
ME\Y -7L$?VP^T_]>\X,'?K6>K#'J<*QY0*4:_N9PFF@6@6TU[M0&+SE+VNS
M-<G.Y:S%:<G$Z>VT-**4_!2E.-C4>@ZIYW\5@F&B3*LP3S.$N;/"GVJ%'$$+
M0C=#]U*6B F^H&V+FLDOE&[E518ZF#[G"G<@JKY=:/< YDCA8L^KP8;=PM2"
MDI)V7!8N.>$&@UHOJ:3!M"U0FZ:S&TW0P[WB3P4_+SW:"%)[X$"WMGN[/XB[
M'H8%$63Q>S4(/N.8#6OKHVFRK+B3.VFE&B)WN;7*U#(&#&1V<0D-6JT_R.!
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M1(_X1<K>"JM)V5W""=BDBBG"U1F\3A>+*K&L[WWCW<%Q]/S5RWC[Y5.2C]1
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MW,-\RH+3!+%TE[(-/Z>A$;:E31#@BHK]*PDH5RY?N?VTCMF^I\,Y.#J.74G
M(OF8$C2^ J[:2W)U@T'S>5>.*01Q%$B;=5\,,.<J(-H$U0RG>]3:(BZTA9"Q
M+83PJ=J\?9X4AQP%YQ@ \=2Z"S%R+%&O-'/S5N4 [6A-#'*;!?T6@Q9JCY[1
MO&Y@FX6,)R9R L*=^6AJ<OBJ0S((8^)@%*>NP8-G+26+^%K6&8&#4;611B6
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M-% E%+MFEHW'TY0.A9AXV!^:9^45!&$2XB>< =K2V3RC @R75IC0Z(+)9QU
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M5W3J$1J??[QX&/:,V07AR#6JD6M5%:.,A(SZR*M47;Y,0S-U@O4,PZW!7,&
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MQOYZ72KW"(-8$O=I^>Z8)5D\(A2=),'^ZGX'2IPK/%KP[@FSLCI,1\/\V,=
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MM0PHU#*PO66@<<XM ZE;I*1WCF(O4&+8?[C]Q[?!X^_?KQ\^?QA&],2D^^!
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M#_R3I@@090'$8#1:S!9+D0X:CXF%96$A/_B=V%46=@7JDR]SJPHE 2P-1X4
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M$6)]X6HC4U)$O:(JHN+40T;6@:Y7C#83%2%_T0S-'#&^2HW/P;]B(S8;,EO
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MU'9+N1E;7K#L-,[MDT%%P6%)-;FQNSNP;"P]3YBT.R>#B0HPD6O=7OXP.;\
M^WHR8:.@C8S/%S$TSFUM_.^%X_*"?LDJ2*@=-\.3Y^[XGO12V:)V 8B[R?7/
MT50SG]AWS667_#?G+I5 2VV RWRJX-WG+D$V5\AFEPQ("-?M*,6I9+LK++9I
M[^SK= BGI\A:)4L[9*]76^@]9YN(B*!9>LUQ14Q*,/C\1*F(G3+1Y#(QMA9#
M@^4OD>&G9^_M[!1*]6112!OW(9IRU!"2<J<U"'A[?9;39=,Z.[)I!+DSAMP)
MTW+=DZ7EHJN(LRTG3&GU.959'KO:QRFK:*.1-8/OO^*&BVFY<+UF,_"%)!WN
M_F1KAC37;-=S@!R&@.1N.+BN8[\;#2YR7/A@QL+#US,HJRX77PXK F]0$?AZ
M$;@B4Q7XB546_T?CIF#^IXR#&S]_T/JGEVBL"T-M57$M'IE=AM723:"6'D)J
M*>21%UPQP\M%)"G7%RWL\+?%#+XTVDC_XG_KYH*-!^ >_'FE.R/#<A8VNYO\
M@YD,]/JM*9P'L.&#H;5P Z(M:7;]<VYHIN9:]FM])/^)M_Q3J4H,'(8Y;CS9
M"[;I921^U-+Q4'K=7F-3825D#VYIZ)/7Y."K*%)=\EYQC5/ I"*9N],N!\CU
MG<TM&_#X5 %F\^&$:9-+_'O1TLVTN1U%S1*TEX"!V\RO>0]L=N$&$<%':F',
MX"+NCK7'GTQ7<[^PY\"N+SH([6@J?77'%]*[*;,9Z*$)J.J/W(3\YW]T5148
M/>Q?"I<80<H_5#Y)EAWZN[A?Z,_O)1W\9FEDZ"9G 7C#3^@J\]M R/;,#&N.
M'O9$MQW,9M9'.+NC)C&>$=:?&<\^CA<VQQ6LQM;F.KSC\%6R@+%P)_RVNYC!
M.O39;&$RB3UK#M^CQ2_:BR?)9HX.#P8'Z4)ZY":1/QZ7J'0^X08N;D(_O4IS
M?<Y@I0PKJHW%&!YS^9O:K$G?'E6E5^,WO!S</WZK-R[X7\3+31= :B#J6)I9
MI@4JW@3[JH$T#ZWQ*RQ9<R%:MD8_X&[7@\O!;TI->IGJ0&YG,4?A=[8O'XS%
M,X:C<!?;6CQ-I=G"<'5DV5QSIR_:JW/AWQ2WH<5]4/B @M[M^'_QFYELX=K6
M?*K#?P/.($R%/RT,S<:=[;DC7L8$JL+C0($P%X-H#@ 7O$6^V8W13K"$$5+4
MQA,X@+5HPF QG%+B3N,%K%LWI_I0!^-5\^[L@$=M *$,-EIPA@)U'!WOJ9G,
M6CC&J_=P1[K]_J!\4/G2'QX'CTAS07QQ_[G-?%A)8")=M*2X/C#&8QV7 P]Z
MK?-A(-SW<6T=] 0;Z1-P"E;9P\PG@*6#Z?>I]!@BV;?_\OX#G"EQT@@\V $J
MFD\U"7@*HHI\]T@-.)L#%1AH+W>JFX)TG"4S?61;S'S6X9M(1X'#D<&T9Z$O
MM3F7 I1"4V 17@."2%@4W@4%!JLE L@*00"&XKN(#NE7R?/X^+IV/AA69X\A
MG)U)/D&05@'A\2:/_.L#Q[' '4'R#8!B3\R4WCT.!N\OI-O?%+4I(R?P:BZ]
M6R@,A/#D7)S2@@3WG]1Z;.+<>R"<@V0$T$O/FJTS>!G@)/=;Q8L(=L#31I9M
M,X.O"*DL:>-GA"%(NNY@P6HMZ(; ^Z$H/8,?@AJ%GXAFH7SXJ &'"PC+G(M=
M69726>#BKA;3*I[NE5XT!SEEV: !.3>!^;>.K8&*T(1T<[$-3 7\>;!X@B5(
M2J_=%=R<PI5#!I@T0+UCTL7BJFS,2V2%^#W"_0:@0B'> 0TL^?N+%4?'</F!
MS<'+'H(24WJ=+H#:E.Y&KH4?J+*BUKP RC-6.D@WP@J0B3H,?N@ 80#OLPZ*
M2[+F())<#8K5P8K_M0"I@CLU5N^DC?Y:Z#8;5QQ^/#+>Z;] 1SY+]_#?,TV8
M87&T'SR 7S2U#/!S4*N;(##B)0+UO&[/Q&WYZURQD7A!55;EE46(>XSQ$16,
M5,0#-]<!2B7"2PA#KL"(*ZR'NM<_C?!-,Z!0A$OX944;[G%.TWQPE&?F@)=@
M\^$?TKL!#^<UQ#3((?H4_Y^]+VMN&\G2?>>OP-5,3=@W*#7WQ=6C"-JRN]W7
M5?)8KN['#I!,BAB# !N+9/6OO^><S,1.$"0!,DEAHJ=L2R20R]F7[[QH?+ZX
M]D98H).[!VEWOM6>P8S-D0R_3Q[N)O^#_/0[&":"1]K]&^VC#C2.\[(=AHJ)
MDMVYR8?A.)I\:!6?]"!W%&Z([^?>@87J\E]!&J(524.XXE?13,1X2Y)DU%)B
MG5WPF#N9 PT3/P#7@C]?"#2N\'<8OC!.D&?NI_NP+,L.:)_^P @_&"2FC[+6
M-.UG@I<#P@"6!3//79N&A_0D-%,'Y#S)613_7/1$-,R0?MG3WK@,J ]$J39&
M0XK(K7C)8K%KBP:=3!_=*%EA(Z>+W%O_(+PQ-I_ 9C"P[.,R[Q=[7FH[^U+#
M@;3,DAZ<MO8=T#XN#:PM>^>Y!/M5O+CPKK"8.KTG$ YIDS$T&*N)RB7J?4@9
M*&8Y'F/=$1LRT!*@QM&#0/>@I]VOU\Q:,OB2 T;?#7QQ9E!NY*ON_-"^@27U
M9'O:<#!LM5L]87+>G(L%K:P]LW_$[3A6S8==PVYEOASL\+_IEH^:#$R,8<P9
MX 5VPB&@7ZST_[4=0WC @8/P_<4!.\7."M$)XT=\0AI -]H=F$Z@K^"5HVS_
M QE'1$IH&>FWD4^ 'CDZ."O#X@N+>R2HSD! VURG]2;YWO29,9>ZJ_UL-4*B
MZK0VW'"^01BKU.KL,-6:.9C* ZOA?O$!GHA/_VY/^$L#Y7K=B6A7T/DLKEN[
MV*B4MAA^0?K[!._ZA_[$TN0NJ5U^0I)[B@[?G[505W>U]U8CB)&,R*1MQVF/
MN<CJAKM$ :.A$0JB[-EB&,V>NL;<0))-A!3^LIK^-?.:@YP"?22:6&CP&#J&
M!'W' 6HT>:C1<%W;?$+!M\91PF 6A*8[!629 X*, C4RA!,"1N,3'L#-^#=S
M3##B:Q*J2G1]8E-'RJX-T;$MLJMW2MG5RY%=GS$9 (KRW[#DC>(K\J&-$NQ#
M37Z5AZ$]^Y%A+H7'%H39TPST3S-VF^C61Z01U0,Z;,$<,MUL"LX6K 5L:KK;
M"&4<TO]?'-M?1R3<6=^^$DZ)ND'6NZ,$6:]N'RC-$>99# I^\E1RD!KHMGED
MBHMA(D-*K<#7?")MTW9Q+C7/(3_JE)6G?J %8C9S)R',?@#9&18H8]WS'&/J
M4^K5)CT;30.RQ8)2WS*/ _O39S-_Y?/<'KX2A>D?#W<[A(BN^\7UP#?FP3K9
M_*/N(*9*(/D'.<7>7>PBZ_5NTF-!P#DR3?@+SZ^&9\AYGZ=9,LY(WH7,=E&.
MT@?K:1:99T%]\BX^.??BI$AS= .S5&_83ZQAP >PGZ#S#!YOD_&XMV";>;:G
MF]6>\E>^L8DU_TK;"F"]O^.[BQTZ(GJW1C=I]"EYZ$"55)F0&J6>5*GCO+#=
M,43LWJ(\,[!6J, X+,P]Q@[?4^)=I%C  /]?-D-VCD@+(/&&L-CYCZ>ZB9<&
M;X2W@UE&XB%BT[NRQQ +A;@ TSWB)_;3<+%TCC_G&8A!FS+P,A8+ V-^'LJ=
MA8]-BB'C828(OHXC@;T&/M6";6CM#M;N>$O@L@=P4JB<&EX>75(0;<1R3%=6
M"&$LV_4IK>3#4PTP+5T#BT-T$ZP]B\O*R&@:9+Y':0+ 4D"\^C.J_D.2G1N>
MCQ$8$!P60]\%+638Q(HQ+S/3N_#Q"WS_#B,3EIY]HYTOJ8D6U\U45G U?[6?
M,4]#PA'.".C(LN%D7=\A&8%4!!;;0I[;/"Y%)37QI(7-I6HD8(8E.P:*S^<E
M0P'$YO@$H,Z%_F2+8C7P-/DM \%1Q8"X;X9>ZLQA]"1,;]'5HW]JRY%&M!:Y
M,J K^ N\^>6&%]C'"IP#)/&22K:/:"@F5I[;!=*KNT!272#MN@ODC)JAZJ:.
M0YHZSJ#507N# 26AG.=O*]U.=60.RD6TR'!_$4WQ4MMDSF(&Q>E3EA\S4Y;J
M,<(G&5ZG)1)0J>.C9:1[GHY5[[:L[.06ULK&P>?_#B+PNK-ZP=)IYCR)( .%
M(;"ZGTJ6T?,T=8>7WE $3?BQ0=G79\?&L#W<LBMB9[04^ CAH(<EG2+4#-;@
M,Q692KCTL/@TL*P9$*N]HCKFN3;U72S%#C(%+]S-%]5I8,"!W<[W@SZ_B98@
M-@D[/+EK&GH333L=S3['7W.NXB[2;*D;= K8"X!!$PP .#88B?BI9F*-^(TG
MVP2[#[_"DQA8ZHW =-A)H,LON4O\UR-]":YL#::P6(RK/0/;::GMTZ.IT@F>
M'$8LP5YF(DJC:XX1?C8H0G7$A: - 10E/+>92*90K38Y;5QQN4OV(U%O082M
M&E&G8YI*+G,B"@B6-CS)E"FL)Y$ DUPGRH2))"7]81V\#S1BF+*O ^LC@]8%
M48H-GYHR[QEKK&5QML5C6;*:$GO@01VX?"BK[9M854#E<4C-5'26Z;E&7')\
M)/"_;WKDZB=^PY^YTG_ !CP0'@YZ3^CAP^>3%=!< DEG37AH-]I[;.N@?AWJ
MZ: 6%8S=PX'Z6/SG.WR$+(H@\."E#^:XZ-2[Z(UA6H=7"FF_P5'+B 1*+=V9
M<>C'2'23BQ_;^8%>YY11B,+&]A&/OXCZ+Z[QZ%XT:OO#>\MX5^#"8CV\;=I4
ML(V2#\M@9[KOLHA(<?&VYL!O+]2N$B8U:35PJ*BNHX7VF(.0V\##I'H3(3?P
M[QY<7U/\$K> [1F6O%W1H"5#/<GKE1*S&<H202&B.6?CK=>RH2S9, _;H)I"
M$U&T-WE7;+4V[1<F "ZP>PC)5-P/4F1 ,3?:PY)A8 L;]<"TF_&(-5+Z-68!
MKI<VJ*85Z!0,8S6UQT")7QLK:IZ@=>"8;L>8":(%#84%V"B%2/D[^I.0,S9E
MYK#/2_?YARGTM])?,#+C@4@@O2++_RA&:#W:@MT6)KR"/@S6*&8_'#@UR2^!
MK1)L7AR'IJ-UPINI@AY$^)[@'_K.7#>H6\K]X9XMM>Z=NQ<C9Z)E%Y;M:7"[
MKB%B97!C<T/(?>S<E K'16$F*MLR+PN;(#&N2^=.I+%1KG!0WKBJ",V60,RX
MW%)+O0G6CXVD<U@]D^HR(L1Y"#?0/H)H-JXF0,F+]@ %ZI8;/K;OS(1]JS\!
M 4DZB]M^2WT%CZ!O1 @Q%7S$J+;+CQ1X.K$L7LL7=$[ 1E8V!JB1F_)[W2BR
M&'7^RL44"B.+RD) O-==P[U??'48:&<Z@OM%%?@/N[\GDA-KM3HJ@S]TM&N-
M]H>T'=FA9/M=@U=55:970(2J5#ZH'MN \\,ZX6PHR"-59<,: I+C?>-@"AB8
M&^+F.Q8$?;9$%H^D;DBK 6H'4JTUUYWT"+NZ\KG*^JVPPF)- D;4SF^MNR(G
M9C8#IJ$D(+_D3]\>M G\T+?B5YI=9X\?#VKV&E@GX[J^].M8@F0R'@ON*/XW
M"%Y-'MX'-?OG<@4Y\D_=17_'TKS&=A*AQE%]C5& \%JG=&D@)N8&^",>(A*
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MF$<X<Z*D=1;C,N1-_ 69@4%#EQB>'(SF1LO0 8+7_M<VB&!S7B<KQR)O03Y
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M"]^A@CE1G'>CW0<?X1WU\1=3L5W6-@43!FS<B(U)D>-8+([MF8"FD*8VM3@
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MV?3(&^V#@.R"JS<X<@ F,AT6)4I.4H8UA\TZ+UB?H".VFNUX[D7=&X]I^*[
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M- BAD?>)E.9%'];9^##O&>S.E^N%[3L-N'%ON>FA?'DSW5UB6)+!&H+(0L1
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M&GM>& VMT%I:VL$Q_L"*0T;VDP5?8C\%&BJ%P6+H>:4]%B:&I5LC0S=A8/B
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MI^ZO#EX0C&G3BA.*?>=2$%6B5B#4BF /[&)[K:9ZJO@MN(POYQ-,_+FX\!.
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M#NB>:(B-N%I]/K<-&A.BV$.L.46<:/Q&&%L[M'5GC,P;&X 4.(5<K-Y'XZL
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M^4">454*;EY!EXY OU^]X&HM5_<7YU*Y=D [&WA_SE"@ZE;X#M!+C7&@[HY
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M>WL9/33#:T)X23C]+#A-: 0[<O.$DO(^(N\_<N4]SSZ_DC_[52+\V[ 69#P
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M\Y0CS$7DV/Z%G5-]&72;%YTV2)@MV&4,SD,#Q0F,K["[@&XN_R245?@.E_7
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M78_,718?,UZ,"/7*KT\=#T]X :;EH<A%=<TT0 '$^!K7AC5@6B>*5V>\BIK
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M_V4Q@Y>,Z*F$U5C827%JM9@T2\24A;*_U&K*C4',\7OE7G^"+?% _E@0:T2
MRJZFU&K^[^D69X]$-('#]A$VC9IGS^&%&D+(_R1XIDV%T<8"6;@WS%CKM)U2
MN#YHG3-F'<>\J44G'TS[@_*XG,/D!XX^-$8?E"^P$=G2?+%Q-1J]Z%/O@L?H
M0N'BADNT<\D<HG^O#0EL?WCQG*YYE-XVAUY<N.@B1;"Q8O#.P:/TXD163$T1
MGB6"_*F4K6/N]"CCOPW[7VR/N!>>K7A3HES9%MT\(-G'P#A+MT8&;(8'#S[
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M;^0[]QY*KVJGL^W]#K0SGW6^C=]5!M</,,TI2&DJS><.>39 TIDA<U%IQ5L
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MT(-,2YPC?C+3=M9T*SH_M!^4CSYX=.SE]PE,CLG9V)F O9V9@&D26>QJO#D
M],0MA'A #Q 21;H+U,";]T&^6^FWV@?Q'FNIWF9YLO6QX#[N9,%Y'GL'8*>[
ML]\!>6Z  "#Q1#T6 JC6M<.B/A_Y?N_8(T+&@K/SD$!+TB;P(#_]I3E.KFFT
MO<1VMXU3!)NP;(DO<W:7<\D0YDDN,-SKU%>"QAUJ"!2=(SGND\BJQ!)]&F9E
MJ\WT!9^PW,A5#]O!CA@B2ZOT&]5&<[LY03[:6,Q-N&Y..%A[5# HQ!>5N^LW
MG<_&V+\O.LD+X9]X$4?/0[S"$8F/K:B'::V.\Z;'"1&#YG<&A1*Y#-8)_TNM
MIMP8Q!R_5^[U)_(!'L,V%".LCMUM*+6:_WL*0?9(9*L<3DECLZQY]AQ>J*'-
MU_\D>*9-O=4;ZV<AH,Q8R\@S8$<'K7/&9&6_:]')!]/^H#PNYS#Y@:,/C=$'
MY0N@ERW-%QM7HUF//O4N>(PN%"V\'RS1SB5SB/Z]-B2P9^#%<[KF47K;''IQ
MX:*+%('.BL$[!X_2BQ-9,34M].[K1)#+0!EM#M'(_=NPCSDU[H5G^XVJ++K-
M=.P5L_+)/'CP 2W-_K=WPWZ99A?P(T.J3U]^$(P7M<ARWT9;-P-+/+]7X_@M
M?R*BKO^!S7"X34#,W@"-"O]E:89!]&5-I5=4.B&67SN-8'=*YOX0@-CK+,MF
ME)#W.\,=!&=[7F$%:9])^X(4=M6HD6FG:<:L=I(4"TWGMM^L])L-GME+N"38
M5XRT_=:R1LD2G%,WBR8F;N777EN1+(&6%[I.@U0S'4AE/=G7P*@43YGD[3I/
M=?EKK4J_7:VKO.K_!2"G /]I8O+#Z 2)_#T#'7 S=I*D!644'=&N]+O<-AA9
M;X3-\D"O 4/[C[F4ROZ((JRR%D5K,2"O#DHI'L2I2J.C8U ZE7Y+Y85G21U.
M .@<.LE25>*2!\QT,6"FV2L"1F]+J\OMC]_9M+7)G7&,4"TNWTCK'5/L2,I3
MH5!36,)3HWYDG8#R9__GD:F]OR0 +W$_4OTAZFCGL/=N$BD&$?&Z1_C:!8K2
M<XSSO-\\+WF:CO$-;^!P?P5T5O9LU[L3<M:_E;G&GX2M$PT+67<2KNKBK@6
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M?ASB$-C1D<9/X95&-GJ"QW%:R[2BEW?9U@_Q]$W%?L.993ZC*TX%'2+[4;+
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M_6CYW]M@-#U*/WN('[VC_P%02P,$%     @ V8!J6JF%.-QB!P  UR<  !P
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MIZCJ6.$RQQ^%Q);08[>X2$/W+.S]6Z7]M62"'2OMCH)&1I.,82..FA[CA%(
MY*5N61>\"\'O2(AXS0R$[.]YO>]>=ZP>E];B3OD^ D7H]DC.(PRT8AW(MR>D
M58F  >  E'S#BR&+ [1%@K.2?PKG2YE:MCZ#_M:B_+>-[ATKX0[D3&P02QN
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MB>I5\=-"T1 G?.'3]$9X%\1B(#UL*56<X"@^*W1T0%&/\9@9DTB(?"B7C&B
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M\C]W92T2&#WB8Q-FN>;BDKF6\P>G\?M[3>@4]]SAXBONQQ]02P,$%     @
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MB65]I4CU$]9+DJV@#>_(-]"1(@IF%HK]OG#P+H(^5:)_MIV[MHW.:Z\X"+O
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MC(<=8*6T;X.UT'7.;CY_(:->M^%(V*8><:C],I*GF62)_E-61C,?4;2B8A$
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M%$;#Q OVL^P5O]7G]@QO7VE/7,LYG1(&8C6-(YIQ>@!;A'H89&P0E1834(]
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M#T!&D75..X>?A_JNZ"<G'3#VE+->D  FEUY$IKOG1)&_P$\5I8S28J5^A^R
M[ YE>!!FD(0S^[^'&^'[,)"?9P0"631!?O.%GH^>%Y<5@'@WI9R:=TZ(M.^'
M.T@_  [<C\'-K0F R,';1W[S- :KYZ:^?K<6T!4BD?F58665::_-C6AW6B4%
MU1F?!ZUN%,)[(V@=*7]'PQQ,$4GH9"3&H.DT/#F23()A".JR?2T^Z[;NPJ9$
MQ9)]<V:JP8=N-"R5%),NT= LG<T@.'_I7(+NA[XPN1+HWXO.N@6Y' <KV+^'
M&MZJ7]*F?]+*[&@5_30/\A!+R1N&X1=_:#$Y@=E*.36]YCACL;0%S.M;) RY
M#)L8J"9/;6E6C*15MVJ@G5GT,%YE+"(;+#_/];:W<FROR'&]Z.T7<#NX,<%G
MK[SN L],Q ('Z9LZG-H$[)?72*_:*-\_X.@6QTNYGKLWX[@DD-I2F=8H<;N>
M'IV@5$$[C6X/0=&]6731D&PY5L/[S,<)PY\3_#((,76 1:#T69!LM\YD.()/
M"/H,._!.4!GO%)5Q#9K95XA]QC)1VUN4"#Q4-0:X%>]N%7< Q5=[^*,8_*,I
MZIEWT9V5-&7))*(,T"AA>?_!)6@"YF6A;=K$E),EYR:PO2+,K#>VY&>7)2/^
MFR@[N_<D!69(#AJ-P$L$>F):3D&HU'LLI:[2/+OP!08P"0R7J@O,<GQNN%%D
MR7O_ N.;EAC)K#C&$>TW"Q+OF*B;_@@N.D.MB"!GN.:=XLK#=#F2$Q@C:J6:
M&'R_IO0OCE_&*HN(_(SBATO/-*3HN4D0A*/MU/(3\TTCDAIUV@XP0[LQ\)R@
M)*,>#B_U&1(0AE2 F6,XS$0*V5Z H+K0C]ST(6\<9R X8=LNYQ),MA]@*#?P
MJD=T-2B!(LJ62'*4&N*40[6,3]L7812X5G][ZL05&X7BHKR?P;=(Z2:_2(@)
M#*\09R=)^P\XT/@F* SC BLA\6GBEMD/\')'-,E]0H*8':[+4?:LH@=I3!^!
M)%JM@A-WCYN7X(^C:-D]?IDC+O0IAO.9UK:-$7#!>*7@L^@"/L,B&R.(6=OC
MX%U.S1I7*>)2 IV]E%S-.LE-61+7)2!4.KM<CYUD.&GF)1+G3JJ_,45+%P+;
M*@M:ES+FL\X26)K?LE%^\_H%,-?N'1* !"/:VEOSR%X.)7$09L4%"#A@*C8O
MO?6/ROD.-X1&"26O(OMH_<8,J.<S:%07^@5S#L4OK'3H($^>_OK\Q=&SPU?O
MCE^]?5.\?5D<_/[B\-6S@S?%\Q?OWAZ].CXX_*LX^NW@\,71EX?/?VT@%'0[
M:4XVOORONGE?_&Y!@&+*._E"0$,'.=& C:@IK>I+*A$\R,+A #1ZU%^+Y_YY
M0<F-E,*C'L!M<?#\2"LBP8\!8 EO.P?Y!F3:V- AW,?,=^B^>YRB*F2Y[VAY
M'EV!YI_2:G\SBQJV9X[\@SYX;9=S1R'U"6Q7/774(9IO2M@"NH!2Y3%,GC1&
M6:3/7/.%8N-R!:J<^1*R(,J [83>)N/4XQ-&9@=A^#T2[-*?+W:7X.YZXU,+
M A!/ %Y1UA-.1.N LA["\IL)6LU'70.L:^2I(/P$C^W_] //8 VMA.F$;&@&
MZ^#QR!33L=^"U/P3]8A+![Y;-_*O>DFD0&%'.DB%'!SL:G]8X/-H&0&52.TR
MH-;<#3S$^['H\E<0O_/\4*L"4[\7!'IP"B[Z*S'Q<R)H+NGO$7<BPKD%GL 1
MYA4B:RLSMP$($":)"'/_?EG;A5]_NEM@_259\7CE'7%&;Q7<2#'56*FJ^*W=
M:4/5?.A]XZ9^SS8?7[O@)G85G$.WE%@UY[]HGTZVH>1GWUJ%Q\"+(+M<PRX?
M-TMT8#U35QIM-M;(1@E^_(R\=S"3Z$1U32/Z')5Q$^\$,A7?#F/=R>DC>"_)
M7HA:]:C:[M^>?B&>CV<78:=Y5F0Z-5@[4SQU4;7H>O816\O)_6UK&]:%@XT<
MYJ3S'RM0(:Z7@C=" OV4WU!VS,E[4UASKE@#@6/9"!LG?5PPV;H:V*&O@,=<
M'"Q^M D62[#XT298_-7*KLATB6R>E.]O;P7M1/6WJ,!)<!H',89EZ1W:V91G
MY!J/:OD*KNVUHDI[K'^$E4EP(SD&V6&K(>;Y+45YZDRC<=3<\1$?T"./?6SA
M^BR[T+I+&A.TV>>.>RJR1\F=^J9E*=B.;-!RA<=)+)QM@8,V%8+AJZQH^$G3
MA,,F1-EQ,@M.VV$?#[<(7 JF*C9F8N'CW:ZLEY-_*9:(%! $$QM(F)N:J")"
MI,S%(I?=<%)X$.>64CS:6/81N"J*=,O^Q.J^UX'C[8\>"HOT?;]I'^_6C4#:
MZ_4LI/Q'I$,-84E-NTP-H,%6[A4OU8^J;J@B*HK)1"BJ"%PVWG940)L+SH7J
MDLV9D _WQ*>CY?-.ZW-.Y)/6 PNG< !44K1.DF29JK,M.'%.+3?!$ _FGQ3'
M1'WI&3"*EZCW'$3U/:.6Q^+?O+7DPGX?7X\P-(!^'A<DO"E_#\RM%V*\R7G\
M!C1(G!6I6T0R6IKQYN6J.8I=P%S]_]WD.FZ6 46:"L8%B $P,'S!:(2XD7J=
M"!X*U:!3Z-+2F9R_1<][!Y6<%9U$2"J1;ZO7"VN6!P\4U5KVM9_Q,>K>Q%!U
M!%K-K&TUFF&K%L%2?ZGD]>ZV4]O:_OPR_;*CPLC:G\$+_. KNYER]]=7MF7M
M!)[!P>_A^'D52J)I7+8KII%PR/)Q5,GZW#+1Q5>38W%_[!WM@4 I2T.]HRCF
MBNXBRB(MJ&)$!'NAFA&<'80/^7X7%'V(WJ0GG40D!%_'#A74,6%E+44%N38>
MKHA5FJCJA-;)LUHQ2W+^L+<"BT?)?LQ)6M0 VK[9P-A'?_-(5> "H;ZJ;5V5
M@BU"<9O<3"Q& J8()]WJ NA6TX[!&KNH,DGV[;S#A-.1LU27LL(611&)!_:%
M#GR-04QM",-QV/Z,,%/942F&WR6(O=+1H6J7"\WEN;72/S_R4X9>^!35I+$"
MTCJCW%2W[\P';<M)ERU0+ 8T3Q&\)? Q11E0#HJ:/\Q9,:2'E=Q%07L%9BZL
M<4]_#]I9$2EGVUM2Q[UX#N:5^< 8#_U,[3+X U:K#B@0YMO_&R[6NZ8^:<R\
M+>Z%MP#%'?5P>UH*GO1>CESC%>Z$#T5WB*X+M5A,F0!=5U^?E&4%T#="P#B:
MBCO&T1T1#-90,AF_:\(A^YG #*02=T/!S5FYQ,XN'6HDRX8/CB!LYYH''3L*
MTMN6NQ[BW 0>2="YMIX'# ^E%*EM$!''G9501UJ.+R.C"&\92",J/9B*=RUD
MH"4X;/(M=K@'N4:539*][PW,U$6$&-Y#!4%*L8 ]IZ3J'[Z/#P8YSL5R8_2#
MD[PT"F-B>FICO"HD?A:,-PZ7P])"XXM)PV3+3+FR72AC+D%[0M=B*2A#VAR!
M,<B/C5+<DW^T4@_76+_-TK<RPO9XYQHPM#0DR?,Z]\FLO7W%\Z0=,X5J<?VK
M$'53N<*^M$L,^SF%VJ!:DE4PBPQ0BMCJY@K"!*3K1YR&&K?L:*,;^HHJ%8>D
MQ:@7400""G5CI,PZQUUZS4"2AE4:RE9\6#>@'$9J>H08$X(&>K#PD.8<1YJ.
M]&Q)5+3H:SU+B<.)\#S1:/+DI1<P?=4H[8K-[7 B.ZCI&4EK[:+C6@16I]>K
M=WG9+3NM0[&HFC:'JXJKCD;*:^P=A.F69H&PKU<2EV1HXZIOAU6UR"Q1*^=Y
M9JG'0CGMT7;[\RE74N7:M.^%*TI[6&3,@EDW$PIV8FBQ84"5R/)8XZ9K*RU0
MAG"S1M#<H7\ZRH5 FL&O%1<=G] 9//SY^^^YY $7U1VI.2R:5/J-/=5KAEPU
MV1(EZ>TM/0U_RWK8QJ2=N>P<@\=Z]*=<,(;;#GJI:Z(O\N,!'U4*/O>/11=5
M>'P@9BPUJ$<87QA!XKMI"MZD1EG#H]MCA2Z:-79O92F?]&KMU3)::VXI<8F<
M\%IT-()D&M=5 BT-ET" T%)]@N)&8=GJ]([AC9&<$C"-M/A@K%#:N$1-VCLK
M63+^T+T"YW.,/NO^C6E10>OQ9+B^Q,P*6V)U!)N:"A'P*CHDZ6S->4G(:^ %
M[PG#6-H3!%-BT8L%:6(34Y):%,QHJB/2U\[Y;B'^R:P&LHD<<F"MU4#UI!ER
MFM#$34.!N'-IH1#1#WL^>MZ#6*:,KJC5O6TT3S :E3P&F5'II=+JQ2"_#I'2
MO"Z7*,%3#RB+ZDWTML.U:07,],[VV/%.S<!ZRAK#J>SV"4#PRM2G15R1ZX0%
MQ7678C!S<X3X#"^4%51%01I=72HL/E6Q3=(C/#0O*+%40>$_5&*S3+;X*!Z+
MCGE_8*E\2OEE\678Y=UR&5VECL,/&VB.0'-^V$!SOEI*/EXC"-H%NA#)M<TQ
M 193PJBUY"3PJ=F2N(N;>^$<5?9*>+DY,Z[4A%>4*1$GHDX[XM[N=1M3[ >+
MO9%7?H,F.= @U\N /RV+S/Q05'HYV+7B]D$;&]-YNH&*$>%=A[-*M:!40H)"
M]>I7PF>RPD.;J@Y(/@ ?4NOWRK.\N745-9LE$PXGGMI]H3HHZ JD1O5."A_D
MOFJJ0LW38X(Y[5U+LNLUMTL0F.ZH^!,D\K0QYZQB(CYB CH!4<0U3>6:(_YQ
M=!_1(PSR)9-K$ZOW9HUX?T75=@R,ALL28XOE.VWD$Q-P?,]@]7#&4&TZC=A+
MW8/+7$M2E5&J.F 8BO0Z#CF%[+FV,_-%^#N, 1I#B-3JY_CZ@2$@?B1I8T=*
M)T9A%XU#CT8/Y:^V#B+S6T&)<',T'^Y1+[J'DR.H23QIY*)N(AQ@*"2K4#L.
MHQGI72OSO(XV0#=X*2<)EI/)!3E4O 4I?...WEO-B&DIA(=TY%$DW/&=:"HT
MH3B/6'W?+QNJ;%!.TA4O9)&[CW$\>'OK\]_.^$I%[<2#VI+SKVQO1>C:^#*F
M,(-"ZR.W<C^C/X'R!V="P5?CBW2Z4.TQXF;HW6"%IE&6@)I1^YXYF&S?Y<O+
M>HI(_=2#(L3*S!I25;,F/A\ PY]Q5]F3A&_PITAET"M0LM#5+_L3HZFTCZU,
MC0SPW-1N.6.:IDX>0HM(3'YLNW.$I&0 _7C@F0RO#<]*>=:AKQ@;T6^&B0D,
M(@+)'[(6/]SB?-1G0AHN2U;\LA?5XLGE*$-T[TU(PT@S+H0+1(\Z;2^00>MG
M)WA0PF/ 4^!:87X9J04-)R?Z,JW1 GQ%.1M=V%I*S*_)$LAG%Q)/TKONH27Y
MQUF8##[.LR]?BCYD0F?8+.=8QKF4'FEV0UT.O^!@_^ J(M?7L/7&V20*&ZQX
M=D>97"PED-GI5>6LAS@*PUD.5!PNQ05'XM4W+'4#A+! &WQ;Z4'@$3VD$R>:
MB%2SB1@'7.T=XG_<)WL0 L$7[.;O.3R+#5+)+)REI7A\T3M?LA"K>@J0B?PL
M,A--04'#KN]T =Z-#,$_HLJ1H#(D@Z432.J8WLE!T[CD#&[P1:=1I(=!,@A?
MQ DO\4[I*'#^#+==:2:PD>!W]"HJDDC5W;"$T:5%"WAM'69?8;%OTU!>E/=2
MC>+X [Z)HB.PZ]*)7&,8:2(/-=K-]]0EO=O-8<.;D$HS\I3(=8?00\AZHCDA
MB**GTK60^D1+;?WV<7FIQ/O'="L5'B\E7X''9^B7P1]H,<)U5!F>?0XV:>0C
MHJ$D5D]9[GA<6JIADUY?0X@"PD/D@H4$?;Z12$RN)-_%@9D?-X$9"<S\N G,
M? IY7?,$7GR@!@3C5=](362IB6LE2+TX0H;Y*BQ)<64/K4DK%$KDGO(9AVX5
M,18B?Y3@#+>W/+(@CF*\K]#)/*9:O*>AA*^MJ H']L6;GE'#"$1195Z+FTX-
MR:J5UDE>(XLC,!L^C+6M&ZLH$%EBGD]'61$$EU(1@,)UONAB=I@R]&Z0QZR(
MIO@H?&VND(Z*J@O>,Q4#IGTO33LN4%X263RHZ!I5C]1-)O$[7O;%"M!,@%2P
M6SHC+]BBPJ/4TH=<Z 7F.:7V-+IE6E:,GA6I69@E6#.-^[<D['"V-#<'A4>P
M#1T6+P]GA.L%X?UA)?UGV?WD_4VTVQRENEA3#*?J543^<I1.GM$\MK=X2D5N
M1G1ZJ(FE1>.\KL!=8]B<E*.)]3&R:.52G5O5&C/PR%^^ A/A^.#IZQ?%LQ>O
M7Q^].WCVZLW__L]W#[ZCW]\=/'^NOW_T[,[=M#O%1Q_\S4O-"6:(+%J0'_K3
M=\3VGQP?Z@!4,A+4/UT)R);O5#0</]>GY.6TH,<@C*;HJ</?]Q_%HN7X^05?
MW<]]%W-?JNY>"V3,RUQ7(?>_?O[AQY_7#/&)[PRZ(?8)BT-(62+EP>'_#C]M
M#S]JUS[;PS<SWYL\UH[2\+&$T9IZN/6">$*4*<L5II9HJ2B/>0PB9G/@W\J!
MYTY0\HU85I(2!!+/(C##(*B]&E1GV>OMWWWBU+_>%7_2G^R>B0U.%J3LJX[A
M2S,M<$,QG+KBO)4VTE^X*S?7]+]CB:Y_6@5,$P"7@V*H?)"#89#+/W!3D3*$
M.99H/U3T!@]<0A_$.L^2*DNK %@:]AE.=%36RKWK)3CG/"R-@AXSXTKIHCDQ
M#08(EEU6G:U#P6?8SXHU1_H*U>3-?PNLFDM06I?;4^*;HO1B@M+"UTXE>*-I
M]FX6[XQ?+"N0[(7!OO/$/>ST&N!87QO=^J+=:CUP,#>4)=C>0LG9=,O*<4^0
M=91H?,P[3BU)CXRR=X2J<L;%2)*B\FX[KFJ([C*T[+1/_(G'\H6Y( N;^"8M
M! ^('<:2<*V-1C16E7/ZDI'1MPG)\%3[VK?M"+;AK>5]%(MYJ5"-%Q+DOZ88
M4":P]G5;5>R@R^A</??FN._>[!WPO0=[#[-V5/CG1_Z''M. V3L!>LF](&[<
M>%]0:,-+ -<DDH'!AX59(3?\A??[ L5-?*>BO.F'=.&''Y=VUEVB:CY[BX?Y
MYG^^V__NZOOUG\_ER<NW;XYC4KDW,W-7KGZYC%AZZJKN_LNZB?8/7_[KQVCJ
M0'>PR!,JZ8"T5S>_%,W)>&?_P=]'^]__--I_]&AWO3;_R?NPAM_(A7CTX&^?
M<Z/^[Z.]!P\HKQU].+OHG,([Q[X^_#C*'=+/=^.]_ ++EY7N_^U*AM 7VF=V
MFWS.K18+K/C"NY=GW9]M%:]:;+O(,I=A(HYZBG$A0OY;*RUN\#/!KB29$O4L
M"C+V\QPT!^W;N;!?EDQOX!)\ :K_MHD^3IM0PL^AUP($-[D6:\IN%MQ%!R&G
MGXG8_SP%9?ZV4'A&"?FL(WW=3.6+T_3_W7OPJ"?X@:R_Z#V]':SL&Q?@!Z&N
M8B22T_R]#3O:L*/K)DM*7D 7^)DIHY:H^"F7N9 >EV@5DU?2S=:E]3/&L#@U
M4ZXD&:611  W_^?@!:-,B9Z"N^&(MURY>]XW3=82551=+ O+D.:135IB8XCS
MWS#;#;/]"G4_^G>"W'=JFF)E3;/A?;==&XRZIK6V.7.3C2VZX4?73H6'2=6K
M)N0+8YKPA@G=<@7L6$\;%?1> 33O*(Y00U$!AYJ+)TOO+"S4D*D>ADJ]@BVX
M?C9:!^J.B^)Q,MB& 6X8X#5? 0WC#ZEWP_UN.?=[ALZ,$8Q2V@_$ 6=F0ME[
MEL7@W+6<]+=#K,M^0.A_6ZY"7RQ7Y>,+NYL0VFTB\V_<TI#N%!@0&_1NZ?7I
MV0C@C0"^;AV4"A.%EF]KNM[T]<JTE,XIXR^E$Y64@.0R2(,6H%)6T5=-&I9)
M&DDMI>FR6ZF6FC3IV:@&MYUG'F!GL F(>R2W#5?<<,6;B!4+\W,5B>M</",V
ML!D7P[Y$)Z#N7+!DP[SN$O/*\RZ?YW4;<?J?7EG]ITT!#RG@\=.F@,=72\F]
M2@.8D6$G7<LUA:B4Z(P:[4I-22H2Y4MN*(;2=YHG'R[W]ZR;)%\B((7]UU5_
MSD PL7FC+X.JOF$JY3BWH*,W5!-CHE8H500?%$W0I8152._,M%(YY6'IA,<K
M[:7%C8QP-OQU=4Z;.;8^33$%\.HQ=^EPU.$Q MO[QPCKXAMSB'DAR)AL.[OM
M+5D "^6J6F(E=&OE/ ;QOFCN6FMP@ ]K9:K^O,:.YQQV@!\@;<%I,Z=Q7;^_
M!T2#HZU:; (J'6#)T<FIPVYA* ?RDD.A6J>R+NDKY@EMN !X K9A@')3Z-#.
M!1N?=D1),>GIJ0SZPA!."0,44G8_:H<=*"*[,M"<;&/*$CNBS)9<3U_[D,&7
M[IFN:V2'_+'!-KJR2&Z;]N"2)V JV+O%36]M,EQ^Y)=TYR23%_\=9N#BIE.M
M.JF!3-=Y*>7,W7R\Q(SU)>_JI&Z[7F'D<%[ 4EHG2;98O[1%TG#M*3=HKK#'
M#+*?*LY3)*P%-ZD= <,RF#TY++X<]&C;!F<O3S.K@VMP[,Q6V"1!&0^]6:X.
M8MSP\[1:6X7(#VS#2Q<7*6JZ[#6:&#B7L_75D'*Y>CP<XM2:DGX8MI\./2UH
M>;JZZ IM;]7G%1L;6'%H-G.EHUHYOKI\G/9*P#[#_::L::JP&UQGNEV 2L!-
MYB?U7#WJ=^Q69!DJ^62I FR_AS<PQQF[N!HJ9Q4Q77\<;51WCXH(F18G:E!X
M4HE#,!J!OW,C#JIJ?5[Y)N!X:IRL3U4BT'B$VS!SP,B=4+1T(DA::89"X%)(
MB2X-''JKI!_E7HR(7O!NEFX.Z^9T?'_7E"ZTZ8N4"."^>YDY,^_F;VDUX*G#
MSJ.DEVJ9Z*3H;D.]$ELL]L37EWV&LL]\ DB.W =@<..VMZ)^[P)@I5?Z L49
M0US/)_0GPV1I%&^SUG9K?/ -C)\13N^IG!9FZ$O-*0[-^^'3A0('(+5&6]?S
MP*OL@B_@+KZ=.*5U _\M9N:L;C@9/BQ_HIA@/YQ,BI@_ERJ3'9];H /B)]K/
M$AZE-X7.Y9R/@PWIHHJ<1 *^C4[$$WUYNC#M6U?;^%WH$'#,+N>[5NSW+ZT<
M,K;]^AQ<B\^W-+@@<*!Z9UU%Q09K8FQK^P#T:KP)^UU;ZDU[EJKVZ#$R-$<-
M+,1OH/M!37BEN%V^$\=5ZLZ)+DI" %3>=$=T$U <DS*J_2C-8H%A;%7 ZO,
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M\9E:J$;Q&$&_&I GXC'K::S56WH-9:YONE'DA<S*E[Z[J_PJYV!U%2B]L"=
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MB@1_(:R+EENX, ]B6;46?J-\']]!FB'G9NQ*;-E%4')4:FS;C4+66E,C MG
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M^6Z=0DZIQ+"\0\' X8X<L0#](^"YT1]+0,@[J)['8$*RE:FX#NX;T;(O5))
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M+IK[3]\^_PL! O=_._[]-?SP_P%02P,$%     @ V8!J6EN$*EM\(P  (<$
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M.0,  %X6   ;    96$P,C,R-#@S,#%E>#@M,5]P=7)P;&4N:'1M[5AM;]I
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MNB7JY*FH&\VI;PNP/[LU>,>U[,R 8W:W08DM87.SL?7"OA&Z[#4S7\Z76/T
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M=.[A0&.K'A-CZF6"G&E'.EQZP'J0?DK5O_=CFQIYZ*M!EXI8\[G'TZ;W<X$
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M!+9.1<1!;O6J'L!JIY"C!RDR8,&0)N/6E K&.]C[51 IG1U20X*,$3)]<S3
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MFE?9![D7?6_CJ. K'V,N0/Z_1JL$1/B__D3V-_MI_?U0UWT(/[@)UPR!AXS
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MVJ!CY'9?]Y8C@W[K)Y;M"R>:G3L;"K*3/GFD4URFF@MNWXA[ ,";DY)>SQ
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M0CC@ *E%SQE$ OFHC@&%'(:M4H_:AU"",!Z_$DHH! DPO<^D@2X9RWK_X?"
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MYWJH%[O/93/</8:>[;J_Z'M'<(._AA\Y"YK1ASIN8RX#1^F*S3-8"72:+?T
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MX;NGRR'\:8L1IB,4IK[#NK,V63F-G4,%(>'DV0W. ,HC1T!MOM-:"#R8.2/
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MP3Q8'OKB!(;S1^G501M??G QV^!,D<@AN%$])#>W<V_%T6=^V@XW(TCVQ)+
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MK3U9L]5*O!'MG%8+OBR9NJVQJ,>^24GF[ >4J>5 ,7$ -=E%1I3.M=:1S7L
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M21C[!GJ1LA<VZHM%G=]1?KF.Q(H77S#5 =N"\A?OV[S8&91G_ "1PUYJ_1E
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M:IN.FK%AL;T,GL5SGP,O4A4O_%S<J7SPE!Y&U62P15,"^NP/$6V430<JN#N
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M"V.1I<L$FZS4&;1'>!Y@?M];4>,KBHO9L-3NUY8^!F6Z\M)NP!^.,5CH<M0
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M 884&H.MD"KK1+&,:6#>L:<K4F(M?Q!^DX++:DILMT>;O6M \*8)_?>NYYO
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MAA9B6D(&,*&9P9;VGP'F-"]$_X(V8$9ULCNJ:H^J!,;) +!Z]+)F#<RN>XO
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M*XYQ]D&G[(@&%GP[%"KNE1&1ON\;I&7KR3R<@B4'4>[4='J% :]GE-Y.+1I
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M"]1#/'F;>\8+LV<=+1;KDI KJ6ZXT+)2K1+]SV$N:HT25]A.[KSKK$=4WA&
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M@==3H"W9W=I. \;0T"AN 3DGJN4X'^0_#8J<D7UY4;*I4V$Q1Z8YZU95KO(
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M@5TZ1Y^2^,DU6XKJHL<A=]37U)+? 5[F71XUI&<6*V%3T6JXOH;#4[U[+L_
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M$%EY_0O7W$N<9A@M2=[>A6^;*6K+5GC&6][/:)LT+RB^7=&:R"O>^P:0W9W
MU;BV$GXON#7DCIJLO,/R[@1B2/U)2M)IU 'MB%Z&N,NDECH7."6+;\,D^\.R
M+E:L\J:QXE_=2L7E*XU+S0Y%>Z^+G99_59#*?H'!1I" (WC(:*7AF0!&:G4V
MY<J-N5H#'8 4L&<S_34KJ880_4O$2:?$L1[D$'OY[X]D6]C.$SA& P<)Z-KD
MM>?.K"O/O@&_CSW;3. .1B4I>*I-*!ZCU->8/V7EHQW::-86F-$J*"09L!U8
MUM"!$D5AT ;X.9:B(_W3,N'(2-B,[P;]NB1T*\5&.7W!\F;\6]JSN<LR<P2Z
M%J^Q[P.AI*C"!YH1^@"O@Z\/>R48^(F:=&BW,1M^?V*>!2M7ZV_I K2&OQNS
M"&)H-KJX)S"AA7#:%Q!)9] %->ITI[4"LZ,5UM%!,)#--ULPZ1GL%[_+R2:X
MJ3J86J6_@3FIX43V*$UKS6X/4H)%%,)1[1^L_1"IB9?GO*(:^BFD.;#\$?]*
MUD*85P ^:#RI7$F,@ARYIL\42^1R3]<L8EO75SCCYN8R_6<J3W\-&S!O<#ZW
MG69"V:N=A/:R%V(DH-%4Z_X9K.+F_+!%=LG4A?P9<%Q3J%&=9EZ>%SD'?SA#
M,8-:&=E&?]*G&9UZ,WN<+@2@=4#?S]7Z;/94M.72H!N2<8<%(-8*<C;?JZOQ
M@*1^*3*T&R:G-<;S*2Z[7?W/$3LI(8J@B^MTWB9N9QVF7O@8OW3@\^&KFLB^
MD1%VPZ^,@Z\&Z.4;>0R:*$K\5( LP*M\M,&Z7?H2=#KFOL#?P0I FR=P^8"Q
M((Z;,^B+>$)^P8C_!,Y,?V/GYY1Z41%U'@E'9WN^APG"C+8BY0IGA_CCVYK.
M+?,+^\I(;W2"N9HU^ARJZVKM:K0?@.KY+DSK%I(U9<<$KI;0QIG*])=7EEQS
MZ_IX2:BJ9(+"%Y0EQ&S=?+?)[],\W9@?C$X982&Y2=U[5ZH91HS+6)9U\ AK
M2?8:Y"UT4C'PY6*T<W[K%<"$=;AT>>J,X0)X"M7%[>X'79/%LJKEO&3]/2 N
MS!"52*MY;1.XOA+%W/:JO3). 1O_ED54^(D)41[9.?>]WN^9[%M9U!I\/2/C
M[&SYJ25_4=(NZ83'WT_@/D=*3TZ6Z%P'^X&3&_/$4;;C:C0<Q;)4=@:HF< 5
MZ'S@?]$>J3U 5_>+6DKQR IYLUR N('IP,&P',STJA_2 H$=ZDLW%$H-O7E]
M<;*L-+D("SMT&M@24OE,P476IU]S>]Y@\O$#^@\V+D]*I,[7F?U6X^QNTG2V
M$3*HEHLP:")@-(4&92']K\3!;\B-P#_,C':^,S3^I=E[U'_>VYYZ?M3Q_L4J
MSM.K(&K^#!'",>VEYL@E6(N:'(')(JGM!"YN F>.Q E)#^.*6'[:E2Q':,<M
MF9-G4[V"SC<BV:Z?,H'+1 =M$TEK1+JY;4FUSY;/0-^S>[D/?;"IT+F])>W@
MP[@<_H)%A0K0F0DTC9-S^>Z\C!^IV[XXW,ZH1, HB7>&[->,M8ZMW^*W9N 2
M[WRR:#BV3$__UO!M(.Y1?MP'GG[6)OK("57*2=7^@;='HQ+C/E2R7>))T"9N
M_]<.F>MH%Q2CX'(.-UIKZ2PK;!%RV1V":H(J_F)]8,%6)="BSBL9>V^H.)9^
M>2IE)1PGW!*?HY+/O-6XGS_'_\(F_#GD'FJ2IHT8D=:155<P(.Y UL'K$SV5
MO'9@(#P4\=9ZLH)A45;-24(6]^%0DXH@O\]V0<IY\;Y:&V>LQF7N1-SEA\Y2
M>.X+;^Q\&@OV,/JUJ+&['.Q/TA3JSP$)/()NEX1*1(8TQV#@5%AKI).KD-OO
MRQ"!)JP%/9B8HAB7T=F'!8=9@((\=:2C0BQ36Y]?>+8N)S8W9#0?+&4%8=.:
MCP */_:[XMMWX+*H+A:H#6._=IZBOX.:LC9 V1E9YY6T/H;2-<TKV&NE:53G
MT6.P^SK%3,^/R(NUK-F4&-FG)<N?+;S\EXI]%01&_'NQN/D'J$T1D7KI&@"A
M[84"M:$8A*D\X'P%IUG<MU4NX:#S>L_?W,6<P(D&DEU@O_9ZZNFR%]^:0&N2
MV8),AO>%]/J'Y/Q>Y+6F!+,O@#4'N06K41,/[8DO@D?AS?J-DI9^8EJR*9#F
MX)I.)?>SDB2UF9W)-"/$5N>] #D9"?W,-RJ:?:DMU.:!F%1LV);FTX_EN&C4
MY2;Z7EK5SM5ZH5T"R]I6N/8&0FR;+G!DV_<3#!&.4&!/L:AZ>8,5!ATKJ)@]
M/*UT]K1PX?H66[.N*<_,I'\[_[ZZQ!WM!&O*1W_!+C*U"LO+R4N16NTFNB0<
MG?26;XRDH02=%^2:Q;9B5C>-=X_PG>&B:ME5LX6@A<[?97E^.T/Q^-@SN575
M_(6[*^LCRZ-+-%5IWX/^,Q(-^JG"F*%1G_[V43#=-UQEK777@7HNWX_=,>[Z
M6PWY'$,2X9--ON%%;"_FD>30?:$Q3<[SW9()1.3H45%0?EO\=?^RR7L<&'N[
M)W"'WSMJO/55 EF=P!%=R10IP#S4@N4 ^XP&E&$IXQ"K>:P@CXJM==N1O?KL
M:\.#^,ZC#TOMN_#YK U5N92U^_-\UK1=OIOS83B9C,R2MG8(>M5*#-9>PELU
M-5!<OC>G4&J)&C$EZY 2Z"?F[5@H9 OT]0*$)2=T9EFAPLFZ:9JU J^;"[KA
MVPZ)FC/K%L68";]('<!F3^K,]PCFU%FPIUPJ$D\=+G75-QQF3[G8S9^I,^[B
M>R#$EHCP%N!W4ZR5%?'%ZG26OV*J'-:D*7Y,OA5TSM-:=\IWRMGY U\>=8]K
MOKZ2,.[4WNJ_1!_55;+SV:](=FJ,QP&GV79(]7&H08%O;N#8]!)!'"L$;7&>
MWS7UZ9182)K3N%W>C1-=[ HVM< P?X$<8^* 3  :\IV8WS5QD*AM)6,#%[66
M&B!#Z[L:O7D14;9G$NJ_^]''_9UZW6=V$>.G%MSGG6N#25( VLCH?2O8H^YC
MM BJ>Y%<GB[\<7<M:,7DA<,;:_>5SGB][ZTNJ>)9);V>E,8B.KPJ-4!2Y:Q?
M5 NHYL]_\YS>73_CR<(DP.27$[CS\R=P]>6RL(^\\'O"+4?$W^I.T@^H8^.,
M!]4!/QL2AL7/*3LY/MDS0IVCXQ;F3=_=*"X9V(QL"7WLD1A[].X.*J+GL!T1
M0/9S5 G1FZEFW8DU@%F"=)K.(V5O_+_+!3TUF3VUZ>^*-IQK?"PR^>-/F_#7
MO][M.G&"35)BDG0EY I -]D6, >IY1N)_\6(C_]:PW%2^Y-LN[E/188<7C3_
M-%<\8/LIAK1L6=EAU9L[<8*!"SSI)RTIZLS>BT279V79.T+,5R\?/:>Q2:Y>
MWP&%IX:<VF,PO"3 $%//MB].I@7\E[L2_K>?27M.3/,LPK,%W!.[#3HW!QA@
M@/1=/?+I?[A1TH*PB="#\>D;>6N.?/[[CY4)4:G]IQ*=KXQ_UWVF?_=IHT&;
MQ-F#MA)=Z(VPD[?UY<+Q5Q5E44,KDW=_77GRZ\HD\89P*9\ .]45L#RO,6\,
MD Y(DJ_ZA-=A++ CX+NQ\OU?!-Y*]Q)"KE QL/E<8V3]B5KZ5][M]XDQ5_;-
M'MA\,)3Q_#4]^LZZVN]5_9VK5JX"(MPJRV[^G^<LIN+_P8\$XH8Q\W!WGH8=
M08&.\? SN@AD":167LK$I_/G,VD;8&X6M:^<C@]^^U=CXIUA<?W\J68WS_QI
M;(97SQ$[VJ>6?'3_^P^_Y ^85OSRP+W4V-XEK?.[KD%/D*]II7C_S6 71NOK
M(O3OI?XEUIG"F,72;6WM2T^?"_7S&E73O5Y''JZX?O7VY^)CA7MC;R4<TSSJ
M<4A\V-<?,?#'HQ/,[8:'U[DX$F<<4Z;,.=P50.0_&=..^5IM7C]_UYQS(6O/
MK7.?N[\FRN)_=HCD_^MSUWC%TW9@? +WG+\<QJL^:TGQ#J^JY2]3-#E(5/F(
M[_3KX(T1WQUW%,$UJO6B;5N,N_MH'0MD!<O>JS)#RUT,1X_--'/V/"M:_E-%
M:Y/JB$.:-8 IV^LSJ8:3GEQ&EY,*9AW2[?-X;DX5*0[G72M[F'Z,.QU)IAP*
MWK2_*/0:SOWC\GM^;1_L S:\QE^Z>Z[H/!_:$CK?V_Q0W<!UV9%Y,?G/H3#[
MTYREZ][O>K*,$=#]%0U-!DA@ B&ON/()K%1FW9.+25].7,H>4^>5KGS2]55%
M!A2[P%L3N$2T_+L: 1.!AS]5*NUL)$ES"'&YQ11J. BMG)FQ#MDNBR1;] \R
MKU"E<??,+1TCOE-_I)W.3+^P]=2MG#G7>-\UO"X&,H\TRCFIW8N^Y4^%G*^;
M8TJ)D&Q:K:3EAM\\0VSIG^Y99EU$; ._+;1B;[>/.67,:V.&Y">QEB4=6G"\
M7SSG\45!?6/EC] _O[VO.)Z<^RM[6ASS!?7((9\G^KJYR0,'S5=&5?Y*H6^[
MP/FQ%/HJN,$4KNEF!<D;M(DAPO'W%[)X-[]<9/5*$[H3F2_B;B_+2.N,/3G?
M\)_[3IXA#[H.+?1ZLJA=&O;ZQ\CJN(0$^K?>70DC!9/M MI[V[ND]I1)&\?
M]>Y]4;OZHHX="Z>Y'OT&'(YT5\>"D>Z9-ILW_%]?S,\;=K*WU?R_KA'_3\_D
M/PV^&(Q+G@H>71H5W4![:-5#'-2,?F; ?DPUE\=:<2\J'7R@HY=-&I_V"(?.
M^4MYY*DE\?G'OSB\NJLW?[[".TM10?3!24UF9X5'Q>6&I2>++CS+:Y'#E]?M
M@1/6>^87UJ4DW-30CY.C/*I>YEZK^H.YXTE?8#C_;@]='%G#^?8<KDMG!4$_
MVZ/G0_B\0X>3I19,VLZW7E$QZQHF<)?,P]?H5HN0\)\$C ULT1<)Y'\#L2H_
M$;J@&Q7#?DJ>AE$P=B0EOFQ+I\ZJ8P)GLRRG-7W;0A#><OZ[N^.IQ<Y+./;Z
M2D!V_N($;@;XN^_35+970K$;,)45'92+>J?^?5I+RFVTO)A3T#"#66-NM?0%
MD75V??.D4_@?AG&QC%CZY,*_%T<,]$>8AD32]TRM=CS2/@4W8UK&K)/?PC[]
M;=OL/O.5Y^[#\UV/A_3=2XB;]SJO[L#%B^^04ELY,/JWU+M=47MXQ\W2YZH&
M45"B0W_/6.?@C%.I\==B#)V6B+KS]#NUT(W_%.?_?Q_>2],P!(/2T>84#%<-
MN*CQ6[/!I8Q"32E)FRK.DPB-)W F%UCA^BS*'U)S0E'!-4).C!!;<^/%D/CB
M_7WO':I]S])2F -MQZ)-(48>:V_JY+'WV9F-?G>9Y[Z^7E=S?M,;]8W.FO,5
MP5Y1KD/216\66J?O-ZD,7)NO([W7_=Z[>Y8@P#<2?K^]7O\7G]"/^ M)=<YW
ML'_,=[AUNT+IY*]1O*%X*BNBPR:-T,R.<C-? '*[LYSFU(3&)>33[>O7IF69
M6J\B29N+W;+5.R>E!ATNU7^G33LX@7OTL^D7WX3%1&"HFS9=E]H-QC&("$_^
MLTCG#OFW.(CRJ'/*BQH)%<+K2':S S%]?<"\)PJ2.?7A[>"_1L]W+#KV:(FN
M$^WE&SQ ,%HW>1V<P>XG&8.RVR1+G0&<(I16E^O\SN_0GZ^EV2,D.4_(,&,J
MUVQ#*M$5$DQ2A.$YV:@+U:6GBW5H<.&B8T$UIVXY\#<A_MJY"*C9ARD468-T
M"M5*9ZA_@(FH+<./2JFO==Z\+W=@<FNI"3S4=!WV605FNLH/U)-0=W6.(_!H
M B?WAH,R]SDO7>BX__3'^)&J2B?7O/ 3/CPY)F@\QC\G:9] Y;DSX;#L1D#A
M2/?P#\V.ZJIY$N55&/'VOG?)K/N?YU> L2/U?L&\&R,/<E=?)1U99^IZ^4/Z
MB=M/,EYDD7W?E9PZ$15;A ]PVGCBY \53817,6Z@O8+JE-81GA'ZDDM ?9EY
M4M0$UMJP7PFFD%FKKWVF>KRID?8-:?([O2H,,998Q'9%>O$,9-4Z9$GER!:C
M-;'.2QT_K.USH[U4#V3(@2*V";NG/^4T<(#65ZWIA;@BL"]? 8P.R;E94L?$
M,OTM=/9GU!?9)8N1ZZTCD9(;(PXD3-C*@YA)J^ (#"FRH2HH)?_RF::[Z9M"
MS[=17P+Z>FG*G9+WOP1ON>^ 0O 0)\/90@+&,W"?3U36PHZ*NE$A=&\]\AAV
MEZF%4L+!P3D()I^F\@5E]/%/:<YI-P*LG,!6Y_F< '=\MM6V,TXE;SG>7P$S
M=-9.5@A"E]%R+HX3<W3$&*78_+/SO(?04&'R16@H[X>7Q.OZ?7.75@?/?WT7
M/3%9'WTT]<.29QT/OZ)N@D1.KUH^U"Q&YI-T-I%M$:31G]J]=-"2[XVV#RY
MKF#Z92>R3V!'60?UZF)AO)!$P@A]KX/FB5QJA>]\])=A,Y48,[M]]>H'SU[Q
M5#2YQYJ]6H..WY<Q(63LUQ2IUEIBZ]'LS38=+IT"<4>?$%O;X649VGT3N/V!
M@RL!QYJ5AJVE!#A(-Z=0GNEV#KGU*'ORM(^[]GDS-/2QANB3^D_2\)'RL6_
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M[.[!U;%T;]4/*&(@HK^DX5[)N7\?.OZYJW[OMBE?"7;V3_&_<O75 ID L)K
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MO[3KAZ4UX<VD'$$M1UB2:"TJYG$JP#B>,=IYHN>JUJMP*RUA2IVASDW80J&
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MQN^O4.DI)HYQ/;-T88=]G^$XG WC&???7PXTD1Z.29N"@PMF+SGRU-I@VQH
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M5>/3/)3,)NP-=CD(M<JX)0-5,A3,;,?,;SJ=:1_2TMY;E3=?5/GIX\JTG9;
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M7+? JR(=*\)@::@,5,8*=[,8S\\4.\ Z.6OK$4 KP"W('%RVTUEV.QQ;0OG
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MDXL8^><F81R29LPY'KB5^GS,E9_;D69@9$[E!,@SH:;J#8N.M04XC>[I;25
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M*^0O#]0NVHGA2N>$)8&W$Y=0-JFHXR+M$5B7"#([4,CM@EYC CC1B$?S3+S
MS4RV]"XM,MOOO>I.(S7+C49L+ A['V/2/S=Y1BDAKR YH\V&\GQ(:8ZYSZ#V
MA<)T)R3"5WME;&>JWV,GOX+ADD^4=)?R?E; @J=<C,42"3Z!VV4NG'#HDGSY
M<O3SL:'$%,V [AY]C]0H2^N];3;"QKM(1OJ-OA5$0AUI)$:4G0N[1N);ELA
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MKAS5YP#!:95,\:K<#%>6$#A$9<(<M51*<GO;7E0P-HXJG)RHC7ZA%:#U68Y
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M!*.^WKNZ,G0W++I8;YC#6LU5:N15T#13)!\VUOXY:58&\HVMX!#O=(@ORL-
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M!07P\?D"/*T"Y/]S]]]:_S'RW[6!\M0#(, &W*,TH*'0 U )4- (4)X& $
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MA,@S)G9K93?995UO6G?.3'E(O9AU+FQ10=PCYL)8:F-=<Y_R$>< -G/?#Z1
MBL'9!%<SKX!D1H/%1Q1U6M<6_EA\JZ--L6VV=$G9?#0ST@&>H/13NW:5ZG0%
M3T]7SL7K&VU%NNAMW 3QY<*T3#EY +E<&RLO&0<JUK74O5;0I#3%0]$CU7$7
M"OQE=9O *F4UX9G<D#.+7IQFBD=5<)J^]^0<8\5K,CQ:X%CWL.;RK^W%$^BV
M48? 3@'N$45S^(3D9X/8:J=L=3I!A#6XFKDC'3-MJ;-=\>SWMSJK7U31CXE;
MK[A'CW>GQ^!I>QJ=H@H*;(/,YZ,V$PL+[8<;P[=\5QDPNZ@+#?Y)<#=GCY4
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MR67EV.4ZD@D6FTQJ*W&E)EK(^5N%GE&'^&V=J$(?+2U*(XIV[8G%/3]_R!,
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M5/]X?H'\)9(TKL>]6][@!@Q?+'14MWX&45KO(7R SN/TME(UU603!R@G6\]
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MYLV^Q(B&/7]2%+UA$CA+V6K5%H?G(<_>S\]9SC0@\$/-EIJ,RJP(2X9;!!6
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M\47Q:/P&\#*,%2*ABW=;+:2 /AZW.W/GZ YC^PV5+M*KM'UR_>6?2LQ)AY[
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M4C2*W?<3_]&"TDU/S4T!%:L!@\#WW3].V+YT_789R91,48)6:ESMP3NO-3>
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M4-\"$IBW/381$G@=E41Y P#X'5Y+O]1#VU,I#! >_F,^V-JS@O#,<KP!CMT
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MQ\.(G^!U&YF?1CU+1 CXIN)4KXIF#UZ@IW5/&8>G6F[R&J,SIN$P_[R^I4_
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M>XLZNPYLT)WZA)NO&Z2F!#H-T<YV^#9KD(XEK&(VWO6_*WGQ^6&XOR]?-DT
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MPY3\;2*FC5,YZ5,UE%'F#,8**99&^L)9"[V,#E?$H/OI?_8\YO\>*N_DG$B
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M++]W N(.(=VO9X0A@"UR1Q>$8-*:QNXAD"#[BX\7PD?0ANAC&P^[ZB"A%Z5
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M=E0AW<Q#\D__D[=M+Y?_&U!+ P04    " #9@&I:UK=+VV@?  !=B@$ $0
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M6&_U<ZT+]]NB MH9RKE$*XG7FTE7/RN$,&A(4D8_U?C\9GQ2B/\6%^%^5.,
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M<B<Y?7+ARO6^$F&^MLN-7PNM<?H1>G-A"3 %E"XC-@ES'; J4SR]G&_K#D.
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MJF@"*63IO,G*I2^VK;?K%JSK$F"J7!/T O!Z7V"-#A/"4EF1H3K!RL_;KLB
M*4UB52X,6[<TYJ"E5V]+A_FER$ +1%*%3C'!LM1=%@5.E!'I5;E%T"N0E)D'
M41@E =UIY!$*NX>+[L%Y(4!E&"Q*FK;(R)1"4[B14$AVG3%U?%I#!H_)-+C5
M7;@>,1+ZDV[8]9<P0OCGKS4Z@-+<'>RVN$TY.06(5((UG\,T_('F-D;LQ5%0
M2&!GKY>\+G3Y(!1Y?\NB8FGZ!*IOH ]RP#8)J RDX01D;\[35"4P/@<6G.HH
ML*EOH'&/UM@JJR9P#7;CI#[$]ISP"& ISOACE[3(WG1YL..XF$,D$[;WDPGP
M:'(?:Z!SB&30[T*\SO:G?AW-8B]##2(4)GGYN:93%%;3%%M%LQ"NZO)EY36J
M?!5<]1)P8?L;]P;@:^4FL7L94&!5A4@AG#FGF(LZNDA<=B47^#3D@T4,T%>?
MLTC"1SMJVCF[2"TZE)E>50U] /Z47FHJ9.Y\LH,BHD6>*GNS*[/H*$*$2O$R
M*QD),E.*/B-+8@.ER$SX$8D98I4F%L+5/N=)-!J+Q^K&W76@J\5$*D#+[*AL
M+$I,W]N-HIW%4HE.F:E@?=X96>-7XC$IY&\==IP+JS5DR)#5R*GR^!</]C61
M.,RJ:X0@IH]<ID%./4AV,O0NY0^X4;)[5G\%;ND"<$N:!]\2NDE9VFR;*G%N
M\TY1]P'^^"MMA$ ?SFENS]0;8O!6$<.I(C!UJ-I&3@&52C_V;J\!#8KZV5[I
M#1!E*//H>H#1%+MS2U!7\:B&VF,1^/D37Y80( 2EHL*W!;D?F0B,).&*)32H
MT4G7C%.(%J3@W/4 Z<-S R*$?N+%=E"E02>G"KG8IU=5,/#(6%C"(PDJ:3:E
M]*$WZH;$2T"3Z1;WY9]A/+M!X1D?M6('L3NBWWY0RN^D/)7!$*)6VD)N1#W3
ME3=BF:\Z=>S80KD93*W9][YB2UE"G@*:/$O:VO'1 ^-XLZ&QA"0-/,6*7JAZ
M@V)@'3T%4 HJ>M"=AC1<QLM6&TMD38I+Z79!]R&SW_NA)?P0(%(<I=T-^W;
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MU-=0;8"!30P'6[7_N=;_:_7:T'5'1XW&R\O+.XU^AV@(0^)X6(.$?5"KU^F
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MR,#S:N! 9?73OS2RYLLQ$0'?"YW*B"?[C2LI]HJF8^GS/:Y=;-^TEY"4*T!
M+;IT?%E@T@R9B;2D4/&ZA7C\^+:M5-<*>Y=Q4?=T9NQ#:BY3-(VM\$'.F+'2
M)NG5$\]ER,R&HY'PO>E$/(TGH4!FQ8C,-0[V'L\YW'D;_+[%OI$==^L-7X(?
MLS0@G5+01;$D-EL4 -Z 309))A2 <19YW8B*+!IZ%V-3\KU#Y3CS?4 .7V2<
M(U-.-I(]MRULX'YR[LE3F5-H9"MO\U?+(-C\VB<CL5$707Y/Q%J-0M;E:Y 4
M>?TWY,9&%J $(9VRB6<@#V&\*6/KNUF7%QFL4K(/Q0W0#\M_O$.(G:"1OTC=
M,TW0\7'>R<NWT7[! *1RCU@ZBE7 '?H_$"_3,L(:L83?NQ-_R=)&N/6C@-66
MCG$)U>7"14:3C34T%F-Z()_C5S@&92+L<6]MN?32D=/H?99%#W&2C''52++K
M(5K9UMJ1%5!=J(SG(K&Q?M:;((9EZ1F/N5J#N/02+6=MO? %4BT33@%J.^OD
M/( I^G..[B<D/G>,JX3'X_,R8[C2J)8(KP:UM54R!M?[ !Z?V2J1<,G;Z)LF
MXJL7X-\,#![CDI%FV/W#J*VU(R^C:B&9[[XF8O$:9KLX'^N:H7/WG&Y%#/RK
M]<!IJ&;Q+D22 JNT^#3R&2QD@-?GHTVD)%,M'/.5N\7<^0RVT6'N.:T,3G#.
M6]&;AX7%X+&2D#)GS\M<91<9>LMVQ!I(72I+R%^F_?GX?B*59&U*WC(-X.M%
MP/&NCJE8^9VHALVQ9KFMFN5UAXC]RJJ>>YH=([QO:F4F_59@M%:P7%U8WI(3
MNSY\T197CB2@$T!<@DL$LUPK4]$8.A$.]#')_Q_ 4_F]M:MPD"3MU:P"\3X2
M@3OU_DK,T WGL3A/R*;X_F4.EO@_C'OI6UF(B&@8HVU76E3[?32V)T&#//MJ
MRZ*P>"P)RW!,"YG5;;@"T3:IV%NF\1\@FJVQ*997S(2_;V.(_C*-FMGG>;Y=
M@XA@H!;(9)2@IR0453UB%F29P!27%<&%QNZQ,'AGT\E4A*?2;:@#C:UG@:S?
M$'KYTN#68/<7F%NZ2DR:H0=@_[0UQ'_:!FD1%R07O+LT;N+EJL@6VWPD/31T
M>?59/<Y0+7)M,<DDH0U<0A^"8@MQJ<LT2)Y(I/)\ [#K*%V2^=:MQ7TO'QT^
M_:I[0XM'2T!BHVOXRIE%917%?BM'S%>K#74U[0SZ7D5#>?;JV#*TH ;+33)T
MV$DC!;'K^MA/P6H_A9ZIVI-1H6WU<X;RG61GHP."$I2^RORTRL7;VGW/M/N!
M]+5.5)O?TFU:D:Q?\TJZ_8$UU+T][I0%Y>W<I9]9DX1]M9!F@7[?5JB0*=^G
MFVKW S'*LC4=+'@FZW<+!F^V/)-J9/WJ4K:\K<$L\2Q@93E\S%+\\HFP09\O
MZRC/W-(JD*,VWNUN&E9_5T=NRQ-K 5#'SB>:8'W<X@6+&/@,L(,41+,=@,$2
MG#\"&,8YN(9QN#]PYAM_>3@&>?;J7'+3*&6P6/W9$3=(GR'N$,^W!=)EGY!\
M+!T:8DK/:J68E(!DL,'@4J=1#$%8?  !_HLRJ'#O^9DO<#A,/H>W .[P<KX!
M(8AWB.O&HGZ/($$3.=O"T52WLC\KWW:.&QWG8'58+-[1#'>MJNZ?/'W$;U#>
M*UCS^/ES+"VN1(3E.*S9ULU$6VYS,>-1R(J4KY3"D[4'UWE"420F']"L-;#C
M2.>A8MR;$7HHCB$VNFOL_ B>/J"M76H(= 3D69H"[YY+=2Z]5+HQMJB,R<I?
MX!V_395 (RNKL4DTJNK=./BD!E[SE :?3)^I@1CZ:GPLTV7*4H3XG[795&>E
MY.P+OH '8R_@5ECPZI/1;SCE1#HCZTEE-FR%U\1(Y]HA.93NN<<=7OY:(3&,
MK1U!OT.H26"_]&7@&'P_,-6P IQF>>'[#L!@Q8\'1E/T:B!+&N]F1+QO8S8&
M(?>9\7>?,RQE"L["UP,WS;7L!';]>7IL23\H<:I-6GK:DZ?H.551H\F6#=A-
M:UYI'L\PYH"T'X?Q_1;__35BTOX*42;LM]:*S76B+@-/"IQ6;-^T8XU-0^=V
MP1]'<U^QAU:]5K#'L.0?XUTII##OW"<X( Q_;-"V-N_0K]!>O8GS+_GL,<Z=
M'?4]PO:LR!7Z$H;;>_ *_2W.N,E2)<FVEFK;B.S#)R[Z.%Q09T0/>Q%51=J>
M*5)+Z%74FF0OU8.Q;MGBJ4&S=W/K4_OUC7<A61<36 3;I# M)XR<K8SENF\2
M)O>A9<LX2LELD?:<,L54*VT)T3"SUZ'L6 W1JL-$VGPQ)1(I9_]07]DAG&XT
MW<?TV//N-AVX/E0D(7,]TZT'5UXB\QNP#& 4I\L]7XTPS$'UWS0(^/:5JMU<
MAF$I#DDUN.M;H;6-$G2CV?<R#$YF=9@0AD1PJJ6(CVI59XNSH BR]KG5ONP9
M*U] .R*=N]>Y3 RPUZJ,'<KPSJ;&8<'+IE*3?'M+\> T6OZ+[/QK $-<0FA)
M@LE9HF.<A<R/O;J@92$7S-]?F=*#AJ(6:C7B0F;%L;;I,3S)SF*+6=R8J /.
M1KFR=O1+A$L.[2P<1E/8S#KBLM!Y]&SOWZ&Z')):+G=HG]<EJIWZO179\NT5
M'[9G.CXD18E8[)\DSXIC7[LR8]X]\7K[3'=EV/?BJ_+BT,>OMS@\OP#X6!_F
M7P]*97A]<U;E"=UE=_#I8[9#0X*O9R<@R1YH3PDL<T%F()]5CG7UX\%@D(+*
M_&VF1?<B6(.'8 =N$>&303)BCC22F"PC8F+#97LO7:[7VS2#\1]9BHF?#I(5
M;S#/O@"S\N*B)E,/8*#4RLOK^_7]#[JBZHTPCL@U(]+IHR.9C:]ALP@9=F:B
MB#GQJS&5K[]*(/M*:CK<RGKM>;)%NT%/P&S08\KI+;@WZG%8W2X9[BAEKXPA
M)LQZH08Q9<)798 !S_WP;"TS"4>8">GYJCIQ6P[K-@*T1=3296>HD\O<EFR?
M)6W 91Q=PP3KV(O5(>O&#<'U4M%6.%TDTAXF$Q)QZ#RBR,2K7TA5(G(^G2&]
M^MSY\3 QCU%>+D_-+L2V0@&)-=Z=F#.)TJG["^?Q(V&&#.SM6D*PK);8RJUR
M(^\FX3^EJ%O(VRM 26W"@;W*Z*]OMYM-$@/H,'%)BIN1]/5ULQ@D!23C_QJB
M"&K*;K7 GJH/QY9O#7" O!+N7PV;RY<1L@#C11SL9U>SWN?;G9-3A:D_G9VG
M)K)JW7SMSV7*Z0G.=HDJN_VH;9G5W)F"(313M.G3%\&C['4T0,9IHK><O/9^
M01,H.@^6RV&Q3^P3N/X607Y/T$/?$-WY&B1%CO]$9$WDW!O.EH]!SJMG;F%C
M*?>Q,IOI'59C_SI+DHH.4I-"OUT.PK\LL]WK^O-2-O6?#K+A#N_-/\=:@!AP
M/B"FX[]XU+A..F,"\.",TX7??'C5GMJGVS.38./A?-CE,KNYA3*9MUG?&)9N
MHUUL^"3,=9=5\K11W5]X93%FXF"XWUS;T]FS'1R&F-/)>W))R!M28@#]E4QO
MF@T0/N&6Z/7%Z0:WK2JR3[E4BHZ)I->?M@&Z816DU&ZO(Q+F)EML<U90B],$
M'CU.M0(*<:=ZD"O(2?D*,XR"J]N+A26SO^4,Q'@,V4"T1&<_"4!,3JP9+'+W
M)B,;B1&_ST;?7@P$E[BO]!X.+PXN W()/:*MHB!CA6N;-2'[2-01B'DLJ3G&
M)2UU0]23-%%/C9='QQ6\&.1'D:PC5G!M0;*@M)=<US4UG(FM1]AS)HA1VXR'
MK[TB;6 # 5ILF%5O8N4R,9Y, X,2YL,N$VIC_8;\ 3>BQ-WCTR!YRF-D,18K
M<)JM-T'ZE!.=TW@(%*8>&+@O=QF:+^;($$80IDO"3M5_T_-=69U+S1>_KH&O
M)*_!MV9]:A:?*21OT=H+B7F#'H"]@=NTWM;:\^SRVMPBZC5;P/CV:2OX-KH6
M:V#4A!Q?@3MD1Y ;0%O/=)E8S@UHDW%X7Z7(Q.O%5%4B=G,#/F;%55"4N9[S
M%/P" NCXTLGFP&O"-%V#M 7% <_2+NJ2FZ51DXF[APS_K7._@1)7HQ>K(L@V
M?4&-T]6M%ZA)>$3NA$%&*@];BS67R,M\X4V<+/KC\2 8$BH3:$L;]&.6AIYE
MRV'A^6U:'MZ2"3I674/5&^(A_#Q.KV&VB-$:NLIR*]5-NT XK[K,9&#0@_8E
MNNM#D-?=U.>IMPTFYL2O&A4M@%Z5%Q&N8XA":@2T%3;#CEHDW/<#I5+7='N^
MSW8 IEB+SK;%*H.47<)P8=*_]/KDQQ/+WMG(F+%U.^X:@DT01W47>-?+I4M^
MU((2@R?[IJ.;-MEBT9FL**0]UU*4EQ0--J%UY>1$V"??6CD,6GF^]7*M*#H_
M&Z28,99VWB%PEU5U_JX#Z-384F+*3^JIWGKA9)0+L;=54V06AG ;)#D)L(D7
M,8AF><6,,X'S>/!YL.G+EHNJQ<.NHG$PBM[#P&E:!H.^YP:0VG)DXBES%*J9
M[K=!$L"G:MNW#CKJ=F0U;A..,C6%*0N.L/+&<//13_&-+G&O[R;Z6XD.I+"D
MAGTWP^TJ@. TV,1%D!BLB$#W@>[C6)M4>PY/IS%9 I9T=!E.:"N>Z! K!U=)
M#V;/U2T9.B4GW+U2DT=I<!B4>L6,>BKHJKX :--&A#M*&A&K%@9O (MGD%Q\
MD^H"/=3 X.(B$<ED3!+ERS4ML$E1(JV!;)G;W# EZ14G%$,;%--.0&G2W;"F
M@1+Q$JED1RB6NM;,<<->9"$2@@J=&FC?>;"OE#?Z'G/JQ,WZ"LH.DBV>"*L*
M,+._]E=34@MN#@R&*RVPR)T,@_WD@/N403_IH&ZL(F>;(*%UJH-XZ\M)@MV>
MN^F^+A1:9]HXGTT>Y[,.SKS[L*;)<M[A3@%MWO?>*H)JH<Y%0ERF4=LO^W&+
M2507P[QZJ<X=EO-D,N#;':AW?Y9!UEI6:)OD99YO031+HPOT;T_70>Q+J!1&
M?#Z>F!4L#669>$Z[99)((_4\3N5=B)8\B,Y?IN4Y&I250ED#7G>77^>[\C(0
M[RCC:I(<LS4E3"-(0U!2E+(U&)^.)TI=&G@N$L;?@%O4?@8YCJJ>+V[RK1KL
M[2]'?7X(,>^@8.6J6-,Z?P0P1';'?/$Y@)0W=P'LE,^GC3T-#\D[I-4CNU@U
MBU.0!V6T1(KL8Y:>9FF!?HT&7=8!TB8KI#>""K+U!H(5=K[B4AF(2S K"AC?
M;PM,[@XS$U*8P0S&Z1:7*4LC+*+RSR"JTBBRU$/TLH.Y# __/*2,^(@ [5'W
MG)/C</U10@#ZLK#@KFX&KLJY.)H?> [2=2L>"EXV7-EU5EZ=9*(BE<-'7L/<
M_<FE@9K8BM&\:H&BKLWD(7^11MSK5<N;CJ3+P6AP6VFHU71DIB5GRRJ-^.<Z
M W4@M]1MJLQ%Q9FH%PB3PWP:$Y !PIEN,,7OGVO!69"W5!<KBTI(\D:M-N2?
MS:!01;P2^C=<H5N]L9<>A2"-/@-<"A)$LQWZXQ+4'H9K&(<@KT+XYALR?>MA
MO#?8\7_P<I0\S!?S;9$7B%6$89,=K]YY35:'N.UYDIJW!-7@XK)\1;D/<ISU
M1"I!S+#G:$E"7-^]>?N=,_AL\3\6E]ZPU=L^7JS)6B9X<^"S$F/"SE^86'R,
MJ':+R24CA-]>F3OYU7J1P06(T4\GJ9=4N!_-DZ8?M:0D:(DW) ,OW6J<^7D0
M5^1Q3&%&-G29EMS$#V*VM1Q)9YVHCI/G?3S! WY4G(*4+3F=:-M$BBNORDV.
MP^=HU0^0E\4H6OD57_T3=@-,4K>I\?\<5Z U68L]6D:-.&GNO&HZ>2Z?^9U4
M4W35HOK69VA3.85L<7/[R:0#M*R_45&9+VJ@,!6Z7Y-5F80_A(DP81)?4J9V
M-[J#2?N=W/M]!O+K+WE2;CTPW#Y#I60]L:/)%I79RA1ROF"D&?.6E35D8<C#
M;K&"%G^5CM4E,XQ;/\X92XI$U?MBIH27+'>UL1+-(0Y/G\A"4N7:4R*N^<6D
M+*XQQ+C/\GR[+DW8!P#!)T1?V(%P@$78(/>Y(G=%+V@EM RY0^DFQ1"!G= %
MEG-14RY598B4PT)6&K(\%.4S!.SP)G]ZFIK<'YTV^#M0]%X!R^RNZ'3H/0!K
MK^4](>*XKU^3II/>YMR>?KWU2Y&"2BFLX8)PV,ZO(PH/!;)T!"'9Q$]/$"=9
M463KRB_FN/4;C;;O-U^*AF@+A@J8K4+;=]G&CVAZA#V[<(5BZ2/E+""(G(K$
MD4QY^?+Y5B1F; 0N'UGK<0C\UIQ_K6<$W]*78F8,[E]UD<OA;*E7WQG(0Q@3
M>OCA: -"1/'G#&>!)[@@;)\=9R+78,U7I<HAXM>1@$SE!A,+HJ1[%2]HZ]+/
M0N"SY-W/-E#^ L!MQ<?5R^XLWL412*-9?HUT$KKXUD>0)\FK\C5!\2M#+RZ(
M:&#CW\3YEPL(0)WX=!,4XU$!LLQ-<#7H"4$J$=&JA[UN7-?L\5JLP"GB,DOB
M"#<IN8C3( WC(+DMT!^)5\VH$YX>$G,'X#J?I1'B)(K+K)L%[\&"X:AWE)JF
MSZWEMP ]^=IZ+C# C??6&(,7INJK@PD1#G^8T&W*5B7G[HUD/).3IX^X@3:X
MR^Y6((87VS0D0G3Y@*',F#6OA-%7#G/[O=,&3EF.ACN(Z+'B^%5%@S5K-U_)
MIQ?=#:J_/!0><EPM$(>O/9I+Q$OC%/^K1.J52=EVN@$Y0!"L<-$)L -)ML%:
ML&9(H9R\U$ ^<QKT=>7>2I$#R]IFO@6DD,=[D (8)(B)6;1&*.) J"+>@8H/
MQP]12DSY?CP<M@9T)6')[3V+?MOF11T>V;.['=J/(D;&DLIDY+ZB(@ Y56#5
MJX&M7\1%5*]VVY7L[Q!Z>4!V4'X"B@< TG;7:\_>"7GV=-T131)!&IT$":X1
MGC_$Q:I-BBTD9:>#:9JV3'%9QX+R(MJ?T<;1=QO(F$,TA;C GM=+I*1V<;1%
M!PS?&[ (\GN"-OJ8;)37("ER_">R4L@J88_K/6C1TG[!*X*#IND81BJIS_4<
M\-Q6\>8N.T^+N'@2WL6U12J@Z.>*+5S43%F) !0>L)9%R+TMVQ2BETNP+3E*
M!E J"_-T%0.<21QNL54^7RSB$$#A_4A6;+S1/01Q#%! M=BX>)GNNXL)GL40
MA.B?C,FD,Z#[BX<!*71!L71]_!$\?0C2H+SI7 .89VD*$ER^%*D PNKM*H-%
M@>Y,Y^M-DCT!<(+NNXO8X<UR"(^^?0W#[5E#LK*8)2#FZSK+T;0P2_@G(UQ
M# 9'5!'#_N)A"<EL3V^UY=QQIHQHQ?1Y^U,M%HIH;+6O$#,SHF7Q)SMPY+*B
M';@WRR>9@/HD(PS.TG\PHQ.49:QR6#!\H8(G-L.DASP;&F%%WLUI@:RU6!9Z
M5K;=Y=-[J30I'U\9W<>X*4..5GN;UD& U#%$ZA@B=0R1.H9(N0^1N@V2 "*3
M^3,RAW'T0&5(:\1(R8WDM["U@3 I2<!,.Y3IL<%*\F%][+6;@@F),%&QL%T
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M%._3\J--100*^)AME<:F/DO3;9#4501P]0!]V5#&FHSFD09'JJ2LGJ-#M@2
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M->G<KC)8% "N21>1N,C)HVJ\B$$TRT^#?'7^^S;>!8G3E$4EIGS+4^OE35<
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MV"#5@T('GNK,&;&G]@>YCO<XFP]61>3,!*L"TH:PNDV3?1@4@9!AV5R$U[G
M58*&0;A"_)D4KE=A[,7^;. J(F<F<!60I@/75=E\SG"5H&$0KA!_S.%*K-,4
M>QF^Q,7_KV,Z["(.Z/^HR;'W(FI_V'13JA'DP ^N2IL$LR'O KT(>"<OJ6'
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M^UGR+=X3T7C1<M7]O9^LXY#I[N;#+$<@'4GT#-3LN!EHOHF?!?ZG 9ILJ4S
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M-J=/"+)^]"_R&GV@GSW2RPRL%5U@=![(ZK#+.*4H2^E2C7/A;</<BZRB%:;
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M2W>"!SC>*-S:GYU)=ON;--Q[.5[$P<WN(0K]ZJ'5?9)[D=KBEW=A6^YR<J#
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M@66;I3DV^(:X$'A*OW'Y9+C/UL9[X<XTC.-E=G&0W7KT;9-&L%2_E64Q]@B
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MZQ: $$D,<N/S.CVD4TMX0!"5_I'-U?S!70=?I;7-(,;#X'FB^"K)^G7,?OU
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M4= 7!@"#SHS'')N7:1#&7EFIVO(Y0CBX@Z.OB [H*,$_Y8^=9W*DD$FQ?:@
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M[(M=QHJ+OT3)%M-W9JV(V"]=VND:#.RI1FWF3V[F#.-CO4[QVLLQ<]\_)E&
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MY_'PM2S6H/A!"9@BIXTW%7$\)6W?F9?1Z7OCJF<1['EGR2N2Y+9IF;'*0_#
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M45*XO%_$.2O?OZZ[;0-I7P5L!/5=HGV8\"\3^6G"ODW&'R?JZT3[O%@<! 9
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M(C*R3G$\RSNI'<I5WE4<:4&%K]"\=R'V9<,,NT>D'_K,CV&XI<\;<H276GU
MKZUZ5TE,C^$CFC=[^(S5:XWHMK[,8K)XL2\P"RGU+65DX&5%<]<#7[4BHAE>
M*,UXN,8TV+A!#;(?5>11[]I34E-R47FBY@]]]<!?;!6X$-N.!\ALP:7<*8/_
MD]N((MS O!UFE,YDR!Z7KL926BOP)'" VZ9YU(#%2CTKG$/8^'DL1]#@OX3X
MC"#G48$7D?)+IYY =0JVC>$_@!GZDI7\NJMRZ>YK0]:S=LOA;OD/&@7^2T7#
M, 2DMY!%<6DQA<V03O*+3*HR8*$S G6FCU^9&<B/ZZ=M5BF<*^?;1A(7?AQ;
M,)5I6%!)F.(2[-A7>G QY.(3%Y&4?8-?<!+&"^B4)Q@HM4U.58VG4Q]73C+)
MS";AL42\AU37X6&TK-#<T&Q97B]>:6#F>_.$)K:T12RA="',5J37@LH0W+F6
MWIFE*M(AML.*=)S@DM\M5_G_'"1H."\B-[:PWE43G$0-O<HUTQI%6;C/-%H7
ME0%'J2-]8<_\Z4*QKX-SA9PZC-.1T.0I#GU""ECE*M2,JT+,9-X92#)?@FE]
MJ9X$^]BRG3X@@A_6==O]N+"ZOO$\A\_S**$EWKA/V1_R"+EJBA92T9@$[AOZ
M4M2'MCQ^J1IA#&6:*VL*RY/]Y[JA>=&MFB=V(M=-UAQO"@ PIQ5D#+ G;-W<
M4_;_.90T?*H?F(*R9D<7:]%P*B'\P.R/_H3/Q*#$4V/?#XL<M'&1CG6 $^,5
M_VG-!T?8-=*IX9&\'Q_/'X410APY&R+AU2;9V=+P49)<#I.3FD8!X, 7XLV0
M?4FC+YEE^.&OUNS9SQ[Z/%3S\?"U+?(B<Q]]/D=\-I#B^FU/S.*)7Y8OWB&$
M6<YXKR!3PA-)K%Q[&*?-Q"5QA[E_34:SLI]_-:)9T[\DW;P8+\@0V\F?C@'H
M@X^P=*(<,3$UPDM.;5F/R+D"<,6$G23'E'X9J1#)PUWH19^IR'QO/Q85O6-7
MN/.Q('LK$PX1_0DC(  $6@(D"*>!&\@<Q::Q,>=()_&5^+[NNGJWVCQ _N!@
MZ+;YGT53V( \/93\ML.#6O4R8-]%3DY3[A-U1+.W(#A780'$7TT0GJQZF7<3
MUL5D8<5Y,SG93I5=;-1.B*\+@1A\9XS:$+"#K[1Y>WJ%@D LRZ3.0TN*<4P+
M?M4&2W1+#*OIG"=,O69/"EIU'UZF!>XM'I.^-1'-+6';R7TD5@Y,OXB'T53'
M!KNL >I'/&*']^[5#E0QY\'-U!>.E23M$$,_(CJBJC)>ELP#/"R Y-Z+24U.
MIW;9UQFELB'N*3,=MOV$L3-W=OCN$! IIJYE#PJ1:PQ/=\#X&9?_92?;SKQV
M9GB8S_@81OCN>4..=%?+J%WY!0Z8*$+]U4?,VM+B.Z8N@NO7/G\E.;S?9TY!
M\J-(SQWF@1\?Z^H9*LV)D>M H*)0<Q1^ZCC-NLU*X307D3<E^X*H[2>2$J;X
MJH7ZC@U?%3TI>[Z0G+ZVLP6?/J'XKNK8/!?L%113':CH6R\C_\3*@GUZ/-RF
M-D8^U?LH*P=KYS%QH%GMI\-W.'2L3*86]3CB84;B[C1Z)%]>(F^0MY@@$'^2
M[S)C2[]'+.F?,'#T@H&BML#01.FJPFNG@K.*JE65<7,9\NR&LPIV14U2#8[.
M4#RCA9$V)2/D\Y$%&@18Q_K(UU:I#I2+^-,VLH#%6GY"[%_QC:65&KF$L$[S
MO<V8!XQ7B0Q$XV"1-8S\P :_VM.&#_&"(7[BV%_WWR!U_Y$_7_#?6>)R/E0N
M-Q?)"_E*<S=7YS_P.!8-'CJRLIPSO[YW!8B'K8B388MBP.#^\Y3^NXBD_#Z'
M"TS"^3DHTS?=B19")QF$'!376"*,>D/7WI*WJ!R4T&Q9K'!>:20,Y8*LO-NR
M_L:/34L1G9 ?EZ<L<@("]*LG008:2W#QQO)I3-D\ :785U#;]J9@#UQVBO@3
M2U4KLVIOT@DP!ZQ+V<5.NO>:#JB@Q1&U4&/*)=H16(0>7-42Z+8,\(@I,\;B
M#G.>\-6LQ?^+JB]PV3+59,?UMZNO]:%[8#I:4P#2ZV/'GD9?JL)2_,4%TBW3
M*?KR.AS8I:=/^ ?(\ 7"/T'@&^XR.QB8WF<+R7RC7T[TR1]A,Q]5GY?Y-IKU
MU@F_7;!LT>!;9/=C2;4<K8 "H=ND>7*)I$#VH^>O!7%\$19J#\<QENJ@P%#3
MD>O=KA!#!?P&_J9^9O_2O,/SDY,'FASK9]U3U7-4[?8O]+RV>0)Q&+S.%'"Z
M"[ER'S.V*W;<O,?VQ0TH=_!@W(!>7M.)_+Z1(6 BCQV\Z_ZXP[Z#*'Y!>)=I
M[&%JH3NY,,0>X#>9E>*>,DKL1?XLXF-H\<)4X:*[I>XJ.WT/&74$?0AT(JP7
MIEG"S8LI_@#;6'90S>YFM\9I%1U.-'E*>*QY1<Y039ZQ0O%;-^>)-B&$EL!2
M[6\^I[U)(L7V#=%.N>F(3<N1E:64:9I4%;J)<'WXHJR5T57W,SW5Y+/]QD>T
M\LWBV)BP$^25SHX.3O,GVNP4:-K/AXSO5)KW&8J@0_+D<==<<B($J RH<@,=
M7D1<4!)H=)P6+I3M'*Y-:_M\F:6KPZ$0B\8J4'OU1^&T7<@^H'!,]#XV8:P?
MIGG=PXYY, 9Y1\8MN*OLF(5S$ N88K$&WPA_Y,(/5,-US#8=J"6;#5UWH*90
M53RS@>*9XF>LK/CY8K%K'/.$FK"6@*5NV%55';+RH6A_OVTH+_/I#M :0GLD
M6C@W%@L*!$@0H,'+H.)Y 2*YM$1KS9!.RL1>$W-!:*[N:$D39H)\,"!"4L^+
MBPUC(OS\XM8J%("[4%C"467/&FLO]DS)>D74)L0/<_,RZ3#MS112TL2(D1\;
ML(/N*AD;%9,JP]W\&^[FYX%H/W PJ*+Z4<6AV?-@<.8QCE7[',X14VHM)6?7
M9;$ILB%H1&9LF>E:3DU%HZ&*N68J*^X'W0*?"4(_(L_E'*8=>LALL24_7=]G
M;;%6F:C@ ])+8-NFD7?H\VV5C\Q6[QL)-,3%D'V* OPGTPWYD_#JF2DY8 I;
M5=1O?.?-2=^>L [H(.T.%@S]PLMJ.K/?[:'*VX<,$/!:;YUOWI#H+1%?N\:H
M#?$Z^$)#(=5QD65-RE85'E$F8&'7FNW1'6%,OR*-I*Y5<NG-[[+:YV)Q2T^2
M4MC->X;PTR;%J&$(!*U5=:,EZ-CM'G)&)2XMT^\M64I8Q@L[+RYCA8_SE ]=
MW2?W>/A:%FN(R(/*6D4N4QGB?))#9S+JC><6#G/F]5!ZI9%VHUS7NWU#MVPL
MQ8O$FW.^G/2F<J-@OX_,T3L>0RXVTR/IK]?-(2M'@ /2O^8,+)-=)K@-LF@C
M?E*=AR7[; 1ED%2[,-,6K),@GIC6Z#TDL3LS-/R\)5_RLLH5W16'G1-V3-;_
MXHVP Q7T =OE:K*4"F!L&N#N+&PWC>9'NRVG(S:N1CM+"<,+_D]6';+F^.[-
MN[_ZW\E:0Q,6+[5<C5$;@G7PE?1TG<*3A4K%3Q#8%H(=:^?"?C;X.$XJ>NTM
M!OMJ57%3241MGOXU))%4X#G$0;.75'TGR)W_?1002F*+^*0NI/*9\=*0\MDM
M_2[J3X'TW5G%-ZER,?+ZFX,I1+FUU-^7GU7]7>1H7TC?<<H2/P%C:MM?.^K:
M8^W^ZW!=>PM?B7<UMXN-*@#Y\=O&Q9%P=Y(Y=KN473PF%K6T1LJ-I^\P#]HK
M[](?=^,S#1W[U<F/2^L(""#5 ^7J^;FASUDGH@6V=9G3IEUM[G:[0U4WQ;_<
M5K^^)]&[<MB$H3-FS$N8-4,%CY5&\D<YW[<6L]A["G!.4+U)Q@_\0O-GMZHH
M#JZUQ33XBGSEI*"JUBL1. AA%V3+Z2W@<(MGWG/RS95@T@? +:4\&V^W*]HV
M#*K(FLM,1M5A(5"*#C[LT^)E.O&MI/O.Q.(0=<WF^26E3PJJT]D=CNCN1AMO
M86^B6R*I[BH5D5B' B2TAOB&'V/4QJWCX NER(<].6MUZ-J.'38\#R6$0^4I
M=N/+C*N';\S+CD/.CSM38O:-=]'IP,SEO\V*YN]9>>B+JQ99J7$ROR(MHT=>
M@.!0GY:1'*VDQ<9YQ LC?!S/%6S*6(+'K,R:@K:_9L\\XN2!EDRG[NO>!TK:
MR,Z$]^898;+_ '6$'>T6Q:!QSL\02]J K1 6ZHD;-PJ-=L8.Q@_.GR\<QT:^
MA,3314L^T&+W]="T(F9S\Y$]D4NFN+>:LFZ[]$?=P## .P).0:NV,J9](,"5
ML7VCI)#0#_I(FY=B#0@^+Q"4%#I616O2-U]"I3 K!^:YZ6$T;>S)"$/);KJS
MFLHF]0^69\ ,<>:(5XF2!UKPL3#YZ'Z%V>JF>*VL1^Z4A8)$>;D-ZY,1PDK]
MCK#D1%F 4.>GCFUZK-@EIXY96'5XSF:(*2&PBCXJ2XVFN0"_/8DE _QZ^#1N
MM7D"2I:+9%$]_>4P^PYDZ+&$0IA.1HR9"+"<3/3&$>Q'61;.'.7JYQW0'\8.
M%@R1>UE-=TA=[6A3K#.5=L%N.H$(LFIRMB;4OUPEQ51O,G17L"B*@/PWXOD4
MQZ+I"9TA&40WS;6 ++FK)H_HDR!"!2TP/D]M%4YHT$68%>.$$%8!YP@SV:'X
M0%_8DP_0/XK:;6C@;0AOA+C7]+%:S =31I(^C)3141DAW;ZS9YE$V<J6R*KQ
M=.#V=6QG#]/S\3.M: ,ZQ1C/O%<V'KNLHZ<Y09X%:792#3#R&8>1'\RI;4]^
MH>_5D^03/L3.$'NR,ZV'UOEC7S04D.*"Y1Y$4XZAAY8:8@[;Z<J><I;PW5FS
MIU33086;04>QB59KB*^E&:,VGXMVOE+%7O!S]2@]5EQ[O\^. &VBIP):L1]Y
MQ]Z%)QXMJJ]ZO2!*/LB8W8T7%D5JE)[=/BL:.-@ R,29*]*W(H#=@@VR,QJS
M_6RW\972ERWO$Z9:7.6[HBK *--QP&KAM>4+P+7X96?NQ!YW'WS9G #:F1[%
MGK$%9@@EU0$U!I9IG[[5LT!T6L)Z+, EYF+#F (_OPNL2>HN)1!7;A3YK HS
M:#^_8@63:,:@ZMEJLRG6M/'O#]G(+.&64/K&8'41.SA)&S59=Q^9%M \;;-J
M5=%_T"P@5=:!@-[0D(YU(1"@>F2=S+Q9-,.2DR7[\@Y(('%Q;>T=^"GK#DW1
M':^JK#RV10O(F!)/D1^=RD<]^_&]DX1))BES/W&/1BDR;Y57WV4U1']]GR">
M\-O[9)FGK'13O+#URC27>P[KTWM*G^HN*]UW%._%]3C13RLXRGOBN5S\'!EZ
M0XP 4NS:]3'_Y_7Q*YA$UWS1 ,[S^SIK1#)(UU&Z:AX/7]?J7P^TW0/^$GMH
MW=;-"HRID-([J@-H=23K'Q% V?PSI/\.J1NB?XEHG^+Q.OW'R&]#+4:D[7QQ
MN>DKY#M-2FHSK$QPO:X]!1EE&Z9KCFN%X:1,:0.V'[,F2VF]!^/T^<$"%858
M4 W9'\HO*M IB8S)(>NL7!]*<8-^'8/,FNBR2\ J,*UT4<)*O1-L0^&8![,0
M)UH)]\3ZX2NH7I;B)V0BA90FI<'/*O"^JA$B="@N2GJI[ZJ^/!)32C0"EJ"H
MY-;L& 9-"W>\6)*>?8^4%V *V+Q"T=><QJO>=0<.UFQL$53P/;:W( ZPV@S&
M[1MOONB2&ZZFY6*>MDU]>-[.K?MA*\73"5(#8 ^[ +]):J]D"B3NI3:3>8>%
M_A0)#CNX'C/+_@T/0ZL/:KVE^:&$2!5&\0C1DCQ,C[TS'[C667]IJ1UG<=O0
MC:#R^MV;=__Q]MU/;__]CS;_MY/I)O.[S1\;"-AV!$E*D(BC:,DX38[:P<E!
M>;TO8!>75PM^?.T9DSYX[$X48CJSQ".%H)6K=VJK!'-Y^$7_;B@Q9'HN,+)Y
M+#R8D^%A-=6NZ@O <4S;F]A:QZ+*\0UVD*UU]!9#CY/'U*^0<9[04)A-_=?,
M/7'B^DXRJ=1E2WXH*JT"GBUM!]E_-%\&]MOV5%FFM<1'P:@I$\P4G!S9"N/#
M3\.'3KO:[\MBS2O$9G^HFGC6K=(WY%@TS:@N(-8FF [>L<;M/)ZG,SX"ZA-/
MKCD^T9;=^?=URPV7_;OS@ZR&"5\\48$\\2/IROF>.=((W5(C3( RJ)2*-M&L
M%XH\KUAITS0Q=<WS%HM%\3Q#W E3RJ_RUI]SQ!J@YQCU@S3$/1E^2IN>!L<"
M .F0A-DQP15]\3=G^AP VO">'#J1]R5#9_D2PPQ)"K)FS$.D,!(^K[JL.X"[
M6;M/K,&JJAUA#9%+Z4[';!XN5J82GA;]-']BJN>AX8%H#Q3 F;SE@K05KW4D
M6D_,$FM^GMQ+W2>#M* @\+I^.\^0\':)AH2W<88$*ZN(L"!13Y_I.]:!)8VG
MJ+M9BGF6VI])*>/R*OGXM]4+L (4UM5K92]87/$$-SOVR0BQG_ \4D"&?Q?P
M!JO-0WMP3X*($V!ZD&S.[=*L Z;Z8^7 .(P\?"9/0@R B\V"MHW!< LBWF+M
MFU,D8=]1I\LTE4E;C\.\@9HV):C=XR3(_JVI5P;51OS$32YZ[)9MEVKAL&Q[
MJF\1[6.$?TU_[(N"8?*+1/LDX=\D0U@=YE:_O R-<^)[35.J908N^W5'\YL"
ML-BJ_*H=2F7J551R^?=_%+3,72M)$2.*&GOM$JV:J%@U$XJ$DT154$\2@K$4
MSA!ENI?SU+E_5WVLJV=([-5+U5I+VJF("-45S@'HS).8%68*8J&[(&?&C,4*
M(VG=7N7F$X<%^/K>Q_HSY:G,O9KOT8'2W9RX?9L.IA,JN#*>_K[,UB(3+R1\
MD4DPM)^^N)'R!Z8,6&3N833A@73_<"-SKY_JI^;XN7ZI6TK_>O6>EO4WO_"U
MON"58+V)ZDY$_R68/V(X-(^F:+%@8J+PY^C\E"O^(%\R I/!E^,5$19%^L3=
MNNWH;E_6/#7K/:WHIE#E%N\JD;VZ:GR8 D#A]4""?!4T^GC6HB)[D>/+WHIC
MU &L7-YHGNWS.%=F26U?@"OI ]7$C3B%$=B%.HP[J=^N;IZV/&WU0Y4S79RN
M^5'YT]MW;][]%(K%9YT)ZTV@.^']R9C  F+QHQ@TW1KQ8D&#=X8% [6CV'\@
MLO@E*T_*Y^6USG@A+?B!#I06?-\$60_?/Y'22Q:98CU3-<MU0*T>]2:R^R@M
M!CML(8Y!4^V>(9>$#G6>T\9SJ)R^=)'A=S_*&DON2AS&:?H/ISPD?#5. R(>
MZ+J&Y#3X!0]-'TQ!;OO*)$:$:$1D8+]F3$-\V,]@UF)RF2FHU.&8([^G:2#B
MX;@]"H(""HMU"Q>6K*(^O'G G-A+LOB7U&GBB'$ISQ-M^F>4A+:0#SOM@.;6
MJ6)3T/RJG5&^0!'LW[^Z0_H56?=42=8&*AJ@/;-.E8GCU76>B-'T5*CUS.0&
MVM8-?:%EO0<VY'-QMKK:2&I<9<T'>D/ZZ%*KW\7*(:R[SI-H*M<8NYIHL6?K
M4^%G#YF/?N55=22KBLBNX%GUA&2E![8.L&;<VY'"2 T=3[D1NWBA/1ZP/]]H
MZ*!!*T_SB= VEXL;5PR#E_ED+[W/=?7W&J[L1UH5=3/VY?@"M(CH1D0_,O%C
MX21X17!DQ@I%"$";C?ADE^NZ:NNRR,$+,.!<:\#^(@-[5F[+7)I)D9[GC,R1
MNJ)3(0,9GB6M):N(>L7XYKP3IUB'D9XMM.3*]'M  /H@ 8#8 X]OC) Q]KT#
M-HC\ELF>V*5$O6S9S^P(2:2TEG_@ABA*I1GJ?5VY@SE5V]X8QUOCQNU8AF^&
MY3AY3)M"*ZX%RC@2]T),4 >T5M!:!HP,$FRNC0O' \_#<=KP<6_U=05LDJ\:
MB/:%^+U0#78K%.P BL;-.0(/9E0&60''Y. Y?>'? O./I7PHR88/HC_Z+BH^
M^U+Y#C.4ZIG(C14?)DJ??W.+"*T/4X5W"<$J'FY,W2/$>;(@UO$1WRI3TO'F
M0'_F;]382ZWM74Q'PCH3T7M)EYR%N="5YY1'<D7PNM[M&[J%W.D7F4UTU75-
M\?70\1CH>O6MH@U37^^SQG/4CLC(=(57)-,HD:XF-:<%!_(^:Y9PCL[DWA%6
M<8H(4VU$=8Q#EG#6W_OA]"#5WBS<@Y<?-.;!?/1[6$U<""[&)MD;'Q>#1N@V
M./IY2WYHR1?T"+[2)69I5P!;OCW?$$G8-A[L(G=SF\R@^#-XA"NNU!VZ;=UX
M$SV'QD1KC5=_QS9VX_#P<)@P:$'N+I'OT.?#N00M6ZMLC[X]IA_#SH$A;A^C
MJ:[&OK2/*/23YP6,(2M]U0+[/D16-^I[C0L'IH=L\3!C2#_,>6*OD413BSC.
M53'N19WEYO =FJ*#S232ME8>^)15F7BBWS?UFK8M&*@[^@Q89OEMF3W/J/DP
MT"(],3)0([\!/2PMYS3N]6D\1WY)XZT/5=X^9&"<$?%;3I08:$A$2QG-A@J"
M-!VW<6PY.$,+.^F=O"/#V,QHD\'IK=LE%QMB$N Y'%D2);1T+DYER+RG35%[
MTJ@EOKAHAG?-CX=KFIDLW(S/GBA7MP8OKQR8(IS]MJR_.9"_@;66\<;Y @*<
MN2[[HZ[JW?$OX/9^_>:GU^_^\R^<,+08?GJ]KIM_#DVX;SQR$(DU%=]87-"-
MJDN?"[&!7E:O*58=@HAIGM0=",DAM2L/8G6[XSV3?,>>RO!FWOM\0ZK#*P)'
M3\?M U1UPB^$:6?&Y=3S\IY\(C9,#>+/B5O*TR\A9-!UL.K-R8:U5T&6V#Y5
M*Q=.^;M93G>3C8.YO:5>W-BC0W \9-X%*^&@FH5G,&R^@.<**_4U$U76Q9D8
M%%\+!__JB>+4<0G-D%*2">05<P=X^/4Q4 &8AR6HMF8AX+1SXAB\+GHO?PE+
MC/892:L-O"UXI1&VCS]FZ]];*)+:_$X[Z6!UWCP#"!)@;"DJ_-SC=.#7(TJ(
MB8TS^#6.NOG"2FFM^%(U=%T_5\6_:.Y-.G!>6CH%HDCPBTHC0A05-#=$/*/&
M#,Z545HP!&'3'/PG0SB#SW[[/#B)GL<1'9@6W"D77C.NG67]%(QZ; ?LBH]P
MF=%G\/^)#X)K.^()SJC].Q/R7QAY_OB&'WCP.7]<G_71- ZQ<X;HBD3W&:U?
M$47R%=>7!JKDMRO+2WTYQNNH)1)AP@Z+-)5K3N+RL8$\/'X)Q%'(MOS$A];8
M:%^VL1M'NIO!M,]U7CQ@M;FN*S;?'22!:V99)\@7=.+&K*&;;KU&?U-XN;*?
MZ1&"2%K 5D"2PFW?O-!;QM\3NV-:R#UFR^;7HML"G#8;;<?HP!L(O$YL!$YG
MCP*&E10)D"0Z30)$"5 E&EFBZ&)ZADX6AK'MSA1KL@#FX# E$-U]UH216R*G
M7L'V29IFZ//RIMTFA1/FW"W,E%M>=Y(9)>:Z>9#1NF&A(SV%9>$_NYDTYG".
M;!);ZGAYTWIS:+7".^\L$\3;O:XWKUE+,[\9Y9J<#MU^,]H93!@4=U-_JQ[
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MZ_'A(,^;_J$4PNFB3*U;!/%L0-4T7>3ND+\H;* *%' M\$"9L[%5\%.EX?!
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M0_A.3J796;+RD765*@O[#?L'O#R@Q?\'4$L#!!0    ( -F :EK!HDY<B5,
M  )_!0 5    <'!B="TR,#(T,3(S,5]P<F4N>&UL[7UID^,VDNCW_16]?E_>
MBXUV'Q[;TQ,SNZ&ZVC6N;I55:O=Z-C8<+!*2Z*9(F:14)?_Z!X"DQ ,@ 3")
MI,H5,3'NKBX"B;R0F<CC[__UN Y>[$B<^%'XCZ_>?/WZJQ<D="//#Y?_^.K3
MW<O)W?GU]5?_]9\O7OS;W__]Y<L7[TE(8B<EWHO[_8OS:+VY<_T7\]@)DT44
MKU_\WW3]_UZ\?+%*T\W?7KUZ>'CXVJ6_D[A^3))H&[LD83]X\?(E7;!8\CPF
M;,&_O?@0A2\^./&+-Z]?O/GN;W_YR]_>?/OBT_S\Q=O7;[_-/OFWOP=^^.7>
M2<@+"G>8_..KTDZ/]W'P=10O7[U]_?J;5\4O?I7]YM\>V0\JO__P#?_M-^_>
MO7O%__7PJXDO^D6Z[)M7__WAYLY=D;7ST@^3U E=MD'B_RWA/[R)7"?EF.R$
MZX7T-]C?7A:_]I+]Z.6;MR^_>?/U8^)]E>'MQ8N_QU% 9F3Q@D/^MW2_(?_X
M*O'7FX !Q'^VBLGB'U]M-O<I7>3M7]Z\S9;X/^PGO\:_GD=A$@6^QW!_Y@3L
M*'<K0M*O7K"E/\VN#X>XW<9TV7L_2HF[8O1[Q7[CE72!5_\)#^%=2O]_3<(T
MB1;3#6-!BN;$";UINB(Q8\28K$B8^#MR$R7)W+EGVQB<Q&@CJ!/?K1RZ>A1X
M5" O?]_ZZ7Y.%WD;Q=\HGZ5EB5><>>!I<^XDJZL@>C#"]^%C#AT(;)F."I3!
M*7Z?00 "P)F3^)1];F.R<3(&BA:4>\K'OO)#*C"^$QSY31E>P^6AF/0#73&F
M2T]<-]J&*;TI;NFVKD_43]"R!"237H=40R]]*J&3)"$:&&Y\""HZE..I/F'_
M80*Z<P(MZDL^!V/>&T*O'75P\E^'1%"F:;=Q3 ^F23C!IZ_@KDR^^JVS9SI?
M$Z;#5X#@9.I=&8[\UR$IQ2\;JHZ(1\_'M,PDIJ;@4E.?M:\"I;:XD>JXQ76>
M6RS)@Y^N9B1@2O/6B5,=+::^(NS-NU[[*<<-4P,15Y_T;S>^<^\'OM8)5-:"
MNY=G)"%.[#+M=4%V)(@V;.?+QPTUIS2 [E@&#MX[JEJ3W#B@FTV\M1_Z2<JN
MW!W1!EMM-3 UGED Q<+7U*=;DX\:UKWL>T#]-7<>J5<89FNK2UWE*TAU2G\W
MVA-R1FFT\#7T5^-#2'$_6'+7U-^,MWJ:5?@QH(!L[Q/R^Y9)WTY/X]<_A,18
MTZ@\V_,_J5^5+4M 0FIFR,_US(]>F\#Q2MVDUCR%Y',P=2FVJC6!;%T$4%-E
M-K<F<)6/P/#6-+@UP9(N &7W5<QO$^!JWT+!E0=G] "J? 1&Q%8#7!-"E;7@
MM(JR":YY"MUUP4C1;MQJGD)I,5!_4,7&U64HC34!=:S$_M4$OGT5,%52,T!U
ME8KX<V!7I&J%&N%1N 0H_[HKXFT#$BTNG-2)PLM')CQ+,J,2K_FFH+ 4V*O!
M82NAE60 LGB=83 ](VZT#/T_B#=9,Z.;VJK9IA.77G8Q\:C0E^(1]-\H^3W3
MD_79#9Y>+0:CP=G:5H.S%4K;Q?&>ND@'1,[\)04U^I3TY#[%A0&5_7'O#TZZ
MC:F)-0F=8,\=)^XKK3=.N$^X"5WB#M,#&FP"Z+0?P,CQ>Q0)/[R-(WH#1+'^
M&ZKFLL/H$HDS87 (V4J#,%W3S3"%N+K((,!R __<V?BI$YC"VEQC"/W$[]O$
M#R$@;EEL&%:FU+P.64X-#]EPIX.JQ#3Z&(4L3D]WHNLMZ45-8I*8\[G1-@,0
MZ^-V?4\M_-#[3)BRI]?SCOYU22UG$KM^0FYCG_I?.>=,-]PQ,SVS^5Z#'9S>
M<7>?>AZHO,8 @')3*$/& V4&>AD;&V'2I> MK,)!+-]&BM%/@X/UV0W^[ R*
MV"->Q4DVM)F;ZPSE#72&+(Q.T+WJ$!:6>NS"Y!)57WP =5"-;!@?0KC,$*3(
M-\I",#VA+2\RB(UU&R6I,"IC +-\K2'0?$'7#PE/)8C]^RW3\;>4.WUJ6B0;
MXJ;,#T@*<,Q#*@:[#*.O[E@J*!4X%I6G!E(:470G+'!R,!C+@1]C43?899CS
MB@)Q'ZC'NF6AD_3*\>.?G6#;4\ 4EX>_,2](ZO@!O;Z73LQ2X \;YC P>,QY
M5G7M@2@'>)8.V'4@9ULF=$^> Y\0]^MEM'OE[KU7[#3L#_Q8_$CG>VKETE_A
ML9.9GWSYX(1.]K(T";T[=O.1Y?["3]P@8E U#];8)'NVU5T7BO'RRSOG#-U\
MY>(S*&C,$@5T@>^W"Z1HR).0=<_4O1*@E5"/S>L"*_L>/#]!%[#J5^!YLKK@
M5+^"-//:7LAUH51:#%)JE%_&=4^BO3 @213R8'6/H['DT#F?NJ!W+ .8O5%.
MY=3F%]''<+#5729M]2'Y'CQ%H6HLF]%:O 9<U*"6[JFMY"3?Z^-2:&UZQ,^L
M3?J'H[7I1CL2=YB0[$L.H1>Y''=4[-E7@P+F^-I03;:>GY;B_ ?2;F*2T%_@
M/[RAT.0PL:^-RS\K9R6/*0D]P@I7_XWAY.]!Y%9^(6 ELU%<?!4X]R3XQU?^
M(DY>+K9!\.O!!IP>G4/J_?H,XLD]"W>Y:0LJV4*\M#9U'JFIN=YSA+Y\_<W+
MM]^_XANPWSC^Z:4;Q;\>?X4C7!.8 _$-3IOG(M@^5VW;H[U08Y%)7#V.$[L%
MC/2/%:YIUC7GO_&*VOUTO9?NR@^\XNM%'*U-J9Y&;1ADD>OX'U^]9I7M]"@+
M$L?$N\GP+@65PYDRIY#_YN%:,: HR\:8"*K]+%%6LOVK_\2DKIC+JW24X0V.
MGJ8*:17%*5UK?4$VC".3\\!)$G_A$V^28)%9"RA\\59A #T\YVSQIB];& IY
MEBAR'>Y(DJ[M"GASZY*V&BUU11C+:?@60+0-Z2BJ/+9$1UGE\LCI*,)83L=O
M\.B(0\+3HYZ8<'\Q(%R4.@$ X3Y&H5N&R;HE+ 4 _](TMXGE6(6Z-DWIS3-[
MH\4V(99EM;%QV21$(6\7ZU=)VD0<MJ-S&T<;$J=[]A#/WLV8><;3;*S15 Y!
M'NXX#=*V(!),7,U(7'\ZXI?_?.6$[Z/(>_"#P!JINR'!OG[U:*Z 67SKN'XD
MM$OYU)1U$W$]3.2:I=4GSF@YOHA/MKYAQ5Y2"&0BEZO3;%O'HKU/V3 6XA+.
M?>WEO-;KP&R[L8W]L6_4%L87>K5-! +&C@UI.X\=CTR*9J(9G(>:K8C_Z]UV
MLPE\NI\U@FL!A2_NRGR@AVS<"/+11/CLL R>0Y[('L'*:H" ?G$KT[P-CW 6
M=/_H\K&+)$)\N=*,\A2H*L8<V$7=[YY&O*)/^7867,RC"#QCVM?M4.!?O1 A
MZ#:;VX0!0%1S"3PLL[L%!/3K5TDZI 0?T [O2^W;.-KY;/9%<A7%S0:@UDG?
M#@^^ NC%"!W('HL!CBS\3T?N!2(/$#<S(V]6S6']0J]MBR_ YC=X'8,Y1;_%
M4N+72;)EXT-X)Q9[#T^57;&-;C%7UYZ6JGC"CX'QDJ7;F*S][=IB@F1I4]SL
M5Q6B57$$EZ6A1;(9<8F_29-IF!<V)M-%'E6ITDU2^-'V_7@EI_74@(^PA@DS
M%%?QCDRSYD3WI<(_B[DS+3",7[1:,0B8NFA:+L#U= ZDO8!2=5M\.T6%DG5<
M0041>D1W<U@LAW4/NXY7JTKQ!&=&ZHE<E7FNZ$'*!<B?_71%/9F7@AYX2E>?
M^>KC)6$/C.5$_@[QVDP=UC'HTHE#"IG-N[*V,;I/KW9'UM&54_![+&\OASK-
M^CVQ!Z!Y-'T(Z=K3Q2T_M6V?O@T4_/NSMY_?BND>\@P2S6%!)D%W4JOA.M'^
M(U'>"E+2#-H)\8D?+2B&'%H5[M%H:6U*%NCJ$3* C+=6FNG;UM#5S9%S'7HK
MY!HJ>US(]2=SU@CB5;T3!&R#"+/QW67"]&XDD36*.0!B_2E MG^?ZJF\K>U$
MU-;6:CA(#@6^*=1!^&9TJ 6E^/?A'>%W=-X#<"+I^VLOKJX&#K9AI"0IM1"\
M(J+Q6>)ZO7'\F!V(Z4Y["JVZ+;Z@&Q"YCCK<'(3\9@R7MJ6XL3&Z_:NEM)MX
M S-_S0CYWO'#A'$42:9AUJ/Y.CPTS9TN+DCL[[@:L2>N.C!AJVLMZFLAV^ !
M[UW&&"%9,DNVIXCGO17/(YOABLJFN"]T6I2M(@N[+JO2_-\V[<KCSD^,? 7"
M#)[GAA"]#!S&4S@TY#N?GA"6T6;P9E>EY!PH:S^;*V?5ZBUMB1Q1TJ)B&5,&
MT?MV\ND0[YI"F\Q73OK9#X(SPI\0,PCF40;DE(\)%,=G),^MVHOB.RL*U--'
M%=PK7:\2MW(X+SOG&5E$,9D[CZQQWU40/?Q O*7UZC=UN##TLZEDB$KE-"A@
M$+^07,OF;". UU[JDV!O+/4 PP)";!IXQ*U*O^^%77W:LAZ-[P3DA"RT;J3F
MQ/\K8F\P(81(&1R*X& [6ZK"HL8-DAP.5+TO@Q4[OT,7+EQE <LG7;D@YC=(
M?_/R"/.OK[$\OI-6"0QMO4.@#>^]]V0'@<6".=NA#1SL2T'+,E!%<<X2[_#*
M'@30C<%2T(4+]R+0DZA.IV'\]D,GT-B&A#& Z#?-H+PT9AM# +Q%8T,6C7@Z
MG# F$X0-(W6+(H=;$O.20.N61SL4)Q&J5D9I(>"]TZ4 ",X,X@)"'&)7($ 6
M<R59:*%U%9M@67%F=+[P@VUZK%]"H70;#+AVH@&I6Q&*U)_@"-UGPL8A$&^R
M([&S)!PL>T:>>'=T"\Z RA(\8C?.G'B_;1,*%BZ9VZ' OZ8-Z-V!6*B,JX$*
M3#B8JRB@0"99D<R<8OAM%'\C+1W1K!$75K!0,Y@G&2;785M7*5EEN.::/<2F
M;+A75Z_4UUB-K(G@@ HB5M>FS$3X>^H(SGF$!<7(,^1C>2Q1R$WF5D#0SZAG
M3F849D?*3_+HVXWQ"+8?3RBP1?:;WKH(D6B4K?0N^T#6]R2V1E;1WOB7?#NO
MMW1^*[ W@OFYQ]9FEDDJV!K[.4>'GB+,X0SP:_1(.[1(2T0D5>T/UUCE%.1-
M 1?8_E-+RS/+$M@-R2D)I )>L8M6#B!6TSZQR"Z$XA2D7!FC<)WL@=N9S4C
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MV//#Y0'T4NY]KPZM!AN,SG85DKX?#N'J#P"U1J7>HM1,=C1Z0P7 T^ >"$H
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M_?'==K,)?+J1-?Y0@^8)61T='*-('8.P^+N,C4*R9,%;F+NF -"N.CGL.K9
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MD.:[U(E3B*YHA.Y.U0$[&1H?M (QIB(*0)9H1[S!Y0G\3EZ'Z=?7J&KAZ3&
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M[\3+JY2B$"&+W\)9^L]Y.U9D820Q-W9'UP<6.5"0_]&D!D["93D]6RTL6OX
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M^D!7]"TZN";L-&?[CTY*F6$>4>3Y\=4V=#D9;;[C:0,VZB@DG&ZL#337)A\
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M.A@1;S5A^Y.QE8 XT+46\!PU(@;ZT]UTO3([H]0); ;]LN<I1_@\U1$"-(T
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MRV"</L$K2 6\ "WT_> W_XPLG=CSP^7!),BM!#Z^:*!N']T[&_?XT%@:M@.
MRM; X6SM+9^K_?%ZE^CS?'<P6Y_G4"O[SP,G82-9%MDM:;=^4K#W.#TW4T52
MJS 3X1J!^N=1N"-QRC)K/M*[2*>B3/@E<@&+G(-Y)9CXL#A]XCX[<>Q0SHJT
MTM2:7V%W.^C N>"8X,;W$],-&"$=+4-+<*HS)V!]2]6LII;OL;G9+'[3AA!S
M[;*A[DSDW:5.G,(1ZO*1Q*ZOV/&X=8$3S2)L1PK*1'@12,70&F,Z'19X0G0Z
M(F4TBJ\ Z3:.7$*\WN0JUCG-7% E#"%- 1+!-B,[^A..6&/*E=<XQ<>'+K3
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M$%>;@6;5M20*ZQ'-O,MD/2H'DO!?:8I1/5#Q3QU'PBP4 ((>^0EO0$8=B-K
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M)J$WN_ND8S )/SPQ@1,?'FV4]=Q/ S)=7(>>O_.];:?[J#H96;SNV,V;%HP
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M+FAT;5!+ 0(4 Q0    ( -F :EI\1JF?QP0  *80   <              "
M 3RA! !E83 R,S(T.#,P,65X,3,M,5]P=7)P;&4N:'1M4$L! A0#%     @
MV8!J6J8QH(0L @  )@<  !P              ( !/:8$ &5A,#(S,C0X,S Q
M97@Q-2TQ7W!U<G!L92YH=&U02P$"% ,4    " #9@&I:T:3_H@A&  #SGP$
M&P              @ &CJ 0 96$P,C,R-#@S,#%E>#(M,5]P=7)P;&4N:'1M
M4$L! A0#%     @ V8!J6EN$*EM\(P  (<$  !P              ( !Y.X$
M &5A,#(S,C0X,S Q97@T+3(S7W!U<G!L92YH=&U02P$"% ,4    " #9@&I:
MDBGV:CD#  !>%@  &P              @ &:$@4 96$P,C,R-#@S,#%E>#@M
M,5]P=7)P;&4N:'1M4$L! A0#%     @ V8!J6DAZ2CK$<P$ 'GP!  T
M         ( !#!8% &EM86=E7S P,2YJ<&=02P$"% ,4    " #9@&I:>(/S
M]I2H  #,K@  #0              @ '[B08 :6UA9V5?,# R+FIP9U!+ 0(4
M Q0    ( -F :EHO,>S%0JX  .JQ   -              "  ;HR!P!I;6%G
M95\P,#,N:G!G4$L! A0#%     @ V8!J6M:W2]MH'P  78H! !$
M     ( !)^$' '!P8G0M,C R-#$R,S$N>'-D4$L! A0#%     @ V8!J6C&M
MUY7Q#P  ),\  !4              ( !O@ ( '!P8G0M,C R-#$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( -F :EKV+3NP3%,  &9<!0 5              "
M >(0" !P<&)T+3(P,C0Q,C,Q7V1E9BYX;6Q02P$"% ,4    " #9@&I:\")8
MHX_#  !EJ0D %0              @ %A9 @ <'!B="TR,#(T,3(S,5]L86(N
M>&UL4$L! A0#%     @ V8!J6L&B3ER)4P   G\% !4              ( !
M(R@) '!P8G0M,C R-#$R,S%?<')E+GAM;%!+!08     #P / /P#  #?>PD
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>ea0232483-20f_purple_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ppbt="http://Purplebiotech.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ppbt-20241231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:ReceiptsOnAccountOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:CapitalReserveFromTransactionsWithNonControllingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2020-08-23</startDate>
            <endDate>2020-08-23</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2024-09-17</startDate>
            <endDate>2024-09-17</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <instant>2020-08-23</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <instant>2024-09-17</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2020-09-15</startDate>
            <endDate>2020-09-15</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <instant>2020-01-07</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ppbt:AdsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToTryNovosee5ABelowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToTryNovosee5ABelowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToFamewaveSee5BBelowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToFamewaveSee5BBelowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToImmunorizonSee5CBelowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToImmunorizonSee5CBelowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToPurpleGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ppbt:IPRDRelatedToPurpleGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">srt:OtherCurrencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">srt:OtherCurrencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:RehovotMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ppbt:LeaseAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-15</startDate>
            <endDate>2020-09-15</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:RehovotMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ppbt:LeaseAgreementsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-15</startDate>
            <endDate>2020-09-15</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <instant>2024-12-05</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2024-12-05</startDate>
            <endDate>2024-12-05</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-05</startDate>
            <endDate>2024-12-05</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">ppbt:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">ppbt:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">ppbt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">ppbt:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-19</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">ppbt:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-19</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-19</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-19</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-19</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-19</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-19</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-19</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-19</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-19</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-19</startDate>
            <endDate>2023-10-19</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-19</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ppbt:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ppbt:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-17</startDate>
            <endDate>2023-10-17</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ppbt:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredShareClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredShareClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredShareClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredShareClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredClassDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:PreferredClassDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:ClassEPreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:ClassesOfPreferredSharesAxis">ppbt:ClassEPreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-15</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ppbt:AdsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-11</instant>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-23</startDate>
            <endDate>2022-05-23</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-23</startDate>
            <endDate>2022-05-23</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-23</startDate>
            <endDate>2022-05-23</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-23</startDate>
            <endDate>2022-05-23</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2022-05-23</startDate>
            <endDate>2022-05-23</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-23</startDate>
            <endDate>2022-05-23</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ppbt:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-23</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ppbt:ShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:RangesAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ppbt:RangesAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:TryNovosTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:YissumsLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:THMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ppbt:BiopharmaceuticalProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:THMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ppbt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:THMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
        </entity>
        <period>
            <startDate>2022-11-07</startDate>
            <endDate>2022-11-07</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:SalariesWagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:SalariesWagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:SalariesWagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ServiceProvidersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ServiceProvidersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ppbt:ServiceProvidersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ppbt:January2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-19</startDate>
            <endDate>2024-06-19</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ppbt:January2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ppbt:January2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ppbt:January2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:SeriesA1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ppbt:SeriesA2WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:NISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:PostemploymentBenefitLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ppbt:EUROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:CashAndCashEquivalentsAndDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:AccountPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">ppbt:OtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:DownRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ppbt:UpRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ppbt:WarrantsoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ppbt:ConvertibleDebtInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <context id="c380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ppbt:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <context id="c381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <context id="c382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ppbt:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <context id="c383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-11</instant>
        </period>
    </context>
    <context id="c384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ppbt:OptionsAndRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <context id="c385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <context id="c386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001614744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ppbt:SubsequentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ppbt:OptionsAndRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-11</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="ils">
        <measure>iso4217:ILS</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-28475">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-28476">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-28477">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-28478">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-28479">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-28480">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-28481">false</dei:DocumentTransitionReport>
    <dei:EntityShellCompany contextRef="c0" id="ixv-28482">false</dei:EntityShellCompany>
    <dei:EntityFileNumber contextRef="c0" id="ixv-75">001-37643</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-28483">Purple Biotech Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-102">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-113">4 Oppenheimer Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-116">Science Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-28484">Rehovot</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-28485">7670104</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-28486">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-28487">Gil Efron</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-132">4 Oppenheimer Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-135">Science Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-28488">Rehovot</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-28489">7670104</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-28490">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelFaxNumber contextRef="c1" id="ixv-28491">+972-3-5097196</dei:ContactPersonnelFaxNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-170">American Depositary Shares, each representing 200 Ordinary Shares(1)</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-176">PPBT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-28492">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-28493"
      unitRef="shares">517128717</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-28494">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-28495">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-28496">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-28497">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-288">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-295">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-28498">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-28499">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-28500">false</dei:DocumentShellCompanyReport>
    <dei:AuditorFirmId contextRef="c0" id="ixv-28501">1057</dei:AuditorFirmId>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c78" id="ixv-28502">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-12315">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We operate in the biotechnology
sector, which is subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of
operations, including intellectual property theft; fraud; extortion; harm to employees; violation of privacy laws and other litigation
and legal risk; and reputational risk. We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity
measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data. We currently have
security measures in place to protect patients&#x2019;, employees&#x2019; and vendors&#x2019; information and prevent data loss and other
security breaches, including a cybersecurity risk assessment program. Both management and the Company&#x2019;s Audit Committee are actively
involved in the continuous assessment of risks from cybersecurity threats, including prevention, mitigation and detection.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Risk Management and Strategy&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our cybersecurity assessment
program outlines policies and procedures and technology we use to oversee and identify risks from cybersecurity threats, and focuses on
the following areas:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Vigilance&lt;/i&gt;: The Company maintains cybersecurity threat operations with the goal of identifying, preventing and mitigating cybersecurity threats and responding to cybersecurity incidents in accordance with our established disaster recovery policy.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Systems Safeguards&lt;/i&gt;: The Company deploys systems safeguards that are designed to protect the Company&#x2019;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through ongoing vulnerability assessments and cybersecurity threat intelligence.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Third Party Service Provider&lt;/i&gt;: The Company utilizes a third-party service provider to assist the Company to identify, assess, prevent and respond to cybersecurity risks. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Training&lt;/i&gt;: The Company provides periodic training for personnel regarding cybersecurity threats, which reinforces the Company&#x2019;s information security policies, standards and practices.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Incident Response and Recovery Planning&lt;/i&gt;: The Company has established and maintains a plan that addresses the Company&#x2019;s response to a cybersecurity incident and the recovery from a cybersecurity incident, which plan is evaluated periodically.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Communication and Disclosure&lt;/i&gt;: The Company&#x2019;s established plan includes procedures for the communication of cybersecurity incidents so that decisions regarding the disclosure and reporting of such incidents can be made in a timely manner.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Governance&lt;/i&gt;: The management&#x2019;s oversight of cybersecurity risk management is supported by the Company&#x2019;s Audit Committee.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c0" id="ixv-28503">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-28504">Both management and the Company&#x2019;s Audit Committee are actively
involved in the continuous assessment of risks from cybersecurity threats, including prevention, mitigation and detection.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c0" id="ixv-28505">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c0" id="ixv-12333">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Risk Management and Strategy&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our cybersecurity assessment
program outlines policies and procedures and technology we use to oversee and identify risks from cybersecurity threats, and focuses on
the following areas:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Vigilance&lt;/i&gt;: The Company maintains cybersecurity threat operations with the goal of identifying, preventing and mitigating cybersecurity threats and responding to cybersecurity incidents in accordance with our established disaster recovery policy.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Systems Safeguards&lt;/i&gt;: The Company deploys systems safeguards that are designed to protect the Company&#x2019;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through ongoing vulnerability assessments and cybersecurity threat intelligence.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Third Party Service Provider&lt;/i&gt;: The Company utilizes a third-party service provider to assist the Company to identify, assess, prevent and respond to cybersecurity risks. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Training&lt;/i&gt;: The Company provides periodic training for personnel regarding cybersecurity threats, which reinforces the Company&#x2019;s information security policies, standards and practices.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Incident Response and Recovery Planning&lt;/i&gt;: The Company has established and maintains a plan that addresses the Company&#x2019;s response to a cybersecurity incident and the recovery from a cybersecurity incident, which plan is evaluated periodically.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Communication and Disclosure&lt;/i&gt;: The Company&#x2019;s established plan includes procedures for the communication of cybersecurity incidents so that decisions regarding the disclosure and reporting of such incidents can be made in a timely manner.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Governance&lt;/i&gt;: The management&#x2019;s oversight of cybersecurity risk management is supported by the Company&#x2019;s Audit Committee.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c0" id="ixv-12381">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c0" id="ixv-12438">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Governance &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Management is responsible
for day-to-day assessment and management of risks from cybersecurity threats, including the prevention, mitigation, detection, and remediation
of cybersecurity incidents (if any). The Company&#x2019;s Chief Executive Officer is the member of the Company&#x2019;s management who is
principally responsible for overseeing the Company&#x2019;s cybersecurity risk management program.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s Audit
Committee, in conjunction with management, oversees the assessment of the Company&#x2019;s risks from cybersecurity threats, including
prevention and mitigation. The Company&#x2019;s Audit Committee receives periodic updates from the Company&#x2019;s Chief Executive Officer
with respect to the management of risks from cybersecurity threats. Additionally, the Audit Committee, in conjunction with management,
considers risks from cybersecurity threats as part of its oversight of the Company&#x2019;s business strategy, risk management, and financial
oversight.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We engage a third-party consultant
to help us assess and identify risks from cybersecurity threats, including the threat of a cybersecurity incident, and assisted us to
establish our cybersecurity program and manage our risk assessment program. Our third-party consultant monitors cybersecurity threats
to our software.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;To date, no risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially
affect our business strategy, results of operations or financial condition. However, an actual or perceived breach of our cybersecurity
could damage our reputation, interfere with the progress of our clinical trials and/or our efforts to pursue regulatory approvals for
our therapeutic candidates, or subject us to third-party lawsuits, regulatory fines or other actions or liabilities, any of which could
adversely affect our business, operating results or financial condition. For further information, see &#x201c;Item 3. Key Information &#x2013;
D. Risk Factors &#x2013; Risks Related to Our Industry &#x2013; &lt;i&gt;Our business and operations may be materially adversely affected in the
event of computer system failures or security or breaches due to cyber-attacks or cyber intrusions, including ransomware, phishing attacks
and other malicious intrusions&lt;/i&gt;.&#x201d;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c0" id="ixv-28506">The Company&#x2019;s Audit Committee receives periodic updates from the Company&#x2019;s Chief Executive Officer
with respect to the management of risks from cybersecurity threats. Additionally, the Audit Committee, in conjunction with management,
considers risks from cybersecurity threats as part of its oversight of the Company&#x2019;s business strategy, risk management, and financial
oversight.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <dei:AuditorOpinionTextBlock contextRef="c0" id="ixv-13184">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Opinion on the Consolidated Financial Statements&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We have audited the accompanying consolidated statements of financial
position of Purple Biotech Ltd. and its subsidiaries (hereinafter &#x2013;&#x201c;the Company&#x201d;) as of December&#160;31, 2024 and 2023,
the related consolidated statements of operations and other comprehensive loss, changes in equity, and cash flows for each of the years
in the three year period ended December&#160;31, 2024, and the related notes (collectively, the consolidated financial statements). In
our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as
of December&#160;31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three year period
ended December&#160;31, 2024, in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board ("IFRS
Accounting Standards").&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="c0" id="ixv-28507">Somekh Chaikin</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-28508">Tel-Aviv, Israel</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-28509" unitRef="usd">7401000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-28510" unitRef="usd">14489000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c2" decimals="-3" id="ixv-28511" unitRef="usd">848000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c3" decimals="-3" id="ixv-28512" unitRef="usd">850000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CurrentInvestments contextRef="c2" decimals="-3" id="ixv-28513" unitRef="usd">275000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments contextRef="c3" decimals="-3" id="ixv-28514" unitRef="usd">73000</ifrs-full:CurrentInvestments>
    <ifrs-full:OtherCurrentAssets contextRef="c2" decimals="-3" id="ixv-28515" unitRef="usd">384000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c3" decimals="-3" id="ixv-28516" unitRef="usd">376000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c2" decimals="-3" id="ixv-28517" unitRef="usd">8908000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c3" decimals="-3" id="ixv-28518" unitRef="usd">15788000</ifrs-full:CurrentAssets>
    <ifrs-full:RightofuseAssets contextRef="c2" decimals="-3" id="ixv-28519" unitRef="usd">164000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c3" decimals="-3" id="ixv-28520" unitRef="usd">316000</ifrs-full:RightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-28521" unitRef="usd">124000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-28522" unitRef="usd">154000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c2" decimals="-3" id="ixv-28523" unitRef="usd">27842000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c3" decimals="-3" id="ixv-28524" unitRef="usd">28044000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:NoncurrentAssets contextRef="c2" decimals="-3" id="ixv-28525" unitRef="usd">28130000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c3" decimals="-3" id="ixv-28526" unitRef="usd">28514000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c2" decimals="-3" id="ixv-28527" unitRef="usd">37038000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c3" decimals="-3" id="ixv-28528" unitRef="usd">44302000</ifrs-full:Assets>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-28529" unitRef="usd">183000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-28530" unitRef="usd">188000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-28531" unitRef="usd">1455000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-28532" unitRef="usd">3532000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:NoncurrentWarrantLiability contextRef="c2" decimals="-3" id="ixv-28533" unitRef="usd">1149000</ifrs-full:NoncurrentWarrantLiability>
    <ifrs-full:NoncurrentWarrantLiability contextRef="c3" decimals="-3" id="ix_0_fact" unitRef="usd">2518000</ifrs-full:NoncurrentWarrantLiability>
    <ifrs-full:OtherCurrentPayables contextRef="c2" decimals="-3" id="ixv-28535" unitRef="usd">1200000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables contextRef="c3" decimals="-3" id="ixv-28536" unitRef="usd">3463000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:CurrentLiabilities contextRef="c2" decimals="-3" id="ixv-28537" unitRef="usd">3987000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c3" decimals="-3" id="ixv-28538" unitRef="usd">9701000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-28539" unitRef="usd">163000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits contextRef="c2" decimals="-3" id="ixv-28540" unitRef="usd">140000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits contextRef="c3" decimals="-3" id="ixv-28541" unitRef="usd">141000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentLiabilities contextRef="c2" decimals="-3" id="ixv-28542" unitRef="usd">140000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c3" decimals="-3" id="ixv-28543" unitRef="usd">304000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:SharePremium contextRef="c2" decimals="-3" id="ixv-28544" unitRef="usd">147631000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c3" decimals="-3" id="ixv-28545" unitRef="usd">133184000</ifrs-full:SharePremium>
    <ppbt:ReceiptsOnAccountsOfWarrant contextRef="c2" decimals="-3" id="ixv-28546" unitRef="usd">21145000</ppbt:ReceiptsOnAccountsOfWarrant>
    <ppbt:ReceiptsOnAccountsOfWarrant contextRef="c3" decimals="-3" id="ixv-28547" unitRef="usd">28467000</ppbt:ReceiptsOnAccountsOfWarrant>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c2" decimals="-3" id="ixv-28548" unitRef="usd">8875000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c3" decimals="-3" id="ixv-28549" unitRef="usd">10088000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:CapitalReserve contextRef="c2" decimals="-3" id="ixv-28550" unitRef="usd">761000</ifrs-full:CapitalReserve>
    <ifrs-full:CapitalReserve contextRef="c3" decimals="-3" id="ixv-28551" unitRef="usd">761000</ifrs-full:CapitalReserve>
    <ifrs-full:OtherReserves contextRef="c3" decimals="-3" id="ixv-28552" unitRef="usd">19000</ifrs-full:OtherReserves>
    <ppbt:CapitalReserveFromTransactionsWithNon-ControllingInterest contextRef="c2" decimals="-3" id="ixv-28553" unitRef="usd">-859000</ppbt:CapitalReserveFromTransactionsWithNon-ControllingInterest>
    <ppbt:CapitalReserveFromTransactionsWithNon-ControllingInterest contextRef="c3" decimals="-3" id="ixv-28554" unitRef="usd">-859000</ppbt:CapitalReserveFromTransactionsWithNon-ControllingInterest>
    <ifrs-full:RetainedEarnings contextRef="c2" decimals="-3" id="ixv-28555" unitRef="usd">-144693000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c3" decimals="-3" id="ixv-28556" unitRef="usd">-137453000</ifrs-full:RetainedEarnings>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c2" decimals="-3" id="ixv-28557" unitRef="usd">32860000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c3" decimals="-3" id="ixv-28558" unitRef="usd">34207000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="c2" decimals="-3" id="ixv-28559" unitRef="usd">51000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="c3" decimals="-3" id="ixv-28560" unitRef="usd">90000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-28561" unitRef="usd">32911000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-28562" unitRef="usd">34297000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c2" decimals="-3" id="ixv-28563" unitRef="usd">37038000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c3" decimals="-3" id="ixv-28564" unitRef="usd">44302000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-28565" unitRef="usd">7620000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" id="ixv-28566" unitRef="usd">17034000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" id="ixv-28567" unitRef="usd">16320000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-28568" unitRef="usd">3183000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c4" decimals="-3" id="ixv-28569" unitRef="usd">5237000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c5" decimals="-3" id="ixv-28570" unitRef="usd">6283000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ImpairmentLoss contextRef="c0" decimals="-3" id="ixv-28571" unitRef="usd">202000</ifrs-full:ImpairmentLoss>
    <ifrs-full:OperatingExpense contextRef="c0" decimals="-3" id="ixv-28572" unitRef="usd">11005000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c4" decimals="-3" id="ixv-28573" unitRef="usd">22271000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c5" decimals="-3" id="ixv-28574" unitRef="usd">22603000</ifrs-full:OperatingExpense>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c0" decimals="-3" id="ixv-28575" unitRef="usd">3341000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c4" decimals="-3" id="ixv-28576" unitRef="usd">3497000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:FinanceCosts contextRef="c0" decimals="-3" id="ixv-28577" unitRef="usd">483000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c4" decimals="-3" id="ixv-28578" unitRef="usd">2195000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c5" decimals="-3" id="ixv-28579" unitRef="usd">67000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="-3" id="ixv-28580" unitRef="usd">868000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c4" decimals="-3" id="ixv-28581" unitRef="usd">992000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c5" decimals="-3" id="ixv-28582" unitRef="usd">910000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncomeCost contextRef="c0" decimals="-3" id="ixv-28583" unitRef="usd">3726000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c4" decimals="-3" id="ixv-28584" unitRef="usd">2294000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c5" decimals="-3" id="ixv-28585" unitRef="usd">843000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-28586" unitRef="usd">-7279000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-28587" unitRef="usd">-19977000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-28588" unitRef="usd">-21760000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxCashFlowHedges contextRef="c0" decimals="-3" id="ixv-28589" unitRef="usd">-19000</ifrs-full:OtherComprehensiveIncomeBeforeTaxCashFlowHedges>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxCashFlowHedges contextRef="c4" decimals="-3" id="ixv-28590" unitRef="usd">25000</ifrs-full:OtherComprehensiveIncomeBeforeTaxCashFlowHedges>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxCashFlowHedges contextRef="c5" decimals="-3" id="ixv-28591" unitRef="usd">-6000</ifrs-full:OtherComprehensiveIncomeBeforeTaxCashFlowHedges>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-28592" unitRef="usd">-7298000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-28593" unitRef="usd">-19952000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c5" decimals="-3" id="ixv-28594" unitRef="usd">-21766000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c0" decimals="-3" id="ixv-28595" unitRef="usd">-7240000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c4" decimals="-3" id="ixv-28596" unitRef="usd">-19880000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c5" decimals="-3" id="ixv-28597" unitRef="usd">-21668000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c0" decimals="-3" id="ixv-28598" unitRef="usd">-39000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c4" decimals="-3" id="ixv-28599" unitRef="usd">-97000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c5" decimals="-3" id="ixv-28600" unitRef="usd">-92000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-28601" unitRef="usd">-7279000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-28602" unitRef="usd">-19977000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-28603" unitRef="usd">-21760000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c0" decimals="-3" id="ixv-28604" unitRef="usd">-7259000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c4" decimals="-3" id="ixv-28605" unitRef="usd">-19855000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c5" decimals="-3" id="ixv-28606" unitRef="usd">-21674000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c0" decimals="-3" id="ixv-28607" unitRef="usd">-39000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c4" decimals="-3" id="ixv-28608" unitRef="usd">-97000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c5" decimals="-3" id="ixv-28609" unitRef="usd">-92000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-28610" unitRef="usd">-7298000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-28611" unitRef="usd">-19952000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c5" decimals="-3" id="ixv-28612" unitRef="usd">-21766000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-28613"
      unitRef="usdPershares">4.44</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c4"
      decimals="2"
      id="ix_1_fact"
      unitRef="usdPershares">17.96</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c5"
      decimals="2"
      id="ix_2_fact"
      unitRef="usdPershares">23.97</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-28616"
      unitRef="usdPershares">4.99</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c4"
      decimals="2"
      id="ix_3_fact"
      unitRef="usdPershares">17.96</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c5"
      decimals="2"
      id="ix_4_fact"
      unitRef="usdPershares">23.97</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="c0"
      decimals="0"
      id="ixv-28619"
      unitRef="shares">1639566</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c4"
      decimals="0"
      id="ix_5_fact"
      unitRef="shares">1106665</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c5"
      decimals="0"
      id="ix_6_fact"
      unitRef="shares">904054</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c0"
      decimals="0"
      id="ixv-28622"
      unitRef="shares">1639787</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c4"
      decimals="0"
      id="ix_7_fact"
      unitRef="shares">1106665</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c5"
      decimals="0"
      id="ix_8_fact"
      unitRef="shares">904054</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:Equity contextRef="c7" decimals="-3" id="ixv-28625" unitRef="usd">133184000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c8" decimals="-3" id="ixv-28626" unitRef="usd">28467000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c9" decimals="-3" id="ixv-28627" unitRef="usd">10088000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c10" decimals="-3" id="ixv-28628" unitRef="usd">19000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c11" decimals="-3" id="ixv-28629" unitRef="usd">761000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c12" decimals="-3" id="ixv-28630" unitRef="usd">-859000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c13" decimals="-3" id="ixv-28631" unitRef="usd">-137453000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c14" decimals="-3" id="ixv-28632" unitRef="usd">34207000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c15" decimals="-3" id="ixv-28633" unitRef="usd">90000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-28634" unitRef="usd">34297000</ifrs-full:Equity>
    <ifrs-full:IssueOfEquity contextRef="c17" decimals="-3" id="ixv-28635" unitRef="usd">5065000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c19" decimals="-3" id="ixv-28636" unitRef="usd">109000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c24" decimals="-3" id="ixv-28637" unitRef="usd">5174000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c0" decimals="-3" id="ixv-28638" unitRef="usd">5174000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c17" decimals="-3" id="ixv-28639" unitRef="usd">7378000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c18" decimals="-3" id="ixv-28640" unitRef="usd">-7322000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c19" decimals="-3" id="ixv-28641" unitRef="usd">100000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c24" decimals="-3" id="ixv-28642" unitRef="usd">156000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c0" decimals="-3" id="ixv-28643" unitRef="usd">156000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c17" decimals="-3" id="ixv-28644" unitRef="usd">2004000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c19" decimals="-3" id="ixv-28645" unitRef="usd">-1422000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c24" decimals="-3" id="ixv-28646" unitRef="usd">582000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c0" decimals="-3" id="ixv-28647" unitRef="usd">582000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c17" decimals="-3" id="ixv-28648" unitRef="usd">14447000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c18" decimals="-3" id="ixv-28649" unitRef="usd">-7322000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c19" decimals="-3" id="ixv-28650" unitRef="usd">-1213000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c24" decimals="-3" id="ixv-28651" unitRef="usd">5912000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c0" decimals="-3" id="ixv-28652" unitRef="usd">5912000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:ProfitLoss contextRef="c23" decimals="-3" id="ixv-28653" unitRef="usd">-7240000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c24" decimals="-3" id="ixv-28654" unitRef="usd">-7240000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c25" decimals="-3" id="ixv-28655" unitRef="usd">-39000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-28656" unitRef="usd">-7279000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome contextRef="c20" decimals="-3" id="ixv-28657" unitRef="usd">-19000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c24" decimals="-3" id="ixv-28658" unitRef="usd">-19000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-28659" unitRef="usd">-19000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:Equity contextRef="c27" decimals="-3" id="ixv-28660" unitRef="usd">147631000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c28" decimals="-3" id="ixv-28661" unitRef="usd">21145000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c29" decimals="-3" id="ixv-28662" unitRef="usd">8875000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c31" decimals="-3" id="ixv-28663" unitRef="usd">761000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c32" decimals="-3" id="ixv-28664" unitRef="usd">-859000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c33" decimals="-3" id="ixv-28665" unitRef="usd">-144693000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c34" decimals="-3" id="ixv-28666" unitRef="usd">32860000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c35" decimals="-3" id="ixv-28667" unitRef="usd">51000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-28668" unitRef="usd">32911000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c37" decimals="-3" id="ixv-28669" unitRef="usd">126407000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c38" decimals="-3" id="ixv-28670" unitRef="usd">28017000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c39" decimals="-3" id="ixv-28671" unitRef="usd">10164000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c40" decimals="-3" id="ixv-28672" unitRef="usd">-6000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c41" decimals="-3" id="ixv-28673" unitRef="usd">761000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c42" decimals="-3" id="ixv-28674" unitRef="usd">-859000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c43" decimals="-3" id="ixv-28675" unitRef="usd">-117573000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c44" decimals="-3" id="ixv-28676" unitRef="usd">46911000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c45" decimals="-3" id="ixv-28677" unitRef="usd">187000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c46" decimals="-3" id="ixv-28678" unitRef="usd">47098000</ifrs-full:Equity>
    <ifrs-full:IssueOfEquity contextRef="c48" decimals="-3" id="ixv-28679" unitRef="usd">1045000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c49" decimals="-3" id="ixv-28680" unitRef="usd">450000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c55" decimals="-3" id="ixv-28681" unitRef="usd">1495000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c4" decimals="-3" id="ixv-28682" unitRef="usd">1495000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary contextRef="c48" decimals="-3" id="ixv-28683" unitRef="usd">3781000</ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary contextRef="c55" decimals="-3" id="ixv-28684" unitRef="usd">3781000</ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary contextRef="c4" decimals="-3" id="ixv-28685" unitRef="usd">3781000</ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c48" decimals="-3" id="ixv-28686" unitRef="usd">1951000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c50" decimals="-3" id="ixv-28687" unitRef="usd">-76000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c55" decimals="-3" id="ixv-28688" unitRef="usd">1875000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c4" decimals="-3" id="ixv-28689" unitRef="usd">1875000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c48" decimals="-3" id="ixv-28690" unitRef="usd">6777000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c49" decimals="-3" id="ixv-28691" unitRef="usd">450000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c50" decimals="-3" id="ixv-28692" unitRef="usd">-76000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c55" decimals="-3" id="ixv-28693" unitRef="usd">7151000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c4" decimals="-3" id="ixv-28694" unitRef="usd">7151000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:ProfitLoss contextRef="c54" decimals="-3" id="ixv-28695" unitRef="usd">-19880000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c55" decimals="-3" id="ixv-28696" unitRef="usd">-19880000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c56" decimals="-3" id="ixv-28697" unitRef="usd">-97000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-28698" unitRef="usd">-19977000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome contextRef="c51" decimals="-3" id="ixv-28699" unitRef="usd">25000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c55" decimals="-3" id="ixv-28700" unitRef="usd">25000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-28701" unitRef="usd">25000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:Equity contextRef="c7" decimals="-3" id="ixv-28702" unitRef="usd">133184000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c8" decimals="-3" id="ixv-28703" unitRef="usd">28467000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c9" decimals="-3" id="ixv-28704" unitRef="usd">10088000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c10" decimals="-3" id="ixv-28705" unitRef="usd">19000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c11" decimals="-3" id="ixv-28706" unitRef="usd">761000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c12" decimals="-3" id="ixv-28707" unitRef="usd">-859000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c13" decimals="-3" id="ixv-28708" unitRef="usd">-137453000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c14" decimals="-3" id="ixv-28709" unitRef="usd">34207000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c15" decimals="-3" id="ixv-28710" unitRef="usd">90000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-28711" unitRef="usd">34297000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c58" decimals="-3" id="ixv-28712" unitRef="usd">123951000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c59" decimals="-3" id="ixv-28713" unitRef="usd">28017000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c60" decimals="-3" id="ixv-28714" unitRef="usd">8862000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c62" decimals="-3" id="ixv-28715" unitRef="usd">761000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c63" decimals="-3" id="ixv-28716" unitRef="usd">-859000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c64" decimals="-3" id="ixv-28717" unitRef="usd">-95905000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c65" decimals="-3" id="ixv-28718" unitRef="usd">64827000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c66" decimals="-3" id="ixv-28719" unitRef="usd">279000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c67" decimals="-3" id="ixv-28720" unitRef="usd">65106000</ifrs-full:Equity>
    <ifrs-full:IssueOfEquity contextRef="c69" decimals="-3" id="ixv-28721" unitRef="usd">1346000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c76" decimals="-3" id="ixv-28722" unitRef="usd">1346000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c5" decimals="-3" id="ixv-28723" unitRef="usd">1346000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c69" decimals="-3" id="ixv-28724" unitRef="usd">1110000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c71" decimals="-3" id="ixv-28725" unitRef="usd">1302000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c76" decimals="-3" id="ixv-28726" unitRef="usd">2412000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c5" decimals="-3" id="ixv-28727" unitRef="usd">2412000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c69" decimals="-3" id="ixv-28728" unitRef="usd">2456000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c71" decimals="-3" id="ixv-28729" unitRef="usd">1302000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c76" decimals="-3" id="ixv-28730" unitRef="usd">3758000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c5" decimals="-3" id="ixv-28731" unitRef="usd">3758000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:ProfitLoss contextRef="c75" decimals="-3" id="ixv-28732" unitRef="usd">-21668000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c76" decimals="-3" id="ixv-28733" unitRef="usd">-21668000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c77" decimals="-3" id="ixv-28734" unitRef="usd">-92000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-28735" unitRef="usd">-21760000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome contextRef="c72" decimals="-3" id="ixv-28736" unitRef="usd">-6000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c76" decimals="-3" id="ixv-28737" unitRef="usd">-6000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c5" decimals="-3" id="ixv-28738" unitRef="usd">-6000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:Equity contextRef="c37" decimals="-3" id="ixv-28739" unitRef="usd">126407000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c38" decimals="-3" id="ixv-28740" unitRef="usd">28017000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c39" decimals="-3" id="ixv-28741" unitRef="usd">10164000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c40" decimals="-3" id="ixv-28742" unitRef="usd">-6000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c41" decimals="-3" id="ixv-28743" unitRef="usd">761000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c42" decimals="-3" id="ixv-28744" unitRef="usd">-859000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c43" decimals="-3" id="ixv-28745" unitRef="usd">-117573000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c44" decimals="-3" id="ixv-28746" unitRef="usd">46911000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c45" decimals="-3" id="ixv-28747" unitRef="usd">187000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c46" decimals="-3" id="ixv-28748" unitRef="usd">47098000</ifrs-full:Equity>
    <ifrs-full:ProfitLossFromContinuingOperations contextRef="c0" decimals="-3" id="ixv-28749" unitRef="usd">7279000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations contextRef="c4" decimals="-3" id="ixv-28750" unitRef="usd">19977000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations contextRef="c5" decimals="-3" id="ixv-28751" unitRef="usd">21760000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c0" decimals="-3" id="ixv-28752" unitRef="usd">186000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c4" decimals="-3" id="ixv-28753" unitRef="usd">197000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c5" decimals="-3" id="ixv-28754" unitRef="usd">201000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c0" decimals="-3" id="ixv-28755" unitRef="usd">202000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c0" decimals="-3" id="ixv-28756" unitRef="usd">3726000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c4" decimals="-3" id="ixv-28757" unitRef="usd">2294000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c5" decimals="-3" id="ixv-28758" unitRef="usd">843000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-28759" unitRef="usd">582000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c4" decimals="-3" id="ixv-28760" unitRef="usd">1875000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c5" decimals="-3" id="ixv-28761" unitRef="usd">2412000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c0" decimals="-3" id="ixv-28762" unitRef="usd">-10035000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c4" decimals="-3" id="ixv-28763" unitRef="usd">-20199000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c5" decimals="-3" id="ixv-28764" unitRef="usd">-19990000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="c0" decimals="-3" id="ixv-28765" unitRef="usd">96000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="c4" decimals="-3" id="ixv-28766" unitRef="usd">178000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="c5" decimals="-3" id="ixv-28767" unitRef="usd">313000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c0" decimals="-3" id="ixv-28768" unitRef="usd">-2076000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c4" decimals="-3" id="ixv-28769" unitRef="usd">1334000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c5" decimals="-3" id="ixv-28770" unitRef="usd">799000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="c0" decimals="-3" id="ixv-28771" unitRef="usd">-2352000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="c4" decimals="-3" id="ixv-28772" unitRef="usd">-1076000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="c5" decimals="-3" id="ixv-28773" unitRef="usd">2132000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c4" decimals="-3" id="ixv-28774" unitRef="usd">-162000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c5" decimals="-3" id="ixv-28775" unitRef="usd">11000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ppbt:AdjustmentsForChangesInAssetsAndLiabilities contextRef="c0" decimals="-3" id="ixv-28776" unitRef="usd">-4332000</ppbt:AdjustmentsForChangesInAssetsAndLiabilities>
    <ppbt:AdjustmentsForChangesInAssetsAndLiabilities contextRef="c4" decimals="-3" id="ixv-28777" unitRef="usd">274000</ppbt:AdjustmentsForChangesInAssetsAndLiabilities>
    <ppbt:AdjustmentsForChangesInAssetsAndLiabilities contextRef="c5" decimals="-3" id="ixv-28778" unitRef="usd">3255000</ppbt:AdjustmentsForChangesInAssetsAndLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-28779" unitRef="usd">-14367000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c4" decimals="-3" id="ixv-28780" unitRef="usd">-19925000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c5" decimals="-3" id="ixv-28781" unitRef="usd">-16735000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ppbt:CashAssumedAsPartOfAcquisitionOfFamewave contextRef="c4" decimals="-3" id="ixv-28782" unitRef="usd">3549000</ppbt:CashAssumedAsPartOfAcquisitionOfFamewave>
    <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="c0" decimals="-3" id="ixv-28783" unitRef="usd">187000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="c4" decimals="-3" id="ixv-28784" unitRef="usd">875000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c5" decimals="-3" id="ixv-28785" unitRef="usd">202000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ppbt:Decreaseincreaseinshorttermdeposits contextRef="c0" decimals="-3" id="ixv-28786" unitRef="usd">2000</ppbt:Decreaseincreaseinshorttermdeposits>
    <ppbt:Decreaseincreaseinshorttermdeposits contextRef="c4" decimals="-3" id="ixv-28787" unitRef="usd">15803000</ppbt:Decreaseincreaseinshorttermdeposits>
    <ppbt:Decreaseincreaseinshorttermdeposits contextRef="c5" decimals="-3" id="ixv-28788" unitRef="usd">19658000</ppbt:Decreaseincreaseinshorttermdeposits>
    <ppbt:IncreaseDecreaseInLongTermDeposits contextRef="c5" decimals="-3" id="ixv-28789" unitRef="usd">160000</ppbt:IncreaseDecreaseInLongTermDeposits>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="c0" decimals="-3" id="ixv-28790" unitRef="usd">320000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="c4" decimals="-3" id="ixv-28791" unitRef="usd">755000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="c5" decimals="-3" id="ixv-28792" unitRef="usd">324000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c4" decimals="-3" id="ixv-28793" unitRef="usd">3000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c5" decimals="-3" id="ixv-28794" unitRef="usd">26000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-28795" unitRef="usd">509000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c4" decimals="-3" id="ixv-28796" unitRef="usd">13881000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c5" decimals="-3" id="ixv-28797" unitRef="usd">19914000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c0" decimals="-3" id="ixv-28798" unitRef="usd">5809000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c4" decimals="-3" id="ixv-28799" unitRef="usd">1563000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c5" decimals="-3" id="ixv-28800" unitRef="usd">1498000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c0" decimals="-3" id="ixv-28801" unitRef="usd">556000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c4" decimals="-3" id="ixv-28802" unitRef="usd">229000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c5" decimals="-3" id="ixv-28803" unitRef="usd">152000</ifrs-full:PaymentsForShareIssueCosts>
    <ppbt:ProceedsFromIssuingWarrants contextRef="c4" decimals="-3" id="ixv-28804" unitRef="usd">5000000</ppbt:ProceedsFromIssuingWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c0" decimals="-3" id="ixv-28805" unitRef="usd">2028000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ppbt:WarrantsIssuanceExpensesPaid contextRef="c0" decimals="-3" id="ixv-28806" unitRef="usd">280000</ppbt:WarrantsIssuanceExpensesPaid>
    <ppbt:WarrantsIssuanceExpensesPaid contextRef="c4" decimals="-3" id="ixv-28807" unitRef="usd">661000</ppbt:WarrantsIssuanceExpensesPaid>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c0" decimals="-3" id="ixv-28808" unitRef="usd">183000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c4" decimals="-3" id="ixv-28809" unitRef="usd">168000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c5" decimals="-3" id="ixv-28810" unitRef="usd">165000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c0" decimals="-3" id="ixv-28811" unitRef="usd">44000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c4" decimals="-3" id="ixv-28812" unitRef="usd">56000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c5" decimals="-3" id="ixv-28813" unitRef="usd">67000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-28814" unitRef="usd">6774000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c4" decimals="-3" id="ixv-28815" unitRef="usd">5449000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c5" decimals="-3" id="ixv-28816" unitRef="usd">1114000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c0" decimals="-3" id="ixv-28817" unitRef="usd">-7084000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-28818" unitRef="usd">-595000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-28819" unitRef="usd">4293000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-28820" unitRef="usd">14489000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c46" decimals="-3" id="ixv-28821" unitRef="usd">15030000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c67" decimals="-3" id="ixv-28822" unitRef="usd">10890000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c0" decimals="-3" id="ixv-28823" unitRef="usd">-4000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-28824" unitRef="usd">54000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-28825" unitRef="usd">-153000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-28826" unitRef="usd">7401000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-28827" unitRef="usd">14489000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c46" decimals="-3" id="ixv-28828" unitRef="usd">15030000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c0" id="ixv-19893">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
1 - General&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Reporting
entity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Purple Biotech Ltd. (hereinafter: the &#x201c;&lt;b&gt;Company&lt;/b&gt;&#x201d; or &#x201c;&lt;b&gt;Purple&lt;/b&gt;&#x201d;) is a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance. The Company&#x2019;s oncology pipeline includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophils extracellular traps is a novel target for the treatment of multiple cancer indications. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. CAPTN-3 is a preclinical platform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The cleavable capping technology confines the compound&#x2019;s therapeutic activity to the local tumor microenvironment. The third arm specifically targets the Tumor Associated Antigen (TAA). IM1240 is the first tri-specific antibody in development that targets 5T4 expressed in a variety of solid tumors and is correlated with advanced disease, increased invasiveness, and poor clinical outcomes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company was incorporated in Israel as a private company in August 1968, and has been listed for trading on the Tel Aviv Stock Exchange
since September 1978. In October 2012, the Company disposed of all of its previous operations, and in July 2013, the Company acquired
shares of Kitov Pharma Ltd. from its shareholders, in exchange for the Company&#x2019;s shares. In December 2020 the Company changed its
name from Kitov Pharma Ltd. to Purple Biotech Ltd.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;B.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s securities (American Depository Shares (&#x201c;ADS&#x201d;)) were listed for trading on the NASDAQ in November 2015. Each ADS represents 200 ordinary shares with &lt;span style="-sec-ix-hidden: hidden-fact-149"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-150"&gt;no&lt;/span&gt;&lt;/span&gt; par value following a reverse split on August 23, 2020 and &#160;September 17, 2024 (see Note 9A). Each 200 warrants enable the purchase of 1 ADS.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s address is 4 Oppenheimer St., Science Park Rehovot 7670104 Israel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;C.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In January 2017, the Company
    acquired the majority of shares of TyrNovo Ltd. (hereinafter: &#x201c;TyrNovo&#x201d;). During 2018, the Company acquired additional
    shares of TyrNovo from various minority shareholders, see also Note 4A.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
January 2020, the Company acquired 100% of FameWave Ltd. (hereinafter &#x201c;FameWave&#x201d;), see also Note 4B.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
October 28, 2021, the Company established a fully owned subsidiary Purple Biotech GmbH (hereinafter &#x201c;&lt;b&gt;Purple GmbH&lt;/b&gt;&#x201d;)
which is currently in dissolving process following the termination of its activities in Switzerland.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
February 2023, the Company acquired 100% of Immunorizon Ltd. (hereinafter &#x201c;Immunorizon&#x201d;), see also Note 4C.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company together with TyrNovo, FameWave, Immunorizon and Purple GmbH are referred to, in these consolidated financial statements, as
&#x201c;&lt;b&gt;the Group&lt;/b&gt;&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;D.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Since incorporation through December 31, 2024, the Group has incurred losses and negative cash flows from operations mainly attributed to its development efforts and has an accumulated loss of USD 144.7 million. The Group has financed its operations mainly through private and public financing rounds. Through December 31, 2024, the Company raised (excluding exercise of warrants) a total of USD 108.5 million net of issuance expenses, see also Note 9.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Based on the projected cash flows and
current cash balances, management currently is of the opinion that its existing cash will be sufficient to fund operations for at least
the next 12 months. Subsequently, management&#x2019;s plans include pursuing out licensing, alternative financing arrangements, or reducing
expenditures as necessary to meet the Company&#x2019;s future cash requirements. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;However, there is no assurance that, if required, the Company will be able to raise additional capital when needed, on favorable terms, or at all or reduce discretionary spending to provide the required liquidity.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;E.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Following
    the brutal attacks on Israel, the mobilization of army reserves and the Government declaring a state of war (&#x201c;Iron Swords&#x201d;
    war) in October 2023, there was a decrease in Israel&#x2019;s economic and business activity. The security situation has led, inter
    alia, to a disruption in the chain of supply and production, a decrease in the volume of national transportation, a shortage in manpower
    as well as a decrease in the value of financial assets and a rise in the exchange rate of foreign currencies in relation to the shekel.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Any
    hostilities involving Israel, or the interruption or curtailment of trade within Israel or between Israel and its trading partners
    could adversely affect the Company&#x2019;s operations and results of operations and could make it more difficult for the Company
    to raise capital. Both CM24 and NT219 are manufactured by service providers outside of Israel. Most of the research and development
    work is being conducted by third-party entities outside of Israel. However, a prolonged war can cause disruptions or delays to activities
    performed in Israel, as the result of shortage of staff, resulting in an adverse effect on the Company&#x2019;s business, financial
    condition and results of operation.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Additionally,
    all of Company&#x2019;s employees are located and reside in Israel. Shelter-in-place and work-from-home measures, government-imposed
    restrictions on movement and travel and other precautions that may be taken to address the ongoing conflict may temporarily disrupt
    the employees&#x2019; ability to effectively perform the daily tasks.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;span style="font-family: Times New Roman, Times, Serif"&gt;It
    is currently not possible to predict the duration or severity of the ongoing conflict or its effects on Company&#x2019;s business,
    operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt Company&#x2019;s business
    and operations, interrupt the sources and availability of supply and hamper the ability to raise additional funds or sell Company&#x2019;s
    securities, among others.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ppbt:AmericanDepositorySharesOrdinaryShares
      contextRef="c79"
      decimals="0"
      id="ixv-28829"
      unitRef="shares">200</ppbt:AmericanDepositorySharesOrdinaryShares>
    <ppbt:AmericanDepositorySharesOrdinaryShares
      contextRef="c80"
      decimals="0"
      id="ixv-28830"
      unitRef="shares">200</ppbt:AmericanDepositorySharesOrdinaryShares>
    <ifrs-full:DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="c0"
      decimals="0"
      id="ixv-28831"
      unitRef="shares">200</ifrs-full:DilutiveEffectOfWarrantsOnWeightedAverageNumberOfOrdinaryShares>
    <ppbt:AmericanDepositorySharesPurchase
      contextRef="c0"
      decimals="0"
      id="ixv-28832"
      unitRef="shares">1</ppbt:AmericanDepositorySharesPurchase>
    <ppbt:PercentageOfContractToAcquire contextRef="c83" decimals="2" id="ixv-28833" unitRef="pure">1</ppbt:PercentageOfContractToAcquire>
    <ppbt:PercentageOfContractToAcquire contextRef="c84" decimals="2" id="ixv-28834" unitRef="pure">1</ppbt:PercentageOfContractToAcquire>
    <ppbt:RetainedEarning contextRef="c0" decimals="-5" id="ixv-28835" unitRef="usd">144700000</ppbt:RetainedEarning>
    <ppbt:PrivateAndPublicFinancingTotal contextRef="c0" decimals="-5" id="ixv-28836" unitRef="usd">108500000</ppbt:PrivateAndPublicFinancingTotal>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c0" id="ixv-20023">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
2 - Basis of Preparation of the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Statement of compliance
    with International Financial Reporting Standards&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group has prepared the consolidated financial statements in accordance with IFRS Accounting Standards (hereinafter: &#x201c;IFRS&#x201d;),
as issued by the International Accounting Standard Board (&#x201c;IASB&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
consolidated financial statements were approved by the board of directors on March 6, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Functional and presentation
    currency&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
consolidated financial statements are presented in US dollars (USD), which is the Group&#x2019;s functional currency, rounded to the nearest
one thousand, unless otherwise noted. The USD is the currency that represents the principal economic environment in which the Group operates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis of measurement&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
consolidated financial statements have been prepared on the historical cost basis except for the following assets and liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial instruments and
    derivatives measured at fair value through profit or loss;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provisions;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities for employee
    benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
further information regarding the measurement of these assets and liabilities see Note 3 regarding material accounting policies.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use of estimates and
    judgment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions
that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results
may differ from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Management
prepares the estimates on the basis of past experience, various facts, external circumstances, and reasonable assumptions according to
the pertinent circumstances of each estimate. The preparation of accounting estimates used in the preparation of the Group&#x2019;s consolidated
financial statements requires management of the Group to make assumptions regarding circumstances and events that involve considerable
uncertainty. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized
in the period in which the estimates are revised and in any future periods affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Information
about assumptions made by the Group with respect to the future and other reasons for uncertainty with respect to estimates that have
a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in the next financial year are
included in the following notes:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 23%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimate&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 26%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal
    assumptions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 23%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Possible
    effects&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Reference&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assessment
    of probability of contingent liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Whether it is more likely than not that an outflow
    of economic resources will be required in respect of legal claims pending against the Company and its investees&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reversal or creation of a provision for a claim&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For information on the Company&#x2019;s exposure to
    claims see Note 12B regarding contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recoverability of intangible assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The discounted cash flows method includes assumptions
    such as future expenses, future revenues, success rates (in respect of transition between phases of the R&amp;amp;D of the clinical trials
    until reaching regulatory approval and marketing) and discount rate. &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of the in-process research and development
    in profit or loss&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See Note 4 regarding Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Determination
of fair value &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Preparation
of the financial statements requires the Group to determine the fair value of certain assets and liabilities. The Group&#x2019;s management
regularly reviews significant unobservable inputs and valuation adjustments, including obtaining valuations prepared by third parties
and assessing the evidence to support the conclusion that these valuations meet the requirements of IFRS, including the level in the
fair value hierarchy in which the valuations should be classified.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;When
determining the fair value of an asset or liability, the Group uses market data as much as possible. There are three levels of fair value
measurements in the fair value hierarchy that are based on the data used in the measurement, as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1: quoted prices
    (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2: inputs other than
    quoted prices included in Level 1 that are observable, either directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3: inputs that are
    not based on observable market data (unobservable inputs).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Further
information about the assumptions made in measuring fair value of share-based payments, intangible assets and financial instruments are
included in Note 10, Note 4 and Note 18, respectively.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exchange rates and linkage
    bases&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balances
in foreign currency (mainly the New Israeli Shekel, or NIS) or linked thereto are included in the consolidated financial statements at
the representative exchange rates, as published by the Bank of Israel, which were prevailing as of the statement of financial position
date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Data
on exchange rates are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Representative&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;exchange rate&lt;br/&gt;
    of USD&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(NIS/USD
    1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Date of consolidated financial statements:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.647&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.627&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.519&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes in exchange rates
    for the year ended:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Change in accounting
    policy&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Amendment
to IAS 1, Presentation of Financial Statements: Classification of liabilities as current or non-current &#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
amendment replaces the specific classification requirement of certain liabilities as current or non-current. According to the amendment,
a liability will be classified as non-current when the entity has a right to defer payment for a period of at least 12 months after the
reporting period, which is &#x201c;substantive&#x201d; (Substance) and which exists at the end of the reporting period. The amendment clarifies
that the conversion right of a liability will affect the classification of the instrument as a whole as current or non-current unless
the conversion component is equity. The amendment is affective retrospectively for reporting periods beginning on or after January 1,
2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
a result of implementing the amendment, the Company changed its policy regarding the classification of warrants classified as a liability.
Prior to the implementation of the amendment, when classifying the warrants as current or non-current, the conversion options of the
counterparty were not considered. Following the implementation of the amendment, since the warrants include a conversion component, the
Company takes into account the possible date at which the warrants can be converted, when classifying the warrants as current or non-current.
Since the conversion option can be exercised within 12 months after the reporting period, the Company retrospectively classified the
warrants as a current liability.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ppbt:FunctionalCurrency contextRef="c0" decimals="-3" id="ixv-28837" unitRef="usd">1000</ppbt:FunctionalCurrency>
    <ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory contextRef="c0" id="ixv-20324">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Data
on exchange rates are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Representative&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;exchange rate&lt;br/&gt;
    of USD&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(NIS/USD
    1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Date of consolidated financial statements:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.647&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.627&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.519&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes in exchange rates
    for the year ended:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory>
    <ifrs-full:AverageForeignExchangeRate contextRef="c0" decimals="3" id="ixv-28838" unitRef="pure">3.647</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate contextRef="c4" decimals="3" id="ixv-28839" unitRef="pure">3.627</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate contextRef="c5" decimals="3" id="ixv-28840" unitRef="pure">3.519</ifrs-full:AverageForeignExchangeRate>
    <ppbt:PercentageOfExchangeRate contextRef="c0" decimals="3" id="ixv-28841" unitRef="pure">0.005</ppbt:PercentageOfExchangeRate>
    <ppbt:PercentageOfExchangeRate contextRef="c4" decimals="2" id="ixv-28842" unitRef="pure">0.03</ppbt:PercentageOfExchangeRate>
    <ppbt:PercentageOfExchangeRate contextRef="c5" decimals="2" id="ixv-28843" unitRef="pure">0.13</ppbt:PercentageOfExchangeRate>
    <ppbt:StockOptionExercisedPeriod contextRef="c85" id="ixv-28844">P12M</ppbt:StockOptionExercisedPeriod>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory contextRef="c0" id="ixv-20502">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note 3
- Material Accounting Policies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
accounting policies set out below have been consistently applied for all periods presented in these consolidated financial statements:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis of consolidation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Acquisition of Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Upon
acquisition of subsidiaries, the Company evaluates whether the acquisition is considered a business acquisition or an acquisition of
an asset (or group of assets). If the Company reaches the conclusion that the subsidiary acquired is a considered a business, it accounts
for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the
acquisition is generally measured at fair value, as are the identifiable net assets acquired. Transaction costs are expensed as incurred,
except if related to the issue of debt or equity securities. If the acquired subsidiary is not considered a business, the Company accounts
for the acquisition as a purchase of assets. The Company uses the optional concentration test to determine the accounting treatment of
such acquisitions. In applying the concentration test, an entity determines whether substantially all the fair value of the gross assets
acquired is concentrated in a single asset or group of similar assets. If so, the asset is not considered a business. As of December
31, 2024, the acquisitions made by the Company were determined to be an acquisition of assets, see Note 4.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contingent
considerations transferred for acquisition of subsidiaries are recorded when the terms and conditions for payment of the consideration
are met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Subsidiaries
are entities controlled by the Group. The financial statements of subsidiaries are included in the consolidated financial statements
from the date on which control commences until the date on which control ceases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Non-controlling interests&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-controlling
interests that are instruments that give rise to a present ownership interest and entitle the holder to a share of net assets in the
event of liquidation (for example: ordinary shares), are measured at the date of the business combination at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes
in the Group&#x2019;s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Foreign currency transactions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Transactions
in foreign currencies are translated to USD which is the functional currency of Group entities at exchange rates at the dates of the
transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional
currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between its cost in
the functional currency on date of translation, and the monetary cost in foreign currency translated at the exchange rate at the end
of the year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-monetary
items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial instruments&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Non-derivative financial
    assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Initial
recognition and measurement of financial assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group initially recognizes debt instruments issued on the date that they are created. All other financial assets are recognized initially
on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially
measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. &#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Subsequent
measurement and gains and losses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Financial
assets at fair value through profit or loss&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
assets are subsequently measured at fair value. Net gains and losses, including any interest income, are recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Non-derivative financial
    liabilities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-derivative
financial liabilities include: finance lease liabilities, accounts payables and other payables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Initial
recognition of financial liabilities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument.
Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value
less any directly attributable transaction costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Subsequent
measurement of financial liabilities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Subsequent
to initial recognition these financial liabilities are measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Derecognition
of financial liabilities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled
or transferred to equity.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Derivative financial
    instruments &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
part of the October 2023 and July 2024 capital raising agreements, the Company issued new warrants and amended previous warrants that
were classified as derivative financial instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Measurement
of derivative financial instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Derivatives
are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial
recognition, derivatives are measured at fair value, and changes therein are accounted for as described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these
derivatives is based on an evaluation and classified as level 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ordinary
shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized
as a deduction from equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Incremental
costs directly attributable to an expected issuance of an instrument that will be classified as an equity instrument are recognized as
an asset in deferred expenses in the statement of financial position. The costs are deducted from equity upon the initial recognition
of the equity instruments, or are amortized as financing expenses in the statement of income when the issuance is no longer expected
to take place.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Issuance of parcel of
    securities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
consideration received from the issuance of parcel of securities is attributed initially to financial liabilities that are measured each
period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair
value. The remaining amount is allocated to equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Direct
issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed
to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described
above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
part of the October 2023 capital raising, the Company issued pre-funded warrants and amended terms for previous warrants. The Company
classified the pre-funded warrants as an equity instrument due to their negligible exercise price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
amended terms for previously issued warrants increased the fair value of those warrants. The amended terms were part of the capital raising
and therefore the Company accounted for the increase in value as issuance cost.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intangible assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research and development&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expenditure
on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized
in profit or loss when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Development
activities involves research for new or substantially improved drug candidates and processes, the manufacturing of such candidates and
the pre-clinical and clinical studies for these candidates. Development expenditure are capitalized only if development costs can be
measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group
has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are
recognized in profit and loss as expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other intangible assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Other intangible assets, including
in-process research and development in respect of the Company&#x2019;s acquisition of TyrNovo, Famewave, Immunorizion, and asset purchased
by Purple GmbH (see also Note 4), which have infinite useful lives, are measured at cost less accumulated impairment losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether
events and circumstances continue to support the decision that the intangible asset has an indefinite useful life and if any impairment
may be needed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Impairment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Timing
of impairment testing&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
carrying amounts of the Group&#x2019;s non-financial assets, are reviewed at each reporting date to determine whether there is any indication
of impairment. If any such indication exists, then the asset&#x2019;s recoverable amount is estimated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Once
a year and on the same date, or more frequently if there are indications of impairment, the Group estimates the recoverable amount of
each cash generating unit that contains intangible assets that have indefinite useful lives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Measurement
of recoverable amount&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs of disposal.
In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects
the assessments of market participants regarding the time value of money and the risks specific to the asset or cash-generating unit,
for which the estimated future cash flows from the asset or cash-generating unit were not adjusted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Recognition
of impairment loss&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;An
impairment loss is recognized if the carrying amount of an asset or cash-generating unit exceeds its estimated recoverable amount. Impairment
losses are recognized in profit or loss.&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group presents basic and diluted loss per share data for its ordinary share capital (including pre-funded warrants). Basic loss per share
is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding
during the year. The loss per share data is presented in the profit and loss statement as loss per ADS giving effect to the number of
200 shares per 1 ADS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;G.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Employee benefits&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance and pension companies,
and they are classified as defined contribution plans and as defined benefit plans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and
has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are
recognized as an expense in profit or loss in the periods during which related services are rendered by employees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term
employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
liability is recognized for the amount expected to be paid under short-term cash bonus if the Group has a present legal or constructive
obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;H.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share-based payment transactions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
grant date fair value of share-based payment awards granted to employees is recognized as a salary expense, with a corresponding increase
in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect
of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect
the number of awards that are expected to vest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;I.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Provisions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated
reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
provision for legal claims is recognized if, as a result of a past event, the Company has a present legal or constructive obligation
and it is more likely than not that an outflow of economic benefits will be required to settle the obligation and the amount of obligation
can be estimated reliably.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;J.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financing income and expense&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance
income comprises changes in the fair value of the financial liability through profit and loss, gains on changes in the fair value of
financial assets at fair value through profit or loss and income from short- term and long-term deposits, foreign currency gains, and
the reclassification of net gains and losses previously recognized in other comprehensive income on cash flow hedges of foreign currency.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance
expenses include loss from exchange rate differences and interest fee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest
income or expense is recognized, using the effective interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
the statements of cash flows, interest received is presented as part of cash flows from investing activities and interest paid is presented
as part of cash flows from financing activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;K.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income tax expense&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
tax comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that they
relate to a business combination, or are recognized directly in equity or in other comprehensive income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that
future taxable profits will be available against which they can be utilized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has not recognized deferred tax assets as no future taxable profits are expected in the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;L.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Leased
assets and lease liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contracts
that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as
leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments (these
payments do not include certain variable lease payments), and concurrently recognizes a right-to-use asset at the same amount of the
lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Since
the interest rate implicit in the Group&#x2019;s leases is not readily determinable, the incremental borrowing rate of the lessee is used.
Subsequent to initial recognition, the right-to-use asset is accounted for using the cost model, and depreciated over the shorter of
the lease term or useful life of the asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;The
lease term&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably
certain that the lessee will or will not exercise the option, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Depreciation
of right-to-use asset&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;After
lease commencement, a right-to-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses
and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over contractual lease
period as follows: office lease from September 15 2020 for 5 years and 3.5 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;M.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Accounting standards issued but not yet effective&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
number of new accounting standards are effective for annual reporting periods beginning after 1 January 2025 and earlier application
is permitted. However, the Group has not early adopted the following new or amended accounting standards in preparing these consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IFRS 18 Presentation and Disclosure in Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IFRS
18 will replace IAS 1 Presentation of Financial Statements and applies for annual reporting periods beginning on or after 1 January 2027.
The new standard introduces the following key new requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Entities
                                            are required to classify all income and expenses into five categories in the statement of
                                            profit or loss, namely the operating, investing, financing, discontinued operations and income
                                            tax categories. Entities are also required to present a newly-defined operating profit subtotal.
                                            Entities&#x2019; net profit will not change.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Management-defined
                                            performance measures (MPMs) are disclosed in a single note in the financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Enhanced
                                            guidance is provided on how to group information in the financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
addition, all entities are required to use the operating profit subtotal as the starting point for the statement of cash flows when presenting
operating cash flows under the indirect method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group is still in the process of assessing the impact of the new standard, particularly with respect to the structure of the Group&#x2019;s
statement of profit or loss, the statement of cash flows and the additional disclosures required for MPMs. The Group is also assessing
the impact on how information is grouped in the financial statements, including for items currently labelled as &#x2018;other&#x2019;.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <ppbt:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock contextRef="c0" id="ixv-20512">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis of consolidation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Acquisition of Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Upon
acquisition of subsidiaries, the Company evaluates whether the acquisition is considered a business acquisition or an acquisition of
an asset (or group of assets). If the Company reaches the conclusion that the subsidiary acquired is a considered a business, it accounts
for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the
acquisition is generally measured at fair value, as are the identifiable net assets acquired. Transaction costs are expensed as incurred,
except if related to the issue of debt or equity securities. If the acquired subsidiary is not considered a business, the Company accounts
for the acquisition as a purchase of assets. The Company uses the optional concentration test to determine the accounting treatment of
such acquisitions. In applying the concentration test, an entity determines whether substantially all the fair value of the gross assets
acquired is concentrated in a single asset or group of similar assets. If so, the asset is not considered a business. As of December
31, 2024, the acquisitions made by the Company were determined to be an acquisition of assets, see Note 4.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contingent
considerations transferred for acquisition of subsidiaries are recorded when the terms and conditions for payment of the consideration
are met.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Subsidiaries
are entities controlled by the Group. The financial statements of subsidiaries are included in the consolidated financial statements
from the date on which control commences until the date on which control ceases.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Non-controlling interests&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-controlling
interests that are instruments that give rise to a present ownership interest and entitle the holder to a share of net assets in the
event of liquidation (for example: ordinary shares), are measured at the date of the business combination at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes
in the Group&#x2019;s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.&lt;/span&gt;&lt;/p&gt;</ppbt:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c0" id="ixv-20586">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Foreign currency transactions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Transactions
in foreign currencies are translated to USD which is the functional currency of Group entities at exchange rates at the dates of the
transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional
currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between its cost in
the functional currency on date of translation, and the monetary cost in foreign currency translated at the exchange rate at the end
of the year.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-monetary
items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c0" id="ixv-20637">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial instruments&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Non-derivative financial
    assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Initial
recognition and measurement of financial assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group initially recognizes debt instruments issued on the date that they are created. All other financial assets are recognized initially
on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially
measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Subsequent
measurement and gains and losses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Financial
assets at fair value through profit or loss&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
assets are subsequently measured at fair value. Net gains and losses, including any interest income, are recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Non-derivative financial
    liabilities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-derivative
financial liabilities include: finance lease liabilities, accounts payables and other payables.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Initial
recognition of financial liabilities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument.
Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value
less any directly attributable transaction costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Subsequent
measurement of financial liabilities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Subsequent
to initial recognition these financial liabilities are measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Derecognition
of financial liabilities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled
or transferred to equity.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Derivative financial
    instruments &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
part of the October 2023 and July 2024 capital raising agreements, the Company issued new warrants and amended previous warrants that
were classified as derivative financial instruments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Measurement
of derivative financial instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Derivatives
are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial
recognition, derivatives are measured at fair value, and changes therein are accounted for as described below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these
derivatives is based on an evaluation and classified as level 3.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ordinary
shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized
as a deduction from equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Incremental
costs directly attributable to an expected issuance of an instrument that will be classified as an equity instrument are recognized as
an asset in deferred expenses in the statement of financial position. The costs are deducted from equity upon the initial recognition
of the equity instruments, or are amortized as financing expenses in the statement of income when the issuance is no longer expected
to take place.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Issuance of parcel of
    securities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
consideration received from the issuance of parcel of securities is attributed initially to financial liabilities that are measured each
period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair
value. The remaining amount is allocated to equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Direct
issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed
to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described
above.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
part of the October 2023 capital raising, the Company issued pre-funded warrants and amended terms for previous warrants. The Company
classified the pre-funded warrants as an equity instrument due to their negligible exercise price.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
amended terms for previously issued warrants increased the fair value of those warrants. The amended terms were part of the capital raising
and therefore the Company accounted for the increase in value as issuance cost.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory contextRef="c0" id="ixv-20905">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intangible assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research and development&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expenditure
on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized
in profit or loss when incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Development
activities involves research for new or substantially improved drug candidates and processes, the manufacturing of such candidates and
the pre-clinical and clinical studies for these candidates. Development expenditure are capitalized only if development costs can be
measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group
has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are
recognized in profit and loss as expense.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other intangible assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Other intangible assets, including
in-process research and development in respect of the Company&#x2019;s acquisition of TyrNovo, Famewave, Immunorizion, and asset purchased
by Purple GmbH (see also Note 4), which have infinite useful lives, are measured at cost less accumulated impairment losses.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether
events and circumstances continue to support the decision that the intangible asset has an indefinite useful life and if any impairment
may be needed.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="c0" id="ixv-20977">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Impairment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Timing
of impairment testing&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
carrying amounts of the Group&#x2019;s non-financial assets, are reviewed at each reporting date to determine whether there is any indication
of impairment. If any such indication exists, then the asset&#x2019;s recoverable amount is estimated.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Once
a year and on the same date, or more frequently if there are indications of impairment, the Group estimates the recoverable amount of
each cash generating unit that contains intangible assets that have indefinite useful lives.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Measurement
of recoverable amount&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs of disposal.
In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects
the assessments of market participants regarding the time value of money and the risks specific to the asset or cash-generating unit,
for which the estimated future cash flows from the asset or cash-generating unit were not adjusted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Recognition
of impairment loss&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;An
impairment loss is recognized if the carrying amount of an asset or cash-generating unit exceeds its estimated recoverable amount. Impairment
losses are recognized in profit or loss.&#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c0" id="ixv-21064">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group presents basic and diluted loss per share data for its ordinary share capital (including pre-funded warrants). Basic loss per share
is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding
during the year. The loss per share data is presented in the profit and loss statement as loss per ADS giving effect to the number of
200 shares per 1 ADS.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ppbt:NumberOfShare
      contextRef="c0"
      decimals="0"
      id="ixv-28845"
      unitRef="shares">200</ppbt:NumberOfShare>
    <ppbt:NumberOfPerShare
      contextRef="c0"
      decimals="0"
      id="ixv-28846"
      unitRef="usdPershares">1</ppbt:NumberOfPerShare>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="c0" id="ixv-21081">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;G.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Employee benefits&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance and pension companies,
and they are classified as defined contribution plans and as defined benefit plans.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and
has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are
recognized as an expense in profit or loss in the periods during which related services are rendered by employees.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term
employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
liability is recognized for the amount expected to be paid under short-term cash bonus if the Group has a present legal or constructive
obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c0" id="ixv-21115">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;H.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share-based payment transactions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
grant date fair value of share-based payment awards granted to employees is recognized as a salary expense, with a corresponding increase
in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect
of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect
the number of awards that are expected to vest.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="c0" id="ixv-21131">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;I.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Provisions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated
reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
provision for legal claims is recognized if, as a result of a past event, the Company has a present legal or constructive obligation
and it is more likely than not that an outflow of economic benefits will be required to settle the obligation and the amount of obligation
can be estimated reliably.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory contextRef="c0" id="ixv-21185">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;J.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financing income and expense&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance
income comprises changes in the fair value of the financial liability through profit and loss, gains on changes in the fair value of
financial assets at fair value through profit or loss and income from short- term and long-term deposits, foreign currency gains, and
the reclassification of net gains and losses previously recognized in other comprehensive income on cash flow hedges of foreign currency.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance
expenses include loss from exchange rate differences and interest fee.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest
income or expense is recognized, using the effective interest method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
the statements of cash flows, interest received is presented as part of cash flows from investing activities and interest paid is presented
as part of cash flows from financing activities.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="c0" id="ixv-21216">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;K.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income tax expense&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
tax comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that they
relate to a business combination, or are recognized directly in equity or in other comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that
future taxable profits will be available against which they can be utilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has not recognized deferred tax assets as no future taxable profits are expected in the foreseeable future.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c0" id="ixv-21243">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;L.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Leased
assets and lease liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contracts
that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as
leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments (these
payments do not include certain variable lease payments), and concurrently recognizes a right-to-use asset at the same amount of the
lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Since
the interest rate implicit in the Group&#x2019;s leases is not readily determinable, the incremental borrowing rate of the lessee is used.
Subsequent to initial recognition, the right-to-use asset is accounted for using the cost model, and depreciated over the shorter of
the lease term or useful life of the asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;The
lease term&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably
certain that the lessee will or will not exercise the option, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Depreciation
of right-to-use asset&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;After
lease commencement, a right-to-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses
and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over contractual lease
period as follows: office lease from September 15 2020 for 5 years and 3.5 months.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ppbt:DepreciationRightofuseAssetsUsefulLife contextRef="c86" id="ixv-28847">P5Y</ppbt:DepreciationRightofuseAssetsUsefulLife>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory contextRef="c0" id="ixv-21321">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;M.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Accounting standards issued but not yet effective&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
number of new accounting standards are effective for annual reporting periods beginning after 1 January 2025 and earlier application
is permitted. However, the Group has not early adopted the following new or amended accounting standards in preparing these consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IFRS 18 Presentation and Disclosure in Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IFRS
18 will replace IAS 1 Presentation of Financial Statements and applies for annual reporting periods beginning on or after 1 January 2027.
The new standard introduces the following key new requirements.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Entities
                                            are required to classify all income and expenses into five categories in the statement of
                                            profit or loss, namely the operating, investing, financing, discontinued operations and income
                                            tax categories. Entities are also required to present a newly-defined operating profit subtotal.
                                            Entities&#x2019; net profit will not change.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Management-defined
                                            performance measures (MPMs) are disclosed in a single note in the financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Enhanced
                                            guidance is provided on how to group information in the financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
addition, all entities are required to use the operating profit subtotal as the starting point for the statement of cash flows when presenting
operating cash flows under the indirect method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group is still in the process of assessing the impact of the new standard, particularly with respect to the structure of the Group&#x2019;s
statement of profit or loss, the statement of cash flows and the additional disclosures required for MPMs. The Group is also assessing
the impact on how information is grouped in the financial statements, including for items currently labelled as &#x2018;other&#x2019;.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="c0" id="ixv-21413">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note 4
- Intangible Assets &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;As of
December 31, 2024, and 2023:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IPR&amp;amp;D related to TyrNovo
    (see 4A below)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,172&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,172&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IPR&amp;amp;D related to Famewave (see 4B below)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,310&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,310&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IPR&amp;amp;D related to Immunorizon (see 4C below)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,360&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,360&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IPR&amp;amp;D related to
    Purple GmbH&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-151; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,842&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,044&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Acquisition of Tyrnovo&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the years 2017 to 2019 the Company acquired shares in Tyrnovo, a company developing NT219.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Since
2019 the Company owns 98.47% of Tyrnovo.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Acquisition of Famewave&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
January 7, 2020 the Company completed the purchase of 100% of FameWave Ltd, a privately held biopharmaceutical Company developing CM24,
(&#x201c;FameWave&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
consideration was recorded based on the fair value of the assets purchased.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Acquisition of Immunorizon&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In February 2023 the Company completed
the acquisition of 100% of Immunorizon Ltd, a privately held biotech Company developing CAPTN-3, a platform for multispecific T and NK
cell engager oncology therapies that selectively activate the immune response within the tumor microenvironment, (&#x201c;Immunorizon&#x201d;)
from its shareholders in consideration of an aggregate upfront payment of $3.5 million in cash, an aggregate of $3.5 million in ADSs (or
110,759 ADSs representing ordinary shares at a price per ADS equal to the NASDAQ volume-weighted average price of the Company&#x2019;s
ADSs for the 60-day period preceding the execution date of the agreement) with three months lock up period including a price protection
mechanism for 12 months (see Note 9D3). Additional future considerations include future payments when achieving certain long-term milestones
set at an aggregate amount of $94 million, including royalties on net sales. The acquisition closed on February 15, 2023. The total acquisition
amounted to $ 3.6 million.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
acquisition was recorded based on the fair value of the consideration transferred and was accounted for as an asset purchase as it did
not meet the definition of a business combination in accordance with IFRS 3.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Identifiable
assets acquired and liabilities assumed&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible asset (1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,360&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total net identifiable
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,375&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible asset - In process research and development&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The fair value of the intangible asset recognized at the acquisition date was determined according to the fair value of the issued equity (110,759 ADSs) which amounted to USD 3,781 thousand and the cash paid.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;According to the agreement, the equity issued included a price protection mechanism for a dilutive event as defined in the agreement, as well as a lock up period of three months. Following the October 2023 registered direct offering, which constituted a dilutive event, the Company issued to the former shareholders of Immunorizon an aggregate 34,974 Additional ADSs.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The fair value of equity issued was based on the assumptions below:&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share price - 1.59&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility - 70.89%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual risk-free rate &#x2013; 4.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield- &lt;span style="-sec-ix-hidden: hidden-fact-152"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;DLOM &#x2013; 10.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D&lt;/b&gt;.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During 2024 the Company impaired the IPR&amp;amp;D related to Purple GmbH following the decision to dissolve Purple GmbH (see note 1).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E&lt;/b&gt;.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2024, the recoverable amount of the in-process research and development assets (hereinafter &#x2013; &#x201c;intangible assets&#x201d;) was based on their value in use and was determined by discounting the future cash flows to be generated from them by using the discounted cash flows method, on the annual year test. The recoverable amount of the intangible assets exceeds their carrying amount, thus no impairment loss was recognized.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The discounted cash flows model considered the risks associated with the clinical/preclinical phase of the intangible assets and the probability of success for each development phase. Certain estimations were determined using industry data reports.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The discount rate used for calculating intangible assets recoverable amount was 19.5%.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company performed sensitivity analysis for estimations such as discount rate and royalty rate and concluded that the recoverable amount of the intangible assets exceeds their carrying amount.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory contextRef="c0" id="ixv-21420">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;As of
December 31, 2024, and 2023:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IPR&amp;amp;D related to TyrNovo
    (see 4A below)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,172&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,172&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IPR&amp;amp;D related to Famewave (see 4B below)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,310&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,310&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IPR&amp;amp;D related to Immunorizon (see 4C below)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,360&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,360&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IPR&amp;amp;D related to
    Purple GmbH&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-151; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,842&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,044&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c92" decimals="-3" id="ixv-28848" unitRef="usd">6172000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c93" decimals="-3" id="ixv-28849" unitRef="usd">6172000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c94" decimals="-3" id="ixv-28850" unitRef="usd">14310000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c95" decimals="-3" id="ixv-28851" unitRef="usd">14310000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c96" decimals="-3" id="ixv-28852" unitRef="usd">7360000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c97" decimals="-3" id="ixv-28853" unitRef="usd">7360000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c99" decimals="-3" id="ixv-28854" unitRef="usd">202000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c2" decimals="-3" id="ixv-28855" unitRef="usd">27842000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c3" decimals="-3" id="ixv-28856" unitRef="usd">28044000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ppbt:EquityMethodInvestmentsOwnershipPercentage contextRef="c87" decimals="4" id="ixv-28857" unitRef="pure">0.9847</ppbt:EquityMethodInvestmentsOwnershipPercentage>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired contextRef="c88" decimals="2" id="ixv-28858" unitRef="pure">1</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired contextRef="c89" decimals="2" id="ixv-28859" unitRef="pure">1</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ppbt:AggregateUpfrontPayment contextRef="c90" decimals="-5" id="ixv-28860" unitRef="usd">3500000</ppbt:AggregateUpfrontPayment>
    <ppbt:AggregateUpfrontPayment contextRef="c84" decimals="-5" id="ixv-28861" unitRef="usd">3500000</ppbt:AggregateUpfrontPayment>
    <ppbt:AmericanDepositorySharesOrdinaryShares
      contextRef="c84"
      decimals="0"
      id="ixv-28862"
      unitRef="shares">110759</ppbt:AmericanDepositorySharesOrdinaryShares>
    <ppbt:LongTermMilestonesAggregateAmount contextRef="c84" decimals="-6" id="ixv-28863" unitRef="usd">94000000</ppbt:LongTermMilestonesAggregateAmount>
    <ppbt:TotalAcquisitionAmount contextRef="c84" decimals="-5" id="ixv-28864" unitRef="usd">3600000</ppbt:TotalAcquisitionAmount>
    <ppbt:ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c0" id="ixv-21657">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible asset (1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,360&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total net identifiable
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,375&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible asset - In process research and development&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ppbt:ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <ifrs-full:Cash contextRef="c2" decimals="-3" id="ixv-28865" unitRef="usd">44000</ifrs-full:Cash>
    <ifrs-full:OtherIntangibleAssets contextRef="c2" decimals="-3" id="ix_9_fact" unitRef="usd">7360000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherReceivables contextRef="c2" decimals="-3" id="ixv-28867" unitRef="usd">1000</ifrs-full:OtherReceivables>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-28868" unitRef="usd">28000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:OtherPayables contextRef="c2" decimals="-3" id="ixv-28869" unitRef="usd">2000</ifrs-full:OtherPayables>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="c2" decimals="-3" id="ixv-28870" unitRef="usd">7375000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ppbt:FairValueOfIssuedEquity
      contextRef="c0"
      decimals="0"
      id="ixv-28871"
      unitRef="shares">110759</ppbt:FairValueOfIssuedEquity>
    <ppbt:FairValueOfIssuedIntangibleAssets contextRef="c0" decimals="-3" id="ixv-28872" unitRef="usd">3781000</ppbt:FairValueOfIssuedIntangibleAssets>
    <ppbt:AggregateShareholdersOfImmunorizon
      contextRef="c91"
      decimals="0"
      id="ixv-28873"
      unitRef="shares">34974</ppbt:AggregateShareholdersOfImmunorizon>
    <ppbt:SharesPrice
      contextRef="c2"
      decimals="2"
      id="ixv-28874"
      unitRef="usdPershares">1.59</ppbt:SharesPrice>
    <ppbt:DescriptionOfExpectedVolatilityPercentage contextRef="c0" decimals="4" id="ixv-28875" unitRef="pure">0.7089</ppbt:DescriptionOfExpectedVolatilityPercentage>
    <ppbt:DescriptionOfExpectedAnnualRiskFreeRate contextRef="c0" decimals="3" id="ixv-28876" unitRef="pure">0.045</ppbt:DescriptionOfExpectedAnnualRiskFreeRate>
    <ppbt:PercentageOfDiscountsForLacksOfMarketability contextRef="c0" decimals="3" id="ixv-28877" unitRef="pure">0.108</ppbt:PercentageOfDiscountsForLacksOfMarketability>
    <ppbt:IntangibleAssetsRecoverableAmountPercentage contextRef="c0" decimals="3" id="ixv-28878" unitRef="pure">0.195</ppbt:IntangibleAssetsRecoverableAmountPercentage>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c0" id="ixv-21865">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
5 - Cash and Cash Equivalents&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance in USD&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,050&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,007&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance in other currencies&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;351&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;482&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,401&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,489&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <ppbt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock contextRef="c0" id="ixv-21871">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance in USD&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,050&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,007&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance in other currencies&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;351&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;482&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,401&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,489&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ppbt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="c100"
      decimals="-3"
      id="ixv-28879"
      unitRef="usd">7050000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="c101"
      decimals="-3"
      id="ixv-28880"
      unitRef="usd">14007000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="c102"
      decimals="-3"
      id="ixv-28881"
      unitRef="usd">351000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="c103"
      decimals="-3"
      id="ixv-28882"
      unitRef="usd">482000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-28883" unitRef="usd">7401000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-28884" unitRef="usd">14489000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c0" id="ixv-21967">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note 6
&#x2013; Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group has lease agreements with respect to offices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Information regarding
    material lease agreements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company entered into an agreement for the lease of offices in Rehovot as from September 15, 2020 for a period of 5 years and 3.5 months.
Accordingly, the Company initially recognized in the statement of financial position a right-to-use asset in the amount of USD 817 thousand
concurrently with the recognition of a lease liability in the same amount. The agreement has an option to extend the lease, for additional
5 years. This additional period is not included in the lease payments used-in the calculation of the liability as the Company does not
expect it is reasonably certain it will exercise the option. The Company has an option to extend the lease agreements for an additional
5 years at the terms as those of the existing agreement with addition of 5% to the current terms and CPI linked.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Right-to-use assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Carrying
amounts of right-to-use assets and change during the period:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Office
    lease&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;316&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation on right-to-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(152&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;164&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;467&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation on right-to-use assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(151&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;316&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Lease liability&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Maturity
analysis of the Company&#x2019;s lease liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;One to two years&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-153; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;376&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current maturities of
    lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Long-term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-154; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;163&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Additional information
    on leases&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Amounts
recognized in profit or loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest expenses
    on lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <ppbt:AgreementLeaseTerm contextRef="c104" id="ixv-28885">P5Y</ppbt:AgreementLeaseTerm>
    <ppbt:AgreementLeaseTerm contextRef="c105" id="ixv-28886">P3M15D</ppbt:AgreementLeaseTerm>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c86" decimals="-3" id="ixv-28887" unitRef="usd">817000</ifrs-full:AdditionsToRightofuseAssets>
    <ppbt:AgreementLeaseAdditionalTerm contextRef="c86" id="ixv-28888">P5Y</ppbt:AgreementLeaseAdditionalTerm>
    <ppbt:AgreementLeaseTerm contextRef="c86" id="ixv-28889">P5Y</ppbt:AgreementLeaseTerm>
    <ppbt:CurrentTerms contextRef="c86" decimals="2" id="ixv-28890" unitRef="pure">0.05</ppbt:CurrentTerms>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="c0" id="ixv-22001">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Carrying
amounts of right-to-use assets and change during the period:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Office
    lease&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;316&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation on right-to-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(152&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;164&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;467&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation on right-to-use assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(151&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;316&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets
      contextRef="c106"
      decimals="-3"
      id="ixv-28891"
      unitRef="usd">316000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="c107"
      decimals="-3"
      id="ixv-28892"
      unitRef="usd">152000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="c108"
      decimals="-3"
      id="ixv-28893"
      unitRef="usd">164000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="c109"
      decimals="-3"
      id="ixv-28894"
      unitRef="usd">467000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="c110"
      decimals="-3"
      id="ixv-28895"
      unitRef="usd">151000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="c106"
      decimals="-3"
      id="ixv-28896"
      unitRef="usd">316000</ifrs-full:RightofuseAssets>
    <ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory contextRef="c0" id="ixv-22146">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Maturity
analysis of the Company&#x2019;s lease liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;One to two years&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-153; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;376&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current maturities of
    lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Long-term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-154; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;163&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory>
    <ifrs-full:LeaseLiabilities
      contextRef="c111"
      decimals="-3"
      id="ixv-28897"
      unitRef="usd">183000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="c112"
      decimals="-3"
      id="ixv-28898"
      unitRef="usd">188000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="c114"
      decimals="-3"
      id="ixv-28899"
      unitRef="usd">188000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c2" decimals="-3" id="ixv-28900" unitRef="usd">183000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c3" decimals="-3" id="ixv-28901" unitRef="usd">376000</ifrs-full:LeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-28902" unitRef="usd">183000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-28903" unitRef="usd">188000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-28904" unitRef="usd">163000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory contextRef="c0" id="ixv-22362">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Amounts
recognized in profit or loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest expenses
    on lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c0" decimals="-3" id="ixv-28905" unitRef="usd">23000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c4" decimals="-3" id="ixv-28906" unitRef="usd">37000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory contextRef="c0" id="ixv-22423">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note 7
- Other Current Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;109&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid expenses and other receivables&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;275&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;205&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total other current assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;384&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;376&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory>
    <ppbt:DisclosureOfOtherCurrentAssettextBlock contextRef="c0" id="ixv-22429">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;109&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid expenses and other receivables&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;275&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;205&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total other current assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;384&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;376&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ppbt:DisclosureOfOtherCurrentAssettextBlock>
    <ppbt:GovernmentAuthorities contextRef="c2" decimals="-3" id="ixv-28907" unitRef="usd">109000</ppbt:GovernmentAuthorities>
    <ppbt:GovernmentAuthorities contextRef="c3" decimals="-3" id="ixv-28908" unitRef="usd">171000</ppbt:GovernmentAuthorities>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c2" decimals="-3" id="ixv-28909" unitRef="usd">275000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c3" decimals="-3" id="ixv-28910" unitRef="usd">205000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:OtherCurrentAssets contextRef="c2" decimals="-3" id="ixv-28911" unitRef="usd">384000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c3" decimals="-3" id="ixv-28912" unitRef="usd">376000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c0" id="ixv-22504">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note 8
- Other Payables&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Due to related parties - salary
    related&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;317&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;620&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;692&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,521&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Government authorities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;53&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salary related&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;269&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,200&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,463&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock contextRef="c0" id="ixv-22510">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Due to related parties - salary
    related&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;317&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;620&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;692&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,521&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Government authorities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;53&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salary related&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;269&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,200&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,463&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="c2" decimals="-3" id="ixv-28913" unitRef="usd">317000</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="c3" decimals="-3" id="ixv-28914" unitRef="usd">620000</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
    <ifrs-full:AccrualsClassifiedAsCurrent contextRef="c2" decimals="-3" id="ixv-28915" unitRef="usd">692000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:AccrualsClassifiedAsCurrent contextRef="c3" decimals="-3" id="ixv-28916" unitRef="usd">2521000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:CurrentGovernmentGrants contextRef="c2" decimals="-3" id="ixv-28917" unitRef="usd">65000</ifrs-full:CurrentGovernmentGrants>
    <ifrs-full:CurrentGovernmentGrants contextRef="c3" decimals="-3" id="ixv-28918" unitRef="usd">53000</ifrs-full:CurrentGovernmentGrants>
    <ppbt:SalaryRelatedOtherPayablesCurrent contextRef="c2" decimals="-3" id="ixv-28919" unitRef="usd">126000</ppbt:SalaryRelatedOtherPayablesCurrent>
    <ppbt:SalaryRelatedOtherPayablesCurrent contextRef="c3" decimals="-3" id="ixv-28920" unitRef="usd">269000</ppbt:SalaryRelatedOtherPayablesCurrent>
    <ifrs-full:OtherCurrentPayables contextRef="c2" decimals="-3" id="ixv-28921" unitRef="usd">1200000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables contextRef="c3" decimals="-3" id="ixv-28922" unitRef="usd">3463000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c0" id="ixv-22644">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
9 - Equity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company&#x2019;s authorized share capital is 1,000,000,000 ordinary shares, with no par value, and 50,000,000 non-voting senior preferred shares, with no par value, divided into 5 classes of 10,000,000 preferred shares in each class.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On September 17, 2024 the ratio between ADSs and shares was changed from 1:10 to 1:200 (each 1 ADS equal 200 shares). In these consolidated financial statements, all numbers of ADSs reflect the reverse share split and ADS ratio change retrospectively&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;The Company&#x2019;s share capital&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and&lt;br/&gt; paid-in&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and&lt;br/&gt; paid-in&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares, no par value&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;517,129&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;252,379&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Class A preferred shares, no par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-155; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-156; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Class B preferred shares, no par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-157; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-158; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Class C preferred shares, no par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-159; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-160; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Class D preferred shares, no par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-161; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-162; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Class E preferred shares, no par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-163; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-164; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Changes in share capital during the year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(*)2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(*)2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of ADSs in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued as at
    January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,261&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;924&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;890&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance
    of ADSs (See D below)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;930&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;319&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vesting of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    of warrants and prefunded warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;379&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-165; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-166; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    as at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,586&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,261&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;924&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;*&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restated to reflect a 1:20 reverse ratio that took place in September 2024. (see also note 9A)&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financing rounds&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On December 5, 2024, in a registered direct offering on the NASDAQ, the Company raised USD 2.83 million gross (approximately USD 2.5 million net of placement agent fees). In this registered direct offering, the Company issued an aggregate of 472,668 ADSs at a purchase price of USD 6 per ADS that were recorded in equity in the amount of USD 2.5 million net of issuance expenses.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In addition, the Company issued to the placement agent (or its designees) registered compensation warrants to purchase up to 33,087 ADSs at a value of USD 109 thousand which is included in the net amount raised above, at an exercise price of USD &lt;span style="-sec-ix-hidden: hidden-fact-167"&gt;7. 5&lt;/span&gt; per ADS. The registered placement agent warrants are immediately exercisable and have a term of 5 years from the date of the effective date of the offering.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On July 2, 2024 the Company raised USD&#160;2&#160;million gross (approximately USD&#160;1.8&#160;million net of placement agent fees) in a warrant inducement transaction. In this transaction, the Company induced the exercise of certain existing warrants to purchase an aggregate of 281,675 American Depositary Shares (ADSs) of which 166,469 ADSs held in abeyance. The existing warrants had original exercise prices ranging from $25 to $400 per ADS and were originally issued by the Company in October 2023, June 2020, January 2019 and June 2018. The exercise price for these existing warrants was reduced to $7.2 per ADS.&#160;As of December 31, 2024, no ADSs are held in abeyance.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In consideration for the exercise of the existing
warrants, the Company issued new unregistered Series A-1 warrants to purchase up to an aggregate of 248,969 ADSs and new unregistered
Series A-2 warrants to purchase up to an aggregate of 314,382 ADSs. The new warrants are immediately exercisable at an exercise price
of $8 per ADS. The Series A-1 warrants have a term of five years from the issuance date and the Series A-2 warrants have a term of twenty-four
months from the issuance date. The cash received in the transaction was allocated to the new warrants, which were recorded as a liability
at their fair value adjusted, for deferred difference between the transaction price and the fair value, of USD 2,028 thousand, and the
exercise of the existing warrants was treated as a reclassification from the receipt on account of warrants to share premium.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, the Company issued to the placement agent (or its designees) unregistered compensation warrants to purchase up to 19,717 ADSs at an exercise price of USD&#160;9&#160;per ADS at value of $100 thousand. The unregistered placement agent warrants are immediately exercisable and have a term of&#160;five years&#160;from the date of July 2, 2024.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On October 19, 2023, in a registered direct offering on the NASDAQ, the Company raised USD 5 million gross (approximately USD 4.3 million net of placement agent fees). In this registered direct offering, the Company issued an aggregate of 121,500 ADSs at a purchase price of USD 23 per ADS and pre-funded warrants to purchase up to 95,891 ADS. The Company also issued unregistered warrants to purchase up to an aggregate of 217,391 ADSs (hereinafter the &#x201c;October 2023 warrants&#x201d;) which are immediately exercisable, that were recorded as a liability at their fair value at a value of USD 5,348 thousand. The October 2023 warrants have a term of five and a half years and have an exercise price of USD 25 per ADS. During 2024, the pre-funded warrants and the October warrants were exercised as part of the warrant inducement transaction in July.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In connection with the offering and effective upon October 19, 2023, the Company amended certain existing warrants to purchase up to an aggregate of 31,578 ADSs that were previously issued in June 2020 and June 2018 at exercise prices of $180 and $560 per ADS, respectively, such that the amended warrants have a reduced exercise price of $25 per ADS and an extended term of five and a half years from the closing of the offering. The Company recorded USD 761 thousand in issuance expenses in relation to the amendment. During 2024, these warrants were exercised as part of the warrant inducement transaction in July.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In addition, the Company issued to the placement agent (or its designees) unregistered compensation warrants to purchase up to 15,217 ADSs at a value of USD 357 thousand at an exercise price of USD 28.75 per ADS. The unregistered placement agent warrants are immediately exercisable and have a term of five years from the date of October 19, 2023.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In connection with the October 2023 Offering, the Company issued 34,975 ADSs pursuant to an anti-dilution mechanism of that certain Lock-Up and Registration Rights Agreements entered into with former Immunorizon shareholders in connection with the acquisition of Immunorizon in February 2023 (refer to Note 4C).&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 9, 2021, the Company entered into sales agreement with Jefferies LLC, for the sale of ADSs. In accordance with the terms of the sales agreement, the Company may offer and sell ADSs from time to time through Jefferies, acting as the Company&#x2019;s agent. The Company originally filed a prospectus for a $50.0 million &#x201c;at the market&#x201d; equity offering program (&#x201c;ATM Program&#x201d;), but the aggregate offering price was subsequently reduced to $21.0 million on March 23, 2022, to $3.0 million on October 17, 2023 and to $1.33 million on January 6 ,2025. During 2024, 2023 and 2022 the Company sold, under the ATM Program, 457,801, 52,202 and 27,170 ADSs at an average price of $9, $32.6 and $53 per ADS and raised USD 2.97 million, USD 1.56 million and USD 1.49 million gross (approximately USD 2.85 million, USD 1.5 million and USD 1.44 million net of placement agent fees), respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other equity transactions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During 2024, the Company issued 3,142 thousand ordinary shares on account of vested RSUs granted in 2021, 2022, 2023 to officers, board members and employees.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During 2023, the Company issued 3,680 thousand ordinary shares on account of vested RSUs granted in 2021, 2022 to officers, board members and employees.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During 2022, the Company issued 1,380 thousand ordinary shares on account of vested RSUs granted in 2020 and 2021 to officers, board members and employees.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In February 2023 the Company
    acquired Immunoraizon &#x2013; see note 4C.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Non-controlling interests&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the information relating to Tyrnovo that has non-controlling interests of 1.53%, before any intra-group eliminations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,
    &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;TyrNovo
    Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;in
    USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;247&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(25,901&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23,419&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(25,711&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23,166&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net assets attributable to non-controlling
    interests&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(394&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(355&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss for the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,545&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,365&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss allocated to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c115"
      decimals="0"
      id="ixv-28923"
      unitRef="shares">1000000000</ifrs-full:NumberOfSharesOutstanding>
    <ppbt:NonVotingSeniorPreferredShares
      contextRef="c0"
      decimals="0"
      id="ixv-28924"
      unitRef="shares">50000000</ppbt:NonVotingSeniorPreferredShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c116"
      decimals="0"
      id="ixv-28925"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesOutstanding>
    <ppbt:StockholdersEquityReversesStockSplit contextRef="c0" id="ixv-28926">1:10 to 1:200</ppbt:StockholdersEquityReversesStockSplit>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c0" id="ixv-22671">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;The Company&#x2019;s share capital&lt;/b&gt;&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and&lt;br/&gt; paid-in&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and&lt;br/&gt; paid-in&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares, no par value&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;517,129&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;252,379&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Class A preferred shares, no par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-155; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-156; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Class B preferred shares, no par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-157; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-158; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Class C preferred shares, no par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-159; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-160; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Class D preferred shares, no par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-161; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-162; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Class E preferred shares, no par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-163; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-164; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c155"
      decimals="-3"
      id="ixv-28927"
      unitRef="shares">1000000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c155"
      decimals="-3"
      id="ixv-28928"
      unitRef="shares">517129000</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c156"
      decimals="-3"
      id="ixv-28929"
      unitRef="shares">1000000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c156"
      decimals="-3"
      id="ixv-28930"
      unitRef="shares">252379000</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c157"
      decimals="-3"
      id="ixv-28931"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c158"
      decimals="-3"
      id="ixv-28932"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c159"
      decimals="-3"
      id="ixv-28933"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c160"
      decimals="-3"
      id="ixv-28934"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c161"
      decimals="-3"
      id="ixv-28935"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c162"
      decimals="-3"
      id="ixv-28936"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c163"
      decimals="-3"
      id="ixv-28937"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c164"
      decimals="-3"
      id="ixv-28938"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c165"
      decimals="-3"
      id="ixv-28939"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c166"
      decimals="-3"
      id="ixv-28940"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesAuthorised>
    <ppbt:DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock contextRef="c0" id="ixv-22982">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Changes in share capital during the year&lt;/b&gt;&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(*)2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(*)2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of ADSs in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued as at
    January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,261&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;924&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;890&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance
    of ADSs (See D below)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;930&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;319&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vesting of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    of warrants and prefunded warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;379&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-165; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-166; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    as at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,586&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,261&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;924&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;*&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restated to reflect a 1:20 reverse ratio that took place in September 2024. (see also note 9A)&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ppbt:DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c3"
      decimals="-3"
      id="ixv-28941"
      unitRef="shares">1261000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c46"
      decimals="-3"
      id="ix_10_fact"
      unitRef="shares">924000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c67"
      decimals="-3"
      id="ix_11_fact"
      unitRef="shares">890000</ifrs-full:NumberOfSharesIssued>
    <ppbt:NumberOfIssuanceShares
      contextRef="c0"
      decimals="-3"
      id="ixv-28944"
      unitRef="shares">930000</ppbt:NumberOfIssuanceShares>
    <ppbt:NumberOfIssuanceShares
      contextRef="c4"
      decimals="-3"
      id="ix_12_fact"
      unitRef="shares">319000</ppbt:NumberOfIssuanceShares>
    <ppbt:NumberOfIssuanceShares
      contextRef="c5"
      decimals="-3"
      id="ix_13_fact"
      unitRef="shares">27000</ppbt:NumberOfIssuanceShares>
    <ppbt:NumberOfVestingOfRsus
      contextRef="c0"
      decimals="-3"
      id="ixv-28947"
      unitRef="shares">16000</ppbt:NumberOfVestingOfRsus>
    <ppbt:NumberOfVestingOfRsus
      contextRef="c4"
      decimals="-3"
      id="ix_14_fact"
      unitRef="shares">18000</ppbt:NumberOfVestingOfRsus>
    <ppbt:NumberOfVestingOfRsus
      contextRef="c5"
      decimals="-3"
      id="ix_15_fact"
      unitRef="shares">7000</ppbt:NumberOfVestingOfRsus>
    <ppbt:NumberOfExerciseOfWarrants
      contextRef="c0"
      decimals="-3"
      id="ixv-28950"
      unitRef="shares">379000</ppbt:NumberOfExerciseOfWarrants>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c2"
      decimals="-3"
      id="ixv-28951"
      unitRef="shares">2586000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c3"
      decimals="-3"
      id="ix_16_fact"
      unitRef="shares">1261000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c46"
      decimals="-3"
      id="ix_17_fact"
      unitRef="shares">924000</ifrs-full:NumberOfSharesIssued>
    <ppbt:ReverseRatio contextRef="c117" id="ixv-28954">1:20</ppbt:ReverseRatio>
    <ppbt:FundsRaisedAmount
      contextRef="c118"
      decimals="-4"
      id="ixv-28955"
      unitRef="usd">2830000</ppbt:FundsRaisedAmount>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="c119"
      decimals="-5"
      id="ixv-28956"
      unitRef="usd">2500000</ifrs-full:ProfessionalFeesExpense>
    <ppbt:NumberOfNonTradableWarrants
      contextRef="c119"
      decimals="0"
      id="ixv-28957"
      unitRef="shares">472668</ppbt:NumberOfNonTradableWarrants>
    <ifrs-full:ParValuePerShare
      contextRef="c118"
      decimals="0"
      id="ixv-28958"
      unitRef="usdPershares">6</ifrs-full:ParValuePerShare>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c119"
      decimals="-5"
      id="ixv-28959"
      unitRef="usd">2500000</ifrs-full:ShareIssueRelatedCost>
    <ppbt:FundsRaisedshares
      contextRef="c120"
      decimals="0"
      id="ixv-28960"
      unitRef="shares">33087</ppbt:FundsRaisedshares>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="c120"
      decimals="-3"
      id="ixv-28961"
      unitRef="usd">109000</ifrs-full:ProfessionalFeesExpense>
    <ppbt:WarrantsTerm contextRef="c119" id="ixv-28962">P5Y</ppbt:WarrantsTerm>
    <ifrs-full:WarrantReserve
      contextRef="c121"
      decimals="-6"
      id="ixv-28963"
      unitRef="usd">2000000</ifrs-full:WarrantReserve>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="c122"
      decimals="-5"
      id="ixv-28964"
      unitRef="usd">1800000</ifrs-full:ProfessionalFeesExpense>
    <ppbt:NumberOfNonTradableWarrants
      contextRef="c123"
      decimals="0"
      id="ixv-28965"
      unitRef="shares">281675</ppbt:NumberOfNonTradableWarrants>
    <ppbt:DepositaryShares
      contextRef="c124"
      decimals="0"
      id="ixv-28966"
      unitRef="shares">166469</ppbt:DepositaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c125"
      decimals="0"
      id="ixv-28967"
      unitRef="usdPershares">25</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c126"
      decimals="0"
      id="ixv-28968"
      unitRef="usdPershares">400</ifrs-full:ParValuePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c124"
      decimals="1"
      id="ixv-28969"
      unitRef="usdPershares">7.2</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ppbt:PurchaseOfCommonStockAndWarrants
      contextRef="c127"
      decimals="0"
      id="ixv-28970"
      unitRef="shares">248969</ppbt:PurchaseOfCommonStockAndWarrants>
    <ppbt:PurchaseOfCommonStockAndWarrants
      contextRef="c128"
      decimals="0"
      id="ixv-28971"
      unitRef="shares">314382</ppbt:PurchaseOfCommonStockAndWarrants>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c129"
      decimals="0"
      id="ixv-28972"
      unitRef="usdPershares">8</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WarrantLiability
      contextRef="c130"
      decimals="-3"
      id="ixv-28973"
      unitRef="usd">2028000</ifrs-full:WarrantLiability>
    <ppbt:WarrantsIssued
      contextRef="c124"
      decimals="0"
      id="ixv-28974"
      unitRef="shares">19717</ppbt:WarrantsIssued>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c131"
      decimals="0"
      id="ixv-28975"
      unitRef="usdPershares">9</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WarrantLiability
      contextRef="c132"
      decimals="-3"
      id="ixv-28976"
      unitRef="usd">100000</ifrs-full:WarrantLiability>
    <ppbt:WarrantsTerm contextRef="c124" id="ixv-28977">P5Y</ppbt:WarrantsTerm>
    <ifrs-full:WarrantReserve
      contextRef="c133"
      decimals="-6"
      id="ixv-28978"
      unitRef="usd">5000000</ifrs-full:WarrantReserve>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="c134"
      decimals="-5"
      id="ixv-28979"
      unitRef="usd">4300000</ifrs-full:ProfessionalFeesExpense>
    <ppbt:PurchaseOfCommonStockAndWarrants
      contextRef="c135"
      decimals="0"
      id="ixv-28980"
      unitRef="shares">121500</ppbt:PurchaseOfCommonStockAndWarrants>
    <ifrs-full:ParValuePerShare
      contextRef="c136"
      decimals="0"
      id="ixv-28981"
      unitRef="usdPershares">23</ifrs-full:ParValuePerShare>
    <ppbt:IssuesOfEquity
      contextRef="c135"
      decimals="0"
      id="ixv-28982"
      unitRef="shares">95891</ppbt:IssuesOfEquity>
    <ppbt:PurchaseOfCommonStockAndWarrants
      contextRef="c137"
      decimals="0"
      id="ixv-28983"
      unitRef="shares">217391</ppbt:PurchaseOfCommonStockAndWarrants>
    <ppbt:ExerciseOfWarrantsEquity
      contextRef="c135"
      decimals="-3"
      id="ixv-28984"
      unitRef="usd">5348000</ppbt:ExerciseOfWarrantsEquity>
    <ppbt:WarrantTermDescription contextRef="c0" id="ixv-28985">The October 2023 warrants have a term of five and a half years and have an exercise price of USD 25 per ADS</ppbt:WarrantTermDescription>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c138"
      decimals="0"
      id="ixv-28986"
      unitRef="usdPershares">25</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ppbt:PurchaseOfCommonStockAndWarrants
      contextRef="c139"
      decimals="0"
      id="ixv-28987"
      unitRef="shares">31578</ppbt:PurchaseOfCommonStockAndWarrants>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c140"
      decimals="0"
      id="ixv-28988"
      unitRef="usdPershares">180</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c141"
      decimals="0"
      id="ixv-28989"
      unitRef="usdPershares">560</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c142"
      decimals="0"
      id="ixv-28990"
      unitRef="usdPershares">25</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ppbt:WarrantTermDescription contextRef="c143" id="ixv-28991">an extended term of five and a half years from the closing of the offering</ppbt:WarrantTermDescription>
    <ifrs-full:OtherExpenseByNature
      contextRef="c144"
      decimals="-3"
      id="ixv-28992"
      unitRef="usd">761000</ifrs-full:OtherExpenseByNature>
    <ppbt:FundsRaisedshares
      contextRef="c145"
      decimals="0"
      id="ixv-28993"
      unitRef="shares">15217</ppbt:FundsRaisedshares>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="c146"
      decimals="-3"
      id="ixv-28994"
      unitRef="usd">357000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c146"
      decimals="2"
      id="ixv-28995"
      unitRef="usdPershares">28.75</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ppbt:WarrantsTerm contextRef="c142" id="ixv-28996">P5Y</ppbt:WarrantsTerm>
    <ppbt:PurchaseOfCommonStockAndWarrants
      contextRef="c147"
      decimals="0"
      id="ixv-28997"
      unitRef="shares">34975</ppbt:PurchaseOfCommonStockAndWarrants>
    <ifrs-full:InsuranceContractsIssuedThatAreAssets
      contextRef="c148"
      decimals="-5"
      id="ixv-28998"
      unitRef="usd">50000000</ifrs-full:InsuranceContractsIssuedThatAreAssets>
    <ifrs-full:OtherExpenseByNature
      contextRef="c149"
      decimals="-5"
      id="ixv-28999"
      unitRef="usd">21000000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature
      contextRef="c150"
      decimals="-5"
      id="ixv-29000"
      unitRef="usd">3000000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature
      contextRef="c151"
      decimals="-4"
      id="ixv-29001"
      unitRef="usd">1330000</ifrs-full:OtherExpenseByNature>
    <ppbt:SalesAgreementShares
      contextRef="c0"
      decimals="0"
      id="ixv-29002"
      unitRef="shares">457801</ppbt:SalesAgreementShares>
    <ppbt:SalesAgreementShares
      contextRef="c4"
      decimals="0"
      id="ixv-29003"
      unitRef="shares">52202</ppbt:SalesAgreementShares>
    <ppbt:SalesAgreementShares
      contextRef="c5"
      decimals="0"
      id="ixv-29004"
      unitRef="shares">27170</ppbt:SalesAgreementShares>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c0"
      decimals="0"
      id="ixv-29005"
      unitRef="usdPershares">9</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c4"
      decimals="1"
      id="ixv-29006"
      unitRef="usdPershares">32.6</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c5"
      decimals="0"
      id="ixv-29007"
      unitRef="usdPershares">53</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:WarrantReserve contextRef="c67" decimals="-4" id="ixv-29008" unitRef="usd">2970000</ifrs-full:WarrantReserve>
    <ifrs-full:WarrantReserve contextRef="c3" decimals="-4" id="ixv-29009" unitRef="usd">1560000</ifrs-full:WarrantReserve>
    <ifrs-full:WarrantReserve contextRef="c46" decimals="-4" id="ixv-29010" unitRef="usd">1490000</ifrs-full:WarrantReserve>
    <ifrs-full:ProfessionalFeesExpense contextRef="c0" decimals="-4" id="ixv-29011" unitRef="usd">2850000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense contextRef="c4" decimals="-5" id="ixv-29012" unitRef="usd">1500000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense contextRef="c5" decimals="-4" id="ixv-29013" unitRef="usd">1440000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c152"
      decimals="-3"
      id="ixv-29014"
      unitRef="shares">3142000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c153"
      decimals="-3"
      id="ixv-29015"
      unitRef="shares">3680000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c154"
      decimals="-3"
      id="ixv-29016"
      unitRef="shares">1380000</ifrs-full:NumberOfSharesIssued>
    <ppbt:DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock contextRef="c0" id="ixv-23419">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the information relating to Tyrnovo that has non-controlling interests of 1.53%, before any intra-group eliminations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,
    &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;TyrNovo
    Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;in
    USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;247&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(25,901&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23,419&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(25,711&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23,166&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net assets attributable to non-controlling
    interests&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(394&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(355&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss for the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,545&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,365&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss allocated to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ppbt:DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock>
    <ppbt:noncontrollingInterests contextRef="c0" decimals="4" id="ixv-29017" unitRef="pure">0.0153</ppbt:noncontrollingInterests>
    <ifrs-full:OtherNoncurrentAssets contextRef="c2" decimals="-3" id="ixv-29018" unitRef="usd">6000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c3" decimals="-3" id="ixv-29019" unitRef="usd">6000</ifrs-full:OtherNoncurrentAssets>
    <ppbt:CurrentAsset contextRef="c2" decimals="-3" id="ixv-29020" unitRef="usd">184000</ppbt:CurrentAsset>
    <ppbt:CurrentAsset contextRef="c3" decimals="-3" id="ixv-29021" unitRef="usd">247000</ppbt:CurrentAsset>
    <ppbt:CurrentLiabiliti contextRef="c2" decimals="-3" id="ixv-29022" unitRef="usd">-25901000</ppbt:CurrentLiabiliti>
    <ppbt:CurrentLiabiliti contextRef="c3" decimals="-3" id="ixv-29023" unitRef="usd">-23419000</ppbt:CurrentLiabiliti>
    <ifrs-full:NetAssetsLiabilities contextRef="c2" decimals="-3" id="ixv-29024" unitRef="usd">-25711000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c3" decimals="-3" id="ixv-29025" unitRef="usd">-23166000</ifrs-full:NetAssetsLiabilities>
    <ppbt:NetAssetsAttributableToNoncontrollingInterest contextRef="c2" decimals="-3" id="ixv-29026" unitRef="usd">-394000</ppbt:NetAssetsAttributableToNoncontrollingInterest>
    <ppbt:NetAssetsAttributableToNoncontrollingInterest contextRef="c3" decimals="-3" id="ixv-29027" unitRef="usd">-355000</ppbt:NetAssetsAttributableToNoncontrollingInterest>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests contextRef="c0" decimals="-3" id="ixv-29028" unitRef="usd">2545000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests contextRef="c4" decimals="-3" id="ixv-29029" unitRef="usd">6365000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests>
    <ppbt:NetAssetsAttributableToNoncontrollingInterests contextRef="c0" decimals="-3" id="ixv-29030" unitRef="usd">39000</ppbt:NetAssetsAttributableToNoncontrollingInterests>
    <ppbt:NetAssetsAttributableToNoncontrollingInterests contextRef="c4" decimals="-3" id="ixv-29031" unitRef="usd">97000</ppbt:NetAssetsAttributableToNoncontrollingInterests>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c0" id="ixv-23608">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note 10
- Share-based Payment Arrangements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On August 15, 2024, the board of directors of the Company granted 3,150 thousand options (to purchase the equivalent of 15,750 ADSs) and 3,150 thousand RSUs (equivalent to 15,750 ADSs) to employees. The options have an exercise price of USD 0.037 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 190 thousand. &lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On March 2, 2023, the board of directors of the Company granted 45 thousand options (to purchase the equivalent of 225 ADSs) and 45 thousand RSUs (equivalent to 225 ADSs) to an employee. The options have an exercise price of USD 0.198 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 16 thousand.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On April 24, 2023, the board of directors of the Company granted 2,732 thousand options (to purchase the equivalent of 14 thousand ADSs) and 2,732 thousand RSUs (equivalent to 14 thousand ADSs) to the Board members, subject to the approval of the shareholders, and to employees. The options have an exercise price of USD 0.190 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 729 thousand. The board members grant was approved by the shareholders on June 15, 2023.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On October 31, 2022, the board of directors of the Company granted 750 thousand options and 750 thousand RSUs to an employee. The options have an exercise price of USD 0.208 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 267 thousand.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On July 11, 2022, the board of directors of the Company granted 3,750 thousand options and 150 thousand RSUs to the new CEO, subject to approval in the annual general meeting. The options have an exercise price of USD 0.245 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 591 thousand. This grant was approved by the shareholders on August 25, 2022.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
May 23, 2022, the board of directors of the Company granted 6,635 thousand options and 5,885 thousand RSUs to officers and employees.
The options have an exercise price of USD 0.304 per one ordinary share, and for certain employee and consultant USD 0.276 per one ordinary
share eligible as from June 23, 2022. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable
for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 3,237 thousand.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;The number and weighted average exercise prices (in USD) of share options are as follows:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    on January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.46&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.52&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.97&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,218,783&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,468,235&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,751,303&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired
    and forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.84&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.54&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.82&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,004,460&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,026,452&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(418,068&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted
    during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.037&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,777,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,135,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    on December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.36&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.46&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.52&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,364,323&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,218,783&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,468,235&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable
    on December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.62&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.97&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,420,406&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,923,032&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,144,318&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The exercise price is denominated in
NIS and is re-measured using historic exchange rates. Options are exercisable to shares, each ADS represent 200 shares.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
options outstanding at December 31, 2024 had an exercise price of USD 0.037- USD 6 (2023 - USD 0.190- USD 6, 2022 -USD 0.208- USD 6),
and weighted average contractual life of 2.51 years (2023 &#x2013; 3.10 years, 2022 &#x2013; 3.87 years).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;The number of RSUs are as follows:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,770,750&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,857,917&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,777,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(859,584&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,187,292&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,142,249&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,676,875&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,918,917&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,770,750&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Each
RSU is convertible to one share, each ADS represent 200 shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The fair value of the Company&#x2019;s
    share options granted to employees, directors and consultants, where fair value of service was not measurable, was measured using
    the binominal model, using the fair value of the traded warrants with similar terms, making certain adjustments to reflect the specific
    terms of the options based on the expected duration.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E&lt;/b&gt;.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following assumptions were used&lt;b&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Share Price - USD&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;0.036&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.160-0.226&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercise price - USD&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0.037&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.19 -0.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;95.93&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;93.54-96.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected duration (years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2-2.8&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2-5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk free rate interest rate (%)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;3.88&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.56%-4.31%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Expenses recognized in the consolidated financial statements:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;768&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;768&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;465&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,107&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,644&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total share-based expense
    recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;582&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,875&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,412&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c167"
      decimals="-3"
      id="ixv-29032"
      unitRef="pure">3150000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c168"
      decimals="0"
      id="ixv-29033"
      unitRef="pure">15750</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c169"
      decimals="-3"
      id="ixv-29034"
      unitRef="pure">3150000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c168"
      decimals="0"
      id="ixv-29035"
      unitRef="pure">15750</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c170"
      decimals="3"
      id="ixv-29036"
      unitRef="usdPershares">0.037</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ppbt:OptionExerciseOrdinaryShare
      contextRef="c171"
      decimals="0"
      id="ixv-29037"
      unitRef="shares">1</ppbt:OptionExerciseOrdinaryShare>
    <ppbt:VestingPeriod contextRef="c169" id="ixv-29038">P3Y</ppbt:VestingPeriod>
    <ppbt:ExercisePeriod contextRef="c167" id="ixv-29039">P5Y</ppbt:ExercisePeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c172"
      decimals="-3"
      id="ixv-29040"
      unitRef="usd">190000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c173"
      decimals="-3"
      id="ixv-29041"
      unitRef="pure">45000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c174"
      decimals="-3"
      id="ixv-29042"
      unitRef="pure">225000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c175"
      decimals="-3"
      id="ixv-29043"
      unitRef="pure">45000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c176"
      decimals="-3"
      id="ixv-29044"
      unitRef="pure">225000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c173"
      decimals="3"
      id="ixv-29045"
      unitRef="usdPershares">0.198</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ppbt:OptionExerciseOrdinaryShare
      contextRef="c177"
      decimals="0"
      id="ixv-29046"
      unitRef="shares">1</ppbt:OptionExerciseOrdinaryShare>
    <ppbt:VestingPeriod contextRef="c175" id="ixv-29047">P3Y</ppbt:VestingPeriod>
    <ppbt:ExercisePeriod contextRef="c173" id="ixv-29048">P5Y</ppbt:ExercisePeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c178"
      decimals="-3"
      id="ixv-29049"
      unitRef="usd">16000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c179"
      decimals="-3"
      id="ixv-29050"
      unitRef="pure">2732000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c180"
      decimals="-3"
      id="ixv-29051"
      unitRef="pure">14000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c181"
      decimals="-3"
      id="ixv-29052"
      unitRef="pure">2732000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c182"
      decimals="-3"
      id="ixv-29053"
      unitRef="pure">14000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c179"
      decimals="3"
      id="ixv-29054"
      unitRef="usdPershares">0.19</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ppbt:OptionExerciseOrdinaryShare
      contextRef="c183"
      decimals="0"
      id="ixv-29055"
      unitRef="shares">1</ppbt:OptionExerciseOrdinaryShare>
    <ppbt:VestingPeriod contextRef="c184" id="ixv-29056">P3Y</ppbt:VestingPeriod>
    <ppbt:ExercisePeriod contextRef="c179" id="ixv-29057">P5Y</ppbt:ExercisePeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c185"
      decimals="-3"
      id="ixv-29058"
      unitRef="usd">729000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c186"
      decimals="-3"
      id="ixv-29059"
      unitRef="pure">750000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c187"
      decimals="-3"
      id="ixv-29060"
      unitRef="pure">750000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c187"
      decimals="3"
      id="ixv-29061"
      unitRef="usdPershares">0.208</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ppbt:OptionExerciseOrdinaryShare
      contextRef="c188"
      decimals="0"
      id="ixv-29062"
      unitRef="shares">1</ppbt:OptionExerciseOrdinaryShare>
    <ppbt:VestingPeriod contextRef="c187" id="ixv-29063">P3Y</ppbt:VestingPeriod>
    <ppbt:ExercisePeriod contextRef="c186" id="ixv-29064">P5Y</ppbt:ExercisePeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c189"
      decimals="-3"
      id="ixv-29065"
      unitRef="usd">267000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c190"
      decimals="-3"
      id="ixv-29066"
      unitRef="pure">3750000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c191"
      decimals="-3"
      id="ixv-29067"
      unitRef="pure">150000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c190"
      decimals="3"
      id="ixv-29068"
      unitRef="usdPershares">0.245</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ppbt:OptionExerciseOrdinaryShare
      contextRef="c192"
      decimals="0"
      id="ixv-29069"
      unitRef="shares">1</ppbt:OptionExerciseOrdinaryShare>
    <ppbt:VestingPeriod contextRef="c191" id="ixv-29070">P3Y</ppbt:VestingPeriod>
    <ppbt:ExercisePeriod contextRef="c190" id="ixv-29071">P5Y</ppbt:ExercisePeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c193"
      decimals="-3"
      id="ixv-29072"
      unitRef="usd">591000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c194"
      decimals="-3"
      id="ixv-29073"
      unitRef="pure">6635000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c195"
      decimals="-3"
      id="ixv-29074"
      unitRef="pure">5885000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c194"
      decimals="3"
      id="ixv-29075"
      unitRef="usdPershares">0.304</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ppbt:OptionExerciseOrdinaryShare
      contextRef="c196"
      decimals="0"
      id="ixv-29076"
      unitRef="shares">1</ppbt:OptionExerciseOrdinaryShare>
    <ppbt:ConsultantPerShares
      contextRef="c197"
      decimals="3"
      id="ixv-29077"
      unitRef="usdPershares">0.276</ppbt:ConsultantPerShares>
    <ppbt:OptionExerciseOrdinaryShare
      contextRef="c198"
      decimals="0"
      id="ixv-29078"
      unitRef="shares">1</ppbt:OptionExerciseOrdinaryShare>
    <ppbt:VestingPeriod contextRef="c199" id="ixv-29079">P3Y</ppbt:VestingPeriod>
    <ppbt:ExercisePeriod contextRef="c194" id="ixv-29080">P5Y</ppbt:ExercisePeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c200"
      decimals="-3"
      id="ixv-29081"
      unitRef="usd">3237000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="c0" id="ixv-23682">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;The number and weighted average exercise prices (in USD) of share options are as follows:&lt;/b&gt;&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    on January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.46&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.52&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.97&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,218,783&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,468,235&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,751,303&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired
    and forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.84&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.54&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.82&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,004,460&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,026,452&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(418,068&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted
    during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.037&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,777,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,135,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    on December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.36&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.46&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.52&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,364,323&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,218,783&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,468,235&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable
    on December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.62&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.97&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,420,406&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,923,032&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,144,318&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="2"
      id="ixv-29082"
      unitRef="usdPershares">0.46</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c46"
      decimals="2"
      id="ixv-29083"
      unitRef="usdPershares">0.52</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c67"
      decimals="2"
      id="ixv-29084"
      unitRef="usdPershares">0.97</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c3" decimals="0" id="ixv-29085" unitRef="pure">19218783</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c46" decimals="0" id="ixv-29086" unitRef="pure">18468235</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c67" decimals="0" id="ixv-29087" unitRef="pure">7751303</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c0"
      decimals="2"
      id="ixv-29088"
      unitRef="usdPershares">0.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c4"
      decimals="2"
      id="ixv-29089"
      unitRef="usdPershares">0.54</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c5"
      decimals="2"
      id="ixv-29090"
      unitRef="usdPershares">0.82</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c0" decimals="0" id="ixv-29091" unitRef="pure">2004460</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c4" decimals="0" id="ixv-29092" unitRef="pure">2026452</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c5" decimals="0" id="ixv-29093" unitRef="pure">418068</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c0"
      decimals="3"
      id="ixv-29094"
      unitRef="usdPershares">0.037</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c4"
      decimals="2"
      id="ixv-29095"
      unitRef="usdPershares">0.19</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c5"
      decimals="2"
      id="ixv-29096"
      unitRef="usdPershares">0.28</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c0" decimals="0" id="ixv-29097" unitRef="pure">3150000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c4" decimals="0" id="ixv-29098" unitRef="pure">2777000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c5" decimals="0" id="ixv-29099" unitRef="pure">11135000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c2"
      decimals="2"
      id="ixv-29100"
      unitRef="usdPershares">0.36</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="2"
      id="ixv-29101"
      unitRef="usdPershares">0.46</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c46"
      decimals="2"
      id="ixv-29102"
      unitRef="usdPershares">0.52</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c2" decimals="0" id="ixv-29103" unitRef="pure">20364323</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c3" decimals="0" id="ixv-29104" unitRef="pure">19218783</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c46" decimals="0" id="ixv-29105" unitRef="pure">18468235</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c2"
      decimals="2"
      id="ixv-29106"
      unitRef="usdPershares">0.45</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="2"
      id="ixv-29107"
      unitRef="usdPershares">0.62</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c46"
      decimals="2"
      id="ixv-29108"
      unitRef="usdPershares">0.97</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c2" decimals="0" id="ixv-29109" unitRef="pure">14420406</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c3" decimals="0" id="ixv-29110" unitRef="pure">10923032</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c46" decimals="0" id="ixv-29111" unitRef="pure">6144318</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ppbt:AmericanDepostioryShares
      contextRef="c0"
      decimals="0"
      id="ixv-29112"
      unitRef="shares">200</ppbt:AmericanDepostioryShares>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c201"
      decimals="3"
      id="ixv-29113"
      unitRef="usdPershares">0.037</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c202"
      decimals="-3"
      id="ixv-29114"
      unitRef="usd">6000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c203"
      decimals="3"
      id="ixv-29115"
      unitRef="usdPershares">0.19</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c204"
      decimals="-3"
      id="ixv-29116"
      unitRef="usd">6000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c205"
      decimals="3"
      id="ixv-29117"
      unitRef="usdPershares">0.208</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c206"
      decimals="-3"
      id="ixv-29118"
      unitRef="usd">6000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c0" id="ixv-29119">P2Y6M3D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c4" id="ixv-29120">P3Y1M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c5" id="ixv-29121">P3Y10M13D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ppbt:DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock contextRef="c0" id="ixv-24013">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;The number of RSUs are as follows:&lt;/b&gt;&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,770,750&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,857,917&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,777,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(859,584&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,187,292&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,142,249&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,676,875&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,918,917&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,770,750&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ppbt:DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c3" decimals="0" id="ixv-29122" unitRef="pure">5770750</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c46" decimals="0" id="ixv-29123" unitRef="pure">7857917</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="c0" decimals="0" id="ixv-29124" unitRef="pure">3150000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="c4" decimals="0" id="ixv-29125" unitRef="pure">2777000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="c0" decimals="0" id="ixv-29126" unitRef="pure">859584</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="c4" decimals="0" id="ixv-29127" unitRef="pure">1187292</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="c0" decimals="0" id="ixv-29128" unitRef="pure">3142249</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="c4" decimals="0" id="ixv-29129" unitRef="pure">3676875</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c2" decimals="0" id="ixv-29130" unitRef="pure">4918917</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c3" decimals="0" id="ixv-29131" unitRef="pure">5770750</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ppbt:ConvertibleShares
      contextRef="c0"
      decimals="0"
      id="ixv-29132"
      unitRef="shares">1</ppbt:ConvertibleShares>
    <ppbt:AmericanDepostioryShares
      contextRef="c207"
      decimals="0"
      id="ixv-29133"
      unitRef="shares">200</ppbt:AmericanDepostioryShares>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="c0" id="ixv-24160">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following assumptions were used&lt;b&gt;:&lt;/b&gt;&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Share Price - USD&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;0.036&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.160-0.226&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercise price - USD&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0.037&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.19 -0.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;95.93&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;93.54-96.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected duration (years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2-2.8&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2-5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk free rate interest rate (%)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;3.88&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.56%-4.31%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c0"
      decimals="3"
      id="ixv-29134"
      unitRef="usdPershares">0.036</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c208"
      decimals="3"
      id="ixv-29135"
      unitRef="usdPershares">0.16</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c209"
      decimals="3"
      id="ixv-29136"
      unitRef="usdPershares">0.226</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c0"
      decimals="3"
      id="ixv-29137"
      unitRef="usdPershares">0.037</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c208"
      decimals="2"
      id="ixv-29138"
      unitRef="usdPershares">0.19</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c209"
      decimals="1"
      id="ixv-29139"
      unitRef="usdPershares">0.2</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c0" decimals="4" id="ixv-29140" unitRef="pure">0.9593</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c208"
      decimals="4"
      id="ixv-29141"
      unitRef="pure">0.9354</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c209"
      decimals="4"
      id="ixv-29142"
      unitRef="pure">0.9604</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="c210"
      decimals="0"
      id="ixv-29143"
      unitRef="pure">2</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="c211"
      decimals="1"
      id="ixv-29144"
      unitRef="pure">2.8</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="c208"
      decimals="0"
      id="ixv-29145"
      unitRef="pure">2</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="c209"
      decimals="0"
      id="ixv-29146"
      unitRef="pure">5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c0" decimals="4" id="ixv-29147" unitRef="pure">0.0388</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c208"
      decimals="4"
      id="ixv-29148"
      unitRef="pure">0.0356</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c209"
      decimals="4"
      id="ixv-29149"
      unitRef="pure">0.0431</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory contextRef="c0" id="ixv-24252">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Expenses recognized in the consolidated financial statements:&lt;/b&gt;&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;768&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;768&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;465&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,107&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,644&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total share-based expense
    recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;582&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,875&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,412&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c212"
      decimals="-3"
      id="ixv-29150"
      unitRef="usd">117000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c213"
      decimals="-3"
      id="ixv-29151"
      unitRef="usd">768000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c214"
      decimals="-3"
      id="ixv-29152"
      unitRef="usd">768000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c215"
      decimals="-3"
      id="ixv-29153"
      unitRef="usd">465000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c216"
      decimals="-3"
      id="ixv-29154"
      unitRef="usd">1107000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c217"
      decimals="-3"
      id="ixv-29155"
      unitRef="usd">1644000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-29156" unitRef="usd">582000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c4" decimals="-3" id="ixv-29157" unitRef="usd">1875000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c5" decimals="-3" id="ixv-29158" unitRef="usd">2412000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c0" id="ixv-24430">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note 11
- Transactions and Balances with Related Parties &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
addition to their salaries or fees, the Group also provides share option programs to directors and officers and contributes to a post-employment
defined contribution plan on behalf of employees, see Note 8 for the balances and Note 10 regarding share-based payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
CEO is entitled to termination benefits of up to 6 monthly salaries or fees, See Note 17.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company pays the members of the board an annual fee for their service and an additional fee for serving on boards committees. In addition,
the Company pays the chairman of the board a monthly fee for his service as the chairman of our medical and clinical committee. A monthly
fee is being paid to one of the directors who has been engaged as an advisor in a 50% capacity&lt;/span&gt;, &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
bonuses for certain strategic or financing transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Expenses
of key management personnel:&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company recorded expenses to executive officers:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short - term employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,257&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,066&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,623&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share based payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;378&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,346&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,930&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,634&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,424&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,564&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company recorded expenses to directors:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short - term benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;394&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;427&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;448&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share based payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;193&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;284&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;311&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;587&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;711&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;759&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ppbt:PercentageOfCapacityOfAnAdvisor contextRef="c0" decimals="2" id="ixv-29159" unitRef="pure">0.50</ppbt:PercentageOfCapacityOfAnAdvisor>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="c0" id="ixv-24456">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company recorded expenses to executive officers:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short - term employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,257&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,066&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,623&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share based payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;378&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,346&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,930&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,634&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,424&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,564&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company recorded expenses to directors:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short - term benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;394&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;427&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;448&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share based payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;193&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;284&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;311&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;587&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;711&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;759&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="c218"
      decimals="-3"
      id="ixv-29160"
      unitRef="usd">1257000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="c219"
      decimals="-3"
      id="ixv-29161"
      unitRef="usd">2066000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="c220"
      decimals="-3"
      id="ixv-29162"
      unitRef="usd">2623000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="c218"
      decimals="-3"
      id="ixv-29163"
      unitRef="usd">-1000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="c219"
      decimals="-3"
      id="ixv-29164"
      unitRef="usd">12000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="c220"
      decimals="-3"
      id="ixv-29165"
      unitRef="usd">11000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="c218"
      decimals="-3"
      id="ixv-29166"
      unitRef="usd">378000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="c219"
      decimals="-3"
      id="ixv-29167"
      unitRef="usd">1346000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="c220"
      decimals="-3"
      id="ixv-29168"
      unitRef="usd">1930000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="c218"
      decimals="-3"
      id="ixv-29169"
      unitRef="usd">1634000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="c219"
      decimals="-3"
      id="ixv-29170"
      unitRef="usd">3424000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="c220"
      decimals="-3"
      id="ixv-29171"
      unitRef="usd">4564000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="c221"
      decimals="-3"
      id="ixv-29172"
      unitRef="usd">394000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="c222"
      decimals="-3"
      id="ixv-29173"
      unitRef="usd">427000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="c223"
      decimals="-3"
      id="ixv-29174"
      unitRef="usd">448000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="c221"
      decimals="-3"
      id="ixv-29175"
      unitRef="usd">193000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="c222"
      decimals="-3"
      id="ixv-29176"
      unitRef="usd">284000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="c223"
      decimals="-3"
      id="ixv-29177"
      unitRef="usd">311000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="c221"
      decimals="-3"
      id="ixv-29178"
      unitRef="usd">587000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="c222"
      decimals="-3"
      id="ixv-29179"
      unitRef="usd">711000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="c223"
      decimals="-3"
      id="ixv-29180"
      unitRef="usd">759000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c0" id="ixv-24794">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note 12
- Commitments and contingent liabilities &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Commitments&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;TyrNovo, has obligations
    to the Israel Innovation Authority (hereinafter: &#x201c;IIA&#x201d;) with respect to grants it received from the IIA in connection
    with TyrNovo&#x2019;s technology. The requirements and restrictions for such grants are found in the Encouragement of Research, Development
    and Technological Innovation in Industry Law 5744-1984 and in the IIA&#x2019;s rules and guidelines and the terms of these grants.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In general, a recipient company is
obligated to pay the IIA royalties from the revenues generated from the sale of products and related services developed as a result of,
a research and development program funded , in whole or in part, by the IIA (currently a yearly rate of 3% to 6%), up to the aggregate
amount of the total grants received by the IIA, plus annual interest. The recipient company is also obligated to manufacture its drug
in Israel unless it receives the approval of the IIA in which case it will be required to pay the higher rate mentioned above. A recipient
company is not required to repay the grants if it does not generate revenue.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;TyrNovo&#x2019;s
technologies were developed, in part, with funds from IIA grants, and accordingly is obligated to pay royalties on sales of any of its
IIA funded products and related services.&#160; &#160;As of December 31, 2024, the maximum royalty amount that would be payable by TyrNovo,
excluding interest, is approximately NIS 5.5 million (USD 1.51 million), and as of such date, TyrNovo had not paid any royalties to the
IIA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group does not recognize a liability for royalties because there is no reasonable assurance, as of the reporting period, that the underlying
sales will occur in the future. Therefore, the financial statements do not include a liability for these royalties.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;TyrNovo has entered into a
    license agreement (the &#x201c;License Agreement&#x201d;) with Yissum Research Development Company of the Hebrew University of
    Jerusalem Ltd. (hereafter &#x201c;Yissum&#x201d;) dated August 15, 2013, as amended. In accordance with the License Agreement, Yissum
    granted the Company an exclusive license to commercialize, exploit, develop, manufacture, market, import, export, distribute, offer
    to sell, or sell products, that are derived from Yissum&#x2019;s licensed technology.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Royalties at a rate of up to three percent (3%) of net sales. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sublicense fees at a rate of twelve percent (12%) of sublicense consideration.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
addition, Yissum is entitled to receive an exit fee of 12% of the transaction proceeds in the event of certain pre - defined transactions
set forth in the License Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;BIRAD
Research &amp;amp; Development Company Ltd. (BIRAD) is entitled to receive a portion of Yissum&#x2019;s royalties on net sales according to
an amendment to the License Agreement signed between TyrNovo and Yissum.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
consolidated financial statements do not include a liability for royalties or sublicense fees for this license agreement as there is
no minimum payments and thus obligation will be recognized when the related sales will occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;cCAM
    Biotherapeutics Ltd. (cCam), a subsidiary of Merck Sharp and Dohme Corp. (MSD), has entered into a license agreement with Tel Hashomer
    &#x2013; Medical Research Infrastructure and Services Ltd. (&#x201c;THM&#x201d;) and Ramot at Tel Aviv University Ltd. (&#x201c;Ramot&#x201d;)
    dated April 16, 2012, which was effective as of May 25, 2010, as subsequently amended (the &#x201c;THM License Agreement&#x201d;).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
    conjunction with the closing of the reversion agreement amongst (MSD), cCAM and FameWave, the parties executed an Assignment and
    Assumption Agreement by and between FameWave and cCAM, according to which cCAM assigned to FameWave all its rights, title and interest
    in, to and under the THM License Agreement.&#160;Pursuant to the THM License Agreement, THM and Ramot granted FameWave a worldwide,
    royalty-bearing, exclusive license to develop, manufacture, produce, market and sell any biopharmaceutical product and/or diagnostic
    product using patents and inventions owned by THM and Ramot in connection with uses of the glycoprotein CEACAM1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
consideration for the license grant, FameWave shall pay to THM the following during the term of the license:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An annual license fee of $10,000 which is credited towards any royalties to be paid during such year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ii)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Royalties of three and &#160;a half percent (3.5%) of net sales with respect to Biopharmaceutical Products, and royalties of six and &#160;a half percent (6.5%) of net sales with respect to Diagnostic Products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;iii)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sublicense fees at a rate of twenty percent (20%) of sublicense consideration with respect to Biopharmaceutical Products, and sublicense fees at a rate of twelve percent (12%) of sublicense consideration with respect to Diagnostic Products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;FameWave
has undertaken to pay certain milestone payments upon the completion of certain pre-defined clinical and sales milestones.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
addition, THM (on behalf of the licensors) are entitled to receive an exit fee of up to three and a half percent (3.5%) of all consideration
received because of or in connection with an exit event (as defined in the THM License Agreement).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finally,
THM also received an assignable warrant to purchase, upon the closing of any IPO of FameWave, ordinary shares of FameWave, at a price
equal to a certain percentage of the forecast initial market value of FameWave for each share as determined, prior to the IPO, for the
purpose of the IPO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
accordance with the THM License Agreement, THM is entitled to appoint an observer to FameWave&#x2019;s board of directors who has all
the rights of any other director of FameWave expect for the right to vote. To date, THM has not acted on this right.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
consolidated financial statements do not include a liability for royalties or sublicense fees for this license agreement as there is
no minimum payments and thus obligation will be recognized when the related sales will occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Claims&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In February 2017, four lawsuits and motions to approve the lawsuits as a class action lawsuit (each, a &#x201c;Motion&#x201d;), were filed against the Company and certain of its office holders at the Tel Aviv District Court (Economic Division), with each Motion relating to the Company announcement that the Israeli Securities Authority (the &#x201c;ISA&#x201d;) has begun a formal investigation into, amongst other matters, the Company&#x2019;s public disclosures around certain aspects of the studies related to its therapeutic candidate, Consensi (the &#x201c;2017 Motions&#x201d;). One of these motions was subsequently withdrawn. The petitioners in one of the motions petitioned the court to dismiss the other two of the 2017 Motions (&#x201c;Petition for Dismissal&#x201d;). On December 19, 2017 the court granted the Petition for Dismissal and dismissed the other remaining 2017 Motions. The remaining motion (the &#x201c;Surviving Motion&#x201d;) was filed against the Company, the Company&#x2019;s executive directors and certain of its present and former directors, by certain shareholders who are requesting to act as representatives of all shareholders of record from December 10, 2015 until February 6, 2017. The plaintiffs allege, among other things, that the Company included misleading information in its public filings which caused the class for which the plaintiffs are seeking recognition an aggregate loss of approximately NIS 29 million (approximately USD 8.0 million). The court ordered a stay of proceedings due to the then-ongoing ISA Investigation. Following approval of an enforcement arrangement in connection with the ISA investigation, the stay was lifted.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
June 19, 2024, the Court issued its final decision in the 2017 Motion, whereby it fully dismissed the lawsuit against the defendants
as well as the motion to approve the lawsuit as a class action lawsuit. Each party will bear its own court expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On November 17, 2022, Fidelity Venture Capital Ltd., a private Israeli company (&#x201c;Fidelity VC&#x201d;) and Mr. Dror Atzmon, an Israeli resident and citizen believed to be the sole shareholder of Fidelity VC (Mr. Atzmon, together with Fidelity VC, the &#x201c;Atzmon Plaintiffs&#x201d;), filed a statement of claim in the Economic Division of the Tel Aviv District Court (the &#x201c;Atzmon Claim&#x201d;) against the Company and a number of other defendants, including our former chief executive officer. The Atzmon Plaintiffs are seeking damages for approximately NIS 9 million (approximately USD 2.5 million) in connection with various claims relating to alleged contractual breaches and torts arising from an alleged contractual undertaking for the Company to engage the Atzmon Plaintiffs to provide advisory services to the Company following the initial public offering in the United States and listing on NASDAQ in November 2015.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company rejects all the claims presented in the Atzmon Claim. On August 3, 2023, the court ordered the parties to inform of their willingness to a mediation process. The parties agreed to a mediation process, a mediator has been appointed and mediation is ongoing. At this stage the Company is unable, with any degree of certainty, to make any evaluations or any assessments with respect to the probability of success or the scope of potential exposure, if any, of the Atzmon Claim.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c224"
      decimals="2"
      id="ixv-29181"
      unitRef="pure">0.03</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c225"
      decimals="2"
      id="ixv-29182"
      unitRef="pure">0.06</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:RevenueFromRoyalties
      contextRef="c226"
      decimals="-5"
      id="ixv-29183"
      unitRef="ils">5500000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="c226"
      decimals="-4"
      id="ixv-29184"
      unitRef="usd">1510000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c227"
      decimals="2"
      id="ixv-29185"
      unitRef="pure">0.03</ifrs-full:PercentageOfEntitysRevenue>
    <ppbt:PercentageOfSublicenseConsideration
      contextRef="c227"
      decimals="2"
      id="ixv-29186"
      unitRef="pure">0.12</ppbt:PercentageOfSublicenseConsideration>
    <ppbt:PercentageOfReceiveExitFee
      contextRef="c227"
      decimals="2"
      id="ixv-29187"
      unitRef="pure">0.12</ppbt:PercentageOfReceiveExitFee>
    <ifrs-full:LicenceFeeIncome contextRef="c228" decimals="0" id="ixv-29188" unitRef="usd">10000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c229"
      decimals="3"
      id="ixv-29189"
      unitRef="pure">0.035</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c230"
      decimals="3"
      id="ixv-29190"
      unitRef="pure">0.065</ifrs-full:PercentageOfEntitysRevenue>
    <ppbt:PercentageOfSublicenseConsideration
      contextRef="c228"
      decimals="2"
      id="ixv-29191"
      unitRef="pure">0.20</ppbt:PercentageOfSublicenseConsideration>
    <ppbt:PercentageOfSublicenseConsideration
      contextRef="c230"
      decimals="2"
      id="ixv-29192"
      unitRef="pure">0.12</ppbt:PercentageOfSublicenseConsideration>
    <ppbt:PercentageOfReceiveExitFee
      contextRef="c228"
      decimals="3"
      id="ixv-29193"
      unitRef="pure">0.035</ppbt:PercentageOfReceiveExitFee>
    <ifrs-full:GainsOnLitigationSettlements contextRef="c0" decimals="-6" id="ixv-29194" unitRef="ils">29000000</ifrs-full:GainsOnLitigationSettlements>
    <ifrs-full:GainsOnLitigationSettlements contextRef="c0" decimals="-5" id="ixv-29195" unitRef="usd">8000000</ifrs-full:GainsOnLitigationSettlements>
    <ifrs-full:GainsOnLitigationSettlements
      contextRef="c231"
      decimals="-6"
      id="ixv-29196"
      unitRef="ils">9000000</ifrs-full:GainsOnLitigationSettlements>
    <ifrs-full:GainsOnLitigationSettlements
      contextRef="c231"
      decimals="-2"
      id="ixv-29197"
      unitRef="usd">2500</ifrs-full:GainsOnLitigationSettlements>
    <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory contextRef="c0" id="ixv-25086">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
13 - Research and Development Expenses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salaries, wages and related
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,536&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,323&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,382&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based payments (see also Note 10)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;768&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;768&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Service providers&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,967&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,943&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,170&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,620&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,034&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,320&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
    <ppbt:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock contextRef="c0" id="ixv-25092">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salaries, wages and related
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,536&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,323&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,382&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based payments (see also Note 10)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;768&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;768&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Service providers&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,967&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,943&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,170&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,620&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,034&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,320&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ppbt:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c232"
      decimals="-3"
      id="ixv-29198"
      unitRef="usd">1536000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c233"
      decimals="-3"
      id="ixv-29199"
      unitRef="usd">2323000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c234"
      decimals="-3"
      id="ixv-29200"
      unitRef="usd">2382000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c235"
      decimals="-3"
      id="ixv-29201"
      unitRef="usd">117000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c236"
      decimals="-3"
      id="ixv-29202"
      unitRef="usd">768000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c237"
      decimals="-3"
      id="ixv-29203"
      unitRef="usd">768000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c238"
      decimals="-3"
      id="ixv-29204"
      unitRef="usd">5967000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c239"
      decimals="-3"
      id="ixv-29205"
      unitRef="usd">13943000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c240"
      decimals="-3"
      id="ixv-29206"
      unitRef="usd">13170000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-29207" unitRef="usd">7620000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" id="ixv-29208" unitRef="usd">17034000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" id="ixv-29209" unitRef="usd">16320000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory contextRef="c0" id="ixv-25272">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note 14
- Sales, General and Administrative Expenses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.05pt; text-indent: -18.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salaries,
    wages and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;925&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,769&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,845&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payments (see also Note 10)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;272&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;823&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,333&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reimbursement
    of legal fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(86&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(116&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    professional fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;772&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,005&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;885&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Board
    member remuneration and insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;627&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;818&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,152&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Board
    member share-based payments (see also Note 10)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;193&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;284&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;311&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Maintenance
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;196&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Travel
    and car expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;108&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;144&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;186&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;197&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;201&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;355&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,183&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,237&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,283&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory>
    <ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock contextRef="c0" id="ixv-25278">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salaries,
    wages and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;925&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,769&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,845&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payments (see also Note 10)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;272&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;823&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,333&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reimbursement
    of legal fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(86&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(116&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    professional fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;772&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,005&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;885&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Board
    member remuneration and insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;627&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;818&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,152&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Board
    member share-based payments (see also Note 10)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;193&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;284&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;311&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Maintenance
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;196&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Travel
    and car expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;108&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;144&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;186&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;197&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;201&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;355&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,183&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,237&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,283&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock>
    <ifrs-full:WagesAndSalaries
      contextRef="c215"
      decimals="-3"
      id="ixv-29210"
      unitRef="usd">925000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="c216"
      decimals="-3"
      id="ixv-29211"
      unitRef="usd">1769000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="c217"
      decimals="-3"
      id="ixv-29212"
      unitRef="usd">1845000</ifrs-full:WagesAndSalaries>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="c215"
      decimals="-3"
      id="ixv-29213"
      unitRef="usd">272000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="c216"
      decimals="-3"
      id="ixv-29214"
      unitRef="usd">823000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="c217"
      decimals="-3"
      id="ixv-29215"
      unitRef="usd">1333000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ppbt:ReimbursementOfLegalFeesExpense
      contextRef="c215"
      decimals="-3"
      id="ixv-29216"
      unitRef="usd">86000</ppbt:ReimbursementOfLegalFeesExpense>
    <ppbt:ReimbursementOfLegalFeesExpense
      contextRef="c216"
      decimals="-3"
      id="ixv-29217"
      unitRef="usd">116000</ppbt:ReimbursementOfLegalFeesExpense>
    <ppbt:ReimbursementOfLegalFeesExpense
      contextRef="c217"
      decimals="-3"
      id="ixv-29218"
      unitRef="usd">63000</ppbt:ReimbursementOfLegalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="c215"
      decimals="-3"
      id="ixv-29219"
      unitRef="usd">772000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="c216"
      decimals="-3"
      id="ixv-29220"
      unitRef="usd">1005000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="c217"
      decimals="-3"
      id="ixv-29221"
      unitRef="usd">885000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="c215"
      decimals="-3"
      id="ixv-29222"
      unitRef="usd">627000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="c216"
      decimals="-3"
      id="ixv-29223"
      unitRef="usd">818000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="c217"
      decimals="-3"
      id="ixv-29224"
      unitRef="usd">1152000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees
      contextRef="c215"
      decimals="-3"
      id="ixv-29225"
      unitRef="usd">193000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees
      contextRef="c216"
      decimals="-3"
      id="ixv-29226"
      unitRef="usd">284000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees
      contextRef="c217"
      decimals="-3"
      id="ixv-29227"
      unitRef="usd">311000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:RentalExpense
      contextRef="c215"
      decimals="-3"
      id="ixv-29228"
      unitRef="usd">62000</ifrs-full:RentalExpense>
    <ifrs-full:RentalExpense
      contextRef="c216"
      decimals="-3"
      id="ixv-29229"
      unitRef="usd">196000</ifrs-full:RentalExpense>
    <ifrs-full:RentalExpense
      contextRef="c217"
      decimals="-3"
      id="ixv-29230"
      unitRef="usd">120000</ifrs-full:RentalExpense>
    <ifrs-full:TravelExpense
      contextRef="c215"
      decimals="-3"
      id="ixv-29231"
      unitRef="usd">108000</ifrs-full:TravelExpense>
    <ifrs-full:TravelExpense
      contextRef="c216"
      decimals="-3"
      id="ixv-29232"
      unitRef="usd">130000</ifrs-full:TravelExpense>
    <ifrs-full:TravelExpense
      contextRef="c217"
      decimals="-3"
      id="ixv-29233"
      unitRef="usd">144000</ifrs-full:TravelExpense>
    <ifrs-full:DepreciationExpense
      contextRef="c215"
      decimals="-3"
      id="ixv-29234"
      unitRef="usd">186000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="c216"
      decimals="-3"
      id="ixv-29235"
      unitRef="usd">197000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="c217"
      decimals="-3"
      id="ixv-29236"
      unitRef="usd">201000</ifrs-full:DepreciationExpense>
    <ppbt:GeneralAndAdministrativeExpensesOther
      contextRef="c215"
      decimals="-3"
      id="ixv-29237"
      unitRef="usd">124000</ppbt:GeneralAndAdministrativeExpensesOther>
    <ppbt:GeneralAndAdministrativeExpensesOther
      contextRef="c216"
      decimals="-3"
      id="ixv-29238"
      unitRef="usd">131000</ppbt:GeneralAndAdministrativeExpensesOther>
    <ppbt:GeneralAndAdministrativeExpensesOther
      contextRef="c217"
      decimals="-3"
      id="ixv-29239"
      unitRef="usd">355000</ppbt:GeneralAndAdministrativeExpensesOther>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c215"
      decimals="-3"
      id="ixv-29240"
      unitRef="usd">3183000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c216"
      decimals="-3"
      id="ixv-29241"
      unitRef="usd">5237000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c217"
      decimals="-3"
      id="ixv-29242"
      unitRef="usd">6283000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c0" id="ixv-25661">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note 15
- Finance Expense (Income), net&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.05pt; text-indent: -18.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Revaluation of warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The gain is related to the fair value adjustments of warrants. The 2023 and 2024 warrants included a cashless exercise feature and customary conditions in case of occurrence of a fundamental transaction. The 2023 warrants were exercised in July 2024, and 2024 warrants will expire within 5 or 2 years from issuance of those warrants (see also note 9D2).&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Finance expenses and income&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Finance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Fees and interest expense&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;41&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;67&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Loss from exchange rate differences, net&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Issuance expenses (see note 9D)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;406&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;483&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,195&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;67&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest income
    from deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(260&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(474&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(532&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income from exchange rate
    differences, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-174; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-175; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(62&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes in fair value of
    finance instruments (see Note 18B2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(608&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(517&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(245&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-176; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(71&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(868&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(992&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(910&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <ppbt:WarrantsExpireTerm contextRef="c211" id="ixv-29243">P5Y</ppbt:WarrantsExpireTerm>
    <ppbt:WarrantsExpireTerm contextRef="c210" id="ixv-29244">P2Y</ppbt:WarrantsExpireTerm>
    <ifrs-full:DisclosureOfFinanceCostExplanatory contextRef="c0" id="ixv-25689">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Finance expenses and income&lt;/b&gt;&lt;/span&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Finance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Fees and interest expense&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;41&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;67&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Loss from exchange rate differences, net&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Issuance expenses (see note 9D)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;406&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;483&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,195&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;67&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinanceCostExplanatory>
    <ifrs-full:FeeAndCommissionExpense contextRef="c0" decimals="-3" id="ixv-29245" unitRef="usd">41000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionExpense contextRef="c4" decimals="-3" id="ixv-29246" unitRef="usd">56000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionExpense contextRef="c5" decimals="-3" id="ixv-29247" unitRef="usd">67000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:ForeignExchangeLoss contextRef="c0" decimals="-3" id="ixv-29248" unitRef="usd">11000</ifrs-full:ForeignExchangeLoss>
    <ifrs-full:ForeignExchangeLoss contextRef="c4" decimals="-3" id="ixv-29249" unitRef="usd">13000</ifrs-full:ForeignExchangeLoss>
    <ppbt:IssuanceExpenses contextRef="c0" decimals="-3" id="ixv-29250" unitRef="usd">406000</ppbt:IssuanceExpenses>
    <ppbt:IssuanceExpenses contextRef="c4" decimals="-3" id="ixv-29251" unitRef="usd">2126000</ppbt:IssuanceExpenses>
    <ppbt:OtherfinancialCost contextRef="c0" decimals="-3" id="ixv-29252" unitRef="usd">25000</ppbt:OtherfinancialCost>
    <ifrs-full:OtherExpenseByNature contextRef="c0" decimals="-3" id="ixv-29253" unitRef="usd">483000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature contextRef="c4" decimals="-3" id="ixv-29254" unitRef="usd">2195000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature contextRef="c5" decimals="-3" id="ixv-29255" unitRef="usd">67000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:DisclosureOfFinanceIncomeExplanatory contextRef="c0" id="ixv-25804">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest income
    from deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(260&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(474&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(532&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income from exchange rate
    differences, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-174; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-175; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(62&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes in fair value of
    finance instruments (see Note 18B2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(608&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(517&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(245&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-176; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(71&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(868&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(992&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(910&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinanceIncomeExplanatory>
    <ifrs-full:InterestIncomeOnDeposits contextRef="c0" decimals="-3" id="ixv-29256" unitRef="usd">260000</ifrs-full:InterestIncomeOnDeposits>
    <ifrs-full:InterestIncomeOnDeposits contextRef="c4" decimals="-3" id="ixv-29257" unitRef="usd">474000</ifrs-full:InterestIncomeOnDeposits>
    <ifrs-full:InterestIncomeOnDeposits contextRef="c5" decimals="-3" id="ixv-29258" unitRef="usd">532000</ifrs-full:InterestIncomeOnDeposits>
    <ifrs-full:ForeignExchangeGain contextRef="c5" decimals="-3" id="ixv-29259" unitRef="usd">62000</ifrs-full:ForeignExchangeGain>
    <ifrs-full:GainsOnChangeInFairValueOfDerivatives contextRef="c0" decimals="-3" id="ixv-29260" unitRef="usd">608000</ifrs-full:GainsOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsOnChangeInFairValueOfDerivatives contextRef="c4" decimals="-3" id="ixv-29261" unitRef="usd">517000</ifrs-full:GainsOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsOnChangeInFairValueOfDerivatives contextRef="c5" decimals="-3" id="ixv-29262" unitRef="usd">245000</ifrs-full:GainsOnChangeInFairValueOfDerivatives>
    <ppbt:OtherExpense contextRef="c4" decimals="-3" id="ixv-29263" unitRef="usd">-1000</ppbt:OtherExpense>
    <ppbt:OtherExpense contextRef="c5" decimals="-3" id="ixv-29264" unitRef="usd">-71000</ppbt:OtherExpense>
    <ifrs-full:OtherFinanceIncome contextRef="c0" decimals="-3" id="ixv-29265" unitRef="usd">868000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome contextRef="c4" decimals="-3" id="ixv-29266" unitRef="usd">992000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome contextRef="c5" decimals="-3" id="ixv-29267" unitRef="usd">910000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c0" id="ixv-26005">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note 16
- Taxes on Income&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Corporate tax rate&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
tax rate applicable to the Group is 23%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Carry-forward
    losses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
    Company and its subsidiaries incurred losses through 2024, which are not expected to be utilized in the foreseeable future. Therefore,
    the Group did not record current taxes or deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
2024, the main reconciling item from the statutory tax rate of the Company (23%, representing a theoretical tax benefit of approximately
USD 1.7 million) to the effective tax rate (0%) is mainly due to the fact that deferred taxes were not created in respect of current
year tax losses and benefits.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
carry-forward loss for tax purposes of the Company and its subsidiaries, and the unrecognized research and development expenses, amount
to USD 100 million as of December 31, 2024 (2023 &#x2013; USD 96 million, 2022 &#x2013; USD 82 million).&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:ApplicableTaxRate contextRef="c0" decimals="2" id="ixv-29268" unitRef="pure">0.23</ifrs-full:ApplicableTaxRate>
    <ppbt:StatutoryTaxRate contextRef="c0" decimals="2" id="ixv-29269" unitRef="pure">0.23</ppbt:StatutoryTaxRate>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense contextRef="c0" decimals="-5" id="ixv-29270" unitRef="usd">1700000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
    <ppbt:EffectiveTaxRate contextRef="c0" decimals="2" id="ixv-29271" unitRef="pure">0</ppbt:EffectiveTaxRate>
    <ppbt:UnrecognizedResearchAndDevelopmentExpenses contextRef="c0" decimals="-6" id="ixv-29272" unitRef="usd">100000000</ppbt:UnrecognizedResearchAndDevelopmentExpenses>
    <ppbt:UnrecognizedResearchAndDevelopmentExpenses contextRef="c4" decimals="-6" id="ixv-29273" unitRef="usd">96000000</ppbt:UnrecognizedResearchAndDevelopmentExpenses>
    <ppbt:UnrecognizedResearchAndDevelopmentExpenses contextRef="c5" decimals="-6" id="ixv-29274" unitRef="usd">82000000</ppbt:UnrecognizedResearchAndDevelopmentExpenses>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="c0" id="ixv-26075">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note 17
- Employee benefits&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee benefits include post-employment benefits and short-term benefits.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balances
include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year ended&lt;br/&gt; December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term
    benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;331&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;549&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Post-employment benefit
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;140&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;141&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Post-employment benefit
    plans &#x2013; defined contribution plan&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has a defined contribution plan in respect of the Company&#x2019;s liability in respect of its employees who are subject to Section
14 of the Severance Pay Law&#160;&#x2013; 1963.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount recognized
    as expense in respect of defined contribution plan&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;322&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;401&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;390&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain of the Company&#x2019;s executives are entitled to annual and special bonuses under the terms of their employment and consulting agreements. These bonuses will become due upon the achievement of certain goals or agreements. These consolidated financial statements include bonuses expenses in the amount of USD 68 thousand for the year ended December 31, 2024, USD 446 thousand for the year ended December 31, 2023, and USD 406 thousand for the year ended December 31, 2022.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The CEO is entitled to benefits upon termination of employment, see Note 11 on related parties. These benefits are measured based on the time of service and monthly pay and the expected term of his employment. These consolidated financial statements include a liability due to these grants of USD 140 thousand and USD 141 thousand, as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <ppbt:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock contextRef="c0" id="ixv-26087">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee benefits include post-employment benefits and short-term benefits.&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year ended&lt;br/&gt; December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term
    benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;331&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;549&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Post-employment benefit
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;140&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;141&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ppbt:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock>
    <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="c0" decimals="-3" id="ixv-29275" unitRef="usd">331000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="c4" decimals="-3" id="ixv-29276" unitRef="usd">549000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss contextRef="c0" decimals="-3" id="ixv-29277" unitRef="usd">140000</ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss>
    <ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss contextRef="c4" decimals="-3" id="ixv-29278" unitRef="usd">141000</ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss>
    <ppbt:DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock contextRef="c0" id="ixv-26206">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has a defined contribution plan in respect of the Company&#x2019;s liability in respect of its employees who are subject to Section
14 of the Severance Pay Law&#160;&#x2013; 1963.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount recognized
    as expense in respect of defined contribution plan&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;322&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;401&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;390&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ppbt:DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="c0" decimals="-3" id="ixv-29279" unitRef="usd">322000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="c4" decimals="-3" id="ixv-29280" unitRef="usd">401000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="c5" decimals="-3" id="ixv-29281" unitRef="usd">390000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ppbt:EmployeeBenefitBonus contextRef="c0" decimals="-3" id="ixv-29282" unitRef="usd">68000</ppbt:EmployeeBenefitBonus>
    <ppbt:EmployeeBenefitBonus contextRef="c4" decimals="-3" id="ixv-29283" unitRef="usd">446000</ppbt:EmployeeBenefitBonus>
    <ppbt:EmployeeBenefitBonus contextRef="c5" decimals="-3" id="ixv-29284" unitRef="usd">406000</ppbt:EmployeeBenefitBonus>
    <ppbt:EmployeeBenefitsLiabilityDueGrants contextRef="c0" decimals="-3" id="ixv-29285" unitRef="usd">140000</ppbt:EmployeeBenefitsLiabilityDueGrants>
    <ppbt:EmployeeBenefitsLiabilityDueGrants contextRef="c4" decimals="-3" id="ixv-29286" unitRef="usd">141000</ppbt:EmployeeBenefitsLiabilityDueGrants>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="c0" id="ixv-26333">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
18 - Financial Instruments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Framework
for risk management&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Board of Directors has overall responsibility for the establishment and oversight of the Group&#x2019;s risk management framework.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group&#x2019;s risk management practice was formulated to identify and analyze the risks that the Group faces, to set appropriate limits
for the risks and controls, and to monitor the risks and their compliance with the limits. The risk policy and risk management methods
are reviewed regularly to reflect changes in market conditions and in the Group&#x2019;s operations. The Group acts to develop an effective
control environment in which all employees understand their roles and commitment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group Audit Committee oversees how management monitors compliance with the Group&#x2019;s risk management policies and procedures, and
reviews the adequacy of the risk management framework in relation to the risks faced by the Group. The Group Audit Committee is assisted
in its oversight role by Internal Audit. Internal Audit undertakes both regular and ad hoc reviews of risk management controls and procedures,
the results of which are reported to the Audit Committee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Risk management&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1&lt;/b&gt;.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Credit risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Credit
risk is the risk of financial loss to the Group if a debtor or counterparty to a financial instrument fails to meet its contractual obligations,
and arises mainly from the Company&#x2019;s receivables. The Group restricts exposure to credit risk by investing only in bank deposits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Group held cash and cash equivalents
and short-term deposits of USD 8,249 thousand at December 31, 2024 (2023 &#x2013; USD 15,339 thousand). These are held with banks, which
are rated BBB+ or BBB-, based on S&amp;amp;P Rating Agency ratings. The short-term deposits, mainly in USD, bear fixed interest ranging between
0.2% - 4.46%.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2024 the Group has an amount of USD 148 thousand in short term deposits guaranteed for the Group&#x2019;s leases and credit
and an amount of USD 700 thousand in short term deposits guaranteed for hedging transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Market risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Market
risk is the risk that changes in market prices, such as foreign currency exchange rates, the CPI, interest rates and the prices of equity
instruments, will influence the Group&#x2019;s results or the value of its holdings in financial instruments. The objective of market
risk management is to manage and control market risk exposures within acceptable parameters, while optimizing returns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group hedges the foreign currency risk exposure that derives from salary expenses by means of foreign currency derivatives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Therefore,
as at December 31, 2024 the Group is of the opinion that these hedging relationships continue to qualify for hedge accounting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Currency risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group is exposed to currency risk mainly for cash and purchases for research and development expenses that are denominated in NIS and
EURO. Therefore, the Group is exposed to exchange rate fluctuations in these currencies against the dollar and takes steps to reduce
the currency risk by maintaining its liquid resources in accordance with its future needs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Set
forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sensitive
    instrument&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; &#160;(U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;br/&gt;
    (U.S.&#160;dollars&lt;br/&gt; in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; (U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents and deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;423&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;704&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&#160;payables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(723&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Post-employment benefit
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(140&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&#160;income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Set
forth below is a sensitivity test to possible changes in USD/ EURO exchange rate as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sensitive
    instrument&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; (U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;br/&gt;
    (U.S.&#160;dollars&lt;br/&gt; in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; (U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents and deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(92&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&#160;payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&#160;income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Set
forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sensitive
    instrument&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; &#160;(U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;br/&gt;
    (U.S.&#160;dollars&lt;br/&gt; in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; (U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents and deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;550&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;660&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(225&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&#160;payables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,340&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Post-employment benefit
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(141&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&#160;income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Set
forth below is a sensitivity test to possible changes in USD/ EURO exchange rate as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sensitive
    instrument&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; (U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;br/&gt;
    (U.S.&#160;dollars&lt;br/&gt; in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; (U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents and deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(153&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&#160;payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(232&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&#160;income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial instruments measured
    at fair value:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The carrying amounts of certain financial assets and liabilities, including cash and cash equivalents, short term deposits, trade payables, and other payables are the same or proximate to their fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;In October 2021, the Company received a convertible note in the amount of $1.5 million and a warrant for 300 thousand Coeptis shares as part of Coeptis termination at an exercise price of $5 per warrant. As of December 31, 2023, the outstanding balance of the convertible note was $625 thousands.&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
June 19, 2024 the Company entered into a payoff agreement with Coeptis in which the Company will receive payment in the amount of $219
thousand (received in January 2025) and 50 thousand Coeptis shares, in lieu of the outstanding convertible note and warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
a result of this agreement, the financial instruments (convertible note and warrant) were derecognized as of December 31, 2024. The fair
value of these financial instruments prior to derecognition were $73 thousand as of December 31, 2023, and $431 thousand as of December
31, 2022. Additionally, the shares received were recognized as a financial asset at a fair value of USD 275 thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In October 2023, as part of a registered direct offering, the Company issued 217,391 warrants, and amended certain existing warrants to purchase up to an aggregate of 27,777 of the Company&#x2019;s ADSs that were previously issued in June 2020 at exercise prices of $180 per ADS such that effective upon the closing of the offering the amended warrants will have a reduced exercise price of $25 per ADS and will expire five and a one-half years from the closing date of the offering.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On July 2, 2024 the Company induced the exercise of certain existing warrants (Including the above October warrants) to purchase an aggregate of 281,675 American Depositary Shares (ADSs). In consideration for the exercise of the existing warrants, the Company issued new unregistered Series A-1 warrants to purchase up to an aggregate of 248,969 ADSs and new unregistered Series A-2 warrants to purchase up to an aggregate of 314,381 ADSs (see Note 9D2).&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The warrants were classified as a non-current financial liability as they can be settled in cash on the occurrence of Fundamental Transaction as determined in the agreement. This liability was initially recognized at its fair value on the closing date of the offering and is subsequently accounted for fair value at each balance sheet date and recorded through profit and loss.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of these financial instruments as of December 31, 2024
was measured at USD 1,149 thousand (net of deferred difference of USD 302 thousand), (December 31, 2023 USD 2,518 thousand).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value hierarchy of financial instruments measured at fair value:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Financial asset and liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Securities (see Note 18B (2))&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;275&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;275&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Financial liability of warrants&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,149&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,149&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial asset and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Convertible debt instrument and
    warrant (see Note 18B (2))&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-185; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-186; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial liability of
    warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-187; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-188; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,518&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,518&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Details
regarding fair value measurement at Level 3:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Financial asset-&lt;br/&gt; convertible note&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Financial liability-&lt;br/&gt; warrant&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Balance as of January 1, 2024&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;73&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;2,518&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(56&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Issuance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,028&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Proceed&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(187&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Revaluation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;114&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(3,341&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,149&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
    asset-&lt;br/&gt; convertible note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
    liability-&lt;br/&gt; warrant&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;431&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,015&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Proceed&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(875&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;517&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,497&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,518&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial
    instrument&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Valuation&lt;br/&gt;
    method for&lt;br/&gt;
    determining &lt;br/&gt;
    fair value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Significant&lt;br/&gt;
    unobservable&lt;br/&gt;
    inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the year ended December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrant
    (see note 9D1)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Black
    - Scholes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expected
    term&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.5, 1.5 years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; width: 30%; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; width: 15%; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 35%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expected
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;97.31%, 129.83&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;annual
    risk free interest&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.30%, 4.54&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;dividend
    yield&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;0&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the year ended December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrant&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Black
    - Scholes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expected
    term&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.3 years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expected
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;89.94&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;annual
    risk free interest&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.88&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;dividend
    yield&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    debt instrument&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;DLOM&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;26.1&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c241"
      decimals="-3"
      id="ixv-29287"
      unitRef="usd">8249000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c242"
      decimals="-3"
      id="ixv-29288"
      unitRef="usd">15339000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c243"
      decimals="3"
      id="ixv-29289"
      unitRef="pure">0.002</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c244"
      decimals="4"
      id="ixv-29290"
      unitRef="pure">0.0446</ifrs-full:BorrowingsInterestRate>
    <ppbt:ShortTermDepositsGuaranteedForLeasesAndCredit
      contextRef="c241"
      decimals="-3"
      id="ixv-29291"
      unitRef="usd">148000</ppbt:ShortTermDepositsGuaranteedForLeasesAndCredit>
    <ppbt:ShortTermDepositsGuaranteedForHedgingTransactions
      contextRef="c241"
      decimals="-3"
      id="ixv-29292"
      unitRef="usd">700000</ppbt:ShortTermDepositsGuaranteedForHedgingTransactions>
    <ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory contextRef="c258" id="ixv-26461">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Set
forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sensitive
    instrument&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; &#160;(U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;br/&gt;
    (U.S.&#160;dollars&lt;br/&gt; in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; (U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents and deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;423&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;704&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&#160;payables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(723&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Post-employment benefit
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(140&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&#160;income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Set
forth below is a sensitivity test to possible changes in USD/ EURO exchange rate as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sensitive
    instrument&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; (U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;br/&gt;
    (U.S.&#160;dollars&lt;br/&gt; in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; (U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents and deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(92&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&#160;payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&#160;income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Set
forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sensitive
    instrument&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; &#160;(U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;br/&gt;
    (U.S.&#160;dollars&lt;br/&gt; in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; (U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents and deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;550&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;660&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(225&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&#160;payables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,340&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Post-employment benefit
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(141&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&#160;income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Set
forth below is a sensitivity test to possible changes in USD/ EURO exchange rate as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sensitive
    instrument&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; (U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;br/&gt;
    (U.S.&#160;dollars&lt;br/&gt; in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income&#160;(loss)&#160;from&lt;br/&gt;
    change&#160;in&#160;exchange rate&lt;br/&gt; (U.S.&#160;dollars&#160;in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Down&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;5%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Up&#160;2%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents and deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(153&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&#160;payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(232&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&#160;income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c259"
      decimals="-3"
      id="ixv-29293"
      unitRef="usd">8000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c260"
      decimals="-3"
      id="ixv-29294"
      unitRef="usd">21000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c261"
      decimals="-3"
      id="ixv-29295"
      unitRef="usd">423000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c262"
      decimals="-3"
      id="ixv-29296"
      unitRef="usd">-21000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c263"
      decimals="-3"
      id="ixv-29297"
      unitRef="usd">-8000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c264"
      decimals="-3"
      id="ixv-29298"
      unitRef="usd">14000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c265"
      decimals="-3"
      id="ixv-29299"
      unitRef="usd">35000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c266"
      decimals="-3"
      id="ixv-29300"
      unitRef="usd">704000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c267"
      decimals="-3"
      id="ixv-29301"
      unitRef="usd">-35000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c268"
      decimals="-3"
      id="ixv-29302"
      unitRef="usd">-14000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c269"
      decimals="-3"
      id="ixv-29303"
      unitRef="usd">-1000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c270"
      decimals="-3"
      id="ixv-29304"
      unitRef="usd">-3000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c271"
      decimals="-3"
      id="ixv-29305"
      unitRef="usd">-60000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c272"
      decimals="-3"
      id="ixv-29306"
      unitRef="usd">3000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c273"
      decimals="-3"
      id="ixv-29307"
      unitRef="usd">1000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c274"
      decimals="-3"
      id="ixv-29308"
      unitRef="usd">-14000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c275"
      decimals="-3"
      id="ixv-29309"
      unitRef="usd">-36000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c276"
      decimals="-3"
      id="ixv-29310"
      unitRef="usd">-723000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c277"
      decimals="-3"
      id="ixv-29311"
      unitRef="usd">36000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c278"
      decimals="-3"
      id="ixv-29312"
      unitRef="usd">14000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c279"
      decimals="-3"
      id="ixv-29313"
      unitRef="usd">-3000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c280"
      decimals="-3"
      id="ixv-29314"
      unitRef="usd">-7000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c281"
      decimals="-3"
      id="ixv-29315"
      unitRef="usd">-140000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c282"
      decimals="-3"
      id="ixv-29316"
      unitRef="usd">7000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c283"
      decimals="-3"
      id="ixv-29317"
      unitRef="usd">3000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c284"
      decimals="-3"
      id="ixv-29318"
      unitRef="usd">4000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c285"
      decimals="-3"
      id="ixv-29319"
      unitRef="usd">10000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c287"
      decimals="-3"
      id="ixv-29320"
      unitRef="usd">-10000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c288"
      decimals="-3"
      id="ixv-29321"
      unitRef="usd">-4000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c289"
      decimals="-3"
      id="ixv-29322"
      unitRef="usd">1000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c290"
      decimals="-3"
      id="ixv-29323"
      unitRef="usd">2000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c291"
      decimals="-3"
      id="ixv-29324"
      unitRef="usd">39000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c292"
      decimals="-3"
      id="ixv-29325"
      unitRef="usd">-2000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c293"
      decimals="-3"
      id="ixv-29326"
      unitRef="usd">-1000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c294"
      decimals="-3"
      id="ixv-29327"
      unitRef="usd">-2000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c295"
      decimals="-3"
      id="ixv-29328"
      unitRef="usd">-5000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c296"
      decimals="-3"
      id="ixv-29329"
      unitRef="usd">-92000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c297"
      decimals="-3"
      id="ixv-29330"
      unitRef="usd">5000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c298"
      decimals="-3"
      id="ixv-29331"
      unitRef="usd">2000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c299"
      decimals="-3"
      id="ixv-29332"
      unitRef="usd">-1000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c300"
      decimals="-3"
      id="ixv-29333"
      unitRef="usd">-2000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c301"
      decimals="-3"
      id="ixv-29334"
      unitRef="usd">-50000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c302"
      decimals="-3"
      id="ixv-29335"
      unitRef="usd">2000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c303"
      decimals="-3"
      id="ixv-29336"
      unitRef="usd">1000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c304"
      decimals="-3"
      id="ixv-29337"
      unitRef="usd">-2000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c305"
      decimals="-3"
      id="ixv-29338"
      unitRef="usd">-5000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c307"
      decimals="-3"
      id="ixv-29339"
      unitRef="usd">5000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c308"
      decimals="-3"
      id="ixv-29340"
      unitRef="usd">2000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c309"
      decimals="-3"
      id="ixv-29341"
      unitRef="usd">11000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c310"
      decimals="-3"
      id="ixv-29342"
      unitRef="usd">28000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c311"
      decimals="-3"
      id="ixv-29343"
      unitRef="usd">550000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c312"
      decimals="-3"
      id="ixv-29344"
      unitRef="usd">-28000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c313"
      decimals="-3"
      id="ixv-29345"
      unitRef="usd">-11000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c314"
      decimals="-3"
      id="ixv-29346"
      unitRef="usd">13000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c315"
      decimals="-3"
      id="ixv-29347"
      unitRef="usd">33000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c316"
      decimals="-3"
      id="ixv-29348"
      unitRef="usd">660000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c317"
      decimals="-3"
      id="ixv-29349"
      unitRef="usd">-33000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c318"
      decimals="-3"
      id="ixv-29350"
      unitRef="usd">-13000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c319"
      decimals="-3"
      id="ixv-29351"
      unitRef="usd">-5000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c320"
      decimals="-3"
      id="ixv-29352"
      unitRef="usd">-11000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c321"
      decimals="-3"
      id="ixv-29353"
      unitRef="usd">-225000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c322"
      decimals="-3"
      id="ixv-29354"
      unitRef="usd">11000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c323"
      decimals="-3"
      id="ixv-29355"
      unitRef="usd">5000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c324"
      decimals="-3"
      id="ixv-29356"
      unitRef="usd">-27000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c325"
      decimals="-3"
      id="ixv-29357"
      unitRef="usd">-67000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c326"
      decimals="-3"
      id="ixv-29358"
      unitRef="usd">-1340000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c327"
      decimals="-3"
      id="ixv-29359"
      unitRef="usd">67000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c328"
      decimals="-3"
      id="ixv-29360"
      unitRef="usd">27000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c329"
      decimals="-3"
      id="ixv-29361"
      unitRef="usd">-3000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c330"
      decimals="-3"
      id="ixv-29362"
      unitRef="usd">-7000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c331"
      decimals="-3"
      id="ixv-29363"
      unitRef="usd">-141000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c332"
      decimals="-3"
      id="ixv-29364"
      unitRef="usd">7000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c333"
      decimals="-3"
      id="ixv-29365"
      unitRef="usd">3000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c334"
      decimals="-3"
      id="ixv-29366"
      unitRef="usd">-11000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c335"
      decimals="-3"
      id="ixv-29367"
      unitRef="usd">-24000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c337"
      decimals="-3"
      id="ixv-29368"
      unitRef="usd">24000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c338"
      decimals="-3"
      id="ixv-29369"
      unitRef="usd">11000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c339"
      decimals="-3"
      id="ixv-29370"
      unitRef="usd">1000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c340"
      decimals="-3"
      id="ixv-29371"
      unitRef="usd">2000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c341"
      decimals="-3"
      id="ixv-29372"
      unitRef="usd">48000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c342"
      decimals="-3"
      id="ixv-29373"
      unitRef="usd">-2000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c343"
      decimals="-3"
      id="ixv-29374"
      unitRef="usd">-1000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c344"
      decimals="-3"
      id="ixv-29375"
      unitRef="usd">-3000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c345"
      decimals="-3"
      id="ixv-29376"
      unitRef="usd">-8000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c346"
      decimals="-3"
      id="ixv-29377"
      unitRef="usd">-153000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c347"
      decimals="-3"
      id="ixv-29378"
      unitRef="usd">8000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c348"
      decimals="-3"
      id="ixv-29379"
      unitRef="usd">3000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c349"
      decimals="-3"
      id="ixv-29380"
      unitRef="usd">-5000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c350"
      decimals="-3"
      id="ixv-29381"
      unitRef="usd">-12000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossValue
      contextRef="c351"
      decimals="-3"
      id="ixv-29382"
      unitRef="usd">-232000</ppbt:IncomelossValue>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c352"
      decimals="-3"
      id="ixv-29383"
      unitRef="usd">12000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c353"
      decimals="-3"
      id="ixv-29384"
      unitRef="usd">5000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c208"
      decimals="-3"
      id="ixv-29385"
      unitRef="usd">-7000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateDown
      contextRef="c354"
      decimals="-3"
      id="ixv-29386"
      unitRef="usd">-18000</ppbt:IncomelossFromChangeInExchangeRateDown>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c209"
      decimals="-3"
      id="ixv-29387"
      unitRef="usd">18000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ppbt:IncomelossFromChangeInExchangeRateUp
      contextRef="c355"
      decimals="-3"
      id="ixv-29388"
      unitRef="usd">7000</ppbt:IncomelossFromChangeInExchangeRateUp>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="c245"
      decimals="-5"
      id="ixv-29389"
      unitRef="usd">1500000</ifrs-full:IssueOfConvertibleInstruments>
    <ppbt:ConvertibleWarrants
      contextRef="c245"
      decimals="-3"
      id="ixv-29390"
      unitRef="shares">300000</ppbt:ConvertibleWarrants>
    <ppbt:TerminationExercisePrice
      contextRef="c246"
      decimals="0"
      id="ixv-29391"
      unitRef="usdPershares">5</ppbt:TerminationExercisePrice>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="c247"
      decimals="-3"
      id="ixv-29392"
      unitRef="usd">625000</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="c248"
      decimals="-3"
      id="ixv-29393"
      unitRef="usd">219000</ifrs-full:IssueOfConvertibleInstruments>
    <ppbt:ConvertiblesWarrants
      contextRef="c248"
      decimals="-3"
      id="ixv-29394"
      unitRef="usd">50000</ppbt:ConvertiblesWarrants>
    <ifrs-full:CurrentInvestments
      contextRef="c249"
      decimals="-3"
      id="ixv-29395"
      unitRef="usd">73000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="c250"
      decimals="-3"
      id="ixv-29396"
      unitRef="usd">431000</ifrs-full:CurrentInvestments>
    <ppbt:FinancialAssetAtAFairValue
      contextRef="c251"
      decimals="-3"
      id="ixv-29397"
      unitRef="usd">275000</ppbt:FinancialAssetAtAFairValue>
    <ppbt:WarrantsIssued
      contextRef="c252"
      decimals="0"
      id="ixv-29398"
      unitRef="shares">217391</ppbt:WarrantsIssued>
    <ppbt:WarrantsIssued
      contextRef="c253"
      decimals="0"
      id="ixv-29399"
      unitRef="shares">27777</ppbt:WarrantsIssued>
    <ifrs-full:ParValuePerShare
      contextRef="c254"
      decimals="0"
      id="ixv-29400"
      unitRef="usdPershares">180</ifrs-full:ParValuePerShare>
    <ppbt:WarrantExercisePricePerShare
      contextRef="c254"
      decimals="0"
      id="ixv-29401"
      unitRef="usdPershares">25</ppbt:WarrantExercisePricePerShare>
    <ppbt:DepositarysShares
      contextRef="c255"
      decimals="0"
      id="ixv-29402"
      unitRef="shares">281675</ppbt:DepositarysShares>
    <ppbt:AggregateWarrantsShares
      contextRef="c256"
      decimals="0"
      id="ixv-29403"
      unitRef="shares">248969</ppbt:AggregateWarrantsShares>
    <ppbt:AggregateWarrantsShares
      contextRef="c257"
      decimals="0"
      id="ixv-29404"
      unitRef="shares">314381</ppbt:AggregateWarrantsShares>
    <ppbt:FinancialInstrumentAmount contextRef="c0" decimals="-3" id="ixv-29405" unitRef="usd">1149000</ppbt:FinancialInstrumentAmount>
    <ppbt:NetOfDeferredDifferenceAmount contextRef="c0" decimals="-3" id="ixv-29406" unitRef="usd">302000</ppbt:NetOfDeferredDifferenceAmount>
    <ppbt:FinancialInstrumentAmount contextRef="c4" decimals="-3" id="ixv-29407" unitRef="usd">2518000</ppbt:FinancialInstrumentAmount>
    <ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory contextRef="c0" id="ixv-27692">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value hierarchy of financial instruments measured at fair value:&lt;/span&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Financial asset and liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Securities (see Note 18B (2))&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;275&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;275&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Financial liability of warrants&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,149&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,149&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial asset and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Convertible debt instrument and
    warrant (see Note 18B (2))&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-185; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-186; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial liability of
    warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-187; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-188; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,518&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,518&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory>
    <ppbt:Securities
      contextRef="c356"
      decimals="-3"
      id="ixv-29408"
      unitRef="usd">275000</ppbt:Securities>
    <ppbt:Securities contextRef="c0" decimals="-3" id="ixv-29409" unitRef="usd">275000</ppbt:Securities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="c361"
      decimals="-3"
      id="ixv-29410"
      unitRef="usd">1149000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c2" decimals="-3" id="ixv-29411" unitRef="usd">1149000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialAssets
      contextRef="c364"
      decimals="-3"
      id="ixv-29412"
      unitRef="usd">73000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialAssets contextRef="c3" decimals="-3" id="ixv-29413" unitRef="usd">73000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="c364"
      decimals="-3"
      id="ixv-29414"
      unitRef="usd">2518000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c3" decimals="-3" id="ixv-29415" unitRef="usd">2518000</ifrs-full:DerivativeFinancialLiabilities>
    <ppbt:ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock contextRef="c0" id="ixv-27923">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Details
regarding fair value measurement at Level 3:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Financial asset-&lt;br/&gt; convertible note&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Financial liability-&lt;br/&gt; warrant&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Balance as of January 1, 2024&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;73&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;2,518&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(56&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Issuance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,028&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Proceed&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(187&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Revaluation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;114&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(3,341&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,149&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
    asset-&lt;br/&gt; convertible note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
    liability-&lt;br/&gt; warrant&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;431&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,015&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Proceed&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(875&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;517&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,497&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,518&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ppbt:ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock>
    <ppbt:FairValueMeasurementBalance
      contextRef="c365"
      decimals="-3"
      id="ixv-29416"
      unitRef="usd">73000</ppbt:FairValueMeasurementBalance>
    <ppbt:FairValueMeasurementBalance
      contextRef="c366"
      decimals="-3"
      id="ixv-29417"
      unitRef="usd">2518000</ppbt:FairValueMeasurementBalance>
    <ppbt:FairValueMeasurementExercise
      contextRef="c368"
      decimals="-3"
      id="ixv-29418"
      unitRef="usd">-56000</ppbt:FairValueMeasurementExercise>
    <ppbt:FairValueMeasurementIssuance
      contextRef="c368"
      decimals="-3"
      id="ixv-29419"
      unitRef="usd">2028000</ppbt:FairValueMeasurementIssuance>
    <ppbt:FairValueMeasurementIssuanceProceed
      contextRef="c367"
      decimals="-3"
      id="ixv-29420"
      unitRef="usd">-187000</ppbt:FairValueMeasurementIssuanceProceed>
    <ppbt:FairValueMeasurementRevaluation
      contextRef="c367"
      decimals="-3"
      id="ixv-29421"
      unitRef="usd">114000</ppbt:FairValueMeasurementRevaluation>
    <ppbt:FairValueMeasurementRevaluation
      contextRef="c368"
      decimals="-3"
      id="ixv-29422"
      unitRef="usd">-3341000</ppbt:FairValueMeasurementRevaluation>
    <ppbt:FairValueMeasurementBalance
      contextRef="c370"
      decimals="-3"
      id="ixv-29423"
      unitRef="usd">1149000</ppbt:FairValueMeasurementBalance>
    <ppbt:FairValueMeasurementBalance
      contextRef="c371"
      decimals="-3"
      id="ixv-29424"
      unitRef="usd">431000</ppbt:FairValueMeasurementBalance>
    <ppbt:FairValueMeasurementIssuance
      contextRef="c374"
      decimals="-3"
      id="ixv-29425"
      unitRef="usd">6015000</ppbt:FairValueMeasurementIssuance>
    <ppbt:FairValueMeasurementIssuanceProceed
      contextRef="c373"
      decimals="-3"
      id="ixv-29426"
      unitRef="usd">-875000</ppbt:FairValueMeasurementIssuanceProceed>
    <ppbt:FairValueMeasurementRevaluation
      contextRef="c373"
      decimals="-3"
      id="ixv-29427"
      unitRef="usd">517000</ppbt:FairValueMeasurementRevaluation>
    <ppbt:FairValueMeasurementRevaluation
      contextRef="c374"
      decimals="-3"
      id="ixv-29428"
      unitRef="usd">-3497000</ppbt:FairValueMeasurementRevaluation>
    <ppbt:FairValueMeasurementBalance
      contextRef="c365"
      decimals="-3"
      id="ixv-29429"
      unitRef="usd">73000</ppbt:FairValueMeasurementBalance>
    <ppbt:FairValueMeasurementBalance
      contextRef="c366"
      decimals="-3"
      id="ixv-29430"
      unitRef="usd">2518000</ppbt:FairValueMeasurementBalance>
    <ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory contextRef="c0" id="ixv-28160">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial
    instrument&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Valuation&lt;br/&gt;
    method for&lt;br/&gt;
    determining &lt;br/&gt;
    fair value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Significant&lt;br/&gt;
    unobservable&lt;br/&gt;
    inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the year ended December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrant
    (see note 9D1)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Black
    - Scholes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expected
    term&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.5, 1.5 years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; width: 30%; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; width: 15%; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 35%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expected
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;97.31%, 129.83&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;annual
    risk free interest&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.30%, 4.54&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;dividend
    yield&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;0&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the year ended December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrant&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Black
    - Scholes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expected
    term&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.3 years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expected
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;89.94&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;annual
    risk free interest&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.88&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;dividend
    yield&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    debt instrument&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;DLOM&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;26.1&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
    <ppbt:DescriptionOfOptionLifeShareOptionGranted contextRef="c375" id="ixv-29431">P4Y6M</ppbt:DescriptionOfOptionLifeShareOptionGranted>
    <ppbt:DescriptionOfOptionLifeShareOptionGranted contextRef="c376" id="ixv-29432">P1Y6M</ppbt:DescriptionOfOptionLifeShareOptionGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c375"
      decimals="4"
      id="ixv-29433"
      unitRef="pure">0.9731</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c376"
      decimals="4"
      id="ixv-29434"
      unitRef="pure">1.2983</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c375"
      decimals="4"
      id="ixv-29435"
      unitRef="pure">0.043</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c376"
      decimals="4"
      id="ixv-29436"
      unitRef="pure">0.0454</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ppbt:ExpectedDividendAsPercentageShareOptionsdividendYield
      contextRef="c377"
      decimals="2"
      id="ixv-29437"
      unitRef="pure">0</ppbt:ExpectedDividendAsPercentageShareOptionsdividendYield>
    <ppbt:DescriptionOfOptionLifeShareOptionGranted contextRef="c374" id="ixv-29438">P5Y3M18D</ppbt:DescriptionOfOptionLifeShareOptionGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c374"
      decimals="4"
      id="ixv-29439"
      unitRef="pure">0.8994</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c374"
      decimals="4"
      id="ixv-29440"
      unitRef="pure">0.0388</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ppbt:ExpectedDividendAsPercentageShareOptionsdividendYield
      contextRef="c374"
      decimals="2"
      id="ixv-29441"
      unitRef="pure">0</ppbt:ExpectedDividendAsPercentageShareOptionsdividendYield>
    <ppbt:Discountforlackofmarketability
      contextRef="c378"
      decimals="3"
      id="ixv-29442"
      unitRef="pure">0.261</ppbt:Discountforlackofmarketability>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c0" id="ixv-28447">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
19 - Subsequent Events&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;  border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On February 11, 2025, the board of directors of the Company agreed to grant 10,500 thousand options (to purchase the equivalent of 52.5 thousand ADSs) and 10,500 thousand RSUs (equivalent to 52.5 thousand ADSs) to the Board members and CEO, subject to the approval of the shareholders. The options have an exercise price of USD 3.40 per one ADS. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The estimated fair value of these options and RSUs as of the board approval date was measured at USD 282 thousand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c379"
      decimals="-3"
      id="ixv-29443"
      unitRef="pure">10500000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c380"
      decimals="-2"
      id="ixv-29444"
      unitRef="pure">52500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c381"
      decimals="-3"
      id="ixv-29445"
      unitRef="pure">10500000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c382"
      decimals="-2"
      id="ixv-29446"
      unitRef="pure">52500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c383"
      decimals="2"
      id="ixv-29447"
      unitRef="usdPershares">3.4</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ppbt:VestingPeriod contextRef="c384" id="ixv-29448">P3Y</ppbt:VestingPeriod>
    <ppbt:StockOptionExercisedPeriod contextRef="c385" id="ixv-29449">P5Y</ppbt:StockOptionExercisedPeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c386"
      decimals="-3"
      id="ixv-29450"
      unitRef="usd">282000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <dei:CityAreaCode contextRef="c1" id="hidden-fact-0">+972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="hidden-fact-1">3-933-3121</dei:LocalPhoneNumber>
    <dei:DocumentAccountingStandard contextRef="c0" id="hidden-fact-2">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssuedCapital
      contextRef="c2"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssuedCapital
      contextRef="c3"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherReserves
      contextRef="c2"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLoss
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLoss
      contextRef="c5"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="c5"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c6"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c16"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c18"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c20"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c21"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c22"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c23"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c25"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c16"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c18"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c20"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c21"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c22"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c23"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c25"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c16"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c20"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c21"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c22"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c23"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c25"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c16"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c17"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c18"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c19"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c20"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c21"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c22"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c16"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c17"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c18"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c19"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c21"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c22"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c23"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c25"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c26"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c30"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c36"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c47"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c50"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c51"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c52"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c53"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c54"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c56"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary
      contextRef="c47"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary
      contextRef="c49"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary
      contextRef="c50"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary
      contextRef="c51"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary
      contextRef="c52"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary
      contextRef="c53"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary
      contextRef="c54"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary
      contextRef="c56"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c47"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c49"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c51"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c52"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c53"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c54"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c56"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c47"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c51"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c52"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c53"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c54"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c56"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c47"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c48"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c49"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c50"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c51"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c52"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c53"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c47"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c48"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c49"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c50"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c52"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c53"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c54"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c56"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c6"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c57"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c61"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c68"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c70"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c71"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c72"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c73"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c74"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c75"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c77"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c68"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c70"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c72"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c73"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c74"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c75"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c77"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c68"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c70"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c72"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c73"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c74"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c75"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c77"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c68"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c69"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c70"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c71"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c72"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c73"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c74"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c68"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c69"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c70"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c71"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c73"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c74"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c75"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c77"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c36"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="c4"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="c5"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="c0"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:CashAssumedAsPartOfAcquisitionOfFamewave
      contextRef="c0"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:CashAssumedAsPartOfAcquisitionOfFamewave
      contextRef="c5"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities
      contextRef="c5"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c0"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c4"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:IncreaseDecreaseInLongTermDeposits
      contextRef="c0"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:IncreaseDecreaseInLongTermDeposits
      contextRef="c4"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="c0"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:ProceedsFromIssuingWarrants
      contextRef="c0"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:ProceedsFromIssuingWarrants
      contextRef="c5"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c4"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c5"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:WarrantsIssuanceExpensesPaid
      contextRef="c5"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:CommonStockNoParValues
      contextRef="c81"
      id="hidden-fact-149"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ppbt:CommonStockNoParValues
      contextRef="c82"
      id="hidden-fact-150"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="c98"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c0"
      id="hidden-fact-152"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="c113"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="c2"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c157"
      id="hidden-fact-155"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c158"
      id="hidden-fact-156"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c159"
      id="hidden-fact-157"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c160"
      id="hidden-fact-158"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c161"
      id="hidden-fact-159"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c162"
      id="hidden-fact-160"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c163"
      id="hidden-fact-161"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c164"
      id="hidden-fact-162"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c165"
      id="hidden-fact-163"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c166"
      id="hidden-fact-164"
      unitRef="shares"
      xsi:nil="true"/>
    <ppbt:NumberOfExerciseOfWarrants
      contextRef="c4"
      id="hidden-fact-165"
      unitRef="shares"
      xsi:nil="true"/>
    <ppbt:NumberOfExerciseOfWarrants
      contextRef="c5"
      id="hidden-fact-166"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c120"
      decimals="1"
      id="hidden-fact-167"
      unitRef="usdPershares">7.5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c0"
      id="hidden-fact-168"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c4"
      id="hidden-fact-169"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:ForeignExchangeLoss
      contextRef="c5"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:IssuanceExpenses
      contextRef="c5"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:OtherfinancialCost
      contextRef="c4"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:OtherfinancialCost
      contextRef="c5"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ForeignExchangeGain
      contextRef="c0"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ForeignExchangeGain
      contextRef="c4"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:OtherExpense
      contextRef="c0"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:IncomelossValue
      contextRef="c286"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:IncomelossValue
      contextRef="c306"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:IncomelossValue
      contextRef="c336"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:IncomelossValue
      contextRef="c4"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:Securities
      contextRef="c357"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:Securities
      contextRef="c358"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="c359"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="c360"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DerivativeFinancialAssets
      contextRef="c362"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DerivativeFinancialAssets
      contextRef="c363"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="c362"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="c363"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:FairValueMeasurementExercise
      contextRef="c367"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:FairValueMeasurementIssuance
      contextRef="c367"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:FairValueMeasurementIssuanceProceed
      contextRef="c368"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:FairValueMeasurementBalance
      contextRef="c369"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:FairValueMeasurementBalance
      contextRef="c372"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:FairValueMeasurementIssuance
      contextRef="c373"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <ppbt:FairValueMeasurementIssuanceProceed
      contextRef="c374"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-29649">0001614744</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-29650">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-29651">FY</dei:DocumentFiscalPeriodFocus>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Restated following amendments to IAS 1 - see Note 2F</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Restated to reflect a 1:20 reverse ratio of the ADS&#x2019;s, that took place September 2024 (see Note 9A)</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Intangible asset - In process research and development</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-166"
          xlink:label="hidden-fact-166"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-165"
          xlink:label="hidden-fact-165"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Restated to reflect a 1:20 reverse ratio that took place in September 2024. (see also note 9A)</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-166"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-165"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
